NCT Number,Title,Acronym,Status,Study Results,Conditions,Interventions,Outcome Measures,Sponsor/Collaborators,Gender,Age,Phases,Enrollment,Funded Bys,Study Type,Study Designs,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents,URL
NCT03949374,Clinical Trial to Evaluate Efficacy and Safety of ROVASRO 10mg Versus CRESTOR 10mg in Hypercholesterolemic Patients,,Completed,No Results Available,Hypercholesterolemia|Dyslipidemias,"Drug: CRESTOR, reference formulation of rosuvastatin|Drug: ROVASRO, generic formulation of rosuvastatin",Percentage change in the level of LDL-C|Target achievement rate in the level of LDL-C|Change in biochemical parameters : total cholesterol (mg/dL)|Change in biochemical parameters : triglyceride (mg/dL)|Change in biochemical parameters : high-density lipoprotein-cholesterol(HDL-C)(mg/dL)|Change in biochemical parameters : apolipoprotein B(mg/dL)|Change in biochemical parameters : apolipoprotein A1(mg/dL)|Change in biochemical parameters : high sensitivity C-reactive protein (hsCRP)(mg/L),Yonsei University,All,"19 Years to 80 Years   (Adult, Older Adult)",Phase 4,126,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4-2015-0730,23-Oct-15,16-Apr-18,1-Jun-18,14-May-19,null,14-May-19,"Division of Cardiology, Cardiovascular Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03949374
NCT03934320,Improving Identification of Familial Hypercholesterolaemia in Primary Care (FAMCAT),FAMCAT,Enrolling by invitation,No Results Available,Familial Hypercholesterolemia,Other: FAMCAT,Detection of genetically confirmed new FH cases using case identification tool (FAMCAT)|Acceptability of FAMCAT|Appropriateness of FAMCAT|Usability of FAMCAT|Self-reported anxiety measures for use in a future trial|Self-reported lifestyle change measures for use in a future trial|Beliefs about predisposition to coronary heart disease|Cost-effective FAMCAT threshold to identify genetically confirmed FH,"University of Nottingham|Newcastle University|University College, London|University of Manchester",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,400,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,16090|332,12-Jun-17,31-Jul-20,31-Jul-20,1-May-19,null,1-May-19,"Division of Primary Care, University of Nottingham, Nottingham, Nottinghamshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT03934320
NCT03916016,Sí Texas Hope Family Health Center,,Completed,No Results Available,Chronic Disease|Hypertension|Diabetes|Hypercholesterolemia|Depression|Obesity,Behavioral: Enhanced Integrated Behavioral Health Care|Behavioral: Usual Care,Blood Pressure|Body mass index|Depressive Symptoms|Blood glucose concentration,"Health Resources in Action, Inc.|Methodist Healthcare Ministries of South Texas, Inc.|Social Innovation Fund",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,585,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,100002,9-Dec-15,29-Mar-18,29-Mar-18,16-Apr-19,null,22-Apr-19,,,https://ClinicalTrials.gov/show/NCT03916016
NCT03885921,Safety and Tolerability Study of Ezetimibe (SCH 058235/MK-0653) Plus Atorvastatin or Simvastatin in Homozygous Familial Hypercholesterolemia (P01417/MK-0653-019),,Completed,No Results Available,Hypercholesterolemia,Drug: Ezetimibe|Drug: Atorvastatin|Drug: Simvastatin,Number of Participants Who Experience an Adverse Event (AE)|Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)|Mean Percent Change from Baseline in Low-density-lipoprotein Cholesterol (LDL-C)|Mean Percent Change from Baseline in Total Cholesterol (TC)|Mean Percent Change from Baseline in High-density-lipoprotein Cholesterol (HDL-C)|Mean Percent Change from Baseline in Triglycerides (TG),Merck Sharp & Dohme Corp.,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,44,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",P01417|MK-0653-019,25-Oct-00,8-Jul-03,8-Jul-03,22-Mar-19,null,22-Mar-19,,,https://ClinicalTrials.gov/show/NCT03885921
NCT03884452,Ezetimibe (SCH 58235) Taken With Either Atorvastatin or Simvastatin in Participants With Familial Hypercholesterolemia (MK-0653-018),,Completed,No Results Available,Familial Hypercholesterolemia,Drug: Atorvastatin|Drug: Simvastatin|Drug: Ezetimibe|Drug: Placebo for Ezetimibe,Percent change from baseline in Low Density Lipoprotein Cholesterol (LDL-C) measured directly|Percentage of participants with an Adverse Event (AE)|Percent change from baseline in calculated LDL-C|Percent change from baseline in Total Cholesterol (TC)|Percent change from baseline in Triglycerides (TG)|Percent change from baseline in High-density-lipoprotein cholesterol (HDL-C)|Percent change from baseline in High-density-lipoprotein 2 cholesterol (HDL2-C)|Percent change from baseline in High-density-lipoprotein 3 cholesterol (HDL3-C)|Percent change from baseline in Apolipoprotein A-I (Apo A-I)|Percent change from baseline in Apolipoprotein B (Apo B)|Percent change from baseline in Lipoprotein(a) [Lp(a)],Merck Sharp & Dohme Corp.,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,50,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",P01030|MK-0653-018,3-May-00,24-May-01,24-May-01,21-Mar-19,null,21-Mar-19,,,https://ClinicalTrials.gov/show/NCT03884452
NCT03885661,Vascepa to Accelerate Lipoprotein Uptake and Elimination,VALUE,"Active, not recruiting",No Results Available,Lipid Disorder|Triglycerides High|Dyslipidemias,Drug: Icosapent Ethyl 1000 MG [Vascepa],Change in VLDL-apoB100 production rate,University of Pennsylvania|Amarin Pharma Inc.,All,"21 Years to 75 Years   (Adult, Older Adult)",Phase 1,null,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Other",823489|AMR-01-01-0024,11-Jan-16,Dec-19,Dec-19,21-Mar-19,null,21-Mar-19,"Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03885661
NCT03882892,"Long-Term Safety and Tolerability of Ezetimibe (SCH 58235, MK-0653) With Atovastatin (P02154, MK-0653-017)",,Completed,No Results Available,Hypercholesterolemia,Drug: Ezetimibe|Drug: Atovastatin|Drug: Placebo,Percentage of Participants Experiencing ≥1 Adverse Event (AE)|Percentage of Participants Discontinuing from Study Treatment due to an Adverse Event (AE)|Mean Percent Change from Baseline in Low-Density Lipoprotein Cholesterol (LDL-C)|Mean Percent Change from Baseline in High-Density Lipoprotein Cholesterol (HDL-C)|Mean Percent Change from Baseline in Triglyceride Levels|Mean Percent Change from Baseline in Total Cholesterol (TC)|Mean Percent Change from Baseline in Calculated Low-Density Lipoprotein Cholesterol (LDL-C),Merck Sharp & Dohme Corp.,All,"18 Years to 86 Years   (Adult, Older Adult)",Phase 3,400,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",P02154|MK-0653-017,2-Feb-01,8-Aug-02,8-Aug-02,20-Mar-19,null,27-Mar-19,,,https://ClinicalTrials.gov/show/NCT03882892
NCT03882905,"A Study of SCH 58235 (Ezetimibe) When Added to Ongoing Therapy With a Statin in Participants With Primary Hypercholesterolemia, Known Coronary Heart Disease, or Multiple Cardiovascular Risk Factors (P02173)",,Completed,No Results Available,Primary Hypercholesterolemia,Drug: Ezetimibe|Drug: Placebo|Drug: Simivastatin|Drug: Statin,Percentage Change from Baseline in LDL-C: Base Study|Percentage Participants with Consecutive Elevations ≥3 x Upper Limit of Normal (ULN) in Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT): Extension|Percentage of Participants Achieving LDL-C National Cholesterol Education Program (NCEP) Adult Treatment Program II (ATP II) Target Levels: Base Study|Percentage Change from Baseline in Total Cholesterol (TC) : Base Study|Percentage Change from Baseline in Triglycerides (TG): Base Study|Percentage Change from Baseline in High-density Lipoprotein-cholesterol (HDL-C) : Base Study|Percentage Change from Baseline in Non-HDL-C: Base Study|Percentage Change from Baseline in Apolipoprotein B (apoB) : Base Study|Percentage Change from Baseline in Apolipoprotein A-I (Apo A-I) : Base Study|Percentage Change from Baseline in Apolipoprotein A-II (Apo A-II) : Base Study|Percentage Change from Baseline in LDL-C:HDL-C Ratio: Base Study|Percentage Change from Baseline in Total-C:HDL-C Ratio: Base Study|Change from Baseline in C-reactive Protein (CRP): Base Study|Percentage Change from Baseline in LDL-C: Extension,Merck Sharp & Dohme Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 3,769,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",P02173|MK-0653-001|SCH 58235 P02173,31-Jan-01,27-Jul-01,27-Jul-01,20-Mar-19,null,20-Mar-19,,,https://ClinicalTrials.gov/show/NCT03882905
NCT03882996,"A Long-term Safety and Tolerability Study of Ezetimibe Plus Atorvastatin in Participants With Coronary Heart Disease, Multiple Risk Factors, or Hypercholesterolemia Not Controlled by Atorvastatin (P01418/MK-0653-032)",,Completed,No Results Available,Hypercholesterolemia,Drug: Ezetimibe|Drug: Atorvastatin,Number of participants who experienced an adverse event|Number of participants who discontinued study drug due to an adverse event|Percentage of participants achieving target LDL-C level (≤100 mg/dL)|Change from baseline in LDL-C levels|Change from baseline in HDL-C levels|Change from baseline in triglyceride levels,Merck Sharp & Dohme Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 3,432,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P01418|MK-0653-032,6-Oct-00,4-Feb-03,4-Feb-03,20-Mar-19,null,20-Mar-19,,,https://ClinicalTrials.gov/show/NCT03882996
NCT03881657,Reverse Colocated Integrated Care Intervention Among Persons With Severe Persistent Mental Illness at US-Mexico Border,,Completed,No Results Available,Mental Illness Persistent|Chronic Disease|Hypertension|Diabetes|Hypercholesterolemia|Depression|Obesity,Behavioral: Reverse Colocated Integrated Care|Behavioral: Usual Care,Blood pressure|Blood glucose concentration|Body mass index|Total cholesterol|Depressive symptoms|Life functioning,"Health Resources in Action, Inc.|Methodist Healthcare Ministries of South Texas, Inc.|Social Innovation Fund",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,416,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,100001,24-Nov-15,22-Aug-17,22-Aug-17,19-Mar-19,null,19-Mar-19,,,https://ClinicalTrials.gov/show/NCT03881657
NCT03878290,RiSE to Prevent Cardiovascular Disease in African Americans,,Recruiting,No Results Available,Atherosclerosis|Stress|Hypertension|Dyslipidemias|Obesity|Diabetes|Coronary Artery Disease,"Behavioral: Resilience, Stress, and Ethnicity (RiSE)",Feasibility of RiSE intervention: questionnaire|Coping|Coping with Discrimination|Resilience|Inflammatory burden,Loyola University,All,"25 Years to 75 Years   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,210130,3-Aug-17,1-Jul-19,1-Jul-19,18-Mar-19,null,18-Mar-19,"Loyola University Chicago, Maywood, Illinois, United States",,https://ClinicalTrials.gov/show/NCT03878290
NCT03867110,"An Efficacy and Safety Study of Ezetimibe (MK-0653, SCH 58235) in Addition to Atorvastatin Compared to Placebo in Participants With Primary Hypercholesterolemia (MK-0653-013)",,Completed,No Results Available,Hypercholesterolemia,Drug: Placebo|Drug: Ezetimibe 10 mg|Drug: Atorvastatin 10 mg|Drug: Atorvastatin 20 mg|Drug: Atorvastatin 40 mg|Drug: Atorvastatin 80 mg,"Percent Change from Baseline at Week 12 of Plasma Low Density Lipoprotein Cholesterol (LDL-C)|Percent Change from Baseline at Week 12 for Calculated Low Density Lipoprotein-Cholesterol (LDL-C)|Percent Change from Baseline at Week 12 for Total Cholesterol (TC)|Percent Change from Baseline at Week 12 for Triglycerides (TG)|Percent Change from Baseline at Week 12 for High Density-Lipoprotein-Cholesterol (HDL-C)|Percent Change from Baseline at Week 12 for Apolipoprotein B (Apo B)|Percent Change from Baseline at Week 12 for Non-High Density-Lipoprotein-Cholesterol (Non-HDL-C)|Percent Change from Baseline at Week 12 for High Density-Lipoprotein 2-Cholesterol (HDL2-C)|Percent Change from Baseline at Week 12 for High Density-Lipoprotein 3-Cholesterol (HDL3-C)|Percent Change from Baseline at Week 12 for Apolipoprotein A-I (Apo A-I),|Percent Change from Baseline at Week 12 for Direct Low Density-Lipoprotein 3-Cholesterol/High Density-Lipoprotein 3-Cholesterol (LDL-C/HDL-C) Ratio|Percent Change from Baseline at Week 12 for Direct Total Cholesterol/High Density-Lipoprotein 3-Cholesterol (TC/HDL-C) Ratio|Percent Change from Baseline at Week 12 for Lipoprotein (a) (Lp[a])|The Percentage of Participants Achieving National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP II) Target Goal for Direct Low Density Lipoprotein-Cholesterol (LDL-C)",Merck Sharp & Dohme Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 3,628,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",P00692|MK-0653-013,6-Mar-00,27-Jul-01,27-Jul-01,7-Mar-19,null,7-Mar-19,,,https://ClinicalTrials.gov/show/NCT03867110
NCT03867318,"Efficacy and Safety Study of Ezetimibe (SCH 58235, MK-0653) in Addition to Atorvastatin in Participants With Coronary Heart Disease or Multiple Cardiovascular Risk Factors (P00693/MK-0653-030)",,Completed,No Results Available,Hypercholesterolemia,Drug: Atorvastatin|Drug: Ezetimibe|Drug: Placebo for Ezetimibe|Drug: Placebo for Atorvastatin,Percentage of Participants Achieving Target Low-Density-Lipoprotein Cholesterol (LDL-C) Levels of ≤100 mg/dL|Percentage of Participants With an Adverse Event|Percentage of Participants Who Discontinued the Study due to an Adverse Event|Percentage of Participants Achieving Target LDL-C level (≤100 mg/dL)|Mean Percent Change from Baseline in Direct LDL-C|Mean Percent Changes from Baseline for Calculated LDL-C|Mean Percent Changes from Baseline for Total Cholesterol (TC)|Mean Percent Changes from Baseline for Triglycerides (TG)|Mean Percent Changes from Baseline for High-Density-Lipoprotein Cholesterol (HDL-C),Merck Sharp & Dohme Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 3,621,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",P00693|MK-0653-030,24-Apr-00,16-Nov-01,16-Nov-01,7-Mar-19,null,14-Mar-19,,,https://ClinicalTrials.gov/show/NCT03867318
NCT03756779,Cross-over Pilot Study of Blood Cholesterol Response to Dietary Saturated Fat in Patients With Autosomal Dominant Hypercholesterolemia,,Withdrawn,No Results Available,Familial Hypercholesterolemia,Other: Dietary intervention,Change in LDL-cholesterol,University of Texas Southwestern Medical Center,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,0,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,122016-032,15-May-17,30-Jun-20,30-Jun-20,28-Nov-18,null,28-Nov-18,"UT Southwestern Medical Center, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT03756779
NCT03742219,Peru Longitudinal Study,,Recruiting,No Results Available,Cardiovascular Diseases|Diabetes Mellitus|Hypertension|Dyslipidemias|Overweight and Obesity,Behavioral: Lifestyle Modification,Weight|Systolic blood pressure|Diastolic Blood Pressure|glycosylated hemoglobin|Total cholesterol|Low-density lipoprotein cholesterol|High density lipoprotein cholesterol|Triglycerides|Herth Hope Index|Household hunger scale|Patient Health Questionnaire - 4 (PHQ-4)|Exercise vital sign|Perceived Stress Scale|24 hour dietary recall,Ohio University,All,"12 Years and older   (Child, Adult, Older Adult)",Not Applicable,1000,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,17-X-88,5-Jun-17,1-Jul-26,30-Jun-27,15-Nov-18,null,15-Nov-18,"Ohio University, Athens, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03742219
NCT03739242,Effect of a Treatment With a Nutraceutical Combination on Sub-optimal LDL Cholesterol Levels,NATCOL,Completed,No Results Available,Hypercholesterolemia,Dietary Supplement: Nutraceutical combination|Other: Placebo,Change in blood LDL cholesterol level|Change in total blood cholesterol level|Change in blood HDL cholesterol level|Change in blood non-HDL cholesterol level|Change in blood triglycerides level|Change in blood apolipoprotein B Level|Change in total cholesterol/HDL cholesterol ratio|Change in total LDL cholesterol/HDL cholesterol ratio|Change in Puse Volume (PV) waveform (endothelial reactivity)|Change in Glycemia|Change in aspartate aminotransferase (AST)|Change in alanine aminotransferase (ALT)|Change in gamma glutamyl transpeptidase (GGT)|Change in serum creatinine|Change in serum uric acid|Change in creatine phosphokinase (CPK),A. Menarini Industrie Farmaceutiche Riunite S.r.l.,All,"30 Years to 75 Years   (Adult, Older Adult)",Not Applicable,88,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",MEIF/MOF-Col/001,12-Oct-17,29-Aug-18,29-Aug-18,12-Nov-18,null,14-Nov-18,"Policlinico S.Orsola - Malpighi Medicina Interna Borghi, Bologna, Italy",,https://ClinicalTrials.gov/show/NCT03739242
NCT03728621,Lifestyle Interventions and Metabolic Profile in Obese Children,,Completed,No Results Available,Childhood Obesity|Obesity|Pediatric Obesity|Dyslipidemias|Cardiovascular Risk Factor|Life Style,"Behavioral: Normocaloric and balanced diet, physical activity",Height|Blood levels of total cholesterol|Weight|Body Mass Index (BMI)|Waist-to-height ratio|Waist circumference|Triceps Skinfold Thickness|Tanner Stage|Blood levels of LDL cholesterol|Blood levels of HDL cholesterol|Blood levels of triglycerides|Blood levels of apolipoprotein A1 (ApoA1)|Blood levels of apolipoprotein B (ApoB)|Blood levels of insulin|Blood levels of glucose|HOmeostatic Model Assessment of Insulin Resistance (HOMA-IR)|QUantitative Insulin sensitivity ChecK (QUICK) index|HOMA-β%|Triglyceride-Glucose index (TyG index)|Atherogenic Index of Plasma (AIP),University of Milan,All,"6 Years and older   (Child, Adult, Older Adult)",Not Applicable,170,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,139/2010/CE,Jan-12,Jun-17,Jun-18,2-Nov-18,null,2-Nov-18,"Ospedale San Paolo, Milan, Italy",,https://ClinicalTrials.gov/show/NCT03728621
NCT03680027,Effects Of Walnut-Enriched Diet On Blood Lipids And Glucose Profiles In Hyperlipidemic Subjects,,Completed,No Results Available,Hyperlipidemias,Dietary Supplement: Walnut-enriched Group,Reduction in serum lipids and fasting glucose levels,Eastern Mediterranean University,All,"30 Years to 65 Years   (Adult, Older Adult)",Not Applicable,37,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,2015/13-04,10-Jul-15,27-Aug-15,30-Sep-15,21-Sep-18,null,24-Sep-18,,,https://ClinicalTrials.gov/show/NCT03680027
NCT03676309,Efficacy and Safety of Nutraceuticals in Patients With Diabetes Mellitus Type II and Dyslipidemia.,,Completed,No Results Available,"Diabetes Mellitus, Type 2|Nutritional and Metabolic Diseases|Vascular System Injury|Therapy-Related Morphologic Change","Drug: Nutriceutical Oral Capsule,|Drug: Placebo Oral Tablet",colesterol|Endothelial function,Villa dei Gerani|University Magna Graecia,null,"30 Years and older   (Adult, Older Adult)",Phase 2,90,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",PON03PE_00078_2,1-Sep-17,26-Mar-18,26-Mar-18,18-Sep-18,null,18-Sep-18,"Capomolla Antonio, Monterosso Calabro, VV, Italy",,https://ClinicalTrials.gov/show/NCT03676309
NCT03663465,The Effect of Hawthorn on Lipoprotein Cholesterol Ratio in Schizophrenics With Antipsychotics,,Completed,No Results Available,Schizophrenia,Other: Hawthorn|Drug: SGAs,lipid profiles,Calo Psychiatric Center,All,"16 Years to 65 Years   (Child, Adult, Older Adult)",Not Applicable,135,Other,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",MAB101-109,1-Jan-13,31-Dec-13,31-Jul-14,10-Sep-18,null,10-Sep-18,,,https://ClinicalTrials.gov/show/NCT03663465
NCT03657472,Bioequivalence Study of CJ-30061 in Healthy Male Volunteers,,Completed,No Results Available,Hypertension|Hyperlipidemia,Drug: CJ-30061|Drug: Exforge® 5/160mg & Lipitor® 20mg,Cmax of amlodipine|Cmax of valsartan|Cmax of atorvastatin|AUCt of amlodipine|AUCt of valsartan|AUCt of atorvastatin|tmax of amlodipine|tmax of valsartan|tmax of atorvastatin|t1/2 of atorvastatin|t1/2 of amlodipine|t1/2 of valsartan|AUCinf of amlodipine|AUCinf of valsartan|AUCinf of atorvastatin|AUCt of 2-OH atorvastatin|Cmax of 2-OH atorvastatin|tmax of 2-OH atorvastatin|t1/2 of 2-OH atorvastatin|AUCinf of 2-OH atorvastatin,CJ HealthCare Corporation,Male,19 Years to 55 Years   (Adult),Phase 1,42,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,CJ_EXA_103,19-Sep-16,29-Oct-16,9-Nov-16,5-Sep-18,null,5-Sep-18,"Samsung Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03657472
NCT03649269,PC-300 Tea Effect on Triglyceride Levels,,Completed,No Results Available,Hypertriglyceridemia,Dietary Supplement: PC-300 tea.|Drug: Bezafibrate,Triglycerides serum levels.,Ciprés Grupo Médico CGM SC,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,34,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2014/02,1-Jan-14,30-Nov-14,31-Dec-14,28-Aug-18,null,28-Aug-18,,,https://ClinicalTrials.gov/show/NCT03649269
NCT03639480,Study to Evaluate the Safety and Efficacy of CJ-30061 in Hypertensive Patients With Hyperlipidemia,,Enrolling by invitation,No Results Available,Hypertension|Hyperlipidemia,Drug: Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg|Drug: Amlodipine 10mg+Valsartan 160mg|Drug: Valsartan 160mg+Atorvastatin 40mg,Change in siSBP|Change in LDL-C,CJ HealthCare Corporation,All,"19 Years to 74 Years   (Adult, Older Adult)",Phase 3,180,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CJ_EXA_301,13-Oct-17,Oct-18,Oct-18,21-Aug-18,null,21-Aug-18,"Asan Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03639480
NCT03638362,Tart Cherry Juice and Chronic Disease Risk,,Completed,No Results Available,CVD|Diabetes|Inflammation,Dietary Supplement: Placebo|Dietary Supplement: Tart cherry juice,TCJ and hsCRP|fasting triglycerides,University of Memphis|Arizona State University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,10,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,10015542,21-Aug-09,30-Sep-11,30-Sep-11,20-Aug-18,null,20-Aug-18,,,https://ClinicalTrials.gov/show/NCT03638362
NCT03618797,A Clinical Trial to Evaluate the Efficacy and Safety of Pitavastatin/Fenofibrate in Complex-dyslipidemia,,Completed,No Results Available,Complex-dyslipidemia,Drug: HL-PIF cap.160/2mg + Placebo|Drug: Livalo tab. 2mg + Placebo,The mean percentage change of Non-HDL Cholesterol|The mean percentage change of LDL-C|The mean percentage change of HDL-C|The mean percentage change of LDL-C/HDL-C|The mean percentage change of TC/HDL-C|The mean percentage change of non-HDL-C/HDL-C|The mean percentage change of VLDL-C|The mean percentage change of TG|The mean percentage change of TC|The mean percentage change of Apo Al|The mean percentage change of Apo B|The mean percentage change of Apo Al/Apo B|The mean percentage change of fibrinogen|The mean percentage change of hs-CRP|Achievement rate(%) of treatment goals after 4 weeks and 8 weeks,"Hanlim Pharm. Co., Ltd.",All,"19 Years to 80 Years   (Adult, Older Adult)",Phase 3,347,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HL-PIF-301,Nov-15,Jan-18,May-18,7-Aug-18,null,7-Aug-18,,,https://ClinicalTrials.gov/show/NCT03618797
NCT03615534,Extended Release Niacin and Fenofibrate for the Treatment of Atherogenic Dyslipidemia in Obese Females,,Completed,Has Results,Atherogenic Dyslipidemia|Obesity Associated Disorder,Other: Therapeutic Lifestyle Changes|Other: Placebo|Drug: Fenofibrate|Dietary Supplement: Wax Matrix Extended Release Niacin (WMER Niacin),Changes Serum Triglyceride Levels|Changes in Serum Lipoprotein Cholesterol Levels|Changes in Serum Apolipoprotein Levels|Changes in Serum Fasting Glucose Levels.|Changes in Estimated Glomerular Filtration Rate (eGFR)|Changes in Serum Uric Acid Levels|Changes in Serum Enzymes Levels|Changes in Systolic and Diastolic Blood Pressure|Adverse Events,"Lewai Sharki Abdulaziz, MSc PhD|Al-Kindy College of Medicine",Female,20 Years to 60 Years   (Adult),Phase 4,161,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,1Al-KindyCM,1-Oct-14,30-Jun-15,30-Oct-15,6-Aug-18,12-Oct-18,19-Apr-19,"Al Kindy College of Medicine, University of Baghdad, Baghdad, Iraq|Lewai S Abdulaziz, Baghdad, Iraq",,https://ClinicalTrials.gov/show/NCT03615534
NCT03604471,Lipid-lowering Therapy Individualization,,Recruiting,No Results Available,Hypercholesterolemia,Drug: Atorvastatin,Atorvastatin population pharmacokinetics|Atorvastatin metabolites population pharmacokinetics|Cholesterol|Creatine kinase|Occurrence of adverse drug events|Pharmacogene genotype|Triglycerides,Université Catholique de Louvain|Cliniques universitaires Saint-Luc- Université Catholique de Louvain,All,"18 Years and older   (Adult, Older Adult)",Phase 4,150,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,2016/26OCT/471,8-Aug-17,Aug-19,Aug-19,27-Jul-18,null,18-Apr-19,"Cliniques universitaires Saint-Luc, Brussels, Belgium",,https://ClinicalTrials.gov/show/NCT03604471
NCT03591588,Effects of Diet Interventions on Monocytes in Metabolic Syndrome,,Recruiting,No Results Available,Metabolic Syndrome|Hypertriglyceridemia,Other: diet,Effects of diet interventions on monocyte phenotypes,Baylor College of Medicine,All,"21 Years to 75 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science,H21418,1-Apr-16,31-Mar-20,31-Mar-20,19-Jul-18,null,16-Jan-19,"Center for Prevention of cardiometabolic disease, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03591588
NCT03590496,Safety and Efficacy of Propionate for Reduction of LDL Cholesterol,PROPER-LDL,Recruiting,No Results Available,Hypercholesterolemia,Drug: Atorvastatin 10mg|Dietary Supplement: Calcium-Propionate 500mg|Other: Placebo,LDL-cholesterol reduction|total cholesterol|HDL-cholesterol|non HDL|Ratio HDL/LDL,"Charite University, Berlin, Germany",All,"20 Years to 70 Years   (Adult, Older Adult)",Phase 2,124,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",PROPER-LDL Trial,21-Nov-17,30-Nov-19,30-Nov-20,18-Jul-18,null,6-Sep-18,"St. Josef-hospital Ruhr-Univesity Bochum, Bochum, Nordrhein-Westfalen, Germany|Charité Universitätsmedizin Berlin, Berlin, Germany",,https://ClinicalTrials.gov/show/NCT03590496
NCT03571087,Efficacy and Safety of Combination of Rosuvastatin and Ezetimibe in Patients With Primary Hypercholesterolemia,,Completed,No Results Available,Primary Hypercholesterolemia,Drug: HL140 5/10|Drug: HL140 10/10|Drug: HL140 20/10|Drug: Rosuvastatin 5mg → HL140 5/10|Drug: Rosuvastatin 10mg → HL140 10/10|Drug: Rosuvastatin 20mg → HL140 20/10,Percentage change in LDL-Cholesterol from baseline|Percentage change in TG from baseline|Percentage change in TC from baseline|Percentage of change in non-HDL-Cholesterol|Percentage of change in HDL-Cholesterol|Percentage of change weeks in Apo A-I|Percentage of change in Apo B|Percentage of change in Lipoprotein(a)|The rate of change in hs-CRP|Percentage of patients reached treatment goals according to NCEP ATP III Guideline,"Hanlim Pharm. Co., Ltd.",All,"19 Years and older   (Adult, Older Adult)",Phase 3,374,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HL_HL140_301,Sep-14,Aug-15,Sep-15,27-Jun-18,null,14-Aug-18,,,https://ClinicalTrials.gov/show/NCT03571087
NCT03566316,Efficacy/Safety of Telmisartan/Amlodipine/Rosuvastatin in Hypertensive Patients With Hyperlipidemia,,Completed,No Results Available,Hypertension With Hyperlipidemia,Drug: Telmisartan/Amlodipine|Drug: Rosuvastatin|Drug: Telmisartan,"Percentage of change in LDL-Cholesterol|The change of sitting systolic blood pressure|Percentage of change in HDL-Cholesterol, total Cholesterol, Triglyceride, Apolipoprotein B|The change of HDL-Cholesterol/LDL-Cholesterol ratio|The change of total cholesterol/HDL-Cholesterol ratio|Percentage of patients reaching treatment goals according to National Cholesterol Education Program-Adults Treatment Panel III Guideline|The change of sitting diastolic blood pressure|Percentage of patients reaching treatment goals according to Joint National Committee VIII Guideline",IlDong Pharmaceutical Co Ltd,All,"19 Years and older   (Adult, Older Adult)",Phase 3,134,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ID-TAR-301,24-Nov-15,16-Jun-17,16-Jun-17,25-Jun-18,null,25-Jun-18,"Korea University Guro Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03566316
NCT03563547,Effects of Soy Protein on Cholesterol Levels in Children Affected With Familial Hypercholesterolemia,SOYFIT,Completed,No Results Available,Heterozygous Familial Hypercholesterolemia,Behavioral: Dietary counseling (fat modifed diet)|Behavioral: Dietary Counseling (fat modified + soy enriched diet),LDL-C change from baseline,Austrian Academic Institute for Clinical Nutrition|Medical University of Vienna,All,4 Years to 14 Years   (Child),Not Applicable,34,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SoyfitKW01,3-Sep-09,9-Oct-14,9-Oct-17,20-Jun-18,null,20-Jun-18,"Austrian Academic Institute for Clinical Nutrition, Vienna, Austria",,https://ClinicalTrials.gov/show/NCT03563547
NCT03557476,Effects of Octacosanol During Taekwondo Training,,Completed,No Results Available,Oxidative Stress|Dyslipidemias,Dietary Supplement: Octacosanol|Dietary Supplement: Placebo,Lipid Profiles|Oxidative stress,"University of Nebraska, Omaha",Male,"17 Years to 19 Years   (Child, Adult)",Not Applicable,26,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Octacosanol,1-Aug-17,1-Mar-18,1-Mar-18,15-Jun-18,null,15-Jun-18,"University of Nebraska at Omaha, Omaha, Nebraska, United States",,https://ClinicalTrials.gov/show/NCT03557476
NCT03550287,Evaluation of the Effect of a Shiitake Extract on Lipid Profile in Subjects With Moderate Hyperlipidemia,Reducol,Completed,No Results Available,Hypercholesterolemia|Hyperlipidemias|Dietary Supplements|Cardiovascular Risk Factor,Dietary Supplement: Experimental product|Dietary Supplement: Placebo product,Change from Baseline Total Cholesterol|Change from Baseline Lipid Metabolism Parameters|Change from Baseline Satiety Hunger Assessment|Total amount of food consumed in 24h|Change from Baseline Vitamin D|Change from Baseline Anthropometric Parameters|Sensory Perception|Change from Baseline Glucose Parameters|Change from Baseline Inflammation Parameters|Adverse Effects|Change from Baseline Markers of oxidation,Instituto de Investigación Hospital Universitario La Paz,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,58,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",4813,8-May-17,30-Jun-17,31-Dec-17,8-Jun-18,null,8-Jun-18,"Institute for Health Research IdiPAZ, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT03550287
NCT03545438,"Study to Evaluate the Safety, PK, and Pharmacodynamics of LIB003",LIB003SAD,Completed,No Results Available,Hypercholesterolemia,Biological: LIB003,The incidence and severity of treatment emergent adverse events (TEAEs)|Absolute change in serum unbound (free) proprotein convertase subtilisin/kexin type 9 (PCSK9) concentrations over time|Absolute change in serum total PCSK9 over time|Percent change in Low Density Lipoprotein cholesterol (LDL-C) over time|Percent change in Apolipoprotein B (Apo B) over time|Changes in serum LIB003 concentrations over time|Presence of anti LIB003 antibodies (ADAs),"LIB Therapeutics LLC|Medpace, Inc.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,63,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",LIB003-001,30-Oct-17,30-May-18,30-Jun-18,4-Jun-18,null,27-Jul-18,"Medpace (MARC/CPU), Cincinnati, Ohio, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT03545438/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT03545438
NCT03536598,Study to Evaluate the Safety and Efficacy of CJ-30060 in Hypertensive Patients With Hyperlipidemia,,Completed,No Results Available,Hypertension With Hyperlipidemia,Drug: Amlodipine 10 mg + Valsartan 160 mg + Rosuvastatin 20 mg|Drug: Amlodipine 10 mg + Valsartan 160 mg|Drug: Valsartan 160 mg + Rosuvastatin 20 mg,Change of LDL-C and siSBP,CJ HealthCare Corporation,All,"19 Years to 74 Years   (Adult, Older Adult)",Phase 3,203,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CJ_EXR_301,14-Oct-16,4-Sep-17,4-Sep-17,24-May-18,null,30-May-18,,,https://ClinicalTrials.gov/show/NCT03536598
NCT03534661,L-NMMA on GLP-2 Mediated Intestinal Lipoprotein Release,LNMMA,Recruiting,No Results Available,Hyperlipidemias,Drug: Teduglutide + Normal Saline|Drug: Teduglutide + L-NMMA|Drug: Placebo + L-NMMA,Plasma Lipid Levels|Blood Flow,"University Health Network, Toronto",All,18 Years to 60 Years   (Adult),Phase 2|Phase 3,15,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,L-NMMA 13-6415,27-Sep-17,31-Dec-19,31-Dec-19,23-May-18,null,18-Apr-19,"Tornto General Hospital, UHN, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT03534661
NCT03523403,Obesity-related Health Benefits of Apples,,Completed,No Results Available,"Obesity, Abdominal|Hyperlipidemias|Inflammation|Dysbiosis",Other: Apples,Plasma triglyceride levels|Plasma inflammatory cytokine levels|Gut microbiota profile|Fatty acid composition of chylomicron-rich fraction of blood|Plasma ApoB48 levels|Rate of gastric emptying|Levels of inflammatory cytokines secreted from peripheral blood mononuclear cells isolated from whole blood samples and stimulated with or without lipopolysaccharide|Plasma lipopolysaccharide binding protein|Plasma glucose levels|Plasma insulin levels,"University of Guelph|Ontario Ministry of Agriculture, Food and Rural Affairs|Ontario Apple Growers|Agriculture and Agri-Food Canada",All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,48,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science,UGuelph Apple Study|UofG2014-2028|REB#16JA013,12-Oct-17,19-Dec-18,19-Dec-18,14-May-18,null,18-Apr-19,"Human Nutraceutical Research Unit, University of Guelph, Guelph, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT03523403
NCT03482180,Evaluate the Efficacy and Safety of KI1106 in Patients Whose TG Level is Not Adequately Controlled With Atorvastatin Calcium Monotherapy While LDL-C is Properly Controlled,,Completed,No Results Available,Dyslipidemias,"Drug: KI1106 4g, QD|Drug: Atorvastatin Calcium 20mg, QD",Variation rate of Non HDL-C|Variation rate of TG|Variation rate of TC|Variation rate of LDL-C|Variation rate of VLDL-C|Variation rate of Apo A-I|Variation rate of Apo B,"Kuhnil Pharmaceutical Co., Ltd.",All,"20 Years to 80 Years   (Adult, Older Adult)",Phase 3,215,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",12-OA-8301,4-May-16,16-May-17,23-Mar-18,29-Mar-18,null,19-Nov-18,,,https://ClinicalTrials.gov/show/NCT03482180
NCT03469518,"Effect of β-cryptoxanthin (β-Cx), Plant Sterols and Galactooligosaccharides on Systemic and Gastrointestinal Markers",,"Active, not recruiting",No Results Available,Hypercholesterolemia|Osteoporosis|Postmenopausal Disorder,Dietary Supplement: β-Cx plus PS plus GOS|Dietary Supplement: β-Cx plus PS,"Serum levels of β-Cx|Serum levels of PS|Serum lipid profile|C reactive protein, ferritin, calprotectin, alpha-1-antitrypsin, alpha-1-acid|Beta C-terminal telopeptide (beta-CrossLaps/betaCTx), osteoprotegerin, Parathyroid hormone (PTH), calcium, phosphorus, Alkaline phosphatase|Sterol fecal levels|β-cryptoxanthin fecal levels|Interleukins|beta-carotene oxygenase 1 (BCO1), beta-carotene oxygenase 2 (BCO2), scavenger receptor class B type I (SR-BI), NPC1L1, ATP-binding cassette (ABC) transporters G5 and G8 (ABCG5 and ABCG8) genes|Taxonomic profiles of microbial communities by ribosomal RNA (16SrRNA) gene metagenomic studies. Microbiota characterization.","Puerta de Hierro University Hospital|Nutrition and Food Science Area, Faculty of Pharmacy, University of Valencia|Global Technology centro, Hero Group|Fundación para la Investigación Biomédica, Hospital Universitario Puerta de Hierro",Female,"45 Years to 65 Years   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science",AGL2015-68006-C2-2-R,Jan-17,Jul-17,Dec-19,19-Mar-18,null,9-May-19,,,https://ClinicalTrials.gov/show/NCT03469518
NCT03470376,NUtraceutical TReatment for hYpercholesterolemia in HIV-infected Patients,NU-TRY(HIV),Completed,No Results Available,Hypercholesterolemia|Inflammation|Atherosclerosis,Dietary Supplement: Nutraceutical combination (NC)|Behavioral: No nutraceutical combination (noNC),Change from baseline in LDL-C levels at 3 months|Change from baseline in PCSK9 levels at 3 months|Change from baseline in subclinical inflammation at 3 months|Change from baseline in arterial stiffness at 3 months,University Of Perugia,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,26,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,2015-006,15-Jan-17,15-Nov-17,30-Nov-17,19-Mar-18,null,23-Mar-18,,,https://ClinicalTrials.gov/show/NCT03470376
NCT03464682,Efficacy and Safety of HS-25 or in Combination With Atorvastatin in Chinese Adults With Primary Hypercholesterolemia,HS-25-C-01,"Active, not recruiting",No Results Available,Primary Hypercholesterolemia,Drug: HS-25 10mg|Drug: HS-25 10mg combination with Atorvastatin|Drug: HS-25 20mg combination with Atorvastatin|Drug: Atorvastatin 10mg|Drug: HS-25 20mg|Drug: Placebe of HS-25 and Atorvastatin,"Percent change of LDL-C|Percent change of Non-HDL-C|Percent change of HDL-C|Percent change of TC, TG, Apo B, Apo Al",Zhejiang Hisun Pharmaceutical Co. Ltd.,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,720,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",HS-25-C-01,28-Feb-15,28-Dec-18,28-May-19,14-Mar-18,null,18-Oct-18,,,https://ClinicalTrials.gov/show/NCT03464682
NCT03463967,Effects of Tomato Products in Children With NAFLD,,Recruiting,No Results Available,NAFLD,Dietary Supplement: Lycopene-enriched tomato juice|Other: Energy-restricted diet,Reduction of liver steatosis|Reduction in BMI|Reduction in ALT serum level|Improvement of inflammatory state|Amelioration of oxidative state,Federico II University,All,4 Years to 14 Years   (Child),Not Applicable,61,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,TD1016,Oct-16,Feb-18,Jun-18,13-Mar-18,null,13-Mar-18,"Unit of Hepatology-Dept. of Pediatric Clinic, Naples, Italy",,https://ClinicalTrials.gov/show/NCT03463967
NCT03464240,Glucose-stimulated Gut Lipid Release,,Completed,No Results Available,Hyperlipidemias,Dietary Supplement: Glucose|Dietary Supplement: Water,Visualization of lipid stores in the gut|Analysis of proteins in the gut,"University Health Network, Toronto|Kensington Screening Clinic",All,18 Years to 60 Years   (Adult),Not Applicable,46,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,Glucose Biopsy 15-9025,16-Oct-15,11-Aug-17,11-Aug-17,13-Mar-18,null,13-Mar-18,"Tornto General Hospital, UHN, Toronto, Ontario, Canada|Kensington Screening Clinic, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT03464240
NCT03461081,Drug-drug Interaction Following Oral Administration of Telmisartan/Amlodipine and Atorvastatin in Healthy Adult Volunteers,,Completed,No Results Available,Hypertension With Hyperlipidemia,Drug: telmisartan/amlodipine and atorvastatin,"AUCτ of telmisartan, amlodipine, atorvastatin, 2-OH atorvastatin|Css,max of telmisartan, amlodipine, atorvastatin, 2-OH atorvastatin","Jeil Pharmaceutical Co., Ltd.",Male,19 Years to 55 Years   (Adult),Phase 1,32,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,JLP-1610-101-DDI,7-May-17,12-Jul-17,12-Dec-17,9-Mar-18,null,12-Mar-18,"Samsung Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03461081
NCT03451214,Evaluation of Zinc Intake on Essential Fatty Acid Metabolism,,Completed,No Results Available,Inflammation|Oxidative Stress|Dyslipidemias,Other: Diet Zinc,Lipidomics changes|DNA strand breaks changes|Polar Metabolomics changes|Mineral analysis changes|Body weight changes|Fat allocation changes,Children's Hospital & Research Center Oakland,Male,18 Years to 50 Years   (Adult),Not Applicable,40,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,CHO22,1-Jul-17,30-Jun-18,30-Jun-18,1-Mar-18,null,14-Aug-18,"UCSF Benioff Children's Hospital Oakland Research Institute, Oakland, California, United States",,https://ClinicalTrials.gov/show/NCT03451214
NCT03435432,Plasma Lipid Response to Glucose Drink,,Completed,No Results Available,Hyperlipidemias,Dietary Supplement: Glucose|Dietary Supplement: Water,Blood lipid responses to glucose drink,"University Health Network, Toronto",All,18 Years to 60 Years   (Adult),Not Applicable,6,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,Glucose Plasma 15-9025,10-Mar-16,16-Jun-16,16-Jun-16,16-Feb-18,null,16-Feb-18,"Tornto General Hospital, UHN, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT03435432
NCT03433196,Efficacy and Safety Study of the HS-25 Combination With Atorvastatin in Subjects With Hypercholesterolemia in Coronary Heart Diseases,HS-25-III-02,Completed,No Results Available,Hypercholesterolemia in Coronaory Heart Disease,Drug: HS-25 and Atorvastatin|Drug: Atorvastatin,"Percent change of LDL-C|Percent change of Non-HDL-C|Percent change of TC,TG,ApoB,ApoAI",Zhejiang Hisun Pharmaceutical Co. Ltd.,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,255,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",HS-25-III-02,7-Jun-16,30-Jun-18,10-Oct-18,14-Feb-18,null,18-Oct-18,,,https://ClinicalTrials.gov/show/NCT03433196
NCT03429998,Evolocumab Versus LDL Apheresis in Patients With Hypercholesterolemia,,Completed,No Results Available,Hypercholesterolemia,Drug: evolocumab|Drug: evolocumab and LDL apheresis|Procedure: LDL apheresis,decrease in LDL-cholesterol (mg/dl)|Decrease apo-B (mg/dl) levels|Decrease lipoprotein A (mg/dl) levels|Decrease in triglycerides (mg/dl) levels|any adverse effects|Modification of C reactive protein|Modification of immunoglobulin G levels (mg/dl)|Modification of immunoglobulin A levels (mg/dl)|Modification of complement levels (mg/dl)|Modification of serum fibrinogen (mg/dl),Hospital General Universitario Gregorio Marañon,All,"18 Years and older   (Adult, Older Adult)",Phase 3,9,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EVOLAFER01,1-Apr-17,28-Jan-18,28-Jan-18,12-Feb-18,null,12-Feb-18,"Hospital General Universitario Gregorio Marañon, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT03429998
NCT03425630,LDL-cholesterol Lowering Effect of a New Dietary Supplement,,Completed,No Results Available,Hypercholesterolemia,Dietary Supplement: Argicolina|Dietary Supplement: Normolip,reduction of LDL-cholesterol|Total cholesterol reduction|Triglycerides reduction|HDL cholesterol increase,Ispharm srl,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DAM/IA/001/16,Jul-16,Apr-17,Apr-17,7-Feb-18,null,12-Feb-18,,,https://ClinicalTrials.gov/show/NCT03425630
NCT03418974,Safety and Efficacy of Statins for Chinese Patients With Dyslipidemia,,"Active, not recruiting",No Results Available,Dyslipidemias,Drug: Pitavastatin|Drug: Atorvastatin|Drug: Rosuvastatin,LDL-C target achieving rate|Blood lipid parameters|Blood glucose levels|Fasting blood glucose|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],"Fudan University|Peking University People's Hospital|Jiangsu Wanbang Medicine Marketing Co., Ltd.",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,10000,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BZ1701,1-Nov-17,31-Dec-21,31-Dec-21,1-Feb-18,null,1-Feb-18,"Heart Center of Peking University People's Hospital, Beijing, Beijing, China|School of Public Health, Fudan University, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT03418974
NCT03415568,Effects of MCDG Oil on Postprandial Lipid Metabolism,,Completed,No Results Available,Hyperlipidemias|Triglycerides High,Dietary Supplement: LCT oil|Dietary Supplement: MCDG oil,Triglyceride levels|The areas under the curve (AUC) of triglycerides|Triglyceride maximum concentration time,Yonsei University,All,21 Years to 29 Years   (Adult),Not Applicable,28,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",DOP_OFTT,30-Jun-17,28-Jul-17,28-Jul-17,30-Jan-18,null,30-Jan-18,"Laboratory of Clinical Nutrigenetics/Nutrigenomics, Yonsei University., Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03415568
NCT03413462,Efficacy and Safety Study of HS-25 in Chinese Adults With Primary Hypercholesterolemia,HS-25-III-01,Completed,No Results Available,Primary Hypercholesterolemia,Drug: HS-25|Drug: Placebo of HS-25,LDL-C|Non-HDL-C|HDL-C|TC|TG,Zhejiang Hisun Pharmaceutical Co. Ltd.,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,374,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HS-25-III-01,12-Apr-16,20-Apr-18,20-Sep-18,29-Jan-18,null,18-Oct-18,,,https://ClinicalTrials.gov/show/NCT03413462
NCT03400800,Inclisiran for Subjects With ACSVD or ACSVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol,ORION-11,"Active, not recruiting",No Results Available,ASCVD|Elevated Cholesterol,Drug: Inclisiran Sodium|Drug: Placebo,Percentage Change in LDL-C from Baseline to Day 510|Time-adjusted Percent Change in LDL-C Levels from Baseline after Day 90 and up to Day 540|Absolute Change In LDL-C from Baseline To Day 510|Time-adjusted Absolute Change in LDL-C from Baseline after Day 90 and up to Day 540|Percentage Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) from Baseline to Day 510|Percentage Change in Total Cholesterol from Baseline to Day 510|Percentage Change in Apolipoprotein B (ApoB) from Baseline to Day 510|Percentage Change in Non-HDL-C from Baseline to Day 510,The Medicines Company,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1617,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",MDCO-PCS-17-08,1-Nov-17,Oct-19,Dec-19,17-Jan-18,null,17-Apr-19,"Research Site 11420-002, Chomutov, Czechia|Research Site 11420-003, Uherské Hradiště, Czechia|Research Site 11049-006, Berlin, Germany|Research Site 11049-002, Bochum, Germany|Research Site 11049-003, Frankfurt, Germany|Research Site 11049-007, Heidelberg, Germany|Research Site 11049-001, Leipzig, Germany|Research Site 11036-001, Budapest, Hungary|Research Site 11036-004, Debrecen, Hungary|Research Site 11036-002, Hatvan, Hungary|Research Site 11036-003, Zalaegerszeg, Hungary|Research Site 11048-018, Bydgoszcz, Kujawsko-pomorskie, Poland|Research Site 11048-016, Brzozów, Podkarpackie, Poland|Research Site 11048-019, Ruda Śląska, Slaskie, Poland|Research Site 11048-011, Bydgoszcz, Poland|Research Site 11048-004, Gdańsk, Poland|Research Site 11048-017, Gdańsk, Poland|Research Site 11048-005, Gdynia, Poland|Research Site 11048-007, Katowice, Poland|Research Site 11048-012, Katowice, Poland|Research Site 11048-014, Kraków, Poland|Research Site 11048-003, Kraków, Poland|Research Site 11048-008, Lublin, Poland|Research Site 11048-001, Poznań, Poland|Research Site 11048-013, Rzeszów, Poland|Research Site 11048-015, Tarnów, Poland|Research Site 11048-009, Warsaw, Poland|Research Site 11048-006, Warszawice, Poland|Research Site 11048-002, Wrocław, Poland|Research Site 11048-010, Wrocław, Poland|Research Site 11027-003, Bloemfontein, Free State, South Africa|Research Site 11027-005, Johannesburg, Gauteng, South Africa|Research Site 11027-001, Cape Town, Western Cape, South Africa|Research Site 11027-013, Cape Town, Western Cape, South Africa|Research Site 11027-007, Kuilsrivier, Western Cape, South Africa|Research Site 11027-004, Somerset West, Western Cape, South Africa|Research Site 11027-006, Pretoria, South Africa|Research Site 11027-011, Welkom, South Africa|Research Site - 11380-005, Cherkasy, Ukraine|Research Site - 11380-008, Kharkiv, Ukraine|Research Site - 11380-004, Kiev, Ukraine|Research Site - 11380-009, Kiev, Ukraine|Research Site - 11380-001, Kyiv, Ukraine|Research Site - 11380-002, Kyiv, Ukraine|Research Site - 11380-003, Kyiv, Ukraine|Research Site - 11380-007, Lviv, Ukraine|Research Site - 11380-006, Uzhhorod, Ukraine|Research Site - 11044-006, Edgbaston, Birmingham, United Kingdom|Research Site - 11044-022, Sale, Cheshire, United Kingdom|Research Site - 11044-023, Sale, Cheshire, United Kingdom|Research Site - 11044-021, Timperley, Cheshire, United Kingdom|Research Site - 11044-012, Liskeard, Cornwall, United Kingdom|Research Site - 11044-009, Exeter, Devon, United Kingdom|Research Site - 11044-019, Plymouth, Devon, United Kingdom|Research Site - 11044-014, Chorley, Lancashire, United Kingdom|Research Site - 11044-004, Waterloo, Liverpool, United Kingdom|Research Site - 11044-027, Davyhulme, Manchester, United Kingdom|Research Site - 11044-028, Bollington, United Kingdom|Research Site - 11044-026, Bury, United Kingdom|Research Site - 11044-007, Cardiff, United Kingdom|Research Site - 11044-024, Cheadle Hulme, United Kingdom|Research Site - 11044-010, Derby, United Kingdom|Research Site - 11044-001, Glasgow, United Kingdom|Research Site - 11044-008, Hexham, United Kingdom|Research Site - 11044-020, Macclesfield, United Kingdom|Research Site - 11044-025, Manchester, United Kingdom|Research Site - 11044-005, Manchester, United Kingdom|Research Site - 11044-029, Manchester, United Kingdom|Research Site - 11044-003, Reading, United Kingdom|Research Site - 11044-002, Stockton, United Kingdom",,https://ClinicalTrials.gov/show/NCT03400800
NCT03399370,Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol,ORION-10,"Active, not recruiting",No Results Available,ASCVD|Elevated Cholesterol,Drug: Inclisiran Sodium|Drug: Placebo,Percentage Change in LDL-C from Baseline to Day 510|Time-adjusted Percentage Change in LDL-C Levels from Baseline after Day 90 and up to Day 540|Absolute Change in LDL-C from Baseline to Day 510|Time-adjusted Absolute Change in LDL-C from Baseline after Day 90 and up to Day 540|Percentage Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) from Baseline to Day 510|Percentage Change in Total Cholesterol from Baseline to Day 510|Percentage Change in Apolipoprotein B (ApoB) from Baseline to Day 510|Percentage Change in Non-HDL-C from Baseline to Day 510,The Medicines Company,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1561,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",MDCO-PCS-17-04,21-Dec-17,Oct-19,Dec-19,16-Jan-18,null,17-Apr-19,"Research Site 10001-015, Birmingham, Alabama, United States|Research Site 10001-138, Foley, Alabama, United States|Research Site 10001-113, Huntsville, Alabama, United States|Research Site 10001-058, Mobile, Alabama, United States|Research Site 10001-037, Montgomery, Alabama, United States|Research Site 10001-076, Saraland, Alabama, United States|Research Site 10001-013, Chandler, Arizona, United States|Research Site 10001-077, Mesa, Arizona, United States|Research Site 10001-136, Phoenix, Arizona, United States|Research Site 10001-051, Surprise, Arizona, United States|Research Site 10001-019, Tucson, Arizona, United States|Research Site 10001-004, Tucson, Arizona, United States|Research Site 10001-132, Tucson, Arizona, United States|Research Site 10001-073, Beverly Hills, California, United States|Research Site 10001-050, Canoga Park, California, United States|Research Site 10001-011, Carlsbad, California, United States|Research Site 10001-065, El Cajon, California, United States|Research Site 10001-150, Los Angeles, California, United States|Research Site 10001-043, Northridge, California, United States|Research Site 10001-022, Northridge, California, United States|Research Site 10001-033, Sacramento, California, United States|Research Site 10001-105, San Ramon, California, United States|Research Site 10001-008, Santa Rosa, California, United States|Research Site 10001-153, Spring Valley, California, United States|Research Site 10001-044, Torrance, California, United States|Research Site 10001-047, Boca Raton, Florida, United States|Research Site 10001-084, Clearwater, Florida, United States|Research Site 10001-155, Clearwater, Florida, United States|Research Site 10001-099, Clearwater, Florida, United States|Research Site 10001-127, Daytona Beach, Florida, United States|Research Site 10001-119, Fleming Island, Florida, United States|Research Site 10001-070, Fort Lauderdale, Florida, United States|Research Site 10001-067, Hialeah, Florida, United States|Research Site 10001-139, Jacksonville, Florida, United States|Research Site 10001-039, Jacksonville, Florida, United States|Research Site 10001-098, Jacksonville, Florida, United States|Research Site 10001-080, Miami Springs, Florida, United States|Research Site 10001-081, Miami, Florida, United States|Research Site 10001-140, Miami, Florida, United States|Research Site 10001-142, Miami, Florida, United States|Research Site 10001-030, Miami, Florida, United States|Research Site 10001-089, Miami, Florida, United States|Research Site 10001-116, Miami, Florida, United States|Research Site 10001-027, Pembroke Pines, Florida, United States|Research Site 10001-115, Pembroke Pines, Florida, United States|Research Site 10001-048, Pembroke Pines, Florida, United States|Research Site 10001-147, Pembroke Pines, Florida, United States|Research Site 10001-003, Pinellas Park, Florida, United States|Research Site 10001-104, Ponte Vedra, Florida, United States|Research Site 10001-090, Saint Augustine, Florida, United States|Research Site 10001-102, Saint Petersburg, Florida, United States|Research Site 10001-123, Sarasota, Florida, United States|Research Site 10001-038, Tampa, Florida, United States|Research Site 10001-143, Tampa, Florida, United States|Research Site 10001-069, Atlanta, Georgia, United States|Research Site 10001-137, Dunwoody, Georgia, United States|Research Site 10001-092, Macon, Georgia, United States|Research Site 10001-059, Arlington Heights, Illinois, United States|Research Site 10001-158, Chicago, Illinois, United States|Research Site 10001-035, Chicago, Illinois, United States|Research Site 10001-036, Evanston, Illinois, United States|Research Site 10001-082, Indianapolis, Indiana, United States|Research Site 1001-020, Sellersburg, Indiana, United States|Research Site 10001-040, Valparaiso, Indiana, United States|Research Site 10001-074, West Des Moines, Iowa, United States|Research Site 10001-028, Hutchinson, Kansas, United States|Research Site 10001-125, Lexington, Kentucky, United States|Research Site 10001-108, Lexington, Kentucky, United States|Research Site 10001-107, Owensboro, Kentucky, United States|Research Site 10001-144, Crowley, Louisiana, United States|Research Site 10001-041, Lake Charles, Louisiana, United States|Research Site 10001-101, Monroe, Louisiana, United States|Research Site 10001-024, Flint, Michigan, United States|Research Site 10001-095, Grandville, Michigan, United States|Research Site 10001-078, Sterling Heights, Michigan, United States|Research Site 10001-034, Troy, Michigan, United States|Research Site 10001-018, Edina, Minnesota, United States|Research Site 10001-056, Saint Paul, Minnesota, United States|Research Site 10001-156, Saint Louis, Missouri, United States|Research Site 10001-007, Saint Louis, Missouri, United States|Research Site 10001-053, Omaha, Nebraska, United States|Research Site 10001-021, Omaha, Nebraska, United States|Research Site 10001-112, Las Vegas, Nevada, United States|Research Site 10001-124, Las Vegas, Nevada, United States|Research Site 10001-060, Bridgewater, New Jersey, United States|Research Site 10001-055, Raritan, New Jersey, United States|Research Site 10001-054, Albany, New York, United States|Research Site 10001-122, Binghamton, New York, United States|Research Site 10001-128, Endwell, New York, United States|Research Site 10001-042, New Windsor, New York, United States|Research Site 10001-129, Poughkeepsie, New York, United States|Research Site 10001-110, Williamsville, New York, United States|Research Site 10001-063, Cary, North Carolina, United States|Research Site 10001-064, Greensboro, North Carolina, United States|Research Site 10001-145, Mooresville, North Carolina, United States|Research Site 10001-046, Shelby, North Carolina, United States|Research Site 10001-016, Akron, Ohio, United States|Research Site 10001-120, Cincinnati, Ohio, United States|Research Site 10001-154, Cincinnati, Ohio, United States|Research Site 10001-010, Cincinnati, Ohio, United States|Research Site 10001-134, Cincinnati, Ohio, United States|Research Site 10001-014, Columbus, Ohio, United States|Research Site 10001-012, Columbus, Ohio, United States|Research Site 10001-141, Dayton, Ohio, United States|Research Site 10001-148, Marion, Ohio, United States|Research Site 10001-017, Edmond, Oklahoma, United States|Research Site 10001-109, Wyomissing, Pennsylvania, United States|Research Site 10001-001, Anderson, South Carolina, United States|Research Site 10001-006, Greer, South Carolina, United States|Research Site 10001-075., Greer, South Carolina, United States|Research Site 10001-111, Myrtle Beach, South Carolina, United States|Research Site 10001-133, Pelzer, South Carolina, United States|Research Site 10001-026, Spartanburg, South Carolina, United States|Research Site 10001-103, Rapid City, South Dakota, United States|Research Site 10001-146, Athens, Tennessee, United States|Research Site 10001-130, Kingsport, Tennessee, United States|Research Site 10001-118, Knoxville, Tennessee, United States|Research Site 10001-100, Amarillo, Texas, United States|Research Site 10001-087, Austin, Texas, United States|Research Site 10001-117, Austin, Texas, United States|Research Site 10001-009, Dallas, Texas, United States|Research Site 10001-068, Edinburg, Texas, United States|Research Site 10001-126, Fort Worth, Texas, United States|Research Site 10001-031, Houston, Texas, United States|Research Site 10001-088, Houston, Texas, United States|Research Site 10001-091, Houston, Texas, United States|Research Site 10001-061, Houston, Texas, United States|Research Site 10001-032, Houston, Texas, United States|Research Site 10001-025, Lubbock, Texas, United States|Research Site 10001-057, New Braunfels, Texas, United States|Research Site 10001-106, Powell, Texas, United States|Research Site 10001-079, Round Rock, Texas, United States|Research Site 10001-071, San Antonio, Texas, United States|Research Site 10001-083, Schertz, Texas, United States|Research Site 10001-149, Shavano Park, Texas, United States|Research Site 10001-045, Tomball, Texas, United States|Research Site 10001-005, Layton, Utah, United States|Research Site 10001-002, Salt Lake City, Utah, United States|Research Site 10001-052, Salt Lake City, Utah, United States|Research Site 10001-093, Falls Church, Virginia, United States|Research Site 10001-085, Manassas, Virginia, United States|Research Site 10001-094, Midlothian, Virginia, United States|Research Site 10001-023, Richmond, Virginia, United States|Research Site 10001-029, Suffolk, Virginia, United States|Research Site 10001-114, Tacoma, Washington, United States",,https://ClinicalTrials.gov/show/NCT03399370
NCT03397121,Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH),ORION-9,"Active, not recruiting",No Results Available,Heterozygous Familial Hypercholesterolemia|Elevated Cholesterol,Drug: Inclisiran|Drug: Placebo,Percentage Change In LDL-C from Baseline To Day 510|Time-adjusted Percentage Change in LDL-C from Baseline After Day 90 and up to Day 540 Levels|Absolute Change in LDL-C from Baseline to Day 510|Time-adjusted Absolute Change in LDL-C from Baseline After Day 90 and up to Day 540|Percentage Change in Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) from Baseline to Day 510|Percentage Change in Total Cholesterol from Baseline to Day 510|Percentage Change in Apolipoprotein B (ApoB) from Baseline To Day 510|Percentage Change in Non-high-density Lipoprotein (HDL)-C from Baseline To Day 510,The Medicines Company,All,"18 Years and older   (Adult, Older Adult)",Phase 3,482,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",MDCO-PCS-17-03|2017-002472-30,28-Nov-17,Sep-19,Sep-19,11-Jan-18,null,17-Apr-19,"Site 90001-005, Mission Viejo, California, United States|Site 90001-001, Newport Beach, California, United States|Site 90001-015, Stanford, California, United States|Site 90001-047, Boca Raton, Florida, United States|Site 90001-004, Boston, Massachusetts, United States|Site 90001-056, Saint Paul, Minnesota, United States|Site 90001-012, Butte, Montana, United States|Site 90001-112, Las Vegas, Nevada, United States|Site 90001-014, Summit, New Jersey, United States|Site 90001-002, Cincinnati, Ohio, United States|Site 90011-005, Chicoutimi, Quebec, Canada|Site 90011-001, Montréal, Quebec, Canada|Site 90011-002, Quebec City, Quebec, Canada|Site 90420-001, Prague, Czechia|Site 90420-006, Prague, Czechia|Site 90420-005, Trutnov, Czechia|Site 90045-001, Aalborg, Denmark|Site 90045-004, Esbjerg, Denmark|Site 90045-003, Herning, Denmark|Site 90045-006, Hvidovre, Denmark|Site 90045-002, Roskilde, Denmark|90045-005, Viborg, Denmark|Site 90031-001, Amersfoort, Netherlands|Site 90031-003, Amsterdam, Netherlands|Site 90031-009, Hoorn, Netherlands|Site 90031-006, Tilburg, Netherlands|Site 90031-005, Utrecht, Netherlands|Site 90027-004, Cape Town, Western Cape, South Africa|Site 90027-003, Bloemfontein, South Africa|Site 90027-005, Cape Town, South Africa|Site 90027-001, Cape Town, South Africa|Site 90027-008, Cape Town, South Africa|Site 90027-010, Johannesburg, South Africa|Site 90027-007, Pretoria, South Africa|Site 90027-006, Pretoria, South Africa|Site 90027-009, Witbank, South Africa|Site 90034-003, A Coruña, Spain|Site 90034-005, Barcelona, Spain|Site 90034-004, Córdoba, Spain|Site 90034-006, L'Hospitalet De Llobregat, Spain|Site 90034-001, Reus, Spain|Site 90034-002, Zaragoza, Spain|Site 90046-002, Göteborg, Sweden|Site 90046-001, Stockholm, Sweden|Site 90046-003, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT03397121
NCT03392350,Randomized Trial of the Impact of Body Scanning and Intensive Behavioral Intervention on Behavioral Change and Health Outcomes,,Completed,No Results Available,Coronary Disease|Behavior and Behavior Mechanisms|Hypertension|Hypercholesterolemia,Behavioral: Physician Body Scan Consultation with Behavioral Intervention,Progression of Coronary Artery Calcium|Epicardial and Thoracic fat volume (in cm3),Reengineering Healthcare Inc.,All,"35 Years and older   (Adult, Older Adult)",Not Applicable,267,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention,20111268,15-Jun-12,15-Sep-15,20-Nov-15,5-Jan-18,null,5-Jan-18,,,https://ClinicalTrials.gov/show/NCT03392350
NCT03382756,A Clinical Trial to Assess the Effects of Food on the Bioavailability of CKD-337,,Completed,No Results Available,Dyslipidemias,Dietary Supplement: High fat diet|Drug: CKD-337,AUC0-t of Atorvastatin|Cmax of Atorvastatin|AUCt of Fenofibric acid|Cmax of Fenofibric acid|AUCinf of Atorvastatin|Tmax of Atorvastatin|T 1/2 of Atorvastatin|CL/F of Atorvastatin|Vd/F of Atorvastatin|AUCinf of Fenofibric acid|Tmax of Fenofibric acid|T 1/2 of Fenofibric acid|CL/F of Fenofibric acid|Vd/F of Fenofibric acid|AUC0-t of 2-hydroxy atorvastatin|Cmax of 2-hydroxy atorvastatin|AUCinf of 2-hydroxy atorvastatin|Tmax of 2-hydroxy atorvastatin|T 1/2 of 2-hydroxy atorvastatin|CL/F of 2-hydroxy atorvastatin|Vd/F of 2-hydroxy atorvastatin,Chong Kun Dang Pharmaceutical,Male,19 Years to 45 Years   (Adult),Phase 1,16,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,146FDI17001,12-Oct-17,2-Nov-17,7-Nov-17,26-Dec-17,null,27-Dec-17,"Dong-A University Hospital, Busan, Seo-gu, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03382756
NCT03371355,"Study of ISIS 703802 in Subjects With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease",,Recruiting,No Results Available,"NAFLD|Diabetes Mellitus, Type 2|Hypertriglyceridemia|Fatty Liver, Nonalcoholic",Drug: ISIS 703802|Drug: Placebo,Percent change in fasting TG level from Baseline at the primary analysis time point.|The safety of ISIS 703802 by the incidence of treatment-emergent adverse events|The effect of ISIS 703802 on changes from Baseline at End-of-Treatment on glucose metabolism|The effect of ISIS 703802 on changes from Baseline at End-of-Treatment lipid metabolism|The effect of ISIS 703802 on changes from Baseline at End-of-Treatment on liver fat|Plasma Cmax of ISIS 703802 across different doses and dose regimens|Plasma Tmax of ISIS 703802 across different doses and dose regimens|Plasma AUC values of ISIS 703802 across different doses and dose regimens|The effect of ISIS 703802 on changes from Baseline on biomarkers related to liver inflammation|The effect of ISIS 703802 on changes from Baseline on adipose tissue as related to body composition|The effect of ISIS 703802 on changes from Baseline on WHR (waist-to-hip ratio) as related to body composition.|The effect of ISIS 703802 on changes from Baseline on BMI (Body Mass Index) as related to body composition,"Akcea Therapeutics|Ionis Pharmaceuticals, Inc.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,144,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 703802-CS2,18-Dec-17,28-Feb-19,31-May-19,13-Dec-17,null,26-Sep-18,"Clinical Sites, Chandler, Arizona, United States|Clinical Site, Fountain Hills, Arizona, United States|Clinical Site, Glendale, Arizona, United States|Clinical Site, Mesa, Arizona, United States|Clinical Site, Mesa, Arizona, United States|Clinical Site, Phoenix, Arizona, United States|Clinical Site, Phoenix, Arizona, United States|Clinical Site, Phoenix, Arizona, United States|Clinical Site, Huntington Park, California, United States|Clinical Site, Los Angeles, California, United States|Clinical Site, Montclair, California, United States|Clinical Site, Panorama City, California, United States|Clinical Site, Boca Raton, Florida, United States|Clinical Site, Jupiter, Florida, United States|Clinical Site, Port Saint Lucie, Florida, United States|Clinical Site, Atlanta, Georgia, United States|Clinical Site, Chicago, Illinois, United States|Clinical Site, Louisville, Kentucky, United States|Clinical Site, Edina, Minnesota, United States|Clinical Site, Bridgeton, New Jersey, United States|Clinical Site, Greensboro, North Carolina, United States|Clinical Site, High Point, North Carolina, United States|Clinical Site, Cincinnati, Ohio, United States|Clinical Site, Cincinnati, Ohio, United States|Clinical Site, Charleston, South Carolina, United States|Clinical Site, Austin, Texas, United States|Clinical Site, Carrollton, Texas, United States|Clinical Site, Dallas, Texas, United States|Clinical Site, Hurst, Texas, United States|Clinical Site, San Antonio, Texas, United States|Clinical Site, San Antonio, Texas, United States|Clinical Site, Layton, Utah, United States|Clinical Site, Hamilton, Ontario, Canada|Clinical Site, Toronto, Ontario, Canada|Clinical Site, Chicoutimi, Quebec, Canada|Clinical Site, Montréal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT03371355
NCT03370848,Effects of Psyllium on Niacin Tolerability,,Completed,No Results Available,Flushing|Hyperlipidemias|Dyslipidemias,Dietary Supplement: Psyllium|Drug: Aspirin,Global Flushing Severity Score|HDL|LDL,VA Greater Los Angeles Healthcare System,All,"18 Years and older   (Adult, Older Adult)",Phase 4,26,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,39,Mar-09,Jul-11,Jul-11,12-Dec-17,null,12-Dec-17,"VA West Los Angeles Medical Center, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT03370848
NCT03366688,Single Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Healthy Subjects.,,Completed,No Results Available,Hypercholesterolemia,Drug: IBI306|Drug: placebo,Number of participants with adverse events（AEs) as assessed by the criteria of National Institute on Aging|The area under the curve (AUC) of serum concentration of the drug after the administration|Maximum concentration (Cmax) of the drug after the administration|Time at which maximum concentration (Tmax) occurs for the drug after the administration|The half-life (t1/2) of drug after the administration|Assessment of serum concentrations of PCSK-9|Change from baseline in lipid parameters|Number of participants with anti-drug antibodies or neutralizing antibodies,Innovent Biologics (Suzhou) Co. Ltd.,All,18 Years to 55 Years   (Adult),Phase 1,58,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other",CIBI306A101,27-Nov-17,5-Nov-18,5-Nov-18,8-Dec-17,null,7-Feb-19,"Peking University First Hospital, Beijing, China",,https://ClinicalTrials.gov/show/NCT03366688
NCT03360747,Phase 2 Study of AKCEA-ANGPTL3-LRX (ISIS 703802) in Patients With Familial Chylomicronemia Syndrome (FCS),,Completed,No Results Available,Familial Chylomicronemia Syndrome|Lipoprotein Lipase Deficiency|Hyperlipoproteinemia Type 1,Drug: AKCEA-ANGPTL3-LRX,Change from baseline in fasting TG|Change from baseline in fasting ANGPTL3|Change from baseline in fasting lipid measurements,"Akcea Therapeutics|Ionis Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,3,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ISIS 703802-CS3,21-Dec-17,4-Sep-18,4-Sep-18,4-Dec-17,null,25-Apr-19,"Investigative Site, Montréal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT03360747
NCT03342807,Intravenous Administration of Insulin and Plasma Exchange on Triglyceride Levels in Early Stage of Hypertriglyceridemia-induced Pancreatitis,,Not yet recruiting,No Results Available,"Pancreatitis, Acute|Hypertriglyceridemia",Drug: Insulin|Device: Aphesis,serum TG,"Peking Union Medical College Hospital|First Hospitals affiliated to the China PLA General Hospital|Nanjing General Hospital|Fujian Provincial Hospital Emergency Center|First Affiliated Hospital, Sun Yat-Sen University|Jinhua Central Hospital|Guangdong Provincial Hospital of Traditional Chinese Medicine|First Affiliated Hospital of Kunming Medical College|Tianjin Medical University General Hospital|The First Hospital of Hebei Medical College|The First Affiliated Hospital with Nanjing Medical University|Shenzhen Baoan District People 's Hospital|The General Hospital of Shenyang Military|Cangzhou Center Hospital|Wuxi Third People 's Hospital|General Hospital of Ningxia Medical University",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,220,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HTG-AP-Insulin,Nov-17,Nov-19,Nov-20,17-Nov-17,null,17-Nov-17,,,https://ClinicalTrials.gov/show/NCT03342807
NCT03346187,A Clinical Trial to Compare Safety and Pharmacokinetic Characteristics of CKD-337,,Completed,No Results Available,Dyslipidemias,Drug: Active Comparator(Atorvastatin Calcium Trihydrate+Fenofibrate)|Drug: Test drug(CKD-337),"Atorvastatin AUCt(Area under the plasma drug concentration-time curve)|Atorvastatin Cmax(Maximum plasma concentration)|Fenofibric acid AUCt|Fenofibric acid Cmax|Atorvastatin AUCinf(Area under plasma concentration-time curve from time point of administration to infinite)|Atorvastatin Tmax(Time taken to reach the maximum concentration)|Atorvastatin t1/2(Terminal half-life, Time for Cmax to drop in half)|Atorvastatin CL/F(Apparent total body clearance after extravascular administration, calculated as Dose/AUC)|Atorvastatin Vd/F(Apparent volume of distribution/Bioavailability)|Fenofibric acid AUCinf|Fenofibric acid Tmax|Fenofibric acid t1/2|Fenofibric acid CL/F|Fenofibric acid Vd/F|2-hydroxy atorvastatin AUCt|2-hydroxy atorvastatin Cmax|2-hydroxy atorvastatin AUCinf|2-hydroxy atorvastatin Tmax|2-hydroxy atorvastatin t1/2|2-hydroxy atorvastatin CL/F|2-hydroxy atorvastatin Vd/F",Chong Kun Dang Pharmaceutical,Male,19 Years to 45 Years   (Adult),Phase 1,60,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,146BE16007,19-May-17,31-May-17,13-Jun-17,17-Nov-17,null,19-Dec-17,"Dong-A University Hospital, Busan, Seo-gu, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03346187
NCT03337308,"A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy",,Completed,No Results Available,Hyperlipidemias,Combination Product: Bempedoic Acid + Ezetimibe Fixed-Dose Combination|Drug: Bempedoic Acid|Drug: Ezetimibe|Drug: Placebos,Percent change in low-density lipoprotein cholesterol (LDL-C),Esperion Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 3,382,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1002FDC-053,23-Oct-17,18-Jun-18,18-Jul-18,8-Nov-17,null,25-Sep-18,"PMG Research of McFarland, Ames, Iowa, United States|Foundation Cardiology, Nashua, New Hampshire, United States|PMG Research of Piedmont Healthcare, Statesville, North Carolina, United States|PMG Research of Wilmington, Wilmington, North Carolina, United States|PMG Research of Knoxville, Knoxville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT03337308
NCT03330548,Pilot Study on the Effects of a Plant-Strong Diet on Cardiovascular Risk Factors,,Recruiting,No Results Available,Hyperlipidemias|Overweight and Obesity|Diabetes,Behavioral: TeleMOVE!|Behavioral: Culinary Rx,Change in Low-density lipoprotein (LDL)|Change in Dietary pattern|Change in carotid plaque|Change in aortic pulse wave velocity|Change in Total Cholesterol|Change in Weight|Change in Hemoglobin A1C (HgbA1c),Phoenix VA Health Care System|Rouxbe Cooking School|Carl T. Hayden Medical Research Foundation,All,"18 Years to 89 Years   (Adult, Older Adult)",Not Applicable,160,U.S. Fed|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,Parrington1092,9-Jul-15,Dec-19,Dec-20,6-Nov-17,null,6-Nov-17,"Phoenix VA Health Care System, Phoenix, Arizona, United States",,https://ClinicalTrials.gov/show/NCT03330548
NCT03332641,Effect of Intake of Citron(Citrus Junos Siebold ex Tanaka) Peel Extract on Blood Cholesterol.,,Completed,No Results Available,Hyperlipidemia,Dietary Supplement: Citron peel extract|Dietary Supplement: Placebo,Changes of Cholesterol|Changes of Lipid profile|Changes of Oxidized LDL,Hanyang University,All,"19 Years to 75 Years   (Adult, Older Adult)",Not Applicable,70,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",HYI-17-060-1,7-Jun-17,28-Sep-17,28-Sep-17,6-Nov-17,null,17-Nov-17,"Hanyang University, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03332641
NCT03307031,The Influence of Pilates Exercises Training Volume on Metabolic Outcomes in Dyslipidemic Women.,,Completed,No Results Available,Dyslipidemias,Other: High Volume Group|Other: Low Volume Group|Other: Control Group,Metabolic outcomes|Secondary outcomes,Federal University of Rio Grande do Sul,Female,"60 Years to 75 Years   (Adult, Older Adult)",Not Applicable,26,Other,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1.990.955,1-Mar-17,28-Jul-17,13-Sep-17,11-Oct-17,null,11-Oct-17,"Adriana Cristine Koch Buttelli, Porto Alegre, Rio Grande do Sul, Brazil",,https://ClinicalTrials.gov/show/NCT03307031
NCT03295448,Fatty Acid Biomarkers of Carbohydrate Intake,CARBIO,Completed,No Results Available,Dyslipidemias,"Other: Low carbohydrate diet|Other: High carbohydrate, high sugar diet|Other: High carbohydrate, low sugar diet","Palmitic acid in different plasma fractions|Even-chain saturated fatty acids (i.e. 14:0, 18:0) and monounsaturated fatty acids",Uppsala University,All,"20 Years to 75 Years   (Adult, Older Adult)",Not Applicable,19,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,CARBIO,25-Oct-17,1-Jun-18,1-Jun-18,27-Sep-17,null,15-Nov-18,"Uppsala univeristy hospital, Uppsala, Sweden",,https://ClinicalTrials.gov/show/NCT03295448
NCT03294044,The Effectiveness of Smart Health Management Program for Patients With Chronic Illness,,Completed,No Results Available,Hypertension|Dyslipidemias|Diabetes Mellitus,Behavioral: ICT programs|Behavioral: A book about chronic disease,Success in clinical outcomes of Hypertension from baseline to 3 months|Success in clinical outcomes of Dyslipidemia from baseline to 3 months|Success in clinical outcomes of primary disease Diabetes from baseline to 3 months|Health behavior patterns|Depression|Health Management Strategies|Quality of life (SF-12)|Quality of life (Mcgill QOL)|Quality of life (Euro-QoL),"Seoul National University Hospital|National Evidence-Based Healthcare Collaborating Agency|National Institute of Health, Korea|National Clinical Research Coordination Center, Seoul, Korea|Korea Health Industry Development Institute",All,"19 Years and older   (Adult, Older Adult)",Not Applicable,106,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,HI16C0455-1,27-Oct-17,26-Mar-18,31-Jul-18,26-Sep-17,null,24-Oct-18,"Seoul National University, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03294044
NCT03291548,Quinoa Biscuit & CVD Risk Trial,,Completed,No Results Available,Cardiovascular Diseases|Dyslipidemias|Lipid Profile,Dietary Supplement: Quinoa biscuit|Dietary Supplement: Control biscuit,Total cholesterol|Triglycerides|LDL-cholesterol|HDL-cholesterol|total/HDL-cholesterol ratio|Poly-unsaturated fatty acid status|Antioxidant status|Inflammatory status|Blood pressure|Weight,"University of Ulster|The Regional Centre for Studies in Food and Health (CREAS), Valparaíso, Chile",All,"50 Years to 75 Years   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",UREC/16/0106,13-Feb-17,19-Jun-17,19-Jun-17,25-Sep-17,null,25-Sep-17,"Human Intervention Studies Unit, Ulster University, Coleraine, Londonderry, United Kingdom",,https://ClinicalTrials.gov/show/NCT03291548
NCT03288038,The Efficacy and Safety of Combination Therapy of Rosuvastatin and Ezetimibe and Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia,,Completed,No Results Available,Hypercholesterolemia,Drug: Rosuvastatin|Drug: Ezetimibe,"Percent change from baseline to 8 week in LDL-Cholesterol|Percent change from baseline to 4 week in LDL-Cholesterol|The change in the LDL-C level from the baseline to Week 4 and Week 8|The change and percent change in the levels of TC, TG, HDL-C, non-HDL-C, apolipoprotein B, and hs-CRP from the baseline to Week 4 and Week 8|The change and percent change in the ratios of LDL-C/HDL-C, TC/HDL-C, non-HDL-C/HDL-C, and Apo B/Apo A-I from the baseline to Week 4 and Week 8|The ratio of the subjects who have reached the target LDL-C level according to the NCEP ATP(National Cholesterol Education Program Adult Treatment Panel) III Guideline at Week 4 and Week 8",Shin Poong Pharmaceutical Co. Ltd.,All,"19 Years and older   (Adult, Older Adult)",Phase 3,382,Industry,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",SP-RE-003,13-Oct-14,19-Nov-15,19-Nov-15,19-Sep-17,null,19-Sep-17,"Chungbuk National University Hospital, Cheongju-si, Korea, Republic of|Yeungnam University Medical Center, Daegu, Korea, Republic of|Chungnam National University Hospital, Daejeon, Korea, Republic of|Dongguk University Ilsan Hospital, Goyang-si, Korea, Republic of|Hallym University Dongtan Sacred Heart Hospital, Hwaseong-si, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Boramae Hospital, Seoul, Korea, Republic of|Chung-Ang University Hospital, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Hanyang University Hospital, Seoul, Korea, Republic of|Kangbuk Samsung Hospital, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|KyungHee University Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Soon Chun Hyang University Hospital Seoul, Seoul, Korea, Republic of|Ajou University Hospital, Suwon-si, Korea, Republic of|Wonju Severance Christian Hospital, Wŏnju, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03288038
NCT03284918,Lipid Lowering Effect of a Cereal Based Snack Bar With Added Plant Stanol Ester,,Completed,No Results Available,Hypercholesterolemia|Hyperlipidemias|Dyslipidemias,Dietary Supplement: Plant stanol ester|Dietary Supplement: Placebo,"Percentage change in serum LDL cholesterol|Absolute change in serum LDL cholesterol (mmol/l)|Absolute and percentage change in serum total, HDL- and non-HDL cholesterol and serum total triglycerides","Raisio Group|Medfiles Ltd., Finland",All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,71,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MFRA004,Jan-16,Mar-16,Sep-16,15-Sep-17,null,15-Sep-17,,,https://ClinicalTrials.gov/show/NCT03284918
NCT03267329,Duowell® vs. Telmisartan Monotherapy in Mild Dyslipidemia Patients With Hypertension,,Recruiting,No Results Available,Hypertension|Dyslipidemia,Drug: Duowell®|Drug: Telmisartan,Changes from baseline in mean central systolic blood pressure|Changes from baseline in mean brachial systolic blood pressure|Changes from baseline in mean brachial pulse pressure|Changes from mean brachial diastolic blood pressure|Changes from baseline in augmentation index|Changes from baseline in carotid femoral pulse wave velocity,Yuhan Corporation,All,"40 Years to 75 Years   (Adult, Older Adult)",Phase 4,158,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,YMC023,11-Sep-17,Dec-19,Dec-19,30-Aug-17,null,12-Apr-19,"Seoul National University Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03267329
NCT03251690,Switching TDF/FTC/EFV to TDF/FTC/RPV VS Continuing TDF/FTC/EFV in HIV Patients With Complete Virological Suppression,STEREOS,Completed,No Results Available,Anti-Retroviral Agents|Efavirenz|HIV-1-infection|Sustained Virologic Response|Dyslipidemias|Rilpivirine,Drug: Tenofovir/Emtricitabine/Rilpivirine|Drug: Tenofovir/Emtricitabine/Efavirenz,Sustained virological response|Lipid adverse outcome|Neurological adverse outcome|Cost -saving after switching regimens,Mahidol University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,246,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ID09-59-06,27-Oct-16,30-Apr-18,30-Apr-18,16-Aug-17,null,7-May-19,,,https://ClinicalTrials.gov/show/NCT03251690
NCT03247140,The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Male Volunteers Volunteers,,Completed,No Results Available,Hypertension With Dyslipidemia,"Drug: JLP-1401|Drug: Telmisartan/Amlodipine, Rosuvastatin",AUC|Cmax,"Jeil Pharmaceutical Co., Ltd.",Male,"19 Years and older   (Adult, Older Adult)",Phase 1,40,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,JLP-1401-101-PK,10-Jun-17,7-Aug-17,27-Nov-17,11-Aug-17,null,26-Dec-17,"Chonbuk National University Hospital, Jeonju, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03247140
NCT03241121,Study of Eating Patterns With a Smartphone App and the Effects of Time Restricted Feeding in the Metabolic Syndrome,,Recruiting,No Results Available,Eating Behavior|Metabolic Syndrome|Obesity|Dyslipidemias|Glucose Intolerance|Steatosis of Liver,Behavioral: Time restricted feeding|Behavioral: Regular dietary advices|Device: Eating patterns,Eating duration|Change of metabolic syndrome components|Adherence to TRF intervention|Weight change|Change in lipid profile|Change in glucose metabolism|Change in blood pressure|Change in hepatic steatosis / fibrosis score|Change in number of meals per day|Change in meal intervals|Change in fraction of calories consumed after noon|Change in fraction of calories consumed after 6pm|Change in eating pattern difference between weekdays and weekends,University of Lausanne Hospitals|Salk Institute for Biological Studies,All,"12 Years and older   (Child, Adult, Older Adult)",Not Applicable,500,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2017-00487|PZ00P3-167826,29-Sep-17,Dec-19,Dec-19,7-Aug-17,null,26-Oct-17,"University Hospital of Lausanne (CHUV), Lausanne, Switzerland",,https://ClinicalTrials.gov/show/NCT03241121
NCT03235362,A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between YHR1705 and YHR1706,,Completed,No Results Available,Dyslipidemia|Type 2 Diabetes Mellitus,Drug: YHR1705|Drug: YHR1706|Drug: YHR1705+YHR1706,"YHR1705, YHR1706 AUCtau|YHR1705, YHR1706 Css, max",Yuhan Corporation,Male,19 Years to 55 Years   (Adult),Phase 1,28,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,YH14755-103,7-Aug-17,19-Sep-17,19-Sep-17,1-Aug-17,null,1-Nov-17,"Chonbuk National University Hospital, Jeonju, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03235362
NCT03234127,Study of cardiovAscular Contrasted Phenotypes in Patients With FamIliaI hypercholesteRolemia,SAFIR,Recruiting,No Results Available,Homozygous Familial Hypercholesterolemia,Genetic: Whole Genome Sequencing,"Identification of genes associated with the resistance to development of coronary atherosclerosis in subjects with heterozygous familial hypercholesterolemia|Identification of new biochemical, lipidemic, metabolomic and metagenomic biomarkers associated with cardiovascular protection in FH patients.|Association of arterial stiffness (reflected by the pulse wave velocity) with the development of coronary atherosclerosis in FH patients|Association of atherosclerosis of supra-aortic trunks (AST) with the development of coronary atherosclerosis in FH patients|Association of atherosclerosis of the lower limbs with the development of coronary atherosclerosis (PAD) in FH patients|Association between aortic valvular score and development of coronary atherosclerosis in FH patients|Association between coronary calcium score and aortic valvular score in HF patients",Nantes University Hospital,All,"40 Years and older   (Adult, Older Adult)",Not Applicable,800,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,RC17_0244,6-Dec-17,Jun-19,Jun-19,31-Jul-17,null,21-Mar-19,"Le Bocage Hospital, Dijon, France|Louis Pradel Cardiovascular Hospital, Lyon, France|La Conception Hospital, Marseille, France|Nantes University Hospital, Nantes, France|Saint-Antoine Hospital, Paris, France|Pitié-Salpêtrière Hospital, Paris, France|Rennes University Hospital, Rennes, France|Toulouse Hospital, Toulouse, France",,https://ClinicalTrials.gov/show/NCT03234127
NCT03221816,"Effect of Polyvitaminics (Pyridoxine Hydrochloride, Folic Acid and Cyanocobalamin) in the Concentration of Homocysteine and Lipid Profile in Postmenopausal Women: a Randomized Controlled, Double-blind Clinical Trial",,Completed,No Results Available,Menopause|Dyslipidemias|Homocystinaemia,Drug: Tenavit®|Drug: Placebo Oral Tablet,"supplementation may be beneficial in postmenopausal patients, with the intention to reduce the level of homocysteine",Casa de Saúde santa Marcelina,Female,"40 Years to 79 Years   (Adult, Older Adult)",Phase 4,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",U1111-1176-6998,Dec-08,Jan-10,May-10,19-Jul-17,null,21-Jul-17,,,https://ClinicalTrials.gov/show/NCT03221816
NCT03217409,A Study to Compare Rosuvastatin/Ezetimibe and Rosuvastatin in Patients With Diabetes Mellitus and Hypercholesterolemia,,Recruiting,No Results Available,Diabetes Mellitus and Hypercholesterolemia,Drug: Rosuvastatin+Ezetimibe|Drug: Rosuvastatin,"Low density lipoprotein cholesterol (LDL-C) (%)|Low density lipoprotein cholesterol (LDL-C) (100mg/dL)|HbA1C, Glycated albumin, Homeostasis model assessment Insulin resistance(HOMA-IR), Homeostasis model assessment ß cell(HOMA-ß) resistance(HOMA-IR), Homeostasis model assessment ß cell(HOMA-ß)|LDL-C, Non HDL-C, HDL-C, Triglyceride(TG), Total cholesterol(TC), Apolipoprotein A1, Apolipoprotein B, Lipid ratios (LDL-C/HDL-C, TC/HDL-C, Non- HDL-C/HDL-C) Apolipoprotein A1, Apolipoprotein B, Lipid ratios (LDL-C/HDL-C, TC/HDL-C, Non- HDL-C/HDL-C)|Thiobarbituric acid reactive substances(TBARs)|Fibroblast Growth Factor 21",Yuhan Corporation|Linical Korea,All,"19 Years to 75 Years   (Adult, Older Adult)",Phase 4,88,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,YMC022,10-Aug-17,Aug-19,Aug-19,14-Jul-17,null,12-Apr-19,"Soon Chun Hyang University Hospital Cheonan, Cheonan, Korea, Republic of|Soon Chun Hyang University Hospital Gumi, Gumi, Korea, Republic of|Soon Chun Hyang University Hospital Bucheon, Gyeonggi-do, Korea, Republic of|Soon Chun Hyang University Hospital Seoul, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03217409
NCT03216057,Safety and Efficacy of Omega-3 Free Fatty Acids in Adolescents With Obesity and Hypertriglyceridemia.,,Completed,No Results Available,Hypertriglyceridemia|Pediatric Obesity,Dietary Supplement: Omega-3 fatty acid 3 grams per day|Dietary Supplement: Placebo,Percent Change from baseline in Triglyceride|Fasting Triglycerides|Percent Change from baseline in cholesterol|Fasting Cholesterol|Percent Change from baseline in HDL-C|Fasting HDL-C|Percent Change from baseline in glucose|Fasting glucose|Percent Change from baseline in Uric Acid|Fasting Uric Acid,Hospital Infantil de Mexico Federico Gomez|Leija Martinez José de Jesús|Miranda Lora América Liliana|Hall Mondragon Margareth Sharon|Fengyang Huang,All,10 Years to 16 Years   (Child),Not Applicable,168,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",HIM/2008/006,20-May-08,22-Nov-16,22-Nov-16,13-Jul-17,null,13-Jul-17,,,https://ClinicalTrials.gov/show/NCT03216057
NCT03216811,Nutraceutical in Cardiovascular Primary Prevention,NIRVANA,Completed,No Results Available,Hypercholesterolemia,Drug: nutraceutical,LDL|triglycerides|total cholesterol|oxidized LDL|HDL|rate of apoptosis|radical oxygen species (ROS)|nitric oxide (NO),University Hospital of Ferrara,All,"40 Years to 65 Years   (Adult, Older Adult)",Phase 2,52,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,170598,20-Jul-17,31-Oct-17,2-Dec-17,13-Jul-17,null,5-Dec-17,"University Hospital of Ferrara, Cona, Ferrara, Italy",,https://ClinicalTrials.gov/show/NCT03216811
NCT03213288,Bilberry Fruit and Black Rice Derived Anthocyanins on Lipid Status,,"Active, not recruiting",No Results Available,Hyperlipidemia,Dietary Supplement: Delphinidin type anthocyanins|Dietary Supplement: Cyanidin type anthocyanins|Dietary Supplement: Placebo,"LDL cholesterol|Total/HDL cholesterol and triglycerides|Cholesterol efflux capacity|PON-1 activity|Bile acids and derivatives|Glucose, fructosamine and insulin|MicroRNA expression",Quadram Institute Bioscience,All,"45 Years and older   (Adult, Older Adult)",Not Applicable,55,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",IFR01/2017,25-Sep-17,Dec-19,Dec-19,11-Jul-17,null,27-Sep-18,"Quadram Institute Bioscience, Norwich, United Kingdom",,https://ClinicalTrials.gov/show/NCT03213288
NCT03210532,Evaluate the Efficacy and Safety of Combination Treatment With DW1501-R1+DW1501-R2 Versus DW1501-R1 or DW1501-R2+DW1501-R3 in Patients With Hypertension and Dyslipidemia,,Completed,No Results Available,Hypertension|Dyslipidemia,Drug: Telmisartan + Amlodipine + Rosuvastatin|Drug: Telmisartan + Amlodipine|Drug: Telmisartan + Rosuvastatin,Change of MSSBP(Mean Sit Systolic Blood Pressure) from baseline|Change of LDL-C(Low Density Lipid Cholesterol) from baseline,"Daewon Pharmaceutical Co., Ltd.",All,"19 Years to 79 Years   (Adult, Older Adult)",Phase 3,129,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",DW1501-301,7-Oct-16,Sep-17,Sep-17,7-Jul-17,null,1-Feb-18,"Sevrance Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03210532
NCT03210649,Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519,,Completed,No Results Available,Dyslipidemia,Drug: CKD-519|Drug: Placebo,Maximum Plasma Concentration [Cmax] of CKD-519|Pharmacodynamics(Lipid Parameter) of CKD-519|Pharmacodynamics(CETP) of CKD-519|Pharmacodynamics(QC/QTc) of CKD-519,Chong Kun Dang Pharmaceutical,All,19 Years to 55 Years   (Adult),Phase 1,18,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",148MAD16018,7-Mar-17,24-Apr-17,24-Apr-17,7-Jul-17,null,7-Jul-17,"Severance Hospital, Seoul, Seodaemun-gu, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03210649
NCT03206164,HealthMatters@24/7 eLearning for People Supporting Adults With Intellectual and Developmental Disabilities,HM@24/7,"Active, not recruiting",No Results Available,Obesity|Hypertension|Hypercholesterolemia|Hyperglycemia,"Other: Asynchronous, eLearning Intervention",online organizational HealthMatters Assessments (oHMA)|Process Evaluation|36-item Corporate eLearning Survey,University of Illinois at Chicago,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,2014-0659,1-Jun-17,30-Jun-18,30-Jun-18,2-Jul-17,null,2-Jul-17,"UIC, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT03206164
NCT03203915,Metabolic Response to Chardonnay Grape Pomace Powder,,"Active, not recruiting",No Results Available,Dyslipidemia|Obesity,Dietary Supplement: Chardonnay grape pomace powder high polyphenol dose (120mg)|Dietary Supplement: Chardonnay grape pomace powder low polyphenol dose (75mg)|Dietary Supplement: Placebo (0mg),Change in lipid profile|Changes in fecal microbiome profile|Changes in gut fermentation profile|Changes in inflammatory markers|Changes in endothelial function measurement|Changes in metabolomic profile|Changes in cognitive function,"USDA, Western Human Nutrition Research Center|Sonomaceuticals LLC",All,"35 Years to 65 Years   (Adult, Older Adult)",Not Applicable,31,U.S. Fed|Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",81946-4,1-Aug-17,Aug-19,Aug-19,29-Jun-17,null,1-Mar-19,"Western Human Nutrition Research Center, Davis, California, United States",,https://ClinicalTrials.gov/show/NCT03203915
NCT03193047,Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy,,Completed,No Results Available,Hypercholesterolemia,Drug: bempedoic acid 180mg|Other: placebo|Drug: evolocumab,"Percent change of low-density lipoprotein cholesterol (LDL-C)|Percent change of apolipoprotein B (ApoB), non-high-density lipoprotein cholesterol (non-HDL-C), total cholesterol (TC), and high-sensitivity C-reactive protein (hs-CRP)|Number of adverse events (AE) and serious adverse events (SAE)",Esperion Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 2,58,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",1002-039,7-Apr-17,29-Jan-18,19-Feb-18,20-Jun-17,null,29-Mar-19,"L-MARC Research Center, Louisville, Kentucky, United States",,https://ClinicalTrials.gov/show/NCT03193047
NCT03175835,Study to Evaluate the Drug Interaction Between CKD-519 and Rosuvastatin in Healthy Male Subjects,,Completed,No Results Available,Dyslipidemias,Drug: Rosuvastatin 20 mg|Drug: CKD-519 200 mg|Drug: Rosuvastatin 20 mg & CKD-519 200 mg,"Pharmacokinetics (Area under the plasma concentration versus time curve (AUCτ))|Pharmacokinetics (Peak plasma Concentration (Cmax,ss))|Pharmacokinetics (Minimum plasma Concentration (Cmin,ss))|Pharmacokinetics (Time to maximum plasma concentration (Tmax,ss))|Pharmacokinetics (t1/2)|Pharmacodynamics (CETP activity)|Pharmacodynamics (CETP Concentration)|Pharmacodynamics (Lipid profiles)",Chong Kun Dang Pharmaceutical,Male,20 Years to 45 Years   (Adult),Phase 1,30,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,148DDI16023,8-May-17,19-Jun-17,19-Jun-17,5-Jun-17,null,7-Jul-17,"Korea University Anam Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03175835
NCT03172611,"A Defined, Plant-based, 4-week Dietary Intervention Reduces Lp(a) and Other Atherogenic Particles",,Completed,No Results Available,Hypercholesterolemia,Other: Dietary Intervention,Change in serum lipoprotein(a)|Change in serum total cholesterol|Change in serum low-density lipoprotein cholesterol|Change in serum high-density lipoprotein cholesterol|Change in serum apolipoprotein-B|Change in serum low-density lipoprotein particles|Change in serum small-dense low-density lipoprotein cholesterol|Change in serum high-density lipoprotein 2 cholesterol|Change in serum apolipoprotein A-1,Texas Woman's University|Montgomery Heart & Wellness,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,33,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,192790,3-Jan-17,8-Mar-17,15-Mar-17,1-Jun-17,null,1-Jun-17,"Montgomery Heart & Wellness, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03172611
NCT03173495,Effects of Exercise on Fructose-induced Postprandial Lipemia,,Completed,No Results Available,Sedentary Lifestyle|Dyslipidemias|Lipid Metabolism Disorders|Carbohydrate Inducible Hyperlipemia,Dietary Supplement: FRUCTOSE|Dietary Supplement: DEXTROSE|Dietary Supplement: EXERCISE,Triglycerides|VLDL|Glycemia|Insulin|HDL|Non-HDL cholesterol,Federal University of Rio Grande do Sul,Male,20 Years to 40 Years   (Adult),Not Applicable,12,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention",48763715.3.0000.5347,10-Jan-16,15-Dec-16,15-Dec-16,1-Jun-17,null,1-Jun-17,,,https://ClinicalTrials.gov/show/NCT03173495
NCT03170752,Implementing and Testing a Cardiovascular Assessment Screening Program (CASP),CASP,Completed,No Results Available,"Cardiovascular Risk Factor|Smoking|Diabetes Mellitus|Dyslipidemias|Hypertension|Physical Activity|Stress, Psychological",Behavioral: Cardiovascular Assessment Screening Program (CASP),Proportion of patients who are comprehensively screened to the number of eligible patients seen in the intervention group compared to the control group as assessed by the completeness of CV Screening Checklist data collection form.|Identification of individuals at high risk for cardiovascular disease as assessed by the calculated Framingham Risk Score.|The management recommendations that are made by the NPs as assessed by the responses collected on the CV Screening Checklist data collection form (intervention group) and the chart review (control group).|The patient and NP factors that influence participation in the CASP as assessed by content analysis of patient and NP feedback questionnaires.,Memorial University of Newfoundland,All,"20 Years to 74 Years   (Adult, Older Adult)",Not Applicable,169,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,20180318,28-Sep-17,29-Sep-18,14-Nov-18,31-May-17,null,13-Mar-19,"Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada",,https://ClinicalTrials.gov/show/NCT03170752
NCT03167996,Chronic Cardiovascular Risk Outpatient Management in South Asians Using Digital Health Technology,HealthPals,Completed,No Results Available,Cardiovascular Risk Factor|Insulin Resistance|PreDiabetes|Diabetes|Coronary Artery Disease|Hypertension|Prehypertension|Dyslipidemias,Behavioral: Use of HealthPals (Telemedicine supported by digital health platform),Change in exercise activity over 6 months|Measuring medication compliance|Measuring trends in Blood Pressure measurements|Measuring trends in weight measurements|Measuring compliance to dietary recommendations|Initial User Assessment,"Stanford University|HealthPals, Inc",All,18 Years to 60 Years   (Adult),Not Applicable,38,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,36464,23-Jun-16,1-Mar-18,23-Mar-18,30-May-17,null,15-Feb-19,"Stanford University, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT03167996
NCT03161327,Digital Ankle Brachial Index (ABI) as a Screening Tool in Detecting Peripheral Arterial Disease,,Completed,Has Results,Peripheral Artery Disease|Amputation|Smoking|Diabetes|Hypercholesterolemia|Hypertension,Device: ABI using QuantaFlo™,Positive Predictive Value of Digital ABI in Diagnosing PAD,St. Louis University,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,238,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,28225,15-Jul-17,14-Sep-17,14-Sep-17,19-May-17,11-Dec-18,11-Dec-18,"Saint Louis University, Saint Louis, Missouri, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT03161327/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03161327
NCT03156621,Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH),ODYSSEY HoFH,Recruiting,No Results Available,Homozygous Familial Hypercholesterolemia,Drug: Alirocumab|Drug: Placebo,"Percent change in LDL-C from baseline to Week 12 (Intent-to-Treat (ITT) population)|Percent change in apolipoprotein (Apo) B from baseline to week 12|Percent change in non-high-density lipoprotein cholesterol (non-HDL-C) from baseline to week 12|Percent change in total cholesterol (TC) from baseline to week 12|Proportion of participants with ≥15% reduction in LDL-C at week 12|Proportion of participants with ≥30% reduction in LDL-C at week 12|Percent change in lipoprotein(a) [Lp(a)] from baseline to week 12|Proportion of participants with ≥50% reduction in LDL-C at week 12|Percent change in HDL-C from baseline to week 12|Percent change in fasting triglycerides (TG) from baseline to week 12|Percent change in Apo A-1 from baseline to week 12|Percent change in LDL-C from baseline to week 12|Percent change in LDL-C from baseline to week 12 (Modified Intent-to-Treat (m)ITT population)|Percent change in Apo B from baseline to week 12|Percent change in non-HDL-C from baseline to week 12|Percent change in TC from baseline to week 12|Percent change in Lp(a) from baseline to week 12|Percent change in fasting TG from baseline to week 12|Proportion of patients with ≥15% reduction, ≥30% reduction, and ≥50% reduction in LDL-C at week 12|Absolute change in the ratio of Apo B/Apo A-1 from baseline to week 12|Incidence of Adverse Events (AEs)",Regeneron Pharmaceuticals|Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,54,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R727-CL-1628|2017-000351-95,10-Oct-17,10-Jan-19,17-Jun-19,17-May-17,null,7-Sep-18,"Regeneron Research Site, Boca Raton, Florida, United States|Regeneron Research Site, New York, New York, United States|Regeneron Research Site, Cincinnati, Ohio, United States|Regeneron Research Site, Portland, Oregon, United States|Regeneron Research Site, Innsbruck, Tirol, Austria|Regeneron Research Site, Chicoutimi, Quebec, Canada|Regeneron Research Site, Québec, Quebec, Canada|Regeneron Research Site, Praha, Czechia|Regeneron Research Site, Marseille, France|Regeneron Research Site, Paris, France|Regeneron Research Site, Berlin, Germany|Regeneron Research Site, Athens, Greece|Regeneron Research Site, Ioánnina, Greece|Regeneron Research Site, Caserta, Italy|Regeneron Research Site, Napoli, Italy|Regeneron Research Site, Roma, Italy|Regeneron Research Site, Kurume, Fukuoka, Japan|Regeneron Research Site, Nishinomiya, Hyogo, Japan|Regeneron Research Site, Kanazawa, Ishikawa, Japan|Regeneron Research Site, Suita, Osaka, Japan|Regeneron Research Site, Parktown, Johannesburg, South Africa|Regeneron Research Site, Cape Town, Western Cape, South Africa|Regeneron Research Site, Besevler, Ankara, Turkey|Regeneron Research Site, Kadıköy, Istanbul, Turkey|Regeneron Research Site, Merkez, Siva, Turkey|Regeneron Research Site, Ankara, Turkey|Regeneron Research Site, Ankara, Turkey|Regeneron Research Site, Fatih, Turkey|Regeneron Research Site, İzmir, Turkey|Regeneron Research Site, Kayseri, Turkey|Regeneron Research Site, Mersin, Turkey|Regeneron Research Site, Ivano-Frankivs'k, Ukraine|Regeneron Research Site, Kharkiv, Ukraine|Regeneron Research Site, Kharkiv, Ukraine|Regeneron Research Site, Kyiv, Ukraine|Regeneron Research Site, Kyiv, Ukraine",,https://ClinicalTrials.gov/show/NCT03156621
NCT03156842,Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia,FIRST,Recruiting,No Results Available,Essential Hypertension|Dyslipidemia,"Drug: Fimasartan/Amlodipine, Rosuvastatin|Drug: Fimasartan/Amlodipine|Drug: Fimasartan, Rosuvastatin",LDL-C|Sitting systolic blood pressure(SiSBP),"Boryung Pharmaceutical Co., Ltd",All,"20 Years to 70 Years   (Adult, Older Adult)",Phase 3,135,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",BR-FARC-CT-301,29-May-17,31-Aug-18,1-May-19,17-May-17,null,25-Jan-18,"Samsung Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03156842
NCT03154216,Milk as a Recovery Beverage After Exercise for Improving Metabolic Health,,Completed,No Results Available,"Hyperlipemia, Carbohydrate Inducible",Behavioral: Exercise|Other: Drink,Change in blood triglycerides|Change in blood glucose|Change in fat oxidation|Change in low density lipoproteins|Change in high density lipoproteins|Change in total cholesterol|Change in insulin level|Change in blood pressure,University of Saskatchewan|Dairy Farmers of Canada,All,18 Years to 44 Years   (Adult),Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science,16-300,20-May-17,1-Dec-18,1-Jan-19,16-May-17,null,7-May-19,"College of Kinesiology, University of Saskatchewan, Saskatoon, Saskatchewan (SK), Canada",,https://ClinicalTrials.gov/show/NCT03154216
NCT03141827,The Effect of Intranasal Insulin on Hepatic and Intestinal Triglyceride-rich Lipoprotein Production,LPNI,Completed,No Results Available,Hyperlipidemia,Drug: Insulin|Drug: Placebo,Triglyceride-rich lipoprotein apolipoprotein B100 production rate|Triglyceride-rich lipoprotein apolipoprotein B48 production rate,"University Health Network, Toronto",All,18 Years to 60 Years   (Adult),Phase 2|Phase 3,9,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,LPNI-REB-15-9475,14-Apr-16,15-Feb-17,26-Apr-17,5-May-17,null,8-May-17,"Tornto General Hospital, UHN, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT03141827
NCT03133975,Vitamin D Supplementation for Treatment of Dyslipidemia,,Recruiting,No Results Available,Dyslipidemias,Drug: Vitamin D3 (Treatment)|Other: Mixed diet of carbohydrate and protein (Control),serum levels of LDL-HDL-Total cholesterol-triglecerides,Mansoura University,Female,35 Years to 45 Years   (Adult),Phase 3,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",R/17.03.86,1-Apr-17,31-Dec-18,1-Jul-19,28-Apr-17,null,21-Aug-18,"Faculty of Medicine, Mansourah, Egypt",,https://ClinicalTrials.gov/show/NCT03133975
NCT03134235,"Effects of a 4-week Raw, Plant-based Diet on Anthropometric and Cardiovascular Risk Factors",,Completed,No Results Available,Hypertension|Elevated Cholesterol|Overweight and Obesity,Other: Dietary Intervention,Change in body weight|Change in serum low-density lipoprotein cholesterol (LDL)|Change in blood pressure|Change in heart rate|Change in waist circumference|Change in serum total cholesterol|Change in serum high-density lipoprotein cholesterol|Change in serum triglycerides|Change in serum insulin|Change in serum glucose|Change in serum hemoglobin A1c (HgA1c)|Change in c-reactive protein (CRP)|Change in medication use,Texas Woman's University|Montgomery Heart & Wellness,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,33,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,19279,3-Jan-17,8-Mar-17,15-Mar-17,28-Apr-17,null,23-May-17,"Montgomery Heart & Wellness, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03134235
NCT03120299,The Effect of Omega-3 FA on Hypertriglyceridemia in Patients With T2DM(OCEAN),,Unknown status,No Results Available,Type 2 Diabetes Mellitus|Hypertriglyceridemia,Drug: Omega-3 fatty acid|Drug: Placebos,Change in serum triglycerides from baseline|Change in blood metabolomics profile of lipid species from baseline|Change in serum metabolomics profile of bile acids from baseline|Change in serum metabolomics profile of amino acid species from baseline|Change in serum Gut microbiome from baseline|Change in fasting glucose levels from baseline|Change in 2-hour postprandial glucose levels from baseline|Change in HbA1c from baseline|Change in Non-HDL-C from baseline|Change in serum total Cholesterol from baseline|Change in serum VLDL-c from baseline|Change in serum HDL-c from baseline|Change in serum LDL-c from baseline|Change in LDL-C/HDL-C from baseline|Change in serum Apo B from baseline|Change in serum AST from baseline|Change in serum ALT from baseline|Change in serum inflammation markers from baseline|Change in liver fat content from baseline|Change in Ankle-Brachial Index from baseline|Change in Brachial-ankle pulse wave velocity from baseline|Change in enrichment of fish oil in red blood cell from baseline|Pharmacogenomics analysis,Shanghai Jiao Tong University School of Medicine,All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 4,350,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CCMED-20160601,1-May-17,Jun-18,Dec-18,19-Apr-17,null,1-May-17,"Ruijin hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT03120299
NCT03116516,Clinical Trial to Compare the Safety and Pharmacokinetics of YHP1604 in Comparison to the Co-administration of Telmisartan/Amlodipine and Rosuvastatin,,Completed,No Results Available,Hypertension|Hyperlipidemia,Drug: Temisartan/Amlodipine+Rosuvastatin|Drug: YHP1604,"Telmisartan/Amlodipine/Rosuvastatin Cmax, AUClast",Yuhan Corporation,Male,19 Years to 55 Years   (Adult),Phase 1,62,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,YHP1604-102,21-Apr-17,26-May-17,26-May-17,17-Apr-17,null,16-Jan-19,"Chonbuk National University Hospital, Jeonju, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03116516
NCT03109834,Effect of Weight Management Programs on Cardiometabolic Risk Profile in Overweight Women,FM-01,Completed,No Results Available,Overweight and Obesity|Dyslipoproteinemia,Dietary Supplement: Meal replacement (MR)|Other: Control (C)|Dietary Supplement: Verum|Other: Placebo,Weight loss (phase 1)|Total antioxidant capacity (phase 3)|Fasting plasma cortisol concentration (phase 3)|Relative body fat (phase 1)|Relative body weight (phase 1)|Responder (weight loss > 5%) (phase 1)|Waist circumference (phase 1)|Total antioxidant capacity (phase 1)|Fasting plasma cortisol concentration (phase 1)|Relative body fat (phase 3)|Relative body weight (phase 3)|Responder (weight loss > 5%)|Waist circumference (phase 3),"Bonn Education Association for Dietetics r.A., Cologne, Germany|FomMed HealthCare AG",Female,18 Years to 60 Years   (Adult),Phase 3,105,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BFD-01/FM-01,25-Mar-04,28-Mar-07,28-Mar-07,12-Apr-17,null,12-Apr-17,,,https://ClinicalTrials.gov/show/NCT03109834
NCT03104543,Communicating Health Information and Improving Coordination With Primary Care,CHIIP,Enrolling by invitation,No Results Available,Hypertension|Dyslipidemias|Diabetes|Childhood Cancer,Behavioral: Education|Behavioral: Test results only,"Undertreatment of hypertension (>=140/90 mmHg), dyslipidemia (LDL >=160 mg/dL or triglyceride >=150 mg/dL), and/or diabetes (hemoglobin A1c >=7%)|Health knowledge|Self-efficacy|Medication adherence|Primary care provider attitudes",Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)|St. Jude Children's Research Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,650,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,8543|R01CA204378,1-Mar-17,1-Mar-22,1-Mar-22,7-Apr-17,null,4-Apr-19,"Fred Hutchinson Cancer Research Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT03104543
NCT03103256,Clinical Trial to Evaluate the Efficacy and Safety of YHP1701,,Completed,No Results Available,Hypertension and Hyperlipidemia,Drug: YHP1701|Drug: YHR1703|Drug: YHR1704,Percent change of LDL-Cholesterol|Change of mean seated Systolic Blood Pressure,Yuhan Corporation,All,"19 Years and older   (Adult, Older Adult)",Phase 3,106,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",YHP1701-301,17-May-17,30-Apr-18,30-Apr-18,6-Apr-17,null,7-Sep-18,"Seoul Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03103256
NCT03097107,Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL,,Suspended,No Results Available,Dyslipidemias,Drug: Saroglitazar Magnesium 1 mg|Drug: Saroglitazar Magnesium 2 mg|Drug: Saroglitazar Magnesium 4 mg|Drug: Placebo,Percentage change in triglyceride cholesterol levels|Percentage change in TG-C|Percentage change in lipid profile.,Zydus Discovery DMCC,All,"18 Years and older   (Adult, Older Adult)",Phase 2,124,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SARO.15.001.05,6-Apr-17,18-Jan-18,31-Dec-19,31-Mar-17,null,4-Feb-19,"Medical Affiliated Research Center, Inc., Huntsville, Alabama, United States|Encompass Clinical Research, Encinitas, California, United States|Integrated Research Center, San Diego, California, United States|Ventura Clinical Trials, Ventura, California, United States|Colorado Springs Health Partners, Colorado Springs, Colorado, United States|Meridien Research - Bradenton, Bradenton, Florida, United States|Meridien Research - Lakeland, Lakeland, Florida, United States|Oviedo Medical Research, LLC, Oviedo, Florida, United States|Meridien Research - Tampa, Tampa, Florida, United States|River Birch Research Alliance LLC, Blue Ridge, Georgia, United States|Drug Studies America, Marietta, Georgia, United States|Herman Clinical Research, LLC, Suwanee, Georgia, United States|Cedar-Crosse Research Center, Chicago, Illinois, United States|Heartland Research Associates, LLC, Newton, Kansas, United States|Heartland Research Associates, LLC, Wichita, Kansas, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Centennial Medical Group, Elkridge, Maryland, United States|MD Medical Research, Oxon Hill, Maryland, United States|Mercury Street Medical, Butte, Montana, United States|Einstein Clinical Research, Charlotte, North Carolina, United States|Triad Clinical Trials LLC, Greensboro, North Carolina, United States|PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States|Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio, United States|Sterling Research Group, Ltd., Cincinnati, Ohio, United States|Wells Institute for Health Awareness, Kettering, Ohio, United States|Ohio Clinical Research - Lyndhurst, Lyndhurst, Ohio, United States|Awasty Research Network, LLC, Marion, Ohio, United States|Ohio Clinical Research, LLC - Willoughby Hills, Willoughby Hills, Ohio, United States|Columbia Research Group, Inc., Portland, Oregon, United States|PMG Research of Bristol, LLC, Bristol, Tennessee, United States|Jackson Clinic, Jackson, Tennessee, United States|Pioneer Research Solutions Inc., Houston, Texas, United States|National Clinical Research - Richmond, Inc, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT03097107
NCT03088254,Study to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Rosuvastatin,,Completed,No Results Available,Dyslipidemia With Hypertension,"Drug: Group I (Telmisartan 80 mg, Amlodipine 10 mg, Rosuvastatin 20 mg)|Drug: Group II (Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin placebo)|Drug: Group III (Telmisartan 80 mg, Amlodipine placebo, Rosuvastatin 20 mg)",change of LDL-C|change of msSBP,"Jeil Pharmaceutical Co., Ltd.",All,"19 Years and older   (Adult, Older Adult)",Phase 3,126,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",J-TAROS-RCT,20-Sep-16,31-Jul-17,4-Dec-17,23-Mar-17,null,6-Jul-18,"Chungnam National University Hospital, Daejeon, Korea, Republic of|Chonnam National University Hospital, Gwangju, Korea, Republic of|Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Inje University Haeundae Paik Hospital, Pusan, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of|Kangbuk Samsung Hospital, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|KyungHee University Hospital at Gangdong, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|SoonChunHyang University Hospital, Seoul, Seoul, Korea, Republic of|The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03088254
NCT03084822,Cardiovascular Health Promotion Among African-Americans by FAITH!,FAITH!,Completed,No Results Available,Cardiovascular Diseases|Prevention|Physical Activity|Diet Modification|Diabetes|Hypertension|High Cholesterol|Pre Diabetes|Smoking Cessation|Obesity,Behavioral: FAITH! App digital intervention,Diet (fruit/vegetable intake using adaptation of NIH Eating at America's Table Quick Food Scan Screener)|Physical activity (using the International Physical Activity Questionnaire (IPAQ))|Diet self-efficacy (using Self-Efficacy and Eating Habits Survey)|Physical activity self-efficacy (using Self-Efficacy and Exercise Habits Survey)|Intervention feasibility|BMI|Blood Pressure|Fasting Cholesterol|Fasting glucose|Smoking (using adaptation of Global Adult Tobacco Survey)|Life's Simple 7 Composite Score|Cardiovascular health knowledge,Mayo Clinic|Mayo Clinic Clinic Center for Innovation|Mayo Clinic Center for Clinical and Translational Science (CCaTS),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,16-000353,Mar-16,Jun-17,Jun-18,21-Mar-17,null,24-Jul-18,,,https://ClinicalTrials.gov/show/NCT03084822
NCT03080935,Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries,,"Active, not recruiting",No Results Available,Dyslipidemia,Drug: Evolocumab,Adverse event measurement|Percent change of LDL-C|Achievement of an LDL-C < 40 mg/dL,Amgen,All,"40 Years to 85 Years   (Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20160250|2016-004066-26,13-Mar-17,4-Dec-22,4-Dec-22,15-Mar-17,null,2-May-19,"Research Site, Aalst, Belgium|Research Site, Antwerpen, Belgium|Research Site, Antwerpen, Belgium|Research Site, Bonheiden, Belgium|Research Site, Brussels, Belgium|Research Site, Brussels, Belgium|Research Site, Bruxelles, Belgium|Research Site, Gent, Belgium|Research Site, Gozee, Belgium|Research Site, La Louvière, Belgium|Research Site, Liege, Belgium|Research Site, Liège, Belgium|Research Site, Turnhout, Belgium|Research Site, Aalborg, Denmark|Research Site, Aarhus N, Denmark|Research Site, Ballerup, Denmark|Research Site, Esbjerg, Denmark|Research Site, Glostrup, Denmark|Research Site, Hvidovre, Denmark|Research Site, Kobenhavn S, Denmark|Research Site, Kobenhavn, Denmark|Research Site, Koge, Denmark|Research Site, Odense C, Denmark|Research Site, Roskilde, Denmark|Research Site, Svendborg, Denmark|Research Site, Vejle, Denmark|Research Site, Viborg, Denmark|Research Site, Besancon cedex, France|Research Site, Chambray les Tours, France|Research Site, Le Coudray, France|Research Site, Montpellier cedex 05, France|Research Site, Nantes Cedex 1, France|Research Site, Nantes Cedex 2, France|Research Site, Nice, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Pau, France|Research Site, Reims cedex, France|Research Site, Toulouse Cedex 9, France|Research Site, Vesoul, France|Research Site, Bad Krozingen, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Dortmund, Germany|Research Site, Dresden, Germany|Research Site, Kassel, Germany|Research Site, Köln, Germany|Research Site, Magdeburg, Germany|Research Site, Mainz, Germany|Research Site, München, Germany|Research Site, München, Germany|Research Site, Stuttgart, Germany|Research Site, Ulm, Germany|Research Site, Witten, Germany|Research Site, Wuppertal, Germany|Research Site, Bergamo, Italy|Research Site, Firenze, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Palermo, Italy|Research Site, Pavia, Italy|Research Site, Perugia, Italy|Research Site, Pisa, Italy|Research Site, Siena, Italy|Research Site, Almada, Portugal|Research Site, Coimbra, Portugal|Research Site, Covilha, Portugal|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Setubal, Portugal|Research Site, Falun, Sweden|Research Site, Helsingborg, Sweden|Research Site, Jönköping, Sweden|Research Site, Lulea, Sweden|Research Site, Lund, Sweden|Research Site, Lund, Sweden|Research Site, Orebro, Sweden|Research Site, Ostersund, Sweden|Research Site, Stockholm, Sweden|Research Site, Umea, Sweden",,https://ClinicalTrials.gov/show/NCT03080935
NCT03079648,Efficacy and Safety of Angelica Gigas N. Extract on Improvement of Blood Triglyceride,,Unknown status,No Results Available,Hyperlipidemias,Dietary Supplement: Angelica gigas N. extract|Dietary Supplement: Placebo,Changes of Triglyceride|Changes of Lipid profile|Changes of Arteriosclerosis index,Chonbuk National University Hospital,All,"19 Years to 80 Years   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",WBP-HL-AG1,14-Feb-17,31-Dec-17,31-Dec-17,14-Mar-17,null,14-Mar-17,"Clinical Trial Center for Functional Foods Chonbuk National University Hospital, Jeonju, Jeollabuk-do, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03079648
NCT03074630,Dapagliflozin and Cholesterol Metabolism in Type 2 Diabetes (DM2),DICE,Completed,No Results Available,"Diabetes Mellitus, Type 2|Hypercholesterolemia",Drug: Dapagliflozin|Drug: Rosuvastatin,Change in LDL synthesis|Cholesterol fluxes|Triglyceride fluxes|Insulin sensitivity|Resting energy expenditure|Liver fat MRI spectrum|Fecal microbiome composition|Bile salt excretion|Urinary glucose excretion|Urinary sodium excretion,VU University Medical Center|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,12,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,METC AMC 2016_016,May-16,Apr-18,Apr-18,9-Mar-17,null,9-May-18,"Academic Medical Center, Amsterdam, North Holland, Netherlands",,https://ClinicalTrials.gov/show/NCT03074630
NCT03071692,Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT),PROMINENT,Recruiting,No Results Available,Type2 Diabetes|Dyslipidemia,Drug: K-877|Drug: Placebo,"Number of patients with first occurrence of nonfatal MI, nonfatal ischemic stroke, hospitalization for unstable angina requiring unplanned coronary revascularization, or CV death.|Time to first occurrence of any component of the 3-component composite endpoint of non-fatal MI, non-fatal stroke, or cardiovascular death|Time to first occurrence of any component of the primary endpoint or hospitalization for Heart failure (HF)|Time to first occurrence of any component of the primary endpoint or all-cause mortality|Time to first occurrence of any component of the primary endpoint, any coronary revascularization, or hospitalization for HF|Time to first occurrence of any new or worsening Peripheral artery disease (PAD)|Lipid Endpoints|Nonfasting Remnant Cholesterol Endpoint","Kowa Research Institute, Inc.|Brigham and Women's Hospital",All,"18 Years and older   (Adult, Older Adult)",Phase 3,10000,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",K-877-302,23-Mar-17,Apr-22,May-22,7-Mar-17,null,21-Feb-19,"Southview Medical Group, Birmingham, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|VA Medical Center - Birmingham, Birmingham, Alabama, United States|Alabama Clinical Therapeutics, LLC, Birmingham, Alabama, United States|Fundamental Research, LLC, Gulf Shores, Alabama, United States|Terence T. Hart, MD, Tuscumbia, Alabama, United States|Summit Medical Group Arizona, LLC, Glendale, Arizona, United States|Arizona Arthritis & Rheumatology Research, PLLC, Peoria, Arizona, United States|Phoenix Veterans Adminstration Health Care System, Phoenix, Arizona, United States|Clinical Research Institute of Arizona, LLC, Surprise, Arizona, United States|Eclipse Clinical Research, Tucson, Arizona, United States|Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, United States|Searcy Medical Center, Searcy, Arkansas, United States|Clinical Research Alliance, Inc, Alhambra, California, United States|Aurora Care Clinic, Costa Mesa, California, United States|AMCR Institute, Inc., Escondido, California, United States|National Institute of Clinical Research, Huntington Beach, California, United States|VA Loma Linda Healthcare System, Loma Linda, California, United States|VA Long Beach Healthcare System, Long Beach, California, United States|Eastside Clinical Research Associates, Los Angeles, California, United States|VA Greater Los Angeles Healthcare System, Los Angeles, California, United States|Richard S. Cherlin, MD, Los Gatos, California, United States|Northridge Clinical Research Inc., Northridge, California, United States|Palo Alto Division, Palo Alto, California, United States|Rancho Cucamonga Clinical Research, Rancho Cucamonga, California, United States|MD Strategies Research Centers, San Diego, California, United States|Alex Harrison, MD Inc., Santa Maria, California, United States|Santa Rosa Cardiology Medical Group, Inc., Santa Rosa, California, United States|Blue Coast Cardiology, Vista, California, United States|Lynn Institute of Denver, Aurora, Colorado, United States|New West Physicians, PC, Golden, Colorado, United States|Southwest Family Medicine, Littleton, Colorado, United States|Chase Medical Research, LLC, Waterbury, Connecticut, United States|VA Connecticut Healthcare Sys, West Haven, Connecticut, United States|Cardiology Physicians, PA, Newark, Delaware, United States|VA Medical Center, Washington, District of Columbia, United States|Bay Pines VA Healthcare System, Bay Pines, Florida, United States|Meridien Research, Bradenton, Florida, United States|Clinical Research Of Brandon, LLC, Brandon, Florida, United States|Clearwater Cardiovascular Consultants, Clearwater, Florida, United States|Daytona Heart Group, Daytona Beach, Florida, United States|Cohen Medical Research Associates, LLC, Delray Beach, Florida, United States|Malcom Randall VA Medical Center, Gainesville, Florida, United States|Indago Research & Health Center, Inc., Hialeah, Florida, United States|Pines Clinical Research, Inc., Hollywood, Florida, United States|Homestead Cardiac & Vein Center, Homestead, Florida, United States|Westside Center for Clinical Research, Jacksonville, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Health Awareness, Inc., Jupiter, Florida, United States|Clearwater Cardiovascular & Interventional Consultants, Largo, Florida, United States|Clinical Research of Miami, Miami, Florida, United States|Finlay Medical Research, Corporation, Miami, Florida, United States|University of Miami, Miami, Florida, United States|Elite Clinical Research, Miami, Florida, United States|Next Phase Research Alliance, Miami, Florida, United States|Oceane7 Clinical Research, LLC, Miami, Florida, United States|Dolphin Medical Research, Miami, Florida, United States|Advanced Medical Research Institute, Miami, Florida, United States|Ocala Research Institute, Inc., Ocala, Florida, United States|Endocrine Associates of Florida, Ocoee, Florida, United States|Andres Patron, D.O., P.A, Pembroke Pines, Florida, United States|DBC Research, Corp, Pembroke Pines, Florida, United States|Langhorne Cardiology Consultants, Inc., Pensacola, Florida, United States|Clinical Research of Central Florida, Plant City, Florida, United States|Professional Health Care of Pinellas, Saint Petersburg, Florida, United States|Tallahassee Research Institute, Inc., Tallahassee, Florida, United States|James A. Haley VA Medical Center, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Atlanta Heart Specialists, LLC, Cumming, Georgia, United States|VA Medical Center - Atlanta, Decatur, Georgia, United States|Alta Pharmaceutical Research Center, Inc., Dunwoody, Georgia, United States|Atlanta Center for Clinical Research/Internal Med, Roswell, Georgia, United States|Apex Medical Research, AMR, Inc., Chicago, Illinois, United States|Healthcare Research Network III, LLC, Flossmoor, Illinois, United States|Clinical Investigation Specialists, Inc., Gurnee, Illinois, United States|Edward Hines Jr. VA Hospital, Hines, Illinois, United States|Advanced Cardiovascular Consultants, Moline, Illinois, United States|Captain James A. Lovell Federal Health Care Center, North Chicago, Illinois, United States|Specialty Physicians of Illinois, Olympia Fields, Illinois, United States|Community Hospital of Anderson and Madison County, Inc., Anderson, Indiana, United States|Synexus Clinical Research US, Inc., Evansville, Indiana, United States|Clinical Research Advantage, Inc., Evansville, Indiana, United States|Deaconess Clinic, Evansville, Indiana, United States|VA Medical Center - Indianapolis, Indianapolis, Indiana, United States|Cardiovascular Research of Northwest Indiana, LLC, Munster, Indiana, United States|Buynak Clinical Research, Valparaiso, Indiana, United States|West Broadway Clinic, Council Bluffs, Iowa, United States|Iowa Diabetes and Endocrinology Research Center, PLC, Des Moines, Iowa, United States|University of Kansas Medical Center Research Institute, Inc., Kansas City, Kansas, United States|VA Eastern Kansas Health Care, Leavenworth, Kansas, United States|The Research Group of Lexington, LLC, Lexington, Kentucky, United States|Robley Rex VA Medical Center, Louisville, Kentucky, United States|Cambridge Medical Trials, Alexandria, Louisiana, United States|Cardiovascular Associates Research, LLC, Covington, Louisiana, United States|Centex Studies Inc., Lake Charles, Louisiana, United States|Baltimore VA medical centre, Baltimore, Maryland, United States|University of Maryland School of Medicine, Baltimore, Maryland, United States|Spectrum Clinical Research, Inc., Baltimore, Maryland, United States|Maryland Cardiovascular Specialists, Baltimore, Maryland, United States|Medstar Health Research Institute, Hyattsville, Maryland, United States|Delmarva Heart Research Foundation, Inc., Salisbury, Maryland, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|Pentucket Medical Associates, Haverhill, Massachusetts, United States|South Shore Internal Medicine Associates, Milton, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan, United States|Northern Pines Health Center, Buckley, Michigan, United States|Cadillac Clinical Research, LLC, Cadillac, Michigan, United States|Detroit Clinical Research Center, PC, Farmington Hills, Michigan, United States|AA MRC LLC Ahmed Arif Medical Research Center, Flint, Michigan, United States|Sparrow Clinical Research Institute, Lansing, Michigan, United States|Covenant Medical Center, Inc., Saginaw, Michigan, United States|Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States|CentraCare Heart & Vascular, Saint Cloud, Minnesota, United States|HealthEast Medical Research Institute, Saint Paul, Minnesota, United States|GV Montgomery VA Medical Center, Jackson, Mississippi, United States|Kansas City VA Medical Center, Kansas City, Missouri, United States|Glacier View Research Institute-Endocrinology, Kalispell, Montana, United States|VA Nebraska-Western Iowa Health Care System, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Clifford J. Molin, MD, LTD, Las Vegas, Nevada, United States|Red Rock Clinical Research LLC, Las Vegas, Nevada, United States|VA Sierra Nevada Health Care System, Reno, Nevada, United States|Southern New Hampshire Diabetes and Endocrinology, Nashua, New Hampshire, United States|Monmouth Cardiology Associates, Eatontown, New Jersey, United States|NJ Heart, Linden, New Jersey, United States|The Valley Hospital, Ridgewood, New Jersey, United States|Albuquerque Clinical Trials, Inc., Albuquerque, New Mexico, United States|Raymond G. Murphy VA Medical Center, Albuquerque, New Mexico, United States|Endocrine Group, L.L.P., Albany, New York, United States|Novel Research of New York,LLC, Bronx, New York, United States|Buffalo VA Medical Center, Buffalo, New York, United States|New York Presbyterian, Flushing, New York, United States|North Shore Diabetes & Endocrine Associates, New Hyde Park, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|VA Medical Center - Syracuse, Syracuse, New York, United States|Randolph Medical Associates, Asheboro, North Carolina, United States|OnSite Clinical Solutions, LLC, Asheville, North Carolina, United States|Kernodle Clinic, Inc., Dept. of the Private Diagnostic Clinic, PLLC, Burlington, North Carolina, United States|Cary Research Group, LLC, Cary, North Carolina, United States|PMG Research of Cary, LLC, Cary, North Carolina, United States|Novant Health - Heart and Vascular Institute, Charlotte, North Carolina, United States|The Presbyterian Hospital, Charlotte, North Carolina, United States|Medication Management, LLC, Greensboro, North Carolina, United States|Triad Clinical Trials, LLC, Greensboro, North Carolina, United States|Clinical Trials of America-NC, LLC, Hickory, North Carolina, United States|PMG Research of Hickory, LLC, Hickory, North Carolina, United States|Research Institute of the Carolinas, PLC, Mooresville, North Carolina, United States|Diabetes and Endocrinology Consultants, Morehead City, North Carolina, United States|Cardiology Associates Carolina, Morganton, North Carolina, United States|Pinehurst Medical Clinic Inc, Pinehurst, North Carolina, United States|PMG Research of Raleigh, LLC, Raleigh, North Carolina, United States|PMG Research of Rocky Mount, LLC, Rocky Mount, North Carolina, United States|PMG Research of Salisbury, LLC, Salisbury, North Carolina, United States|Carolina Research Center, Inc., Shelby, North Carolina, United States|OhioHealth Heart & Vascular Physicians (Heartcare, Inc.) - Athens, Athens, Ohio, United States|Hometown Urgent Care & Occupational Health, Cincinnati, Ohio, United States|Cincinnati Veterans Affairs Medical Center, Cincinnati, Ohio, United States|Louis Stokes Cleveland Dept of VA Medical Center, Cleveland, Ohio, United States|Prestige Clinical Research Center, Franklin, Ohio, United States|Craig S Thompson MD LLC, Marion, Ohio, United States|Oklahoma City Clinic - Edmond, Edmond, Oklahoma, United States|Intend Research, Norman, Oklahoma, United States|Lynn Institute of Norman, Norman, Oklahoma, United States|South Oklahoma Heart Research Group, Oklahoma City, Oklahoma, United States|Heart Clinic of Southern Oregon, Medford, Oregon, United States|Fox, Bradley P., Erie, Pennsylvania, United States|AMH Feasterville Family Health Care Center, Feasterville, Pennsylvania, United States|Family Medical Associates, Levittown, Pennsylvania, United States|VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States|Preferred Primary Care Physicians, Pittsburgh, Pennsylvania, United States|Fay West Family Practice, Scottdale, Pennsylvania, United States|Montgomery Medical Inc., Smithfield, Pennsylvania, United States|Partners in Clinical Research, Cumberland, Rhode Island, United States|Ocean State Clinical Research Partners, Lincoln, Rhode Island, United States|Providence Veteran Administration Medical Center, Providence, Rhode Island, United States|Ralph H. Johnson VA Medical Center, Charleston, South Carolina, United States|Mountain View Clinical Research, Inc., Greer, South Carolina, United States|Palmetto Research Center, LLC, Greer, South Carolina, United States|Piedmont Research Partners, Indian Land, South Carolina, United States|Main Street Physician's Care - Waterway, Little River, South Carolina, United States|Family Medicine of Sayebrook, Myrtle Beach, South Carolina, United States|PMG Research of Bristol, LLC, Bristol, Tennessee, United States|Chattanooga Medical Research, LLC, Chattanooga, Tennessee, United States|Chattanooga Research and Medicine (CHARM), Chattanooga, Tennessee, United States|University Diabetes & Endocrine Consultants, Chattanooga, Tennessee, United States|WR-ClinSearch, LLC, Chattanooga, Tennessee, United States|Collierville Medical Specialists, Collierville, Tennessee, United States|Holston Medical Group, P.C., Kingsport, Tennessee, United States|Metro Knoxville HMA, LLC, Knoxville, Tennessee, United States|VA Medical Center - Memphis, Memphis, Tennessee, United States|Tennessee Valley Healthcare System, Nashville, Tennessee, United States|Central Texas Clinical Research, LLC, Austin, Texas, United States|Protenium Clinical Research, Dallas, Texas, United States|VA Medical Center - Dallas, Dallas, Texas, United States|North Texas Endocrine Center, Dallas, Texas, United States|Research Institute of Dallas, P.A., Dallas, Texas, United States|Doctors Hospital at Renaissance, Edinburg, Texas, United States|Texas Health Physicians Group, Fort Worth, Texas, United States|University of North Texas Health Science Center, Fort Worth, Texas, United States|Diabetes and Thyroid Center of Fort Worth, Fort Worth, Texas, United States|Rockwood Medical Clinic, Fort Worth, Texas, United States|East Texas Cardiology PA, Houston, Texas, United States|Endocrine Associates, LLC, Houston, Texas, United States|Heights Doctors Clinic, Houston, Texas, United States|Associates in Medicine, Houston, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Michael E. DeBakey VA Medical Center, Houston, Texas, United States|Southwest Clinical Trials, Houston, Texas, United States|Research Trials Worldwide LLC, Humble, Texas, United States|Grace Research, LLC, Huntsville, Texas, United States|Texas Cardiac Center, Lubbock, Texas, United States|Wellness Clinical Research Associates, McKinney, Texas, United States|Houston Methodist Research Institute - CCAT Pearland, Pearland, Texas, United States|Legacy Heart Center, Plano, Texas, United States|Clinical Investigations of Texas, Plano, Texas, United States|Advanced Clinical Research Associates, Plano, Texas, United States|Austin Heart PLLC, Round Rock, Texas, United States|Consano Clinical Research, LLC, San Antonio, Texas, United States|Sant Antonio Premiere Internal Medicine, San Antonio, Texas, United States|Briggs Clinical Research, LLC., San Antonio, Texas, United States|Schnitzler Cardiovascular Consultants (SCC), PLLC, San Antonio, Texas, United States|Bandera Family Healthcare Research LLC, San Antonio, Texas, United States|Northeast Clinical Research of San Antonio, Schertz, Texas, United States|Spring Family Practice Associates, Spring, Texas, United States|Northwest Houston Heart Center, Tomball, Texas, United States|Victoria Heart & Vascular Center, Victoria, Texas, United States|Hillcrest Family Health Clinics, Waco, Texas, United States|Utah Cardiology, P.C. (Davis), Farmington, Utah, United States|Optimum Clinical Research, Inc., Salt Lake City, Utah, United States|Burke Internal Medicine & Research, Burke, Virginia, United States|Virginia Endocrinology Research, Chesapeake, Virginia, United States|LMG Clinical Research Center, Herndon, Virginia, United States|Carient Heart and Vascular, Manassas, Virginia, United States|Clinical Research Partners, LLC, Richmond, Virginia, United States|McGuire DVA Medical Center, Richmond, Virginia, United States|Roanoke Heart Institute, Roanoke, Virginia, United States|Hampton Roads Center for Clinical Research, Suffolk, Virginia, United States|Corporation Lane Internal Medicine, Virginia Beach, Virginia, United States|Cardiology Associates of Bellin Health, Green Bay, Wisconsin, United States|Clinical Investigation Specialists Inc, Kenosha, Wisconsin, United States|Mayo Clinic Health System, La Crosse, Wisconsin, United States|Meriter Medical Group, Inc., Madison, Wisconsin, United States|Zablocki VA Medical Center, Milwaukee, Wisconsin, United States|Hospital Interzonal General de Agudos Dr Jose Penna, Bahia Blanca, Buenos Aires, Argentina|Hospital Italiano Regional del Sur, Bahia Blanca, Buenos Aires, Argentina|Hospital Italiano, Ciudad Autonoma Buenos Aires, Buenos Aires, Argentina|CICLO, La Plata, Buenos Aires, Argentina|Centro de Investigaciones Medicas Mar del Plata, Mar del Plata, Buenos Aires, Argentina|Instituto de Investigaciones Clinicas, Mar del Plata, Buenos Aires, Argentina|Instituto de Investigaciones Clinicas Quilmes, Quilmes, Buenos Aires, Argentina|Instituto de Investigaciones Clinicas San Nicolas, San Nicolas, Buenos Aires, Argentina|Instituto Clinico Metabolico, San Nicolas, Buenos Aires, Argentina|Clinica Olivos, Vicente Lopez, Buenos Aires, Argentina|Hospital Sirio Libanes, Caba, Ciudad Autonoma Buenos Aires, Argentina|Sanatorio Güemes, Ciudad Autonoma de Bs. As., Ciudad Autonoma Buenos Aires, Argentina|Centro Medico Viamonte SRL, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina|CEMEDIC - Centro de Especialidades Medicas, Villa Luro, Ciudad Autonoma Buenos Aires, Argentina|Centro Medico Luquez, San Vicente, Cordoba, Argentina|Consultorio Dr. Litvak Bruno, Ciudad Autonoma Buenos Aires, Argentina|Fundacion Favaloro, Ciudad Autonoma Buenos Aires, Argentina|CIPREC, Ciudad Autonoma Buenos Aires, Argentina|Investigaciones Medicas IMOBA S.R.L, Ciudad Autonoma Buenos Aires, Argentina|Centro Medico Dra Laura Maffei Investigacion Clinica Aplicada, Ciudad Autonoma Buenos Aires, Argentina|CEDIC Centro de Investigaciones Clinicas, Ciudad Autonoma Buenos Aires, Argentina|Instituto Cardiovascular Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina|CCBR - Buenos Aires - AR, Ciudad Autonoma Buenos Aires, Argentina|Inst. Privado de Inv. Clinicas de Cordoba, Cordoba, Argentina|Clinica Colombo, Cordoba, Argentina|Instituto Medico DAMIC, Cordoba, Argentina|Hospital Privado Centro Medico de Cordoba S.A, Cordoba, Argentina|Clinica del Prado, Cordoba, Argentina|Instituto de Cardiologia de Corrientes, Corrientes, Argentina|Prevencion Cardiovascular Salta, Salta, Argentina|Axismed S.R.L.- Clínica Mayo, Tucuman, Argentina|L2IP - Instituto de Pesquisas Clínicas Ltda., Brasília, Distrito Federal, Brazil|ICDF - Instituto de Cardiologia do Distrito Federal, Brasília, Distrito Federal, Brazil|CECAP - Centro de Cardiologia Clínica, Brasília, Distrito Federal, Brazil|Hospital Universitário de Brasília, Brasília, Distrito Federal, Brazil|Clínica de Endocrinologia e Metabologia Ltda., Brasília, Distrito Federal, Brazil|CARDIOINTERV Centro de Pesquisa S/S, Goiânia, Goiás, Brazil|*IMA*, Goiânia, Goiás, Brazil|HC-UFG - Hospital das Clínicas da Universidade Federal de Goiás, Goiânia, Goiás, Brazil|Hospital Felício Rocho, Belo Horizonte, Minas Gerais, Brazil|CARDRESEARCH - Cardiologia Assistencial, Belo Horizonte, Minas Gerais, Brazil|Hospital e Maternidade Therezinha de Jesus, Juiz de Fora, Minas Gerais, Brazil|Sociedade Hospitalar Angelina Caron, Campina Grande do Sul, Paraná, Brazil|Núcleo de Pesquisa Clínica S/S, Curitiba, Paraná, Brazil|Paraná Medical Research Center, Maringá, Paraná, Brazil|HUJBB-UFPA - Hospital Universitário João de Barros Barreto - Universidade Federal do Pará, Belém, Pará, Brazil|Total Care - Unidade Botafogo, Rio de Janeiro, Rio Do Janeiro, Brazil|CCBR Brasil Centro de Pesquisas e Análises Clínicas Ltda., Rio de Janeiro, Rio Do Janeiro, Brazil|Eurolatino Natal Pesquisas Médicas Ltda., Natal, Rio Grande Do Norte, Brazil|Hospital Universitário, Canoas, Rio Grande Do Sul, Brazil|Santa Casa de Misericórdia de Pelotas, Pelotas, Rio Grande Do Sul, Brazil|Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Centro de Pesquisas em Diabetes Ltda., Porto Alegre, Rio Grande Do Sul, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Centro de Pesquisa Médica Santa Maria Ltda., Santa Maria, Rio Grande Do Sul, Brazil|Loema - Instituto de Pesquisa Clínica, Campinas, Sao Paulo, Brazil|IPCC - Instituto de Pesquisa Clínica de Campinas, Campinas, Sao Paulo, Brazil|Fundação Faculdade Regional de Medicina de São José do Rio Preto, São José do Rio Preto, Sao Paulo, Brazil|ISPEM - Instituto São José dos Campos em Pesquisas Médicas, São José dos Campos, Sao Paulo, Brazil|CPQuali Pesquisa Clínica Ltda., São Paulo, Sao Paulo, Brazil|CPCLIN - Centro de Pesquisas Clínicas Ltda., São Paulo, Sao Paulo, Brazil|Clínica Paulista de Doenças Cardiovasculares Ltda., São Paulo, Sao Paulo, Brazil|CEPIC - Centro Paulista de Investigação Clínica e Serviços Médicos, São Paulo, Sao Paulo, Brazil|Hospital das Clínicas da Faculdade de Medicina da USP, São Paulo, Sao Paulo, Brazil|Incor - Instituto do Coração - HCFMUSP, São Paulo, Sao Paulo, Brazil|IMC - Instituto de Moléstias Cardiovasculares Tatuí, Tatuí, Sao Paulo, Brazil|Santa Casa de Votuporanga, Votuporanga, Sao Paulo, Brazil|MHAT - Blagoevgrad, EOOD, Blagoevgrad, Bulgaria|MHAT ""Yuliya Vrevska - Byala"", EOOD, Byala, Bulgaria|MHAT-Haskovo, AD, Haskovo, Bulgaria|MHAT ""Higia"", AD - Pazardzhik, Pazardzhik, Bulgaria|MHAT - Pazardzhik AD, Pazardzhik, Bulgaria|MHAT ""Sv. Pantaleymon - Pleven"", OOD, Pleven, Bulgaria|SHATC Pleven EAD, Pleven, Bulgaria|UMHAT 'Dr. Georgi Stranski', EAD, Pleven, Bulgaria|UMHAT ""Sv. Georgi"", EAD, Plovdiv, Bulgaria|UMHAT ""Kaspela"", EOOD, Plovdiv, Bulgaria|Diagnostic Consultative Center II - Sofia OOD, Sofia, Bulgaria|Fifth MHAT - Sofia EAD, Sofia, Bulgaria|NMTH ""Tsar Boris III"", Sofia, Bulgaria|MHAT ""Lyulin"", EAD, Sofia, Bulgaria|MC Start - d-r Todor Dimitrov EOOD, Sofia, Bulgaria|UMHAT ""Alexandrovska"" EAD, Sofia, Bulgaria|UMHAT 'Tsaritsa Yoanna - ISUL', EAD, Sofia, Bulgaria|Fourth MHAT - Sofia EAD, Sofia, Bulgaria|UMHAT 'Sveta Anna' AD, Sofia, Bulgaria|MC ""Synexus - Sofia"", EOOD, Sofia, Bulgaria|UMHAT ""SofiaMed"", OOD, Sofia, Bulgaria|MC ""Orfey"", EOOD, Stara Zagora, Bulgaria|SHATC - Varna, EOOD, Varna, Bulgaria|LMC Clinical Research Inc. (Calgary), Calgary, Alberta, Canada|ALTA Clinical Research Inc., Edmonton, Alberta, Canada|Royal Alexandra Hospital, CK Hui Heart Centre, Edmonton, Alberta, Canada|The Bailey Clinic, Red Deer, Alberta, Canada|Fraser Clinical Trials Inc., New Westminster, British Columbia, Canada|BC Diabetes As Operated by Dr. TG Elliott, Inc., Vancouver, British Columbia, Canada|Discovery Clinical Services Ltd., Victoria, British Columbia, Canada|Saint Boniface General Hospital, Winnipeg, Manitoba, Canada|Rivergrove Medical Clinic, Winnipeg, Manitoba, Canada|Winnipeg Clinic, Winnipeg, Manitoba, Canada|Health Sciences Centre, St. John's, Newfoundland and Labrador, Canada|LMC Clinical Research Inc. (Barrie), Barrie, Ontario, Canada|LMC Clinical Research Inc. (Brampton), Brampton, Ontario, Canada|Aggarwal and Associates Ltd, Brampton, Ontario, Canada|Brampton Research Associates, Brampton, Ontario, Canada|Aviva Clinical Trial Group Inc. - TMG, Burlington, Ontario, Canada|JBN Medical Diagnostic Services Inc., Burlington, Ontario, Canada|Joanne F. Liutkus Medicine Professional Corporation, Cambridge, Ontario, Canada|Saul Vizel Professional Medicine Corporation, Cambridge, Ontario, Canada|LMC Clinical Research Inc. (Thornhill), Concord, Ontario, Canada|LMC Clinical Research Inc. (Etobicoke), Etobicoke, Ontario, Canada|Dawson Road Family Medical Clinic, Guelph, Ontario, Canada|LMC Clinical Research Inc. (Ottawa), Nepean, Ontario, Canada|LMC Clinical Research Inc. (Oakville), Oakville, Ontario, Canada|James Cha, MD, Oshawa, Ontario, Canada|The Ottawa Hospital - Riverside Campus, Ottawa, Ontario, Canada|Kawartha Cardiology Clinical Trials, Peterborough, Ontario, Canada|Scarborough Cardiology Research, Scarborough, Ontario, Canada|Humber River Hospital, Toronto, Ontario, Canada|LMC Clinical Research Inc. (Bayview), Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|LMC Clinical Research dba Manna Research Inc. Toronto, Toronto, Ontario, Canada|Ecogene-21, Chicoutimi, Quebec, Canada|ViaCar Recherche Clinique Inc, Greenfield Park, Quebec, Canada|Centre de Dépistage et Recherche Cardiovasculaire Rive-Sud, Longueuil, Quebec, Canada|Clinique de Cardiologie de Levis, Lévis, Quebec, Canada|LMC Clinical Research dba Manna Research Inc. Mirabel, Mirabel, Quebec, Canada|CHUM Hôtel-Dieu, Montreal, Quebec, Canada|Applied Medical Informatics Research Inc., Montreal, Quebec, Canada|Clinique Santé Cardio MC, Montréal, Quebec, Canada|Recherche Clinique Sigma Inc., Québec, Quebec, Canada|Clinique Médicale St-Louis (Recherche) inc d/b/a/ Centre de Recherche Saint-Louis, Québec, Quebec, Canada|ALPHA Recherche Clinique, Québec, Quebec, Canada|Recherche Médicale St-Jérôme Inc., St-Jérôme, Quebec, Canada|Centre Medical des Carrieres, St-Marc-des-Carrieres, Quebec, Canada|LMC Clinical Research Inc. (Montreal), Ville Saint-Laurent, Quebec, Canada|DIEX Recherche Quebec Inc., Quebec, Canada|Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Quebec, Canada|Clinique des maladies Lipidiques de Quebec, Quebec, Canada|Centro de Investigacion Medico Asistencial S.A.S, Barranquilla, Colombia|IPS Centro Cientifico Asistencial S.A.S, Barranquilla, Colombia|CardioColombia S.A.S., Bogota, Colombia|Dexa Diab Servicios Médicos Limitada., Bogota, Colombia|Solano y Terront Servicios Médicos Ltda., Bogota, Colombia|Clínica Cardiovascular Santa Lucia, Cartagena, Colombia|Fundación Centro de Investigaciones Biomédicas Riescard, Espinal, Colombia|Fundación Oftalmológica de Santander - FOSCAL, Floridablanca, Colombia|Centro Integral de Reumatología REUMALAB S.A.S., Medellin, Colombia|Fundacion Centro de Investigacion Clinica CIC, Medellin, Colombia|Fundación de Investigaciones Medicas San Gil - IPS, San Gil, Colombia|Medicentrum Beroun spol. s.r.o., Beroun, Czechia|Fakultni nemocnice u sv. Anny v Brne, Brno, Czechia|EDUMED s.r.o, Broumov, Czechia|Poliklinika Chocen a.s., Chocen, Czechia|Ordinace pro choroby srdce s.r.o., Chomutov, Czechia|MUDr. Jan Hubac s.r.o., Chrudim, Czechia|Nemocnice Havlickuv Brod p.o., Havlickuv Brod, Czechia|Kardio-Pisova s.r.o., Hradec Kralove, Czechia|MUDr. Tomas Edelsberger, Krnov, Czechia|Agentura Science Pro Spol. s.r.o., Olomouc, Czechia|PreventaMed s.r.o., Olomouc, Czechia|CCBR Ostrava s.r.o., Ostrava, Czechia|RESEARCH SITE s.r.o., Plzen, Czechia|Corintez s.r.o., Prague, Czechia|MUDr. Jan KVASNICKA CSc. Angiologie kardiologie a interna, Praha 10, Czechia|Nemocnice na Frantisku, Praha 1, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia|ResTrial s.r.o., Praha 8, Czechia|Synexus Czech s.r.o., Praha, Czechia|MUDr.Eva Mandakova MBA, Rakovnik, Czechia|Nemocnice Slany, Slany, Czechia|AeskuLab k.s., Teplice, Czechia|Kardiologicka ambulance MUDr. Ferkl s.r.o., Trutnov, Czechia|Clinical Trials Services s.r.o, Uherske Hradiste, Czechia|MUDr. Nina Zemkova s.r.o., Uherske Hradiste, Czechia|CCBR - Ålborg - DK, Aalborg, Denmark|Aalborg University Hospital, Aalborg, Denmark|Aarhus University Hospital, Aarhus N, Denmark|CCBR - Ballerup - DK, Ballerup, Denmark|Amager Hospital, Copenhagen S, Denmark|Sydvestjyds Sygehus Esbjerg, Esbjerg, Denmark|Amager-Hvidovre Hospital, Glostrup, Denmark|Gentofte Hospital, Hellerup, Denmark|Herlev og Gentofte Hospital, Herlev, Denmark|Regionshospitalet Herning-Hospitalsenheden Vest, Herning, Denmark|Holbæk Sygehus, Holbæk, Denmark|Køge Sygehus, Køge, Denmark|Sygehus Fyn Svendborg, Svendborg, Denmark|CCBR - Vejle - DK, Vejle, Denmark|CHU Dijon - Hopital General, Dijon cedex, Cote dÝOr, France|Centre Hospitalier Sud Francilien, Corbeil-Essonnes, Essonne, France|Clinique Pasteur - Toulouse, Toulouse cedex 3, Haute Garonne, France|CHU Tours - Hôpital Trousseau, Chambray Les Tours, Indre Et Loire, France|CHU Nantes - Hopital Nord Laënnec, Nantes cedex 01, Loire Atlantique, France|Groupe Hospitalier Pitie-Salpetriere, Paris cedex 13, Paris, France|Hôpital Bichat - Claude Bernard, Paris cedex 18, Paris, France|Universitaetsklinikum Freiburg, Freiburg, Baden Wuerttemberg, Germany|Praxis fuer Praevention und Therapie, Villingen-Schwenningen, Baden Wuerttemberg, Germany|Gemeinschaftspraxis Dr. Klein/ Minnich, Künzing, Bayern, Germany|Deutsches Herzzentrum Muenchen, Muenchen, Bayern, Germany|Klinikum der Universitaet Muenchen, Munich, Bayern, Germany|ZKS-Südbrandenburg -center for clinical studies Südbrandenburg GmbH, Elsterwerda, Brandenburg, Germany|Neurologische Praxis Dr. Schoell & Kollegen, Bad Homburg, Hessen, Germany|ClinPhenomics GmbH & Co KG, Frankfurt, Hessen, Germany|Klinische Forschung Schwerin GmbH, Schwerin, Mecklenburg Vorpommern, Germany|Synexus Clinical Research GmbH, Bochum, Nordrhein Westfalen, Germany|Gemeinschaftspraxis Diabeteszentrum Dortmund Dr.med. Klaus Busch, Dortmund, Nordrhein Westfalen, Germany|St. Johannes Hospital, Dortmund, Nordrhein Westfalen, Germany|Klinikum Bielefeld gem. GmbH, Dortmund, Nordrhein Westfalen, Germany|Universitaetsklinikum Koeln, Koeln, Nordrhein Westfalen, Germany|Institut fuer Diabetesforschung GmbH in Muenster, Muenster, Nordrhein Westfalen, Germany|Zentrum fuer Praevention und Rehabilitation, Siegen, Nordrhein Westfalen, Germany|Katholisches Klinikum Mainz, Mainz, Rheinland Pfalz, Germany|Praxis Segner & Braun, Sankt Ingbert, Saarland, Germany|Gemeinschaftspraxis Dr. Taeschner / Dr. Bonigut, Leipzig, Sachsen, Germany|Internistische Praxis Parkstrasse, Neumünster, Schleswig Holstein, Germany|RED - Institut GmbH, Oldenburg, Schleswig Holstein, Germany|Diabetespraxis Prenzlauer Allee, Berlin, Germany|Studienzentrum Rankestrasse, Berlin, Germany|Gemeinschaftspraxis fuer innere Medizin und Diabetologie, Hamburg, Germany|Lausmed Kft., Baja, Hungary|Principal SMO Kft., Baja, Hungary|DRC Gyogyszervizsgalo Kozpont Kft., Balatonfured, Hungary|Bekes Megyei Kozponti Korhaz Dr. Rethy Pal Tagkorhaz, Bekescsaba, Hungary|Clinexpert Kft., Budapest, Hungary|Synexus Magyarorszag Kft., Budapest, Hungary|Semmelweis Egyetem, Budapest, Hungary|CSALADGYOGYASZ Bt., Budapest, Hungary|Felnott Haziorvosi Rendelo, Cegled, Hungary|Borvo Clinic Kft., Debrecen, Hungary|Debreceni Egyetem, Debrecen, Hungary|Meditoll Kft., Godollo, Hungary|Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaza, Gyula, Hungary|Synexus Magyarorszag Egeszsegugyi Szolgaltato Kft.- Gyula DRS, Gyula, Hungary|BKS Research Kft., Hatvan, Hungary|Z+P MED Egeszsegugyi, Kereskedelmi es Szolgaltato Bt., Kalocsa, Hungary|Somogy Megyei Kaposi Mor Oktato Korhaz, Kaposvar, Hungary|IPR Hungary Kft., Miskolc, Hungary|Medifarma-98 Kft., Nyiregyhaza, Hungary|BORBANYA PRAXIS Kft., Nyiregyhaza, Hungary|Dr. Nagy Laszlo Kardiologiai Maganrendeles, Oroshaza, Hungary|Mazso-Pharma Kutatas-fejlesztesi Kft., Szeged, Hungary|Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz, Szekesfehervar, Hungary|Csolnoky Ferenc Korhaz, Veszprem, Hungary|Zala Megyei Szent Rafael Korhaz, Zalaegerszeg, Hungary|GNRC Hospital, Guwahati, Assam, India|Loknayak Hospital, New Delhi, Delhi, India|Fortis Flight Lieutenant Rajan Dhall Hospital, New Delhi, Delhi, India|DDMM Heart Institute, Nadiad, Gujarat, India|Shri B. D. Mehta Mahavir Heart Institute, Surat, Gujarat, India|Rhythm Heart Institute, Vadodara, Gujarat, India|Medanta The Medicity, Gurgaon, Haryana, India|Fortis Hospitals Ltd., Bangalore, Karnataka, India|K.L.E. Society's Dr. Prabhakar Kore Hospital and Medical Research Centre, Belgaum, Karnataka, India|Meditrina Institute Of Medical Sciences, Nagpur, Maharashtra, India|Eternal Heart Care Centre, Jaipur, Rajasthan, India|Institute of Cardiovascular Diseases Madras Medical Mission, Chennai, Tamilnadu, India|IPGMER and SSKM Hospital, Kolkata, West Bengal, India|HaEmek Medical Center, Afula, Israel|Bnei Zion Medical Center, Haifa, Israel|Rambam Health Care Center, Haifa, Israel|The Lady Davis Carmel Medical Center, Haifa, Israel|Wolfson Medical Center, Holon, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Hadassah University Hospital - ",,
NCT03070782,Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Patients With Hyperlipoproteinemia(a) and Cardiovascular Disease,,Completed,No Results Available,Elevated Lipoprotein(a)|Cardiovascular Disease,Drug: ISIS 681257|Drug: Placebo,"Percent change in plasma Lp(a) from baseline at the primary analysis time point for ISIS 681257 treatment groups compared to placebo.|Safety and tolerability of different doses and dosing regimens of ISIS 681257 as measured by proportion of patients with treatment-related adverse events by severity, and number of patients meeting safety stopping rules|Evaluate the effect of ISIS 681257 on the percent change from baseline in LDL-C.|Evaluate the effect of ISIS 681257 on the proportion of patients who achieve plasma Lp(a) ≤ 50 mg/dL.|Evaluate the effect of ISIS 681257 on the percent change from baseline in plasma levels of apolipoprotein B (apoB).|Evaluate the effect of ISIS 681257 on the percent change from baseline in plasma levels of oxidized phospholipids (OxPL) on apolipoprotein (a) [apo(a)] [OXPL-apo(a)].|Evaluate the effect of ISIS 681257 on the percent change from baseline in plasma levels of oxidized phospholipids (OxPL) on apoB (OXPL-apoB).","Akcea Therapeutics|Ionis Pharmaceuticals, Inc.",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,286,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 681257-CS6,7-Mar-17,18-Jul-18,13-Nov-18,6-Mar-17,null,13-Dec-18,"Clinical Site, Cottonwood, Arizona, United States|Clinical Site, Huntington Beach, California, United States|Clinical Site, La Jolla, California, United States|Clinical Site, Los Angeles, California, United States|Clinical Site, Stanford, California, United States|Clinical Site, Colorado Springs, Colorado, United States|Clinical Site, Boca Raton, Florida, United States|Clinical Site, Jacksonville, Florida, United States|Clinical Site, Kansas City, Kansas, United States|Clinical Site, Baltimore, Maryland, United States|Clinical Site, Boston, Massachusetts, United States|Clinical Site, Cooperstown, New York, United States|Clinical Site, New York, New York, United States|Clinical Site, New York, New York, United States|Clinical Site, Cleveland, Ohio, United States|Clinical Site, Portland, Oregon, United States|Clinical Site, Lancaster, Pennsylvania, United States|Clinical Site, Philadelphia, Pennsylvania, United States|Clinical Site, Providence, Rhode Island, United States|Clinical Site, Houston, Texas, United States|Clinical Site, Falls Church, Virginia, United States|Clinical Site, Milwaukee, Wisconsin, United States|Clinical Site, Chicoutimi, Quebec, Canada|Clinical Site, Montreal, Quebec, Canada|Clinical Site, Montréal, Quebec, Canada|Clinical Site, Québec, Quebec, Canada|Clinical Site, Ottawa, Canada|Clinical Site, Herlev, Denmark|Clinical Site, Viborg, Denmark|Clinical Site, Berlin, Germany|Clinical Site, Cologne, Germany|Clinical Site, Amsterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT03070782
NCT03066921,Evaluation Of The Efficacy of a Strain-Specific Probiotic Formulation in Hemodialysis Patients,,Completed,No Results Available,End Stage Renal Disease,Dietary Supplement: Probiotic packet|Dietary Supplement: Placebo,"Change from Baseline Triglyceride/HDL cholesterol ratio at 3 months, 6 months and 3 months after the trial|Plasma concentrations of typical gut-derived uremic toxins(Indoxyl sulfate and p-cresyl sulfate)|plasma concentrations of inflammatory biomarkers|plasma concentrations of microbial translocation biomarkers|Quality of life|Nutritional Status|Gut function questionnaire as a measure of tolerability",Paik Seong Lim|Tungs’ Taichung Metroharbour Hospital,All,"20 Years to 75 Years   (Adult, Older Adult)",Not Applicable,52,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",104012,Jun-16,Oct-17,Dec-17,1-Mar-17,null,11-Jan-18,"Tungs' Taichung MetroHarbour Hospital, Taichung, Taiwan",,https://ClinicalTrials.gov/show/NCT03066921
NCT03067441,Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE),,"Active, not recruiting",No Results Available,Hypercholesterolemia|Atherosclerotic Cardiovascular Disease,Drug: bempedoic acid,Number of participants with treatment-related adverse events as assessed by MedDRA 18.1|Percent change in Low-Density Lipoprotein Cholesterol (LDL-C)|Change in Low-Density Lipoprotein Cholesterol (LDL-C)|Percent change in non-High-Density Lipoprotein Cholesterol (non-HDL-C)|Percent change in Total Cholesterol|Percent change in Apolipoprotein B (ApoB)|Percent change in High-Sensitivity C-Reactive Protein (hs-CRP)|Percent change in Trigycerides|Percent change in High-Density Lipoprotein Cholesterol (HDL-C),Esperion Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1452,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1002-050|2016-004115-12,3-Feb-17,31-Dec-19,31-Dec-19,1-Mar-17,null,5-Mar-19,"Jedidiah Clinical Research, Tampa, Florida, United States|L-MARC Research Center, Louisville, Kentucky, United States|Sentral Clinical Research Services, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03067441
NCT03067688,Clinical Trial of Temisartan/Amlodipine & Rosuvastatin in Subjects With Hypertension and Hyperlipidemia,,Completed,No Results Available,Hypertension|Hyperlipidemia,Drug: Temisartan+Amlodipine+Rosuvastatin (Combination drug)|Drug: Temisartan+Amlodipine|Drug: Temisartan+Rosuvastatin,Mean sitting systolic blood pressure (MSSBP)|Low density lipoprotein cholesterol (LDL-C)|MSSBP (Mean sitting systolic blood pressure)|Mean sitting diastolic blood pressure (MSDBP)|Total Cholesterol (TC)|High density lipoprotein cholesterol (HDL-C)|Low density lipoprotein cholesterol/High density lipoprotein cholesterol (LDL-C/HDL-C)|Total Cholesterol/High density lipoprotein cholesterol (TC/HDL-C)|Triglyceride (TG),Yuhan Corporation,All,"19 Years and older   (Adult, Older Adult)",Phase 3,202,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",YHP1604-301,11-Apr-17,27-Mar-18,27-Mar-18,1-Mar-17,null,16-Jan-19,"Seoul Natuional University Hospital, Seoul, Jongno, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03067688
NCT03068078,A Reduced-carbohydrate Diet High in Monounsaturated Fats in Type 2 Diabetes,ReDuCtion,Recruiting,No Results Available,Type2 Diabetes|Nonalcoholic Steatohepatitis|Non-Alcoholic Fatty Liver Disease|Atherosclerosis|Dyslipidemias,Dietary Supplement: Low carbohydrate diet high in monounsaturated fats,"Glycemic control, dyslipidemia and metabolic markers|Endothelial function|Non-Alcoholic Fatty Liver Disease (NAFLD)|Quality of life|Gut dysbiosis",Odense University Hospital|Danish Diabetes Academy|Region of Southern Denmark|Odense Patient Data Explorative Network|Novo Nordisk A/S|University of Southern Denmark,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,135,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,S-20150217,Nov-16,Dec-19,Dec-20,1-Mar-17,null,13-Mar-19,"Odense University Hospital, Odense, Denmark",,https://ClinicalTrials.gov/show/NCT03068078
NCT03065491,"Effect of Red Yeast Rice, Phytosterols and L-tyrosol on Lipid Profile and Endothelial Function",,Completed,No Results Available,Hypercholesterolemia,Dietary Supplement: Combined nutraceutical|Other: Placebo,LDL-cholesterolemia absolute reduction from baseline and between groups|LDL-cholesterolemia % reduction from baseline and between groups|Flow-mediated dilation improvement from baseline and between groups,University of Bologna,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MPT_trial_2016,15-Nov-16,15-Feb-17,17-Feb-17,28-Feb-17,null,28-Feb-17,"S. Orsola-Malpighi University Hospital, Bologna, BO, Italy",,https://ClinicalTrials.gov/show/NCT03065491
NCT03060577,An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol,,"Active, not recruiting",No Results Available,Atherosclerotic Cardiovascular Disease|Symptomatic Atherosclerosis|Type2 Diabetes|Familial Hypercholesterolemia,Drug: Inclisiran|Drug: Evolocumab,"Percentage Change in LDL-C from Day 1 to Day 210 in the Inclisiran Group|Percentage Change of Participants in the Inclisiran Group from Day 1 to Day 210 and to Day 1440 (or Final Visit) in LDL-C|Change of Participants in the Inclisiran Group from Day 1 to Day 210 and to Day 1440 (or Final Visit) in LDL-C|Percentage Change of Participants in the Inclisiran Group from Day 1 to Day 210 and to Day 1440 (or Final Visit) in PCSK9 Levels|Change of Participants in the Inclisiran Group from Day 1 to Day 210 and to Day 1440 (or Final Visit) in PCSK9 Levels|Percentage Change of Participants in the Inclisiran Group from Day 1 to Day 210 and to Day 1440 (or Final Visit) in Total Cholesterol, Triglycerides, HDL-C, non-HDL-C, VLDL-C, Apo-A1, Apo-B, and Lp(a)|Change of Participants in the Inclisiran Group from Day 1 to Day 210 and to Day 1440 (or Final Visit) in Total Cholesterol, Triglycerides, HDL-C, non-HDL-C, VLDL-C, Apo-A1, Apo-B, and Lp(a)|Proportion of Participants in the Inclisiran Group and the Evolocumab Group Who Attain Global Lipid Modification Targets for Their Level of ASCVD Risk|Proportion of Participants in the Evolocumab Group Who Attain Global Lipid Modification Targets for Their Level of ASCVD Risk at Day 570 (210 Days After Starting Inclisiran)|Proportion of Participants in the Inclisiran Group and the Evolocumab Group with ≥50% LDL-C Reduction|Number of Participants in the Inclisiran Group and the Evolocumab Group Reaching on Treatment LDL-C Levels of <25 mg/dL, <50 mg/dL, <70 mg/dL, and <100 mg/dL|Time to Lipid Lowering Effect in Participants in the Inclisiran Group and the Evolocumab Group|Change from Day 1 to Day 360 in LDL-C (Beta Quantification) of Participants in the Evolocumab Group|Change from Day 30 to Day 360 in Participant-Reported Scores Using the Treatment Satisfaction Questionnaire for Medication (TSQM) Questionnaire of Participants in the Inclisiran Group and the Evolocumab Group|Change from Day 450 to Day 720 in Participant-Reported Scores Using the TSQM Questionnaire of Participants in the Inclisiran Group|Participant-Reported Adherence to Self-Injectable Evolocumab",The Medicines Company,All,"18 Years and older   (Adult, Older Adult)",Phase 2,490,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MDCO-PCS-16-01,24-Mar-17,29-Aug-18,Jan-22,23-Feb-17,null,30-Nov-18,"Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Midwest Institute For Clinical Research, Indianapolis, Indiana, United States|Mount Sinai Icahn School of Medicine, New York, New York, United States|Metabolic And Atherosclerosis Research Center, Cincinnati, Ohio, United States|Sterling Research Group, Cincinnati, Ohio, United States|Wellmont CVA Heart Institute, Greeneville, Tennessee, United States|Amarillo Heart Clinical Research Institute, Inc., Amarillo, Texas, United States|National Clinical Research, Inc., Richmond, Virginia, United States|St. Paul's Hospital, Vancouver, British Columbia, Canada|St. Boniface Hospital, Winnipeg, Manitoba, Canada|Eastern Regional Health Authority, Patient Research Centre, Saint John's, Newfoundland and Labrador, Canada|Brampton Research Associates, Brampton, Ontario, Canada|Lawson Health Research Institute, London, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|ECOGENE-21 Clinical Trials Center, Chicoutimi, Quebec, Canada|Institut de Recherches Cliniques de Montreal, Montreal, Quebec, Canada|Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke (CIUSSS de l'Estrie - CHUS), Sherbrooke, Quebec, Canada|Université Laval Quebec, Quebec, Canada|Clinique des maladies lipidique Quebec, Quebec, Canada|Medical University Berlin, Berlin, Germany|Medical Center Essen, Essen, Germany|University Hospital Frankfurt, Frankfurt, Germany|Medical University Hospital Heidelberg, Internal Medicine III, Heidelberg, Germany|Technical University Munich, German Heart Center, Munich, Germany|Amsterdam Medical Center, Amsterdam, Netherlands|Haga Hospital, Den Haag, Netherlands|Deventer Ziekenhuis, Deventer, Netherlands|Andromed Eindoven, Eindhoven, Netherlands|Admiraal de Ruyter Hospital, Cardiology, Goes, Netherlands|Bethesda Diabetes Research Center, Hoogeveen, Netherlands|Medisch Centrum Gorecht, Hoogezand, Netherlands|VOC Hoorn, Hoorn, Netherlands|Leids Universitair Medisch Centrum (LUMC), Leiden, Netherlands|Andromed Rotterdam, Rotterdam, Netherlands|Diakonesseshuis, Vascular Policlinic, Utrecht, Netherlands|UMC Utrecht, Utrecht, Netherlands|VieCurie Venlo, Cardiology, Venlo, Netherlands|Albert Schweitzer Hospital, Cardiology, Zwijndrecht, Netherlands|Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom|Edinburgh Royal Infirmary, Edinburgh, United Kingdom|The Royal Devon and Exeter NHS Trust, Exeter, United Kingdom|Fowey River Practice, Fowey, United Kingdom|Buckinghamshire NHS Trust, High Wycombe, United Kingdom|Oak Tree Surgery, Liskeard, United Kingdom|Royal Free Hospital, London, United Kingdom|Central Manchester University Hospital NHS Foundation Trust, Manchester, United Kingdom|The Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, United Kingdom|The Alverton Practice, Penzance, United Kingdom|Knowle House Surgery, Plymouth, United Kingdom|Brannel Surgery, Saint Austell, United Kingdom|Rame Medical Ltd (Rame Research), Torpoint, United Kingdom|Worcestershire Acute NHS Trust, Worcester, United Kingdom",,https://ClinicalTrials.gov/show/NCT03060577
NCT03051100,"Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C",,Completed,No Results Available,Hypercholesterolemia,Drug: Bempedoic acid 180mg|Drug: Ezetimibe 10mg|Drug: Atorvastatin 20mg|Other: Placebo,Percent change in low-density lipoprotein cholesterol (LDL-C),Esperion Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 2,63,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1002-038,19-Jan-17,1-Jun-17,5-Jul-17,13-Feb-17,null,25-Jul-18,"PMG Research of Christie Clinic, Champaign, Illinois, United States|PMG Research of Cary, Cary, North Carolina, United States|PMG Research of Charlotte, Charlotte, North Carolina, United States|Sensenbrenner Primary Care, Charlotte, North Carolina, United States|PMG Research of Hickory, Hickory, North Carolina, United States|PMG Research of Raleigh, Raleigh, North Carolina, United States|PMG Research of Rocky Mount, Rocky Mount, North Carolina, United States|PMG Research Salisbury, Salisbury, North Carolina, United States|PMG Research of Wilmington, Wilmington, North Carolina, United States|PMG Research of Charleston, Mount Pleasant, South Carolina, United States|Hampton Roads Center for Clinical Research, Virginia Beach, Virginia, United States",,https://ClinicalTrials.gov/show/NCT03051100
NCT03047538,Fixed Combination for Lipid and Blood Pressure Control,FILIP,Recruiting,No Results Available,Arterial Hypertension|Dyslipidemias|Blood Pressure|Lipid Metabolism Disorders,"Drug: Atorvastatin, Amlodipine, Perindopril",Blood pressure control|Lipids control|Adherence|Blood pressure variability|Arterial properties,"Charles University, Czech Republic|University Hospital Olomouc|University Hospital Pilsen|General Teaching Hospital, Prague|St. Anne|Brno University Hospital|Na Homolce Hospital",All,"18 Years and older   (Adult, Older Adult)",Phase 4,160,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FILIP_V1.2,1-Sep-17,31-Dec-19,31-Dec-19,9-Feb-17,null,31-Jan-18,"Center for Cardiovascular Prevention, Charles University Medical Faculty and Thomayer Hospital, Prague, Czechia",,https://ClinicalTrials.gov/show/NCT03047538
NCT03047668,POLY-unsaturated Fatty Acids in the Preservation of Dietary Effects on Hepatosteatosis and Energy Metabolism in Type 2 Diabetes,POLYPHEM,Unknown status,No Results Available,Type 2 Diabetes|NAFLD|Obesity|Dyslipidemia|Hypertension|Metabolic Syndrome,Dietary Supplement: diet with/without supplementation,"change in insulin secretion (glucagon stimulation test)|change in hepatic fat content (MR-S)|change in insulin secretion in the mixed-meal tolerance test (MMTT) - combined parameter|change in insulin sensitivity in the mixed-meal tolerance test (MMTT) - combined parameter|change in blood glucose profile in the mixed-meal tolerance test (MMTT) - combined parameter|inflammatory reaction in subcutaneous adipose tissue (SCAT analysis on protein and RNA level - IL-1; IL1beta, IL-6)|change in parameters of peripheral neuropathy - vibration threshold|change in parameters of peripheral neuropathy - thermal sensitivity|change in parameters of peripheral neuropathy - pain thresholds|change in parameters of autonomic neuropathy - measures of cardio-autonomic neuropathy (MSDD)|change in parameters of autonomic neuropathy - measures of cardio-autonomic neuropathy (SANN)",German Institute of Human Nutrition|German Center for Diabetes Research|California Walnut Commission|Institute for Cereal Processing GmbH/Institut für Getreideverarbeitung (IGV),All,"18 Years to 79 Years   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,POLYPHEM,May-13,Sep-18,Dec-18,9-Feb-17,null,9-Feb-17,"DIfE (German Institute for Human Nutrition), Berlin, Germany",,https://ClinicalTrials.gov/show/NCT03047668
NCT03038022,Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH),,Completed,No Results Available,Heterozygous Familial Hypercholesterolemia,Drug: MGL-3196|Drug: Placebo,Mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C)|Safety and tolerability of MGL-3196 based on Adverse Events and Changes in Laboratory Values|Mean percent change from baseline on selected lipid parameters,"Madrigal Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,116,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MGL-3196-06,9-Feb-17,18-Dec-17,15-Jan-18,31-Jan-17,null,25-Jan-18,"Madrigal Research Site, Aalborg, Denmark|Madrigal Research Site, Viborg, Denmark",,https://ClinicalTrials.gov/show/NCT03038022
NCT03027336,Efficacy and Tolerability of the Nutraceutical Formulation Coleosoma in Dyslipidemic Subjects,Coleosoma,Completed,No Results Available,Dyslipidemias,Dietary Supplement: Coleosoma|Dietary Supplement: Placebo,"Change from baseline values of non-HDL cholesterol (mg/dl) after 12 weeks of coleosoma treatment vs placebo|change from baseline values of non-HDL cholesterol (mg/dl) at 4 weeks of coleosoma treatment vs placebo|change from baseline values of Free Plasma Glucose (mg/dl) at 12 weeks of coleosoma treatment vs placebo|change from baseline values of Body Mass Index (Kg/m2) at 12 weeks of coleosoma treatment vs placebo|change from baseline values of waist circumference (cm) at 12 weeks of coleosoma treatment vs placebo|Change from baseline values of HbA1C (%) at 12 weeks of coleosoma treatment vs placebo|Change from baseline values of LDL Cholesterol, triglycerides and HDL cholesterol at 12 weeks of coleosoma treatment vs placebo|Change from baseline values of ApoB/Apo A1 ratio at 12 weeks of coleosoma treatment vs placebo|Change from baseline values of inflammatory cytokines (IL-1, IL6, IL-10, hsPCR, TNFalpha ) at 12 weeks of coleosoma treatment vs placebo|Change from baseline values of insulin (pmol/l) at 12 weeks of coleosoma treatment vs placebo|Change from baseline values of hormone profile (glucagon, active GLP-1 and GIP) at 12 weeks of coleosoma treatment vs placebo|Change from baseline values of Endothelial Progenitor Cells (EPC) number at 12 weeks of coleosoma treatment vs placebo",Azienda Ospedaliero-Universitaria di Parma|DOC generici srl,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,39,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",COLEOSOMA 29-06,Jan-16,Aug-16,Oct-16,23-Jan-17,null,23-Jan-17,"Endocrinology Unit, Parma, Italy",,https://ClinicalTrials.gov/show/NCT03027336
NCT03026933,Evaluate the Efficacy and Safety of KI1107 in Patients Whose TG Level is Not Adequately Controlled With Rosuvastatin Calcium Monotherapy While LDL-C is Properly Controlled,ROMANTIC,Completed,No Results Available,Dyslipidemias,"Drug: KI1107 4 Capsules, QD|Drug: Rosuvastatin Calcium 20 MG, QD",Variation rate of Non HDL-C|Variation rate of TG|Variation rate of TC|Variation rate of LDL-C|Variation rate of VLDL-C|Variation rate of Apo A-I|Variation rate of Apo B,"Kuhnil Pharmaceutical Co., Ltd.",All,"19 Years to 80 Years   (Adult, Older Adult)",Phase 3,215,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",13-OR-8301,May-14,Mar-16,Mar-16,20-Jan-17,null,20-Jan-17,,,https://ClinicalTrials.gov/show/NCT03026933
NCT03025451,Retrospective Evaluation of Athens Complete Health Improvement Program (CHIP) Database,,Completed,No Results Available,Cardiovascular Diseases|Diabetes Mellitus|Hypertension|Dyslipidemias|Overweight and Obesity,Behavioral: The Complete Health Improvement Program,Weight|Blood Pressure|Fasting Lipid Profile|Fasting Glucose,Ohio University,All,"Child, Adult, Older Adult",Not Applicable,512,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16X44,May-11,Dec-15,Mar-16,19-Jan-17,null,2-Nov-18,"Ohio University, Athens, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03025451
NCT03021889,Nutritional Therapy Improves Dyslipidemia in HIV Infected Teenagers With Antiretroviral Treatment,,Completed,No Results Available,Adolescent Behavior|Hiv|Dyslipidemias,Behavioral: Nutritional therapy|Behavioral: Control group,Blood plasma level of total cholesterol|Food intake|Nutritional status|Blood plasma level of triglycerides|Blood plasma level of HDL cholesterol,Hospital de Clinicas de Porto Alegre|Centro Universitario La Salle,All,"13 Years to 19 Years   (Child, Adult)",Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Supportive Care,150018,May-15,Nov-15,Nov-15,16-Jan-17,null,23-Aug-17,,,https://ClinicalTrials.gov/show/NCT03021889
NCT03019263,"Berberine, Chlorogenic Acid and Tocotrienols in Menopause-associated Dyslipidemia",,Completed,No Results Available,Dyslipidemia,Dietary Supplement: Nutraceutical|Other: Control,LDL cholesterol|Insulin resistance|Total cholesterol|HDL cholesterol|Blood glucose|Serum Insulin|Body weight|Fat distribution|Fat Mass|Menopausal symptoms|Quality of life,IRCCS Policlinico S. Matteo|University of Pavia,Female,"Child, Adult, Older Adult",Not Applicable,63,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20140012470,31-Mar-17,12-Jan-18,12-Jan-18,12-Jan-17,null,16-Jan-18,"Fondazione IRCCS Policlinico San Matteo, Pavia, Italy",,https://ClinicalTrials.gov/show/NCT03019263
NCT03017950,Pharmacokinetic Drug-drug Interaction of CKD-330 and D086,,Completed,No Results Available,Hypertension|Hyperlipidemias,Drug: CKD-330|Drug: D086|Drug: CKD-330 + D086,"AUCτ,ss of Candesartan and Amlodipine|AUCτ,ss of atorvastatin and 2-hydroxy atorvastatin",Chong Kun Dang Pharmaceutical,Male,19 Years to 45 Years   (Adult),Phase 1,83,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,170DDI16017,Dec-16,Mar-17,May-17,11-Jan-17,null,21-Jul-17,"Inha University Hospital, Incheon, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03017950
NCT03011450,Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment,,"Active, not recruiting",No Results Available,Severe Hypertriglyceridemia,Drug: K-877|Drug: Fenofibrate|Drug: Placebo (for K-877),Percent change of fasting triglyceride(TG) levels|Percent change of fasting TG levels|Percent change of other lipid perimeter,"Kowa Research Institute, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,420,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",K-877-303,26-Nov-16,Sep-19,Sep-19,5-Jan-17,null,18-Dec-18,"Central Research Associates, Inc., Birmingham, Alabama, United States|Central Alabama Research, Birmingham, Alabama, United States|Cahaba Research, Inc., Birmingham, Alabama, United States|Boyett Health Services Inc, Hamilton, Alabama, United States|Longwood Research - Saadat Ansari, MD, LLC, Huntsville, Alabama, United States|Terence T. Hart, MD, Tuscumbia, Alabama, United States|Arrowhead Health Centers, Glendale, Arizona, United States|Phoenix Medical Research Institute, LLC, Peoria, Arizona, United States|Elite Clinical Studies, Phoenix, Arizona, United States|Clinical Research Institute of Arizona, Surprise, Arizona, United States|iResearch, Little Rock, Arkansas, United States|Lynn Institute of the Ozarks, Little Rock, Arkansas, United States|Advanced Research Center, Anaheim, California, United States|Torrance Clinical Research Institute Inc., Lomita, California, United States|Downtown L.A. Research Center, Inc., Los Angeles, California, United States|Catalina Research Institute, LLC, Montclair, California, United States|Pacific Coast Cardiology and Research, Newport Beach, California, United States|Lucita M. Cruz, MD., Inc., Norwalk, California, United States|Integrated Research Center, San Diego, California, United States|Optimus Medical Group, San Francisco, California, United States|Creekside Endocrine Associates, PC, Denver, Colorado, United States|Atlantic Clinical Research Collaborative, Boynton Beach, Florida, United States|ALL Medical Research, LLC, Cooper City, Florida, United States|S & W Clinical Research, Fort Lauderdale, Florida, United States|Indago Research and Health Center, Hialeah, Florida, United States|Jacksonville Impotence Treatment Center, Jacksonville, Florida, United States|Advanced Medical Pain Management (AMPM) Research Clinic, Miami Gardens, Florida, United States|AMPM Research Clinic, Miami Gardens, Florida, United States|Advanced Research Institute Inc, New Port Richey, Florida, United States|Ocala Cardiovascular Research, Ocala, Florida, United States|South Florida Research Solutions LLC., Pembroke Pines, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Cardiovascular Center of Sarasota, Sarasota, Florida, United States|Meridien Research, Tampa, Florida, United States|Columbus Regional Research Institute, Columbus, Georgia, United States|iResearch - Atlanta, Decatur, Georgia, United States|Physicians Research Associates, Inc, Lawrenceville, Georgia, United States|Georgia Institute for Clinical Research, Marietta, Georgia, United States|Endocrine Research Solutions, Inc, Roswell, Georgia, United States|Meridian Clinical Research - Savannah, GA, Savannah, Georgia, United States|Solaris Clinical Research, Meridian, Idaho, United States|Lemah Creek Clinical Research, Burr Ridge, Illinois, United States|Cedar-Crosse Research Center, Chicago, Illinois, United States|Apex Medical Research, Chicago, Illinois, United States|Koch Family Medicine, Morton, Illinois, United States|Community Hospital of Anderson and Madison County, Inc, Anderson, Indiana, United States|American Health Network - Avon Clinical Research Department, Avon, Indiana, United States|Medisphere Medical Research Center, Evansville, Indiana, United States|Midwest Institute for Clinical Research, Indianapolis, Indiana, United States|Buynak Clinical Research, P.C., Valparaiso, Indiana, United States|West Broadway Clinic, Council Bluffs, Iowa, United States|The Iowa Clinic - Cardiovascular Services, West Des Moines, Iowa, United States|Professional Research Network of Kansas, LLC, Wichita, Kansas, United States|Kentucky Diabetes Endocrinology Center, Lexington, Kentucky, United States|The Research Group of Lexington, LLC, Lexington, Kentucky, United States|Research Integrity LLC, Owensboro, Kentucky, United States|Clinical Trials Management, LLC - Northshore, Covington, Louisiana, United States|Mandeville, Louisiana, United States|Clinical Trials Management LLC - Southshore, Metairie, Louisiana, United States|Grace Research, LLC, Shreveport, Louisiana, United States|Clinical Trials of America, LLC, West Monroe, Louisiana, United States|Maryland Cardiovascular Specialist, Baltimore, Maryland, United States|Regeneris Medical, North Attleboro, Massachusetts, United States|Aa Mrc, Llc, Flint, Michigan, United States|Oakland Medical Research Center, Troy, Michigan, United States|David M. Headley, MD P.A., Port Gibson, Mississippi, United States|Consult and Research Associates, Saint Louis, Missouri, United States|Advance Clinical Research, Inc, Saint Louis, Missouri, United States|Glacier View Research Institute, Kalispell, Montana, United States|Desert Endocrinology Clinical Research Center, Henderson, Nevada, United States|Palm Research Center, Inc., Las Vegas, Nevada, United States|Lovelace Scientific Resources, Albuquerque, New Mexico, United States|Lakeshore Primary Care Associate, Hamburg, New York, United States|Mid-Hudson Medical Research, PLLC - Hopewell Junction, New Windsor, New York, United States|Mid-Hudson Medical Research, PLLC - New Windsor, New Windsor, New York, United States|Orchard Park Family Practice, Orchard Park, New York, United States|Diabetes and Endocrinology Consultants, P.C., Morehead City, North Carolina, United States|Lillestol Research, LLC, Fargo, North Dakota, United States|Sterling Research Group, Ltd. - Auburn, Cincinnati, Ohio, United States|Aventiv Research, Inc., Columbus, Ohio, United States|Alpha Research Associates, LLC, Dayton, Ohio, United States|Prestige Clinical Research, Franklin, Ohio, United States|Ohio Clinical Research - Lyndhurst, Lyndhurst, Ohio, United States|Rama Research LLC, Marion, Ohio, United States|RAS Health Ltd, Marion, Ohio, United States|Summit Research Group, LLC, Munroe Falls, Ohio, United States|Ohio Clinical Research, LLC - Willoughby Hills, Willoughby Hills, Ohio, United States|COR Clinical Research, LLC., Oklahoma City, Oklahoma, United States|South Oklahoma Heart Research, Oklahoma City, Oklahoma, United States|Clinical Research Associates of Central PA, LLC, Altoona, Pennsylvania, United States|Harleysville Medical Associates, Harleysville, Pennsylvania, United States|Richard M.Kastelic MD and Associates, Johnstown, Pennsylvania, United States|Green and Seidner Family Practice Associates, Lansdale, Pennsylvania, United States|Center for Medical Research, LLC, Providence, Rhode Island, United States|MD First Research, Anderson, South Carolina, United States|DeGarmo Institute Of Medical Research, Greer, South Carolina, United States|MD First Research, Lancaster, South Carolina, United States|Family Medicine of SayeBrook, Myrtle Beach, South Carolina, United States|Health Concepts, Rapid City, South Dakota, United States|PMG Research of Bristol, LLC - State, Bristol, Tennessee, United States|Chattanooga Research & Medicine, PLLC, Chattanooga, Tennessee, United States|Holston Medical Group, Kingsport, Tennessee, United States|New Phase Research & Development, Knoxville, Tennessee, United States|Clinical Research Solutions - Smyrna, TN, Smyrna, Tennessee, United States|Health Innovation Research Group, Arlington, Texas, United States|DCT-AACT, LLC, dba Discovery Clinical Trials, Austin, Texas, United States|Inquest Clinical Research, Baytown, Texas, United States|Padre Coast Clinical Research, Corpus Christi, Texas, United States|Protenium Clinical Research, LLC - Dallas, Dallas, Texas, United States|VA North Texas Health Care System - Dallas VA Medical Center (DVAMC), Dallas, Texas, United States|Academy of Diabetes, Thyroid and Endocrine, P.A., El Paso, Texas, United States|Juno Research, LLC, Houston, Texas, United States|Centex Studies, Inc., Houston, Texas, United States|Juno Research, LLC - Houston, Houston, Texas, United States|Pioneer Research Solutions Inc., Houston, Texas, United States|Grace Research, LLC - Huntsville, TX, Huntsville, Texas, United States|Protenium Clinical Research, LLC, Hurst, Texas, United States|Juno Research, LLC - Katy, Katy, Texas, United States|FMC Science, Lampasas, Texas, United States|Pinnacle Clinical Research, Live Oak, Texas, United States|DCT - McAllen Primary Care, LLC, McAllen, Texas, United States|San Antonio Premier Internal Medicine, San Antonio, Texas, United States|Physician PrimeCare Research Institute, PLLC dba Health Texas Research Institute, San Antonio, Texas, United States|Bandera Family HealthCare Research, LLC (BFHC), San Antonio, Texas, United States|Manassas Clinical Research Center, Manassas, Virginia, United States|York Clinical Research LLC, Norfolk, Virginia, United States|Cardiovascular Associates, Ltd, Virginia Beach, Virginia, United States|Exemplar Research Inc. - Fairmont, WV, Morgantown, West Virginia, United States|Allegiance Research Specialists, LLC, Wauwatosa, Wisconsin, United States|Brest Regional Hospital, Brest, Belarus|Gomel Regional Clinical Hospital, Gomel, Belarus|Gomel Regional Clinical Center of Cardiology, Gomel, Belarus|Grodno Regional Clinical Hospital, Grodno, Belarus|City Clinical Hospital #1, Minsk, Belarus|City Clinical Hospital #9, Minsk, Belarus|City Clinical Hospital #10, Minsk, Belarus|Minsk Regional Clinical Hospital, Minsk, Belarus|Mogilev Regional Medical and Diagnostic Center, Mogilev, Belarus|Vitebsk Regional Clinical Hospital, Vitebsk, Belarus|Medical Center Diamedical 2013 OOD, Dimitrovgrad, Bulgaria|University Multiprofile Hospital for Active Treatment Dr. Georgi Stranski EAD- First Cardiology Clinic, Pleven, Bulgaria|University Multiprofile Hospital for Active Treatment Dr. Georgi Stranski EAD- Second Cardiology Clinic, Pleven, Bulgaria|University Multiprofile Hospital for Active Treatment (UMHAT) Sveti Georgi, EAD - Clinic of Cardiology, Plovdiv, Bulgaria|MHAT Dr. Bratan Shukjerov, Smolyan, Bulgaria|Multiprofile Hospital For Active Treatment - Dr. Bratan Shukerov AD, Smolyan, Bulgaria|Fifth Multiprofile Hospital for Active Treatment - Sofia EAD - Department of Cardiology, Sofia, Bulgaria|Fifth Multiprofile Hospital for Active Treatment - Sofia EAD - Department of Endocrinology and Meteorism Diseases, Sofia, Bulgaria|Medical Center Orfey OOD, Stara Zagora, Bulgaria|Medicus Services SRO, Brandýs nad Labem, Czechia|Lipidova poradna, Bílina, Czechia|Fakultni nemocnice Hradec Kralove, Klinika gerontologicka a metabolicka, Hradec Králové, Czechia|Ordinace pro choroby srdce a cev, Praha 10, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia|Fakultni nemocnice v Motole, Praha 5, Czechia|Oblastni nemocnice Trutnov, Oddeleni klinicke biochemie, Trutnov, Czechia|MUDr. Nina Zemkova s.r.o. Interni Ambulance, Uherské Hradište, Czechia|Unimed Ajara LLC, Batumi, Georgia|Clinic LJ Ltd, Kutaisi, Georgia|Aleksandre Aladashvili Clinic - LLC, Tbilisi, Georgia|Archangel St Michael Multiprofile Clinical Hospital Ltd, Tbilisi, Georgia|Emergency Cardiology Center by Academician G. Chapidze Ltd, Tbilisi, Georgia|Institute of Clinical Cardiology Ltd, Tbilisi, Georgia|Unimed Kakheti - Caraps Medline LLC, Tbilisi, Georgia|Unimed Kakheti - Telavi Referral Hospital LLC, Telavi, Georgia|DRC Gyogyszervizsgalo Kozpont Kft, Balatonfüred, Hungary|DRC Balatongyorok, Balatongyörök, Hungary|Magyar Honvedseg Allami Egeszsegugyi Kozpont, II. sz Belgyogyaszat Osztaly, Budapest, Hungary|Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary|Dr Lakatos Ferenc Belgyogyaszati-Kardiologiai Maganrendelo, Békéscsaba, Hungary|Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary|BKS Research Kft., Hatvan, Hungary|Pecsi Tudomanyegyetem Klinikai Kozpont I.sz. Belgyogyaszati Klinika, Pécs, Hungary|Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz, Székesfehérvár, Hungary|Indywidualna Specjalistyczna Praktyka Lekarska w Dziedzinie Kardiologii, lek. med. Krzysztof Cymerman, Gdynia, Poland|SALVIA Lekston i Madej s.j., Katowice, Poland|Malopolskie Centrum Alergii i Immunoterapii Allmedis SP Z O O, Krakow, Poland|MEDICOME Sp. z o.o., Oświęcim, Poland|Centrum Zdrowia Metabolicznego Pawel Bogdanski, Poznań, Poland|Praktyka Lekarska Ewa Krzyzagorska, Poznań, Poland|Niepubliczny Zaklad Opieki Zdrowotnej Centrum Medyczne OMEGA SP Z O O, Płock, Poland|Clinmedica Research Omc Sp z o.o. Sp, Skierniewice, Poland|Centrum Kardiologiczne Pro Corde Sp. z o. o., Wrocław, Poland|AppleTreeClinics Sp. z o.o., Łódź, Poland|Nzoz Salusmed, Łódź, Poland|NZOZ All - Med Centrum Medyczne Specjalistyczne Gabinety Lekarskie Marcin Ogorek, Łódź, Poland|Northern Medical Clinical Center named after N.A. Semashko of the Federal Medical and Biological Agency, Arkhangelsk, Russian Federation|First City Clinical Hospital n.a. E.E.Volosevich, Arkhangelsk, Russian Federation|Altay Regional Cardiology Dispensary, Cardiology Department for Patients with Acute Myocardial Infarction, Barnaul, Russian Federation|Chita State Medical Academy, Chita, Russian Federation|Ural State Medical University based at Central City Clinical Hospital No.1 of Oktyabrskiy District, Ekaterinburg, Russian Federation|Interregional Clinical Diagnostic Center, Kazan, Russian Federation|Kazan State Medical University based at City Clinical Hospital #7, Kazan, Russian Federation|Federal State Budget Institution ""Scientific-Research Institute of Complex Problems of Cardiovascular Diseases, Kemerovo, Russian Federation|Medical Center Alliance, Kirovsk, Russian Federation|Krasnoyarsk State Medical University n.a. prof. V.F. Voino-Yasenetsky, Krasnoyarsk, Russian Federation|National Medical Research Center of Preventive Medicine, Moscow, Russian Federation|City Clinical Hospital #15 n.a. O.M. Filatov, Moscow, Russian Federation|Central Clinical Hospital of Russian Academy of Sciences, Moscow, Russian Federation|City Clinical Hospital n.a. M.E. Zhadkevich of Moscow Healthcare Department, Moscow, Russian Federation|National Medical Research Center of Cardiology - Department of Atherosclerosis, Moscow, Russian Federation|National Medical Research Center of Cardiology, Moscow, Russian Federation|City Clinical Hospital n.a. M.P. Konchalovskiy, Moscow, Russian Federation|Non-governmental Private Healthcare Institution ""Scientific Clinical Centre of Open Joint-Stock Company Russian Railways"" (JSC ""RZD""), Moscow, Russian Federation|Federal State Budget Institution ""Outpatient Clinic #3"" of Russian Federation President's Management Department, Moscow, Russian Federation|City Clinical Hospital No.2, Novosibirsk, Russian Federation|RC Medical LLC, Novosibirsk, Russian Federation|Research Institute of Physiology and Fundamental Medicine, Novosibirsk, Russian Federation|Orenburg State Medical University based at City Clinical Hospital #1, Orenburg, Russian Federation|Clinical-diagnostic center ""Zdorovye"", Rostov-on-Don, Russian Federation|Rostov-on-Don City Hospital of Emergency Care, Rostov-on-Don, Russian Federation|Clinic Complex JSC, Saint Petersburg, Russian Federation|North-Western State Medical University named after I.I. Mechnikov, Saint Petersburg, Russian Federation|Medical Technologies LLC, Saint Petersburg, Russian Federation|Limited Liability Company ""MedPomosch"", Saint Petersburg, Russian Federation|City hospital #38 n.a. N.A. Semashko, Saint Petersburg, Russian Federation|BioTechService LLC, Saint Petersburg, Russian Federation|Consultative Diagnostic Center with Out-patient Clinic, Saint Petersburg, Russian Federation|Almazov National Medical Research Centre, Scientific Laboratory of Electrocardiology, Saint Petersburg, Russian Federation|Saint-Petersburg State Budget Healthcare Institution ""City Pokrovskaya Hospital"", Department of Cardiology N.3, Saint Petersburg, Russian Federation|Regional Clinical Cardiology Dispensary, Saratov, Russian Federation|Saratov State Medical University n. a. V.I. Razumovsky, Saratov, Russian Federation|Almazov National Medical Research Centre, St. Petersburg, Russian Federation|Clinical Hospital #122 n. a. L.G. Sokolov of the Federal Medical Biological Agency, St. Petersburg, Russian Federation|Tomsk National Research Medical Center of Russian Academy of Sciences, Tomsk, Russian Federation|Autonomous Institution of healthcare of the Voronezh region ""Voronezh regional clinical consultative and diagnostic centre, Voronezh, Russian Federation|Yaroslavl Regional Clinical Hospital for War Veterans - International Center on the Problems of the Elderly ""Zdorovoe Dolgoletie"", Yaroslavl, Russian Federation|Ivano-Frankivsk Regional Clinical Cardiological Dispensary, Chronic Ischaemic Heart Disease Department, Ivano-Frankivs'k, Ukraine|Municipal Healthcare Institution Kharkiv City Clinical Hospital #27, Intensive Therapy Department, Kharkiv, Ukraine|Kharkiv Medical Academy of Postgraduate Education, Kharkiv, Ukraine|Kharkiv Railway Clinic. Hosp.#1, Branch Office of ""Healthcare Center"" of PJSC ""Ukr. Railways"", Cardiology Depart #2, Kharkiv, Ukraine|Kharkiv Railway Clinic. Hosp.#1, Branch Office of Healthcare Center of PJSC Ukr. Railways, Cardiology Depart #1, Kharkiv, Ukraine|Municipal Healthcare Institution Kharkiv City Outpatient Clinic #9, General Practice and Family Medicine Department #1, Kharkiv, Ukraine|Limited Liability Company Treatment and Diagnostic Center Adonis Plus, Outpatient Department, Kyiv, Ukraine|Kyiv City Clinical Hospital #1, Urgent Cardiology Department, Kyiv, Ukraine|SI Institute of Gerontology n.a. D.F.Chebotarev NAMS of Ukraine, Cardiol. Un. of Clin. Physiology and Int. Organs Path. Dep-t., Gen. Ther.Unit, Kyiv, Ukraine|SI Institute of Gerontology n.a. D.F.Chebotarev NAMS of Ukraine, Cardiol. Un. of Clin. Physiology and Int. Organs Path. Dep-t, Kyiv, Ukraine|Municipal Institution City Clinical Hospital #3 n.a. prof. L.J. Aleinikova, Cardiology Intensive Therapy Department, Odesa, Ukraine|Small Private Enterprise, Medical Centre Puls, Vinnytsya, Ukraine|Municipal Institution City Clinical Hospital #6, Therapeutic Department, Zaporizhzhia, Ukraine",,https://ClinicalTrials.gov/show/NCT03011450
NCT03009474,Pharmacokinetics Study of CJ-30060 After Single Dose Administration in Health Male Volunteers,,Completed,No Results Available,Hypertension|Hyperlipidemias,"Drug: CJ-30060|Drug: Exforge tab 5/160mg, Crestor tab 10mg","Peak Plasma Concentration (Cmax) of amlodipine, valsartan, rosuvastatin|Area under the plasma concentration versus time curve (AUC) of amlodipine, valsartan, rosuvastatin|Time of maximum observed concentration (Tmax) of amlodipine, valsartan, rosuvastatin|Half life (t1/2) of amlodipine, valsartan, rosuvastatin|Oral clearance (CL/F) of amlodipine, valsartan, rosuvastatin|Apparent volume of distribution (Vd/F) of amlodipine, valsartan, rosuvastatin",CJ HealthCare Corporation,Male,20 Years to 45 Years   (Adult),Phase 1,52,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CJ_EXR_102,Feb-15,Apr-15,Apr-15,4-Jan-17,null,4-Jan-17,"Korea University Anam Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03009474
NCT03009487,A Clinical Trial to Evaluate the Efficacy and Safety of Olmesartan/Amlodipine/Rosuvastatin Combination Treatment in Patients With Concomitant Hypertension and Hyperlipidemia,,Unknown status,No Results Available,Hypertension|Hyperlipidemias,"Drug: Amlodipine/Olmesartan 10/40mg (Combination drug), Rosuvastatin 20mg|Drug: Olmesartan 40 mg, Rosuvastatin 20mg|Drug: Amlodipine/Olmesartan 10/40mg (Combination drug)",the change of sitSBP based on baseline between Treatment arm and control 1 arm|the change of LDL-C based on baseline between Treatment arm and control2 arm,Daewoong Pharmaceutical Co. LTD.,All,"20 Years to 80 Years   (Adult, Older Adult)",Phase 3,102,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",DWJ1351003,Nov-16,Jul-17,null,4-Jan-17,null,4-Jan-17,"Seoul national university bundang hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03009487
NCT03004001,Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic Syndrome,,Unknown status,No Results Available,Nephrotic Syndrome,Drug: Alirocumab|Drug: Alirocumab placebo|Drug: Atorvastatin,Levels of plasma lipoproteins|Levels of PCSK9|Triglyceride-rich lipoproteins (Remnants)|Lipidomics,Gloria Vega|Regeneron Pharmaceuticals|Aventis Pharmaceuticals|Dallas VA Medical Center,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,20,U.S. Fed|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",VA16-029,Jan-17,Dec-18,Dec-18,28-Dec-16,null,13-Mar-17,"DallasVAMC, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT03004001
NCT03001817,Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function,,"Active, not recruiting",No Results Available,Severe Hypertriglyceridemia,Drug: K-877|Drug: Fenofibrate|Drug: Placebo (for K-877)|Drug: Placebo (for Fenofibrate),Percent change of Fasting Triglyceride(TG) Levels|Percent change of Fasting TG Levels|Percent Change of Other Lipid Parameters,"Kowa Research Institute, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,630,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",K-877-301,28-Nov-16,Sep-19,Sep-19,23-Dec-16,null,18-Dec-18,"Central Research Associates, Inc., Birmingham, Alabama, United States|Central Alabama Research, Birmingham, Alabama, United States|Cahaba Research, Inc., Birmingham, Alabama, United States|Boyett Health Services Inc, Hamilton, Alabama, United States|Longwood Research - Saadat Ansari, MD, LLC, Huntsville, Alabama, United States|Terence T. Hart, MD, Tuscumbia, Alabama, United States|Arrowhead Health Centers, Glendale, Arizona, United States|Phoenix Medical Research Institute, LLC, Peoria, Arizona, United States|Elite Clinical Studies, Phoenix, Arizona, United States|Clinical Research Institute of Arizona, Surprise, Arizona, United States|iResearch, Little Rock, Arkansas, United States|Lynn Institute of the Ozarks, Little Rock, Arkansas, United States|Advanced Research Center, Anaheim, California, United States|Torrance Clinical Research Institute Inc., Lomita, California, United States|Downtown L.A. Research Center, Inc., Los Angeles, California, United States|Catalina Research Institute, LLC, Montclair, California, United States|Pacific Coast Cardiology and Research, Newport Beach, California, United States|Lucita M. Cruz, MD., Inc., Norwalk, California, United States|Integrated Research Center, San Diego, California, United States|Optimus Medical Group, San Francisco, California, United States|Creekside Endocrine Associates, PC, Denver, Colorado, United States|Atlantic Clinical Research Collaborative, Boynton Beach, Florida, United States|ALL Medical Research, LLC, Cooper City, Florida, United States|S & W Clinical Research, Fort Lauderdale, Florida, United States|Indago Research and Health Center, Hialeah, Florida, United States|Jacksonville Impotence Treatment Center, Jacksonville, Florida, United States|Advanced Medical Pain Management (AMPM) Research Clinic, Miami Gardens, Florida, United States|AMPM Research Clinic, Miami Gardens, Florida, United States|Advanced Research Institute Inc, New Port Richey, Florida, United States|Ocala Cardiovascular Research, Ocala, Florida, United States|South Florida Research Solutions LLC., Pembroke Pines, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Cardiovascular Center of Sarasota, Sarasota, Florida, United States|Meridien Research, Tampa, Florida, United States|Columbus Regional Research Institute, Columbus, Georgia, United States|iResearch - Atlanta, Decatur, Georgia, United States|Physicians Research Associates, Inc, Lawrenceville, Georgia, United States|Georgia Institute for Clinical Research, Marietta, Georgia, United States|Endocrine Research Solutions, Inc, Roswell, Georgia, United States|Meridian Clinical Research - Savannah, GA, Savannah, Georgia, United States|Solaris Clinical Research, Meridian, Idaho, United States|Lemah Creek Clinical Research, Burr Ridge, Illinois, United States|Cedar-Crosse Research Center, Chicago, Illinois, United States|Apex Medical Research, Chicago, Illinois, United States|Koch Family Medicine, Morton, Illinois, United States|Community Hospital of Anderson and Madison County, Inc, Anderson, Indiana, United States|American Health Network - Avon Clinical Research Department, Avon, Indiana, United States|Medisphere Medical Research Center, Evansville, Indiana, United States|Midwest Institute for Clinical Research, Indianapolis, Indiana, United States|Buynak Clinical Research, P.C., Valparaiso, Indiana, United States|West Broadway Clinic, Council Bluffs, Iowa, United States|The Iowa Clinic - Cardiovascular Services, West Des Moines, Iowa, United States|Professional Research Network of Kansas, LLC, Wichita, Kansas, United States|Kentucky Diabetes Endocrinology Center, Lexington, Kentucky, United States|The Research Group of Lexington, LLC, Lexington, Kentucky, United States|Research Integrity LLC, Owensboro, Kentucky, United States|Clinical Trials Management, LLC - Northshore, Covington, Louisiana, United States|Mandeville, Louisiana, United States|Clinical Trials Management LLC - Southshore, Metairie, Louisiana, United States|Grace Research, LLC, Shreveport, Louisiana, United States|Clinical Trials of America, LLC, West Monroe, Louisiana, United States|Maryland Cardiovascular Specialist, Baltimore, Maryland, United States|Regeneris Medical, North Attleboro, Massachusetts, United States|Aa Mrc, Llc, Flint, Michigan, United States|Oakland Medical Research Center, Troy, Michigan, United States|David M. Headley, MD P.A., Port Gibson, Mississippi, United States|Consult and Research Associates, Saint Louis, Missouri, United States|Advance Clinical Research, Inc, Saint Louis, Missouri, United States|Glacier View Research Institute, Kalispell, Montana, United States|Desert Endocrinology Clinical Research Center, Henderson, Nevada, United States|Palm Research Center, Inc., Las Vegas, Nevada, United States|Lovelace Scientific Resources, Albuquerque, New Mexico, United States|Lakeshore Primary Care Associate, Hamburg, New York, United States|Mid-Hudson Medical Research, PLLC - Hopewell Junction, New Windsor, New York, United States|Mid-Hudson Medical Research, PLLC - New Windsor, New Windsor, New York, United States|Orchard Park Family Practice, Orchard Park, New York, United States|Diabetes and Endocrinology Consultants, P.C., Morehead City, North Carolina, United States|Lillestol Research, LLC, Fargo, North Dakota, United States|Sterling Research Group, Ltd. - Auburn, Cincinnati, Ohio, United States|Aventiv Research, Inc., Columbus, Ohio, United States|Alpha Research Associates, LLC, Dayton, Ohio, United States|Prestige Clinical Research, Franklin, Ohio, United States|Ohio Clinical Research - Lyndhurst, Lyndhurst, Ohio, United States|Rama Research LLC, Marion, Ohio, United States|RAS Health Ltd, Marion, Ohio, United States|Summit Research Group, LLC, Munroe Falls, Ohio, United States|Ohio Clinical Research, LLC - Willoughby Hills, Willoughby Hills, Ohio, United States|COR Clinical Research, LLC., Oklahoma City, Oklahoma, United States|South Oklahoma Heart Research, Oklahoma City, Oklahoma, United States|Clinical Research Associates of Central PA, LLC, Altoona, Pennsylvania, United States|Harleysville Medical Associates, Harleysville, Pennsylvania, United States|Richard M.Kastelic MD and Associates, Johnstown, Pennsylvania, United States|Green and Seidner Family Practice Associates, Lansdale, Pennsylvania, United States|Center for Medical Research, LLC, Providence, Rhode Island, United States|MD First Research, Anderson, South Carolina, United States|DeGarmo Institute Of Medical Research, Greer, South Carolina, United States|MD First Research, Lancaster, South Carolina, United States|Family Medicine of SayeBrook, Myrtle Beach, South Carolina, United States|Health Concepts, Rapid City, South Dakota, United States|PMG Research of Bristol, LLC - State, Bristol, Tennessee, United States|Chattanooga Research & Medicine, PLLC, Chattanooga, Tennessee, United States|Holston Medical Group, Kingsport, Tennessee, United States|New Phase Research & Development, Knoxville, Tennessee, United States|Clinical Research Solutions - Smyrna, TN, Smyrna, Tennessee, United States|Health Innovation Research Group, Arlington, Texas, United States|DCT-AACT, LLC, dba Discovery Clinical Trials, Austin, Texas, United States|Inquest Clinical Research, Baytown, Texas, United States|Padre Coast Clinical Research, Corpus Christi, Texas, United States|Protenium Clinical Research, LLC - Dallas, Dallas, Texas, United States|VA North Texas Health Care System - Dallas VA Medical Center (DVAMC), Dallas, Texas, United States|Academy of Diabetes, Thyroid and Endocrine, P.A., El Paso, Texas, United States|Juno Research, LLC, Houston, Texas, United States|Centex Studies, Inc., Houston, Texas, United States|Juno Research, LLC - Houston, Houston, Texas, United States|Pioneer Research Solutions Inc., Houston, Texas, United States|Grace Research, LLC - Huntsville, TX, Huntsville, Texas, United States|Protenium Clinical Research, LLC, Hurst, Texas, United States|Juno Research, LLC - Katy, Katy, Texas, United States|FMC Science, Lampasas, Texas, United States|Pinnacle Clinical Research, Live Oak, Texas, United States|DCT - McAllen Primary Care, LLC, McAllen, Texas, United States|San Antonio Premier Internal Medicine, San Antonio, Texas, United States|Physician PrimeCare Research Institute, PLLC dba Health Texas Research Institute, San Antonio, Texas, United States|Bandera Family HealthCare Research, LLC (BFHC), San Antonio, Texas, United States|Manassas Clinical Research Center, Manassas, Virginia, United States|York Clinical Research LLC, Norfolk, Virginia, United States|Cardiovascular Associates, Ltd, Virginia Beach, Virginia, United States|Exemplar Research Inc. - Fairmont, WV, Morgantown, West Virginia, United States|Allegiance Research Specialists, LLC, Wauwatosa, Wisconsin, United States|Brest Regional Hospital, Brest, Belarus|Gomel Regional Clinical Hospital, Gomel, Belarus|Gomel Regional Clinical Center of Cardiology, Gomel, Belarus|Grodno Regional Clinical Hospital, Grodno, Belarus|City Clinical Hospital #1, Minsk, Belarus|City Clinical Hospital #9, Minsk, Belarus|City Clinical Hospital #10, Minsk, Belarus|Minsk Regional Clinical Hospital, Minsk, Belarus|Mogilev Regional Medical and Diagnostic Center, Mogilev, Belarus|Vitebsk Regional Clinical Hospital, Vitebsk, Belarus|Medical Center Diamedical 2013 OOD, Dimitrovgrad, Bulgaria|University Multiprofile Hospital for Active Treatment Dr. Georgi Stranski EAD- First Cardiology Clinic, Pleven, Bulgaria|University Multiprofile Hospital for Active Treatment Dr. Georgi Stranski EAD- Second Cardiology Clinic, Pleven, Bulgaria|University Multiprofile Hospital for Active Treatment (UMHAT) Sveti Georgi, EAD - Clinic of Cardiology, Plovdiv, Bulgaria|MHAT Dr. Bratan Shukjerov, Smolyan, Bulgaria|Multiprofile Hospital For Active Treatment - Dr. Bratan Shukerov AD, Smolyan, Bulgaria|Fifth Multiprofile Hospital for Active Treatment - Sofia EAD - Department of Cardiology, Sofia, Bulgaria|Fifth Multiprofile Hospital for Active Treatment - Sofia EAD - Department of Endocrinology and Meteorism Diseases, Sofia, Bulgaria|Medical Center Orfey OOD, Stara Zagora, Bulgaria|Medicus Services SRO, Brandýs nad Labem, Czechia|Lipidova poradna, Bílina, Czechia|Fakultni nemocnice Hradec Kralove, Klinika gerontologicka a metabolicka, Hradec Králové, Czechia|Ordinace pro choroby srdce a cev, Praha 10, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia|Fakultni nemocnice v Motole, Praha 5, Czechia|Oblastni nemocnice Trutnov, Oddeleni klinicke biochemie, Trutnov, Czechia|MUDr. Nina Zemkova s.r.o. Interni Ambulance, Uherské Hradište, Czechia|Unimed Ajara LLC, Batumi, Georgia|Clinic LJ Ltd, Kutaisi, Georgia|Aleksandre Aladashvili Clinic - LLC, Tbilisi, Georgia|Archangel St Michael Multiprofile Clinical Hospital Ltd, Tbilisi, Georgia|Emergency Cardiology Center by Academician G. Chapidze Ltd, Tbilisi, Georgia|Institute of Clinical Cardiology Ltd, Tbilisi, Georgia|Unimed Kakheti - Caraps Medline LLC, Tbilisi, Georgia|Unimed Kakheti - Telavi Referral Hospital LLC, Telavi, Georgia|DRC Gyogyszervizsgalo Kozpont Kft, Balatonfüred, Hungary|DRC Balatongyorok, Balatongyörök, Hungary|Magyar Honvedseg Allami Egeszsegugyi Kozpont, II. sz Belgyogyaszat Osztaly, Budapest, Hungary|Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary|Dr Lakatos Ferenc Belgyogyaszati-Kardiologiai Maganrendelo, Békéscsaba, Hungary|Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary|BKS Research Kft., Hatvan, Hungary|Pecsi Tudomanyegyetem Klinikai Kozpont I.sz. Belgyogyaszati Klinika, Pécs, Hungary|Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz, Székesfehérvár, Hungary|Indywidualna Specjalistyczna Praktyka Lekarska w Dziedzinie Kardiologii, lek. med. Krzysztof Cymerman, Gdynia, Poland|SALVIA Lekston i Madej s.j., Katowice, Poland|Malopolskie Centrum Alergii i Immunoterapii Allmedis SP Z O O, Krakow, Poland|MEDICOME Sp. z o.o., Oświęcim, Poland|Centrum Zdrowia Metabolicznego Pawel Bogdanski, Poznań, Poland|Praktyka Lekarska Ewa Krzyzagorska, Poznań, Poland|Niepubliczny Zaklad Opieki Zdrowotnej Centrum Medyczne OMEGA SP Z O O, Płock, Poland|Clinmedica Research Omc Sp z o.o. Sp, Skierniewice, Poland|Centrum Kardiologiczne Pro Corde Sp. z o. o., Wrocław, Poland|AppleTreeClinics Sp. z o.o., Łódź, Poland|Nzoz Salusmed, Łódź, Poland|NZOZ All - Med Centrum Medyczne Specjalistyczne Gabinety Lekarskie Marcin Ogorek, Łódź, Poland|Northern Medical Clinical Center named after N.A. Semashko of the Federal Medical and Biological Agency, Arkhangelsk, Russian Federation|First City Clinical Hospital n.a. E.E.Volosevich, Arkhangelsk, Russian Federation|Altay Regional Cardiology Dispensary, Cardiology Department for Patients with Acute Myocardial Infarction, Barnaul, Russian Federation|Chita State Medical Academy, Chita, Russian Federation|Ural State Medical University based at Central City Clinical Hospital No.1 of Oktyabrskiy District, Ekaterinburg, Russian Federation|Interregional Clinical Diagnostic Center, Kazan, Russian Federation|Kazan State Medical University based at City Clinical Hospital #7, Kazan, Russian Federation|Federal State Budget Institution ""Scientific-Research Institute of Complex Problems of Cardiovascular Diseases, Kemerovo, Russian Federation|Medical Center Alliance, Kirovsk, Russian Federation|Krasnoyarsk State Medical University n.a. prof. V.F. Voino-Yasenetsky, Krasnoyarsk, Russian Federation|National Medical Research Center of Preventive Medicine, Moscow, Russian Federation|City Clinical Hospital #15 n.a. O.M. Filatov, Moscow, Russian Federation|Central Clinical Hospital of Russian Academy of Sciences, Moscow, Russian Federation|City Clinical Hospital n.a. M.E. Zhadkevich of Moscow Healthcare Department, Moscow, Russian Federation|National Medical Research Center of Cardiology - Department of Atherosclerosis, Moscow, Russian Federation|National Medical Research Center of Cardiology, Moscow, Russian Federation|City Clinical Hospital n.a. M.P. Konchalovskiy, Moscow, Russian Federation|Non-governmental Private Healthcare Institution ""Scientific Clinical Centre of Open Joint-Stock Company Russian Railways"" (JSC ""RZD""), Moscow, Russian Federation|Federal State Budget Institution ""Outpatient Clinic #3"" of Russian Federation President's Management Department, Moscow, Russian Federation|City Clinical Hospital No.2, Novosibirsk, Russian Federation|RC Medical LLC, Novosibirsk, Russian Federation|Research Institute of Physiology and Fundamental Medicine, Novosibirsk, Russian Federation|Orenburg State Medical University based at City Clinical Hospital #1, Orenburg, Russian Federation|Clinical-diagnostic center ""Zdorovye"", Rostov-on-Don, Russian Federation|Rostov-on-Don City Hospital of Emergency Care, Rostov-on-Don, Russian Federation|Clinic Complex JSC, Saint Petersburg, Russian Federation|North-Western State Medical University named after I.I. Mechnikov, Saint Petersburg, Russian Federation|Medical Technologies LLC, Saint Petersburg, Russian Federation|Limited Liability Company ""MedPomosch"", Saint Petersburg, Russian Federation|City hospital #38 n.a. N.A. Semashko, Saint Petersburg, Russian Federation|BioTechService LLC, Saint Petersburg, Russian Federation|Consultative Diagnostic Center with Out-patient Clinic, Saint Petersburg, Russian Federation|Almazov National Medical Research Centre, Scientific Laboratory of Electrocardiology, Saint Petersburg, Russian Federation|Saint-Petersburg State Budget Healthcare Institution ""City Pokrovskaya Hospital"", Department of Cardiology N.3, Saint Petersburg, Russian Federation|Regional Clinical Cardiology Dispensary, Saratov, Russian Federation|Saratov State Medical University n. a. V.I. Razumovsky, Saratov, Russian Federation|Almazov National Medical Research Centre, St. Petersburg, Russian Federation|Clinical Hospital #122 n. a. L.G. Sokolov of the Federal Medical Biological Agency, St. Petersburg, Russian Federation|Tomsk National Research Medical Center of Russian Academy of Sciences, Tomsk, Russian Federation|Autonomous Institution of healthcare of the Voronezh region ""Voronezh regional clinical consultative and diagnostic centre, Voronezh, Russian Federation|Yaroslavl Regional Clinical Hospital for War Veterans - International Center on the Problems of the Elderly ""Zdorovoe Dolgoletie"", Yaroslavl, Russian Federation|Ivano-Frankivsk Regional Clinical Cardiological Dispensary, Chronic Ischaemic Heart Disease Department, Ivano-Frankivs'k, Ukraine|Municipal Healthcare Institution Kharkiv City Clinical Hospital #27, Intensive Therapy Department, Kharkiv, Ukraine|Kharkiv Medical Academy of Postgraduate Education, Kharkiv, Ukraine|Kharkiv Railway Clinic. Hosp.#1, Branch Office of ""Healthcare Center"" of PJSC ""Ukr. Railways"", Cardiology Depart #2, Kharkiv, Ukraine|Kharkiv Railway Clinic. Hosp.#1, Branch Office of Healthcare Center of PJSC Ukr. Railways, Cardiology Depart #1, Kharkiv, Ukraine|Municipal Healthcare Institution Kharkiv City Outpatient Clinic #9, General Practice and Family Medicine Department #1, Kharkiv, Ukraine|Limited Liability Company Treatment and Diagnostic Center Adonis Plus, Outpatient Department, Kyiv, Ukraine|Kyiv City Clinical Hospital #1, Urgent Cardiology Department, Kyiv, Ukraine|SI Institute of Gerontology n.a. D.F.Chebotarev NAMS of Ukraine, Cardiol. Un. of Clin. Physiology and Int. Organs Path. Dep-t., Gen. Ther.Unit, Kyiv, Ukraine|SI Institute of Gerontology n.a. D.F.Chebotarev NAMS of Ukraine, Cardiol. Un. of Clin. Physiology and Int. Organs Path. Dep-t, Kyiv, Ukraine|Municipal Institution City Clinical Hospital #3 n.a. prof. L.J. Aleinikova, Cardiology Intensive Therapy Department, Odesa, Ukraine|Small Private Enterprise, Medical Centre Puls, Vinnytsya, Ukraine|Municipal Institution City Clinical Hospital #6, Therapeutic Department, Zaporizhzhia, Ukraine",,https://ClinicalTrials.gov/show/NCT03001817
NCT03001076,Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility),,Completed,No Results Available,Hypercholesterolemia|Atherosclerosis|Statin Adverse Reaction,Drug: Bempedoic acid|Drug: Ezetimibe|Other: Placebo,Percent change in low-density lipoprotein cholesterol (LDL-C),Esperion Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 3,269,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1002-048,29-Nov-16,11-Jan-18,12-Feb-18,22-Dec-16,null,29-Mar-19,"Georgetown, Texas, United States",,https://ClinicalTrials.gov/show/NCT03001076
NCT02994745,A Clinical Trial to Evaluate the Pharmacokinetics and Safety/Tolerability of Fimasartan and Atorvastatin in Healthy Male Volunteers.,,Completed,No Results Available,"Hypertension, Hyperlipidemia","Drug: Fimasartan, Atorvastatin","Cmax(Maximum concentration of drug in plasma) of Fimasartan, Atorvastatin|AUClast(Area under the plasma drug concentration-time curve over the time interval from 0 to the last quantifiable plasma concentration) of Fimasartan, Atorvastatin","Boryung Pharmaceutical Co., Ltd",Male,19 Years to 50 Years   (Adult),Phase 1,60,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BR-FAVC-CT-102,23-Dec-16,21-Feb-17,Aug-17,16-Dec-16,null,18-Jan-18,"Seoul National University Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02994745
NCT02995720,A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin,,Completed,No Results Available,"Hypertension, Hyperlipidemia","Drug: Fimasartan/Amlodipine combination drug, Rosuvastatin","Cmax (Maximum concentration of drug in plasma) of Fimasartan, Amlodipine and Rosuvastatin|AUCt (Area Under the Curve from the dosing time to the last measurable concentration) of Fimasartan, Amlodipine and Rosuvastatin","Boryung Pharmaceutical Co., Ltd",Male,19 Years to 50 Years   (Adult),Phase 1,60,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BR-FARC-CT-103,26-Aug-16,10-Nov-16,30-May-17,16-Dec-16,null,10-Aug-17,,,https://ClinicalTrials.gov/show/NCT02995720
NCT02992301,Assessment of Atherosclerotic Plaque Characteristics Change by DCE-MRI With Alirocumab,,"Active, not recruiting",No Results Available,Atherosclerosis|Hyperlipidemia,Drug: Alirocumab,Changes in carotid atherosclerotic plaque characteristics as evidenced by effect on the volume transfer constant( Ktrans) and lipid-rich necrotic core (LRNC) size.|Associations between reductions in atherogenic lipids and changes in atherosclerotic plaque characteristics,Westside Medical Associates of Los Angeles|University of Washington|Regeneron Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 4,35,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,WMALA-99-032,Nov-16,Nov-19,Nov-19,14-Dec-16,null,26-Apr-19,"Westside Medical Associates of Los Angeles, Beverly Hills, California, United States",,https://ClinicalTrials.gov/show/NCT02992301
NCT02990260,Effect of Saccharomyces Cerevisiae in LDL Cholesterol,HONEY,Completed,No Results Available,Dyslipidemias,Dietary Supplement: Saccharomyces cerevisiae|Dietary Supplement: Lynside Wall Basic|Dietary Supplement: Placebo,Plasma LDL cholesterol|LDL cholesterol|Total cholesterol|Triglycerides|HDL cholesterol|Apo B|Apo A1|gamma GT|ASAT|ALAT,Lesaffre International,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,201,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",2016-A011094-47,Dec-16,Nov-17,May-18,13-Dec-16,null,12-Jun-18,"Institut Pasteur de Lille, Lille, France",,https://ClinicalTrials.gov/show/NCT02990260
NCT02990637,The Effect of Olive Leaf Extract Administration on Cardiovascular Health,,Completed,No Results Available,Overweight and Obesity|Elevated Cholesterol,Dietary Supplement: OLECOL|Dietary Supplement: Placebo,Blood lipid profile|Lipid peroxidation|Glucose metabolism|Systolic and diastolic blood pressure,Maastricht University Medical Center,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,80,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",163004,Jun-16,Apr-17,Apr-17,13-Dec-16,null,10-May-17,"Maastricht University Medical Center, Maastricht, Netherlands",,https://ClinicalTrials.gov/show/NCT02990637
NCT02991118,Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk,CLEAR Wisdom,Completed,No Results Available,Hypercholesterolemia|Atherosclerotic Cardiovascular Disease,Drug: bempedoic acid|Drug: placebo,Percent change in low-density lipoprotein cholesterol (LDL-C),Esperion Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 3,779,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1002-047|2016-003486-26,18-Nov-16,22-Aug-18,25-Sep-18,13-Dec-16,null,12-Nov-18,"Clearwater, Florida, United States|Georgetown, Texas, United States",,https://ClinicalTrials.gov/show/NCT02991118
NCT02991534,Cardiovascular Risk Screening and Risk Reduction in Women Vets,,Recruiting,No Results Available,Cardiovascular Diseases|Hypertension|Hyperlipidemias|Dyslipidemias|Obesity|Diabetes Mellitus|Tobacco Use Disorder|Overweight,Behavioral: CV Toolkit Components,Referrals to Health Promotion and Disease Prevention Services|Altarum Consumer Engagement (ACE)|PROMIS Global Health|Patient Satisfaction|Overall Anxiety Severity and Impairment Scale (OASIS)|Depression screen (PHQ-4),VA Office of Research and Development,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,260,U.S. Fed,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,QUX 16-007,15-Nov-16,30-Jun-19,30-Sep-20,13-Dec-16,null,30-Nov-18,"VA Greater Los Angeles Healthcare System, Sepulveda, CA, Sepulveda, California, United States|VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States|VA Connecticut Healthcare System West Haven Campus, West Haven, CT, West Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT02991534
NCT02989753,Effects of Two Herbal Dietary Supplements on Lipid Metabolism in Moderate Hypercholesterolemia and Hypertriglyceridemia,Lipiback,Completed,No Results Available,Hypercholesterolemia|Hypertriglyceridemia,Dietary Supplement: VAL070-A|Dietary Supplement: VAL070-B|Dietary Supplement: Placebo,Comparison between VAL070-B and placebo on changes between V1 and V2 visits of the fasting blood LDL cholesterol|Comparison between VAL070-A and placebo on changes between V1 and V2 visits of the fasting blood LDL cholesterol|Changes in fasting blood concentrations of triglycerides|Changes in fasting blood concentrations of total cholesterol|Changes in fasting blood concentrations of HDL cholesterol|Changes in fasting blood concentrations of non-HDL cholesterol|Changes in fasting blood concentrations of glucose|Changes in fasting blood concentrations of hsCRP|Changes in fasting blood concentrations of fructosamine|Changes in fasting blood concentrations of total free fatty acid|Changes in body weight|Changes in waist circumference|Changes in hip circumference|Changes in waist to hip ratio|Changes in fasting blood concentrations of urea|Changes in fasting blood concentrations of creatinine|Changes in fasting blood concentrations of AST (Aspartate aminotransferase)|Changes in fasting blood concentrations of ALT (Alanine aminotransferase)|Changes in fasting blood concentrations of GGT (Gamma glutamyltransferase)|Changes in complete blood count|Changes in heart rate|Changes in systolic blood pressure|Changes in diastolic blood pressure,Valbiotis|Biofortis Mérieux NutriSciences,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,40,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",2016-A01178-43,Jan-17,Jun-18,Jul-18,12-Dec-16,null,4-Jul-18,"Biofortis Mérieux NutriSciences Clinical Investigation Center, Saint Herblain, France",,https://ClinicalTrials.gov/show/NCT02989753
NCT02988115,Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant,CLEAR Serenity,Completed,No Results Available,Hypercholesterolemia|Atherosclerotic Cardiovascular Disease|Statin Adverse Reaction,Drug: bempedoic acid|Other: placebo,Percent change in low-density lipoprotein cholesterol (LDL-C),Esperion Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 3,345,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1002-046,15-Nov-16,19-Mar-18,16-Apr-18,9-Dec-16,null,25-Sep-18,"Kenosha, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02988115
NCT02984982,Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia,ODYSSEY J-IVUS,Completed,No Results Available,Hypercholesterolemia|Acute Coronary Syndrome,Drug: alirocumab SAR236553|Drug: atorvastatin|Drug: rosuvastatin|Drug: fenofibrate|Drug: bezafibrate|Drug: ezetimibe|Drug: antiplatelets|Drug: anticoagulants,"Percent change in normalized total atheroma volume (TAV)|Absolute change in PAV|Absolute change in normalized TAV|Absolute change in external elastic membrane (EEM) volume and lumen volume|Percent change in EEM volume and lumen volume|Absolute change in calculated LDL-C|Percent change in calculated LDL-C|Absolute change in other lipid parameters|Percent change in other lipid parameters|Cardiovascular adverse events (CHD death, non-fatal MI, fatal/non-fatal ischemic and/or haemorrhagic stroke, unstable angina causing hospitalization, congestive heart failure causing hospitalization, ischemia-driven coronary revascularization procedure)|Incidence of adverse events based on standard and systematic assessment including physical examinations, electrocardiograms (ECGs), vital signs and laboratory tests",Sanofi|Regeneron Pharmaceuticals,All,"20 Years and older   (Adult, Older Adult)",Phase 4,205,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ALIROL08069|U1111-1184-8764,15-Nov-16,27-Jul-18,27-Jul-18,7-Dec-16,null,1-Feb-19,"Investigational Site Number 392026, Bunkyoku-ku, Japan|Investigational Site Number 392022, Chiyoda-ku, Japan|Investigational Site Number 392032, Fujisawa-shi, Japan|Investigational Site Number 392004, Fukui-shi, Japan|Investigational Site Number 392007, Fukuoka-shi, Japan|Investigational Site Number 392048, Fukuoka-shi, Japan|Investigational Site Number 392008, Gifu-shi, Japan|Investigational Site Number 392039, Hiroshima-shi, Japan|Investigational Site Number 392028, Isehara-shi, Japan|Investigational Site Number 392036, Itabashi-ku, Japan|Investigational Site Number 392037, Itabashi-ku, Japan|Investigational Site Number 392024, Izumisano-shi, Japan|Investigational Site Number 392013, Izunokuni-shi, Japan|Investigational Site Number 392020, Kawaguchi-shi, Japan|Investigational Site Number 392041, Kisarazu-shi, Japan|Investigational Site Number 392009, Kitakyushu-shi, Japan|Investigational Site Number 392034, Kitakyushu-shi, Japan|Investigational Site Number 392044, Kochi-shi, Japan|Investigational Site Number 392002, Kumamoto-shi, Japan|Investigational Site Number 392011, Kumamoto-shi, Japan|Investigational Site Number 392003, Kurashiki-shi, Japan|Investigational Site Number 392018, Matsuyama-shi, Japan|Investigational Site Number 392021, Morioka-shi, Japan|Investigational Site Number 392017, Nagakute-shi, Aichi, Japan|Investigational Site Number 392047, Nagaoka-shi, Japan|Investigational Site Number 392038, Nagoya-shi, Japan|Investigational Site Number 392042, Nagoya-shi, Japan|Investigational Site Number 392033, Okayama-shi, Japan|Investigational Site Number 392006, Osaka-shi, Japan|Investigational Site Number 392010, Osaka-shi, Japan|Investigational Site Number 392045, Osaka-shi, Japan|Investigational Site Number 392046, Osaka-shi, Japan|Investigational Site Number 392015, Sagamihara-shi, Japan|Investigational Site Number 392019, Sakai-shi, Japan|Investigational Site Number 392035, Sapporo-shi, Japan|Investigational Site Number 392001, Tenri-shi, Japan|Investigational Site Number 392016, Toyoake-shi, Japan|Investigational Site Number 392025, Tsukuba-shi, Japan|Investigational Site Number 392040, Tsukuba-shi, Japan|Investigational Site Number 392005, Wakayama-shi, Japan|Investigational Site Number 392027, Yokohama-shi, Japan|Investigational Site Number 392043, Yokohama-shi, Japan",,https://ClinicalTrials.gov/show/NCT02984982
NCT02982408,Impact of Overfeeding and Following Exercise Training in Individuals With and Without Increased Risk of Type 2 Diabetes,,Unknown status,No Results Available,Type 2 Diabetes Mellitus|Insulin Resistance|Dyslipidemia,Dietary Supplement: High carbohydrate overfeeding|Behavioral: Exercise|Behavioral: Normal physical activity,Adipose tissue expandability|Glucose turnover rate|Lipid turnover rate|Epigenetics,"Rigshospitalet, Denmark|Novo Nordisk A/S|Augustinus Fonden",Male,35 Years to 40 Years   (Adult),Not Applicable,50,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,H-4-2014-128,Aug-16,Aug-18,Aug-18,5-Dec-16,null,5-Dec-16,"Rigshospitalet, Denmark, Copenhagen, Capital Region, Denmark",,https://ClinicalTrials.gov/show/NCT02982408
NCT02982798,The PK Characteristics of the Co-administration of Metformin SR and Rosuvastatin and JLP-1310 in Healthy Male Volunteers,,Completed,No Results Available,Diabetes|Hyperlipidemia,Drug: Metformin + Rosuvastatin|Drug: JLP-1310,AUClast of Metformin and rosuvastatin|Cmax of Metformin and rosuvastatin,"Jeil Pharmaceutical Co., Ltd.",Male,"19 Years and older   (Adult, Older Adult)",Phase 1,40,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,JLP-1310-103-PK,6-Jul-17,30-Aug-17,31-Jan-18,5-Dec-16,null,29-Mar-18,"Inha University Hospital, Incheon, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02982798
NCT02979704,A Comparative Study of Rosuvastatin and Atorvastatin in Patients With Hyperlipidemia,,Unknown status,No Results Available,Hyperlipidemia,Drug: Rosuvastatin|Drug: Atorvastatin,Establishment of superiority between rosuvastatin and atorvastatin on reduction of MDA in patients with hyperlipidemia|Establishment of superiority between rosuvastatin and atorvastatin on reduction of inflammation in patients with hyperlipidemia|Establishment of superiority between rosuvastatin and atorvastatin on reduction platelet count in patients with hyperlipidemia|Establishment of superiority between rosuvastatin and atorvastatin on increase prothrombin time in patients with hyperlipidemia|Establishment of superiority between rosuvastatin and atorvastatin on increase level of erythrocytic GSH in patients with hyperlipidemia,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 2|Phase 3,90,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,No.BSMMU/2016/8307,Sep-16,Jun-17,Jul-17,2-Dec-16,null,2-Dec-16,"BSMMU, Dhaka, Bangladesh",,https://ClinicalTrials.gov/show/NCT02979704
NCT02979015,"A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous (SC) Administered Alirocumab in Healthy Chinese Subjects",,Completed,No Results Available,Hypercholesterolemia,Drug: alirocumab SAR236553 (REGN727)|Drug: placebo,"Incidence of adverse events based on standard and systematic assessment including physical examinations, 12 lead ECGs, vital signs and laboratory tests|Incidence of injection site reactions|Change from baseline in LDL-C|Change from baseline in other lipid parameters|Pharmacokinetics: Assessment of serum concentrations of alirocumab|Pharmacokinetics: Assessment of serum concentrations of PCSK9",Sanofi|Regeneron Pharmaceuticals,All,18 Years to 45 Years   (Adult),Phase 1,35,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",PKD13404|U1111-1133-7871,29-Nov-16,27-Nov-17,27-Nov-17,1-Dec-16,null,5-Dec-17,"Investigational Site Number 156001, Beijing, China",,https://ClinicalTrials.gov/show/NCT02979015
NCT02977065,"To Assess the Safety, Efficacy and Tolerability of CKD-519, Administered With HMG-CoA Reductase Inhibitors",,Completed,No Results Available,Dyslipidemias,Drug: Atorvastatin 20mg|Drug: Atorvastatin 20 mg + CKD-519 50 mg|Drug: Atorvastatin 20 mg + CKD-519 100 mg|Drug: Atorvastatin 20 mg + CKD-519 200 mg|Drug: Rosuvastatin 10 mg|Drug: Rosuvastatin 10 mg + CKD-519 100 mg,"Percentage change from baseline (Visit 3) in LDL-C|Percentage change from baseline in HDL-C|Percentage change from baseline in concentration of HDL particles (HDL-P)|Change from baseline in size of HDL particles (HDL-P)|Percentage change from baseline in LDL-C|Change in concentration from baseline in LDL-C|Change in concentration from baseline in HDL-C|Percentage change from baseline in total cholesterol, TG, and non-HDL-C|Change in concentration from baseline in total cholesterol, TG, and non-HDL-C|Percentage change from baseline in apolipoprotein B (Apo B), apolipoprotein A1 (Apo A1), and apolipoprotein E (Apo E)|Change in concentration from baseline in Apo B, Apo A1, and Apo E|Percentage change from baseline in lipoprotein(a) (Lp-a)|Change in concentration from baseline in Lp-a|Change in concentration from baseline in high-sensitivity C-reactive protein at",Chong Kun Dang Pharmaceutical,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,62,Industry,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",148HL16011,23-Mar-17,30-Dec-17,30-Jan-18,30-Nov-16,null,6-Nov-18,"Not provided, Adelaide, Australia",,https://ClinicalTrials.gov/show/NCT02977065
NCT02977884,Complete Health Improvement Program (CHIP) Risk Reduction/Claims Evaluation Project,,Recruiting,No Results Available,Cardiovascular Diseases|Diabetes Mellitus|Hypertension|Dyslipidemias|Overweight and Obesity,Behavioral: The Complete Health Improvement Program,Healthcare expenses|Weight|Fasting Glucose|Fasting Lipid Profile|Absenteeism: Sick days on record at Ohio University Human Resources,Ohio University|Touro University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12X81,Aug-12,Nov-20,Dec-20,30-Nov-16,null,2-Nov-18,"Ohio University, Athens, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02977884
NCT02969070,"Effects of Nutraceutical Therapies on Endothelial Function, Platelet Aggregation, and Coronary Flow Reserve",NUTRENDO,Completed,No Results Available,Hypercholesterolemia|Endothelial Dysfunction,Dietary Supplement: LopiGLIK™ therapy|Dietary Supplement: Armolipid Plus® therapy,"Effects on endothelial function as evaluated by Reactive Hyperemia Index (RHI)|Evaluation of treatment tolerability|Reasons for treatment discontinuation|Effects on lipid profile (total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides)|Effects on metabolic indexes (glucose levels)|Effects on metabolic indexes [insulin plasma levels and insulin sensitivity index (HOMA index)]|Effects on platelet aggregation as evaluated by light transmission aggregometry (LTA)|Effects on coronary flow reserve (CFR) as evaluated by echocardiocolorDoppler visualization of coronary flow in the distal left anterior descending artery at rest and after cold pressure test (CPT)",Federico II University,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,28,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FedericoIIU 259/16,Nov-16,Sep-17,Oct-17,21-Nov-16,null,15-Feb-19,"University of Naples ""Federico II"", Naples, Italy",,https://ClinicalTrials.gov/show/NCT02969070
NCT02963311,A Study of ALN-PCSSC in Participants With Homozygous Familial Hypercholesterolemia (HoFH),ORION-2,Completed,No Results Available,Homozygous Familial Hypercholesterolemia,Drug: ALN-PCSSC|Drug: Standard of Care,"Percentage Change From Day 1 to Day 90 in LDL-C|Percentage Change From Day 1 to Day 180 (or Final Visit) in LDL-C|Absolute Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in LDL-C|Percentage Change From Day 1 to Day 60 and to Day 90 in PCSK9|Absolute Change From Day 1 to Day 60 and to Day 90 in PCSK9|Percentage Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Total Cholesterol, Triglycerides, HDLC, non-HDL-C, VLDL-C, Apo-A1 Apo-B and Lp(a)|Absolute Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Total Cholesterol, Triglycerides, HDLC, non-HDL-C, VLDL-C, Apo-A1 Apo-B and Lp(a)",The Medicines Company,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 2,4,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MDCO-PCS-16-02,13-Dec-16,8-Oct-18,8-Oct-18,15-Nov-16,null,21-Dec-18,"Research Site 201001, Los Angeles, California, United States|Research Site 231001, Amsterdam, Netherlands|Research Site 227001, Parktown, Johannesburg, South Africa",,https://ClinicalTrials.gov/show/NCT02963311
NCT02959762,Vitamin K to Slow Progression of Dyslipidemia and Diabetes Risk (Vita-K 'n' Kids Study II),,Recruiting,No Results Available,Obesity|Insulin Resistance|Obesity in Diabetes|Nutritional and Metabolic Diseases|Hyperlipidemia|Hyperglycemia|Cardiovascular Diseases,Dietary Supplement: Placebo-Control|Dietary Supplement: Low-Dose Vitamin K2 (menaquinone-7; 45-mcg/d)|Dietary Supplement: High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d),Change in serum lipid concentrations|Change in insulin sensitivity|Change in beta-cell function|Change in coagulation|Change in arterial stiffness (pulse wave velocity)|Change in endothelial function (flow-mediated dilation),Augusta University,All,8 Years to 17 Years   (Child),Phase 1|Phase 2,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",931430|16GRNT31090037,Oct-16,1-Dec-18,30-Dec-18,9-Nov-16,null,12-Jul-18,"Medical College of Georgia; Augusta University, Augusta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT02959762
NCT02957682,Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo,,"Active, not recruiting",No Results Available,Hypercholesterolemia,Drug: Praluent (Alirocumab)|Drug: Placebo,"Change in Cambridge Neuropsychological Test Automated Battery cognitive domain Spatial Working Memory strategy score|Percent change in calculated low density lipoprotein cholesterol (LDL-C)|Percent change in apolipoprotein (Apo) B|Percent change in non-high-density lipoprotein cholesterol (HDL-C),|Percent change in total cholesterol (Total-C)|Percent change in lipoprotein a [Lp(a)]|Percent change in HDL-C|Percent change in triglyceride (TG)|Percent change in apolipoprotein (Apo) A-1|Proportion of participants reaching LDL-C <70 mg/dL (1.81 mmol/L)|Proportion of participants reaching LDL-C <50 mg/dL (1.29 mmol/L)",Regeneron Pharmaceuticals|Sanofi,All,"40 Years to 85 Years   (Adult, Older Adult)",Phase 4,2176,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R727-CL-1532|2016-003189-16,18-Nov-16,27-Mar-20,4-May-20,8-Nov-16,null,10-May-18,"Alexander City, Alabama, United States|Birmingham, Alabama, United States|Site 1, Mobile, Alabama, United States|Site 2, Mobile, Alabama, United States|Beverly Hills, California, United States|Los Gatos, California, United States|North Hollywood, California, United States|Port Hueneme, California, United States|Westminster, California, United States|Colorado Springs, Colorado, United States|Denver, Colorado, United States|Atlantis, Florida, United States|Lake Worth, Florida, United States|Miami Springs, Florida, United States|Covington, Georgia, United States|Champaign, Illinois, United States|Site 1, Chicago, Illinois, United States|Site 2, Chicago, Illinois, United States|Rock Island, Illinois, United States|Site 1, Evansville, Indiana, United States|Site 2, Evansville, Indiana, United States|Site 1, Indianapolis, Indiana, United States|Site 2, Indianapolis, Indiana, United States|Ames, Iowa, United States|Iowa City, Iowa, United States|Waterloo, Iowa, United States|Hutchinson, Kansas, United States|Newton, Kansas, United States|Overland Park, Kansas, United States|Louisville, Kentucky, United States|Bangor, Maine, United States|Site 1, Baltimore, Maryland, United States|Site 2, Baltimore, Maryland, United States|Oxon Hill, Maryland, United States|Olive Branch, Mississippi, United States|Washington, Missouri, United States|Site 1, Buffalo, New York, United States|Site 2, Buffalo, New York, United States|New Hyde Park, New York, United States|Charlotte, North Carolina, United States|Greensboro, North Carolina, United States|Hickory, North Carolina, United States|High Point, North Carolina, United States|Site 1, Raleigh, North Carolina, United States|Site 2, Raleigh, North Carolina, United States|Rocky Mount, North Carolina, United States|Salisbury, North Carolina, United States|Statesville, North Carolina, United States|Wilmington, North Carolina, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Dayton, Ohio, United States|Duncansville, Pennsylvania, United States|Charleston, South Carolina, United States|Greenville, South Carolina, United States|Summerville, South Carolina, United States|Rapid City, South Dakota, United States|Bristol, Tennessee, United States|Jefferson City, Tennessee, United States|Site 1, Knoxville, Tennessee, United States|Site 2, Knoxville, Tennessee, United States|Site 3, Knoxville, Tennessee, United States|Site 4, Knoxville, Tennessee, United States|Dallas, Texas, United States|Site 1, Houston, Texas, United States|Site 2, Houston, Texas, United States|Schertz, Texas, United States|Shavano Park, Texas, United States|Falls Church, Virginia, United States|Winchester, Virginia, United States|Everett, Washington, United States|Puyallup, Washington, United States|Walla Walla, Washington, United States|Manitowoc, Wisconsin, United States|Pleven, Bulgaria|Plovdiv, Bulgaria|Site 1, Sofia, Bulgaria|Site 2, Sofia, Bulgaria|Site 3, Sofia, Bulgaria|Stara Zagora, Bulgaria|Varna, Bulgaria|Osorno, Chile|Site 1, Santiago, Chile|Site 2, Santiago, Chile|Site 3, Santiago, Chile|Site 4, Santiago, Chile|Site 5, Santiago, Chile|Site 1, Temuco, Chile|Site 2, Temuco, Chile|Viña del Mar, Chile|Site 1, Paide, Estonia|Site 2, Paide, Estonia|Site 1, Tallinn, Estonia|Site 2, Tallinn, Estonia|Tartu, Estonia|Bunkyō-Ku, Japan|Chuo Ku, Japan|Hachiōji, Japan|Iruma-gun, Japan|Itabashi-ku, Japan|Kahoku-gun, Japan|Kawasaki, Japan|Nakagami-gun, Japan|Shinagawa-Ku, Japan|Uji-shi, Japan|Yokohama, Japan|Aguascalientes, Mexico|Site 4, Ciudad de mexico, Mexico|Cuernavaca, Mexico|Culiacán, Mexico|Site 1, Guadalajara, Mexico|Site 2, Guadalajara, Mexico|Site 3, Guadalajara, Mexico|Site 4, Guadalajara, Mexico|Site 1, Mexico City, Mexico|Site 2, Mexico City, Mexico|Site 3, Mexico City, Mexico|Pachuca, Mexico|Querétaro, Mexico|San Juan Del Río, Mexico|Torreon, Mexico|Kirov, Russian Federation|Moscow, Russian Federation|Novosibirsk, Russian Federation|Rostov-on-Don, Russian Federation|Site 1, Saint Petersburg, Russian Federation|Site 2, Saint Petersburg, Russian Federation|Site 3, Saint Petersburg, Russian Federation|Site 4, Saint Petersburg, Russian Federation|Site 5, Saint Petersburg, Russian Federation|Site 6, Saint Petersburg, Russian Federation|Site 7, Saint Petersburg, Russian Federation|Site 8, Saint Petersburg, Russian Federation|Saratov, Russian Federation|Tyumen', Russian Federation|Site 1, Yaroslavl, Russian Federation|Site 2, Yaroslavl, Russian Federation|Site 3, Yaroslavl, Russian Federation|Site 1, Bloemfontein, South Africa|Site 2, Bloemfontein, South Africa|Site 1, Cape Town, South Africa|Site 2, Cape Town, South Africa|Claremont, South Africa|Halfway House, South Africa|Kempton Park, South Africa|Kuils River, South Africa|Mamelodi East, South Africa|Middelburg, South Africa|Observatory, South Africa|Paarl, South Africa|Port Elizabeth, South Africa|Site 1, Pretoria, South Africa|Site 2, Pretoria, South Africa|Site 3, Pretoria, South Africa|Somerset West, South Africa|Soweto, South Africa|Worcester, South Africa|Site 1, Kharkiv, Ukraine|Site 2, Kharkiv, Ukraine|Site 1, Kyiv, Ukraine|Site 2, Kyiv, Ukraine|Site 3, Kyiv, Ukraine|Site 4, Kyiv, Ukraine|Site 5, Kyiv, Ukraine|Site 6, Kyiv, Ukraine|Site 7, Kyiv, Ukraine|Site 8, Kyiv, Ukraine|L'viv, Ukraine|Site 1, Vinnitsa, Ukraine|Site 2, Vinnitsa, Ukraine|Site 3, Vinnitsa, Ukraine|Úzhgorod, Ukraine",,https://ClinicalTrials.gov/show/NCT02957682
NCT02955238,Latinos Understanding the Need for Adherence,LUNA,Completed,No Results Available,Atherosclerosis|High Blood Pressure|Type 2 Diabetes Mellitus|Heart Disease|Hypercholesterolemia,Behavioral: Special Intervention,Change in Carotid Intimal Medial Thickness (CIMT) Measurement|Medication Adherence,San Diego State University,All,"40 Years and older   (Adult, Older Adult)",Not Applicable,587,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,G00007349,Aug-09,Oct-13,Oct-13,4-Nov-16,null,4-Nov-16,"South Bay Latino Research Center, Chula Vista, California, United States",,https://ClinicalTrials.gov/show/NCT02955238
NCT02955368,Clinical Trial to Evaluate the Efficacy and Safety of DP-R212,,Withdrawn,No Results Available,Hypertension|Hypercholesterolemia,Drug: DP-R212|Drug: C1-R212|Drug: C2-R212,Percent change of LDL-Cholesterol|Change of mean seated Systolic Blood Pressure,Alvogen Korea,All,"19 Years and older   (Adult, Older Adult)",Phase 3,0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",DP-CTR212-III-03,Feb-17,Jul-17,Aug-17,4-Nov-16,null,5-Jun-17,,,https://ClinicalTrials.gov/show/NCT02955368
NCT02951962,A Study to Investigate Pharmacokinetic Drug Interaction and Safety of Telmisartan/Amlodipine and Rosuvastatin,,Completed,No Results Available,Hypertension|Hyperlipidemia,Drug: Twynsta 80/5mg|Drug: Crestor 20mg,"Telmisartan, Amlodipine, Rosuvastatin AUCτ|Telmisartan, Amlodipine, Rosuvastatin Cmax|Telmisartan, Amlodipine, Rosuvastatin Tmax|Telmisartan, Amlodipine, Rosuvastatin Cmin",Yuhan Corporation,Male,19 Years to 50 Years   (Adult),Phase 1,60,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,YHP1604-101,Aug-16,Sep-16,Sep-16,1-Nov-16,null,1-Feb-17,"Chonbuk National University Hospital, Chunju, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02951962
NCT02947620,"A Multi-center, Randomized, Double-blind, Active-controlled, Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Metformin/Atorvastatin Combination Therapy in Subjects With Type II Diabetes and Dyslipidemia",,Unknown status,No Results Available,Type II Diabetes|Dyslipidemia,"Drug: Metformin/Atorvastatin 1500mg/40mg, QD|Drug: Metformin 1500mg, QD|Drug: Atorvastatin 40mg, QD",Change in HbA1c|Change in LDL Cholesterol,Daewoong Pharmaceutical Co. LTD.,All,"19 Years to 80 Years   (Adult, Older Adult)",Phase 3,180,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",DW_MA001,Aug-15,Feb-17,null,28-Oct-16,null,31-Oct-16,"Samsung Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02947620
NCT02947334,Efficacy And Safety Of Bococizumab For Lipid Lowering In Asian Hypercholesterolemia Subjects,SPIRE-ASIA,Withdrawn,No Results Available,Primary Hyperlipidemia or Mixed Dyslipidemia,Biological: Bococizumab|Drug: Placebo,• Percent change from baseline in fasting LDL-C,Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",B1481047,31-Oct-16,3-May-19,3-May-19,27-Oct-16,null,2-Dec-17,"Beijing Anzhen Hospital, Capital Medical University, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT02947334
NCT02944383,A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia,INDIGO-1,"Active, not recruiting",No Results Available,Severe Hypertriglyceridemia|Mixed Dyslipidemia,Drug: Gemcabene|Drug: Placebo Oral Tablet,Change in fasting triglycerides from Baseline (Day 1) to Week 12 (Day 84),"Gemphire Therapeutics, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,91,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",GEM-401,Dec-16,11-Jan-18,May-18,25-Oct-16,null,14-Feb-18,"Appalachian Research Associates, Fort Payne, Alabama, United States|Del Sol Research Mangagement, LLC, Tucson, Arizona, United States|Westside Medical Associates of Los Angeles, Beverly Hills, California, United States|Hope Clinical Research, Canoga Park, California, United States|SC Clinical Research, Garden Grove, California, United States|National Research Institute, Huntington Park, California, United States|National Research Institute, Los Angeles, California, United States|Paradigm Clinical Research, San Diego, California, United States|Paradigm Research, Wheat Ridge, Colorado, United States|Excel Medical Research, Boca Raton, Florida, United States|Meridien Research, Bradenton, Florida, United States|Direct Helpers Research Center, Hialeah, Florida, United States|Indago Research and Health Center, Hialeah, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Sunrise Medical Research, Lauderdale Lakes, Florida, United States|AR Developoment Solutions, Miami Lakes, Florida, United States|San Marcus Research Clinic, Inc., Miami, Florida, United States|Millenium Clinical Research, Inc., Miami, Florida, United States|Medcare Research, Miami, Florida, United States|Soma Medical Research, West Palm Beach, Florida, United States|Evanston Premier Clinical Research, Evanston, Illinois, United States|Midwest Institute for Clinical Research, Inc., Indianapolis, Indiana, United States|Richard Lochamy, M.D., Junction City, Kansas, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|L-MARC Research Center, Louisville, Kentucky, United States|Clinical Trials Management, LLC, Covington, Louisiana, United States|Clinical Trials Management, LLC, Metairie, Louisiana, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|University of Michigan Health Systems, Ann Arbor, Michigan, United States|Elite Clinical Research, Jackson, Mississippi, United States|Clinical Research of South Nevada, Las Vegas, Nevada, United States|CHEAR Center, LLC, Bronx, New York, United States|Advantage Clinical Trials, Bronx, New York, United States|Eastern Carolina Medical Clinic, Benson, North Carolina, United States|Physicians East, NA, Farmville, North Carolina, United States|Physicians East, NA, Greenville, North Carolina, United States|Cary Medical Clinic, Morrisville, North Carolina, United States|Optimed Research, Columbus, Ohio, United States|PriMed Clinical Research, Dayton, Ohio, United States|Green and Seidner Family Practice Associates, Lansdale, Pennsylvania, United States|BTC of Lincoln, Lincoln, Rhode Island, United States|Carolinas Research Partners, LLC, Rock Hill, South Carolina, United States|Airline Complete Healthcare, Houston, Texas, United States|Sante Clinical Research, Kerrville, Texas, United States|FMC Science, Lampasas, Texas, United States|Clinical Investigations of Texas, Plano, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|Clinical Investigation Specialists, Kenosha, Wisconsin, United States|Ecogene-21, Chicoutimi, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02944383
NCT02942602,Effect of Lipid Modifying Drugs on HDL Function in Patients With Hyperlipidemia,,Completed,No Results Available,Hyperlipidemia,Drug: Atorvastatin 20 mg|Drug: Cholestyramine 8 g|Drug: Omega-3 2g|Drug: Concurrent with Atorvastatin 5 mg + Ezetimibe 10 mg|Behavioral: Lifestyle modification,Cholesterol efflux capacity (%)|Endothelial NO production (Arbitrary unit)|VCAM-1 expression (Arbitrary unit)|ROS generation (Arbitrary unit)|ApoA-I|ApoA-II|ApoC-I|ApoC-II|ApoC-III,Yonsei University,All,"20 Years to 80 Years   (Adult, Older Adult)",Not Applicable,58,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,4-2013-0281,3-Apr-14,23-May-16,23-May-16,24-Oct-16,null,18-Jul-18,"Division of Cardiology, Department of Internal Medicine,, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02942602
NCT02941796,"Pharmacokinetics and Safety of HCP1105 and Co-administration of HGP0918, HGP0816 in Healthy Male Volunteers",,Completed,No Results Available,Hyperlipidemias,Drug: HCP1105|Drug: HCP0918|Drug: HCP0816,baseline-corrected Cmax of DHA total lipid & EPA total lipid|baseline-corrected AUCt of DHA total lipid & EPA total lipid|Cmax of Rosuvastatin|AUCt of Rosuvastatin|Cmax of DHA total lipid & EPA total lipid|AUCt of DHA total lipid & EPA total lipid|Tmax of DHA total lipid & EPA total lipid|t1/2β of DHA total lipid & EPA total lipid|baseline-corrected partial AUC12/24/48 of DHA total lipid & EPA total lipid|AUC∞ of Rosuvastatin|Tmax of Rosuvastatin|t1/2β of Rosuvastatin|CL/F of Rosuvastatin|Vdz/F of Rosuvastatin,Hanmi Pharmaceutical Company Limited,All,19 Years to 55 Years   (Adult),Phase 1,68,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HM-ROMA-106,Jun-16,Jul-16,Oct-16,21-Oct-16,null,21-Oct-16,"Inje University Busan Paik Hospital, Busan, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02941796
NCT02941848,"Evaluate the Pharmacokinetics and Safety of HCP1306 and Co-administration of HGP0816, HGP1404 in Healthy Male Volunteers",,Completed,No Results Available,Primary Hypercholesterolemia,Drug: HGP0816|Drug: HGP1404|Drug: HCP1306,AUClast of Rosuvastatin|Cmax of Rosuvastatin|AUClast of Free Ezetimibe|Cmax of Free Ezetimibe|AUCinf of Rosuvastatin|tmax of Rosuvastatin|t1/2 of Rosuvastatin|CL/F of Rosuvastatin|Vd/F of Rosuvastatin|MRT of Rosuvastatin|AUCinf of Free Ezetimibe|Tmax of Free Ezetimibe|T1/2 of Free Ezetimibe|CL/F of Free Ezetimibe|Vd/F of Free Ezetimibe|MRT of Free Ezetimibe,Hanmi Pharmaceutical Company Limited,All,19 Years to 50 Years   (Adult),Phase 1,60,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HM-ROZE-102,Nov-14,Dec-14,Jan-15,21-Oct-16,null,21-Oct-16,,,https://ClinicalTrials.gov/show/NCT02941848
NCT02938091,Dietary Modulation of Hepatic Lipase (LIPC) -514 C/T Variant Associations With Lipids and Glucose,,Completed,No Results Available,Dyslipidemia|Impaired Glucose Tolerance,Other: High-fat diet|Other: Low-fat diet,change in fasting high-density lipoprotein cholesterol|change in fasting plasma triglycerides|change in fasting plasma glucose|oral glucose tolerance test|post-prandial lipemia 4 hours|post-prandial lipemia 8 hours,Tufts University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,42,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,Study 2480,Jan-08,Jul-12,Jul-12,19-Oct-16,null,19-Oct-16,,,https://ClinicalTrials.gov/show/NCT02938091
NCT02938949,Alirocumab in Patients With Acute Myocardial Infarction,,Completed,No Results Available,Myocardial Infarction|Hypercholesterolemia,Drug: alirocumab|Drug: placebo,Placebo-corrected percentage change in calculated LDL cholesterol from baseline to day 14|Placebo-corrected percentage change in inflammatory markers (hsCRP) from baseline to 3 days and 14 days,Virginia Commonwealth University|Regeneron Pharmaceuticals|Sanofi,All,"21 Years and older   (Adult, Older Adult)",Phase 4,20,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",HM20008008,Jan-17,Aug-18,16-Aug-18,19-Oct-16,null,12-Feb-19,"Virginia Commonwealth University, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02938949
NCT02933658,Study of Multiple Oral Dosing to Evaluate the Safety and the Pharmacokinetic Drug-drug Interaction of Telmisartan/Amlodipine and Rosuvastatin in Healthy Male Volunteers,,Completed,No Results Available,Hypertension and Dyslipidemia,Drug: Telmisartan|Drug: Amlodipine|Drug: Rosuvastatin,AUC of Reference 1|Cmax of Reference 1|AUC of Reference 2|Cmax of Reference 2,"Daewon Pharmaceutical Co., Ltd.",Male,19 Years to 49 Years   (Adult),Phase 1,71,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DW-1501-P101,Nov-15,Nov-15,null,14-Oct-16,null,14-Oct-16,,,https://ClinicalTrials.gov/show/NCT02933658
NCT02926027,Effect of Vascepa on Improving Coronary Atherosclerosis in People With High Triglycerides Taking Statin Therapy,EVAPORATE,"Active, not recruiting",No Results Available,Hypertriglyceridemia,Drug: Vascepa|Drug: placebo,Progression rates of low attenuation plaque under influence of Vascepa as compared to placebo.|The morphology of non-calcified coronary atherosclerotic plaque (NCP)|markers of inflammation (Lp-PLA2)|changes in markers of LDL and HDL cholesterol|The composition of non-calcified coronary atherosclerotic plaque (NCP),Los Angeles Biomedical Research Institute|Intermountain Research and Medical Foundation,All,"30 Years to 85 Years   (Adult, Older Adult)",Phase 4,80,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",21733-01,14-Sep-16,Sep-19,Sep-19,6-Oct-16,null,15-Feb-19,"Los Angeles Biomedical Research Institute, Torrance, California, United States|Intermountain Medical Center, Intermountain Heart Institute, Murray, Utah, United States",,https://ClinicalTrials.gov/show/NCT02926027
NCT02927184,Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease,,"Active, not recruiting",No Results Available,Hyperlipidemia|NAFLD,Drug: VK2809|Drug: Placebo,Change in LDL-C in patients receiving VK2809 compared to placebo,"Viking Therapeutics, Inc.",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,59,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",VK2809-201,28-Sep-16,28-Dec-18,28-Jun-19,6-Oct-16,null,30-Oct-18,"Radiant Research, Inc., Chandler, Arizona, United States|SC Clinical Research, Garden Grove, California, United States|ACTCA, Los Angeles, California, United States|Catalina Research Institute, Montclair, California, United States|North America Research, Inc, Pomona, California, United States|Orange County Research Center, Tustin, California, United States|Research Institute of South Florida, Miami, Florida, United States|Research Institute of South Florida, Miami, Florida, United States|Avant Research Associates, LLC, Crowley, Louisiana, United States|HCI- MetroMedic Walk-in, New Bedford, Massachusetts, United States|HCI- MetroMedic Walk-in, New Bedford, Massachusetts, United States|Flint Clinical Research, PLLC, Flint, Michigan, United States|CHEAR Center, LLC, Bronx, New York, United States|Mid Hudson Medical, Hopewell Junction, New York, United States|Wake Research Associcates, LLC., Raleigh, North Carolina, United States|Avant Research, Beaumont, Texas, United States|Clinical Trials of Texas, INC, San Antonio, Texas, United States|Radiant Research, Inc., San Antonio, Texas, United States|Wasatch Clinical Research, LLC, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT02927184
NCT02924558,Metabolic Effects of Egg Protein and Unsaturated Fat Intakes in Subjects With Hypertriglyceridemia,,Completed,No Results Available,Hypertriglyceridemia,Other: Egg protein/unsaturated fatty acid|Other: Control,Matsuda composite index of insulin sensitivity (MISI)|Lipoprotein lipids|Lipoprotein particle concentrations|Apolipoprotein (Apo) B|Homeostasis model assessment of insulin sensitivity (HOMA2-%S)|LMTT disposition index|Homeostasis model assessment of pancreatic beta-cell function (HOMA2%B)|Blood pressure,Midwest Center for Metabolic and Cardiovascular Research|American Egg Board|Egg Nutrition Center,All,"21 Years to 70 Years   (Adult, Older Adult)",Not Applicable,28,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MC-1412,Feb-15,Feb-16,Feb-16,5-Oct-16,null,15-May-18,,,https://ClinicalTrials.gov/show/NCT02924558
NCT02924896,Effect of Palm Olein Intake on Lipid Profile and Appetite Regulation,APO,Completed,No Results Available,Lipidaemia,Dietary Supplement: Palm olein|Dietary Supplement: Interesterified palm olein|Dietary Supplement: Soybean oil,change from baseline in appetite hormones|change from baseline in lipids,Imperial College London|Malaysia Palm Oil Board,All,18 Years to 60 Years   (Adult),Not Applicable,12,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,16/WA/0117,Sep-16,Apr-17,Apr-17,5-Oct-16,null,9-Mar-18,"NIHR/Wellcome Trust Imperial Clinical Research Facility, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02924896
NCT02916901,Study to Investigate the Influence of CKD-519 on 24-h Ambulatory Blood Pressure in Healthy Adult Volunteers,,Completed,No Results Available,Healthy Volunteers,Drug: CKD-519 200mg|Drug: Placebo,"Change in 24h average SBP and DBP from baseline to Day 14 Each time point is as following: Daytime: 06:00~21:59 Nighttime: 22:00~05:59|Cmax,ss of CKD-519|AUCτ,ss of CKD-519|Tmax,ss of CKD-519",Chong Kun Dang Pharmaceutical,All,19 Years to 55 Years   (Adult),Phase 1,32,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",148HPS16006,Aug-16,Oct-16,Jan-17,28-Sep-16,null,23-Feb-17,"Severance Hospital, Seoul, Seodaemun-gu 120-752, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02916901
NCT02913170,Nattokinase Supplementation and Hemostatic Factors,,Completed,No Results Available,Hypercholesterolemia,Dietary Supplement: Nattokinase|Dietary Supplement: Placebo,Collagen-epinephrine closure time at baseline|Collagen-epinephrine closure time at 8-week follow-up|Prothrombin time at baseline|Prothrombin time at 8-week follow-up|Activated partial thromboplastin time at baseline|Activated partial thromboplastin time at 8-week follow-up|Fibrinogen concentration at baseline|Fibrinogen concentration at 8-week follow-up,Yonsei University,All,"20 Years to 69 Years   (Adult, Older Adult)",Phase 4,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",NP_intervention,May-15,Sep-16,Sep-16,23-Sep-16,null,23-Sep-16,"Laboratory of Clinical Nutrigenetics/Nutrigenomics, Yonsei University., Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02913170
NCT02911753,Feasibility and Acceptability of a Beverage Intervention for Hispanic Adults,,Completed,No Results Available,Obesity|Hypercholesterolemia|Hyperglycemia|Hypertriglyceridemia,Other: Mediterranean Lemonade|Other: Green Tea|Other: Flavored Water,Study Recruitment: Interest in Participation|Study Recruitment: Screened for Eligibility|Study Recruitment: Eligibility|Study Recruitment: Ineligibility|Enrollment|Retention|Treatment satisfaction|Change in total cholesterol|Change in fasting glucose|Change in hemoglobin A1C|Change in high sensitive C-reactive protein|Change in body weight,University of Arizona,All,18 Years to 64 Years   (Adult),Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,1606621176,Jun-16,Aug-17,Aug-17,22-Sep-16,null,1-Nov-17,"University of Arizona Collaboratory for Metabolic Disease Prevention and Treatment, Tucson, Arizona, United States",,https://ClinicalTrials.gov/show/NCT02911753
NCT02907112,Impact of Reducing Dietary Intake of Red and Processed Meat Intake on Fasting Lipemia in Healthy Participants,ELM,Completed,No Results Available,Lipidemia,Behavioral: Meat reduction,"Fasting Serum total cholesterol concentration|Fasting Serum LDL cholesterol concentration|Fasting Serum HDL cholesterol concentration|Fasting whole blood glucose concentration|Fasting Serum Insulin concentration|Resting, supine blood pressure|Body mass index calculated from measured height and weight (BMI)|% body fat determined by Bio-electrical Impedance|Flow-mediated dilatation|Quality of Life Questionnaire|Dietary macro-nutrient intake|Dietary energy intake|Meat intake|Full blood count",University of Nottingham|Biotechnology and Biological Sciences Research Council,All,21 Years to 50 Years   (Adult),Not Applicable,37,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,TS/L005891/1,Jul-15,Sep-16,Sep-16,20-Sep-16,null,6-Mar-18,"David Greenfield Human Physiology Unit, Nottingham, Notts, United Kingdom",,https://ClinicalTrials.gov/show/NCT02907112
NCT02904772,Alipogene Tiparvovec for the Treatment of LPLD Patients,,Withdrawn,No Results Available,LPL Deficiency,Drug: alipogene tiparvovec|Drug: Prednisolone|Drug: Cyclosporins|Drug: Mycophenolate mofetil,"The Clinical Response of alipogene tiparvovec in LPLD patients|The long term effect of alipogene tiparvovec on post prandial metabolism of chylomicrons (ppCM) in LPLD patients.|The effect of alipogene tiparvovec on postprandial metabolism of chylomicrons (ppCM) in LPLD patients with and without immunosuppression treatment, at 14 weeks post-administration.|Immuno response of alipogene tiparvovec by analysis of antibody formation|Immuno response of alipogene tiparvovec by analysis of T-cell response",UniQure Biopharma B.V.|Chiesi Farmaceutici S.p.A.,All,"18 Years and older   (Adult, Older Adult)",Phase 2,0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Gly-CD-001,Oct-16,Jun-20,Sep-20,19-Sep-16,null,17-Aug-17,"Perelman School of Medicine at The University of Pennsylvania Translational Medicine & Human Genetics, Philadelphia, Pennsylvania, United States|Centre hospitalier universitaire de Sherbrooke, Sherbrooke, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02904772
NCT02905448,Low Fat Plant-Based Supplemented Diet Effects on Risk Factors for Chronic Non-communicable Diseases,LFPBDS2,Unknown status,No Results Available,Hyperlipidemia|Metabolic Syndrome X,Other: Low fat plant-based nutrition,Serum LDL cholesterol concentration change from baseline|Serum total cholesterol concentration change from baseline|Serum triglyceride concentration change from baseline|Fasting serum glucose concentration change from baseline|Serum uric acid concentration change from baseline|Serum IGF-1 concentration change from baseline|Body fat mass change from baseline,Barbara Jakše s.p.,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,KR2,Jan-16,Dec-16,Mar-17,19-Sep-16,null,19-Sep-16,,,https://ClinicalTrials.gov/show/NCT02905448
NCT02899455,"Clinical Efficacy and Safety Evaluation of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia",,Completed,No Results Available,Hypertension|Hyperlipidemia,Drug: HGP0904|Drug: HGP0608|Drug: HGP0816|Drug: HGP0904 Placebo|Drug: HGP0816 Placebo,"Percentage change from baseline in LDL-cholesterol at Week 8|Change from baseline in sitDBP at Week 8|Percentage change from baseline in LDL cholesterol at Week 4|Percentage change from baseline in Total cholesterol, HDL cholesterol, Triglyceride at Week 4,8|Change from baseline in sitDBP at Week 4|Change from baseline in sitSBP at week 4, 8|Proportion of subjects achieving LDL-cholesterol goals by cardiovascular risk category at Week 4, 8|Proportion of subjects achieving Blood Pressure control by cardiovascular risk category at Week 4, 8|Proportion of subjects achieving LDL-cholesterol goals and Blood Pressure control by cardiovascular risk category at Week 4, 8",Hanmi Pharmaceutical Company Limited,All,"19 Years to 75 Years   (Adult, Older Adult)",Phase 3,146,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",HM-ALRO-301,Jul-14,Jun-16,Jun-16,14-Sep-16,null,20-Oct-16,"23 institutions including Samsung Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02899455
NCT02900027,"Safety, Tolerability, PK, and Pharmacodynamics(PD) of IONIS APOCIII-LRx in Healthy Volunteers With Elevated Triglycerides",,Completed,No Results Available,Elevated Triglycerides (TG),Drug: APOC-III-L-Rx|Drug: Placebo Comparator,"To evaluate the safety and tolerability of single and multiple doses of IONIS- APOC-III-LRx - (incidence, severity, and dose-relationship of adverse effects and changes in the laboratory parameters)|To evaluate the plasma pharmacokinetics of single and multiple doses of IONIS- APOC-III-LRx|To evaluate the urine pharmacokinetics of single and multiple doses of IONIS¬-APOC-III-LRx","Ionis Pharmaceuticals, Inc.|Akcea Therapeutics",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,56,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other",IONIs-ApoCIII-LRx,Sep-16,30-Apr-18,30-Apr-18,14-Sep-16,null,22-May-18,"BioPharma Services, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02900027
NCT02900612,Effects of Two Aquatic Training Models in Physiological Parameters of Elderly Dyslipidemic Women.,,Completed,No Results Available,Dyslipidemias,Other: Water aerobics training.|Other: Water resistance training.|Other: Control Group,Total Cholesterol (TC) Change|Triglycerides (TG) Change|High Density Lipoprotein (HDL) Change|C-Reactive Protein (CRP) Change|Low Density Lipoprotein (LDL) Change|Total Cholesterol/High Density Lipoprotein Ratio (TC/HDL ratio) Change|Peak Oxygen Consumption (VO2peak) Change|Oxygen Consumption at anaerobic threshold (VO2VT2) Change|Heart Rate at anaerobic threshold (HRVT2) Change|Rest Heart Rate (HRrest) Change|Lipoprotein Lipase (LPL) Change|Maximal dynamic muscle strength of knees extensors (MSKE) Change|Maximal dynamic muscle strength of knees flexors (MSKF) Change|Maximal dynamic muscle strength of horizontal shoulder flexors (MSHSF) Change|Rest Cardiac Output (COrest) Change|Rest Stroke Volume (SVrest) Change|Peak Cardiac Output (COpeak) Change|Peak Stroke Volume (SVpeak) Change|Rest Arterial Systolic Blood Pressure (SBPrest) Change|Rest Arterial Diastolic Blood Pressure (DBPrest) Change|Cardiovascular Risk Score (CRS) Change|Quality of Life Change,Hospital de Clinicas de Porto Alegre,Female,"60 Years to 75 Years   (Adult, Older Adult)",Not Applicable,45,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,14-0547,Dec-15,Mar-16,May-16,14-Sep-16,null,14-Sep-16,,,https://ClinicalTrials.gov/show/NCT02900612
NCT02898142,Intestines and Liver Contribution to Fasting Postprandial Hypertriglyceridemia,TRIGPP,Completed,No Results Available,Hypertriglyceridemia|Metabolic Syndrome,Other: Postprandial test,Apo B48 plasma concentration|Apo B48 peak plasma concentration,Assistance Publique - Hôpitaux de Paris,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,39,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,P111003,Feb-12,Feb-15,Sep-15,13-Sep-16,null,29-Sep-16,"Pitié Salpetriere Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT02898142
NCT02894112,Effects of Fluid Milk in Attenuating Hyperglycemia and Hypertriglyceridemia After Meal,,Completed,No Results Available,Oral Glucose Tolerance Test|High Fat Tolerance Test,Dietary Supplement: non-fat milk|Dietary Supplement: carbohydrate control beverage|Dietary Supplement: caloric control beverage,blood glucose|plasma triglyceride|femoral artery blood flow|brachial artery flow-mediated dilation,University of Texas at Austin|Dairy Research Institute,All,20 Years to 40 Years   (Adult),Not Applicable,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1198,Apr-13,Dec-15,Dec-15,9-Sep-16,null,9-Sep-16,"Cardiovascular Aging Research Laboratory, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT02894112
NCT02894541,Study to Investigate the Effects of Food on the Pharmacokinetics/Pharmacodynamics of CKD-519,,Completed,No Results Available,Healthy Volunteers,Drug: CKD-519 100mg|Drug: CKD-519 200mg,Cmax of CKD-519|AUClast of CKD-519|Tmax of CKD-519|AUCinf of CKD-519|T1/2 of CKD-519|CL/F of CKD-519|Vd/F of CKD-519|Inhibition of CETP(Cholesteryl ester transfer protein) Activity,Chong Kun Dang Pharmaceutical,Male,20 Years to 45 Years   (Adult),Phase 1,48,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,148FDI16004,Aug-16,Nov-16,Jan-17,9-Sep-16,null,23-Feb-17,"Korea university medical center, Seoul, Sungbuk-gu, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02894541
NCT02890992,An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia,ODYSSEY KIDS,Completed,No Results Available,Hypercholesterolaemia,Drug: alirocumab SAR236553 (REGN727)|Drug: statins|Drug: ezetimibe|Drug: cholestyramine|Drug: fenofibrate|Drug: omega-3 fatty acids|Drug: nicotinic acid,Percent change in calculated low-density lipoprotein cholesterol (LDL-C)|Absolute change in calculated LDL-C|Proportion of patients achieving a calculated LDL-C <130 mg/dL (3.37 mmol/L)|Proportion of patients achieving a calculated LDL-C level <110 mg/dL (2.84 mmol/L)|Percent change in calculated LDL-C (for Cohort 4)|Percent change in Apolipoprotein B (Apo B)|Percent change in non-high density lipoprotein cholesterol (non HDL-C)|Percent change in Total-C|Percent change in Lipoprotein (a) (Lp[a])|Percent change in triglycerides (TG)|Percent change in HDL-C|Percent change in Apo A-1|Absolute change in Apo B|Absolute change in non-HDL-C|Absolute change in Total-C|Absolute change in Lp(a)|Absolute change in HDL-C|Absolute change in TG|Absolute change in Apo A-1|Absolute change in ratio Apo B/Apo A-1,Sanofi|Regeneron Pharmaceuticals,All,8 Years to 17 Years   (Child),Phase 2,42,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DFI14223|2015-003766-85|U1111-1178-4764,15-Sep-16,13-Sep-18,22-Feb-19,7-Sep-16,null,14-Mar-19,"Investigational Site Number 8400002, Saint Louis, Missouri, United States|Investigational Site Number 8400005, Charlotte, North Carolina, United States|Investigational Site Number 8400001, Cincinnati, Ohio, United States|Investigational Site Number 1240001, Quebec, Canada|Investigational Site Number 2030001, Brno, Czechia|Investigational Site Number 2030003, Praha 5 - Motol, Czechia|Investigational Site Number 2030002, Zlin, Czechia|Investigational Site Number 2500001, Bron Cedex, France|Investigational Site Number 5280001, Amsterdam, Netherlands|Investigational Site Number 5780001, Oslo, Norway|Investigational Site Number 6430001, Kemerovo, Russian Federation|Investigational Site Number 6430004, Saint-Petersburg, Russian Federation|Investigational Site Number 7100001, Parow, South Africa|Investigational Site Number 7240004, A Coruna, Spain|Investigational Site Number 7240001, Madrid, Spain|Investigational Site Number 7520001, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT02890992
NCT02886299,Randomized Comparative Efficacy and Safety Study of Intermittent Simvastatin and Fenofibrate in Hemodialysis,,Completed,No Results Available,Fenofibrate/Simvastatin Comparison,Drug: Fenofibrate|Drug: Simvastatin,oxidative stress markers (serum ox-LDL and GSH-Px)|C-reactive protein,Cairo University,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CL (746),Oct-13,Jan-16,Jan-16,1-Sep-16,null,5-Sep-16,,,https://ClinicalTrials.gov/show/NCT02886299
NCT02881658,The Effect of 3-Week Consumption of Soya Beverage Enriched With Plant Sterols on Serum LDL-C,,Completed,Has Results,Dyslipidemia,Dietary Supplement: Plant sterols-enriched soya beverage provided by Vitasoy|Dietary Supplement: Soya beverage provided by Vitasoy,Mean of Serum Low-density Lipoprotein Cholesterol (LDL-C) Via Blood Test at Baseline and Week 3|Change of Low Density Lipoprotein Cholesterol (LDL-C) Via Blood Test at Baseline and Week 3|Change of High-density Lipoprotein Cholesterol (HDL-C) Via Blood Test at Baseline and Week 3|Change of Total Cholesterol Via Blood Test at Baseline and Week 3|Change of Triglycerides (TAG) Via Blood Test at Baseline and Week 3|Change of Serum Creatinine Via Blood Test at Baseline and Week 3|Changes of Fasting Blood Glucose Via Blood Test at Baseline and Week 3|Changes of Cardiometabolic Risk Factors Via Measuring Anthropometry at Baseline and Week 3|Changes of Cardiometabolic Risk Factors Via Measuring Blood Pressure at Baseline and Week 3|Changes of Cardiometabolic Risk Factors Via Measuring Body Temperature at Baseline and Week 3|Changes of Musculoskeletal-related Traits Via Measuring Hand Grip Strength at Baseline and Week 3|Changes of Musculoskeletal-related Traits Via Measuring Bio-Impedance at Baseline and Week 3|Changes of Musculoskeletal-related Traits Via Measuring Peak Expiratory Flow Rate at Baseline and Week 3|Changes of Musculoskeletal-related Traits Via Measuring 6 Metres Gait Speed at Baseline and Week 3|Changes of Musculoskeletal-related Traits Via Measuring Centre of Pressure Excursion Index for Left and Right Foot at Baseline and Week 3,The University of Hong Kong,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,201,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CTC1521,May-16,1-Feb-17,1-Feb-17,29-Aug-16,21-Sep-17,3-May-18,"Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, Hong Kong","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT02881658/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02881658
NCT02867813,Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension,,"Active, not recruiting",No Results Available,Dyslipidemia,Biological: Evolocumab,Subject incidence of adverse events|Percent change of LDL-C from baseline at each scheduled yearly visit|Achieve an LDL-C < 40 mg/dL (1.03 mmol/L) at each scheduled yearly visit,Amgen,All,"40 Years to 85 Years   (Adult, Older Adult)",Phase 3,5037,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20130295|2015-004780-36,2-Sep-16,29-Sep-21,29-Sep-21,16-Aug-16,null,25-Oct-18,"Research Site, Birmingham, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, Banning, California, United States|Research Site, Long Beach, California, United States|Research Site, Oceanside, California, United States|Research Site, Oxnard, California, United States|Research Site, Palm Springs, California, United States|Research Site, Roseville, California, United States|Research Site, San Diego, California, United States|Research Site, San Pedro, California, United States|Research Site, Tarzana, California, United States|Research Site, Torrance, California, United States|Research Site, Valley Village, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Littleton, Colorado, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Crystal River, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Largo, Florida, United States|Research Site, Miami, Florida, United States|Research Site, New Port Richey, Florida, United States|Research Site, Pensacola, Florida, United States|Research Site, Ponte Vedra Beach, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Athens, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Augusta, Georgia, United States|Research Site, Dunwoody, Georgia, United States|Research Site, Gainesville, Georgia, United States|Research Site, Savannah, Georgia, United States|Research Site, Suwanee, Georgia, United States|Research Site, Coeur d'Alene, Idaho, United States|Research Site, Meridian, Idaho, United States|Research Site, Addison, Illinois, United States|Research Site, Belleville, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Jerseyville, Illinois, United States|Research Site, Evansville, Indiana, United States|Research Site, Munster, Indiana, United States|Research Site, Iowa City, Iowa, United States|Research Site, Waterloo, Iowa, United States|Research Site, Kansas City, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Lexington, Kentucky, United States|Research Site, Hammond, Louisiana, United States|Research Site, Metairie, Louisiana, United States|Research Site, Monroe, Louisiana, United States|Research Site, Natchitoches, Louisiana, United States|Research Site, Slidell, Louisiana, United States|Research Site, Auburn, Maine, United States|Research Site, Bangor, Maine, United States|Research Site, Biddeford, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Columbia, Maryland, United States|Research Site, Salisbury, Maryland, United States|Research Site, Haverhill, Massachusetts, United States|Research Site, Newton, Massachusetts, United States|Research Site, Grandville, Michigan, United States|Research Site, Lansing, Michigan, United States|Research Site, Muskegon, Michigan, United States|Research Site, Saginaw, Michigan, United States|Research Site, Saint Cloud, Minnesota, United States|Research Site, Saint Paul, Minnesota, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Kalispell, Montana, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Brooklyn, New York, United States|Research Site, Cortlandt Manor, New York, United States|Research Site, New Hyde Park, New York, United States|Research Site, New Windsor, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, West Seneca, New York, United States|Research Site, Williamsville, New York, United States|Research Site, Calabash, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Hickory, North Carolina, United States|Research Site, High Point, North Carolina, United States|Research Site, Mooresville, North Carolina, United States|Research Site, Statesville, North Carolina, United States|Research Site, Tabor City, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Elyria, Ohio, United States|Research Site, Marion, Ohio, United States|Research Site, Sandusky, Ohio, United States|Research Site, Springfield, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Willoughby, Ohio, United States|Research Site, Pryor, Oklahoma, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Portland, Oregon, United States|Research Site, Camp Hill, Pennsylvania, United States|Research Site, Chambersburg, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Pawtucket, Rhode Island, United States|Research Site, Charleston, South Carolina, United States|Research Site, Indian Land, South Carolina, United States|Research Site, Moncks Corner, South Carolina, United States|Research Site, North Myrtle Beach, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Germantown, Tennessee, United States|Research Site, Memphis, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Tullahoma, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Kerrville, Texas, United States|Research Site, Plano, Texas, United States|Research Site, Plano, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Wichita Falls, Texas, United States|Research Site, Layton, Utah, United States|Research Site, West Jordan, Utah, United States|Research Site, Burke, Virginia, United States|Research Site, Falls Church, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Suffolk, Virginia, United States|Research Site, Federal Way, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Green Bay, Wisconsin, United States|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Jihlava, Czechia|Research Site, Liberec, Czechia|Research Site, Mohelnice, Czechia|Research Site, Ostrava-Dubina, Czechia|Research Site, Ostrava, Czechia|Research Site, Praha 2, Czechia|Research Site, Prerov, Czechia|Research Site, Pribram VIII, Czechia|Research Site, Znojmo, Czechia|Research Site, Bekescsaba, Hungary|Research Site, Miskolc, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Bielsko-Biala, Poland|Research Site, Bydgoszcz, Poland|Research Site, Gdansk, Poland|Research Site, Gdynia, Poland|Research Site, Gdynia, Poland|Research Site, Gizycko, Poland|Research Site, Katowice, Poland|Research Site, Kielce, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Nysa, Poland|Research Site, Olsztyn, Poland|Research Site, Plock, Poland|Research Site, Poznan, Poland|Research Site, Pszczyna, Poland|Research Site, Pulawy, Poland|Research Site, Ruda Slaska, Poland|Research Site, Skierniewice, Poland|Research Site, Staszow, Poland|Research Site, Swidnik, Poland|Research Site, Tarnow, Poland|Research Site, Torun, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wloclawek, Poland|Research Site, Wroclaw, Poland|Research Site, Zamosc, Poland|Research Site, Moscow, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, Kosice, Slovakia|Research Site, Svidnik, Slovakia|Research Site, Zaporizhzhya, Ukraine",,https://ClinicalTrials.gov/show/NCT02867813
NCT02868177,"Effect of Totum-63, Active Ingredient of Valedia, on Glucose and Lipid Homeostasis on Subjects With Prediabetes",TOTUM-63 TWO,"Active, not recruiting",No Results Available,Prediabetes|Type 2 Diabetes|Hypertriglyceridemia|Obesity|Disease|Insulin Resistance,Dietary Supplement: Totum-63|Dietary Supplement: Placebo,"Changes in fasting glycemia|Changes in fasting blood levels of HbA1c|Changes in fasting blood levels of fructosamine|Changes in fasting insulinemia|Changes in the evolution of glycemia during an oral glucose tolerance test|Changes in the evolution of insulinemia during an oral glucose tolerance test|Changes in HOMA-IR, HOMA-β, QUICKI, ISI-M, OGIS and PREDIM indices|Changes in HOMA-IR, HOMA-β and QUICKI indices|Changes in fasting blood concentrations of triglycerides, non esterified fatty acids, LDL cholesterol, HDL cholesterol and Total cholesterol|Changes in fasting blood level of PON-1 (Paraoxonase)|Changes in the ratio of fasting blood oxidized LDL / fasting blood LDL cholesterol|Changes in fasting blood level of hsCRP|Changes in fasting blood levels of ASAT (Aspartate aminotransferase) and ALAT (Alanine aminotransferase)|Changes in fasting blood levels of GGT (Gamma glutamyltransferase)|Changes in fasting blood levels of bilirubin|Changes in fasting blood levels of creatinine|Changes in heart rate|Changes in SBP (systolic blood pressure) and DBP (diastolic blood pressure)|Changes in body weight|Changes in WC (waist circumference)|Changes in HC (hip circumference)|Changes in HP (hip circumference)|Changes in WHR (waist to hip ratio)",Valbiotis|Biofortis Mérieux NutriSciences|Institut Pasteur de Lille,All,"35 Years to 75 Years   (Adult, Older Adult)",Phase 2|Phase 3,66,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",2016-A00484-47,Jan-16,Jul-19,Aug-19,16-Aug-16,null,22-Feb-19,"Institut Pasteur de Lille, Lille, France|Biofortis Mérieux NutriSciences Clinical Investigation Center, Saint Herblain, France|Atlantia Food Clinical Trials, Cork, Ireland|Clinical center of Kragujevac, / Poseidon CRO, Kragujevac, Serbia|Clinical Center of Vojvodina / Poseidon CRO, Novi Sad, Serbia|University Medical Centre Ljubljana / Poseidon CRO, Ljubljana, Slovenia",,https://ClinicalTrials.gov/show/NCT02868177
NCT02859480,Dose-dependent Effect of Rosuvastatin on Long-term Clinical Outcomes After PCI,ROSUVA-30,Recruiting,No Results Available,Coronary Artery Disease|Coronary Disease|Cardiovascular Diseases,Drug: Rosuvastatin 5mg|Drug: Rosuvastatin 20mg,Major adverse cardiovascular outcome|All-cause death|Cardiac death|Non-fatal myocardial infarction|Repeat revascularization|Stent thrombosis|Target LDL-C level achievement|LDL-C level change|HDL-C level change|Level change of other biomarkers,"Korea University Anam Hospital|Samjin Pharmaceutical Co., Ltd.",All,"35 Years and older   (Adult, Older Adult)",Phase 4,300,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ED15175,Sep-15,Jun-19,Dec-19,9-Aug-16,null,9-Aug-16,"Korea University Anam Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02859480
NCT02858102,"Impact of Aerobic Exercise on Metabolic Syndrome, Neurocognition and Empowerment in Individuals With Mental Disorders",EXERTMG,Recruiting,No Results Available,Metabolic Syndrome|Mental Disorders,Behavioral: Physical activity program,Change in abdominal obesity measured by waist circumference|Change in dyslipidemia measured by serum triglycerides and/or high-density lipoprotein (HDL cholesterol) levels.|Change in hypertension measured by blood pressure|Change in hyperglycemia measured by fasting plasma glucose|Effect of physical activity intervention on serum biomarkers by using metabolomics,Fundación Marques de Valdecilla|Centro de Investigación Biomédica en Red de Salud Mental|Instituto de Investigación Marqués de Valdecilla,All,35 Years to 50 Years   (Adult),Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,EXERTMG,Jun-16,Dec-19,Dec-19,8-Aug-16,null,15-Feb-19,"University Hospital Marqués de Valdecilla, Santander, Cantabria, Spain",,https://ClinicalTrials.gov/show/NCT02858102
NCT02858830,Familial Partial Lipodystrophy Study,FPL,"Active, not recruiting",No Results Available,"Lipodystrophy, Familial Partial",Other: High fat mixed meal,Upper body muscle strength measured by chest press dynamometry|Change in fractional mitochondrial protein synthesis rates|Lower body muscle strength measured by knee extension,Mayo Clinic,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,12,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,15-009144,Aug-16,Feb-18,Dec-19,8-Aug-16,null,7-Feb-19,"Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02858830
NCT02859129,Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®),ECLIPSEIII,Completed,No Results Available,Hypertriglyceridemia,Drug: rosuvastatin 40 mg tablet|Drug: Epanova™ QD (2 x 1 g capsules)|Drug: Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose|Drug: Multiple (20) oral doses of 2 g Vascepa® every 12 hours,"ln-transformed Cmax,ss of baseline-adjusted total EPA, total DHA, and total EPA+DHA|ln-transformed AUC0-tau of baseline-adjusted total EPA, total DHA, and total EPA+DHA|ln-transformed Cmax,ss of unadjusted total EPA, total DHA, and total EPA+DHA|dose proportionality of baseline-adjusted total EPA, total DHA, and total EPA+DHA systemic exposure will be assessed following multiple doses of Epanova™ 2 g and 4 g|ln-transformed AUC0-tau of unadjusted total EPA, total DHA, and total EPA+DHA",AstraZeneca,All,18 Years to 55 Years   (Adult),Phase 1,114,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OM-EPA-009,Sep-13,Nov-13,Nov-13,8-Aug-16,null,17-Aug-16,"Celerion, Neptune, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT02859129
NCT02857543,"Plant-Based, American Heart Assoc. or Mediterranean Diets In 9-18 yo With BMI >95%, Cholesterol >169 and Their Parents",,"Active, not recruiting",No Results Available,Obesity|Hypercholesterolemia|Cardiovascular Disease,Other: Plant-Based Diet|Other: American Heart Association Diet|Other: Mediterranean Diet,Change from baseline Biomarkers of Cardiovascular Risk at 4 weeks and 52 weeks|Change from baseline weight at 4 weeks and 52 weeks|Change from baseline blood pressure at 4 weeks and 52 weeks|Change in baseline waist circumference at 4 weeks and 52 weeks,The Cleveland Clinic,All,"9 Years to 18 Years   (Child, Adult)",Not Applicable,180,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,16-745,Jun-16,30-Sep-17,Dec-19,5-Aug-16,null,19-Feb-19,"Cleveland Clinic, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02857543
NCT02850224,Pediatric Preventative Health Screenings - Obesity and Family-Centered Outcomes,,"Active, not recruiting",No Results Available,Obesity|Overweight|Blood Pressure|Hypercholesteremia|Diabetes,Behavioral: Motivational interviewing to elicit PCO in pediatrics,"Number of participants with improved patient-centered outcomes (physical, social, and emotional health) as assessed by the PROMIS 25.|Number of participants with improved health-related quality of life as assessed by the PEDsQL.",Henry Ford Health System,All,"2 Years to 18 Years   (Child, Adult)",Not Applicable,703,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research,B21201,20-Apr-17,19-Feb-18,Dec-19,29-Jul-16,null,8-Mar-19,"Henry Ford Health System, Detroit, Michigan, United States",,https://ClinicalTrials.gov/show/NCT02850224
NCT02842359,Evaluation of the Fixed-dose Combination of Irbesartan/Atorvastatin in Type 2 Diabetic Patients Diagnosed With Hyperlipidemia and Hypertension,,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: Irbesartan/atorvastatin fixed dose combination|Drug: Irbesartan SR47436|Drug: Atorvastatin,"Change from baseline in flow mediated dilatation|Rate of change from baseline in nytrotyrosine marker|Rate of change from baseline in Intercellular Adhesion Molecule-1|Rate of change from baseline in Interleukin-6|Rate of change from baseline in C-reactive protein|Change from baseline in blood pressure (irbesartan/atorvastatin fixed-dose combination group and irbesartan group)|Change from baseline in low density lipoprotein-C (irbesartan/atorvastatin fixed-dose combination group and atorvastatin group)|Change from baseline in total cholesterol (irbesartan/atorvastatin fixed-dose combination group and atorvastatin group)|Change from baseline in high density lipoprotein-C (irbesartan/atorvastatin fixed-dose combination group and atorvastatin group)|Change from baseline in triglycerides (irbesartan/atorvastatin fixed-dose combination group and atorvastatin group)|Change from baseline in apolipoprotein-A1 (irbesartan/atorvastatin fixed-dose combination group and atorvastatin group)|Change from baseline in apolipoprotein-B (irbesartan/atorvastatin fixed-dose combination group and atorvastatin group) - Time Frame: 4 weeks, up to maximum 5 weeks|Percentage of participants with decreased level of blood pressure (irbesartan/atorvastatin fixed-dose combination group and irbesartan group)|Rate of change from baseline in immunosenescence T cell fractionation|Rate of change from baseline in T-cell induced inflammatory factors",Sanofi,All,"19 Years to 74 Years   (Adult, Older Adult)",Phase 4,11,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ATOIRL07827|U1111-1182-8092,23-Aug-16,19-Apr-18,19-Apr-18,22-Jul-16,null,18-May-18,"Korea, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02842359
NCT02839382,The Northwest Coalition for Primary Care Practice Support,H2N,"Active, not recruiting",No Results Available,Cardiovascular Disease|Essential Hypertension|Nicotine Dependence|Hyperlipidemia,Other: Coaching|Other: Educational Outreach|Other: Site Visits,Appropriate use of Aspirin|Hypertension|Smoking|Change Process Capacity|Quality Improvement Capacity Assessment,Kaiser Permanente|University of Washington|Oregon Health and Science University,All,"Child, Adult, Older Adult",Not Applicable,210,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research,AHRQ 1R8HS023908-01,May-15,Apr-18,Apr-18,21-Jul-16,null,13-Oct-17,"GroupHealthCoop, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT02839382
NCT02839902,Exploratory Study of the Effects of Omega-3-acid Ethyl Esters on the Lipid and Lipoprotein Profile in the Blood,LOTUS,Completed,Has Results,Hyperlipidemia,Drug: TAK-085|Other: Not treated with omega-3-acid ethyl esters,Percent Changes From Baseline in Concentration of Major 4 Lipid Constituents in Small Dense Low Density Lipoprotein (sdLDL) Fraction|Percent Changes From Baseline in Triglycerides (TG) to Cholesterol Ratio in sdLDL Fraction|Percent Change From Baseline in Mean Particle Sizes of Small Dense Low Density Lipoprotein-cholesterol (sdLDL-C) and Low Density Lipoprotein-cholesterol (LDL-C) Monitored by Major 4 Lipid Constituents|Percent Changes From Baseline in Concentration of Major 4 Lipid Constituents in Chylomicron (CM) Fraction|Percent Changes From Baseline in Concentration of Major 4 Lipid Constituents in Very Low-density Lipoprotein (VLDL) Fraction|Percent Changes From Baseline in Concentration of Major 4 Lipid Constituents in Low-density Lipoprotein (LDL) Fraction|Percent Changes From Baseline in Concentration of Major 4 Lipid Constituents in High-density Lipoprotein (HDL) Fraction|Percent Changes From Baseline in Concentration of Fatty Acids in Total Lipids|Percent Changes From Baseline in Eicosatrienoic Acid to Arachidonic Acid (T/T) Ratio in Total Lipids|Percent Changes From Baseline in Eicosapentaenoic Acid to Arachidonic Acid (EPA/AA) Ratio in Total Lipids|Percent Changes From Baseline in Eicosapentaenoic Acid Plus Docosahexaenoic Acid to Arachidonic Acid (EPA+DHA/AA) Ratio in Total Lipids|Percent Changes From Baseline in Docosahexaenoic Acid to Arachidonic Acid (DHA/AA) Ratio in Total Lipids|Change From Baseline in Mean Concentration of sd LDL-C in Total Lipids|Percent Change From Baseline in Concentration of Lipids in the Blood|Percent Change From Baseline in Concentration of Apolipoproteins in the Blood|Percent Change From Baseline in Lipoprotein Particle Numbers in the Blood,Takeda,All,"20 Years and older   (Adult, Older Adult)",Phase 4,53,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,TAK-085-4002|U1111-1185-0054|JapicCTI-163322,27-Dec-16,30-Aug-17,30-Aug-17,21-Jul-16,11-Feb-19,11-Feb-19,"Noda, Chiba, Japan|Koga, Ibaragi, Japan|Moriguchi, Osaka, Japan|Suita, Osaka, Japan|Fujimi, Saitama, Japan|Mitaka, Tokyo, Japan|Saitama, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT02839902/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT02839902/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02839902
NCT02837367,Use of Nutrigenomic Models for the Personalized Treatment With Medical Foods in Obese People,NutriGen,Recruiting,No Results Available,Obesity|Dyslipidemia,Dietary Supplement: Administration of supplements containing methyl-donors,Lipid profile|Insulin sensitivity,"University of Medicine and Pharmacy ""Victor Babes"" Timisoara|Romania:The National Authority for Scientific Research",All,"7 Years to 70 Years   (Child, Adult, Older Adult)",Not Applicable,600,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care",UniversityMedPharmaVBT,Sep-16,Sep-19,Sep-19,19-Jul-16,null,18-Oct-18,"Clinica II Pediatrie Bega, Timisoara, Timis, Romania|Spitalul Judetean Timisoara; Centrul de Diabet, Timisoara, Timis, Romania",,https://ClinicalTrials.gov/show/NCT02837367
NCT02835287,Diabetes Complication Control in Community Clinics (D4C) Trial,D4C,Recruiting,No Results Available,Diabetes|Hypertension|Dyslipidemia|Cardiovascular Disease,Other: Protocol-based integrated care,"Net change in HbA1C, SBP, and LDL-cholesterol levels between intervention and control groups, simultaneously modeled using a scaled marginal model which allows estimation of a single overall treatment effect|Incidence of composite major cardiovascular disease events (non-fatal stroke, non-fatal myocardial infarction, hospitalized heart failure, and CVD mortality)|HbA1C|SBP|LDL-cholesterol|10-year risk of CVD using ACC/AHA Risk Scores|Health-related quality of life by the 12-item Short-Form Health Survey|Cost-effectiveness by Incremental Cost-Effectiveness Ratio",Tulane University|Xiamen University,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,12000,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,889920-1,Sep-16,Dec-18,Jun-20,18-Jul-16,null,1-Dec-16,"Tulane University, New Orleans, Louisiana, United States|Xiamen Diabetes Institute, Xiamen University, Xiamen, Fujian, China",,https://ClinicalTrials.gov/show/NCT02835287
NCT02835651,Saturated Fatty Acids and HDL Metabolism,,Completed,No Results Available,Dyslipidemia,Dietary Supplement: Palmitic acid|Dietary Supplement: Stearic acid,Cholesterol efflux capacity after dietary period high in palmitic acid compared to dietary period high in stearic acid|Change in fasted lipid metabolism markers between dietary period high in palmitic acid and dietary period high in stearic acid|Change in fasted lipid ratios between dietary period high in palmitic acid and dietary period high in stearic acid|Change in fasted apolipoproteins between dietary period high in palmitic acid and dietary period high in stearic acid|Change in postprandial triacylglycerol levels between dietary period high in palmitic acid and dietary period high in stearic acid,Maastricht University Medical Center|Unilever R&D,All,"45 Years to 70 Years   (Adult, Older Adult)",Not Applicable,41,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",METC 15-3-052,14-Apr-16,1-Jul-17,1-Jul-17,18-Jul-16,null,22-Aug-17,"Maastricht University Medical Center, Maastricht, Limburg, Netherlands",,https://ClinicalTrials.gov/show/NCT02835651
NCT02835872,A Study to Evaluate the Effects of Dietary Fiber on Blood Lipids in Men and Women,,Completed,No Results Available,Hypercholesterolemia,Other: dietary fiber,Change in LDL Cholesterol|Change in Total cholesterol|Change in HDL- Cholesterol|Change in Non-HDL- Cholesterol|Change in Triglycerides|Total / HDL Cholesterol Ratio,Tate & Lyle|BioFortis,All,"21 Years to 79 Years   (Adult, Older Adult)",Not Applicable,90,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",BIO1604,May-16,Sep-16,Sep-16,18-Jul-16,null,28-Sep-16,"Biofortis, Addison, Illinois, United States",,https://ClinicalTrials.gov/show/NCT02835872
NCT02833844,"Safety, Tolerability & Efficacy on LDL-C of Evolocumab in Subjects With HIV & Hyperlipidemia/Mixed Dyslipidemia",,"Active, not recruiting",No Results Available,"Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection",Drug: Repatha (Evolocumab)|Drug: Placebo,Effect of Repatha (Evolocumab) on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in human immunodeficiency virus (HIV)-positive subjects with hyperlipidemia or mixed dyslipidemia|Effect of Repatha (Evolocumab) on change from baseline in LDL-C in HIV-positive subjects with hyperlipidemia or mixed dyslipidemia|Effect of Repatha (Evolocumab) on percent of subjects attaining LDL-C < 70 mg/dL (1.8 mmol/L) in HIV-positive subjects with hyperlipidemia or mixed dyslipidemia|Effect of Repatha (Evolocumab) on percent of subjects attaining a 50% reduction in LDL-C from baseline in HIV-positive subjects with hyperlipidemia or mixed dyslipidemia|Effect of Repatha (Evolocumab) on percent change from baseline in ApoB in HIV-positive subjects with hyperlipidemia or mixed dyslipidemia|Effect of Repatha (Evolocumab) on percent change from baseline in TC in HIV-positive subjects with hyperlipidemia or mixed dyslipidemia|Effect of Repatha (Evolocumab) on percent chang from baseline in Lp(a) in HIV-positive subjects with hyperlipidemia or mixed dyslipidemia|Effect of Repatha (Evolocumab) on percent change from baseline in triglycerides in HIV-positive subjects with hyperlipidemia or mixed dyslipidemia|Effect of Repatha (Evolocumab) on percent change from baseline in HDL-C in HIV-positive subjects with hyperlipidemia or mixed dyslipidemia|Effect of Repatha (Evolocumab) on percent change from baseline in non-HDL-C in HIV-positive subjects with hyperlipidemia or mixed dyslipidemia|Effect of Repatha (Evolocumab) on percent change from baseline in VLDL-C in HIV-positive subjects with hyperlipidemia or mixed dyslipidemia,Amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 3,467,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",20130286|2015-004735-12,22-May-17,10-Jul-19,22-Jan-20,14-Jul-16,null,31-Jan-19,"Research Site, Los Angeles, California, United States|Research Site, Hartford, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Washington, District of Columbia, United States|Research Site, Washington, District of Columbia, United States|Research Site, Miami, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Vero Beach, Florida, United States|Research Site, Augusta, Georgia, United States|Research Site, Berkley, Michigan, United States|Research Site, Detroit, Michigan, United States|Research Site, Southfield, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Camden, New Jersey, United States|Research Site, Albany, New York, United States|Research Site, Bronx, New York, United States|Research Site, New York, New York, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Falls Church, Virginia, United States|Research Site, Darlinghurst, New South Wales, Australia|Research Site, East Sydney, New South Wales, Australia|Research Site, Sydney, New South Wales, Australia|Research Site, Fortitude Valley, Queensland, Australia|Research Site, Melbourne, Victoria, Australia|Research Site, Prahran, Victoria, Australia|Research Site, Antwerp, Belgium|Research Site, Brussels, Belgium|Research Site, Gent, Belgium|Research Site, Sao Paulo, São Paulo, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, São Paulo, Brazil|Research Site, Calgary, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Bordeaux, France|Research Site, Lyon cedex 04, France|Research Site, Montpellier cedex 5, France|Research Site, Nantes Cedex 1, France|Research Site, Paris Cedex 10, France|Research Site, Paris Cedex 12, France|Research Site, Paris Cedex 13, France|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Thessaloniki, Greece|Research Site, Bologna, Italy|Research Site, Genova, Italy|Research Site, Milano, Italy|Research Site, Modena, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Warszawa, Poland|Research Site, Almada, Portugal|Research Site, Aveiro, Portugal|Research Site, Coimbra, Portugal|Research Site, Porto, Portugal|Research Site, Brasov, Romania|Research Site, Bucharest, Romania|Research Site, Constanta, Romania|Research Site, Timisoara, Romania|Research Site, Pretoria, Gauteng, South Africa|Research Site, Westdene, Gauteng, South Africa|Research Site, Bloemfontein, South Africa|Research Site, Barcelona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Geneva 14, Switzerland|Research Site, Lausanne, Switzerland|Research Site, Lugano, Switzerland|Research Site, Zuerich, Switzerland|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02833844
NCT02827630,Proteus Discover in Subjects With Uncontrolled Hypertension and Type 2 Diabetes,,Completed,No Results Available,"Hypertension|Diabetes Mellitus, Type 2|Hypercholesterolemia",Other: Proteus Discover|Other: Usual Care,Week 4 Change in Systolic Blood Pressure|Change in Diastolic Blood Pressure|Proportion at blood pressure goal|Change in Systolic Blood Pressure|Change in fasting plasma glucose|Change in glycated hemoglobin|Average Daily Medication Adherence as Measured by DH|Average daily physical activity duration as measured by DH in DH-12 subjects|Average daily rest duration as measured by DH in DH-12 subjects|Average daily step count as measured by DH in DH-12 subjects|Average daily step count as measured by DH in all DH subjects|Average daily physical activity duration as measured by DH in all DH subjects|Average daily rest duration as measured by DH in all DH subjects|Table Summary of the Number of Subjects with Medication Changes|Table Summary of the Number of Subjects with Medical Decisions Other than Medication Changes|Number of Treatment-Related Adverse Events,"Proteus Digital Health, Inc.|Syneos Health",All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,118,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PB-DISC_CMB_01,May-15,Nov-15,Jan-16,11-Jul-16,null,11-Jul-16,,,https://ClinicalTrials.gov/show/NCT02827630
NCT02827903,Metformin/Rosuvastatin Combination Therapy With in Patients With Type 2 Diabetes and Dyslipidemia,,Completed,No Results Available,Type 2 Diabetes|Dyslipidemia,Drug: Metformin + Rosuvastatin|Drug: Metformin + placebo|Drug: placebo + Rosuvastatin,LDL-C (% change)|change of HbA1c,"Jeil Pharmaceutical Co., Ltd.",All,"19 Years and older   (Adult, Older Adult)",Phase 3,237,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",JLP-1310-P3-15,15-Jan-16,21-Nov-17,16-Mar-18,11-Jul-16,null,6-Jul-18,"Buchoen St. mary's Hospital, Bucheon, Korea, Republic of|SeJong Hostpital, Bucheon, Korea, Republic of|SoonChunHyang University Bucheon Hospital, Bucheon, Korea, Republic of|InJe University Busan paik Hospital, Busan, Korea, Republic of|Inje University Haeundae paik hospital, Busan, Korea, Republic of|Daegu Catholic University Medical Center, Daegu, Korea, Republic of|Youngnam University Hostpital, Daegu, Korea, Republic of|Daeheon Eulji Medical Center, Daejeon, Korea, Republic of|KonYang University Hostpital, Daejeon, Korea, Republic of|Chosun University Hospital, Gwangju, Korea, Republic of|BunDang Jesang Hospital(DMC), Gyeonggi-do, Korea, Republic of|Hallym University Sacred Heart hospital, Gyeonggi-do, Korea, Republic of|HanYang University Guri Hospital, Gyeonggi-do, Korea, Republic of|Inje University Ilsan paik hospital, Gyeonggi-do, Korea, Republic of|Myoung Ji Hospital, Gyeonggi-do, Korea, Republic of|Gachon Gil Hospital, Incheon, Korea, Republic of|Inchoen St. mary's Hospital, Incheon, Korea, Republic of|Eulji Hospital Nowon, Seoul, Korea, Republic of|Hallym University Kangnam Sacred Heart hospital, Seoul, Korea, Republic of|KangBuk SamSung Hospital, Seoul, Korea, Republic of|Kangdong Sacred Heart Hospital, Seoul, Korea, Republic of|KonKuk University Medical Center, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|KyungHee University Hospital at Gangdong, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital(Famlily medicine), Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance hospital, Seoul, Korea, Republic of|SoonChunHayng University Hospital Seoul, Seoul, Korea, Republic of|The catholic University of Korea YEOUIDO St mary's Hospital, Seoul, Korea, Republic of|Korea University Guro hospital, Soeul, Korea, Republic of|Ajou University hospital, Suwon, Korea, Republic of|Wonju Severance Christian hospital, Wŏnju, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02827903
NCT02826083,Study to Evaluate the Effects of XXS on Oxidative Stress in Patients With Mild or Moderate Hyperlipidemia,XXS SYMPA,Unknown status,No Results Available,Oxidative Stress,Dietary Supplement: XXS|Dietary Supplement: non-XXS,Quantification of Malondialdehyde (MDA)|Quantification of oxidized Low Density Lipoprotein (LDL)|Measure of overall free-radical defences in the blood by KRL Kyrial Internationaltest,Centre Hospitalier Universitaire Dijon,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,110,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)",VERGES FUI 2014,Nov-14,May-18,null,7-Jul-16,null,7-Jul-16,"Centre Hospitalier Universitaire, Dijon, France",,https://ClinicalTrials.gov/show/NCT02826083
NCT02823912,Capsaicin Effect on Cytokines Profile in Dyslipidemia,,Unknown status,No Results Available,Dyslipidemia|Overweight or Obesity,Drug: Capsaicin|Drug: Magnesia calcinada,Inflammatory cytokines profile|Lipids profile,University of Guadalajara|PhD. Teresa Arcelia Garcia Cobian|LN. Jessica Lucia Barajas Vega,All,25 Years to 45 Years   (Adult),Phase 2|Phase 3,17,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Capdis,Oct-16,Apr-17,Oct-17,6-Jul-16,null,19-Jul-16,,,https://ClinicalTrials.gov/show/NCT02823912
NCT02824432,Exploratory Study of the Effect of Omega-3-acid Ethyl Esters (TAK-085) on Vascular Endothelial Function in Patients With Hyperlipidemia by Flow Mediated Dilation,Oasis Flow,Completed,Has Results,Hyperlipidemia,Drug: TAK-085,"Flow-mediated Dilation (FMD) With Fasting State at Baseline, Week 4 and Week 8|Change From Baseline in FMD With Fasting State at Week 4 and Week 8|Percent Change From Baseline in FMD With Fasting State at Baseline, Week 4 and Week 8|FMD With 4-Hours Postprandial State at Baseline and Week 8|Change From Baseline in FMD With 4-Hours Postprandial State at Week 8|Percent Change From Baseline in FMD With 4-Hours Postprandial State at Week 8|Triglyceride (TG) Level With Fasting State at Baseline, Week 4, and Week 8|Change From Baseline in TG Level With Fasting State at Week 4 and Week 8|Percent Change From Baseline in TG Level With Fasting State at Week 4 and Week 8|TG Level With 4-Hours Postprandial State at Baseline, Week 4 and Week 8|Change From Baseline in TG Level With 4-Hours Postprandial State at Week 4 and Week 8|Percent Change From Baseline in TG Level With 4-Hours Postprandial State at Week 4 and Week 8|Dihomo-gamma-linolenic Acid Concentration With Fasting State at Baseline, Week 4 and Week 8|Change From Baseline in Dihomo-gamma-linolenic Acid Concentration With Fasting State at Week 4 and Week 8|Percent Change From Baseline in Dihomo-gamma-linolenic Acid Concentration With Fasting State at Week 4 and Week 8|Arachidonic Acid Concentration With Fasting State at Baseline, Week 4 and Week 8|Change From Baseline in Arachidonic Acid Concentration With Fasting State at Week 4 and Week 8|Percent Change From Baseline in Arachidonic Acid Concentration With Fasting State at Week 4 and Week 8|Eicosapentaenoic Acid Concentration With Fasting State at Baseline, Week 4 and Week 8|Change From Baseline in Eicosapentaenoic Acid Concentration With Fasting State at Week 4 and Week 8|Percent Change From Baseline in Eicosapentaenoic Acid Concentration With Fasting State at Week 4 and Week 8|Docosahexaenoic Acid Concentration With Fasting State at Baseline, Week 4 and Week 8|Change From Baseline in Docosahexaenoic Acid Concentration With Fasting State at Week 4 and Week 8|Percent Change From Baseline in Docosahexaenoic Acid Concentration With Fasting State at Week 4 and Week 8|Eicosapentaenoic Acid to Arachidonic Acid (EPA/AA) Ratio With Fasting State at Baseline, Week 4 and Week 8|Change From Baseline in EPA/AA Ratio With Fasting State at Week 4 and Week 8|Percent Change From Baseline in EPA/AA Ratio With Fasting State at Week 4 and Week 8|Docosahexaenoic Acid to Arachidonic Acid (DHA/AA) Ratio With Fasting State at Baseline, Week 4 and Week 8|Change From Baseline in DHA/AA Ratio With Fasting State at Week 4 and Week 8|Percent Change From Baseline in DHA/AA Ratio With Fasting State at Week 4 and Week 8|Number of Participants Reporting One or More Adverse Events (AEs)|Number of Participants Reporting One or More AEs Related to Body Weight|Number of Participants Reporting One or More AEs Related to Blood Pressure in the Sitting Position|Number of Participants Reporting One or More AEs Related to Pulse in the Sitting Position|Number of Participants Reporting One or More AEs Related to Laboratory Tests of Fasting Plasma Glucose",Takeda,All,"20 Years and older   (Adult, Older Adult)",Phase 4,37,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,TAK-085-4001|U1111-1182-6745|JapicCTI-163269,4-Aug-16,19-Aug-17,19-Aug-17,6-Jul-16,6-May-19,6-May-19,"Yufu, Oita, Japan|Shinjuku, Tokyo, Japan|Kagoshima, Japan|Oita, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT02824432/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT02824432/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02824432
NCT02818283,"Soy Modulation of Immune Activation, LDL- Levels, and Lowering Inflammation by Pretzel Isoflavone Dietary Intervention",SMALL LIPIDS,Recruiting,No Results Available,Human Immunodeficiency Virus (HIV) Infection|Hypercholesterolemia,Other: Soy Pretzel|Other: Wheat Pretzel,Serious and Non-Serious Adverse Events with Pretzel Intervention (Division of AIDS Adverse Event version 2.0)|Self-Reported Daily Diary to Assess Adherence of Dietary Intervention|Evidence of Improved lipid parameters in Antiretroviral Therapy Treated HIV+ patients with soy pretzel intervention|Evidence of Improved Arterial Function in Antiretroviral Therapy-Treated HIV+ Patients after Soy Pretzel Intervention|Evidence of Improved Immunologic Function of Soy Pretzels in Antiretroviral Therapy-Treated HIV+ patients,Ohio State University,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention",2015H0375,Jun-16,Dec-18,Dec-20,29-Jun-16,null,19-Sep-17,"The Ohio State University Medical Center, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02818283
NCT02799758,Efficacy & Long-term Safety Comparison Study of NK-104-CR & Livalo® IR With Primary Hyperlipidemia or Mixed Dyslipidemia,,Terminated,No Results Available,Hyperlipidemia|Dyslipidemia,Drug: NK-104-CR|Drug: Livalo® IR|Drug: Placebo (for NK-104-CR)|Drug: Placebo (for Livalo® IR),Percent change in Low-density lipoprotein cholesterol (LDL-C),"Kowa Research Institute, Inc.",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NK-104-CR-3.02US,Feb-16,Jul-17,Nov-17,15-Jun-16,null,15-Jun-16,"Foley, Alabama, United States|Huntsville, Alabama, United States|Montgomery, Alabama, United States|Muscle Shoals, Alabama, United States|Little Rock, Arkansas, United States|Greenbrae, California, United States|Huntington Park, California, United States|Lomita, California, United States|Long Beach, California, United States|Los Angeles, California, United States|Santa Ana, California, United States|Spring Valley, California, United States|Tustin, California, United States|Walnut Creek, California, United States|Milford, Connecticut, United States|Atlantis, Florida, United States|Cooper City, Florida, United States|Coral Springs, Florida, United States|Fleming Island, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Oviedo, Florida, United States|Dawnsonville, Georgia, United States|Macon, Georgia, United States|Suwanee, Georgia, United States|Addison, Illinois, United States|Chicago, Illinois, United States|Gurnee, Illinois, United States|Morton, Illinois, United States|Evansville, Indiana, United States|Topeka, Kansas, United States|Louisville, Kentucky, United States|Owensboro, Kentucky, United States|Oxon Hill, Maryland, United States|Biloxi, Mississippi, United States|Olive Branch, Mississippi, United States|Jefferson City, Missouri, United States|St. Louis, Missouri, United States|Omaha, Nebraska, United States|Manlius, New York, United States|High Point, North Carolina, United States|Sailsbury, North Carolina, United States|Wilmington, North Carolina, United States|Winston Salem, North Carolina, United States|Fargo, North Dakota, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Franklin, Ohio, United States|Oklahoma City, Oklahoma, United States|Medford, Oregon, United States|Beaver, Pennsylvania, United States|Harleysville, Pennsylvania, United States|Jersey Shore, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Moncks Corner, South Carolina, United States|Simpsonville, South Carolina, United States|Summerville, South Carolina, United States|Austin, Texas, United States|Houston, Texas, United States|Katy, Texas, United States|Plano, Texas, United States|Round Rock, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Richmond, Virginia, United States|Suffolk, Virginia, United States|Seattle, Washington, United States|Kenosha, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02799758
NCT02789475,DP-R212 Pharmacokinetic Study,,Unknown status,No Results Available,Hypertension|Hyperlipidemias,Drug: Amlodipine|Drug: Rosuvastatin,"AUCτ,ss of Amlodipine and Rosuvastatin|Cmax,ss of Amlodipine and Rosuvastatin",Alvogen Korea,Male,19 Years to 45 Years   (Adult),Phase 1,38,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DP-CTR-212-I-01,May-16,Jul-16,Jul-16,3-Jun-16,null,3-Jun-16,"Inha university hospital, Jung-gu, Incheon, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02789475
NCT02789800,Patient-Centred Innovations for Persons With Multimorbidity - Quebec,PACEinMM-QC,"Active, not recruiting",No Results Available,Hypertension|Depression|Anxiety|Musculoskeletal Pain|Arthritis|Rheumatoid Arthritis|Osteoporosis|Chronic Obstructive Pulmonary Disease (COPD)|Asthma|Chronic Bronchitis|Cardiovascular Disease|Heart Failure|Stroke|Transient Ischemic Attacks|Ulcer|Gastroesophageal Reflux|Irritable Bowel|Crohn's Disease|Ulcerative Colitis|Diverticulosis|Chronic Hepatitis|Diabetes|Thyroid Disorder|Cancer|Kidney Disease|Urinary Tract Problem|Dementia|Alzheimer's Disease|Hyperlipidemia|HIV,Behavioral: DIMAC02,Evaluation of Intervention Effectiveness - Change in Self-Management outcomes|Evaluation of Intervention Effectiveness - Change in Chronic Diseases|Evaluation of Intervention Effectiveness - Change in Health Status|Evaluation of Intervention Effectiveness - Change in Quality of Life|Evaluation of Intervention Effectiveness - Change in Psychological Well-being|Evaluation of Intervention Effectiveness - Change in Lifestyle/Health Behaviours|Evaluation of Intervention Effectiveness - Equity|Demographics|Evaluation of Intervention Effectiveness - Change in Transitions of Care|Evaluation of Intervention Effectiveness - Change in Self-Efficacy|Evaluation of Intervention Effectiveness - Change in Patient-Centredness,"Université de Sherbrooke|Canadian Institutes of Health Research (CIHR)|Western University, Canada|Agence de la Sante et des Services Sociaux du Saguenay-Lac-Saint-Jean",All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,1956,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,2013-010,22-Apr-16,8-Mar-19,1-Mar-20,3-Jun-16,null,15-Dec-17,"Université de Sherbrooke, Chicoutimi, Quebec, Canada|CIUSSS du Sageunay-Lac-Saint-Jean, Chicoutimi, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02789800
NCT02781675,The Mediterranean Full-Fat Dairy Study,MFFD,"Active, not recruiting",No Results Available,Cardiovascular Disease|Dyslipidemia|Inflammation,Other: Dietary Intervention,Plasma LDL-cholesterol|Plasma Apolipoprotein B|Plasma Small LDL concentrations|Plasma Large LDL particle concentrations|Plasma Total LDL particle concentrations|Plasma triglycerides|Plasma HDL-cholesterol|Plasma apolipoprotein AI|Plasma oxidized LDL|Plasma C-reactive protein|Plasma Interleukin-6|Plasma Intercellular Adhesion Molecule 1 (ICAM-1)|Plasma Vascular Cell Adhesion Molecule 1 (VCAM-1)|RH-PAT index (endothelial function),Children's Hospital & Research Center Oakland|Dairy Management Inc.,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,40,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",2016-012,May-16,Jun-18,Dec-18,24-May-16,null,17-Jul-18,"Cholesterol Research Center, Berkeley, California, United States",,https://ClinicalTrials.gov/show/NCT02781675
NCT02775448,Dose-response Study of Carduus Marianus in Centesimal Scale for Dyslipidemia in Climacteric Overweighed or Obese Women.,,Terminated,No Results Available,Dyslipidemia|Menopause|Obesity,Drug: Carduus marianus 6cH|Drug: Carduus marianus 12cH|Drug: Carduus marianus 30cH|Drug: Placebo|Behavioral: Exercise|Other: Diet,Change from baseline level of triglycerides at 4 and 8 weeks.|Change from baseline level of total cholesterol at 4 and 8 weeks.|Change from baseline level of LDL cholesterol at 4 and 8 weeks.|Change from baseline level of HDL cholesterol at 4 and 8 weeks.|Change from baseline level of fasting glucose at 4 and 8 weeks.|Change from baseline level of glycosylated hemoglobin at 4 and 8 weeks.|Change from baseline [HOMA-IR=insulin(mU/ml) X glucose (mg/dl)/405] at 4 and 8 weeks.|Change from baseline weight (kg) at 4 and 8 weeks.|Change from baseline body mass index (Kg/m2) at 4 and 8 weeks.|Change from baseline waist circumference (cm) at 4 and 8 weeks.|Adverse events,"Hospital Nacional Homeopático, Mexico|Laboratorio Similia, México",Female,"40 Years to 65 Years   (Adult, Older Adult)",Phase 2,62,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HospitalNHMexico,Feb-16,Aug-17,Sep-17,17-May-16,null,28-Feb-19,"Hospital Nacional Homeopático, Mexico City, Mexico",,https://ClinicalTrials.gov/show/NCT02775448
NCT02772900,"Aging, Nitrate, Endothelial Function and Muscle Oxygenation",,Completed,No Results Available,Aging|Hypertension|Dyslipidemia|Abdominal Obesity,Other: Beetroot-based nutritional gel|Other: Placebo,Changes in endothelial function as evaluated by the flow-mediated dilation.|Changes in the arterial stiffness as evaluated by the peak wave velocity.|Changes in the clinical blood pressure|Changes in the muscle oxygenation as evaluated by the levels of oxygenated|Changes in the muscle function as evaluated by the maximal voluntary contraction of the forearm muscle|Changes in endothelial function as evaluated by blood flow velocity|Changes in endothelial function as evaluated by reactive hyperemia.|Changes in the arterial stiffness as evaluated by augmentation index|Changes in the arterial stiffness as evaluated by the stiffness parameter|Changes in the arterial stiffness as evaluated by the pressure-strain elasticity modulus|Changes in the arterial stiffness as evaluated by the arterial compliance.|Changes in the muscle oxygenation as evaluated by the levels of deoxygenated hemoglobin,Universidade Federal do Rio de Janeiro|Rio de Janeiro State Research Supporting Foundation (FAPERJ),All,65 Years to 80 Years   (Older Adult),Not Applicable,25,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",15510313.5.0000.5257,May-15,Nov-15,Jan-16,16-May-16,null,17-May-16,,,https://ClinicalTrials.gov/show/NCT02772900
NCT02772640,Effectiveness of Treatment of Hypercholesterolemia With Rosuvastatin and Ezetimibe,ROSEZE,Unknown status,No Results Available,Hypercholesterolemia,Drug: Rosuvastatin and Ezetimibe morning or evening administration,"Change in total cholesterol and LDL-Cholesterol|Change in HDL-Cholesterol|Change in triglycerides|Change in apolipoproteins ApoB, APO AI|Change in non - HDL-Cholesterol|Change in sd-LDL-Cholesterol|Change in lipoprotein (a)|Assessment of change of glucose concentration|Assessment of HbA1c|Assessment of hsCRP|Assessment of ALT|Assessment of AST|Assessment of CK|Assessment of plasma fluorescence using stationary and time-resolved spectrofluorimetry",Collegium Medicum w Bydgoszczy,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,200,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AMI9,Mar-16,Dec-16,Dec-16,13-May-16,null,25-May-16,"Cardiology Department, Dr. A. Jurasz University Hospital, Bydgoszcz, Kujawsko-Pomorskie, Poland",,https://ClinicalTrials.gov/show/NCT02772640
NCT02767440,Families on Track: A Digital Health Behavioral Intervention for Parents Seeking Treatment for Their Child With Obesity,,Completed,No Results Available,Obesity|Childhood Obesity|Hypertension|Diabetes|Dyslipidemia,Behavioral: Families on Track Intervention,"change in parent weight over 6 months|change in parent BMI over 6 months|change in parent waist circumference over 6 months|change in parent blood pressure over 6 months|change in child lipid panel (total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides) over 6 months|change in child glucose, insulin, and HbA1c over 6 months|change in child z-BMI over 6 months|change in child blood pressure over 6 months|change in child cardiovascular fitness/physical conditioning|change in parent diet over 6 months|change in parent exercise behaviors over 6 months|change in child consumption of sugar sweetened beverages over 6 months|change in child consumption of fruits and vegetables over 6 months|change in child consumption of sugary snacks over 6 months|change in child number of minutes of physical activity|change in child number of minutes of screen time|change in parent depression over 6 months|change in child quality of life over 6 months|change in child perceived healthy eating and physical activity social/environmental support over 6 months|change in parent perceived healthy eating and physical activity social/environmental support over 6 months|change in home food environment over 6 months",Duke University,All,18 Years to 60 Years   (Adult),Not Applicable,50,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00072648,Jun-16,Jun-17,29-Jun-17,10-May-16,null,4-Oct-17,"Duke Pediatrics Healthy Lifestyles Clinic, Durham, NC, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT02767440
NCT02767531,Orlistat for the Treatment of Type I Hyperlipoproteinemia,T1HLP,"Active, not recruiting",Has Results,Hyperlipoproteinemia Type I|Hypertriglyceridemia,Drug: Orlistat,Fasting Serum Triglycerides,University of Texas Southwestern Medical Center,All,"8 Years to 18 Years   (Child, Adult)",Phase 2,2,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,012013-042,Dec-15,31-May-18,31-Jul-19,10-May-16,1-Feb-19,1-Feb-19,"UT Southwestern Medical Center 5323 Harry Hines Blvd, Dallas, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT02767531/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02767531
NCT02765841,Evaluate the Efficacy and Safety of Lomitapide in Pediatric Patients With Homozygous Familial Hypercholesterolemia on Stable Lipid-lowering Therapy,,Withdrawn,No Results Available,Homozygous Familial Hypercholesterolemia,Drug: Lomitapide,Percent change in LDL-C|Percent Change in TC|Percent change in non-HDL-C|Percent change in HDL-C|Percent change in TG|Percent change in VLDL-C|Percent change in Lp(a)|Percent change in apo B|Percent change in apo A-1|Changes in lipid-lowering therapy|Changes in LDL apheresis|Percent of patients achieving goal (LDL-C of <100 mg/dL [2.6 mmol/L] for patients without documented cardiovascular disease [CVD] at Baseline|Percent of patients achieving goal LDL-C of <70 mg/dL [1.8 mmol/L]) for patients with documented CVD at Baseline.|Changes in laboratory parameters (including hepatic and renal function)|Reported Adverse Events|Electrocardiogram (ECG) changes|Pulmonary function tests (PFTs)|Bone health/age (x-ray of the wrist)|Height Measurement|Weight Measurement|Body Mass Measurement|Tanner Staging|Percent change in hepatic fat|Blood Pressure|Heart Rate|Temperature|Respiration (breaths/min),"Aegerion Pharmaceuticals, Inc.",All,5 Years to 17 Years   (Child),Phase 3,0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AEGR-733-020,May-16,Mar-17,Dec-19,9-May-16,null,22-Feb-18,,,https://ClinicalTrials.gov/show/NCT02765841
NCT02765516,Genetic Basis for Prediction of Non-responders to Dietary Plant Sterol Intervention,GenePredict-PS,Recruiting,No Results Available,Hypercholesterolemia|Cardiovascular Disease,Other: Plant sterols|Other: Placebo,Change in fasting low-density lipoprotein cholesterol (LDL-C) levels between placebo and treatment endpoints (in a crossover design)|Change in fasting total cholesterol (TC) levels between placebo and treatment endpoints (in a crossover design)|Change in fasting high-density lipoprotein cholesterol levels between placebo and treatment endpoints|Change in fasting triglyceride (TG) levels between placebo and treatment endpoints (in a crossover design)|Change in body weight between placebo and treatment endpoints (in a crossover design)|Change in body mass index (BMI) between placebo and treatment endpoints (in a crossover design)|Change in waist circumference between placebo and treatment endpoints (in a crossover design)|Change in blood pressure between placebo and treatment endpoints (in a crossover design)|Change in arterial stiffness-Pulse wave velocity between placebo and treatment endpoints (in a crossover design)|Change in arterial stiffness-augmentation index between placebo and treatment endpoints (in a crossover design)|Change in fasting glucose levels between placebo and treatment endpoints (in a crossover design)|Change in blood sterols and sterol precursors (non-cholesterol sterols) levels between placebo and treatment endpoints (in a crossover design)|Change in fractional cholesterol synthesis between placebo and treatment endpoints (in a crossover design),University of Manitoba|Mitacs|Unilever R&D|Nutritional Fundamentals for Health,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,64,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",MITACS Converge MC00009,5-Jul-17,Apr-19,Dec-19,6-May-16,null,3-Dec-18,"Department of Human Nutritional sciences, University of Manitoba, Winnipeg, Manitoba, Canada",,https://ClinicalTrials.gov/show/NCT02765516
NCT02753504,Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519,,Completed,No Results Available,Dyslipidemia,Drug: CKD-519|Drug: placebo,"Cmax,ss of CKD-519|AUCt,ss of CKD-519|AUCinf,ss of CKD-519|Tmax,ss of CKD-519|T1/2 of CKD-519|Cmin,ss of CKD-519|Cavg,ss of CKD-519|CLss/F of CKD-519|accumulation ratio(D14/D1: Cmax, AUC0-t) of CKD-519|CETP activity of CKD-519|CETP concentration of CKD-519|Lipid parameter(HDL-c, LDL-c, Total Cholesterol, Triglyceride) of CKD-519|Lipid parameter(Apolipoprotein A-I, E, B) of CKD-519|QT/QTc(QTcF, QTcB, QT, HR, RR, PR, QRS) of CKD-519",Chong Kun Dang Pharmaceutical,All,19 Years to 55 Years   (Adult),Phase 1,24,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",148HPS15001,Apr-16,Jul-16,Jul-16,28-Apr-16,null,13-Jul-17,"Severance Hospital, Seoul, Seodaemun-gu, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02753504
NCT02749994,A Clinical Trial to Compare the Efficacy and Safety of a Combination Therapy of Ezetimibe and Rosuvastatin Versus Monotherapy of Rosuvastatin in Hypercholesterolemia Patients (I-ROSETTE Study),I-ROSETTE,Completed,No Results Available,Hypercholesterolemia,Drug: Rosuvastatin|Drug: Ezetimibe,Percent change from baseline to 8 week in LDL-Cholesterol|Percent change from baseline to 4 and 8 week in Total Cholesterol|Percent change from baseline to 4 and 8 week in Triglyceride|Percent change from baseline to 4 and 8 week in HDL-Cholesterol|Percent change from baseline to 4 and 8 week in non-HDL-Cholesterol|Percent change from baseline to 4 and 8 week in Apolipoprotein B|Percent change from baseline to 4 and 8 week in Apolipoprotein A1|Percent change from baseline to 4 week in LDL-Cholesterol|Percent change from baseline to 4 and 8 week in hs-CRP(high-sensitivity C-reactive protein)|The change of LDL-Cholesterol/HDL-Cholesterol ratio|The change of Total Cholesterol/HDL-Cholesterol ratio|The change of non-HDL-Cholesterol/HDL-Cholesterol ratio|The change of Apolipoprotein B/Apolipoprotein A1 ratio|The ratio of subjects who reach the goal of LDL-Cholesterol according to NCEP(National Cholesterol Education Program Adult Treatment Panel) III Guideline,IlDong Pharmaceutical Co Ltd,All,"19 Years to 79 Years   (Adult, Older Adult)",Phase 3,396,Industry,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ID-ROEZ-302,Apr-16,Feb-17,Feb-17,25-Apr-16,null,13-Jun-18,"Seoul National University Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02749994
NCT02748057,A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-833),,Completed,Has Results,Hypercholesterolemia|Familial Hypercholesterolemia,Drug: Ezetimibe|Drug: Rosuvastatin,Percentage of Participants Who Experience at Least 1 Adverse Event (AE)|Percentage of Participants Who Had Study Drug Discontinued Due to an AE|Percentage Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C),Merck Sharp & Dohme Corp.,All,"20 Years to 80 Years   (Adult, Older Adult)",Phase 3,135,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0653H-833|163314|MK-0653H-833,18-May-16,11-Dec-17,11-Dec-17,22-Apr-16,4-Dec-18,2-Apr-19,,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02748057/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02748057
NCT02742545,Impact of MayoExpertAdvisor on Provider Adherence,MEA Research,Completed,No Results Available,Hyperlipidemia|Atrial Fibrillation|Heart Failure,Behavioral: MayoExpertAdvisor,Percentage of pre-visit recommendations for hyperlipidemia acted upon by providers|Percentage of pre-visit recommendations for atrial fibrillation acted upon by providers|Percentage of pre-visit recommendations for heart failure acted upon by providers,Mayo Clinic,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2248,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,15-008444,Apr-16,Nov-16,Nov-16,19-Apr-16,null,18-Apr-19,"Mayo Clinic in Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02742545
NCT02742597,Patient-Centred Innovations for Persons With Multimorbidity - Ontario,PACEinMM-ON,"Active, not recruiting",No Results Available,Hypertension|Depression|Anxiety|Musculoskeletal Pain|Arthritis|Rheumatoid Arthritis|Osteoporosis|Chronic Obstructive Pulmonary Disease (COPD)|Asthma|Chronic Bronchitis|Cardiovascular Disease|Heart Failure|Stroke|Transient Ischemic Attacks|Ulcer|Gastroesophageal Reflux|Irritable Bowel|Crohn's Disease|Ulcerative Colitis|Diverticulosis|Chronic Hepatitis|Diabetes|Thyroid Disorder|Cancer|Kidney Disease|Urinary Tract Problem|Dementia|Alzheimer's Disease|Hyperlipidemia|HIV|Multimorbidity,Behavioral: TIP / IMPACT Plus Care Coordination,Evaluation of Intervention Effectiveness - Change in Self-Management outcomes|Evaluation of Intervention Effectiveness - Change in Transitions of Care|Evaluation of Intervention Effectiveness - Change in Self-Efficacy|Evaluation of Intervention Effectiveness - Change in Patient-Centredness|Evaluation of Intervention Effectiveness - Change in Chronic Diseases|Evaluation of Intervention Effectiveness - Change in Health Status|Evaluation of Intervention Effectiveness - Change in Quality of Life|Evaluation of Intervention Effectiveness - Change in Psychological Well-being|Evaluation of Intervention Effectiveness - Change in Lifestyle/Health Behaviours|Evaluation of Intervention Effectiveness - Change in Equity|Evaluation of Intervention Effectiveness - Change in Demographics,"Lawson Health Research Institute|Western University, Canada|Université de Sherbrooke|Canadian Institutes of Health Research (CIHR)|Sunnybrook Health Sciences Centre|St. Michael's Hospital, Toronto|University Health Network, Toronto|Toronto East General Hospital|Providence Healthcare|Mount Sinai Hospital, Canada|Toronto Central Community Care Access Centre|Women's College Hospital",All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,1980,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,104191,12-Jan-16,7-Apr-19,1-Mar-20,19-Apr-16,null,18-Dec-17,"Western University, London, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|Providence Healthcare, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Toronto Central Community Care Access Centre, Toronto, Ontario, Canada|Toronto East General Hospital, Toronto, Ontario, Canada|University Hospital Network, Toronto, Ontario, Canada|Women's College Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02742597
NCT02741245,A Study of the Efficacy and Safety of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-832),,Completed,Has Results,Hypercholesterolemia,Drug: Ezetimibe 10 mg|Drug: Rosuvastatin 2.5 mg|Drug: Placebo for Ezetimibe|Drug: Placebo for Rosuvastatin,Percentage Change From Baseline in Low-density Lipoprotein-cholesterol (LDL-C)|Percentage of Participants Who Experience at Least 1 Adverse Event (AE)|Percentage of Participants Who Had Study Drug Discontinued Due to Adverse Event|Percentage of Participants Who Experience 1 or More Gastrointestinal-related AEs|Percentage of Participants Who Experience 1 or More Gallbladder-related AEs|Percentage of Participants Who Experience 1 or More Allergic Reaction or Rash AEs|Percentage of Participants Who Experience 1 or More Hepatitis-related AEs|Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) ≥3 Times Upper Normal Limit (ULN)|Percentage of Participants Who Experience Consecutive Elevations in Aspartate Aminotransferase (AST) ≥3 Times Upper Normal Limit (ULN)|Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) ≥3 Times Upper Normal Limit (ULN)|Percentage of Participants Who Experience Elevation in Alanine Aminotransferase (ALT) ≥5 Times Upper Normal Limit (ULN)|Percentage of Participants Who Experience Elevation in Aspartate Aminotransferase (AST) ≥5 Times Upper Normal Limit (ULN)|Percentage of Participants Who Experience Elevation in Alanine Aminotransferase (ALT) ≥10 Times Upper Normal Limit (ULN)|Percentage of Participants Who Experience Elevation in Aspartate Aminotransferase (AST) ≥10 Times Upper Normal Limit (ULN)|Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) ≥10 Times Upper Normal Limit (ULN)|Percentage of Participants With Potential Hy's Law Condition|Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN|Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN With Muscle Symptoms|Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN and Drug-Related Muscle Symptoms,Merck Sharp & Dohme Corp.,All,"20 Years to 80 Years   (Adult, Older Adult)",Phase 3,321,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0653H-832|163336,9-Jun-16,18-Jan-17,18-Jan-17,18-Apr-16,9-Mar-18,15-Mar-19,,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT02741245/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02741245
NCT02739984,Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia,BANTING,Completed,Has Results,Hypercholesterolemia|Mixed Dyslipidemia|Type 2 Diabetes,Biological: Evolocumab|Drug: Placebo to Evolocumab,Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12|Percent Change From Baseline in LDL-C at Week 12|Change From Baseline in LDL-C at the Mean of Weeks 10 and 12|Change From Baseline in LDL-C at Week 12|Percent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12|Percent Change From Baseline in Non-HDL-C at Week 12|Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12|Percent Change From Baseline in Apolipoprotein B at Week 12|Percent Change From Baseline in Total Cholesterol at the Mean of Weeks 10 and 12|Percent Change From Baseline in Total Cholesterol at Week 12|Percentage of Participants With Mean LDL-C at Weeks 10 and 12 Less Than 70 mg/dL (1.8 mmol/L)|Percentage of Participants With LDL-C at Week 12 Less Than 70 mg/dL (1.8 mmol/L)|Percentage of Participants With at Least a 50% Reduction From Baseline in Mean LDL-C at Weeks 10 and 12|Percentage of Participants With at Least a 50% Reduction From Baseline in LDL-C at Week 12|Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12|Percent Change From Baseline in Lipoprotein(a) at Week 12|Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12|Percent Change From Baseline in Triglycerides at Week 12|Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12|Percent Change From Baseline in HDL-C at Week 12|Percent Change From Baseline in VLDL-C at the Mean of Weeks 10 and 12|Percent Change From Baseline in VLDL-C at Week 12,Amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 3,424,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",20130287|2015-004711-21,17-May-16,3-Aug-17,3-Aug-17,15-Apr-16,31-Aug-18,31-Aug-18,"Research Site, Tuscumbia, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, Lomita, California, United States|Research Site, Los Angeles, California, United States|Research Site, Roseville, California, United States|Research Site, San Ramon, California, United States|Research Site, Spring Valley, California, United States|Research Site, Tarzana, California, United States|Research Site, Walnut Creek, California, United States|Research Site, Denver, Colorado, United States|Research Site, Lakewood, Colorado, United States|Research Site, Wilmington, Delaware, United States|Research Site, Boca Raton, Florida, United States|Research Site, Coral Gables, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Fleming Island, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Inverness, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Dunwoody, Georgia, United States|Research Site, Meridian, Idaho, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Louisville, Kentucky, United States|Research Site, Auburn, Maine, United States|Research Site, Scarborough, Maine, United States|Research Site, Salisbury, Maryland, United States|Research Site, Methuen, Massachusetts, United States|Research Site, Bay City, Michigan, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, New Windsor, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Shelby, North Carolina, United States|Research Site, Tabor City, North Carolina, United States|Research Site, Columbus, Ohio, United States|Research Site, Norman, Oklahoma, United States|Research Site, Austin, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Suffolk, Virginia, United States|Research Site, Edegem, Belgium|Research Site, Leuven, Belgium|Research Site, Liege, Belgium|Research Site, Vancouver, British Columbia, Canada|Research Site, Gatineau, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, St-Jérôme, Quebec, Canada|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Verona, Italy|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Chihuahua, Mexico|Research Site, Katowice, Poland|Research Site, Krakow, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Almeria, Andalucía, Spain|Research Site, Granada, Andalucía, Spain|Research Site, Badalona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT02739984/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT02739984/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02739984
NCT02734706,Efficacy of a LRC™ (L. Reuteri NCIMB 30242) Capsule on Managing Cholesterol in Adults,,Completed,No Results Available,Hypercholesterolemia,Dietary Supplement: LRC™ capsule|Other: Placebo capsule,Serum LDL-cholesterol after 9 weeks of product consumption.|Serum LDL-cholesterol after 6 weeks of product consumption.|Serum total cholesterol after 6 and 9 weeks of product consumption.|Serum HDL-cholesterol after 6 and 9 weeks of product consumption.|Serum non-HDL-cholesterol after 6 and 9 weeks of product consumption.|Serum triglycerides after 6 and 9 weeks of product consumption.|Serum apolipoprotein B-100 after 6 and 9 weeks of product consumption.|Serum hs-CRP after 9 weeks of product consumption.|Plasma fibrinogen after 9 weeks of product consumption.|Plasma homocysteine after 9 weeks of product consumption.|GI health questionnaire score after 6 and 9 weeks of product consumption.,UAS Labs LLC,All,"20 Years to 75 Years   (Adult, Older Adult)",Not Applicable,111,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",15LCHU,Mar-16,Nov-18,Feb-19,12-Apr-16,null,10-May-19,"KGK Synergize Inc., London, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02734706
NCT02729025,Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a)),ANITSCHKOW,Completed,Has Results,"Subjects With Hyperlipidemia, Dyslipidemia",Drug: Evolocumab|Drug: Placebo,Percent Change From Baseline in Maximum Target-to-background Ratio in the Most Diseased Segment of the Index Vessel at Week 16|Percent Change From Baseline in Lipoprotein(a) Concentration at Week 16|Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) Concentration at Week 16|Percent Change From Baseline in Apolipoprotein B Concentration at Week 16,Amgen,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 3,129,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",20130293|2015-003731-35,14-Apr-16,5-Apr-18,5-Apr-18,6-Apr-16,23-Apr-19,23-Apr-19,"Research Site, Miami, Florida, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Mooresville, North Carolina, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Hurst, Texas, United States|Research Site, Newmarket, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Amsterdam, Netherlands|Research Site, Apeldoorn, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Venlo, Netherlands|Research Site, Waalwijk, Netherlands","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT02729025/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT02729025/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02729025
NCT02729857,Postprandial Response After Intake of Meals With Different Fatty Acid Composition,,Completed,No Results Available,Healthy|Familial Hypercholesterolemia,Dietary Supplement: SFA muffin|Dietary Supplement: PUFA muffin,Change in levels of circulating triglycerides|Changes in markers of lipid- and glucose metabolism|Changes in circulating levels of inflammatory markers|Changes in PBMC gene expression levels of markers of inflammation and lipid metabolism|Changes in lipid classes and lipoprotein size|Changes in plasma and urine metabolomics|Check DNA for single nuclear polymorphisms|Changes in PBMC Whole genome transcriptomics,University of Oslo|Oslo University Hospital|Mills DA,All,18 Years to 30 Years   (Adult),Not Applicable,31,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",2015/2392/REK sør-øst B,Mar-16,Jun-16,Jun-16,6-Apr-16,null,30-Jun-16,"University of Oslo, Oslo, Post box 1046, Blindern, Norway",,https://ClinicalTrials.gov/show/NCT02729857
NCT02730559,Motivational Interviewing With Dyslipidemic Adolescents Together With a Parent Versus With Adolescents Alone: A Mixed Methods Clinical Trial,,Completed,No Results Available,Dyslipidemias,Other: Motivational Interviewing/Counselling,Changes in total cholesterol to HDL-C ratio,The Hospital for Sick Children,All,10 Years to 17 Years   (Child),Not Applicable,32,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,1000035605,Nov-12,Jun-14,null,6-Apr-16,null,6-Apr-16,,,https://ClinicalTrials.gov/show/NCT02730559
NCT02728583,The Effects of a Spread With Added Plant Sterols and Omega-3 Fatty Acids on Blood Lipids,,Completed,No Results Available,Vascular Diseases|Hypercholesterolemia,Dietary Supplement: Margarine enriched with plant sterols and fish oil|Dietary Supplement: Placebo margarine,Change in TG concentrations|Change in blood lipids,Unilever R&D,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,260,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",FDS-SCC-2150,Apr-16,Nov-16,Jan-17,5-Apr-16,null,19-Jan-17,"Charite Research Organisation, Berlin, Germany",,https://ClinicalTrials.gov/show/NCT02728583
NCT02727036,Effect of Pumpkin Seed Oil or Pumpkin Seeds on Blood Pressure and Menopausal Symptoms in Postmenopausal Women,,Completed,No Results Available,Hypertension|Dyslipidemia,Dietary Supplement: Pumpkin seed oil|Dietary Supplement: Pumpkin seeds,Change in systolic and diastolic blood pressure|Change in Total Cholesterol level (mg/dl)|Change in Plasma Triglycerides (mg/dl)|Change in Plasma High-Density Lipoprotein Cholesterol (mg/dl)|Change in Plasma Low-Density Lipoprotein Cholesterol (mg/dl)|Change in C-reactive protein (CRP)|Change in Endothelial Function,Texas Woman's University,Female,"Child, Adult, Older Adult",Not Applicable,27,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,17696,1-Aug-15,16-Jun-17,10-Nov-17,4-Apr-16,null,3-May-18,"Texas Woman's University, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02727036
NCT02726100,SMARTHealth Diabetes in China Using Lay Family Health Promoters,,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Type 2|Hypertension|Dyslipidemias",Behavioral: SMARTHealth Diabetes,proportion of chronic diseases controlled|proportion of chronic disease partly controlled|changes of chronic disease condition after intervention|quality of life|cost-effectiveness/utility,"The George Institute for Global Health, China|Global Alliance for Chronic Diseases (GACD)|National Health and Medical Research Council, Australia",All,"40 Years to 75 Years   (Adult, Older Adult)",Not Applicable,2000,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research",APP1094712,1-Aug-17,Dec-19,Apr-20,1-Apr-16,null,15-Feb-19,"Hebei Medical University, Shijiazhuang, Hebei, China|Center of Disease Control and Prevention, Luquan, Shijiazhuang, Hebei, China",,https://ClinicalTrials.gov/show/NCT02726100
NCT02726555,The Efficacy and Safety of Combined Therapy With Red Yeast Rice and Low-dose Statin：Comparing With Standardized Statin,,Recruiting,No Results Available,Dyslipidemia|Atherosclerosis,Drug: Red yeast rice and atorvastatin|Drug: Atorvastatin alone,Mean percentage change from baseline at week 24 (or the last assessment) on serum low-density lipoprotein cholesterol (LDL-C) level|Mean percentage change from baseline at week 24 (or the last assessment on serum total cholesterol (TC) level|Mean percentage change from baseline at week 24 (or the last assessment) on serum high-density lipoprotein cholesterol (HDL-C) level|Mean percentage change from baseline at week 24 (or the last assessment) on serum triglyceride (TG) level|Mean percentage change from baseline at week 24 (or the last assessment) on serum non-HDL cholesterol level|Percentage of Participants Who Experienced Statin-associated muscle symptoms (SAMs),Wenzhou Medical University,All,"20 Years to 80 Years   (Adult, Older Adult)",Phase 3,240,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",wzfeyxzk,Nov-15,May-19,May-19,1-Apr-16,null,4-Oct-18,"The Second Hispital of Wenzhou Medical University, Wenzhou, Zhejiang, China",,https://ClinicalTrials.gov/show/NCT02726555
NCT02722408,"Efficacy and Safety of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid-Lowering Therapy (COBALT-1)",,Completed,No Results Available,Hypercholesteremia,Drug: Gemcabene 300 mg|Drug: Gemcabene 600 mg|Drug: Gemcabene 900 mg,LDL-C|non-HDL-C|Total Cholesterol [TC]|Triglycerides [TG]|HDL-C|Very low-density lipoprotein [VLDL-C]|hsCRP|Fibrinogen|Lipoprotein(a)|Apolipoprotein B (ApoB)|Apolipoprotein A-1 (ApoA-1)|Apolipoprotein A-II (ApoA-II)|Apolipoprotein C-II (ApoC-II)|Apolipoprotein C-III (ApoC-III)|Apolipoprotein E(ApoE)|Adverse Events|Clinical Laboratory,"Gemphire Therapeutics, Inc.",All,"17 Years and older   (Child, Adult, Older Adult)",Phase 2,8,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GEM-201,May-16,Apr-17,Aug-17,30-Mar-16,null,25-Aug-17,"Westside Medical Associates of Los Angeles, Beverly Hills, California, United States|Robarts Research Institute, London, Ontario, Canada|Ecogene-21, Chicoutimi, Quebec, Canada|Montreal Heart Institute, Montreal, Quebec, Canada|Wolfson Medical Center Internal Medicine Dept., Holon, Israel|Center for Research, Prevention and Treatment of Atherosclerosis - Cardiology Department of Medicine Kiryat Hadassah, Jerusalem, Israel|Ziv Medical Center Internal Medicine Department, Safed, Israel",,https://ClinicalTrials.gov/show/NCT02722408
NCT02719028,Trial of Antroquinonol in Patients With Hypercholesterolemia and Hyperlipidemia,,Completed,No Results Available,Hyperlipidemias,Drug: Antroquinonol|Drug: placebo,TG change (mg/dL )|LDL& HDL (mg/dL)|Non-invasive arterial stiffness measurement|Fatty level in The Hounsfield Unit (HU),Golden Biotechnology Corporation,All,"30 Years to 75 Years   (Adult, Older Adult)",Phase 2,120,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",GHLIP-2-001,May-16,27-Sep-18,31-Mar-19,25-Mar-16,null,14-May-19,"Chang Gung Memorial Hospital, Linkou branch, New Taipei City, Taiwan|Far Eastern Memorial Hospital, New Taipei city, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT02719028
NCT02715726,Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia,ODYSSEY EAST,Completed,No Results Available,Hypercholesterolemia,Drug: alirocumab SAR236553 (REGN727)|Drug: placebo for alirocumab|Drug: ezetimibe|Drug: placebo for ezetimibe|Drug: atorvastatin|Drug: rosuvastatin|Drug: simvastatin,Percent change in calculated LDL-C in the intent-to-treat (ITT) population|Percent change in calculated LDL-C in the modified ITT (mITT) population|Percent change in calculated LDL-C|Percent change in Apo B|Percent change in non-HDL-C|Percent change in TC|Proportion of patients reaching calculated LDL-C <70 mg/dL (1.81 mmol/L)|Percent change in Lp(a)|Percent change in HDL-C|Percent change in fasting TG|Percent change in Apo A-1,Sanofi|Regeneron Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 3,615,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EFC13889|U1111-1150-8859,27-Jul-16,6-Aug-18,6-Aug-18,22-Mar-16,null,14-Aug-18,"Investigational Site Number 1560027, Beijing, China|Investigational Site Number 1560043, Beijing, China|Investigational Site Number 1560039, Beijing, China|Investigational Site Number 1560012, Beijing, China|Investigational Site Number 1560018, Beijing, China|Investigational Site Number 1560006, Changchun, China|Investigational Site Number 1560020, Changchun, China|Investigational Site Number 1560023, Changsha, China|Investigational Site Number 1560030, Fuzhou, China|Investigational Site Number 1560005, Guangzhou, China|Investigational Site Number 1560040, Guangzhou, China|Investigational Site Number 1560025, Guangzhou, China|Investigational Site Number 1560048, Hangzhou, China|Investigational Site Number 1560037, Hangzhou, China|Investigational Site Number 1560008, Hangzhou, China|Investigational Site Number 1560014, Hohhot, China|Investigational Site Number 1560016, Jinan, China|Investigational Site Number 1560044, Lanzhou, China|Investigational Site Number 1560028, Nanchang, China|Investigational Site Number 1560045, Nanjing, China|Investigational Site Number 1560017, Nanjing, China|Investigational Site Number 1560031, Nanjing, China|Investigational Site Number 1560035, Nanning, China|Investigational Site Number 1560029, Shanghai, China|Investigational Site Number 1560041, Shanghai, China|Investigational Site Number 1560053, Shanghai, China|Investigational Site Number 1560009, Shenyang, China|Investigational Site Number 1560001, Shenyang, China|Investigational Site Number 1560042, Shenyang, China|Investigational Site Number 1560036, Shenzhen, China|Investigational Site Number 1560056, Siping, China|Investigational Site Number 1560021, Taiyuan, China|Investigational Site Number 1560002, Tianjin, China|Investigational Site Number 1560022, Tianjin, China|Investigational Site Number 1560052, Tianjin, China|Investigational Site Number 1560055, Wenzhou, China|Investigational Site Number 1560003, Wuhan, China|Investigational Site Number 1560004, Xi'An, China|Investigational Site Number 1560019, Xuzhou, China|Investigational Site Number 1560054, Yinchuan, China|Investigational Site Number 1560057, Zhanjiang, China|Investigational Site Number 3560017, Belgaum, India|Investigational Site Number 3560001, Gurgaon, India|Investigational Site Number 3560003, Hubli, India|Investigational Site Number 3560010, Kolkata, India|Investigational Site Number 3560019, Kolkata, India|Investigational Site Number 3560020, Mangalore, India|Investigational Site Number 3560006, Mumbai, India|Investigational Site Number 3560007, Nagpur, India|Investigational Site Number 3560004, Nagpur, India|Investigational Site Number 3560008, Nagpur, India|Investigational Site Number 3560016, Nagpur, India|Investigational Site Number 3560014, New Delhi, India|Investigational Site Number 3560005, Pune, India|Investigational Site Number 3560011, Pune, India|Investigational Site Number 3560013, Surat, India|Investigational Site Number 3560015, Vijayawada, India|Investigational Site Number 3560012, Vijaywada, India|Investigational Site Number 7640003, Bangkok-Noi, Thailand|Investigational Site Number 7640004, Bangkok, Thailand|Investigational Site Number 7640001, Muang, Thailand|Investigational Site Number 7640002, Pratumwan, Thailand",,https://ClinicalTrials.gov/show/NCT02715726
NCT02714569,A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia,,Completed,No Results Available,Dyslipidemias,Drug: LY3202328|Drug: Placebo|Drug: Atorvastatin|Drug: Simvastatin,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration|Maximum Plasma Concentration (Cmax) of LY3202328|Area Under the Serum Concentration time Curve (AUC) from Zero to Infinity of LY3202328|Area Under the Serum Concentration-Time Curve (AUC tau) of LY3202328|Time to Maximum Concentration (Tmax) of LY3202328|Change from Baseline in Fasting High-Density Lipoprotein Cholesterol (HDL-c)|Change from Baseline in Fasting Total Triglycerides|Change from Baseline in Fasting Total Cholesterol|Change from Baseline in Fasting Low-Density Lipoprotein Cholesterol (LDL-c)|Simvastatin Cmax in LY3202328 Co-administration|Atorvastatin Cmax in LY3202328 Co-administration|Simvastatin AUC 0-24 in LY3202328 Co-administration|Atorvastatin AUC 0-24 in LY3202328 Co-administration,Eli Lilly and Company,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,58,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",16417|I8Q-MC-GSEA,Mar-16,Feb-17,Feb-17,21-Mar-16,null,14-Mar-17,"Clinical Pharmacology of Miami, Inc., Miami, Florida, United States|PRA Health Sciences, Lenexa, Kansas, United States|PRA Health Sciences, Marlton, New Jersey, United States|PRA Health Sciences, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT02714569
NCT02709850,"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS ANGPTL3-LRx in Healthy Volunteers With Elevated Triglycerides and Subjects With Familial Hypercholesterolemia",,Completed,No Results Available,Hypertriglyceridemia|Familial Hypercholesterolemia,"Drug: IONIS ANGPTL3-LRx|Drug: Placebo (0.9%NaCl, water, riboflavin)","Safety and tolerability of single and multiple doses of IONIS ANGPTL3-LRx (incidence, severity, and dose-relationship of adverse effects and changes in the laboratory parameters)|Pharmacokinetics after single and multiple doses of IONIS ANGPTL3-LRx.|Pharmacodynamics of IONIS ANGPTL3-LRx (Changes in serum ANGPTL3 levels)|Pharmacodynamic effects of IONIS ANGPTL3-LRx","Ionis Pharmaceuticals, Inc.|Akcea Therapeutics",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,48,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other",IONIS ANGPTL3-LRx,Nov-15,12-Apr-17,26-Jun-17,16-Mar-16,null,13-Feb-18,"Clinical Site, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02709850
NCT02697136,CER-001 Therapy as a Novel Approach to Treat Genetic Orphan Diseases,TANGO,Terminated,No Results Available,Familial Hypoalphalipoproteinemia,Drug: CER-001|Drug: Placebo,Change in mmean vessel wall area (MVWA) of the carotid artery|Change in mean vessel wall area (MVWA) of the carotid artery|Change in Target to Background Ratio (TBR) of the carotid artery,"Cerenis Therapeutics, SA",All,"18 Years and older   (Adult, Older Adult)",Phase 3,30,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CER-001-CLIN-009,Dec-15,Oct-18,21-Dec-18,3-Mar-16,null,11-Feb-19,"Investigative Site, Salt Lake City, Utah, United States|Investigative Site, La Louvière, Belgium|Investigative Site, Vancouver, British Columbia, Canada|Investigative Site, Halifax, Nova Scotia, Canada|Investigative Site, London, Ontario, Canada|Investigative Site, Chicoutimi, Quebec, Canada|Investigative Site, Montreal, Quebec, Canada|Investigative Site, Lille, France|Investigative Site, Montpellier, France|Investigative Site, Rouen, France|Investigative Site, Toulouse, France|Investigative Site, Jerusalem, Israel|Investigative Site, Tel Aviv, Israel|Investigative Site, Genoa, Italy|Investigative Site, Milan, Italy|Investigative Site, Pisa, Italy|Investigative Site, Rome, Italy|Investigative Site, Amsterdam, Netherlands|Investigative Site, Utrecht, Netherlands",,https://ClinicalTrials.gov/show/NCT02697136
NCT02697422,Veteran Peer Coaches Optimizing and Advancing Cardiac Health,Vet-COACH,Recruiting,No Results Available,Cardiovascular Disease (CVD)|Hypertension|Hyperlipemia|Obesity,Other: Community-based peer health coach intervention,"Reduction in systolic blood pressure|Reduction in Framingham Cardiovascular risk score|Tobacco use|Overall Health, 12-Item Short-Form Health Survey|Number of outpatient clinic visits, ER visits and hospitalizations in the previous year|Body Mass Index (BMI)|Low density lipoprotein cholesterol (LDL-c).|Participant self-reported use of non-VA care services, High Risk Patient Survey",VA Office of Research and Development,All,"up to 75 Years   (Child, Adult, Older Adult)",Not Applicable,400,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,IIR 14-063,30-May-17,31-Aug-20,28-Feb-21,3-Mar-16,null,18-Feb-19,"VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT02697422
NCT02693782,Fabulous Fibre Study - Effect of Wheat Bran Extract on Gut and General Health in Healthy Aging Subjects (FFS),FFS,Completed,No Results Available,Hypercholesterolemia|Flatulence|Intestinal Diseases,Dietary Supplement: Placebo|Dietary Supplement: Fibre supplement,Changes in the gut microbiota metabolites|Changes in the gut microbiota|Changes in blood glucose|Changes in blood HDL|Changes in blood LDL|Changes in blood triglycerides|Changes in blood cholesterol|Gastrointestinal tolerance|Volunteer's habitual diet food intake|General health and well-being (This is assessed via questionnaires at the end of the study)|Changes in faecal inflammatory markers,University of Aberdeen|Cargill,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,21,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",15/HSMC/004,Jun-15,Feb-16,Feb-16,29-Feb-16,null,2-May-17,"Rowett Institute of Nutrition and Health, University of Aberdeen, Aberdeen, United Kingdom",,https://ClinicalTrials.gov/show/NCT02693782
NCT02689934,Efficacy of a Red Yeast Rice Based Nutraceutical Plus Probiotic in Patients With Moderate Hypercholesterolemia,,Completed,No Results Available,Hypercholesterolemia,Dietary Supplement: Lactoflorene colesterolo|Dietary Supplement: Placebo lactoflorene colesterolo,"Percent Change in LDL-C From Baseline|Safety and tolerability of Lactoflorene colesterolo (Incidence of treatment-related adverse events)|Changes in Other Lipids (non HDL-C, TG, HDL-C) and Apolipoproteins|Changes in Vital Signs",Montefarmaco OTC SpA,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,33,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PROBIOTICO - BB536,Apr-16,21-Feb-17,9-Mar-17,24-Feb-16,null,14-Mar-19,"Centro Dislipidemie Dip. Cardiotoracovasc ASST Grande Ospedale Metropolitano Niguarda Cà Granda, Milano, Mi, Italy",,https://ClinicalTrials.gov/show/NCT02689934
NCT02681055,Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects,,Completed,No Results Available,Non-alcoholic Steatohepatitis|Hypertriglyceridemia|Non-alcoholic Fatty Liver Disease|Hypercholesterolemia,Drug: MN-001,To measure the change from baseline at 12 weeks of MN-001 on Cholesterol Efflux Capacity in NASH subjects with hypertriglyceridemia|To measure the change from baseline at 12 weeks of MN-001 on serum triglyceride levels in NASH subjects with hypertriglyceridemia|To measure the safety and tolerability of MN-001 by assessing the number of treatment-related adverse events.|To measure blood the concentration of MN-001/MN-002 (metabolite) change from pre-dose after 24 hours|To measure the effect of MN-001 on serum lipid panel|To measure the effect of MN-001/002 on liver enzymes|To measure the effect of MN-001/002 on percentage of fat in the liver by MRI from baseline to Week 12,MediciNova,All,"18 Years and older   (Adult, Older Adult)",Phase 2,19,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MN-001-NATG-201,Mar-16,30-May-18,14-Jan-19,12-Feb-16,null,18-Jan-19,"Southern California Research Center, Coronado, California, United States|Scripps Research, La Jolla, California, United States|Harborview Medical Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT02681055
NCT02676596,"Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of K-312 in Healthy Subjects",,Completed,No Results Available,Hyperlipidemia,Drug: K-312 10 mg QD|Drug: K-312 25 mg QD|Drug: K-312 50 mg QD|Drug: K-312 100 mg QD|Drug: K-312 200 mg QD|Drug: K-312 400 mg QD|Other: Placebo,CETP activity|Area under the plasma concentration,"Kowa Research Institute, Inc.",All,18 Years to 45 Years   (Adult),Phase 1,120,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",K-312-1.02US,Apr-14,Nov-14,Jan-15,8-Feb-16,null,12-Feb-16,"Glendale, California, United States",,https://ClinicalTrials.gov/show/NCT02676596
NCT02676830,"Evaluation of Absorption, Metabolism, and Excretion and Estimation of the Absolute Bioavailability of K-312",,Completed,No Results Available,Dyslipidemia,Drug: K-312 100 mg|Drug: K-312 100 ug C14 IV,Area under the plasma-concentration time curve to last measured time point|Oral bioavailability based on the ratio of AUC after oral dosing to the AUC after i.v. dosing,"Kowa Research Institute, Inc.",Male,25 Years to 45 Years   (Adult),Phase 1,13,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,K-312-1.03US,Aug-14,Feb-15,Apr-15,8-Feb-16,null,18-Feb-16,"Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02676830
NCT02670356,Study Comparing Fish Oil and Krill Oil,,Terminated,No Results Available,Inflammation|Dyslipidemia,Dietary Supplement: Fish oil|Dietary Supplement: Krill oil,Omega-3 index|interleukin-6 (IL-6)|Tumor necrosis factor alpha (TNF-alpha)|Monocyte chemoattractant protein 1 (MCP-1)|Total cholesterol|LDL cholesterol|HDL cholesterol|TG,Tufts University|Prevention Pharmaceuticals,All,"50 Years to 75 Years   (Adult, Older Adult)",Not Applicable,2,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,11787,Oct-15,Jul-16,Jul-16,1-Feb-16,null,26-Apr-17,"Jean Mayer Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02670356
NCT02670434,Safety and Efficacy Comparison Study of NK-104-CR (Controled Release) in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia,,Terminated,No Results Available,Hyperlipidemia|Dyslipidemia,Drug: NK-104-CR|Drug: Placebo|Drug: Livalo,Percent change in LDL-C from baseline|The percent change from baseline in fasting serum total cholesterol (TC ),"Kowa Research Institute, Inc.",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,216,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NK-104-CR-3.01US,Jan-16,Jul-17,Oct-17,1-Feb-16,null,9-Jun-16,"Beverly Hills, California, United States|Chino, California, United States|Lincoln, California, United States|Los Angeles, California, United States|Newport Beach, California, United States|North Hollywood, California, United States|Thousand Oaks, California, United States|Vista, California, United States|Brooksville, Florida, United States|Ft. Lauderdale, Florida, United States|Jacksonville, Florida, United States|Jupiter, Florida, United States|Miami, Florida, United States|Pembroke Pines, Florida, United States|Port Orange, Florida, United States|Marietta, Georgia, United States|Meridian, Idaho, United States|Chicago, Illinois, United States|Evanston, Illinois, United States|Evansville, Indiana, United States|Indianapolis, Indiana, United States|Newton, Kansas, United States|Wichita, Kansas, United States|Auburn, Maine, United States|Elkridge, Maryland, United States|Edina, Minnesota, United States|Jackson, Mississippi, United States|Butte, Montana, United States|Las Vegas, Nevada, United States|Berlin, New Jersey, United States|Endwell, New York, United States|Rochester, New York, United States|Greensboro, North Carolina, United States|Cincinnati, Ohio, United States|Kettering, Ohio, United States|Lyndhurst, Ohio, United States|Marion, Ohio, United States|Willoughby Hills, Ohio, United States|Dowingtown, Pennsylvania, United States|Charleston, South Carolina, United States|Mount Pleasant, South Carolina, United States|Kingsport, Tennessee, United States|Houston, Texas, United States|Hurst, Texas, United States|Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02670434
NCT02668016,Self-Assessment Method for Statin Side-effects Or Nocebo,SAMSON,Recruiting,No Results Available,Adverse Effects|Cardiovascular Diseases|Hyperlipidemias,Drug: Atorvastatin|Other: Placebo,Individual Nocebo Proportion|Currently prescribed statins|Attribution of adverse symptoms,Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 4,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",15SM2947|2015-004109-18,Mar-16,Mar-20,Sep-20,29-Jan-16,null,8-Apr-19,"Imperial College London, London, Greater London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02668016
NCT02666664,Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony),,Completed,No Results Available,Hypercholesterolemia|Atherosclerotic Cardiovascular Diseases,Drug: ETC-1002|Drug: Placebo,Number of participants with treatment-related adverse events as assessed by MedDRA 18.1|Percent change in low-density lipoprotein cholesterol (LDL-C)|Percent change in high-sensitivity C-reactive protein (hs-CRP),Esperion Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 3,2230,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1002-040|2015-004136-36,18-Jan-16,21-Feb-18,28-Mar-18,28-Jan-16,null,29-Mar-19,"Huntsville, Alabama, United States|Cottonwood, Arizona, United States|Phoenix, Arizona, United States|Canoga Park, California, United States|Santa Rosa, California, United States|Bridgeport, Connecticut, United States|Hartford, Connecticut, United States|Atlantis, Florida, United States|Boca Raton, Florida, United States|Crestview, Florida, United States|Crystal River, Florida, United States|Daytona Beach, Florida, United States|Lake Worth, Florida, United States|Miami Lakes, Florida, United States|Tampa, Florida, United States|Park Ridge, Illinois, United States|Iowa City, Iowa, United States|Overland Park, Kansas, United States|Covington, Kentucky, United States|Louisville, Kentucky, United States|Monroe, Louisiana, United States|Shreveport, Louisiana, United States|Auburn, Maine, United States|Midland, Michigan, United States|Saginaw, Michigan, United States|Saint Cloud, Minnesota, United States|Tupelo, Mississippi, United States|Jefferson City, Missouri, United States|Nashua, New Hampshire, United States|Bridgewater, New Jersey, United States|Cary, North Carolina, United States|Mount Airy, North Carolina, United States|Raleigh, North Carolina, United States|Wilmington, North Carolina, United States|Cincinnati, Ohio, United States|Sandusky, Ohio, United States|Willoughby, Ohio, United States|Hillsboro, Oregon, United States|Fort Worth, Texas, United States|Houston, Texas, United States|Katy, Texas, United States|Kingwood, Texas, United States|Orem, Utah, United States|Richmond, Virginia, United States|Tacoma, Washington, United States|Vancouver, British Columbia, Canada|Gatineau, Ontario, Canada|Mississauga, Ontario, Canada|Oshawa, Ontario, Canada|Peterborough, Ontario, Canada|Scarborough, Ontario, Canada|Chicoutimi, Quebec, Canada|Longueuil, Quebec, Canada|Montreal, Quebec, Canada|Saint-Jean-Sur-Richelieu, Quebec, Canada|St-Charles-Borromee, Quebec, Canada|Berlin, Germany|Dresden, Germany|Essen, Germany|Frankfurt, Germany|Leipzig, Germany|Muenchen, Germany|Amsterdam, Netherlands|Arnhem, Netherlands|Eindhoven, Netherlands|Goes, Netherlands|Groningen, Netherlands|Hardenberg, Netherlands|Leiden, Netherlands|Rotterdam, Netherlands|Tilburg, Netherlands|Venlo, Netherlands|Zutphen, Netherlands|Gdansk, Poland|Gdynia, Poland|Katowice, Poland|Krakow, Poland|Lodz, Poland|Lowicz, Poland|Poznan, Poland|Pulawy, Poland|Torun, Poland|Warsaw, Poland|Warszawa, Poland|Wroclaw, Poland|Bexhill, United Kingdom|Birmingham, United Kingdom|Chesterfield, United Kingdom|Chichester, United Kingdom|Chippenham, United Kingdom|Chorley, United Kingdom|Glasgow, United Kingdom|Hexham, United Kingdom|Hull, United Kingdom|Ipswich, United Kingdom|Liverpool, United Kingdom|Manchester, United Kingdom|Reading, United Kingdom",,https://ClinicalTrials.gov/show/NCT02666664
NCT02667223,Pharmacokinetic and Pharmacodynamic Study of Bococizumab Alone and When Combined With Recombinant Human Hyaluronidase,,Terminated,No Results Available,Healthy|Hypercholesterolemia,Biological: Cohort 1: bococizumab 150 mg + rHuPH20|Biological: Cohort 2: bococizumab 300 mg|Biological: Cohort 3: bococizumab 300 mg + rHuPH20|Biological: Cohort 5: bococizumab 450 mg + rHuPH20|Biological: Cohort 4: bococizumab 300 mg + rHuPH20,"AUCinf of bococizumab|Cmax of bococizumab|Tmax|CL/F|Vz/F|t1/2|LDL-C at Week 4|MaxELDL-C|Tmax, LDL-C|AUEC85|AEs|Laboratory tests|Vital signs|AUClast of bococizumab|ADA|nAb",Pfizer|Halozyme Therapeutics,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,60,Industry,Interventional,Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Basic Science,B1481051|2015-003568-36,Feb-16,Jul-16,Jul-16,28-Jan-16,null,21-Oct-16,"Pfizer Clinical Research Unit, Brussels, Belgium",,https://ClinicalTrials.gov/show/NCT02667223
NCT02664428,Measuring the Impact of Dietary Supplementation With a New Baking Product on Gut Microbiota and Cholesterol Metabolism,,Completed,No Results Available,Hypercholesterolemia,Dietary Supplement: PreBIOil|Dietary Supplement: Control,Faecal microbiota analysis|Cholesterol Metabolism|Triglycerides|Apolipoproteins,Fondazione Edmund Mach|Casa di Cura Eremo di Arco (TN) Italy|OlioCRU Consorzio srl Arco (TN) Italy,All,"30 Years to 65 Years   (Adult, Older Adult)",Not Applicable,65,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",PreBIOil 2,Nov-15,Aug-16,Jan-17,27-Jan-16,null,12-Jan-17,"Casa di Cura Eremo, Arco, Trento, Italy|Centro Ricerca Innovazione Fondazione Edmund Mach, San Michele all'Adige, Trento, Italy",,https://ClinicalTrials.gov/show/NCT02664428
NCT02662569,Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia,BERSON,Completed,Has Results,"Diabetes, Hyperlipidemia, Mixed Dyslipidemia",Biological: Evolocumab|Drug: Atorvastatin|Other: Placebo,Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12|Percent Change From Baseline in LDL-C at Week 12|Change From Baseline in LDL-C at the Mean of Weeks 10 and 12|Change From Baseline in LDL-C at Week 12|Percent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12|Percent Change From Baseline in Non-HDL-C at Week 12|Percent Change From Baseline in Apolipoprotein B100 at the Mean of Weeks 10 and 12|Percent Change From Baseline in Apolipoprotein B100 at Week 12|Percent Change From Baseline in Total Cholesterol at the Mean of Weeks 10 and 12|Percent Change From Baseline in Total Cholesterol at Week 12|Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12|Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12|Percent Change From Baseline in Apolipoprotein B100/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12|Percent Change From Baseline in Apolipoprotein B100/Apolipoprotein A1 Ratio at Week 12|Percentage of Participants With Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL (1.8 mmol/L)|Percentage of Participants With LDL-C Less Than 70 mg/dL (1.8 mmol/L) at Week 12|Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12|Percent Change From Baseline in Lipoprotein(a) at Week 12|Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12|Percent Change From Baseline in Triglycerides at Week 12|Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12|Percent Change From Baseline in HDL-C at Week 12|Percent Change From Baseline in VLDL-C at the Mean of Weeks 10 and 12,Amgen,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,986,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",20120119|2013-000723-14,14-Apr-16,6-Dec-17,6-Dec-17,25-Jan-16,11-Jan-19,11-Jan-19,"Research Site, Miami, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Iowa City, Iowa, United States|Research Site, Overland Park, Kansas, United States|Research Site, Monroe, Louisiana, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Columbus, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Dallas, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Caba, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Mar del Plata, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Córdoba, Argentina|Research Site, Brasília, Distrito Federal, Brazil|Research Site, Goiania, Goiás, Brazil|Research Site, Sao Paulo, São Paulo, Brazil|Research Site, Rio De Janeiro, Brazil|Research Site, Winnipeg, Manitoba, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Woodstock, Ontario, Canada|Research Site, Laval, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, St Jean sur Richelieu, Quebec, Canada|Research Site, Beijing, Beijing, China|Research Site, Chongqing, Chongqing, China|Research Site, Guangzhou, Guangdong, China|Research Site, Guangzhou, Guangdong, China|Research Site, Nanning, Guangxi, China|Research Site, Guiyang, Guizhou, China|Research Site, Shijiazhuang, Hebei, China|Research Site, Wuhan, Hubei, China|Research Site, Wuhan, Hubei, China|Research Site, Changsha, Hunan, China|Research Site, Changsha, Hunan, China|Research Site, Changsha, Hunan, China|Research Site, Hengyang, Hunan, China|Research Site, Zhuzhou, Hunan, China|Research Site, Baotou, Inner Mongolia, China|Research Site, Nanjing, Jiangsu, China|Research Site, Nanjing, Jiangsu, China|Research Site, Nanjing, Jiangsu, China|Research Site, Nanjing, Jiangsu, China|Research Site, Suzhou, Jiangsu, China|Research Site, Wuxi, Jiangsu, China|Research Site, Xuzhou, Jiangsu, China|Research Site, Zhenjiang, Jiangsu, China|Research Site, Nanchang, Jiangxi, China|Research Site, Changchun, Jilin, China|Research Site, Changchun, Jilin, China|Research Site, ChangChun, Jilin, China|Research Site, Siping, Jilin, China|Research Site, Shenyang, Liaoning, China|Research Site, XI An, Shaanxi, China|Research Site, Jinan, Shandong, China|Research Site, Shanghai, Shanghai, China|Research Site, Chengdu, Sichuan, China|Research Site, Tianjin, Tianjin, China|Research Site, Urumqi, Xinjiang, China|Research Site, Hangzhou, Zhejiang, China|Research Site, Hangzhou, Zhejiang, China|Research Site, Hangzhou, Zhejiang, China|Research Site, Linhai, Zhejiang, China|Research Site, Wenzhou, Zhejiang, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Medellin, Antioquia, Colombia|Research Site, Barranquilla, Atlántico, Colombia|Research Site, Barranquilla, Atlántico, Colombia|Research Site, Barranquilla, Atlántico, Colombia|Research Site, Pasto, Nariño, Colombia|Research Site, Dijon, France|Research Site, Nantes Cedex 1, France|Research Site, Toulouse Cedex 9, France|Research Site, Bucheon-si, Wonmi-gu, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Kemerovo, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Antalya, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Kocaeli, Turkey","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT02662569/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT02662569/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02662569
NCT02659397,"A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg",,Completed,No Results Available,Hyperlipidemia,Drug: ETC-1002|Drug: Atorvastatin|Drug: Placebo,Peak plasma concentration (Cmax) pharmacokinetics of atorvastatin and its active metabolites|24-hour area under the curve (AUC) pharmacokinetics of atorvastatin and its active metabolites|Percent change in LDL-cholesterol|Percent change in hsCRP|Percent change in total cholesterol|Percent change in non-HDL-cholesterol|Percent change in apolipoprotein B|24-hour post dose plasma concentration pharmacokinetics of ETC-1002 and its active metabolite,Esperion Therapeutics,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,68,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1002-035,Dec-15,Jul-16,Jul-16,20-Jan-16,null,29-Mar-19,"Anaheim, California, United States|Los Angeles, California, United States|Northridge, California, United States|Clearwater, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Port Orange, Florida, United States|Boise, Idaho, United States|Chicago, Illinois, United States|Springfield, Illinois, United States|Louisville, Kentucky, United States|Berlin, New Jersey, United States|Rapid City, South Dakota, United States|Carrollton, Texas, United States|West Jordan, Utah, United States|Arlington, Virginia, United States|Lynchburg, Virginia, United States|Richmond, Virginia, United States|Renton, Washington, United States",,https://ClinicalTrials.gov/show/NCT02659397
NCT02657759,"EFFECTS OF CARDICHOL, AN HERBAL DIETARY SUPPLEMENT, IN MODERATE HYPERCHOLESTEROLEMIA",CARDICHOL 1,Unknown status,No Results Available,HYPERCHOLESTEROLEMIA,Dietary Supplement: CARDICHOL|Dietary Supplement: PLACEBO,Change of the fasting blood LDL cholesterol NCEP concentration|Change of the fasting blood LDL cholesterol concentration (NCEP and Friedewald estimation methods)|Change of the fasting blood LDL cholesterol concentration (Friedewald estimation method)|Change of the fasting blood HDL cholesterol concentration (NCEP and direct methods)|Change of the fasting blood total cholesterol concentration|Change of the fasting blood triglycerides concentration|Change of the fasting blood tiglycerides concentration|Change of the fasting blood apolipoprotein B100 concentration|Change of the fasting blood glucose concentration|Change of the fasting blood hsCRP concentration|Change of the ratio of fasting blood concentrations LDLox/LDLc (NCEP method)|Change of the fasting arylesterase activity (PON-1) in blood,Direct Plantes,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,50,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",DPlantes,Dec-15,May-16,May-16,18-Jan-16,null,20-Jan-16,"Biofortis, Saint-Herblain, France",,https://ClinicalTrials.gov/show/NCT02657759
NCT02658175,The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome,,"Active, not recruiting",No Results Available,Familial Chylomicronemia Syndrome|Lipoprotein Lipase Deficiency|Hyperlipoproteinemia Type 1,Drug: Volanesorsen,Efficacy of extended dosing of volanesorsen as measured by the percent change in fasting triglycerides from baseline.,"Ionis Pharmaceuticals, Inc.|Akcea Therapeutics",All,"18 Years and older   (Adult, Older Adult)",Phase 3,69,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ISIS 304801-CS7,31-Dec-15,Jun-20,Oct-20,18-Jan-16,null,16-Nov-18,"IONIS Investigative Site, Huntington Beach, California, United States|IONIS Investigative Site, San Francisco, California, United States|IONIS Investigative Site, Boca Raton, Florida, United States|IONIS Investigative Site, Boston, Massachusetts, United States|IONIS Investigative Site, Philadelphia, Pennsylvania, United States|IONIS Investigative Site, Houston, Texas, United States|IONIS Investigative Site, Norfolk, Virginia, United States|IONIS Investigative Site, Seattle, Washington, United States|IONIS Investigative Site, Sao Paulo, Brazil|IONIS Investigative Site, Sao Paulo, Brazil|IONIS Investigative Site, Vancouver, British Columbia, Canada|IONIS Investigative Site, Chicoutimi, Quebec, Canada|IONIS Investigative Site, Montreal, Quebec, Canada|IONIS Investigative Site, Quebec, Canada|IONIS Investigative Site, Paris, Cedex 13, France|IONIS Investigative Site, Marseille Cedex 05, France|IONIS Investigative Site, Nantes cedex 1, France|IONIS Investigative Site, Berlin, Germany|IONIS Investigative Site, Safed, Israel|IONIS Investigative Site, Palermo, Italy|IONIS Investigative Site, Roma, Italy|IONIS Investigative Site, Rome, Italy|IONIS Investigative Site, Amsterdam-Zuidoost, Netherlands|IONIS Investigative Site, Cape Town, South Africa|IONIS Investigative Site, Barcelona, Spain|IONIS Investigative Site, La Coruna, Spain|IONIS Investigative Site, Madrid, Spain|IONIS Investigative Site, Sevilla, Spain|IONIS Investigative Site, Zaragoza, Spain|IONIS Investigative Site, Birmingham, United Kingdom|IONIS Investigative Site, London, United Kingdom|IONIS Investigative Site, Manchester, United Kingdom|IONIS Investigative Site, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT02658175
NCT02654899,Single Dose Study of PF-06815345 in Healthy Subjects,,Terminated,No Results Available,Hypercholesterolemia,Drug: PF-06815345|Other: Placebo,Number of Subjects With Treatment Emergent Treatment-Related Adverse Events (AEs)|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-06815345|Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0- infinity)] for PF-06815345|Maximum Observed Plasma Concentration (Cmax) for PF-06815345|Time to Reach Maximum Observed Concentration for PF-06815345|Plasma Decay Half-Life (t1/2) for PF-06815345|Apparent Oral Clearance (CL/F) for PF-06815345|Apparent Volume of Distribution (Vz/F) for PF-06815345|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for the metabolite (PF-06811701)|Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0- infinity)] for metabolite (PF-06811701)|Maximum Observed Plasma Concentration (Cmax) for metabolite (PF-06811701)|Time to Reach Maximum Observed Concentration for metabolite (PF-06811701)|Plasma Decay Half-Life (t1/2) for metabolite (PF-06811701),Pfizer,All,18 Years to 55 Years   (Adult),Phase 1,25,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science",C0281001|2015-003935-36,Nov-15,Mar-16,Mar-16,13-Jan-16,null,28-Sep-18,"Pfizer Clinical Research Unit, Brussels, Belgium",,https://ClinicalTrials.gov/show/NCT02654899
NCT02651675,A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH),,Recruiting,No Results Available,Homozygous Familial Hypercholesterolemia,Biological: AAV directed hLDLR gene therapy,Number of participants experiencing investigational product-related adverse events|Percent change in LDL-C compared to baseline|Percent change in lipid parameters compared to baseline values|Fractional catabolic rate (FCR) of LDL apoB|Number of investigational product-related adverse events,Regenxbio Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,12,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,823176,Mar-16,Jan-19,Jan-19,11-Jan-16,null,3-Dec-18,"Excel Medical Clinical Trials, LLC, Boca Raton, Florida, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Oregon Health and Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Ecogene-21, Chicoutimi, Quebec, Canada|Montreal Heart Institute, Montreal, Quebec, Canada|AOUP Paolo Giaccone, Palermo, Italy|Policlinico Umberto I, Roma, Italy|Erasmus MC, Rotterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT02651675
NCT02651753,A Clinical Trial to Compare Safety and Pharmacokinetic Characteristics of CKD-337,,Completed,No Results Available,Dyslipidemia,Drug: Lipitor + Lipidil supra|Drug: CKD-337,Atorvastatin AUCt|Atorvastatin Cmax|Fenofibric acid AUCt|Fenofibric acid Cmax|Atorvastatin AUCinf|Atorvastatin Tmax|Atorvastatin t1/2|Atorvastatin CL/F|Atorvastatin Vd/F|Fenofibric acid AUCinf|Fenofibric acid Tmax|Fenofibric acid t1/2|Fenofibric acid CL/F|Fenofibric acid Vd/F|2-hydroxy atorvastatin AUCt|2-hydroxy atorvastatin Cmax|2-hydroxy atorvastatin AUCinf|2-hydroxy atorvastatin Tmax|2-hydroxy atorvastatin t1/2|2-hydroxy atorvastatin CL/F|2-hydroxy atorvastatin Vd/F,Chong Kun Dang Pharmaceutical,Male,"19 Years and older   (Adult, Older Adult)",Phase 1,48,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,146BE15025,Jan-16,Mar-16,May-16,11-Jan-16,null,7-Jul-16,,,https://ClinicalTrials.gov/show/NCT02651753
NCT02644109,Effect On Serum Cholesterol Of Dairy Products With Addition Of Esterified Phytosterols,ACTICOL,Completed,Has Results,Dyslipidemias|Hypercholesterolemia,Dietary Supplement: Phytosterol|Dietary Supplement: Placebo,Serum LDL Cholesterol,University of Chile|Pontificia Universidad Catolica de Chile,All,"40 Years to 65 Years   (Adult, Older Adult)",Phase 4,52,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",Acticol - 001,Oct-15,Mar-16,May-16,31-Dec-15,2-Aug-16,12-Sep-16,"Instituto de Nutricion y Tecnologia de los Alimentos, Universidad de Chile, Santiago, Región Metropolitana de Santiago, Chile|Department of Nutrition, Diabetes and Metabolism. Pontificia Universidad Catolica de Chile, Santiago, Chile",,https://ClinicalTrials.gov/show/NCT02644109
NCT02642159,Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia),,Completed,Has Results,Dyslipidemia,Drug: Alirocumab|Drug: Statins|Drug: Ezetimibe|Drug: Fenofibrate|Drug: Nicotinic acid|Drug: Omega-3 fatty acids|Drug: Antihyperglycemic Drug,Percent Change From Baseline in Non-HDL-C at Week 24: Overall Intent-to-treat (ITT) Analysis|Percent Change From Baseline in Non-HDL-C at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum|Percent Change From Baseline in Measured Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24: Overall ITT Analysis|Percent Change From Baseline in Measured LDL-C at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum|Percent Change From Baseline in Non-HDL-C at Week 12: Overall ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12: ITT- Intent to Prescribe Fenofibrate Stratum|Percent Change From Baseline in Measured LDL-C at Week 12: Overall ITT Analysis|Percent Change From Baseline in Measured LDL-C at Week 12: ITT- Intent to Prescribe Fenofibrate Stratum|Percent Change From Baseline in Apolipoprotein B (Apo-B) at Week 24: Overall ITT Analysis|Percent Change From Baseline in Apo B at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 : Overall ITT Analysis|Percent Change From Baseline in Total-C at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum|Percent Change From Baseline in Lipoprotein(a) at Week 24 : Overall ITT Analysis|Percent Change From Baseline in Lipoprotein(a) at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum|Percent Change From Baseline in Fasting Triglycerides at Week 24: Overall ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum|Percent Change From Baseline in HDL-C at Week 24 : Overall ITT Analysis|Percent Change From Baseline in HDL-C at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum|Percent Change From Baseline in LDL-C Particle Number at Week 24: Overall ITT Analysis|Percent Change From Baseline in LDL-C Particle Number at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum|Absolute Change From Baseline in Hemoglobin A1c (HbA1c) at Week 12 and 24 : Overall ITT Analysis|Absolute Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12 and 24 : Overall ITT Analysis|Absolute Change From Baseline in Number of Glucose-Lowering Treatments at Week 12 and 24 : Overall ITT Analysis,Sanofi|Regeneron Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 4,413,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LPS14354|2015-001934-19|U1111-1172-5262,15-Mar-16,22-Mar-17,15-May-17,30-Dec-15,1-May-18,1-May-18,"Investigational Site Number 840-163, Little Rock, Arkansas, United States|Investigational Site Number 840-141, Fresno, California, United States|Investigational Site Number 840-152, Huntington Beach, California, United States|Investigational Site Number 840-115, La Jolla, California, United States|Investigational Site Number 840-118, Los Angeles, California, United States|Investigational Site Number 840-106, Northridge, California, United States|Investigational Site Number 840-176, Port Hueneme, California, United States|Investigational Site Number 840-122, Tarzana, California, United States|Investigational Site Number 840-156, Tustin, California, United States|Investigational Site Number 840-160, Van Nuys, California, United States|Investigational Site Number 840-107, Boca Raton, Florida, United States|Investigational Site Number 840-170, Boynton Beach, Florida, United States|Investigational Site Number 840-114, Bradenton, Florida, United States|Investigational Site Number 840-132, Ocoee, Florida, United States|Investigational Site Number 840-179, Oviedo, Florida, United States|Investigational Site Number 840-123, Tampa, Florida, United States|Investigational Site Number 840-137, Bainbridge, Georgia, United States|Investigational Site Number 840-128, Columbus, Georgia, United States|Investigational Site Number 840-169, Stockbridge, Georgia, United States|Investigational Site Number 840-167, Idaho Falls, Idaho, United States|Investigational Site Number 840-161, Chicago, Illinois, United States|Investigational Site Number 840-184, Crystal Lake, Illinois, United States|Investigational Site Number 840-174, Evanston, Illinois, United States|Investigational Site Number 840-138, Springfield, Illinois, United States|Investigational Site Number 840-108, Louisville, Kentucky, United States|Investigational Site Number 840-183, Paducah, Kentucky, United States|Investigational Site Number 840-190, Metairie, Louisiana, United States|Investigational Site Number 840-151, Rockville, Maryland, United States|Investigational Site Number 840-113, Jefferson City, Missouri, United States|Investigational Site Number 840-120, Saint Louis, Missouri, United States|Investigational Site Number 840-148, Omaha, Nebraska, United States|Investigational Site Number 840-101, Las Vegas, Nevada, United States|Investigational Site Number 840-140, Las Vegas, Nevada, United States|Investigational Site Number 840-178, Albany, New York, United States|Investigational Site Number 840-181, New York, New York, United States|Investigational Site Number 840-157, New York, New York, United States|Investigational Site Number 840-188, Greensboro, North Carolina, United States|Investigational Site Number 840-131, Morehead City, North Carolina, United States|Investigational Site Number 840-158, Morganton, North Carolina, United States|Investigational Site Number 840-129, Fargo, North Dakota, United States|Investigational Site Number 840-104, Columbus, Ohio, United States|Investigational Site Number 840-105, Marion, Ohio, United States|Investigational Site Number 840-175, Maumee, Ohio, United States|Investigational Site Number 840-136, Bend, Oregon, United States|Investigational Site Number 840-187, Murrells Inlet, South Carolina, United States|Investigational Site Number 840-111, Summerville, South Carolina, United States|Investigational Site Number 840-147, Chattanooga, Tennessee, United States|Investigational Site Number 840-159, Knoxville, Tennessee, United States|Investigational Site Number 840-153, Dallas, Texas, United States|Investigational Site Number 840-143, Houston, Texas, United States|Investigational Site Number 840-168, Houston, Texas, United States|Investigational Site Number 840-142, Round Rock, Texas, United States|Investigational Site Number 840-133, Tomball, Texas, United States|Investigational Site Number 840-185, Orem, Utah, United States|Investigational Site Number 840-150, Salt Lake City, Utah, United States|Investigational Site Number 840-126, Chesapeake, Virginia, United States|Investigational Site Number 840-171, Richmond, Virginia, United States|Investigational Site Number 036102, Herston, Australia|Investigational Site Number 036104, Merewether, Australia|Investigational Site Number 036101, St Leonards, Australia|Investigational Site Number 076103, Campinas, Brazil|Investigational Site Number 076104, Fortaleza, Brazil|Investigational Site Number 076101, Sao Paulo, Brazil|Investigational Site Number 076105, São paulo, Brazil|Investigational Site Number 076106, São Paulo, Brazil|Investigational Site Number 076102, SãO Paulo, Brazil|Investigational Site Number 246102, Oulu, Finland|Investigational Site Number 246101, Oulu, Finland|Investigational Site Number 246104, Tampere, Finland|Investigational Site Number 276112, Berlin, Germany|Investigational Site Number 276109, Berlin, Germany|Investigational Site Number 276104, Dippoldiswalde, Germany|Investigational Site Number 276101, Dresden, Germany|Investigational Site Number 276110, Essen, Germany|Investigational Site Number 276108, Essen, Germany|Investigational Site Number 276111, Goch, Germany|Investigational Site Number 276107, Karlsruhe, Germany|Investigational Site Number 276103, Künzing, Germany|Investigational Site Number 276102, Oldenburg in Holstein, Germany|Investigational Site Number 376101, Beer Sheva, Israel|Investigational Site Number 376103, Petach Tikva, Israel|Investigational Site Number 376104, Petach tikva, Israel|Investigational Site Number 376102, Rehovot, Israel|Investigational Site Number 376106, Tel-Aviv, Israel|Investigational Site Number 380104, Bergamo, Italy|Investigational Site Number 380107, Catanzaro, Italy|Investigational Site Number 380103, Napoli, Italy|Investigational Site Number 380108, Padova, Italy|Investigational Site Number 380106, Partinico, Italy|Investigational Site Number 380101, Pisa, Italy|Investigational Site Number 380105, Roma, Italy|Investigational Site Number 380102, Torino, Italy|Investigational Site Number 414101, Kuwait, Kuwait|Investigational Site Number 422101, Beirut, Lebanon|Investigational Site Number 422102, Hazmieh, Lebanon|Investigational Site Number 578101, Oslo, Norway|Investigational Site Number 578102, Oslo, Norway|Investigational Site Number 752102, Göteborg, Sweden|Investigational Site Number 752101, Stockholm, Sweden|Investigational Site Number 756101, Genève, Switzerland|Investigational Site Number 756102, Olten, Switzerland|Investigational Site Number 756103, Reinach, Switzerland|Investigational Site Number 792105, Adana, Turkey|Investigational Site Number 792106, Ankara, Turkey|Investigational Site Number 792102, Ankara, Turkey|Investigational Site Number 792108, Corum, Turkey|Investigational Site Number 792109, Hatay, Turkey|Investigational Site Number 792104, Izmir, Turkey|Investigational Site Number 792101, Izmir, Turkey|Investigational Site Number 792110, Izmir, Turkey|Investigational Site Number 792107, Kayseri, Turkey|Investigational Site Number 792103, Samsun, Turkey|Investigational Site Number 784101, Dubai, United Arab Emirates|Investigational Site Number 826104, Exeter, United Kingdom|Investigational Site Number 826106, Manchester, United Kingdom|Investigational Site Number 826105, Middlesborough, United Kingdom|Investigational Site Number 826103, Stevenage, United Kingdom|Investigational Site Number 826101, Torquay, United Kingdom|Investigational Site Number 826102, West Bromwich, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT02642159/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT02642159/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02642159
NCT02637115,Evaluation of the Effects Associated With the Administration of Akkermansia Muciniphila on Parameters of Metabolic Syndrome,Microbes4U,Completed,No Results Available,Metabolic Syndrome x|Glucose Metabolism Disorders|Dyslipidemias|Obesity,Dietary Supplement: Placebo|Dietary Supplement: Live Akk 9|Dietary Supplement: Live Akk 10|Dietary Supplement: Killed Akk,Tolerance|Concentration of urea (mg/dl)|Glomerular filtration rate (mL/min/1.73m2)|Concentration of creatinine (mg/dl)|Concentration of liver transaminases|Concentration of white blood cells (10exp3/µl)|concentration of CRP (c-reactive protein) (mg/dl)|Insulin resistance|Concentration of blood lipids|Obesity|Adiposity|Visceral adiposity|Measure of the concentration of Akkermansia in the feces (bacterial cells/g of feces)|Gut barrier function|Metabolic endotoxemia|Gut microbial-related metabolites in urine|Gut microbial-related metabolites in plasma,Patrice D. Cani|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Université Catholique de Louvain,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,54,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Basic Science",2015/02JUL/369|B403201525111,Dec-15,20-Feb-18,20-Feb-18,22-Dec-15,null,17-May-19,"Cliniques universitaires Saint-Luc, Brussels, Belgium",,https://ClinicalTrials.gov/show/NCT02637115
NCT02634580,Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4,GAUSS-4,Completed,Has Results,Hypercholesterolemia,Biological: Evolocumab|Drug: Ezetimibe|Drug: Placebo to Evolocumab|Drug: Placebo Ezetimibe,Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at the Mean of Weeks 10 and 12|Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12|Change From Baseline in LDL-C at the Mean of Weeks 10 and 12|Change From Baseline in LDL-C at Week 12|Percentage of Participants Who Achieved a Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL|Percentage of Participants Who Achieved a LDL-C of Less Than 70 mg/dL at Week 12|Percent Change From Baseline in Total Cholesterol at the Mean of Weeks 10 and 12|Percent Change From Baseline in Total Cholesterol at Week 12|Percent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12|Percent Change From Baseline in Non-HDL-C at Week 12|Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12|Percent Change From Baseline in Apolipoprotein B at Week 12|Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12|Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 Ratio at the Mean of Weeks 10 and 12|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 Ratio at Week 12|Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12|Percent Change From Baseline in Lipoprotein(a) at Week 12|Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12|Percent Change From Baseline in Triglycerides at Week 12|Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12|Percent Change From Baseline in HDL-C at Week 12|Percent Change From Baseline in VLDL-C at the Mean of Weeks 10 and 12|Percent Change From Baseline in VLDL-C at Week 12,Amgen,All,"20 Years to 80 Years   (Adult, Older Adult)",Phase 3,61,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",20140234,27-Feb-16,10-Aug-17,26-May-18,18-Dec-15,31-Aug-18,31-Aug-18,"Research Site, Nagoya-shi, Aichi, Japan|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Chiba-shi, Chiba, Japan|Research Site, Kisarazu-shi, Chiba, Japan|Research Site, Matsudo-shi, Chiba, Japan|Research Site, Chikushino-shi, Fukuoka, Japan|Research Site, Koga-shi, Fukuoka, Japan|Research Site, Sukagawa-shi, Fukushima, Japan|Research Site, Sukagawa-shi, Fukushima, Japan|Research Site, Hiroshima-shi, Hiroshima, Japan|Research Site, Kobe-shi, Hyogo, Japan|Research Site, Koga-shi, Ibaraki, Japan|Research Site, Kahoku-gun, Ishikawa, Japan|Research Site, Kanazawa-shi, Ishikawa, Japan|Research Site, Komatsu-shi, Ishikawa, Japan|Research Site, Morioka-shi, Iwate, Japan|Research Site, Morioka-shi, Iwate, Japan|Research Site, Kagoshima-shi, Kagoshima, Japan|Research Site, Yokohama-shi, Kanagawa, Japan|Research Site, Kumamoto-shi, Kumamoto, Japan|Research Site, Kumamoto-shi, Kumamoto, Japan|Research Site, Kyoto-shi, Kyoto, Japan|Research Site, Ohsaki-shi, Miyagi, Japan|Research Site, Nakagami-gun, Okinawa, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Osaka-Shi, Osaka, Japan|Research Site, Fujimi-shi, Saitama, Japan|Research Site, Iruma-gun, Saitama, Japan|Research Site, Kawaguchi-shi, Saitama, Japan|Research Site, Hamamatsu-shi, Shizuoka, Japan|Research Site, Bunkyo-ku, Tokyo, Japan|Research Site, Chuo-ku, Tokyo, Japan|Research Site, Higashiyamato-shi, Tokyo, Japan|Research Site, Musashino-shi, Tokyo, Japan|Research Site, Shinagawa-ku, Tokyo, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT02634580/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT02634580/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02634580
NCT02634606,Effects of a Supplement Derived From Palm Oil on Cholesterol Levels in the Blood,TRF,Terminated,Has Results,Hypercholesterolemia,Drug: Gamma Delta Tocotrienols - Low Dose|Drug: Gamma Delta Tocotrienols - High Dose|Drug: Sugar Pill,Change in LDL Cholesterol Over Time Between the 3 Groups,"University of California, Los Angeles",All,"35 Years to 70 Years   (Adult, Older Adult)",Phase 3,13,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",TOCO 11-000665,22-Mar-11,13-Nov-15,13-Nov-15,18-Dec-15,12-Feb-19,12-Feb-19,"UCLA Center for Human Nutrition, 900 Veteran Avenue, WH 14-187, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT02634606
NCT02634034,A Comparison Study to Evaluate the Pharmacokinetics and Safety of NK-104-CR in Healthy Adult Volunteers,,Completed,No Results Available,Hyperlipidemia,Drug: A: NK-104-CR 8 mg|Drug: B: Pitavastatin IR 4 mg|Drug: C: Pitavastatin IR 8 mg,Area Under the Curve,"Kowa Research Institute, Inc.",All,18 Years to 45 Years   (Adult),Phase 1,18,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),NK-104-CR-1.01US,Dec-15,Dec-15,Dec-15,17-Dec-15,null,11-Jan-16,"Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT02634034
NCT02634151,"A 12-Week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity Statins",ROYAL-1,Completed,No Results Available,Hypercholesteremia,Drug: Gemcabene 600 mg|Drug: Placebo,LDL-C,"Gemphire Therapeutics, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,105,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GEM-301,Nov-16,Jun-17,Aug-17,17-Dec-15,null,25-Aug-17,"Central Research Associates, Inc., Birmingham, Alabama, United States|Westside Medical Associates of Los Angeles, Beverly Hills, California, United States|National Research Institute, Huntington Park, California, United States|National Research Institute, Los Angeles, California, United States|Atlantic Clinical Research Collaborative- Cardiology, Atlantis, Florida, United States|Excel Medical Clinical Trials, Boca Raton, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Health Awareness, Inc., Jupiter, Florida, United States|Meridien Research, Inc., Maitland, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Varkey Medical, Tampa, Florida, United States|Evanston Premier Healthcare Research, LLC, Evanston, Illinois, United States|Midwest Institute for Clinical Research, Indianapolis, Indiana, United States|L-MARC, Louisville, Kentucky, United States|Mid-Hudson Medical Research, New Windsor, New York, United States|Rochester Clinical Research, Inc., Rochester, New York, United States|Sterling Research Group, Ltd., Cincinnati, Ohio, United States|Sentral Clinical Research Services, Cincinnati, Ohio, United States|Sterling Research Group, Ltd., Cincinnati, Ohio, United States|Green and Seidner Family Practice Associates, Lansdale, Pennsylvania, United States|Associates in Medicine, Houston, Texas, United States|Diagnostics Research Grup, San Antonio, Texas, United States|Sugar Lakes Family Practice, Sugar Land, Texas, United States|National Research Institute, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02634151
NCT02628990,Lipid-lowering Effect of Plant Stanol Ester Yoghurt Drinks,,Completed,No Results Available,Hypercholesterolemia|Hyperlipidemias|Dyslipidemias,Other: 1.6 g plant stanols|Other: 2 g plant stanols|Other: 1.6 g plant stanols and camelina oil|Other: 2 g plant stanols and camelina oil|Other: Placebo,Percentual change in serum LDL-cholesterol|Absolute change in serum LDL-cholesterol|Percentual change in serum total cholesterol|Absolute change in serum total cholesterol|Percentual change in serum non-HDL cholesterol|Absolute change in serum non-HDL cholesterol|Percentual change in serum triglycerides|Absolute change in serum triglycerides,Raisio Group|University of Turku,All,"25 Years to 65 Years   (Adult, Older Adult)",Not Applicable,155,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",YD2005,Jun-05,Aug-05,Nov-05,11-Dec-15,null,11-Dec-15,,,https://ClinicalTrials.gov/show/NCT02628990
NCT02624869,"Open Label Study to Evaluate Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Pediatric Subjects (10 to 17 Years of Age) With Heterozygous Familial Hypercholesterolemia (HeFH) or Homozygous Familial Hypercholesterolemia (HoFH).",HAUSER-OLE,Recruiting,No Results Available,Familial Hypercholesterolemia,Biological: evolocumab (AMG 145),Number of participants with treatment-related Adverse Events as assessed by CTCAE V4.0|Percent change from baseline in low-density lipoprotein cholesterol (LDL-C)|Percent change from baseline in non-HDL-C (non high density lipoprotein cholesterol)|Percent change from baseline in apoliprotein-b (ApoB)|Percent change from baseline total cholesterol/HDL-C ratio|Percent change from baseline ApoB/ApoA1 ratio|Change from baseline in LDL-C|Change from baseline in steroid hormones|Change from baseline in Carotid intima-media thickness (cIMT) at week 80|Subject incidence of abnormal muscle enzyme levels|Subject incidence of abnormal liver enzyme levels|Change from baseline in height|Change from baseline in weight.|Change from baseline in pubertal development|Number of participants with abnormal neurological examination findings|Change from baseline score in the components of the Cogstate battery (cognitive function assessments),Amgen,All,10 Years to 17 Years   (Child),Phase 3,115,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20120124|2015-002276-25,10-Sep-16,29-Jun-21,29-Jun-21,9-Dec-15,null,8-Feb-19,"Research Site, Cincinnati, Ohio, United States|Research Site, Nashville, Tennessee, United States|Research Site, Camperdown, New South Wales, Australia|Research Site, Feldkirch, Austria|Research Site, Salzburg, Austria|Research Site, Wien, Austria|Research Site, Gent, Belgium|Research Site, La Louvière, Belgium|Research Site, Leuven, Belgium|Research Site, Fortaleza, Ceará, Brazil|Research Site, São Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Chicoutimi, Quebec, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Barranquilla, Atlántico, Colombia|Research Site, Svitavy, Czechia|Research Site, Athens, Greece|Research Site, Thessaloniki, Greece|Research Site, Budapest, Hungary|Research Site, Palermo, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Torino, Italy|Research Site, Amsterdam, Netherlands|Research Site, Bergen, Norway|Research Site, Oslo, Norway|Research Site, Parktown, Gauteng, South Africa|Research Site, Parow, Western Cape, South Africa|Research Site, Cordoba, Andalucía, Spain|Research Site, A Coruña, Galicia, Spain|Research Site, Lugo, Galicia, Spain|Research Site, Geneva 14, Switzerland|Research Site, Reinach, Switzerland|Research Site, Ankara, Turkey|Research Site, Izmir, Turkey|Research Site, Birmingham, United Kingdom",,https://ClinicalTrials.gov/show/NCT02624869
NCT02625870,Omega-3-Acid Ethyl Esters 90 Soft Capsules for Lowering Very High Triglycerides,OMEELVHT,Unknown status,No Results Available,Hypertriglyceridemia,Drug: Omega-3-Acid Ethyl Esters 90 Soft Capsules|Drug: Corn Oil,End-of-treatment Serum Triglycerides percentage change from baseline under fasting conditions|End-of-treatment non-HDL-C percentage change from baseline under fasting conditions|End-of-treatment TC percentage change from baseline under fasting conditions|End-of-treatment VLDL-C percentage change from baseline under fasting conditions|End-of-treatment HDL-C percentage change from baseline under fasting conditions|End-of-treatment LDL-C percentage change from baseline under fasting conditions|End-of-treatment LDL-C/HDL-C percentage change from baseline under fasting conditions|End-of-treatment Apo A5 percentage change from baseline under fasting conditions|End-of-treatment Apo C3 percentage change from baseline under fasting conditions,"Jiangsu HengRui Medicine Co., Ltd.",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,240,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",HROMEE2015,Dec-15,Dec-16,null,9-Dec-15,null,9-Dec-15,,,https://ClinicalTrials.gov/show/NCT02625870
NCT02623868,"Study to Assess PK/PD Character, Safety/Tolerability of CKD-519 New Formulation in Healthy Male Subject.",,Completed,No Results Available,Dyslipidemia,Drug: CKD-519 50mg 2Tabs.|Drug: CKD-519 100mg 1Tab.|Drug: CKD-519 100mg 1Cap.,Cmax of CKD-519|Tmax of CKD-519|AUClast of CKD-519|AUC0-∞ of CKD-519|t1/2 of CKD-519|CL/F of CKD-519|Vd/F of CKD-519|Emax of CKD-519 CETP(Cholesteryl ester transfer protein) Activity|Tmax of CKD-519 CETP Activity|AUEC of CKD-519 CETP Activity|EC50(half maximal effective concentration ) of CKD-519 CETP Activity,Chong Kun Dang Pharmaceutical,Male,20 Years to 45 Years   (Adult),Phase 1,30,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,148NF15010,Oct-15,Dec-15,Dec-15,8-Dec-15,null,20-Jan-16,"Korea university medical center, Seoul, Sungbuk-gu, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02623868
NCT02612090,The Cholesterol Lowering Effects of Strawberry,STR4,"Active, not recruiting",No Results Available,Hypercholesterolemia|Glycemic Response,Dietary Supplement: Active Treatment Beverage|Dietary Supplement: Placebo Treatment Beverage,Changes in plasma LDL cholesterol in 4-week intervention of strawberries vs control treatment.|Changes in endothelial function as measured by Flow Medicated Vasodilation (FMD) in 4-week intervention of strawberries vs control treatment.,"Institute for Food Safety and Health, United States",All,"40 Years to 69 Years   (Adult, Older Adult)",Not Applicable,50,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",IRB2015-058,4-Jan-16,4-May-22,4-May-22,23-Nov-15,null,22-Apr-19,"Clinical Nutrition Research Center, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT02612090
NCT02608697,A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia,,Completed,No Results Available,Hypercholesterolemia,Drug: CAT-2054|Drug: Placebo|Drug: Atorvastatin,"Percent change in LDL-C from baseline in patients with hypercholesterolemia.|Frequency of adverse events|Percent change in TG, non-HDL-C, total cholesterol, HDL-C, apoB from baseline in patients with hypercholesterolemia",Catabasis Pharmaceuticals,All,"18 Years to 74 Years   (Adult, Older Adult)",Phase 2,153,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CAT-2054-201,Oct-15,May-16,Jun-16,20-Nov-15,null,20-Jun-17,"Muscle Shoals, Alabama, United States|Huntington Park, California, United States|Lomita, California, United States|Los Angeles, California, United States|Brooksville, Florida, United States|Hialeah, Florida, United States|Jupiter, Florida, United States|Pembroke Pines, Florida, United States|Winter Park, Florida, United States|Chicago, Illinois, United States|Evanston, Illinois, United States|Indianapolis, Indiana, United States|Kansas City, Kansas, United States|Louisville, Kentucky, United States|Auburn, Maine, United States|Troy, Michigan, United States|Las Vegas, Nevada, United States|New York, New York, United States|Rochester, New York, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Franklin, Ohio, United States|Lyndhurst, Ohio, United States|Marion, Ohio, United States|Willoughby Hills, Ohio, United States|Mount Pleasant, South Carolina, United States|Summerville, South Carolina, United States|Houston, Texas, United States|Houston, Texas, United States|Orem, Utah, United States|Richmond, Virginia, United States|Olympia, Washington, United States",,https://ClinicalTrials.gov/show/NCT02608697
NCT02609243,Diabetes Nutrition Algorithm - Prediabetes,DiNA-P,Recruiting,No Results Available,Prediabetes|Diabetes Mellitus Type 2|Obesity|NAFLD|Dyslipoproteinemia,Behavioral: dietary consulting,change in postprandial glycaemia (2h plasma glucose level of the 75 g oral glucose tolerance test (OGTT))|change in hepatic fat content confirmed by proton magnetic resonance spectroscopy by 3 T MR imaging|change in insulin sensitivity confirmed by 75 g oral glucose tolerance test (OGTT)|change in insulin secretion confirmed by 75 g oral glucose tolerance test (OGTT)|change in distribution of body fat confirmed by MR-Imaging by 3 T whole body imager,German Institute of Human Nutrition|German Diabetes Center,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,250,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,DiNA-P,Jul-13,Dec-18,Dec-20,20-Nov-15,null,22-Nov-16,"German Institut for Human Nutrition; Department for Clinical Nutrition, Nuthetal, Brandenburg, Germany|German Institute for Human Nutrition, Department for Clinical Nutrition, Berlin, Germany",,https://ClinicalTrials.gov/show/NCT02609243
NCT02609295,Effects of α-linolenic Acid Supplementation on Hemostasis in Nondiabetic and Hypercholesterolemic Subjects,,Completed,No Results Available,Hypercholesterolemia,Dietary Supplement: Placebo|Dietary Supplement: ALA group,Collagen-Epinephrine Closure Time (C-EPI CT)|Prothrombin Time (PT)|Activated partial thromboplastin time (aPTT)|Fibrinogen,Yonsei University,All,"40 Years to 68 Years   (Adult, Older Adult)",Phase 3,86,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",HP-ALA-hyperchol,Feb-15,Aug-15,Aug-15,20-Nov-15,null,22-Jan-16,"Yonsei University, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02609295
NCT02611102,Effect of Butter & MCT Oil on Lipoproteins - A RCT,,Recruiting,No Results Available,Hyperlipidemia,Dietary Supplement: MCT oil + Butter in Coffee,Changes in apolipoprotein B|non-HDL-c|LDL-c|triglycerides|Blood pressure|waist circumference|Fasting Blood Glucose|HbA1c,Walter Reed National Military Medical Center,All,18 Years to 45 Years   (Adult),Not Applicable,60,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,404482-2,Mar-16,Jul-18,Jul-19,20-Nov-15,null,26-Sep-16,"Walter Reed National Military Medical Center, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02611102
NCT02608242,PK Study of YH22189 FDC Compared to Combination of Telmisartan/Amlodipine and Rosuvastatin,,Terminated,No Results Available,Hypertension|Hyperlipidemia,Drug: YH22189|Drug: Twynsta 80/10mg|Drug: Crestor 20mg,Telmisartan Cmax|Telmisartan AUClast|Amlodipine Cmax|Amlodipine AUClast|Rosuvastatin Cmax|Rosuvastatin AUClast,Yuhan Corporation,Male,19 Years to 50 Years   (Adult),Phase 1,123,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,YH22189-102,Nov-15,Jun-16,Jun-16,18-Nov-15,null,1-Feb-17,"Chonbuk National University Hospital, Chunju, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02608242
NCT02603276,"Lipid-lowering Effect of Phytosterols, Red Yeast Rice and Their Combination",,Completed,No Results Available,Hypercholesterolemia,Dietary Supplement: Plant sterols|Dietary Supplement: Red Yeast Rice|Dietary Supplement: Red Yeast Rice plus Plant sterols,LDL cholesterolemia reduction from baseline and between groups|Non-HDL cholesterolemia reduction from baseline and between groups|Number of Participants With Treatment-Related Adverse Events,University of Bologna,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",PhytoRed,Apr-15,Dec-15,Dec-15,11-Nov-15,null,8-Feb-17,"S. Orsola-Malpighi University Hospital, Bologna, Italy",,https://ClinicalTrials.gov/show/NCT02603276
NCT02597127,Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C),ORION-1,Completed,Has Results,Atherosclerotic Cardiovascular Disease|Familial Hypercholesterolemia|Diabetes,Drug: ALN-PCSSC|Drug: Normal Saline,"Percentage Change in LDL-C From Baseline to Day 180|Percentage Change in LDL-C From Baseline to Day 90|Percent Change From Baseline In LDL-C Levels At Day 60, Day 120, and Day 210|Number of Participants With an LDL-C Greater Than 80% of the Baseline Value at Day 180 and Day 210|Number of Participants With Individual Responsiveness as Measured By LDL-C Levels at Day 90 and Day 180|Number of Participants With Greater Or Equal To 50% LDL-C Reduction From Baseline At Day 180|Percentage Change in PCSK9 Levels From Baseline at Day 180|Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180|Number of Participants Who Attained Global Lipid Modification Targets for Level of Atherosclerotic Cardiovascular Disease Risk|Percentage Change in Other Lipids and Inflammatory Markers From Baseline to Day 180",The Medicines Company,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,501,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MDCO-PCS-15-01,Jan-16,7-Jun-17,7-Jun-17,5-Nov-15,17-May-19,17-May-19,"Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Midwest Institute For Clinical Research, Indianapolis, Indiana, United States|Mount Sinai Icahn School of Medicine, New York, New York, United States|Metabolic And Atherosclerosis Research Center, Cincinnati, Ohio, United States|Sterling Research Group, Cincinnati, Ohio, United States|Wellmont CVA Heart Institute, Greeneville, Tennessee, United States|Amarillo Heart Clinical Research Institute, Inc., Amarillo, Texas, United States|National Clinical Research, Inc., Richmond, Virginia, United States|St. Paul's Hospital, Vancouver, British Columbia, Canada|St. Boniface Hospital, Winnipeg, Manitoba, Canada|Eastern Regional Health Authority, Patient Research Centre, St. Johns, Newfoundland and Labrador, Canada|Brampton Research Associates, Brampton, Ontario, Canada|Lawson Health Research Institute, London, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|ECOGENE-21 Clinical Trials Center, Chicoutimi, Quebec, Canada|Clinic Sante Cardio MC, Montreal, Quebec, Canada|Institut de Recherches Cliniques de Montreal, Montreal, Quebec, Canada|Université Laval Quebec, Quebec City, Quebec, Canada|Clinique des maladies lipidique Quebec, Quebec City, Quebec, Canada|Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke (CIUSSS de l'Estrie - CHUS), Sherbrooke, Quebec, Canada|Medical University Berlin, Berlin, Germany|Medical Center Essen, Essen, Germany|University Hospital Frankfurt, Frankfurt, Germany|University Heart Center Hamburg, Hamburg, Germany|Medical University Hospital Heidelberg, Internal medicine III, Heidelberg, Germany|Technical University Munich, German Heart Center, Munich, Germany|Amsterdam Medical Center, Amsterdam, Netherlands|Haga Hospital, Den Haag, Netherlands|Deventer Ziekenhuis, Deventer, Netherlands|Andromed Eindhoven, Eindhoven, Netherlands|Admiraal de Ruyter Hospital, Cardiology, Goes, Netherlands|Bethesda Diabetes Research Center, Hoogeveen, Netherlands|Medisch Centrum Gorecht, Hoogezand, Netherlands|VOC Hoorn, Hoorn, Netherlands|Leids Universitair Medisch Centrum (LUMC), Leiden, Netherlands|Andromed Rotterdam, Rotterdam, Netherlands|Diakonessenhuis, Vascular Policlinic, Utrecht, Netherlands|UMC Utrecht, Utrecht, Netherlands|VieCurie Venlo, Cardiology, Venlo, Netherlands|Albert Schweitzer Hospital, Cardiology, Zwijndrecht, Netherlands|Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom|Edinburgh Royal Infirmary, Edinburgh, United Kingdom|The Royal Devon and Exeter NHS Trust, Exeter, United Kingdom|Fowey River Practice, Fowey, United Kingdom|Buckinghamshire NHS Trust, High Wycombe, United Kingdom|Oak Tree Surgery, Liskeard, United Kingdom|Royal Free Hospital, London, United Kingdom|Central Manchester University Hospital NHS Foundation Trust, Manchester, United Kingdom|The Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, United Kingdom|The Alverton Practice, Penzance, United Kingdom|Knowle House Surgery, Plymouth, United Kingdom|Brannel Surgery, St. Austell, United Kingdom|Rame Medical Ltd (Rame Research), Torpoint, United Kingdom|Worcestershire Acute NHS Trust, Worcester, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT02597127/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT02597127/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02597127
NCT02596087,Improving Quality by Maintaining Accurate Problems in the EHR,IQ-MAPLE,Unknown status,No Results Available,Asthma|Atrial Fibrillation|Chronic Obstructive Pulmonary Disease|Coronary Artery Disease|Congestive Heart Failure|Hyperlipidemia|Hypertension|Myocardial Infarction|Sickle Cell Disease|Sleep Apnea|Smoking|Stroke|Tuberculosis,Other: Problem List Suggestion,"Measuring the rate of acceptance of alerts calculated by number of acceptances for each alert divided by the total number of unique presentations of the alert|Determining the effect of problem list completion by comparing the number of study-related problems added to problem lists in the electronic health record|Determining the quality of care impact of adding suggested problems to the problem list based on 4 outcome measures from NCQA's HEDIS 2013 measure set|Evaluating process measures using key process measures for each study condition from CMS, NHLBI, and NQMC",Brigham and Women's Hospital|Geisinger Clinic|Oregon Health and Science University|Vanderbilt University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2386,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant),2009P001846-14,Apr-16,Mar-18,null,4-Nov-15,null,7-Dec-16,"Brigham and Women's Hospital, Boston, Massachusetts, United States|Oregon Health and Science University, Portland, Oregon, United States|Holy Spirit Hospital, Camp Hill, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT02596087
NCT02593487,Effect of Rosuvastatin Therapy on HDL2 Level,,Unknown status,No Results Available,Hyperlipemia|Coronary Heart Disease,Drug: Rosuvastatin 10mg/d group|Drug: Rosuvastatin 20mg/d group,The primary efficacy endpoint is to detect the percentage change of HDL2 level by using rosuvastatin after 12 weeks in hyperlipidemia patients with CAD compared with baseline.,Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|AstraZeneca,All,"30 Years to 75 Years   (Adult, Older Adult)",Phase 4,300,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,ESR-14-10333,Nov-15,Dec-16,Jun-17,2-Nov-15,null,3-Nov-15,"Xu-kai Wang, Chongqing, Chongqing, China",,https://ClinicalTrials.gov/show/NCT02593487
NCT02591836,Efficacy and Safety of Gemcabene in Hypercholesterolemic Patients as Monotherapy or in Combination With Atorvastatin,,Completed,No Results Available,Hypercholesterolemia,Drug: Gemcabene|Drug: Atorvastatin|Drug: Placebo,LDL‐C percent change from baseline|HDL-C percent change from baseline|TG percent change from baseline|Apolipoprotein-B percent change from baseline|Adverse Events|Clinical Laboratory,"Gemphire Therapeutics, Inc.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,277,Industry,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A4141001,Jan-03,Jun-03,Jun-03,30-Oct-15,null,30-Oct-15,,,https://ClinicalTrials.gov/show/NCT02591836
NCT02593032,Effects of Use of a Connected Pillbox On Medication Adherence,(TVHST2DM),Completed,No Results Available,Diabetes Mellitus|Hypertension|Hyperlipidemia,Device: Pre-filled trays,Medication adherence rate averaged over months 1 to 6,University of Pennsylvania|TowerView Health,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,821737,Feb-15,Apr-17,21-Sep-17,30-Oct-15,null,23-Jan-19,"University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02593032
NCT02587390,Effect of Gemcabene on the Pharmacokinetics of Simvastatin in Healthy Volunteers,,Completed,No Results Available,Hypercholesterolemia,Drug: Gemcabene 900 mg|Drug: Simvastatin 80 mg,"Pharmacokinetics|Adverse Events|Clinical Laboratory - hematology, chemistry, urinalysis|ECG","Gemphire Therapeutics, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,20,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,1027-008,May-00,Jul-00,Jul-00,27-Oct-15,null,27-Oct-15,,,https://ClinicalTrials.gov/show/NCT02587390
NCT02587416,Effect of Gemcabene on the Pharmacokinetics of Atorvastatin in Healthy Volunteers,,Completed,No Results Available,Hypercholesteremia,Drug: Gemcabene 300 mg|Drug: Gemcabene 900 mg|Drug: Atorvastatin,"Pharmacokinetics|Adverse Events|Clinical Laboratory - hematology, chemistry, urinalysis|ECG","Gemphire Therapeutics, Inc.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,20,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,A4141002,Nov-02,Dec-02,Dec-02,27-Oct-15,null,27-Oct-15,,,https://ClinicalTrials.gov/show/NCT02587416
NCT02585895,Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment,,Completed,Has Results,Hypercholesterolemia,Biological: Evolocumab|Procedure: Low-density Lipoprotein Cholesterol (LDL-C) Apheresis,Percentage of Participants With Apheresis Avoidance at the End of Randomized Therapy|Percent Change From Baseline in Low-density Lipoprotein Cholesterol|Percent Change From Baseline in Non-high-density Lipoprotein-Cholesterol|Percent Change From Baseline in Total Cholesterol/High-density Lipoprotein Cholesterol Ratio,Amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 3,39,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20140316|2015-001343-37,21-Dec-15,1-Sep-16,20-Jan-17,26-Oct-15,19-Sep-17,19-Sep-17,"Research Site, Boca Raton, Florida, United States|Research Site, Kansas City, Kansas, United States|Research Site, Grandville, Michigan, United States|Research Site, Portland, Oregon, United States|Research Site, Heidelberg, Victoria, Australia|Research Site, Hradec Kralove, Czechia|Research Site, Bron, France|Research Site, Nantes Cedex 1, France|Research Site, Berlin, Germany|Research Site, Dresden, Germany|Research Site, Düsseldorf, Germany|Research Site, Flensburg, Germany|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Sevilla, Andalucía, Spain|Research Site, Harefield, United Kingdom|Research Site, Penarth, United Kingdom",,https://ClinicalTrials.gov/show/NCT02585895
NCT02586129,Clinical Trial of YH14755 in Subjects With Dyslipidemia and Type II Diabetes,,Completed,No Results Available,Dyslipidemia|Type II Diabetes,Drug: YH14755|Drug: Metformin|Drug: Rosuvastatin,Change in LDL Cholesterol|Change in HbA1c,Yuhan Corporation,All,"19 Years to 75 Years   (Adult, Older Adult)",Phase 3,249,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",YH14755-301,4-Nov-15,7-Jul-17,7-Jul-17,26-Oct-15,null,3-Oct-18,"Seoul National Universitiy Bundang Hospital, Seongnam-Si, Gyeonggi-Do, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02586129
NCT02585778,Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin),,Completed,Has Results,Hypercholesterolaemia,Drug: Alirocumab|Drug: Placebo|Drug: Lipid-Modifying Therapy (LMT)|Drug: Antihyperglycemic Drug,Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis|Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (AEs)|Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Measured LDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Measured LDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Apolipoprotein B (Apo-B) at Week 24 - ITT Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis|Percentage of Participants Reaching Calculated LDL-C <50 mg/dL (1.3 mmol/L) at Week 24 - On-Treatment Analysis|Percentage of Participants Reaching Calculated Non-HDL-C <100 mg/dL at Week 24 - On-Treatment Analysis|Percentage of Participants Reaching Calculated Non-HDL-C <80 mg/dL at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis|Percent Change From Baseline in LDL-C Particle Number at Week 24 - ITT Analysis|Percent Change From Baseline in LDL-C Particle Size at Week 24 - ITT Analysis|Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Weeks 12 and 24 - ITT Analysis|Absolute Change From Baseline in HbA1c at Weeks 12 and 24 - On-Treatment Analysis|Absolute Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 12 and 24 - ITT Analysis|Absolute Change From Baseline in FPG at Weeks 12 and 24 - On-Treatment Analysis|Absolute Change From Baseline in Total Daily Insulin Dose at Weeks 12 and 24 - ITT Analysis|Absolute Change From Baseline in Total Daily Insulin Dose at Weeks 12 and 24 - On-Treatment Analysis|Absolute Change From Baseline in Insulin Daily Dose/Kg at Weeks 12 and 24 - ITT Analysis|Absolute Change From Baseline in Insulin Daily Dose/Kg at Weeks 12 and 24 - On-Treatment Analysis|Absolute Change From Baseline in Number of Glucose-Lowering Treatments at Weeks 12 and 24 - ITT Analysis|Absolute Change From Baseline in Number of Glucose-Lowering Treatments at Weeks 12 and 24 - On-Treatment Analysis,Sanofi|Regeneron Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 3,517,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",LPS14355|2015-000799-92|U1111-1172-4772,23-Oct-15,3-Apr-17,3-Apr-17,23-Oct-15,17-May-18,17-May-18,"Investigational Site Number 840020, Encino, California, United States|Investigational Site Number 840002, Fresno, California, United States|Investigational Site Number 840029, Oakland, California, United States|Investigational Site Number 840027, Loveland, Colorado, United States|Investigational Site Number 840026, Atlantis, Florida, United States|Investigational Site Number 840006, Bradenton, Florida, United States|Investigational Site Number 840023, Jacksonville, Florida, United States|Investigational Site Number 840028, Palm Harbor, Florida, United States|Investigational Site Number 840022, Ponte Vedra Beach, Florida, United States|Investigational Site Number 840021, Roswell, Georgia, United States|Investigational Site Number 840007, Springfield, Illinois, United States|Investigational Site Number 840011, Indianapolis, Indiana, United States|Investigational Site Number 840015, Valparaiso, Indiana, United States|Investigational Site Number 840010, Des Moines, Iowa, United States|Investigational Site Number 840005, Louisville, Kentucky, United States|Investigational Site Number 840018, Auburn, Maine, United States|Investigational Site Number 840013, Hyattsville, Maryland, United States|Investigational Site Number 840016, Rockville, Maryland, United States|Investigational Site Number 840004, Minneapolis, Minnesota, United States|Investigational Site Number 840012, Jamaica, New York, United States|Investigational Site Number 840014, Maumee, Ohio, United States|Investigational Site Number 840009, Greer, South Carolina, United States|Investigational Site Number 840024, Chattanooga, Tennessee, United States|Investigational Site Number 840001, Austin, Texas, United States|Investigational Site Number 840003, Dallas, Texas, United States|Investigational Site Number 840019, Dallas, Texas, United States|Investigational Site Number 840025, Houston, Texas, United States|Investigational Site Number 840017, Ogden, Utah, United States|Investigational Site Number 840008, Salt Lake City, Utah, United States|Investigational Site Number 040002, Innsbruck, Austria|Investigational Site Number 040005, Linz, Austria|Investigational Site Number 040003, Salzburg, Austria|Investigational Site Number 040004, Salzburg, Austria|Investigational Site Number 040001, Wien, Austria|Investigational Site Number 056002, Edegem, Belgium|Investigational Site Number 056003, Haine-Saint-Paul, Belgium|Investigational Site Number 056001, Leuven, Belgium|Investigational Site Number 250-008, Besancon, France|Investigational Site Number 250-005, Corbeil Essonnes, France|Investigational Site Number 250-004, La Rochelle Cedex 1, France|Investigational Site Number 250-003, Le Creusot, France|Investigational Site Number 250-009, Mulhouse, France|Investigational Site Number 250-002, Nantes cedex 01, France|Investigational Site Number 250-007, Paris, France|Investigational Site Number 250-006, Strasbourg Cedex 2, France|Investigational Site Number 250-001, TOULOUSE Cedex 9, France|Investigational Site Number 276015, Aschaffenburg, Germany|Investigational Site Number 276002, Berlin, Germany|Investigational Site Number 276011, Dortmund, Germany|Investigational Site Number 276019, Dresden, Germany|Investigational Site Number 276014, Dresden, Germany|Investigational Site Number 276009, Dresden, Germany|Investigational Site Number 276021, Hamburg, Germany|Investigational Site Number 276018, Hamburg, Germany|Investigational Site Number 276005, Heidelberg, Germany|Investigational Site Number 276013, Lüneburg, Germany|Investigational Site Number 276022, Magdeburg, Germany|Investigational Site Number 276008, Neumünster, Germany|Investigational Site Number 276017, Neuwied, Germany|Investigational Site Number 276004, Oldenburg, Germany|Investigational Site Number 276003, Pirna, Germany|Investigational Site Number 276006, Riesa, Germany|Investigational Site Number 276010, Saarlouis, Germany|Investigational Site Number 276016, Sulzbach-Rosenberg, Germany|Investigational Site Number 380004, Catania, Italy|Investigational Site Number 380003, Catanzaro, Italy|Investigational Site Number 380011, Como, Italy|Investigational Site Number 380006, Milano, Italy|Investigational Site Number 380007, Milano, Italy|Investigational Site Number 380005, Moncalieri, Italy|Investigational Site Number 380009, Napoli, Italy|Investigational Site Number 380008, Padova, Italy|Investigational Site Number 380002, Palermo, Italy|Investigational Site Number 380001, Pisa, Italy|Investigational Site Number 380010, Roma, Italy|Investigational Site Number 380012, Verona, Italy|Investigational Site Number 528002, Apeldoorn, Netherlands|Investigational Site Number 528005, Groningen, Netherlands|Investigational Site Number 528003, Hoogeveen, Netherlands|Investigational Site Number 528001, Rotterdam, Netherlands|Investigational Site Number 528004, Utrecht, Netherlands|Investigational Site Number 724007, Badalona, Spain|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724006, Ferrol, Spain|Investigational Site Number 724013, Granada, Spain|Investigational Site Number 724005, Madrid, Spain|Investigational Site Number 724004, Madrid, Spain|Investigational Site Number 724011, Majadahonda, Spain|Investigational Site Number 724008, Málaga, Spain|Investigational Site Number 724014, Oviedo, Spain|Investigational Site Number 724009, Palma de Mallorca, Spain|Investigational Site Number 724002, Pamplona, Spain|Investigational Site Number 724010, Sant Joan Despí, Spain|Investigational Site Number 724012, Segovia, Spain|Investigational Site Number 724003, Sevilla, Spain|Investigational Site Number 756001, Olten, Switzerland|Investigational Site Number 756003, St. Gallen, Switzerland|Investigational Site Number 826010, Airdrie, United Kingdom|Investigational Site Number 826011, Bath, United Kingdom|Investigational Site Number 826009, Bournemouth, United Kingdom|Investigational Site Number 826005, Bradford, United Kingdom|Investigational Site Number 826004, Bristol, United Kingdom|Investigational Site Number 826001, Burton On Trent, United Kingdom|Investigational Site Number 826015, Durham, United Kingdom|Investigational Site Number 826012, High Wycombe, United Kingdom|Investigational Site Number 826007, Manchester, United Kingdom|Investigational Site Number 826006, Peterborough, United Kingdom|Investigational Site Number 826003, Southampton, United Kingdom|Investigational Site Number 826008, Truro, United Kingdom|Investigational Site Number 826002, Welwyn Garden City, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02585778/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02585778/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02585778
NCT02584504,Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin,ODYSSEY-NIPPON,Completed,Has Results,Hypercholesterolemia,Drug: Alirocumab|Drug: Placebo|Drug: Atorvastatin|Drug: Non-statin Lipid-Modifying Therapy|Other: Diet Alone,Percent Change From Baseline in Calculated LDL-C at Week 12- Intent to Treat (ITT) Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12- On-Treatment Analysis|Percent Change From Baseline in Calculated LDL-C to Averaged Week 10 to 12: ITT Analysis|Percent Change From Baseline in Calculated LDL-C to Averaged Week 10 to 12- On-Treatment Analysis|Percent Change From Baseline in Apolipoprotein B (Apo-B) at Week 12: ITT Analysis|Percent Change From Baseline in Apo-B at Week 12- On-Treatment Analysis|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12: ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12- On-treatment Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 12- ITT Analysis|Percentage of Participants Reaching Calculated LDL-C Goal at Week 12- ITT Analysis|Percentage of Participants Reaching Calculated LDL-C Goal at Week 12- On-Treatment Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 12: ITT Analysis|Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12- ITT Analysis|Percent Change From Baseline in Fasting Triglycerides (TGs) at Week 12: ITT Analysis|Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 12: ITT Analysis,Sanofi|Regeneron Pharmaceuticals,All,"20 Years and older   (Adult, Older Adult)",Phase 3,163,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EFC14305|U1111-1170-7697,30-Nov-15,5-Apr-17,9-Jan-18,22-Oct-15,7-May-18,23-Jan-19,"Investigational Site Number 392028, Ageo-Shi, Japan|Investigational Site Number 392007, Chuo-Ku, Japan|Investigational Site Number 392029, Chuo-Ku, Japan|Investigational Site Number 392014, Fukui-Shi, Japan|Investigational Site Number 392023, Hachioji-Shi, Japan|Investigational Site Number 392013, Itoshima-Shi, Japan|Investigational Site Number 392010, Kanazawa-Shi, Japan|Investigational Site Number 392024, Kasuga-Shi, Japan|Investigational Site Number 392004, Kawanishi-Shi, Japan|Investigational Site Number 392015, Kitakyushu-Shi, Japan|Investigational Site Number 392005, Komatsu-Shi, Japan|Investigational Site Number 392032, Matsudo-Shi, Japan|Investigational Site Number 392017, Matsumoto-Shi, Japan|Investigational Site Number 392003, Mito-Shi, Japan|Investigational Site Number 392018, Morioka-Shi, Japan|Investigational Site Number 392009, Moriya-Shi, Japan|Investigational Site Number 392006, Nagoya-Shi, Japan|Investigational Site Number 392011, Nagoya-Shi, Japan|Investigational Site Number 392019, Nagoya-Shi, Japan|Investigational Site Number 392025, Nagoya-Shi, Japan|Investigational Site Number 392027, Osaka-Shi, Japan|Investigational Site Number 392030, Sakura-Shi, Japan|Investigational Site Number 392016, Shinagawa-Ku, Japan|Investigational Site Number 392001, Shinjuku-Ku, Japan|Investigational Site Number 392008, Shinjuku-Ku, Japan|Investigational Site Number 392012, Shizuoka-Shi, Japan|Investigational Site Number 392002, Suita-Shi, Japan|Investigational Site Number 392031, Suita-Shi, Japan|Investigational Site Number 392020, Toyonaka-Shi, Japan|Investigational Site Number 392022, Yao-Shi, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT02584504/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT02584504/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02584504
NCT02581449,Effect of Omega-3 Fatty Acids on Oxidative Stress and Dyslipidemia in Pediatric Patients Undergoing Hemodialysis,,Unknown status,No Results Available,End Stage Renal Disease,Dietary Supplement: omega-3|Other: empty soft gelatin capsules,"effect on oxidative stress status via measurement of superoxide dismutase and glutathione peroxidase and malondialdehyde|effect on serum lipid levels (HDL cholesterol, LDL cholesterol, total cholesterol, and triglycerides)",Ain Shams University,All,"8 Years to 18 Years   (Child, Adult)",Phase 2,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,PHCL31528,Sep-15,Jan-16,Jan-16,21-Oct-15,null,21-Oct-15,,,https://ClinicalTrials.gov/show/NCT02581449
NCT02582424,Safety and Efficacy of PDL-0101 in Patients With Hyperlipidemias: a Pilot Study.,,Completed,No Results Available,Hyperlipidemia,Other: PD-L0101|Other: placebo,lowering serum TG levels|lower serum LDL levels,Primus Pharmaceuticals,All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,103,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PDT-0101,Jul-12,Aug-13,Sep-13,21-Oct-15,null,26-Jan-16,,,https://ClinicalTrials.gov/show/NCT02582424
NCT02579655,Assessing Outcomes of Enhanced Chronic Disease Care Through Patient Education and a Value-based Formulary Study,ACCESS,"Active, not recruiting",No Results Available,Coronary Disease|Stroke|Chronic Kidney Disease|Heart Failure|Diabetes Mellitus|Hypertension|Hypercholesterolemia,Behavioral: Copayment Elimination|Behavioral: Personalized Education,"Composite rate of all-cause mortality, nonfatal myocardial infarction, nonfatal stroke, need for coronary revascularization, hospitalizations for chronic disease-related ambulatory care sensitive conditions|All-cause mortality|Non-fatal myocardial infarction|Non-fatal stroke|Need for coronary revascularization|hospitalizations for chronic disease-related ambulatory care sensitive conditions|Full adherence to statins|Overall quality of life as measured by the Euroqol EQ5D-5L index score|Overall health care costs",University of Calgary|Alberta Innovates Health Solutions,All,65 Years and older   (Older Adult),Not Applicable,4764,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,REB13-1241,Nov-15,Apr-21,Jan-22,19-Oct-15,null,10-Oct-18,"University of Calgary, Calgary, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT02579655
NCT02577159,Dapagliflozin on Hyperlipidemia and Insulin Resistance in Type 2 Diabetic Patients (DAPHNIS Study),DAPHNIS,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Type 2",Drug: Dapagliflozin,Changes in fasting lipoprotein profiles|Changes in fasting lipid profiles|Changes in fasting blood glucose and HbA1c|Changes in insulin and adiponectin|Frequency of adverse side effects|Changes in biomarkers for renal and hepatic function,Osaka University,All,"20 Years to 65 Years   (Adult, Older Adult)",Phase 4,50,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DAPHNIS,1-Jul-15,31-Dec-17,31-Aug-18,16-Oct-15,null,29-Aug-18,"Sousei Hospital, Kadoma, Osaka, Japan|Osaka Central Hospital, Osaka city, Osaka, Japan|Osaka University Hospital, Suita, Osaka, Japan",,https://ClinicalTrials.gov/show/NCT02577159
NCT02571257,Efficacy and Safety of Gemcabene in Hypercholesterolemic Patients on Stable Statin Therapy,,Completed,No Results Available,Hypercholesterolemia,Drug: Gemcabene|Drug: Placebo,LDL-C - percent change from baseline at Week 8|Plasma lipid levels - percent change from baseline at Week 8|Adverse Events|Clinical Laboratory,"Gemphire Therapeutics, Inc.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,66,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1027-018,Aug-00,Apr-02,Apr-02,8-Oct-15,null,14-Oct-15,,,https://ClinicalTrials.gov/show/NCT02571257
NCT02569814,A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin,,Completed,No Results Available,Hypertension|Hyperlipidemia,Drug: Fimasartan/Amlodipine/Rosuvastatin|Drug: Fimasartan/Amlodipine|Drug: Rosuvastatin,"Cmax of Fimasartan, Amlodipine and Rosuvastatin|AUCt(Area Under the Curve) of Fimasartan, Amlodipine and Rosuvastatin","Boryung Pharmaceutical Co., Ltd",Male,19 Years to 50 Years   (Adult),Phase 1,100,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BR-FARC-CT-102,Sep-15,Dec-15,Dec-15,7-Oct-15,null,24-Feb-16,"Inje University Busan Paik Hospital, Busan, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02569814
NCT02566187,A Study to Compare the Pharmacokinetics of Fimasartan/Atorvastatin Combination Tablet,,Completed,No Results Available,Hypertension|Hyperlipidemia,Drug: Fimasartan/Atorvastatin Combination Tablet|Drug: Fimasartan|Drug: Atorvastatin,Maximum observed concentration(Cmax) of Fimasartan and Atorvastatin|Area under the curve(AUCt) of Fimasartan and Atorvastatin,"Boryung Pharmaceutical Co., Ltd",Male,19 Years to 50 Years   (Adult),Phase 1,99,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BR-FAVC-CT-101,Aug-15,Oct-15,Oct-15,2-Oct-15,null,25-Feb-16,"Inje University Busan Paik Hospital, Busan, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02566187
NCT02557412,Effect of Nasal CPAP on Lipid Profile in Patients With Dyslipidaemia and Sleep Apnea,,Recruiting,No Results Available,Sleep Apnea|Dyslipidaemia,Device: Continuous positive airway pressure|Behavioral: Intensive lifestyle intervention|Other: Conventional treatment,LDL-cholesterol|Lipid profile|Systemic biomarkers|Glycated hemoglobin|Insulin resistance|Health-related quality of life|Daily physical activity|Clinical adverse events|CPAP compliance|Sleepiness,Hospital Universitario La Paz|Hospital Universitario Principe de Asturias,All,"35 Years to 75 Years   (Adult, Older Adult)",Phase 4,114,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PINML01,May-15,Dec-19,May-20,23-Sep-15,null,11-Sep-18,"Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT02557412
NCT02551172,Evaluating the Efficacy and Safety of HCP1105 in Combined Hyperlipidemic Patients With High Risk for CHD,,Unknown status,No Results Available,Hyperlipidemias,Drug: HCP1105|Drug: HGP0816|Drug: Placebo of HCP1105|Drug: Placebo of HGP0816,Mean rate of change of non-HDL-C (%) from baseline|Mean rate of change of HDL-C (%) from baseline|Mean rate of change of LDL-C (%) from baseline|Mean rate of change of Triglyceride (%) from baseline|Mean rate of change of Total cholesterol (%) from baseline|Mean rate of change of Total apo A1 (%) from baseline|Mean rate of change of Total apo B (%) from baseline|Mean rate of change of Lipoprotein(a) (%) from baseline|Mean rate of change of hs-CRP (%) from baseline|Rate of the subjects who meet the target level of treatment,Hanmi Pharmaceutical Company Limited,All,"19 Years and older   (Adult, Older Adult)",Phase 3,270,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",HM-ROMA-301,Oct-14,Jan-16,Feb-16,16-Sep-15,null,16-Sep-15,"Euljii General Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02551172
NCT02550288,A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383),,Completed,Has Results,Hypercholesterolemia,Drug: Ezetimibe 10 mg|Drug: Atorvastatin 10 mg|Drug: Placebo for Ezetimibe 10 mg tablet|Drug: Placebo for Atorvastatin 10 mg capsule|Behavioral: Diet control/Daily Exercise,Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12|Percentage of Participants Who Experience 1 or More Gastrointestinal-related Adverse Events (AEs)|Percentage of Participants Who Experience 1 or More Gallbladder-related AEs|Percentage of Participants Who Experience 1 or More Allergic Reaction or Rash AEs|Percentage of Participants Who Experience 1 or More Hepatitis-related AEs|Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) ≥3 Times Upper Limit of Normal (ULN)|Percentage of Participants Who Experience Consecutive Elevations in Aspartate Aminotransferase (AST) ≥3 Times ULN|Percentage of Participants Who Experience Consecutive Elevations in ALT and/or AST ≥3 Times ULN|Percentage of Participants Who Experience Consecutive Elevations in ALT ≥5 Times ULN|Percentage of Participants Who Experience Consecutive Elevations in AST ≥5 Times ULN|Percentage of Participants Who Have Consecutive Elevations in ALT and/or AST ≥5 Times ULN|Percentage of Participants Who Experience Consecutive Elevations in ALT ≥10 Times ULN|Percentage of Participants Who Experience Consecutive Elevations in AST ≥10 Times ULN|Percentage of Participants Who Have Consecutive Elevations in ALT and/or AST ≥10 Times ULN|Percentage of Participants With Potential Hy's Law Condition|Percentage of Participants Who Have Elevations in Creatine Kinase (CK) ≥10xULN|Percentage of Participants Who Have Elevations in CK ≥10xULN With Muscle Symptoms|Percentage of Participants Who Have Elevations in CK ≥10xULN and Drug-Related Muscle Symptoms,Merck Sharp & Dohme Corp.,All,"20 Years to 80 Years   (Adult, Older Adult)",Phase 3,309,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0653C-383|153060,29-Sep-15,30-May-16,30-May-16,15-Sep-15,21-Jun-17,17-Aug-18,,,https://ClinicalTrials.gov/show/NCT02550288
NCT02548832,Effect of Administration of the Combination Bezafibrate More Berberine on Lipid Profile in Patients With Dyslipidemia,,Unknown status,No Results Available,Mixed Dyslipidemia,Drug: Berberine|Drug: Bezafibrate|Drug: Placebo,Total cholesterol|Triglycerides|High density lipoprotein cholesterol|Low density lipoprotein|Very low density lipoprotein|Body weight|Body mass index|Waist circumference|Fasting glucose|Blood pressure|Alanine aminotransferasa|Aspartate aminotransferase|Creatinine,University of Guadalajara,All,30 Years to 60 Years   (Adult),Phase 2,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",EABYBL,Apr-13,May-16,Jul-16,14-Sep-15,null,14-Sep-15,"Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of Guadalajara, Guadalajara, Jalisco, Mexico",,https://ClinicalTrials.gov/show/NCT02548832
NCT02541201,The Effect of a Plant Sterols-Enriched Low-Fat Milk on Lipid Profile in Healthy Southern Chinese (COME-PASS),COME-PASS,Completed,No Results Available,Dyslipidemia,Dietary Supplement: Plant sterols-enriched low-fat milk|Dietary Supplement: Low-fat milk,Mean of serum low-density lipoprotein cholesterol (LDL-C)|Change of serum LDL-C|Change of high-density lipoprotein cholesterol (HDL-C)|Change of total cholesterol|Change of triglycerides (TAG)|Change of serum creatinine|Changes of fasting blood glucose,The University of Hong Kong,All,"18 Years and older   (Adult, Older Adult)",Phase 2,221,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",CTC1430,Aug-15,Sep-15,Sep-15,4-Sep-15,null,14-Oct-15,,,https://ClinicalTrials.gov/show/NCT02541201
NCT02537236,Omega-3 Supplementation in HIV Patients With Therapeutic Lifestyle Change Diet.,,Completed,No Results Available,Human Immunodeficiency Virus,Dietary Supplement: Omega-3 fatty acids|Behavioral: TLC nutritional intervention|Dietary Supplement: Omega-3 fatty acid supplementation with fish oil and TLC nutritional intervention.,Triglycerides (TG)|Total cholesterol (TC)|High density cholesterol (HD-C)|Low density cholesterol (LD-C)|Very low density cholesterol (VLD-C)|Body weight|Body mass index (BMI)|TG 4|TC 4|HD-C 4|LD-C 4|VLD-C 4|Weight 4|BMI 4|TG 12|TC 12|HD-C 12|LD-C 12|VLD-C 12|Weight 12|BMI 12,Instituto Mexicano del Seguro Social|Hospital Civil de Guadalajara,All,18 Years to 60 Years   (Adult),Phase 3,200,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",omega-3-HIV/2009,Jan-09,May-09,Dec-09,1-Sep-15,null,2-Sep-15,,,https://ClinicalTrials.gov/show/NCT02537236
NCT02532218,"Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia",REASCEND,Unknown status,No Results Available,Hyperlipidemia,Drug: ARI-3037MO,LDL-c|HDL-c|TG|HbA1C,Arisaph Pharmaceuticals Inc,All,"18 Years and older   (Adult, Older Adult)",Phase 2,176,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ARI-3037MO-005,Aug-15,Sep-16,Dec-16,25-Aug-15,null,8-Aug-16,"Catalina Reserch Institute, LLC, Chino, California, United States|S&W Clinical Reserch, Ft Lauderdale, Florida, United States|Jacksonville Center for Clinical Research, Jacksonvile, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Sestron Clinical Research 833 Campbell Hill Street Suite 230, Marietta, Georgia, United States|Midwest Institute for Clinical Research, Indianapolis, Indiana, United States|Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky, United States|Rochester clinical Research,Inc, Rochester, New York, United States|Sterling Research Group Ltd, Cincinnati, Ohio, United States|The Carl and Edyth Lindner Center for Reserch and education at the Christ Hospital, Cincinnati, Ohio, United States|Metabolic and atherosclerosis Research center, Cincinnati, Ohio, United States|IVA reserch, Cincinnati, Ohio, United States|Sterling Research group, Ltd, Cincinnati, Ohio, United States|Ohio Clinical Research-Lyndhurst, Lyndhurst, Ohio, United States|COR Clinical Research, Oklahoma City, Oklahoma, United States|Willamette Valley Clinical studies, Eugene, Oregon, United States|Health Research of Hampton Roads - Norfolk, Norfolk, Virginia, United States|National Clinical Research inc, Richmond, Virginia, United States|Raninier Clinical Reserach, Renton, Washington, United States",,https://ClinicalTrials.gov/show/NCT02532218
NCT02529709,The Effect of Meal Composition on Blood Lipids,,Completed,No Results Available,Dyslipidemia,Other: High-Protein Condition|Other: High-Monounsaturated Fat Condition,Blood lipid concentrations.|IL-6|TNF-α|C-reactive protein|GLP-1|Insulin|Glucagon|Glucose|Leptin,Texas Christian University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,24,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,TexasCU,Oct-15,Apr-16,Apr-16,20-Aug-15,null,21-Apr-16,"Texas Christian University, Fort Worth, Texas, United States",,https://ClinicalTrials.gov/show/NCT02529709
NCT02526121,Effect of Therapeutic Phlebotomies on the Triglycerides Concentration in Patients With Hypertriglyceridemia and Hyperferritinemia,,Completed,No Results Available,Hyperferritinemia|Hypertriglyceridemia,Procedure: Phlebotomy|Behavioral: Dietary and lifestyle counseling.,Triglycerides concentration|Iron parameters,Instituto Aragones de Ciencias de la Salud,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CEICA;PI10/099,Apr-13,Dec-15,Dec-15,18-Aug-15,null,30-Aug-16,"Hospital Universitario Miguel Servet, Zaragoza, Spain",,https://ClinicalTrials.gov/show/NCT02526121
NCT02523391,Bioequivalence Study of Capsule and Tablet Formulations of TA-8995,,Completed,No Results Available,Dyslipidaemia,Drug: TA-8995,Area under the plasma concentration versus time curve (AUC) of TA-8995 capsule and tablet formulations|Peak Plasma Concentration (Cmax) of TA-8995 capsule and tablet formulations,Xention Ltd,Male,18 Years to 55 Years   (Adult),Phase 1,26,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TA-8995-08,Jul-15,Nov-15,Nov-15,14-Aug-15,null,29-Jan-16,"Covance Clinical Research Unit Ltd, Leeds, United Kingdom",,https://ClinicalTrials.gov/show/NCT02523391
NCT02524106,Bococizumab HIV Evaluation (B-HIVE) Study,B-HIVE,Terminated,No Results Available,Dyslipidemia|Cardiovascular Disease,Drug: Bococizumab|Drug: Placebo,LDL-C|Total Cholesterol|ApoB|non HDL-C|HDL-C|Lp(a),"University of California, San Francisco|Pfizer|San Francisco General Hospital",All,"40 Years and older   (Adult, Older Adult)",Phase 3,11,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",WI204426,Aug-16,Nov-17,Nov-17,14-Aug-15,null,12-Dec-18,"San Francisco General Hospital, San Francisco, California, United States|Quest Clinical Research, San Francisco, California, United States|San Francisco Veteran's Affair Medical Center, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT02524106
NCT02512276,Tele-Pharmacy Intervention to Improve Treatment Adherence,STIC2IT,Completed,No Results Available,Hyperlipidemia|Diabetes|Hypertension,Behavioral: Telepharmacist intervention,Medication adherence|Disease control|Healthcare utilization,Brigham and Women's Hospital|Harvard Vanguard Medical Associates,All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,4076,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,2013P001076,Aug-15,Aug-17,Oct-17,30-Jul-15,null,6-Oct-17,"Harvard Vanguard Medical Associates, Newton, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02512276
NCT02508896,"Study Assessing Safety, Immunogenicity and LDLc -Lowering Activity of 2 PCSK9 Targeting AFFITOPE Vaccines in Healthy Subjects",AFF012,Completed,No Results Available,Hypercholesterolemia,Biological: AFFITOPE® AT04A+adjuvant|Biological: AFFITOPE® AT06A+adjuvant|Biological: Adjuvant without active component,Occurence of any Serious Adverse Event (SAE)|Immunological activity of AFFITOPE® AT04A: Titer of vaccination-induced antibodies|Immunological activity of AFFITOPE® AT06A: Titer of vaccination-induced antibodies|Mean Levels of Low Density Lipoprotein Cholesterol (LDLc)|Mean Levels of High Density Lipoprotein Cholesterol (HDLc)|Mean Levels of Very Low Density Lipoprotein (VLDL)|Mean Levels of Total Cholesterol (TC)|Mean Levels of Triglycerides (TG)|Mean Levels of PCSK9|Correlation analysis: Relating the strength of antibody responses to Lipid lowering effects,Affiris AG|Medical University of Vienna,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,72,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,AFFiRiS 012|2015-001719-11,Jul-15,May-16,31-Aug-17,27-Jul-15,null,20-Oct-17,"Medical University of Vienna, Vienna, Austria",,https://ClinicalTrials.gov/show/NCT02508896
NCT02505854,"Influence of Probiotic and Symbiotic in Body Weight, Blood Sugar and Lipemia of Obese Women",,"Active, not recruiting",No Results Available,Obesity,Dietary Supplement: Probiotic|Dietary Supplement: Symbiotic|Dietary Supplement: Placebo,Evaluate the effects of probiotic and symbiotic on weight loss of women obese in baseline and after 60 days.|Effect of probiotic and symbiotic on blood glucose|Effect probiotic and symbiotic on insulin resistance by HOMA-IR calculation|Effect probiotic and symbiotic on insulin sensitivity by QUICKY calculation|Effect of probiotic and symbiotic on lipemia|Effect probiotic and symbiotic on blood pressure|Effect of probiotic and symbiotic on compoused gut microbiota|Effect of probiotic and symbiotic on stool consitency by Bristol scale|Effect of probiotic and symbiotic on gastrointestinal symptons,Universidade Federal do Rio de Janeiro|Rio de Janeiro State Research Supporting Foundation (FAPERJ),Female,25 Years to 45 Years   (Adult),Not Applicable,32,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CEP 104-14,Jul-15,Dec-16,30-Nov-19,22-Jul-15,null,7-May-19,"Louise Crovesy de Oliveira, Rio de Janeiro, Brazil",,https://ClinicalTrials.gov/show/NCT02505854
NCT02501200,CKD-391 Pharmacokinetic Study Phase I,,Completed,No Results Available,Healthy,Drug: CKD-391|Drug: Atrovastatin and Ezetimibe combination therapy,AUClast|Cmax|Tmax|T1/2|AUCinf|Adverse events,Chong Kun Dang Pharmaceutical,Male,19 Years to 45 Years   (Adult),Phase 1,46,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,152BE15026,Aug-15,Dec-15,Dec-15,17-Jul-15,null,26-Dec-16,,,https://ClinicalTrials.gov/show/NCT02501200
NCT02499185,Study Evaluating Novel Biomarkers of AKI (Acute Kidney Injury) in Post-operative Patients,,Terminated,No Results Available,Acute Kidney Injury|Arterial Hypertension|Obesity|Cardio Vascular Disease|Diabetes Mellitus|Chronic Liver Disease|Hypercholesterolemia,Device: Nephro Check Test|Other: serum creatinine measurement,"Number of participants diagnosed with AKI stage 2 or 3 using the updated rifle ""KDIGO"" guidelines|Number of participants who need renal replacement therapy",Universitair Ziekenhuis Brussel,All,"18 Years and older   (Adult, Older Adult)",Phase 4,100,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,NOVELBIO,1-Apr-15,31-Jul-17,31-Aug-17,16-Jul-15,null,15-Oct-18,"Universitair Ziekenhuis Brussel, Jette, Brussels, Belgium",,https://ClinicalTrials.gov/show/NCT02499185
NCT02500147,Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS),,Recruiting,No Results Available,Polycystic Ovary Syndrome|Non-Alcoholic Fatty Liver Disease|Metabolic Syndrome,Drug: Metformin|Drug: Placebo,"Difference in percentage liver fat between Metformin arm and Placebo arm in adolescents and young adults with PCOS and with elevated percentage liver fat (>/=4.8%)|Proportion of PCOS subjects with the PNPLA3 allele comparing those with elevated percentage liver fat (>/=4.8%) and those with normal percentage liver fat (<4.8%) by magnetic resonance spectroscopy|The association of percentage liver fat by magnetic resonance spectroscopy with insulin resistance as measured by HOMA-IR in adolescents with PCOS|The association of percentage liver fat with triglycerides|The association of percentage liver fat with visceral adipose tissue|The association of percentage liver fat with total body adipose tissue|The association of percentage liver fat with pancreatic polypeptide|The association of percentage liver fat with M30, a hepatic apoptosis marker",Columbia University,Female,"13 Years to 25 Years   (Child, Adult)",Phase 4,46,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",AAAF4452,Jul-13,Jun-19,Jun-20,16-Jul-15,null,4-Nov-16,"Columbia University Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02500147
NCT02497833,Retinoic Acid Supplementation and Subjects With Hypercholesterolemia,,Completed,No Results Available,Hypercholesterolemia,Dietary Supplement: retinoic acid|Other: placebo,PON1 activity|Lp-PLA2 activity,Sun Yat-sen University,All,"25 Years to 65 Years   (Adult, Older Adult)",Early Phase 1,130,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ZXYZM-2,Nov-14,May-15,May-15,15-Jul-15,null,15-Jul-15,"Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Department of Nutrition, School of Public Health, Sun Yat-Sen University (Northern Campus), Guangzhou, Guangdong, China",,https://ClinicalTrials.gov/show/NCT02497833
NCT02498990,Low Calorie Diet and Diabetes,LCD,Enrolling by invitation,No Results Available,Diabetes Mellitus Type 2|Dyslipidemia|Non-alcoholic Fatty Liver Disease|Obesity,Behavioral: Low calorie diet followed by life style intervention,"Change from Baseline in HbA1c (mmol/mol) at 12 and 24 months|Change from Baseline in BMI (kg/m2) at 7 weeks, 6,12, and 24 months|Change from Baseline in Liver Fat (Controlled Attenuation Parameter, db/m) at 7 weeks, 6, 12 and 24 months|Change from Baseline in Cholesterol (mmo/l) and Triglycerides (mmol/l) at 7 weeks, 6, 12 and 24 months|Change from Baseline in 2-hour Glucose (mmol/l) and Insulin (mU/l) by Glucose tolerance test at 7 weeks, 6, 12 and 24 months",Karolinska University Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2015/628-31,Aug-15,Feb-19,Aug-19,15-Jul-15,null,25-Aug-17,"Karolinska University Hospital, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT02498990
NCT02487225,Pentoxifylline Treatment in Acute Pancreatitis (AP),AP,Completed,Has Results,Acute Pancreatitis (AP)|Gallstone Pancreatitis|Alcoholic Pancreatitis|Trauma Acute Pancreatitis|Hypertriglyceridemia Acute Pancreatitis|Idiopathic (Unknown) Acute Pancreatitis|Medication Induced Acute Pancreatitis|Cancer Acute Pancreatitis|Miscellaneous (i.e. Acute on Chronic Pancreatitis),Drug: Pentoxifylline|Drug: Placebo,Change in C-reactive Protein (C-RP) From Admission Baseline at One Week.|Change in Tumor Necrosis Factor-alpha (TNF-a) Levels From Admission Baseline at One Week.|Change in Interleukin-6 (IL-6) Levels From Admission Baseline at One Week.|Change in Interleukin-8 (IL-8) Levels From Admission Baseline at One Week.,Mayo Clinic|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 3,83,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",15-001710|1R21DK101889-01A1,May-15,30-Apr-17,31-Oct-17,1-Jul-15,23-Jan-19,23-Jan-19,"Mayo Clinic in Rochester, Rochester, Minnesota, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT02487225/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02487225
NCT02484482,Study to Investigate the Effect of Food on the Pharmacokinetics/Pharmacodynamics and Safety of CKD-519(CKD-519 FDI),,Completed,No Results Available,Dyslipidemia,"Drug: CKD-519 200mg / Fasting, Standard Meal, High Fat Meal",Cmax of CKD-519|Area under the plasma drug concentration-time curve(AUC0-last) of CKD-519|AUC0-∞ of CKD-519|Tmax of CKD-519|T1/2 of CKD-519|CL/F(Clearance/Bioavailability) of CKD-519|Vd/F of CKD-519|Inhibition of CETP(Cholesteryl ester transfer protein) Activity,Chong Kun Dang Pharmaceutical,All,19 Years to 55 Years   (Adult),Phase 1,45,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,148FDI15009,Jun-15,Aug-15,Aug-15,29-Jun-15,null,7-Dec-15,"Severance Hospital, Seoul, Seodaemun-gu, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02484482
NCT02480816,Cardiometabolic Response to a Sodium-bicarbonated Mineral Water,,Completed,No Results Available,Dyslipidemia,Dietary Supplement: Mineral water,LDL-cholesterol|Total-cholesterol|Triglycerides|HDL-cholesterol|Apolipoprotein A|Apolipoprotein B|Glucose|Insulin|Urine creatinin|Urine calcium|Urine potassium|Urine sodium|Urine pH|Systolic Blood Pressure|Diastolic Blood Pressure|Oxidized LDL|Serum aldosterone|BMI|Dietary energy intake|Dietary protein intake|Dietary fat intake|Dietary cholesterol intake|Dietary carbohydrate intake,"National Research Council, Spain",All,18 Years to 45 Years   (Adult),Not Applicable,72,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,BW-13,1-May-15,1-Nov-15,1-Feb-16,25-Jun-15,null,25-Sep-18,,,https://ClinicalTrials.gov/show/NCT02480816
NCT02481466,The Combined Portfolio Diet and Exercise Study,PortfolioEx,Recruiting,No Results Available,Cardiovascular Diseases|Hypercholesterolemia|Type 2 Diabetes|Metabolic Syndrome,Behavioral: Portfolio diet and structured exercise|Behavioral: DASH-like diet and structured exercise|Behavioral: Portfolio diet and routine exercise|Behavioral: DASH-like diet and routine exercise,"Change from baseline of the maximum vessel wall volume of the carotid arteries by MRI at year 1 and 3|Coronary atheroma in the large vessels by MRI at year 1 and 3|Lipid rich necrotic core by MRI at year 1 and 3|intra plaque hemorrhage by MRI at year 1 and 3|Blood pressure and pulse rate|Treatment difference in initiation of statin therapy|Composite endpoint of Myocardial Infarction, Revascularization, Cardio Vascular hospitalization, Cardiovascular mortality and stroke|Atrial Fibrillation and heart failure","St. Michael's Hospital, Toronto|Canadian Institutes of Health Research (CIHR)|University of Toronto|Laval University|University of Manitoba|University of British Columbia",All,"21 Years and older   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",REB # 14-316|FRN 130278|FRN 129920,25-Nov-16,Dec-20,Dec-22,25-Jun-15,null,17-Sep-18,"Healthy Heart Lipid Clinic, St. Paul's Hospital, Vancouver, British Columbia, Canada|Richardson Centre for Functional Foods and Nutraceuticals, University of Manitoba, Winnipeg, Manitoba, Canada|Risk Factor Modification Centre, St. Michael's Hospital, Toronto, Ontario, Canada|Institute of Nutraceuticals and Functional Foods, Laval University, Quebec City, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02481466
NCT02480673,EFFECT OF Salvia Hispanica l. (CHIA) IN THE BIOCHEMICAL METABOLIC SYNDROME COMPONENTS,,Unknown status,No Results Available,Metabolic Syndrome X,Dietary Supplement: Chia|Dietary Supplement: Oatmeal|Behavioral: Normocaloric diet,Change in serum glucose levels|Variation in lipid profile|Modification in insulin resistance|Change in systolic blood pressure|Change in diastolic blood pressure|Variation in body weight|Modification in waist circumference,Instituto Mexicano del Seguro Social,All,18 Years to 50 Years   (Adult),Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,R-2015-785-047,Jun-15,Dec-15,May-16,24-Jun-15,null,26-Jun-15,"Instituto Mexicano Del Seguro Social Hospital de Especialidades, Centro Medico Nacional de Occidente Lic. Ignacio Garcia Tellez Unidad Medica de Alta Especialidad, Guadalajara, Jalisco, Mexico",,https://ClinicalTrials.gov/show/NCT02480673
NCT02478541,Understanding Liver Fat Metabolism: Studies to Understand the Role of Dietary Sugars on Liver Fat Metabolism,,Completed,No Results Available,Hypertriglyceridaemia,Other: Sugar study,Plasma Triglycerides|Plasma glucose,University of Oxford,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,16,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,Oxlip-2013_expt2,Mar-15,May-16,Jun-16,23-Jun-15,null,20-Jan-17,"Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford, United Kingdom",,https://ClinicalTrials.gov/show/NCT02478541
NCT02476006,"Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)",,Completed,No Results Available,Hypercholesterolemia,Drug: ALIROCUMAB SAR236553 (REGN727)|Drug: placebo (for injection training only),Proportion of patients with adverse events|Assessment of patient's acceptability of self-injection using Self Injection Assessment Questionnaire (SIAQ)|Percent change from baseline in calculated LDL-C levels|Percent change from baseline in total-C levels|Percent change from baseline in HDL-C levels|Percent change from baseline in TG levels,Sanofi|Regeneron Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 3,998,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LPS14245|2015-000620-28|U1111-1163-0984,23-Jun-15,12-Apr-19,12-Apr-19,19-Jun-15,null,19-Apr-19,"Investigational Site Number 040001, Graz, Austria|Investigational Site Number 040008, Innsbruck, Austria|Investigational Site Number 040005, Linz, Austria|Investigational Site Number 040006, Linz, Austria|Investigational Site Number 040003, Wien, Austria|Investigational Site Number 040002, Wien, Austria|Investigational Site Number 040004, Wien, Austria|Investigational Site Number 040007, Wien, Austria|Investigational Site Number 040010, Wien, Austria|Investigational Site Number 056005, Aalst, Belgium|Investigational Site Number 056018, Antwerpen, Belgium|Investigational Site Number 056008, Arlon, Belgium|Investigational Site Number 056013, Brugge, Belgium|Investigational Site Number 056010, Brussel, Belgium|Investigational Site Number 056003, Bruxelles, Belgium|Investigational Site Number 056006, Charleroi, Belgium|Investigational Site Number 056007, Edegem, Belgium|Investigational Site Number 056019, Genk, Belgium|Investigational Site Number 056001, Gent, Belgium|Investigational Site Number 056017, Gent, Belgium|Investigational Site Number 056002, Haine St Paul, Belgium|Investigational Site Number 056015, Kortrijk, Belgium|Investigational Site Number 056009, La Louvière, Belgium|Investigational Site Number 056004, Leuven, Belgium|Investigational Site Number 056014, Liège, Belgium|Investigational Site Number 056011, Overpelt, Belgium|Investigational Site Number 056016, Roeselare, Belgium|Investigational Site Number 124018, Calgary, Canada|Investigational Site Number 124015, Cambridge, Canada|Investigational Site Number 124002, Chicoutimi, Canada|Investigational Site Number 124027, Coquitlam, Canada|Investigational Site Number 124025, Edmonton, Canada|Investigational Site Number 124017, Halifax, Canada|Investigational Site Number 124013, Hamilton, Canada|Investigational Site Number 124008, London, Canada|Investigational Site Number 124026, Maple Ridge, Canada|Investigational Site Number 124020, Montreal, Canada|Investigational Site Number 124022, Montreal, Canada|Investigational Site Number 124032, Mount Pearl, Canada|Investigational Site Number 124005, Ottawa, Canada|Investigational Site Number 124024, Peterborough, Canada|Investigational Site Number 124003, Quebec, Canada|Investigational Site Number 124007, Sarnia, Canada|Investigational Site Number 124001, Sherbrooke, Canada|Investigational Site Number 124030, Smiths Falls, Canada|Investigational Site Number 124019, St-Charles Borromee, Canada|Investigational Site Number 124023, Toronto, Canada|Investigational Site Number 124014, Toronto, Canada|Investigational Site Number 124028, Trois-Rivieres, Canada|Investigational Site Number 124011, Vancouver, Canada|Investigational Site Number 124012, Victoria, Canada|Investigational Site Number 124031, Winnipeg, Canada|Investigational Site Number 124009, Woodstock, Canada|Investigational Site Number 203004, Brno, Czechia|Investigational Site Number 203002, Hradec Kralove, Czechia|Investigational Site Number 203001, Praha, Czechia|Investigational Site Number 203005, Uherske Hradiste, Czechia|Investigational Site Number 208001, Esbjerg, Denmark|Investigational Site Number 208002, Roskilde, Denmark|Investigational Site Number 208003, Ålborg, Denmark|Investigational Site Number 246003, Turku, Finland|Investigational Site Number 246001, Varkaus, Finland|Investigational Site Number 250027, Amiens Cedex 1, France|Investigational Site Number 250034, Auxerre, France|Investigational Site Number 250016, Avignon, France|Investigational Site Number 250021, Bayonne, France|Investigational Site Number 250030, Bobigny, France|Investigational Site Number 250045, BORDEAUX Cedex, France|Investigational Site Number 250049, Brest Cedex, France|Investigational Site Number 250054, Bron, France|Investigational Site Number 250015, Caen, France|Investigational Site Number 250047, Clermont Ferrand, France|Investigational Site Number 250013, Corbeil Essonnes, France|Investigational Site Number 250032, Coudray, France|Investigational Site Number 250002, Dijon, France|Investigational Site Number 250040, Dijon, France|Investigational Site Number 250038, GRENOBLE cedex, France|Investigational Site Number 250012, Grenoble, France|Investigational Site Number 250033, Jossigny, France|Investigational Site Number 250035, LE CHESNAY Cedex, France|Investigational Site Number 250036, Lens, France|Investigational Site Number 250042, Lille, France|Investigational Site Number 250004, Lille, France|Investigational Site Number 250037, Limoges Cedex, France|Investigational Site Number 250057, Lyon, France|Investigational Site Number 250048, Marseille Cedex 05, France|Investigational Site Number 250028, Marseille, France|Investigational Site Number 250024, Montpellier, France|Investigational Site Number 250006, Nantes cedex 01, France|Investigational Site Number 250022, Nantes, France|Investigational Site Number 250017, Nice cedex 1, France|Investigational Site Number 250039, NIMES Cedex 9, France|Investigational Site Number 250044, PARIS Cedex 04, France|Investigational Site Number 250001, Paris Cedex 10, France|Investigational Site Number 250014, Paris, France|Investigational Site Number 250041, Paris, France|Investigational Site Number 250026, Paris, France|Investigational Site Number 250051, Pessac, France|Investigational Site Number 250011, POITIERS Cedex, France|Investigational Site Number 250031, Poitiers, France|Investigational Site Number 250010, Reims Cedex, France|Investigational Site Number 250008, Rennes, France|Investigational Site Number 250018, Rouen, France|Investigational Site Number 250023, Saint-Mandé, France|Investigational Site Number 250046, Toulouse Cedex 3, France|Investigational Site Number 250025, TOULOUSE Cedex 9, France|Investigational Site Number 250007, Tours, France|Investigational Site Number 250019, Venissieux, France|Investigational Site Number 250050, VICHY Cedex, France|Investigational Site Number 276001, Berlin, Germany|Investigational Site Number 276003, Magdeburg, Germany|Investigational Site Number 300003, Ampelokipoi, Greece|Investigational Site Number 300002, Ioannina, Greece|Investigational Site Number 300001, Kallithea, Greece|Investigational Site Number 348001, Budapest, Hungary|Investigational Site Number 348002, Debrecen, Hungary|Investigational Site Number 348004, Pécs, Hungary|Investigational Site Number 348003, Szeged, Hungary|Investigational Site Number 616005, Gdansk, Poland|Investigational Site Number 616003, Krakow, Poland|Investigational Site Number 616001, Lodz, Poland|Investigational Site Number 616004, Olsztyn, Poland|Investigational Site Number 616002, Warszawa, Poland|Investigational Site Number 642-003, Bucuresti, Romania|Investigational Site Number 642-002, Iasi, Romania|Investigational Site Number 642-001, Timisoara, Romania|Investigational Site Number 703003, Bratislava, Slovakia|Investigational Site Number 703002, Bratislava, Slovakia|Investigational Site Number 703001, Kosice, Slovakia|Investigational Site Number 705001, Maribor, Slovenia|Investigational Site Number 724009, Alicante, Spain|Investigational Site Number 724011, Alicante, Spain|Investigational Site Number 724003, Córdoba, Spain|Investigational Site Number 724012, Donostia, Spain|Investigational Site Number 724014, Donostia, Spain|Investigational Site Number 724019, Elche, Spain|Investigational Site Number 724017, Galdakao, Spain|Investigational Site Number 724001, Hospitalet de Llobregat, Spain|Investigational Site Number 724020, Inca, Spain|Investigational Site Number 724007, Las Palmas de Gran Canaria, Spain|Investigational Site Number 724004, Madrid, Spain|Investigational Site Number 724008, Madrid, Spain|Investigational Site Number 724010, Madrid, Spain|Investigational Site Number 724005, Málaga, Spain|Investigational Site Number 724002, Santiago de Compostela, Spain|Investigational Site Number 724006, Valencia, Spain|Investigational Site Number 724016, Valencia, Spain|Investigational Site Number 724015, Valladolid, Spain|Investigational Site Number 756005, Baden, Switzerland|Investigational Site Number 756002, Olten, Switzerland|Investigational Site Number 756004, Reinach, Switzerland|Investigational Site Number 756003, St. Gallen, Switzerland|Investigational Site Number 756001, Zürich, Switzerland",,https://ClinicalTrials.gov/show/NCT02476006
NCT02475018,The Effect of Shuhua Milk Fortified With Plant Sterol Esters on Serum Cholesterol in Human,,Completed,No Results Available,Hypercholesterolemia,Dietary Supplement: Milk fortified with plant sterol esters|Dietary Supplement: Plain milk,Change in Total Cholesterol(TC) during and after intervention|Change in Triglyceride(TG) during and after intervention|Change in LDL-C level during and after intervention|Change in HDL-C level during and after intervention,"Inner Mongolia Yili Industrial Group Co., Ltd",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,179,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",YL/CL-004,Jul-14,Dec-14,Jan-15,18-Jun-15,null,18-Jun-15,"BaiZhiFang Community Health Service Centre, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT02475018
NCT02472535,Study to Evaluate the Effects of MBX-8025 in Patients With HoFH,,Completed,No Results Available,Homozygous Familial Hypercholesterolemia,"Other: Run-In Period: Placebo|Drug: MBX-8025 50 mg (Dose Escalation Period 1)|Drug: MBX-8025 50 mg or 100 mg (Dose Escalation Period 2)|Drug: MBX-8025 50 mg, 100 mg or 200 mg (Dose Escalation Period 3)",LDL-C|Total Cholesterol (TC)|High-density lipoprotein (HDL) cholesterol [HDL-C]|Very Low-Density Lipoprotein (VLDL)|Non HDL-C|Remnant-like Particle (RLP-C)|Apolipoprotein B (Apo B)|Apolipoprotein A-I (Apo A-I)|Lipoprotein|Serum Triglyceride (TG)|Apolipoprotein C-III (Apo CIII),"CymaBay Therapeutics, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,13,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CB8025-21427,Apr-15,Feb-16,Feb-16,16-Jun-15,null,9-Mar-16,"Ecogene-21, Chicoutimi, Quebec, Canada|Montreal Heart Institute, Montreal, Quebec, Canada|Endocrinologie metabolisme et prevention cardiovasulaire, Institut E3M et IHU cardiometabolique (ICAN), Hôpital Pitié Salpêtrière, Paris, France|Radbound UMC, Nijmegen, Netherlands|Lipidklinikken, Oslo Universitetssykehus, Oslo, Norway",,https://ClinicalTrials.gov/show/NCT02472535
NCT02462655,Effects of LDL Apheresis System on the Expression of Genes Involved in Lipoprotein Metabolism and Inflammation in Homozygotes for Familial Hypercholesterolemia,LA-PBMC,Completed,No Results Available,Familial Hypercholesterolemia,Other: Pre-lipid apheresis|Other: Post-lipid apheresis,Change in mRNA expression of genes involved in cardiovascular disease using microarrays analysis.|Change in serum levels of C-reactive protein,Laval University,All,18 Years to 60 Years   (Adult),Not Applicable,9,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LA-PBMC,Oct-15,Dec-15,Feb-16,4-Jun-15,null,8-Mar-16,"Institute of Nutrition and Functional Foods (INAF), Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02462655
NCT02463071,AZD0585 Phase III Long-term Study in Japan,,Completed,Has Results,Hypertriglyceridemia,Drug: AZD0585|Drug: AZD0585 placebo,"Efficacy of AZD0585 by Assessment of Percent Change in Serum Triglycerides|Safety of AZD0585 by Assessment of Adverse Events in Patients|Efficacy of AZD0585 by Assessment of Percent Change in Serum Lipid Profile|Efficacy of AZD0585 by Assessment of Percent Changes in Plasma Fatty Acids Profile.|Efficacy of AZD0585 by Assessment of Percent Changes in Apolipoproteins Profile|Efficacy of AZD0585 by Assessment of Percent Changes in Small Dense LDL and LDL-C/Apo B Ratio|Efficacy of AZD0585 by Assessment of Percent Changes in Lp(a), RLP-C, PCSK9, and Hs-CRP",AstraZeneca,All,"20 Years to 130 Years   (Adult, Older Adult)",Phase 3,383,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",D5884C00002,10-Jun-15,11-Mar-17,11-Mar-17,4-Jun-15,1-Oct-18,1-Oct-18,"Research Site, Aki-gun, Japan|Research Site, Chiba-shi, Japan|Research Site, Chofu-shi, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Fukuyama-shi, Japan|Research Site, Funabashi-shi, Japan|Research Site, Gifu-shi, Japan|Research Site, Itami-shi, Japan|Research Site, Kanazawa-shi, Japan|Research Site, Kawasaki-shi, Japan|Research Site, Koga-shi, Japan|Research Site, Komatsu-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Naha-shi, Japan|Research Site, Niigata-shi, Japan|Research Site, Ota-ku, Japan|Research Site, Sendai-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Shinagawa-ku, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Takamatsu-shi, Japan|Research Site, Takamatsu-shi, Japan|Research Site, Toyonaka-shi, Japan|Research Site, Urasoe-shi, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT02463071/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT02463071/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02463071
NCT02461004,CKD-391 Pharmacokinetic Study,,Completed,No Results Available,Healthy,Drug: CKD-391|Drug: Atrovastatin and Ezetimibe combination therapy,AUClast|Cmax|Tmax|T1/2|AUCinf|Adverse events,Chong Kun Dang Pharmaceutical,Male,19 Years to 45 Years   (Adult),Phase 1,52,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,152BE15016,Jul-15,Oct-15,Oct-15,3-Jun-15,null,17-Oct-16,"The Korea University Anam Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02461004
NCT02459249,Metabolic Syndrome Diagnosis and Treatment for Adults of Low Socioeconomic Status Communities,PrEVEnTYCM,Unknown status,No Results Available,Obesity|High Blood Pressure|Hyperglycemia|Dyslipidemia,Other: Healthy Lifestyle|Other: Placebo Comparator (Treatment of Mexican Health Minister),Number of Participants with Metabolic Syndrome|Changes in body weight,Mexican National Institute of Public Health,All,20 Years to 55 Years   (Adult),Not Applicable,120,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,1206-6941 CI:1198,Apr-15,Jun-16,Jul-16,2-Jun-15,null,25-Feb-16,"National Institute of Public Health, Cuernavaca, Morelos, Mexico",,https://ClinicalTrials.gov/show/NCT02459249
NCT02459314,Comparison of the Efficacy of Plant Sterol-Enriched Soymilk Versus Plain Soymilk in Volunteers With High LDL-Cholesterol,sterols,Completed,No Results Available,Hypercholesterolemia,Dietary Supplement: plant sterol and soluble fiber-enriched soymilk|Dietary Supplement: soymilk,"the change of serum LDL-C levels between 8-week ingestion of plant sterol and soluble fiber-enriched soymilk (SFSM) versus plain soymilk (SM).|changes in other lipid profiles (total cholesterol, HDL-C and triglyceride)|scale of study product satisfaction|evaluate any adverse events",Chiang Mai University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,242,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Dutchmill 002,Apr-13,Nov-13,Apr-14,2-Jun-15,null,2-Jun-15,"Clinical trial Unit, Faculty of Medicine, Chiang Mai University, Muang, ChiangMai, Thailand",,https://ClinicalTrials.gov/show/NCT02459314
NCT02459496,Diabetes Nutrition Algorithms in Patients With Overt Diabetes Mellitus,DiNA-D,Recruiting,No Results Available,Type 2 Diabetes|NAFLD|Obesity|Dyslipoproteinaemia|Hypertension,Behavioral: dietary consulting and advise,"change in insulin secretion (glucagon stimulation test)|change in hepatic fat content (MR-S)|change in insulin secretion in the mixed-meal tolerance test (MMTT) - combined parameter|change in insulin sensitivity in the mixed-meal tolerance test (MMTT) - combined parameter|change in blood glucose profile in the mixed-meal tolerance test (MMTT) - combined parameter|inflammatory reaction in subcutaneous adipose tissue (SCAT analysis on protein and RNA level - IL-1; IL1beta, IL-6)|change in parameters of peripheral - vibration threshold, thermal sensitivity and pain thresholds|change in parameters of autonomic neuropathy - measures of cardio-autonomic neuropathy (SANN, MSDD)",German Institute of Human Nutrition|German Center for Diabetes Research|California Walnut Company|Institute for Cereal Processing GmbH/Institut für Getreideverarbeitung (IGV),All,"18 Years to 79 Years   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DiNA-D,Sep-13,Dec-18,Dec-20,2-Jun-15,null,22-Nov-16,"German Institut for Human Nutrition; Department for Clinical Nutrition, Nuthetal, Brandenburg, Germany|German Institute for Human Nutrition, Department for Clinical Nutrition, Berlin, Germany",,https://ClinicalTrials.gov/show/NCT02459496
NCT02460159,A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384),,Completed,Has Results,Hypercholesterolemia|Heterozygous Familial Hypercholesterolemia,Drug: EZ 10 mg/Atorva 20 mg FDC|Drug: EZ 10 mg/Atorva 10 mg FDC,Percentage of Participants Who Experience 1 or More Adverse Event (AE)|Percentage of Participants Who Experience 1 or More Gastrointestinal-related AEs|Percentage of Participants Who Experience 1 or More Gallbladder-related AEs|Percentage of Participants Who Experience 1 or More Allergic Reaction or Rash AEs|Percentage of Participants Who Experience 1 or More Hepatitis-related AEs|Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) ≥3 Times Upper Normal Limit (ULN)|Percentage of Participants Who Experience Elevations in ALT or AST ≥5 Times ULN|Percentage of Participants Who Experience Elevations in ALT or AST ≥10 Times ULN|Percentage of Participants With Potential Hy's Law Condition|Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN|Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN With Muscle Symptoms|Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN and Drug-Related Muscle Symptoms,Merck Sharp & Dohme Corp.,All,"20 Years to 80 Years   (Adult, Older Adult)",Phase 3,135,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0653C-384|152982,23-Jun-15,22-Dec-16,22-Dec-16,2-Jun-15,11-Jan-18,17-Aug-18,,,https://ClinicalTrials.gov/show/NCT02460159
NCT02458287,"Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia",SPIRE-AI,Completed,Has Results,Hyperlipidemia,Biological: Bococizumab 150mg|Biological: Bococizumab 75mg|Biological: Bococizumab 150mg placebo|Biological: Bococizumab 75mg placebo,"Percent Change From Baseline at Week 12 in Fasting Low Density Lipoprotein Cholesterol (LDL-C) Level for Bococizumab 150 mg Dose Group and Matched Placebo|Percentage of Injections That Met the Definition for Successful Assessment Using the Participant Assessment Tool (PAT) for Bococizumab 150 mg Dose Group at Week 0 (Day 1)|Percentage of Injections That Met the Definition for Successful Assessment Using the Participant Assessment Tool (PAT) for Bococizumab 150 mg Dose Group at Week 2|Percentage of Injections That Met the Definition for Successful Assessment Using the Participant Assessment Tool (PAT) for Bococizumab 150 mg Dose Group at Week 4|Percentage of Injections That Met the Definition for Successful Assessment Using the Participant Assessment Tool (PAT) for Bococizumab 150 mg Dose Group at Week 6|Percentage of Injections That Met the Definition for Successful Assessment Using the Participant Assessment Tool (PAT) for Bococizumab 150 mg Dose Group at Week 8|Percentage of Injections That Met the Definition for Successful Assessment Using the Participant Assessment Tool (PAT) for Bococizumab 150 mg Dose Group at Week 10|Percentage of Injections That Met the Definition for Successful Assessment Using the Participant Assessment Tool (PAT) for Bococizumab 75 mg Dose Group and Combined Bococizumab 150 mg and 75 mg Dose Group at Week 0 (Day 1), 2, 4, 6, 8 and 10|Percentage of Injections That Met the Definition for Successful Assessment Using the Observer Assessment Tool (OAT) for Bococizumab 150 mg Dose, Bococizumab 75 mg Dose Group and Combined Bococizumab 150 mg and 75 mg Dose Group at Week 0 (Day 1), 4 and 8|Percent Change From Baseline at Week 12 in Fasting Low Density Lipoprotein Cholesterol (LDL-C) Level for Bococizumab 75 mg Dose Group and Matched Placebo|Percent Change From Baseline in Fasting Total Cholesterol (TC) at Week 12|Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 12|Percent Change From Baseline in Fasting Non- High Density Lipoprotein Cholesterol (Non HDL-C) at Week 12|Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Percentage of Participants With Anti-Drug Antibodies (ADA) and Neutralizing Antibodies (nAb)|Plasma Concentration of Bococizumab at Week 12|Plasma Concentration of Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) at Week 12",Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,299,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",B1481046|SPIRE-AI,Jun-15,Feb-16,Feb-16,1-Jun-15,19-Dec-17,19-Dec-17,"Radiant Research Incorporated, Chandler, Arizona, United States|Clinical Trial Research, Lincoln, California, United States|National Research Institute, Los Angeles, California, United States|California Medical Research Associates Inc., Northridge, California, United States|Northern California Research, Sacramento, California, United States|Diablo Clinical Research, Inc., Walnut Creek, California, United States|ACRC - Cardiology, Atlantis, Florida, United States|Clinical Research of South Florida, Coral Gables, Florida, United States|Invesclinic, LLC, Fort Lauderdale, Florida, United States|Clinical Research of Miami, Inc., Miami, Florida, United States|Prestige Clinical Research Center, Inc., Miami, Florida, United States|A & R Research Group LLC, Pembroke Pines, Florida, United States|Clinical Research Atlanta, Stockbridge, Georgia, United States|North Georgia Clinical Research, Woodstock, Georgia, United States|North Georgia Internal Medicine, Woodstock, Georgia, United States|Solaris Clinical Research, Meridian, Idaho, United States|Evanston Premier Healthcare Research,LLC, Evanston, Illinois, United States|Midwest Institute For Clinical Research, Indianapolis, Indiana, United States|Buynak Clinical Research, P.C., Valparaiso, Indiana, United States|L-MARC Research Center, Louisville, Kentucky, United States|Omega Clinical Research Center, Metairie, Louisiana, United States|PharmQuest, Greensboro, North Carolina, United States|Sterling Research Group, Ltd., Cincinnati, Ohio, United States|PMG Research Of Charleston, Mount Pleasant, South Carolina, United States|Palmetto Clinical Research, Summerville, South Carolina, United States|Texas Center for Drug Development, Inc., Houston, Texas, United States|Heart Care Associates, P.C., Hopewell, Virginia, United States|Manassas Clinical Research Center, Manassas, Virginia, United States|National Clinical Research-Richmond, Inc., Richmond, Virginia, United States|Rainier Clinical Research Center, Inc., Renton, Washington, United States",,https://ClinicalTrials.gov/show/NCT02458287
NCT02458586,Ernährungs-Interventions-Fettleber-Studie (Interventional Study on Nutritional Effects on NAFLD),UFOP-2,Unknown status,No Results Available,NAFLD|Obesity|Prediabetes|Dyslipoproteinemia,Dietary Supplement: Dietary intervention / counseling,change in liver fat content|change in hepatic insulin sensitivity,German Institute of Human Nutrition|ufop: Union zur Förderung von Oel- und Proteinpflanzen e.V.,Male,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Investigator)|Primary Purpose: Treatment",UFOP-2,May-15,May-17,Nov-17,1-Jun-15,null,22-Nov-16,"German Institut for Human Nutrition; Department for Clinical Nutrition, Nuthetal, Brandenburg, Germany",,https://ClinicalTrials.gov/show/NCT02458586
NCT02455336,Fenofibrate Treatment in SCI,,Completed,No Results Available,Spinal Cord Injury|Dyslipidemia,Drug: Fenofibrate|Other: No intervention,Triglyceride concentration (mg/dl),VA Office of Research and Development,All,"21 Years to 69 Years   (Adult, Older Adult)",Phase 2|Phase 3,24,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,B1925-P,18-May-15,1-Aug-18,1-Aug-18,27-May-15,null,21-Sep-18,"Kessler Institute for Rehabilitation, West Orange, New Jersey, United States|James J. Peters VA Medical Center, Bronx, NY, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT02455336
NCT02451098,Clinical Trial to Evaluate the Efficacy and Safety of CKD-391,,Completed,No Results Available,Hyperlipidemia,"Drug: Atorvastatin10mg, Ezetimibe10mg|Drug: Atorvastatin10mg, Ezetimibe placebo|Drug: Atorvastatin20mg, Ezetimibe10mg|Drug: Atorvastatin20mg, Ezetimibe placebo|Drug: Atorvastatin40mg, Ezetimibe10mg|Drug: Atorvastatin40mg, Ezetimibe placebo",Change form baseline in LDL-C|Change form baseline in Total cholesterol|Change form baseline in Triglyceride|Change form baseline in HDL-C|Change form baseline in Non-HDL-C|Change form baseline in LDL-C/HDL-C ratio|Change form baseline in TC/HDL-C ratio|Change form baseline in Non-HDL-C/HDL-C ratio|Change form baseline in Apo-B ratio|Change form baseline in Apo-B|Change form baseline in Apo-A1|Change form baseline in Apo-B/Apo-A1 ratio,Chong Kun Dang Pharmaceutical,All,"19 Years and older   (Adult, Older Adult)",Phase 3,385,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",152PDL14025,Mar-15,Oct-15,Jan-16,21-May-15,null,28-Jan-16,"The catholic university of korea seoul st. Mary's hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02451098
NCT02449187,Investigate the Effect of Food on the Pharmacokinetics of JLP-1310 in Healthy Male Volunteers,,Completed,No Results Available,Diabetes|Hyperlipidemia,"Drug: JLP-1310, Fasted followed by fed|Drug: JLP-1310, Fed followed by fasted",Cmax|AUC(last)|AUC(inf)|Tmax|T1/2|CL/F|Vd/F,"Jeil Pharmaceutical Co., Ltd.",Male,"19 Years and older   (Adult, Older Adult)",Phase 1,16,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,JLP-1310-102-FE,2-Aug-17,15-Sep-17,9-Mar-18,20-May-15,null,29-Mar-18,"Inha University Hospital, Incheon, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02449187
NCT02445352,Efficacy/Safety of DP-R207 Tablet Versus CRESTOR Tablet in Patients With Primary Hypercholesterolemia,ROSE,Completed,No Results Available,Primary Hypercholesterolemia,Drug: Rosuvastatin 5mg|Drug: DP-R207 5/10mg|Drug: Rosuvastatin 10mg|Drug: DP-R207 10/10mg|Drug: Rosuvastatin 20mg|Drug: DP-R207 20/10mg|Drug: Placebo (for Rosuvastatin 5mg and DP-R207 5/10mg)|Drug: Placebo (for Rosuvastatin 10mg and DP-R207 10/10mg)|Drug: Placebo (for Rosuvastatin 20mg and DP-R207 20/10mg),Percent change from baseline to 8 weeks in LDL-Cholesterol|Percent change from baseline to 4 weeks in LDL-Cholesterol|Percent change from baseline to 4 weeks in lipid related blood test results|Percent change from baseline to 8 weeks in lipid related blood test results|Percentage of patients reaching treatment goals according to NCEP ATP III Guideline,Alvogen Korea,All,"19 Years and older   (Adult, Older Adult)",Phase 3,379,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DP-CTR207-III-02,Jul-14,Jan-15,Mar-15,15-May-15,null,15-May-15,"Severance Hospital, Seodaemun-gu, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02445352
NCT02442700,Effects of Pitavastatin on Lipid Profiles in HIV-infected Patients With Dyslipidemia and Receiving Atazanavir/Ritonavir,,Completed,Has Results,HIV|Dyslipidemia,Drug: pitavastatin|Drug: placebo,Efficacy of Pitavastatin in HIV-infected Patients With Dyslipidemia and Receiving Atazanavir/Ritonavir|Safety of Pitavastatin in HIV-infected Patients,Ramathibodi Hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 4,24,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Ramathibodi Hospital 01-57-18,May-14,Jan-15,Jan-15,13-May-15,10-Oct-16,10-Oct-16,,,https://ClinicalTrials.gov/show/NCT02442700
NCT02438943,An Intervention to Improve Management of Dyslipidemia in Primary Care,,Unknown status,No Results Available,Cardiovascular Disease|Dyslipidemia|Diabetes Melletus|Obesity,Other: Audit|Other: Physician Intervention,Proportion of persons attending health centers in the Southeast Health region with normal lipid values|Proportion of persons attending health centers in the Southeast Health region with normal glucose values|Proportion of persons attending health centers in the Southeast Health region with normal blood pressure values,The University of The West Indies,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,500,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research,"ECP218,11/12",Feb-14,Dec-16,Dec-16,8-May-15,null,8-May-15,"University of the West Indies, mona, Kingston, Jamaica",,https://ClinicalTrials.gov/show/NCT02438943
NCT02437084,"Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling",,Recruiting,No Results Available,Hyperlipidemia,Drug: Atorvastatin,"Change from baseline in glucose tolerance in two groups, those with elevated LDL-C (mg/dL) versus those with elevated LDL-C (mg/dL) and elevated triglycerides (mg/dL).|Change from baseline in insulin sensitivity in two groups, those with elevated LDL-C (mg/dL) versus those with elevated LDL-C (mg/dL) and elevated triglycerides (mg/dL).|Change from Baseline in insulin secretion in two groups, those with elevated LDL-C (mg/dL) versus those with elevated LDL-C (mg/dL) and elevated triglycerides (mg/dL).",Stanford University,All,"30 Years to 65 Years   (Adult, Older Adult)",Phase 4,20,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,STANFORD,May-15,Feb-19,Dec-19,7-May-15,null,10-Sep-18,"Stanford University School of Medicine, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT02437084
NCT02434497,A Study to Evaluate the Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia,,Completed,Has Results,Homozygous Familial Hypercholesterolemia (HoFH),Drug: Rosuvastatin 20mg,"The Number of Participants Who Experianced Adverse Events and Serious Adverse Events|Safety and Tolerability in Terms of Number of Participants Who Had Adverse Events, Discontinuations Due to Adverse Events|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Basophils/Leukocytes (%) >Upper Limite of Normal (ULN)|Safety and Tolerability in Terms of Growth, Height|Safety and Tolerability in Terms of Abnormalitites in Sexual Maturation|Safety and Tolerability in Terms of Growth, Height SD-score (or Z-score)|Safety and Tolerability in Terms of Growth, Weight|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Alanine Aminotransferase (U/L) >ULN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Albumin (g/dL) >ULN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Aspartate Aminotransferase (U/L) >ULN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Bicarbonate (Mol/L) <LLN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Bicarbonate (Mol/L) >ULN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Ery. Mean Corpuscular HGB Concentration (g/dL) <LLN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Ery. Mean Corpuscular HGB (pg) <LLN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Ery. Mean Corpuscular Volume (fL) <LLN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Ery. Mean Corpuscular Volume (fL) >ULN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Erythrocytes (10^12/L) <LLN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Erythrocytes (10^12/L) >ULN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Hematocrit (%) <LLN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Hemoglobin (g/dL) <LLN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Leukocytes >ULN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Lymphocytes/Leukocytes (%) <LLN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Lymphocytes/Leukocytes (%) >ULN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Monocytes/Leukocytes (%) >ULN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Platelets (10^9/L) >ULN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Blood Urea Nitrogen (mg/dL) <LLN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Chloride (mmol/L) >ULN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Creatine Kinase (U/L) >ULN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Glucose (mg/dL) >ULN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Lactate Dehydrogenase (U/L) <LLN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Phosphate (mg/dL) >ULN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Protein (g/dL) >ULN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Sodium (mmol/L) <LLN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Urate (mg/dL) >ULN|Safety and Tolerability in Terms of Abnormal Urine Laboratory Values, Urine Ketones|Safety and Tolerability in Terms of Abnormal Urine Laboratory Values, Urine Occult Blood|Safety and Tolerability in Terms of Abnormal Urine Laboratory Values, Urine Protein|Safety and Tolerability in Terms of Abnormal ECG, Abnormalities|Safety and Tolerability in Terms of Abnormal Physical Exams, Cardiovascular|Safety and Tolerability in Terms of Abnormal Physical Exams, General Appearance|Safety and Tolerability in Terms of Abnormal Physical Exams, Head and Neck|Safety and Tolerability in Terms of Abnormal Physical Exams, Musculoskeletal/Extremities|Safety and Tolerability in Terms of Abnormal Physical Exams, Skin|Safety and Tolerability in Terms of Abnormal Vital Signs|Percent Change in LDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis|Percent Change in HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis|Percent Change in Total Cholesterol (TC) From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis|Percent Change in Triglycerides (TG) From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis|Percent Change in Non-HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis|Percent Change in LDL-C/HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis|Percent Change in TC/HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis|Percent Change in Non-HDL-C/HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis|Percent Change in ApoB From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis|Percent Change in ApoA-1 From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis|Percent Change in ApoB/ApoA-1 From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis|Pharmacokinetic Profile in Terms of Trough Concentrations in Pediatric HoFH Taking a Daily Dose of Rosuvastatin 40mg",AstraZeneca,All,"6 Years to 18 Years   (Child, Adult)",Phase 3,9,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D356NC00001,6-Jun-15,17-Nov-16,17-Nov-16,5-May-15,27-Feb-18,27-Feb-18,"Research Site, Brussels (Woluwé-St-Lambert), Belgium|Research Site, Chicoutimi, Quebec, Canada|Research Site, Copenhagen, Denmark|Research Site, Halfa, Israel|Research Site, Kubang Kerian, Malaysia|Research Site, Taipei City, Taiwan",,https://ClinicalTrials.gov/show/NCT02434497
NCT02433288,Rosuvastatin Adherence App Study in China,eHELP China,Completed,Has Results,Dyslipidemia|Hyperlipidemia,Other: Smart phone based patient support tool|Other: Control application: only for data collection,Duration of Treatment|Percentage of Fully Adherent Patients|Treatment Adherence|Percent Change in Low-Density Lipoprotein-Cholesterol (LDL-C) From Baseline,AstraZeneca,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,885,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,D3560C00088,20-Jul-15,28-Oct-16,28-Oct-16,4-May-15,31-Jan-19,31-Jan-19,"Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Changsha, China|Research Site, Chengdu, China|Research Site, Chongqing, China|Research Site, Hang Zhou, China|Research Site, Huzhou, China|Research Site, Nanchang, China|Research Site, Shandong, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Tianjin, China|Research Site, Tianjin, China|Research Site, Tianjin, China|Research Site, Waifang, China|Research Site, Wenzhou, China|Research Site, Wuhan, China",,https://ClinicalTrials.gov/show/NCT02433288
NCT02431013,Cilostazol-Simvastatin Drug Interaction Study,,Unknown status,No Results Available,Dyslipidemias|Peripheral Artery Disease,Drug: Simvastatin|Drug: Pravastatin|Drug: Cilostazol,AUC (area under the time-concentration curve) of Simvastatin|Cmax (maximum plasma concentration) of Simvastatin|Cmax (maximum plasma concentration) of Pravastatin|AUC (area under the time-concentration curve) of Pravastatin,Ajou University School of Medicine,Male,20 Years to 45 Years   (Adult),Phase 1,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DDI-103,Apr-15,Aug-15,null,30-Apr-15,null,1-May-15,"Ajou University Medical Center, Suwon, Gyeonggi, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02431013
NCT02428998,Safety for 24 Weeks Intake of Korean Red Ginseng in Adults,,Completed,No Results Available,Healthy|Diabetes|Hypertension|Hyperlipidemia,Dietary Supplement: Korean Red Ginseng|Dietary Supplement: Placebo,All adverse events occurring up to 24 weeks time after taking the Investigational product|Adverse events that occurred up to 24 weeks to collect all focus point after taking the Investigational product|Cardiovascular adverse events that occurred after taking the Investigational product|Gastrointestinal adverse events that occurred after ingestion of Investigational product|Neuropsychiatric adverse events that occurred after ingestion of Investigational product|Grade 3 adverse events that occurred after ingestion of Investigational product|Baseline by 24 weeks after the change in quality of life measures ingestion of Investigational product,Korea Ginseng Corporation,All,"19 Years and older   (Adult, Older Adult)",Not Applicable,1000,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",KGC-S-01,Sep-14,Aug-16,Apr-17,29-Apr-15,null,11-Aug-17,"Catholic Universtiy of Korea. Seoul St Mary's Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02428998
NCT02422927,Nutraceutical Combination in Patients With Low-grade Systemic Inflammation,,Completed,No Results Available,Atherosclerosis|Inflammation|Hypercholesterolemia,Dietary Supplement: Nutraceutical Combination|Other: Standard of Care|Other: Placebo,Change from Baseline in LDL cholesterol at 3 months|Change from Baseline in Circulating endothelial microparticles at 3 months|Change from Baseline in C-reactive protein at 3 months,University Of Perugia,All,"25 Years to 75 Years   (Adult, Older Adult)",Phase 4,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,UPerugia01,Jul-14,Jan-15,Feb-15,22-Apr-15,null,22-Apr-15,,,https://ClinicalTrials.gov/show/NCT02422927
NCT02418637,Pilot Study Testing Feasibility of Health Screening at Farm Site,,Completed,No Results Available,Diabetes Screening|Hyperlipidemia Screening|Hypertension Screening,"Other: Worksite screening for DM, HTN and hyperlipidemia",Feasibility (Likert scale),Mayo Clinic,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,15-000647,Apr-15,Sep-16,Sep-16,16-Apr-15,null,9-Nov-16,"Mayo Clinic in Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02418637
NCT02418715,Effects of Water-Based Exercise on Lipid Profile and Lipoprotein Lipase of Dyslipidemic Premenopausal Women,,Completed,No Results Available,Dyslipidemia,Other: Water Aerobics Training,"Lipid Profile Levels (total cholesterol, LDL, HDL, triglycerides)|Lipoprotein Lipase Levels",Hospital de Clinicas de Porto Alegre,Female,40 Years to 50 Years   (Adult),Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,Water-Based Exercise Trial,Feb-11,Jun-11,Jun-11,16-Apr-15,null,16-Apr-15,,,https://ClinicalTrials.gov/show/NCT02418715
NCT02409537,Effects of Dietary Antioxidants to Prevent Cardiovascular Disease,RWTAC,Completed,No Results Available,Hypercholesterolemia|Healthy,Dietary Supplement: red wine|Dietary Supplement: resveratrol|Other: placebo,Total antioxidant activity (TAC)|Vitamin E|Total Cholesterol|LDL/HDL|Vitamin E/ Total Cholesterol,"Aeromedical Center, Thessaloniki",All,"20 Years to 70 Years   (Adult, Older Adult)",Phase 2,37,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,11,Mar-13,Mar-14,Mar-15,7-Apr-15,null,7-Apr-15,,,https://ClinicalTrials.gov/show/NCT02409537
NCT02407548,The Effects of Dietary Supplement of Coenzyme Q10（CoQ10） on Dyslipidemia,TEDSCD,Completed,No Results Available,Dyslipidemia,Dietary Supplement: coenzyme Q10 vitamin E softgel|Dietary Supplement: coenzyme Q10 softgel|Dietary Supplement: placebo softgel,Effects of CoQ10 on lipid profile|Effects of CoQ10 on blood glucose and insulin|Effects of CoQ10 on oxidative stress and inflammation,Sun Yat-sen University,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,150,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SunYat-senU002,Jul-15,Apr-17,Apr-17,3-Apr-15,null,22-Jun-17,"Hongshan Street community health service centre, Guangzhou, Guangdong, China",,https://ClinicalTrials.gov/show/NCT02407548
NCT02408055,ADME Study in Healthy Male Subjects With TA-8995,,Completed,No Results Available,Dyslipidemia,Drug: TA-8995,"AUC of TA-8995|Mass balance recovery of total radioactivity from excreta for radiolabelled TA-8995|Measure the amount of radiolabelled TA-8995 recovered from urine and faeces.|Measure the levels of major metabolites of TA-8995 in plasma, urine and faeces after oral administration of radiolabelled TA-8995|Elimination of half-life of radiolabelled TA-8995|Number of adverse events",Xention Ltd,Male,"30 Years to 65 Years   (Adult, Older Adult)",Phase 1,6,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TA-8995-07,Jun-15,Aug-15,Aug-15,3-Apr-15,null,3-Oct-16,"Covance Clinical Research Unit Ltd, Leeds, United Kingdom",,https://ClinicalTrials.gov/show/NCT02408055
NCT02400775,A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia.,ALIVE,Withdrawn,No Results Available,Essential Hypertension With Stable Angina and Dyslipidemia,Drug: Azilsartan,Change in percentage of the lipid pool in the coronary artery plaque|Change in volume of the coronary artery plaque|Change in percentage of the fibrotic component in the coronary artery plaque|Change in percentage of the calcified component in the coronary artery plaque|Change in number of microchannels|Change in thickness of the fibrous cap,Takeda,All,"20 Years and older   (Adult, Older Adult)",Phase 4,0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Azilsartan-4001|U1111-1167-9135|JapicCTI-152834,Mar-15,Apr-16,Apr-16,27-Mar-15,null,24-May-16,"Tokushima, Japan",,https://ClinicalTrials.gov/show/NCT02400775
NCT02392559,"Trial Assessing Efficacy, Safety and Tolerability of PCSK9 Inhibition in Paediatric Subjects With Genetic LDL Disorders",HAUSER-RCT,Recruiting,No Results Available,Heterozygous Familial Hypercholesterolemia,Drug: Evolocumab|Drug: Placebo,Percentage change from baseline in low density lipoprotein-cholesterol levels|Change from baseline in LDL-C levels|Percentage change from baseline in apoliprotein-b (ApoB)|Percentage change from baseline in total cholesterol:HDL-C ratio|Change in ApoB:ApoA1 ratio|Percentage change in from baseline in non-HDL-C|Mean percentage change from baseline in low density lipoprotein-cholesterol levels at week 22 and week 24,Amgen,All,10 Years to 17 Years   (Child),Phase 3,150,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",20120123|2014-002277-11,15-Feb-16,18-Feb-20,18-Feb-20,19-Mar-15,null,18-Apr-19,"Research Site, Farmington, Connecticut, United States|Research Site, Wilmington, Delaware, United States|Research Site, Iowa City, Iowa, United States|Research Site, Towson, Maryland, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Bronx, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Morgantown, West Virginia, United States|Research Site, Camperdown, New South Wales, Australia|Research Site, Feldkirch, Austria|Research Site, Salzburg, Austria|Research Site, Wien, Austria|Research Site, Bruxelles, Belgium|Research Site, La Louvière, Belgium|Research Site, Leuven, Belgium|Research Site, Fortaleza, Ceará, Brazil|Research Site, Brasília, Distrito Federal, Brazil|Research Site, Vitória, Espírito Santo, Brazil|Research Site, São Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Chicoutimi, Quebec, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Barranquilla, Atlántico, Colombia|Research Site, Floridablanca, Santander, Colombia|Research Site, Ostrava-Poruba, Czechia|Research Site, Praha 5, Czechia|Research Site, Svitavy, Czechia|Research Site, Helsinki, Finland|Research Site, Kuopio, Finland|Research Site, Athens, Greece|Research Site, Thessaloniki, Greece|Research Site, Budapest, Hungary|Research Site, Palermo, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Torino, Italy|Research Site, Kota Bharu, Kelantan, Malaysia|Research Site, Amsterdam, Netherlands|Research Site, Christchurch, New Zealand|Research Site, Bergen, Norway|Research Site, Oslo, Norway|Research Site, Gdansk, Poland|Research Site, Guimaraes, Portugal|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Ljubljana, Slovenia|Research Site, Pretoria, Gauteng, South Africa|Research Site, Parow, Western Cape, South Africa|Research Site, Cordoba, Andalucía, Spain|Research Site, Sevilla, Andalucía, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, A Coruña, Galicia, Spain|Research Site, Lugo, Galicia, Spain|Research Site, Geneva 14, Switzerland|Research Site, Reinach, Switzerland|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Ankara, Turkey|Research Site, Izmir, Turkey|Research Site, Birmingham, United Kingdom|Research Site, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02392559
NCT02390375,Phase 3 Study to Evaluate the Efficacy and Safety of the DW0929 in Patients With Primary Hypercholesterolemia,,Completed,No Results Available,Hypercholesterolemia,Drug: DW-0929|Drug: Rosuvastatin,LDL-C level,"Daewon Pharmaceutical Co., Ltd.",All,"19 Years and older   (Adult, Older Adult)",Phase 3,348,Industry,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",DW-0929_P301,Nov-14,Apr-16,May-16,17-Mar-15,null,10-Oct-16,"Boramae Hospital, Seoul, Dongjak-gu, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02390375
NCT02387619,The Pharmacokinetic Drug Interaction Between Rosuvastatin and Telmisartan/Amlodipine,,Completed,No Results Available,Hypertension|Hyperlipidemia,Drug: Rosuvastatin|Drug: Telmisartan/Amlodipine|Drug: Rosuvastatin and Telmisartan/Amlodipine,"AUCτ,ss , Cmax, ss of Rosuvastatin and Telmisartan, Amlodipine|AUClast,ss of Rosuvastatin|AUCinf,ss of Rosuvastatin|Tmax,ss of Rosuvastatin|t1/2 of Rosuvastatin|AUClast,ss of Telmisartan, Amlodipine|AUCinf,ss of Telmisartan, Amlodipine|Tmax,ss of Telmisartan, Amlodipine|t1/2 of Telmisartan, Amlodipine","Jeil Pharmaceutical Co., Ltd.",Male,19 Years to 55 Years   (Adult),Phase 1,41,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,JLP-1401-P1-DI,Feb-15,Mar-15,Jul-15,13-Mar-15,null,24-Jun-16,"Yonsei University Health System, Seoul, Seodaemun-gu, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02387619
NCT02380534,Use of Apheretic Technologies in Cardiovascular Disease,,Unknown status,No Results Available,Dyslipidemia,Procedure: H.E.L.P. apheresis,Lp(a) reduction|Inflammatory adypocytokines,University of Pavia|IRCCS Policlinico S. Matteo,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,16,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P-20140023880,Feb-15,Feb-18,Feb-18,5-Mar-15,null,5-Mar-15,"IRCCS Policlinico S. Matteo, Pavia, Italy",,https://ClinicalTrials.gov/show/NCT02380534
NCT02380911,Statins at the Primary Care Level,EPRINA,Completed,No Results Available,Dyslipidemia,Other: Educational Intervention,Cholesterol Level|Global Cardiovascular Risk|Clinical practice guidelines compliance|Cholesterol reduction|Treatment compliance|Costs of the intervention,Institute for Clinical Effectiveness and Health Policy,All,"40 Years to 75 Years   (Adult, Older Adult)",Not Applicable,357,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other,11526941,Apr-15,Apr-17,Apr-17,5-Mar-15,null,16-Aug-17,"Centro de Atención Primaria de la Salud ""Dr. Favaloro"", Puerto Madryn, Chubut, Argentina|Centro de Atención Primaria de la Salud ""Ruca Calil"", Puerto Madryn, Chubut, Argentina|Centro de Atención Primaria de la Salud ""Malvinas Argentinas"", Rawson, Chubut, Argentina|Centro de Atención Primaria de la Salud ""Etcheparre"", Trelew, Chubut, Argentina|Hospital San Luis del Palmar, San Luis del Palmar, Corrientes, Argentina|Centro de Atención Primaria de la Salud N°11, Corrientes, Argentina|Centro de Atención Primaria de la Salud Dr. Balbastro, Corrientes, Argentina|Centro de Atención Primaria de la Salud N°13, Corrientes, Argentina|Centro de Atención Primaria ""Jardín Residencial"", La Rioja, Argentina|Centro de Atención Primaria de la Salud ""Faldeo del Velazco"", La Rioja, Argentina",,https://ClinicalTrials.gov/show/NCT02380911
NCT02374047,"A 2-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CAT-2054 in Healthy Subjects",,Completed,No Results Available,Hypercholesterolemia,Drug: CAT-2054|Drug: Placebo|Drug: CAT-2054-C|Drug: Atorvastatin,"Frequency and severity of adverse events|AUCinf of CAT-2054|Cmax of CAT-2054|Changes from baseline for hematology, chemistry, coagulation and urinalysis|Assess the pharmacodynamic effects of multiple doses of CAT-2054 on serum lipids LDL-C, non-HDL-C, total cholesterol, triglycerides, HDL-C, apoB, and PCSK9.|AUC48 of Atorvastatin",Catabasis Pharmaceuticals,All,18 Years to 55 Years   (Adult),Phase 1,118,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",CAT-2054-101,Jan-15,Jul-15,Jul-15,27-Feb-15,null,22-Mar-16,"Spaulding Clinical Research, West Bend, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02374047
NCT02366156,"A 12 Week, 3-Period Study to Evaluate the Effects of a Dietary Supplement on Lipid Metabolism",,Completed,No Results Available,Hyperlipidemia,Dietary Supplement: Placebo|Dietary Supplement: Low Dose Grape Blend|Dietary Supplement: High Dose Grape Blend,Fasting triglycerides|Area under the curve (AUC) for plasma TG|Maximal Concentration (Cmax) and time to Cmax (Tmax)|Plasma TG during the OFTT|Fasting lipoprotein lipids|Body weight,Access Business Group,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,93,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",BIO-1403,Jul-14,Mar-15,Mar-15,19-Feb-15,null,12-Mar-15,"Biofortis, Addison, Illinois, United States",,https://ClinicalTrials.gov/show/NCT02366156
NCT02364258,Pharmacokinetics of Rosuvastatin and Atorvastatin in Pediatric Dyslipidemia Patients,SD2,Completed,No Results Available,Dyslipidemia,Drug: Rosuvastatin|Drug: Atorvastatin,Evaluate effect of genotype (SLCO1BI) on Cmax rosuvastatin|Evaluate effect of genotype (SLCO1B1) on AUC rosuvastatin|Evaluate effect of genotype (SLCO1BI) on Cmax atorvastatin|Evaluate effect of genotype (SLCO1B1) on AUC atorvastatin|Evaluate the effect of age on Cmax of rosuvastatin|Evaluate the effect of gender on Cmax of rosuvastatin|Evaluate the effect of race on Cmax of rosuvastatin|Evaluate the effect of sexual maturity on Cmax of rosuvastatin|Evaluate the effect of age on Cmax of atorvastatin|Evaluate the effect of age on AUC of atorvastatin|Evaluate the effect of gender on AUC of atorvastatin|Evaluate the effect of race on AUC of atorvastatin|Evaluate the effect of sexual maturity on AUC of atorvastatin|Evaluate the effect of age on AUC of rosuvastatin|Evaluate the effect of gender on AUC of rosuvastatin|Evaluate the effect of race on AUC of rosuvastatin|Evaluate the effect of sexual maturity on AUC of rosuvastatin|Evaluate the effect of age on Ka of atorvastatin|Evaluate the effect of gender on Ka of atorvastatin|Evaluate the effect of race on Ka of atorvastatin|Evaluate the effect of sexual maturity on Ka of atorvastatin|Evaluate the effect of age on Ka of rosuvastatin|Evaluate the effect of gender on Ka of rosuvastatin|Evaluate the effect of race on Ka of rosuvastatin|Evaluate the effect of sexual maturity on Ka of rosuvastatin,Children's Mercy Hospital Kansas City,All,"8 Years to 21 Years   (Child, Adult)",Phase 1,28,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,13020063,Jul-14,27-Dec-17,27-Dec-17,18-Feb-15,null,31-Jan-19,"Children's Mercy Hospital, Kansas City, Missouri, United States",,https://ClinicalTrials.gov/show/NCT02364258
NCT02360826,Statin Distribution,,Completed,No Results Available,Drug Distribution,Drug: Pravastatin|Drug: Simvastatin,Evaluate effect of genotype (SLCO1B1) on Cmax pravastatin|Evaluate effect of genotype (SLCO1B1) on AUC pravastatin|Evaluate effect of genotype (SLCO1B1) on Cmax Simvastatin|Evaluate effect of genotype on AUC Simvastatin|Evalaute the effect of age on Cmax of pravastatin|Evalaute the effect of gender on Cmax of pravastatin|Evalaute the effect of race Cmax of pravastatin|Evaluate the effect of sexual maturity on Cmax of pravastatin based|Evaluate the effect of age on Cmax of simvastatin|Evaluate the effect of gender on Cmax of simvastatin|Evaluate the effect of race on Cmax of simvastatin|Evaluate the effect of sexual maturity on Cmax of simvastatin|Evaluate the effect of age on AUC of pravastatin|Evaluate the effect of gender on AUC of pravastatin|Evaluate the effect of race on AUC of pravastatin|Evaluate the effect of sexual maturity on AUC of pravastatin|Evaluate the effect of age on AUC of simvastatin|Evaluate the effect of gender on AUC of simvastatin|Evaluate the effect of race on AUC of simvastatin|Evaluate the effect of sexual maturity on AUC of simvastatin|Evaluate the effect of age on Ka of pravastatin|Evaluate the effect of gender on Ka of pravastatin|Evaluate the effect of race on Ka of pravastatin|Evaluate the effect of sexual maturity on Ka of pravastatin|Evaluate the effect of age on Ka of simvastatin|Evaluate the effect of gender on Ka of simvastatin|Evaluate the effect of race on Ka of simvastatin|Evaluate the effect of sexual maturity on Ka of simvastatin,Children's Mercy Hospital Kansas City|American Heart Association,All,"8 Years to 21 Years   (Child, Adult)",Phase 1,32,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,13CRP1711002,17-Jun-14,5-Jul-16,5-Jul-16,11-Feb-15,null,19-Jul-17,"Children's Mercy Hospital, Kansas City, Missouri, United States",,https://ClinicalTrials.gov/show/NCT02360826
NCT02358967,Palm Tocotrienols in Chronic Hemodialysis (USA),PATCH,"Active, not recruiting",No Results Available,End Stage Renal Disease|Chronic Kidney Disease,Dietary Supplement: TRF (Tocotrienol-rich-fraction)|Dietary Supplement: Placebo,Inflammatory markers|Plasma lipids|Restless Legs Syndrome|Dietary history,"Wayne State University|DaVita Dialysis|Great Lakes Dialysis, LLC|National University of Malaysia|Universiti Putra Malaysia|Ministry of Health, Malaysia|National Kidney Foundation|PEMANDU|Henry Ford Hospital|Kidney Foundation Hospital and Research Institute Bangladesh|Fortis Hospital, India",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,400,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",123314MP4F,15-Jun-17,31-Jan-20,14-Jun-20,9-Feb-15,null,26-Mar-19,"Wayne State University, Detroit, Michigan, United States",,https://ClinicalTrials.gov/show/NCT02358967
NCT02358109,The Flamenco (Fitness League Against MENopause COsts) Project,FLAMENCO,Completed,No Results Available,Cardiovascular Diseases|Diabetes|Dyslipidemias|Metabolic Syndrome|Quality of Life,Behavioral: exercise,The Incremental Cost Effectiveness Ratio (ICER)|Quality Adjusted Life Years (QALYs),Universidad de Granada|Andalusian Regional Ministry of Health,Female,45 Years to 60 Years   (Adult),Not Applicable,160,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,FLAMENCO,Jan-14,Nov-15,May-16,6-Feb-15,null,25-Oct-16,"Department of Physiology, Faculty of Farmacy, University of Granada, Granada, Andalucía, Spain",,https://ClinicalTrials.gov/show/NCT02358109
NCT02354079,HYPOCHOL : A Genetically-based Strategy to Identify New Targets in Cholesterol Metabolism,HYPOCHOL,Recruiting,No Results Available,Hypobetalipoproteinemia,Genetic: hypobetalipoproteinemia genetic and genotypic screening,type and number of genetic abnormalities leading to FHBL,Nantes University Hospital,All,"Child, Adult, Older Adult",Not Applicable,400,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,RC14_0400,7-Jan-16,Jan-20,Jan-30,3-Feb-15,null,31-Jan-19,"CHU de Nantes, Nantes, France",,https://ClinicalTrials.gov/show/NCT02354079
NCT02354794,Effect of Arginine Supplementation in the Metabolic Syndrome,,Completed,No Results Available,Overweight|Hypertriglyceridemic Waist,Dietary Supplement: One form of arginine|Dietary Supplement: placebo,Physiological assessment of endothelial function in postprandial and fasting (Endothelial function was assessed by flow-mediated dilation (FMD) and peripheral arterial tonometry (EndoPAT)|Evaluation of plasma vascular cell adhesion molecule-1 (VCAM-1) of endothelial function in postprandial and fasting|Evaluation of plasma intercellular adhesion molecule (ICAM-1) of endothelial function in postprandial and fasting|Evaluation of plasma E-Selectin of endothelial function in postprandial and fasting|Evaluation of plasma P-Selectin of endothelial function in postprandial and fasting|Evaluation of plasma Plasminogen activator inhibitor-1 (PAI-1) of endothelial function in postprandial and fasting|Evaluation of plasma C-reactive protein (CRP) of endothelial function in postprandial and fasting|Evaluation of plasma Endothelin-1 of endothelial function in postprandial and fasting|Asymmetric Dimethyl-L-Arginine (ADMA) measurement|Amino acids measurement|Nitrite measurement|Complete blood count (CBC) analysis|Insulin and glucose measurement|Lipid profile analysis|Metabolomic analysis,Institut National de la Recherche Agronomique|Institut de Recherche Pierre Fabre|Hospital Avicenne|Adeprina,All,18 Years to 60 Years   (Adult),Not Applicable,36,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)",FRMA13-1|2013-A01043-42,Feb-14,May-14,Sep-14,3-Feb-15,null,3-Feb-15,"Centre de Recherche sur Volontaires (CRV), Hospital Avicenne, Bobigny, Ile-de-France, France",,https://ClinicalTrials.gov/show/NCT02354794
NCT02354976,A Double-blind Randomized Placebo-controlled Study Comparing Epanova and Fenofibrate on Liver Fat in Overweight Subjects.,,Completed,Has Results,Non-alcoholic Fatty Liver Disease (NAFLD|Hypertriglyceridemia,Drug: Placebo|Drug: Omega-3 carboxylic acid|Drug: Fenofibrate 200mg,Geometric Mean Ratio (Week 12/Baseline) of % Liver Fat as Assessed by MRI (Epanova Versus Placebo)|Geometric Mean Ratio (Week 12/Baseline) of % Liver Fat as Assessed by MRI (Epanova Versus Fenofibrate),AstraZeneca,All,"40 Years to 75 Years   (Adult, Older Adult)",Phase 2,78,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",D5881C00007,1-Sep-15,26-May-16,26-May-16,3-Feb-15,25-Sep-18,25-Sep-18,"Research Site, Göteborg, Sweden|Research Site, Malmö, Sweden|Research Site, Stockholm, Sweden|Research Site, Uppsala, Sweden",,https://ClinicalTrials.gov/show/NCT02354976
NCT02352740,Characterization of the Metabolic Fate of an Oral Arginine Form,,Completed,No Results Available,Overweight|Hypertriglyceridemic Waist,Dietary Supplement: A form Arginine|Dietary Supplement: B form Arginine,Estimate of total conversion of a dose of oral arginine into NO|Estimate of kinetic profiles of plasma arginine concentrations over 24 hours|Quantitative analysis of plasma markers of endothelial function|Estimate of kinetics use of arginine for NO and urea synthesis|Other quantitative analysis,Institut National de la Recherche Agronomique|Institut de Recherche Pierre Fabre|Hospital Avicenne|Adeprina,All,18 Years to 60 Years   (Adult),Not Applicable,32,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant),FRMA12-1|2012-A00755-38,Mar-13,May-13,null,2-Feb-15,null,2-Feb-15,"Centre de Recherche sur Volontaires (CRV), Hospital Avicenne, Bobigny, Ile-de-France, France",,https://ClinicalTrials.gov/show/NCT02352740
NCT02343471,The Effect of Whey Protein Consumed as a Pre-meal on Postprandial Lipemia in Healthy and Subjects With Type 2 Diabetes,PREMEAL 3,Completed,No Results Available,Healthy|Type 2 Diabetes,Dietary Supplement: 20 g whey protein,Effect on triglyceride response of whey protein as pre-meal after a high-fat meal in healthy subjects and subjects with type 2 diabetes measured as incremental Area Under the Curve (iAUC -15 - 360 min).|Effect on apolipoprotein B48 of whey protein as pre-meal after a high-fat meal in healthy subjects and subjects with type 2 diabetes measured as incremental Area Under the Curve (iAUC -15 - 360 min).|Glucose responses measured as incremental Area Under the Curve (AUC -15 - 360 min)|Insulin responses measured as incremental Area Under the Curve (AUC -15 - 360 min)|Glucagon responses measured as incremental Area Under the Curve (AUC -15 - 360 min)|Glucagon-like peptide 1 (GLP-1) responses measured as incremental Area Under the Curve (AUC -15 - 360 min)|Gastric inhibitory peptide (GIP) responses measured as incremental Area Under the Curve (AUC -15 - 360 min).,Aarhus University Hospital|University of Aarhus|University of Copenhagen,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,26,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,CERN-Premeal3,Mar-15,Apr-15,Apr-15,22-Jan-15,null,5-May-15,,,https://ClinicalTrials.gov/show/NCT02343471
NCT02343497,Lipid-lowering Effects of an Astaxanthin Supplement in Volunteers With Mild Dyslipidaemia,LLAX,Completed,No Results Available,Dyslipidemias,Dietary Supplement: Astaxanthin|Dietary Supplement: Placebo,fasting plasma triglycerides|fasting cholesterol|fasting HDL-cholesterol|fasting LDL-cholesterol|apolipoprotein A1|apolipoprotein B|apolipoprotein balance|resting blood pressure|resting heart rate|fasting glucose|fasting insulin|homeostatic model assessment to quantify insulin resistance (HOMA-IR)|fasting adiponectin|fasting leptin|fasting ghrelin|fasting resistin|phosphatidylcholine hydroperoxides|plasmatic concentrations in astaxanthin|compliance with study product|adverse events,Ajinomoto Foods Europe SAS|Institut Polytechnique LaSalle Beauvais|Naturalpha,All,18 Years to 60 Years   (Adult),Not Applicable,68,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",2014-A00198-39,Aug-14,Sep-15,Nov-15,22-Jan-15,null,9-Jan-18,"Centre Nutrition Clinique Naturalpha, Lille, France",,https://ClinicalTrials.gov/show/NCT02343497
NCT02341794,Rosuvastatin Treatment for Intracranial Arterial Stenosis Based on Magnetic Resonance Angiography,,Unknown status,No Results Available,Intracranial Arterial Diseases,Drug: Rosuvastatin,"Progression of intracranial arterial stenosis after two years|Any stroke (ischemic stroke, intracerebral haemorrhage, subarachnoid haemorrhage)|Ischemic stroke or transient ischemic attack|Intracerebral haemorrhage or subarachnoid haemorrhage|Death from any cause|Cardiovascular events (ischemic stork, cardiac infarction, and other vascular events|The change of percentage in LDL-C from baseline|The change in HDL-C level from baseline|Intracranial haemorrhage|Number of cerebral microbleeds on MRI|Carotid intima-media thickness|Ankle brachial index|Brachial-ankle pulse wave velocity|Adverse events and adverse drug reactions",Tokyo Medical University,All,"30 Years to 80 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2900,Jan-15,Dec-17,Jul-18,19-Jan-15,null,21-Jan-15,"Tokyo Medical University, Shinjuku-ku, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT02341794
NCT02341924,"Validating the ""Foods for Health"" Portfolio of Functional Food Products",,Completed,No Results Available,Hypercholesterolemia,Other: Portfolio of functional foods|Other: Control foods,"Change in fasting serum lipids (total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol and triglycerides)|Change in fasting serum glucose|Change in fasting insulin|Change in fasting C-reactive protein",University of Manitoba|Manitoba Agri-Health Research Network|Manitoba Jobs and the Economy|TM Therapeutics|StepOne Canada,All,21 Years to 64 Years   (Adult),Not Applicable,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other",B2014:113,Sep-15,29-Sep-17,29-Sep-17,19-Jan-15,null,20-Sep-18,"Mayo Clinic, Rochester, Minnesota, United States|Richardson Centre for Functional Foods and Nutraceuticals, Winnipeg, Manitoba, Canada",,https://ClinicalTrials.gov/show/NCT02341924
NCT02342015,Effect of Atorvastatin on Bone-vascular Axis,,Completed,No Results Available,Osteoporosis|Hypercholesterolemia,Drug: Atorvastatin,OPG/RANK/RANKL gene expression (Gene expression analysis will be performed to assess modification in OPG/RANK/RANKL expression in isolated T-cells and monocytes)|Circulating osteoprogenitor cells (flow cytometry analysis will be used to study changes in the levels of circulating osteoprogenitor cells),University of Padova,Female,"Child, Adult, Older Adult",Phase 4,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,Studio clinico n° 14/AULSS 9,Sep-09,Nov-11,Mar-13,19-Jan-15,null,19-Jan-15,,,https://ClinicalTrials.gov/show/NCT02342015
NCT02331043,Serum Cholesterol Reduction Efficacy of Biscuit With Plant Stanol Ester,,Completed,No Results Available,Dyslipidemias|Hypercholesterolemia|Hyperlipidemias,Dietary Supplement: Plant stanol ester|Dietary Supplement: Placebo,Change (proportional) in LDL-c from baseline after 4-weeks' plant stanol ester biscuit consumption compared to controls|Change (proportional) in LDL-c from baseline after 4-weeks' plant stanol ester biscuit consumption in subjects consuming the biscuit with or without a meal,Raisio Group|Mahidol University,All,"20 Years to 65 Years   (Adult, Older Adult)",Not Applicable,119,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CL 2012_034,Mar-13,Aug-13,Aug-13,5-Jan-15,null,8-Jan-15,"Mahidon University, Nutrition Institute, Center of Innovation and Reference on Food for Nutrition (CIRFON), Phutthamonthon, Nakhon Pathom, Thailand",,https://ClinicalTrials.gov/show/NCT02331043
NCT02326220,Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy,ODYSSEY ESCAPE,Completed,No Results Available,Heterozygous Familial Hypercholesterolemia,Drug: Alirocumab|Drug: Placebo,Rate of apheresis treatments during a 12-week period normalized by the number of planned apheresis treatments according to each patient's established schedule at screening|Percent change from baseline in low-density lipoprotein cholesterol (LDL-C) (pre-apheresis)|Standardized rate of apheresis treatments during a 4-week period|Percent change from baseline in apolipoprotein B (ApoB) (pre-apheresis) (pre-apheresis) to week 6|Percent change from baseline in non-high-density lipoprotein cholesterol (HDL-C) (pre-apheresis)|Percent change from baseline in total cholesterol (pre-apheresis)|Percent change from baseline in ApoA-1 (pre-apheresis)|Proportion of patients with ≥30% reduction in LDL-C (pre-apheresis)|Proportion of patients with ≥50% reduction in LDL-C (pre-apheresis)|Percent change from baseline in LDL-C (pre-apheresis)|Percent change from baseline in ApoB (pre-apheresis)|Percent change from baseline in non-HDL-C (pre-apheresis) to week 18|Percent change from baseline in total cholesterol (pre-apheresis) to week 18|Percent change from baseline in ApoA-1(pre-apheresis) to week 18|Proportion of patients with ≥30% reduction in LDL-C (pre-apheresis) at week 18 (pre-apheresis)|Proportion of patients with ≥50% reduction in LDL-C (pre-apheresis) at week 18|Change of W-BQ22 (Well-Being Questionnaire 22-item version) from baseline to week 18|Percent change from baseline in lipoprotein (a) [Lp(a)] (pre-apheresis)|Percent change from baseline in HDL-C (pre-apheresis)|Percent change from baseline in triglyceride (TG) levels (pre-apheresis)|Percent change from baseline in Lp(a) (pre-apheresis) to week 18|Percent change from baseline in HDL-C (pre-apheresis) to week 18|Percent change from baseline in TG levels (pre-apheresis) to week 18,Regeneron Pharmaceuticals|Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,62,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R727-CL-1216,Mar-15,Jan-16,Apr-16,29-Dec-14,null,7-Feb-17,"Aurora, Colorado, United States|Hartford, Connecticut, United States|Kansas City, Kansas, United States|Scarborough, Maine, United States|Rochester, Minnesota, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Dresden, Sachsen, Germany|Berlin, Germany|Goettlinger, Germany|Muenchen (2 locations), Germany|Passau, Germany|Rostock, Germany",,https://ClinicalTrials.gov/show/NCT02326220
NCT02316808,Cholesterol-lowering Effects of Plant Stanol Ester,,Completed,No Results Available,Dyslipidemias|Hypercholesterolemia|Hyperlipidemias,Dietary Supplement: Plant stanol ester|Dietary Supplement: placebo,Change (proportional) in LDL-C from baseline up to 4-weeks after plant stanol ester smoothie drink consumption.,Raisio Group|Indonesia University,All,"20 Years to 70 Years   (Adult, Older Adult)",Not Applicable,91,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PCL_2011_Kal,Aug-11,Dec-11,Dec-11,15-Dec-14,null,23-Dec-14,,,https://ClinicalTrials.gov/show/NCT02316808
NCT02317003,Physical Exercise Prescription With PEdometeR in General Practice for Patients With Cardiovascular Risk Factors - The PEPPER Pragmatic Trial,PEPPER,"Active, not recruiting",No Results Available,"Sedentary Lifestyle|Cardiovascular Diseases|Hypertension|Hypercholesterolemia|Diabetes Mellitus, Type 2",Behavioral: Intervention PPIL|Behavioral: Control OR,Change in total energy expenditure by accelerometry at 3 months compared to baseline|Change in total energy expenditure by accelerometry at 12 months compared to baseline|Change in total energy expenditure by questionnaire at 3 months compared to baseline|Change in total energy expenditure by questionnaire at 12 months compared to baseline|Change in quality of life at 3 months compared to baseline|Change in quality of life at 12 months compared to baseline|Change in waist circumference at 3 months compared to baseline|Change in waist circumference at 12 months compared to baseline|Change in weight at 3 months compared to baseline|Change in weight at 12 months compared to baseline|Change in arterial blood pressure at 3 months compared to baseline|Change in arterial blood pressure at 12 months compared to baseline|Perceived obstacles to physical exercise|Adherence of doctors and patients to the suggested strategy,"University Hospital, Angers",All,"35 Years to 74 Years   (Adult, Older Adult)",Not Applicable,126,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,CHU-P 2014-04,Mar-15,Dec-18,Apr-19,15-Dec-14,null,10-Aug-18,"Angers University Hospital, Angers, France",,https://ClinicalTrials.gov/show/NCT02317003
NCT02314442,"A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C)",,Completed,No Results Available,Hypercholesterolemia,Drug: ALN-PCSSC|Drug: Sterile Normal Saline (0.9% NaCl),"The safety of ALN-PCSSC evaluated by the proportion of subjects experiencing adverse events (AEs), serious adverse events (SAEs), and AEs leading to study drug discontinuation|The pharmacokinetics (PK) of ALN-PCSSC (Cmax, tmax, AUC, t1/2)|The effect of ALN-PCSSC on serum levels of LDL-C|The effect of ALN-PCSSC on plasma levels of PCSK9",Alnylam Pharmaceuticals|The Medicines Company,All,18 Years to 60 Years   (Adult),Phase 1,70,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,ALN-PCSSC-001,Dec-14,May-15,Nov-15,11-Dec-14,null,17-Dec-15,"Covance Clinical Research Unit, Leeds, United Kingdom|Richmond Pharmacology, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02314442
NCT02314663,Effectiveness of a Combined Strategy to Improve Therapeutic Compliance and Degree of Control Among Patients With Hypercholesterolaemia,EFESCOM,Unknown status,No Results Available,Hypercholesterolemia|Medication Adherence|Primary Health Care,"Device: ""COMBINED STRATEGY""","The proportion of subjects who attain the LDL-C levels set as targets by the Guidelines for Management of Dyslipidaemias and CVR|adherence to lifestyle guidelines and adherence to drug treatment|variation in plasma lipid profile levels|variation in cardiovascular risk level|Occurrence of cardiovascular events|determination of the frequency of food consumption|smoking habit (answers affirmatively to the question, ""Do you smoke?"")|physical activity (degree of aerobic physical exercise performed (active, partially active or inactive)|anthropometric measures (i.e., weight, height, body mass index (BMI), and waist circumference)|systolic and diastolic blood pressure|degree of satisfaction with the combined strategy ((Likert scale with 5 response options ranging from 1 ""very dissatisfied"" to 5 ""very satisfied"")|health problems (WONCA ICPC-2 classification)|use of hypolipidaemic drug treatment","Gerencia de Atención Primaria, Albacete|Instituto de Salud Carlos III",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,358,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,GAPALBACETE,Jan-13,Dec-15,Dec-15,11-Dec-14,null,11-Dec-14,,,https://ClinicalTrials.gov/show/NCT02314663
NCT02312492,Development of a Novel Method to Study in Vivo Fatty Acid Metabolism Using Stable Isotope Labeled Fatty Acids in Humans,,Completed,No Results Available,Dyslipidemia,Other: Oleic Diet|Other: Palmitic Diet|Other: Stearic Diet,fatty acid kinetics in total plasma|fatty acid kinetics in cholesterol ester|fatty acid kinetics in triglyceride|fatty acid kinetics in phospholipid|fatty acid kinetics in monoglyceride subfraction|fatty acid kinetics in diglyceride subfraction|fatty acid kinetics in chylomicrons|fatty acid kinetics in VLDL (very low density lipoprotein)|fatty acid kinetics in TRL (triglyceride-rich lipoprotein)|fatty acid kinetics in LDL (low density lipoprotein)|fatty acid kinetics in HDL (high density lipoprotein)|rate of oxidation,Tufts University,Female,"50 Years to 85 Years   (Adult, Older Adult)",Not Applicable,6,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",1542 - Fatty Acid Kinetics,Jan-13,Jun-16,Dec-18,9-Dec-14,null,18-Apr-19,"Jean Mayer Human Nutrition Research Center on Aging, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02312492
NCT02310022,A PK and PD Study of Two Formulations of Omega-3 One Gram Capsules,PK/PD,Unknown status,No Results Available,Hypertriglyceridemia,Drug: Drug Omega 3|Drug: Drug Omega-3 Comparator,Bioavailability comparison after single and multiple doses over a 24 hour period at day 1 and day 14|Comparison of baseline changes of triglycerides and other related lipid protein parameter levels over 14 days,"Matinas Biopharma, Inc",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,48,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MB-70001,Nov-14,May-15,May-15,5-Dec-14,null,10-Mar-15,"Pharma Medica Reserach Inc, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02310022
NCT02306122,Pharmacy Home Adherence Reporting and Monitoring Outcomes Study,PHARxMOS,Completed,No Results Available,Diabetes|Hypertension|Hypercholesterolemia,Behavioral: Pharmacist calls patient unless physician cancels call|Behavioral: Patient nonadherence information sent to physician|Behavioral: Pharmacist calls patient if physician requests call|Behavioral: Patient HMO/PPO status revealed to physician,Patient participant medication adherence outcomes|Duration of non-adherence event|Physician participant behavioral outcomes|Physician participant engagement with the system,Brown University|National Institute on Aging (NIA)|Tufts Medical Center|Harvard University|Johns Hopkins University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2697,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research,PHARxMOS|7RC4AG039072-02,Mar-11,Feb-14,Feb-14,3-Dec-14,null,3-Dec-14,"Brown University, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT02306122
NCT02304484,Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab,,Completed,Has Results,Hypercholesterolemia,Biological: Evolocumab,Number of Participants With Adverse Events|Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C),Amgen,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,770,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20140128|2014-001524-30,24-Nov-14,9-Mar-18,9-Mar-18,2-Dec-14,19-Mar-19,19-Mar-19,"Research Site, Huntsville, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Long Beach, California, United States|Research Site, San Diego, California, United States|Research Site, Torrance, California, United States|Research Site, Jacksonville, Florida, United States|Research Site, Munster, Indiana, United States|Research Site, Lexington, Kentucky, United States|Research Site, Covington, Louisiana, United States|Research Site, Bethesda, Maryland, United States|Research Site, Columbia, Maryland, United States|Research Site, Bay City, Michigan, United States|Research Site, Midland, Michigan, United States|Research Site, Duluth, Minnesota, United States|Research Site, Saint Cloud, Minnesota, United States|Research Site, Columbia, Missouri, United States|Research Site, Ridgewood, New Jersey, United States|Research Site, Fargo, North Dakota, United States|Research Site, Canton, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Oak Ridge, Tennessee, United States|Research Site, Amarillo, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Wichita Falls, Texas, United States|Research Site, La Plata, Buenos Aires, Argentina|Research Site, Cordoba, Córdoba, Argentina|Research Site, Córdoba, Argentina|Research Site, Córdoba, Argentina|Research Site, Liverpool, New South Wales, Australia|Research Site, New Lambton Heights, New South Wales, Australia|Research Site, Chermside, Queensland, Australia|Research Site, Herston, Queensland, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, Fullarton, South Australia, Australia|Research Site, Epping, Victoria, Australia|Research Site, Footscray, Victoria, Australia|Research Site, Nedlands, Western Australia, Australia|Research Site, Antwerpen, Belgium|Research Site, Edegem, Belgium|Research Site, Genk, Belgium|Research Site, Hasselt, Belgium|Research Site, Lodelinsart, Belgium|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, São Paulo, Brazil|Research Site, Calgary, Alberta, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, St. Johns, Newfoundland and Labrador, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, London, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Laval, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Québec, Quebec, Canada|Research Site, Temuco, Cautín, Chile|Research Site, Brno, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Praha 2, Czechia|Research Site, Zlin, Czechia|Research Site, Besancon cedex, France|Research Site, Chambray les Tours, France|Research Site, Marseille cedex 5, France|Research Site, Paris, France|Research Site, Pessac Cedex, France|Research Site, Essen, Germany|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Heraklion, Greece|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Szeged, Hungary|Research Site, Reykjavik, Iceland|Research Site, Galway, Ireland|Research Site, Hadera, Israel|Research Site, Jerusalem, Israel|Research Site, Novara, Italy|Research Site, Rozzano MI, Italy|Research Site, Sesto San Giovanni (MI), Italy|Research Site, Torino, Italy|Research Site, Daejeon, Korea, Republic of|Research Site, Seongnam-si, Gyeonggi-do, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Kuantan, Pahang, Malaysia|Research Site, Penang, Malaysia|Research Site, Guadalajara, Jalisco, Mexico|Research Site, San Luis Potosi, San Luis Potosí, Mexico|Research Site, Culiacan, Sinaloa, Mexico|Research Site, Aguascalientes, Mexico|Research Site, Alkmaar, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Leeuwarden, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Zwolle, Netherlands|Research Site, Oslo, Norway|Research Site, Chrzanow, Poland|Research Site, Kedzierzyn Kozle, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Warszawa, Poland|Research Site, Kemerovo, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Centurion, Gauteng, South Africa|Research Site, Sunninghill, Gauteng, South Africa|Research Site, Kuils River, Western Cape, South Africa|Research Site, Malaga, Andalucía, Spain|Research Site, Gijon, Asturias, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, L Hospitalet De Llobregat, Cataluña, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Göteborg, Sweden|Research Site, Stockholm, Sweden|Research Site, Geneva 14, Switzerland|Research Site, New Taipei, Taiwan|Research Site, Newcastle Upon Tyne, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT02304484/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT02304484/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02304484
NCT02304926,Effects of Simvastatin and Ezetimibe on Cardiovascular Risk Markers in Patients With Dyslipidemia,,Completed,Has Results,Dyslipidemia,Drug: Simvastatin|Drug: Ezetimibe|Drug: Simvastatin + Ezetimibe,Total Cholesterol Before and After Simvastatin/Ezetimibe Administration|Low-density Lipoprotein Cholesterol (LDLc) Before and After Simvastatin/Ezetimibe Administration|High-density Lipoprotein Cholesterol (HDLc) Before and After Simvastatin/Ezetimibe Administration|Triglycerides Before and After Simvastatin/Ezetimibe Administration|Non-HDL Cholesterol Before and After Simvastatin/Ezetimibe Administration|Low Density Lipoprotein Size Before and After Simvastatin/Ezetimibe Administration|Apolipoprotein B Before and After Simvastatin/Ezetimibe Administration|Levels of High-sensitive C-reactive Protein (hsCRP) Before and After Simvastatin/Ezetimibe Administration|Levels of Interleukin-6 (IL-6) Before and After Simvastatin/Ezetimibe Administration|Levels of Tumor Necrosis Factor α (TNF-α) Before and After Simvastatin/Ezetimibe Administration|Mitochondrial Oxygen (O2) Consumption Before and After Simvastatin/Ezetimibe Administration|Reactive Oxygen Species (ROS) Production Before and After Simvastatin/Ezetimibe Administration|Membrane Potential Before and After Simvastatin/Ezetimibe Administration|Levels of Glutathione (GSH) Before and After Simvastatin/Ezetimibe Administration|Leukocyte Rolling Flux Before and After Simvastatin/Ezetimibe Administration|Leukocyte Adhesion Before and After Simvastatin/Ezetimibe Administration|Leukocyte Rolling Velocity Before and After Simvastatin/Ezetimibe Administration|Levels of Vascular Cell Adhesion Molecule 1 (VCAM-1) Before and After Simvastatin/Ezetimibe Administration|Levels of Intercellular Adhesion Molecule 1 (ICAM-1) Before and After Simvastatin/Ezetimibe Administration|Levels of E-selectin Before and After Simvastatin/Ezetimibe Administration,Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,42,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SIM-EZE-2009-01,Jan-09,Dec-11,Dec-11,2-Dec-14,21-May-15,8-Mar-18,,,https://ClinicalTrials.gov/show/NCT02304926
NCT02305355,Efficacy and Safety of Prescription Omega-3 Fatty Acid Added to Stable Statin Therapy in Patients With Type 2 Diabetes and Hypertriglyceridemia,,Completed,No Results Available,"Diabetes Mellitus, Type 2|Hypertriglycemia","Drug: Omega-3-acids ethylesters 90 4g|Drug: Pravastatin, Simvastatin, Atorvastatin, Rosuvastatin",The mean percent change of Triglyceride(TG)|The mean percent change of Total Cholesterol(TC)|The mean percent change of LDL-C|The mean percent change of HDL-C|The mean percent change of HBA1c|The mean percent change of FPG|The mean percent change of hs-CRP|The mean percent change of PAI-1|The mean percent change of Apolipoprotein A1|The mean percent change of apolipoprotein B,"Kuhnil Pharmaceutical Co., Ltd.",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,68,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,08-OM-9412,Feb-09,Feb-11,Feb-11,2-Dec-14,null,2-Dec-14,"Bucheon St. Mary's Hospital, Bucheon, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02305355
NCT02302612,The CREATE Wellness Study,,Completed,No Results Available,Diabetes|Heart Disease|Hypertension|Dyslipidemia,Behavioral: CREATE Wellness|Other: Usual Care Control,Composite CVD Goal|Perceived efficacy in patient-physician interactions (PEPPI) - 10 items|Effective Consumer Scale (EC-17)|Patient Activation Measure (PAM) - 13 items,"Kaiser Permanente|National Heart, Lung, and Blood Institute (NHLBI)",All,"40 Years to 85 Years   (Adult, Older Adult)",Not Applicable,647,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,CN-13-1672-H|R01HL117939,Jan-15,30-Sep-18,30-Sep-18,27-Nov-14,null,16-Oct-18,"Kaiser Permanente San Jose Sabrina Wood, BA (510) 891-3551 Sabrina.B.Wood@kp.org, San Jose, California, United States",,https://ClinicalTrials.gov/show/NCT02302612
NCT02300233,The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia,,Completed,No Results Available,Hypertriglyceridemia,Drug: volanesorsen|Drug: Placebo,The percent change in fasting triglycerides (TG) from baseline,"Ionis Pharmaceuticals, Inc.|Akcea Therapeutics",All,"18 Years and older   (Adult, Older Adult)",Phase 3,114,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 304801-CS16,5-Feb-15,27-Jul-16,24-Jan-17,24-Nov-14,null,9-May-18,"IONIS Investigative Site, Encinitas, California, United States|IONIS Investigative Site, San Francisco, California, United States|IONIS Investigative Site, Boca Raton, Florida, United States|IONIS Investigative Site, Miami, Florida, United States|IONIS Investigative Site, Sterling, Illinois, United States|IONIS Investigative Site, Kansas City, Kansas, United States|IONIS Investigative Site, Salisbury, Maryland, United States|IONIS Investigative Site, Towson, Maryland, United States|IONIS Investigative Site, Boston, Massachusetts, United States|IONIS Investigative Site, Grandville, Michigan, United States|IONIS Investigative Site, North Massapequa, New York, United States|IONIS Investigative Site, Benson, North Carolina, United States|IONIS Investigative Site, Chapel Hill, North Carolina, United States|IONIS Investigative Site, Farmville, North Carolina, United States|IONIS Investigative Site, Greenville, North Carolina, United States|IONIS Investigative Site, Morrisville, North Carolina, United States|IONIS Investigative Site, Raleigh, North Carolina, United States|IONIS Investigative Site, Wilson, North Carolina, United States|IONIS Investigative Site, Wilson, North Carolina, United States|IONIS Investigative Site, Cincinnati, Ohio, United States|IONIS Investigative Site, Kettering, Ohio, United States|IONIS Investigative Site, Marion, Ohio, United States|IONIS Investigative Site, Oklahoma City, Oklahoma, United States|IONIS Investigative Site, Portland, Oregon, United States|IONIS Investigative Site, Providence, Rhode Island, United States|IONIS Investigative Site, Houston, Texas, United States|IONIS Investigative Site, Salt Lake City, Utah, United States|IONIS Investigative Site, Norfolk, Virginia, United States|IONIS Investigative Site, Seattle, Washington, United States|IONIS Investigative Site, Vancouver, British Columbia, Canada|IONIS Investigative Site, London, Ontario, Canada|IONIS Investigative Site, Chicoutimi, Quebec, Canada|IONIS Investigative Site, Sainte-Foy, Quebec, Canada|IONIS Investigative Site, Dijon, France|IONIS Investigative Site, Marseille, France|IONIS Investigative Site, Paris, France|IONIS Investigative Site, Saint Herblain, France|IONIS Investigative Site, Koeln, North Rhine-Westphalia, Germany|IONIS Investigative Site, Berlin, Germany|IONIS Investigative Site, Dresden, Germany|IONIS Investigative Site, Amsterdam, North Holland, Netherlands|IONIS Investigative Site, Rotterdam, South Holland, Netherlands|IONIS Investigative Site, Utrecht, Netherlands|IONIS Investigative Site, Manchester, United Kingdom|IONIS Investigative Site, Peterborough, United Kingdom",,https://ClinicalTrials.gov/show/NCT02300233
NCT02295293,The Effects of Rhus Coriaria L. on Serum Lipid Levels of Patients With Hyperlipidemia,SomaghLipid,Completed,No Results Available,Hyperlipidemias,Drug: Rhus Coriaria L. (Rhus)|Drug: Placebo,Serum total cholesterol level|Serum triglyceride level|Serum HDL-cholesterol level|Serum LDL-cholesterol level|Fasting Blood Sugar (FBS)|Serum creatinin level|Serum ALT level|Serum AST level|Serum alkaline phosphatase level|Number of patients with adverse events,Shiraz University of Medical Sciences,All,"20 Years to 65 Years   (Adult, Older Adult)",Early Phase 1,74,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CT-P-92-5581,Dec-14,Apr-15,May-15,20-Nov-14,null,7-Jun-16,"Shahid Motahhari Clinic, Shiraz University of Medical Sciences, Shiraz, Fars, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT02295293
NCT02289963,Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan,,Completed,Has Results,Hypercholesterolemia,Drug: Placebo (for Alirocumab)|Drug: Alirocumab|Drug: Lipid-Modifying Therapy (LMT),Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis|Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis|Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 24 - On-treatment Analysis|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 - On-treatment Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 12 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 - ITT Analysis|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-treatment Analysis|Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis|Percent Change From Baseline in High Density Lipoprotein (HDL-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis|Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein(a) at Week 12- ITT Analysis|Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis,Sanofi|Regeneron Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 3,199,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EFC14074|U1111-1157-3294,Jan-15,Apr-16,Apr-16,13-Nov-14,26-Jun-17,26-Jun-17,"Investigational Site Number 410009, Anyang-Si, Korea, Republic of|Investigational Site Number 410001, Anyang, Korea, Republic of|Investigational Site Number 410017, Busan, Korea, Republic of|Investigational Site Number 410007, Busan, Korea, Republic of|Investigational Site Number 410002, Daegu, Korea, Republic of|Investigational Site Number 410011, Goyang-Si, Korea, Republic of|Investigational Site Number 410003, Gwangju, Korea, Republic of|Investigational Site Number 410012, Incheon, Korea, Republic of|Investigational Site Number 410018, Jeonju-Si, Korea, Republic of|Investigational Site Number 410006, Seoul, Korea, Republic of|Investigational Site Number 410004, Seoul, Korea, Republic of|Investigational Site Number 410015, Seoul, Korea, Republic of|Investigational Site Number 410008, Seoul, Korea, Republic of|Investigational Site Number 410005, Seoul, Korea, Republic of|Investigational Site Number 410010, Seoul, Korea, Republic of|Investigational Site Number 410013, Ulsan, Korea, Republic of|Investigational Site Number 158007, Changhua, Taiwan|Investigational Site Number 158005, Hsinchu, Taiwan|Investigational Site Number 158011, Kaohsiung, Taiwan|Investigational Site Number 158010, Kaohsiung, Taiwan|Investigational Site Number 158006, Taichung, Taiwan|Investigational Site Number 158009, Tainan Hsien, Taiwan|Investigational Site Number 158008, Tainan, Taiwan|Investigational Site Number 158001, Taipei, Taiwan|Investigational Site Number 158003, Taipei, Taiwan|Investigational Site Number 158002, Taipei, Taiwan|Investigational Site Number 158004, Taoyuan Hsien, Taiwan",,https://ClinicalTrials.gov/show/NCT02289963
NCT02288572,Probiotic Bacteria in Prevention of the Metabolic Syndrome,,Completed,No Results Available,Metabolic Syndrome X,Dietary Supplement: Lactobacillus plantarum PCS 26|Dietary Supplement: Placebo,Serum lipids concentrations after daily consumption of dietary supplement in patients with the metabolic syndrome|Measures of body composition after daily consumption of dietary supplement in patients with the metabolic syndrome,University Maribor|Slovenian Research Agency,All,"21 Years to 85 Years   (Adult, Older Adult)",Phase 2,16,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science",MGPS001,May-13,Mar-14,May-14,11-Nov-14,null,11-Nov-14,,,https://ClinicalTrials.gov/show/NCT02288572
NCT02288585,The Effect of Plant Sterols on the Blood Lipid Profile of Subjects With and at High Risk of Type 2 Diabetes Mellitus,,Completed,No Results Available,Vascular Diseases|Hypercholesterolemia|Diabetes Mellitus,Dietary Supplement: Plant sterols|Dietary Supplement: Placebo product,Change in TG concentrations|Change in LDL-C|Change in blood lipids,Unilever R&D|CSIRO,All,"30 Years to 75 Years   (Adult, Older Adult)",Not Applicable,150,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",FDS-SCC-1552,Oct-14,Dec-16,Dec-16,11-Nov-14,null,19-Jan-17,"CSIRO, Adelaide, Australia|CSIRO, North Ryde, Sydney, Australia",,https://ClinicalTrials.gov/show/NCT02288585
NCT02281253,Effects of a Bakery Product Enriched With Fibre and L-carnitine on Insulin Resistance in Patients With Metabolic Syndrome,,Completed,No Results Available,Metabolic X Syndrome|Overweight|Dyslipidemias,Dietary Supplement: dietary fibre plus L-carnitine bread|Dietary Supplement: Placebo bread,To assess changes in hydrocarbonated metabolism parameters before and after fibre+carnitine/placebo administration|To evaluate changes in lipid parameters before and after fibre+carnitine/placebo administration|To evaluate changes in a composite measure of inflammatory parameters before and after fibre+carnitine/placebo administration,Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana|AINIATechnology Center,All,"25 Years to 70 Years   (Adult, Older Adult)",Not Applicable,54,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",PAN-CAR-2010-01,Apr-10,Jul-12,Jul-12,3-Nov-14,null,3-Nov-14,,,https://ClinicalTrials.gov/show/NCT02281253
NCT02280590,Comparison of the Efficacy and Safety of Cresnon® and Crestor® in Patients With Hyperlipidemia,,Completed,No Results Available,Hyperlipidemia,Drug: Rosuvastatin(Cresnon®)|Drug: Rosuvastatin(Crestor®),"The percent change in LDL-C|The percent change in total cholesterol, Triglyceride, HDL-C, non-HDL-C, and non-HDL-C/HDL-C|The proportion of subjects reaching LDL-C targeted level in accordance with the treatment guidelines for dyslipidemia released by Korean Society of Lipidology and Atherosclerosis","Dong-A ST Co., Ltd.",All,"20 Years and older   (Adult, Older Adult)",Phase 4,223,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CNT_HLP_IV,Sep-14,Jun-15,null,31-Oct-14,null,7-Jul-15,"Seoul National University Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02280590
NCT02278471,The SCCS Polypill Pilot Trial,,Completed,No Results Available,Hypertension|Hyperlipidemia,"Drug: Polypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)",Systolic blood pressure|Medication adherence|LDL cholesterol|Insulin resistance|Inflammatory profile,Vanderbilt University|Vanderbilt University Medical Center,All,"45 Years to 75 Years   (Adult, Older Adult)",Phase 2,303,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,141583,Dec-15,27-Jun-18,27-Jun-18,30-Oct-14,null,13-Aug-18,"Franklin Primary Health Center, Mobile, Alabama, United States",,https://ClinicalTrials.gov/show/NCT02278471
NCT02278757,Effect of Two Diets With Different Content of Protein on Weight Loss in Adults With Metabolic Syndrome,DPMS,Completed,No Results Available,Metabolic Syndrome X|Weight Loss,Other: High protein diet|Other: Low protein diet,Changes in body weight (weight loss),Mexican National Institute of Public Health,All,"20 Years to 65 Years   (Adult, Older Adult)",Not Applicable,118,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,120-6707,Jan-14,Jan-15,Mar-15,30-Oct-14,null,16-Mar-16,"Mexican National Institute of Public Health, Cuernavaca,, Morelos, Mexico",,https://ClinicalTrials.gov/show/NCT02278757
NCT02275156,Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab,,Completed,Has Results,Hyperlipidemia|Mixed Dyslipidemia,Biological: Evolocumab,Maximum Observed Serum Concentration (Cmax) of Evolocumab|Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC0-last) for Evolocumab|Number of Participants With Adverse Events|Number of Participants With Clinically Relevant Vital Sign or Clinical Laboratory Changes|Number of Participants With Anti-evolocumab Antibodies|Area Under the Effect Curve From Baseline to Day 57 (AUECday1-57) for Low-density Lipoprotein Cholesterol (LDL-C)|Mean Percent Change From Baseline in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9),Amgen,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,18,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20140213,19-Aug-14,19-Dec-14,19-Dec-14,27-Oct-14,29-Jan-16,29-Nov-18,"Research Site, Denver, Colorado, United States",,https://ClinicalTrials.gov/show/NCT02275156
NCT02271971,Effect of Vitamin D Supplementation on Metabolic Parameters of Patients With Psoriasis,,Completed,No Results Available,Psoriasis|Metabolic Syndrome|Vitamin D Deficiency,Dietary Supplement: Vitamin D3|Dietary Supplement: Placebo,Change in Total Cholesterol Levels|Change in Fasting Glucose Levels|Change in HOMA Index|Change in Glycated Hemoglobin Levels|Change in Low-Density Lipoprotein Levels|Change in High-Density Lipoprotein Levels|Change in Triglycerides Levels|Change in C-Reactive Protein Levels|Change in Vitamin D Levels|Change in PASI (Psoriasis Area Severity Index),Pontificia Universidad Catolica de Chile,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,39,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",14-412,Oct-14,Apr-15,Oct-15,22-Oct-14,null,4-Nov-15,"Pontificia Universidad Católica de Chile, Santiago, Región Metropolitana, Chile",,https://ClinicalTrials.gov/show/NCT02271971
NCT02269046,Acupuncture and Moxibustion for Hyperlipemia,AMH-RCT,Unknown status,No Results Available,Hyperlipidemias,Other: acupuncture and moxibustion|Drug: Simvastatin|Other: Therapeutic Lifestyle Change,low-density lipoprotein cholesterol (LDL-C)|high-density lipoprotein cholesterol (HDL-C)|total cholesterol (TC)|triglyceride(TG)|the rate of subjects achieving LDL-C goal,The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine|University of British Columbia|State Administration of Traditional Chinese Medicine of the People's Republic of China,All,"20 Years to 75 Years   (Adult, Older Adult)",Not Applicable,210,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,LML,Dec-14,Dec-16,Sep-17,20-Oct-14,null,20-Oct-14,"Changsha Hospital of Chinese Medicine, Changsha, Hunan, China|Second Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, China|First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, China",,https://ClinicalTrials.gov/show/NCT02269046
NCT02265952,Study of REGN1500 in Patients With Homozygous Familial Hypercholesterolemia (HoFH),,Completed,No Results Available,Homozygous Familial Hypercholesterolemia,Drug: REGN1500,"Percent change in low-density lipoprotein cholesterol (LDL-C) from baseline (week 0) to week 4.|Percent change in LDL-C from week 2 to week 4|Absolute change in LDL-C from week 2 to week 4|Percent change from baseline in LDL-C over time in the main study period|Absolute change from baseline in LDL-C over time in the main study period|Percent change in LDL-C from baseline over time in the open label extension (OLE) period|Absolute change in LDL-C from baseline over time in the OLE period|Absolute change in LDL-C from baseline (week 0) to week 4|Percent change from baseline in Apo B, non-high-density lipoprotein cholesterol (non-HDL-C), total cholesterol (total-C), and lipoprotein (Lp) (a) over time in the main study period|Absolute change from baseline in Apo B, non-HDL-C, total-C, and Lp (a) over time in the main study period|Percent change in Apo B, non-HDL-C, total-C, and Lp (a) from baseline over time in the OLE period|Absolute change in Apo B, non-HDL-C, total-C, and Lp (a) from baseline over time in the OLE period|Proportion of patients who achieve a reduction in LDL-C of ≥15% from baseline in the main study|Proportion of patients who achieve a reduction in LDL-C of ≥15% from baseline in the OLE period|Proportion of patients with ≥30% reduction in LDL-C from baseline in the main study|Proportion of patients with ≥30% reduction in LDL-C from baseline in the OLE period|Percent change in HDL-C, triglycerides, and Apo A-1 over time in the main study period|Absolute change in HDL-C, triglycerides, and Apo A-1 over time in the main study period|Percent change in HDL-C, triglycerides, and Apo A-1 from baseline over time in the OLE period|Absolute change in HDL-C, triglycerides, and Apo A-1 from baseline over time in the OLE period|Percent change from baseline in Apo CIII over time in the main study period|Absolute change from baseline in Apo CIII over time in the main study period|Percent change in Apo CIII from baseline over time in the OLE period|Absolute change in Apo CIII from baseline over time in the OLE period|Treatment-emergent adverse events (TEAEs) reported from the first dose of study drug to the end of study or the last visit in subjects treated with REGN1500|Serum concentration of REGN1500 over time|Presence and titer of anti-REGN1500 antibodies over time",Regeneron Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 2,9,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R1500-CL-1331,4-Feb-15,21-Nov-16,23-Jul-18,16-Oct-14,null,1-Aug-18,"Los Angeles, California, United States|Saint Louis, Missouri, United States|Philadelphia, Pennsylvania, United States|Dallas, Texas, United States|Chicoutimi, Quebec, Canada|Quebec City, Quebec, Canada|Amsterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT02265952
NCT02262806,Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy,,Enrolling by invitation,No Results Available,Diabetes|Lipodystrophy|Hyperlipidemia,Drug: Metreleptin,Serum hemoglobin A1C|Serum triglycerides|Bone mineral density &amp; metabolism|Ectopic lipid &amp; body composition|Steatohepatosis|Pituitary &amp; Reproductive Function,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC),All,"6 Months and older   (Child, Adult, Older Adult)",Phase 3,30,NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,150002|15-DK-0002,9-Oct-14,31-Jul-19,31-Jul-25,13-Oct-14,null,15-Aug-18,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02262806
NCT02262832,Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy,,Enrolling by invitation,No Results Available,Lipodystrophy|Diabetes|Hyperlipidemia,Drug: Metreleptin,Serum triglycerides|Serum hemoglobin A1C|Steatohepatosis|Pituitary &amp; Reproductive Function|Ectopic lipid &amp; body composition|Bone mineral density &amp; metabolism,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC),All,"6 Months and older   (Child, Adult, Older Adult)",Phase 3,23,NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,150003|15-DK-0003,10-Oct-14,31-Jul-19,31-Jul-25,13-Oct-14,null,10-Sep-18,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02262832
NCT02261402,"Effectiveness of ""Medisinstart""",,Completed,No Results Available,Cardiovascular Diseases,Other: Medisinstart,Adherence by Morisky 8-item Medication Adherence Scale (MMAS-8) at 7 weeks|Adherence by Morisky 8-item Medication Adherence Scale (MMAS-8) at 18 weeks|Self reported adherence at 7 weeks|Adherence by Medication Possession Ratio (MPR) at 18 weeks|Patients' beliefs about their medicines by Beliefs about Medicines Questionnaire (BMQ) at inclusion|Self reported adherence at 18 weeks|Adherence by Medication Possession Ratio (MPR) at 1 year|Patients' beliefs about their medicines by Beliefs about Medicines Questionnaire (BMQ) at 7 weeks|Patients' beliefs about their medicines by Beliefs about Medicines Questionnaire (BMQ) at 18 weeks,Apokus AS|Norwegian Pharmacy Association,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1480,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,Apokus-001,Oct-14,Dec-15,Dec-17,10-Oct-14,null,8-May-18,"Apotek 1 Alta, Alta, Norway|Apotek 1 Andselv, Andselv, Norway|Boots apotek Harebakken, Arendal, Norway|Sykehusapoteket Arendal, Arendal, Norway|Apotek 1 Horisont, Bergen, Norway|Boots apotek Bryggen, Bergen, Norway|Sjukehusapoteket i Bergen, Bergen, Norway|Sykehusapoteket i Bodø, Bodø, Norway|Apotek 1 Brandbu, Brandbu, Norway|Apotek 1 Bømlo, Bremnes, Norway|Apotek 1 Åssiden, Drammen, Norway|Sykehusapoteket Drammen, Drammen, Norway|Boots apotek Elverum, Elverum, Norway|Sykehusapoteket Elverum, Elverum, Norway|Boots apotek Flisa, Flisa, Norway|Apotek 1 Helsehuset Fredrikstad, Fredrikstad, Norway|Sjukehusapoteket i Førde, Førde, Norway|Boots apotek Hamar, Hamar, Norway|Sjukehusapoteket i Haugesund, Haugesund, Norway|Apotek 1 Lerka, Kleppe, Norway|Apotek 1 Kopervik, Kopervik, Norway|Vitusapotek Sørlandssenteret, Kristiansand, Norway|Boots apotek Larvik, Larvik, Norway|Apotek 1 Lofotsenteret, Leknes, Norway|Apotek 1 Malvik, Malvik, Norway|Apotek 1 Mandal, Mandal, Norway|Ditt apotek Maura, Maura, Norway|Ditt apotek Meyer, Mo i Rana, Norway|Ditt apotek Ytteren, Mo i Rana, Norway|Apotek 1 Sjøsiden, Mosjøen, Norway|Vitusapotek Varnaveien Moss, Moss, Norway|Apotek 1 Morenen, Mysen, Norway|Vitusapotek Nesbru, Nesbru, Norway|Apotek 1 St. Hanshaugen senter, Oslo, Norway|Boots apotek Bogstadveien, Oslo, Norway|Boots apotek Skøyen, Oslo, Norway|Boots apotek Solli, Oslo, Norway|Diakonhjemmets sykehusapotek, Oslo, Norway|Lovisenberg sykehusapotek, Oslo, Norway|Sykehusapoteket Oslo, Ullevål, Oslo, Norway|Vitusapotek Storo, Oslo, Norway|Vitusapotek Raufoss, Raufoss, Norway|Vitusapotek Syv Søstre, Sandnessjøen, Norway|Apotek 1 Kvadrat, Sandnes, Norway|Vitusapotek Ganddal, Sandnes, Norway|Apotek 1 Sandvika Storsenter, Sandvika, Norway|Sykehusapoteket Bærum, Sandvika, Norway|Boots apotek Lande, Sarpsborg, Norway|Boots apotek Saupstad, Saupstad, Norway|Vitusapotek Selbak, Sellebakk, Norway|Sykehusapoteket Skien, Skien, Norway|Apotek 1 Ski Amfi, Ski, Norway|Apotek 1 Hjorten Stavanger, Stavanger, Norway|Sjukehusapoteket i Stavanger, Stavanger, Norway|Vitusapotek Løven Stavanger, Stavanger, Norway|Vitusapotek Medisinsk senter - Steinkjer, Steinkjer, Norway|Sykehusapoteket Lørenskog, Strømmen, Norway|Vitusapotek Strømmen storsenter, Strømmen, Norway|Vitusapotek K1 Tromsø, Tromsø, Norway|Boots apotek Nordre, Trondheim, Norway|Vitusapotek Solsiden, Trondheim, Norway|Sykehusapoteket Tønsberg, Tønsberg, Norway|Vitusapotek Innherred, Verdal, Norway|Boots apotek Moa, Ålesund, Norway|Vitusapotek Raumnes, Årnes, Norway|Vitusapotek Årnes, Årnes, Norway|Gausdal apotek, Østre Gausdal, Norway",,https://ClinicalTrials.gov/show/NCT02261402
NCT02262143,Phase III Study of Rosuvastatin and Fenofibrate Versus Rosuvastatin in Mixed Dyslipidemia,,Completed,No Results Available,Mixed Dyslipidemias,Drug: Rosuvastatin|Drug: Fenofibrate,"The mean percent change of Non-HDL Cholesterol|The mean change, percent change of Non-LDL-C|The mean change of Non-LDL-C|The mean percent change of LDL-C, HDL-C, VLDL-C, TG, TC, Apo-AI, Apo-B|The achievement rate of Non-HDL-C<130mg/dl",IlDong Pharmaceutical Co Ltd,All,"19 Years to 80 Years   (Adult, Older Adult)",Phase 3,362,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ID-ROFE-301,Nov-14,Oct-16,Jun-17,10-Oct-14,null,24-Aug-18,"Ildong Pharm., Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02262143
NCT02260635,A Study of Evacetrapib (LY2484595) in Japanese Participants With Primary Hypercholesterolemia,,Terminated,Has Results,Hypercholesterolemia,Drug: Evacetrapib|Drug: Placebo,Percent Change From Baseline to Week 12 in Low-Density Lipoprotein Cholesterol (LDL-C) Measured by Beta Quantification|Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C)|Percent Change From Baseline in LDL-C (Direct)|Percent Change From Baseline in Non HDL-C|Percent Change From Baseline in Lipoprotein-a|Percent Change From Baseline in Apolipoprotein A-I|Percent Change From Baseline in Apolipoprotein B,Eli Lilly and Company,All,"20 Years and older   (Adult, Older Adult)",Phase 3,54,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",14503|I1V-JE-EIBI,Nov-14,Jul-15,Dec-15,9-Oct-14,8-Oct-18,8-Oct-18,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT02260635
NCT02260648,A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia,,Terminated,Has Results,Hypercholesterolemia,Drug: Evacetrapib|Drug: Ezetimibe|Drug: Atorvastatin|Drug: Placebo,Percent Change From Baseline to Week 12 in Low-Density Lipoprotein Cholesterol (LDL-C) Measured by Beta Quantification|Percent Change From Baseline to Week 12 in High-Density Lipoprotein Cholesterol (HDL-C)|Percent Change From Baseline to Week 12 in LDL-C (Direct)|Percent Change From Baseline to Week 12 in Non HDL-C|Percent Change From Baseline to Week 12 in Lipoprotein-a|Percent Change From Baseline to Week 12 in Apolipoprotein A-I|Percent Change From Baseline to Week 12 in Apolipoprotein B,Eli Lilly and Company,All,"20 Years and older   (Adult, Older Adult)",Phase 3,149,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",14501|I1V-JE-EIBG,Jan-15,Nov-15,Nov-15,9-Oct-14,8-Oct-18,8-Oct-18,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyogo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ibaragi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ibaraki, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kyoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saitama, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shizuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT02260648
NCT02259153,Effect of Different Fat Enriched Meats on the Hepatic Cholesterol Synthesis,,Completed,No Results Available,"Lipid Metabolism Disorders|Sterols|Diet, High-Fat|Cholesterol|Fatty Acids|Hyperlipidemias",Behavioral: Changes in cholesterol metabolism|Other: Lean red meat diet|Other: Fat red meat diet,Changes in lipid profile|Changes in non cholesterol sterols and oxysterols serum concentrations,Instituto Aragones de Ciencias de la Salud,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,CEICA;PI13-00106,Mar-14,May-14,Aug-14,8-Oct-14,null,8-Oct-14,,,https://ClinicalTrials.gov/show/NCT02259153
NCT02251847,The Efficacy and Safety of a Combination Therapy of Rosuvastatin and Ezetimibe Versus Monotherapy of Rosuvastatin in Hypercholesterolemia Patients,,Unknown status,No Results Available,Hypercholesterolemia,Drug: Rosuvastatin/Ezetimibe,Percent change from baseline to 8 week in LDL-Cholesterol|Percent change from baseline to 4 week in LDL-Cholesterol,IlDong Pharmaceutical Co Ltd,All,"19 Years to 80 Years   (Adult, Older Adult)",Phase 3,400,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ID-ROEZ-301,Jul-14,Jul-15,null,29-Sep-14,null,29-Sep-14,"Gil Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02251847
NCT02250105,Trial of ARI-3037MO to Reduce Triglyceride Levels in Adults With Severe (≥500 mg/dl) Hypertriglyceridemia,,Completed,No Results Available,Hypertriglyceridemia,Drug: ARI-3037MO|Drug: Placebo,Change in Triglyceride levels|Change in LDL cholesterol|Change in HDL cholesterol,Arisaph Pharmaceuticals Inc|Baim Institute for Clinical Research,All,"18 Years and older   (Adult, Older Adult)",Phase 2,80,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ARI-3037MO-004,Sep-14,Jun-16,Jun-16,26-Sep-14,null,8-Aug-16,"Orange County Research Center, Tustin, California, United States|Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky, United States|Maine Research Associates, Auburn, Maine, United States|Sterling Clinical Research Inc, Cincinnati, Ohio, United States|National Clinical Research inc, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02250105
NCT02247635,Effect of a Treatment of Lifestyle Changes on the Prevalence of Metabolic Syndrome and Body Weight in Mexican Women,MPATPCDNC,Completed,No Results Available,Obesity|Diabetes|High Blood Pressure|Dyslipidemia,Behavioral: Healthy lifestyle and adherence,"Reduction in the prevalence of metabolic syndrome (obesity, diabetes, hypertension, dyslipidemia)|Reduction of hyperglycemia|Weight loss|Reduction of high blood pressure|Reduction of hypercholesterolemia",Mexican National Institute of Public Health,Female,"20 Years to 65 Years   (Adult, Older Adult)",Not Applicable,180,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CINYS 410|000000000044415,Nov-08,May-09,Aug-10,25-Sep-14,null,3-Nov-14,"Mexican National Institute of Public Health, Cuernavaca,, Morelos, Mexico",,https://ClinicalTrials.gov/show/NCT02247635
NCT02241759,Study of the Electrocardiographic Effects of TA-8995,,Completed,No Results Available,Dyslipidaemia,Drug: TA-8995|Drug: Moxifloxacin|Drug: Placebo,Change from baseline in QT interval corrected for heart rate (QTc) for TA-8995 versus placebo|Relationship between plasma levels of TA-8995 and the QTcF effect,Xention Ltd,All,18 Years to 55 Years   (Adult),Phase 1,136,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TA-8995-04,Aug-14,Nov-14,Dec-14,16-Sep-14,null,16-Feb-15,"Covance Clinical Research Unit Ltd, Leeds, United Kingdom",,https://ClinicalTrials.gov/show/NCT02241759
NCT02236533,Healthy Effects of an Innovative Probiotic Pasta,SFLABPASTA,Completed,No Results Available,OBESITY|INFLAMMATION|DYSLIPIDEMIA|CONSTIPATION,Dietary Supplement: whole grain pasta,Variation of plasma lipids|Variation of fecal microbiota composition|Variation of antioxidant activity on fecal waters|Variation of body weight|Variation of serum inflammatory marker concentration|Variation of blood pressure|Variation of body circumferences|Variation of urine antioxidant marker,University of Parma|Universita di Verona,All,"30 Years to 65 Years   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,SFLAB14,Mar-14,Sep-14,Mar-15,10-Sep-14,null,1-Nov-18,"University of Parma - Department of Food Sciences, Parma, PR, Italy|University of Parma, Parma, Italy",,https://ClinicalTrials.gov/show/NCT02236533
NCT02230345,Effects of a Probiotics on the Health of Normal Young Males,FFF,Completed,No Results Available,Inflammation|Dyslipidemia,Dietary Supplement: Probiotic yogurt|Dietary Supplement: Acidified milk,Metabolomic analyses|Glucose|Insulin|Glucagon like polypeptide-1|Gastric inhibitory polypeptide|Total cholesterol|LDL-cholesterol|HDL-cholesterol|Non esterified fatty acids|Triglycerides|Interleukin-6|Chemokine CCK2|Chemokine CCK5|Tunour necrosis factor alpha|Lipo-poly-saccharide,Centre Hospitalier Universitaire Vaudois|Agroscope Liebefeld-Posieux Research Station ALP,Male,18 Years to 40 Years   (Adult),Not Applicable,14,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",392/13,Mar-14,Dec-14,Jul-15,3-Sep-14,null,21-Aug-15,"Clinical research center, Lausanne University hospital, Lausanne, Vaud, Switzerland",,https://ClinicalTrials.gov/show/NCT02230345
NCT02227784,A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol,ACCENTUATE,Terminated,Has Results,Hyperlipidemia,Drug: Evacetrapib|Drug: Atorvastatin|Drug: Ezetimibe|Drug: Placebo,Percent Change From Baseline to 3 Months in Low-Density Lipoprotein Cholesterol (LDL-C)|Percent Change From Baseline to 3 Months in High-Density Lipoprotein Cholesterol (HDL-C)|Percent Change From Baseline to 3 Months in Apolipoprotein AI (apoAI)|Percent Change From Baseline to 3 Months in Non-HDL-C|Percent Change From Baseline to 3 Months in Apolipoprotein B (apoB)|Percent Change From Baseline to 3 Months in Cholesterol Efflux Capacity|Percent Change From Baseline to 3 Months in Lipoprotein(a) (Lp[a]),Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 3,366,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",14502|I1V-MC-EIBH,Oct-14,Dec-15,Dec-15,28-Aug-14,22-Mar-18,22-Mar-18,"Heart Center Research, LLC, Huntsville, Alabama, United States|Desert Clinical Research, Mesa, Arizona, United States|Central Phoenix Med Clinic LLC, Phoenix, Arizona, United States|Advanced Clinical Research, Carmichael, California, United States|Tooraj Joseph Raoof M.D., Inc., Encino, California, United States|Irvine Clinical Research Center, Irvine, California, United States|VA Long Beach Healthcare System, Long Beach, California, United States|Rancho Cucamonga Clinical, Rancho Cucamonga, California, United States|Encompass Clinical Research, Spring Valley, California, United States|University Clinical Investigators, Inc., Tustin, California, United States|Diablo Clinical Research, Walnut Creek, California, United States|University of Colorado Health Sciences Center, Aurora, Colorado, United States|Cardiac Research, Colorado Springs, Colorado, United States|ZASA Clinical Research, Boynton Beach, Florida, United States|Cardiology Research Assoc., Daytona Beach, Florida, United States|Avail Clinical Research LLC, DeLand, Florida, United States|Alan Graff, MD, PA, Fort Lauderdale, Florida, United States|Nature Coast Clinical Research, LLC, Inverness, Florida, United States|Suncoast Research Group, LLC, Miami, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Cardiology Partners Clinical Research Institute, LLC, Wellington, Florida, United States|Georgia Heart Specialists, Covington, Georgia, United States|United Osteoporosis Center, Gainesville, Georgia, United States|East West Medical Institute, Honolulu, Hawaii, United States|Solaris Clinical Research, Meridian, Idaho, United States|Northwest Heart Clinical Research, LLC, Arlington Heights, Illinois, United States|Cedar-Crosse Research Center, Chicago, Illinois, United States|Midwest CRC, Crystal Lake, Illinois, United States|Indiana Heart Physicians Inc, Indianapolis, Indiana, United States|Midwest Institute for Clinical Research, Indianapolis, Indiana, United States|Hutchinson Clinic, Hutchinson, Kansas, United States|Community Medical Associates, Louisville, Kentucky, United States|Grace Research, Bossier City, Louisiana, United States|Maryland Cardiovascular Specialists, Baltimore, Maryland, United States|Overlea Personal Physicians, Baltimore, Maryland, United States|Cape Cod Research Institute, Hyannis, Massachusetts, United States|ActivMed Practices & Research, Inc, Methuen, Massachusetts, United States|Medex Healthcare Research, Inc., Saint Louis, Missouri, United States|Palm Research Center, Las Vegas, Nevada, United States|Heart and Vascular Center of New Brunswick LLC, Somerset, New Jersey, United States|Medex Healthcare Research, Inc., New York, New York, United States|Saratoga Clinical Research LLC, Saratoga Springs, New York, United States|Buffalo Cardiology and Pulmonary Associates, P.C., Williamsville, New York, United States|Asheville Cardiology Associates, Asheville, North Carolina, United States|Metrolina Internal Medicine, P.A., Charlotte, North Carolina, United States|High Point Clinical Trials Center, High Point, North Carolina, United States|Boice Willis Clinic, PA, Rocky Mount, North Carolina, United States|PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States|Lillestol Research LLC, Fargo, North Dakota, United States|Aventiv Research, Columbus, Ohio, United States|South Oklahoma Heart Research, LLC, Oklahoma City, Oklahoma, United States|Portland Preventive Cardiology, LLC, Portland, Oregon, United States|Partners in Clinical Research, Cumberland, Rhode Island, United States|PMG Research of Charleston, LLC, Mount Pleasant, South Carolina, United States|Black Hills Cardiovascular Research Group, Rapid City, South Dakota, United States|Holston Medical Group Clinical Research, Kingsport, Tennessee, United States|Northwest Houston Heart Center, Tomball, Texas, United States|National Clinical Research - Richmond, Richmond, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Kootenai Heart Clinics, LLC, Spokane, Washington, United States|Clinical Investigation Specialists Inc, Kenosha, Wisconsin, United States|Research and Cardiovascular Corp., Ponce, Puerto Rico|Clinical Research Puerto Rico, Inc., San Juan, Puerto Rico|GCM Medical Group PSC, San Juan, Puerto Rico",,https://ClinicalTrials.gov/show/NCT02227784
NCT02228252,The Effect of Protein Quality and Time-factor by Consumption of a Pre-meal on Postprandial Lipemia in Subjects With the Metabolic Syndrome.,,Completed,No Results Available,Metabolic Syndrome,Other: Whey protein|Other: Casein|Other: Gluten protein,Effect on triglyceride response of whey protein as pre-meal after a high-fat meal in subjects with the metabolic syndrome measured as incremental Area Under the Curve (iAUC -15 - 360 min).|Effect on apolipoprotein B48 of whey protein as pre-meal after a high-fat meal in subjects with the metabolic syndrome measured as incremental Area Under the Curve (iAUC -15 - 360 min).|Glucose responses measured as incremental Area Under the Curve (AUC -30/-15 - 360 min)|Insulin responses measured as incremental Area Under the Curve (AUC -30/-15 - 360 min)|Glucagon responses measured as incremental Area Under the Curve (AUC -30/-15 - 360 min)|Glucagon-like peptide 1 (GLP-1) responses measured as incremental Area Under the Curve (AUC -30/-15 - 360 min)|Gastric inhibitory peptide (GIP) responses measured as incremental Area Under the Curve (AUC -30/-15 - 360 min),Aarhus University Hospital|University of Aarhus|University of Copenhagen,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,16,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,CERN-Premeal2,Aug-14,Mar-15,Mar-15,28-Aug-14,null,5-May-15,"Aarhus University Hospital, Aarhus, Aarhus C, Denmark",,https://ClinicalTrials.gov/show/NCT02228252
NCT02226198,A Study to Evaluate the Efficacy and Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia,HYDRA,Completed,Has Results,Homozygous Familial Hypercholesterolemia (HoFH),Drug: Rosuvastatin 20mg|Drug: Placebo,"LDL-Cholesterol (mg/dL)|LDL-Cholesterol (mmol/L)|TC (mg/dL)|TC (mmol/L)|Non-HDL C (mg/dL)|Non-HDL C (mmol/L)|ApoB (mg/dL)|ApoB (g/L)|HDL-C (mg/dL)|HDL-C (mmol/L)|LDL-C, Not on Apheresis (mg/dL)|LDL-C, Not on Apheresis (mmol/L)|LDL-C From End of Placebo (mg/dL)|LDL-C From End of Placebo (mmol/L)|Trough Concentrations|Adverse Events|AE's Leading to Discontinuation|Abnormal Serum Levels|Height|Height Z-score|Weight|Tanner Stage|TG (mg/dL)|TG (mmol/L)|LDL C/HDL C|TC/HDL C|Non-HDL C/HDL C|ApoB/ApoA|Urinalysis Abnormalitites|ECG Abnormalities|Physical Exam Abnormalitites|Abnormal Vital Signs",AstraZeneca,All,6 Years to 17 Years   (Child),Phase 3,20,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",D3561C00004,Nov-14,Jul-15,Jul-15,27-Aug-14,4-Jul-16,4-Jul-16,"Research Site, Brussels (Woluwé-St-Lambert), Belgium|Research Site, Chicoutimi, Quebec, Canada|Research Site, København Ø, Denmark|Research Site, Haifa, Israel|Research Site, Kuala Lumpur, Malaysia|Research Site, Kubang Kerian, Malaysia|Research Site, Amsterdam, Netherlands|Research Site, Goteborg, Netherlands|Research Site, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT02226198
NCT02223793,Vascular Lifestyle-Intervention and Screening in Pharmacy,VISA,"Active, not recruiting",No Results Available,"Cardiovascular Diseases|Hypercholesterolemia|Dyslipidemia|Hypertensive Disease|Diabetes Mellitus, Type 2","Behavioral: Information on high risk factor levels and lifestyle advice|Behavioral: No information on high risk factor levels but lifestyle advice|Behavioral: No information on high risk factor levels, nor lifestyle advice",Change in risk score|Change in composite biochemical and anthropometric measurement levels,University of Oslo|University of Tromso|University of Minnesota - Clinical and Translational Science Institute|Boots Norway AS|Mills DA,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,581,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Screening,2013/1660|39255 (NSD)|1660/2013,Sep-14,Dec-15,Feb-22,22-Aug-14,null,30-Oct-17,"University of Oslo, Oslo, P.B. 1046 Blinderen, Norway",,https://ClinicalTrials.gov/show/NCT02223793
NCT02221973,Effect of a Low Fat Milk Product on Lipids Profile in Dyslipidemia Subjects,Lipidown,Completed,No Results Available,Primary Dyslipidemia,Dietary Supplement: sterols and hawthorn powder,"serum concentration of Total Cholesterol (TC),|other lipid and lipoprotein parameters in serum samples that could reveal cardiovascular disease (CVD) risk etc.|biomarkers of lipid oxidation and inflammation|phytosterol metabolism parameters|predictive marker for cardiovascular disease|safety parameters",Nestlé,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,75,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",12.03.NRC,Jul-13,Oct-14,Oct-14,21-Aug-14,null,13-Nov-15,"Anzhen Hospital, Capital University of Medical Sciences, Beijing, China|Chao Yang 2nd Hospital, Beijing, China|Chui Yang Liu Hospital, Beijing, China",,https://ClinicalTrials.gov/show/NCT02221973
NCT02221297,Lipid-lowering Effect of a Plant Stanol Ester Supplement Product,,Completed,No Results Available,Hypercholesterolemia|Hyperlipidemias|Dyslipidemias,Dietary Supplement: Supplement product with plant stanol ester,Proportional change in serum LDL cholesterol|Proportional change in total cholesterol|Proportional change in non-HDL-cholesterol|Proportional change in serum triglycerides|Proportional change in lipids in all study participants|Proportional change in lipids in subjects without metabolic derangements,Raisio Group|Clinical Research Institute HUCH Ltd,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,103,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CL2014_035,May-14,Nov-14,Nov-14,20-Aug-14,null,29-Oct-15,,,https://ClinicalTrials.gov/show/NCT02221297
NCT02216825,Effect of L. Reuteri NCIMB 30242 on Plasma Bile Acid Profile,,Completed,No Results Available,Hypercholesterolemia,"Dietary Supplement: Delayed release capsule, L. reuteri NCIMB 30242, escalated dose|Dietary Supplement: Standard vegetarian capsule, L. reuteri NCIMB 30242, escalated dose",The primary outcome will be the change in plasma bile acid profile from baseline to endpoint,Micropharma Limited,All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 2,10,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)",MP-12LCHMe,Nov-13,Dec-13,Jun-14,15-Aug-14,null,15-Aug-14,,,https://ClinicalTrials.gov/show/NCT02216825
NCT02215408,MEDication Focused Outpatient Care for Underutilization of Secondary Prevention,MEDFOCUS,Completed,No Results Available,Diabetes|Hyperlipidemia|Hypertension|Cardiovascular Disease,Behavioral: CVRS Intervention,"The mean percent of applicable Guideline Advantage standards of care that are met at 12 months|The average cost per subject, measured in dollars and cents, of implementing the intervention|The percent of intervention group patients who rate the intervention as helpful (versus not helpful)",Korey Kennelty|University of Iowa,All,"55 Years and older   (Adult, Older Adult)",Not Applicable,402,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,201309828,20-Jan-15,30-Jun-17,30-Sep-18,13-Aug-14,null,19-Feb-19,"University of Florida, Gainesville, Florida, United States|University of South Florida, Tampa, Florida, United States|Idaho State University, Pocatello, Idaho, United States|Midwestern University, Downers Grove, Illinois, United States|Genesis Health System, Davenport, Iowa, United States|University of Iowa, Iowa City, Iowa, United States|Siouxland Medical Education Foundation, Sioux City, Iowa, United States|Northeast Iowa Medical Education Foundation, Waterloo, Iowa, United States|SUNY-University of Buffalo, Buffalo, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Temple University, Philadelphia, Pennsylvania, United States|Texas Tech University Health Science Center, Amarillo, Texas, United States|Memorial Hermann Hospital System, Houston, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|University of Utah, Salt Lake City, Utah, United States|University of Wisconsin, Madison, Wisconsin, United States|Wheaton Franciscan Medical Group, Milwaukee, Wisconsin, United States|Milwaukee Health Services,Inc., Milwaukee, Wisconsin, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT02215408/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT02215408
NCT02215694,Supplementation of Dual Probiotic Strains Reduced Fasting Triglyceride and Enhanced Apolipoprotein A-V Levels,,Completed,No Results Available,Hypertriglyceridemia,Dietary Supplement: dual probiotics|Dietary Supplement: placebo,ApoA5-1131 genotype|Fasting glucose at baseline and 12-week follow-up|Insulin at baseline and 12-week follow-up|C-peptide at baseline and 12-week follow-up|Apolipoprotein A-V at baseline and 12-week follow-up|Triglyceride at baseline and 12-week follow-up|Free fatty acid at baseline and 12-week follow-up,Yonsei University,All,"24 Years to 68 Years   (Adult, Older Adult)",Phase 3,128,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",probiotics_140801,Jun-12,Mar-14,Mar-14,13-Aug-14,null,13-Aug-14,"Laboratory of Clinical Nutrigenetics/Nutrigenomics, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02215694
NCT02211209,The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome,,Completed,No Results Available,Familial Chylomicronemia Syndrome,Drug: volanesorsen|Drug: Placebo,Efficacy of ISIS-APOCIIIRx as measured by the percent change in fasting triglycerides from baseline,"Ionis Pharmaceuticals, Inc.|Akcea Therapeutics",All,"18 Years and older   (Adult, Older Adult)",Phase 3,67,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 304801-CS6,Dec-14,Dec-16,27-Mar-17,7-Aug-14,null,12-Jul-18,"IONIS Investigative Site, Encinitas, California, United States|IONIS Investigative Site, San Francisco, California, United States|IONIS Investigative Site, Kansas City, Kansas, United States|IONIS Investigative Site, Boston, Massachusetts, United States|IONIS Investigative Site, New York, New York, United States|IONIS Investigative Site, Oklahoma City, Oklahoma, United States|IONIS Investigative Site, Portland, Oregon, United States|IONIS Investigative Site, Philadelphia, Pennsylvania, United States|IONIS Investigative Site, Houston, Texas, United States|IONIS Investigative Site, Norfolk, Virginia, United States|IONIS Investigative Site, Seattle, Washington, United States|IONIS Investigative Site, Campinas, Brazil|IONIS Investigative Site, Sao Paulo, Brazil|IONIS Investigative Site, Sao Paulo, Brazil|IONIS Investigative Site, Vancouver, British Columbia, Canada|IONIS Investigative Site, Chicoutimi, Quebec, Canada|IONIS Investigative Site, Sainte-Foy, Quebec, Canada|IONIS Investigative Site, Marseille, France|IONIS Investigative Site, Nantes, France|IONIS Investigative Site, Paris, France|IONIS Investigative Site, Berlin, Germany|IONIS Investigative Site, Dresden, Germany|IONIS Investigative Site, Szikszo, Hungary|IONIS Investigative Site, Holan, Israel|IONIS Investigative Site, Safed, Israel|IONIS Investigative Site, Milan, Italy|IONIS Investigative Site, Palermo, Italy|IONIS Investigative Site, Rome, Italy|IONIS Investigative Site, Amsterdam, Netherlands|IONIS Investigative Site, Rotterdam, Netherlands|IONIS Investigative Site, Cape Town, South Africa|IONIS Investigative Site, Zaragoza, Aragon, Spain|IONIS Investigative Site, La Coruna, Galicia, Spain|IONIS Investigative Site, Barcelona, Spain|IONIS Investigative Site, Madrid, Spain|IONIS Investigative Site, Malaga, Spain|IONIS Investigative Site, Sevilla, Spain|IONIS Investigative Site, Birmingham, United Kingdom|IONIS Investigative Site, Manchester, United Kingdom|IONIS Investigative Site, Manchester, United Kingdom|IONIS Investigative Site, Nyne And Wear EST, United Kingdom|IONIS Investigative Site, Peterborough, United Kingdom",,https://ClinicalTrials.gov/show/NCT02211209
NCT02208674,Early Identification and Action in CKD,,Completed,No Results Available,Chronic Kidney Disease|Hypertension,"Other: Protocolized, pharmacist-delivered CKD Action Plan",Screening Urinary Albumin Excretion|Dyslipidemia Screening|ACEI or ARB Treatment if urine ACR is > 30 mg/g (diabetic) or > 300 mg/g (non-diabetic)|Statin Treatment|Blood Pressure Control-1|Blood Pressure--II|Blood Pressure--III|Biochemical Surveillance|Symptomatic Adverse Drug Event|Patient and Provider Satisfaction|Cystatin C Supplementary Screening,Geisinger Clinic,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,47,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,2014-0251,Sep-14,Mar-16,Mar-16,5-Aug-14,null,15-Nov-16,"Geisinger Health System, Danville, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02208674
NCT02207634,Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects,EBBINGHAUS,Completed,Has Results,Dyslipidemia,Biological: Evolocumab|Drug: Placebo|Drug: Background Statin Therapy,Mean Change From Baseline in Spatial Working Memory Strategy Index of Executive Function (6-8 Boxes) Z Score|Mean Change From Baseline in Spatial Working Memory (SWM) Between-errors Z Score|Mean Change From Baseline in Paired Associated Learning (PAL) Total Errors Adjusted Z Score|Mean Change From Baseline in Reaction Time (RTI) Median 5-choice Reaction Time Z Score,Amgen,All,"40 Years to 85 Years   (Adult, Older Adult)",Phase 3,1974,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",20130385|2014-001976-75,10-Sep-14,11-Nov-16,11-Nov-16,4-Aug-14,16-Jan-18,16-Jan-18,"Research Site, Birmingham, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Glendale, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Alhambra, California, United States|Research Site, Banning, California, United States|Research Site, Harbor City, California, United States|Research Site, Laguna Hills, California, United States|Research Site, Long Beach, California, United States|Research Site, Long Beach, California, United States|Research Site, Oceanside, California, United States|Research Site, Oxnard, California, United States|Research Site, Palm Springs, California, United States|Research Site, Roseville, California, United States|Research Site, Sacramento, California, United States|Research Site, San Pedro, California, United States|Research Site, Tarzana, California, United States|Research Site, Thousand Oaks, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Bridgeport, Connecticut, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Crystal River, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Deerfield Beach, Florida, United States|Research Site, Fleming Island, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Palm Harbor, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Ponte Vedra, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Augusta, Georgia, United States|Research Site, Gainesville, Georgia, United States|Research Site, Savannah, Georgia, United States|Research Site, Suwanee, Georgia, United States|Research Site, Coeur d'Alene, Idaho, United States|Research Site, Addison, Illinois, United States|Research Site, Belleville, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Jerseyville, Illinois, United States|Research Site, Hammond, Indiana, United States|Research Site, Waterloo, Iowa, United States|Research Site, Hutchinson, Kansas, United States|Research Site, Lexington, Kentucky, United States|Research Site, Owensboro, Kentucky, United States|Research Site, Baton Rouge, Louisiana, United States|Research Site, Hammond, Louisiana, United States|Research Site, Lafayette, Louisiana, United States|Research Site, Metairie, Louisiana, United States|Research Site, Monroe, Louisiana, United States|Research Site, Slidell, Louisiana, United States|Research Site, Biddeford, Maine, United States|Research Site, Salisbury, Maryland, United States|Research Site, Towson, Maryland, United States|Research Site, Haverhill, Massachusetts, United States|Research Site, Newton, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Grandville, Michigan, United States|Research Site, Lansing, Michigan, United States|Research Site, Muskegon, Michigan, United States|Research Site, Saint Paul, Minnesota, United States|Research Site, Jefferson City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Great Falls, Montana, United States|Research Site, Kalispell, Montana, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Westwood, New Jersey, United States|Research Site, Brooklyn, New York, United States|Research Site, Buffalo, New York, United States|Research Site, Cortlandt Manor, New York, United States|Research Site, New Hyde Park, New York, United States|Research Site, New Windsor, New York, United States|Research Site, Rochester, New York, United States|Research Site, Troy, New York, United States|Research Site, West Seneca, New York, United States|Research Site, Williamsville, New York, United States|Research Site, Calabash, North Carolina, United States|Research Site, Hickory, North Carolina, United States|Research Site, Hickory, North Carolina, United States|Research Site, Mooresville, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Tabor City, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Grand Forks, North Dakota, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Springfield, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Pryor, Oklahoma, United States|Research Site, Bend, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Camp Hill, Pennsylvania, United States|Research Site, Chambersburg, Pennsylvania, United States|Research Site, Feasterville, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Pawtucket, Rhode Island, United States|Research Site, Fort Mill, South Carolina, United States|Research Site, Moncks Corner, South Carolina, United States|Research Site, Mount Pleasant, South Carolina, United States|Research Site, North Myrtle Beach, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Jackson, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Tullahoma, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Plano, Texas, United States|Research Site, Wichita Falls, Texas, United States|Research Site, West Jordan, Utah, United States|Research Site, Burke, Virginia, United States|Research Site, Falls Church, Virginia, United States|Research Site, Hopewell, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Suffolk, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Green Bay, Wisconsin, United States|Research Site, Woden, Australian Capital Territory, Australia|Research Site, Auchenflower, Queensland, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, Ashford, South Australia, Australia|Research Site, Fullarton, South Australia, Australia|Research Site, Hobart, Tasmania, Australia|Research Site, Box Hill, Victoria, Australia|Research Site, Epping, Victoria, Australia|Research Site, Geelong, Victoria, Australia|Research Site, Aalst, Belgium|Research Site, Bonheiden, Belgium|Research Site, Brussels, Belgium|Research Site, Brussels, Belgium|Research Site, Gozee, Belgium|Research Site, Ieper, Belgium|Research Site, La Louvière, Belgium|Research Site, Liege, Belgium|Research Site, Liège, Belgium|Research Site, St. Johns, Newfoundland and Labrador, Canada|Research Site, London, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Peterborough, Ontario, Canada|Research Site, Sarnia, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Gatineau, Quebec, Canada|Research Site, Pointe-Claire, Quebec, Canada|Research Site, St Jean sur Richelieu, Quebec, Canada|Research Site, St-Jérôme, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Beroun, Czechia|Research Site, Bilovec, Czechia|Research Site, Brandys nad Labem, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Chomutov, Czechia|Research Site, Havlickuv Brod, Czechia|Research Site, Hodonin, Czechia|Research Site, Klatovy IV, Czechia|Research Site, Liberec, Czechia|Research Site, Litomysl, Czechia|Research Site, Mohelnice, Czechia|Research Site, Olomouc, Czechia|Research Site, Ostrava - Vitkovice, Czechia|Research Site, Pardubice, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 3, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 5 - Smichov, Czechia|Research Site, Prerov, Czechia|Research Site, Uherske Hradiste, Czechia|Research Site, Aalborg, Denmark|Research Site, Ballerup, Denmark|Research Site, Esbjerg, Denmark|Research Site, Hvidovre, Denmark|Research Site, København S, Denmark|Research Site, Køge, Denmark|Research Site, Vejle, Denmark|Research Site, Paide, Estonia|Research Site, Tallinn, Estonia|Research Site, Tallinn, Estonia|Research Site, Tallinn, Estonia|Research Site, Helsinki, Finland|Research Site, Helsinki, Finland|Research Site, Jyväskylä, Finland|Research Site, Kuopio, Finland|Research Site, Oulu, Finland|Research Site, OYS, Finland|Research Site, Tampere, Finland|Research Site, Turku, Finland|Research Site, Besançon Cedex, France|Research Site, Le Coudray, France|Research Site, Montepellier Cedex, France|Research Site, Nantes Cedex 1, France|Research Site, Paris, France|Research Site, Pessac Cedex, France|Research Site, Toulouse Cedex 9, France|Research Site, Bad Krozingen, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Bochum, Germany|Research Site, Dresden, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Köln, Germany|Research Site, Leipzig, Germany|Research Site, Stuttgart, Germany|Research Site, Witten, Germany|Research Site, Wuppertal, Germany|Research Site, Alexandroupoli, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Ioannina, Greece|Research Site, Larissa, Greece|Research Site, Piraeus, Greece|Research Site, Hong Kong, Hong Kong|Research Site, Bekescsaba, Hungary|Research Site, Berettyoujfalu, Hungary|Research Site, Budapest, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Pecs, Hungary|Research Site, Szeged, Hungary|Research Site, Szekszard, Hungary|Research Site, Szikszo, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Pavia, Italy|Research Site, Ichinomiya-shi, Aichi, Japan|Research Site, Kasugai-shi, Aichi, Japan|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Toyohashi-shi, Aichi, Japan|Research Site, Matsudo-shi, Chiba, Japan|Research Site, Saijo-shi, Ehime, Japan|Research Site, Chikushi-gun, Fukuoka, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Itoshima-shi, Fukuoka, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Himeji-shi, Hyogo, Japan|Research Site, Toride-shi, Ibaraki, Japan|Research Site, Tsukuba-city, Ibaraki, Japan|Research Site, Kyoto-shi, Kyoto, Japan|Research Site, Okinawa-shi, Okinawa, Japan|Research Site, Shimajiri-gun, Okinawa, Japan|Research Site, Urasoe-shi, Okinawa, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Saga-shi, Saga, Japan|Research Site, Saga-shi, Saga, Japan|Research Site, Kawaguchi-shi, Saitama, Japan|Research Site, Komatsushima-shi, Tokushima, Japan|Research Site, Chuo-ku, Tokyo, Japan|Research Site, Daugavpils, Latvia|Research Site, Kuldiga, Latvia|Research Site, Liepaja, Latvia|Research Site, Ogre, Latvia|Research Site, Ogre, Latvia|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Vilnius, Lithuania|Research Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Research Site, Kuala Lumpur, Malaysia|Research Site, Arnhem, Netherlands|Research Site, Ede, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Hoorn, Netherlands|Research Site, Uden, Netherlands|Research Site, Christchurch, New Zealand|Research Site, Tauranga, New Zealand|Research Site, Hamar, Norway|Research Site, Lierskogen, Norway|Research Site, Oslo, Norway|Research Site, Skedsmokorset, Norway|Research Site, Skien, Norway|Research Site, Stavanger, Norway|Research Site, Ålesund, Norway|Research Site, Gdansk, Poland|Research Site, Gdynia, Poland|Research Site, Gdynia, Poland|Research Site, Katowice, Poland|Research Site, Katowice, Poland|Research Site, Katowice, Poland|Research Site, Kielce, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Olsztyn, Poland|Research Site, Poznan, Poland|Research Site, Pulawy, Poland|Research Site, Ruda Slaska, Poland|Research Site, Staszow, Poland|Research Site, Swidnik, Poland|Research Site, Tarnow, Poland|Research Site, Torun, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wloclawek, Poland|Research Site, Wroclaw, Poland|Research Site, Wroclaw, Poland|Research Site, Wroclaw, Poland|Research Site, Zamosc, Poland|Research Site, Almada, Portugal|Research Site, Carnaxide, Portugal|Research Site, Coimbra, Portugal|Research Site, Covilha, Portugal|Research Site, Ekaterinburg, Russian Federation|Research Site, Ivanovo, Russian Federation|Research Site, Izhevsk, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Kirov, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Pushkin, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Bardejov, Slovakia|Research Site, Brezno, Slovakia|Research Site, Kosice, Slovakia|Research Site, Lucenec, Slovakia|Research Site, Moldava nad Bodvou, Slovakia|Research Site, Nove Zamky, Slovakia|Research Site, Rimavska Sobota, Slovakia|Research Site, Roznava, Slovakia|Research Site, Snina, Slovakia|Research Site, Svidnik, Slovakia|Research Site, Trencin, Slovakia|Research Site, Trnava, Slovakia|Research Site, Centurion, Gauteng, South Africa|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Pretoria west, Gauteng, South Africa|Research Site, Pretoria, Gauteng, South Africa|Research Site, Paarl, Western Cape, South Africa|Research Site, Parow, Western Cape, South Africa|Research Site, Somerset West, Western Cape, South Africa|Research Site, Worcester, Western Cape, South Africa|Research Site, Cape Town, South Africa|Research Site, Kempton Park, South Africa|Research Site, Zaragoza, Aragón, Spain|Research Site, L'Hospitalet de Llobregat, Cataluña, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Santiago de Compostela, Galicia, Spain|Research Site, Vigo, Galicia, Spain|Research Site, Galdakao, País Vasco, Spain|Research Site, Madrid, Spain|Research Site, Helsingborg, Sweden|Research Site, Linköping, Sweden|Research Site, Lund, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Uddevalla, Sweden|Research Site, Västerås, Sweden|Research Site, Adana, Turkey|Research Site, Ankara, Turkey|Research Site, Gaziantep, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Kocaeli, Turkey|Research Site, Belfast, United Kingdom|Research Site, Birmingham, United Kingdom|Research Site, Birmingham, United Kingdom|Research Site, Bournemouth, United Kingdom|Research Site, Cardiff, United Kingdom|Research Site, Chesterfield, United Kingdom|Research Site, Chippenham, United Kingdom|Research Site, Chorley, United Kingdom|Research Site, Doncaster, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Hexham, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Newport, United Kingdom|Research Site, Nuneaton, United Kingdom|Research Site, Reading, United Kingdom|Research Site, Sandbach, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, West Bromwich, United Kingdom|Research Site, Whitby, United Kingdom|Research Site, Worcester, United Kingdom",,https://ClinicalTrials.gov/show/NCT02207634
NCT02205606,Efficacy/Safety of HCP1306 Tablet Versus HGP0816 Tablet in Patients With Primary Hypercholesterolemia,,Completed,No Results Available,Primary Hypercholesterolemia,Drug: HGP0816 5mg|Drug: HGP0816 10mg|Drug: HGP0816 20mg|Drug: HCP1306 5/10mg|Drug: HCP1306 10/10mg|Drug: HCP1306 20/10mg,Percent change from baseline to 8 week in LDL-Cholesterol|Percent change from baseline to 4 week in LDL-Cholesterol|Percentage of patients reaching treatment goals according to NCEP ATP III Guideline|Percent change from baseline to 4 week and 8 week in TC|Percent change from baseline to 4 week and 8 week in HDL-C|Percent change from baseline to 4 week and 8 week in TG,Hanmi Pharmaceutical Company Limited,All,"19 Years and older   (Adult, Older Adult)",Phase 3,412,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",HM-ROZE-301,Jun-14,Feb-15,Apr-15,31-Jul-14,null,22-Sep-15,"19 institutions including Seoul National University Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02205606
NCT02203227,Efficacy and Safety Study of Dietary Supplements in Chronic Smokers Having Mild to Moderate Hyperlipidemia,,Unknown status,No Results Available,Chronic Smokers|Hyperlipidemia,Dietary Supplement: Placebo|Dietary Supplement: BioTurmin (Curcuma longa rhizomes extract)|Dietary Supplement: BioTurmin-WD (Water dispersible curcuminoids)|Dietary Supplement: MaQxan,change in urine cotinine and serum oxidative stress marker (malondialdehyde) level|Change in serum lipid profile,Olive Lifesciences Pvt Ltd,Male,"20 Years to 65 Years   (Adult, Older Adult)",Not Applicable,60,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",OLS-SH/06-14 VER 01,Aug-14,Feb-15,Feb-15,29-Jul-14,null,29-Jul-14,"Sreenivasa Clinic Diabetic Research Center, Bangalore, Karnataka, India",,https://ClinicalTrials.gov/show/NCT02203227
NCT02198703,A Trial to Evaluate the Efficacy of AB-Life Probiotic Product on LDL-Cholesterol Reduction in Moderate Hypercholesterolemia,,Completed,No Results Available,Moderate Hypercholesterolemia,Dietary Supplement: Probiotics bacterial strains|Dietary Supplement: Placebo,Change of the fasting blood LDL cholesterol concentration|Change in fasting blood total cholesterol concentration|Change in fasting blood LDLc concentration|Change in fasting blood HDLc concentration|Change in fasting blood ratio total cholesterol / HDLc concentrations|Change in fasting blood ratio LDLc / HDLc concentrations|Change in fasting blood triglycerides concentration|Change in fasting blood Apo A1 concentration|Change in fasting blood Apo B100 concentration|Change in fasting blood insulin concentration|Change in fasting blood glucose concentration|Change in fasting blood acetate concentration|Change in fasting blood propionate concentration|Change in fasting blood acetate / propionate concentrations|Change in SCORE - European Low Risk Chart of fatal cardiovascular disease|Change in fasting blood hsCRP concentration|Complete blood count|Blood Alkaline Phosphatase|Blood Alanine Amino Transferase|Blood Aspartate Amino Transferase|Blood Gamma Glutamyl Transpeptidase|Blood total bilirubin|Blood urea|Blood creatinine|Heart rate|Systolic Blood Pressure|Diastolic Blood Pressure|Body weight|Physical Activity Score|Total energy intake|Percentage of energy intake from fat|Dietary fiber intake|Saturated Fatty Acids intake,"AB Biotics, SA",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,104,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",AB-Life study #3,Sep-14,Jul-15,Jul-15,24-Jul-14,null,31-May-18,"Naturalpha, Lille, France|Biofortis, Saint-Herblain, France",,https://ClinicalTrials.gov/show/NCT02198703
NCT02191111,A Cluster-randomized Controlled Knowledge Translation Feasibility Study in Alberta Community Pharmacies,,Unknown status,No Results Available,Chronic Diseases,Behavioral: Task-focused facilitation,Process evaluation|Change in the number of medication management services|Patient care clinical outcomes,University of Alberta|Alberta Innovates Health Solutions|University of Waterloo|University of Mississippi Medical Center,All,"Child, Adult, Older Adult",Not Applicable,10,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,Pro00047475|201300643,Jul-14,Jun-15,Aug-15,16-Jul-14,null,27-May-15,"EPICORE Centre, University of Alberta, Edmonton, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT02191111
NCT02189837,Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody,FLOREY,Completed,Has Results,Primary Hyperlipidemia and Mixed Dyslipidemia,Biological: Evolocumab|Drug: Atorvastatin|Drug: Placebo to Evolocumab|Drug: Placebo to Atorvastatin,Percent Change From Baseline in Low-density Lipoprotein (LDL) Apolipoprotein B-100 Fractional Catabolic Rate (FCR)|Percent Change From Baseline in LDL-C at Day 50|Percent Change From Baseline in LDL Apolipoprotein B-100 Production Rate (PR)|Percent Change From Baseline in Lipoprotein (a) Fractional Catabolic Rate (FCR)|Percent Change From Baseline in Lipoprotein(a) Production Rate (PR),Amgen,Male,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,89,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",20130194|FLOREY,8-Jul-14,13-Feb-15,5-Mar-15,15-Jul-14,31-Aug-16,3-Oct-18,"Research Site, Adelaide, South Australia, Australia|Research Site, Nedlands, Western Australia, Australia",,https://ClinicalTrials.gov/show/NCT02189837
NCT02189200,Nutritional Counseling Associated With the Ingestion of Oat Bran in Hypercholesterolemic Subjects,,Completed,No Results Available,Dietary Modification,Dietary Supplement: oat bran - 40g|Dietary Supplement: refined rice flour- 40g,Change from baseline in LDL-cholesterol in three months|Change from baseline in glucose profile in three months,Universidade Federal do Rio de Janeiro,All,"20 Years to 85 Years   (Adult, Older Adult)",Not Applicable,132,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",03131712.3.0000.5265,Oct-12,Apr-14,Apr-14,14-Jul-14,null,12-May-16,"Instituto Estadual de Cardiologia Aloysio de Castro - IECAC, Rio de Janeiro, Brazil",,https://ClinicalTrials.gov/show/NCT02189200
NCT02189252,"An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis",ECLIPSEIV,Completed,Has Results,Severe Hypertriglyceridemia,Drug: Epanova|Drug: Lovaza,Baseline-adjusted AUC0-24 for Plasma Total EPA + Total DHA|Baseline-adjusted Cmax for Plasma Total EPA + Total DHA|Baseline-adjusted AUC0-24 for Plasma Total EPA|Baseline-adjusted Cmax for Plasma Total EPA|Baseline-adjusted AUC0-24 for Plasma Total DHA|Baseline-adjusted Cmax for Plasma Total DHA|Baseline-adjusted AUC0-24 for Plasma Total DPA|Baseline-adjusted Cmax for Plasma Total DPA,AstraZeneca,All,"18 Years to 130 Years   (Adult, Older Adult)",Phase 1,30,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D5880C00003|OM-EPA-013,Oct-14,Jul-15,Jul-15,14-Jul-14,20-Jun-16,20-Jun-16,"Research Site, Kansas City, Kansas, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Chocoutimi, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02189252
NCT02187757,Study to Evaluate Efficacy and Safety of PreLipid® on Subjects With Higher Than Normal Blood Lipid Levels,Prelip,Completed,No Results Available,Hyperlipidemia,Dietary Supplement: Study Dietary Supplement (Prelipid 500 mg capsules)|Dietary Supplement: Placebo,Efficacy of Dietary Supplement PreLipid 600 mg twice-daily in lowering LDL-C levels|Safety of Dietary Supplement PreLipid 600 mg twice-daily|Changes in Glycemic Status,"PreEmptive Meds, Pvt. Ltd|Abbott",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,180,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Prelip/Nutra001/PMI13,Nov-13,Nov-14,Nov-14,11-Jul-14,null,15-May-15,"Division of Clinical & Preventive Cardiology, Heart Institute, Gurgaon, Delhi, India|Life Care Institute of Medical Science & Research, Ahmedabad, Gujarat, India|Bhatia Hospital Medical Research Society, Mumbai, Maharashtra, India|Dr. Vikas Govind Pai Clinical Research Foundation, Pune, Maharashtra, India|Fortis Escorts Hospital, Jaipur, Rajasthan, India|Pace Clinical Research Center, Bangalore, Tamil Nadu, India|Singvi Health Centre, Chennai, Tamil Nadu, India|Rangammal Hospital, Tiruvannamalai, Tamil Nadu, India",,https://ClinicalTrials.gov/show/NCT02187757
NCT02185963,Effect of Rosuvastatin on Function of High Density Lipoprotein Cholesterol in Type 2 Diabetes,,Completed,No Results Available,Diabetes,Drug: Rosuvastatin,Functional HDL-C|Non-HDL-cholesterol = total cholesterol - HDL-C|Patients with LDL-C < 70 mg/dl and HDL > 40 mg/dl in men; > 50 in women,Seoul National University Bundang Hospital,All,"30 Years to 80 Years   (Adult, Older Adult)",Phase 4,50,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SNUBH_ENDO05,Oct-14,Dec-15,May-16,10-Jul-14,null,3-May-16,"Seoul National University Bundang Hospital, Seongnam, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02185963
NCT02186483,Clinical Trial to Investigate the Pharmacokinetics Drug Interaction Between Metformin and Rosuvastatin,,Completed,No Results Available,Hyperlipidemia|Diabetes,Drug: Metformin|Drug: Rosuvastatin|Drug: Metformin and Rosuvastatin,"Cmax,ss, AUCτ|Tmax,ss|t1/2|Cmin,ss|CL/Fss|Vd/Fss","Jeil Pharmaceutical Co., Ltd.",Male,19 Years to 55 Years   (Adult),Phase 1,24,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,JLP_1310-P1-DI,Aug-14,Feb-15,Feb-15,10-Jul-14,null,29-Mar-18,"Samsung Medical Center(SMC), Seoul, Gangnam-Gu, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02186483
NCT02181244,"Egg Effects on Atherogenic Dyslipidemias, Glucose Metabolism and Inflammation in Diabetic Subjects",,Completed,No Results Available,Diabetes Mellitus|Inflammation,"Other: Egg, one a day, for breakfast|Other: Oatmeal, one cup a day",glycosylated hemoglobin|plasma LDL cholesterol,University of Connecticut,All,"35 Years to 65 Years   (Adult, Older Adult)",Not Applicable,33,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,H12-059,May-13,Jan-14,Jun-14,3-Jul-14,null,3-Jul-14,"Centro de Investigacion y Desarrollo, Hermosillo, Sonora, Mexico",,https://ClinicalTrials.gov/show/NCT02181244
NCT02180035,Treatment With Nutritional Eating Plan and Dietary Fibers in Adult Patients With HIV/AIDS,PRECOR-NUT,Completed,No Results Available,"Dietary Modification|Dyslipidemia|Signs and Symptoms, Digestive|HIV",Dietary Supplement: Symbiotic|Dietary Supplement: Maltodextrin (placebo for symbiotic)|Behavioral: Nutritional intervention,Seric lipid levels|Fasting blood glucose|Gastrointestinal symptoms|Adherence to the nutritional intervention and nutritional appointments|Body composition|Anthropometric measures,Conselho Nacional de Desenvolvimento Científico e Tecnológico,All,"19 Years and older   (Adult, Older Adult)",Not Applicable,290,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",CNPq- 478741/2008-1,Oct-09,Jul-11,Jul-11,2-Jul-14,null,17-Jul-14,"Outpatient Infectoparasitary Diseases, Hospital das Clinicas, Federal University of Goiás, Goiânia, Goiás, Brazil",,https://ClinicalTrials.gov/show/NCT02180035
NCT02178098,Evaluation of ETC-1002 in Patients With Hypercholesterolemia and Hypertension,,Completed,No Results Available,Hypercholesterolemia|Hypertension,Drug: ETC-1002|Drug: Placebo,"Percent change in calculated LDL-cholesterol (LDL-C)|Change in 24-hour, day-time and night-time mean systolic blood pressure|Change in 24-hour, day-time and night-time mean diastolic blood pressure|Percent change in high-sensitivity C-reactive protein (hsCRP)","Esperion Therapeutics|Medpace, Inc.",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,143,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1002-014,Jun-14,Jul-15,Jul-15,30-Jun-14,null,29-Mar-19,"Birmingham, Alabama, United States|Chandler, Arizona, United States|Phoenix, Arizona, United States|DeLand, Florida, United States|Fort Lauderdale, Florida, United States|Hialeah, Florida, United States|Pembroke Pines, Florida, United States|Pembroke Pines, Florida, United States|Port Orange, Florida, United States|Gurnee, Illinois, United States|Indianapolis, Indiana, United States|Kansas City, Kansas, United States|Paducah, Kentucky, United States|Auburn, Maine, United States|Olive Branch, Mississippi, United States|Butte, Montana, United States|Las Vegas, Nevada, United States|Berlin, New Jersey, United States|Endwell, New York, United States|Wilmington, North Carolina, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Willoughby Hills, Ohio, United States|Eugene, Oregon, United States|Downingtown, Pennsylvania, United States|Charleston, South Carolina, United States|Simpsonville, South Carolina, United States|Corpus Christi, Texas, United States|Dallas, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|Salt Lake City, Utah, United States|Salt Lake City, Utah, United States|Kenosha, Wisconsin, United States|Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02178098
NCT02173600,Cardiovascular Risk Factors And Intensive Dietary Counselling,,Unknown status,No Results Available,High Blood Pressure|Hypercholesterolemia|Tobacco Smoking,Behavioral: Group-level Intensive dietary Counselling|Behavioral: Individual-level Intensive Dietary Counselling,Cardiovascular risk as calculated by means of the SCORE (Systematic Coronary Risk Evaluation) scale. Low-risk regions version.|Health-Related Quality of Life,Andalusian Regional Ministry of Health|Andaluz Health Service,All,"40 Years to 65 Years   (Adult, Older Adult)",Not Applicable,630,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention,PI-0969-12,May-14,Jun-15,Dec-15,25-Jun-14,null,25-Jun-14,,,https://ClinicalTrials.gov/show/NCT02173600
NCT02173158,Efficacy and Safety of Lomitapide in Japanese Patients With HoFH on Concurrent Lipid-Lowering Therapy,,Completed,Has Results,Familial Hypercholesterolemia - Homozygous,Drug: lomitapide,Percent Change in LDL-C|Change in Total Cholesterol|Change in Apo B|Change in Triglycerides|Change in Non-HDL-C|Change in VLDL-C|Change in Lp(a)|Change in HDL-C|Change in Apo AI|Change in LDL-C,"Aegerion Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,9,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AEGR-733-030,2-Apr-14,3-Apr-15,17-Dec-15,24-Jun-14,10-Oct-18,10-Oct-18,"Kurume-shi, Fukuoka, Japan|Kanazawa, Ishikawa, Japan|Osakashi, Osaka, Japan|Suita-shi, Osaka, Japan|Tokorozawa, Saitama, Japan|Bunkyo-ku, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT02173158
NCT02168803,A Study of Evacetrapib in Participants With Abnormal Cholesterol,,Completed,Has Results,Dyslipidemia,Drug: Evacetrapib,Pharmacokinetics (PK) Parameters of Evacetrapib: Area Under the Concentration Versus Time Curve From Time Zero to the Last Time Point With a Measurable Concentration (AUC[0-tlast])|PK Parameters of Evacetrapib: Maximum Concentration (Cmax)|PK Parameters of Evacetrapib: Terminal Half-life|PD Parameters of Evacetrapib: High Density Lipoprotein Cholesterol (HDL-C) Level|PD Parameters of Evacetrapib: Low-Density Lipoprotein Cholesterol (LDL-C) Level|PD Parameters of Evacetrapib: Total Cholesterol Level|PD Parameters of Evacetrapib: Triglyceride Level,Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 1,101,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,15340|I1V-MC-EIBM,May-14,Dec-15,Dec-15,20-Jun-14,3-Oct-18,3-Oct-18,"Covance Clinical Research Inc, Daytona Beach, Florida, United States|Covance, Dallas, Texas, United States|Covance Clinical Research Inc, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02168803
NCT02166593,Clinical Trial to Evaluate the Efficacy and Safety of Pravafenix Cap to Verify the Superiority Than Atorvastatin,,Completed,No Results Available,Combined Dyslipidemia,Drug: Pravastatin40mg/Fenofibrate160mg|Drug: Atorvastatin Sodium 10mg,Percent change (%) from baseline in Non-HDL-C|◦Percent change (%) from baseline at Week 4 and Week 8 in TG|Percent change (%) from baseline at Week 4 and Week 8 in TC|Percent change (%) from baseline at Week 4 and Week 8 in LDL-C|Percent change (%) from baseline at Week 4 and Week 8 in HDL-C|Percent change (%) from baseline at Week 4 and Week 8 in Apo A-I|Percent change (%) from baseline at Week 4 and Week 8 in Apo B,"Yooyoung Pharmaceutical Co., Ltd.",All,"20 Years to 80 Years   (Adult, Older Adult)",Phase 3,302,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",YYP-Pravafenix-C31301,May-14,Jan-18,Jan-18,18-Jun-14,null,28-Sep-18,"Seoul National University Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02166593
NCT02166814,"A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and Dyslipidemia",,Completed,No Results Available,"Essential Hypertension, Dyslipidemia",Drug: Fimasartan and Rosuvastatin|Drug: Fimasartan|Drug: Rosuvastatin,Change rate of LDL-C at week 8 of Fimasartan/Rosuvastatin combination administration from the Baseline to compare the one of Fimasartan 120mg single administration|Change of SiSBP at week 8 of Fimasartan/Rosuvastatin combination administration from the Baseline to compare the one of Rosuvastatin 20mg single administration,"Boryung Pharmaceutical Co., Ltd",All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 3,140,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",BR-FRC-CT-301,Aug-14,Sep-15,Sep-15,18-Jun-14,null,13-Feb-17,"Seoul university Bundang hospital, Bundang, Korea, Republic of|Dong-A university hospital, Busan, Korea, Republic of|Inje Heaundai Paik hospital, Busan, Korea, Republic of|Inje university Busan Paik hospital, Busan, Korea, Republic of|ChungNam university hospital, ChungNam, Korea, Republic of|DanGuk university hospital, Chungnam, Korea, Republic of|The Catholic university of Korea Daegu hospital, Daegu, Korea, Republic of|DongGuk university Gyeongju hospital, Gyeongju, Korea, Republic of|DongGuk university Ilsan hospital, Ilsan, Korea, Republic of|Inje university Ilsan Paik hospital, Ilsan, Korea, Republic of|Gachon university Gil medical center, Incheon, Korea, Republic of|Inha university hospital, Incheon, Korea, Republic of|Jeju national university hospital, Jeju, Korea, Republic of|JeonNam university hospital, JeonNam, Korea, Republic of|Kyungbook National university hospital, Kyungbook, Korea, Republic of|Gangnam Severance hospital, Seoul, Korea, Republic of|Jeil hospital, Seoul, Korea, Republic of|Korea university Anam hospital, Seoul, Korea, Republic of|Korea university Guro hospital, Seoul, Korea, Republic of|Kyunghee university hospital, Seoul, Korea, Republic of|Samsung Seoul hospital, Seoul, Korea, Republic of|Seoul national university hospital, Seoul, Korea, Republic of|Severance hospital, Seoul, Korea, Republic of|The Catholic university St. Mary hospital, Seoul, Korea, Republic of|Aju university hospital, Suwon, Korea, Republic of|YoungNam university hospital, YoungNam, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02166814
NCT02156544,Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519,CKD-519 FIH,Completed,No Results Available,Dyslipidemia,Drug: CKD-519|Drug: placebo,Cmax of CKD-519|AUC0-last of CKD-519|AUC0-∞ of CKD-519|Tmax of CKD-519|t1/2 of CKD-519|CL/F of CKD-519|Vd/F of CKD-519|CETP activity,Chong Kun Dang Pharmaceutical,All,19 Years to 55 Years   (Adult),Phase 1,41,Industry,Interventional,"Allocation: Randomized|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",148HPS14001,Jun-14,Oct-14,Aug-15,5-Jun-14,null,11-Sep-15,"Severance Hospital, Seoul, Seodaemun-gu, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02156544
NCT02153879,Characterization of High Density Lipoprotein (HDL) in Type 2 Diabetes (T2D) After Fenofibrate or Niacin Treatment,LOWHDL,Completed,No Results Available,Type 2 Diabetes Mellitus|Dyslipidemia,Drug: Fenofibrate|Drug: Niacin plus laropiprant,"HDL particles size and number assessed by nuclear magnetic resonance (NMR) and reported as nm and micromol/L|Apolipoprotein A1 (Apo A1), apolipoprotein A2 (Apo A2), paraoxonase (PON) HDL concentration (g/l - mg/l)",Institut Investigacio Sanitaria Pere Virgili|Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders,All,"30 Years to 70 Years   (Adult, Older Adult)",Phase 4,30,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,IISPV-HUSJR-LOWHDL,Feb-09,Dec-11,Dec-13,3-Jun-14,null,3-Jun-14,"Hospital Universitari Sant Joan, Reus, Tarragona, Spain",,https://ClinicalTrials.gov/show/NCT02153879
NCT02153983,Effects of Colchicine in Non-Diabetic Adults With Metabolic Syndrome,,Completed,No Results Available,Obesity|Metabolic Disease,Drug: Colchicine 0.6 mg given|Drug: Placebo capsules given,Change in insulin sensitivity|Change in metabolic parameters|Changes in other inflammatory markers,"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)",All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 1|Phase 2,213,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",140119|14-CH-0119,31-May-14,15-Aug-18,15-Aug-18,3-Jun-14,null,4-Feb-19,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02153983
NCT02148458,Short Term Intermittent Fasting and Mediterranean Diet,,Completed,No Results Available,Overweight|Pre-hypertension|Hypertension|Hypercholesterolemia|Glucose Intolerance,Other: Mediterranean diet|Other: Control group,Decrease in high sensitivity C-reactive protein (hsCRP),Washington University School of Medicine,All,"30 Years to 65 Years   (Adult, Older Adult)",Not Applicable,53,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,201404045,Jun-14,Jun-17,Jun-17,28-May-14,null,9-Oct-18,"Washington University school of Medicine, Saint Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT02148458
NCT02147041,The Effect of Extract of Green Tea on Obese Women and Obese Related Hormone Peptides,,Unknown status,No Results Available,Diabetes Mellitus|Hyperlipidemia,Drug: EGCG(Epigallocatechin Gallate)|Drug: Placebo,composite of anthropometric measures|Hormone peptide change|biochemical characteristic change|traditional chinese medicine syndrome classification|Quality of life evaluation,Taipei City Hospital|National Yang Ming University,Female,20 Years to 60 Years   (Adult),Phase 2|Phase 3,92,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",100XDAA00110,May-12,Aug-14,Aug-14,26-May-14,null,26-May-14,"Taipei City Hospital, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT02147041
NCT02145936,Effect of Dietary Fatty Acids on Cardiovascular Disease Risk Indicators and Inflammation,,Completed,No Results Available,Dyslipidemia,Other: diet,inflammation|lymphocyte proliferation and ex vivo cytokine secretion|plasma lipids and lipoproteins|desaturase activity|insulin sensitivity|coagulation biomarkers,Tufts University,Female,"50 Years to 85 Years   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",1541 - Fatty Acid Pilot,Jan-13,Jun-17,Dec-17,23-May-14,null,13-Jul-18,"Jean Mayer Human Nutrition Research Center on Aging, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02145936
NCT02143011,Stress and Sugar Synergy,SSS,Completed,No Results Available,Metabolic Syndrome|Insulin Resistance|Dyslipidemia,Other: orange juice|Other: sucrose,24-hour triglyceride area under the curve|Markers of immune cell aging,"University of California, Davis|University of California, San Francisco|USDA, Western Human Nutrition Research Center",Female,25 Years to 40 Years   (Adult),Not Applicable,23,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,574149,Apr-14,Dec-16,Dec-16,20-May-14,null,16-Jan-19,"Clinical Research Center, Sacramento, California, United States",,https://ClinicalTrials.gov/show/NCT02143011
NCT02136199,Use of Decision Aids in Clinical Encounters,,Completed,No Results Available,"Diabetes, Depression, Cardiovascular Disease,Hypercholesterolemia, Osteoporosis",Other: Active Implementation of ShareEBM Toolkit|Other: Passive Dissemination of Share EBM,Frequency of use of decision aids in clinical encounters by weekly reports,Mayo Clinic,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,62,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),14-002055,Sep-14,May-16,May-16,12-May-14,null,24-May-16,"Park Nicollet- Brookdale, Brooklyn Center, Minnesota, United States|Ridgeview Medical Center, Delano, Minnesota, United States|Essentia Health-Lakeside Clinic, Duluth, Minnesota, United States|Fairview Clinic-Eagan, Eagan, Minnesota, United States|Park Nicollet-Golden Valley, Golden Valley, Minnesota, United States|Essentia Hermantown Clinic, Hermantown, Minnesota, United States|Native American Community Clinic, Minneapolis, Minnesota, United States|Community Health Service, Inc., Rochester, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Fairview Medical-Rosemount, Rosemount, Minnesota, United States|Baldwin Area Medical Center, Inc., Baldwin, Wisconsin, United States|Hudson Physicians S.C., Hudson, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02136199
NCT02135029,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins,SPIRE-SI,Completed,Has Results,Hyperlipidemia,Drug: Bococizumab (PF-04950615;RN316)|Drug: Atorvastatin|Other: Placebo for Bococizumab (PF-04950615;RN316)|Other: Placebo for atorvastatin,"Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 12|Percent Change From Baseline in Fasting Total Cholesterol (TC) at Weeks 12 and 24|Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) at Weeks 12 and 24|Percent Change From Baseline in Fasting Non High Density Lipoprotein Cholesterol (Non HDL-C) at Weeks 12 and 24|Percent Change From Baseline in Fasting Lipoprotein (a) (Lp[a]) at Weeks 12 and 24|Percent Change From Baseline in Fasting High Density Lipoprotein Cholesterol (HDL-C) at Weeks 12 and 24|Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 24|Percent Change From Baseline in Fasting Triglycerides (TG) at Weeks 12 and 24|Percent Change From Baseline in Fasting Apolipoprotein A-I (ApoA-I) at Weeks 12 and 24|Percent Change From Baseline in Fasting Apolipoprotein A-II (ApoA-II) at Weeks 12 and 24|Percent Change From Baseline in Fasting Very Low Density Lipoprotein Cholesterol (VLDL-C) at Weeks 12 and 24|Absolute Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 12|Absolute Change From Baseline in Fasting Total Cholesterol (TC) at Week 12|Absolute Change From Baseline in Fasting High Density Lipoprotein Cholesterol (HDL-C) at Week 12|Absolute Change From Baseline in Fasting Non High Density Lipoprotein Cholesterol (Non HDL-C) at Week 12|Absolute Change From Baseline in Fasting Triglycerides (TG) at Week 12|Absolute Change From Baseline in Apolipoprotein B (ApoB) at Week 12|Absolute Change From Baseline in Lipoprotein (A) (Lp[A]) at Week 12|Absolute Change From Baseline in Fasting Total Cholesterol (TC)/ High Density Lipoprotein Cholesterol (HDL-C) Ratio at Weeks 12 and 24|Absolute Change From Baseline in Fasting Apolipoprotein B (ApoB)/Apolipoprotein A-I (ApoA-I) Ratio at Weeks 12 And 24|Percentage of Participants Achieving Fasting Low Density Lipoprotein Cholesterol (LDL-C) Less Than or Equal to (<=) 100 Milligram Per Deciliter (mg/dL) at Weeks 12 and 24|Percentage of Participants Achieving Fasting Low Density Lipoprotein Cholesterol (LDL-C) Less Than or Equal to (<=) 70 Milligram Per Deciliter (mg/dL) at Weeks 12 and 24|Plasma PF-04950615 Concentrations at Weeks 12 and 24|Number of Participants With Adverse Events Related to Type 1 and 3 Hypersensitivity Reactions, Injection Site Reactions, Myalgia, Myopathy, Creatinine Kinase (CK) and Liver Function Tests (LFT) Elevations|Number of Participants With Positive Anti-drug Antibodies (ADA) and Neutralizing Antibodies (nAb)|Anti-drug Antibody (ADA) and Neutralizing Anti-body (nAb) Titer Level in Participants Who Tested Positive for ADA and nAb Respectively|Percentage of Participants Discontinued Due to Myalgia, Myopathy, Creatinine Kinase (CK) and Liver Function Tests (LFT) Elevations",Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,184,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",B1481030|STATIN INTOLERANT|SPIRE-SI,Jun-14,Nov-15,Nov-15,9-May-14,14-Dec-17,14-Dec-17,"Creekside Endocrine Associates, PC, Denver, Colorado, United States|Bridgeport Hospital, Bridgeport, Connecticut, United States|Watson Clinic Center for Research, Inc. (for Drug Shipment only), Lakeland, Florida, United States|Cardiovascular Research Center Of South Florida, Miami, Florida, United States|St. Johns Center for Clinical Research, Ponte Vedra, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|East-West Medical Research Institute, Honolulu, Hawaii, United States|NorthShore University HealthSystem - Evanston Hospital, Evanston, Illinois, United States|Health Care Centers of Illinois Mokena Medical Commons, Mokena, Illinois, United States|Advocate Medical Group Cardiology, Normal, Illinois, United States|Advocate Medical Group Midwest Heart Specialists, Park Ridge, Illinois, United States|Prairie Education & Research Cooperative (Administrative), Springfield, Illinois, United States|Prairie Heart Institute, Springfield, Illinois, United States|St. John's Hospital, Springfield, Illinois, United States|The University of Iowa - College of Public Health - Preventive Intervention Center, Iowa City, Iowa, United States|The Iowa Clinic, PC, West Des Moines, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Crescent City Clinical Research Center, Metairie, Louisiana, United States|Allina Health System, dba Abbott Northwestern Hospital, Minneapolis, Minnesota, United States|Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States|PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States|Dayton Heart Center, Dayton, Ohio, United States|Clinical and Translational Research Center, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States|Berks Cardiologists, Ltd., Wyomissing, Pennsylvania, United States|PMG Research of Bristol, Bristol, Tennessee, United States|PMG Research of Knoxville, LLC, Knoxville, Tennessee, United States|San Antonio Military Medical Center, Fort Sam Houston, Texas, United States|Office of Michelle Zaniewski MD., PA., Houston, Texas, United States|Utah Cardiology, P.C., Layton, Utah, United States|Aspen Clinical Research LLC, Orem, Utah, United States|The Medical Arts Health Research Group, Kelowna, British Columbia, Canada|Corunna Medical Research Centre, Corunna, Ontario, Canada|The Office of Dr. James Cha, Oshawa, Ontario, Canada|Kawartha Cardiology Clinical Trials, Peterborough, Ontario, Canada|Devonshire Clinical Research Inc., Woodstock, Ontario, Canada|Ecogene-21, Chicoutimi, Quebec, Canada|Omnispec clinical research inc., Mirabel, Quebec, Canada|Diex Research Sherbrooke Inc., Sherbrooke, Quebec, Canada|Clinique des maladies lipidiques de Quebec, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02135029
NCT02133534,The Effect of Atorvastatin on Endothelial Cell Dysfunction in Chronic Kidney Disease,,Terminated,Has Results,Chronic Kidney Disease|High Cholesterol,Drug: Atorvastatin,Improved Counts of Endothelial Progenitor Cells,Duke University,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,1,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00011172,Feb-08,May-09,May-09,8-May-14,3-Jul-14,3-Jul-14,,,https://ClinicalTrials.gov/show/NCT02133534
NCT02130505,Inflammatory Aspects of Glucose in Hyperlipidemia and Diabetes,INFORM,Completed,No Results Available,Atherosclerosis|Leukocyte Activation Disorder|Type 2 Diabetes Mellitus|Familial Combined Hyperlipidemia,Dietary Supplement: OGTT,Postprandial change in leukocyte activation|Correlation between chronic glycemia and leukocyte activation|Correlation between acute glycemia and leukocyte activation,Sint Franciscus Gasthuis,All,"45 Years to 65 Years   (Adult, Older Adult)",Not Applicable,51,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,NL17100.101.07,Jun-07,Jun-08,Jun-08,5-May-14,null,5-May-14,,,https://ClinicalTrials.gov/show/NCT02130505
NCT02126358,Gemigliptin-Rosuvastatin Fix-dose Combination Phase 3(BALANCE),,Completed,No Results Available,Type 2 Diabetes|Dyslipidemia,Drug: Gemigliptin and/or Rosuvastatin,HbA1c change|LDL-C change rate|HbA1c,LG Life Sciences,All,"19 Years and older   (Adult, Older Adult)",Phase 3,290,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",LG-GSCL002,May-14,Mar-16,Mar-16,30-Apr-14,null,18-Oct-16,"Severance hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02126358
NCT02127177,Long-term Effects of CPAP on Lipidemia and Hs-CRP Levels in OSA Patients,,Completed,No Results Available,Obstructive Sleep Apnea|Coronary Heart Disease,Device: Continuous Positive Airway Pressure Ventilator,lipid profiles|High-sensitivity C-reactive protein,Chinese Pulmonary Vascular Disease Research Group,All,"45 Years to 75 Years   (Adult, Older Adult)",Not Applicable,78,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,SF2009,Jan-10,Dec-13,Dec-13,30-Apr-14,null,30-Apr-14,"center of pulmonary vascular disease, Fuwai hospital, Beijing, China",,https://ClinicalTrials.gov/show/NCT02127177
NCT02125682,The HDL Particle Protection Study,HDL PROTECT,Completed,No Results Available,Dyslipidemia in Patients With Diabetes Mellitus,Drug: atovastatin 10 mg/day|Drug: Atorvastatin 80 mg/day,effect on HDL function,Hotel Dieu de France Hospital|Nouvelle Société Française d'Athérosclérose|Pfizer,All,"21 Years to 80 Years   (Adult, Older Adult)",Phase 4,16,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,HDLPROTECT,Jan-12,14-May-17,14-May-17,29-Apr-14,null,1-Feb-18,"Hotel Dieu de France Hospital, Beirut, Lebanon",,https://ClinicalTrials.gov/show/NCT02125682
NCT02116517,Effects of Green Tea Extract on Obese Women With High Level of LDL,GTE-LDL,Completed,No Results Available,Obese|Hyperlipidemia,Dietary Supplement: green tea extract|Dietary Supplement: Placebo,percentage of reduction of LDL-C|HDL-C,National Yang Ming University|Taipei City Hospital,Female,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,73,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",100WFA2200449,Aug-11,Oct-13,Dec-13,17-Apr-14,null,17-Apr-14,"Taipei City Hospital, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT02116517
NCT02113163,PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA,,Unknown status,No Results Available,"Diabetes Mellitus, Non-Insulin-Dependent|Hypertriglyceridemia",Drug: Metformin Eicosapentaenoate|Drug: Metformin HCl and Vascepa,"AUC following single and repeat single oral administration of metformin eicosapentaenoate, metformin hydrochloride and Vascepa",Thetis Pharmaceuticals LLC,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,32,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TP-101-CS01,Mar-14,Jun-14,Jul-14,14-Apr-14,null,14-Apr-14,"Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States",,https://ClinicalTrials.gov/show/NCT02113163
NCT02107898,Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN),,Completed,Has Results,Hypercholesterolemia,Drug: Placebo (for alirocumab)|Drug: Alirocumab|Drug: Lipid-Modifying Therapy (LMT),Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT Analysis)|Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis|Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 12 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 - ITT Analysis|Percentage of Participants Reaching Calculated LDL-C Goal at Week 24 - ITT Analysis|Percentage of Participants Reaching Calculated LDL-C Goal at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Apo A1 at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Apo A1 at Week 12 - ITT Analysis,Sanofi|Regeneron Pharmaceuticals,All,"20 Years to 80 Years   (Adult, Older Adult)",Phase 3,216,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EFC13672|U1111-1115-7486,Mar-14,Jan-15,Sep-15,8-Apr-14,29-Jan-16,4-Oct-16,"Investigational Site Number 392016, Adachi-Ku, Japan|Investigational Site Number 392029, Adachi-Ku, Japan|Investigational Site Number 392024, Aki-Gun, Japan|Investigational Site Number 392012, Chuo-Ku, Japan|Investigational Site Number 392013, Chuo-Ku, Japan|Investigational Site Number 392032, Fukui-Shi, Japan|Investigational Site Number 392004, Hakusan-Shi, Japan|Investigational Site Number 392028, Kaga-Shi, Japan|Investigational Site Number 392002, Kanazawa-Shi, Japan|Investigational Site Number 392005, Kanazawa-Shi, Japan|Investigational Site Number 392023, Kawanishi-Shi, Japan|Investigational Site Number 392009, Kisarazu-Shi, Japan|Investigational Site Number 392026, Kitakyushu-Shi, Japan|Investigational Site Number 392003, Komatsu-Shi, Japan|Investigational Site Number 392011, Kuki-Shi, Japan|Investigational Site Number 392017, Matsumoto-Shi, Japan|Investigational Site Number 392007, Mito-Shi, Japan|Investigational Site Number 392006, Moriya-Shi, Japan|Investigational Site Number 392018, Nagoya-Shi, Japan|Investigational Site Number 392014, Oota-Ku, Japan|Investigational Site Number 392019, Osaka-Shi, Japan|Investigational Site Number 392020, Osaka-Shi, Japan|Investigational Site Number 392022, Osaka-Shi, Japan|Investigational Site Number 392030, Osaka-Shi, Japan|Investigational Site Number 392027, Oyabe-Shi, Japan|Investigational Site Number 392010, Saitama-Shi, Japan|Investigational Site Number 392015, Shinjuku-Ku, Japan|Investigational Site Number 392031, Shizuoka-Shi, Japan|Investigational Site Number 392021, Suita-Shi, Japan|Investigational Site Number 392025, Takamatsu-Shi, Japan|Investigational Site Number 392008, Tsuchiura-Shi, Japan|Investigational Site Number 392001, Yamagata-Shi, Japan",,https://ClinicalTrials.gov/show/NCT02107898
NCT02104817,Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia,STRENGTH,"Active, not recruiting",No Results Available,Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD),Drug: Epanova® (omega-3 carboxylic acids)|Drug: corn oil control,"The primary outcome measure is the time to the first occurrence of any component of the composite of MACE.|The composite measure of CV events that include the first occurrence of cardiovascular death, non-fatal MI and non-fatal stroke.|The composite measure of coronary events that include the first occurrence of cardiac death.|The first occurrence of individual components of MACE: cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, emergent/elective coronary revascularization, or hospitalization for unstable angina.|Time to CV death","AstraZeneca|The Cleveland Clinic|Quintiles, Inc.",All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,13086,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D5881C00004|2014-001069-28,30-Oct-14,30-Sep-20,30-Sep-20,4-Apr-14,null,14-May-19,"Research Site, Birmingham, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Muscle Shoals, Alabama, United States|Research Site, Chandler, Arizona, United States|Research Site, Gilbert, Arizona, United States|Research Site, Glendale, Arizona, United States|Research Site, Mesa, Arizona, United States|Research Site, Mesa, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Carlsbad, California, United States|Research Site, Fresno, California, United States|Research Site, Fresno, California, United States|Research Site, Greenbrae, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Angeles, California, United States|Research Site, Milpitas, California, United States|Research Site, Newport Beach, California, United States|Research Site, Northridge, California, United States|Research Site, Palm Springs, California, United States|Research Site, San Diego, California, United States|Research Site, Santa Ana, California, United States|Research Site, Santa Rosa, California, United States|Research Site, Tarzana, California, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Waterbury, Connecticut, United States|Research Site, Boca Raton, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Coral Gables, Florida, United States|Research Site, Davie, Florida, United States|Research Site, Delray Beach, Florida, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Homestead, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Lake Worth, Florida, United States|Research Site, Lakeland, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, New Port Richey, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Pensacola, Florida, United States|Research Site, Pinellas Park, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Spring Hill, Florida, United States|Research Site, Tamarac, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Marietta, Georgia, United States|Research Site, Sandy Springs, Georgia, United States|Research Site, Arlington Heights, Illinois, United States|Research Site, Blue Island, Illinois, United States|Research Site, Champaign, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Evanston, Illinois, United States|Research Site, Oakbrook Terrace, Illinois, United States|Research Site, Sterling, Illinois, United States|Research Site, Anderson, Indiana, United States|Research Site, Avon, Indiana, United States|Research Site, Elkhart, Indiana, United States|Research Site, Evansville, Indiana, United States|Research Site, Evansville, Indiana, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Franklin, Indiana, United States|Research Site, Greenfield, Indiana, United States|Research Site, Muncie, Indiana, United States|Research Site, Valparaiso, Indiana, United States|Research Site, Iowa City, Iowa, United States|Research Site, Augusta, Kansas, United States|Research Site, Overland Park, Kansas, United States|Research Site, Louisville, Kentucky, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Slidell, Louisiana, United States|Research Site, Auburn, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Elkridge, Maryland, United States|Research Site, Hyannis, Massachusetts, United States|Research Site, Quincy, Massachusetts, United States|Research Site, Bay City, Michigan, United States|Research Site, Cadillac, Michigan, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Saginaw, Michigan, United States|Research Site, Saginaw, Michigan, United States|Research Site, Edina, Minnesota, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Port Gibson, Mississippi, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Bridgeton, Missouri, United States|Research Site, Hazelwood, Missouri, United States|Research Site, Omaha, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Bridgewater, New Jersey, United States|Research Site, Camden, New Jersey, United States|Research Site, Elmer, New Jersey, United States|Research Site, Sewell, New Jersey, United States|Research Site, Sicklerville, New Jersey, United States|Research Site, Albany, New York, United States|Research Site, Albany, New York, United States|Research Site, Binghamton, New York, United States|Research Site, Laurelton, New York, United States|Research Site, Lawrence, New York, United States|Research Site, New York, New York, United States|Research Site, Saratoga Springs, New York, United States|Research Site, Southampton, New York, United States|Research Site, Troy, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Cary, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Hickory, North Carolina, United States|Research Site, Mooresville, North Carolina, United States|Research Site, Morganton, North Carolina, United States|Research Site, Rocky Mount, North Carolina, United States|Research Site, Salisbury, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Grand Forks, North Dakota, United States|Research Site, Akron, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Marion, Ohio, United States|Research Site, Maumee, Ohio, United States|Research Site, Middleburg Hts, Ohio, United States|Research Site, Norman, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Bend, Oregon, United States|Research Site, Corvallis, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Allentown, Pennsylvania, United States|Research Site, Beaver, Pennsylvania, United States|Research Site, Danville, Pennsylvania, United States|Research Site, Doylestown, Pennsylvania, United States|Research Site, Ephrata, Pennsylvania, United States|Research Site, Flourtown, Pennsylvania, United States|Research Site, Johnstown, Pennsylvania, United States|Research Site, Natrona Heights, Pennsylvania, United States|Research Site, Newport, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Port Matilda, Pennsylvania, United States|Research Site, Tipton, Pennsylvania, United States|Research Site, Wilkes-Barre, Pennsylvania, United States|Research Site, Anderson, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Greer, South Carolina, United States|Research Site, Greer, South Carolina, United States|Research Site, Rock Hill, South Carolina, United States|Research Site, Simpsonville, South Carolina, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Bristol, Tennessee, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Kingsport, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Arlington, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Corpus Christi, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Mission, Texas, United States|Research Site, Odessa, Texas, United States|Research Site, Plano, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Victoria, Texas, United States|Research Site, Clinton, Utah, United States|Research Site, Ogden, Utah, United States|Research Site, Orem, Utah, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Burke, Virginia, United States|Research Site, Danville, Virginia, United States|Research Site, Herndon, Virginia, United States|Research Site, Lynchburg, Virginia, United States|Research Site, Manassas, Virginia, United States|Research Site, Port Orchard, Washington, United States|Research Site, Green Bay, Wisconsin, United States|Research Site, La Crosse, Wisconsin, United States|Research Site, Madison, Wisconsin, United States|Research Site, Wausau, Wisconsin, United States|Research Site, Adelaide, Australia|Research Site, Blacktown, Australia|Research Site, Box Hill, Australia|Research Site, Cowra, Australia|Research Site, Forbes, Australia|Research Site, Herston, Australia|Research Site, Joondalup, Australia|Research Site, Maroubra, Australia|Research Site, Milton, Australia|Research Site, South Brisbane, Australia|Research Site, Southport, Australia|Research Site, Tumbi Umbi, Australia|Research Site, Aalst, Belgium|Research Site, Antwerpen, Belgium|Research Site, Brugge, Belgium|Research Site, Brussels, Belgium|Research Site, Bruxelles, Belgium|Research Site, Genk, Belgium|Research Site, Halen, Belgium|Research Site, Leuven, Belgium|Research Site, Liège, Belgium|Research Site, Mol, Belgium|Research Site, New Westminster, British Columbia, Canada|Research Site, Barrie, Ontario, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Etobicoke, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, North York, Ontario, Canada|Research Site, Peterborough, Ontario, Canada|Research Site, Thornhill, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Granby, Quebec, Canada|Research Site, Laval, Quebec, Canada|Research Site, Longueuil, Quebec, Canada|Research Site, Mirabel, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Changchun, China|Research Site, Changchun, China|Research Site, Changsha, China|Research Site, Changsha, China|Research Site, Chengdu, China|Research Site, Chongqing, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Haerbin, China|Research Site, Haikou, China|Research Site, Hohhot, China|Research Site, Jilin, China|Research Site, Lanzhou, China|Research Site, Nanchang, China|Research Site, Nanjing, China|Research Site, Nanning, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shenyang, China|Research Site, Suzhou, China|Research Site, Taiyuan, China|Research Site, Tianjin, China|Research Site, Tianjin, China|Research Site, Urumqi, China|Research Site, Xian, China|Research Site, Xuzhou, China|Research Site, Yanji, China|Research Site, Yinchuan, China|Research Site, Yueyang, China|Research Site, Zhanjiang, China|Research Site, Zhenjiang, China|Research Site, Beroun, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Chocen, Czechia|Research Site, Chrudim, Czechia|Research Site, Hodonin, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Jindrichuv Hradec, Czechia|Research Site, Olomouc, Czechia|Research Site, Ostrava, Czechia|Research Site, Pardubice, Czechia|Research Site, Praha 10 - Strasnice, Czechia|Research Site, Praha 5, Czechia|Research Site, Praha 5, Czechia|Research Site, Praha 8, Czechia|Research Site, Praha, Czechia|Research Site, Prerov, Czechia|Research Site, Slany, Czechia|Research Site, Tremosna, Czechia|Research Site, Trutnov, Czechia|Research Site, Zlin, Czechia|Research Site, Hellerup, Denmark|Research Site, Herlev, Denmark|Research Site, København Ø, Denmark|Research Site, Svendborg, Denmark|Research Site, Viborg, Denmark|Research Site, Ålborg, Denmark|Research Site, Århus N, Denmark|Research Site, Pärnu, Estonia|Research Site, Tallinn, Estonia|Research Site, Tallinn, Estonia|Research Site, Tallinn, Estonia|Research Site, Tartu, Estonia|Research Site, Baja, Hungary|Research Site, Balatonfured, Hungary|Research Site, Balatongyorok, Hungary|Research Site, Ballasagyarmat, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Békéscsaba, Hungary|Research Site, Csorna, Hungary|Research Site, Debrecen, Hungary|Research Site, Debrecen, Hungary|Research Site, Eger, Hungary|Research Site, Godollo, Hungary|Research Site, Gödöllő, Hungary|Research Site, Hajdúszoboszló, Hungary|Research Site, Hatvan, Hungary|Research Site, Kalocsa, Hungary|Research Site, Kiskunhalas, Hungary|Research Site, Komarom, Hungary|Research Site, Mohacs, Hungary|Research Site, Nagykanizsa, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Szeged, Hungary|Research Site, Szeged, Hungary|Research Site, Szekszárd, Hungary|Research Site, Szentes, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Veszprem, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Bergamo, Italy|Research Site, Bologna, Italy|Research Site, Brescia, Italy|Research Site, Cinisello Balsamo, Italy|Research Site, Cona, Italy|Research Site, L'Aquila, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Parma, Italy|Research Site, Pavia, Italy|Research Site, Roma, Italy|Research Site, San Giovanni Rotondo, Italy|Research Site, Trieste, Italy|Research Site, Adachi-ku, Japan|Research Site, Adachi-ku, Japan|Research Site, Akishima-shi, Japan|Research Site, Akita-shi, Japan|Research Site, Amagasaki-shi, Japan|Research Site, Chikushino-shi, Japan|Research Site, Chuo-ku, Japan|Research Site, Fujisawa-shi, Japan|Research Site, Gifu-shi, Japan|Research Site, Hachioji-shi, Japan|Research Site, Hachioji-shi, Japan|Research Site, Hakusan-shi, Japan|Research Site, Ichikawa-shi, Japan|Research Site, Imabari-shi, Japan|Research Site, Itoshima-shi, Japan|Research Site, Kasugai-shi, Japan|Research Site, Kawanishi-shi, Japan|Research Site, Kishiwada-shi, Japan|Research Site, Kitakyushu-shi, Japan|Research Site, Kochi-shi, Japan|Research Site, Kyoto-shi, Japan|Research Site, Maebashi-shi, Japan|Research Site, Matsudo-shi, Japan|Research Site, Matsumoto-shi, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Meguro-ku, Japan|Research Site, Minato-ku, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nakagami-gun, Japan|Research Site, Niigata-shi, Japan|Research Site, Oita-shi, Japan|Research Site, Onga-gun, Japan|Research Site, Osaka-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Saga-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Shinagawa-ku, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Takamatsu-shi, Japan|Research Site, Takasaki-shi, Japan|Research Site, Tokorozawa-shi, Japan|Research Site, Toshima-ku, Japan|Research Site, Tsuchiura-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Busan, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Gwangju, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Ulsan, Korea, Republic of|Research Site, Alytus, Lithuania|Research Site, Kaunas, Lithuania|Research Site, Kaunas, Lithuania|Research Site, Kaunas, Lithuania|Research Site, Kaunas, Lithuania|Research Site, Kaunas, Lithuania|Research Site, Klaipeda, Lithuania|Research Site, Klaipeda, Lithuania|Research Site, Siauliai, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Chihuahua, Mexico|Research Site, Cuautitlan Izcalli, Mexico|Research Site, Culiacan, Mexico|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, Merida, Mexico|Research Site, Mexico, Mexico|Research Site, Monterrey, Mexico|Research Site, Zapopan, Jalisco, Mexico|Research Site, Almelo, Netherlands|Research Site, Almere, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Apeldoorn, Netherlands|Research Site, Arnhem, Netherlands|Research Site, Beek, Netherlands|Research Site, Delft, Netherlands|Research Site, EDE, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Harderwijk, Netherlands|Research Site, Heerlen, Netherlands|Research Site, Hilversum, Netherlands|Research Site, Hoofddorp, Netherlands|Research Site, Hoorn, Netherlands|Research Site, Maastricht, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Schiedam, Netherlands|Research Site, Sneek, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Venlo, Netherlands|Research Site, Zwijndrecht, Netherlands|Research Site, Auckland, New Zealand|Research Site, Auckland, New Zealand|Research Site, Auckland, New Zealand|Research Site, Christchurch, New Zealand|Research Site, Christchurch, New Zealand|Research Site, Havelock North, New Zealand|Research Site, Rotorua, New Zealand|Research Site, Wellington, New Zealand|Research Site, Białystok, Poland|Research Site, Chorzów, Poland|Research Site, Elbląg, Poland|Research Site, Gdańsk, Poland|Research Site, Gdańsk, Poland|Research Site, Gdańsk, Poland|Research Site, Gdynia, Poland|Research Site, Gdynia, Poland|Research Site, Katowice, Poland|Research Site, Krakow, Poland|Research Site, Kraków, Poland|Research Site, Lodz, Poland|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Oświęcim, Poland|Research Site, Parczew, Poland|Research Site, Piaseczno, Poland|Research Site, Poznań, Poland|Research Site, Poznań, Poland|Research Site, Puławy, Poland|Research Site, Ruda Śląska, Poland|Research Site, Rzeszów, Poland|Research Site, Sobótka, Poland|Research Site, Sopot, Poland|Research Site, Staszów, Poland|Research Site, Warszawa, Poland|Research Site, Wrocław, Poland|Research Site, Wrocław, Poland|Research Site, Zamość, Poland|Research Site, Zgierz, Poland|Research Site, Łódź, Poland|Research Site, Barnaul, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Orenburg, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Rostov-na-Donu, Russian Federation|Research Site, Ryazan, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, St Petersburg, Russian Federation|Research Site, St-Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Bloemfontein, South Africa|Research Site, Breyton, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Centurion, South Africa|Research Site, Durban, South Africa|Research Site, Durban, South Africa|Research Site, Durban, South Africa|Research Site, George, South Africa|Research Site, Johannesburg, South Africa|Research Site, Johannesburg, South Africa|Research Site, Johannesburg, South Africa|Research Site, Krugersdorp, South Africa|Research Site, Kuilsrivier, South Africa|Research Site, Mamelodi East, South Africa|Research Site, Middelburg, South Africa|Research Site, Moloto, South Africa|Research Site, Paarl, South Africa|Research Site, Port Elizabeth, South Africa|Research Site, Port Elizabeth, South Africa|Research Site, Potchefstroom, South Africa|Research Site, Pretoria, South Africa|Research Site, Pretoria, South Africa|Research Site, Pretoria, South Africa|Research Site, Pretoria, South Africa|Research Site, Pretoria, South Africa|Research Site, Pretoria, South Africa|Research Site, Somerset West, South Africa|Research Site, Stanger, South Africa|Research Site, Verulam, South Africa|Research Site, Worcester, South Africa|Research Site, Kaohsiung, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Cherkasy, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kiev, Ukraine|Research Site, Kiev, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lutsk, Ukraine|Research Site, Lviv, Ukraine|Research Site, Lviv, Ukraine|Research Site, Mykolayiv, Ukraine|Research Site, Poltava, Ukraine|Research Site, Uzhgorod, Ukraine|Research Site, Uzhgorod, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Zaporizhzhia, Ukraine|Research Site, Zaporizhzhia, Ukraine|Research Site, Zhytomyr, Ukraine|Research Site, Airdrie, United Kingdom|Research Site, Bournemouth, United Kingdom|Research Site, Cardiff, United Kingdom|Research Site, Chelmsford, United Kingdom|Research Site, Chorley, United Kingdom|Research Site, East Kilbride, United Kingdom|Research Site, Edgbaston, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, Exeter, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Hexham, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Reading, United Kingdom|Research Site, Romford, United Kingdom|Research Site, Stevenage, United Kingdom|Research Site, Swansea, United Kingdom|Research Site, Torquay, United Kingdom",,https://ClinicalTrials.gov/show/NCT02104817
NCT02103049,The Impact of Ezetimibe on Biochemical Markers of Cardiovascular Risk in Kidney Transplant Patients,,Completed,No Results Available,Dyslipidemia|Transplants,Drug: Ezetimibe,Decrease of LDL cholesterol concentration.|Change in oxidative markers,University Medical Centre Ljubljana,All,"18 Years and older   (Adult, Older Adult)",Phase 4,80,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UMCL-2014-TX,Apr-14,Nov-15,Dec-15,3-Apr-14,null,17-May-16,"University Medical Center Ljubljana, Ljubljana, Slovenia",,https://ClinicalTrials.gov/show/NCT02103049
NCT02100514,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events,SPIRE-LL,Completed,Has Results,Hyperlipidemia,Drug: Bococizumab (PF-04950615; RN316)|Other: Placebo,"Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 12|Percent Change From Baseline in Fasting Total Cholesterol (TC) at Week 12, 24 and 52|Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) at Week 12, 24 and 52|Percent Change From Baseline in Fasting Non High Density Lipoprotein Cholesterol (Non HDL-C) at Week 12, 24 and 52|Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) by Triglycerides Cut-off of Less Than (<) 200 Milligram Per Deciliter (mg/dL) at Week 12, 24 and 52|Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) by Triglycerides Cut-off of Greater Than or Equal to (>=) 200 Milligram Per Deciliter (mg/dL) at Week 12, 24 and 52|Percent Change From Baseline in Fasting Lipoprotein (A) (Lp[A]) at Week 12, 24 and 52|Percent Change From Baseline in Fasting High Density Lipoprotein Cholesterol (HDL-C) at Week 12, 24 and 52|Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 24, 52: Treatment Period|Percent Change From Baseline in Fasting Triglycerides (TG) at Week 12, 24 and 52|Percent Change From Baseline in Fasting Apolipoprotein A-I (ApoA-I) at Week 12, 24 and 52|Percent Change From Baseline in Fasting Apolipoprotein A-II (ApoA-II) at Week 12, 24 and 52|Percent Change From Baseline in Fasting Very Low Density Lipoprotein Cholesterol (VLDL-C) at Week 12, 24 and 52|Absolute Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) by Triglycerides Cut-off of Less Than (<) 200 Milligram Per Deciliter (mg/dL) at Week 12|Absolute Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) by Triglycerides Cut-off of Greater Than or Equal to (>=) 200 Milligram Per Deciliter (mg/dL) at Week 12|Absolute Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 12|Absolute Change From Baseline in Fasting Total Cholesterol (TC) at Week 12|Absolute Change From Baseline in Fasting Non High Density Lipoprotein Cholesterol (Non HDL-C) at Week 12|Absolute Change From Baseline in Fasting Apolipoprotein B (ApoB) at Week 12|Absolute Change From Baseline in Fasting Lipoprotein (A) (Lp[A]) at Week 12|Absolute Change From Baseline in Fasting High Density Lipoprotein Cholesterol (HDL-C) at Week 12|Absolute Change From Baseline in Ratio of Fasting Total Cholesterol (TC) to High Density Lipoprotein Cholesterol (HDL-C) at Week 12, 24 and 52|Absolute Change From Baseline in Ratio of Fasting Apolipoprotein B (ApoB) to Apolipoprotein A-I (ApoA-I) at Week 12, 24 and 52|Percentage of Participants Achieving Fasting Low Density Lipoprotein Cholesterol (LDL-C) Less Than or Equal to (<=) 100 Milligram Per Deciliter (mg/dL) at Week 12, 24 and 52|Percentage of Participants Achieving Fasting Low Density Lipoprotein Cholesterol (LDL-C) Less Than or Equal to (<=) 70 Milligram Per Deciliter (mg/dL) at Week 12, 24 and 52|Plasma Concentration Versus Time Summary of PF-04950615|Percentage of Participants With Adverse Events (AEs) Related to Type 1 and 3 Hypersensitivity Reactions and Injection Site Reactions|Percentage of Participants With Anti-Drug Antibodies (ADA) and Neutralizing Antibodies (nAb): Treatment Period|Number of Participants Who Changed Concomitant Medication During Extension Period|Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 58 (Follow up), 71, 84, 97 and 110: Extension Period|Percentage of Participants With Anti-Drug Antibodies (ADA) and Neutralizing Antibodies (nAb): Extension Period",Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,746,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",B1481045|SPIRE-LL|2014-000478-20,28-Oct-14,15-Jul-16,10-Jul-17,1-Apr-14,21-Jul-17,31-Jul-18,"Advanced Cardiovascular, LLC Research, Alexander City, Alabama, United States|Advanced Cardiovascular, LLC, Research, Auburn, Alabama, United States|Clinical Research Advantage, Inc./Family Practice Specialists, Ltd., Phoenix, Arizona, United States|Clinical Research Advantage, Inc./Family Practice Specialists, LTD, Phoenix, Arizona, United States|Radiant Research, Inc., Tucson, Arizona, United States|Radiant Research, Inc, Tucson, Arizona, United States|Lynn Institute of the Ozarks, Little Rock, Arkansas, United States|The Office of Larry Watkins, MD, Little Rock, Arkansas, United States|American Institute of Research, Los Angeles, California, United States|lntermed Group, Los Angeles, California, United States|IMD Medical Group, Los Angeles, California, United States|The Office of Lucita M. Cruz, M.D., Inc., Norwalk, California, United States|Superior Research, LLC, Sacramento, California, United States|Superior Research ,LLC, Sacramento, California, United States|Radiant Research, Inc., Santa Rosa, California, United States|Orange County Research Center, Tustin, California, United States|Ventura Clinical Trials, Ventura, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|Clinical Research Advantage, Inc. / Colorado Springs Family Practice, Colorado Springs, Colorado, United States|Creekside Endocrine Associates, PC, Denver, Colorado, United States|Boca Raton Clinical Research Associates, Boca Raton, Florida, United States|BRCR Medical Center, Inc., Boca Raton, Florida, United States|Meridien Research, Brooksville, Florida, United States|Linfritz Research Institute Inc., Coral Gables, Florida, United States|Florida Health Center, Fort Lauderdale, Florida, United States|Health Care Family Rehab & Research Center, Hialeah, Florida, United States|Indago Research & Health Center, Inc., Hialeah, Florida, United States|NewPhase Clinical Trials, Corp., Miami Beach, Florida, United States|Panax Clinical Research, Miami Lakes, Florida, United States|Precision Research Organization, Miami Lakes, Florida, United States|Sunrise Research Institute, Inc, Miami, Florida, United States|Prestige Clinical Research Center, Inc., Miami, Florida, United States|Suncoast Research Group, LLD, Miami, Florida, United States|Elite Clinical Research, Miami, Florida, United States|Advanced Clinical Research of Miami, Miami, Florida, United States|The Research Specialists of Florida, Inc., Miami, Florida, United States|Columbus Clinical Services, LLC, Miami, Florida, United States|First Quality, Miramar, Florida, United States|American Family Medical, Ocala, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Andres Patron, D.O.P.A., Pembroke Pines, Florida, United States|Pines Care Research Center, LLC, Pembroke Pines, Florida, United States|DBC Research USA, Pembroke Pines, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Accord Clinical Research, Llc, Port Orange, Florida, United States|East Coast Institute for Research, LLC/ Baker-Gilmour Cardiovascular Institute, Saint Augustine, Florida, United States|East Coast Institute for RSCH, St. Augustine Cardiology Associates, Research, Saint Augustine, Florida, United States|Meridien Research, Saint Petersburg, Florida, United States|Cardiovascular Center of Sarasota, Sarasota, Florida, United States|Meridien Research, Tampa, Florida, United States|Northwest Clinical Trials, Inc., Boise, Idaho, United States|American Health Network of Indiana, LLC, Avon, Indiana, United States|Heartland Research Associates, LLC, Augusta, Kansas, United States|Heartland Research Associates, LLC, Wichita, Kansas, United States|Northwest Family Physicians, Wichita, Kansas, United States|Heartland Research Associates, LLC, Wichita, Kansas, United States|Imperial Health, LLP, Lake Charles, Louisiana, United States|Crescent City Clinical Research Center, LLC, Metairie, Louisiana, United States|Clinical Trials of America LA, Monroe, Louisiana, United States|Bethesda Health Research, Bethesda, Maryland, United States|Centennial Medical Group, Elkridge, Maryland, United States|McLaren Flint, Flint, Michigan, United States|CentraCare Heart & Vascular Center @ St. Cloud Hospital, Saint Cloud, Minnesota, United States|CentraCare Heart & Vascular Center at St. Cloud Hospital, Saint Cloud, Minnesota, United States|Riser Medical Research, Picayune, Mississippi, United States|Washington University, The Center for Advanced Medicine, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Clinical Research Advantage, Inc. (Prairie Fields Family Medicine, PC), Fremont, Nebraska, United States|ActivMed Practices & Research, Inc., Portsmouth, New Hampshire, United States|Albuquerque Clinical Trials, Inc., Albuquerque, New Mexico, United States|Physician's East Endocrinology, Greenville, North Carolina, United States|Physician's East P.A., Greenville, North Carolina, United States|Physician's East, PA, Greenville, North Carolina, United States|Catawba Valley Medical Group, Inc., Hickory, North Carolina, United States|Clinical Trials of America, Inc., Hickory, North Carolina, United States|PMG Research of Hickory, Hickory, North Carolina, United States|Wake Internal Medicine Consultants, Inc., Raleigh, North Carolina, United States|Wake Research Associates, LLC, Raleigh, North Carolina, United States|Primed Clinical Research, Dayton, Ohio, United States|Office of Daniel G. Williams, MD, Perrysburg, Ohio, United States|South Oklahoma Heart Research, LLC, Oklahoma City, Oklahoma, United States|Castlerock Clinical Research Consultants,LLC, Tulsa, Oklahoma, United States|Harleysville Medical Associates, Harleysville, Pennsylvania, United States|Berks Cardiologists, Ltd., Wyomissing, Pennsylvania, United States|Medical Research South, LLC, Charleston, South Carolina, United States|Ellipsis Research Group, LLC, Columbia, South Carolina, United States|Spartanburg Medical Research, Spartanburg, South Carolina, United States|Stern Cardiovascular Foundation, Inc, Germantown, Tennessee, United States|Apex Cardiology, Jackson, Tennessee, United States|Research Associates of Jackson, Jackson, Tennessee, United States|PMG Research, Inc d/b/a PMG Research of Knoxville, Knoxville, Tennessee, United States|Punzi Medical Center, Carrollton, Texas, United States|Juno Research, LLC, Houston, Texas, United States|Gulf Coast Medical Research,LLC, Houston, Texas, United States|Office of Michelle Zaniewski MD., PA., Houston, Texas, United States|Juno Research, LLC, Katy, Texas, United States|Gulf Coast Medical Research, LLC, Missouri City, Texas, United States|Clinical Research Advantage, Inc./ Plano Internal Medicine Associates, Plano, Texas, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|Gulf Coast Medical Research, LLC, Sugar Land, Texas, United States|Aspen Clinical Research, Orem, Utah, United States|Millennium Clinical Trials, LLC, Arlington, Virginia, United States|National Clinical Research-Norfolk, Inc., Norfolk, Virginia, United States|Sound Health Care Center, Port Orchard, Washington, United States|Sound Medical Research, Port Orchard, Washington, United States|Walla Walla Clinic, Walla Walla, Washington, United States|Clinical Investigation Specialists, Inc., Kenosha, Wisconsin, United States|HFM Heart and Vascular Center/Holy Family Memorial, Inc, Manitowoc, Wisconsin, United States|LMC Clinical Research Inc. (Calgary), Calgary, Alberta, Canada|Office of Dr. Ronald Collette MD, Burnaby, British Columbia, Canada|Medical Arts Health Research Group, Kamloops, British Columbia, Canada|The Medical Arts Health Research Group, Kelowna, British Columbia, Canada|Glover Medical Clinic, Langley, British Columbia, Canada|Fraser Clinical Trials, New Westminster, British Columbia, Canada|The Medical Arts Health Research Group, Penticton, British Columbia, Canada|The Office of James K. Lai, MD Inc., Vancouver, British Columbia, Canada|Cook Street Medical Clinic, Victoria, British Columbia, Canada|LMC Clinical Research Inc. (Barrie), Barrie, Ontario, Canada|LMC Clinical Research Inc. (Brampton), Brampton, Ontario, Canada|Aggarwal And Associates Ltd, Brampton, Ontario, Canada|Corunna Medical Research Centre, Corunna, Ontario, Canada|LMC Clinical Research Inc. (Etobicoke), Etobicoke, Ontario, Canada|LMC Clinical Research Inc. (Markham), Markham, Ontario, Canada|SKDS Research Inc., Newmarket, Ontario, Canada|LMC Clinical Research Inc. (Oakville), Oakville, Ontario, Canada|The Office of Dr. James Cha, Oshawa, Ontario, Canada|Kawartha Cardiology Clinical Trials, Peterborough, Ontario, Canada|Scarborough Cardiology Research, Scarborough, Ontario, Canada|LMC Clinical Research Inc. (Thornhill), Thornhill, Ontario, Canada|Rouge Valley Health System - Centenary, Toronto, Ontario, Canada|LMC Clinical Research Inc. (Bayview), Toronto, Ontario, Canada|Manna Research Inc., Toronto, Ontario, Canada|Ecogene-21, Chicoutimi, Quebec, Canada|ViaCar Recherche Clinique Inc., Greenfield Park, Quebec, Canada|Centre de Depistage et de Recherche Cardiovasculaire Rive-Sud, Longueuil, Quebec, Canada|Montreal Heart Institute, Montreal, Quebec, Canada|Centre De Sante Et De Services Sociaux De Beauce (CSSSB), Saint-Georges, Beauce, Quebec, Canada|C.I.C. Maurice Inc., Trois-Rivieres, Quebec, Canada|C.I.C. Mauricie Inc., Trois-Rivieres, Quebec, Canada|Clinique des maladies lipidiques de Quebec, Quebec, Canada|Alpha Recherche Clinique, Quebec, Canada|Kardiologicka ambulance, Trutnov, Kralovehradecky KRAJ, Czechia|Fakultni Nemocnice Kralovske Vinohrady, II. interni klinika, Praha 10, Vinohrady, Czechia|Fakultni nemocnice u sv. Anny Brno. Oddeleni klinicke biochemie, Brno, Czechia|Fakultni nemocnice u sv. Anny. Nemoenicni lekarna (pharmacy), Brno, Czechia|Cardiocentrum Kladno s.r.o., Kardiologicka ambulance, Kladno, Czechia|Lekarna - P-P Klinika Kladno, Kladno, Czechia|Lunacor s.r.o., Kromeriz, Czechia|Fakultni Nemocnice Olomouc, III. interni klinika ¿ nefrologicka, revmatologicka a endokrinologicka, Olomouc, Czechia|Lekarna Fakultni nemocnice Olomouc (pharmacy), Olomouc, Czechia|Lekarna Domovina, Olomouc, Czechia|PreventaMed, s.r.o., Olomouc, Czechia|IKEM, Oddeleni preventivni kardiologie, Praha 4, Czechia|IKEM, Ustavni lekarna, Praha 4, Czechia|BENU lekarna, Pribram, Czechia|Kardiologicka ambulance, III. Poliklinika, Pribram, Czechia|Lekarna 203-02, Slany, Czechia|Nemocnice Slany, Interni oddeleni, Slany, Czechia|AeskuLab k.s., Lipidova poradna, Teplice, Czechia|Lekarna Centrum (pharmacy), Teplice, Czechia|Dr.Max lekarna, Trutnov, Czechia|Etela-Karjalan Keskussairaala, Lappeenranta, Finland|Turku University Hospital, Turku, Finland|Sacred Heart Hospital-Hallym University, Anyang-si, Gyeonggi-do, Korea, Republic of|Hanyang University Guri Hospital, Guri-si, Gyeonggi-do, Korea, Republic of|Dong-A University Hospital, Busan, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Medisch Spectrum Twente, Enschede, ER, Netherlands|St Lucas Andreas Hospital, Amsterdam, North Holland, Netherlands|Gelre Hospitals, Apeldoorn, Netherlands|Andromed Eindhoven, Eindhoven, Netherlands|Medisch Spectrum Twente, Enschede, Netherlands|Beatrix Hospital, Gorinchem, Netherlands|Martini Ziekenhuis, Groningen, Netherlands|Zuyderland Medisch Centrum, Heerlen, Netherlands|Andro Medical Research B.V., Rotterdam, Netherlands|Ikazia Hospital, Rotterdam, Netherlands|D&A Research and Genetics, Sneek, Netherlands|St. Elisabeth Hospital, Tilburg, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|Ossum Gronert Legetjeneste AS, Honefoss, Norway|Oslo Universitetssykehus HF, Oslo, Norway|Oslo Universitetssykehus HF, Ulleval, Oslo, Norway|KO-MED Centra Kliniczne Lublin, Lublin, Lubelskie, Poland|KO-MED Centra Kliniczne Zamosc, Zamosc, Lubelskie, Poland|KO-MED. Centra Kliniczne Staszow, Staszow, Swietokrzyskie, Poland|Synexus Polska Sp. z o.o. Oddzial w Gdyni, Gdynia, Poland|MCBK Sc lwona Czajkowska Monika Barney, Grodzisk Mazowiecki, Poland|Synexus Polska Sp. z o. o. Oddizial w Katowicach., Katowice, Poland|Clinport Tura Lipinska Dabrowski S.C., Katowice, Poland|Krakowski Szpital Specjalistyczny im. Jana Pawla II, Krakow, Poland|Jan Zbigniew Peruga NZOZ SALUS, Lodz, Poland|Zespol Opieki Zdrowotnej W Olawie, Oddzial Chorob Wewnetrznych, Olawa, Poland|Synexus Polska Sp. z o.o Oddzial w Poznaniu, Poznan, Poland|KO-MED Centra Kliniczne Sp. z o.o., Pulawy, Poland|Synexus Polska Sp. z o.o. Oddzial w Warszawie, Warszawa, Poland|Synexus Polska Sp. z o.o. Oddzial we Wroclawiu, Wroclaw, Poland|.WroMedica Irena Bielicka, Janusz Szczepanik Spolka Cywlina, Wroclaw, Poland|Ponce School Of Medicine, Ponce, Puerto Rico|Cardiometabolic Research Center, Inc, Ponce, Puerto Rico|Caparra Internal Medicine, Rio Grande, Puerto Rico|National University Hospital, Singapore, Singapore|National Heart Centre Singapore, Singapore, Singapore|Clinical Trial Center (CTC)/Centrum foer klinisk proevning, Goteborg, Sweden|Vardcentralen Lessebo, Lessebo, Sweden|Clinical Trials Consultants AB, Linkoping, Sweden|ProbarE i Lund AB, Lund, Sweden|Capio Citykliniken Hjartmottagning, Lund, Sweden|Dalecarlia Clinical Research Center, Rattvik, Sweden|Citydiabetes, Stockholm, Sweden|Karolinska Universitetssjukhuset Huddinge, Stockholm, Sweden|Synexus Thames Valley Clinical Research Centre, Reading, Berkshire, United Kingdom|Salford Royal NHS Foundation Trust, Salford, Greater Manchester, United Kingdom|Synexus Scotland Clinical Research Centre, Glasgow, Lanarkshire Scotland, United Kingdom|Synexus Lancashire Clinical Research Centre, Chorley, Lancashire, United Kingdom|Synexus North East Clinical Research Centre - Hexham General Hospital, Hexham, Northumberland, United Kingdom|Worcestershire Acute Hospitals NHS Trust - Worcestershire Royal Hospital, Worcester, Worcestershire, United Kingdom|University Hospital Ayr - Nhs Ayrshire And Arran, Ayr, United Kingdom|Synexus Midlands Clinical Research Centre, Birmingham, United Kingdom|Hull and East Yorkshire Hospitals NHS Trust, Hull, United Kingdom|Synexus Merseyside Clinical Research Centre, Liverpool, United Kingdom|Synexus Manchester Clinical Research Centre, Manchester, United Kingdom|Abertawe Bro Morgannwg University Local Health Board Joint Clinical Research Facility,, Swansea, United Kingdom",,https://ClinicalTrials.gov/show/NCT02100514
NCT02100839,Safety Study of AEM-28 to Treat Refractory Hypercholesterolemia,,Completed,Has Results,Hypercholesterolemia|Hyperlipoproteinemia Type II,Drug: AEM-28|Drug: Normal Saline,Number of Participants Who Incurred at Least One Treatment Emergent Event|Number of Participants Who Incurred Mild Treatment Emergent Adverse Events|Number of Participants Who Incurred Moderate Treatment Emergent Events|Very Low Density Lipoprotein Cholesterol (VLDL-C) Percent Change,"LipimetiX Development, LLC",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,52,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",LPMX-112,Mar-14,Nov-14,Dec-14,1-Apr-14,29-Dec-15,29-Dec-15,"Linear Clinical Research Ltd., Nedlands, Western Australia, Australia",,https://ClinicalTrials.gov/show/NCT02100839
NCT02100202,Efficacy and Safety Study of Dietary Supplements in Chronic Smokers Having Mild to Moderate Hyperlipidemia,,Unknown status,No Results Available,Chronic Smokers|Hyperlipidemia,Other: Placebo|Dietary Supplement: BioTurmin (Curcuma longa rhizomes extract)|Dietary Supplement: BioTurmin-WD (Water dispersible curcuminoids)|Dietary Supplement: MaQxan (Tagetes erecta flower extract),Change in urine cotinine and serum oxidative stress marker levels|Change in serum lipid profile,Olive Lifesciences Pvt Ltd,Male,"20 Years to 65 Years   (Adult, Older Adult)",Not Applicable,60,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",OLS-SH/02-14 Ver 01,Apr-14,Jul-14,Jul-14,31-Mar-14,null,31-Mar-14,"Sreenivasa Clinic Diabetic Research Center, Bangalore, Karnataka, India",,https://ClinicalTrials.gov/show/NCT02100202
NCT02098278,Pilot Study To Assess CAT-2003 in Patients With Chylomicronemia,,Completed,No Results Available,"Lipoprotein Lipase Deficiency, Familial|Hyperlipoproteinemia Type I|Chylomicronemia, Familial|Hypertriglyceridemia",Drug: CAT-2003|Drug: Placebo,Percent change from baseline in fasting triglycerides in patients with chylomicronemia|Absolute and percent change from baseline on postprandial total and chylomicron triglyceride levels|Absolute and percent change from baseline on chylomicron triglyceride clearance|Absolute and percent change from baseline in plasma non-HDL-C|Frequency of adverse events,Catabasis Pharmaceuticals,All,"18 Years to 74 Years   (Adult, Older Adult)",Phase 2,13,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,CAT-2003-203,Mar-14,Apr-15,Apr-15,28-Mar-14,null,21-Jul-16,"Chicoutimi, Quebec, Canada|Quebec City, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02098278
NCT02098460,To Compare the Effect of Concomitant Administration of Probucol and Cilostazol With Probucol Single Treatment on the Atherosclerosis Related Markers (Including the Thickness of the Achilles Tendon) and Evaluate Safety (Based on Atorvastatin Treatment) in Severe Hypercholesterolemia Subject,,Unknown status,No Results Available,Severe Hypercholesterolemia,"Drug: Atorvastatin, Probucol, Cilostazol","the effect of concomitant administration of Probucol and Cilostazol on the mean achilles tendon thickness (ATT)|the additional effect of concomitant administration of Probucol and Cilostazol on mean carotid intima-media thickness (IMT)|the preventive effect of concomitant administration of Probucol and Cilostazol on the incidence of cerebrovascular and cardiovascular events (including intervention)|the effect of concomitant administration of Probucol and Cilostazol on biomarkers|the safety of Probucol or concomitant administration of Probucol and Cilostazol as determined by physical examination, vital signs, adverse events (AEs), laboratory examinations and 12-lead electrocardiogram (ECGs)",Otsuka Beijing Research Institute,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,250,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",260-13-806-01,Oct-13,Apr-17,Apr-17,28-Mar-14,null,31-Mar-14,"Anzhen hospital, Beijing, China",,https://ClinicalTrials.gov/show/NCT02098460
NCT02097108,Changes in Lipids and Lipoproteins in HIV Infected Women After Switch From Protease Inhibitor to Raltegravir,,Completed,Has Results,HIV Infections,Drug: Raltegravir,Patients With Low-density Lipoprotein (LDL) Cholesterol Reduction|Total Cholesterol Baseline and After 24 Weeks|Triglycerides Baseline and After 24 Weeks|High-density Lipoprotein (HDL) Cholesterol Baseline and After 24 Weeks,Arbeitsgemeinschaft medikamentoese Tumortherapie|Merck Sharp & Dohme Corp.,Female,"18 Years and older   (Adult, Older Adult)",Phase 2,11,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AGMT_HIV1,May-14,Dec-15,Dec-15,26-Mar-14,13-Sep-16,13-Sep-16,"PMU Salzburg, Salzburg, Austria|AKH Wien, Wien, Austria|Ottto Wagner Spital, Wien, Austria",,https://ClinicalTrials.gov/show/NCT02097108
NCT02094768,Soda and Milk Study,SAMS,Completed,No Results Available,Obesity|Dyslipidemia,Dietary Supplement: Reduced Fat Milk|Dietary Supplement: Sugar Sweetened Soda,LDL peak particle diameter|Plasma triglycerides|LDL-cholesterol|HDL-cholesterol|Blood pressure|LDL subclass concentrations|Apolipoprotein B|Apolipoprotein AI|Apolipoprotein CIII,Children's Hospital & Research Center Oakland|Almond Board of California,Male,"13 Years to 18 Years   (Child, Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention,MM7267,Apr-14,Sep-16,May-17,24-Mar-14,null,6-Nov-17,"Cholesterol Research Center, Berkeley, California, United States",,https://ClinicalTrials.gov/show/NCT02094768
NCT02091024,Blood Lipid-lowering Effect of Brown Alga Ecklonia Cava,,Completed,No Results Available,Hypercholesterolemia,Dietary Supplement: ECE (Ecklonia cava extract)|Dietary Supplement: Placebo,Changes in total cholesterol|Changes in LDL-cholesterol|Changes in triglyceride|Changes in HDL-cholesterol|Changes in waist to hip ratio,Chonbuk National University Hospital,All,"19 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,80,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care",LVCM-HL-SEAPOLYNOL,Apr-11,Dec-11,Dec-11,19-Mar-14,null,19-Mar-14,"Clinical Trial Center for Functional Foods; Chonbuk National University Hospital, Jeonju, Jeollabuk-do, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02091024
NCT02089035,Replacement of Saturated Fat in Dairy on Total Cholesterol,RESET,Completed,No Results Available,Hypercholesterolemia,"Dietary Supplement: MUFA-rich dairy products (UHT milk, cheese and butter)|Dietary Supplement: Conventional dairy products (UHT milk, cheese, butter)",Chronic study: Changes in fasting plasma circulating levels of total cholesterol|Acute study: Changes in postprandial flow-mediated dilatation|Changes in vascular stiffness by Carotid Intima Media Thickness (CIMT)|Change in 24-hour ambulatory blood pressure|Changes in plasma circulating markers of vascular health|Changes in plasma circulating markers of inflammatory status|Changes in plasma circulating markers related to lipid metabolism|Changes in plasma circulating markers related to insulin resistance|Changes in vascular stiffness by Pulse Wave Velocity (PWV)|Changes in vascular stiffness by Pulse Wave Analysis (PWA)|Changes in vascular stiffness by Digital Volume Pulse (DVP)|Changes in monocytic cytokine production from whole blood culture|Changes in vascular reactivity by Flow Mediated Dilatation (FMD)|Changes in anthropometric measurements|Change in plasma phospholipid fatty acid composition,University of Reading|Medical Research Council,All,"25 Years to 70 Years   (Adult, Older Adult)",Not Applicable,54,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",13/43|University of Reading,May-14,Apr-16,Apr-16,17-Mar-14,null,24-Jul-17,"Department of Food and Nutritional Sciences, University of Reading, Reading, Berks, United Kingdom",,https://ClinicalTrials.gov/show/NCT02089035
NCT02087124,Dose-response Effect of Whey Protein Consumed as Pre-meal on Postprandial Lipaemia in Subjects With Metabolic Syndrome,,Completed,No Results Available,Metabolic Syndrome,Other: Whey protein,Dose-response of whey protein as pre-meal on triglycerides after a high-fat meal in subjects with the metabolic syndrome measured as incremental Area Under the Curve (iAUC -15 - 360 min)|Dose-response of whey protein as pre-meal on apolipoprotein B48 after a high-fat meal in subjects with the metabolic syndrome measured as incremental Area Under the Curve (iAUC -15 - 360 min)|Glucose responses measured as incremental Area Under the Curve (AUC -15 - 360 min)|Insulin responses measured as incremental Area Under the Curve (AUC -15 - 360 min)|Glucagon responses measured as incremental Area Under the Curve (AUC -15 - 360 min)|Glucagon-like peptide 1 (GLP-1) responses measured as incremental Area Under the Curve (AUC -15 - 360 min)|Gastric inhibitory peptide (GIP) responses measured as incremental Area Under the Curve (AUC -15 - 360 min),Aarhus University Hospital|University of Aarhus,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,CERN-Premeal1,Mar-14,Jun-14,Jun-14,14-Mar-14,null,21-Jul-14,"Aarhus University Hospital, Aarhus, Aarhus C., Denmark",,https://ClinicalTrials.gov/show/NCT02087124
NCT02087540,Efficacy and Safety of Telmisartan/Rosuvastatin Co-administration in Hypertensive Patients With Hyperlipidemia,,Unknown status,No Results Available,Hypertension|Hyperlipidemia,Drug: Telmisartan 80mg|Drug: Rosuvastatin 20mg|Drug: Rosuvastatin 10mg|Drug: Placebo(for Telmisartan 80mg)|Drug: Placebo(for Rosuvastatin 20mg)|Drug: Placebo(for Rosuvastatin 10mg),"•Change in seated diastolicblood pressure at 8 weeks compared to the base value|Change in LDL-Cat 8 weeks compared to the base value (% change)|Change in seateddiastolic blood pressure|Change in seated systolic blood pressure|Rate of patients achieving a therapeutic purpose according to JNC VII Guideline [therapeutic purpose for blood pressure: < 140/90 mmHg (however, < 130/80 mmHg for Group III)]|Change in LDL-Cat compared to the base value (% change)|Change in TC, TG, HDL-C and Apolipoprotein B compared to the base value (% change)|Rate of patients achieving a therapeutic purpose according to NCEP ATP III Guideline therapeutic purpose for LDL-C- (Group I: < 160 mg/dL, Group II: < 130 mg/dL, Group III: < 100 mg/dL)",IlDong Pharmaceutical Co Ltd,All,"19 Years to 80 Years   (Adult, Older Adult)",Phase 3,310,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ID_Telotan_1203,May-13,Dec-14,null,14-Mar-14,null,14-Mar-14,"The Catholic University of Saint Mary's Hosiptal, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02087540
NCT02087917,"A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia",,Completed,No Results Available,Primary Hypercholesterolemia,Drug: HS-25|Drug: Placebo,"Percent change from baseline in LDL-C after 4 weeks of double-blind treatment|Percentage of participants with reported adverse events during a 4-week period of treatment as a measure of safety and tolerability of HS-25|Percent change from baseline in LDL-C after a 1 and 2-week period of double-blind treatment|Percent change from baseline in apoprotein B, non-high density lipoprotein-cholesterol, total cholesterol, triglycerides, high density lipoprotein-cholesterol and apoprotein A1 levels after a 1, 2 and 4-week period of treatment|Mean concentration of HS-25 dose and its major metabolite (HS-25-M1) during treatment with HS-25 5, 10, 20 or 30 mg.|Correlation between trough HS-25 and HS-25-M1 levels and percent change in LDL-C, apoA1, apoB, non-HDL-C, TC, TG, and HDL-C during a 4-week period of HS-25 treatment.",Zhejiang Hisun Pharmaceutical Co. Ltd.|Covance,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,376,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",HS-25-III,Mar-14,Sep-14,Dec-14,14-Mar-14,null,6-Jan-15,"Chandler, Arizona, United States|Phoenix, Arizona, United States|West Hills, California, United States|Doral, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|South Miami, Florida, United States|Chicago, Illinois, United States|Evansville, Indiana, United States|Indianapolis, Indiana, United States|Overland Park, Kansas, United States|Louisville, Kentucky, United States|Auburn, Maine, United States|Bethesda, Maryland, United States|Methuen, Massachusetts, United States|Trenton, New Jersey, United States|Rochester, New York, United States|Raleigh, North Carolina, United States|Cincinnati, Ohio, United States|Tulsa, Oklahoma, United States|Penndel, Pennsylvania, United States|Greensboro, South Carolina, United States|Dallas, Texas, United States|Houston, Texas, United States|Salt Lake City, Utah, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02087917
NCT02083510,Apolipoprotein CIII Reduction Via Colchicine,,Completed,No Results Available,Hypertriglyceridemia|Gout|Pericarditis,Drug: Colchicine,Reduction in ApoCIII levels|Reduction of triglycerides and very low density lipoprotein (VLDL) levels|Measurement of Apolipoprotein A and Apolipoprotein B via Vertical Auto Profile (VAP),Scripps Translational Science Institute,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,5,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,13-6293|1UL1TR001114-01,Feb-14,May-14,May-14,11-Mar-14,null,30-May-14,"Scripps Translational Science Institute, La Jolla, California, United States",,https://ClinicalTrials.gov/show/NCT02083510
NCT02079922,A Multiple Dose Study Of PF-06678552 In Healthy Subjects,,Completed,No Results Available,Healthy,Drug: PF-06678552|Drug: Placebo,"Assessment of adverse events (AEs), clinical laboratory tests, vital signs (including blood pressure and pulse rate), and cardiac conduction intervals as assessed by 12 lead ECG.|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-06644927 on day 1|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-06644927 on day 7|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-06644927 on day 14|Area Under the Curve during the dosing interval (AUCtau) for PF-06644927 on day 1|Area Under the Curve during the dosing interval (AUCtau) for PF-06644927 on day 7|Area Under the Curve during the dosing interval (AUCtau) for PF-06644927 on day 14|Maximum Observed Plasma Concentration (Cmax) for PF-06644927 on day 1|Maximum Observed Plasma Concentration (Cmax) for PF-06644927 on day 7|Maximum Observed Plasma Concentration (Cmax) for PF-06644927 on day 14|Time to Reach Maximum Observed Plasma Concentration (Tmax) for PF-06644927 on day 1|Time to Reach Maximum Observed Plasma Concentration (Tmax) for PF-06644927 on day 7|Time to Reach Maximum Observed Plasma Concentration (Tmax) for PF-06644927 on day 14|Plasma Decay Half-Life (t1/2) for PF-06644927 on day 14|Accumulation ratio for Maximum Observed Plasma Concentration (Rac(Cmax)) for PF-06644927 on day 7 relative to day 1|Accumulation ratio for Maximum Observed Plasma Concentration (Rac(Cmax)) for PF-06644927 on day 14 relative to day 1|Accumulation ratio for Area Under the Curve during the dosing interval (Rac(AUC)) for PF-06644927 on day 7 relative to day 1|Accumulation ratio for Area Under the Curve during the dosing interval (Rac(AUC)) for PF-06644927 on day 14 relative to day 1|Amount of PF-06644927 excreted in urine (Ae) on day 14|Percent of dose excreted in urine as PF-06644927 (Ae%) on day 14|Renal clearance of PF-06644927 (CLr) on day 14|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-06678552 on day 1|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-06678552 on day 7|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-06678552 on day 14|Area Under the Curve during the dosing interval (AUCtau) for PF-06678552 on day 1|Area Under the Curve during the dosing interval (AUCtau) for PF-06678552 on day 7|Area Under the Curve during the dosing interval (AUCtau) for PF-06678552 on day 14|Maximum Observed Plasma Concentration (Cmax) for PF-06678552 on day 1|Maximum Observed Plasma Concentration (Cmax) for PF-06678552 on day 7|Maximum Observed Plasma Concentration (Cmax) for PF-06678552 on day 14|Time to Reach Maximum Observed Plasma Concentration (Tmax) for PF-06678552 on day 1|Time to Reach Maximum Observed Plasma Concentration (Tmax) for PF-06678552 on day 7|Plasma Decay Half-Life (t1/2) for PF-06678552 on day 14|Accumulation ratio for Maximum Observed Plasma Concentration (Rac(Cmax)) for PF-06678552 on day 7 relative to day 1|Accumulation ratio for Maximum Observed Plasma Concentration (Rac(Cmax)) for PF-06678552 on day 14 relative to day 1|Accumulation ratio for Area Under the Curve during the dosing interval (Rac(AUC)) for PF-06678552 on day 7 relative to day 1|Accumulation ratio for Area Under the Curve during the dosing interval (Rac(AUC)) for PF-06678552 on day 14 relative to day 1|Apparent Oral Clearance (CL/F) of PF-06678552 on day 7|Apparent Oral Clearance (CL/F) of PF-06678552 on day 14|Apparent Volume of Distribution (Vz/F) of PF-06678552 on day 7|Apparent Volume of Distribution (Vz/F) of PF-06678552 on day 14",Pfizer,All,18 Years to 55 Years   (Adult),Phase 1,38,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science",B7611002,Mar-14,Jul-14,Jul-14,6-Mar-14,null,31-Jul-14,"Pfizer Investigational Site, Brussels, Belgium",,https://ClinicalTrials.gov/show/NCT02079922
NCT02078167,"Long Term Efficacy and Tolerability of a Nutraceutical Combination (Red Yeast Rice, Policosanols and Berberine) in Low-moderate Risk Hypercholesterolemic Patients: a Double-blind, Placebo Controlled Study",,Completed,No Results Available,Hypercholesterolemia,"Other: nutraceutical combination (red yeast rice, policosanols and berberine)",level of cholesterol|level of tryglicerides,Comitato Etico di Area Vasta Sud Est|Carla Caffarelli,All,18 Years to 60 Years   (Adult),Phase 4,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ARMOLIPID,Jan-09,Jan-11,Dec-13,5-Mar-14,null,5-Mar-14,,,https://ClinicalTrials.gov/show/NCT02078167
NCT02075619,Relative Bioavailability Study of One Amlodipine 10mg Tablet and One Rosuvastatin 20mg Tablet to Two Fixed Dose Combinations of Amlodipine (10mg) and Rosuvastatin (20mg) in Healthy Subjects Under Fasting Conditions,,Completed,No Results Available,Hypertension,Drug: Amlodipine+Rosuvastatin|Drug: GSK3074477 FDC - 1|Drug: GSK3074477 FDC - 2,Plasma pharmacokinetics (PK) parameters of amlodipine and rosuvastatin following single dose administration|Additional PK parameters of amlodipine and rosuvastatin following single dose administration|Safety as assessed by adverse events|Safety as assessed by vital signs|Safety as assessed by clinical laboratory safety data|Safety as assessed by Electrocardiogram (ECG) parameters,"GlaxoSmithKline|SingHealth Investigational Medicine Unit, Singapore",All,"21 Years to 65 Years   (Adult, Older Adult)",Phase 1,24,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,200561,24-Mar-14,11-Jul-14,11-Jul-14,3-Mar-14,null,10-May-17,"GSK Investigational Site, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT02075619
NCT02073084,A Thorough Corrected QT Interval Trial,,Completed,No Results Available,Dyslipidemia,Drug: K-877 Low Dose|Drug: Moxifloxacin|Other: Placebo|Drug: K-877 High Dose,QTcI (QT interval corrected) duration,"Kowa Research Institute, Inc.",All,18 Years to 45 Years   (Adult),Phase 1,56,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",K-877-102,Jan-14,Mar-14,null,27-Feb-14,null,10-Apr-15,"Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT02073084
NCT02072161,Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy,,Completed,No Results Available,Hypercholesterolemia,Drug: ETC-1002|Drug: Placebo|Drug: Statin Therapy,Percent change from baseline in calculated low density lipoprotein-cholesterol (LDL-C)|Percent change in non-high-density lipoprotein cholesterol (non-HDL-C)|Percent change in apolipoprotein B (ApoB)|Percent change in total cholesterol (TC)|Percent change in high-sensitivity C-reactive protein (hsCRP)|Percent change in triglycerides (TG)|Percent change in lipoprotein particle number|Safety using adverse event reports; clinical laboratory results|Safety using adverse event reports; vital signs|Pharmacokinetic plasma trough concentrations of ETC-1002 and metabolite 15228,"Esperion Therapeutics|Medpace, Inc.",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,133,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1002-009,Mar-14,Jan-15,Jan-15,26-Feb-14,null,29-Mar-19,"Muscle Shoals, Alabama, United States|Chandler, Arizona, United States|Chino, California, United States|Los Angeles, California, United States|Sacramento, California, United States|Walnut Creek, California, United States|Denver, Colorado, United States|Hartford, Connecticut, United States|Brandon, Florida, United States|Jacksonville, Florida, United States|Oviedo, Florida, United States|Ponte Vedra, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Marietta, Georgia, United States|Boise, Idaho, United States|Meridian, Idaho, United States|Evansville, Indiana, United States|Indianapolis, Indiana, United States|Wichita, Kansas, United States|Louisville, Kentucky, United States|Port Gibson, Mississippi, United States|Rochester, New York, United States|Salisbury, North Carolina, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Franklin, Ohio, United States|Lyndhurst, Ohio, United States|Marion, Ohio, United States|Tulsa, Oklahoma, United States|Greer, South Carolina, United States|Mount Pleasant, South Carolina, United States|Summerville, South Carolina, United States|Kingsport, Tennessee, United States|Houston, Texas, United States|Bountiful, Utah, United States|Orem, Utah, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02072161
NCT02069106,Efficacy Study of Daily Pro-Omega LDL for Low-Density Lipoprotein Cholesterol and Triglyceride Reduction,PrOteCT,Withdrawn,No Results Available,Mixed Hyperlipoproteinemia,Dietary Supplement: Pro-Omega LDL|Other: Placebo,Low-density lipoprotein cholesterol (LDL-C)|Triglycerides (TG)|Total cholesterol|High-density lipoprotein cholesterol (HDL-C)|non-HDL-C|LDL-C/HDL-C ratio|C-reactive protein|Adverse events|Offset effect,"Nordic Pharma, USA|Nutrasource Diagnostics Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 4,0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1001-PR-003-09092013,Feb-14,May-14,Jul-14,21-Feb-14,null,14-Dec-15,,,https://ClinicalTrials.gov/show/NCT02069106
NCT02066207,CKD-337 Drug Interaction Study,,Completed,No Results Available,Dyslipidemia (Fredrickson Type Ⅱa)|Dyslipidemia (Fredrickson Type Ⅱb),Drug: Fenofibrate|Drug: Atorvastatin,"AUCt, Cmax,ss of fenofibric acid and atorvastatin|Tmax,ss, Cmin,ss, t1/2, CL/Fss, Vd/Fss, %swing, Cav, %fluctuation",Chong Kun Dang Pharmaceutical,Male,19 Years to 55 Years   (Adult),Phase 1,30,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,146DDI13024,18-Mar-14,7-Apr-14,29-May-14,19-Feb-14,null,8-Aug-17,"Samsung Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02066207
NCT02064881,Efficacy Study of Metformin Glycinate on Postprandial Lipemia,,Recruiting,No Results Available,Type 2 Diabetes,Drug: Metformin glycinate|Drug: Metformin Hydrochloride,Change in postprandial lipemia at 4 months|Change in oxidized LDL at 4 months|Change in FGF-21 levels at 4 months|Change in A1C at 4 months|Change in alanine aminotransferase at 4 months|Change in uric acid at 4 months|Number of Participants with Serious and Non-Serious Adverse Events,Laboratorios Silanes S.A. de C.V.|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,All,"35 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,72,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",DMMET_LP001,Oct-15,Apr-20,Aug-20,17-Feb-14,null,30-Jan-18,"Instituto Nacional de Ciencias Médicas Y Nutrición Salvador Zubirán, México, Distrito Federal, Mexico",,https://ClinicalTrials.gov/show/NCT02064881
NCT02065024,Food Matrix and Genetic Variability as Determinants of Bioavailability and Biological Effects of Beta-cryptoxanthin and Phytosterols,foodmagenpol,Completed,No Results Available,Hypercholesterolemia|Osteoporosis,Dietary Supplement: b-cryptoxanthin plus phytosterols,serum response of B-cryptoxanthin|Serum response of phytosterols|Serum lipid profile|bone resorption markers|interleukins|Serum C-reactive protein|Bone formation markers|Sterols faecal levels|Erythrocytes for eryptosis evaluation,Puerta de Hierro University Hospital,Female,"45 Years to 65 Years   (Adult, Older Adult)",Phase 1,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science",AGL2012-39503-C02-02,Mar-14,Aug-15,Aug-15,17-Feb-14,null,10-Apr-18,"Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda (Madrid), Madrid, Spain",,https://ClinicalTrials.gov/show/NCT02065024
NCT02065180,The Effect of a Red Rice and Olive Extract Nutrition Supplement on Cholesterol Levels in Patients With Metabolic Syndrome,,Completed,No Results Available,Hypercholesterolaemia,Dietary Supplement: commercially available nutrition supplement|Dietary Supplement: placebo,LDL level|total cholesterol level|triglyceride level|HDL level|OxLDL|BMI|malondialdehyde (MDA)|8-OH-deoxyguanosine (8-OHdG)|side effects|waist circumference,Universiteit Antwerpen,All,"18 Years and older   (Adult, Older Adult)",Phase 4,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",verhoevenhermans,Feb-14,May-14,May-14,17-Feb-14,null,20-May-14,"University of Antwerp, Antwerp, Belgie, Belgium",,https://ClinicalTrials.gov/show/NCT02065180
NCT02063165,Healthy Oils for Women (HOW Study),HOW,Completed,No Results Available,Metabolic Syndrome,Dietary Supplement: High Linoleic Safflower Oil,Changes in trunk adipose mass|Changes in Alpha and Gamma Tocopherol Levels|Changes in mood|Changes in Lipid Profile|Oil Supplementation Compliance|Changes in glycemic control|Changes in lean mass|Changes in visceral adipose tissue|Changes in adipocytokine levels,"Ohio State University|Corr-Jensen, LLC provided some of the study oil from Arista Industries, Inc",Female,"50 Years to 69 Years   (Adult, Older Adult)",Not Applicable,18,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2012H0259|2011-039,Feb-14,Aug-15,Aug-15,14-Feb-14,null,31-Mar-16,"The Ohio State University Exercise Physiology Lab, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02063165
NCT02057302,A Study on Postmarketing Xuezhikang Capsule for Treating Dyslipidemia,,Completed,No Results Available,Dyslipidemia,Drug: Xuezhikang capsule,"Blood samples were drawn were detected,including TC,TG,LDL-C and HDL-C|Traditional Chinese medicine syndrome scores (TCM-SS) and single TCM symptom",China Academy of Chinese Medical Sciences,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,2400,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",2008ZX09202-007,Mar-10,Dec-12,null,7-Feb-14,null,7-Feb-14,,,https://ClinicalTrials.gov/show/NCT02057302
NCT02056847,to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia,SIPHON,Completed,No Results Available,HbA1c Level Associated With Lipid Compositions,Drug: Pitavastatin calcium 4mg|Drug: Pitavastatin calcium 2mg,"The change of HbA1c before and after taking LIVALO®|Incidence of diabetes|Incidence of total cardiovascular (TVR-MACE) events|The change of the lipid composition (T-chol, TG, LDL-C, HDL-C, ApoA1/ApoB)|The changes of hs-CRP, Adiponectin, blood glucose and Insulin levels",JW Pharmaceutical|The Catholic University of Korea|Kyunghee University Medical Center|Korea University Guro Hospital|Dong-A University Hospital|Seoul National University Bundang Hospital|Samsung Medical Center|Seoul National University Hospital|Ajou University School of Medicine|Gangnam Severance Hospital|Severance Hospital|Yeungnam University Hospital|Ulsan University Hospital|Eulji University Hospital|Asan Medical Center|Chonnam National University Hospital|Chonbuk National University Hospital|Chungnam National University Hospital|Hallym University Medical Center,All,"20 Years to 70 Years   (Adult, Older Adult)",Phase 4,313,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,JW-PTV-713,Sep-13,May-17,May-17,6-Feb-14,null,8-Mar-18,"JW pharmaceutical, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02056847
NCT02055976,Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects,,Completed,Has Results,Hypercholesterolemia,Drug: Bococizumab (PF-04950615;RN316)|Drug: Placebo|Drug: Ezetimibe,"Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85|Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 113|Low Density Lipoprotein-Cholesterol (LDL-C)|Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85 and Day 113|Total Cholesterol (TC)|Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113|Percent Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113|Apolipoprotein B (ApoB)|Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113|Percent Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113|Apolipoprotein A-I (ApoA-I)|Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113|Percent Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113|Apolipoprotein A-II (ApoA-II)|Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113|Percent Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113|Lipoprotein (a) (Lp[a])|Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113|Percent Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113|High Density Lipoprotein- Cholesterol (HDL-C)|Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113|Percent Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113|Very Low Density Lipoprotein-Cholesterol (VLDL-C)|Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113|Percent Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113|Triglyceride (TG)|Change From Baseline in Triglyceride (TG) at Day 85 and Day 113|Percent Change From Baseline in Triglyceride (TG) at Day 85 and Day 113|Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)|Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113|Percent Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113|Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio|Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113|Percent Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113|Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio|Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113|Percent Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113|Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter|Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs)|Number of Participants With Anti-Drug Antibody (ADA) Response|Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-04950615|Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of PF-04950615|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-04950615|Maximum Observed Plasma Concentration (Cmax) of PF-04950615|Minimum Observed Plasma Trough Concentration (Cmin) of PF-04950615|Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04950615|Terminal Elimination Half-Life (t1/2) of PF-04950615|Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)",Pfizer,All,"20 Years and older   (Adult, Older Adult)",Phase 2,218,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",B1481036,Mar-14,Jan-15,Jan-15,5-Feb-14,8-Feb-19,8-Feb-19,"Maebashi Hirosegawa Clinic, Maebashi, Gunma, Japan|Yokohama Minoru Clinic, Yokohama, Kanagawa, Japan|Heishinkai Medical Group Incorporated OCROM Clinic, Suita, Osaka, Japan|Meiwa Hospital, Chiyoda-ku, Tokyo, Japan|Tokyo-Eki Center-building Clinic, Chuo-ku, Tokyo, Japan|Heishinkai Medical Group Incorporated ToCROM Clinic, Shinjuku-ku, Tokyo, Japan|Clinical Research Hospital Tokyo, Shinjuku-ku, Tokyo, Japan|Oda Clinic, Shinjuku-ku, Tokyo, Japan|Sekino Hospital, Toshima-ku, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT02055976
NCT02048410,Efficacy of a New Symbiotic Formulation in Children With Familial Hypercholesterolemia,,Completed,No Results Available,Dyslipidemia|Familial Hypercholesterolemia,Dietary Supplement: Lactobacillus paracasei B21060|Other: low satured diet,change of LDL cholesterol after 6 months of treatment wiyh symbiotic,Federico II University,All,6 Years to 12 Years   (Child),Phase 1|Phase 2,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,14-Sep,Jan-12,Sep-12,Jun-13,29-Jan-14,null,29-Jan-14,,,https://ClinicalTrials.gov/show/NCT02048410
NCT02047175,"CKD-346 DDI Study(Telmisartan/S-Amlodipine, Rosuvastatin)",,Completed,No Results Available,Hypertension|Hyperlipidemia,Drug: Telmisartan/S-Amlodipine|Drug: Rosuvastatin|Drug: Telmisartan/S-Amlodipine + Rosuvastatin,"AUCt,ss of Telmisartan/S-Amlodipine|Cmax,ss of Telmisartan/S-Amlodipine|AUCt,ss of Rosuvastatin|Cmax,ss of Rosuvastatin|Tmax,ss of Telmisartan/S-Amlodipine|T1/2 of Telmisartan/S-Amlodipine|CL/F of Telmisartan/S-Amlodipine|Vd/F of Telmisartan/S-Amlodipine|R of Telmisartan/S-Amlodipine|Tmax,ss of Rosuvastatin|T1/2 of Rosuvastatin|CL/F of Rosuvastatin|Vd/F of Rosuvastatin|R of Rosuvastatin",Chong Kun Dang Pharmaceutical,All,20 Years to 45 Years   (Adult),Phase 1,64,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,147DDI13019,Feb-14,Mar-14,Mar-14,28-Jan-14,null,17-Apr-14,"The catholic university of Korea, seoul ST.Mary's hospital, Seoul, Gangnam-gu, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02047175
NCT02044627,"Single Radiolabeled Dose Study to Investigate the Absorption, Metabolism and Excretion of [14C]-ETC-1002",,Completed,No Results Available,Hyperlipidemia,Drug: [14C-ETC-1002],Level of [14C]-ETC-1002 in urine and feces after a single dose,Esperion Therapeutics,Male,"30 Years to 65 Years   (Adult, Older Adult)",Phase 1,6,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,1002-011,Dec-13,Jan-14,Jan-14,24-Jan-14,null,15-Feb-19,"Quotient Clinical, Nottingham, United Kingdom",,https://ClinicalTrials.gov/show/NCT02044627
NCT02043301,"Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper Arm",,Completed,No Results Available,Hypercholesterolemia,Biological: Bococizumab (PF-04950615; RN316),Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - inf)]|Maximum Observed Plasma Concentration (Cmax)|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)|Apparent SC Clearance (CL/F)|Time to Reach Maximum Observed Plasma Concentration (Tmax)|Apparent Volume of Distribution (Vz/F)|Plasma Terminal Elimination Half-Life (t1/2)|Area under the LDL-C effect curve|Maximum LDL-C lowering|Time to reach maximum LDL-C lowering,Pfizer,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,75,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,B1481024,Apr-14,Nov-14,Nov-14,23-Jan-14,null,13-Jan-15,"Anaheim Clinical Trials, LLC, Anaheim, California, United States|Miami Research Associates, South Miami, Florida, United States|MRA Clinical Research, LLC, South Miami, Florida, United States|Vince & Associates Clinical Research, Inc., Overland Park, Kansas, United States|Vince & Associates Clinical Research, Inc., Overland Park, Kansas, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT02043301
NCT02041104,Impact of Consumption of Beta-glucans on the Intestinal Microbiota and Glucose and Lipid Metabolism,,Enrolling by invitation,No Results Available,"Metabolic Syndrome|Dyslipidemia|Obesity, Abdominal|Hyperglycemia|Hypertension",Dietary Supplement: Bread with added beta-glucans|Dietary Supplement: Placebo Comparator: Bread without added beta-glucans,Lipid profile|Genetic analysis|Determination of Composition of Intestinal Microbiota from Fecal Samples|Oral Glucose Tolerance Test (OGTT) for Insulin Resistance determination (outcome measures of plasma insulin concentrations)|Oral Glucose Tolerance Test (OGTT) for Insulin Resistance determination (outcome measures of plasma glucose concentrations)|Systolic / diastolic blood pressure|Determination of concentration of Short Chain Fatty Acids (SCFA) present in fecal Samples|Systolic / diastolic Blood pressure,Mlinotest Zivilska Industrija d.d.|University of Ljubljana|University Medical Centre Ljubljana,All,"30 Years to 70 Years   (Adult, Older Adult)",Not Applicable,70,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MLINOTEST/618-001,Feb-14,Mar-18,Mar-18,20-Jan-14,null,30-Mar-18,"Community Health Center Ajdovscina, Ajdovscina, Slovenia|Community Healt Center Ljubljana, Ljubljana, Slovenia|Community Health Center Franca Amrozica Postojna, Postojna, Slovenia",,https://ClinicalTrials.gov/show/NCT02041104
NCT02037685,Improving Adherence to Statins Among Minority Populations,,Completed,No Results Available,Dyslipidemia,Behavioral: Motivational Interviewing (MINT)|Other: Usual Care,Medication possession ratio (MPR)|Self-reported adherence score (Morisky Medication Adherence Scale-8),"University of Miami|Humana, Inc",All,"35 Years to 85 Years   (Adult, Older Adult)",Not Applicable,779,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,1KG11|4KB13,Jun-10,Dec-15,Dec-15,16-Jan-14,null,25-Jan-16,"University of Miami, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT02037685
NCT02036307,Supplementation With Omega-3: Mechanism of Action,SOMA,Terminated,No Results Available,Hypertriglyceridemia,Dietary Supplement: DHA-enriched|Dietary Supplement: EPA-enriched,Fasting triglyceride level|Seated blood pressure,Johns Hopkins University,All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 2,13,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",NA_00076636,Apr-13,May-13,Jan-15,15-Jan-14,null,1-Mar-17,"Johns Hopkins University, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02036307
NCT02035215,Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3-acids Ethylesters 90 in Type Ⅱb Hyperlipidemia,,Unknown status,No Results Available,"Hyperlipidemia, Familial Combined",Drug: Atorvastatin 20mg|Drug: Omega-3-acids ethylesters 90 4g|Other: Placebo(Omega-3-acids ethylesters 90),"The mean percent change of Triglyceride(TG)|The mean percent change of Total Cholesterol(TC), LDL-C, HDL-C","Kuhnil Pharmaceutical Co., Ltd.",All,"20 Years to 80 Years   (Adult, Older Adult)",Phase 3,80,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",13-OM-8302,Jan-14,Oct-14,Dec-14,14-Jan-14,null,20-Mar-14,"Hallym University Sacred Heart Hospital, Anyang, Gyeonggi, Korea, Republic of|Gachon University Gil Hospital, Incheon, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Uijongbu St. Mary`s Hospital, Uijongbu, Gyeonggi, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02035215
NCT02035644,Study on the Efficacy aNd Safety of Jinlida Granules in Patients With Inadequately cOntrolled tYpe-2 Diabetes and dysLIpidemia Under liFe Style Intervention (ENJOY LIFE Study),,Unknown status,No Results Available,Type 2 Diabetes|Dyslipidemia,Drug: Jinlida granules|Drug: placebo granules,"change in HbA1c levels|fasting, postload 30-min and 2-h plasma glucose|fasting, postload 30-min and 2-h serum insulin|serum lipids|glucose disposal rate (GDR) values from hyperinsulinemic euglycemic clamp|incretins|metabolomic parameters|BMI|blood pressures",Shanghai Jiao Tong University School of Medicine|Shijiazhuang Yiling Pharmaceutical Co. Ltd,All,"20 Years to 70 Years   (Adult, Older Adult)",Phase 4,360,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CCEMD021,Feb-14,Feb-15,null,14-Jan-14,null,14-Jan-14,"Guang Ning, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT02035644
NCT02029625,Compare the Pharmacokinetics of NVP-1205 and Coadministration of Rosuvastatin and Ezetimibe,NVP-1205,Completed,No Results Available,Dyslipidemia,Drug: NVP-1205|Drug: rosuvastatin and ezetimibe,AUClast|AUCinf,Navipharm Corporation,Male,19 Years to 55 Years   (Adult),Phase 1,41,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Screening,NVP-1205-01,Feb-14,Mar-14,Mar-14,8-Jan-14,null,25-Mar-16,"Kyungpook National Hospital, Jung-gu, Daegu, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02029625
NCT02029989,Point-of-Care Testing (POCT) Detection and Management of Metabolic Syndrome in Patients With Mental Illness,,Completed,Has Results,Hyperlipidemia|Diabetes|Hypertension,Device: Glucose and lipids|Device: Glycosylated Hemoglobin A1c|Device: Blood Pressure and Heart Rate|Device: Body mass index|Device: Waist and Hip circumference|Behavioral: Comprehensive Medication Management,Metabolic Syndrome (MetS),University of Minnesota - Clinical and Translational Science Institute|Medica Foundation,All,18 Years to 64 Years   (Adult),Not Applicable,121,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,090M72212,Feb-10,Feb-12,Feb-12,8-Jan-14,15-May-14,31-May-18,"Family Life Mental Health Center, Coon Rapids, Minnesota, United States|Human Development Center, Duluth, Minnesota, United States|Range Mental Health Center, Hibbing, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02029989
NCT02030041,Effect of Vitamin D Supplementation on Exercise Adaptations in Patients on Statin Therapy,,Completed,Has Results,Dyslipidemias,Drug: Vitamin D|Drug: Simvastatin|Drug: Placebo,Peak Oxygen Consumption|Skeletal Muscle Mitochondrial Content,Postgraduate Institute of Medical Education and Research,All,25 Years to 50 Years   (Adult),Phase 3,33,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",Simvavitd,Dec-13,Dec-15,Dec-15,8-Jan-14,31-Mar-17,31-Mar-17,"PGIMER, Chandigarh, India",,https://ClinicalTrials.gov/show/NCT02030041
NCT02028702,Alternative Treatments for Menopausal Women,,Completed,No Results Available,Menopause|Hot Flushes|Osteoporosis|Dyslipidemia,Dietary Supplement: Placebo|Dietary Supplement: Red Clover extract,Primary Menopause-related symptoms,Aarhus University Hospital,Female,"45 Years to 65 Years   (Adult, Older Adult)",Not Applicable,61,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",Mntl-1877,Jun-12,Dec-14,Dec-14,7-Jan-14,null,6-Feb-15,"Center for Clinical Research, Hospital Vendsyssel, Hjorring, Nordjylland, Denmark",,https://ClinicalTrials.gov/show/NCT02028702
NCT02024399,"Cardiovascular Risk Factors, Body Composition, Fitness Levels And Quality Of Life In Overweight And Obese 8-17 Year Olds",,Completed,No Results Available,Childhood Obesity|Type 2 Diabetes|Hypercholesterolemia|Hypertension,Other: Exercise,"Improved body compositon (decrease in % fat; increase in % lean tissue) using DEXA|Improved levels of fitness using ACSM guidelines / assessments to measure such constructs of fitness as flexibility, muscle strength, cardiovascular endurance and agility.",Stony Brook University,All,8 Years to 17 Years   (Child),Not Applicable,48,Other,Interventional,"Intervention Model: Single Group Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",87468,Aug-04,Aug-05,Aug-05,31-Dec-13,null,31-Dec-13,"Stony Brook University, Stony Brook, New York, United States",,https://ClinicalTrials.gov/show/NCT02024399
NCT02023879,Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II),,Completed,Has Results,Hypercholesterolemia,Drug: Alirocumab|Drug: Placebo (for Alirocumab)|Drug: Non-statin LMT|Other: Diet Alone,Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT Analysis)|Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis|Percent Change From Baseline in Calculated LDL-C to Averaged Weeks 9 to 12 - ITT- Analysis|Percent Change From Baseline in Calculated LDL-C at Averaged Week 9 to 12 - On-Treatment Analysis|Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 24 - On-treatment Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 - On-treatment Analysis|Percent Change From Baseline in Total-C at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 12 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 - ITT Analysis|Percentage of Very High Cardiovascular (CV) Risk Participants Achieving Calculated LDL-C <70 mg/dL (<1.81 mmol/L) or Moderate or High CV Risk Participants Achieving Calculated LDL-C <100 mg/dL (<2.59 mmol/L) at Week 24 - ITT Analysis|Percentage of Very High CV Risk Participants Achieving Calculated LDL-C< 70 mg/dL (<1.81 mmol/L) or Moderate or High CV Risk Participants Achieving Calculated LDL-C< 100 mg/dL (<2.59 mmol/L) at Week 24 - On-treatment Analysis|Percentage of Participants Achieving Calculated LDL-C< 70 mg/dL (<1.81 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (<1.81 mmol/L) at Week 24 - On-treatment Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis,Sanofi|Regeneron Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 3,233,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",EFC13786|2013-002659-14|U1111-1146-3517,16-Dec-13,27-Oct-14,30-Jun-17,30-Dec-13,15-Mar-17,27-Jul-18,"Investigational Site Number 840703, Beverly Hills, California, United States|Investigational Site Number 840704, Atlantis, Florida, United States|Investigational Site Number 840708, Jacksonville, Florida, United States|Investigational Site Number 840701, Sarasota, Florida, United States|Investigational Site Number 840706, Fall River, Massachusetts, United States|Investigational Site Number 840705, Saint Louis, Missouri, United States|Investigational Site Number 840707, Durham, North Carolina, United States|Investigational Site Number 840702, Summerville, South Carolina, United States|Investigational Site Number 036703, Ashford, Australia|Investigational Site Number 036702, Perth, Australia|Investigational Site Number 036701, Woolloongabba, Australia|Investigational Site Number 056702, Antwerpen, Belgium|Investigational Site Number 056703, Haine-Saint-Paul, Belgium|Investigational Site Number 056701, Leuven, Belgium|Investigational Site Number 124703, Chicoutimi, Canada|Investigational Site Number 124701, Quebec, Canada|Investigational Site Number 124704, Sherbrooke, Canada|Investigational Site Number 124706, Toronto, Canada|Investigational Site Number 124702, Vancouver, Canada|Investigational Site Number 124705, Victoria, Canada|Investigational Site Number 208703, Aarhus, Denmark|Investigational Site Number 208702, Esbjerg, Denmark|Investigational Site Number 208701, Glostrup, Denmark|Investigational Site Number 208704, Hvidovre, Denmark|Investigational Site Number 208705, Køge, Denmark|Investigational Site Number 528701, Amsterdam, Netherlands|Investigational Site Number 528708, Den Helder, Netherlands|Investigational Site Number 528702, Hoogeveen, Netherlands|Investigational Site Number 528703, Hoorn, Netherlands|Investigational Site Number 528706, Rotterdam, Netherlands|Investigational Site Number 528709, Sneek, Netherlands|Investigational Site Number 528704, Utrecht, Netherlands|Investigational Site Number 528707, Venlo, Netherlands|Investigational Site Number 554702, Auckland, New Zealand|Investigational Site Number 554701, Christchurch, New Zealand|Investigational Site Number 724703, A Coruna, Spain|Investigational Site Number 724707, Barcelona, Spain|Investigational Site Number 724710, Barcelona, Spain|Investigational Site Number 724702, Córdoba, Spain|Investigational Site Number 724705, Granada, Spain|Investigational Site Number 724709, Sant Joan Despí, Spain|Investigational Site Number 724706, Santiago De Compostela, Spain|Investigational Site Number 724701, Zaragoza, Spain",,https://ClinicalTrials.gov/show/NCT02023879
NCT02015988,Simvastatin and Fenofibrate vs Simvastatin Alone in Patients With Type 2 Diabetes Mellitus and Acute Coronary Syndrome,,Unknown status,No Results Available,"Acute Coronary Syndrome|Diabetes Mellitus, Type 2|Hypertriglyceridemia",Drug: Fenofibrate|Drug: Simvastatin,"Percentage change from baseline in triglycerides (TG) at week 12|Percentage of patients who achieved non-High-Density Lipoprotein-Cholesterol (non-HDL-C) level less than 2,6 mmol/l at week 12|Percentage changes from baseline in apoB/apoA1 ratio at week 12|Percentage changes from baseline in non-High-Density Lipoprotein-Cholesterol (non-HDL-C) at week 12|Percentage changes from baseline in High-Density Lipoprotein-Cholesterol (HDL-C) at week 12|Percentage changes from baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) at week 12|Percentage changes from baseline in uric acid at week 12|Percentage of patients who achieved non-High-Density Lipoprotein-Cholesterol (non-HDL-C) level less than 2,6 mmol/l at week 52|Percentage changes from baseline in apoB/apoA1 ratio at week 52|Percentage changes from baseline in non-High-Density Lipoprotein-Cholesterol (non-HDL-C) at week 52|Percentage changes from baseline in High-Density Lipoprotein-Cholesterol (HDL-C) at week 52|Percentage changes from baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) at week 52|Percentage changes from baseline in uric acid at week 52","Koval' O., MD|Dnipropetrovsk State Medical Academy",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A14-284,Jan-14,Sep-16,May-17,19-Dec-13,null,4-Aug-16,"State Institution ""Dnipropetrovsk Medical Academy of Health Ministry of Ukraine"", Dnipropetrovsk, Ukraine",,https://ClinicalTrials.gov/show/NCT02015988
NCT02013843,"Treatment of Overweight and Obese Children -Using the ""Holbaek-Method"" in a Municipality Based Treatment Program.",,Completed,No Results Available,Pediatric Obesity|Dyslipidemia|Hypertension|Diabetes|Quality of Life,Behavioral: Community-based treatment of overweight and obesity,"Body mass index standard deviation score|Change in blood pressure standard deviation score|Change in the concentration of blood lipids|change in the concentration of fasting blood-glucose, HBA1C and insulin|Change in body composition measured by Tanita BC 418|Change in quality of life assessed by PedsQL",Holbaek Sygehus|University of Copenhagen,All,"3 Years to 18 Years   (Child, Adult)",Not Applicable,1007,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,TCOCmunicipalities|Region Sjaelland 2012,Mar-13,Mar-15,Mar-15,17-Dec-13,null,29-Mar-16,"Pediatric department, Holbaek, Denmark",,https://ClinicalTrials.gov/show/NCT02013843
NCT02012855,Effect of Different Types of Carbohydrates Consumed After Exercise on Blood Fat Levels,,Completed,No Results Available,Hyperlipidemia,Behavioral: Exercise|Other: Diet (meal type),Change in blood triglycerides|Change in blood glucose|Change in fat oxidation|Change in low density lipoproteins|Change in high density lipoproteins|Change in total cholesterol|Change in insulin level,University of Saskatchewan|Heart and Stroke Foundation of Canada,All,18 Years to 44 Years   (Adult),Not Applicable,23,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science,41,Aug-13,Aug-15,Aug-15,16-Dec-13,null,5-May-17,"University of Saskatchewan, Saskatoon, Saskatchewan, Canada",,https://ClinicalTrials.gov/show/NCT02012855
NCT02011789,Metabolism And Health Effects Of Citrus Limonoids in Hypercholesterolemic Humans,,Completed,No Results Available,Hypercholesterolemia,Dietary Supplement: Citrus Limonoid Beverage|Dietary Supplement: Placebo beverage,Change in plasma lipids|Change in liver and renal function,"USDA, Western Human Nutrition Research Center|The Beverage Institute for Health & Wellness|United States Department of Agriculture (USDA)",All,"20 Years to 65 Years   (Adult, Older Adult)",Not Applicable,10,U.S. Fed|Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",FL45,Apr-07,Jul-10,Jul-10,13-Dec-13,null,13-Dec-13,"USDA Western Human Nutrition Research Center, Davis, California, United States",,https://ClinicalTrials.gov/show/NCT02011789
NCT02009787,Efficacy Study of Vitamin D and Statins to Treat Hypercholesterolemia,,Unknown status,No Results Available,Primary Hypercholesterolemia,Drug: vitamin D3 tablets|Drug: placebo tablets,a change in serum total cholesterol level|a change in serum triglycerides level|differences in the incidences of treatment-emergent adverse events,Shi Yang|Chinese PLA General Hospital,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,56,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",S2013-098-01,Dec-13,Jan-15,Jan-15,12-Dec-13,null,12-Dec-13,"PLA General Hospital, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT02009787
NCT02009865,Epanova® for Lowering Very High Triglycerides II (EVOLVE II),EVOLVEII,Completed,Has Results,Hypertriglyceridemia,Drug: Epanova|Drug: Olive Oil,Percent Change in Triglyceride for All Subjects|Percent Change in Triglycerides for Subjects With at Least 1 Qualifying Triglyceride >885 mg/dL|Percent Change in Non-High-Density Lipoprotein Cholesterol (mg/dL)|Percent Change in High-Density Lipoprotein Cholesterol (mg/dL)|Percent Change in Triglyceride(mg/dL) in Subjects With Biochemically Defined Fredrickson Type V (Triglyceride/Very-Low-Density Lipoprotein Cholesterol ≥6),AstraZeneca,All,"Child, Adult, Older Adult",Phase 3,379,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",D5880C00001|OM-EPA-011,Dec-13,Dec-14,Dec-14,12-Dec-13,15-Jan-16,21-Jun-16,"Research Site, Los Angeles, California, United States|Research Site, St. Petersburg, Florida, United States|Research Site, Addison, Illinois, United States|Research Site, Louisville, Kentucky, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Kettering, Ohio, United States|Research Site, Lyndhurst, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Orangeburg, South Carolina, United States|Research Site, Bristol, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Katy, Texas, United States|Research Site, Chocoutimi, Quebec, Canada|Research Site, Hradec Kralova, Czech Republic|Research Site, Trutnov, Czech Republic|Research Site, Zlín, Czech Republic|Research Site, Esbjerg, Denmark|Research Site, Gentofte, Denmark|Research Site, Herlev, Denmark|Research Site, Viborg, Denmark|Research Site, Baja, Hungary|Research Site, Balatonfured, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Szikszó, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Sátoraljaújhely, Hungary|Research Site, Alkmaar, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Barnaul, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Tomsk, Russian Federation",,https://ClinicalTrials.gov/show/NCT02009865
NCT02008084,A Pilot Study to Evaluate the Lipid Effects of TRIA-662,,Completed,No Results Available,Hypertriglyceridemia|Mixed Hyperlipidemia,Drug: TRIA-662|Drug: Placebo,Recruitment Rate|Compliance to investigational product|Completion rate|Effect on serum high-density lipoprotein cholesterol (HDL-C)|Variability of serum triglycerides|Effect on fasting glucose|Effect on C-reactive protein|Effect on interleukin-6 (IL-6)|Effect on total cholesterol (TC)|Effect on low-density lipoprotein cholesterol (LDL-C)|Effect on very low-density lipoprotein cholesterol (VLDL-C)|Effect on total apolipoprotein B (apoB)|Effect on total apolipoprotein A1 (apoA1)|Effect on lipoprotein (a) [Lp(a)]|Effect on non-high density lipoprotein cholesterol (non-HDL-C)|Effect on TG/HDL-C ratio|Effect on tumor necrosis factor - alpha (TNF-α),Cortria Corporation|Montreal Heart Institute,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,71,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",PNAI-MNA-03,Dec-13,Oct-15,Oct-15,11-Dec-13,null,27-Jan-16,"Crowfoot Village Family Practice, Calgary, Alberta, Canada|Dr. Senaratne Professional Corporation, Edmonton, Alberta, Canada|The Bailey Clinic, Red Deer, Alberta, Canada|Manna Research Vancouver, Vancouver, British Columbia, Canada|GA Research Associates, Ltd, Moncton, New Brunswick, Canada|Commonwealth Medical Clinic, Mount Pearl, Newfoundland and Labrador, Canada|Scisco Clinical Research, Cornwall, Ontario, Canada|Sameh Fikry Medicine Professional Corp, Kitchener, Ontario, Canada|Aging, Rehabilitation & Geriatric Care, Lawson Health Research Institute-St Joseph's Health Care, Parkwood, London, Ontario, Canada|Prime Health Clinical Research, Toronto, Ontario, Canada|Manna Research Inc., Toronto, Ontario, Canada|Rhodin Recherche, Drummondville, Quebec, Canada|Recherche Invascor, Inc., Longueuil, Quebec, Canada|Montreal Heart Institute, Montreal, Quebec, Canada|Diex Recherche Sherbrooke, Sherbrooke, Quebec, Canada|Centre de santé et de services sociaux de Trois-Rivières, Trois-Rivières, Quebec, Canada|Clinique des Maladies Lipidiques de Quebec, Inc., Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02008084
NCT02005900,Effect of DHA on Lipid and Carbohydrate Metabolism Alterations and Body Fat Distribution in HIV Patients Under HAART.,,Completed,No Results Available,HIV-associated Hypertriglyceridemia|HIV-associated Hypercholesterolemia|HIV-associated Inflammatory State,Drug: Docosahexaenoic acid (DHA) administration to modulate Triglycerides in HIV patients under HAART,Triglyceride level|Fasting Serum total cholesterol level,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Hospital Clinic of Barcelona|University of Barcelona,All,"18 Years and older   (Adult, Older Adult)",Phase 3,66,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HSP/DHA/2010,Jun-11,Jun-13,Oct-13,9-Dec-13,null,9-Dec-13,"Hospital de la Santa Creu i Sant Pau, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT02005900
NCT01995149,Effect of Weight Loss on Cholesterol Metabolism in Hereditary Hypercholesterolemias and Overweight or Obesity.,,Completed,No Results Available,Familial Hypercholesterolemias|Weight Loss|Familial Combined Hypercholesterolemia|Obesity,Behavioral: Weight loss and dietary intervention,Change in lipids and non-cholesterol sterols concentration,Instituto Aragones de Ciencias de la Salud|Hospital Clinic of Barcelona|Instituto de Salud Carlos III,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,78,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,I+CS;CEICA-B80|I+CS-HUMS-B80,Jun-10,Sep-12,null,26-Nov-13,null,26-Nov-13,,,https://ClinicalTrials.gov/show/NCT01995149
NCT01992614,A Single Dose Study Of PF-06678552 In Healthy Subjects,,Completed,No Results Available,Healthy,Drug: PF-06678552 or Placebo,"Assessment of adverse events (AEs), clinical laboratory tests, vital signs (including blood pressure and pulse rate) and cardiac conduction intervals as assessed via 12-lead electrocardiogram (ECG).|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-06678552|Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - infinity)] for PF-06678552|Maximum Observed Plasma Concentration (Cmax) for for PF-06678552|Time to Reach Maximum Observed Plasma Concentration (Tmax) for PF-06678552|Plasma Decay Half-Life (t1/2) for PF-06678552|Apparent Oral Clearance (CL/F) for PF-06678552|Apparent Volume of Distribution (Vz/F) for PF-06678552|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-06644927|Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - infinity)] for PF-06644927|Maximum Observed Plasma Concentration (Cmax) for PF-06644927|Time to Reach Maximum Observed Plasma Concentration (Tmax) for PF-06644927|Plasma Decay Half-Life (t1/2) for PF-06644927|Amount of PF-06644927 excreted in the urine (Ae)|Percent of PF-06678552 dose excreted in the urine as PF-06644927 (Ae%)|Renal Clearance (CLr) for PF-06644927",Pfizer,All,18 Years to 55 Years   (Adult),Phase 1,24,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science",B7611001,Dec-13,Mar-14,Mar-14,25-Nov-13,null,28-Mar-14,"Pfizer Investigational Site, Brussels, Belgium",,https://ClinicalTrials.gov/show/NCT01992614
NCT01990391,"Brazil Nut Consumption in Microvascular Endothelial Function, Oxidative Stress and Metabolic Abnormalities",,Completed,No Results Available,Dyslipidemia|Oxidative Stress,Dietary Supplement: Brazil nut flour|Dietary Supplement: Placebo (cassava flavored flour),Antioxidant biomarker|Oxidative stress biomarker|microvascular endothelial function,Universidade Federal do Rio de Janeiro|Instituto Nacional de Cardiologia de Laranjeiras|Oswaldo Cruz Foundation|Rio de Janeiro State Research Supporting Foundation (FAPERJ),All,"20 Years and older   (Adult, Older Adult)",Not Applicable,125,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",0008.0.197.185-11|U1111-1132-2061,Sep-11,Apr-13,Apr-13,21-Nov-13,null,25-Nov-13,,,https://ClinicalTrials.gov/show/NCT01990391
NCT01988389,Effect of Apples on cardioVascular Risk And Gut Health,AVAG,Completed,No Results Available,Mild Hypercholesterolemia,Dietary Supplement: whole apples (WA)|Dietary Supplement: apple juice (AJ),"Changes in blood lipid levels|Evaluation of endothelial function by using laser doppler iontophoresis (LDI)|Changes in vascular stiffness by pulse wave analysis (PWA)|Changes in faecal bacterial population|Ambulatory blood pressure|Changes in inflammatory, endothelial function and oxidative stress markers|Changes in insulin resistance and gut hormones|Metabolomic analysis for the determination of the low molecular weight metabolite profiles in the biological fluids (blood, urine and faecal sample).",University of Reading|Fondazione Edmund Mach di San Michele all'Adige,All,"23 Years to 69 Years   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,13/22|University of Reading,Sep-13,Oct-14,Nov-14,20-Nov-13,null,9-Mar-15,"Department of Food and Nutritional Sciences, University of Reading, Reading, Berkshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT01988389
NCT01985204,Iodine Supplementation in Obesity,,Completed,No Results Available,Iodine Deficiency|Subclinical Hypothyroidism,Dietary Supplement: Iodine tablet|Dietary Supplement: Placebo tablet,Change in TSH (thyroid-stimulating hormone)|change in fasting insulin|change in the LDL cholesterol/ HDL cholesterol ratio|fasting glucose|plasma leptin|LDL cholesterol|HDL cholesterol|Urinary iodine,Swiss Federal Institute of Technology,Female,20 Years to 50 Years   (Adult),Not Applicable,162,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",EK 2013-N-24,Nov-13,Jun-14,Jul-14,15-Nov-13,null,30-Jul-14,"Universite Caddi Ayad, Faculte de Medecine et de Pharmacie, Marrakech, Morocco|University Cadi Ayyad, Faculte des Sciences, Marrakech, Morocco",,https://ClinicalTrials.gov/show/NCT01985204
NCT01984073,Effects of Niacin On Fatty Acid Trapping,NOFAT,Unknown status,No Results Available,Dyslipidemia,Drug: ER Niacin Oral Fat Challenge|Drug: IR Niacin Oral Fat Challenge|Other: Placebo Oral Fat Challenge,Plasma Triglycerides,"University of Pennsylvania|National Heart, Lung, and Blood Institute (NHLBI)|Arizona Pharmaceuticals Inc.",All,"22 Years to 75 Years   (Adult, Older Adult)",Phase 1,20,Other|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",NOFAT|K23HL091130,Dec-12,Oct-18,Oct-18,14-Nov-13,null,1-May-17,"Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Presbyterian Hospital, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01984073
NCT01984424,Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3,GAUSS-3,Completed,Has Results,Hyperlipidemia,Drug: Atorvastatin|Drug: Placebo to Atorvastatin|Other: Placebo to Ezetimibe|Drug: Ezetimibe|Other: Placebo to Evolocumab|Drug: Evolocumab,Percent Change From Baseline in LDL-C at the Mean of Weeks 22 and 24|Percent Change From Baseline in LDL-C at Week 24|Change From Baseline in LDL-C at the Mean of Weeks 22 and 24|Change From Baseline in LDL-C at Week 24|Percentage of Participants Who Achieved a Mean LDL-C at Weeks 22 and 24 of Less Than 70 mg/dL|Percentage of Participants Who Achieved LDL-C at Week 24 of Less Than 70 mg/dL|Percent Change From Baseline in Total Cholesterol at the Mean of Weeks 22 and 24|Percent Change From Baseline in Total Cholesterol at Week 24|Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at the Mean of Weeks 22 and 24|Percent Change From Baseline in Non-HDL-C at Week 24|Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 22 and 24|Percent Change From Baseline in Apolipoprotein B at Week 24|Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at the Mean of Weeks 22 and 24|Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 24|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 22 and 24|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 24|Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 22 and 24|Percent Change From Baseline in Lipoprotein(a) at Week 24|Percent Change From Baseline in Triglycerides at the Mean of Weeks 22 and 24|Percent Change From Baseline in Triglycerides at Week 24|Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at Week 24|Percent Change From Baseline in HDL-C at Week 24|Percent Change From Baseline in Very Low-density Lipoprotein Cholesterol (VLDL-C) at the Mean of Weeks 22 and 24|Percent Change From Baseline in VLDL-C at Week 24,Amgen,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,511,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",20120332|2013-000935-29,10-Dec-13,10-Nov-15,21-Nov-17,14-Nov-13,13-Mar-18,29-Nov-18,"Research Site, Beverly Hills, California, United States|Research Site, Huntington Beach, California, United States|Research Site, Los Angeles, California, United States|Research Site, San Pedro, California, United States|Research Site, Atlanta, Georgia, United States|Research Site, Sterling, Illinois, United States|Research Site, Kansas City, Kansas, United States|Research Site, Baltimore, Maryland, United States|Research Site, Towson, Maryland, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Rochester, Minnesota, United States|Research Site, Saint Louis, Missouri, United States|Research Site, New York, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Cleveland, Ohio, United States|Research Site, York, Pennsylvania, United States|Research Site, Charleston, South Carolina, United States|Research Site, Houston, Texas, United States|Research Site, Camperdown, New South Wales, Australia|Research Site, Woolloongabba, Queensland, Australia|Research Site, Ashford, South Australia, Australia|Research Site, Vancouver, British Columbia, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Peterborough, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, St-Charles-Borromee, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Hradec Kralove, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 4, Czechia|Research Site, Aarhus N, Denmark|Research Site, Glostrup, Denmark|Research Site, Nantes Cedex 1, France|Research Site, Paris Cedex 13, France|Research Site, Vénissieux, France|Research Site, Berlin, Germany|Research Site, Köln, Germany|Research Site, München, Germany|Research Site, Bologna, Italy|Research Site, Cagliari, Italy|Research Site, Cinisello Balsamo (MI), Italy|Research Site, Ferrara, Italy|Research Site, Perugia, Italy|Research Site, Pisa, Italy|Research Site, Amsterdam, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Zwijndrecht, Netherlands|Research Site, Christchurch, New Zealand|Research Site, Oslo, Norway|Research Site, Ålesund, Norway|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Midrand, Gauteng, South Africa|Research Site, Observatory, Western Cape, South Africa|Research Site, Parow, Western Cape, South Africa|Research Site, Birmingham, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Newcastle upon Tyne, United Kingdom",,https://ClinicalTrials.gov/show/NCT01984424
NCT01982461,A Study to Evaluate the Efficacy and Safety of Rosuvastatin in Hypercholesterolemia.,,Unknown status,No Results Available,Hypercholesterolemia,Drug: Rosuvastatin|Drug: Crestor®,"The primary efficacy variable will be defined as the percent mean change in LDL-C from baseline to 12 weeks.|The secondary efficacy variable will be described as the change of plasma AGE, sRAGE, Gas6 and sAx1.","Pin Siang Medical Biotechnology Co., Ltd.",All,"20 Years to 85 Years   (Adult, Older Adult)",Not Applicable,40,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PSMB102ROS10-01,Nov-13,Jan-14,null,13-Nov-13,null,13-Nov-13,"Tri-Service General Hospital, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT01982461
NCT01979601,"Safety, Tolerability, PK and PD of LGT209 in Healthy Volunteers and Patients With Hypercholesterolemia",,Completed,No Results Available,Hypercholesterolemia,Drug: LGT209|Drug: Placebo,"Number of patients with adverse events, serious adverse events and death|Change from baseline in low density lipoprotein-cholesterol (LDL-C) concentration in healthy volunteers|Change from baseline in proprotein convertase subtilisin/kexin type 9 (PCSK9) in healthy volunteers|Pharmacokinetics of LGT209: : Area under the serum concentration-time curve from time zero to infinity (AUC0-inf) of LGT209 in patients and healthy volunteers following intravenous administration|Pharmacokinetics of LGT209: observed maximum serum concentrations (Cmax) of LGT209 in patients and healthy volunteers following intravenous administration|Pharmacokinetics of LGT209: Area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration (AUC0-last) of LGT209 in patients and healthy volunteers following intravenous administration|Pharmacokinetics of LGT209: Elimination half-life associated with the terminal slope of a semi-logarithmic concentration-time curve (T1/2) of LGT209 in patients and healthy volunteers following intravenous administration|Number of healthy volunteers with adverse events, serious adverse events and death|Pharmacokinetics of intravenous LGT209 in relationship to concentrations of PCSK9 and LDL-C in patients and healthy volunteers|Change from baseline in low density lipoprotein-cholesterol (LDL-C) concentration in patients|Change from baseline in proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients|Pharmacokinetics of LGT209: Area under the serum concentration-time curve from time zero to time 't' (AUC0-t)|Pharmacokinetics of LGT209: Dose-normalized area under the serum concentration-time curve (AUC/D) of LGT209 in patients and healthy volunteers following intravenous administration|Pharmacokinetics of LGT209: Dose-normalized maximum serum concentrations (Cmax/D) of LGT209 in patients and healthy volunteers following intravenous administration|Pharmacokinetics of LGT209: Volume of distribution during the terminal elimination phase (Vz) of LGT209 in patients and healthy volunteers following intravenous administration|Pharmacokinetics of LGT209: Volume of distribution at steady state (Vss) of LGT209 in patients and healthy volunteers following intravenous administration|Pharmacokinetics of LGT209: Mean residence time (MRT) of LGT209 in patients and healthy volunteers following intravenous administration|Pharmacokinetics of LGT209: the systemic (or total body) clearance from serum following intravenous administration",Novartis Pharmaceuticals|Novartis,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,74,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CLGT209X2101,Dec-10,Nov-11,Nov-11,8-Nov-13,null,10-Dec-13,"Novartis Investigative Site, Miami Gardens, Florida, United States|Novartis Investigative Site, Fargo, North Dakota, United States",,https://ClinicalTrials.gov/show/NCT01979601
NCT01975961,PK Study of Telmisartan/Rosuvastatin FDC Compared to Combination of Telmisartan and Rosuvastatin,,Completed,No Results Available,Dyslipidemia & Hypertension,"Drug: Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg) , FDC",plasma pharmacokinetic parameters for telmisartan and rosuvastatin in relevant treatments,Yuhan Corporation,All,20 Years to 50 Years   (Adult),Phase 1,185,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),YH16410-102,Jul-13,Aug-13,Sep-13,5-Nov-13,null,5-Nov-13,"Severance Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01975961
NCT01974297,Comparison of the Efficacy and Safety of AtorVastatin mOnotherapy vs. Combination Atorvastatin/Fenofibric Acid,AVOCADO,Unknown status,No Results Available,Mixed Hyperlipidemia,"Drug: Atorvastatin 10mg, fenofibric acid 135mg|Drug: atorvastatin 20mg","Changes of non-HDL cholesterol|levelresponse rate of non-HDL cholesterol level < 130mg/dL|changes of TC,HDL-C,LDL-C,TG,Apo B/A1|Changes of Glucose, HbA1c, HOMA-IR level|Changes of hs-CRP, adiponectin, resistin level",Sang Hak Lee|Yonsei University,All,"20 Years and older   (Adult, Older Adult)",Not Applicable,194,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVOCADO,Jul-13,Jun-14,Jul-14,1-Nov-13,null,4-Nov-13,"Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01974297
NCT01972113,Vitamin K and Glucose Metabolism in Children at Risk for Diabetes (Vita-K 'n' Kids Study),,Recruiting,No Results Available,Obesity|Insulin Resistance|Insulin Sensitivity|Prediabetes|Dyslipidemia|Diabetes,Dietary Supplement: Placebo-Control|Dietary Supplement: Low-Dose Vitamin K2 (menaquinone-7; 45 mcg/d)|Dietary Supplement: High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d),"Change in serum lipid concentrations|Change in insulin sensitivity|Change in beta-cell function|Change in coagulation|Change in arterial stiffness (pulse wave velocity)|Change in endothelial function (Flow-mediated dilation)|Effects of sex, race, bone age, and pubertal stage on changes in glucosemetabolism (insulin sensitivity and beta-cell function)",Augusta University|University of Alabama at Birmingham|Yale University|Tufts University|Nattopharma ASA,All,8 Years to 17 Years   (Child),Phase 1|Phase 2,30,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",611523 (Pro00000912)|16GRNT31090037,Sep-13,Aug-18,Dec-18,30-Oct-13,null,12-Jul-18,"Medical College of Georgia; Augusta University, Augusta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT01972113
NCT01972178,Efficacy and Safety of PRC-4016 in Subjects With Mixed Dyslipidemia,,Terminated,No Results Available,Dyslipidemia,Drug: PRC-4016|Drug: Placebo|Drug: Statins,Percent change in Non-HDL-C from baseline to Week 12|Change in triglycerides from baseline to Week 12|Change in HDL-C from baseline to Week 12|Change in LDL-C from baseline to Week 12|Change in VLDL-C from baseline to Week 12|Change in total cholesterol from baseline to Week 12|Change in ApoA1 from baseline to Week 12|Change in ApoB from baseline to Week 12|Change in insulin from baseline to Week 12|Change in fasting plasma glucose from baseline to Week 12|Change in HbA1c from baseline to Week 12|Change in Lp-PLA2 from baseline to Week 12|Change in hsCRP from baseline to Week 12|Change in red blood cell content of EPA and DHA from baseline to Week 12|Change in Insulin Resistance (HOMA) from baseline to Week 12,Pronova BioPharma,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 2,113,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CTN 4016 13202,Nov-13,Jul-14,Aug-14,30-Oct-13,null,30-Oct-15,"Medical Affiliated Research Center, Inc., Huntsville, Alabama, United States|Terence Hart, MD, Muscle Shoals, Alabama, United States|Pacific Oaks Medical Group, Beverly Hills, California, United States|National Research Institute - Wilshire, Los Angeles, California, United States|Research Across America - Santa Ana, Santa Ana, California, United States|Encompass Clinical Research, Spring Valley, California, United States|Jacksonville Impotence Treatment Center, Jacksonville, Florida, United States|Compass Research East, LLC, Oviedo, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Meridien Research, St. Petersburg, Florida, United States|Meridien Research- Tampa, Tampa, Florida, United States|Evanston Premier Healthcare Research LLC, Evanston, Illinois, United States|Medisphere Medical Research Center, Evansville, Indiana, United States|Heartland Research Assoc., LLC, Newton, Kansas, United States|Louisville Metabolic and Atherosclerosis Research Center (L-MARC), Louisville, Kentucky, United States|Troy Internal Medicine, P.C., Troy, Michigan, United States|Radiant Research - Edina, Edina, Minnesota, United States|Peters Medical Research, High Point, North Carolina, United States|PMG Research of Raleigh, LLC, Raleigh, North Carolina, United States|Sterling Research Group, Ltd. - Auburn, Cincinnati, Ohio, United States|Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio, United States|Columbus Clinical Research, Inc., Columbus, Ohio, United States|PSB Research/P. S. Bains, M.S., D.O., Marion, Ohio, United States|RAS Health Ltd, Marion, Ohio, United States|Willamette Valley Clinical Studies, Eugene, Oregon, United States|Green and Seidner Family Practice Associates, Lansdale, Pennsylvania, United States|Padre Coast Clinical Research, Corpus Christi, Texas, United States|National Clinical Research - Norfolk, Inc., Norfolk, Virginia, United States|National Clinical Research - Richmond, Inc., Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01972178
NCT01970215,TA-8995: Its Use in Patients With Mild Dyslipidaemia (TULIP),TULIP,Completed,No Results Available,Dyslipidemia,Drug: TA-8995|Drug: Atorvastatin|Drug: Rosuvastatin|Drug: TA-8995 0mg (placebo)|Drug: Placebo Statin,The co-primary efficacy endpoints are the percentage changes in both HDL-C and LDL-C levels at Week 12 compared to baseline.,Xention Ltd,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,364,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TA-8995-03|2012-005643-24,Aug-13,Jul-14,Jul-14,28-Oct-13,null,21-Aug-14,"H:S Amager Hospital, Copenhagen, Denmark|Sydvestjysk Sygehus, Esbjerg, Denmark|Herlev University Hospital, Herlev, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Regionshopitalet - Silkeborg, Silkeborg, Denmark|EB FlevoResearch B.V, Almere, Netherlands|Academic Medical Centre, Amsterdam-Zuidoost, Netherlands|Andromed Amsterdam, Amsterdam, Netherlands|Andromed Leiden, Amsterdam, Netherlands|Andromed Breda B.V, Breda, Netherlands|Andromed Eindhoven, Eindhoven, Netherlands|Andromed Noord B.V, Groningen, Netherlands|Andromed Zoetermeer, Leiderdorp, Netherlands|Andromed Rotterdam BV, Rotterdam, Netherlands|Albert Schweitzer Ziekenhuis, Sliedrecht, Netherlands|Andromed Oost, Velp, Netherlands|Praktijk Zwijndrecht, Zwijndrecht, Netherlands",,https://ClinicalTrials.gov/show/NCT01970215
NCT01968720,Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia,,Completed,No Results Available,Hyperlipidemias|Hypertriglyceridemia|Dyslipidemias|Lipid Metabolism Disorders|Metabolic Diseases,Drug: CAT-2003|Drug: Placebo,Percent change from baseline in fasting triglycerides in patients with severe hypertriglyceridemia|Frequency of adverse events|Absolute and percent change from baseline on postprandial total and chylomicron triglyceride levels,Catabasis Pharmaceuticals,All,"18 Years to 74 Years   (Adult, Older Adult)",Phase 2,16,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,CAT-2003-202,Oct-13,Apr-14,Apr-14,24-Oct-13,null,14-Aug-15,"Miami, Florida, United States|Indianapolis, Indiana, United States|Auburn, Maine, United States|Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01968720
NCT01968876,Is a Smartphone Application Effective as an Oral Medication Adherence Aid,,Terminated,No Results Available,Hypertension|Diabetes|Dyslipidemia,Other: Medication Adherence Smartphone App,Change from baseline in number of pills taken over number of pills prescribed at 4 weeks|Change from baseline in number of pills taken over number of pills prescribed at 12 weeks,University of Arkansas,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,68,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,202266,30-Oct-13,14-Nov-17,14-Nov-17,24-Oct-13,null,20-Nov-17,"Internal Medicine Clinic North; University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Remedy Drug, Little Rock, Arkansas, United States|Internal Medicine Clinic West; University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States",,https://ClinicalTrials.gov/show/NCT01968876
NCT01968954,Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events,SPIRE-HR,Completed,Has Results,Hyperlipidemia,Drug: Bococizumab (PF-04950615;RN316)|Other: Placebo,"Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Week 12|Percent Change From Baseline in Total Cholesterol (TC) at Week 12, 24 and 52|Percent Change From Baseline in Non- High Density Lipoprotein-Cholesterol (Non HDL-C) at Week 12, 24 and 52|Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 12, 24 and 52|Percent Change From Baseline in Lipoprotein(a) at Week 12, 24 and 52|Percent Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) at Week 12, 24 and 52|Percent Change From Baseline in Fasting Low-Density Lipoprotein-Cholesterol (LDL-C) at Week 12 in Participants With Primary Hyperlipidemia|Percent Change From Baseline in Fasting Low-Density Lipoprotein-Cholesterol (LDL-C) at Week 12 in Participants With Mixed Dyslipidemia|Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Week 24 and 52|Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 24 and 52 by Triglyceride Cut-off|Percent Change From Baseline in Fasting Triglyceride (TG) at Week 12, 24 and 52|Percent Change From Baseline in ApolipoproteinA-I (ApoA-I) at Week 12, 24 and 52|Percent Change From Baseline in ApolipoproteinA-II (ApoA-II) at Week 12, 24 and 52|Percent Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Week 12, 24 and 52|Absolute Change From Baseline in Fasting Low Density Lipoprotein-C (LDL-C) at Week 12 by Trigylceride Cut-Off|Absolute Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Week 12, 24 and 52|Absolute Change From Baseline in Total Cholesterol (TC) at Week 12, 24 and 52|Absolute Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12, 24 and 52|Absolute Change From Baseline in Apolipoprotein B (ApoB) at Week 12, 24 and 52|Absolute Change From Baseline in Lipoprotein(a) at Week 12, 24 and 52|Absolute Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) at Week 12, 24 and 52|Absolute Change From Baseline in Ratio of Fasting Total Cholesterol to High Density Lipoprotein-Cholesterol (TC/HDL-C Ratio) at Week 12, 24 and 52|Absolute Change From Baseline in Ratio of Apolipoprotein B to ApolipoproteinA-I (ApoB/ApoA-I Ratio) at Week 12, 24 and 52|Percentage of Participants Achieving Fasting Low Density Lipoprotein-Cholesterol (LDL-C) Less Than or Equal to (<=) 100 Milligram Per Deciliter (2.59 Millimoles Per Litre) at Week 12, 24 and 52|Percentage of Participants Achieving Fasting Low Density Lipoprotein-Cholesterol (LDL-C) Less Than or Equal to (<=) 70 Milligram Per Deciliter (1.81 Millimoles Per Litre) at Week 12, 24 and 52|Plasma PF-04950615 Concentrations at Week 12, 24 and 52|Number of Participants With Adverse Events (AEs) Related to Type 1 or 3 Hypersensitivity Reactions and Injection Site Reactions|Percentage of Participants With Anti-Drug Antibodies (ADA) and Neutralizing Antibodies (nAb)",Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,711,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",B1481019|2013-002642-37|SPIRE-HR,Oct-13,Apr-16,Apr-16,24-Oct-13,17-May-17,17-May-17,"Achieve Clinical Research, LLC, Birmingham, Alabama, United States|Cardiovascular Associates of the Southeast, LLC, Birmingham, Alabama, United States|Southwest Heart Group, Tucson, Arizona, United States|ARA-Arizona Research Associates, Tucson, Arizona, United States|Diagnamics, Inc., Encinitas, California, United States|Encompass Clinical Research North Coast, Encinitas, California, United States|MD Studies, Inc., Fountain Valley, California, United States|Alliance Research Centers, Laguna Hills, California, United States|Prime Care Clinical Research, Laguna Hills, California, United States|Providence Clinical Research, North Hollywood, California, United States|San Diego Family Care, San Diego, California, United States|St. Joseph's Medical Associates, Stockton, California, United States|Orange County Research Center, Tustin, California, United States|Clinical Research Advantage, Inc./Cassidy Medical Group - Vista, Vista, California, United States|Elite Clinical Trials, Wildomar, California, United States|Expresscare Clinical Research, Colorado Springs, Colorado, United States|Soundview Medical Associates, Norwalk, Connecticut, United States|Eastern Research, Inc., Hialeah, Florida, United States|East Coast Institute for Research, LLC at Northeast Florida Endocrine & Diabetes Associates, Jacksonville, Florida, United States|Care Partners Clinical Research, LLC, Jacksonville, Florida, United States|Prestige Clinical Research Center Inc, Miami, Florida, United States|Edgewater Medical Research, New Smyrna Beach, Florida, United States|Gulfcoast Medical Research Center, LLC, Tampa, Florida, United States|Fellows Research Alliance, Inc., Savannah, Georgia, United States|SouthCoast Medical Group, Savannah, Georgia, United States|Evanston Premier Healthcare Research LLC, Evanston, Illinois, United States|Comunity Clinical Research Center, Anderson, Indiana, United States|American Health Network of Indiana, LLC, Avon, Indiana, United States|Midwest Institute for Clinical Research, Indianapolis, Indiana, United States|Horizon Research Group of Opelousas, LLC, Eunice, Louisiana, United States|Internal Medicine Associates, Eunice, Louisiana, United States|Beacon Clinical Research, LLC, Quincy, Massachusetts, United States|Allina Health System, dba Abbott Northwestern Hospital, Minneapolis, Minnesota, United States|Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States|University of MN, Lillehei Clinical Trials Unit, Minneapolis, Minnesota, United States|Montana Medical Research Inc., Missoula, Montana, United States|PMG Research of Raleigh, LLC d/b/a PMG Research of Cary, Cary, North Carolina, United States|Clinical Trials of America, Inc., Winston Salem, North Carolina, United States|Radiant Research, Inc, Akron, Ohio, United States|Rapid Medical Research, Inc., Cleveland, Ohio, United States|The Office of Daniel G. Williams, MD, Perrysburg, Ohio, United States|Great Lakes Medical Research, LLC, Willoughby, Ohio, United States|South Oklahoma Heart Research LLC, Oklahoma City, Oklahoma, United States|Integrated Medical Research, PC, Ashland, Oregon, United States|Columbia Research Group, Inc., Portland, Oregon, United States|Harleysville Medical Associates, Harleysville, Pennsylvania, United States|Perelman Center for Advanced Medicine Heart & Vascular Center, Philadelphia, Pennsylvania, United States|Berks Cardiologists, Ltd., Wyomissing, Pennsylvania, United States|Medical Research South,LLC, Charleston, South Carolina, United States|Berkeley Family Practice, Moncks Corner, South Carolina, United States|Internal Medicine and Pediatric Associates of Bristol, PC, Bristol, Tennessee, United States|3 rd Coast Research Associates, Corpus Christi, Texas, United States|Texas Center For Drug Development, Inc., Houston, Texas, United States|Pioneer Research Solutions, Inc., Houston, Texas, United States|Protenium Clinical Research, Hurst, Texas, United States|Utah Cardiology, P.C., Layton, Utah, United States|National Clinical Research - Norfolk, Inc., Norfolk, Virginia, United States|Premier Clinical Research, Spokane, Washington, United States|Australian Clinical Research Network, Maroubra, New South Wales, Australia|Core Research Group Pty Ltd, Milton, Queensland, Australia|The Avenue Cardiovascular Centre, St. Kilda East, Victoria, Australia|Ecogene-21, Chicoutimi, Quebec, Canada|Montreal Heart Institute, Montreal, Quebec, Canada|Diex Research Montreal Inc., Montreal, Quebec, Canada|ALPHA Recherche Clinique, Quebec City, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke (CHUS), Sherbrooke, Quebec, Canada|Medexa Recherche, Victoriaville, Quebec, Canada|Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czech Republic|Kardiologie a interni lekarstvi, Praha 5, Czech Republic|Lekarsky dum Ormiga, Zlin, Czech Republic|Klinische Forschung Berlin-Mitte GmbH, Berlin, Germany|Klinische Forschung Hannover - Mitte GmbH, Hannover, Germany|Klinikum der Stadt Ludwigshafen am Rhein gGmbH, Ludwigshafen, Germany|Klinische Forschung Schwerin GmbH, Schwerin, Germany|Department of Medicine & Therapeutics-The Chinese University of Hong Kong, Shatin, NT, Hong Kong|The Chinese University of Hong Kong, Shatin, Hong Kong|IRCCS Ospedale San Raffaele, Milano, MI, Italy|IRCCS Centro Cardiologico Fondazione Monzino, Milano, MI, Italy|IRCCS Istituto Auxologico Italiano, Milano, MI, Italy|Azienda Ospedaliera Universitaria Policlinico ""Paolo Giaccone"", Palermo, PA, Italy|Dipartimento di Medicina Interna e Specialita Mediche Policlinico Umberto I, Roma, RM, Italy|The Catholic University of Korea, Uijeongbu St. Mary's Hospital, Uijeongbu-si, Gyeonggi-do, Korea, Republic of|Yonsei University Wonju Severance Christian Hospital, Gangwon-Do, Korea, Republic of|Chonnam National University Hospital, Gwangju, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Gangnam Sevrance Hospital, Yeonsei University Health System, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Ajou University Hospital, Suwon, Korea, Republic of|Ulsan University Hospital, Ulsan, Korea, Republic of|SYNEXUS Polska Sp. z o.o. Oddzial w Katowicach, Katowice, Mazowieckie, Poland|NZOZ Terapia Optima, Katowice, Slaskie, Poland|Synexus Polska Sp. z o.o. Oddzial w Gdyni, Gdynia, Poland|Niepubliczny Zaklad Opieki Zdrowotnej CEREO-MED Sp. z o.o., Lodz, Poland|Medicus w Opolu Sp z o.o., Opole, Poland|Medicome Sp. z o.o., Oswiecim, Poland|Synexus Polska Sp. z o.o Oddzial w Poznaniu, Poznan, Poland|Centrum Medyczne Ogrodowa Sp. z o.o., Skierniewice, Poland|Centrum Medyczne ""SOPMED"" Sp. z o.o., Sopot, Poland|Synexus Polska Sp. z o.o. Oddzial w Warszawie, Warszawa, Poland|Centrum Medyczne AMED, Warszawa, Poland|CSK MSW w Warszawie, Klinika Kardiologii Zachowawczej i Nadcisnienia Tetniczego, Warszawa, Poland|Synexus Polska Sp. z o.o. Oddzial we Wroclawiu, Wroclaw, Poland",,https://ClinicalTrials.gov/show/NCT01968954
NCT01968967,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events,SPIRE-LDL,Completed,Has Results,Hyperlipidemia,Drug: Bococizumab (PF-04950615; RN316)|Other: Placebo,"Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 12|Percent Change From Baseline in Fasting Total Cholesterol (TC) at Week 12, 24 and 52|Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) at Week 12, 24 and 52|Percent Change From Baseline in Fasting Non High Density Lipoprotein Cholesterol (HDL-C) at Week 12, 24 and 52|Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) by Triglycerides (TG) Cut-off of Less Than (<) 200 Milligram Per Deciliter (mg/dL) at Week 12, 24 and 52|Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) by Triglycerides Cut-off of Greater Than or Equal to (>=) 200 Milligram Per Deciliter (mg/dL) at Week 12, 24 and 52|Percent Change From Baseline in Fasting Lipoprotein (a) (Lp[a]) at Week 12, 24 and 52|Percent Change From Baseline in Fasting High Density Lipoprotein Cholesterol (HDL-C) at Week 12, 24 and 52|Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 24, 52: Treatment Period|Percent Change From Baseline in Fasting Triglycerides (TG) at Week 12, 24 and 52|Percent Change From Baseline in Fasting Apolipoprotein A-I (ApoA-I) at Week 12, 24 and 52|Percent Change From Baseline in Fasting Apolipoprotein A-II (ApoA-II) at Week 12, 24 and 52|Percent Change From Baseline in Fasting Very Low Density Lipoprotein Cholesterol (VLDL-C) at Week 12, 24 and 52|Absolute Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) by Triglycerides Cut-off of Less Than (<) 200 Milligram Per Deciliter (mg/dL) at Week 12|Absolute Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) by Triglycerides Cut-off of Greater Than or Equal to (>=) 200 Milligram Per Deciliter (mg/dL) at Week 12|Absolute Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 12|Absolute Change From Baseline in Fasting Total Cholesterol (TC) at Week 12|Absolute Change From Baseline in Fasting Non High Density Lipoprotein Cholesterol (HDL-C) at Week 12|Absolute Change From Baseline in Fasting Apolipoprotein B (ApoB) at Week 12|Absolute Change From Baseline in Fasting Lipoprotein (a) (Lp[a]) at Week 12|Absolute Change From Baseline in Fasting High Density Lipoprotein Cholesterol (HDL-C) at Week 12|Absolute Change From Baseline in Ratio of Fasting Total Cholesterol (TC) to High Density Lipoprotein Cholesterol (HDL-C) at Week 12, 24 and 52|Change From Baseline in Ratio of Fasting Apolipoprotein B (ApoB) to Apolipoprotein A-I (ApoA-I) at Week 12, 24 and 52|Percentage of Participants Achieving Fasting Low Density Lipoprotein Cholesterol (LDL-C) Less Than or Equal to (<=) 100 Milligram Per Deciliter (mg/dL) at Week 12, 24 and 52|Percentage of Participants Achieving Fasting Low Density Lipoprotein Cholesterol (LDL-C) Less Than or Equal to (<=) 70 Milligram Per Deciliter (mg/dL) at Week 12, 24 and 52|Plasma Concentration of PF-04950615 at Week 12, 24 and 52|Number of Participants With Adverse Events (AEs) Related to Type 1 or 3 Hypersensitivity Reactions and Injection Site Reactions|Percentage of Participants With Anti-Drug Antibodies (ADA) and Neutralizing Antibodies (nAb): Treatment Period|Number of Participants Who Changed Concomitant Medication During Extension Period|Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 58 Follow-up Visit, 71, 84, 97 and 110: Extension Period|Percentage of Participants With Anti-Drug Antibodies (ADA) and Neutralizing Antibodies (nAb): Extension Period",Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,2139,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",B1481020|2013-002643-28|SPIRE-LDL,29-Oct-13,5-Jul-16,10-Jul-17,24-Oct-13,24-Jul-17,31-Jul-18,"Ernest L. Hendrix, MD, PC, Athens, Alabama, United States|North Alabama Research Center, LLC, Athens, Alabama, United States|The Kirklin Clinic, Birmingham, Alabama, United States|Alabama Internal Medicine, P.C., Birmingham, Alabama, United States|Drug Shipment and Study Conducted at Address: University of Alabama at Birmingham, Birmingham, Alabama, United States|Heart Center Research, Llc, Huntsville, Alabama, United States|Radiant Research Incorporated, Chandler, Arizona, United States|Advanced Research Associates, Glendale, Arizona, United States|Arizona Center For Internal Medicine, Mesa, Arizona, United States|Holland Center for Family Health, Peoria, Arizona, United States|Elite Clinical Studies, LLC, Phoenix, Arizona, United States|Phoenix Clinical, Phoenix, Arizona, United States|Desert Sun Clinical Research, LLC, Tucson, Arizona, United States|Advanced Arizona Clinical Research, Tucson, Arizona, United States|Care Clinical Research Corporation, Banning, California, United States|Med Center, Carmichael, California, United States|Med Investigations, Fair Oaks, California, United States|California Heart Specialists, Huntington Beach, California, United States|Alia Clinical Research, Inc., Huntington Park, California, United States|Downtown L.A. Research Center, Inc., Los Angeles, California, United States|Richard S. Cherlin, M.D., Los Gatos, California, United States|California Medical Research Associates Inc., Northridge, California, United States|Arch Health Partners Clinical Research Department, Poway, California, United States|Clinical Trials Research, Sacramento, California, United States|Northern California Research, Sacramento, California, United States|Alta California Medical Group, Simi Valley, California, United States|Orange County Research Center, Tustin, California, United States|Empire Clinical Research, Upland, California, United States|Diablo Clinical Research, Inc., Walnut Creek, California, United States|Infosphere Clinical Research, INC, West Hills, California, United States|Clinicos, LLC, Colorado Springs, Colorado, United States|Clinical Research Advantage, Inc./Colorado Springs Health Partners, SW, Colorado Springs, Colorado, United States|YNHH, Heart and Vascular, North Haven, Connecticut, United States|ACRC-Cardiology, Atlantis, Florida, United States|Morton Plant Mease Health Care, Inc. Cardiovascular Research, Clearwater, Florida, United States|Avail Clinical Research, LLC, DeLand, Florida, United States|Fleming Island Center for Clinical Research, Fleming Island, Florida, United States|Invesclinic, LLC, Fort Lauderdale, Florida, United States|Florida Research Network, LLC, Gainesville, Florida, United States|AGA Clinical Trials, Hialeah, Florida, United States|The Research Center, Inc., Hialeah, Florida, United States|Homestead Medical Research Inc., Homestead, Florida, United States|Nature Coast Clinical Research, Inverness, Florida, United States|Westside Center for Clinical Research, Jacksonville, Florida, United States|East Coast Institute for Research, LLC at Baker-Gilmour Cardiovascular Institute, PA, Jacksonville, Florida, United States|East Coast Institute for Research, LLC at Jacksonville Cardiovascular Center, Jacksonville, Florida, United States|East Coast Institute for Research, LLC at Northeast Florida Cardiology Clinic, Jacksonville, Florida, United States|East Coast Institute for Research, LLC at Northeast Florida Endocrine & Diabetes Associates, Jacksonville, Florida, United States|St. Vincent's Cardiology, Jacksonville, Florida, United States|San Marcus Research Clinic, Inc., Miami, Florida, United States|Clinical Research of Miami, Miami, Florida, United States|Finlay Medical Research, Miami, Florida, United States|Medical Research Center, Miami, Florida, United States|International Research Associates, LLC, Miami, Florida, United States|Kendall South Medical Center, Miami, Florida, United States|Florida Institute For Clinical Research, LLC, Orlando, Florida, United States|Oviedo Medical Research, LLC, Oviedo, Florida, United States|A&R Research Group, LLC, Pembroke Pines, Florida, United States|DBC Research, Pembroke Pines, Florida, United States|St. Johns Center for Clinical Research, Ponte Vedra, Florida, United States|South Miami Clinical Research Center, LLC, South Miami, Florida, United States|Dolphin Medical Research, Virginia Gardens, Florida, United States|Metabolic Research Institute Incorporated, West Palm Beach, Florida, United States|Clinical Research of Central Florida, Winter Haven, Florida, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Atlanta Center for Clinical Research / Internal Medicine, Roswell, Georgia, United States|North Georgia Clinical Research, Woodstock, Georgia, United States|North Georgia Internal Medicine, Woodstock, Georgia, United States|East-West Medical Research Institute, Honolulu, Hawaii, United States|Northwest Clinical Trials, Inc., Boise, Idaho, United States|Solaris Clinical Research, Meridian, Idaho, United States|Investigators Research Group, LLC, Brownsburg, Indiana, United States|American Health Network, LLC, Indianapolis, Indiana, United States|Midwest Institute for Clinical Research, Indianapolis, Indiana, United States|Buynak Clinical Research, P.C., Valparaiso, Indiana, United States|West Broadway Clinic, Council Bluffs, Iowa, United States|The University of Iowa - College of Public Health - Preventive Intervention Center, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Midwest Heart and Vascular Specialists, Overland Park, Kansas, United States|Omega Clinical Research, Metairie, Louisiana, United States|New Orleans Center for Clinical Research, New Orleans, Louisiana, United States|Southern Maine Health Care, Biddeford, Maine, United States|Columbia Medical Practice, Columbia, Maryland, United States|MD Medical Research, Oxon Hill, Maryland, United States|IHA Chelsea Family & Internal Medicine, Chelsea, Michigan, United States|QUEST Research Institute, Farmington Hills, Michigan, United States|Westside Family Medical Center, Pc, Kalamazoo, Michigan, United States|Michigan Heart and Vascular Specialists, Petoskey, Michigan, United States|Oakland Medical Research Center, Troy, Michigan, United States|Radiant Research, Inc., Edina, Minnesota, United States|HealthEast Medical Research Institute, Saint Paul, Minnesota, United States|HealthEast St. Joseph's Hospital Pharmacy, Saint Paul, Minnesota, United States|KCUMB Center for Community and Clinical Research, Kansas City, Missouri, United States|Mercy Health Research, Washington, Missouri, United States|Om Medical, Las Vegas, Nevada, United States|Clinical Research of South Nevada, Las Vegas, Nevada, United States|Rutgers Biomedical and Health Sciences- Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|Cardio Metabolic Institute, Somerset, New Jersey, United States|Premier Research, Trenton, New Jersey, United States|Albany Medical College, Division of Community Endocrinology, Albany, New York, United States|Drug Trials Brooklyn, Brooklyn, New York, United States|Drug Trials America, Hartsdale, New York, United States|SJH Cardiology Associates, Liverpool, New York, United States|Mid Hudson Medical Research, PLLC, New Windsor, New York, United States|Sensenbrenner Primary Care, Charlotte, North Carolina, United States|PharmQuest, Greensboro, North Carolina, United States|Crossroads Clinical Research, Inc., Mooresville, North Carolina, United States|PMG Research of Salisbury, LLC, Salisbury, North Carolina, United States|PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States|PMG Research of Winston-Salem, Winston-Salem, North Carolina, United States|Radiant Research, Inc, Akron, Ohio, United States|Community Health Care, Inc., Canal Fulton, Ohio, United States|Sterling Research Group, Ltd., Cincinnati, Ohio, United States|The Lindner Center for Research and Education at The Christ Hospital, Cincinnati, Ohio, United States|Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio, United States|Sentral Clinical Research Services - Admin Only, Cincinnati, Ohio, United States|Sentral Clinical Research Services, Cincinnati, Ohio, United States|Sterling Research Group, Ltd., Cincinnati, Ohio, United States|LION Research, Norman, Oklahoma, United States|Clinical Research Institute of Southern Oregon, PC, Medford, Oregon, United States|Brandywine Clinical Research, Downingtown, Pennsylvania, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Liberty Family Practice, Erie, Pennsylvania, United States|Detweiler Family Medicine and Associates, PC, Lansdale, Pennsylvania, United States|Suburban Research Associates, Media, Pennsylvania, United States|Allegheny Endocrinology Associates, Pittsburgh, Pennsylvania, United States|Guthrie Medical Group, PC, Sayre, Pennsylvania, United States|Warminster Medical Associates, P.C., Warminster, Pennsylvania, United States|Coastal Cardiology, Charleston, South Carolina, United States|Upstate Pharmaceutical Research, Greenville, South Carolina, United States|Palmetto Clinical Research, Summerville, South Carolina, United States|Cardiovascular Research of Knoxville, Knoxville, Tennessee, United States|New Orleans Center for Clinical Research, Knoxville, Tennessee, United States|Volunteer Research Group, Knoxville, Tennessee, United States|KRK Medical Research, Arlington, Texas, United States|North Texas Healthcare System, Dallas VAMC, Dallas, Texas, United States|Research Institute of Dallas, Dallas, Texas, United States|University of North Texas Health Science Center at Fort Worth, Fort Worth, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|lnvestigational Drug Services (IDA), Houston, Texas, United States|Northwest Houston Cardiology, Houston, Texas, United States|Texas Center for Drug Development, Inc., Houston, Texas, United States|Pioneer Research Solutions, Inc., Houston, Texas, United States|Hill Country Medical Associates, New Braunfels, Texas, United States|Advanced Clinical Research Associates, Plano, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|Bandera Family Health Care, LLC, San Antonio, Texas, United States|Northwest Heart Center, Tomball, Texas, United States|Radiant Research, Murray, Utah, United States|Manassas Clinical Research Center, Manassas, Virginia, United States|National Clinical Research-Richmond, Inc., Richmond, Virginia, United States|Amherst Family Practice, P.C., Winchester, Virginia, United States|Selma Medical Associates, Winchester, Virginia, United States|Rainier Clinical Research Center, Renton, Washington, United States|Zain Research LLC, Richland, Washington, United States|Discovery Clinical Services Ltd., Victoria, British Columbia, Canada|Vizel Cardiac Research, Saul Vizel Professional Medicine Corporation, Cambridge, Ontario, Canada|The Office of Dr. Allen Greenspoon, Hamilton, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|Stroke Prevention & Atherosclerosis Research Centre (SPARC), London, Ontario, Canada|Newmarket Cardiology Research Group, Newmarket, Ontario, Canada|London Road Diagnostic Clinic and Medical Centre, Sarnia, Ontario, Canada|St. Michael's Hospital Health Centre, Toronto, Ontario, Canada|Rhodin Recherche Clinique, Drummondville, Quebec, Canada|LMC Research Inc. d.b.a. Manna Research Inc., Levis, Quebec, Canada|Omnispec Clinical Research Inc., Mirabel, Quebec, Canada|Montreal Heart Institute, Montreal, Quebec, Canada|DIEX Research Sherbrooke Inc., Sherbrooke, Quebec, Canada|Rodrigo Botero S.A.S, Medellin, Antioquia, Colombia|Centro de Medicina del Ejercicio y Rehabilitacion Cardiaca S.A. CEMDE S.A., Medellin, Antioquia, Colombia|Fundacion del Caribe para la Investigacion Biomedica-Fundacion Bios, Barranquilla, Atlantico, Colombia|BIOMELAB Ltda., Barranquilla, Atlantico, Colombia|IPS Centro Cientifico Asistencial Jose Luis Accini S.A.S., Barranquilla, Atlantico, Colombia|Centro de Diagnostico Cardiologico LTDA., Cartagena, Bolivar, Colombia|Asociacion IPS Medicos InterniStas de Caldas, Manizales, Caldas, Colombia|Dexa Diab Servicios Medicos Ltda. IPS, Bogota, Cundinamarca, Colombia|Instituto de Investigacion Endocrinologia y Prevencion Metabolica ENDOCARE LTDA, Bogota, Cundinamarca, Colombia|Fundacion Cardiomet - CEQUIN, Armenia, Quindio, Colombia|Fundacion Cardiovascular De Colombia, Floridablanca, Santander, Colombia|Fundacion Centro de Investigaciones Biomedicas RIESCARD, Espinal, Tolima, Colombia|Centro de Investigaciones Clinicas S.A.S, Cali, Valle DEL Cauca, Colombia|Nouvelles Cliniques Nantaises, Nantes, France|CHU La Miletrie, Poitiers, France|CHU de Toulouse - Hopital Rangueil, Toulouse cedex 9, France|Hopital Guy Chatiliez, Tourcoing, France|Hopital Guy Chatillez, Tourcoing, France|Magyar Imre Korhaz, Belgyogyaszati Szakrendeles, Ajka, Hungary|Bajai Szent Rokus Korhaz, Baja, Hungary|Lausmed Kft., Baja, Hungary|DRC Kft., Balatonfured, Hungary|SYNEXUS Magyarorszag Kft., Budapest, Hungary|Synexus Magyarorzag Kft., Budapest, Hungary|Pharma 4 Trial Kft., Gyongyos, Hungary|Borsod-Abauj-Zemplen Megyei Korhaz, es Egyetemi Oktatokorhaz, Miskolc, Hungary|TaNaMed Kft., Mosonmagyarovar, Hungary|Pecsi Tudomanyegyetem, Pecs, Hungary|Zala Megyei Korhaz, Zalaegerszeg, Hungary|PI Kaunas Silainiai Outpatient Clinic, Kaunas, Lithuania|Private Clinic Elite Medicale, Kaunas, Lithuania|PI Klaipeda Seamen Hospital, Klaipeda, Lithuania|Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania|Clinicos Asociados BOCM, S.C., Mexico, Distrito Federal, Mexico|Hospital General de Naucalpan ""Dr. Maximiliano Ruiz Castaneda"" (Emergencies), Naucalpan, Estado DE Mexico, Mexico|Instituto Jalisciense de Investigacion en Diabetes y Obesidad, S.C., Guadalajara, Jalisco, Mexico|Instituto de Diabetes, Obesidad y Nutricion S.C., Cuernavaca, Morelos, Mexico|Administradora de Clinicas S.A. de C.V. Hospital Inovamed Cuernavaca, Cuernavaca, Morelos, Mexico|Centro de Atención e Investigación Cardiovascular del Potosí S.C., San Luis Potosí, SAN LUIS Potosi, Mexico|Centenario Hospital Miguel Hidalgo, Aguascalientes, Mexico|Centro de Investigacion Cardiometabolica de Aguascalientes SA de CV, Aguascalientes, Mexico|Centro Hospitalario Mac, S.A. De C.V. (Emergencies), Aguascalientes, Mexico|Hospital Angeles Centro Medico del Potosi (Emergencies), San Luis Potosi, Mexico|Spitalul Clinic Judetean de Urgenta Craiova, Cardiologie, Craiova, Dolj, Romania|Centrul Medical de Diagnostic si Tratament Ambulator Neomed, Medicina Interna, Brasov, Romania|Spitalul Universitar de Urgenta Militar Central, Dr. Carol Davila"", Bucuresti, Romania|Centrul Medical Unirea, Diabet Nutritie si Boli Metabolice, Cluj-Napoca, Romania|Elit Medical SRL, Ploiesti, Romania|Federal State Budgetary Institution ""Research Institute of Complex problems of Cardio-vascular, Kemerovo, Russian Federation|FSAEI of Higher Education ""People's Friendship University of Russia"",, Moscow, Russian Federation|Saint-Petersburg State Budgetary Institution of Healthcare Municipal hospital # 40 of the Kurortnyi, Saint-Petersburg, Russian Federation|Saint-Petersburg State Budgetary Institution of Healthcare ""Municipal Hospital #15"", Saint-Petersburg, Russian Federation|Municipal Institution of Healthcare ""City Clinical Hospital 12, Saratov, Russian Federation|LLC ""Institute of medical research"", St. Petersburg, Russian Federation|Centro Salud Petrer I, Petrer, Alicante, Spain|Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Clinico Universitario Santiago de Compostela, Santiago de Compostela, Galicia, Spain|Hospital Universitario Quiron Madrid, Pozuelo de Alarcon, Madrid, Spain|Hospital Universitario Sant Joan de Reus, Reus, Tarragona, Spain|Hospital Universitario La Ribera, Alzira, Valencia, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitario La Paz; Unidad Metabolico-Vascular, Madrid, Spain|Hospital Clinico Universitario Miguel Servet; Medicina Interna, Zaragoza, Spain|Cardinal Tien Hospital, New Taipei City, Taiwan|China Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Synexus Thames Valley Clinical Research Centre, Reading, Berkshire, United Kingdom|Synexus Manchester Clinical Research Centre, Manchester, Greater Manchester, United Kingdom|Synexus Scotland Clinical Research Centre, Glasgow, Lanarkshire, United Kingdom|Synexus Lancashire Clinical Research Centre, Chorley, Lancashire, United Kingdom|Synexus Wales Clinical Research Centre, Cardiff, Llanishen, United Kingdom|Synexus Merseyside Clinical Research Centre, Liverpool, Merseyside, United Kingdom|Northmed Clinical Research Ltd, Randalstown Health Centre, Antrim, Northern Ireland, United Kingdom|Southern Health & Social Care Trust, Craigavon Area Hospital, Portadown, Northern Ireland, United Kingdom|Synexus North East Clinical Research Centre-Hexham General Hospital, Hexham, Northumberland, United Kingdom|Synexus North East Clinical Research Centre, Hexham, Northumberland, United Kingdom|The Crouch Oak Family Practice, Addlestone, Surrey, United Kingdom|Synexus Midlands Clinical Research Centre, Birmingham, WEST Midlands, United Kingdom|The Bradford on Avon & Melksham Health Partnership, Bradford on Avon, Wiltshire, United Kingdom|Ninewells Hospital & Medical School, Dundee, United Kingdom",,https://ClinicalTrials.gov/show/NCT01968967
NCT01968980,A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia,SPIRE-FH,Completed,Has Results,Heterozygous Familial Hypercholesterolemia,Drug: Bococizumab (PF-04950615;RN316)|Other: Placebo,"Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12|Percent Change From Baseline in Total Cholesterol (TC) at Week 12|Percent Change From Baseline in Non High Density Lipoprotein Cholesterol (Non HDL-C) at Week 12|Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 12|Percent Change From Baseline in Lipoprotein (a) at Week 12|Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12|Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 24 and 52|Percent Change From Baseline in Total Cholesterol (TC) at Week 24 and 52|Percent Change From Baseline in Non High Density Lipoprotein Cholesterol (Non HDL-C) at Week 24 and 52|Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 24 and 52|Percent Change From Baseline in Lipoprotein (a) at Week 24 and 52|Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 24 and 52|Percent Change From Baseline in Triglycerides (TG) at Week 12, 24 and 52|Percent Change From Baseline in Apolipoprotein A-I (ApoA-I) at Week 12, 24 and 52|Percent Change From Baseline in Apolipoprotein A-II (ApoA-II) at Week 12, 24 and 52|Percent Change From Baseline in Very Low Density Lipoprotein Cholesterol (VLDL-C) at Week 12, 24 and 52|Absolute Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 12|Absolute Change From Baseline in Total Cholesterol (TC) at Week 12|Absolute Change From Baseline in Non- High Density Lipoprotein Cholesterol (Non HDL-C) at Week 12|Absolute Change From Baseline in Apolipoprotein B (ApoB) at Week 12|Absolute Change From Baseline in Lipoprotein (a) at Week 12|Absolute Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12|Absolute Change From Baseline in Ratio of Total Cholesterol to High Density Lipoprotein Cholesterol (TC/HDL-C Ratio) at Week 12, 24 and 52|Absolute Change From Baseline in Ratio of Apolipoprotein B to Apolipoprotein A-I (ApoB/ApoA-I Ratio) at Week 12, 24 and 52|Percentage of Participants Achieving Low Density Lipoprotein Cholesterol (LDL-C) Level Less Than or Equal to (<=) 100 Milligram Per Deciliter (2.59 Millimoles Per Liter) at Week 12, 24 and 52|Percentage of Participants Achieving Low Density Lipoprotein Cholesterol (LDL-C) Level Less Than or Equal to (<=) 70 Milligram Per Deciliter (1.81 Millimoles Per Liter) at Week 12, 24 and 52|Plasma PF-04950615 Concentrations at Week 12, 24 and 52|Number of Participants With Adverse Events Related to Type 1 or 3 Hypersensitivity Reactions and Injection Site Reactions|Percentage of Participants With Positive Anti-Drug Antibodies (ADA) and Neutralizing Antibodies (nAb)",Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,370,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",B1481021|2013-002644-87|SPIRE-HF,23-Oct-13,15-Apr-16,15-Apr-16,24-Oct-13,19-May-17,26-Jun-17,"IMD Medical Group, Los Angeles, California, United States|Hartford Hospital, JB704, Hartford, Connecticut, United States|Best Quality Research, Inc., Hialeah, Florida, United States|NewPhase Clinical Trials, Corp., Miami Beach, Florida, United States|Medical Research Center, Miami, Florida, United States|Premier Research Associate, Inc, Miami, Florida, United States|Columbus Clinical Services, LLC, Miami, Florida, United States|Om Medical, Las Vegas, Nevada, United States|The University of North Carolina at Chapel Hill Center for Heart & Vascular Care, Chapel Hill, North Carolina, United States|The University of North Carolina Hospitals - Clinical and Translational Research Center Clinic, Chapel Hill, North Carolina, United States|Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio, United States|Oklahoma Heart Hospital Physicians, Oklahoma City, Oklahoma, United States|Oklahoma Heart Hospital Research Foundation, Oklahoma City, Oklahoma, United States|Oklahoma Heart Hospital, Oklahoma City, Oklahoma, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|OnSite Clinical Solutions, LLC, Gaffney, South Carolina, United States|Galenos Research, Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Pioneer Research Solutions, Inc., Houston, Texas, United States|Pioneer Research Solutions, Inc., Sugar Land, Texas, United States|Focus Clinical Research, LLC, Draper, Utah, United States|Burke Internal Medicine & Research, Burke, Virginia, United States|SHAT in Cardiology EAD, Pleven, Bulgaria|UMHAT ""Sveti Georgi"" EAD, Clinic of Cardiology, Plovdiv, Bulgaria|Second MHAT - Sofia EAD, Sofia, Bulgaria|MHAT ""Sveta Anna"", Clinic of Internal Diseases, Sofia, Bulgaria|St. Paul's Hospital, Healthy Heart, Vancouver, British Columbia, Canada|Discovery Clinical Services Ltd., Victoria, British Columbia, Canada|Asper Clinical Research Institute, Winnipeg, Manitoba, Canada|Health Sciences Centre, St. John's, Newfoundland and Labrador, Canada|University of Ottawa Heart Institute, Ottawa, Ontario, Canada|Ecogene-21, Chicoutimi, Quebec, Canada|Montreal Heart Institute, Montreal, Quebec, Canada|Institut de Recherches Cliniques de Montreal, Montreal, Quebec, Canada|Clinique des maladies lipidiques de Quebec Inc, Quebec, Canada|Helsinki Central University Hospital, Helsinki, Finland|Pohjois-Karjala Projekti Saatio/Ita-Suomen, Joensuu, Finland|Pohjois-Karjala Projekti Saatio, Joensuu, Finland|Laakarikeskus Aava Kerava/Aava Kerava Medical Center, Kerava, Finland|Oulu University Hospital, Oulu, Finland|Division of Medicine Turku University Hospital, Turku, Finland|Policlinico ""Paolo Giaccone"", Palermo, PA, Italy|Ospedale ""Santa Maria della Misericordia"", Perugia, PG, Italy|Ospedale di Circolo e Fondazione Macchi, Varese, VA, Italy|Azienda Ospedaliero Universitaria ""Federico II"" di Napoli, Napoli, Italy|Admiraal de Ruyter ziekenhuis, Goes, Zeeland, Netherlands|St. Franciscus Gasthuis, Rotterdam, Zuid-holland, Netherlands|Academic Medical Center, Amsterdam, Netherlands|Amphia Hospital, Breda, Netherlands|Hagaziekenhuis, Den Haag, Netherlands|Deventer Ziekenhuis, Deventer, Netherlands|Rotterdam Research Institute, Rotterdam, Netherlands|Albert Schweitzer Hospital, Sliedrecht, Netherlands|UMC Utrecht, Utrecht, Netherlands|Oslo Universitetssykehus HF, Oslo, Norway|Oslo Universitetssykehus HF, Ulleval, Oslo, Norway|NZOZ Vitamed, Bydgoszcz, Poland|NZOZ Centrum Zdrowia i Profilaktyki Dabie Sp zo.o., Krakow, Poland|NZOZ Przychodnia Specjalistyczna Andrzej Wittek Henryk Rudzki S.C, Ruda Slaska, Poland|IATROS International, Bloemfontein, Free State, South Africa|Unitas hospital, Centurion, Gauteng, South Africa|Midrand Medical Centre, Halfway House, Gauteng, South Africa|Medipark Centre for Clinical Research, Pretoria, Gauteng, South Africa|Jongaie Research, Pretoria, Gauteng, South Africa|Synexus Watermeyer Clinical Research Centre, Pretoria, Gauteng, South Africa|Roodepoort Medicross Clinical Research Centre, Roodepoort, Gauteng, South Africa|Chelmsford Medical Centre 3, Durban, Kwa-zulu Natal, South Africa|Tiervlei Trial Centre, Karl Bremer Hospital, Bellville, Cape Town, Western Cape, South Africa|TREAD Research cc., Parow, Cape Town, Western Cape, South Africa|Synexus Helderberg Clinical Research Centre, Somerset West, Western Cape, South Africa|Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Clinico Universitario, Santiago de Compostela, Santiago de Compostela, Galicia, Spain|Hospital Universitario Sant Joan de Reus, Reus, Tarragona, Spain|Hospital Clinic, Barcelona, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Fundacion Jimenez Diaz; Servicio de Medicina Interna, Madrid, Spain|Hospital Clinico San Carlos; U. de Lipidos; Medicina Interna III, Madrid, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Clinico Universitario Miguel Servet; Medicina Interna, Zaragoza, Spain|Clinical Trials Pharmacy, 4th Floor Inpatient Pharmacy, Manchester, Greater Manchester, United Kingdom|Pennine Acute Hospitals NHS Trust, Oldham, Greater Manchester, United Kingdom|East and North Hertfordshire NHS Trust, Stevenage, Hertfordshire, United Kingdom|Burton Hospitals NHS Foundation Trust, Burton-on-Trent, Staffordshire, United Kingdom|Heart of England NHS Foundation Trust, Birmingham, West Midlands, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom|Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom|Peterborough and Stamford Hospitals NHS Foundation Trust, Peterborough, United Kingdom",,https://ClinicalTrials.gov/show/NCT01968980
NCT01967355,Prolongation of Pregnancy in Preeclampsia by Therapeutic Lipid Apheresis,,Completed,No Results Available,Preeclampsia|Dyslipidemia|Proteinuria|Hypertension,Other: lipid apheresis,Prolongation of pregnancy|Reduction of lipoprotein levels,Karl Winkler|University Hospital Freiburg,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,6,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2013-15,Apr-13,8-May-14,8-May-14,22-Oct-13,null,9-Aug-18,"Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Freiburg, Freiburg, Baden-Württemberg, Germany",,https://ClinicalTrials.gov/show/NCT01967355
NCT01964326,Actual Use Trial of Atorvastatin Calcium 10 mg,,Completed,Has Results,Hypercholesterolemia,Drug: Atorvastatin calcium 10 mg,"Percentage of Participants Who Complied With the Direction to Check Their Low-density Lipoprotein Cholesterol (LDL-C) Level|Percentage of Participants Who Took Appropriate Action Based on Their LDL-C Results|Percentage of Participants Taking an ""Ask a Doctor or Pharmacist Before Use"" Medication Who Followed the Labeling and Contacted a Doctor or Pharmacist Before Using Study Medication|Percentage of Participants Who Stopped Study Medication Use and Asked a Doctor if They Experienced Any of the Labeled ""Stop Use and Ask a Doctor"" Symptoms",Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1311,Industry,Interventional,Masking: None (Open Label)|Primary Purpose: Treatment,A2581189,Oct-13,Dec-14,Dec-14,17-Oct-13,27-Jan-16,18-May-16,"Robert's Discount Pharmacy, Hoover, Alabama, United States|Pharmacy at the Pig, McCalla, Alabama, United States|Pinson Discount Drugs, Pinson, Alabama, United States|Community Clinical Pharmacy, Mesa, Arizona, United States|Melrose Pharmacy, Phoenix, Arizona, United States|Bi-Rite Quality Pharmacies, La Habra, California, United States|Parkview Compounding Pharmacy, Rancho Cucamonga, California, United States|Garden Drug, Fort Lauderdale, Florida, United States|Pill Box Pharmacy and Medical Supply, Pembroke Pines, Florida, United States|Summerfield Pharmacy, Riverview, Florida, United States|Sutton Family Pharmacy, Dalton, Georgia, United States|Wynn's Pharmacy Inc., Griffin, Georgia, United States|Catonsville Pharmacy, Baltimore, Maryland, United States|Kemper Drug, Elk River, Minnesota, United States|Goodrich Pharmacy, Fridley, Minnesota, United States|Northfield Pharmacy, Northfield, Minnesota, United States|Cub Pharmacy, Rosemount, Minnesota, United States|Goodrich Pharmacy, St Francis, Minnesota, United States|Albers' Medical Pharmacy, Kansas City, Missouri, United States|Countryside Pharmacy, Savannah, Missouri, United States|Texas Road Pharmacy, Monroe, New Jersey, United States|Duran Central Pharmacy, Albuquerque, New Mexico, United States|Sam's Regent Pharmacy, Albuquerque, New Mexico, United States|Family Prescription Center, Bethlehem, Pennsylvania, United States|T.B. Bond Pharmacy, Hillsboro, Texas, United States|Inwood Pharmacy, Houston, Texas, United States|Brick Street Pharmacy, Tyler, Texas, United States|Mountain West Apothecary, Bountiful, Utah, United States|Ridgeview Pharmacy, Roy, Utah, United States|The Apothecary Shoppe, Salt Lake City, Utah, United States|The Medicine Center, Salt Lake City, Utah, United States|Family Plaza Pharmacy, West Jordan, Utah, United States|Montpelier Pharmacy, Inc., Montpelier, Virginia, United States|Lafayette Pharmacy, Richmond, Virginia, United States|Jim's Pharmacy, Enuwclaw, Washington, United States|Ostrom Drugs, Kenmore, Washington, United States|Katterman's Sand Point Professional Pharmacy, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01964326
NCT01959971,Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-Cholesterol,,Completed,No Results Available,Hypercholesterolemia,Drug: alirocumab|Drug: Placebo,"Percent change in Fractional Clearance Rate of apolipoprotein B (apoB) in Low Density Lipoproteins (pools/day) in plasma during alirocumab treatment|Change in lipids turnover parameters measured in isolated Very Low Density Lipoproteins (VLDL), Intermediate Density Lipoproteins (IDL), Low Density Lipoproteins (LDL) and High Density Lipoproteins (HDL)|Change in post-heparin hepatic lipase and lipoprotein lipase activities|Change in lipids and apolipoproteins in plasma lipids panel|Assessment of Lipoprotein particle size profiles|Assessment of serum concentrations of PCSK9|Assessment of safety parameters (clinical laboratory, ECG, vital signs)|Assessment of the serum concentration of alirocumab|Assessment of the serum concentration of anti-alirocumab antibodies",Sanofi|Regeneron Pharmaceuticals,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,20,Industry,Interventional,Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,PDY13670|U1111-1141-4567,Dec-13,May-15,May-15,10-Oct-13,null,2-May-17,"Investigational Site Number 840001, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01959971
NCT01958775,Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon Like Peptide 2,,Completed,No Results Available,Dyslipidemia,Drug: GLP-2|Drug: Placebo,Lipoprotein production and clearance rate|Plasma and TRL triglyceride and TRL retinyl palmitate,"University Health Network, Toronto",All,18 Years to 60 Years   (Adult),Phase 3,12,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,REB-07-0394,Mar-12,Jun-14,Jun-14,9-Oct-13,null,10-Mar-15,"Toronto General Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01958775
NCT01956201,Efficacy and Safety of Fenofibrate Added on to Atorvastatin Compared With Atorvastatin,,Unknown status,No Results Available,Mixed Hyperlipidemia,Drug: Atorvastatin 20mg|Drug: Fenofibrate 160mg|Other: Placebo (Fenofibrate 160 mg),"The mean percent change of Non-HDL Cholesterol|The achievement rate of LDL-C<100mg/dl, Non-HDL-C<130mg/dl|The mean percent change of LDL-C, HDL-C, TG, TC, Apo-AI, Apo-B|The mean percent change of Non-LDL-C/HDL-C, TC/HDL-C, LDL-C/HDL-C, Apo-B/Apo-AI|The mean percent change of Fibrinogen, hs-CRP|Safety evaluation (Physical examination, Vital sign, Laboratory, AE etc.)",Chong Kun Dang Pharmaceutical,All,"19 Years and older   (Adult, Older Adult)",Phase 3,476,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",146MHL13011,Dec-13,Aug-16,Aug-16,8-Oct-13,null,4-Feb-15,"Inje University Busan Paik Hospital, Busan, Korea, Republic of|Pusan National University Hospital, Busan, Korea, Republic of|Kangwon University Hospital, Chuncheon, Korea, Republic of|Daegu Catholic University Medical Center, Daegu, Korea, Republic of|Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|Konyang University Hospital, Daejeon, Korea, Republic of|Chonnam National University Hospital, Gwangju, Korea, Republic of|Dongguk University Ilsan Hospital, Ilsan, Korea, Republic of|Inje University Ilsan Paik Hospital, Ilsan, Korea, Republic of|Chonbuk National University Hospital, Jeonju, Korea, Republic of|Hanyang University Guri Hospital, Kyunggi, Korea, Republic of|Seoul National University Hospital, Bundang, Seongnam, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Eulji General Hospital, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Kangbuk Samsung Medical Center, Seoul, Korea, Republic of|Kangdong Sacred Heart Hospital, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Korea University Huro Hospital, Seoul, Korea, Republic of|Kyunghee University Hospital at Gangdong, Seoul, Korea, Republic of|Kyunghee University Medical center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea, St. Mary's Hospital, Seoul, Korea, Republic of|The Catholic University of Korea, Uijeongbu St. Mary's Hospital, Seoul, Korea, Republic of|The Catholic University of korea, Yeouido St. Mary's Hospital, Seoul, Korea, Republic of|Ajou University hospital, Suwon, Korea, Republic of|Wonju Severance Christian Hospital, Wonju, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01956201
NCT01954394,Open Label Study of Long Term Safety Evaluation of Alirocumab,ODYSSEY OLE,Completed,Has Results,Hypercholesterolemia,Drug: Alirocumab|Drug: Lipid-Modifying Therapy (LMT),"Percentage of Participants Who Experienced Adverse Events (AEs)|Percent Change From Baseline in Calculated LDL-C at Weeks 8, 24, 48, 72, 96, 120, 144 and 168|Absolute Change From Baseline in Calculated LDL-C (mg/dL) at Weeks 8, 24, 48, 72, 96, 120, 144 and 168|Absolute Change From Baseline in Calculated LDL-C (mmol/L) at Weeks 8, 24, 48, 72, 96, 120, 144 and 168|Percentage of Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) Over Time|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) Over Time|Percentage of Participants With Calculated LDL-C <70 mg/dL (1.81mmol/L) and/or >=50% Reduction in Calculated LDL-C From Baseline (if Calculated LDL-C >=70 mg/dL [1.81mmol/L]) Over Time|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Weeks 8, 24, 48, 72, 96, 120, 144 and 168|Percent Change From Baseline in Total-cholesterol at Weeks 8, 24, 48, 72, 96, 120, 144 and 168|Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Weeks 8, 24, 48, 72, 96, 120, 144 and 168|Percent Change From Baseline in Fasting Triglycerides (TGs) at Weeks 8, 24, 48, 72, 96, 120, 144 and 168|Percent Change From Baseline in Lipoprotein (a) at Weeks 48, 96, 144 and 168|Percent Change From Baseline in Apolipoprotein-B (Apo-B) at Weeks 48, 96, 144, and 168|Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Weeks 48, 96, 144, and 168|Absolute Change From Baseline in Apo B/Apo A-1 Ratio at Weeks 48, 96, 144, and 168",Sanofi|Regeneron Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 3,986,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LTS13463|2013-002572-40|U1111-1143-3810,17-Dec-13,30-Jun-17,30-Jun-17,1-Oct-13,24-Jul-18,24-Jul-18,"Investigational Site Number 840321, Huntsville, Alabama, United States|Investigational Site Number 840341, Tempe, Arizona, United States|Investigational Site Number 840334, Bell Gardens, California, United States|Investigational Site Number 840319, Fountain Valley, California, United States|Investigational Site Number 840336, Los Angeles, California, United States|Investigational Site Number 840339, Mission Viejo, California, United States|Investigational Site Number 840337, Newport Beach, California, United States|Investigational Site Number 840306, Golden, Colorado, United States|Investigational Site Number 840328, Washington, District of Columbia, United States|Investigational Site Number 840344, Atlantis, Florida, United States|Investigational Site Number 840353, Clearwater, Florida, United States|Investigational Site Number 840318, Fort Lauderdale, Florida, United States|Investigational Site Number 840327, Jacksonville, Florida, United States|Investigational Site Number 840309, Miami, Florida, United States|Investigational Site Number 840351, Sarasota, Florida, United States|Investigational Site Number 840315, Evanston, Illinois, United States|Investigational Site Number 840305, Oakbrook Terrace, Illinois, United States|Investigational Site Number 840333, Iowa City, Iowa, United States|Investigational Site Number 840329, Kansas City, Kansas, United States|Investigational Site Number 840345, Auburn, Maine, United States|Investigational Site Number 840338, Biddeford, Maine, United States|Investigational Site Number 840322, Boston, Massachusetts, United States|Investigational Site Number 840346, Framingham, Massachusetts, United States|Investigational Site Number 840317, Saint Louis, Missouri, United States|Investigational Site Number 840349, Saint Louis, Missouri, United States|Investigational Site Number 840314, Morristown, New Jersey, United States|Investigational Site Number 840316, New York, New York, United States|Investigational Site Number 840324, Poughkeepsie, New York, United States|Investigational Site Number 840303, Charlotte, North Carolina, United States|Investigational Site Number 840320, Durham, North Carolina, United States|Investigational Site Number 840348, Raleigh, North Carolina, United States|Investigational Site Number 840340, Cincinnati, Ohio, United States|Investigational Site Number 840302, Marion, Ohio, United States|Investigational Site Number 840330, Portland, Oregon, United States|Investigational Site Number 840352, Beaver, Pennsylvania, United States|Investigational Site Number 840308, Philadelphia, Pennsylvania, United States|Investigational Site Number 840342, Scranton, Pennsylvania, United States|Investigational Site Number 840304, Summerville, South Carolina, United States|Investigational Site Number 840311, Dallas, Texas, United States|Investigational Site Number 840312, Dallas, Texas, United States|Investigational Site Number 840301, Fort Worth, Texas, United States|Investigational Site Number 840343, Bountiful, Utah, United States|Investigational Site Number 840354, Chesapeake, Virginia, United States|Investigational Site Number 840350, Spokane, Washington, United States|Investigational Site Number 032302, Caba, Argentina|Investigational Site Number 032301, Coronel Suarez, Argentina|Investigational Site Number 040302, Graz, Austria|Investigational Site Number 040303, Sankt Stefan, Austria|Investigational Site Number 040301, Wien, Austria|Investigational Site Number 056301, Natoye, Belgium|Investigational Site Number 100302, Sofia, Bulgaria|Investigational Site Number 100301, Sofia, Bulgaria|Investigational Site Number 124303, Chicoutimi, Canada|Investigational Site Number 124302, Montreal, Canada|Investigational Site Number 124301, Quebec, Canada|Investigational Site Number 124306, Sherbrooke, Canada|Investigational Site Number 124305, Toronto, Canada|Investigational Site Number 124304, Victoria, Canada|Investigational Site Number 203307, Hradec Kralove, Czechia|Investigational Site Number 203305, Praha 2, Czechia|Investigational Site Number 203301, Praha 4, Czechia|Investigational Site Number 203306, Praha 5 - Motol, Czechia|Investigational Site Number 203303, Praha 8, Czechia|Investigational Site Number 203309, Trutnov, Czechia|Investigational Site Number 203304, Uherske Hradiste, Czechia|Investigational Site Number 203302, Zlin, Czechia|Investigational Site Number 208301, Aalborg, Denmark|Investigational Site Number 208306, Aarhus, Denmark|Investigational Site Number 208302, Esbjerg, Denmark|Investigational Site Number 208303, Roskilde, Denmark|Investigational Site Number 208304, Svendborg, Denmark|Investigational Site Number 246302, Joensuu, Finland|Investigational Site Number 246301, Kokkola, Finland|Investigational Site Number 246304, Vantaa, Finland|Investigational Site Number 250303, Dijon, France|Investigational Site Number 250304, Lille Cedex, France|Investigational Site Number 250302, Nantes, France|Investigational Site Number 250301, Paris, France|Investigational Site Number 250305, Pessac, France|Investigational Site Number 250306, Rennes, France|Investigational Site Number 276302, Berlin, Germany|Investigational Site Number 276305, Frankfurt A.M., Germany|Investigational Site Number 276306, Leipzig, Germany|Investigational Site Number 276301, Magdeburg, Germany|Investigational Site Number 276307, Witten, Germany|Investigational Site Number 348301, Baja, Hungary|Investigational Site Number 376302, Holon, Israel|Investigational Site Number 376304, Jerusalem, Israel|Investigational Site Number 376303, Safed, Israel|Investigational Site Number 376301, Tel Hashomer, Israel|Investigational Site Number 380302, Chieti, Italy|Investigational Site Number 380304, Milano, Italy|Investigational Site Number 380303, Napoli, Italy|Investigational Site Number 380301, Palermo, Italy|Investigational Site Number 484301, Mexico, Mexico|Investigational Site Number 528317, Alkmaar, Netherlands|Investigational Site Number 528301, Amsterdam-Zuidoost, Netherlands|Investigational Site Number 528320, Apeldoorn, Netherlands|Investigational Site Number 528309, Delfzijl, Netherlands|Investigational Site Number 528313, Eindhoven, Netherlands|Investigational Site Number 528319, Enschede, Netherlands|Investigational Site Number 528322, Goes, Netherlands|Investigational Site Number 528325, Groningen, Netherlands|Investigational Site Number 528302, Groningen, Netherlands|Investigational Site Number 528324, Hoogeveen, Netherlands|Investigational Site Number 528318, Hoorn, Netherlands|Investigational Site Number 528305, Leiden, Netherlands|Investigational Site Number 528311, Maastricht, Netherlands|Investigational Site Number 528312, Nijmegen, Netherlands|Investigational Site Number 528315, Rotterdam, Netherlands|Investigational Site Number 528326, Rotterdam, Netherlands|Investigational Site Number 528303, Utrecht, Netherlands|Investigational Site Number 528323, Utrecht, Netherlands|Investigational Site Number 528321, Venlo, Netherlands|Investigational Site Number 528316, Waalwijk, Netherlands|Investigational Site Number 578301, Bodo, Norway|Investigational Site Number 578305, Oslo, Norway|Investigational Site Number 578304, Oslo, Norway|Investigational Site Number 620302, Funchal, Portugal|Investigational Site Number 620301, Lisboa, Portugal|Investigational Site Number 642302, Timisoara, Romania|Investigational Site Number 643304, Arkhangelsk, Russian Federation|Investigational Site Number 643303, Kazan, Russian Federation|Investigational Site Number 643302, Moscow, Russian Federation|Investigational Site Number 643308, Moscow, Russian Federation|Investigational Site Number 643305, Moscow, Russian Federation|Investigational Site Number 643310, Novosibirsk, Russian Federation|Investigational Site Number 643301, St Petersbourg, Russian Federation|Investigational Site Number 643306, St. Petersburg, Russian Federation|Investigational Site Number 643312, St.Petersburg, Russian Federation|Investigational Site Number 710311, Bellville, South Africa|Investigational Site Number 710307, Bloemfontein, South Africa|Investigational Site Number 710306, Cape Town, South Africa|Investigational Site Number 710302, Cape Town, South Africa|Investigational Site Number 710309, Centurion, South Africa|Investigational Site Number 710312, Parktown, South Africa|Investigational Site Number 710304, Parow, South Africa|Investigational Site Number 710313, Pretoria, South Africa|Investigational Site Number 710303, Pretoria, South Africa|Investigational Site Number 710305, Pretoria, South Africa|Investigational Site Number 710314, Pretoria, South Africa|Investigational Site Number 710315, Roodepoort, South Africa|Investigational Site Number 710310, Somerset West, South Africa|Investigational Site Number 710308, Witbank, South Africa|Investigational Site Number 724303, A Coruna, Spain|Investigational Site Number 724308, Barcelona, Spain|Investigational Site Number 724306, Córdoba, Spain|Investigational Site Number 724312, Granada, Spain|Investigational Site Number 724307, Hospitalet De Llobregat, Spain|Investigational Site Number 724301, Madrid, Spain|Investigational Site Number 724309, Madrid, Spain|Investigational Site Number 724305, Madrid, Spain|Investigational Site Number 724311, Madrid, Spain|Investigational Site Number 724314, Málaga, Spain|Investigational Site Number 724315, Quart De Poblet, Spain|Investigational Site Number 724310, Sabadell, Spain|Investigational Site Number 724313, Sevilla, Spain|Investigational Site Number 724304, Tarragona, Spain|Investigational Site Number 724302, Zaragoza, Spain|Investigational Site Number 752302, Goteborg, Sweden|Investigational Site Number 752301, Stockholm, Sweden|Investigational Site Number 752304, Stockholm, Sweden|Investigational Site Number 826318, Birmingham, United Kingdom|Investigational Site Number 826304, Brighton, United Kingdom|Investigational Site Number 826301, Bristol, United Kingdom|Investigational Site Number 826311, Cambridge, United Kingdom|Investigational Site Number 826310, Cardiff, United Kingdom|Investigational Site Number 826302, Dundee, United Kingdom|Investigational Site Number 826317, Liverpool, United Kingdom|Investigational Site Number 826306, Liverpool, United Kingdom|Investigational Site Number 826312, Manchester, United Kingdom|Investigational Site Number 826303, Manchester, United Kingdom|Investigational Site Number 826305, Middlesex, United Kingdom|Investigational Site Number 826313, Newcastle Upon Tyne, United Kingdom|Investigational Site Number 826309, Reading, United Kingdom|Investigational Site Number 826315, West Bromwich, United Kingdom|Investigational Site Number 826316, West Bromwich, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT01954394/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT01954394/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01954394
NCT01953328,Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk,AMG145,Completed,Has Results,Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events,Drug: Atorvastatin|Biological: Evolocumab|Other: Placebo to Evolocumab,Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at the Mean of Weeks 10 and 12|Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12|Change From Baseline in LDL-C at the Mean of Weeks 10 and 12|Change From Baseline in LDL-C at Week 12|Percent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12|Percent Change From Baseline in Non-HDL-C at Week 12|Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12|Percent Change From Baseline in Apolipoprotein B at Week 12|Percent Change From Baseline in Total Cholesterol at the Mean of Weeks 10 and 12|Percent Change From Baseline in Total Cholesterol at Week 12|Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12|Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 Ratio at the Mean of Weeks 10 and 12|Percent Change From Baseline in the Apolipoprotein B/Apolipoprotein A-1 Ratio at Week 12|Percentage of Participants Who Achieved a Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL|Percentage of Participants Who Achieved LDL-C < 70 mg/dL at Week 12|Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12|Percent Change From Baseline in Lipoprotein(a) at Week 12|Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12|Percent Change From Baseline in Triglycerides at Week 12|Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12|Percent Change From Baseline in HDL-C at Week 12|Percent Change From Baseline in VLDL-C at the Mean of Weeks 10 and 12|Percent Change From Baseline in VLDL-C at Week 12,Amgen,All,"20 Years to 85 Years   (Adult, Older Adult)",Phase 3,409,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",20120122,Oct-13,Jun-14,Jun-14,30-Sep-13,23-Dec-15,23-Dec-15,"Research Site, Akita-shi, Akita, Japan|Research Site, Noda-shi, Chiba, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Kitakyusyu-shi, Fukuoka, Japan|Research Site, Koriyama-shi, Fukushima, Japan|Research Site, Koriyama-shi, Fukushima, Japan|Research Site, Koriyama-shi, Fukushima, Japan|Research Site, Koriyama-shi, Fukushima, Japan|Research Site, Koriyama-shi, Fukushima, Japan|Research Site, Maebashi-shi, Gunma, Japan|Research Site, Takasaki-shi, Gunma, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Tsuchiura-shi, Ibaraki, Japan|Research Site, Hanamaki-shi, Iwate, Japan|Research Site, Morioka-shi, Iwate, Japan|Research Site, Takamatsu-shi, Kagawa, Japan|Research Site, Takamatsu-shi, Kagawa, Japan|Research Site, Yokohama-shi, Kanagawa, Japan|Research Site, Kyoto-shi, Kyoto, Japan|Research Site, Sendai-shi, Miyagi, Japan|Research Site, Sendai-shi, Miyagi, Japan|Research Site, Sendai-shi, Miyagi, Japan|Research Site, Tomigusuku-shi, Okinawa, Japan|Research Site, Urasoe-shi, Okinawa, Japan|Research Site, Ibaraki-shi, Osaka, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Toyonaka-shi, Osaka, Japan|Research Site, Koshigaya-shi, Saitama, Japan|Research Site, Kumagaya-shi, Saitama, Japan|Research Site, Niiza-shi, Saitama, Japan|Research Site, Arakawa-ku, Tokyo, Japan|Research Site, Chiyoda-ku, Tokyo, Japan|Research Site, Chiyoda-ku, Tokyo, Japan|Research Site, Chofu-shi, Tokyo, Japan|Research Site, Chuo-ku, Tokyo, Japan|Research Site, Edogawa-ku, Tokyo, Japan|Research Site, Hachioji-shi, Tokyo, Japan|Research Site, Itabashi-ku, Tokyo, Japan|Research Site, Katsushika-ku, Tokyo, Japan|Research Site, Koto-ku, Tokyo, Japan|Research Site, Minato-ku, Tokyo, Japan|Research Site, Minato-ku, Tokyo, Japan|Research Site, Ota-ku, Tokyo, Japan|Research Site, Setagaya-ku, Tokyo, Japan|Research Site, Shibuya-ku, Tokyo, Japan|Research Site, Shinagawa-ku, Tokyo, Japan|Research Site, Shinagawa-ku, Tokyo, Japan|Research Site, Shinagawa-ku, Tokyo, Japan|Research Site, Shinagawa-ku, Tokyo, Japan|Research Site, Toshima-ku, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT01953328
NCT01941836,"Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients",,Completed,No Results Available,Hypercholesterolemia,Drug: ETC-1002|Drug: Ezetimibe,Percent change in calculated low density lipoprotein-cholesterol (LDL-C)|Percent change in other lipid measures non high density lipoprotein cholesterol (nonHDL-C)|Safety using adverse event reports; vital signs|Percent change in Apolipoprotein B (ApoB)|Percent change in high sensitivity C-reactive protein (hsCRP)|Safety using adverse event reports; clinical laboratory results|Safety using adverse event reports; rates of muscle-related adverse,"Esperion Therapeutics|Medpace, Inc.",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,349,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1002-008,Sep-13,Oct-14,Nov-14,13-Sep-13,null,29-Mar-19,"Birmingham, Alabama, United States|Muscle Shoals, Alabama, United States|Chandler, Arizona, United States|Beverly Hills, California, United States|Chino, California, United States|Lincoln, California, United States|Long Beach, California, United States|Los Angeles, California, United States|Newport Beach, California, United States|Thousand Oaks, California, United States|Vista, California, United States|Denver, Colorado, United States|Hartford, Connecticut, United States|Atlantis, Florida, United States|Brandon, Florida, United States|Hialeah, Florida, United States|Jacksonville, Florida, United States|Oviedo, Florida, United States|Ponte Vedra, Florida, United States|Port Orange, Florida, United States|Saint Petersburg, Florida, United States|West Palm Beach, Florida, United States|Decatur, Georgia, United States|Marietta, Georgia, United States|Meridian, Idaho, United States|Evansville, Indiana, United States|Kansas City, Kansas, United States|Auburn, Maine, United States|Lincoln, Nebraska, United States|Clifton, New Jersey, United States|Albuquerque, New Mexico, United States|New Windsor, New York, United States|Rochester, New York, United States|Williamsville, New York, United States|Greensboro, North Carolina, United States|Raleigh, North Carolina, United States|Salisbury, North Carolina, United States|Wilmington, North Carolina, United States|Beachwood, Ohio, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Franklin, Ohio, United States|Lyndhurst, Ohio, United States|Marion, Ohio, United States|Willoughby Hills, Ohio, United States|Oklahoma City, Oklahoma, United States|Tulsa, Oklahoma, United States|Eugene, Oregon, United States|Mount Pleasant, South Carolina, United States|Kingsport, Tennessee, United States|Austin, Texas, United States|Dallas, Texas, United States|Dallas, Texas, United States|Fort Worth, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Round Rock, Texas, United States|Orem, Utah, United States|Salt Lake City, Utah, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Olympia, Washington, United States|Renton, Washington, United States|Seattle, Washington, United States|Spokane, Washington, United States",,https://ClinicalTrials.gov/show/NCT01941836
NCT01942291,Short-term Effect of Extended-release Niacin on Endothelial Function.,,Completed,No Results Available,Hypoalphalipoproteinemia,Drug: Niacin,The short-term effect of niacin on endothelial function.|Plasma C-reactive protein levels|HDL-C and HDL size,"University of Campinas, Brazil",All,20 Years to 60 Years   (Adult),Phase 4,18,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",Unicamp845/2011,Mar-12,Dec-12,Jun-13,13-Sep-13,null,13-Sep-13,"University of Campinas, Campinas, SP, Brazil",,https://ClinicalTrials.gov/show/NCT01942291
NCT01940263,Purified Anthocyanin and Nonalcoholic Fatty Liver Disease,,Completed,No Results Available,Nonalcoholic Fatty Liver Disease,Dietary Supplement: Anthocyanin|Dietary Supplement: Placebo,Biomarkers related to oxidative stress|Biomarkers related to inflammation,Shaoguan University|Sun Yat-sen University,All,"18 Years to 65 Years   (Adult, Older Adult)",Early Phase 1,63,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",SGU-02|81372994,Jun-13,Jan-14,Jun-14,12-Sep-13,null,1-Aug-14,"Shaoguan University, Shaoguan, Guangdong, China",,https://ClinicalTrials.gov/show/NCT01940263
NCT01935674,Treatment With Rosuvastatin Versus Switching PI (Protease Inhibitor) in Patients HIV With High Cholesterol Levels,SOS,Completed,No Results Available,HIV|Hypercholesterolaemia,Drug: Switch ritonavir-boosted PI|Drug: Continue Ritonavir-boosted PI+Rosuvastatin,"Percentage change from baseline in total cholesterol at 12 weeks.|Total cholesterol through week 12|Safety parameters (HIV viral load, clinical adverse events, serious adverse events, laboratory adverse events, modifications to antiretroviral therapy)|Quality of life (SF-12)|Fasting LDL cholesterol (estimated with Friedewald equation unless triglycerides >400mg/dL, in which case LDL-C would be measured directly), HDL cholesterol, total : HDL cholesterol ratio, LDL particles sizes, triglycerides|Fasting glucose and insulin.|Framingham cardiovascular risk score.|D:A:D 5-year estimated risk calculator.",Juan A. Arnaiz|Hospital Clinic of Barcelona,All,"18 Years and older   (Adult, Older Adult)",Phase 4,21,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SOS,Sep-13,Sep-14,Sep-14,5-Sep-13,null,8-Oct-14,"Hospital Clinic of Barcelona, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT01935674
NCT01934543,Effects of Polyunsaturated Fatty Acids on Intestinal Lipid Metabolism in Insulin-resistant Men,PUFA,Completed,No Results Available,Metabolic Syndrome,Other: Polyunsaturated fatty acids diet|Other: Saturated fatty acids diet,"Change in TRL apolipoprotein B48 (apoB-48) production rate.|Changes in duodenal expression of genes that regulate intestinal lipid absorption.|Changes in duodenal expression of genes that regulate intestinal lipid synthesis.|Change in synthesis of apoB-48 containing lipoproteins (Microsomal triglyceride transfer protein (MTP), apoB-48).",Laval University|Canadian Institutes of Health Research (CIHR),Male,18 Years to 60 Years   (Adult),Not Applicable,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention",INAF-PUFA,Jan-14,Sep-15,May-16,4-Sep-13,null,8-Sep-16,"Institute of Nutrition and Functional Foods (INAF), Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01934543
NCT01934608,The Effect of Synching Prescription Refills on Adherence,,Completed,No Results Available,Hypertension|Hypercholesterolemia|Diabetes|Medication Adherence,Behavioral: Refill synch,"Medication adherence to each of the chronic medications as measured by the proportion of days covered (PDC) measure|Secondary outcomes will be continuous gaps (e.g. 15, 30, or 60 days) in medication use.",University of Pennsylvania,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,691,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,HUM-001,Sep-13,Nov-15,Nov-15,4-Sep-13,null,22-Dec-15,"Humana, Inc, Louisville, Kentucky, United States",,https://ClinicalTrials.gov/show/NCT01934608
NCT01931241,Safety Study of Bile Acid to Treat Hypercholesteremia,,Unknown status,No Results Available,Hypercholesterolemia,Drug: AHRO-001,Number of participants with adverse events|Number of participants with adverse effects,AtheroNova Inc.,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,110,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AHRO-001-12-101,Jun-13,Jun-15,Jun-15,29-Aug-13,null,20-Nov-14,"City Hospital #15, Moscow, Russian Federation",,https://ClinicalTrials.gov/show/NCT01931241
NCT01928342,The Effects of Coenzyme A Combined With Statin on Serum Lipids in Patients With Hyperlipidemia,,Unknown status,No Results Available,Hyperlipoproteinemia,Drug: Coenzyme A|Drug: Placebo,serum triglyceride level|serum total cholesterol level|low-density lipoprotein cholesterol level|serum high-density lipoprotein cholesterol level,Zhejiang University,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,320,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2012MMXX2CoA008,Mar-12,Sep-13,Oct-13,23-Aug-13,null,23-Aug-13,"1st Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China",,https://ClinicalTrials.gov/show/NCT01928342
NCT01926782,Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1),,Completed,Has Results,Hypercholesterolemia,Drug: Placebo (for alirocumab)|Drug: Alirocumab|Drug: Statin,Percent Change From Baseline in Calculated LDL-C in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Calculated LDL-C in Participants Receiving Concomitant Statin Therapy - Intent-to-Treat (ITT Analysis)|Percent Change From Baseline in Calculated LDL-C at Week 24 in Participants Not Receiving Concomitant Statin Therapy - On-Treatment Analysis|Percent Change From Baseline in Calculated LDL-C at Week 24 in Participants Receiving Concomitant Statin Therapy - On-Treatment Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 in Participants Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 in Participants Not Receiving Concomitant Statin Therapy - On-treatment Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 in Participants Receiving Concomitant Statin Therapy - On-treatment Analysis|Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Apo B at Week 24 in Participants Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Apo B at Week 24 in Participants Not Receiving Concomitant Statin Therapy - On-Treatment Analysis|Percent Change From Baseline in Apo B at Week 24 in Participants Receiving Concomitant Statin Therapy - On-Treatment Analysis|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 in Participants Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 in Participants Not Receiving Concomitant Statin Therapy - On-Treatment Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 in Participants Receiving Concomitant Statin Therapy - On-Treatment Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Total-C at Week 24 in Participants Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Apo B at Week 12 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Apo B at Week 12 in Participants Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 in Participants Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 in Participants Receiving Concomitant Statin Therapy - ITT Analysis|Percentage of Very High CV Risk Participants Reaching Calculated LDL-C<70 mg/dL or Moderate or High CV Risk Participants Reaching Calculated LDL-C<100 mg/dL (Without Concomitant Statin Therapy) at Week 24 - ITT Analysis|Percentage of Very High Cardiovascular (CV) Risk Participants Reaching Calculated LDL-C <70 mg/dL or Moderate or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (With Concomitant Statin Therapy) at Week 24 - ITT Analysis|Percentage of Very High CV Risk Participants Reaching Calculated LDL-C<70 mg/dL (1.81 mmol/L) or Moderate or High CV Risk Participants Reaching Calculated LDL-C<100 mg/dL(2.59 mmol/L) (Without Concomitant Statin Therapy) at Week 24 - On-Treatment Analysis|Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL(1.81 mmol/L) or Moderate or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL(2.59 mmol/L) (With Concomitant Statin Therapy) at Week 24 - On-Treatment Analysis|Percentage of Participants (Without Concomitant Statin Therapy) Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants (With Concomitant Statin Therapy) Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants (Without Concomitant Statin Therapy) Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis|Percentage of Participants (With Concomitant Statin Therapy) Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Lipoprotein (a) in Participants Not Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein (a) in Participants Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein (a) in Participants Not Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis|Percent Change From Baseline in Lipoprotein (a) in Participants Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis|Percent Change From Baseline in HDL-C in Participants Not Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C in Participants Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C in Participants Not Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis|Percent Change From Baseline in HDL-C in Participants Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides in Participants Not Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides in Participants Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides in Participants Not Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides in Participants Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis|Percent Change From Baseline in Apo A1 in Participants Not Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis|Percent Change From Baseline in Apo A1 in Participants Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis|Percent Change From Baseline in Apo A1 in Participants Not Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis|Percent Change From Baseline in Apo A1 in Participants Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis,Regeneron Pharmaceuticals|Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,803,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R727-CL-1308,Sep-13,Sep-14,Apr-15,21-Aug-13,21-Mar-17,21-Mar-17,"Chandler, Arizona, United States|Goodyear, Arizona, United States|Carmichael, California, United States|Fresno, California, United States|West Hills, California, United States|Wildomar, California, United States|Colorado Springs, Colorado, United States|Golden, Colorado, United States|Boynton Beach, Florida, United States|Jacksonville, Florida, United States|Safety Harbor, Florida, United States|Atlanta, Georgia, United States|Boise, Idaho, United States|Meridian, Idaho, United States|Chicago, Illinois, United States|Gurnee, Illinois, United States|Evansville, Indiana, United States|Indianapolis, Indiana, United States|Iowa City, Iowa, United States|Kansas City, Kansas, United States|Louisville, Kentucky, United States|Monroe, Louisiana, United States|Auburn, Maine, United States|Methuen, Massachusetts, United States|Minneapolis, Minnesota, United States|St. Louis, Missouri, United States|Rochester, New York, United States|Farmville, North Carolina, United States|Greensboro, North Carolina, United States|Greenville, North Carolina, United States|Raleigh, North Carolina, United States|Wilson, North Carolina, United States|Cincinnati, Ohio, United States|Marion, Ohio, United States|Tulsa, Oklahoma, United States|Philadelphia, Pennsylvania, United States|Wyomissing, Pennsylvania, United States|Knoxville, Tennessee, United States|Dallas, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Orem, Utah, United States|Salt Lake City, Utah, United States|South Jordan, Utah, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Spokane, Washington, United States|Tacoma, Washington, United States|Kenosha, Wisconsin, United States|Sofia, Bulgaria|Varna, Bulgaria|Victoria, British Columbia, Canada|Oshawa, Ontario, Canada|Toronto, Ontario, Canada|Woodstock, Ontario, Canada|Montreal, Quebec, Canada|Trois-Rivieres, Quebec, Canada|Quebec, Canada|Budapest, Becsi ut, Hungary|Debrecen, HBM, Hungary|Nyiregyhaza, Sz-sz-b_m, Hungary|Ajka, VeszprÃ©m, Hungary|Nagykanizsa, Zala, Hungary|Zalaegerszeg, Zala, Hungary|Tel Hashomer, IL, Israel|Safed, ISR, Israel|Ofakim, South, Israel|Holon, Israel|Tel Hashomer, Israel|Skedsmokorset, Akershus, Norway|Oslo, Norway|Svidnik, Presov, Slovakia|Bratislava, SK, Slovakia|Bratislava, SR, Slovakia|Lucenec, Slovakia|PovaÅ¾skÃ¡ Bystrica, Slovakia|Worton Grange, Reading, Berkshire, United Kingdom|Edgbaston, Birmingham, United Kingdom|Llanishen, Cardiff, United Kingdom|Choley, Lancashire, United Kingdom|Waterloo, Liverpool, United Kingdom|Lloyd Street North, Manchester, United Kingdom|Glasgow, Scotland, United Kingdom",,https://ClinicalTrials.gov/show/NCT01926782
NCT01925716,Effects of The Effects of Dietary Oils on Fasting Lipoprotein Lipids,,Completed,No Results Available,Hypercholesterolemia,Other: Corn oil|Other: Olive oil,Low Density Lipoprotein cholesterol|total cholesterol,"ACH Food Companies, Inc.|PepsiCo Global R&D",All,"18 Years to 74 Years   (Adult, Older Adult)",Not Applicable,57,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",PRV-1303,Mar-13,Aug-13,Aug-13,20-Aug-13,null,21-Aug-13,,,https://ClinicalTrials.gov/show/NCT01925716
NCT01925365,Health Benefits of Whole Grain Oats in Population at Risk of Cardio-metabolic Disease,,Completed,No Results Available,Cardiovascular Disease|Hypercholesterolemia,Dietary Supplement: wholegrain cereals oats (WGO)|Dietary Supplement: Non wholegrain cereals,Changes in faecal bacteria population|Faecal short chain fatty acids|Changes in plasma lipids,"University of Reading|Jordans Cereals (Biggleswade, UK)",All,23 Years to 64 Years   (Adult),Not Applicable,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",UREC 09/12|University of Reading,May-09,Dec-09,May-10,19-Aug-13,null,19-Aug-13,"Department of Food and Nutritional Sciences, University of Reading, Reading, Berkshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT01925365
NCT01918709,Drug Interaction and Safety Between Valsartan and Rosuvastatin in Healthy Male Volunteers,,Completed,No Results Available,"Hypertension, Hyperlipidemia",Drug: Sequence 1 : Period 1(V) Period 2(R) Period 3(V+R)|Drug: Sequence 2 : Period 1(V+R) Period 2(V) Period 3(R)|Drug: Sequence 3 : Period 1(R) Period 2(V+R) Period 3(V)|Drug: Sequence 4 : Period 1(V+R) Period 2(R) Period 3(V)|Drug: Sequence 5 : Period 1(R) Period 2(V) Period 3(V+R)|Drug: Sequence 6 : Period 1(V) Period 2(V+R) Period 3(R),PK parameters of valsartan and rosuvastatin,LG Life Sciences,Male,20 Years to 45 Years   (Adult),Phase 1,30,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LG-VRCL001,Sep-11,Nov-11,Nov-11,8-Aug-13,null,8-Aug-13,"Clinical Trial Center, Samsung Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01918709
NCT01918332,Efficacy and Safety of Valsartan 160mg and Rosuvastatin 20mg in Patients With Hypertension and Hyperlipidemia,,Completed,Has Results,"Hypertension,|Hyperlipidemia",Drug: Valsartan 160mg|Drug: Rosuvastatin 20mg|Drug: Valsartan 160mg placebo|Drug: Rosuvastatin 20mg placebo,sitDBP Changes at Week 8 From Baseline|LDL-C Percentage Changes at Week 8 From Baseline,LG Life Sciences,All,"20 Years to 80 Years   (Adult, Older Adult)",Phase 3,168,Industry,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",LG-VRCL002,Apr-12,Mar-13,Mar-13,7-Aug-13,15-Dec-14,15-Dec-14,"Yonsei University Health System Severance Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01918332
NCT01918358,Safety and Pharmacokinetics Between Fixed-dose Combination VR 160/20 mg and Co-administration of Diovan® (Valsartan) Film-coated Tablet 160 mg and Crestor® (Rosuvastatin) 20 mg,,Completed,No Results Available,Hypertension|Hyperlipidemia,"Drug: Sequence 1 : Period 1 (VR 160/20 mg-1), Period 2(VR 160/20 mg-2), Period (V+R)|Drug: Sequence 2 : Period 1 (VR 160/20 mg-2), Period 2 (V+R), Period 3 (VR 160/20 mg-1)|Drug: Sequence 3 : Period 1 (V+R), Period 2 (VR 160/20 mg-2), Period 3 (VR 160/20 mg-1)|Drug: Sequence 4 : Period 1 (VR 160/20 mg-1), Period 2 (V+R), Period 3 (VR 160/20 mg-2 )|Drug: Sequence 5 : Period 1 (VR 160/20 mg-2), Period 2 (VR 160/20 mg-1), Period 3 (V+R )|Drug: Sequence 6 : Period 1 (V+R), Period 2 (VR 160/20 mg-1), Period 3 (VR 160/20 mg-2)",Cmax of valsartan and rosuvastatin|AUC last of valsartan and rosuvastatin,LG Life Sciences,Male,20 Years to 45 Years   (Adult),Phase 1,60,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LG-VRCL005,Dec-12,Jan-13,Jan-13,7-Aug-13,null,7-Aug-13,"Samsung Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01918358
NCT01914432,Efficacy and Safety Study of YH16410 Versus Rosuvastatin and Telmisartan Monotherapies in Patients With Hypertension and Hyperlipidemia,,Completed,No Results Available,Hyperlipidemia|Hypertension,Drug: YH16410|Drug: Rosuvastatin|Drug: Telmisartan|Drug: YH16410 placebo|Drug: Rosuvastatin placebo|Drug: Telmisartan placebo,"Change in Diastolic Blood Pressure, Change in LDL Cholesterol",Yuhan Corporation,All,"19 Years and older   (Adult, Older Adult)",Phase 3,210,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",YH16410-301,Nov-13,Jun-14,Jun-14,2-Aug-13,null,8-Jul-14,"Seoul National University Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01914432
NCT01912560,Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia,PATHWAYS I,Completed,No Results Available,Dyslipidemia|Hypercholesterolemia|Hypertriglyceridemia,Drug: CAT-2003|Drug: Placebo|Drug: Statin,Absolute and percent change from baseline in plasma triglycerides in patients with hypertriglyceridemia|Absolute and percent change from baseline in plasma low density lipoprotein-cholesterol in patients with hypercholesterolemia|Absolute and percent change from baseline in plasma non-high-density lipoprotein cholesterol|Pharmacodynamic effects of CAT-2003 on other lipid biomarkers in patients with hyperlipidemia|Frequency of adverse events,Catabasis Pharmaceuticals,All,"18 Years to 69 Years   (Adult, Older Adult)",Phase 2,99,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CAT-2003-201,Jul-13,Dec-13,Dec-13,31-Jul-13,null,28-Jul-16,"Muscle Shoals, Alabama, United States|Los Angeles, California, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Winter Park, Florida, United States|Kansas City, Kansas, United States|Louisville, Kentucky, United States|Auburn, Maine, United States|Raleigh, North Carolina, United States|Raleigh, North Carolina, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Sainte-Foy, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01912560
NCT01911390,Effect of Rice Bran and Cooked Navy Beans on Cholesterol Levels in Healthy Children,,Completed,Has Results,Hyperlipidemias,Dietary Supplement: Bean powder|Dietary Supplement: Rice bran|Dietary Supplement: Control arm|Dietary Supplement: Bean powder and rice bran,Total Cholesterol|Palatability,Poudre Valley Health System|Colorado State University,All,8 Years to 13 Years   (Child),Not Applicable,41,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Version 06/18/2013,Jul-13,Oct-16,Nov-16,30-Jul-13,5-Apr-17,15-May-17,"Colorado State University, Fort Collins, Colorado, United States|Medical Center of the Rockies, Loveland, Colorado, United States",,https://ClinicalTrials.gov/show/NCT01911390
NCT01908374,Bioavailability of EPA and DHA From Two Dietary Supplements,,Unknown status,No Results Available,Hypertriglyceridemia,Dietary Supplement: DHA-rich fish oil versus Phospholipid-rich fish oil,Area under the curve for plasma phosphatidylcholine omega-3 fatty acids|Maximum concentration and Time to maximum concentration for plasma omega-3 phosphatidylcholine fatty acids|Area under the curve for plasma phosphatidylcholine omega-3 fatty acids Part 2|Plasma sphingomyelin and total plasma phosphatidylcholine|Fasting plasma lipoprotein lipids|Gastrointestinal (GI) Tolerability Questionnaire|Product Acceptability Questionnaire|Adverse Events (AE),Arctic Nutrition AS|BioFortis|University of British Columbia,All,18 Years to 59 Years   (Adult),Not Applicable,32,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PRV-1302,Jul-13,Dec-13,Dec-13,25-Jul-13,null,25-Jul-13,"Biofortis, Addison, Illinois, United States",,https://ClinicalTrials.gov/show/NCT01908374
NCT01894217,Statin Therapy to Improve Medication Adherence,,Completed,No Results Available,Hypercholesterolemia|HMG COA Reductase Inhibitor Adverse Reaction,Genetic: Genetic testing and reporting for SLCO1B1*5 allele,"Change in Beliefs about Medicines|Change in Medication adherence|Percentage of patients who meets their National Cholesterol Education Program (NCEP) low-density lipoprotein cholesterol (LDLc)goals|Number of new statin prescriptions written|Patient reported medication utilization, as a surrogate for medication adherence",Duke University,All,"18 Years and older   (Adult, Older Adult)",Phase 1,63,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,Pro00029836,May-11,Dec-12,Apr-14,10-Jul-13,null,8-Jan-15,"Duke Center for Living, Durham, North Carolina, United States|Duke Primary Care Clinic at Pickett Road, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01894217
NCT01894230,Genetically Guided Statin Therapy,,Completed,Has Results,Hypercholesterolemia|Hydroxy-methylglutaryl-coenzyme A (HMG Co-A) Reductase Inhibitors Adverse Reaction,"Genetic: SLCO1B1*5 allele testing, results reported at randomization|Genetic: SLCO1B1*5 allele testing, results reported at end of study|Genetic: Genetic testing for SLCO1B1*5 allele","Morisky Medication Adherence Scale (MMAS) Score|Low Density Lipoprotein Cholesterol (LDLc) at Baseline, Month 3 and Month 8|Medication Possession Ratio (MPR) From Baseline to Last Patient Follow-up|Number of Participants Reporting New Statin Prescriptions|Brief Pain Inventory (BPI) Score - Pain Severity at Month 3 and Month 8|Brief Pain Inventory (BPI) Score - Pain Interference at Month 3 and Month 8|Change in Short Form -12 Item (SF-12) Health Survey - Physical Component (PC)|Change in Short Form -12 Item (SF-12) Health Survey - Mental Component (MC)|Physical Activity Scale Score|Beliefs About Medications (BMQ) Score at Baseline, Month 3 and Month 8",Duke University|David Grant U.S. Air Force Medical Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,167,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,Pro00044989|Pro00045542,Jul-13,30-Apr-16,30-Apr-16,10-Jul-13,23-Jun-17,23-Jun-17,"David Grant US Air Force Medical Center, Travis Air Force Base, California, United States|Duke University, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01894230
NCT01893515,The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects,,Completed,No Results Available,Dyslipidemia,Drug: PRC-4016|Drug: Placebo,Percent change in triglycerides from baseline to week 12|Change in HDL-C from baseline to Week 12|Change in non-HDL-C from baseline to Week 12|Change in LDL-C from baseline to Week 12|Change in VLDL-C from baseline to Week 12|Change in total cholesterol from baseline to Week 12|Change in ApoA1 from baseline to Week 12|Change in Apo B from baseline to Week 12|Change in insulin from baseline to Week 12|Change in fasting plasma glucose from baseline to Week 12|Change in HbA1c from baseline to Week 12|Change in insulin resistance (HOMA) from baseline to Week 12|Change in Lp-PLA2 from baseline to Week 12|Change in hsCRP from baseline to Week 12|Change in red blood cell content of EPA and DHA from baseline to Week 12;,Pronova BioPharma,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 2,87,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CTN 4016 13201,Jul-13,Jul-14,Jul-14,9-Jul-13,null,30-Oct-15,"Medical Affiliated Research Center, Inc., Huntsville, Alabama, United States|Terence Hart, MD, Muscle Shoals, Alabama, United States|Central Phoenix Medical Clinic, Phoenix, Arizona, United States|Pacific Oaks Medical Group, Beverly Hills, California, United States|National Research Institute - Wilshire, Los Angeles, California, United States|National Research Institute - East 118, Los Angeles, California, United States|Research Across America - Santa Ana, Santa Ana, California, United States|Encompass Clinical Research, Spring Valley, California, United States|Colorado Springs Health Partners, Colorado Springs, Colorado, United States|Clinical Research of South Florida, Coral Gables, Florida, United States|Jacksonville Impotence Treatment Center, Jacksonville, Florida, United States|Compass Research East, LLC, Oviedo, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Meridien Research, St. Petersburg, Florida, United States|Meridien Research- Tampa, Tampa, Florida, United States|Evanston Premier Healthcare Research LLC, Evanston, Illinois, United States|Medisphere Medical Research Center, Evansville, Indiana, United States|Heartland Research Assoc., LLC, Newton, Kansas, United States|Louisville Metabolic and Atherosclerosis Research Center (L-MARC), Louisville, Kentucky, United States|Troy Internal Medicine, P.C., Troy, Michigan, United States|Radiant Research - Edina, Edina, Minnesota, United States|Mercury Street Medical, Butte, Montana, United States|Peters Medical Research, High Point, North Carolina, United States|PMG Research of Raleigh, LLC, Raleigh, North Carolina, United States|PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States|PMG Research of Winston-Salem, LLC, Winston-Salem, North Carolina, United States|Sterling Research Group, Ltd. - Auburn, Cincinnati, Ohio, United States|Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio, United States|Columbus Clinical Research, Inc., Columbus, Ohio, United States|PSB Research/P. S. Bains, M.S., D.O., Marion, Ohio, United States|RAS Health Ltd, Marion, Ohio, United States|Lynn Health Science Institute - Oklahoma City, Oklahoma City, Oklahoma, United States|Willamette Valley Clinical Studies, Eugene, Oregon, United States|Green and Seidner Family Practice Associates, Lansdale, Pennsylvania, United States|UnitedResearch - Orangeburg, LLC, Orangeburg, South Carolina, United States|Padre Coast Clinical Research, Corpus Christi, Texas, United States|Advanced Clinical Research, West Jordan, Utah, United States|National Clinical Research - Norfolk, Inc., Norfolk, Virginia, United States|National Clinical Research - Richmond, Inc., Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01893515
NCT01890889,Study of Changes in Total Cholesterol Levels as a Function of Consuming a Supplement Designed to Improve Cardiovascular Health,AdBiotech,Unknown status,No Results Available,Cholesterol|Hyperlipidemia|Hypercholesteremia,Dietary Supplement: Ad-Chol-Pre|Dietary Supplement: Half-dose Ad-Chol-Pre|Other: Defatted egg yolk without the active ingredient of the other two interventions,Change from baseline in Total Cholesterol and LDL levels at 30 days|Change from baseline in Total Cholesterol and LDL levels at 60 days|Change from mid-point in Total Cholesterol and LDL levels at 60 days|Blood Chemistry Measurements|Self-reported Quality of Life|Number of participants with adverse effects,"Integrative Health Technologies, Inc.",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,150,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)",65,Jul-13,Nov-13,Dec-13,2-Jul-13,null,25-Nov-13,"Integrative Health Technologies, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT01890889
NCT01890967,A Study of LY3015014 in Participants With High Cholesterol,,Completed,Has Results,Hypercholesterolemia,Drug: LY3015014|Drug: Placebo|Drug: Statin|Drug: Ezetimibe,"Percentage Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C)|Percentage Change From Baseline in LDL-C, Total Cholesterol (TC), High-Density Lipoprotein Cholesterol (HDL-C), Triglycerides (TG), Non-HDL-C|Percentage Change From Baseline in Apolipoprotein A1 (Apo A1), Apolipoprotein B (Apo B)|Percentage Change From Baseline in Lipoprotein(a) [Lp(a)]|Change From Baseline in High Sensitivity C-Reactive Protein (hsCRP)|Number of Participants Who Develop Treatment Emergent Anti-LY3015014 Antibodies|Percentage Change From Baseline in Total Proprotein Convertase Subtilisin/Kexin Type 9 Antibody (PCSK9) Levels|Percentage Change From Baseline in Free Proprotein Convertase Subtilisin/Kexin Type 9 Antibody (PCSK9) Levels|Pharmacokinetics (PK): Area Under the Concentration-Time Curve at Steady-State (AUC,ss) for LY3015014|Number of Participants With an Injection Site Reaction",Eli Lilly and Company,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,527,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",14853|I5S-MC-EFJE,Jun-13,Apr-14,Jun-14,2-Jul-13,21-Jun-17,17-Aug-17,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Encino, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lancaster, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Spring Valley, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aurora, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Safety Harbor, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampa, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Iowa City, Iowa, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Louisville, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bossier City, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charlotte, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Raleigh, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cincinnati, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toledo, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Knoxville, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kamloops, British Columbia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kelowna, British Columbia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brampton, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toronto, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gatineau, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montreal, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St Marc Des Carrieres, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cesky Krumlov, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hodonin, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Prague, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Svitavy, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aalborg, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Copenhagen, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Esbjerg, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hellerup, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hvidovre, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amsterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Breda, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Goes, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Groningen, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Maastricht, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nijmegen, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rotterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Utrecht, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bialystok, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gdansk, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Krakow, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lodz, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lublin, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ponce, Puerto Rico",,https://ClinicalTrials.gov/show/NCT01890967
NCT01890226,A Mobile Personal Health Record for Behavioral Health Homes,mPHR,Completed,No Results Available,Hypertension|Hyperlipidemia|Diabetes,Behavioral: Mobile Personal Health Record App.,Quality of General Medical Care,Emory University|National Institute of Mental Health (NIMH),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,300,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,IRB00067447|1R01MH100467-01,Nov-14,Nov-18,Jan-19,1-Jul-13,null,17-Jan-19,"Viewpoint Health & Oakhurst Medical Center, Conyers, Georgia, United States",,https://ClinicalTrials.gov/show/NCT01890226
NCT01886482,Effect of High Protein Diet on Cardiovascular Diseases Risk Factors Among Overweight and Obese Children,,Completed,No Results Available,Body Mass Index Quantitative Trait Locus 7 Disorder|Tangier Disease,Other: nutrition intervention,the amount of weight reduction in two dietary groups|LDL (mg/ml)|HDL (mg/ml)|fasting blood glucose|total cholesterol (mg/dl)|blood pressure,Isfahan University of Medical Sciences,All,6 Years to 11 Years   (Child),Phase 3,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research,high protein diet in childhood,Sep-11,Dec-11,Sep-12,26-Jun-13,null,26-Jun-13,"Isfahan University of Medical Sciences, Isfahan, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT01886482
NCT01886495,Effect of High Protein Diet on Adiponectin and Inflammation Among Overweight and Obese Children,,Completed,No Results Available,Body Mass Index Quantitative Trait Locus 5 Disorder|Tangier Disease,Other: nutrition intervention,adiponectin (mcg/ml)|interlukine 6 (mcg/ml)|tumor necrosis factor alpha (ng/ml)|C reactive protein (mcg/ml)|fibrinogen (mcg/ml),Isfahan University of Medical Sciences,All,6 Years to 11 Years   (Child),Phase 3,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research,high protein diet in children,Sep-11,Dec-11,Sep-12,26-Jun-13,null,26-Jun-13,"Isfahan University of Medical Sciences Leila Azadbakht, Phd, Isfahan, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT01886495
NCT01886326,Eating Peanuts for Health,,Completed,No Results Available,Obesity|Overweight|Hyperlipidemia,Other: Consumption of 42 grams of peanuts daily,Change in Weight|Change in Blood Lipids|Change in Blood Pressure|Change in Hedonics of peanut consumption|Change in Body Composition|Change in Fasting Blood Glucose|Change in Cortisol|Change in Insulin|Change in Pulse|Personality Questionnaires|Flavor attribute liking measures|Compliance|Appetitive Ratings|Consumption Parameters,Purdue University|United States Agency for International Development (USAID),All,18 Years to 50 Years   (Adult),Not Applicable,196,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,912008773,Feb-10,May-12,May-12,25-Jun-13,null,25-Jun-13,"Purdue University, West Lafayette, Indiana, United States",,https://ClinicalTrials.gov/show/NCT01886326
NCT01884714,Exploring the Molecular Basis to Healthy Obesity: The Diabetes Risk Assessment Study,DRA,Completed,No Results Available,Obesity|Type-2 Diabetes|Metabolic Syndrome|Dyslipidemia,Other: High fat/high calorie meal,Measure circulating inflammatory markers and fatty acids associated with obesity and diabetes.|Analyze adipose tissue gene expression in obese and diabetic subjects|Measure standard clinical and anthropometric markers associated with obesity and diabetes.|Examine global serum metabolite profiles associated with obesity and diabetes.|Measure standard clinical and anthropometric parameters in obese and diabetic participants following a standardized meal.,University of Guelph|Public Health Agency of Canada (PHAC),All,"35 Years to 70 Years   (Adult, Older Adult)",Not Applicable,80,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,10AP033,Jul-11,Dec-13,Dec-13,24-Jun-13,null,11-Jul-16,"University of Guelph, Human Nutraceutical Research Unit, Guelph, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01884714
NCT01883401,Chronic Effects of Freeze-Dried Strawberry Beverage on Cardiovascular Risk Factors,,Completed,No Results Available,Dyslipidemia|Obesity,Dietary Supplement: Freeze-dried strawberries|Dietary Supplement: Dietary fiber,Lipids (mg/dL)|Adhesion molecules (ng/mL),Oklahoma State University|University of Oklahoma|California Strawberry Commission,All,"19 Years to 72 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,HE1015,Apr-10,Mar-13,Mar-13,21-Jun-13,null,21-Jun-13,"Oklahoma State University, Stillwater, Oklahoma, United States",,https://ClinicalTrials.gov/show/NCT01883401
NCT01884246,Improving Heart Health in Appalachia,HeartHealth,Completed,No Results Available,Obesity|Hypertension|Hyperlipidemia|Depression,Behavioral: Self-care CVD risk reduction|Other: Referral to primary care provider for CVD risk management,cardiovascular risk factor selected by patient|all CVD risk factors of each patient,Debra Moser|University of Kentucky Center for Excellence in Rural Health-Hazard|University of Kentucky,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,330,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",PCORI 3048110484,1-Aug-13,31-Dec-16,31-Dec-16,21-Jun-13,null,10-Mar-17,"University of Kentucky, Lexington, Kentucky, United States",,https://ClinicalTrials.gov/show/NCT01884246
NCT01882283,Effects of Black Tea Intake on Serum Lipids,,Completed,No Results Available,Hypercholesterolemia,Dietary Supplement: Tea Treatment Group|Dietary Supplement: Placebo,Serum lipid levels,University of Minnesota - Clinical and Translational Science Institute|National Center for Research Resources (NCRR),All,"45 Years to 65 Years   (Adult, Older Adult)",Not Applicable,57,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",10205345-A2|M01RR000400,Apr-02,Apr-04,Apr-04,20-Jun-13,null,7-May-19,"General Clinical Research Center, University of Minnesota, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT01882283
NCT01882517,Lipid-lowering Effect of Plant Stanol Yogurt,,Completed,No Results Available,Hypercholesterolemia|Hyperlipidemias|Dyslipidemias,Dietary Supplement: Yogurt that contains plant stanol esters|Dietary Supplement: Placebo yogurt,Change in serum LDL cholesterol,Raisio Group,All,"20 Years to 70 Years   (Adult, Older Adult)",Not Applicable,70,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PCL_2010_024,Mar-11,Jan-12,Jan-12,20-Jun-13,null,20-Jun-13,"Hacettepe University, Ankara, Turkey",,https://ClinicalTrials.gov/show/NCT01882517
NCT01879800,One-Day Acceptance and Commitment Training Intervention in Primary Care Patients,,Completed,Has Results,Mood Disorders|Hypertension|Diabetes|Hypercholesterolemia,Behavioral: Acceptance and Commitment Therapy plus Illness Management,Mean Change in Participants World Health Organization Quality of Life Measure- Physical Score: Change From Baseline to 3 and 6 Month Follow-up.|Mean Change in Hamilton Depression Rating Scale (HAM-D) From Baseline to 3 and 6 Month Follow-up|Mean Change in Hamilton Anxiety Rating Scale (HAM-A) From Baseline to 3 and 6 Month Follow-up,Lilian N. Dindo|University of Iowa,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,44,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,201207748,Aug-12,Dec-13,Dec-13,18-Jun-13,28-Aug-15,25-May-17,"University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States",,https://ClinicalTrials.gov/show/NCT01879800
NCT01878474,"Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 With Single, Escalating Doses in Healthy Subjects",,Completed,No Results Available,Dyslipidemia,Drug: TA-8995|Drug: Placebo,"Number of participants with adverse events|Laboratory tests (haematology, biochemistry and urinalysis)|Vital signs (supine systolic and diastolic blood pressure, heart rate and body temperature)|Peak concentration (ng/mL) of TA-8995|Time of peak concentration (hr) of TA-8995|Area under the concentration-time curve (mg/L・hr) up to 24 h (AUC0-24), 72 h (AUC0-72), 168 h (AUC0-168), 336 h (AUC0-336) and infinity (AUC0-∞) of TA-8995|Plasma Cholesterol Ester Transfer Protein (CETP) activity (%) and concentration (mg/mL)",Mitsubishi Tanabe Pharma Corporation,All,18 Years to 55 Years   (Adult),Phase 1,96,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",TA-8995-01,Mar-08,Jun-09,Jun-09,17-Jun-13,null,17-Jun-13,"Hammersmith Medicines Research (HMR), London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01878474
NCT01879020,"Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 After Multiple Doses in Healthy Subjects",,Completed,No Results Available,Dyslipidemia,Drug: TA-8995|Drug: Placebo,"Number of participants with adverse events|Laboratory tests (haematology, biochemistry and urinalysis)|Vital signs (supine systolic and diastolic blood pressure, heart rate and body temperature)|Area under the plasma concentration (AUC) versus time curve over the final dosing interval (AUC0-τ, Steady-state)|The last time point 't' with a concentration Ct ≥ Lower limit quantification (LLQ) (AUC0-t, Steady-state)|Cholesterol ester transfer protein (CETP) activity (%)|CETP concentration (mg/mL)",Mitsubishi Tanabe Pharma Corporation,Male,18 Years to 55 Years   (Adult),Phase 1,61,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",TA-8995-E02,Aug-09,Jun-10,Jun-10,17-Jun-13,null,17-Jun-13,"Momentum Pharma Services GmbH, Hamburg, Germany",,https://ClinicalTrials.gov/show/NCT01879020
NCT01879319,Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen,,Completed,Has Results,Primary Hypercholesterolemia|Mixed Dyslipidemia,Biological: Evolocumab AMD|Biological: Evolocumab AI/pen,Percentage of Participants With Full Administration of Evolocumab at Both Weeks 4 and 8|Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12,Amgen,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,164,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20120356,Jul-13,Dec-13,Dec-13,17-Jun-13,23-Dec-15,23-Dec-15,"Research Site, Phoenix, Arizona, United States|Research Site, Encino, California, United States|Research Site, Thousand Oaks, California, United States|Research Site, Tustin, California, United States|Research Site, Ventura, California, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Saint Augustine, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Gainesville, Georgia, United States|Research Site, Lexington, Kentucky, United States|Research Site, Lewiston, Maine, United States|Research Site, Ayer, Massachusetts, United States|Research Site, Manlius, New York, United States|Research Site, Cadiz, Ohio, United States|Research Site, Marion, Ohio, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Lansdale, Pennsylvania, United States|Research Site, Jackson, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Burnaby, British Columbia, Canada|Research Site, London, Ontario, Canada|Research Site, Sarnia, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Pointe-Claire, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01879319
NCT01878227,Comparison of Coenzyme A and Fenofibrate for Safety and Efficacy On Patients With Hyperlipidemia,,Completed,No Results Available,Hyperlipoproteinemia,Drug: Coenzyme A|Drug: Fenofibrate 200mg,serum triglyceride level|serum total cholesterol level|low-density lipoprotein cholesterol level|serum high-density lipoprotein cholesterol level,Zhejiang University,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,420,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2010MMXX2CoA007,Jul-10,May-11,Jun-11,14-Jun-13,null,14-Jun-13,"1st Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China",,https://ClinicalTrials.gov/show/NCT01878227
NCT01865370,Efficacy and Safety of Kochujang Pills on Blood Lipids Profiles in Hyperlipidemia Subjects,,Completed,No Results Available,Hyperlipidemia,Dietary Supplement: Kochujang Pills|Dietary Supplement: Placebo,Changes in Total Cholesterol|Changes in LDL-C (LDL Low Density Lipoprotein-cholesterol)|Changes in Triglyceride|Changes in HDL-C(High Density Lipoprotein-cholesterol),Chonbuk National University Hospital,All,19 Years to 55 Years   (Adult),Phase 2|Phase 3,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",ISFSP-HL-KOCHUJANG,Nov-11,Feb-12,Apr-12,30-May-13,null,30-May-13,"Clinical Trial Center for Functional Foods; Chonbuk National University Hospital, Jeonju, Jeollabuk-do, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01865370
NCT01864239,The Medicines Advice Service Evaluation,,Completed,No Results Available,Type 2 Diabetes|Hyperlipidemias,Other: Medicines Advice Service,Self-reported medication adherence|Prescription refill adherence|Self-reported medicine-related problems and concerns|Beliefs about Medicines|HbA1c|Serum Cholesterol Levels,"University College, London|Pharmacy2U",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,677,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,12/0326,Nov-12,Sep-14,Sep-14,29-May-13,null,27-May-15,"UCL School of Pharmacy, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01864239
NCT01863225,Characterization of Multi-dose RVX000222 in Combination With Statin Treatment in Dyslipidemia,,Terminated,No Results Available,Dyslipidemia|Coronary Artery Disease,Drug: RVX000222|Drug: Rosuvastatin|Drug: Atorvastatin,Characterization of the pharmacokinetics of RVX000222 capsule formulation in combination with either atorvastatin or rosuvastatin in patients with dyslipidemia.|Characterization of the pharmacokinetics of atorvastatin and rosuvastatin when either is administered in combination with RVX000222 capsule formulation to patients with dyslipidemia.|Evaluation of safety and tolerability of RVX000222 capsule formulation administered in combination with stable doses of either atorvastatin or rosuvastatin in patients with dyslipidemia.,Resverlogix Corp|South Australian Health and Medical Research Institute,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,13,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,RVX222-CS-009,May-13,Jun-13,Jun-13,27-May-13,null,12-May-15,"Royal Adelaide Hospital / CMAX, Adelaide, South Australia, Australia",,https://ClinicalTrials.gov/show/NCT01863225
NCT01860729,A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022),,Completed,No Results Available,Hypercholesterolemia,Drug: Anacetrapib|Drug: Placebo,"Percent Change from Baseline in LDL-C (beta-quantification [BQ] method)|Percent Change from Baseline in HDL-C|Number of Participants with Alanine Transaminase (ALT) or Aspartate Aminotransferase (AST) Consecutive Elevations ≥3x Upper Limit of Normal (ULN)|Number of Participants with Creatine Phosphokinase Elevations ≥10xULN with or without Muscle Symptoms|Number of Participants with Sodium, Chloride, or Bicarbonate Elevations >ULN or Potassium Levels <Lower Limit of Normal (LLN)|Number of Participants with Pre-specified Adjudicated Cardiovascular Serious Adverse Events or Death from Any Cause|Number of Participants with Significant Increase in Blood Pressure|Percent Change from Baseline in non-HDL-C|Percent Change from Baseline in Apolipoprotein B (Apo-B)|Percent Change from Baseline in Apolipoprotein A-I (Apo-A-I)|Percent Change from Baseline in Lipoprotein(a) (lp[a])|Percent Change from Baseline in HDL-C Among Participants with Low HDL-C at LDL-C Goal",Merck Sharp & Dohme Corp.,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,589,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0859-022,May-13,May-15,Aug-15,23-May-13,null,27-Aug-15,,,https://ClinicalTrials.gov/show/NCT01860729
NCT01859455,"Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in Hypercholesterolemic Patients Treated With Statins",,Completed,No Results Available,Hypercholesterolemia|LDL Cholesterol,Drug: LGT209 50 mg|Drug: LGT209 300 mg|Drug: Placebo|Drug: Statins (atorvastatin or simvastatin),"Number of subjects (patients and healthy volunteers) with adverse events, serious adverse events and death|Plasma concentrations of LGT209 following subcutaneous administration|Change from baseline in proprotein convertase subtilisin/kexin type 9 (PCSK9) concentration|Change from baseline in low density lipoprotein-cholesterol (LDL-C) concentration|Plasma concentrations of atorvastatin in patients|Plasma concentrations of simvastatin in patients|Serum concentrations of PCSK9",Novartis Pharmaceuticals|Novartis,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,25,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CLGT209X2105,Jul-11,Jul-12,Jul-12,22-May-13,null,31-Mar-17,"Novartis Investigative Site, Fort Myers, Florida, United States|Novartis Investigative Site, Miramar, Florida, United States",,https://ClinicalTrials.gov/show/NCT01859455
NCT01858376,Effect Of Capros Supplementation On Cardiovascular Disease Risk Factors In Humans,Capros,Completed,Has Results,Hyperlipidemia,Dietary Supplement: Capros dietary supplement,Change From Baseline in Lipid Profile|Changes in High-Sensitivity C-reactive Protein|C-reactive Protein|Changes From Baseline in Platelet Aggregometry,"Chandan K Sen|Natreon, Inc.|Ohio State University",All,"21 Years to 70 Years   (Adult, Older Adult)",Not Applicable,24,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,2012H0381,Mar-13,Jan-15,Jan-15,21-May-13,9-Nov-15,27-Jul-18,"The Ohio State University, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01858376
NCT01856179,Supplementation of Land-based Stearidonic Acid (SDA)-Rich Oils in Humans,,Completed,No Results Available,Hypercholesterolemia|Overweight,Dietary Supplement: Echium oil,"eicosapentaenic acid|Lipid mediators derived from AA, EPA and DGLA such as HETE species (5-HETE; 8-HETE, etc.)",University of Jena|German Research Foundation,All,"20 Years to 70 Years   (Adult, Older Adult)",Early Phase 1,78,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",LSEP H42-KK,Mar-11,Aug-11,Apr-12,17-May-13,null,17-May-13,"Friedrich Schiller University of Jena, Jena, Thuringia, Germany",,https://ClinicalTrials.gov/show/NCT01856179
NCT01854918,Open Label Study of Long Term Evaluation Against LDL-C Trial-2,OSLER-2,Completed,No Results Available,Hyperlipidemia and Mixed Dyslipidemia,Biological: evolocumab (AMG 145) and standard of care|Other: Standard of care,Subject incidence of adverse events|Percent change from baseline in LDL-C at weeks 48 and 104|Change from baseline in LDL-C at weeks 48 and 104,Amgen,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 3,3681,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20120138,23-Apr-13,18-May-18,18-May-18,16-May-13,null,2-Nov-18,"Research Site, Birmingham, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Chandler, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Beverly Hills, California, United States|Research Site, Carmichael, California, United States|Research Site, Encinitas, California, United States|Research Site, Huntington Beach, California, United States|Research Site, Los Angeles, California, United States|Research Site, Mission Viejo, California, United States|Research Site, Newport Beach, California, United States|Research Site, San Diego, California, United States|Research Site, Santa Ana, California, United States|Research Site, Santa Rosa, California, United States|Research Site, Spring Valley, California, United States|Research Site, Thousand Oaks, California, United States|Research Site, Torrance, California, United States|Research Site, Tustin, California, United States|Research Site, Ventura, California, United States|Research Site, Littleton, Colorado, United States|Research Site, Daytona Beach, Florida, United States|Research Site, DeLand, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Melbourne, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Ponte Vedra, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Sanford, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Gainesville, Georgia, United States|Research Site, Savannah, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Sterling, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Munster, Indiana, United States|Research Site, Iowa City, Iowa, United States|Research Site, Kansas City, Kansas, United States|Research Site, Lexington, Kentucky, United States|Research Site, Louisville, Kentucky, United States|Research Site, Monroe, Louisiana, United States|Research Site, Auburn, Maine, United States|Research Site, Bangor, Maine, United States|Research Site, Portland, Maine, United States|Research Site, Bethesda, Maryland, United States|Research Site, Columbia, Maryland, United States|Research Site, Towson, Maryland, United States|Research Site, Ayer, Massachusetts, United States|Research Site, Quincy, Massachusetts, United States|Research Site, Ypsilanti, Michigan, United States|Research Site, Edina, Minnesota, United States|Research Site, Olive Branch, Mississippi, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Henderson, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Endwell, New York, United States|Research Site, Manlius, New York, United States|Research Site, New Windsor, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Williamsville, New York, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Akron, Ohio, United States|Research Site, Cadiz, Ohio, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Mansfield, Ohio, United States|Research Site, Marion, Ohio, United States|Research Site, Sandusky, Ohio, United States|Research Site, Norman, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Hillsboro, Oregon, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Lansdale, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, York, Pennsylvania, United States|Research Site, Anderson, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Mount Pleasant, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Jackson, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Norfolk, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Suffolk, Virginia, United States|Research Site, Renton, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, Camperdown, New South Wales, Australia|Research Site, Maroubra, New South Wales, Australia|Research Site, Sydney, New South Wales, Australia|Research Site, Sydney, New South Wales, Australia|Research Site, Auchenflower, Queensland, Australia|Research Site, Carina Heights, Queensland, Australia|Research Site, Sherwood, Queensland, Australia|Research Site, Woolloongabba, Queensland, Australia|Research Site, Ashford, South Australia, Australia|Research Site, Fullarton, South Australia, Australia|Research Site, Heidelberg Heights, Victoria, Australia|Research Site, Melbourne, Victoria, Australia|Research Site, Perth, Western Australia, Australia|Research Site, Salzburg, Austria|Research Site, Anthée, Belgium|Research Site, Blankenberge, Belgium|Research Site, Bruxelles, Belgium|Research Site, Bruxelles, Belgium|Research Site, Chênée, Belgium|Research Site, Gent, Belgium|Research Site, Gozee, Belgium|Research Site, Gribomont, Belgium|Research Site, Halen, Belgium|Research Site, Ham, Belgium|Research Site, Hasselt, Belgium|Research Site, La Louvière, Belgium|Research Site, Linkebeek, Belgium|Research Site, Oostende, Belgium|Research Site, Tessenderlo, Belgium|Research Site, Tremelo, Belgium|Research Site, Vilvoorde, Belgium|Research Site, Burnaby, British Columbia, Canada|Research Site, Kelowna, British Columbia, Canada|Research Site, Surrey, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Bay Roberts, Newfoundland and Labrador, Canada|Research Site, Mount Pearl, Newfoundland and Labrador, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Peterborough, Ontario, Canada|Research Site, Sarnia, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Woodstock, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Granby, Quebec, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Lachine, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Pointe-Claire, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Chomutov, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Kladno, Czechia|Research Site, Litomerice, Czechia|Research Site, Moravske Budejovice, Czechia|Research Site, Olomouc, Czechia|Research Site, Pardubice, Czechia|Research Site, Plzen, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 3, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 5, Czechia|Research Site, Slany, Czechia|Research Site, Svitavy, Czechia|Research Site, Aalborg, Denmark|Research Site, Aarhus N, Denmark|Research Site, Ballerup, Denmark|Research Site, Glostrup, Denmark|Research Site, Vejle, Denmark|Research Site, Brest Cedex 2, France|Research Site, Bron, France|Research Site, Caen Cedex 9, France|Research Site, Dijon, France|Research Site, Montpellier cedex 05, France|Research Site, Nantes Cedex 1, France|Research Site, Paris Cedex 12, France|Research Site, Paris Cedex 13, France|Research Site, Vénissieux, France|Research Site, Bad Krozingen, Germany|Research Site, Berlin (Hellersdorf), Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Dresden, Germany|Research Site, Heppenheim, Germany|Research Site, Homburg, Germany|Research Site, Köln, Germany|Research Site, Leipzig, Germany|Research Site, Magdeburg, Germany|Research Site, Messkirch, Germany|Research Site, München, Germany|Research Site, Witten, Germany|Research Site, Hong Kong, Hong Kong|Research Site, New Territories, Hong Kong|Research Site, Baja, Hungary|Research Site, Berettyoujfalu, Hungary|Research Site, Budapest, Hungary|Research Site, Eger, Hungary|Research Site, Gyongyos, Hungary|Research Site, Hodmezovasarhely, Hungary|Research Site, Jaszbereny, Hungary|Research Site, Komarom, Hungary|Research Site, Mosonmagyarovar, Hungary|Research Site, Pecs, Hungary|Research Site, Szeged, Hungary|Research Site, Bologna, Italy|Research Site, Cagliari, Italy|Research Site, Chieti, Italy|Research Site, Cinisello Balsamo (MI), Italy|Research Site, Ferrara, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Padova, Italy|Research Site, Perugia, Italy|Research Site, Pisa, Italy|Research Site, Pisa, Italy|Research Site, Trieste, Italy|Research Site, Noda-shi, Chiba, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Kitakyusyu-shi, Fukuoka, Japan|Research Site, Koriyama-shi, Fukushima, Japan|Research Site, Koriyama-shi, Fukushima, Japan|Research Site, Koriyama-shi, Fukushima, Japan|Research Site, Koriyama-shi, Fukushima, Japan|Research Site, Koriyama-shi, Fukushima, Japan|Research Site, Maebashi-shi, Gunma, Japan|Research Site, Takasaki-shi, Gunma, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Tsuchiura-shi, Ibaraki, Japan|Research Site, Morioka-shi, Iwate, Japan|Research Site, Takamatsu-shi, Kagawa, Japan|Research Site, Takamatsu-shi, Kagawa, Japan|Research Site, Yokohama-shi, Kanagawa, Japan|Research Site, Kyoto-shi, Kyoto, Japan|Research Site, Sendai-shi, Miyagi, Japan|Research Site, Sendai-shi, Miyagi, Japan|Research Site, Sendai-shi, Miyagi, Japan|Research Site, Tomigusuku-shi, Okinawa, Japan|Research Site, Ibaraki-shi, Osaka, Japan|Research Site, Toyonaka-shi, Osaka, Japan|Research Site, Koshigaya-shi, Saitama, Japan|Research Site, Niiza-shi, Saitama, Japan|Research Site, Arakawa-ku, Tokyo, Japan|Research Site, Chiyoda-ku, Tokyo, Japan|Research Site, Chofu-shi, Tokyo, Japan|Research Site, Edogawa-ku, Tokyo, Japan|Research Site, Hachioji-shi, Tokyo, Japan|Research Site, Katsushika-ku, Tokyo, Japan|Research Site, Koto-ku, Tokyo, Japan|Research Site, Minato-ku, Tokyo, Japan|Research Site, Minato-ku, Tokyo, Japan|Research Site, Ota-ku, Tokyo, Japan|Research Site, Setagaya-ku, Tokyo, Japan|Research Site, Shibuya-ku, Tokyo, Japan|Research Site, Shinagawa-ku, Tokyo, Japan|Research Site, Shinagawa-ku, Tokyo, Japan|Research Site, Shinagawa-ku, Tokyo, Japan|Research Site, Shinagawa-ku, Tokyo, Japan|Research Site, Toshima-ku, Tokyo, Japan|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Amsterdam, Netherlands|Research Site, Den Helder, Netherlands|Research Site, Groningen, Netherlands|Research Site, Groningen, Netherlands|Research Site, Hoogeveen, Netherlands|Research Site, Hoorn, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Waalwijk, Netherlands|Research Site, Zwijndrecht, Netherlands|Research Site, Christchurch, New Zealand|Research Site, Oslo, Norway|Research Site, Ålesund, Norway|Research Site, Lodz, Poland|Research Site, Barnaul, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, Centurion, Gauteng, South Africa|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Midrand, Gauteng, South Africa|Research Site, Sunninghill, Gauteng, South Africa|Research Site, Amanzimtoti, KwaZulu-Natal, South Africa|Research Site, Observatory, Western Cape, South Africa|Research Site, Paarl, Western Cape, South Africa|Research Site, Parow, Western Cape, South Africa|Research Site, Somerset West, Western Cape, South Africa|Research Site, Bloemfontein, South Africa|Research Site, Cordoba, Andalucía, Spain|Research Site, Zaragoza, Aragón, Spain|Research Site, L'Hospitalet de Llobregat, Cataluña, Spain|Research Site, Reus, Cataluña, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Göteborg, Sweden|Research Site, Lund, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Uddevalla, Sweden|Research Site, Örebro, Sweden|Research Site, Bellinzona, Switzerland|Research Site, Geneva 14, Switzerland|Research Site, Lausanne, Switzerland|Research Site, Lugano, Switzerland|Research Site, Muensterlingen, Switzerland|Research Site, Reinach, Switzerland|Research Site, St. Gallen, Switzerland|Research Site, Zurich, Switzerland|Research Site, Zurich, Switzerland|Research Site, Kaohsiung, Taiwan|Research Site, Taipei, Taiwan|Research Site, Birmingham, United Kingdom|Research Site, Birmingham, United Kingdom|Research Site, Blackpool, United Kingdom|Research Site, Cardiff, United Kingdom|Research Site, Chesterfield, United Kingdom|Research Site, Chorley, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, Doncaster, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Newcastle upon Tyne, United Kingdom|Research Site, Reading, United Kingdom|Research Site, Telford, United Kingdom|Research Site, Wakefield, United Kingdom|Research Site, West Bromwich, United Kingdom|Research Site, Whitby, United Kingdom",,https://ClinicalTrials.gov/show/NCT01854918
NCT01849185,Probiotic BIO-25 as a Supplement to Statins for the Treatment of Hypercholesterolemia,,Unknown status,No Results Available,Hypercholesterolemia,Other: Food supplement,LDL-Cholesterol levels.|Hemoglobin A1C,Meir Medical Center,All,"18 Years and older   (Adult, Older Adult)",Phase 4,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",mmc120213ctil,May-13,Jan-14,Mar-14,8-May-13,null,8-May-13,"Division of Cardiology Meir MC, Kfar Saba, Israel",,https://ClinicalTrials.gov/show/NCT01849185
NCT01849497,Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen,,Completed,Has Results,Primary Hypercholesterolemia|Mixed Dyslipidemia,Biological: Evolocumab Pre-filled Syringe|Biological: Evolocumab AI/pen,Percentage of Participants With Full Administration of Evolocumab at Both Weeks 2 and 4|Percent Change From Baseline in LDL-C at Week 6,Amgen,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,149,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20120348,18-Apr-13,2-Sep-13,null,8-May-13,9-Oct-15,29-Nov-18,"Research Site, Encino, California, United States|Research Site, Thousand Oaks, California, United States|Research Site, Ventura, California, United States|Research Site, Westlake Village, California, United States|Research Site, Miami, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Hammond, Indiana, United States|Research Site, Auburn, Maine, United States|Research Site, Manlius, New York, United States|Research Site, Syracuse, New York, United States|Research Site, Cadiz, Ohio, United States|Research Site, Marion, Ohio, United States|Research Site, Hillsboro, Oregon, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Lansdale, Pennsylvania, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Jackson, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, London, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Woodstock, Ontario, Canada|Research Site, Pointe-Claire, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01849497
NCT01845428,Lipid Lowering Agents to Limit Lipid Oxidation and Activation of Clotting System in Nephrotic Syndrome,OxLDL,Completed,No Results Available,Nephrotic Syndrome|Hyperlipidemia,Drug: Pravastatin,Changes in Microparticle tissue factor (MP-TF) activity|Changes in plasma coagulation activation,"University of North Carolina, Chapel Hill|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,7,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,12-0789|U54DK083912,May-12,Jan-17,Jan-17,3-May-13,null,29-Aug-18,"Unc Kidney Center, Chapel Hill, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01845428
NCT01842230,Study to Investigate the Effect of Atorvastatin on the Pharmacokinetic Properties of Telmisartan/S-amlodipine,CKD-345 DDI,Completed,No Results Available,Essential Hypertension|Hyperlipidemia,"Drug: Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg|Drug: Telmisartan 80mg and S-amlodipine 5mg",In the steady state Telmisartan 80mg and S-amlodipine 5mg AUClast|In the steady state Telmisartan 80mg and S-amlodipine 5mg Cmax|In the steady state Telmisartan 80mg & S-amlodipine 5mg AUCinf|In the steady state Telmisartan 80mg & S-amlodipine 5mg Tmax|In the steady state Telmisartan 80mg & S-amlodipine 5mg T1/2|Number of Participants with Adverse Events,Chong Kun Dang Pharmaceutical,All,20 Years to 45 Years   (Adult),Phase 1,24,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,142HPS13001,Apr-13,May-13,Jul-13,29-Apr-13,null,1-Aug-13,"Severance Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01842230
NCT01842256,Study to Investigate the Effect of Telmisartan/S-amlodipine on the Pharmacokinetic Properties of Atorvastatin.,CKD-345,Completed,No Results Available,Essential Hypertension|Hyperlipidemia,"Drug: Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg|Drug: atorvastatin 40mg",In the steady state atorvastatin 40mg AUClast|In the steady state atorvastatin 40mg Cmax|In the steady state atorvastatin 40mg AUCinf|In the steady state atorvastatin 40mg Tmax|In the steady state atorvastatin 40mg t1/2|Number of participants with adverse events|In the steady state Orthohydroxy-atorvastatin AUClast|In the steady state Orthohydroxy-atorvastatin Cmax|In the steady state Orthohydroxy-atorvastatin AUCinf|In the steady state Orthohydroxy-atorvastatin Tmax|In the steady state Orthohydroxy-atorvastatin t1/2,Chong Kun Dang Pharmaceutical,All,20 Years to 45 Years   (Adult),Phase 1,24,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,142HPS13002,Apr-13,May-13,Jul-13,29-Apr-13,null,1-Aug-13,"Severance Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01842256
NCT01841684,Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042),,Terminated,No Results Available,Hyperlipoproteinemia Type II|Homozygous Familial Hypercholesterolemia,Drug: Anacetrapib|Drug: Placebo,"Percent change from Baseline in Low-density Lipoprotein-Cholesterol (LDL-C) using beta-quantification method|Number of Participants with Alanine Transaminase (ALT) or Aspartate Aminotransferase (AST) Consecutive Elevations ≥3x Upper Limit of Normal (ULN)|Number of Participants with Creatine Phosphokinase Elevations ≥10xULN with or without Muscle Symptoms|Number of Participants with Sodium, Chloride, or Bicarbonate Elevations >ULN or Potassium Levels <Lower Limit of Normal (LLN)|Number of Participants with Pre-specified Adjudicated Cardiovascular Serious Adverse Events or Death from Any Cause|Number of Participants with Significant Increase in Blood Pressure|Percent Change from Baseline in High-density Lipoprotein-cholesterol (HDL-C)|Percent Change from Baseline in Apolipoprotein A-I (apoA-I)",Merck Sharp & Dohme Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 3,2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0859-042|2012-002434-37,Jun-13,Jun-14,Jun-14,26-Apr-13,null,1-Jun-15,,,https://ClinicalTrials.gov/show/NCT01841684
NCT01825668,Effect of Plant Sterol Enriched Milk on Plasma Lipid Levels of Humans Breast-fed During Infancy,,Unknown status,No Results Available,Hypercholesterolemia|CVD,Other: Plant Sterols|Other: High cholesterol|Other: Placebo,Change in LDL-cholesterol|Change in Cholesterol Absorption|Change in Cholesterol Synthesis,University of Manitoba,All,18 Years to 50 Years   (Adult),Not Applicable,55,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)",B2013:019,Mar-13,Sep-13,Jun-16,8-Apr-13,null,3-Feb-16,"Richardson Centre for Functional Foods and Nutraceuticals, Winnipeg, Manitoba, Canada",,https://ClinicalTrials.gov/show/NCT01825668
NCT01824238,A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050),,Completed,No Results Available,Heterozygous Familial Hypercholesterolemia (HeFH),Drug: Anacetrapib|Drug: Placebo for anacetrapib,Percent Change from Baseline in LDL-C (beta-quantification [BQ] method)|Percentage of Participants who Experience at Least One Adverse Event (AE)|Percent Change from Baseline in High-density Lipoprotein-cholesterol (HDL-C)|Percent Change from Baseline in Non-HDL-C|Percent Change from Baseline in Apolipoprotein A-I (Apo-A-I)|Percent Change from Baseline in Apolipoprotein B (Apo-B)|Percent Change from Baseline in Lipoprotein(a) (Lp[a]),Merck Sharp & Dohme Corp.,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,68,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0859-050|132234,May-13,May-14,May-14,4-Apr-13,null,25-Apr-16,,,https://ClinicalTrials.gov/show/NCT01824238
NCT01819636,Effects Of Consumption Of A Highly Mineralized Sodium Bicarbonated Water On Blood Lipid Profile,,Completed,No Results Available,Hypertriglyceridemia,Other: sparkling highly mineral bicarbonated sodium water,Fasting plasma triglyceride|Fasting plasma total cholesterol|Incremental Area Under Curve (iAUC) between T0 and T480min of plasma triglycerides|Fasting plasma High Density Lipoprotein cholesterol|Fasting plasma Low Density Lipoprotein cholesterol|Fasting plasma glucose|Heart rate|Systolic Blood Pressure|Diastolic Blood Pressure|Incremental Area Under Curve (iAUC) between T0 and T480min of plasma total cholesterol|Incremental Area Under Curve (iAUC) between T0 and T480min of plasma High Density Lipoprotein cholesterol|Incremental Area Under Curve (iAUC) between T0 and T480min of plasma Low Density Lipoprotein cholesterol|Cmax between T0 and T480min of plasma triglyceride|Cmax between T0 and T480min of plasma High Density Lipoprotein cholesterol|Cmax between T0 and T480min of plasma total cholesterol|Cmax between T0 and T480min of plasma Low Density Lipoprotein cholesterol|Delta peak between T0 and T480min of plasma Low Density Lipoprotein cholesterol|Delta peak between T0 and T480min of plasma High Density Lipoprotein cholesterol|Delta peak between T0 and T480min of plasma total cholesterol|Kinetic between T0 and T480min of plasma Low Density Lipoprotein cholesterol|Kinetic between T0 and T480min of plasma High Density Lipoprotein cholesterol|Kinetic between T0 and T480min of plasma total cholesterol|Kinetic between T0 and T480min of plasma triglycerides|Delta peak between T0 and T480min of plasma triglycerides|Alanine Amino Transferase|Aspartate Amino Transferase|Plasmatic urea|Plasmatic creatinine|Plasmatic potassium|Plasmatic sodium|Plasmatic Chloride|Gamma Glutamyl Transferase|Bilirubin|Complete blood count,Neptune,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,162,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",LIPO-2|2012-A01645-38,Mar-13,May-14,Jun-14,27-Mar-13,null,29-Jul-14,"OPTIMED, Gières, France|Naturalpha, Lille, France|Biofortis, Saint Herblain, France",,https://ClinicalTrials.gov/show/NCT01819636
NCT01817491,Low Fat Vegan or American Heart Association Diets & Cardiovascular Risk in Obese 9-18 y.o. With Elevated Cholesterol,,Completed,Has Results,Cardiovascular Disease|Hypercholesterolemia|Obesity|Fatty Liver,Other: American Heart Association Diet|Other: Reduced Fat Vegan Diet,Change in Body Mass Index BMI Percentile|Children Change in BMI Z Score|Change in Blood Pressure (BP)|Change in Weight|Change in Circumference|Change in PAQ (Physical Activity Questionnaire)|Change in Lipid Profile|Change in Glucose|Change in hsCRP (High-sensitivity C-reactive Protein)|Change in Liver Enzymes|Change in IL-6 (Interleukin-6)|Change in MPO (Myeloperoxidase)|Change in HgbA1c (Hemoglobin A1c)|Change in Insulin|PB/AHA - Adjusted Mean Difference BMI|PB/AHA - Adjusted Mean Difference BMI Z Score Children|PB/AHA - Adjusted Mean BP|PB/AHA - Adjusted Mean Difference Weight|PB/AHA - Adjusted Mean Difference Circumference|PB/AHA - Adjusted Mean Difference PAQ Children|PB/AHA - Adjusted Mean Lipid Profile|PB/AHA - Adjusted Mean Ratio Glucose|PB/AHA - Adjusted Mean Ratio hsCRP|PB/AHA - Adjusted Mean Ratio Liver Enzymes|PB/AHA - Adjusted Mean Ratio IL-6|PB/AHA - Adjusted Mean Ratio MPO|PB/AHA - Adjusted Mean Ratio HgbA1c|PB/AHA - Adjusted Mean Ratio Insulin,The Cleveland Clinic,All,"9 Years to 18 Years   (Child, Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,12-1298,Mar-13,May-14,Dec-14,25-Mar-13,8-Jun-18,20-Feb-19,"Cleveland Clinic, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01817491
NCT01813422,GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound,GLAGOV,Completed,Has Results,Hypercholesterolemia,Biological: Evolocumab|Drug: Placebo,Change From Baseline in Percent Atheroma Volume at Week 78|Change From Baseline in Total Atheroma Volume at Week 78|Percentage of Participants With Regression in Percent Atheroma Volume|Percentage of Participants With Regression in Total Atheroma Volume,Amgen,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,970,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",20120153|2012-004208-37,18-Apr-13,12-Jul-16,29-Jul-16,19-Mar-13,4-Jan-18,20-Feb-19,"Research Site, Huntsville, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Little Rock, Arkansas, United States|Research Site, La Jolla, California, United States|Research Site, La Jolla, California, United States|Research Site, Long Beach, California, United States|Research Site, Newport Beach, California, United States|Research Site, Orange, California, United States|Research Site, San Diego, California, United States|Research Site, Santa Monica, California, United States|Research Site, Torrance, California, United States|Research Site, Washington, District of Columbia, United States|Research Site, Atlantis, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Melbourne, Florida, United States|Research Site, Safety Harbor, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Hammond, Indiana, United States|Research Site, Valparaiso, Indiana, United States|Research Site, Lexington, Kentucky, United States|Research Site, Louisville, Kentucky, United States|Research Site, Covington, Louisiana, United States|Research Site, Bethesda, Maryland, United States|Research Site, Columbia, Maryland, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Bay City, Michigan, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, Marquette, Michigan, United States|Research Site, Midland, Michigan, United States|Research Site, Petoskey, Michigan, United States|Research Site, Saginaw, Michigan, United States|Research Site, Duluth, Minnesota, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Saint Cloud, Minnesota, United States|Research Site, Saint Paul, Minnesota, United States|Research Site, Columbia, Missouri, United States|Research Site, Missoula, Montana, United States|Research Site, Omaha, Nebraska, United States|Research Site, Ridgewood, New Jersey, United States|Research Site, Buffalo, New York, United States|Research Site, Johnson City, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Canton, Ohio, United States|Research Site, Elyria, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Hillsboro, Oregon, United States|Research Site, Springfield, Oregon, United States|Research Site, Doylestown, Pennsylvania, United States|Research Site, Hershey, Pennsylvania, United States|Research Site, Oak Ridge, Tennessee, United States|Research Site, Amarillo, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Wichita Falls, Texas, United States|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, La Plata, Buenos Aires, Argentina|Research Site, Cordoba, Córdoba, Argentina|Research Site, Cordoba, Córdoba, Argentina|Research Site, Rosario, Santa Fe, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Corrientes, Argentina|Research Site, Córdoba, Argentina|Research Site, Concord, New South Wales, Australia|Research Site, Darlinghurst, New South Wales, Australia|Research Site, Liverpool, New South Wales, Australia|Research Site, New Lambton Heights, New South Wales, Australia|Research Site, Chermside, Queensland, Australia|Research Site, Herston, Queensland, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, Bedford Park, South Australia, Australia|Research Site, Epping, Victoria, Australia|Research Site, Footscray, Victoria, Australia|Research Site, Heidelberg, Victoria, Australia|Research Site, Melbourne, Victoria, Australia|Research Site, Nedlands, Western Australia, Australia|Research Site, Antwerpen, Belgium|Research Site, Brussels, Belgium|Research Site, Bruxelles, Belgium|Research Site, Edegem, Belgium|Research Site, Genk, Belgium|Research Site, Gent, Belgium|Research Site, Hasselt, Belgium|Research Site, Lodelinsart, Belgium|Research Site, Cariacica, Espírito Santo, Brazil|Research Site, Goiania, Goiás, Brazil|Research Site, Curitiba, Paraná, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Sao Paulo, São Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Saint John, New Brunswick, Canada|Research Site, St. Johns, Newfoundland and Labrador, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, London, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Laval, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Quebec City, Quebec, Canada|Research Site, Temuco, Cautín, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Brno, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 4, Czechia|Research Site, Usti nad Labem, Czechia|Research Site, Zlin, Czechia|Research Site, Aarhus N, Denmark|Research Site, Odense C, Denmark|Research Site, Besançon Cedex, France|Research Site, Chambray les Tours, France|Research Site, Creteil, France|Research Site, Marseille cedex 5, France|Research Site, Paris, France|Research Site, Pessac Cedex, France|Research Site, Aachen, Germany|Research Site, Essen, Germany|Research Site, München, Germany|Research Site, Neuss, Germany|Research Site, Regensburg, Germany|Research Site, Ulm, Germany|Research Site, Alexandroupoli, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Heraklion, Greece|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Pecs, Hungary|Research Site, Szeged, Hungary|Research Site, Reykjavik, Iceland|Research Site, Dublin, Ireland|Research Site, Galway, Ireland|Research Site, Hadera, Israel|Research Site, Jerusalem, Israel|Research Site, Rehovot, Israel|Research Site, Novara, Italy|Research Site, Roma, Italy|Research Site, Rozzano MI, Italy|Research Site, Sesto San Giovanni (MI), Italy|Research Site, Torino, Italy|Research Site, Daejeon, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Kuantan, Pahang, Malaysia|Research Site, Penang, Malaysia|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Queretaro, Querétaro, Mexico|Research Site, San Luis Potosi, San Luis Potosí, Mexico|Research Site, Culiacan, Sinaloa, Mexico|Research Site, Aguascalientes, Mexico|Research Site, Puebla, Mexico|Research Site, Alkmaar, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Leeuwarden, Netherlands|Research Site, Nieuwegein, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Venlo, Netherlands|Research Site, Zwolle, Netherlands|Research Site, Oslo, Norway|Research Site, Tromso, Norway|Research Site, Pasig City, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon City, Philippines|Research Site, Chrzanow, Poland|Research Site, Kedzierzyn Kozle, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Warszawa, Poland|Research Site, Kemerovo, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Singapore, Singapore|Research Site, Boksburg, Gauteng, South Africa|Research Site, Centurion, Gauteng, South Africa|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Kuils River, Western Cape, South Africa|Research Site, Pinelands, Cape Town, Western Cape, South Africa|Research Site, Somerset West, Western Cape, South Africa|Research Site, Malaga, Andalucía, Spain|Research Site, Gijon, Asturias, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, L Hospitalet De Llobregat, Cataluña, Spain|Research Site, Santiago de Compostela, Galicia, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Göteborg, Sweden|Research Site, Helsingborg, Sweden|Research Site, Lund, Sweden|Research Site, Solna, Sweden|Research Site, Stockholm, Sweden|Research Site, Örebro, Sweden|Research Site, Geneva 14, Switzerland|Research Site, St. Gallen, Switzerland|Research Site, Kaohsiung, Taiwan|Research Site, New Taipei, Taiwan|Research Site, Taichung City, Taiwan|Research Site, Taipei, Taiwan|Research Site, Newcastle Upon Tyne, United Kingdom",,https://ClinicalTrials.gov/show/NCT01813422
NCT01812707,Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy in Japan,,Completed,Has Results,Hypercholesterolemia,Drug: Alirocumab|Drug: Placebo (for alirocumab)|Drug: Atorvastatin,"Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis|Absolute Change From Baseline in Calculated LDL-C (mmol/L) at Week 12 - On-Treatment Analysis|Absolute Change From Baseline in Calculated LDL-C (mg/dL) at Week 12 - On-Treatment Analysis|Percentage of Participants Achieving Calculated LDL-C <100 mg/dL (2.59 mmol/L) and < 70 mg/dL (1.81 mmol/L) at Week 12 - On-Treatment Analysis|Percent Change From Baseline in Total Cholesterol, High-Density Lipoprotein Cholesterol (HDL-C), Non-HDL-C, and Apolipoprotein B (Apo-B) at Week 12 - On-Treatment Analysis|Percent Change From Baseline in Fasting Triglycerides and Lipoprotein (a) at Week 12 - On-Treatment Analysis|Absolute Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 (ApoB/ApoA-1) Ratio at Week 12 - On-Treatment Analysis",Sanofi|Regeneron Pharmaceuticals,All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",DFI12361|U1111-1134-4749,Mar-13,Jan-14,Jan-14,18-Mar-13,24-Sep-15,4-Oct-16,"Investigational Site Number 392002, Koganei-Shi, Japan|Investigational Site Number 392001, Shinjuku-Ku, Japan|Investigational Site Number 392003, Suita-Shi, Japan|Investigational Site Number 392004, Suita-Shi, Japan",,https://ClinicalTrials.gov/show/NCT01812707
NCT01813006,Effect of Omega-3 Fatty Acid on Endothelial Function,,Completed,No Results Available,Familial Hypercholesterolemia,Drug: Omega-3|Drug: placebo,Reactive Hyperemia Index (RHI)|Markers of inflammation|Inflammatory markers,Nordlandssykehuset HF|Pronova BioPharma,All,18 Years to 60 Years   (Adult),Phase 3,34,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2011/899(REK)|2012-000505-68,Mar-13,Dec-16,Dec-17,18-Mar-13,null,13-May-19,"Division of Internal Medicine, Nordland Hospital, Bodø, Norway",,https://ClinicalTrials.gov/show/NCT01813006
NCT01811082,Comparison of Coenzyme A and Pantethine Capsule for Safety and Efficacy On Patients With Hyperlipidemia,,Completed,No Results Available,Hyperlipoproteinemia,Drug: Coenzyme A|Drug: Pantethine,"serum triglyceride level|serum total cholesterol, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol levels",Zhejiang University,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,240,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2010MMXX2CoA006,Jul-10,May-11,Jun-11,14-Mar-13,null,15-Mar-13,"1st Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China",,https://ClinicalTrials.gov/show/NCT01811082
NCT01806142,Effects of Medium-Chain Triglycerides on Chylomicron Secretion and Expression of Genes That Regulate Intestinal Lipid Metabolism in Men With Dyslipidemia Associated With the Metabolic Syndrome,MCT,Completed,No Results Available,Metabolic Syndrome X,Other: Medium-chain triglycerides|Other: Corn oil,"Change in TRL apolipoprotein B48 (apoB-48) production rate.|Changes in duodenal expression of genes that regulate intestinal lipid absorption.|Changes in duodenal expression of genes that regulate intestinal lipid synthesis.|Change in synthesis of apoB-48 containing lipoproteins (Microsomal triglyceride transfer protein (MTP), apoB-48).",Laval University|Canadian Institutes of Health Research (CIHR),Male,18 Years to 60 Years   (Adult),Not Applicable,28,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention",INAF-C10-08-053,Feb-11,Apr-12,Feb-13,7-Mar-13,null,7-Mar-13,"Institute of Nutrition and Functional Foods (INAF), Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01806142
NCT01806324,"A Study to Evaluate Pharmacokinetics and Potential Drug Interactions of a Fixed-dose Combination Tablet, HL-040XC, in Healthy Male Subjects",,Completed,No Results Available,Hypertension|Hyperlipidemia,Drug: HL040XC|Drug: Losartan + Atorvastatin,Cmax|AUC,"HanAll BioPharma Co., Ltd.",Male,19 Years to 50 Years   (Adult),Phase 1,30,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HL-040XC-US-001,Apr-12,Nov-12,Dec-12,7-Mar-13,null,7-Mar-13,"Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01806324
NCT01806506,Randomized Comparison of Laparoscopic Sleeve Gastrectomy and Gastric Bypass for Morbid Obesity,,Completed,Has Results,Morbid Obesity|Metabolic Syndrome X|Diabetes Mellitus|Dyslipidemia|Hypertension,Procedure: Laparoscopic sleeve gastrectomy|Procedure: Roux-en-Y Gastric Bypass,Excess Weight Loss From Baseline|Number of Patients With Complications|Comorbidities Prevalence Changes|Change in Weight From Baseline|Change in BMI From Baseline|Plasma Total Cholesterol at 12 Months|Plasma HDL at 12 Months|Plasma LDL at 12 Months|Plasma Triglycerides at 12 Months|Plasma Glucose at 12 Months|Plasma Insulin at 12 Months|Plasma C-peptide at 12 Months|HOMA Index at 12 Months|HbA1c at 12 Months|Plasma CRP at 12 Months|Plasma Uric Acid at 12 Months|Plasma Ghrelin at 12 Months|Plasma Leptin at 12 Months|Plasma Glucagon at 12 Months|Plasma IGF-1 at 12 Months|AST Level|ALT Level|INR|Albumin Level|GGT Level|ALP Level|LDH Level,Medical University of Warsaw,All,18 Years to 60 Years   (Adult),Not Applicable,72,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KBN N N403 3882 33,Nov-08,Mar-12,Nov-13,7-Mar-13,20-Feb-19,20-Feb-19,"Department of General, Transplant and Liver Surgery, Public Central Teaching Hospital, Medical University of Warsaaw, Warsaw, Poland",,https://ClinicalTrials.gov/show/NCT01806506
NCT01803178,The Effect of Plant Sterols on Vascular Function,,Completed,No Results Available,Vascular Diseases|Hypercholesterolemia,Dietary Supplement: Plant Sterols|Dietary Supplement: Placebo Product,Change in flow-mediated dilation|Change in pulse wave velocity,Unilever R&D,All,"40 Years to 65 Years   (Adult, Older Adult)",Not Applicable,240,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",FDS-SCC-0574,Feb-13,Aug-13,Aug-13,4-Mar-13,null,28-Oct-13,"Charité Research Organisation, Berlin, Germany",,https://ClinicalTrials.gov/show/NCT01803178
NCT01803594,Feeding Trial to Determine How Combinations of Different Dietary Bioactive Ingredients Influence High Density Lipoprotein (HDL) Metabolism,HDL,Completed,No Results Available,Dyslipidemia,Dietary Supplement: Krill Oil|Dietary Supplement: Lutein|Dietary Supplement: Nicotinic acid|Dietary Supplement: Dairy phospholipids|Other: Control,Plasma lipoprotein profile|Plasma HDL proteome|Urinary metabolomics|Red blood cell functionality,"University of California, Davis|Unilever R&D",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,18,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,264254,Aug-12,Dec-12,Dec-12,4-Mar-13,null,5-Feb-16,"UC Davis, Ragle Human Nutrition Center, Davis, California, United States",,https://ClinicalTrials.gov/show/NCT01803594
NCT01792648,Effects of Almond Intake on Atherogenic Lipoprotein Particles,,Completed,No Results Available,"Dyslipidemia|Obesity, Abdominal",Other: Standard reference diet|Other: Almond supplemented diet|Other: Low carbohydrate reference diet,Change in Total and LDL cholesterol|Change in small and medium LDL particles|Change in apolipoprotein B|Change in total/HDL-cholesterol ratio|Change in LDL peak particle diameter|Change in plasma triglycerides|Change in HDL-cholesterol|Change in large HDL particles|Change in apolipoprotein AI|Change in HOMA-IR,Children's Hospital & Research Center Oakland|Almond Board of California,All,"20 Years and older   (Adult, Older Adult)",Not Applicable,24,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,MM2222,Apr-13,Feb-16,Apr-16,15-Feb-13,null,6-Nov-17,"Cholesterol Research Center, Berkeley, California, United States",,https://ClinicalTrials.gov/show/NCT01792648
NCT01785329,Pharmacokinetic of Alirocumab SAR236553 (REGN727) Administered Subcutaneously at 3 Different Injection Sites in Healthy Subjects,,Completed,No Results Available,Hypercholesterolemia,Drug: alirocumab SAR236553 (REGN727),Assessment of the serum concentrations of alirocumab SAR236553 (REGN727) after a single subcutaneous administration at 3 different injection sites in healthy subjects as a measure of the pharmacokinetics of this investigational medicinal product.|Assessment of the serum concentrations of low-density lipoprotein cholesterol after a single subcutaneous administration of alirocumab SAR236553 (REGN727) as a measure of the pharmacodynamic effect of this investigational medicinal product.|Assessment of the number of subjects with adverse events after a single subcutaneous administration of alirocumab SAR236553 (REGN727) as a measure of the safety/tolerability of this investigational medicinal product.|Assessment of the serum concentration of anti-drug antibodies after a single subcutaneous dose of alirocumab SAR236553 (REGN727) as a measure of the immunogenicity of this investigational medicinal product.,Sanofi|Regeneron Pharmaceuticals,All,18 Years to 45 Years   (Adult),Phase 1,60,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,BDR13362|2012-005005-40|U1111-1134-2618,Feb-13,Jul-13,Jul-13,7-Feb-13,null,19-Aug-13,"Investigational Site Number 826001, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01785329
NCT01784952,Consumption of Whole Grains and Legumes Modulates the Genetic Effect of the APOA5 -1131C Variant,,Completed,No Results Available,Subjects With Mild Hypertriglyceridemia in Type 2 DM,Dietary Supplement: Dietary intervention,Triglyceride|Apolipoprotein A5,Yonsei University,All,"25 Years to 72 Years   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",WG_APOA5,Jan-12,Jun-12,Oct-12,6-Feb-13,null,6-Feb-13,"Yonsei university, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01784952
NCT01782027,Mendelian Reverse Cholesterol Transport Study,,Suspended,No Results Available,"Cholesterol, HDL|Lipid Metabolism, Inborn Errors|Tangier Disease|LCAT Deficiency|Cholesteryl Ester Transfer Protein (CETP) Deficiency",Drug: 3H-cholesterol bound to albumin,determination of 3H cholesterol in plasma and lipoproteins|determination of 3H cholesterol and its metabolites in red blood cells over time,University of Pennsylvania,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,815075,Oct-12,Jan-19,Jan-20,1-Feb-13,null,4-Mar-19,"University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01782027
NCT01779453,"A Study of the Safety, Pharmacokinetic Drug Interaction and Efficacy of ETC-1002 and Atorvastatin in Subjects With Hypercholesterolemia",,Completed,No Results Available,Hypercholesterolemia,Drug: ETC-1002|Drug: Placebo|Drug: Atorvastatin,"Area under the plasma concentration versus time curve (AUC) of atorvastatin and its active metabolites|Peak plasma concentration (Cmax) of atorvastatin and its active metabolites|Number of subjects with adverse events, clinical lab abnormalities and other safety findings|Percent change in LDL-C|Percent change in other lipids and cardio-metabolic risk factors",Esperion Therapeutics,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,58,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1002-007,Dec-12,Aug-13,Aug-13,30-Jan-13,null,29-Mar-19,"Indianapolis, Indiana, United States|Louisville, Kentucky, United States|Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01779453
NCT01779687,Pharmacokinetic Drug Interaction Study Between Raltegravir and Atorvastatin.,AVIATOR,Completed,No Results Available,HIV|Hypercholesterolaemia,Drug: raltegravir|Drug: Atorvastatin,raltegravir AUC and atorvastatin AUC|adverse events|serum LDL cholesterol,Radboud University|Merck Sharp & Dohme Corp.,All,18 Years to 55 Years   (Adult),Phase 1,24,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),UMCNAKF-12.03,Mar-13,Jul-13,Aug-13,30-Jan-13,null,15-Jun-15,"CRCN Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands",,https://ClinicalTrials.gov/show/NCT01779687
NCT01778244,Metformin for Treatment of Antipsychotic-induced Dyslipidemia,,Completed,No Results Available,Dyslipidemia,Drug: metformin,low-density lipoprotein cholesterol|high-density lipoprotein cholesterol|adverse effects,Central South University,All,18 Years to 50 Years   (Adult),Phase 4,162,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RRWu,Nov-08,Dec-11,Jun-12,29-Jan-13,null,29-Jan-13,"Institute of Mental Health of The Second Xiangya Hospital, Central South University, Changsha, Hunan, China",,https://ClinicalTrials.gov/show/NCT01778244
NCT01773278,Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS),,Recruiting,No Results Available,Smith-Lemli-Opitz Syndrome|Cone-Rod Dystrophy|Hearing Loss,Drug: Antioxidants|Drug: Cholesterol,Change in Electroretinogram (ERG) results over time|Change in ABR (Auditory Brainstem response) testing over time,"University of Colorado, Denver",All,"up to 65 Years   (Child, Adult, Older Adult)",Phase 2,100,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,01-410,Dec-08,Dec-18,Dec-18,23-Jan-13,null,19-Sep-18,"Children's Hospital Colorado, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT01773278
NCT01768481,Intima Media Thickness Regression in Dyslipidemic Teenagers,,Completed,No Results Available,Obesity|Dyslipidemia,Drug: Atorvastatin|Drug: sugar pill,carotid intima media thickness|weight,Université de Montréal|Pfizer,All,"14 Years to 18 Years   (Child, Adult)",Phase 3,16,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HMR,Jan-04,Dec-09,Jun-10,15-Jan-13,null,15-Jan-13,"Hôpital Maisonneuve-Rosemont, Montréal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01768481
NCT01767077,Role of Milk Fat Globule Membranes in Dairy Foods: Health Effects in Humans,MFGM,Completed,No Results Available,Hypercholesterolemia,Dietary Supplement: Butter oil|Dietary Supplement: Cream,LDL-cholesterol|Other major blood lipids|Homeostasis model of assessment - insulin resistance|Peripheral blood mononuclear cell gene expression|Inflammatory markers,"Uppsala University|Lund University|LRF Mjölk, Sweden|Arla Foods|Skånemejerier, Sweden|Semper AB, Sweden|The Swedish Research Council for Environment, Agricultural Sciences and Spatial Planning (FORMAS)|Swedish Nutrition Foundation SNF|Vinnova|The Swedish Farmers' Foundation for Agricultural Research|Livsmedelsföretagen, Sweden|Svensk Dagligvaruhandel, Sweden",All,"20 Years to 70 Years   (Adult, Older Adult)",Not Applicable,52,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,TvärLivs-MFGM,Feb-13,Jun-13,Jun-13,14-Jan-13,null,25-Sep-13,"Uppsala university, Dept of public health and caring sciences; Clinical nutrition and metabolism, Uppsala, Sweden",,https://ClinicalTrials.gov/show/NCT01767077
NCT01763528,"High Protein Weight Loss Diet, High Sensitivity C-Reactive Protein and Cardiovascular Risks Among Obese Women",,Completed,No Results Available,Body Mass Index Quantitative Trait Locus 8 Disorder|Tangier Disease,Other: nutrition intervention,the amount of weight reduction in two dietary groups|LDL-C (mg/dl|HDL-C (mg/dl)|total cholesterol (mg/dl)|fasting blood glucose(mg/dl)|blood pressure (mmHg)|C-reactive protein (mc/dl),Isfahan University of Medical Sciences,Female,"20 Years to 65 Years   (Adult, Older Adult)",Phase 3,63,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research,high protein in women,Jan-11,Jul-12,Aug-12,9-Jan-13,null,9-Jan-13,,,https://ClinicalTrials.gov/show/NCT01763528
NCT01763827,Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2,MENDEL-2,Completed,Has Results,Hyperlipidemia,Biological: Evolocumab|Drug: Ezetimibe|Biological: Placebo to Evolocumab|Other: Placebo to Ezetimibe,Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12|Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12|Change From Baseline in LDL-C at the Mean of Weeks 10 and 12|Change From Baseline in LDL-C at Week 12|Percentage of Participants Who Achieved a Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL|Percentage of Participants Who Achieved LDL-C < 70 mg/dL at Week 12|Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at the Mean of Weeks 10 and 12|Percent Change From Baseline in Non-HDL-C at Week 12|Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12|Percent Change From Baseline in Apolipoprotein B at Week 12|Percent Change From Baseline in Total Cholesterol/High Density Lipoprotein-cholesterol Ratio at the Mean of Weeks 10 and 12|Percent Change From Baseline in Total Cholesterol/High Density Lipoprotein-cholesterol Ratio at Week 12|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12|Percent Change From Baseline in Lipoprotein (a) at the Mean of Weeks 10 and 12|Percent Change From Baseline in Lipoprotein (a) at Week 12|Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12|Percent Change From Baseline in Triglycerides at Week 12|Percent Change From Baseline in Very Low Density Lipoprotein Cholesterol (VLDL-C) at the Mean of Weeks 10 and 12|Percent Change From Baseline in VLDL-C at Week 12|Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at the Mean of Weeks 10 and 12|Percent Change From Baseline in HDL-C at Week 12,Amgen,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,615,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",20110114,21-Jan-13,10-Oct-13,null,9-Jan-13,30-Dec-15,4-Apr-19,"Research Site, Birmingham, Alabama, United States|Research Site, Chandler, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Carmichael, California, United States|Research Site, Encinitas, California, United States|Research Site, San Diego, California, United States|Research Site, Tustin, California, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Ponte Vedra, Florida, United States|Research Site, Sanford, Florida, United States|Research Site, Boise, Idaho, United States|Research Site, Chicago, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Overland Park, Kansas, United States|Research Site, Louisville, Kentucky, United States|Research Site, Bethesda, Maryland, United States|Research Site, Brockton, Massachusetts, United States|Research Site, Edina, Minnesota, United States|Research Site, Olive Branch, Mississippi, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Endwell, New York, United States|Research Site, New Windsor, New York, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Akron, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Norman, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Anderson, South Carolina, United States|Research Site, Mount Pleasant, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Jackson, Tennessee, United States|Research Site, Boerne, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Norfolk, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Renton, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Darlinghurst, New South Wales, Australia|Research Site, Maroubra, New South Wales, Australia|Research Site, Carina Heights, Queensland, Australia|Research Site, Sherwood, Queensland, Australia|Research Site, Anthée, Belgium|Research Site, Bruxelles, Belgium|Research Site, Gozee, Belgium|Research Site, Gribomont, Belgium|Research Site, Halen, Belgium|Research Site, Ham, Belgium|Research Site, Linkebeek, Belgium|Research Site, Retie, Belgium|Research Site, Tessenderlo, Belgium|Research Site, Bay Roberts, Newfoundland and Labrador, Canada|Research Site, Mount Pearl, Newfoundland and Labrador, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Granby, Quebec, Canada|Research Site, Aalborg, Denmark|Research Site, Ballerup, Denmark|Research Site, Vejle, Denmark|Research Site, Gières, France|Research Site, Grenoble Cedex 9, France|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Alberton, Gauteng, South Africa|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Parow, Western Cape, South Africa|Research Site, Somerset West, Western Cape, South Africa|Research Site, Worcester, Western Cape, South Africa|Research Site, Bloemfontein, South Africa|Research Site, Kaohsiung, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Taipei, Taiwan|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT01763827
NCT01763866,LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2,LAPLACE-2,Completed,Has Results,Hyperlipidemia,Biological: Evolocumab|Drug: Ezetimibe|Drug: Placebo to Evolocumab|Drug: Placebo to Ezetimibe|Drug: Atorvastatin|Drug: Rosuvastatin|Drug: Simvastatin,Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12|Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12|Change From Baseline in LDL-C at at the Mean of Weeks 10 and 12|Change From Baseline in LDL-C at Week 12|Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at the Mean of Weeks 10 and 12|Percent Change From Baseline in Non-HDL-C at Week 12|Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12|Percent Change From Baseline in Apolipoprotein B at Week 12|Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12|Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12|Percentage of Participants Who Achieved a Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL|Percentage of Participants Who Achieved LDL-C < 70 mg/dL at Week 12|Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12|Percent Change From Baseline in Lipoprotein(a) at Week 12|Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12|Percent Change From Baseline in Triglycerides at Week 12|Percent Change From Baseline in Very Low-Density Cholesterol (VLDL-C) at the Mean of Weeks 10 and 12|Percent Change From Baseline in Very Low-Density Cholesterol (VLDL-C) at Week 12|Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12|Percent Change From Baseline in HDL-C at Week 12,Amgen,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,2067,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",20110115|2012-001363-70,15-Jan-13,12-Nov-13,null,9-Jan-13,22-Dec-15,6-Mar-19,"Research Site, Birmingham, Alabama, United States|Research Site, Glendale, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Carmichael, California, United States|Research Site, Encino, California, United States|Research Site, Long Beach, California, United States|Research Site, Newport Beach, California, United States|Research Site, San Diego, California, United States|Research Site, Santa Ana, California, United States|Research Site, Santa Rosa, California, United States|Research Site, Thousand Oaks, California, United States|Research Site, Torrance, California, United States|Research Site, Tustin, California, United States|Research Site, Westlake Village, California, United States|Research Site, Littleton, Colorado, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Melbourne, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Boise, Idaho, United States|Research Site, Hammond, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Valparaiso, Indiana, United States|Research Site, Iowa City, Iowa, United States|Research Site, Crestview Hills, Kentucky, United States|Research Site, Monroe, Louisiana, United States|Research Site, Auburn, Maine, United States|Research Site, Bangor, Maine, United States|Research Site, Portland, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Ypsilanti, Michigan, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Billings, Montana, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Manlius, New York, United States|Research Site, Rochester, New York, United States|Research Site, Syracuse, New York, United States|Research Site, Williamsville, New York, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Cadiz, Ohio, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Mansfield, Ohio, United States|Research Site, Marion, Ohio, United States|Research Site, Sandusky, Ohio, United States|Research Site, Norman, Oklahoma, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, York, Pennsylvania, United States|Research Site, Florence, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Jackson, Tennessee, United States|Research Site, Jackson, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Suffolk, Virginia, United States|Research Site, Winchester, Virginia, United States|Research Site, Tacoma, Washington, United States|Research Site, Sydney, New South Wales, Australia|Research Site, Ashford, South Australia, Australia|Research Site, Fullarton, South Australia, Australia|Research Site, Fitzroy, Victoria, Australia|Research Site, Heidelberg Heights, Victoria, Australia|Research Site, Richmond, Victoria, Australia|Research Site, Blankenberge, Belgium|Research Site, ChÃªnÃ©e, Belgium|Research Site, Hasselt, Belgium|Research Site, Oostende, Belgium|Research Site, Tremelo, Belgium|Research Site, Vilvoorde, Belgium|Research Site, Burnaby, British Columbia, Canada|Research Site, Kelowna, British Columbia, Canada|Research Site, Kelowna, British Columbia, Canada|Research Site, Surrey, British Columbia, Canada|Research Site, Saint Johnâ€™s, Newfoundland and Labrador, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Sarnia, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Woodstock, Ontario, Canada|Research Site, Brossard, Quebec, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Lachine, Quebec, Canada|Research Site, Longueuil, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Pointe-Claire, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Kladno, Czechia|Research Site, Litomerice, Czechia|Research Site, Moravske Budejovice, Czechia|Research Site, Olomouc, Czechia|Research Site, Pardubice, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 3, Czechia|Research Site, Praha 4, Czechia|Research Site, Slany, Czechia|Research Site, Svitavy, Czechia|Research Site, Usti nad Orlici, Czechia|Research Site, Aalborg, Denmark|Research Site, Ballerup, Denmark|Research Site, Vejle, Denmark|Research Site, Brest Cedex 2, France|Research Site, Caen Cedex 9, France|Research Site, Dijon, France|Research Site, Le Creusot, France|Research Site, Montpellier cedex 05, France|Research Site, Nantes Cedex 1, France|Research Site, Paris cedex 12, France|Research Site, Paris, France|Research Site, Poitiers, France|Research Site, Strasbourg, France|Research Site, Bad Krozingen, Germany|Research Site, Berlin (Hellersdorf), Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Freiburg, Germany|Research Site, Heidelberg, Germany|Research Site, Homburg, Germany|Research Site, Leipzig, Germany|Research Site, Magdeburg, Germany|Research Site, Messkirch, Germany|Research Site, Witten, Germany|Research Site, Hong Kong, Hong Kong|Research Site, New Territories, Hong Kong|Research Site, Baja, Hungary|Research Site, Berettyoujfalu, Hungary|Research Site, Dunaujvaros, Hungary|Research Site, Eger, Hungary|Research Site, Gyongyos, Hungary|Research Site, Hodmezovasarhely, Hungary|Research Site, Jaszbereny, Hungary|Research Site, Komarom, Hungary|Research Site, Marcali, Hungary|Research Site, Mosonmagyarovar, Hungary|Research Site, Pecs, Hungary|Research Site, Bologna, Italy|Research Site, Cagliari, Italy|Research Site, Chieti, Italy|Research Site, Ferrara, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Padova, Italy|Research Site, Perugia, Italy|Research Site, Pisa, Italy|Research Site, Trieste, Italy|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Suwon, Korea, Republic of|Research Site, Mexico, Distrito Federal, Mexico|Research Site, Mexico, Distrito Federal, Mexico|Research Site, Leon, Guanajuato, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Monterrey, Nuevo LeÃ³n, Mexico|Research Site, San Luis Potosi, San Luis PotosÃ-, Mexico|Research Site, Tampico, Tamaulipas, Mexico|Research Site, Durango, Mexico|Research Site, Amsterdam, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Den Helder, Netherlands|Research Site, Groningen, Netherlands|Research Site, Hoogeveen, Netherlands|Research Site, Nieuwegein, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Waalwijk, Netherlands|Research Site, Zwijndrecht, Netherlands|Research Site, Barnaul, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, Alberton, Gauteng, South Africa|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Lyttelton, Gauteng, South Africa|Research Site, Pretoria, Gauteng, South Africa|Research Site, Kuils River, Western Cape, South Africa|Research Site, Somerset West, Western Cape, South Africa|Research Site, Bloemfontein, South Africa|Research Site, Cape Town, South Africa|Research Site, Almeria, AndalucÃ-a, Spain|Research Site, AlmerÃ-a, AndalucÃ-a, Spain|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, L'Hospitalet de Llobregat, CataluÃ±a, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Pozuelo de Alarcon, Madrid, Spain|Research Site, Pozuelo De AlarcÃ³n, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, GÃ¶teborg, Sweden|Research Site, Lund, Sweden|Research Site, Lund, Sweden|Research Site, Stockholm, Sweden|Research Site, Uddevalla, Sweden|Research Site, Ã-rebro, Sweden|Research Site, Bellinzona, Switzerland|Research Site, Geneva 14, Switzerland|Research Site, Lausanne, Switzerland|Research Site, Muensterlingen, Switzerland|Research Site, St. Gallen, Switzerland|Research Site, Zurich, Switzerland|Research Site, Kaohsiung, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Taipei, Taiwan|Research Site, Birmingham, United Kingdom|Research Site, Blackpool, United Kingdom|Research Site, Cardiff, United Kingdom|Research Site, Chesterfield, United Kingdom|Research Site, Chorley, United Kingdom|Research Site, Doncaster, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Harrow, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Reading, United Kingdom|Research Site, Reading, United Kingdom|Research Site, Scunthorpe, United Kingdom|Research Site, Wakefield, United Kingdom|Research Site, Whitby, United Kingdom",,https://ClinicalTrials.gov/show/NCT01763866
NCT01763905,Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2,GAUSS-2,Completed,Has Results,Hyperlipidemia,Biological: Evolocumab|Drug: Placebo to Evolocumab|Drug: Ezetimibe|Drug: Placebo to Ezetimibe,Percent Change From Baseline in LDL-C at Week 12|Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12|Change From Baseline in LDL-C at the Mean of Weeks 10 and 12|Change From Baseline in LDL-C at Week 12|Percentage of Participants With Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL (1.8 mmol/L)|Percentage of Participants With LDL-C < 70 mg/dL (1.8 mmol/L) at Week 12|Percent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12|Percent Change From Baseline in Non-HDL-C at Week 12|Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12|Percent Change From Baseline in Apolipoprotein B at Week 12|Percent Change From Baseline in the Total Cholesterol/High Density Lipoprotein Cholesterol Ratio at the Mean of Weeks 10 and 12|Percent Change From Baseline in the Total Cholesterol/High Density Lipoprotein Cholesterol Ratio at Week 12|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12|Percent Change From Baseline in Lipoprotein (a) at the Mean of Weeks 10 and 12|Percent Change From Baseline in Lipoprotein (a) at Week 12|Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12|Percent Change From Baseline in Triglycerides at Week 12|Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at the Mean of Weeks 10 and 12|Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Week 12|Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol at the Mean of Weeks 10 and 12|Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol at Week 12,Amgen,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,307,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",20110116|2012-001364-30,24-Jan-13,19-Nov-13,null,9-Jan-13,22-Dec-15,6-Mar-19,"Research Site, Carmichael, California, United States|Research Site, Los Angeles, California, United States|Research Site, Mission Viejo, California, United States|Research Site, Thousand Oaks, California, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Savannah, Georgia, United States|Research Site, Auburn, Maine, United States|Research Site, Traverse City, Michigan, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Henderson, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, New York, New York, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Akron, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Norman, Oklahoma, United States|Research Site, Houston, Texas, United States|Research Site, Camperdown, New South Wales, Australia|Research Site, Milton, Queensland, Australia|Research Site, Melbourne, Victoria, Australia|Research Site, Perth, Western Australia, Australia|Research Site, Brussels, Belgium|Research Site, Gent, Belgium|Research Site, La Louvière, Belgium|Research Site, Newmarket, Ontario, Canada|Research Site, Lachine, Quebec, Canada|Research Site, Pointe-Claire, Quebec, Canada|Research Site, Aalborg, Denmark|Research Site, Ballerup, Denmark|Research Site, Vejle, Denmark|Research Site, Lille Cedex, France|Research Site, Paris Cedex 13, France|Research Site, Vénissieux, France|Research Site, Bad Krozingen, Germany|Research Site, Dresden, Germany|Research Site, Heppenheim, Germany|Research Site, Hong Kong, Hong Kong|Research Site, New Territories, Hong Kong|Research Site, Alkmaar, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Groningen, Netherlands|Research Site, Lodz, Poland|Research Site, Warszawa, Poland|Research Site, Midrand, Gauteng, South Africa|Research Site, Observatory, Western Cape, South Africa|Research Site, Somerset West, Western Cape, South Africa|Research Site, Cordoba, Andalucía, Spain|Research Site, Zaragoza, Aragón, Spain|Research Site, Reus, Cataluña, Spain|Research Site, Lugano, Switzerland|Research Site, Reinach, Switzerland|Research Site, Liverpool, United Kingdom|Research Site, London, United Kingdom|Research Site, Telford, United Kingdom|Research Site, West Bromwich, United Kingdom",,https://ClinicalTrials.gov/show/NCT01763905
NCT01763918,Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2,RUTHERFORD-2,Completed,Has Results,Hyperlipidemia,Biological: Evolocumab|Drug: Placebo,Percent Change From Baseline in LDL-C at Week 12|Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12|Change From Baseline in LDL-C at the Mean of Weeks 10 and 12|Change From Baseline in LDL-C at Week 12|Percentage of Participants With Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL (1.8 mmol/L)|Percentage of Participants With LDL-C < 70 mg/dL (1.8 mmol/L) at Week 12|Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at the Mean of Weeks 10 and 12|Percent Change From Baseline in Non-HDL-C at Week 12|Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12|Percent Change From Baseline in Apolipoprotein B at Week 12|Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12|Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12|Percent Change From Baseline in Lipoprotein (a) at the Mean of Weeks 10 and 12|Percent Change From Baseline in Lipoprotein (a) at Week 12|Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12|Percent Change From Baseline in Triglycerides at Week 12|Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12|Percent Change From Baseline in HDL-C at Week 12|Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol (VLDL-C) at the Mean of Weeks 10 and 12|Percent Change From Baseline in VLDL-C at Week 12,Amgen,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,331,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",20110117|2012-001365-32,7-Feb-13,27-Nov-13,null,9-Jan-13,22-Dec-15,6-Mar-19,"Research Site, Scottsdale, Arizona, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Camperdown, New South Wales, Australia|Research Site, Perth, Western Australia, Australia|Research Site, Vancouver, British Columbia, Canada|Research Site, London, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Bron, France|Research Site, Nantes Cedex 1, France|Research Site, Paris Cedex 13, France|Research Site, Köln, Germany|Research Site, New Territories, Hong Kong|Research Site, Amersfoort, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Gouda, Netherlands|Research Site, Groningen, Netherlands|Research Site, Hoorn, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Christchurch, New Zealand|Research Site, Oslo, Norway|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Midrand, Gauteng, South Africa|Research Site, Observatory, Western Cape, South Africa|Research Site, Parow, Western Cape, South Africa|Research Site, Cordoba, Andalucía, Spain|Research Site, Zaragoza, Aragón, Spain|Research Site, Reus, Cataluña, Spain|Research Site, Madrid, Spain|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Reinach, Switzerland|Research Site, Coventry, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT01763918
NCT01764178,Pharmacokinetic Study of Livalo® Fixed Combination Drug in Healthy Subjects,,Completed,No Results Available,Hyperlipidemia|Hypertension,"Drug: Livalo fixed combination drug|Drug: Pitavastatin, Valsartan",Cmax and AUC of study drugs after single oral administration|AUCinf of study drugs after single oral administration|t1/2β of study drugs after single oral administration|Tmax of study drugs after single oral administration,JW Pharmaceutical,Male,20 Years to 55 Years   (Adult),Phase 1,52,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,JW-PTV-102A,22-Jan-13,15-Mar-13,27-Dec-13,9-Jan-13,null,10-Mar-17,"Asan Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01764178
NCT01764295,Clinical Study for Patients With Hypertension Associated With Dyslipidemia,,Completed,No Results Available,Hypertension|Dyslipidemia,Drug: DWJ1276|Drug: Olmesartan|Drug: Rosuvastatin|Drug: Placebo,LDL-C percent change of DWJ1276 from baseline|DBP change of DWJ1276 from baseline|Proportion of subjects who reached LDL-C treatment goal defined by NCEP ATP III guideline|Proportion of subjects who reached blood pressure treatment goal defined by JNC VII report,Daewoong Pharmaceutical Co. LTD.,All,"20 Years to 80 Years   (Adult, Older Adult)",Phase 3,150,Industry,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",DW_DWJ1276003,Sep-12,May-13,Jul-13,9-Jan-13,null,23-Aug-13,"Seoul National University Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01764295
NCT01764633,Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk,FOURIER,Completed,Has Results,Dyslipidemia,Biological: Evolocumab|Drug: Placebo,"Time to Cardiovascular Death, Myocardial Infarction, Hospitalization for Unstable Angina, Stroke, or Coronary Revascularization|Time to Cardiovascular Death, Myocardial Infarction, or Stroke|Time to Cardiovascular Death|Time to All Cause Death|Time to First Myocardial Infarction|Time to First Stroke|Time to First Coronary Revascularization|Time to Cardiovascular Death or First Hospitalization for Worsening Heart Failure|Time to First Ischemic Fatal or Non-Fatal Stroke or Transient Ischemic Attack",Amgen,All,"40 Years to 85 Years   (Adult, Older Adult)",Phase 3,27564,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",20110118|2014/01/004324|2012-001398-97,8-Feb-13,11-Nov-16,11-Nov-16,9-Jan-13,15-Feb-18,15-Feb-18,"Research Site, Birmingham, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Anchorage, Alaska, United States|Research Site, Glendale, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Alhambra, California, United States|Research Site, Banning, California, United States|Research Site, Beverly Hills, California, United States|Research Site, Encino, California, United States|Research Site, Escondido, California, United States|Research Site, Glendale, California, United States|Research Site, Harbor City, California, United States|Research Site, Huntington Beach, California, United States|Research Site, Laguna Hills, California, United States|Research Site, Long Beach, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Alamitos, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Newport Beach, California, United States|Research Site, Oceanside, California, United States|Research Site, Oxnard, California, United States|Research Site, Palm Springs, California, United States|Research Site, Roseville, California, United States|Research Site, Sacramento, California, United States|Research Site, San Diego, California, United States|Research Site, San Diego, California, United States|Research Site, San Pedro, California, United States|Research Site, Santa Ana, California, United States|Research Site, Tarzana, California, United States|Research Site, Thousand Oaks, California, United States|Research Site, Torrance, California, United States|Research Site, Torrance, California, United States|Research Site, Valley Village, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Greeley, Colorado, United States|Research Site, Littleton, Colorado, United States|Research Site, Longmont, Colorado, United States|Research Site, Bridgeport, Connecticut, United States|Research Site, Newark, Delaware, United States|Research Site, Seaford, Delaware, United States|Research Site, Wilmington, Delaware, United States|Research Site, Washington, District of Columbia, United States|Research Site, Atlantis, Florida, United States|Research Site, Aventura, Florida, United States|Research Site, Bay Pines, Florida, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Bradenton, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Crystal River, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Deerfield Beach, Florida, United States|Research Site, Delray Beach, Florida, United States|Research Site, Edgewater, Florida, United States|Research Site, Fleming Island, Florida, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Jacksonville Beach, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Lakeland, Florida, United States|Research Site, Largo, Florida, United States|Research Site, Melbourne, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, New Port Richey, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Palm Harbor, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Pensacola, Florida, United States|Research Site, Ponte Vedra, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Safety Harbor, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Sanford, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Wellington, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Athens, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Augusta, Georgia, United States|Research Site, Dunwoody, Georgia, United States|Research Site, East Point, Georgia, United States|Research Site, Eatonton, Georgia, United States|Research Site, Gainesville, Georgia, United States|Research Site, Macon, Georgia, United States|Research Site, Savannah, Georgia, United States|Research Site, Suwanee, Georgia, United States|Research Site, Boise, Idaho, United States|Research Site, Boise, Idaho, United States|Research Site, Coeur d'Alene, Idaho, United States|Research Site, Meridian, Idaho, United States|Research Site, Nampa, Idaho, United States|Research Site, Addison, Illinois, United States|Research Site, Belleville, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Hazel Crest, Illinois, United States|Research Site, Jerseyville, Illinois, United States|Research Site, Quincy, Illinois, United States|Research Site, Evansville, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Munster, Indiana, United States|Research Site, Valparaiso, Indiana, United States|Research Site, Ames, Iowa, United States|Research Site, Des Moines, Iowa, United States|Research Site, Iowa City, Iowa, United States|Research Site, Waterloo, Iowa, United States|Research Site, Hutchinson, Kansas, United States|Research Site, Kansas City, Kansas, United States|Research Site, Overland Park, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Lexington, Kentucky, United States|Research Site, Owensboro, Kentucky, United States|Research Site, Baton Rouge, Louisiana, United States|Research Site, Covington, Louisiana, United States|Research Site, Hammond, Louisiana, United States|Research Site, Lafayette, Louisiana, United States|Research Site, Metairie, Louisiana, United States|Research Site, Monroe, Louisiana, United States|Research Site, Natchitoches, Louisiana, United States|Research Site, Slidell, Louisiana, United States|Research Site, Auburn, Maine, United States|Research Site, Bangor, Maine, United States|Research Site, Biddeford, Maine, United States|Research Site, Portland, Maine, United States|Research Site, Annapolis, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Charlotte Hall, Maryland, United States|Research Site, Columbia, Maryland, United States|Research Site, Columbia, Maryland, United States|Research Site, Hollywood, Maryland, United States|Research Site, Salisbury, Maryland, United States|Research Site, Towson, Maryland, United States|Research Site, Ayer, Massachusetts, United States|Research Site, Billerica, Massachusetts, United States|Research Site, Fall River, Massachusetts, United States|Research Site, Haverhill, Massachusetts, United States|Research Site, Hyannis, Massachusetts, United States|Research Site, Newton, Massachusetts, United States|Research Site, Quincy, Massachusetts, United States|Research Site, Springfield, Massachusetts, United States|Research Site, Watertown, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Dearborn, Michigan, United States|Research Site, Flint, Michigan, United States|Research Site, Grandville, Michigan, United States|Research Site, Lansing, Michigan, United States|Research Site, Muskegon, Michigan, United States|Research Site, Novi, Michigan, United States|Research Site, Saginaw, Michigan, United States|Research Site, Saginaw, Michigan, United States|Research Site, Traverse City, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Saint Cloud, Minnesota, United States|Research Site, Saint Paul, Minnesota, United States|Research Site, Olive Branch, Mississippi, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Columbia, Missouri, United States|Research Site, Jefferson City, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Billings, Montana, United States|Research Site, Billings, Montana, United States|Research Site, Great Falls, Montana, United States|Research Site, Kalispell, Montana, United States|Research Site, Missoula, Montana, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Elizabeth, New Jersey, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Westwood, New Jersey, United States|Research Site, Albany, New York, United States|Research Site, Buffalo, New York, United States|Research Site, Buffalo, New York, United States|Research Site, Cortlandt Manor, New York, United States|Research Site, Kingston, New York, United States|Research Site, New Hyde Park, New York, United States|Research Site, New Windsor, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Stony Brook, New York, United States|Research Site, Syracuse, New York, United States|Research Site, Troy, New York, United States|Research Site, West Seneca, New York, United States|Research Site, Williamsville, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Asheville, North Carolina, United States|Research Site, Calabash, North Carolina, United States|Research Site, Cary, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Hickory, North Carolina, United States|Research Site, High Point, North Carolina, United States|Research Site, Lenoir, North Carolina, United States|Research Site, Mooresville, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Statesville, North Carolina, United States|Research Site, Tabor City, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Grand Forks, North Dakota, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Elyria, Ohio, United States|Research Site, Garfield Heights, Ohio, United States|Research Site, Marion, Ohio, United States|Research Site, Sandusky, Ohio, United States|Research Site, Springfield, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Westlake, Ohio, United States|Research Site, Willoughby, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Pryor, Oklahoma, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Bend, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Abington, Pennsylvania, United States|Research Site, Altoona, Pennsylvania, United States|Research Site, Camp Hill, Pennsylvania, United States|Research Site, Chambersburg, Pennsylvania, United States|Research Site, Feasterville, Pennsylvania, United States|Research Site, Indiana, Pennsylvania, United States|Research Site, Jersey Shore, Pennsylvania, United States|Research Site, Norristown, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Sellersville, Pennsylvania, United States|Research Site, Uniontown, Pennsylvania, United States|Research Site, York, Pennsylvania, United States|Research Site, Cranston, Rhode Island, United States|Research Site, Cumberland, Rhode Island, United States|Research Site, Johnston, Rhode Island, United States|Research Site, Pawtucket, Rhode Island, United States|Research Site, Anderson, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Columbia, South Carolina, United States|Research Site, Fountain Inn, South Carolina, United States|Research Site, Indian Land, South Carolina, United States|Research Site, Moncks Corner, South Carolina, United States|Research Site, Mount Pleasant, South Carolina, United States|Research Site, North Myrtle Beach, South Carolina, United States|Research Site, Orangeburg, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Germantown, Tennessee, United States|Research Site, Jackson, Tennessee, United States|Research Site, Memphis, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Tullahoma, Tennessee, United States|Research Site, Arlington, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Grapevine, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Kerrville, Texas, United States|Research Site, Longview, Texas, United States|Research Site, Odessa, Texas, United States|Research Site, Plano, Texas, United States|Research Site, Plano, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Sugar Land, Texas, United States|Research Site, Tomball, Texas, United States|Research Site, Wichita Falls, Texas, United States|Research Site, Layton, Utah, United States|Research Site, Murray, Utah, United States|Research Site, West Jordan, Utah, United States|Research Site, White River Junction, Vermont, United States|Research Site, Burke, Virginia, United States|Research Site, Danville, Virginia, United States|Research Site, Falls Church, Virginia, United States|Research Site, Hopewell, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Roanoke, Virginia, United States|Research Site, Suffolk, Virginia, United States|Research Site, Virginia Beach, Virginia, United States|Research Site, Federal Way, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Selah, Washington, United States|Research Site, Green Bay, Wisconsin, United States|Research Site, Madison, Wisconsin, United States|Research Site, Marshfield, Wisconsin, United States|Research Site, Bahia Blanca, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, La Plata, Buenos Aires, Argentina|Research Site, La Plata, Buenos Aires, Argentina|Research Site, Mar del Plata, Buenos Aires, Argentina|Research Site, Mar del Plata, Buenos Aires, Argentina|Research Site, Quilmes, Buenos Aires, Argentina|Research Site, Cordoba, Córdoba, Argentina|Research Site, Cordoba, Córdoba, Argentina|Research Site, Cordoba, Córdoba, Argentina|Research Site, Cordoba, Córdoba, Argentina|Research Site, Rosario, Santa Fe, Argentina|Research Site, San Miguel de Tucuman, Tucuman, Argentina|Research Site, San Miguel de Tucuman, Tucuman, Argentina|Research Site, Corrientes, Argentina|Research Site, Córdoba, Argentina|Research Site, Salta, Argentina|Research Site, Salta, Argentina|Research Site, Woden, Australian Capital Territory, Australia|Research Site, Camperdown, New South Wales, Australia|Research Site, Concord, New South Wales, Australia|Research Site, Kogarah, New South Wales, Australia|Research Site, Liverpool, New South Wales, Australia|Research Site, Woolloongabba, New South Wales, Australia|Research Site, Auchenflower, Queensland, Australia|Research Site, Herston, Queensland, Australia|Research Site, Woolloongabba, Queensland, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, Ashford, South Australia, Australia|Research Site, Ashford, South Australia, Australia|Research Site, Fullarton, South Australia, Australia|Research Site, Woodville South, South Australia, Australia|Research Site, Hobart, Tasmania, Australia|Research Site, Box Hill, Victoria, Australia|Research Site, Epping, Victoria, Australia|Research Site, Footscray, Victoria, Australia|Research Site, Geelong, Victoria, Australia|Research Site, Heidelberg, Victoria, Australia|Research Site, Nedlands, Western Australia, Australia|Research Site, Graz, Austria|Research Site, Innsbruck, Austria|Research Site, Linz, Austria|Research Site, Salzburg, Austria|Research Site, Wels, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Aalst, Belgium|Research Site, Antwerpen, Belgium|Research Site, Antwerpen, Belgium|Research Site, Blankenberge, Belgium|Research Site, Bonheiden, Belgium|Research Site, Brussels, Belgium|Research Site, Brussels, Belgium|Research Site, Bruxelles, Belgium|Research Site, Gent, Belgium|Research Site, Gozee, Belgium|Research Site, Ieper, Belgium|Research Site, La Louviere, Belgium|Research Site, La Louvière, Belgium|Research Site, Liege, Belgium|Research Site, Liège, Belgium|Research Site, Lodelinsart, Belgium|Research Site, Natoye, Belgium|Research Site, Turnhout, Belgium|Research Site, Fortaleza, Ceará, Brazil|Research Site, Brasília, Distrito Federal, Brazil|Research Site, Vitória, Espírito Santo, Brazil|Research Site, Goiania, Goiás, Brazil|Research Site, Belo Horizonte, Minas Gerais, Brazil|Research Site, Campina Grande do Sul, Paraná, Brazil|Research Site, Curitiba, Paraná, Brazil|Research Site, Curitiba, Paraná, Brazil|Research Site, Canoas, Rio Grande Do Sul, Brazil|Research Site, Passo Fundo, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Campinas, São Paulo, Brazil|Research Site, Campinas, São Paulo, Brazil|Research Site, Sao Jose do Rio Preto, São Paulo, Brazil|Research Site, Sao Paulo, São Paulo, Brazil|Research Site, Sao Paulo, São Paulo, Brazil|Research Site, Rio De Janeiro, Brazil|Research Site, São Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Haskovo, Bulgaria|Research Site, Kazanlak, Bulgaria|Research Site, Pazardzhik, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Kelowna, British Columbia, Canada|Research Site, New Westminster, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, St. Johns, Newfoundland and Labrador, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Peterborough, Ontario, Canada|Research Site, Sarnia, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Strathroy, Ontario, Canada|Research Site, Thunder Bay, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Gatineau, Quebec, Canada|Research Site, Granby, Quebec, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Lachine, Quebec, Canada|Research Site, Longueuil, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Pointe-Claire, Quebec, Canada|Research Site, Québec, Quebec, Canada|Research Site, St Jean sur Richelieu, Quebec, Canada|Research Site, St-Charles-Borromee, Quebec, Canada|Research Site, St-Jérôme, Quebec, Canada|Research Site, Terrebonne, Quebec, Canada|Research Site, Westmout, Quebec, Canada|Research Site, Regina, Saskatchewan, Canada|Research Site, Quebec, Canada|Research Site, Temuco, Cautín, Chile|Research Site, Temuco, Cautín, Chile|Research Site, Osorno, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Beijing, Beijing, China|Research Site, Beijing, Beijing, China|Research Site, Guangzhou, Guangdong, China|Research Site, Harbin, Heilongjiang, China|Research Site, Zhengzhou, Henan, China|Research Site, Wuhan, Hubei, China|Research Site, Wuhan, Hubei, China|Research Site, Changde, Hunan, China|Research Site, Changsha, Hunan, China|Research Site, Changsha, Hunan, China|Research Site, Changsha, Hunan, China|Research Site, Changsha, Hunan, China|Research Site, Xiangtan, Hunan, China|Research Site, Zhuzhou, Hunan, China|Research Site, Baotou, Inner Mongolia, China|Research Site, Hohhot, Inner Mongolia, China|Research Site, Suzhou, Jiangsu, China|Research Site, Wuxi, Jiangsu, China|Research Site, Xuzhou, Jiangsu, China|Research Site, Changchun, Jilin, China|Research Site, Changchun, Jilin, China|Research Site, Changchun, Jilin, China|Research Site, Siping, Jilin, China|Research Site, Dalian, Liaoning, China|Research Site, Shenyang, Liaoning, China|Research Site, Yinchuan, Ningxia, China|Research Site, Qingdao, Shandong, China|Research Site, Taiyuan, Shanxi, China|Research Site, Tianjin, Tianjin, China|Research Site, Tianjin, Tianjin, China|Research Site, Urumqi, Xinjiang, China|Research Site, Hangzhou, Zhejiang, China|Research Site, Linhai, Zhejiang, China|Research Site, Ningbo, Zhejiang, China|Research Site, Wenzhou, Zhejiang, China|Research Site, Beijing, China|Research Site, Tianjin, China|Research Site, Medellin, Antioquia, Colombia|Research Site, Medellin, Antioquia, Colombia|Research Site, Barranquilla, Atlántico, Colombia|Research Site, Barranquilla, Atlántico, Colombia|Research Site, Cartagena, Bolívar, Colombia|Research Site, Manizales, Caldas, Colombia|Research Site, Bogota, Cundinamarca, Colombia|Research Site, Bogota, Cundinamarca, Colombia|Research Site, Bogota, Cundinamarca, Colombia|Research Site, Armenia, Quindío, Colombia|Research Site, Floridablanca, Santander, Colombia|Research Site, Santiago de Cali, Valle Del Cauca, Colombia|Research Site, Benatky nad Jizerou, Czechia|Research Site, Benesov, Czechia|Research Site, Beroun, Czechia|Research Site, Bilovec, Czechia|Research Site, Brandys nad Labem, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Ceske Budejovice, Czechia|Research Site, Cesky Krumlov, Czechia|Research Site, Chomutov, Czechia|Research Site, Havlickuv Brod, Czechia|Research Site, Hodonin, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Hranice na Morave, Czechia|Research Site, Jihlava, Czechia|Research Site, Kladno, Czechia|Research Site, Klatovy IV, Czechia|Research Site, Kutna Hora, Czechia|Research Site, Liberec, Czechia|Research Site, Litomerice, Czechia|Research Site, Litomysl, Czechia|Research Site, Milevsko, Czechia|Research Site, Mlada Boleslav, Czechia|Research Site, Mohelnice, Czechia|Research Site, Moravske Budejovice, Czechia|Research Site, Nymburk, Czechia|Research Site, Olomouc, Czechia|Research Site, Ostrava - Zabreh, Czechia|Research Site, Ostrava-Poruba, Czechia|Research Site, Ostrava, Czechia|Research Site, Pardubice, Czechia|Research Site, Plzen, Czechia|Research Site, Policka, Czechia|Research Site, Prachatice, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 3, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 5 - Smichov, Czechia|Research Site, Praha 5, Czechia|Research Site, Praha 5, Czechia|Research Site, Prerov, Czechia|Research Site, Pribram VIII, Czechia|Research Site, Svitavy, Czechia|Research Site, Teplice, Czechia|Research Site, Uherske Hradiste, Czechia|Research Site, Znojmo, Czechia|Research Site, Aalborg, Denmark|Research Site, Aarhus N, Denmark|Research Site, Ballerup, Denmark|Research Site, Esbjerg, Denmark|Research Site, Glostrup, Denmark|Research Site, Hvidovre, Denmark|Research Site, København S, Denmark|Research Site, København, Denmark|Research Site, Køge, Denmark|Research Site, Odense, Denmark|Research Site, Roskilde, Denmark|Research Site, Svendborg, Denmark|Research Site, Vejle, Denmark|Research Site, Viborg, Denmark|Research Site, Harjumaa, Estonia|Research Site, Paide, Estonia|Research Site, Tallinn, Estonia|Research Site, Tallinn, Estonia|Research Site, Tallinn, Estonia|Research Site, Helsinki, Finland|Research Site, Helsinki, Finland|Research Site, Hämeenlinna, Finland|Research Site, Jyväskylä, Finland|Research Site, Kokkola, Finland|Research Site, Kuopio, Finland|Research Site, Oulo, Finland|Research Site, Oulu, Finland|Research Site, Tampere, Finland|Research Site, Tampere, Finland|Research Site, Turku, Finland|Research Site, Besançon Cedex, France|Research Site, Brest Cedex 2, France|Research Site, Chambray les Tours, France|Research Site, Clermont Ferrand, France|Research Site, Créteil, France|Research Site, Dijon cedex, France|Research Site, Le Coudray, France|Research Site, Lille Cedex, France|Research Site, Lyon, France|Research Site, Marseille Cedex 08, France|Research Site, Metz cedex 03, France|Research Site, Montpellier cedex 05, France|Research Site, Montpellier cedex 5, France|Research Site, Nantes Cedex 1, France|Research Site, Nantes Cedex 2, France|Research Site, Nice, France|Research Site, Nimes, France|Research Site, Orleans, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Pau, France|Research Site, Perpignan Cedex, France|Research Site, Pessac Cedex, France|Research Site, Poitiers, France|Research Site, Reims cedex, France|Research Site, Rennes, France|Research Site, Saint Priest en Jarez, France|Research Site, Strasbourg, France|Research Site, Toulouse Cedex 9, France|Research Site, Vandoeuvre les Nancy, France|Research Site, Vesoul, France|Research Site, Bad Krozingen, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Bochum, Germany|Research Site, Demmin, Germany|Research Site, Dortmund, Germany|Research Site, Dresden, Germany|Research Site, Düsseldorf, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Giessen, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Heidelberg, Germany|Research Site, Ingelheim, Germany|Research Site, Kassel, Germany|Research Site, Köln, Germany|Research Site, Lahr, Germany|Research Site, Leipzig, Germany|Research Site, Limburg, Germany|Research Site, Magdeburg, Germany|Research Site, Mainz, Germany|Research Site, Mannheim, Germany|Research Site, Marburg, Germany|Research Site, München, Germany|Research Site, München, Germany|Research Site, Regensburg, Germany|Research Site, Stuttgart, Germany|Research Site, Ulm, Germany|Research Site, Witten, Germany|Research Site, Wuppertal, Germany|Research Site, Alexandroupoli, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Chalkida, Greece|Research Site, Heraklion, Greece|Research Site, Ioannina, Greece|Research Site, Larissa, Greece|Research Site, Nikaia, Piraeus, Greece|Research Site, Piraeus, Greece|Research Site, Rhodes, Greece|Research Site, Thessaloniki, Greece|Research Site, Thessaloniki, Greece|Research Site, Hong Kong, Hong Kong|Research Site, New Territories, Hong Kong|Research Site, Balatonfured, Hungary|Research Site, Bekescsaba, Hungary|Research Site, Berettyoujfalu, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Cegled, Hungary|Research Site, Debrecen, Hungary|Research Site, Gyongyos, Hungary|Research Site, Gyula, Hungary|Research Site, Kaposvar, Hungary|Research Site, Kecskemet, Hungary|Research Site, Komarom, Hungary|Research Site, Miskolc, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Pecs, Hungary|Research Site, Szeged, Hungary|Research Site, Szekszard, Hungary|Research Site, Szolnok, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Kopavogur, Iceland|Research Site, Reykjavik, Iceland|Research Site, Vijayawada, Andhra Pradesh, India|Research Site, New Delhi, Delhi, India|Research Site, Ahmedabad, Gujarat, India|Research Site, Ahmedabad, Gujarat, India|Research Site, Ahmedabad, Gujarat, India|Research Site, Ahmedabad, Gujarat, India|Research Site, Vadodara, Gujarat, India|Research Site, Gurgaon, Haryana, India|Research Site, Belgaum, Karnataka, India|Research Site, Mysore, Karnataka, India|Research Site, Mumbai, Maharashtra, India|Research Site, Mumbai, Maharashtra, India|Research Site, Mumbai, Maharashtra, India|Research Site, Nagpur, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Lucknow, Uttar Pradesh, India|Research Site, Kolkata, West Bengal, India|Rese",,
NCT01761955,Metabolic Health Benefits of Dairy Protein,,Completed,No Results Available,Hyperlipidemia|Obesity,Other: High Dairy,markers of metabolic (cardiometabolic) health,University of Manitoba,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,21,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Screening,J2008:075,Feb-09,May-11,May-11,7-Jan-13,null,10-Jan-13,"Richardson Centre for Functional Foods and Nutraceuticals, Winnipeg, Manitoba, Canada",,https://ClinicalTrials.gov/show/NCT01761955
NCT01760460,A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1),,Completed,No Results Available,Dyslipidemia,Drug: Anacetrapib|Drug: Placebo for anacetrapib,Percent Change from Baseline in LDL-C (beta-quantification [BQ] method)|Percentage of Participants who Experience at Least One Adverse Event (AE)|Percent Change from Baseline in High-density Lipoprotein-cholesterol (HDL-C)|Percent Change from Baseline in Non-HDL-C|Percent Change from Baseline in Apolipoprotein B (Apo-B)|Percent Change from Baseline in Apolipoprotein A-I (Apo-A-I)|Percent Change from Baseline in Lipoprotein(a) (Lp[a]),Merck Sharp & Dohme Corp.,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,307,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0859-051|132236,14-Mar-13,4-Mar-15,4-Mar-15,4-Jan-13,null,1-Jun-17,,,https://ClinicalTrials.gov/show/NCT01760460
NCT01752803,RCT Examining Effects of Probiotics in T2DM Individuals,,Unknown status,No Results Available,Type 2 Diabetes Mellitus|Obesity|Hypertension|Hyperlipidemia,Dietary Supplement: Probiotic|Dietary Supplement: Placebo,Hb A1c|inflammatory markers,Universiti Kebangsaan Malaysia Medical Centre,All,"30 Years to 65 Years   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",04-02-12-1815RU|Universiti Putra Malaysia,Dec-12,Jul-13,Jul-15,19-Dec-12,null,1-Oct-14,"Universiti Kebangsaan Malaysia Medical Center, Kuala Lumpur, WP, Malaysia",,https://ClinicalTrials.gov/show/NCT01752803
NCT01751984,A Study of the Efficacy and Safety of ETC-1002 in Subjects With Statin Intolerance,,Completed,No Results Available,Hypercholesterolemia,Drug: ETC-1002|Drug: Placebo,Percent change from baseline in LDL-C|Percent change from baseline in other lipids and cardio-metabolic risk factors|Percent achieving LDL-C goal|Number of subjects with adverse events|Number of subjects with muscle related adverse events,Esperion Therapeutics,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,56,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1002-006,Oct-12,May-13,May-13,18-Dec-12,null,29-Mar-19,"Hartford, Connecticut, United States|Indianapolis, Indiana, United States|Raleigh, North Carolina, United States|Wilmington, North Carolina, United States|Knoxville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT01751984
NCT01749878,Study to Assess the Safety and Tolerability of Single Doses of REGN1500,,Completed,No Results Available,Hypertriglyceridemia,Drug: REGN1500|Drug: placebo,Safety|Serum concentration of REGN1500,Regeneron Pharmaceuticals,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,99,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R1500-HV-1214,Dec-12,Jan-16,Jan-16,17-Dec-12,null,12-May-16,"Philadelphia, Pennsylvania, United States|Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT01749878
NCT01744977,Cholesterol Medication Packaging Study,MWV_CAPS,Completed,Has Results,Hypercholesterolemia,Behavioral: packaging,"Cholesterol Medication Adherence|Change in LDL Cholesterol Level as Measured at Baseline, 6months, 12months",Durham VA Medical Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,240,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,1642,Dec-12,May-15,Aug-15,7-Dec-12,18-May-16,18-May-16,"Durham VAMC, Durham, North Carolina, United States|Raleigh Community-based Outpatient Clinic (CBOC- Raleigh), Raleigh, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01744977
NCT01744392,Medication Adherence With Polyglot Meducation,,Completed,Has Results,Hypertension|Diabetes|Hypercholesterolemia,Behavioral: education intervention,Medication Possession Ratio at Baseline|Medication Possession Ratio at 6 Months|Blood Pressure at Baseline|Blood Pressure at 6 Months|Cholesterol & Creatinine Levels at Baseline|Cholesterol & Creatinine Levels at 6 Months|Weight at Baseline|Weight at 6 Months|Pulse at Baseline|Pulse at 6 Months,Durham VA Medical Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,23,U.S. Fed,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,1658,Feb-13,Jun-14,Jul-14,6-Dec-12,24-Nov-15,24-Nov-15,"Durham VA Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01744392
NCT01739153,Effect of Cheese on Cardiovascular Risk,ECCA,Completed,No Results Available,Hyperlipidemia,Other: Dietary intervention: CHEESE (High cheese intake)|Other: Dietary intervention: MEAT (High Meat intake)|Other: Dietary intervention: CARB (High Carbohydrate intake),LDL cholesterol|Blood lipid concentrations|ApoA1 and ApoB|Dietary fat digestibility|Blood pressure|Anthropometry|Insulin sensitivity|Bile acid metabolism,"University of Copenhagen|The Danish Dairy Research Foundation, Denmark|Dairy Research Institute|Dairy Farmers of Canada|Centre National Interprofessionel de l'Economie Laitière|Dairy Australia|Nederlandse Zuivel Organisatie",Female,"45 Years to 68 Years   (Adult, Older Adult)",Not Applicable,19,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,B302,Jan-13,Aug-13,Nov-14,3-Dec-12,null,21-Nov-14,"Department of Nutrition, Exercise and Sports, Copenhagen, Frederiksberg, Denmark",,https://ClinicalTrials.gov/show/NCT01739153
NCT01737099,Efficacy and Safety Study of DHA-O in Adults With Hypertriglyceridemia,DHA-O,Completed,No Results Available,Hypertriglyceridemia,Dietary Supplement: DHA-O|Dietary Supplement: Fish oil|Dietary Supplement: Placebo,Change from baseline in TG levels|Change from baseline in lipid panel measures,"DSM Nutritional Products, Inc.",All,"18 Years to 79 Years   (Adult, Older Adult)",Not Applicable,93,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2012-1048,Nov-12,Nov-13,Nov-13,29-Nov-12,null,25-Apr-14,"Biofortis Clinical Research, Addison, Illinois, United States",,https://ClinicalTrials.gov/show/NCT01737099
NCT01735149,Efficacy and Safety of Kochujang Pills on Improvement of Blood Lipids,,Unknown status,No Results Available,Hyperlipidemia,Dietary Supplement: Kochujang Pills|Dietary Supplement: Placebo,Changes in Total Cholesterol|Changes in LDL-C (LDL Low Density Lipoprotein-cholesterol)|Changes in Triglyceride|Changes in HDL-C(High Density Lipoprotein-cholesterol),Chonbuk National University Hospital,All,19 Years to 55 Years   (Adult),Phase 2|Phase 3,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",SRCM-HL-KOCHUJANG,Nov-12,Nov-12,Jun-13,28-Nov-12,null,29-Nov-12,"Clinical Trial Center for Functional Foods; Chonbuk National University Hospital, Jeonju, Jeollabuk-do, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01735149
NCT01730040,Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I),,Completed,Has Results,Hypercholesterolemia,Drug: Alirocumab|Drug: Atorvastatin|Drug: Ezetimibe|Drug: Rosuvastatin|Drug: Placebo,Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis|Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis|Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 12 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 - ITT Analysis|Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis|Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein(a) at Week 12 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis,Regeneron Pharmaceuticals|Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,355,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R727-CL-1110,Oct-12,Apr-14,May-14,21-Nov-12,31-Aug-15,31-Aug-15,"Mobile, Alabama, United States|Chandler, Arizona, United States|Tucson, Arizona, United States|Anaheim, California, United States|Beverly Hills, California, United States|Lakeland, California, United States|Newport Beach, California, United States|Northridge, California, United States|Sacramento, California, United States|Walnut Creek, California, United States|Milford, Connecticut, United States|Atlantis, Florida, United States|Boca Raton, Florida, United States|Clearwater, Florida, United States|Jacksonville, Florida, United States|Miami (2 locations), Florida, United States|Oviedo, Florida, United States|Pinellas Park, Florida, United States|Port Orange, Florida, United States|Sarasota, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Boise, Idaho, United States|Meridian, Idaho, United States|Chicago, Illinois, United States|Morton, Illinois, United States|Indianapolis, Indiana, United States|Newton, Kansas, United States|Overland Park, Kansas, United States|Wichita, Kansas, United States|Lexington, Kentucky, United States|Louisville, Kentucky, United States|Auburn, Maine, United States|Bethesda, Maryland, United States|Edina, Minnesota, United States|Rochester, Minnesota, United States|Olive Branch, Mississippi, United States|Port Gibson, Mississippi, United States|St. Louis, Missouri, United States|Butte, Montana, United States|Las Vegas, Nevada, United States|Williamsville, New York, United States|Winston-Salem, North Carolina, United States|Cleveland, Ohio, United States|Oklahoma City, Oklahoma, United States|Warwick, Rhode Island, United States|Greer, South Carolina, United States|Summerville, South Carolina, United States|Kingsport, Tennessee, United States|Dallas (2 locations), Texas, United States|Fort Worth, Texas, United States|Houston, Texas, United States|Bountiful, Utah, United States|Marion, Utah, United States|Salt Lake City, Utah, United States|Renton, Washington, United States|Herston QLD, Australia|New Lambton Heights, Australia|Perth, Australia|Sherwood, Australia|Woolloongabba, Australia|Brampton, Ontario, Canada|Etobicoke, Ontario, Canada|London, Ontario, Canada|Newmarke, Ontario, Canada|Thornhill, Ontario, Canada|Toronto, Ontario, Canada|Chicoutimi, Quebec, Canada|Dijon, France|Lille, France|Venissieux, France|Bad Oeynhausen, Germany|Berlin, Germany|Koeln, Germany|Munich, Germany|Regensburg, Germany|Ulm, Germany|Chiete, Italy|Genova, Italy|Napoli, Italy|Palermo, Italy|Roma (2 locations), Italy|Distrito Federal, Mexico|Guadalajara, Jalisco, Mexico|Guadalajara, Mexico|Monterrey Nuevo Leon, Mexico|Tijuana Baja California, Mexico|Zapopan Jalisco, Mexico|Barcelona (3 locations), Spain|Madrid, Spain|Sant Joan Despi, Spain|Carmarthen, United Kingdom|Chester, United Kingdom|Peterborough, United Kingdom|Salford, United Kingdom|Stevenage, United Kingdom|West Bromwich, West Midlands, United Kingdom",,https://ClinicalTrials.gov/show/NCT01730040
NCT01730053,Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II),,Completed,Has Results,Hypercholesterolemia,Drug: Alirocumab|Drug: Rosuvastatin|Drug: Ezetimibe|Drug: Placebo,Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis|Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis|Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 12 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 - ITT Analysis|Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis|Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis,Regeneron Pharmaceuticals|Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,305,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R727-CL-1118,Nov-12,Apr-14,May-14,21-Nov-12,28-Oct-15,28-Oct-15,"Chandler, Arizona, United States|Tucson, Arizona, United States|Anaheim, California, United States|Beverly Hills, California, United States|Fair Oaks, California, United States|Newport Beach, California, United States|Northridge, California, United States|Sacramento, California, United States|Walnut Creek, California, United States|Milford, Connecticut, United States|Atlantis, Florida, United States|Bradenton, Florida, United States|Clearwater, Florida, United States|Fort Lauderdale, Florida, United States|Jacksonville, Florida, United States|Lakeland, Florida, United States|Miami (2 locations), Florida, United States|Oviedo, Florida, United States|Pinellas Park, Florida, United States|Port Orange, Florida, United States|Sarasota, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Winter Park, Florida, United States|Boise, Idaho, United States|Morton, Illinois, United States|Evansville, Indiana, United States|Indianapolis, Indiana, United States|Newton, Kansas, United States|Overland Park, Kansas, United States|Wichita, Kansas, United States|Lexington, Kentucky, United States|Louisville, Kentucky, United States|Auburn, Maine, United States|Bethesda, Maryland, United States|Edina, Minnesota, United States|Rochester, Minnesota, United States|Olive Branch, Mississippi, United States|Port Gibson, Mississippi, United States|St. Louis, Missouri, United States|Butte, Montana, United States|Williamsville, New York, United States|Cincinatti, Ohio, United States|Marion, Ohio, United States|Portland, Oregon, United States|Warwick, Rhode Island, United States|Greer, South Carolina, United States|Summerville, South Carolina, United States|Kingsport, Tennessee, United States|Dallas (2 locations), Texas, United States|Fort Worth, Texas, United States|Houston, Texas, United States|Bountiful, Utah, United States|Salt Lake City, Utah, United States|Herston QLD, Australia|New Lambton Heights, Australia|Perth, Australia|Sherwood, Australia|Woolloongabba, Australia|Brampton, Ontario, Canada|Burlington, Ontario, Canada|Etobicoke, Ontario, Canada|London, Ontario, Canada|Newmarke, Ontario, Canada|Thornhill, Ontario, Canada|Toronto, Ontario, Canada|Chicoutimi, Quebec, Canada|Dijon, France|Lille, France|Bad Oeynhausen, Germany|Berlin, Germany|Koeln, Germany|Regensburg, Germany|Ulm, Germany|Chiete, Italy|Genova, Italy|Napoli, Italy|Palermo, Italy|Roma (2 locations), Italy|Distrito Federal, Mexico|Guadalajara Jalisco, Mexico|Guadalajara, Jal., Mexico|Guadalajara, Mexico|Monterrey Nuevo Leon, Mexico|Tijuana Baja California, Mexico|Zapopan Jalisco, Mexico|Alcalà de Henares (Madrid), Spain|Barcelona (2 locations), Spain|Santiago, Spain|Sevilla, Spain|Chester, United Kingdom|Peterborough, United Kingdom|Salford, United Kingdom|Stevenage, United Kingdom|West Bromwich, West Midlands, United Kingdom",,https://ClinicalTrials.gov/show/NCT01730053
NCT01729156,Effects of Metformin on Hepatic FFA Metabolism,,Completed,No Results Available,Type 2 Diabetes|Dyslipidemia,Drug: Metformin|Drug: Placebo,Hepatic fatty acid oxidation|Hepatic fatty acid reesterification|Hepatic fatty acid uptake|VLDL-TG secretion|Whole body glucose metabolism|Weight loss|Fatty acid turnover|VLDL-TG oxidation,Lars Christian Gormsen|University of Aarhus,All,"50 Years to 70 Years   (Adult, Older Adult)",Phase 4,36,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",C11palmitatMetformin,Jan-13,5-May-17,5-May-17,20-Nov-12,null,12-Mar-19,,,https://ClinicalTrials.gov/show/NCT01729156
NCT01725594,"A Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CAT-2003",,Completed,No Results Available,Dyslipidemia,Drug: CAT 2003|Drug: Placebo,"Frequency and severity of adverse events|AUCinf of CAT-2003|Cmax of CAT-1004|Changes from baseline for hematology, chemistry, coagulation and urinalysis|Changes from baseline for Physical exams|Changes from baseline for ECGs|Changes from baseline in vital signs|Assess the pharmacodynamic effects of multiple doses of CAT-2003 on triglycerides and other lipids (LDL-C, VLDL-C, VLDL-triglycerides, non-HDL-C, total cholesterol, HDL-C), apoB, lipoprotein(a), and PCSK9 in healthy subjects with mild dyslipidemia",Catabasis Pharmaceuticals,All,18 Years to 55 Years   (Adult),Phase 1,99,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",CAT-2003-101,Nov-12,May-13,May-13,14-Nov-12,null,11-Jul-13,"Medpace CPU, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01725594
NCT01725646,An Efficacy and Safety Study of Omacor® in Taiwanese Hypertriglyceridemic Patients,,Completed,No Results Available,Hypertriglyceridemia,Drug: Omacor®|Drug: Placebo,Change in Triglycerides from baseline,Excelsior,All,"20 Years to 79 Years   (Adult, Older Adult)",Phase 3,253,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",OM3-99001,Jul-11,Jul-13,Aug-13,14-Nov-12,null,19-May-14,"Taichung Veterans General Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT01725646
NCT01725815,The Health Access and Recovery Peer Program,HARP,Completed,No Results Available,Hypertension|Arthritis|Coronary Artery Disease|Hepatitis|Diabetes|Asthma|Hyperlipidemia|HIV,Behavioral: HARP Intervention,Health related quality of life|Patient Activation|Health Behaviors,Emory University|National Institute of Mental Health (NIMH),All,"18 Years and older   (Adult, Older Adult)",Phase 3,400,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,IRB00047631a|1R01MH090584-01A1,Jun-11,1-Jun-16,31-Mar-17,14-Nov-12,null,13-Jul-17,"Central Fulton Community Mental Health Center at Grady Hospital, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT01725815
NCT01723735,Effect of Alirocumab (SAR236553/REGN727) Administered on Top of Ezetimibe or Fenofibrate on Lipid Profiles in Healthy Subjects,,Completed,No Results Available,Hypercholesterolemia,Drug: Alirocumab|Drug: Ezetimibe|Drug: Ezetimibe Placebo|Drug: Fenofibrate,Assessment of the effect of alirocumab on LDL-C|Assessment of the pharmacodynamic profile of alirocumab|Pharmacokinetics: Assessment of serum concentrations of alirocumab|Pharmacokinetics: Assessment of serum concentrations of proprotein convertase subtilisin kexin type 9 (PCSK9),Sanofi|Regeneron Pharmaceuticals,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,79,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,PKD12910|U1111-1131-3203|2012-003049-13,Nov-12,Jul-13,Jul-13,8-Nov-12,null,28-Sep-16,"Investigational Site Number 250001, Rennes, France|Investigational Site Number 250002, Rueil Malmaison, France",,https://ClinicalTrials.gov/show/NCT01723735
NCT01720537,A Study To Assess The Safety Of PF-05335810 In Hypercholesterolemic Subjects,,Completed,No Results Available,Hypercholesterolemia,Biological: PF-05335810 Dose A|Biological: PF-05335810 Dose B|Biological: Placebo|Biological: PF-04950615 Dose A|Biological: PF-05335810 Dose C|Biological: PF-04950615|Biological: PF-05335810 Dose D|Biological: PF-05335810 Dose E,Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Laboratory Test Values of Potential Clinical Importance|Change From Baseline in Heart Rate|Diastolic Blood Pressure|Change From Baseline in Electrocardiogram (ECG) Parameters|Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)]|Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)]|Maximum Observed Plasma Concentration (Cmax)|Time to Reach Maximum Observed Plasma Concentration (Tmax)|Apparent Volume of Distribution (Vz/F)|Apparent Oral Clearance (CL/F)|Plasma Decay Half-Life (t1/2)|Absolute Bioavailability (%F),Pfizer,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,133,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",B3091001,Jul-12,Oct-13,Oct-13,2-Nov-12,null,4-Dec-18,"Pfizer Investigational Site, New Haven, Connecticut, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, South Miami, Florida, United States|Pfizer Investigational Site, Overland Park, Kansas, United States|Pfizer Investigational Site, Kalamazoo, Michigan, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT01720537
NCT01720719,Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease,,Unknown status,No Results Available,Fatty Liver|Dyslipidemias|Diabetes Mellitus,Drug: atorvastatin|Drug: Vitamin E,Liver fat content(%)|Abdominal visceral fat area(cm2)|Abdominal subcutaneous fat area(cm2)|Lipid profiles|Liver enzymes|Glucose metabolism|Body weight|Anthropometric test|Muscle enzymes,Xin Gao|Pfizer|Fudan University,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,120,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,WS2334187,May-13,Dec-16,Dec-16,2-Nov-12,null,3-Feb-16,"Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT01720719
NCT01717300,A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021),,Completed,No Results Available,Hypercholesterolemia,Drug: Anacetrapib 100 mg|Drug: Placebo for anacetrapib 100 mg|Drug: Anacetrapib 25 mg|Drug: Placebo for anacetrapib 25 mg,"Percent Change from Baseline in LDL-C (beta-quantification [BQ] method)|Percent Change from Baseline in HDL-C|Number of Participants with Alanine Transaminase (ALT) or Aspartate Aminotransferase (AST) Consecutive Elevations ≥3xULN (Upper Limit of Normal)|Number of Participants with Creatine Phosphokinase Elevations ≥10xULN with or without Muscle Symptoms|Number of Participants with Sodium, Chloride, or Bicarbonate Elevations >ULN or Potassium Levels <LLN (Lower Limit of Normal)|Number of Participants with Pre-specified Adjudicated Cardiovascular Serious Adverse Events or Death from Any Cause|Number of Participants with Significant Increase in Blood Pressure|Percent change from Baseline in non-HDL-C|Percent Change from Baseline in Apolipoprotein B (Apo-B)|Percent Change from Baseline in Apolipoprotein A-I (Apo-A-I)|Percent Change from Baseline in Lipoprotein(a) (lp[a])|Percent Change from Baseline in HDL-C Among Participants with Low HDL-C at LDL-C goal",Merck Sharp & Dohme Corp.,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,459,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0859-021|2012-003110-14,6-Nov-12,29-Oct-14,29-Oct-14,30-Oct-12,null,17-Apr-17,,,https://ClinicalTrials.gov/show/NCT01717300
NCT01716390,Lipid-lowering Effect of Plant Stanol Drink,,Completed,No Results Available,Hypercholesterolemia,Dietary Supplement: Drink that contains plant stanols|Dietary Supplement: Placebo drink,Change in serum LDL cholesterol,Raisio Group,All,"25 Years to 65 Years   (Adult, Older Adult)",Not Applicable,56,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CL2010_029,Jan-11,May-11,Jun-11,29-Oct-12,null,29-Oct-12,"Good Food Practice, Uppsala, Sweden",,https://ClinicalTrials.gov/show/NCT01716390
NCT01712867,The Effect of Phytosterol Esters of Omega-3 (Vayarol) Versus Omega-3 Acids Ethyl Esters in Reducing Triglyceride Levels,,Completed,No Results Available,Patients With Hypertriglyceridemia,Other: Omega-3 acid ethyl esters|Other: Phytosterol esters of omega-3,fasting triglycerides levels|Difference between phytosterol esters of omega-3 and Omega-3 acids ethyl esters treatment groups in other lipid and biomarker levels,"Enzymotec|Daewon Pharmaceutical Co., Ltd.",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,201,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Vayarol_006,Oct-12,Nov-14,Dec-14,24-Oct-12,null,11-Apr-18,"Maccabi Healthcare Services, Tel-Aviv, Israel",,https://ClinicalTrials.gov/show/NCT01712867
NCT01711749,Rosuvastatin Calcium Bioequivalence Study - Fast,,Completed,No Results Available,Hypercholesterolaemia,Drug: Crestor®|Drug: rosuvastatin calcium tablets,Area Under the Curve 0-t (AUC)|Area Under the Curve 0-infinite (AUC)|Half Life (T1/2)|Maximum concentration (Cmax)|Time to Cmax (Tmax),GlaxoSmithKline,All,18 Years to 50 Years   (Adult),Phase 1,60,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,117120,25-Feb-13,13-Mar-13,13-Mar-13,22-Oct-12,null,20-Jun-17,"GSK Investigational Site, Bragança Paulista, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT01711749
NCT01709500,Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy),ODYSSEY FH II,Completed,Has Results,Heterozygous Familial Hypercholesterolemia,"Drug: LMT (atorvastatin, simvastatin, or rosuvastatin)|Drug: alirocumab|Drug: Placebo",Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent--to--Treat (ITT) Analysis|Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - On- Treatment Analysis|Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Non-High -Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 12 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis|Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis|Percentage of Very High CV Risk Participants Reaching Calculated LDL--C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL--C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants Reaching Calculated LDL--C <70 mg/dL (1.81 mmol/L) at Week 52 - On-Treatment Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis,Regeneron Pharmaceuticals|Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,249,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R727-CL-1112,Dec-12,May-14,Jan-15,18-Oct-12,28-Oct-15,28-Oct-15,"Hradec Kralove, Czech Republic|Praha 2, Czech Republic|Praha 5, Czech Republic|Praha 8, Czech Republic|Trutnov, Czech Republic|Vyskov, Czech Republic|Alkmaar, Netherlands|Amsterdam, Netherlands|Apeldoorn, Netherlands|Enschede, Netherlands|Goes, Netherlands|Groningen, Netherlands|Hoogeveen, Netherlands|Hoorn, Netherlands|Rotterdam, Netherlands|Sittard- Geleen, Netherlands|Utrecht (2 locations), Netherlands|Venlo, Netherlands|Waalwijk, Netherlands|Oslo, Norway|Cardiff, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Middlesex, United Kingdom|Newcastle upon Tyne, United Kingdom|West Bromwich, United Kingdom",,https://ClinicalTrials.gov/show/NCT01709500
NCT01709513,"Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)",,Completed,Has Results,Hypercholesterolemia,Drug: Atorvastatin|Drug: Ezetimibe|Drug: Alirocumab|Drug: Placebo,Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent--To-Treat (ITT) Analysis|Percent Change From Baseline in Calculated LDL-C at Week 24 - On--Treatment Analysis|Percent Change From Baseline in Calculated LDL--C at Week 12 -- ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - On--Treatment Analysis|Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 -- ITT Analysis|Percent Change From Baseline in Apo B at Week 24 -- On--Treatment Analysis|Percent Change From Baseline in Non--High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 -- ITT Analysis|Percent Change From Baseline in Non--HDL-C at Week 24 -- On--Treatment Analysis|Percent Change From Baseline in Total Cholesterol (Total--C) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 12 -- ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 - ITT Analysis|Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or Moderate or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis|Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or Moderate or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein(a) at Week 12 -- ITT Analysis|Percent Change in HDL-C From Baseline to Week 12 -- ITT Analysis|Percent Change in Fasting Triglycerides From Baseline to Week 12 -- ITT Analysis|Percent Change From Baseline in Apo A--1 at Week 12 -- ITT Analysis,Regeneron Pharmaceuticals|Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,314,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R727-CL-1119,Sep-12,May-14,May-17,18-Oct-12,28-Aug-15,28-Aug-17,"Anaheim, California, United States|Beverly Hills, California, United States|Mission Viejo, California, United States|Newport Beach, California, United States|Northridge, California, United States|Thousand Oaks, California, United States|Hartford, Connecticut, United States|Boynton Beach, Florida, United States|Jacksonville, Florida, United States|Lakeland, Florida, United States|Pembroke Pines, Florida, United States|Sarasota, Florida, United States|Tampa, Florida, United States|Trinity, Florida, United States|Addison, Illinois, United States|Chicago, Illinois, United States|Indianapolis, Indiana, United States|Kansas City, Kansas, United States|Auburn, Maine, United States|Boston, Massachusetts, United States|Minneapolis, Minnesota, United States|Rochester, Minnesota, United States|Saint Louis, Missouri, United States|Clifton, New Jersey, United States|New York, New York, United States|Poughkeepsie, New York, United States|Durham, North Carolina, United States|Cincinnati, Ohio, United States|Marion, Ohio, United States|Danville, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Port Matilda, Pennsylvania, United States|Scranton, Pennsylvania, United States|Wilkes-Barre, Pennsylvania, United States|Summerville, South Carolina, United States|Kingsport, Tennessee, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Fort Worth, Texas, United States|Salt Lake City, Utah, United States|Richmond, Virginia, United States|Feldkirch, Austria|Graz, Austria|Innsbruck, Austria|Chicoutimi, Quebec, Canada|Montreal (2 locations), Quebec, Canada|Sainte-Foy, Quebec, Canada|Bron, France|Dijon, France|Lille, France|Paris, France|Saint-Herblain, France|Venissieux, France|Holon, Israel|Jerusalem, Israel|Ofakim, Israel|Safed, Israel|Tel-Hashomer, Israel|Cinisello Balsamo, Italy|Napoli, Italy|Palermo, Italy|Roma, Italy|Oslo (2 locations), Norway|Burton-on-Trent, United Kingdom|Chesterfield, United Kingdom|Isle of White, United Kingdom|Londonderry/N. Ireland, United Kingdom|Peterborough, United Kingdom|Salford, United Kingdom|Stevenage, United Kingdom",,https://ClinicalTrials.gov/show/NCT01709513
NCT01710007,Efficacy and Safety Study of Pitavastatin for Hypercholesterolemia,,Completed,No Results Available,Hypercholesterolemia,Drug: 1PC002|Drug: Lipitor,LDL-C|total cholesterol|HDL-C|Triglyceride,"Orient Pharma Co., Ltd.|Orient Europharma Co., Ltd.",All,"20 Years to 80 Years   (Adult, Older Adult)",Phase 3,202,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",QCR10022,Nov-11,Sep-12,Nov-12,18-Oct-12,null,17-Jun-13,"Buddhist Taipei TzuChi General Hospital, New Taipei City, Taiwan|Cardinal Tien Hospital, New Taipei City, Taiwan|Taipei Medical University - Shuang Ho Hospital, New Taipei City, Taiwan|Taichung Veterans General Hospital, Taichung City, Taiwan|Taipei Veterans General Hospital, Taipei City, Taiwan|Cheng Hsin General Hospital, Taipei City, Taiwan|Tri-Service General Hospital, Taipei City, Taiwan|Chang Gung Medical Foundation- LinKuo Branch, Taoyuan City, Taiwan",,https://ClinicalTrials.gov/show/NCT01710007
NCT01708681,Lean Seafood Intake and Postprandial Metabolism,LeSIP,Completed,No Results Available,Hyperlipidemias|Nutritional and Metabolic Diseases|Nutrition Disorders|Metabolic Diseases|Glucose Metabolism Disorders,"Dietary Supplement: Lean seafood|Dietary Supplement: Meat, egg, milk",Postprandial lipid measurement|Postprandial glucose measurement,"National Institute of Nutrition and Seafood Research, Norway|The Research Council of Norway",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,27,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Basic Science,NIFES-001|2012/1084/REK vest,Oct-12,May-13,Sep-15,17-Oct-12,null,6-Oct-15,"National Institute of Nutrition and Seafood Research, Bergen, Norway",,https://ClinicalTrials.gov/show/NCT01708681
NCT01707914,Clinical Investigation on the Effects of Bayberry Juice Treatment in Adult Subjects With Features of Fatty Liver Disease,,Completed,No Results Available,Nonalcoholic Fatty Liver Disease,Dietary Supplement: Chinese bayberry juice|Dietary Supplement: placebo,Plasma lipids profile,Shaoguan University,All,18 Years to 25 Years   (Adult),Not Applicable,44,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",SGU-01|81172655,Jun-12,Oct-12,Nov-12,16-Oct-12,null,4-Dec-12,"The affiliated hospital of Shaoguan University, Shaoguan, Guangdong, China",,https://ClinicalTrials.gov/show/NCT01707914
NCT01702883,The Medication Experience Study,,"Active, not recruiting",No Results Available,Hypertension|Elevated Cholesterol|Diabetes|Depression,Other: Internet Survey,The primary measure will be adherence as measured by pharmacy refills in each group.,Wake Forest University|Wake Forest University Health Sciences,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,186,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other",IRB00020789,Oct-12,Jul-15,Jun-19,10-Oct-12,null,21-Dec-18,"Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01702883
NCT01702987,Evaluation of Ubiquinol on Mitochondrial Oxidative Capacity in Statin Patients Using 31PMRS,,Completed,Has Results,Myopathy|HMG COA Reductase Inhibitor Adverse Reaction|Hypercholesterolemia,Dietary Supplement: ubiquinol|Dietary Supplement: placebo|Drug: statin,Phosphocreatine Recovery,Beth Israel Deaconess Medical Center,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,22,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic",2012P000219,Oct-12,Oct-13,Oct-13,10-Oct-12,17-Apr-17,17-Apr-17,"Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01702987
NCT01697735,The Therapeutic Effects of Statins and Berberine on the Hyperlipemia,,Terminated,No Results Available,Dyslipidemias,Drug: Berberine;Atorvastatin or Rosuvastatin|Drug: Atorvastatin or Rosuvastatin,Change from baseline in combination statins with berberine on lipid level|Adherence of statins and berberine treatment,Wenzhou Medical University,All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 4,24,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),WZ medical college,Sep-12,Sep-15,Sep-15,2-Oct-12,null,28-Apr-16,"Second Hospital of Wenzhou Medical College, Wenzhou, Zhejiang, China",,https://ClinicalTrials.gov/show/NCT01697735
NCT01695837,Live Well: A Practical and Effective Low-Intensity Dietary Counseling Intervention for Use in Primary Care Patients With Dyslipidemia,,Completed,No Results Available,Dyslipidemia,Behavioral: Group A: Dietary counseling month 0-6 Group B: Dietary counseling month 3-6,LDL-Cholesterol|Total Cholesterol|Triglycerides|HDL-Cholesterol|diet score,"University of Nevada, Las Vegas",All,"21 Years to 75 Years   (Adult, Older Adult)",Not Applicable,61,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,5P20RR016464-11/8|5P20RR016464,Jul-11,May-12,Jun-12,28-Sep-12,null,28-Sep-12,"UNSOM Internal Medicine, Reno, Nevada, United States",,https://ClinicalTrials.gov/show/NCT01695837
NCT01695954,Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz,,Unknown status,No Results Available,Hyperlipidemia|HIV,Drug: Pitavastatin|Drug: Darunavir|Drug: Ritonavir|Drug: Efavirenz,"AUC of pitavastatin after coadministration of efavirenz. AUC of pitavastatin after coadministration of darunavir with ritonavir. AUC of efavirenz after coadministration of pitavastatin. AUC of darunavir after coadministration of pitavastatin.|Other pharmacokinetic parameters of pitavastatin and efavirenz and of pitavastatin and darunavir+ritonavir. Lipid measurements at days 0,4,14 and 18.","New York University School of Medicine|Bellevue/NYU AIDS Clinical Trials Unit|Kowa Pharmaceuticals America, Inc.|University at Buffalo",All,18 Years to 60 Years   (Adult),Phase 1,28,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),NYU 11-01787,May-12,Oct-12,Oct-12,28-Sep-12,null,28-Sep-12,"Bellevue/NYU AIDS Clinical Trials Unit, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01695954
NCT01696097,The Effects of Pork vs. Chicken/Fish in a DASH Diet on Blood Pressure Regulation in Middle Aged and Older Adults,S31,Completed,No Results Available,Hypertension|Dyslipidemias,Behavioral: DASH diet counseling,Change in blood pressure|Change in blood lipids,Purdue University,All,"40 Years to 75 Years   (Adult, Older Adult)",Not Applicable,19,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1112011665|S31 Campbell Lab,Apr-12,Feb-14,Oct-14,28-Sep-12,null,17-Aug-15,"Purdue University, West Lafayette, Indiana, United States",,https://ClinicalTrials.gov/show/NCT01696097
NCT01694446,Regulation of Intestinal and Hepatic Lipoprotein Production by Glucose and Fructose,glucose,Completed,No Results Available,Hyperlipidemia,Other: Intraduodenal glucose or fructose,Assessment of intestinal and hepatic lipoprotein production,"University Health Network, Toronto",All,18 Years to 60 Years   (Adult),Not Applicable,14,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,Glucose 090428B,Sep-11,Jan-13,Jan-13,27-Sep-12,null,10-Mar-15,"Toronto General Hopital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01694446
NCT01686451,The Effect of XueZhiKang on Fatigue：Comparing With Simvastatin,,Completed,Has Results,Dyslipidemias,Drug: XueZhiKang|Drug: simvastatin,Comparison Between XueZhiKang and Simvastatin on Fatigue Scores|Treatment Efficacy,Wenzhou Medical University,All,"20 Years to 65 Years   (Adult, Older Adult)",Phase 4,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),Wenzhou,Aug-12,Sep-13,Sep-13,18-Sep-12,19-May-14,19-May-14,"Second Hispital of Wenzhou Medical University, Wenzhou, Zhejiang, China",,https://ClinicalTrials.gov/show/NCT01686451
NCT01680211,Safety and Efficacy Study of Herbal Supplements in Prediabetic and Mild to Moderate Hyperlipidemic Patients,,Completed,No Results Available,Prediabetes|Hyperlipidemia,Dietary Supplement: Salacia bark extract|Dietary Supplement: Salacia leaf extract|Dietary Supplement: Sesame seed extract|Behavioral: TLC|Other: Placebo,Change in Blood Sugar and lipid profiles|Clinical laboratory evaluations,Olive Lifesciences Pvt Ltd,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,40,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",OL-S-OB-LP/03-12|CTRI/2012/05/002678,Apr-12,Jun-12,Jun-12,7-Sep-12,null,7-Sep-12,"Srinivasa Clinic & Diabetic Care Center, Bangalore, Karnataka, India",,https://ClinicalTrials.gov/show/NCT01680211
NCT01678183,Financial Incentives for Medication Adherence,FIMA,Completed,No Results Available,Diabetes Mellitus|Hypertension|Hyperlipidemia,Behavioral: Monthly Financial Incentive|Behavioral: Final Financial Incentive,Improvement in hemoglobin A1c|Improvement in blood pressure.,"Boston Medical Center|Pfizer|National Bureau of Economic Research, Inc.",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,74,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BU IRB H-30045|WS2069417,Sep-12,Apr-14,Jan-15,3-Sep-12,null,2-Feb-15,"Boston Medical Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01678183
NCT01674712,A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate/Simvastatin 145/20mg and Fenofibrate/Simvastatin 145/40mg Tablets Versus Fenofibrate or Simvastatin Monotherapies in Subjects With Abnormal Blood Levels of Fats (Lipids) and at High Risk of Cardiovascular Disease,,Completed,Has Results,Dyslipidemia,Drug: Fixed Combination of Fenofibrate/simvastatin 145/20 mg|Drug: Simvastatin 20 mg|Drug: Fenofibrate 145 mg|Drug: Fixed Combination of Fenofibrate/simvastatin 145/40 mg|Drug: Simvastatin 40 mg,Percentage of Change of TG (Triglyceride)|Percentage of Change of HDL-C (High Density Lipoprotein Cholesterol)|Percentage of Change of LDL-C (Low Density Lipoprotein Cholesterol)|Percentage of Non-HDL (High Density Lipoprotein)-C From Baseline|Percentage of TC (Triglyceride) From Baseline|Percentage of Apolipoprotein AI From Baseline|Percentage of Apolipoprotein B From Baseline|Percentage of High-sensitivity C-reactive Protein (hsCRP) From Baseline|Percentage of Subjects Meeting Target Levels of Lipids (According to Very High or High Risk)|Adverse Events|Creatine Kinase (CK)|Alanine Aminotransferase (ALT)|Plasma Creatinine|Total Bilirubin|Cystatin C,Abbott,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,575,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",M13-377|2011-005924-16,Jun-12,Oct-13,Oct-13,29-Aug-12,30-Oct-14,11-Dec-14,"Site Reference ID/Investigator# 77961, Buenos Aires, Argentina|Site Reference ID/Investigator# 77957, Buenos Aires, Argentina|Site Reference ID/Investigator# 77958, Buenos Aires, Argentina|Site Reference ID/Investigator# 77960, Buenos Aires, Argentina|Site Reference ID/Investigator# 77959, Buenos Aires, Argentina|Site Reference ID/Investigator# 77969, Buenos Aires, Argentina|Site Reference ID/Investigator# 77967, Buenos Aires, Argentina|Site Reference ID/Investigator# 77968, Buenos Aires, Argentina|Site Reference ID/Investigator# 77965, Buenos Aires, Argentina|Site Reference ID/Investigator# 77956, Buenos Aires, Argentina|Site Reference ID/Investigator# 77966, Cipolletti - Rio Negro, Argentina|Site Reference ID/Investigator# 77955, Santa Fe, Argentina|Site Reference ID/Investigator# 77962, Santa Fe, Argentina|Site Reference ID/Investigator# 77964, Santa Fe, Argentina|Site Reference ID/Investigator# 77963, Tucuman, Argentina|Site reference ID/Investigator # 99617, Benatky nad Jizerou, Czech Republic|Site Reference ID/Investigator# 80097, Brno, Czech Republic|Site reference ID/Investigator # 102335, Brno, Czech Republic|Site Reference ID/Investigator# 80094, Prague 10, Czech Republic|Site Reference ID/Investigator# 80095, Prague 4, Czech Republic|Site Reference ID/Investigator# 80093, Praha 8, Czech Republic|Site Reference ID/Investigator# 80098, Teplice, Czech Republic|Site Reference ID/Investigator# 80096, Usti nad Labem, Czech Republic|Site Reference ID/Investigator# 80099, Znojmo, Czech Republic|Site reference ID/Investigator # 97356, Berlin, Germany|Site Reference ID/Investigator# 90673, Berlin, Germany|Site Reference ID/Investigator# 80100, Berlin, Germany|Site reference ID/Investigator # 97357, Berlin, Germany|Site reference ID/Investigator # 102017, Dortmund, Germany|Site reference ID/Investigator # 99876, Dresden, Germany|Site Reference ID/Investigator# 80102, Dusseldorf, Germany|Site Reference ID/Investigator# 80104, Essen, Germany|Site Reference ID/Investigator# 80103, Essen, Germany|Site Reference ID/Investigator# 80105, Frankfurt, Germany|Site Reference ID/Investigator# 80101, Goch, Germany|Site reference ID/Investigator # 99902, Hamburg, Germany|Site reference ID/Investigator # 102015, Karlsruhe, Germany|Site reference ID/Investigator # 102016, Koeln, Germany|Site Reference ID/Investigator# 77970, Guadalajara, Jal., Mexico|Site Reference ID/Investigator# 77973, Mexico D.F., Mexico|Site Reference ID/Investigator# 77972, Mexico D.F., Mexico|Site Reference ID/Investigator# 77974, Zapopan, Mexico|Site Reference ID/Investigator# 80111, Gdansk, Poland|Site Reference ID/Investigator# 80112, Gdansk, Poland|Site Reference ID/Investigator# 80110, Gdynia, Poland|Site Reference ID/Investigator# 80106, Katowice, Poland|Site Reference ID/Investigator# 80109, Plock, Poland|Site Reference ID/Investigator# 80108, Skierniewice, Poland|Site Reference ID/Investigator# 80107, Warsaw, Poland|Site reference ID/Investigator # 80115, Bucharest, Romania|Site Reference ID/Investigator# 80114, Bucharest, Romania|Site Reference ID/Investigator# 80117, Bucharest, Romania|Site Reference ID/Investigator# 80116, Bucharest, Romania|Site Reference ID/Investigator# 80119, Bucharest, Romania|Site Reference ID/Investigator# 80113, Bucharest, Romania|Site Reference ID/Investigator# 80118, Iasi, Romania|Site Reference ID/Investigator# 80120, Kemerovo, Russian Federation|Site Reference ID/Investigator# 80135, Moscow, Russian Federation|Site Reference ID/Investigator# 80137, Moscow, Russian Federation|Site Reference ID/Investigator# 80124, Moscow, Russian Federation|Site Reference ID/Investigator# 80127, Moscow, Russian Federation|Site Reference ID/Investigator# 80122, Novosibirsk, Russian Federation|Site Reference ID/Investigator# 80121, Novosibirsk, Russian Federation|Site Reference ID/Investigator# 80133, Novosibirsk, Russian Federation|Site reference ID/Investigator # 80134, St. Petersburg, Russian Federation|Site reference ID/Investigator # 80126, St. Petersburg, Russian Federation|Site reference ID/Investigator # 80128, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 80136, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 80125, Yaroslavl, Russian Federation",,https://ClinicalTrials.gov/show/NCT01674712
NCT01675154,Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia,,Recruiting,No Results Available,Type 1 Hyperlipoproteinemia,Drug: SLx-4090 placebo|Drug: Orlistat Placebo|Drug: Orlistat|Drug: Slx-4090,"Change in serum triglycerides from baseline for each crossover arm phase of placebo/placebo, orlistat/placebo, orlistat/SLx-4090, SLx-4090/placebo",University of Texas Southwestern Medical Center,All,"12 Years to 100 Years   (Child, Adult, Older Adult)",Phase 2,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3940|FD-R-003940,Nov-15,31-Jul-19,31-Jul-19,29-Aug-12,null,12-Oct-18,"UT Southwestern Medical Center 5323 Harry Hines Blvd, Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT01675154
NCT01671085,A Study of LY3015014 in Healthy Participants With High Cholesterol,,Completed,Has Results,Healthy Volunteers|Hypercholesterolemia,Drug: LY3015014|Drug: Placebo,Number of Participants With One or More Other Non-Serious Adverse Events (AEs) or Any Serious AEs (SAEs)|Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3015014|PK: Area Under the Concentration Curve During One Dosing Interval (AUCt) of LY3015014|PK: Time of Maximum Concentration (Tmax) of LY3015014|Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C),Eli Lilly and Company,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,13,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",14938|I5S-EW-EFJD,Aug-12,Mar-13,Mar-13,23-Aug-12,25-Feb-19,15-Mar-19,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miramar, Florida, United States",,https://ClinicalTrials.gov/show/NCT01671085
NCT01671254,Effect of Citrus Bioflavonoids/Vitamin E in Conjunction With Fish Oil Supplementation,,Completed,No Results Available,Hyperlipidemia,Dietary Supplement: FishOil|Dietary Supplement: CBE75|Dietary Supplement: CBE150|Dietary Supplement: placebo,LDL cholesterol|Triglyceride|oxLDL|Total cholesterol|HDL cholesterol,MetaProteomics LLC,All,"18 Years to 72 Years   (Adult, Older Adult)",Not Applicable,18,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care",POT2-FMR-CT,Aug-12,Dec-12,Dec-12,23-Aug-12,null,18-May-18,"Functional Medicine Research Center, Gig Harbor, Washington, United States",,https://ClinicalTrials.gov/show/NCT01671254
NCT01670734,Pharmacokinetic and Tolerability of Alirocumab SAR236553 (REGN727) in Patients With Hepatic Impairment and in Healthy Subjects,,Completed,No Results Available,Hypercholesterolemia,Drug: alirocumab SAR236553 (REGN727),Pharmacokinetics: Assessment of serum concentrations of alirocumab SAR236553 (REGN727)|Assessment of PK parameter - terminal elimination half-life (t1/2z) [|Assessment of PK parameter - apparent total body clearance (CL/F)|Assessment of PK parameter - Distribution volume at the steady-state (Vss/F)|Assessment of PK parameter - time to maximum concentration (tmax)|Assessment of PK parameter - Mean Residence Time (MRT [area])|Pharmacodynamics: Change in LDL-C from baseline|Number of participants with Adverse Events,Sanofi|Regeneron Pharmaceuticals,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,25,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,POP12671|2012-002292-33|U1111-1129-0248,Sep-12,May-13,May-13,22-Aug-12,null,28-Jun-13,"Investigational Site Number 250001, Rennes, France|Investigational Site Number 498001, Chisinau, Moldova, Republic of",,https://ClinicalTrials.gov/show/NCT01670734
NCT01666041,Vascular and Metabolic Effects of Fenofibrate/Omega vs Fenofibrate,,Completed,No Results Available,Hypertriglyceridemia,Drug: placebo|Drug: fenofibrate/omega|Drug: fenofibrate,flow-mediated dilation|insulin resistance,Gachon University Gil Medical Center,All,"25 Years to 80 Years   (Adult, Older Adult)",Phase 4,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,GMC-201202,Jan-12,Feb-13,Jul-13,16-Aug-12,null,4-Nov-14,"Gil Medical Center, Incheon, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01666041
NCT01666067,Vascular and Metabolic Effects of Vytorin vs Simvastatin,,Completed,No Results Available,Hypercholesterolemia,Drug: placebo|Drug: vytorin|Drug: simvastatin,flow-mediated dilation|insulin resistance,Gachon University Gil Medical Center,All,"25 Years to 80 Years   (Adult, Older Adult)",Phase 4,204,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,GMC-201110,Nov-11,Oct-12,Nov-12,16-Aug-12,null,4-Nov-14,"Gil Medical Center, Incheon, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01666067
NCT01660919,Vascular and Metabolic Effects of Rosuvastatin,,Completed,No Results Available,Hypercholesterolemia,Drug: placebo|Drug: rosuvastatin,flow-mediated dilation|insulin resistance,Gachon University Gil Medical Center,All,"25 Years to 80 Years   (Adult, Older Adult)",Phase 4,160,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,GMC-201105,Oct-11,Jan-13,Dec-13,9-Aug-12,null,4-Nov-14,"Gil Medical Center, Incheon, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01660919
NCT01660932,Vascular and Metabolic Effects of Omega-3 Fatty Acids,,Completed,No Results Available,Hypertriglyceridemia,Drug: placebo|Drug: omega,flow-mediated dilation|insulin resistance,Gachon University Gil Medical Center,All,"25 Years to 80 Years   (Adult, Older Adult)",Phase 4,176,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,GMC-201103,Mar-11,Aug-12,Sep-12,9-Aug-12,null,4-Nov-14,"Gil Medical Center, Incheon, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01660932
NCT01660945,Vascular and Metabolic Effects of Vytorin,,Completed,No Results Available,Hypercholesterolemia,Drug: placebo|Drug: vytorin,flow-mediated dilation|insulin resistance,Gachon University Gil Medical Center,All,"25 Years to 80 Years   (Adult, Older Adult)",Phase 4,204,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,GMC-201102,Jul-11,Jul-12,Nov-12,9-Aug-12,null,4-Nov-14,"Gil Medical Center, Incheon, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01660945
NCT01661543,U of A/ U of M Beans and Peas Health Claim Project,,Completed,No Results Available,Hypercholesterolemia,Dietary Supplement: Beans|Dietary Supplement: Control (rice)|Dietary Supplement: Peas,Lowering of Cholesterol,University of Alberta|Alberta Innovates Health Solutions|Pulse Canada|University of Manitoba,All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,180,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,QFH-11-044,Jan-13,Dec-15,Dec-15,9-Aug-12,null,24-Dec-15,"University of Alberta, Edmonton, Alberta, Canada|University of Manitoba, Winnipeg, Manitoba, Canada",,https://ClinicalTrials.gov/show/NCT01661543
NCT01660191,A Study Comparing CoQ10 Levels While Taking 3 Different Statins,SPARQ,Completed,Has Results,Hypercholesterolemia,Drug: Pitavastin 4mg|Drug: Atorvastatin 20mg|Drug: Rosuvastatin 5mg,Changes in Plasma CoQ10 Levels|Changes in Major Lipid Parameters - VLDL Size|Changes to Glucose Metabolism - HbA1c and Insulin|Changes in HDL and LDL Size|Changes to Glucose Metabolism - Fructosamine|Changes HDL Particle Number and LDL Particle Number,"University of Kansas Medical Center|Kowa Pharmaceuticals America, Inc.|Eli Lilly and Company",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,134,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",12943,Dec-11,Aug-13,Oct-13,8-Aug-12,18-Jan-17,18-Jan-17,"University of Kansas Medical Center, Kansas City, Kansas, United States",,https://ClinicalTrials.gov/show/NCT01660191
NCT01658137,Diet Intervention and GEnetic STudy (DIGEST-Pilot),DIGEST,Unknown status,No Results Available,Cardiovascular Diseases|Inflammation|Dyslipidemias|Blood Pressure|Hyperglycemia,Other: Prudent Diet|Other: Typical Western Diet,gene expression measuring ANRIL production|epigenetic marks|high-sensitivity C-reactive protein|interferon-alpha-21|interferon-gamma|interleukin-1-alpha|total cholesterol|low-density lipoprotein-cholesterol|high-density lipoprotein-cholesterol|apolipoprotein-B|fasting glucose|systolic blood pressure|diastolic blood pressure|interleukin-6,McMaster University,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,84,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,DIGEST-Pilot,Jul-12,Dec-16,Dec-16,6-Aug-12,null,7-Jun-16,"McMaster University, Hamilton, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01658137
NCT01652703,A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japanese Subjects,AMG145,Completed,Has Results,Hypercholesterolemia and High Risk for Cardiovascular Events,Biological: Evolocumab|Other: Placebo,Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12|Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12|Percentage of Participants With an LDL-C Response at Week 12|Percent Change From Baseline to Week 12 in Non-HDL-C|Percent Change From Baseline to Week 12 in Apolipoprotein B|Percent Change From Baseline to Week 12 in VLDL-C|Percent Change From Baseline to Week 12 in Total Cholesterol/HDL-C Ratio|Percent Change From Baseline to Week 12 in Apolipoprotein B/Apolipoprotein A-1 Ratio,Amgen,All,"20 Years to 80 Years   (Adult, Older Adult)",Phase 2,310,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",20110231,10-Jul-12,14-May-13,null,30-Jul-12,5-Oct-15,28-Nov-18,"Research Site, Nagoya-shi, Aichi, Japan|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Fukui-shi, Fukui, Japan|Research Site, Fukui-shi, Fukui, Japan|Research Site, Fukui-shi, Fukui, Japan|Research Site, Kasuga-shi, Fukuoka, Japan|Research Site, Gifu-shi, Gifu, Japan|Research Site, Fujioka-shi, Gunma, Japan|Research Site, Maebashi-shi, Gunma, Japan|Research Site, Maebashi-shi, Gunma, Japan|Research Site, Takasaki-shi, Gunma, Japan|Research Site, Kawani-shi, Hyogo, Japan|Research Site, Kobe-shi, Hyogo, Japan|Research Site, Hitachi-shi, Ibaraki, Japan|Research Site, Koga-shi, Ibaraki, Japan|Research Site, Mito-shi, Ibaraki, Japan|Research Site, Komatsu-shi, Ishikawa, Japan|Research Site, Takamatsu-shi, Kagawa, Japan|Research Site, Kochi-shi, Kochi, Japan|Research Site, Kumamoto-shi, Kumamoto, Japan|Research Site, Kyoto-shi, Kyoto, Japan|Research Site, Kyoto-shi, Kyoto, Japan|Research Site, Ina-shi, Nagano, Japan|Research Site, Matsumoto-shi, Nagano, Japan|Research Site, Suwa-shi, Nagano, Japan|Research Site, Ibaraki-shi, Osaka, Japan|Research Site, Suita-shi, Osaka, Japan|Research Site, Toyonaka-shi, Osaka, Japan|Research Site, Hanyu-shi, Saitama, Japan|Research Site, Sayama-shi, Saitama, Japan|Research Site, Toda-shi, Saitama, Japan|Research Site, Otsu-shi, Shiga, Japan|Research Site, Bunkyo-ku, Tokyo, Japan|Research Site, Bunkyo-ku, Tokyo, Japan|Research Site, Chiyoda-ku, Tokyo, Japan|Research Site, Chuo-ku, Tokyo, Japan|Research Site, Hachioji-shi, Tokyo, Japan|Research Site, Itabashi-ku, Tokyo, Japan|Research Site, Shinagawa-ku, Tokyo, Japan|Research Site, Taito-ku, Tokyo, Japan|Research Site, Toshima-ku, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT01652703
NCT01651273,A Safety Study of BMS-852927 in Subjects With Hypercholesterolemia,,Terminated,No Results Available,Hypercholesterolemia,Drug: BMS-852927|Drug: Placebo,"Number and percent of subjects that experience the Serious adverse events, Deaths, Adverse events leading to discontinuation of study therapy|Number and percent of subjects with potentially clinically significant changes in ECG parameter|Number and percent of subjects with potentially clinically significant changes in low density lipoprotein (LDL)-c (measured)|Trough observed concentration (Cmin) of BMS-852927 will be derived from plasma concentration versus time data|Area under the concentration-time curve from zero (pre-dose) to 8 h [AUC(0-8h)] of BMS-852927 will be derived from plasma concentration versus time data",Bristol-Myers Squibb,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,97,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CV201-008|2012‐001946‐17,Nov-12,Jun-13,Jun-13,27-Jul-12,null,5-Aug-13,"Local Institution, Brampton, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Pointe-Claire, Quebec, Canada|Local Institution, Victoriaville, Quebec, Canada|Local Institution, Quebec, Canada|Local Institution, Quebec, Canada|Local Institution, Berlin, Germany|Local Institution, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT01651273
NCT01651065,Micro-Clinic Obesity and Metabolic Risk Prevention Program,,Completed,No Results Available,"Diabetes Mellitus, Type II|Heart Disease|Obesity|Hypertension|Dyslipidemia",Behavioral: Microclinic Diabetes Education Program|Behavioral: Control,"Weight|Waist circumference|Blood pressure|HDL|Hemoglobin A1c (%, HbA1c)","Microclinic International|Bell County Department of Health, Kentucky",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,919,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,20110766,Jun-11,Dec-14,Dec-14,26-Jul-12,null,17-Mar-16,"Bell County Health Department, Pineville, Kentucky, United States",,https://ClinicalTrials.gov/show/NCT01651065
NCT01649986,Nutraceuticals to Improve Lipid Profile in European Countries,PIN,Unknown status,No Results Available,Hyperlipidemia,Behavioral: Non-pharmacologic intervention|Drug: Nutraceuticals (Armolipid Plus),Evaluation of treatment tolerability|Evaluation of drug effects on lipid and metabolic features,University of Roma La Sapienza,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",450/2012/D,Jan-14,Dec-15,Dec-17,25-Jul-12,null,7-Mar-13,"Sapienza University, Rome, Italy",,https://ClinicalTrials.gov/show/NCT01649986
NCT01647438,Translating a Heart Disease Lifestyle Intervention Into the Community,,Completed,Has Results,Obesity|Hyperlipidemia|Hypertension|Pre-diabetes|Diabetes,Behavioral: Lifestyle Intervention|Other: Print Health Education,Change in Physical Activity (Minutes/Week)|Change in Saturated Fat (% of Daily Kilo-calories From Fat) Intake,Northwestern University,All,30 Years to 60 Years   (Adult),Not Applicable,63,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,R21HL113743-01,Aug-12,Dec-13,Feb-15,23-Jul-12,2-Nov-15,2-Nov-15,"Northwestern University-Feinberg School of Medicine, Chicago, Illinois, United States|Metropolitan Asian Family Services, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT01647438
NCT01644474,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia,ODYSSEY MONO,Completed,Has Results,Hypercholesterolemia,Drug: Alirocumab|Drug: Ezetimibe|Drug: Placebo (for Alirocumab)|Drug: Placebo (for Ezetimibe),Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 24 - ITT Analysis|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 12 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 - ITT Analysis|Percentage of Participants Achieving Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis|Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis,Sanofi|Regeneron Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 3,103,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EFC11716|U1111-1124-1167|2011-001424-38,Jul-12,Jul-13,Jul-13,19-Jul-12,6-Nov-15,6-Nov-15,"Investigational Site Number 840603, Overland Park, Kansas, United States|Investigational Site Number 840601, Cincinnati, Ohio, United States|Investigational Site Number 840602, Richmond, Virginia, United States|Investigational Site Number 056601, Antwerpen, Belgium|Investigational Site Number 246601, Helsinki, Finland|Investigational Site Number 528602, Groningen, Netherlands|Investigational Site Number 528601, Rotterdam, Netherlands|Investigational Site Number 528603, Velp, Netherlands",,https://ClinicalTrials.gov/show/NCT01644474
NCT01644942,Identification in Obese Patients of the Mechanism Involved in Intramuscular Lipid Accumulation,,Completed,No Results Available,Obesity|Insulin Resistance|Hyperlipidemia,Other: Lipid accumulation analysis,lipid accumulation in skeletal muscle|lipid accumulation in myotubes from obese patients,"University Hospital, Montpellier",Male,"40 Years to 70 Years   (Adult, Older Adult)",Not Applicable,33,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),8193,May-08,Jun-13,Jun-13,19-Jul-12,null,18-Jun-13,"CHRU Montpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT01644942
NCT01645046,The Effects of Coenzyme A on Serum Lipids in Patients With Hyperlipidemia,,Completed,No Results Available,Hyperlipoproteinemia,Drug: Coenzyme A|Drug: Placebo,"The changes of TG levels.|The changes of TC, LDL-C, and HDL-C levels.",Zhejiang University,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,294,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2008MMXX2CoA005,Oct-08,Jun-09,Aug-09,19-Jul-12,null,19-Jul-12,,,https://ClinicalTrials.gov/show/NCT01645046
NCT01644175,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I),,Completed,Has Results,Hypercholesterolemia,Drug: Placebo (for alirocumab)|Drug: Alirocumab|Drug: Lipid-Modifying Therapy (LMT),Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis|Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis|Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 24 - On-treatment Analysis|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 - On-treatment Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 12 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-treatment Analysis|Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis|Percent Change From Baseline in Apolipoprotein A-1 at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein(a) at Week 12- ITT Analysis|Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis,Sanofi|Regeneron Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 3,316,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EFC11568|U1111-1121-4356,Jul-12,Apr-14,Apr-14,18-Jul-12,6-Nov-15,6-Nov-15,"Investigational Site Number 840857, Birmingham, Alabama, United States|Investigational Site Number 840891, Mobile, Alabama, United States|Investigational Site Number 840876, Montgomery, Alabama, United States|Investigational Site Number 840865, Glendale, Arizona, United States|Investigational Site Number 840826, Jonesboro, Arkansas, United States|Investigational Site Number 840870, Burbank, California, United States|Investigational Site Number 840851, Los Angeles, California, United States|Investigational Site Number 840845, Los Gatos, California, United States|Investigational Site Number 840844, Sacramento, California, United States|Investigational Site Number 840801, San Jose, California, United States|Investigational Site Number 840886, Tarzana, California, United States|Investigational Site Number 840862, Torrance, California, United States|Investigational Site Number 840893, Vista, California, United States|Investigational Site Number 840867, Boca Raton, Florida, United States|Investigational Site Number 840884, Boynton Beach, Florida, United States|Investigational Site Number 840836, Clearwater, Florida, United States|Investigational Site Number 840866, Coral Gables, Florida, United States|Investigational Site Number 840895, Ft. Lauderdale, Florida, United States|Investigational Site Number 840820, Hialeah, Florida, United States|Investigational Site Number 840805, Miami, Florida, United States|Investigational Site Number 840811, Oviedo, Florida, United States|Investigational Site Number 840881, Port Orange, Florida, United States|Investigational Site Number 840816, West Palm Beach, Florida, United States|Investigational Site Number 840850, Columbus, Georgia, United States|Investigational Site Number 840840, Eagle, Idaho, United States|Investigational Site Number 840842, Chicago, Illinois, United States|Investigational Site Number 840898, Evanston, Illinois, United States|Investigational Site Number 840847, Morton, Illinois, United States|Investigational Site Number 840896, Indianapolis, Indiana, United States|Investigational Site Number 840894, Michigan City, Indiana, United States|Investigational Site Number 840838, Mishawaka, Indiana, United States|Investigational Site Number 840823, Paducah, Kentucky, United States|Investigational Site Number 840858, Eunice, Louisiana, United States|Investigational Site Number 840802, New Orleans, Louisiana, United States|Investigational Site Number 840855, Salisbury, Massachusetts, United States|Investigational Site Number 840890, Battle Creek, Michigan, United States|Investigational Site Number 840832, Southfield, Michigan, United States|Investigational Site Number 840839, Edina, Minnesota, United States|Investigational Site Number 840888, Minneapolis, Minnesota, United States|Investigational Site Number 840837, Port Gibson, Mississippi, United States|Investigational Site Number 840814, Jefferson City, Missouri, United States|Investigational Site Number 840833, Sparks, Nevada, United States|Investigational Site Number 840817, Newington, New Hampshire, United States|Investigational Site Number 840853, New Windsor, New York, United States|Investigational Site Number 840822, Rochester, New York, United States|Investigational Site Number 840824, Cary, North Carolina, United States|Investigational Site Number 840880, Smithfield, North Carolina, United States|Investigational Site Number 840502, Winston-Salem, North Carolina, United States|Investigational Site Number 840852, Winston-Salem, North Carolina, United States|Investigational Site Number 840846, Cincinnati, Ohio, United States|Investigational Site Number 840899, Cincinnati, Ohio, United States|Investigational Site Number 840831, Columbus, Ohio, United States|Investigational Site Number 840860, Kettering, Ohio, United States|Investigational Site Number 840809, Willoughby Hills, Ohio, United States|Investigational Site Number 840818, Norman, Oklahoma, United States|Investigational Site Number 840812, Eugene, Oregon, United States|Investigational Site Number 840803, Downington, Pennsylvania, United States|Investigational Site Number 840869, Philadelphia, Pennsylvania, United States|Investigational Site Number 840825, Pittsburgh, Pennsylvania, United States|Investigational Site Number 840872, Anderson, South Carolina, United States|Investigational Site Number 840885, Charleston, South Carolina, United States|Investigational Site Number 840813, Greer, South Carolina, United States|Investigational Site Number 840827, Mt. Pleasant, South Carolina, United States|Investigational Site Number 840868, Corpus Christi, Texas, United States|Investigational Site Number 840877, Houston, Texas, United States|Investigational Site Number 840841, Houston, Texas, United States|Investigational Site Number 840830, San Antonio, Texas, United States|Investigational Site Number 840854, San Antonio, Texas, United States|Investigational Site Number 840883, San Antonio, Texas, United States|Investigational Site Number 840889, Tomball, Texas, United States|Investigational Site Number 840878, Bountiful, Utah, United States|Investigational Site Number 840819, Orem, Utah, United States|Investigational Site Number 840863, Salt Lake City, Utah, United States|Investigational Site Number 840804, Manassas, Virginia, United States|Investigational Site Number 840882, Norfolk, Virginia, United States|Investigational Site Number 840810, Weber City, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01644175
NCT01644188,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II),,Completed,Has Results,Hypercholesterolemia,Drug: Alirocumab|Drug: Placebo (for alirocumab)|Drug: Ezetimibe|Drug: Placebo (for ezetimibe)|Drug: Lipid Modifying Therapy (LMT),Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis|Percent Change From Baseline in Calculated LDL--C at Week 24 - On--Treatment Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis|Percent Change From Baseline in Apolipoprotein B (Apo-B) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo-B at Week 12 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis|Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis|Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein(a) at Week 12 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis,Sanofi|Regeneron Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 3,720,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EFC11569|U1111-1121-4315|2011-004130-34,Aug-12,May-14,Jul-15,18-Jul-12,6-Nov-15,4-Aug-16,"Investigational Site Number 840980, Birmingham, Alabama, United States|Investigational Site Number 840918, Phoenix, Arizona, United States|Investigational Site Number 840925, Tucson, Arizona, United States|Investigational Site Number 840959, Anaheim, California, United States|Investigational Site Number 840301, Beverly Hills, California, United States|Investigational Site Number 840933, Chino, California, United States|Investigational Site Number 840991, Lincoln, California, United States|Investigational Site Number 840979, Los Angeles, California, United States|Investigational Site Number 840952, Palm Springs, California, United States|Investigational Site Number 840930, Thousand Oaks, California, United States|Investigational Site Number 840921, Vista, California, United States|Investigational Site Number 840962, Boynton Beach, Florida, United States|Investigational Site Number 840987, Bradenton, Florida, United States|Investigational Site Number 840302, Clearwater, Florida, United States|Investigational Site Number 840935, Jacksonville, Florida, United States|Investigational Site Number 840903, Miami, Florida, United States|Investigational Site Number 840920, Miami, Florida, United States|Investigational Site Number 840943, Ocala, Florida, United States|Investigational Site Number 840981, Oveido, Florida, United States|Investigational Site Number 840961, Port Orange, Florida, United States|Investigational Site Number 840303, Sarasota, Florida, United States|Investigational Site Number 840986, St. Petersburg, Florida, United States|Investigational Site Number 840988, St. Petersburg, Florida, United States|Investigational Site Number 840995, Meridian, Idaho, United States|Investigational Site Number 840902, Evansville, Indiana, United States|Investigational Site Number 840960, Topeka, Kansas, United States|Investigational Site Number 840940, Oxon Hill, Maryland, United States|Investigational Site Number 840966, Fall River, Massachusetts, United States|Investigational Site Number 840917, Kansas City, Missouri, United States|Investigational Site Number 840998, St. Louis, Missouri, United States|Investigational Site Number 840946, Butte, Montana, United States|Investigational Site Number 840914, Lincoln, Nebraska, United States|Investigational Site Number 840949, Albuquerque, New Mexico, United States|Investigational Site Number 840974, New Windsor, New York, United States|Investigational Site Number 840955, Greenville, North Carolina, United States|Investigational Site Number 840938, Lexington, North Carolina, United States|Investigational Site Number 840976, Smithfield, North Carolina, United States|Investigational Site Number 840985, Winston-Salem, North Carolina, United States|Investigational Site Number 840963, Cincinnati, Ohio, United States|Investigational Site Number 840970, Lyndhust, Ohio, United States|Investigational Site Number 840906, Marion, Ohio, United States|Investigational Site Number 840997, Marion, Ohio, United States|Investigational Site Number 840964, Perrysburg, Ohio, United States|Investigational Site Number 840913, Charleston, South Carolina, United States|Investigational Site Number 840912, Greer, South Carolina, United States|Investigational Site Number 840992, Summerville, South Carolina, United States|Investigational Site Number 840932, Bristol, Tennessee, United States|Investigational Site Number 840944, Nashville, Tennessee, United States|Investigational Site Number 840994, Fort Worth, Texas, United States|Investigational Site Number 840973, Houston, Texas, United States|Investigational Site Number 840939, Houston, Texas, United States|Investigational Site Number 840945, Sugar Land, Texas, United States|Investigational Site Number 840971, Tomball, Texas, United States|Investigational Site Number 840982, Orem, Utah, United States|Investigational Site Number 840931, Norfolk, Virginia, United States|Investigational Site Number 840984, Richmond, Virginia, United States|Investigational Site Number 840928, Renton, Washington, United States|Investigational Site Number 840990, Spokane, Washington, United States|Investigational Site Number 124902, Brampton, Canada|Investigational Site Number 124914, Mirabel, Canada|Investigational Site Number 124903, Montreal, Canada|Investigational Site Number 124918, Toronto, Canada|Investigational Site Number 208913, Esbjerg, Denmark|Investigational Site Number 208914, Glostrup, Denmark|Investigational Site Number 208905, Hellerup, Denmark|Investigational Site Number 208911, Herlev, Denmark|Investigational Site Number 208907, Hvidovre, Denmark|Investigational Site Number 208901, København S, Denmark|Investigational Site Number 208906, Køge, Denmark|Investigational Site Number 208908, Roskilde, Denmark|Investigational Site Number 208903, Silkeborg, Denmark|Investigational Site Number 250906, Dijon, France|Investigational Site Number 250907, Montpellier Cedex 5, France|Investigational Site Number 250903, Nantes, France|Investigational Site Number 250905, Nimes, France|Investigational Site Number 348908, Budapest, Hungary|Investigational Site Number 348901, Budapest, Hungary|Investigational Site Number 348903, Budapest, Hungary|Investigational Site Number 348905, Debrecen, Hungary|Investigational Site Number 348906, Szekesfehervar, Hungary|Investigational Site Number 376908, Holon, Israel|Investigational Site Number 376903, Kfar Saba, Israel|Investigational Site Number 376906, Ofakim, Israel|Investigational Site Number 376902, Petach Tikva, Israel|Investigational Site Number 376904, Rehovot, Israel|Investigational Site Number 376907, Safed, Israel|Investigational Site Number 376901, Tel Aviv, Israel|Investigational Site Number 410908, Anyang-Si, Korea, Republic of|Investigational Site Number 410920, Busan, Korea, Republic of|Investigational Site Number 410926, Daegu, Korea, Republic of|Investigational Site Number 410923, Gwangju, Korea, Republic of|Investigational Site Number 410909, Seoul, Korea, Republic of|Investigational Site Number 410922, Seoul, Korea, Republic of|Investigational Site Number 410921, Seoul, Korea, Republic of|Investigational Site Number 410905, Seoul, Korea, Republic of|Investigational Site Number 410901, Seoul, Korea, Republic of|Investigational Site Number 410914, Seoul, Korea, Republic of|Investigational Site Number 410924, Seoul, Korea, Republic of|Investigational Site Number 410915, Suwon, Korea, Republic of|Investigational Site Number 410913, Uijeongbu, Korea, Republic of|Investigational Site Number 410927, Wonju, Korea, Republic of|Investigational Site Number 643906, Barnaul, Russian Federation|Investigational Site Number 643903, Kemerovo, Russian Federation|Investigational Site Number 643927, Moscow, Russian Federation|Investigational Site Number 643928, Moscow, Russian Federation|Investigational Site Number 643931, Moscow, Russian Federation|Investigational Site Number 643924, Moscow, Russian Federation|Investigational Site Number 643932, Moscow, Russian Federation|Investigational Site Number 643908, Moscow, Russian Federation|Investigational Site Number 643904, Moscow, Russian Federation|Investigational Site Number 643911, Orenburg, Russian Federation|Investigational Site Number 643921, Ryazan, Russian Federation|Investigational Site Number 643925, Saint-Petersburg, Russian Federation|Investigational Site Number 643922, Saint-Petersburg, Russian Federation|Investigational Site Number 643929, Saratov, Russian Federation|Investigational Site Number 643914, St-Petersburg, Russian Federation|Investigational Site Number 710917, Alberton, South Africa|Investigational Site Number 710909, Bloemfontein, South Africa|Investigational Site Number 710914, Bloemfontein, South Africa|Investigational Site Number 710905, Cape Town, South Africa|Investigational Site Number 710904, Cape Town, South Africa|Investigational Site Number 710918, Middelburg, South Africa|Investigational Site Number 710913, Pretoria, South Africa|Investigational Site Number 710915, Somerset West, South Africa|Investigational Site Number 804905, Kiev, Ukraine|Investigational Site Number 804902, Uzhhorod, Ukraine",,https://ClinicalTrials.gov/show/NCT01644188
NCT01642355,Prevention Trial to Achieve Cardiovascular Targets,IMPACT,Completed,No Results Available,Coronary Artery Disease|Peripheral Arterial Disease|Hyperlipidemia|Hypertension|Diabetes|Prediabetes|Obesity,Behavioral: Prevention Consult|Behavioral: Consult & Behavioral Intervention,Reduction of Non-HDL cholesterol|Lipids|Metabolic risk factors|Physical Activity|Nutrition|Medication Adherence|Optimal medical regimen|Quality of life|Smoking cessation|Cardiovascular risk|Cardiovascular events,New York University School of Medicine|The Rainer Arnhold Foundation,All,"21 Years to 99 Years   (Adult, Older Adult)",Not Applicable,400,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,IMPACT-2012-400,Jun-12,May-16,May-16,17-Jul-12,null,2-Jan-17,"New York University Langone Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01642355
NCT01634646,Observational Study of Lyzme5 Impact on Cholesterol and Body Weight in Man,Lyzme5,Terminated,No Results Available,Overweight|Elevated Cholesterol,Dietary Supplement: Lyzme5,Weight loss|Cholesterol reduction,Jeff Golini|All American Pharmaceutical,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,19,Industry,Interventional,"Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)",Lyzme5-IRB26715/1,May-12,Jan-13,Jan-13,6-Jul-12,null,16-Jul-13,"All American Pharmaceutical and Natural Foods Corporation, Billings, Montana, United States",,https://ClinicalTrials.gov/show/NCT01634646
NCT01634906,Erythrocyte-bound Apolipoprotein B After Withdrawal of Statin Therapy,EBABAST,Completed,No Results Available,Hyperlipidemia|Atherosclerosis,Drug: Temporary discontinuation of statin therapy,Apolipoprotein B bound to erythrocytes|Apolipoprotein B bound to leukocytes|Leukocyte activation,Sint Franciscus Gasthuis,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,55,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,NL37698.101.11,Jul-12,Mar-13,Mar-13,6-Jul-12,null,22-Mar-13,"Sint Franciscus Gasthuis, Rotterdam, Zuid Holland, Netherlands",,https://ClinicalTrials.gov/show/NCT01634906
NCT01632358,Safety and Pharmacokinetis of TAP311 in Dyslipidemic Patients,,Completed,No Results Available,Dyslipidaemia,Drug: TAP311 capsules|Drug: Placebo,"Number of patients with adverse events|Pharmacokinetics of TAP311: The observed maximum plasma concentration following drug administration at steady state (Cmax,ss)|Pharmacokinetics of TAP311: The time to reach the maximum concentration after drug administration at steady state(Tmax, ss)|Pharmacokinetics of TAP311: The area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)|Pharmacokinetics of TAP311: The Racc ratio from the plasma concentration-time data|Pharmacokinetics of TAP311: The AUCtau, from the plasma concentration-time data",Novartis Pharmaceuticals|Novartis,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,279,Industry,Interventional,"Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CTAP311X2201|2012-000857-29,Jun-12,Dec-12,Dec-12,2-Jul-12,null,2-Dec-13,"Novartis Investigative Site, Miramar, Florida, United States|Novartis Investigative Site, Amman, Jordan|Novartis Investigative Site, Taichung, Taiwan",,https://ClinicalTrials.gov/show/NCT01632358
NCT01629888,A Clinical Study for Evaluating the Safety of Excessive Consumption of a Plant Sterol-enriched Yoghurt Drink,,Completed,No Results Available,Healthy|Mild Hypercholesterolemia,"Other: 1- plain low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).|Other: 2- plain low-fat dairy fermented product (drinkable) without plant sterols-esters",,Danone Japan|Danone Research,All,"20 Years to 65 Years   (Adult, Older Adult)",Not Applicable,48,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)",NU336,Feb-10,Apr-10,Jun-10,28-Jun-12,null,10-Oct-16,"Senri Chuo Ekimae Clinic, Osaka, Japan",,https://ClinicalTrials.gov/show/NCT01629888
NCT01630668,Efficacy of a One-a-Day L. Reuteri NCIMB 30242 Probiotic Supplement Capsule,,Completed,No Results Available,Hypercholesterolemia,Dietary Supplement: One-a-Day L. reuteri NCIMB 30242 supplement capsule|Dietary Supplement: One-a-Day placebo capsule,The primary outcome will be the change in serum LDL-cholesterol from baseline to endpoint between control and treatment groups.,Micropharma Limited,All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 2,150,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MP-12LCHM,Aug-12,Dec-13,Jun-14,28-Jun-12,null,26-Jun-14,"KGK Synergize Inc., London, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01630668
NCT01625442,Crocus Sativus (Saffron) and Berberis Vulgaris (Barberry Fruit) in Metabolic Syndrome,,Completed,No Results Available,Metabolic Syndrome|Hypercholesterolemia|Hypertriglyceridemia|Hyperglycemia,Drug: Saffron tablet|Drug: Barberry tablet|Drug: Placebo,Serum LDL cholesterol|Serum total cholesterol|serum HDL cholesterol|serum triglyceride|Fasting Blood Sugar|Hematocrit,Birjand University of Medical Sciences,All,"18 Years and older   (Adult, Older Adult)",Phase 4,732,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,3132012|3132012n,Jan-10,Jul-11,Feb-12,21-Jun-12,null,21-Jun-12,"Birjand University of medical sciences, Birjand, South khorasan, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT01625442
NCT01624142,Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders,TAUSSIG,Completed,Has Results,Severe Familial Hypercholesterolemia,Biological: Evolocumab,Number of Participants With Adverse Events|Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)|Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)|Percent Change From Baseline in Lipoprotein (a)|Percent Change From Baseline in Apolipoprotein B|Percent Change From Baseline in Total Cholesterol/HDL-C Ratio|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio|Percentage of Participants With a 15% or Greater Reduction in LDL-C,Amgen,All,"12 Years to 80 Years   (Child, Adult, Older Adult)",Phase 2|Phase 3,300,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20110271|2011-005400-15,1-Jun-12,11-May-18,11-May-18,20-Jun-12,28-Jan-19,28-Jan-19,"Research Site, Los Angeles, California, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Nashville, Tennessee, United States|Research Site, Hobart, Tasmania, Australia|Research Site, Perth, Western Australia, Australia|Research Site, Bruxelles, Belgium|Research Site, La Louvière, Belgium|Research Site, Sao Paulo, São Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, London, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Olomouc, Czechia|Research Site, Praha 2, Czechia|Research Site, Uherske Hradiste, Czechia|Research Site, Dijon, France|Research Site, Paris Cedex 13, France|Research Site, Athens, Greece|Research Site, New Territories, Hong Kong|Research Site, Ramat Gan, Israel|Research Site, Cinisello Balsamo (MI), Italy|Research Site, Napoli, Italy|Research Site, Pisa, Italy|Research Site, Kanazawa, Ishikawa, Japan|Research Site, Suita, Osaka, Japan|Research Site, Beirut, Lebanon|Research Site, Amsterdam, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Christchurch, New Zealand|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Observatory, Western Cape, South Africa|Research Site, Cordoba, Andalucía, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, A Coruña, Galicia, Spain|Research Site, Lugo, Galicia, Spain|Research Site, Madrid, Spain|Research Site, Manchester, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT01624142/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT01624142/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01624142
NCT01624207,The Efficacy and Safety of Atorva® 20mg Versus Lipitor® 20mg,,Completed,No Results Available,Hypercholesterolemia,Drug: generic formulation of atorvastatin (Atorva®)|Drug: branded formulation of atorvastatin (Lipitor®),"% change of LDL cholesterol|% change of other lipid paramenters(total cholesterol, high-density lipoprotein [HDL] cholesterol, triglyceride [TG], apolipoprotein B [ApoB] and apolipoprotein A1 [ApoA1])|% change of lipoprotein and apolipoprotein ratios (ApoB/ApoA1 ratio, total cholesterol/HDL cholesterol ratio)|Change of highly sensitive C-reactive protein (hsCRP)|LDL cholesterol goal achievement rate","Seoul National University Hospital|Yuhan corp., Seoul, Korea",All,"20 Years to 79 Years   (Adult, Older Adult)",Phase 4,376,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ROYAL|H-1002-038-309,Mar-10,Jan-11,Apr-11,20-Jun-12,null,17-Dec-13,"Seoul National University Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01624207
NCT01623115,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy,ODYSSEY FH I,Completed,Has Results,Hypercholesterolemia,Drug: Alirocumab|Drug: Placebo (for alirocumab)|Drug: Lipid Modifying Therapy (LMT),Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis|Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis|Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 12 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis|Percentage of Very High Cardiovascular (CV) Risk Participants Achieving Calculated LDL-C < 70 mg/dL (<1.81 mmol/L) or High CV Risk Participants Achieving Calculated LDL-C < 100 mg/dL (<2.59 mmol/L) at Week 24 - ITT Analysis|Percentage of Very High CV Risk Participants Achieving Calculated LDL-C < 70 mg/dL (<1.81 mmol/L) or High CV Risk Participants Achieving Calculated LDL-C < 100 mg/dL (<2.59 mmol/L) at Week 24 - On- Treatment Analysis|Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis|Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis,Sanofi|Regeneron Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 3,486,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EFC12492|U1111-1121-4275|2011-005109-56,Jul-12,Apr-14,Dec-14,19-Jun-12,4-Nov-15,8-Feb-16,"Investigational Site Number 840417, Bell Gardens, California, United States|Investigational Site Number 840429, Long Beach, California, United States|Investigational Site Number 840419, Los Angeles, California, United States|Investigational Site Number 840421, Mission Viejo, California, United States|Investigational Site Number 840412, Newport Beach, California, United States|Investigational Site Number 840428, Newport Beach, California, United States|Investigational Site Number 840461, Northridge, California, United States|Investigational Site Number 840452, Washington, District of Columbia, United States|Investigational Site Number 840456, Miami, Florida, United States|Investigational Site Number 840418, Ponte Vedra, Florida, United States|Investigational Site Number 840455, Evanston, Illinois, United States|Investigational Site Number 840415, Kansas City, Kansas, United States|Investigational Site Number 840425, Auburn, Maine, United States|Investigational Site Number 840411, Boston, Massachusetts, United States|Investigational Site Number 840409, St Louis, Missouri, United States|Investigational Site Number 840407, Morristown, New Jersey, United States|Investigational Site Number 840408, New York, New York, United States|Investigational Site Number 840401, Charlotte, North Carolina, United States|Investigational Site Number 840410, Durham, North Carolina, United States|Investigational Site Number 840430, Cincinnati, Ohio, United States|Investigational Site Number 840424, Portland, Oregon, United States|Investigational Site Number 840404, Philadelphia, Pennsylvania, United States|Investigational Site Number 840426, Philadelphia, Pennsylvania, United States|Investigational Site Number 840406, Nashville, Tennessee, United States|Investigational Site Number 840460, Dallas, Texas, United States|Investigational Site Number 840422, Bountiful, Utah, United States|Investigational Site Number 040403, Graz, Austria|Investigational Site Number 040402, Wien, Austria|Investigational Site Number 040405, Wien, Austria|Investigational Site Number 124404, Chicoutimi, Canada|Investigational Site Number 124401, Montreal, Canada|Investigational Site Number 124403, Quebec, Canada|Investigational Site Number 124406, Sherbrooke, Canada|Investigational Site Number 124407, Toronto, Canada|Investigational Site Number 203401, Praha, Czech Republic|Investigational Site Number 203403, Praha, Czech Republic|Investigational Site Number 203405, Uherske Hradiste, Czech Republic|Investigational Site Number 203402, Zlin, Czech Republic|Investigational Site Number 208401, Copenhagen, Denmark|Investigational Site Number 208403, Esbjerg, Denmark|Investigational Site Number 250403, Dijon, France|Investigational Site Number 250401, Paris Cedex 13, France|Investigational Site Number 250402, Saint Herblain, France|Investigational Site Number 376402, Holon, Israel|Investigational Site Number 376405, Jerusalem, Israel|Investigational Site Number 376404, Safed, Israel|Investigational Site Number 376401, Tel Hashomer, Israel|Investigational Site Number 528406, Amsterdam, Netherlands|Investigational Site Number 528410, Amsterdam, Netherlands|Investigational Site Number 528408, Den Helder, Netherlands|Investigational Site Number 528402, Groningen, Netherlands|Investigational Site Number 528411, Leiden, Netherlands|Investigational Site Number 528416, Maastricht, Netherlands|Investigational Site Number 528409, Nieuwegein, Netherlands|Investigational Site Number 528412, Sliedrecht, Netherlands|Investigational Site Number 578401, Bodø, Norway|Investigational Site Number 643402, Arkhangelsk, Russian Federation|Investigational Site Number 643407, Kazan, Russian Federation|Investigational Site Number 643409, Moscow, Russian Federation|Investigational Site Number 643413, Moscow, Russian Federation|Investigational Site Number 643401, Moscow, Russian Federation|Investigational Site Number 643412, Novisibirsk, Russian Federation|Investigational Site Number 643408, St-Petersburg, Russian Federation|Investigational Site Number 643406, St-Petersburg, Russian Federation|Investigational Site Number 643404, St-Petersburg, Russian Federation|Investigational Site Number 643410, Yaroslavl, Russian Federation|Investigational Site Number 710401, Bloemfontein, South Africa|Investigational Site Number 710405, Bloemfontein, South Africa|Investigational Site Number 710406, Cap Town, South Africa|Investigational Site Number 710402, Cape Town, South Africa|Investigational Site Number 710407, Parktown, South Africa|Investigational Site Number 710403, Parow, South Africa|Investigational Site Number 710408, Pretoria, South Africa|Investigational Site Number 710404, Rondebosch, South Africa|Investigational Site Number 710409, Somerset West, South Africa|Investigational Site Number 724403, A Coruna, Spain|Investigational Site Number 724408, Barcelona, Spain|Investigational Site Number 724406, Córdoba, Spain|Investigational Site Number 724407, Hospitalet De Llobregat, Spain|Investigational Site Number 724409, Madrid, Spain|Investigational Site Number 724401, Madrid, Spain|Investigational Site Number 724405, Madrid, Spain|Investigational Site Number 724404, Reus, Spain|Investigational Site Number 724402, Zaragoza, Spain|Investigational Site Number 752404, Goteborg, Sweden|Investigational Site Number 752401, Stockholm, Sweden|Investigational Site Number 826402, London, United Kingdom|Investigational Site Number 826403, London, United Kingdom|Investigational Site Number 826408, London, United Kingdom|Investigational Site Number 826409, London, United Kingdom|Investigational Site Number 826405, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT01623115
NCT01618071,Vascular Effects of Triglyceride-rich Lipoproteins,,Completed,No Results Available,Postprandial Period|Lipemia|Vasodilation|Vascular Resistance|Nitric Oxide,Dietary Supplement: High-fat meals varying in their fatty acid composition,Activation of inflammatory/oxidative stress pathways within cultured endothelial cells following treatment with 6 h postprandial chylomicron remnant-rich lipoprotein fraction|Incremental area under the plasma concentration versus time curve (iAUC) of triacylglycerol|Incremental area under the plasma concentration versus time curve (iAUC) of glucose|Incremental area under the plasma concentration versus time curve (iAUC) for non-esterified fatty acids|Incremental area under the plasma concentration versus time curve (iAUC) for plasma fatty acid composition (%)|Incremental area under the plasma concentration versus time curve (iAUC) for cholesterol|Incremental area under the unit measure versus time curve for brachial augmentation index|Incremental area under the unit measure versus time curve for systolic blood pressure|Incremental area under the unit measure versus time curve for diastolic blood pressure|Change in digital volume pulse stiffness index|Change in digital volume pulse reflection index|Change in plasma nitrite/nitrate concentrations|Change in plasma 8-isoprostane F2alpha concentrations|Activation of inflammatory/oxidative stress pathways within cultured endothelial cells following treatment with 4 h postprandial chylomicron remnant-rich lipoprotein fraction|Activation of inflammatory/oxidative stress pathways within cultured endothelial cells following treatment with 5 h postprandial chylomicron remnant-rich lipoprotein fraction,King's College London|Royal Veterinary College,Male,"35 Years to 70 Years   (Adult, Older Adult)",Not Applicable,16,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",DRINC 11-LO-0116|BB/1005862/1,Jun-12,Oct-12,Oct-12,13-Jun-12,null,11-Oct-12,"Diabetes & Nutritional Sciences Division, King's College London, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01618071
NCT01617525,A Comparison of the Effects on Cardiovascular Risk Factors of Korean and American Dietary Profiles,,Completed,No Results Available,Hypercholesterolemia,Other: Controlled Feeding Dietary Intervention,"Cardiovascular Disease Biomarkers|Inflammatory Markers|Markers of appetite and food intake regulation|Blood pressure|Urinary sodium excretion, potassium, urea nitrogen, phosphorus, and creatinine|Change in fecal microbiota|Dietary Questionnaires",USDA Beltsville Human Nutrition Research Center,All,"25 Years to 65 Years   (Adult, Older Adult)",Not Applicable,29,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,Korean Diet Study,Jan-12,May-12,May-12,12-Jun-12,null,11-May-16,"USDA Beltsville Human Nutrition Research Center, Beltsville, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01617525
NCT01617655,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH),,Completed,Has Results,Hypercholesterolaemia,Drug: Alirocumab|Drug: Placebo (for alirocumab)|Drug: Lipid Modifying Therapy (LMT),Percent Change From Baseline in Calculated LDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis|Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 12 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis|Percentage of Very High Cardiovascular (CV) Risk Participants Achieving Calculated LDL-C < 70 mg/dL (<1.81 mmol/L) or High CV Risk Participants Achieving Calculated LDL-C < 100 mg/dL (<2.59 mmol/L) at Week 24 - ITT Analysis|Percentage of Very High CV Risk Participants Achieving Calculated LDL-C < 70 mg/dL (<1.81 mmol/L) or High CV Risk Participants Achieving Calculated LDL-C < 100 mg/dL (<2.59 mmol/L) at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis|Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis|Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis,Sanofi|Regeneron Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 3,107,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EFC12732|U1111-1128-5459|2012-001096-37,Jun-12,May-14,Jan-15,12-Jun-12,6-Nov-15,4-Oct-16,"Investigational Site Number 840742, Bell Gardens, California, United States|Investigational Site Number 840703, Newport Beach, California, United States|Investigational Site Number 840712, Newport Beach, California, United States|Investigational Site Number 840743, Northridge, California, United States|Investigational Site Number 840734, Washington, District of Columbia, United States|Investigational Site Number 840738, Miami, Florida, United States|Investigational Site Number 840710, Ponte Vedra, Florida, United States|Investigational Site Number 840701, New York, New York, United States|Investigational Site Number 840702, Durham, North Carolina, United States|Investigational Site Number 840714, Cincinnati, Ohio, United States|Investigational Site Number 840705, Philadelphia, Pennsylvania, United States|Investigational Site Number 840709, Philadelphia, Pennsylvania, United States|Investigational Site Number 840713, Philadelphia, Pennsylvania, United States|Investigational Site Number 840736, Dallas, Texas, United States|Investigational Site Number 124704, Quebec, Canada|Investigational Site Number 124703, Sherbrooke, Canada|Investigational Site Number 528713, Amsterdam, Netherlands|Investigational Site Number 528701, Amsterdam, Netherlands|Investigational Site Number 528704, Groningen, Netherlands|Investigational Site Number 528716, Leiden, Netherlands|Investigational Site Number 528709, Utrecht, Netherlands|Investigational Site Number 643706, Arkhangelsk, Russian Federation|Investigational Site Number 643705, Kazan, Russian Federation|Investigational Site Number 643703, Moscow, Russian Federation|Investigational Site Number 643711, Moscow, Russian Federation|Investigational Site Number 643708, Moscow, Russian Federation|Investigational Site Number 643702, Saint Petersburg, Russian Federation|Investigational Site Number 643710, St-Petersburg, Russian Federation|Investigational Site Number 643709, St-Petersburg, Russian Federation|Investigational Site Number 643707, Yaroslavl, Russian Federation|Investigational Site Number 710701, Bloemfontein, South Africa|Investigational Site Number 710704, Bloemfontein, South Africa|Investigational Site Number 710706, Cap Town, South Africa|Investigational Site Number 710702, Parktown, South Africa|Investigational Site Number 710703, Somerset West, South Africa",,https://ClinicalTrials.gov/show/NCT01617655
NCT01613729,Efficacy and Safety Study of 5 mg and 10 mg Rosuvastatin,Cor16,Unknown status,No Results Available,Dyslipidemia,Drug: Rosuvastatin 5 mg|Drug: Rosuvastatin 10 mg,Efficacy of Rosuvastatin 5 mg once daily with Rosuvastatin 10 mg once daily by assessment of the number of patients with hypercholesterolemia reaching the LDL-C target goal of <100 mg/dL after 12 weeks of therapy.|To compare the safety,"D16 Pharma & Biotec Ltd.|Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh|Dhaka Medical College|National Institute of Cardiovascular Diseases",All,"45 Years to 75 Years   (Adult, Older Adult)",Phase 4,2000,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,corestin/bd/2012-16,Jul-12,Jul-13,Dec-13,7-Jun-12,null,25-Sep-12,"BSMMU, Dhaka, Bangladesh",,https://ClinicalTrials.gov/show/NCT01613729
NCT01611883,A Study of the Effect of Ezetimibe on Glucose Metabolism in Type 2 Diabetics With Hypercholesterolemia (P06541),,Completed,Has Results,Hypercholesterolemia,Drug: Ezetimibe|Drug: Placebo,"Change in Glycated Hemoglobin (HbA1c) From Baseline|Change in Glycoalbumin From Baseline|Change in Fasting Plasma Glucose (FPG) From Baseline|Percentage of Participants With Adverse Event (AE) ""Exacerbation of Diabetes""|Percentage of Participants With Changes in Diabetes Medications Due to Worsening of Diabetes|Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline|Percent Change in Total Cholesterol (TC) From Baseline|Percent Change in Triglycerides From Baseline|Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline|Percent Change in Non-HDL-cholesterol From Baseline",Merck Sharp & Dohme Corp.,All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 4,152,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",P06541|MK-0653-367,2-Jul-12,16-Jan-14,16-Jan-14,5-Jun-12,17-Dec-14,17-Aug-18,,,https://ClinicalTrials.gov/show/NCT01611883
NCT01610661,Dietary Carbohydrate Type and Cardiovascular Disease (CVD) Risk Indicators,,Completed,No Results Available,Dyslipidemia,Other: Diet,fasting plasma lipid profile|glucose|insulin|adipose tissue inflammatory markers|gut microbiome|High-sensitivity C-reactive protein(hsCRP)|Interleukin 6 (IL-6)|Monocyte Chemoattractant Protein 1 (MCP-1)|Tumor necrosis factor-alpha (TNF-alpha)|Monocyte gene expression,Tufts University,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,10,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,2735,Jan-12,Apr-15,Dec-17,4-Jun-12,null,13-Jul-18,"Jean Mayer Human Nutrition Research Center on Aging, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01610661
NCT01609907,Pharmacokinetic Drug Interaction Between Rosuvastatin and Valsartan,,Completed,No Results Available,Hypertension|Hyperlipidemia,Drug: Rosuvastatin+Valsartan (Sequence 1)|Drug: Rosuvastatin+Valsartan (Sequence 2)|Drug: Rosuvastatin+Valsartan (Sequence 3)|Drug: Rosuvastatin+Valsartan (Sequence 4)|Drug: Rosuvastatin+Valsartan (Sequence 5)|Drug: Rosuvastatin+Valsartan (Sequence 6),"Cmax,ss of valsartan|AUCt,ss of valsartan|Cmax,ss of rosuvastatin|AUCt,ss of rosuvastatin|t1/2 of rosuvastatin|Tmax,ss of valsartan|t1/2 of valsartan|Cmin,ss of valsartan|Tmax,ss of rosuvastatin|Cmin,ss of rosuvastatin|Cmax,ss of N-desmetyl rosuvastatin|AUCt,ss of N-desmetyl rosuvastatin",Yuhan Corporation,Male,20 Years to 50 Years   (Adult),Phase 1,30,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,YH14700-101,Nov-11,May-12,May-12,1-Jun-12,null,1-Jun-12,"Yuhan Corporation, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01609907
NCT01609140,A Phase II Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease,,Completed,No Results Available,Coronary Heart Disease,Drug: MPSK3169A|Drug: Placebo,"Absolute change from baseline in LDL-c concentration|Absolute change from baseline in LDL-c concentration for each arm at the nadir for that arm|Average value over time of the change in LDL-c (absolute and percent change) for each arm, up to Day 169, weighted by the number of weeks between consecutive LDL-c measurements|Percent change from baseline in LDL-c concentration at Day 169 and at the nadir for each arm|Percent and absolute change from baseline in LDL-c concentration at all other designated timepoints|Percent and absolute change from baseline in total cholesterol, non-HDL-c, and apolipoprotein B (ApoB) at Day 169 and at the nadir for each arm","Genentech, Inc.",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,248,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",GC28210,May-12,May-13,Jul-13,31-May-12,null,2-Nov-16,"Goodyear, Arizona, United States|Carmichael, California, United States|Spring Valley, California, United States|Walnut Creek, California, United States|Wildomar, California, United States|Jacksonville, Florida, United States|Ponte Verde, Florida, United States|Boise, Idaho, United States|Indianapolis, Indiana, United States|Iowa City, Iowa, United States|Auburn, Maine, United States|Baltimore, Maryland, United States|Bethesda, Maryland, United States|St. Louis, Missouri, United States|Rochester, New York, United States|Wilmington, North Carolina, United States|Fargo, North Dakota, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Springdale, Ohio, United States|Oklahoma City, Oklahoma, United States|Tulsa, Oklahoma, United States|Greer, South Carolina, United States|Mount Pleasant, South Carolina, United States|Spartanburg, South Carolina, United States|Rapid City, South Dakota, United States|Bristol, Tennessee, United States|Knoxville, Tennessee, United States|Boerne, Texas, United States|Dallas, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|Richmond, Virginia, United States|Wenatchee, Washington, United States|Mount Pearl, Newfoundland and Labrador, Canada|St. John's, Newfoundland and Labrador, Canada|Sarnia, Ontario, Canada|Toronto, Ontario, Canada|Woodstock, Ontario, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Sainte-foy, Quebec, Canada|St-jerome, Quebec, Canada|Trois-Rivières, Quebec, Canada|Hodonin, Czech Republic|Jičícin, Czech Republic|Marianske Lazne, Czech Republic|Ostrava - Poruba, Czech Republic|Rakovník, Czech Republic|Berlin, Germany|Köln, Germany|Komarom, Hungary|Nagykanizsa, Hungary|Nyíregyháza, Hungary|Sopron, Hungary|Auckland, New Zealand|Auckland, New Zealand|Christchurch, New Zealand|Nelson, New Zealand|Tauranga, New Zealand|Elverum, Norway|Hamar, Norway|Oslo, Norway|Oslo, Norway|Sandnes, Norway|Bardejov, Slovakia|Bratislava, Slovakia|Presov, Slovakia|Rimavska Sobota, Slovakia|Cape Town, South Africa|Cape Town, South Africa|Centurion, South Africa|Pretoria, South Africa",,https://ClinicalTrials.gov/show/NCT01609140
NCT01607294,A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes,,Completed,No Results Available,Hyperlipidemia|Type 2 Diabetes,Drug: ETC-1002|Drug: Placebo,"assess the LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with type 2 diabetes|assess the effect of ETC-1002 versus placebo on glycemic parameters including fasting plasma and postprandial glucose and insulin|assess the effect of ETC-1002 versus placebo on measures of insulin sensitivity in subjects with type 2 diabetes|assess safety using adverse event reports, physical exams, vital signs, ECGs and clinical laboratory parameters",Esperion Therapeutics,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,60,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1002-005,Apr-12,Oct-12,Oct-12,30-May-12,null,29-Mar-19,"Miramar, Florida, United States",,https://ClinicalTrials.gov/show/NCT01607294
NCT01606904,The Effect of CBT- Based Weight Loss Program on Obesity,CognObe,Completed,No Results Available,"Obesity|Hypercholesterolemia|Diabetes Mellitus, Type 2|Anhedonia",Behavioral: Cognitive behavioral therapy -based weight loss program,"change in weight|change in eating behavior|change in total cholesterol,HDL, LDL,Trigly and glucose|DNA|change in incretins",University of Oulu|Juho Vainio Foundation|Yrjo Jahnsson Foundation|Oulu University Hospital,All,"20 Years to 65 Years   (Adult, Older Adult)",Not Applicable,62,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,58/2012,May-12,Mar-16,Mar-16,28-May-12,null,11-May-18,"Deparment of Internal Medicine, Oulu University Hospital, Oulu, Finland",,https://ClinicalTrials.gov/show/NCT01606904
NCT01606930,A Pilot Study to Improve Patient-Doctor Communication,,Completed,No Results Available,Chronic Disease|Hypertension|Hyperlipidemia|Diabetes Mellitus|Osteoarthritis|COPD|Cardiovascular Disease,Behavioral: Patient Primer Tool,"Degree of shared medical decision-making|Adherence to anti-hypertensive drug treatment at baseline|Adherence to anti-hypertensive drug treatment at one month|Adherence to anti-hypertensive drug treatment at three months|Patient satisfaction|Clinician rating of patient as ""difficult""|Patient Trust in their physician at baseline|Patient Trust in their physician at one month|Patient Trust in their physician at three months|Systolic and Diastolic Blood Pressure at baseline|Systolic and Diastolic Blood Pressure at one month|Systolic and Diastolic Blood Pressure at three months","Walter Reed National Military Medical Center|University of Wisconsin, Milwaukee",All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,106,U.S. Fed|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",A-14352.4,Nov-10,Nov-11,Nov-11,28-May-12,null,28-May-12,"Walter Reed National Medical Military Center (WRNMMC), Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01606930
NCT01604681,Supplementation With Flaxseed Oil in the State of Rio de Janeiro,,Unknown status,No Results Available,Hypertension|Dyslipidemia,Dietary Supplement: Placebo|Dietary Supplement: Flaxseed Oil,Polymorphisms|Cognitive decline|Quality of life|Oxidative stress|Lipid profile,Universidade Federal do Rio de Janeiro|Rio de Janeiro State Research Supporting Foundation (FAPERJ)|Conselho Nacional de Desenvolvimento Científico e Tecnológico,All,"20 Years to 90 Years   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)",171/2011,Jan-11,Dec-12,Dec-13,24-May-12,null,24-May-12,"Clementino Fraga Filho University Hospital Rio de Janeiro, Rio de Janeiro, Brazil",,https://ClinicalTrials.gov/show/NCT01604681
NCT01604824,A Study of Alirocumab (REGN727/SAR236553) in Patients With ADH and GOFm of the PCSK9 Gene or LOFm of the apoB Gene,,Unknown status,No Results Available,Hypercholesterolemia,Drug: alirocumab|Drug: placebo,Percent change in serum LDL-C|TEAEs|Percent change in ApoB100|Percent change in non-HDL-C|Percent change in total cholesterol|Percent change in ApoB100/ApoA1 ratio|Trough concentrations of total alirocumab|Immunogenicity of repeat SC dosing,Regeneron Pharmaceuticals|Sanofi,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,23,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R727-CL-1018,Sep-12,May-14,Sep-16,24-May-12,null,30-Jan-15,"Salt Lake City, Utah, United States|Lille, Cedex, France|Nante, Cedex, France|Paris, France",,https://ClinicalTrials.gov/show/NCT01604824
NCT01603758,Physiological Study of Human Cholesterol Metabolism and Excretion,,Completed,No Results Available,Coronary Heart Disease|Cardiovascular Disease|Dyslipidemia|Disorder of Cholesterol Metabolism,Drug: Ezetimibe,Fractional Excretion of Endogenous Cholesterol,"Richard E. Ostlund Jr., MD|National Heart, Lung, and Blood Institute (NHLBI)|Washington University School of Medicine",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,132,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",201110042|R01HL108160,Jan-14,Jun-15,Jun-15,23-May-12,null,6-May-16,"Washington University School of Medicine, St. Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT01603758
NCT01600313,Effect of Low Calorie Diet With Rice Bran Oil on Cardiovascular Risk Factors in Hyperlipidemic Patients,,Unknown status,No Results Available,Hyperlipidemias,Dietary Supplement: rice bran oil,"LDL, HDL, Cholesterol,Triglyceride(mg/dl)|BMI (Kg/m2)|WHR (Ratio)",Qazvin University Of Medical Sciences,All,"25 Years to 65 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,QUMS-2225,Jun-08,May-10,Jun-12,17-May-12,null,17-May-12,"Qazvin University of Medical Sciences, Qazvin, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT01600313
NCT01600690,Effects of 5-day Statin Withdrawal on Endothelial Progenitor Cells and Inflammatory Markers in Type 2 Diabetic Patients,SStatin-EPC,Completed,No Results Available,Type 2 Diabetes Mellitus|Atherosclerosis|Dyslipidemia,Other: Statin withdrawal,Change in EPC levels|Change in M1/M2 polarization|Change in hsCRP,University of Padova,All,"35 Years to 80 Years   (Adult, Older Adult)",Phase 4,34,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,2616P,May-12,Aug-13,Aug-13,17-May-12,null,13-Aug-13,"University Hospital Diabetes Outpatient Clinic, Padova, Italy",,https://ClinicalTrials.gov/show/NCT01600690
NCT01600703,Sitagliptin Regulation of Intestinal and Hepatic Lipoprotein Particle and Hepatic Glucose Production in Humans,,Completed,Has Results,Hyperlipidemia,Drug: Sitagliptin|Drug: Placebo,Apolipoprotein B48 Production Rate After Acute Oral Administration of 100mg Sitagliptin (Compared to Placebo)|Apolipoprotein B100 Production Rate After Acute Oral Administration of 100mg Sitagliptin (Compared to Placebo),"University Health Network, Toronto|Merck Frosst Canada Ltd.",All,18 Years to 60 Years   (Adult),Phase 2|Phase 3,21,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,Sitagliptin-REB-09-0428-B,Jul-12,May-13,Aug-13,17-May-12,5-May-14,23-Jan-17,"Toronto General Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01600703
NCT01600820,Effect of the Consumption of a Fermented Milk Enriched With Plant Sterols (Spain),,Completed,No Results Available,Hypercholesterolemia,Other: 1- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) per unit|Other: 2- Low fat drinkable fermented dairy product enriched with 2.0g of plant sterol (as free equivalent) per unit|Other: 3- Low fat drinkable fermented dairy product without plant sterols(control),,Danone Spain|Danone Research,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,126,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)",NU146,Feb-05,Jul-05,Jul-05,17-May-12,null,7-Dec-16,"Hospital de Sant Joan, Reus, Spain",,https://ClinicalTrials.gov/show/NCT01600820
NCT01598649,Intervention With Lupin Protein-enriched Foods in Hypercholesterolemic Subjects,,Completed,No Results Available,Hypercholesterolemia,Dietary Supplement: Fabricated foods with lupin protein|Dietary Supplement: Mannitol|Dietary Supplement: Arginine|Dietary Supplement: Fabricated foods with milk protein,Changes in cholesterol metabolism|Changes in protein metabolism|Changes in body composition (body status)|Changes in high-sensitive CRP|Changes in parameter of diabetes mellitus,University of Jena|German Federal Ministry of Education and Research,All,"20 Years to 80 Years   (Adult, Older Adult)",Not Applicable,72,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",LSEP H52-12,Jun-12,Dec-12,Oct-13,15-May-12,null,29-Oct-13,"Friedrich Schiller University Jena, Department of Nutritional Physiology, Jena, Thuringia, Germany",,https://ClinicalTrials.gov/show/NCT01598649
NCT01598948,Effect of Mipomersen on LDL-Cholesterol Levels in Patients Treated by Regular Apheresis,MICA,Completed,No Results Available,Atherosclerosis|LDL-hypercholesterolemia,Drug: mipomersen,Change in pre-apheresis LDL-cholesterol (phase 1 of the study)|Fraction of patients in whom apheresis conditions can be modified (phase 2 of the study)|change in other lipid parameters|Number of participants with adverse events|Plasma concentrations of mipomersen,Ludwig-Maximilians - University of Munich,All,"18 Years and older   (Adult, Older Adult)",Phase 3,17,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MICA,Aug-12,May-15,Jun-15,15-May-12,null,2-Sep-15,"University Munich, Munich, Germany",,https://ClinicalTrials.gov/show/NCT01598948
NCT01597700,Acotral® Versus Zetia® Ezetimibe Bioequivalance Study.,,Completed,No Results Available,Hypercholesterolaemia,Drug: 10mg Ezetimibe|Drug: 10 mg Ezetimibe - wash out period,Changes from baseline in plasma ezetimibe concentrations in time after dosing|Number of participants with adverse events|Number of participants with changes in haematology and/or chemistry,GlaxoSmithKline,Male,18 Years to 45 Years   (Adult),Phase 1,52,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,116051,13-Jan-12,30-Jan-12,30-Jan-12,14-May-12,null,20-Jun-17,"GSK Investigational Site, Electronics City, Bengalore, India",,https://ClinicalTrials.gov/show/NCT01597700
NCT01597843,Veterans Service Organizations and My HealtheVet (MHV),,Completed,Has Results,Hypertension|Hyperlipidemia|Coronary Artery Disease|Diabetes Mellitus,Other: Education,Registration for MHV,US Department of Veterans Affairs|The American Legion Department of Wisconsin|VA Office of Research and Development,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,282,U.S. Fed|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),RRP 11-408,Jun-12,Jun-13,Jan-14,14-May-12,12-Sep-14,28-Apr-15,"Clement J. Zablocki VA Medical Center, Milwaukee, WI, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT01597843
NCT01594983,A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia,,Completed,No Results Available,Non Familial Chylocmicronemia Syndrome (Non-FCS),Drug: LCQ908|Drug: Fenofibrate|Drug: Fish Oil|Drug: Placebo of LCQ908|Drug: Placebo of fenofibrate|Drug: Placebo of fish oil,"Change from baseline in triglycerides (TG) relative to placebo at 6 weeks|Change from baseline in triglycerides after adding LCQ908 to background therapy of fenofibrate or Fish Oil at 12 weeks|Changes from baseline in triglycerides after treatment with LCQ908 monotherapy relative to fenofibrate or fish oil at 6 weeks|Change from baseline in triglycerides after treatment with LCQ908 monotherapy relative to placebo at 12 weeks|Number of patients in LCQ908 monotherapy with adverse events , serious adverse events and death|changefrom baseline in lipids and lipoprotein profiles",Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 2,58,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CLCQ908C2201|2012-000872-40,Jun-12,Jul-13,Jul-13,9-May-12,null,28-Oct-15,"Novartis Investigative Site, Muscle Shoals, Alabama, United States|Novartis Investigative Site, Glendale, Arizona, United States|Novartis Investigative Site, Encinitas, California, United States|Novartis Investigative Site, Colorado Springs, Colorado, United States|Novartis Investigative Site, Brandon, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Ocala, Florida, United States|Novartis Investigative Site, Orange City, Florida, United States|Novartis Investigative Site, Orlando, Florida, United States|Novartis Investigative Site, Port Orange, Florida, United States|Novartis Investigative Site, St. Petersburg, Florida, United States|Novartis Investigative Site, Louisville, Kentucky, United States|Novartis Investigative Site, Oxon Hill, Maryland, United States|Novartis Investigative Site, Butte, Montana, United States|Novartis Investigative Site, Cary, North Carolina, United States|Novartis Investigative Site, Salisbury, North Carolina, United States|Novartis Investigative Site, Lyndhurst, Ohio, United States|Novartis Investigative Site, Marion, Ohio, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, Tulsa, Oklahoma, United States|Novartis Investigative Site, Eugene, Oregon, United States|Novartis Investigative Site, Lansdale, Pennsylvania, United States|Novartis Investigative Site, Bristol, Tennessee, United States|Novartis Investigative Site, Boerne, Texas, United States|Novartis Investigative Site, Corpus Christi, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Chicoutimi, Quebec, Canada|Novartis Investigative Site, Ste-Foy, Quebec, Canada|Novartis Investigative Site, Moscow, Russia, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation",,https://ClinicalTrials.gov/show/NCT01594983
NCT01592240,Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin,,Completed,Has Results,Hypercholesterolemia,Drug: PBO|Drug: 200mg PF-04950615 (RN316)|Drug: 300mg PF-04950615 (RN316)|Drug: PF-04950615,"Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12|Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 24|Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 and 24|Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12 and 24|Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12 and 24|Change From Baseline in Apolipoprotein B (ApoB) at Week 12 and 24|Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 12 and 24|Change From Baseline in Apolipoprotein A1 (ApoA1) at Week 12 and 24|Percent Change From Baseline in Apolipoprotein A1 (ApoA1) at Week 12 and 24|Change From Baseline in Apolipoprotein AII (ApoAII) at Week 12 and 24|Percent Change From Baseline in Apolipoprotein AII (ApoAII) at Week 12 and 24|Change From Baseline in Total Cholesterol at Week 12 and 24|Percent Change From Baseline in Total Cholesterol at Week 12 and 24|Change From Baseline in Lipoprotein (a) (Lp [a]) at Week 12 and 24|Percent Change From Baseline in Lipoprotein (a) (Lp [a]) at Week 12 and 24|Change From Baseline in Very Low Density Lipoprotein (VLDL) Cholesterol at Week 12 and 24|Percent Change From Baseline in Very Low Density Lipoprotein (VLDL) Cholesterol at Week 12 and 24|Change From Baseline in Triglycerides at Week 12 and 24|Percent Change From Baseline in Triglycerides at Week 12 and 24|Change From Baseline in Non-High Density Lipoprotein-Cholesterol (Non-HDL-C) at Week 12 and 24|Percent Change From Baseline in Non-High Density Lipoprotein-Cholesterol (Non-HDL-C) at Week 12 and 24|Percentage of Participants With Positive Anti-drug (Anti-PF-04950615) Antibodies (ADA)|Percentage of Participants With Injection Site Adverse Events|Plasma Concentration of PF-04950615 at Week 12 and 24|Percentage of Participants With Low Density Lipoprotein-cholesterol Less Than (<) 100, <70, <40 and <25 Milligram Per Deciliter (mg/dL)",Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 2,354,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",B1481015|2012-001226-10,Jul-12,Apr-13,May-13,7-May-12,5-Dec-17,5-Dec-17,"Achieve Clinical Research, LLC, Birmingham, Alabama, United States|Medical Affiliated Research Center, Inc., Huntsville, Alabama, United States|The Office of James G. McMurray, MD, Huntsville, Alabama, United States|Southwest Heart Group, Tucson, Arizona, United States|Aureus Research Inc., Little Rock, Arkansas, United States|Universal Biopharma Research Institute Inc. - Alta Family Health Clinic, Dinuba, California, United States|Clinical Trials Research, Lincoln, California, United States|The Office of Lucita M. Cruz, MD, Inc., Norwalk, California, United States|Radiant Research, Santa Rosa, California, United States|St. Joseph's Medical Associates, Stockton, California, United States|Orange County Research Center, Tustin, California, United States|Diablo Clinical Research, Inc., Walnut Creek, California, United States|Chase Medical Research, LLC, Waterbury, Connecticut, United States|Zasa Clinical Research, Boynton Beach, Florida, United States|Florida Health Center, Davie, Florida, United States|Avail Clinical Research, LLC, DeLand, Florida, United States|Florida Research Network, LLC, Gainesville, Florida, United States|In Vivo Clinical Research, Inc., Hialeah, Florida, United States|Health Care Family Rehab and Research Center, Hialeah, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Community Research Foundation, Inc., Miami, Florida, United States|Kendall South Medical Center, Inc., Miami, Florida, United States|Omega Research Consultants, LLC, Orlando, Florida, United States|DMI Research, Pinellas Park, Florida, United States|St Johns Center for Clinical Research, Ponte Vedra, Florida, United States|The Office of Bridget Bellingar, DO, Seminole, Florida, United States|Miami Research Associates, South Miami, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Radiant Research, Inc., Atlanta, Georgia, United States|North Georgia Clinical Research, Woodstock, Georgia, United States|East-West Medical Research Institute, Honolulu, Hawaii, United States|Northwest Clinical Trials, Boise, Idaho, United States|Fox Valley Clinical Research Center, LLC, Aurora, Illinois, United States|Radiant Research, Inc., Chicago, Illinois, United States|Midwest Institute for Clinical Research, Indianapolis, Indiana, United States|Midwest Heart & Vascular Specialists, Overland Park, Kansas, United States|L-MARC Research Center, Louisville, Kentucky, United States|Crescent City Clinical Research Center, Metairie, Louisiana, United States|Maine Research Associates, Auburn, Maine, United States|Maine Research Associates, Lewiston, Maine, United States|ActivMed Practices and Research, Haverhill, Massachusetts, United States|Radiant Research, Inc., Edina, Minnesota, United States|Dybedal Clinical Research Center, Kansas City, Missouri, United States|Montana Medical Research, Inc., Missoula, Montana, United States|Meridian Clinical Research, Omaha, Nebraska, United States|New Mexico Clinical Research and Osteoporosis Center, Inc., Albuquerque, New Mexico, United States|Central New York Clinical Research, Manlius, New York, United States|Clinical Trials of America, Inc., Hickory, North Carolina, United States|North Carolina Clinical Research, Raleigh, North Carolina, United States|PMG Research of Raleigh, Raleigh, North Carolina, United States|Wake Internal Medicine Consultants, Raleigh, North Carolina, United States|PMG Research of Salisbury, Salisbury, North Carolina, United States|Ardmore Family Practice, Winston-Salem, North Carolina, United States|Clinical Trials of America, Inc., Winston-Salem, North Carolina, United States|Sterling Research Group, Ltd., Cincinnati, Ohio, United States|Sentral Clinical Research Services, Cincinnati, Ohio, United States|Sterling Research Group, LTD., Cincinnati, Ohio, United States|Albert J. Weisbrot, M.D., Inc., Mason, Ohio, United States|Lynn Institute of Norman, Norman, Oklahoma, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Upstate Pharmaceutical Research, Greenville, South Carolina, United States|Coastal Carolina Research Center, Mount Pleasant, South Carolina, United States|Palmetto Clinical Research, Summerville, South Carolina, United States|New Orleans Center for Clinical Research, Knoxville, Tennessee, United States|Volunteer Research Group, Knoxville, Tennessee, United States|Baylor College of Medicine - Center for Cardiovascular Disease Prevention, Houston, Texas, United States|Texas Center for Drug Development, Inc., Houston, Texas, United States|Protenium Clinical Research, LLC, Hurst, Texas, United States|Paragon Research Center, LLC, San Antonio, Texas, United States|Innovative Clinical Trials, San Antonio, Texas, United States|National Clinical Research- Norfolk, Inc, Norfolk, Virginia, United States|National Clinical Research - Richmond, Inc., Richmond, Virginia, United States|Premier Clinical Research, Spokane, Washington, United States",,https://ClinicalTrials.gov/show/NCT01592240
NCT01588496,Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities,TESLA,Completed,Has Results,Homozygous Familial Hypercholesterolemia,Biological: Evolocumab|Drug: Placebo,Part A: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12|Part B: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12|Part A: Change From Baseline in LDL-C at Week 12|Part A: Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12|Part A: Percent Change From Baseline in Apolipoprotein B at Week 12|Part A: Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12|Part A: Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12|Part A: Percentage of Participants With 15% or Greater Reduction in LDL-C From Baseline at Week 12|Part A: Change From Baseline in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) at Week 12|Part B: Percent Change From Baseline in LDL-C at the Mean of Weeks 6 and 12|Part B: Percent Change From Baseline in Apolipoprotein B at Week 12|Part B: Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 6 and 12|Part B: Percent Change From Baseline in Lipoprotein (a) at Week 12|Part B: Percent Change From Baseline in Lipoprotein (a) at the Mean of Weeks 6 and 12,Amgen,All,"12 Years to 80 Years   (Child, Adult, Older Adult)",Phase 2|Phase 3,58,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",20110233|2011-005399-40,5-Apr-12,31-Jan-14,31-Jan-14,1-May-12,2-Oct-15,29-Nov-18,"Research Site, New York, New York, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Bruxelles, Belgium|Research Site, La Louvière, Belgium|Research Site, London, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Uherske Hradiste, Czechia|Research Site, Dijon, France|Research Site, Paris Cedex 13, France|Research Site, New Territories, Hong Kong|Research Site, Pisa, Italy|Research Site, Beirut, Lebanon|Research Site, Amsterdam, Netherlands|Research Site, Christchurch, New Zealand|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Observatory, Western Cape, South Africa|Research Site, Cordoba, Andalucía, Spain|Research Site, Lugo, Galicia, Spain|Research Site, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT01588496
NCT01589237,"Extension to a Randomized, Double-blind, Placebo Controlled Study of LCQ908 in Subjects With Familial Chylomicronemia Syndrome.",,Terminated,Has Results,Familial Chylomicronemia Syndrome (FCS) (HLP Type I),Drug: LCQ908,"Number of Patients With Any Adverse Events, Serious Adverse Events and Death|Changes From Baseline in Triglyceride Levels up to 52 Weeks|Changes From Baseline in Cholesterol Levels up to 52 Weeks|Changes From Baseline in HDL and Non HDL Cholesterol Levels up to 52 Weeks|Changes From Baseline in Glycerol Levels up to 52 Weeks|Changes From Baseline in Free Fatty Acid Levels up to 52 Weeks|Changes From Baseline in Apolipoprotein A1 Levels up to 52 Weeks|Changes From Baseline in Apolipoprotein B-48 Levels up to 52 Weeks|Changes From Baseline in Apolipoprotein B-100 Levels up to 52 Weeks",Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 3,38,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLCQ908B2305|2012-000802-32,Feb-13,Jul-15,Jul-15,1-May-12,15-Nov-16,15-Nov-16,"Novartis Investigative Site, Seatlle, Washington, United States|Novartis Investigative Site, Chicoutimi, Quebec, Canada|Novartis Investigative Site, Ste-Foy, Quebec, Canada|Novartis Investigative Site, Ouest-Montreal, Canada|Novartis Investigative Site, Nantes, France|Novartis Investigative Site, Paris Cedex 13, France|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Meibergdreef 9, Netherlands|Novartis Investigative Site, Cape Town, South Africa|Novartis Investigative Site, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT01589237
NCT01587235,"A Study to Evaluate the Efficacy and Safety of Vytorin Versus Standard Treatment of Other Statins in Moderate, Moderately High and High Risk Participants (MK-0653A-406)",VYCTORY,Withdrawn,No Results Available,Dyslipidemia,Drug: Ezetimibe/simvastatin|Drug: Other Statin,Number of Participants who Achieve Low-density Lipoprotein Cholesterol (LDL-C) goal (High-risk <100 mg/dL; Moderate-high and High risk <130 mg/dL)|Change in LDL-C level From Baseline|Number of High-risk Participants who Achieve an LDL-C < 70 mg/dL|Change in Serum LDL From Baseline|Change in Total Cholesterol From Baseline|Change in High-density lipoprotein (HDL) From Baseline|Change in Serum Triglycerides (TG) From Baseline|Change in Serum Non-HDL From Baseline|Change in LDL-C/HDL-C Ratio From Baseline|Change in Apolipoprotein B (ApoB) From Baseline|Number of Participants who Achieve non-HDL-C goal (High-risk <100 mg/dL; Moderate-high and High risk <160 mg/dL)),Merck Sharp & Dohme Corp.,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 4,0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0653A-406,Mar-13,May-14,May-14,30-Apr-12,null,30-Dec-14,,,https://ClinicalTrials.gov/show/NCT01587235
NCT01586897,The Medication Metronome Project - Study to Facilitate Follow-up Testing Resulting From Prescribed Medications to Improve Patient Safety and Care,,Completed,Has Results,"Diabetes Mellitus, Type 2|Hypertension|Hyperlipidemia",Device: Medication Metronome|Other: Usual Care,"Primary Effectiveness Outcome - LDL|Primary Effectiveness Outcome - A1c|Medication Safety Monitoring - Statins|Medication Safety Monitoring - Metformin|Medication Safety Monitoring - ACE/ARB, Thiazide",Massachusetts General Hospital|Agency for Healthcare Research and Quality (AHRQ),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,52,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R18HS018648,May-12,May-13,May-13,27-Apr-12,9-Dec-15,11-Jan-16,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01586897
NCT01583647,A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158),,Terminated,Has Results,"Hypercholesterolemia, Familial|Heterozygous Familial Hypercholesterolemia",Drug: MK-0524A,Plasma Area Under the Concentration Curve From 0 to Infinity (AUC0-∞) of Laropiprant|Plasma Maximum Concentration (Cmax) of Laropiprant|Total Urinary Excretion of Niacin and Niacin Metabolites|Plasma Cmax of Nicotinuric Acid (NUA),Merck Sharp & Dohme Corp.,All,10 Years to 16 Years   (Child),Phase 1,10,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0524A-158|2012-001443-49,Jun-12,Dec-12,Dec-12,24-Apr-12,4-Dec-13,3-Nov-15,,,https://ClinicalTrials.gov/show/NCT01583647
NCT01584206,Sitosterolemia Metabolism,STAIR7002,Unknown status,No Results Available,Sitosterolemia,Drug: Ezetimibe,Plasma cholesterol level|Plasma sitosterol level|Cholesterol absorption|Cholesterol synthesis,University of Manitoba,All,"16 Years to 99 Years   (Child, Adult, Older Adult)",Not Applicable,8,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,B2011:051,Apr-12,Aug-13,Dec-16,24-Apr-12,null,10-Mar-16,"Richardson Centre for Functional Foods and Nutraceuticals, Winnipeg, Manitoba, Canada",,https://ClinicalTrials.gov/show/NCT01584206
NCT01581372,A Community Based Approach to Dyslipidemia Management: Pharmacist Prescribing to Achieve Cholesterol Targets,RxACT,Completed,No Results Available,Dyslipidemias,Other: Pharmacist care,Proportion of participants achieving their target LDL-c in the intervention versus usual care group,University of Alberta|AstraZeneca,All,"19 Years and older   (Adult, Older Adult)",Not Applicable,100,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00020054,Dec-11,Jan-13,Jan-13,20-Apr-12,null,28-Apr-15,"Safeway, Calgary, Alberta, Canada|London Drugs, Lethbridge, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT01581372
NCT01580319,Primary Prevention of Cardiovascular Diseases in Childhood and Adolescence: the Role of Physical Activity,,Terminated,No Results Available,Obesity|Hypercholesterolemia|High Blood Pressure|Sedentary Lifestyle,Other: physical exercise,"Reduction on risk factors for a cardiovascular diseases (reduction on BMI, cholesterol, LDL, glucose, high-sensitivity C-reactive protein, blood pressure and/or increase on HDL)","Instituto de Cardiologia do Rio Grande do Sul|Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul, Brazil",All,6 Years to 17 Years   (Child),Not Applicable,27,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,2994/01,Apr-09,Dec-10,Dec-11,19-Apr-12,null,9-May-12,"Instituto de Cardiologia / Fundação Universitária de Cardiologia, Porto Alegre, Rio Grande do Sul, Brazil",,https://ClinicalTrials.gov/show/NCT01580319
NCT01577056,Postprandial Lipid Metabolism in Familial Hypercholesterolaemia:Effects of Fish Oils,FIFH,Unknown status,No Results Available,Hypertriglyceridaemia|Familial Hypercholesterolaemia,Dietary Supplement: Fish oil capsule|Drug: HMG Coenzyme reductase,Postprandial changes in triglyceride-rich lipoprotein concentrations|Triglyceride-rich lipoprotein kinetics,"The University of Western Australia|National Health and Medical Research Council, Australia",All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,1028883|NHMRC1028883,Apr-12,Dec-13,Mar-14,13-Apr-12,null,13-Apr-12,"School of Medicine & Pharmacology,University of Western Australia, Perth, Western Australia, Australia",,https://ClinicalTrials.gov/show/NCT01577056
NCT01576484,Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 (SAR236553) in Patients With Hypercholesterolemia,,Completed,No Results Available,Hypercholesterolemia,Drug: REGN727 (SAR236553),"Incidence of AEs from baseline to end of study|Percent change in LDL-C: Baseline to weeks 12, 24, 52 and 218|Changes in other lipids and other lipoproteins",Regeneron Pharmaceuticals|Sanofi,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,58,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R727-CL-1032,Mar-12,Dec-16,Dec-16,12-Apr-12,null,9-Feb-18,"Mission Viejo, California, United States|Newport Beach, California, United States|Thousand Oaks, California, United States|Miami, Florida, United States|Port Orange, Florida, United States|Kansas City, Kansas, United States|Auburn, Maine, United States|Saint Louis, Missouri, United States|Durham, North Carolina, United States|Cincinnati, Ohio, United States|Houston, Texas, United States|Chicoutimi, Quebec, Canada|Montreal, Quebec, Canada|Sainte-Foy, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01576484
NCT01574417,Plant Stanols and Gene Expression Profile,,Completed,No Results Available,Hypercholesterolemia,Dietary Supplement: control margarine|Dietary Supplement: plant stanol-enriched margarine,intestinal mucosal gene expression profiles|microbiota composition|lipoprotein profile|plasma glucose concentration|plasma plant stanol concentration,Maastricht University Medical Center|Raisio Group,All,18 Years to 60 Years   (Adult),Not Applicable,20,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",METC 12-3-005,Mar-12,Oct-12,Oct-12,10-Apr-12,null,25-Oct-12,"Maastricht University Medical Centre, Maastricht, Limburg, Netherlands",,https://ClinicalTrials.gov/show/NCT01574417
NCT01574482,Effect of the Consumption of a Fermented Milk Enriched With Plant Sterols (Italy),,Completed,No Results Available,Mildly Hypercholesterolemic Subjects,"Other: 1- plain low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).|Other: 2- plain low-fat dairy fermented product (drinkable) without plant sterols-esters",,Danone Research,All,"20 Years to 75 Years   (Adult, Older Adult)",Not Applicable,116,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)",NU216,Jan-07,Apr-07,Jun-07,10-Apr-12,null,25-Nov-16,"Ospedale Silvestrini, Perugia, Italy",,https://ClinicalTrials.gov/show/NCT01574482
NCT01571609,Baseline Physiology Studies in Carriers of Gene Variant X Conferring Major Risk of CVD-prone Metabolic Disorders,,Completed,No Results Available,Hyperlipidemia|Diabetes Mellitus|Metabolic Syndrome|Arterial Hypertension|Obesity,"Other: first phase insulin secretion (FPIR), Hyperinsulinemic euglycemic clamp (HEC), glucose tracer, and palmitate tracer",insulin secretion|Insulin resistance|body composition|atherosclerosis|biochemical blood profiling|Blood pressure|Indirect calorimetry,University of Aarhus|Lundbeck Foundation|Aarhus University Hospital|Vejle Hospital|Sydvestjysk Hospital|Steno Diabetes Center Copenhagen|University of Copenhagen,Male,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,1-10-72-113-12,Aug-12,Jul-13,Nov-14,5-Apr-12,null,2-Dec-14,"Medicinsk forskningslaboratorium, Aarhus Universitet, Aarhus, Denmark",,https://ClinicalTrials.gov/show/NCT01571609
NCT01571869,"Pilot Study in the Cholesterol Absorption Reduction After Consumption of Low-fat, Drinkable Fermented Milk Enriched With Plant Sterols",,Completed,No Results Available,Mildly Hypercholesterolemic Subjects,Other: 1- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) per unit|Other: 2- Low fat drinkable fermented dairy product without plant sterols (control),,Danone Research,All,"40 Years to 80 Years   (Adult, Older Adult)",Not Applicable,30,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant),NU142,Apr-05,Dec-05,Apr-06,5-Apr-12,null,7-Dec-16,"McGill University, Ste-anne-de-bellevue, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01571869
NCT01571882,Effects of Fermented Milk Product Enriched With Plant Sterols and Policosanols in Mild Hypercholesterolaemic Adults,,Completed,No Results Available,Mildly Hypercholesterolemic Subjects,Other: 1- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) + 10 mg of policosanols per unit|Other: 2- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) + 20 mg of policosanols per unit|Other: 3- Low fat drinkable fermented dairy product with 1.6g of plant sterol (as free equivalent) but without policosanols (Active control),,Danone Research,All,"20 Years to 75 Years   (Adult, Older Adult)",Not Applicable,72,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)",NU235,Jun-07,Sep-07,Oct-07,5-Apr-12,null,25-Nov-16,"Guildford Clinical Pharmacology Unit Ltd. (Gcpl), Guildford, Surrey, United Kingdom",,https://ClinicalTrials.gov/show/NCT01571882
NCT01570270,Cheese Intake and Hypercholesterolemia,,Completed,No Results Available,Hypercholesterolemia,Dietary Supplement: CLA enriched cheese,modification of LDL-cholesterol levels,Azienda Ospedaliera Brotzu,All,30 Years to 60 Years   (Adult),Phase 1|Phase 2,42,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,CASU,May-09,Dec-09,Apr-10,4-Apr-12,null,4-Apr-12,,,https://ClinicalTrials.gov/show/NCT01570270
NCT01569724,Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell Lymphoma,TgBEX,Completed,No Results Available,Hypertriglyceridemia|Cutaneous T Cell Lymphoma,Other: oral glucose tolerance test (OGTT),glucose intolerance or diabetes|hypothyroidism|response to bexarotene,Rennes University Hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 4,10,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2010-A23465-21,Jan-12,Dec-16,Apr-17,3-Apr-12,null,21-Jul-17,"Service de dermatologie - Hôpital de Pontchaillou, Rennes, France",,https://ClinicalTrials.gov/show/NCT01569724
NCT01566266,Gut Flora and Lipid Metabolism,,Completed,No Results Available,Hypercholesterolemia,Drug: Amoxicillin|Drug: Placebo capsule,LDL-cholesterol|Lipid metabolism|Glucose metabolism,Maastricht University Medical Center,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,77,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",METC 12-3-011,Mar-12,Apr-13,Apr-13,29-Mar-12,null,14-May-13,"Maastricht University Medical Center, Maastricht, Limburg, Netherlands",,https://ClinicalTrials.gov/show/NCT01566266
NCT01566305,Effects of Buttermilk on Serum LDL Cholesterol Concentrations,,Completed,No Results Available,Hypercholesterolemia|Buttermilk|Dietary Modification|Cardiovascular Disease,Dietary Supplement: Buttermilk without added egg-yolk|Dietary Supplement: Buttermilk with added egg yolk|Dietary Supplement: Skimmed milk with added egg-yolk|Dietary Supplement: Skimmed milk without added egg yolk,"Change in serum LDL cholesterol concentrations|Changes in serum total and HDL cholesterol, triacylglycerol, apoA-I, apoB and hsCRP concentrations",Maastricht University Medical Center,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,108,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",NL33461.068.10,Oct-10,1-May-12,1-Dec-12,29-Mar-12,null,6-Sep-18,"Maastricht University, Maastricht, Limburg, Netherlands",,https://ClinicalTrials.gov/show/NCT01566305
NCT01564719,Study of a Holistic Health Program for United Methodist Clergy,SpiritedLife,Completed,No Results Available,Obesity|Depression|Diabetes|Hypertension|Hypercholesterolemia,Behavioral: Holistic health,Metabolic Syndrome|Depression|Stress,Duke Clergy Health Initiative|The Duke Endowment,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1114,Other,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,ORC-1447SP,Oct-10,Aug-16,Aug-16,28-Mar-12,null,13-Feb-17,"Duke Divinity School, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01564719
NCT01564875,"Efficacy and Safety of Simvast Controlled Release (CR) and Zocor in Chronic Kidney Disease(CKD) Stage 3, 4 and 5 Patients With Hyperlipidemia",HM-SIM4,Unknown status,No Results Available,Chronic Kidney Disease|Hyperlipidemia,Drug: Simvast CR|Drug: Zocor,"Percent change of LDL-C|Change and percent change of TC, HDL-C, TG|Accomplishment rate of therapeutic goals",Hanmi Pharmaceutical Company Limited,All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 4,122,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",HM-SIM4,Dec-10,May-12,May-12,28-Mar-12,null,28-Mar-12,"Hallym University Medical Center, Anyang-si, Gyeonggi-do, Korea, Republic of|Inje University Ilsan Paik Hospital, Goyang-si, Gyeonggi-do, Korea, Republic of|Gachon University Gil Hospital, Incheon, Korea, Republic of|Eulji General Hospital, Seoul, Korea, Republic of|Hanyang University Seoul Hospital, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01564875
NCT01563770,Cardiovascular Effects of Salvia Miltiorrhiza Extract (Danshen),,Unknown status,No Results Available,Dyslipidemias|Hypertension|Vasodilation|Oxidative Stress|Inflammation,Dietary Supplement: Salvia miltiorrhiza extract|Dietary Supplement: Placebo,Hyperlipidemia|Hypertension|Endothelial function|Plasma markers of oxidative stress|Vascular inflammation and inflammatory activation of adipose tissue|Hemostasis and hemorheological parameters|Insulin sensitivity,Radboud University,All,"40 Years to 70 Years   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",QPHT-35,Apr-12,Dec-12,Mar-13,27-Mar-12,null,24-May-12,"Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands",,https://ClinicalTrials.gov/show/NCT01563770
NCT01564498,Effects of Purple Vegetables on Cardiovascular Disease (CVD) Risk Factors,,Unknown status,No Results Available,Hypertension|Hypercholesterolemia|Type II Diabetes|Obesity|Inflammation,Other: vegetable,Blood cholesterol|blood pressure|body composition|insulin resistance|blood and urinary polyphenol metabolites|circulating biomarkers of cardiovascular disease and type II diabetes risk,"University of Guelph|Ontario Ministry of Agriculture, Food and Rural Affairs",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,2012MeckPurpleVeg,Apr-12,Dec-17,Dec-17,27-Mar-12,null,26-Oct-16,"Human Nutraceutical Research Unit, Guelph, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01564498
NCT01562782,Change of Fructose to Fat in South Asians,,Unknown status,No Results Available,Elevated Triglycerides|Diabetes|Cardiovascular Disease|Dyslipidemia,Other: Fructose + Glucose Beverage,De novo lipogenesis|Biomarkers in South Asians and Caucasians,The Rogosin Institute|Weill Medical College of Cornell University,All,18 Years to 35 Years   (Adult),Not Applicable,36,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,1110011995,Mar-12,Apr-17,Apr-17,26-Mar-12,null,21-Jul-16,"The Rogosin Institute, New York, New York, United States|Weill Cornell Medical College Clinical and Translational Science Center (CTSC), New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01562782
NCT01562080,Combined Effects of Bioactive Compounds in Lipid Profile,ARM-PLUS-LDL,Completed,No Results Available,Hyperlipidemia|Low-density-lipoprotein-type|Elevated Triglycerides,Dietary Supplement: Armolipid Plus|Dietary Supplement: placebo,investigate whether the addition of Armolipid Plus ® decreases by 20% LDL-C levels compared to baseline in patients with initial levels of LDL-C ≥ 130 mg / dL.|Cardiovascular risk (according to the Framingham tables).|Criteria for Metabolic Syndrome|Levels of triglycerides and cholesterol high density lipoprotein (HDL-C).,Rottapharm Spain|Centro Tecnológico de Nutrición y Salud,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,118,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ARM-PLUS-LDL,Jan-12,Jun-12,Oct-12,23-Mar-12,null,28-Feb-13,"Hosp. Universitario San Joan, Reus, Tarragona, Spain",,https://ClinicalTrials.gov/show/NCT01562080
NCT01562171,Lentils as a Functional Food to Improve Glucose and Decrease Cardiovascular Risk,LEN-0-2012,Completed,No Results Available,Obesity|Hypercholesterolemia,Other: Cooked Lentils|Other: Potato-Based Foods,"To examine the effect of lentils on glucose tolerance and LDL-cholesterol.|To examine the effect of lentils on glycated hemoglobin; fasting plasma glucose, insulin, triglycerides, HDL-cholesterol and C-reactive protein.","University of Manitoba|Glycemic Index Laboratories, Inc|Agriculture and Agri-Food Canada|Saskatchewan Pulse Growers",All,"30 Years to 75 Years   (Adult, Older Adult)",Not Applicable,102,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),B2012:010,Mar-12,Sep-14,Sep-14,23-Mar-12,null,12-Dec-14,"I.H. Asper Clinical Research Institute, Winnipeg, Manitoba, Canada|Glycemic Index Laboratories, Incorporated, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01562171
NCT01559441,Beetroot Juice and Postprandial Vascular Activity,,Completed,No Results Available,Dyslipidemia,Dietary Supplement: Beetroot Juice with oral fat load|Dietary Supplement: Carbohydrate control drink with oral fat load,Vascular activity|Arterial stiffness|Microcirculatory effects|Metabolic risk markers related to the metabolic syndrome|Postprandial lipid metabolism|Postprandial glucose metabolism,Maastricht University Medical Center|Top Institute Food and Nutrition,Male,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,METC 11-3-085,Mar-12,Aug-12,Aug-12,21-Mar-12,null,16-Jul-13,"Maastricht University Medical Center, Maastricht, Netherlands",,https://ClinicalTrials.gov/show/NCT01559441
NCT01556906,"Safety, Tolerability and Efficacy of Microsomal Triglyceride Protein (MTP) Inhibitor",,Completed,Has Results,Homozygous Familial Hypercholesterolemia,Drug: Lomitapide,LDL-C|Absolute Change From Baseline in Alanine Aminotransferase (ALT)|Absolute Change From Baseline in Aspartate Aminotransferase (AST)|Absolute Change From Baseline in Total Bilirubin|Absolute Change From Baseline in Hepatic Fat Percent|Absolute Change From Baseline in Forced Expiratory Volume During 1 Second (FEV1)|Absolute Change From Baseline in Carbon Monoxide Lung Diffusing Capacity (DLCO)(a Pulmonary Function Test)|Absolute Change From Baseline in Vitamin A|Absolute Change From Baseline in Vitamin E|Absolute Change From Baseline in Vitamin D|Absolute Change From Baseline in Ratio of Vitamin E to Total Lipids|Absolute Change From Baseline in Alpha Linoleic Acid (ALA)|Absolute Change From Baseline in Eicosapentaenoic Acid (EPA)|Absolute Change From Baseline in Docosahexaenoic Acid (DHA)|Absolute Change From Baseline in Linoleic Acid (LA),"Aegerion Pharmaceuticals, Inc.|University of Pennsylvania|Doris Duke Charitable Foundation",All,"13 Years and older   (Child, Adult, Older Adult)",Phase 2,6,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UP1001,Jun-03,Feb-04,Feb-04,19-Mar-12,22-Feb-13,10-Apr-13,"University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01556906
NCT01556113,Genetic Effect on Omega 3 Fatty Acids for the Treatment of Fatty Liver Disease,,Completed,No Results Available,"Non Alcoholic Fatty Liver Disease|Steatohepatitis|Hypertriglyceridemia|Alanine Aminotransferase, Plasma Level of, Quantitative Trait Locus 1",Other: Omega diet,reduction in hepatic fat fraction|reduction in triglycerides|lower ALT levels,Yale University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),All,"10 Years to 19 Years   (Child, Adult)",Not Applicable,17,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1112009408|R01HD040787,Mar-12,Feb-17,Feb-17,16-Mar-12,null,28-Apr-17,"Yale School of Medicine, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01556113
NCT01550432,Effects of Glutathione (an Antioxidant) and N-Acetylcysteine on Inflammation,,Completed,No Results Available,Obesity|Hyperlipidemia|Insulin Resistance|Hypertension,Dietary Supplement: Glutathione|Dietary Supplement: N-Acetylcysteine|Other: Placebo,Inflammatory Markers|Oxidized LDL|Insulin Sensitivity|Weight|Blood pressure|Serum lipids|Insulin|Glucose|Plasma Glutathione levels,Stanford University|National Center for Complementary and Integrative Health (NCCIH),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,78,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",SU-03252010-5442|R21AT004475,Jun-11,Jul-12,Jul-12,12-Mar-12,null,30-May-17,"Stanford University School of Medicine, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT01550432
NCT01551173,Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia,,Completed,Has Results,Lipid Metabolism Disorders,Drug: Fluvastatin sodium,"Mean Percent Change in LDL-C From Baseline at Study Endpoint, Week 12 (LOCF)|Change From Baseline at Week 4, Week 8, Week 12, and Endpoint for Lipid Variables Low Density Lipoprotein Cholesterol (LDL-C) , Total Cholesterol (TC), High Density Lipoprotein Cholesterol (HDL-C) , Non HDL-C, Triglycerides (TG)|Proportion of Patients Achieving Their LDL-C Treatment Goals at Week 4, Week 8, Week 12, and Endpoint",Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 4,436,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CXUO320BCN01,Jan-12,May-13,May-13,12-Mar-12,11-Jun-14,13-Aug-15,"Novartis Investigative Site, Changsha, Hunan, China",,https://ClinicalTrials.gov/show/NCT01551173
NCT01547585,A Human Trial to Assess the Low Density Lipoprotein Cholesterol (LDL-C) Lowering Effect of Soy,SOY-LDL,Completed,No Results Available,Hypercholesterolemia|Cardiovascular Disease|CRP,Other: Standardized soy containing muffin,Low Density Lipoprotein Cholesterol (LDL-Cholesterol)|high sensitivity c-reactive protein (hsCRP),"Guelph Food Research Centre|University of Guelph|Glycemic Index Laboratories, Inc|Canadian Centre for Agri-Food Research in Health and Medicine",All,"30 Years to 70 Years   (Adult, Older Adult)",Not Applicable,243,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",SOY-CVD-2012|RBPI#1746,May-12,Sep-13,Oct-13,8-Mar-12,null,17-Mar-15,"Canadian Centre for Agri-food Research in Health and Medicine, Winnipeg, Manitoba, Canada|Human Nutraceutical Research Unit. University of Guelph, Guelph, Ontario, Canada|Glycemic Index Laboratories, Inc, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01547585
NCT01544309,LIpid Lowering With Highly Potent Statins in Hyperlipidaemia With Type 2 Diabetes patiENts,LISTEN,Completed,Has Results,Hypercholesterolemia With Concomitant Type 2 Diabetes,Drug: Atorvastatin|Drug: Rosuvastatin,"Percent Change in Non-high-density Lipoprotein Cholesterol (HDL-C) Level|Change in HbA1c Level|Occurrence of Deterioration of Diabetic Treatment Status|Number of Participants Stratified by Time to the Occurrence of Deterioration of Diabetic Treatment Status|Percent Change in 1,5-AG Level|Percent Change in Blood Glucose Level (Fasting)|Change in Blood Glucose Level (Fasting)|Percent Change in Insulin Level|Change From Baseline in Insulin Level|Frequency of Cardiovascular Events (Coronary Artery Disease, Heart Failure, Cerebrovascular Disease, Peripheral Artery Disease and Aortic Disease)|Frequency of Serious Adverse Events (SAE)|Percent Changes in Lipids (LDL-C, HDL-C, TC, TG, Non-HDL-C/HDL-C Ratio, and FFA)|Percent Change in Non-HDL-C Level|Percent Changes in Lipids and Inflammatory Marker (Hs-CRP) and Their Correlation|Rate of Patients Who Have Reached the Target LDL-C Level Specified in Japan Atherosclerosis Society Guidelines (JASGL) 2007|Change From Baseline in 1,5-AG Level",Listen Trial Group,All,"20 Years and older   (Adult, Older Adult)",Not Applicable,1049,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,59,Mar-12,Jun-14,null,5-Mar-12,17-Mar-15,17-Mar-15,"Hiramitsu Heart Clinic, Nagoya city, Aichi pref., Japan|Honjo Daiichi Hospital, Yurihonjo city, Akita pref., Japan|Iryouhoujin Syadan Yanagisawakai Yanagisawa Iin, Matsudo city, Chiba pref., Japan|Matsuno Medical Clinic, Iyo gun, Ehime pref., Japan|Ishite Matsumoto Naika Junkanki Clinic, Matsuyama city, Ehime pref., Japan|Ehime Medical CO OP Izumigawa Clinic, Niihama city, Ehime pref., Japan|Fukui Chuoh Clinic, Fukui city, Fukui pref., Japan|Fukuoka City Medical Association Hospital, Fukuoka city, Fukuoka pref., Japan|Matsumoto Clinic, Fukuoka city, Fukuoka pref., Japan|Saku Hospital, Fukuoka city, Fukuoka pref., Japan|Soejima Medical Clinic, Fukuoka city, Fukuoka pref., Japan|Takei's Clinic Internal Medicine, Fukuoka city, Fukuoka pref., Japan|Nakamura Cardiovascular Clinic, Itoshima city, Fukuoka pref., Japan|Morizono Naika, Kitakyushu city, Fukuoka pref., Japan|Seino Internal Medicine Clinic, Koriyama city, Fukushima pref., Japan|Kawade Iin, Gifu city, Gifu pref., Japan|Hashimoto Naika Clinic, Gifu city, Gifu pref., Japan|Iinuma Iin, Gifu city, Gifu pref., Japan|Ishimura Clinic, Gifu city, Gifu pref., Japan|Kawai Clinic, Gifu city, Gifu pref., Japan|Niimi Clinic, Gifu city, Gifu pref., Japan|Takai Clinic, Gifu city, Gifu pref., Japan|Kobayashi Internal Medicine, Kakamigahara city, Gifu pref., Japan|Horibe Clinic, Motosu city, Gifu pref., Japan|Kondo Cardiovascular Clinic, Ogaki, Gifu pref., Japan|Yoshida Naika, Ogaki, Gifu pref., Japan|Kogure Clinic, Maebashi city, Gunma pref., Japan|Nakano Clinic, Shibukawa city, Gunma pref., Japan|Yoshii Central Clinic, Takasaki city, Gunma pref., Japan|Shigenobu Clinic, Miyoshi city, Hiroshima pref., Japan|Takahashi Kiyohito Clinic, Hakodate city, Hokkaido pref., Japan|Hokuto Internal Medicine Clinic, Sapporo city, Hokkaido pref., Japan|Katsuya Clinic, Amagasaki city, Hyogo pref., Japan|Nakatani Hospital, Himeji city, Hyogo pref., Japan|Kosumo Clinic, Kako gun, Hyogo pref., Japan|Harima Clinic, Kakogawa, Hyogo pref., Japan|Kusunose Clinic, Kobe city, Hyogo pref., Japan|Yanagi Medical Clinic, Hakusan city, Ishikawa pref., Japan|Okyozuka Clinic, Ishikawa gun, Ishikawa pref., Japan|Doniwa Clinic, Kanazawa city, Ishikawa pref., Japan|Wakasa Medical Clinic, Kanazawa city, Ishikawa pref., Japan|Association Medical Corporation Neurology Internal Medicine Kanamori Clinic, Iwate gun, Iwate pref., Japan|Medical Corporation Kuon-kai Kamata Medical Clinic, Morioka city, Iwate pref., Japan|Kagawa Clinic, Marugame city, Kagawa pref., Japan|Hasegawa Outpatients Clinic for Cardiovascular Disease, Takamatsu city, Kagawa pref., Japan|Tempozan Naika Clinic, Kagoshima city, Kagoshima pref., Japan|Kashiwagi Clinic, Ayase city, Kanagawa pref., Japan|Hayashi Diabetes Clinic, Chigasaki city, Kanagawa pref., Japan|Takada Internal Medicine Clinic, Hiratsuka city, Kanagawa pref., Japan|Iroden Clinic, Kamakura city, Kanagawa pref., Japan|Nagasu Clinic, Kamakura city, Kanagawa pref., Japan|Kobayashi Hospital, Odawara city, Kanagawa pref., Japan|Hakuai Iin, Sagamihara city, Kanagawa pref., Japan|Yamamoto Clinic, Sagamihara city, Kanagawa pref., Japan|Arima Clinic, Yokohama city, Kanagawa pref., Japan|Kikuchi Clinic, Yokohama city, Kanagawa pref., Japan|Miho cho Cardiovascular Medical Clinic, Yokohama city, Kanagawa pref., Japan|Minamisawa Clinic, Yokohama city, Kanagawa pref., Japan|Shimokurata Heart Clinic, Yokohama city, Kanagawa pref., Japan|Yokohama Sotetsu Bldg. Clinic of Internal Medicine, Yokohama city, Kanagawa pref., Japan|Jinnouchi Clinic Diabetes Care Center, Kumamoto city, Kumamoto pref., Japan|Maki Cardiovascular Clinic, Kumamoto city, Kumamoto pref., Japan|Munakata Clinic, Kumamoto city, Kumamoto pref., Japan|Terao Hospital, Kumamoto city, Kumamoto pref., Japan|Higashi Diabetes and Cardiovascular Clinic, Tamana city, Kumamoto pref., Japan|Matsuo Clinic, Tamana city, Kumamoto pref., Japan|Miyagi Clinic Cardiovascular Medicine, Yatsushiro city, Kumamoto pref., Japan|Sawai Naika Iin, Kyotanabe city, Kyoto pref., Japan|Asamoto Internal Medical Clinic, Kyoto city, Kyoto pref., Japan|Ijinkai Takeda General Hospital, Kyoto city, Kyoto pref., Japan|Koseikai Clinic, Kyoto city, Kyoto pref., Japan|Sakabe International Clinic, Kyoto city, Kyoto pref., Japan|Takenaka Clinic, Kyoto city, Kyoto pref., Japan|Tegoshi Clinic, Kyoto city, Kyoto pref., Japan|Iwasaki Hospital, Tsu city, Mie pref., Japan|Ishikawa Clinic, Miyazaki city, Miyazaki pref., Japan|Yokota Naika, Miyazaki city, Miyazaki pref., Japan|Etou Clinic, Nichinan city, Miyazaki pref., Japan|Kawano Clinic, Nichinan city, Miyazaki pref., Japan|Yamaguchi Clinic, Nichinan city, Miyazaki pref., Japan|Hasegawa Clinic, Nakano city, Nagano pref., Japan|Nara Prefectural Gojo Hospital, Gojo city, Nara pref., Japan|Fujii Internal Medicine Clinic, Kashihara city, Nara pref., Japan|Matsuoka Clinic, Kita katsuragi gun, Nara pref., Japan|Ote Clinic of Internal, Sakurai city, Nara pref., Japan|Uchiyama Clinic, Joetsu city, Niigata pref., Japan|Inoue Clinic, Niigata city, Niigata pref., Japan|Maeda Medical Clinic, Niigata city, Niigata pref., Japan|Nishimura Clinic, Fujiidera city, Osaka pref., Japan|Shoseikai Matsuda Iin, Fujiidera city, Osaka pref., Japan|Ikeda Clinic, Higashiosaka city, Osaka pref., Japan|Kanazawa Clinic, Izumi city, Osaka pref., Japan|Fukuda Clinic, Osaka city, Osaka pref., Japan|Jikuhara Clinic, Osaka city, Osaka pref., Japan|Kawagishi-naika Clinic, Osaka city, Osaka pref., Japan|Kinugawa Cardiology Clinic, Osaka city, Osaka pref., Japan|Kubota Clinic, Osaka city, Osaka pref., Japan|Masaki Clinic, Osaka city, Osaka pref., Japan|Nanko Clinic, Osaka city, Osaka pref., Japan|Osaka Ekisaikai Hospital, Osaka city, Osaka pref., Japan|Tamatani Clinic, Osaka city, Osaka pref., Japan|Hayashi Clinic, Sakai city, Osaka pref., Japan|Nakao Medical Clinic, Sakai city, Osaka pref., Japan|Saga Memorial Clinic, Saga city, Saga pref., Japan|Enomoto Clinic, Ageo city, Saitama pref., Japan|Asano Internal Medicine Clinic, Kawagoe city, Saitama pref., Japan|Iryohojin Hogi Sinryojyo, Kawaguchi city, Saitama pref., Japan|Tokutake Iin, Kawaguchi city, Saitama pref., Japan|Medical Corporation Shibuya Clinic, Kumagaya city, Saitama pref., Japan|Tanaka Medical Clinic, Saitama city, Saitama pref., Japan|Yoshimura Eye&Internal Medical Clinic, Mishima city, Shizuoka pref., Japan|Shizuoka Municipal Hospital, Shizuoka city, Shizuoka pref., Japan|Takada Clinic, Tochigi city, Tochigi pref., Japan|Murakami Clinic, Anan city, Tokushima pref., Japan|Ota Clinic, Awa city, Tokushima pref., Japan|Arizumi Clinic, Itano gun, Tokushima pref., Japan|Yuki National Health Insurance Hospital of Minami Town, Kaifu gun, Tokushima pref., Japan|Sekishinkan Hospital, Komatsushima city, Tokushima pref., Japan|Iryohojin Tokujikai Tanaka Iin, Myozai gun, Tokushima pref., Japan|Kensei Uchimachi Clinic, Tokushima city, Tokushima pref., Japan|Yata Clinic, Yoshinogawa city, Tokushima pref., Japan|Tokyo Center Clinic, Chuo ku, Tokyo, Japan|Okudo Poly Clinic, Katsushika ku, Tokyo, Japan|Nakano Sunbright Clinic, Nakano ku, Tokyo, Japan|Sugawara Clinic, Nerima ku, Tokyo, Japan|Tsurumachi Clinic, Setagaya ku, Tokyo, Japan|Oda Clinic, Shinjuku ku, Tokyo, Japan|Ishii Clinic, Tachikawa city, Tokyo, Japan|Ayame Medical Clinic, Shimonoseki city, Yamaguchi pref., Japan|Matsuda Medical Clinic, Shimonoseki city, Yamaguchi pref., Japan|Mizumachi Medical Clinic, Shimonoseki city, Yamaguchi pref., Japan|Kuroda Iin, Otsuki city, Yamanashi pref., Japan|Yasue Naika, Gifu city, Japan",,https://ClinicalTrials.gov/show/NCT01544309
NCT01541943,Efficacy and Safety of HL-040XC in Essential Hypertension and Hyperlipidemia,,Completed,No Results Available,Essential Hypertension|Hyperlipidemia,Drug: Atorvastatin|Drug: Losartan|Drug: Placebo|Drug: HL-040XC,Change from baseline to 8 week in SiDBP (Sitting Diastolic Blood Pressure)|Percent change from baseline to 8 week in LDL-Cholesterol|Percentage of patients reaching treatment goals according to NCEP ATP III Guideline and Blood Pressure Responder according to JNC VII Guideline.,"HanAll BioPharma Co., Ltd.",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,356,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",HATLO11III_1,Mar-12,Nov-14,Nov-14,1-Mar-12,null,23-Sep-15,"Korea University Guro Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01541943
NCT01539616,A Clinical Trial to Evaluate the Safety and Efficacy of ZYH7 Compared to Fenofibrate in Patients With Dyslipidemia,,Completed,No Results Available,Hypertriglyceridemia|Dyslipidemia,Drug: ZYH7|Drug: Fenofibrate,Percentage change in mean triglyceride level from baseline|Percentage change from baseline in lipid parameters,Cadila Healthcare Limited,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,109,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",ZYH7.10.001.01|CTRI/2011/11/002147,Nov-11,Jun-12,Aug-12,27-Feb-12,null,28-Oct-13,"Vijayratna Diabetes Diagnosis & Treatment Centre, Upper Ground Floor, Sumeru Centre, Nr Parimal Underbridge, Paldi, Ahmedabad, Gujarat, India|Devi Hospital,Ground floor, Naranpura, Ahmedabad, Gujarat, India|Private clinic, 4, Stadium House, Ground Floor, Navrangpura, Ahmedabad, Gujarat, India|Dia Care Reseach, 1&2- Gandhi Park Society, Nr. Nehrunagar Cross Roads, Ambawadi, Ahmedabad, Gujarat, India|Govt. Medical College, Bhavnagar, Bhavnagar, Gujarat, India|Gastrocare Clinic,Ground floor, Karansinhji Main Road,, Rajkot, Gujarat, India|Balaji Hospital,First floor,clinical research department, Opp. Vidya Vikas School, Subhanpura,, Vadodara, Gujarat, India|Pace Clinical Research (A. Unit of Pranav Diabetes Centre), No. 53, Nanda Complex, Ramamurthy Nagar Main Road, Banasawadi, Bangalore, Karnataka, India|Srinivasa clinic and Diabetic Care centre, 197, 2nd floor, Near Avalahalli BDA park, BSK 3rd stage, Bangalore, Karnataka, India|Mallige Healthcare Centre, # 402, 8th main, 8th cross, Near Dr. M. C. Modi Compound. P.J.EXTN,, Davangere, Karnataka, India|Deogiri Diabetes Centre, 46 Samata Nagar, Near Kranti Chowk Police Station, Aurangabad, Maharashtra, India|Bhatia Hospital, Tardeo Road,Room no 19, Basement floor,Research room,, Mumbai, Maharashtra, India|Pai Clinic & Diagnostic Centre - Abhinav Apartments, 778/B-4, First floor, Shivajinagar, Next to Congress House, Pune, Maharashtra, India|Shree Nidan Hospital, Clinical trial department, First floor, 27-28 Vidhyut nagar-A, Ajmer road, Jaipur, Rajasthan, India|Mother's Care Diabetes Centre, Room no 9, Phase 1, Sathuvachari, Vellore, Tamil Nadu, India|Aruna Diabetes Centre, 56,Thiruvengatapuram, Near Nungambakkam Railway Station, Choolamedu, Chennai, Tamilnadu, India|Department of Endocrinology, Room No.9, 4 th Floor, Ronald Ross Building, Institute of Post Graduate Medical Education & Research, 244 AJC Bose Road., Kolkata, West Bengal, India|Room no 3027,Research block B,Department of Endocrinology PGIMER, Chandigarh, India",,https://ClinicalTrials.gov/show/NCT01539616
NCT01531569,Single Oral Dose of BeneFlax to Healthy Young and Older Adults,SOD,Completed,No Results Available,"Diabetes Mellitus, Type 2|Hypercholesterolemia",Other: BeneFlax - 38% secoisolariciresinol diglucoside (SDG),"Peak plasma concentration (Cmax) of secoisolariciresinol, enterodiol and enterolactone.|Time to reach peak plasma concentration (tmax) of secoisolariciresinol, enterodiol and enterolactone.|Area under the plasma concentration versus time curve (AUC) of secoisolariciresinol, enterodiol and enterolactone.|Elimination rate constant (k) of secoisolariciresinol, enterodiol and enterolactone.|Terminal phase half-life of secoisolariciresinol, enterodiol and enterolactone.|Food frequency questionnaire|Activity questionnaire|Inflammatory markers",University of Saskatchewan|Saskatchewan Health Research Foundation,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,22,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),NHPD - 174041,Dec-11,Jun-12,Jun-12,13-Feb-12,null,26-Oct-16,"Saskatoon Centre for Patient Oriented Research - Saskatoon City Hospital, Saskatoon, Saskatchewan, Canada",,https://ClinicalTrials.gov/show/NCT01531569
NCT01531062,Effect of Nigella Sativa on Lipid Profiles in Elderly,,Completed,No Results Available,Dyslipidemia,Drug: Nigella sative|Dietary Supplement: black sticky rice,"Decreased level of total cholesterol, LDL, dan triglyceride, and increased level of HDL",Indonesia University,All,"60 Years and older   (Adult, Older Adult)",Phase 2,96,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Nigella sativa,Sep-11,Dec-11,Dec-11,10-Feb-12,null,10-Feb-12,"Internal Medicine Department, Faculty of Medicine, University Indonesia, Jakarta, Indonesia",,https://ClinicalTrials.gov/show/NCT01531062
NCT01529424,"Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia",,Completed,No Results Available,Hypertriglyceridemia,Drug: ISIS apoC-III Rx|Drug: Placebo,VLDL apoC-III,"Ionis Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,89,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 304801-CS2,Feb-12,Jan-14,Jan-14,8-Feb-12,null,16-Jun-16,"Farmville Internal Medicine, Farmville, North Carolina, United States|Mark R. Cervi, Greenville, North Carolina, United States|Physicians East, Quadrangle Medical Specialists, Greenville, North Carolina, United States|Carolina East Family Medicine, Greenville, North Carolina, United States|Eastern Carolina Physicians, Kinston, North Carolina, United States|Natalie A Doyle, MD PA, Wilson, North Carolina, United States|Isis Investigational site, Chicoutimi, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01529424
NCT01527747,Effects of DPP-4 Inhibition on Triglycerides,,Enrolling by invitation,No Results Available,Type 2 Diabetes|Hypertriglyceridemia,Drug: Saxagliptin,Change in fasting and postprandial triglyceride concentrations|Changes in glycemia,Oregon Health and Science University,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",CV181-142,Jan-12,Nov-20,Dec-20,7-Feb-12,null,20-Nov-18,"Oregon Health & Science University, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT01527747
NCT01524601,The Rosuvastatin In TrAnsplant Recipients Study,RITA,Completed,No Results Available,Disorder Related to Renal Transplantation|Hypercholesterolemia,Drug: Rosuvastatin,"compare the treatment efficacy (blood lipid lowering effect) of rosuvastatin versus fluvastatin|Area Under Curve (AUC) of rosuvastatin in renal transplant recipients treated with everolimus. Time frame: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post dose.|1. Area Under Curve (AUC) of everolimus during rosuvastatin versus fluvastatin therapy, including intracellular everolimus concentrations within T-lymphocytes. Time frame: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 hours post-dose.|2. Investigate P-gp activity in whole blood in everolimus treated patients|3. Study inter individual variation in rosuvastatin and everolimus pharmacokinetics in renal transplant recipients due to polymorphism in the genes encoding P-gp, OATP1B1 and CYP3A5|4. Compare effect of rosuvastatin versus fluvastatin therapy on the renal function (eGFR)",University of Oslo School of Pharmacy|Oslo University Hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 4,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RITA-11,Feb-12,Oct-12,Oct-12,2-Feb-12,null,12-Oct-12,"Oslo University Hospital, Rikshospitalet, Oslo, Norway",,https://ClinicalTrials.gov/show/NCT01524601
NCT01524289,Study to Assess the Tolerability and Efficacy of Anacetrapib Co-administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020),REALIZE,Completed,No Results Available,Hyperlipoproteinemia Type II|Heterozygous Familial Hypercholesterolemia,Drug: Anacetrapib|Drug: Placebo for Anacetrapib,Percent Change from Baseline in Low Density Lipoprotein Cholesterol (LDL-C)(beta quantification method)|Percent Change from Baseline in High Density Lipoprotein Cholesterol (HDL-C)|Percent Change from Baseline in Non-high Density Lipoprotein Cholesterol (Non-HDL-C)|Percent Change from Baseline in Apolipoprotein B (Apo B)|Percent Change from Baseline in Apolipoprotein A1 (Apo A1)|Percent Change from Baseline in Lipoprotein(a) (Lp[a]),Merck Sharp & Dohme Corp.,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,306,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0859-020|2011-004525-27,3-Feb-12,12-Feb-14,13-Nov-18,1-Feb-12,null,19-Dec-18,,,https://ClinicalTrials.gov/show/NCT01524289
NCT01516541,"A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease",,Completed,No Results Available,"Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD)",Other: Background care|Drug: Placebo|Drug: dalcetrapib,Time to first occurrence of any component of the composite cardiovascular event (cardiovascular mortality and morbidity)|All cause mortality|Safety: Incidence of adverse events|Change in blood lipid and lipoprotein levels,Hoffmann-La Roche,All,"45 Years and older   (Adult, Older Adult)",Phase 3,2220,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NC25608|2011-001891-21,Jan-12,Jul-12,Jul-12,25-Jan-12,null,2-Nov-16,"Birmingham, Alabama, United States|Huntsville, Alabama, United States|Anaheim, California, United States|Fullerton, California, United States|San Diego, California, United States|Santa Ana, California, United States|Santa Rosa, California, United States|Torrance, California, United States|Torrance, California, United States|Colorado Springs, Colorado, United States|Denver, Colorado, United States|Lonetree, Colorado, United States|Bridgeport, Connecticut, United States|Hartford, Connecticut, United States|Boynton Beach, Florida, United States|Daytona Beach, Florida, United States|Daytona Beach, Florida, United States|Fort Myers, Florida, United States|Jacksonville, Florida, United States|Panama City, Florida, United States|Plantation, Florida, United States|Port Charlotte, Florida, United States|Tallahassee, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Covington, Georgia, United States|Cumming, Georgia, United States|Decatur, Georgia, United States|Aurora, Illinois, United States|Rock Island, Illinois, United States|Winfield, Illinois, United States|Elkhart, Indiana, United States|Hammond, Indiana, United States|Indianapolis, Indiana, United States|Indianapolis, Indiana, United States|Muncie, Indiana, United States|South Bend, Indiana, United States|Overland Park, Kansas, United States|Louisville, Kentucky, United States|Alexandria, Louisiana, United States|Bangor, Maine, United States|Beltsville, Maryland, United States|Salisbury, Maryland, United States|Boston, Massachusetts, United States|Haverhill, Massachusetts, United States|Hyannis, Massachusetts, United States|North Dartmouth, Massachusetts, United States|Jackson, Michigan, United States|Kalamazoo, Michigan, United States|Marquette, Michigan, United States|Midland, Michigan, United States|Rochester Hills, Michigan, United States|Saginaw, Michigan, United States|Ypsilanti, Michigan, United States|Rochester, Minnesota, United States|St. Cloud, Minnesota, United States|Chesterfield, Missouri, United States|Columbia, Missouri, United States|Kansas City, Missouri, United States|Kalispell, Montana, United States|Nashua, New Hampshire, United States|Camden, New Jersey, United States|Haddon Heights, New Jersey, United States|Mine Hill, New Jersey, United States|Wayne, New Jersey, United States|Westwood, New Jersey, United States|Albany, New York, United States|Albany, New York, United States|Bronx, New York, United States|Buffalo, New York, United States|Cortlandt Manor, New York, United States|Poughkeepsi, New York, United States|Saratoga Springs, New York, United States|Smithtown, New York, United States|Syracuse, New York, United States|Troy, New York, United States|Asheville, North Carolina, United States|Durham, North Carolina, United States|Elizabeth City, North Carolina, United States|Hickory, North Carolina, United States|Morehead City, North Carolina, United States|Rocky Mount, North Carolina, United States|Statesville, North Carolina, United States|Wilmington, North Carolina, United States|Fargo, North Dakota, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Mansfield, Ohio, United States|Mentor, Ohio, United States|Thornville, Ohio, United States|Toledo, Ohio, United States|Zanesville, Ohio, United States|Allentowm, Pennsylvania, United States|Altoona, Pennsylvania, United States|Camp Hill, Pennsylvania, United States|Doylestown, Pennsylvania, United States|Erie, Pennsylvania, United States|Erie, Pennsylvania, United States|Langhorne, Pennsylvania, United States|Lansdale, Pennsylvania, United States|North Wales, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pottstown, Pennsylvania, United States|Tipton, Pennsylvania, United States|West Chester, Pennsylvania, United States|Anderson, South Carolina, United States|Greer, South Carolina, United States|Rapid City, South Dakota, United States|Johnson City, Tennessee, United States|Dallas, Texas, United States|Humble, Texas, United States|Odessa, Texas, United States|Tyler, Texas, United States|Provo, Utah, United States|Charlottesville, Virginia, United States|Danville, Virginia, United States|Lynchburg, Virginia, United States|Manassas, Virginia, United States|Richmond, Virginia, United States|Winchester, Virginia, United States|Milton, Queensland, Australia|Geelong, Victoria, Australia|Joondalup, Western Australia, Australia|Coquitlam, British Columbia, Canada|Kelowna, British Columbia, Canada|Vancouver, British Columbia, Canada|Moncton, New Brunswick, Canada|Ajax, Ontario, Canada|Barrie, Ontario, Canada|Burlington, Ontario, Canada|Cambridge, Ontario, Canada|London, Ontario, Canada|Oakville, Ontario, Canada|Oshawa, Ontario, Canada|Oshawa, Ontario, Canada|Sudbury, Ontario, Canada|Sudbury, Ontario, Canada|Thunder Bay, Ontario, Canada|Toronto, Ontario, Canada|Granby, Quebec, Canada|Greenfield Park, Quebec, Canada|Lachine, Quebec, Canada|Longueuil, Quebec, Canada|Longueuil, Quebec, Canada|Mirabel, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Montréal, Quebec, Canada|Montréal, Quebec, Canada|Québec, Quebec, Canada|St-Lambert, Quebec, Canada|Trois-Rivières, Quebec, Canada|Val D'Or, Quebec, Canada|Quebec, Canada|Beijing, China|Nanchang, China|Shijiazhuang, China|Benatky nad Jizerou, Czech Republic|Jindrichuv Hradec, Czech Republic|Ostrava, Czech Republic|Pardubice, Czech Republic|Praha 4, Czech Republic|Slany, Czech Republic|Trutnov, Czech Republic|Ballerup, Denmark|Hvidovre, Denmark|Vejle, Denmark|Århus N, Denmark|Pessac, France|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Kisvarda, Hungary|Komarom, Hungary|Nagykanizsa, Hungary|Pecs, Hungary|Urhida, Hungary|Aguascalientes, Mexico|Aguascaliente, Mexico|Celaya, Mexico|Chihuahua, Mexico|Cuernavaca, Mexico|D. F., Mexico|Durango, Mexico|Guadalajara, Mexico|Guadalajara, Mexico|Guadalajara, Mexico|Mexico City, Mexico|Monterrey, Mexico|Monterrey, Mexico|Pachuca, Mexico|Queretaro, Mexico|San Luis Potosi S.L.P., Mexico|San Luis Potosí, Mexico|San Luís Potosí, Mexico|Tampico, Mexico|Alkmaar, Netherlands|Amsterdam, Netherlands|Apeldoorn, Netherlands|Breda, Netherlands|Delft, Netherlands|Eindhoven, Netherlands|Eindhoven, Netherlands|Gouda, Netherlands|Groningen, Netherlands|Heerlen, Netherlands|Hoorn, Netherlands|Leiden, Netherlands|Rotterdam, Netherlands|Rotterdam, Netherlands|Utrecht, Netherlands|Velp, Netherlands|Venlo, Netherlands|Zoetermeer, Netherlands|Bialystok, Poland|Gdansk, Poland|Gdynia, Poland|Katowice, Poland|Krakow, Poland|Lodz, Poland|Lodz, Poland|Lublin, Poland|Lublin, Poland|Lublin, Poland|Poznan, Poland|Pulway, Poland|Ruda Slaska, Poland|Warsawa, Poland|Warszawa, Poland|Almeria, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Malaga, Spain|Birmingham, United Kingdom|Cardiff, United Kingdom|Glasgow, United Kingdom|Liverpool, United Kingdom|Manchester, United Kingdom|Reading, United Kingdom",,https://ClinicalTrials.gov/show/NCT01516541
NCT01516879,Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study,DESCARTES,Completed,Has Results,Hypercholesterolemia,Biological: Evolocumab|Biological: Placebo|Drug: Atorvastatin|Drug: Ezetimibe|Other: Diet Only,Percent Change From Baseline in LDL-C at Week 52|Change From Baseline in LDL-C at Week 52|Percentage of Participants With an LDL-C Response at Week 52|Percent Change From Baseline in LDL-C at Week 12|Percent Change From Baseline in Total Cholesterol at Week 12|Percent Change From Baseline in Total Cholesterol at Week 52|Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at Week 52|Percent Change From Baseline in Apolipoprotein B at Week 52|Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 52|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 52|Percent Change From Baseline in Lipoprotein(a) at Week 52|Percent Change From Baseline in Triglycerides at Week 52|Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at Week 52|Percent Change From Baseline in Very Low-density Lipoprotein Cholesterol (VLDL-C) at Week 52|Percent Change From Week 12 to Week 52 in LDL-C,Amgen,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,905,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",20110109,5-Jan-12,14-Oct-13,14-Oct-13,25-Jan-12,29-Sep-15,28-Nov-18,"Research Site, Birmingham, Alabama, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Anaheim, California, United States|Research Site, Encinitas, California, United States|Research Site, Spring Valley, California, United States|Research Site, Westlake Village, California, United States|Research Site, DeLand, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Ponte Vedra, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Savannah, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Louisville, Kentucky, United States|Research Site, Auburn, Maine, United States|Research Site, Bethesda, Maryland, United States|Research Site, Chevy Chase, Maryland, United States|Research Site, Columbia, Maryland, United States|Research Site, Brockton, Massachusetts, United States|Research Site, Saint Paul, Minnesota, United States|Research Site, Olive Branch, Mississippi, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Endwell, New York, United States|Research Site, New Windsor, New York, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Akron, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Norman, Oklahoma, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Mount Pleasant, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Houston, Texas, United States|Research Site, Richmond, Virginia, United States|Research Site, Renton, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Camperdown, New South Wales, Australia|Research Site, Maroubra, New South Wales, Australia|Research Site, Carina Heights, Queensland, Australia|Research Site, Milton, Queensland, Australia|Research Site, Fitzroy, Victoria, Australia|Research Site, Perth, Western Australia, Australia|Research Site, Feldkirch, Austria|Research Site, Innsbruck, Austria|Research Site, Salzburg, Austria|Research Site, Wels, Austria|Research Site, AnthÃ©e, Belgium|Research Site, Bruxelles, Belgium|Research Site, Gent, Belgium|Research Site, Gozee, Belgium|Research Site, Ham, Belgium|Research Site, Oostende, Belgium|Research Site, Victoria, British Columbia, Canada|Research Site, Bay Roberts, Newfoundland and Labrador, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Pointe-Claire, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Chomutov, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Pardubice, Czechia|Research Site, Plzen, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 5, Czechia|Research Site, Slany, Czechia|Research Site, Aalborg, Denmark|Research Site, Ballerup, Denmark|Research Site, Vejle, Denmark|Research Site, Baja, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Komarom, Hungary|Research Site, Pecs, Hungary|Research Site, Szeged, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Lyttelton, Gauteng, South Africa|Research Site, Amanzimtoti, KwaZulu-Natal, South Africa|Research Site, Chatsworth, Durban, KwaZulu-Natal, South Africa|Research Site, Observatory, Western Cape, South Africa|Research Site, Paarl, Western Cape, South Africa|Research Site, Parow, Western Cape, South Africa|Research Site, Somerset West, Western Cape, South Africa|Research Site, Bloemfontein, South Africa",,https://ClinicalTrials.gov/show/NCT01516879
NCT01515241,Exploratory Study of Plaque Regression,EXPRESS,Completed,No Results Available,Heterozygous Familial Hypercholesterolemia,Drug: CER-001,Change in Total Plaque Volume|Percent Change in Plaque Volume|Change in carotid plaque volume,"Cerenis Therapeutics, SA",All,"18 Years and older   (Adult, Older Adult)",Phase 2,10,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CER-001-CLIN-005,Jan-12,Apr-12,May-12,24-Jan-12,null,3-Mar-14,"Montreal Heart Institute, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01515241
NCT01516151,Assess the Safety and Efficacy of NKPL66 (CaPre™) in the Treatment of Mild-to-high Hypertriglyceridemia,,Completed,No Results Available,Hypertriglyceridemia,Dietary Supplement: CaPre™|Drug: Lipid Lowering Medication,"Percent change in fasting blood circulating serum TGs|Absolute change in fasting plasma TGs|Patients achieving target TG fasting plasma levels|Change in fasting plasma LDL-C, VLDL-C, HDL-C, total cholesterol, hs-CRP and non-HDL|Change in fasting plasma concentrations of LDL-C, VLDL-C, HDL-C, total cholesterol, hs-CRP and non-HDL|Calculated ratios|Change in fasting plasma concentrations of biomarkers",Acasti Pharma Inc.|JSS Medical Research Inc.,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,289,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PRT-API-NKPL66-CT-PIIB,Dec-11,May-13,Sep-13,24-Jan-12,null,8-Jan-14,"Alberta Health Services Clinical Trials, Red Deer, Alberta, Canada|Abbotsford, British Columbia, Canada|Kelowna, British Columbia, Canada|BC Diabetes, Vancouver, British Columbia, Canada|Victoria, British Columbia, Canada|Winnipeg, Manitoba, Canada|Dieppe, New Brunswick, Canada|Entralogix Clinical Research, Aurora, Ontario, Canada|Entralogix Clinical Research, Brampton, Ontario, Canada|Cambridge Cardiac Care Center, Cambridge, Ontario, Canada|Thamesview Ctr of Family Med, Chatam, Ontario, Canada|Moran Medical Centre, Colingwood, Ontario, Canada|C & L Research, Fort Erie, Ontario, Canada|Hamilton, Ontario, Canada|Entralogix Clinical Research, Kitchener, Ontario, Canada|Entralogix Clinical Research, Mississauga, Ontario, Canada|Malton Medical Research Group, Mississauga, Ontario, Canada|Niagara Falls, Ontario, Canada|Entralogix Clinical Research, North York, Ontario, Canada|Taunton Health Centre, Oshawa, Ontario, Canada|Steeple Hill Medical centre, Pickering, Ontario, Canada|G.S. Cardiac Lab Medicine Professional Corp, Sudbury, Ontario, Canada|Entralogix Clinical Research, Toronto, Ontario, Canada|Eric Silver Medicine Professional Corporation, Toronto, Ontario, Canada|Clinique Médicale des Trois Lacs, Vaudreuil Dorion, Ontario, Canada|Clinique Medicale Valcartier, Courcelette, Quebec, Canada|Clinique Reseau le Trait d'Union, Delson, Quebec, Canada|Clinique Medicale Mistassini, Dolbeau-Mistassini, Quebec, Canada|GMF Grand Mere, Grand Mere, Quebec, Canada|Clinique medicale, Grand-Mere, Quebec, Canada|CRM Lanaudiere, Joliette, Quebec, Canada|Applied Medical Information Research AMIR, Montreal, Quebec, Canada|Clinique Services Sante Rosemere, Rosemere, Quebec, Canada|Csss de St-Jerome, Saint-Jerome, Quebec, Canada|CSSS Vallee De L'Or, Val d'Or, Quebec, Canada|Applied Medical Information Research (AMIR), Westmount, Quebec, Canada|Centre de recherche A&E, Quebec, Canada|Clinique des maladies lipidiques de Quebec Inc., Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01516151
NCT01514461,"A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome",,Completed,Has Results,Familial Chylomicronemia Syndrome (FCS),Drug: LCQ908|Drug: Placebo,"Percent Change in Fasting Triglycerides From Baseline to 12 Weeks|Percentage of Patients Responding to Investigational Treatment by Achieving Fasting Triglycerides (TG) of at Least 40% From Baseline or Final Fasting TG < 8.4 mmol/L (750 mg/dL)|Percentage of Patients Responding to Investigational Treatment by Achieving Final Fasting Triglycerides < 8.4 mmol/L (750 mg/dL)|Percentage of Patients Responding to Investigational Treatment by Achieving Fasting Triglycerides (TG) of at Least 40% From Baseline|Percentage of Patients Achieving Fasting Triglycerides (TG) Target Thresholds|Percent Change From Baseline in Fasting Triglycerides|Percent Change From Baseline for Postprandial Triglycerides Following the Standardized Meal Tolerance Test at Week 12|Pharmacokinetics of LCQ908 - Trough Concentration (Cmin) and Observed Maximum Blood Concentration (Cmax)|Pharmacokinetics of LCQ908- Area Under the Plasma Concentration Time Curve AUC (0-24hour)|Pharmacokinetics of LCQ908- Time to Reach Maximum Concentration Following Drug Administration Tmax (Hours)|Pharmacokinetics of LCQ908- Average Observed Blood Concentration (Cavg)|Number of Patients Reported With Any Adverse Event, Serious Adverse Event and Death",Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 3,45,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CLCQ908B2302|2011-005535-68,Jul-12,May-14,May-14,23-Jan-12,3-Jun-15,3-Jun-15,"Novartis Investigative Site, Seatlle, Washington, United States|Novartis Investigative Site, Chicoutimi, Quebec, Canada|Novartis Investigative Site, Ste-Foy, Quebec, Canada|Novartis Investigative Site, Ouest-Montreal, Canada|Novartis Investigative Site, Bron, France|Novartis Investigative Site, Nantes, France|Novartis Investigative Site, Paris Cedex 13, France|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Köln, Germany|Novartis Investigative Site, Meibergdreef 9, Netherlands|Novartis Investigative Site, Cape Town, South Africa|Novartis Investigative Site, Malaga, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT01514461
NCT01507831,Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term),,Completed,Has Results,Hypercholesterolemia,Drug: Placebo (for alirocumab)|Drug: Alirocumab|Drug: Lipid-Modifying Therapy (LMT),Percentage of Participants Who Experienced Adverse Events (AEs)|Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis|Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis|Percent Change From Baseline in Measured LDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 12 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 - ITT Analysis|Percentage of Very High Cardiovascular (CV) Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis|Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis|Percent Change From Baseline in Apo A1 at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis|Percent Change From Baseline in Apo A1 at Week 12 - ITT Analysis,Sanofi|Regeneron Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 3,2341,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",LTS11717|2011-002806-59|U1111-1121-3928,Jan-12,Nov-14,Nov-14,11-Jan-12,22-Dec-15,22-Dec-15,"Investigational Site Number 840159, Huntsville, Alabama, United States|Investigational Site Number 840028, Gilbert, Arizona, United States|Investigational Site Number 840035, Sierra Vista, Arizona, United States|Investigational Site Number 840052, Tempe, Arizona, United States|Investigational Site Number 840065, Tempe, Arizona, United States|Investigational Site Number 840079, Tempe, Arizona, United States|Investigational Site Number 840094, Tempe, Arizona, United States|Investigational Site Number 840103, Tucson, Arizona, United States|Investigational Site Number 840209, Beverly Hills, California, United States|Investigational Site Number 840194, Beverly Hills, California, United States|Investigational Site Number 840207, Fresno, California, United States|Investigational Site Number 840101, Lincoln, California, United States|Investigational Site Number 840076, Long Beach, California, United States|Investigational Site Number 840214, Pasadena, California, United States|Investigational Site Number 840045, Sacramento, California, United States|Investigational Site Number 840163, Santa Rosa, California, United States|Investigational Site Number 840086, Colorado Springs, Colorado, United States|Investigational Site Number 840077, Golden, Colorado, United States|Investigational Site Number 840224, Bridgeport, Connecticut, United States|Investigational Site Number 840134, Guilford, Connecticut, United States|Investigational Site Number 840246, Hartford, Connecticut, United States|Investigational Site Number 840055, Stamford, Connecticut, United States|Investigational Site Number 840091, Stamford, Connecticut, United States|Investigational Site Number 840150, Atlantis, Florida, United States|Investigational Site Number 840020, Bradenton, Florida, United States|Investigational Site Number 840041, Brandon, Florida, United States|Investigational Site Number 840184, Clearwater, Florida, United States|Investigational Site Number 840242, Clearwater, Florida, United States|Investigational Site Number 840039, Clearwater, Florida, United States|Investigational Site Number 840182, Crystal River, Florida, United States|Investigational Site Number 840002, Daytona Beach, Florida, United States|Investigational Site Number 840166, Daytona Beach, Florida, United States|Investigational Site Number 840167, Fleming Island, Florida, United States|Investigational Site Number 840018, Fort Lauderdale, Florida, United States|Investigational Site Number 840090, Ft. Lauderdale, Florida, United States|Investigational Site Number 840153, Jacksonville, Florida, United States|Investigational Site Number 840181, Jacksonville, Florida, United States|Investigational Site Number 840152, Jacksonville, Florida, United States|Investigational Site Number 840154, Lake Mary, Florida, United States|Investigational Site Number 840059, Largo, Florida, United States|Investigational Site Number 840221, Miami, Florida, United States|Investigational Site Number 840021, New Port Richey, Florida, United States|Investigational Site Number 840122, New Smyrna Beach, Florida, United States|Investigational Site Number 840151, Ocala, Florida, United States|Investigational Site Number 840108, Ormond Beach, Florida, United States|Investigational Site Number 840067, Palm Harbor, Florida, United States|Investigational Site Number 840006, Pembroke Pines, Florida, United States|Investigational Site Number 840168, Ponte Vedra, Florida, United States|Investigational Site Number 840164, Sarasota, Florida, United States|Investigational Site Number 840175, Sarasota, Florida, United States|Investigational Site Number 840001, St. Petersburg, Florida, United States|Investigational Site Number 840003, St. Petersburg, Florida, United States|Investigational Site Number 840036, West Palm Beach, Florida, United States|Investigational Site Number 840117, Cumming, Georgia, United States|Investigational Site Number 840110, Roswell, Georgia, United States|Investigational Site Number 840026, Savannah, Georgia, United States|Investigational Site Number 840075, Meridian, Idaho, United States|Investigational Site Number 840027, Evansville, Indiana, United States|Investigational Site Number 840093, Indianapolis, Indiana, United States|Investigational Site Number 840222, Iowa City, Iowa, United States|Investigational Site Number 840165, West Des Moines, Iowa, United States|Investigational Site Number 840200, Kansas City, Kansas, United States|Investigational Site Number 840040, Wichita, Kansas, United States|Investigational Site Number 840061, Wichita, Kansas, United States|Investigational Site Number 840032, Wichita, Kansas, United States|Investigational Site Number 840084, Wichita, Kansas, United States|Investigational Site Number 840244, Biddeford, Maine, United States|Investigational Site Number 840158, Framingham, Maine, United States|Investigational Site Number 840193, Novi, Michigan, United States|Investigational Site Number 840162, Saginaw, Michigan, United States|Investigational Site Number 840033, Saint Louis, Missouri, United States|Investigational Site Number 840113, St. Louis, Missouri, United States|Investigational Site Number 840095, Henderson, Nevada, United States|Investigational Site Number 840096, Henderson, Nevada, United States|Investigational Site Number 840022, Edison, New Jersey, United States|Investigational Site Number 840011, Hillsborough, New Jersey, United States|Investigational Site Number 840049, Trenton, New Jersey, United States|Investigational Site Number 840097, Bronxville, New York, United States|Investigational Site Number 840129, Brooklyn, New York, United States|Investigational Site Number 840160, Poughkeepsie, New York, United States|Investigational Site Number 840217, Asheville, North Carolina, United States|Investigational Site Number 840023, Charlotte, North Carolina, United States|Investigational Site Number 840083, Greensboro, North Carolina, United States|Investigational Site Number 840104, Raleigh, North Carolina, United States|Investigational Site Number 840068, Cincinnati, Ohio, United States|Investigational Site Number 840007, Dayton, Ohio, United States|Investigational Site Number 840013, Marion, Ohio, United States|Investigational Site Number 840161, Mentor, Ohio, United States|Investigational Site Number 840005, Tulsa, Oklahoma, United States|Investigational Site Number 840170, Beaver, Pennsylvania, United States|Investigational Site Number 840180, Camp Hill, Pennsylvania, United States|Investigational Site Number 840004, Duncansville, Pennsylvania, United States|Investigational Site Number 840046, Jersey Shore, Pennsylvania, United States|Investigational Site Number 840155, Phoenixville, Pennsylvania, United States|Investigational Site Number 840177, Scranton, Pennsylvania, United States|Investigational Site Number 840202, Wyomissing, Pennsylvania, United States|Investigational Site Number 840073, Charleston, South Carolina, United States|Investigational Site Number 840087, Greenville, South Carolina, United States|Investigational Site Number 840074, Simpsonville, South Carolina, United States|Investigational Site Number 840105, Varnville, South Carolina, United States|Investigational Site Number 840190, Knoxville, Tennessee, United States|Investigational Site Number 840092, Dallas, Texas, United States|Investigational Site Number 840212, Dallas, Texas, United States|Investigational Site Number 840058, Fort Worth, Texas, United States|Investigational Site Number 840149, Fort Worth, Texas, United States|Investigational Site Number 840070, Fort Worth, Texas, United States|Investigational Site Number 840038, Houston, Texas, United States|Investigational Site Number 840047, Houston, Texas, United States|Investigational Site Number 840053, Plano, Texas, United States|Investigational Site Number 840072, Sugar Land, Texas, United States|Investigational Site Number 840241, Tyler, Texas, United States|Investigational Site Number 840031, Salt Lake City, Utah, United States|Investigational Site Number 840204, Chesapeake, Virginia, United States|Investigational Site Number 840120, Spokane, Washington, United States|Investigational Site Number 840111, Milwaukee, Wisconsin, United States|Investigational Site Number 032006, Buenos Aires, Argentina|Investigational Site Number 032010, Caba, Argentina|Investigational Site Number 032008, Capital Federal, Argentina|Investigational Site Number 032001, Coronel Suarez, Argentina|Investigational Site Number 032004, Resistencia, Argentina|Investigational Site Number 032007, Zarate, Argentina|Investigational Site Number 056005, Antwerpen, Belgium|Investigational Site Number 056004, Genk, Belgium|Investigational Site Number 056001, Natoye, Belgium|Investigational Site Number 056002, Wetteren, Belgium|Investigational Site Number 100008, Pleven, Bulgaria|Investigational Site Number 100014, Plovdiv, Bulgaria|Investigational Site Number 100005, Sofia, Bulgaria|Investigational Site Number 100012, Sofia, Bulgaria|Investigational Site Number 100015, Sofia, Bulgaria|Investigational Site Number 100009, Sofia, Bulgaria|Investigational Site Number 100001, Sofia, Bulgaria|Investigational Site Number 100013, Stara Zagora, Bulgaria|Investigational Site Number 100007, Varna, Bulgaria|Investigational Site Number 124013, Cambridge, Canada|Investigational Site Number 124027, Coquitlam, Canada|Investigational Site Number 124001, Hawkesbury, Canada|Investigational Site Number 124002, London, Canada|Investigational Site Number 124009, Mirabel, Canada|Investigational Site Number 124018, Montreal, Canada|Investigational Site Number 124007, Ottawa, Canada|Investigational Site Number 124011, Quebec, Canada|Investigational Site Number 124005, Saint John'S, Canada|Investigational Site Number 124008, Sarnia, Canada|Investigational Site Number 124022, Terrebonne, Canada|Investigational Site Number 124003, Vancouver, Canada|Investigational Site Number 124006, Victoria, Canada|Investigational Site Number 124015, Woodstock, Canada|Investigational Site Number 152007, Osorno, Chile|Investigational Site Number 152008, Santiago, Chile|Investigational Site Number 152006, Santiago, Chile|Investigational Site Number 152004, Temuco, Chile|Investigational Site Number 170004, Barranquilla, Colombia|Investigational Site Number 170005, Barranquilla, Colombia|Investigational Site Number 170008, Barranquilla, Colombia|Investigational Site Number 170001, Manizales, Colombia|Investigational Site Number 170003, Medellin, Colombia|Investigational Site Number 203004, Praha 2, Czech Republic|Investigational Site Number 203007, Praha 5, Czech Republic|Investigational Site Number 203006, Praha 5, Czech Republic|Investigational Site Number 208005, Aarhus, Denmark|Investigational Site Number 208004, Hellerup, Denmark|Investigational Site Number 208003, Slagelse, Denmark|Investigational Site Number 208001, Svendborg, Denmark|Investigational Site Number 208002, Viborg, Denmark|Investigational Site Number 246002, Joensuu, Finland|Investigational Site Number 246001, Kokkola, Finland|Investigational Site Number 246003, Kuopio, Finland|Investigational Site Number 246004, Vantaa, Finland|Investigational Site Number 250007, Bandol, France|Investigational Site Number 250003, Broglie, France|Investigational Site Number 250014, Bron Cedex, France|Investigational Site Number 250004, Dijon, France|Investigational Site Number 250006, Lille Cedex, France|Investigational Site Number 250009, Nantes, France|Investigational Site Number 250001, Nantes, France|Investigational Site Number 250002, Paris Cedex 13, France|Investigational Site Number 250010, Pessac, France|Investigational Site Number 250012, Rennes, France|Investigational Site Number 250005, Vieux Conde, France|Investigational Site Number 250008, Vihiers, France|Investigational Site Number 276001, Bad Wörishofen, Germany|Investigational Site Number 276007, Berlin, Germany|Investigational Site Number 276005, Berlin, Germany|Investigational Site Number 276014, Berlin, Germany|Investigational Site Number 276008, Bochum, Germany|Investigational Site Number 276009, Dresden, Germany|Investigational Site Number 276004, Essen, Germany|Investigational Site Number 276010, Frankfurt A.M., Germany|Investigational Site Number 276011, Görlitz, Germany|Investigational Site Number 276019, Hannover, Germany|Investigational Site Number 276013, Leipzig, Germany|Investigational Site Number 276012, Magdeburg, Germany|Investigational Site Number 276003, Magdeburg, Germany|Investigational Site Number 276006, Schwerin, Germany|Investigational Site Number 276015, Witten, Germany|Investigational Site Number 348003, Baja, Hungary|Investigational Site Number 348007, Budapest, Hungary|Investigational Site Number 348009, Budapest, Hungary|Investigational Site Number 348008, Budapest, Hungary|Investigational Site Number 348013, Budapest, Hungary|Investigational Site Number 348004, Debrecen, Hungary|Investigational Site Number 348002, Nagykanizsa, Hungary|Investigational Site Number 348006, Nyiregyhaza, Hungary|Investigational Site Number 348001, Sopron, Hungary|Investigational Site Number 348011, Urhida, Hungary|Investigational Site Number 376002, Afula, Israel|Investigational Site Number 376003, Holon, Israel|Investigational Site Number 376005, Holon, Israel|Investigational Site Number 376004, Nazareth, Israel|Investigational Site Number 380006, Chieti, Italy|Investigational Site Number 380002, Cinisello Balsamo, Italy|Investigational Site Number 380009, Milano, Italy|Investigational Site Number 380007, Napoli, Italy|Investigational Site Number 380001, Palermo, Italy|Investigational Site Number 380005, Pozzilli, Italy|Investigational Site Number 380008, Vittorio Veneto, Italy|Investigational Site Number 380010, Zingonia-Osio Sotto, Italy|Investigational Site Number 484010, Df, Mexico|Investigational Site Number 484004, Mexico, Mexico|Investigational Site Number 484008, Not Provided, Mexico|Investigational Site Number 484001, San Luis Potosi, Mexico|Investigational Site Number 484002, Tijuana, Mexico|Investigational Site Number 484009, Torreon, Mexico|Investigational Site Number 484003, Xalapa, Mexico|Investigational Site Number 528013, Amsterdam, Netherlands|Investigational Site Number 528001, Amsterdam, Netherlands|Investigational Site Number 528004, Breda, Netherlands|Investigational Site Number 528005, Eindhoven, Netherlands|Investigational Site Number 528007, Groningen, Netherlands|Investigational Site Number 528011, Hoogeveen, Netherlands|Investigational Site Number 528002, Hoorn, Netherlands|Investigational Site Number 528008, Leiderdorp, Netherlands|Investigational Site Number 528009, Rotterdam, Netherlands|Investigational Site Number 528006, Velp, Netherlands|Investigational Site Number 528012, Venlo, Netherlands|Investigational Site Number 528010, Zoetermeer, Netherlands|Investigational Site Number 578005, Elverum, Norway|Investigational Site Number 578001, Hamar, Norway|Investigational Site Number 578002, Oslo, Norway|Investigational Site Number 578004, Skedsmokorset, Norway|Investigational Site Number 578003, Stavanger, Norway|Investigational Site Number 616008, Gdynia, Poland|Investigational Site Number 616003, Gdynia, Poland|Investigational Site Number 616001, Gniewkowo, Poland|Investigational Site Number 616010, Katowice, Poland|Investigational Site Number 616018, Krakow, Poland|Investigational Site Number 616004, Piotrkow Trybunalski, Poland|Investigational Site Number 616013, Pulawy, Poland|Investigational Site Number 616009, Warszawa, Poland|Investigational Site Number 616007, Wroclaw, Poland|Investigational Site Number 620006, Funchal / Madeira, Portugal|Investigational Site Number 620002, Lisboa, Portugal|Investigational Site Number 620001, Lisboa, Portugal|Investigational Site Number 620005, Porto, Portugal|Investigational Site Number 642005, Baia Mare, Romania|Investigational Site Number 642002, Brasov, Romania|Investigational Site Number 642004, Targu Mures, Romania|Investigational Site Number 642001, Timisoara, Romania|Investigational Site Number 643005, Barnaul, Russian Federation|Investigational Site Number 643012, Moscow, Russian Federation|Investigational Site Number 643008, Moscow, Russian Federation|Investigational Site Number 643014, Perm, Russian Federation|Investigational Site Number 643006, St Petersburg, Russian Federation|Investigational Site Number 643009, St.Petersburg, Russian Federation|Investigational Site Number 643004, Yaroslavl, Russian Federation|Investigational Site Number 710010, Centurion, South Africa|Investigational Site Number 710008, Meyerspark, South Africa|Investigational Site Number 710011, Middelburg, South Africa|Investigational Site Number 710006, Parktown, South Africa|Investigational Site Number 710004, Pretoria, South Africa|Investigational Site Number 710001, Pretoria, South Africa|Investigational Site Number 710002, Pretoria, South Africa|Investigational Site Number 710009, Roodepoort, South Africa|Investigational Site Number 710003, Somerset West, South Africa|Investigational Site Number 710005, Witbank, South Africa|Investigational Site Number 710007, Worcester, South Africa|Investigational Site Number 724006, Córdoba, Spain|Investigational Site Number 724003, Granada, Spain|Investigational Site Number 724002, Madrid, Spain|Investigational Site Number 724007, Málaga, Spain|Investigational Site Number 724008, Quart De Poblet, Spain|Investigational Site Number 724005, Reus, Spain|Investigational Site Number 724001, Sabadell, Spain|Investigational Site Number 724004, Sevilla, Spain|Investigational Site Number 752002, Rättvik, Sweden|Investigational Site Number 752006, Stockholm, Sweden|Investigational Site Number 752003, Stockholm, Sweden|Investigational Site Number 752004, Stockholm, Sweden|Investigational Site Number 752001, Örebro, Sweden|Investigational Site Number 804012, Chernivtsi, Ukraine|Investigational Site Number 804003, Dnipropetrovsk, Ukraine|Investigational Site Number 804002, Donetsk, Ukraine|Investigational Site Number 804014, Kharkiv, Ukraine|Investigational Site Number 804016, Kiev, Ukraine|Investigational Site Number 804011, Kyiv, Ukraine|Investigational Site Number 804010, Kyiv, Ukraine|Investigational Site Number 804001, Kyiv, Ukraine|Investigational Site Number 804008, Kyiv, Ukraine|Investigational Site Number 804013, Kyiv, Ukraine|Investigational Site Number 804005, Zhytomyr, Ukraine|Investigational Site Number 826004, Addlestone, United Kingdom|Investigational Site Number 826009, Birmingham, United Kingdom|Investigational Site Number 826016, Birmingham, United Kingdom|Investigational Site Number 826021, Blackpool, United Kingdom|Investigational Site Number 826023, Cambridge, United Kingdom|Investigational Site Number 826012, Cardiff, United Kingdom|Investigational Site Number 826024, Chichester, United Kingdom|Investigational Site Number 826006, Chorley, United Kingdom|Investigational Site Number 826010, Glasgow, United Kingdom|Investigational Site Number 826003, Irvine, United Kingdom|Investigational Site Number 826008, Liverpool, United Kingdom|Investigational Site Number 826005, Liverpool, United Kingdom|Investigational Site Number 826025, Manchester, United Kingdom|Investigational Site Number 826007, Manchester, United Kingdom|Investigational Site Number 826001, Middlesex, United Kingdom|Investigational Site Number 826019, Penzance, United Kingdom|Investigational Site Number 826011, Reading, United Kingdom|Investigational Site Number 826013, Romford, United Kingdom|Investigational Site Number 826014, Soham, United Kingdom",,https://ClinicalTrials.gov/show/NCT01507831
NCT01505803,The Effect of a Nutritional Supplement in Individuals With Type 2 Diabetes Mellitus: a Pilot Study,,Completed,No Results Available,"Diabetes Mellitus, Type 2|Insulin Resistance",Dietary Supplement: Zinc supplements|Dietary Supplement: Omega 3 supplements|Dietary Supplement: Placebo supplements,"Plasma lipids (total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides)|Glycaemic control (glucose, insulin, HbA1c)|Inflammation & oxidative stress (CRP, TNF-α, IL-1, IL-2, IL-6, IL-10 F2 isoprostanes, NF-κB, MPO, other)|Zinc transporter mRNA expression in peripheral blood mononuclear cells|Plasma zinc|Plasma fatty acids",University of Sydney,Female,"48 Years and older   (Adult, Older Adult)",Phase 1,48,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HREC 12392,Jul-10,Dec-11,Dec-11,9-Jan-12,null,9-Jan-12,"University of Sydney, Sydney, New South Wales, Australia",,https://ClinicalTrials.gov/show/NCT01505803
NCT01505023,Partial Meal Replacement and Inulin in Obese Women,,Completed,No Results Available,Obesity,Dietary Supplement: Partial meal replacement|Dietary Supplement: Partial meal replacement with inulin|Dietary Supplement: Inulin,Weight|Blood lipids|Micronutrients intake,Cindetec|Nucitec SA de CV,Female,18 Years to 50 Years   (Adult),Phase 2,179,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,PEE-001-2004,Apr-06,Nov-06,Feb-07,6-Jan-12,null,6-Jan-12,"Universidad Autónoma de Querétaro, Querétaro, Mexico",,https://ClinicalTrials.gov/show/NCT01505023
NCT01502904,Neointimal Coverage After Implantation of Biolimus Eluting Stent With Biodegradable Polymer: Optical Coherence Tomographic Assessment According to the Treatment of Dyslipidemia and Hypertension and the Types of Implanted Drug-eluting Stents,,Completed,No Results Available,Stable Angina or Acute Coronary Syndrome Considered for Percutaneous Coronary Intervention With Dyslipidemia or Hypertension,Device: Sirolimus-eluting stent|Device: Biolimus-eluting stents|Drug: pravastatin 20mg/day after DES implantation|Drug: pitavastatin 2mg/day after DES implantation|Drug: Non-ARB /day after DES implantation|Drug: Eposartan 600mg/day after DES implantation,neointimal coverage|stent malapposition and thrombus,Yonsei University,All,"20 Years to 80 Years   (Adult, Older Adult)",Phase 4,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,1-2010-0007,Jul-10,May-15,Jun-15,2-Jan-12,null,27-Jul-16,"Severance Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01502904
NCT01497912,Treatment Effects of Atorvastatin on Hemostasis and Skin Microcirculation in Patients With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes Mellitus|Dyslipidemia,Drug: Atorvastatin|Drug: Placebo,Fibrin network permeability|platelet and endothelial microparticles|skin microvascular reactivity,Karolinska Institutet,All,"30 Years to 70 Years   (Adult, Older Adult)",Phase 4,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",Dnr 04-681/2|Dnr 151:2004/52378,Jan-05,Jan-09,Jan-10,23-Dec-11,null,23-Dec-11,"Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT01497912
NCT01493752,Investigation of the Effect of Dietary Nitrate Treatment on Endothelial Function and Platelet Reactivity in Hypercholesterolemics.,,Completed,No Results Available,Hypercholesterolemia,Dietary Supplement: beetroot juice,"Flow Mediated Dilatation (FMD)|Platelet aggregation studies, pulse wave analysis, pulse wave velocity, plasma nitrate and nitrate concentration.",Queen Mary University of London|British Heart Foundation,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,69,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",11/LO/0715,Aug-11,May-13,May-13,16-Dec-11,null,9-Apr-14,"Barts & The London Medical School, William Harvey Research Institute, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01493752
NCT01492361,A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.,REDUCE-IT,Completed,No Results Available,Cardiovascular Diseases,Drug: AMR101|Drug: Placebo,"Composite of CV death, nonfatal MI (including silent MI), nonfatal stroke, coronary revascularization, and unstable angina determined to be caused by myocardial ischemia by invasive / non-invasive testing and requiring emergent hospitalization.|Composite of CV death, nonfatal MI (including silent MI), or nonfatal stroke.|Composite of CV death or nonfatal MI (including silent MI).|Fatal or nonfatal MI (including silent MI).|Non-elective coronary revascularization represented as the composite of emergent or urgent classifications.|CV death.|Unstable angina determined to be caused by myocardial ischemia by invasive / non-invasive testing and requiring emergent hospitalization.|Fatal or nonfatal stroke.|Total mortality, nonfatal MI (including silent MI), or nonfatal stroke.|Total mortality.",Amarin Pharma Inc.,All,"45 Years and older   (Adult, Older Adult)",Phase 3,8179,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",AMR-01-01-0019,Nov-11,May-18,May-18,15-Dec-11,null,16-Oct-18,"Amarin Investigational Site, Birmingham, Alabama, United States|Amarin Investigational Site, Birmingham, Alabama, United States|Amarin Investigational Site, Huntsville, Alabama, United States|Amarin Investigational Site, Mobile, Alabama, United States|Amarin Investigational Site, Muscle Shoals, Alabama, United States|Amarin Investigational Site, Mesa, Arizona, United States|Amarin Investigational Site, Phoenix, Arizona, United States|Amarin Investigational Site, Tucson, Arizona, United States|Amarin Investigational Site, Little Rock, Arkansas, United States|Amarin Investigational Site, Beverly Hills, California, United States|Amarin Investigational Site, Chino, California, United States|Amarin Investigational Site, Concord, California, United States|Amarin Investigational Site, El Cajon, California, United States|Amarin Investigational Site, Encino, California, United States|Amarin Investigational Site, Fair Oaks, California, United States|Amarin Investigational Site, Hawaiian Gardens, California, United States|Amarin Investigational Site, Lancaster, California, United States|Amarin Investigational Site, Lincoln, California, United States|Amarin Investigational Site, Los Angeles, California, United States|Amarin Investigational Site, Los Angeles, California, United States|Amarin Investigational Site, Los Angeles, California, United States|Amarin Investigational Site, National City, California, United States|Amarin Investigational Site, Orange, California, United States|Amarin Investigational Site, Paramount, California, United States|Amarin Investigational Site, Roseville, California, United States|Amarin Investigational Site, San Diego, California, United States|Amarin Investigational Site, Torrance, California, United States|Amarin Investigational Site, Ventura, California, United States|Amarin Investigational Site, Walnut Creek, California, United States|Amarin Investigational Site, Aurora, Colorado, United States|Amarin Investigational Site, Colorado Springs, Colorado, United States|Amarin Investigational Site, Golden, Colorado, United States|Amarin Investigational Site, Guilford, Connecticut, United States|Amarin Investigational Site, Hartford, Connecticut, United States|Amarin Investigational Site, Newark, Delaware, United States|Amarin Investigational Site, Wilmington, Delaware, United States|Amarin Investigational Site, Washington, District of Columbia, United States|Amarin Investigational Site, Boynton Beach, Florida, United States|Amarin Investigational Site, Bradenton, Florida, United States|Amarin Investigational Site, Clearwater, Florida, United States|Amarin Investigational Site, Edgewater, Florida, United States|Amarin Investigational Site, Fleming Island, Florida, United States|Amarin Investigational Site, Fort Lauderdale, Florida, United States|Amarin Investigational Site, Fort Lauderdale, Florida, United States|Amarin Investigational Site, Inverness, Florida, United States|Amarin Investigational Site, Jacksonville, Florida, United States|Amarin Investigational Site, Jacksonville, Florida, United States|Amarin Investigational Site, Jacksonville, Florida, United States|Amarin Investigational Site, Jacksonville, Florida, United States|Amarin Investigational Site, Miami Beach, Florida, United States|Amarin Investigational Site, Miami Lakes, Florida, United States|Amarin Investigational Site, Miami, Florida, United States|Amarin Investigational Site, Miami, Florida, United States|Amarin Investigational Site, Ocala, Florida, United States|Amarin Investigational Site, Orlando, Florida, United States|Amarin Investigational Site, Pembroke Pines, Florida, United States|Amarin Investigational Site, Plantation, Florida, United States|Amarin Investigational Site, Safety Harbor, Florida, United States|Amarin Investigational Site, Saint Petersburg, Florida, United States|Amarin Investigational Site, Sarasota, Florida, United States|Amarin Investigational Site, Vero Beach, Florida, United States|Amarin Investigational Site, West Palm Beach, Florida, United States|Amarin Investigational Site, Conyers, Georgia, United States|Amarin Investigational Site, Covington, Georgia, United States|Amarin Investigational Site, Cumming, Georgia, United States|Amarin Investigational Site, Roswell, Georgia, United States|Amarin Investigational Site, Honolulu, Hawaii, United States|Amarin Investigational Site, Addison, Illinois, United States|Amarin Investigational Site, Chicago, Illinois, United States|Amarin Investigational Site, Norman, Illinois, United States|Amarin Investigational Site, North Chicago, Illinois, United States|Amarin Investigational Site, Peoria, Illinois, United States|Amarin Investigational Site, Winfield, Illinois, United States|Amarin Investigational Site, Evansville, Indiana, United States|Amarin Investigational Site, Iowa City, Iowa, United States|Amarin Investigational Site, Wichita, Kansas, United States|Amarin Investigational Site, Wichita, Kansas, United States|Amarin Investigational Site, Louisville, Kentucky, United States|Amarin Investigational Site, Alexandria, Louisiana, United States|Amarin Investigational Site, Eunice, Louisiana, United States|Amarin Investigational Site, Marrero, Louisiana, United States|Amarin Investigational Site, Auburn, Maine, United States|Amarin Investigational Site, Baltimore, Maryland, United States|Amarin Investigational Site, Lutherville, Maryland, United States|Amarin Investigational Site, Takoma Park, Maryland, United States|Amarin Investigational Site, Boston, Massachusetts, United States|Amarin Investigational Site, Boston, Massachusetts, United States|Amarin Investigational Site, Fall River, Massachusetts, United States|Amarin Investigational Site, Lansing, Michigan, United States|Amarin Investigational Site, Marquette, Michigan, United States|Amarin Investigational Site, Troy, Michigan, United States|Amarin Investigational Site, Saint Cloud, Minnesota, United States|Amarin Investigational Site, Biloxi, Mississippi, United States|Amarin Investigational Site, Tupelo, Mississippi, United States|Amarin Investigational Site, Chesterfield, Missouri, United States|Amarin Investigational Site, Florissant, Missouri, United States|Amarin Investigational Site, Jefferson City, Missouri, United States|Amarin Investigational Site, Kansas City, Missouri, United States|Amarin Investigational Site, Saint Louis, Missouri, United States|Amarin Investigational Site, Saint Peters, Missouri, United States|Amarin Investigational Site, Hastings, Nebraska, United States|Amarin Investigational Site, Omaha, Nebraska, United States|Amarin Investigational Site, Omaha, Nebraska, United States|Amarin Investigational Site, Henderson, Nevada, United States|Amarin Investigational Site, Las Vegas, Nevada, United States|Amarin Investigational Site, Ocean City, New Jersey, United States|Amarin Investigational Site, Albuquerque, New Mexico, United States|Amarin Investigational Site, Albany, New York, United States|Amarin Investigational Site, Brooklyn, New York, United States|Amarin Investigational Site, Great Neck, New York, United States|Amarin Investigational Site, Liverpool, New York, United States|Amarin Investigational Site, New York, New York, United States|Amarin Investigational Site, New York, New York, United States|Amarin Investigational Site, North Massapequa, New York, United States|Amarin Investigational Site, Smithtown, New York, United States|Amarin Investigational Site, Vestal, New York, United States|Amarin Investigational Site, West Seneca, New York, United States|Amarin Investigational Site, Charlotte, North Carolina, United States|Amarin Investigational Site, Durham, North Carolina, United States|Amarin Investigational Site, Gastonia, North Carolina, United States|Amarin Investigational Site, Kernersville, North Carolina, United States|Amarin Investigational Site, Raleigh, North Carolina, United States|Amarin Investigational Site, Winston-Salem, North Carolina, United States|Amarin Investigational Site, Fargo, North Dakota, United States|Amarin Investigational Site, Cincinnati, Ohio, United States|Amarin Investigational Site, Dayton, Ohio, United States|Amarin Investigational Site, Lorain, Ohio, United States|Amarin Investigational Site, Sandusky, Ohio, United States|Amarin Investigational Site, Tulsa, Oklahoma, United States|Amarin Investigational Site, Bend, Oregon, United States|Amarin Investigational Site, Portland, Oregon, United States|Amarin Investigational Site, Beaver, Pennsylvania, United States|Amarin Investigational Site, Doylestown, Pennsylvania, United States|Amarin Investigational Site, Jersey Shore, Pennsylvania, United States|Amarin Investigational Site, Newport, Pennsylvania, United States|Amarin Investigational Site, Philadelphia, Pennsylvania, United States|Amarin Investigational Site, Phoenixville, Pennsylvania, United States|Amarin Investigational Site, Sellersville, Pennsylvania, United States|Amarin Investigational Site, Tipton, Pennsylvania, United States|Amarin Investigational Site, Wyomissing, Pennsylvania, United States|Amarin Investigational Site, Yardley, Pennsylvania, United States|Amarin Investigational Site, Lancaster, South Carolina, United States|Amarin Investigational Site, Simpsonville, South Carolina, United States|Amarin Investigational Site, Rapid City, South Dakota, United States|Amarin Investigational Site, Bristol, Tennessee, United States|Amarin Investigational Site, Columbia, Tennessee, United States|Amarin Investigational Site, Germantown, Tennessee, United States|Amarin Investigational Site, Jackson, Tennessee, United States|Amarin Investigational Site, Knoxville, Tennessee, United States|Amarin Investigational Site, Smyrna, Tennessee, United States|Amarin Investigational Site, Austin, Texas, United States|Amarin Investigational Site, Beaumont, Texas, United States|Amarin Investigational Site, Carrollton, Texas, United States|Amarin Investigational Site, Dallas, Texas, United States|Amarin Investigational Site, Houston, Texas, United States|Amarin Investigational Site, Houston, Texas, United States|Amarin Investigational Site, Houston, Texas, United States|Amarin Investigational Site, Houston, Texas, United States|Amarin Investigational Site, Houston, Texas, United States|Amarin Investigational Site, Houston, Texas, United States|Amarin Investigational Site, Houston, Texas, United States|Amarin Investigational Site, Hurst, Texas, United States|Amarin Investigational Site, New Braunfels, Texas, United States|Amarin Investigational Site, Plano, Texas, United States|Amarin Investigational Site, San Antonio, Texas, United States|Amarin Investigational Site, San Antonio, Texas, United States|Amarin Investigational Site, Splendora, Texas, United States|Amarin Investigational Site, Tomball, Texas, United States|Amarin Investigational Site, West Jordan, Utah, United States|Amarin Investigational Site, Falls Church, Virginia, United States|Amarin Investigational Site, Manassas, Virginia, United States|Amarin Investigational Site, Midlothian, Virginia, United States|Amarin Investigational Site, Newport News, Virginia, United States|Amarin Investigational Site, Burien, Washington, United States|Amarin Investigational Site, Tacoma, Washington, United States|Amarin Investigational Site, Huntington, West Virginia, United States|Amarin Investigational Site, Camperdown, New South Wales, Australia|Amarin Investigational Site, Lismore, New South Wales, Australia|Amarin Investigational Site, Brisbane, Queensland, Australia|Amarin Investigational Site, Chermside, Queensland, Australia|Amarin Investigational Site, Bedford Park, South Australia, Australia|Amarin Investigational Site, Launceston, Tasmania, Australia|Amarin Investigational Site, Fitzroy, Victoria, Australia|Amarin Investigational Site, Geelong, Victoria, Australia|Amarin Investigational Site, Heidelberg Heights, Victoria, Australia|Amarin Investigational Site, Melbourne, Victoria, Australia|Amarin Investigational Site, Fremantle, Western Australia, Australia|Amarin Investigational Site, Joondalup, Western Australia, Australia|Amarin Investigational Site, Murdoch, Western Australia, Australia|Amarin Investigational Site, Nedlands, Western Australia, Australia|Amarin Investigational Site, Perth, Western Australia, Australia|Amarin Investigational Site, Edmonton, Alberta, Canada|Amarin Investigational Site, Coquitlam, British Columbia, Canada|Amarin Investigational Site, Vancouver, British Columbia, Canada|Amarin Investigational Site, Vancouver, British Columbia, Canada|Amarin Investigational Site, Brampton, Ontario, Canada|Amarin Investigational Site, Collingwood, Ontario, Canada|Amarin Investigational Site, Corunna, Ontario, Canada|Amarin Investigational Site, Newmarket, Ontario, Canada|Amarin Investigational Site, Sarnia, Ontario, Canada|Amarin Investigational Site, Strathroy, Ontario, Canada|Amarin Investigational Site, Laval, Quebec, Canada|Amarin Investigational Site, Montreal, Quebec, Canada|Amarin Investigational Site, Montreal, Quebec, Canada|Amarin Investigational Site, Sherbrooke, Quebec, Canada|Amarin Investigational Site, St. Charles-Borromée, Quebec, Canada|Amarin Investigational Site, Québec, Canada|Amarin Investigational Site, Québec, Canada|Amarin Investigational Site, Hyderabad, Andhra Pradesh, India|Amarin Investigational Site, Hyderabad, Andhra Pradesh, India|Amarin Investigational Site, Secunderabad, Andhra Pradesh, India|Amarin Investigational Site, Visakhapatnam, Andhra Pradesh, India|Amarin Investigational Site, New Delhi, Delhi, India|Amarin Investigational Site, New Delhi, Delhi, India|Amarin Investigational Site, Bangalore, Karnataka, India|Amarin Investigational Site, Bangalore, Karnataka, India|Amarin Investigational Site, Bangalore, Karnataka, India|Amarin Investigational Site, Mysore, Karnataka, India|Amarin Investigational Site, Mysore, Karnataka, India|Amarin Investigational Site, Kottayam, Kerala, India|Amarin Investigational Site, Mumbai, Maharashtra, India|Amarin Investigational Site, Nashik, Maharashtra, India|Amarin Investigational Site, Pune, Maharashtra, India|Amarin Investigational Site, Chennai, Tamil Nadu, India|Amarin Investigational Site, Coimbatore, Tamil Nadu, India|Amarin Investigational Site, Almelo, Netherlands|Amarin Investigational Site, Amersfoort, Netherlands|Amarin Investigational Site, Blaricum, Netherlands|Amarin Investigational Site, Capelle aan den Ijssel, Netherlands|Amarin Investigational Site, Den Haag, Netherlands|Amarin Investigational Site, Den Helder, Netherlands|Amarin Investigational Site, Deventer, Netherlands|Amarin Investigational Site, Ede, Netherlands|Amarin Investigational Site, Eindhoven, Netherlands|Amarin Investigational Site, Enschede, Netherlands|Amarin Investigational Site, Goes, Netherlands|Amarin Investigational Site, Gorinchem, Netherlands|Amarin Investigational Site, Gouda, Netherlands|Amarin Investigational Site, Groningen, Netherlands|Amarin Investigational Site, Haarlem, Netherlands|Amarin Investigational Site, Harderwijk, Netherlands|Amarin Investigational Site, Heerenveen, Netherlands|Amarin Investigational Site, Heerlen, Netherlands|Amarin Investigational Site, Hoofddorp, Netherlands|Amarin Investigational Site, Leeuwarden, Netherlands|Amarin Investigational Site, Leiderdorp, Netherlands|Amarin Investigational Site, Nijmegen, Netherlands|Amarin Investigational Site, Roosendaal, Netherlands|Amarin Investigational Site, Rotterdam, Netherlands|Amarin Investigational Site, Rotterdam, Netherlands|Amarin Investigational Site, Rotterdam, Netherlands|Amarin Investigational Site, s'Hertogenbosch, Netherlands|Amarin Investigational Site, Schiedam, Netherlands|Amarin Investigational Site, Sneek, Netherlands|Amarin Investigational Site, Tilburg, Netherlands|Amarin Investigational Site, Tilburg, Netherlands|Amarin Investigational Site, Uden, Netherlands|Amarin Investigational Site, Veldhoven, Netherlands|Amarin Investigational Site, Zoetermeer, Netherlands|Amarin Investigational Site, Zutphen, Netherlands|Amarin Investigational Site, Takapuna, Auckland, New Zealand|Amarin Investigational Site, Christchurch, New Zealand|Amarin Investigational Site, Dunedin, New Zealand|Amarin Investigational Site, Hamilton, New Zealand|Amarin Investigational Site, Hastings, New Zealand|Amarin Investigational Site, Nelson, New Zealand|Amarin Investigational Site, New Plymouth, New Zealand|Amarin Investigational Site, Takapuna, Auckland, New Zealand|Amarin Investigational Site, Tauranga, New Zealand|Amarin Investigational Site, Whangarei, New Zealand|Amarin Investigational Site, Bialystok, Poland|Amarin Investigational Site, Bialystok, Poland|Amarin Investigational Site, Katowice, Poland|Amarin Investigational Site, Katowice, Poland|Amarin Investigational Site, Kraków, Poland|Amarin Investigational Site, Mikolów, Poland|Amarin Investigational Site, Skierniewice, Poland|Amarin Investigational Site, Tarnów, Poland|Amarin Investigational Site, Warszawa, Poland|Amarin Investigational Site, Warszawa, Poland|Amarin Investigational Site, Warszawska, Poland|Amarin Investigational Site, Wroclaw, Poland|Amarin Investigational Site, Wroclaw, Poland|Amarin Investigational Site, Zgierz, Poland|Amarin Investigational Site, Argeş, Romania|Amarin Investigational Site, Brăila, Romania|Amarin Investigational Site, Bucharest, Romania|Amarin Investigational Site, Bucharest, Romania|Amarin Investigational Site, Bucharest, Romania|Amarin Investigational Site, Bucuresti, Romania|Amarin Investigational Site, Bucuresti, Romania|Amarin Investigational Site, Bucuresti, Romania|Amarin Investigational Site, Cluj-Napoca, Romania|Amarin Investigational Site, Constanţa, Romania|Amarin Investigational Site, Craiova, Dolj, Romania|Amarin Investigational Site, Iaşi, Romania|Amarin Investigational Site, Maramureş, Romania|Amarin Investigational Site, Mureş, Romania|Amarin Investigational Site, Sibiu, Romania|Amarin Investigational Site, Timişoara, Romania|Amarin Investigational Site, Târgu Mureş, Romania|Amarin Investigational Site, Arkhangelsk, Russian Federation|Amarin Investigational Site, Arkhangelsk, Russian Federation|Amarin Investigational Site, Arkhangelsk, Russian Federation|Amarin Investigational Site, Ekaterinburg, Russian Federation|Amarin Investigational Site, Ekaterinburg, Russian Federation|Amarin Investigational Site, Kazan, Russian Federation|Amarin Investigational Site, Kazan, Russian Federation|Amarin Investigational Site, Kemerovo, Russian Federation|Amarin Investigational Site, Kemerovo, Russian Federation|Amarin Investigational Site, Kirovsk, Leningradskaya Region, Russian Federation|Amarin Investigational Site, Krasnodar, Russian Federation|Amarin Investigational Site, Moscow, Russian Federation|Amarin Investigational Site, Moscow, Russian Federation|Amarin Investigational Site, Moscow, Russian Federation|Amarin Investigational Site, Moscow, Russian Federation|Amarin Investigational Site, Moscow, Russian Federation|Amarin Investigational Site, Moscow, Russian Federation|Amarin Investigational Site, Moscow, Russian Federation|Amarin Investigational Site, Moscow, Russian Federation|Amarin Investigational Site, Moscow, Russian Federation|Amarin Investigational Site, Moscow, Russian Federation|Amarin Investigational Site, Moscow, Russian Federation|Amarin Investigational Site, Nizhny Novgorod, Russian Federation|Amarin Investigational Site, Novosibirsk, Russian Federation|Amarin Investigational Site, Novosibirsk, Russian Federation|Amarin Investigational Site, Novosibirsk, Russian Federation|Amarin Investigational Site, Petrozavodsk, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saratov, Russian Federation|Amarin Investigational Site, Saratov, Russian Federation|Amarin Investigational Site, Sestroretsk, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Tomsk, Russian Federation|Amarin Investigational Site, Tomsk, Russian Federation|Amarin Investigational Site, Volgograd, Russian Federation|Amarin Investigational Site, Voronezh, Russian Federation|Amarin Investigational Site, Voronezh, Russian Federation|Amarin Investigational Site, Yaroslavl, Russian Federation|Amarin Investigational Site, Yaroslavl, Russian Federation|Amarin Investigational Site, Bloemfontein, Freestate, South Africa|Amarin Investigational Site, Benoni, Gauteng, South Africa|Amarin Investigational Site, Pretorio, Gauteng, South Africa|Amarin Investigational Site, Soweto, Gauteng, South Africa|Amarin Investigational Site, Witbank, Gauteng, South Africa|Amarin Investigational Site, Durban, KwaZulu-Natal, South Africa|Amarin Investigational Site, Newlands, KwaZulu-Natal, South Africa|Amarin Investigational Site, Bellville, Western Cape, South Africa|Amarin Investigational Site, Cape Town, Western Cape, South Africa|Amarin Investigational Site, Durbanville, Western Cape, South Africa|Amarin Investigational Site, Goodwood, Western Cape, South Africa|Amarin Investigational Site, Kraaifontein, Western Cape, South Africa|Amarin Investigational Site, Paarl, Western Cape, South Africa|Amarin Investigational Site, Panorama, Western Cape, South Africa|Amarin Investigational Site, Parow, Western Cape, South Africa|Amarin Investigational Site, Pinelands, Western Cape, South Africa|Amarin Investigational Site, Somerset West, Western Cape, South Africa|Amarin Investigational Site, Worcester, Western Cape, South Africa|Amarin Investigational Site, Lutsk, Volyn Region, Ukraine|Amarin Investigational Site, Cherkasy, Ukraine|Amarin Investigational Site, Chernivtsi, Ukraine|Amarin Investigational Site, Dnipropetrovsk, Ukraine|Amarin Investigational Site, Dnipropetrovsk, Ukraine|Amarin Investigational Site, Dnipropetrovsk, Ukraine|Amarin Investigational Site, Donetsk, Ukraine|Amarin Investigational Site, Donetsk, Ukraine|Amarin Investigational Site, Ivano-Frankivsk, Ukraine|Amarin Investigational Site, Ivano-Frankivsk, Ukraine|Amarin Investigational Site, Kharkiv, Ukraine|Amarin Investigational Site, Kharkiv, Ukraine|Amarin Investigational Site, Kharkiv, Ukraine|Amarin Investigational Site, Kharkiv, Ukraine|Amarin Investigational Site, Kyiv, Ukraine|Amarin Investigational Site, Kyiv, Ukraine|Amarin Investigational Site, Kyiv, Ukraine|Amarin Investigational Site, Kyiv, Ukraine|Amarin Investigational Site, Kyiv, Ukraine|Amarin Investigational Site, Kyiv, Ukraine|Amarin Investigational Site, Kyiv, Ukraine|Amarin Investigational Site, Kyiv, Ukraine|Amarin Investigational Site, Kyiv, Ukraine|Amarin Investigational Site, Luhansk, Ukraine|Amarin Investigational Site, Lutsk, Ukraine|Amarin Investigational Site, Lviv, Ukraine|Amarin Investigational Site, Odesa, Ukraine|Amarin Investigational Site, Odesa, Ukraine|Amarin Investigational Site, Odesa, Ukraine|Amarin Investigational Site, Poltava, Ukraine|Amarin Investigational Site, Ternopil, Ukraine|Amarin Investigational Site, Uzhgorod, Ukraine|Amarin Investigational Site, Uzhgorod, Ukraine|Amarin Investigational Site, Vinnytsya, Ukraine|Amarin Investigational Site, Vinnytsya, Ukraine|Amarin Investigational Site, Zaporizhzhia, Ukraine|Amarin Investigational Site, Zaporizhzhia, Ukraine|Amarin Investigational Site, Zaporizhzhia, Ukraine|Amarin Investigational Site, Zaporizhzhia, Ukraine",,https://ClinicalTrials.gov/show/NCT01492361
NCT01491490,Treatment on Iatrogenic Weight Gain and Dyslipidaemia Associated With Olanzapine,GWMD09126,Terminated,Has Results,Schizophrenia,Drug: GWP42003 : GWP42004 (40:1)|Drug: Placebo,Change in Bodyweight.,GW Research Ltd,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GWMD09126,Oct-11,Oct-12,Oct-12,14-Dec-11,1-Nov-13,18-Sep-14,"Birmingham, United Kingdom|Leicester, United Kingdom|Oxford, United Kingdom|South London, United Kingdom|Surrey, United Kingdom|West London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01491490
NCT01488409,Effects of Acipimox on Mitochondrial Function in Obesity,,Completed,Has Results,Abdominal Obesity|Insulin Resistance|Hypertriglyceridemia,Drug: Acipimox|Drug: Placebo,Change From Baseline in Phosphocreatine Recovery (ViPCr) at 6-months|Change From Baseline in Insulin Sensitivity at 6-months|Change From Baseline in Mitochondrial Density at 6 Months|Change From Baseline in Intramyocellular Lipid Content at 6-months|Change From Baseline in Lipid Profile at 6-months,Massachusetts General Hospital|American Diabetes Association,All,18 Years to 55 Years   (Adult),Phase 2,39,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2011-P-000175,May-12,Jan-15,Jan-15,8-Dec-11,3-Feb-16,1-Mar-16,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01488409
NCT01487460,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients",,Completed,No Results Available,Dyslipidemia|Healthy Volunteers,Drug: TAP311,Safety and tolerability of single and multiple doses of TAP311 in healthy subjects and patients with dyslipidemia|TAP311 concentrations in blood and urine following administration of single and multiple doses in healthy subjects and in patients with dyslipidemia.|Effect of TAP311 administration on simvastatin (and metabolite) blood concentration in healthy subjects.|Effect of food on TAP311 blood concentration in healthy subjects.|Effects of TAP311 on total cholesterol in patients with dyslipidemia|Effects of TAP311 on Low Density Lipoprotein (LDL-C) in patients with dyslipidemia|Effects of TAP311 on high density lipoprotein (HDL-C)in patients with dyslipidemia.|Effects of TAP311 on triglycerides in patients with Dyslipidemia,Novartis Pharmaceuticals|Novartis,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,137,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)",CTAP311X2101,Nov-11,Jun-12,Jun-12,7-Dec-11,null,19-Apr-16,"Novartis Investigative Site, Miramar, Florida, United States",,https://ClinicalTrials.gov/show/NCT01487460
NCT01486433,The Effect of Multiple Doses of Epanova® on the Multiple-Dose Pharmacokinetics of Simvastatin in Healthy Normal Subjects,,Completed,No Results Available,Hypertriglyceridemia,Drug: Simvastatin|Drug: acetylsalicylic acid (ASA)|Drug: omefas,"Area under the plasma concentration versus time curve (AUC0-tau)|Concentration at the end of a dosing interval (Cmax,ss) for simvastatin and beta- hydroxysimvastatin acid,",AstraZeneca,All,18 Years to 55 Years   (Adult),Phase 1,52,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OM-EPA-007,Nov-11,Mar-12,Mar-12,6-Dec-11,null,30-Apr-15,"Tempe, Arizona, United States",,https://ClinicalTrials.gov/show/NCT01486433
NCT01486667,"Thyroxin Treatment in Sub Clinical Hypothyroidism, on the Apnea Hypopnea Index Score, Lipids and Highly Sensitive CRP",,Unknown status,No Results Available,Dyslipidemia,Drug: levothyroxine|Drug: sugar pill,Effect of the treatment of subclinical hypothyroidism on the apnea hypopnea index (AHI) score.|Effect of the treatment of subclinical hypothyroidism on the lipid profile in patient with dyslipidemia and on hs-CRP,King Saud University,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,200,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",E-11-465,Oct-11,Oct-13,null,6-Dec-11,null,8-Dec-11,"University Sleep Disorders Center, Riyadh, Saudi Arabia",,https://ClinicalTrials.gov/show/NCT01486667
NCT01483235,Reduced Cardiac Rehabilitation Program,rCRP,Completed,No Results Available,Cardiovascular Disease|Obesity|Dyslipidemia,Behavioral: Reduced cardiac rehabilitation group intervention (rCRP).|Behavioral: Standard cardiac rehabilitation intervention,Exercise Capacity|Metabolic risk factors.|Lifestyle|Psychosocial measures|Anthropometry|Program adherence,Simon Fraser University,All,"30 Years to 90 Years   (Adult, Older Adult)",Not Applicable,118,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,37553,Sep-06,Sep-11,Sep-11,1-Dec-11,null,2-Dec-11,"St Paul's Hospital, Vancouver, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT01483235
NCT01480687,Fish Oil Supplementation and Vascular Function in Hypertensive Patients With Hypertriglyceridemia,,Unknown status,No Results Available,Hypertension|Hypertriglyceridemia,Dietary Supplement: DHA-EPA|Drug: Ciprofibrate,Endothelial function,Hospital Universitario Pedro Ernesto|Rio de Janeiro State Research Supporting Foundation (FAPERJ),All,"40 Years to 65 Years   (Adult, Older Adult)",Phase 4,52,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,FO-1800,May-11,Dec-12,Dec-12,29-Nov-11,null,29-Nov-11,"Hospital Universitario Pedro Ernesto, Rio de Janeiro, RJ, Rio de Janeiro, Brazil",,https://ClinicalTrials.gov/show/NCT01480687
NCT01480895,Prevention of Diabetes Mellitus Type 2 in Women Post Gestational Diabetes Mellitus Diagnosis,GDM,Completed,No Results Available,Gestational Diabetes Mellitus,Behavioral: Lifestyle instruction for Jews and Bedouin GDM women.,Change in HOMA ratios (Homeostasis Model Assessments of Insulin Resistance).|Change in HOMA.|Determinations of blood lipids .|Change in lipids levels after two years post partum.|Post partum BMI changes.|BMI changes after delivery.,Soroka University Medical Center,Female,18 Years to 43 Years   (Adult),Not Applicable,180,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,SOR452307CTL,Mar-07,Mar-10,Apr-10,29-Nov-11,null,29-Nov-11,,,https://ClinicalTrials.gov/show/NCT01480895
NCT01478789,Efficacy of Plant Sterol-Fortified Dairy Product on Plasma Lipid and Plant Sterol Concentrations in Humans,,Completed,No Results Available,Hypercholesterolemia,Dietary Supplement: WD-PS intervention phase|Dietary Supplement: PS-Ester intervention phase|Dietary Supplement: placebo,Lipid Profile,University of Manitoba,All,19 Years to 60 Years   (Adult),Not Applicable,47,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",B2010:096,Sep-10,Feb-11,Oct-11,23-Nov-11,null,21-Dec-11,"Richarson Centre for Funtional Foods and Nutraceuticals, Winnipeg, Manitoba, Canada",,https://ClinicalTrials.gov/show/NCT01478789
NCT01476436,Low Carbohydrate Diet - Effect on Plasma Lipids and Metabolic Markers,,Completed,No Results Available,Overweight and Obesity|Type IIb Hyperlipidaemia|Hypercholesterolemia Aggravated,Other: Low carbohydrate dietary advice|Other: Continue usual diet,Percent change in mean LDL-cholesterol after intervention with low carbohydrate diet,Oslo University Hospital|University of Oslo,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,REK195276,Nov-11,22-Sep-17,22-Sep-17,22-Nov-11,null,8-Oct-18,"Oslo University Hospital, Oslo, Norway|Oslo University Hospital, Oslo, Norway",,https://ClinicalTrials.gov/show/NCT01476436
NCT01475825,A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol,FOCUS FH,Completed,Has Results,Hypercholesterolemia|Heterozygous Familial,Drug: mipomersen sodium 200 mg|Drug: Placebo|Drug: mipomersen sodium 70 mg,Percent Change From Baseline To Primary Endpoint Visit (PET) In LDL-C In Cohort 1|Percent Change From Baseline To PET In LDL-C In Cohort 2|Percent Change From Baseline To PET In Apolipoprotein B (Apo B) In Cohort 1|Percent Change From Baseline To PET In Apolipoprotein B (Apo B) In Cohort 2|Percent Change From Baseline To PET in Lipoprotein (a) In Cohort 1|Percent Change From Baseline To PET in Lipoprotein (a) In Cohort 2,"Kastle Therapeutics, LLC",All,"18 Years and older   (Adult, Older Adult)",Phase 3,309,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MIPO3801011|2011-001480-42|EFC12875,Dec-11,29-Dec-15,29-Dec-15,21-Nov-11,14-Mar-19,26-Mar-19,"Mission Viejo, California, United States|Aurora, Colorado, United States|Cooper City, Florida, United States|Winter Park, Florida, United States|Indianapolis, Indiana, United States|Kansas City, Kansas, United States|Boston, Massachusetts, United States|Ann Arbor, Michigan, United States|Grandville, Michigan, United States|Rochester, Minnesota, United States|Saint Louis, Missouri, United States|Omaha, Nebraska, United States|Summit, New Jersey, United States|North Massapequa, New York, United States|Portland, Oregon, United States|Lancaster, Pennsylvania, United States|Charleston, South Carolina, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Norfolk, Virginia, United States|Ciudad Autonoma de Buenos Aires, Argentina|Cordoba, Argentina|Perth, Australia|South Brisbane, Australia|Edegem, Belgium|Haine St. Paul, Belgium|Leuven, Belgium|Rio de Janeiro, Brazil|Sao Paulo, Brazil|Chicoutimi, Quebec, Canada|Montreal, Quebec, Canada|Sainte-Foy, Quebec, Canada|Osijek, Croatia|Zagreb, Croatia|Hradec Kralove, Czechia|Praha 1, Czechia|Aarhus, Denmark|Viborg, Denmark|Aachen, Germany|Berlin, Germany|Freiburg, Germany|Hamburg, Germany|Heidelberg, Germany|Koeln, Germany|Magdeburg, Germany|Ioannina, Greece|Kallithea, Greece|Hong Kong, Hong Kong|Baja, Hungary|Budapest, Hungary|Debrecen, Hungary|New Delhi, India|Holon, Israel|Kfar Saba, Israel|Ofakim, Israel|Bologna, Italy|Napoli, Italy|Padova, Italy|Palermo, Italy|Pisa, Italy|Roma, Italy|Seoul, Korea, Republic of|Kuala Lumpur, Malaysia|Kubang Kerian, Malaysia|Alkmaar, Netherlands|Amsterdam, Netherlands|Maastricht, Netherlands|Nijmegen, Netherlands|Utrecht, Netherlands|Waalwijk, Netherlands|Christchurch, New Zealand|Bodo, Norway|Oslo, Norway|Sandefjord, Norway|Bialystok, Poland|Gdansk, Poland|Katowice, Poland|Krakow, Poland|Naleczow, Poland|Poznan, Poland|Sopot, Poland|Szczecin, Poland|Warszawa, Poland|Wroclaw, Poland|Barnaul, Russian Federation|Kemerovo, Russian Federation|Moscow, Russian Federation|Novosibirsk, Russian Federation|Petrozavodsk, Russian Federation|Ryazan, Russian Federation|Saint Petersburg, Russian Federation|St-Petersburg, Russian Federation|St. Petersburg, Russian Federation|Tomsk, Russian Federation|Yaroslavl, Russian Federation|Cape Town, South Africa|Pretoria, South Africa|Madrid, Spain|Stockholm, Sweden|New Taipei City, Taiwan|Taipei, Taiwan|Ankara, Turkey|Istanbul, Turkey|Izmir, Turkey|Sivas, Turkey|Ivano-Frankivsk, Ukraine|Kiev, Ukraine|Kyiv, Ukraine|Odesa, Ukraine|Odessa, Ukraine|Birmingham, United Kingdom|Cardiff, United Kingdom|Liverpool, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Oldham, United Kingdom",,https://ClinicalTrials.gov/show/NCT01475825
NCT01474161,Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505,,Completed,No Results Available,"Type 2 Diabetes|Diabetes Mellitus, Type 2|Metabolic Diseases|Cardiovascular Diseases|Obese|Dyslipidemia",Drug: GFT505 120mg - old formulation|Drug: GFT505 120mg - new formulation|Drug: GFT505 180mg - new formulation|Drug: GFT505 240mg - new formulation|Drug: GFT505 300mg - new formulation|Drug: Placebo,"Pharmacokinetics parameters (Study Part I)|Safety parameters (Study Parts II, III and IV)|Safety parameters (Study Part I)|Pharmacokinetics parameters (Study Parts II, III and IV)",Genfit|SGS Aster S.A.S.|Naturalpha,All,18 Years to 60 Years   (Adult),Phase 1,96,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GFT505-111-7|2011-004723-13,Nov-11,Nov-12,Nov-12,18-Nov-11,null,27-Nov-12,"SGS Aster S.A.S. - Phase I Clinical Unit, Paris, France",,https://ClinicalTrials.gov/show/NCT01474161
NCT01474434,Efficacy of LCQ908 on Cardiovascular Risk,,Terminated,Has Results,Coronary Artery Disease|Hypertriglyceridemia,Drug: pradigastat (LCQ908)|Drug: Placebo,"Change From Baseline in Myocardial Perfusion Reserve Index (MPRi) Overall Mean (Part A, Cohort 1)|Change From Baseline in Total Exercise Duration (Part A, Cohort 1)|Time to Onset of Angina (Part A, Cohort 1)|Time to Onset of Exercise-induced Ischemia(Part A, Cohort 1)|Aortic Plaque Inflammation (Part B)|Number of Participants With Adverse Events (Part A, Cohort 1)|Number of Participants With Adverse Events (Part A, Cohort 2)|Postprandial Triglycerides (Part A, Cohort 1)|Postprandial Triglycerides (Part A, Cohort 2)|Pharmacokinetics of Pradigastat (LCQ908): Plasma Concentration (Part A)|Other Related Lipid Parameters (Part A)|Interleukin-6 (IL-6) Level (Part A)|C-reactive Protein (CRP) Level (Part A)|Adiponectin Level ( Part B)",Novartis Pharmaceuticals|Novartis,All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 2,41,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CLCQ908A2213,Dec-11,Jun-14,Jun-14,18-Nov-11,14-Apr-16,14-Apr-16,"Novartis Investigative Site, Pasadena, California, United States",,https://ClinicalTrials.gov/show/NCT01474434
NCT01471366,Method of Fish Oil Administration on Patient Compliance,,Completed,No Results Available,Adverse Effects,Dietary Supplement: Frozen capsule|Dietary Supplement: Capsule with food|Dietary Supplement: Capsule without food|Dietary Supplement: Capsule with milk,Adverse Effects|Compliance,"University of Mississippi, Oxford|Walgreen's",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor),UMO-0003,Nov-11,Jul-14,Jul-14,16-Nov-11,null,28-Jul-14,"University of Mississippi School of Pharmacy, Jackson, Mississippi, United States",,https://ClinicalTrials.gov/show/NCT01471366
NCT01471275,"Chinese Medicine Treatment of Obesity With Type 2 Diabetes, Dyslipidemia",,Unknown status,No Results Available,"Type 2 Diabetes Mellitus ;Obesity,High Triglycerides；TCM",Drug: Metformin|Drug: Jiangtangtiaozhi decoction,Glycosylated hemoglobin|Waistline|Triglycerides|Liver function|Renal function|Whole blood cell analysis|Urinalysis|Adverse events recorded,Guang'anmen Hospital of China Academy of Chinese Medical Sciences,All,"30 Years to 65 Years   (Adult, Older Adult)",Not Applicable,450,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,368,Nov-11,Sep-13,Dec-13,15-Nov-11,null,6-Dec-11,"Guang'anmen Hospital of China Academy ofChinese Medical Sciences, Beijing, Beijing, China|Baoding Hospital of TCM, Baoding, Hebei, China|Affiliated Hospital of Changchun University of TCM, Changchun, Jilin, China|Qinghai Provence Hospital of TCM, Xining, Qinghai, China|Tianjin Dagang Hospital, Dagang, Tianjin, China|Tianjin University of Traditional Chinese Medicine, First Affiliated Hospital, Tianjin, Tianjin, China|Yichang City Yiling Hospital, Yichang, Yichang, China|Hangzhou Hospital of TCM, Hangzhou, Zhejiang, China",,https://ClinicalTrials.gov/show/NCT01471275
NCT01466608,"Influence of OATP1B1 and BRCP Genotype on Rosuvastatin PK, PD and Lipidomics in Hyperlipidemic Patients",,Completed,No Results Available,Hypercholesterolemia,Drug: Rosuvastatin,Changes of serum lipid levels from baseline for 8 weeks|Urinary and plasma levels of the lipid metabolites for 8 weeks,Seoul National University Hospital,All,35 Years to 55 Years   (Adult),Phase 4,21,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SNUCPT11_Rosuvastatin_Pt,Nov-11,Jan-13,Aug-13,8-Nov-11,null,16-May-14,"Clinical Trials Center, Seoul National University Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01466608
NCT01462877,A Study to Evaluate Fenofibrate Combination With Statin in Chinese Patients With Dyslipidemic,,Completed,Has Results,Dyslipidemias|Cardiovascular Diseases|Hypertriglyceridemia,Drug: fenofibrate,Percentage of Triglyceride (TG) Change|Change in Serum Total Cholesterol|Change in Serum Low-density Lipoprotein Cholesterol|Change in Serum High-density Lipoprotein Cholesterol|Change in Serum Non-high-density Lipoprotein Cholesterol|Change in Serum Apolipoprotein A1|Change in Serum Apolipoprotein B|Change in Serum Alanine Aminotransferase|Change in Serum Aspartate Aminotransferase|Change in Serum Creatine Kinase|Change in Serum Creatinine|Change in Serum High Sensitivity C-reactive Protein,"Abbott|Rundo International Pharmaceutical Research & Development Co.,Ltd.",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,506,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,W13-254,Oct-11,Feb-14,Mar-14,1-Nov-11,23-Feb-15,17-Mar-15,"Site Reference ID/Investigator# 64695, Xiamen, China",,https://ClinicalTrials.gov/show/NCT01462877
NCT01458977,Trial To Assess The Lipid-Lowering Effect Of Adding Tenofovir/Emtricitabine Co-Formulation Vs Placebo To Hiv-1-Infected Subjects With Dyslipidemia And Sustained Viral Load Suppression Under Monotherapy With Ritonavir-Boosted Protease Inhibitors,,Completed,No Results Available,HIV|Dyslipidemia,Drug: Truvada® (300 mg tenofovir disoproxil fumarato/200 mg emtricitabine)|Drug: Placebo,Total fasting cholesterol|LDL-cholesterol|CD4 cell count|Changes in liver enzymes|Changes in phosphate|Changes in creatinine|Changes in glomerular filtration rate|Changes in HDL cholesterol|Changes in triglycerides|Adverse events|Resistance mutations|lipid-lowering drugs,Fundacio Lluita Contra la SIDA,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,48,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",TULIP,Jan-12,Feb-14,Feb-14,25-Oct-11,null,19-Jun-14,"Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain|Hospital de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital Valle Hebrón, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT01458977
NCT01457690,Study of the Absorption of Vitamin E Water-soluble Form (Pegylated) in the Familial Hypocholesterolemia With Chylomicron Retention,VEDROP,Completed,No Results Available,Hypobetalipoproteinemias,Drug: Tocofersolan|Drug: tocopherol alpha|Drug: Tocofersolan and tocopherol alpha,Measurement the area under the curve of absorption of vitamin E according to its dosage form (fat-soluble versus water-soluble) in the beginning of each treatment period. versus water-soluble) in the beginning of each treatment period.|Measurement of serum (membranes erythrocytic) of vitamin E at the beginning and after each treatment.|Measurement of tissue (subcutaneous adipose tissue) of vitamin E at the beginning and after each treatment.,Hospices Civils de Lyon,All,"6 Years and older   (Child, Adult, Older Adult)",Phase 3,14,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2010.634,Oct-11,Aug-15,Aug-15,24-Oct-11,null,13-Nov-15,"Hopital Femme Mere Enfant-Hospices Civils de Lyon, Bron, France",,https://ClinicalTrials.gov/show/NCT01457690
NCT01455844,TRIal For Efficacy of Capre on hyperTriglyceridemiA,TRIFECTA,Completed,No Results Available,Hypertriglyceridemia,Drug: CaPre (TM)|Other: Placebo,Percent (%) change in triglycerides between the baseline and the 12-week assessment visit.|Absolute change in triglycerides between the baseline and the 12-week assessment visit.,Acasti Pharma Inc.|JSS Medical Research Inc.,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,387,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",PRT-API-NKPL66-CT-PII,Sep-11,Jun-14,Aug-14,20-Oct-11,null,22-Aug-14,"Cardiology Research, Edmonton, Alberta, Canada|Kelowna, British Columbia, Canada|Medical Arts Health Research Group, Penticton, British Columbia, Canada|St Paul's Hospital, Vancouver, British Columbia, Canada|CookMed Research, Victoria, British Columbia, Canada|First Line Medical Services Ltd, St. John's, Newfoundland and Labrador, Canada|White Hills Medical Clinic, St. John's, Newfoundland and Labrador, Canada|Scisco Clinical Research, Cornwall, Ontario, Canada|Corunna Medical Resarch Centre, Corunna, Ontario, Canada|Hamilton Health Sciences, Hamilton, Ontario, Canada|MD-Medical Professional Corporation, Hamilton, Ontario, Canada|Source Unique Research Inc., Hawkesbury, Ontario, Canada|Bagot Street Medical Centre, Kingston, Ontario, Canada|KGK Synergize Inc., London, Ontario, Canada|Milestone Research, London, Ontario, Canada|Robarts Research Institute, London, Ontario, Canada|SPARC, Siebens-Drake Research Institute, London, Ontario, Canada|S & G Clinical Research, Mississauga, Ontario, Canada|SKDA Research Inc., Newmarket, Ontario, Canada|Niagara Falls, Ontario, Canada|Centre Medical Phoenix, Ottawa, Ontario, Canada|University of Ottawa Heart Institute, Ottawa, Ontario, Canada|London Road Diagnostic Clinic and Medical Centre, Sarnia, Ontario, Canada|Sarnia Institute of Clinical Research, Sarnia, Ontario, Canada|Scarborough Cardiology Research, Scarborough, Ontario, Canada|Canadian Phase Onward, Toronto, Ontario, Canada|Source Unique Research Inc., Dollard Des-Ormeaux, Quebec, Canada|CLIN DE MED Grand-Mere, Grand-Mere, Quebec, Canada|Diex Research Montreal Inc., Montreal, Quebec, Canada|Institut de recherches cliniques de Montréal (IRCM), Montreal, Quebec, Canada|Royal Victoria Hospital, Montreal, Quebec, Canada|Dynamik Research Inc., Pointe-Claire, Quebec, Canada|Kells Medical Research, Pointe-Claire, Quebec, Canada|Clinique des Maladies Lipidiques de Quebec Inc, Québec, Quebec, Canada|Clinique Médicale St-Louis, Québec, Quebec, Canada|Diex Research Sherbrooke Inc., Sherbrooke, Quebec, Canada|Centre médical-des-carrières, St-Marc-des-carrières, Quebec, Canada|Pro-Recherche Inc., St-Romuald, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01455844
NCT01451918,Regulation of Intestinal and Hepatic Lipoprotein Secretion by Resveratrol,,Completed,No Results Available,Dyslipidaemia|Insulin Resistance,Drug: Resveratrol,Examine the effect of resveratrol on ApoB 100 and ApoB 48 production in humans|Assess the change in insulin sensitivity with resveratrol treatment,"University Health Network, Toronto|Canadian Institutes of Health Research (CIHR)",All,23 Years to 60 Years   (Adult),Phase 2,8,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",RESV10-0537-A,Oct-11,Sep-13,Sep-13,14-Oct-11,null,6-May-14,"Toronto General Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01451918
NCT01450410,Nicotinic Acid Composition of HDL and Arterial Endothelium Function in Premature Coronary Heart Disease and High HDL,11MSP011,Terminated,No Results Available,Dyslipidemias,Drug: Nicotinic acid|Drug: Placebo,Apo A1 of HDL,Xavier Pinto Sala|Hospital Universitari de Bellvitge,All,"25 Years and older   (Adult, Older Adult)",Phase 4,12,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",CompHDL2011,Jul-12,Mar-13,May-13,12-Oct-11,null,29-Jan-13,"Unitat Funcional de Risc Vascular. Servei Medicina Interna. Hospital Universitari de Bellvitge., L'Hospitalet de Llobregat, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT01450410
NCT01448174,Salusin-alpha - a New Factor in the Pathogenesis of Lipid Abnormalities in Hemodialysis Patients,,Completed,No Results Available,Renal Failure Chronic Requiring Hemodialysis|Metabolic Syndrome|Diabetes Mellitus Type 2|Hyperlipidemia,Drug: Atorvastatin,normalization of serum LDL cholesterol,Poznan University of Medical Sciences,All,"18 Years and older   (Adult, Older Adult)",Phase 4,310,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Basic Science",ALGN-001,Oct-11,Oct-14,Oct-14,7-Oct-11,null,7-Oct-14,"BBraun Avitum Dialysis Center, Nowy Tomyśl, Wielkopolska, Poland",,https://ClinicalTrials.gov/show/NCT01448174
NCT01448239,"Injection Site Tolerability, Safety, Pharmacokinetics and Pharmacodynamics Study After a Single Dose Subcutaneous Treatment of Alirocumab SAR236553 (REGN727)",,Completed,No Results Available,Hypercholesterolemia,Drug: alirocumab SAR236553 (REGN727),Pain using present pain intensity (PPI) verbal questionnaire|Erythema at injection site by measuring diameter and qualitative assessment|Edema at injection site by measuring diameter and qualitative assessment|Assessment of PK parameter - time to maximum concentration (tmax)|Assessment of PK parameter - maximum concentration (Cmax)|Assessment of PK parameter - area under curve (AUC)|Assessment of PK parameter - cluster of differentiation (CD) biomarker (CD29)|Assessment of PK parameter - terminal elimination half-life (t1/2z)|Pharmacodynamics: Change in LDL-C from baseline|Number of participants with Adverse Events,Sanofi|Regeneron Pharmaceuticals,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,24,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",PKD12010|U1111-1118-2935,Feb-11,May-11,May-11,7-Oct-11,null,28-Jun-13,"Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT01448239
NCT01448304,"Study of the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Alirocumab SAR236553 (REGN727)",,Completed,No Results Available,Hypercholesterolemia,Drug: alirocumab SAR236553 (REGN727),Pain using present pain intensity (PPI) verbal questionnaire|Erythema at injection site by measuring diameter and qualitative assessment|Edema at injection site by measuring diameter and qualitative assessment|Assessment of PK parameter - time to maximum concentration (tmax)|Assessment of PK parameter - maximum concentration (Cmax)|Assessment of PK parameter - area under curve (AUC)|Assessment of PK parameter - cluster of differentiation (CD) biomarker (CD29)|Assessment of PK parameter - terminal elimination half-life (t1/2z)|Pharmacodynamics: Change in LDL-C from baseline|Number of participants with Adverse Events,Sanofi|Regeneron Pharmaceuticals,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,24,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",PKD12011|U1111-1119-3056,Jun-11,Sep-11,Sep-11,7-Oct-11,null,28-Jun-13,"Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT01448304
NCT01448317,Ascending Dose Study of the Safety and Tolerability of Alirocumab (SAR236553/REGN727) in Japanese Healthy Volunteers,,Completed,No Results Available,Hypercholesterolemia,Drug: Alirocumab (Solution)|Drug: Alirocumab (Lyophilized formulation)|Drug: Placebo (Solution)|Drug: Placebo (Lyophilized formulation),"Number of participants with Adverse Events|Change in serum Low-Density Lipoprotein Cholesterol (LDL-C) from baseline to each visit.|Change in ApolipoproteinB, ApolipoproteinA1 and Lipoprotein(a) from baseline to each visit.|Change in Total Cholesterol (T-C), High-Density Lipoprotein Cholesterol (HDL-C), Very Low-Density Lipoprotein Cholesterol (VLDL-C) and Triglycerides (TG) from baseline to each visit.",Sanofi|Regeneron Pharmaceuticals,Male,"20 Years to 65 Years   (Adult, Older Adult)",Phase 1,32,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",TDU12190|U1111-1118-1213,May-11,Jan-12,Jan-12,7-Oct-11,null,28-Sep-16,"Sanofi-Aventis Administrative Office, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT01448317
NCT01445730,Fructose Consumption and Metabolic Dysregulation,,Completed,No Results Available,Central Obesity|Hypertriglyceridemia,Dietary Supplement: Fructose,Plasma Triglyceride (TG) area under curve (AUC)|Very low density lipoprotein 1 (VLDL1) apolipoprotein B-100 (ApoB-100) kinetics|VLDL1 ApoB-100 kinetics|Metabolic parameters,"Marja-Riitta Taskinen|Sahlgrenska University Hospital, Sweden|Lund University|University of Naples|Laval University|Helsinki University Central Hospital",Male,20 Years to 60 Years   (Adult),Not Applicable,82,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,T1010K0029,Aug-11,May-15,Jun-15,4-Oct-11,null,9-Aug-17,"Université Laval, Québec, Canada|Helsinki University Central Hospital, Biomedicum, Helsinki, Finland|University of Naples, Federico II, and Faculty of Medicine, Naples, Italy|Sahlgrenska Academy at University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden",,https://ClinicalTrials.gov/show/NCT01445730
NCT01443650,"Injection Site Tolerability, Safety, Pharmacokinetics, Pharmacodynamics in Different Single-Dose Treatments of Alirocumab SAR236553 (REGN727) in Healthy Subjects",,Completed,No Results Available,Hypercholesterolemia,Drug: alirocumab SAR236553 (REGN727),Pain using Present Pain Intensity (PPI) verbal questionnaire and Visual Analog Scale (VAS)|Erythema at injection site by measuring diameter and qualitative assessment|Edema at injection site by measuring diameter and qualitative assessment|Assessment of PK parameter - time to maximum concentration (tmax)|Pharmacodynamics: Change in LDL-C from baseline|Number of participants with Adverse Events|Assessment of PK parameter - maximum concentration (Cmax)|Assessment of PK parameter - area under curve (AUC)|Assessment of PK parameter - area under curve versus time curve (AUC0-D29)|Assessment of PK parameter - plasma concentration on Day 29 (C D29)|Assessment of PK parameter - terminal elimination half-life (t1/2z),Sanofi|Regeneron Pharmaceuticals,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,36,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",PKD12275|U1111-1120-0670,Jul-11,Nov-11,Nov-11,30-Sep-11,null,28-Jun-13,"Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT01443650
NCT01442987,Efficacy and Safety of Irbesartan and Atorvastatin in Hypertension and Hyperlipidemia,,Completed,No Results Available,Hypertension|Hyperlipidemia,Drug: Irbesartan/Atorvastatin A|Drug: Irbesartan|Drug: Atorvastatin A|Drug: Placebo|Drug: Irbesartan/Atorvastatin B|Drug: Atorvastatin B,Percent change from baseline to 8 week in LDL-Cholesterol|Change from baseline to 8 week in Blood Pressure.|Percentage of patients reaching treatment goals according to NCEP ATP III Guideline and Blood pressure responder rate according to JNC VII Guideline.,Hanmi Pharmaceutical Company Limited,All,"19 Years to 75 Years   (Adult, Older Adult)",Phase 3,230,Industry,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",HM-IBAT-301,May-11,Apr-13,May-13,29-Sep-11,null,13-Aug-13,"16 institutions including Seoul National University Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01442987
NCT01441908,Longitudinal Study of Multi-Analyte Profile for Dyslipidemia,,Unknown status,No Results Available,Dyslipidemia,Drug: Pravastatin,Comparison of 29 specific cardiovascular related lab assays from baseline through a period of 6 months in a control population with dyslipidemia vs a study group with dyslipidemia receiving an FDA approved Statin (Pravastatin).|Limited time-course of different stages of disease regression,MaiHealth Inc,All,"30 Years to 65 Years   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,MAI-001|6R44HL082382-0|6R44HL082382,Jun-11,Apr-12,Apr-12,28-Sep-11,null,16-Apr-12,"Wake Research Associates, Raleigh, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01441908
NCT01439880,Open Label Study of Long Term Evaluation Against LDL-C Trial,OSLER,Completed,No Results Available,Hypercholesterolemia,Biological: Evolocumab (AMG 145) and standard of care|Other: Standard of care,Subject incidence of treatment emergent adverse events|Absolute low density lipoprotein cholesterol (LDL-C) at week 24 and week 52|Absolute non-high density lipoprotein cholesterol (non-HDL-C) at week 24 and week 52|Absolute apolipoprotein B (ApoB) at week 24 and week 52|Absolute total cholesterol/high density lipoprotein cholesterol (HDL-C) ratio at week 24 and week 52|Absolute Apolipoprotein B (ApoeB)/Apolipoprotein A1 (ApoA1) ratio at week 24 and week 52,Amgen,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,1324,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20110110,7-Oct-11,20-Jun-18,20-Jun-18,23-Sep-11,null,2-Nov-18,"Research Site, Birmingham, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Tucson, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Malvern, Arkansas, United States|Research Site, Anaheim, California, United States|Research Site, Carmichael, California, United States|Research Site, Inglewood, California, United States|Research Site, Mission Viejo, California, United States|Research Site, Newport Beach, California, United States|Research Site, Thousand Oaks, California, United States|Research Site, Tustin, California, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Littleton, Colorado, United States|Research Site, Daytona Beach, Florida, United States|Research Site, DeLand, Florida, United States|Research Site, Green Cove Springs, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Melbourne, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Ponte Vedra, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Sanford, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Savannah, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Munster, Indiana, United States|Research Site, Iowa City, Iowa, United States|Research Site, Louisville, Kentucky, United States|Research Site, Auburn, Maine, United States|Research Site, Portland, Maine, United States|Research Site, Bethesda, Maryland, United States|Research Site, Chevy Chase, Maryland, United States|Research Site, Brockton, Massachusetts, United States|Research Site, Marquette, Michigan, United States|Research Site, Brooklyn Center, Minnesota, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Great Falls, Montana, United States|Research Site, Henderson, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Cortlandt Manor, New York, United States|Research Site, Endwell, New York, United States|Research Site, New York, New York, United States|Research Site, Williamsville, New York, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Akron, Ohio, United States|Research Site, Cadiz, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Norman, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Camp Hill, Pennsylvania, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, York, Pennsylvania, United States|Research Site, Mount Pleasant, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Bristol, Tennessee, United States|Research Site, Arlington, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Norfolk, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Renton, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, Camperdown, New South Wales, Australia|Research Site, Maroubra, New South Wales, Australia|Research Site, Sydney, New South Wales, Australia|Research Site, Perth, Western Australia, Australia|Research Site, Anthée, Belgium|Research Site, Bruxelles, Belgium|Research Site, Gozee, Belgium|Research Site, Gribomont, Belgium|Research Site, Halen, Belgium|Research Site, Ham, Belgium|Research Site, Linkebeek, Belgium|Research Site, Ukkel, Belgium|Research Site, Kelowna, British Columbia, Canada|Research Site, Bay Roberts, Newfoundland and Labrador, Canada|Research Site, Mount Pearl, Newfoundland and Labrador, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Sarnia, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Woodstock, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Gatineau, Quebec, Canada|Research Site, Granby, Quebec, Canada|Research Site, Lachine, Quebec, Canada|Research Site, Pointe-Claire, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Olomouc, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 4, Czechia|Research Site, Slany, Czechia|Research Site, Svitavy, Czechia|Research Site, Usti nad Orlici, Czechia|Research Site, Znojmo, Czechia|Research Site, Aalborg, Denmark|Research Site, Ballerup, Denmark|Research Site, Vejle, Denmark|Research Site, Helsinki, Finland|Research Site, OYS, Finland|Research Site, Berlin, Germany|Research Site, Köln, Germany|Research Site, New Territories, Hong Kong|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Dunaujvaros, Hungary|Research Site, Gyula, Hungary|Research Site, Kecskemet, Hungary|Research Site, Komarom, Hungary|Research Site, Szolnok, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Fukui-shi, Fukui, Japan|Research Site, Kasuga-shi, Fukuoka, Japan|Research Site, Fujioka-shi, Gunma, Japan|Research Site, Maebashi-shi, Gunma, Japan|Research Site, Maebashi-shi, Gunma, Japan|Research Site, Takasaki-shi, Gunma, Japan|Research Site, Kawanishi-shi, Hyogo, Japan|Research Site, Kobe-shi, Hyogo, Japan|Research Site, Hitachi-shi, Ibaraki, Japan|Research Site, Koga-shi, Ibaraki, Japan|Research Site, Mito-shi, Ibaraki, Japan|Research Site, Komatsu-shi, Ishikawa, Japan|Research Site, Takamatsu-shi, Kagawa, Japan|Research Site, Kochi-shi, Kochi, Japan|Research Site, Kyoto-shi, Kyoto, Japan|Research Site, Kyoto-shi, Kyoto, Japan|Research Site, Ina-shi, Nagano, Japan|Research Site, Matsumoto-shi, Nagano, Japan|Research Site, Suwa-shi, Nagano, Japan|Research Site, Ibaraki-shi, Osaka, Japan|Research Site, Toyonaka-shi, Osaka, Japan|Research Site, Hanyu-shi, Saitama, Japan|Research Site, Sayama-shi, Saitama, Japan|Research Site, Toda-shi, Saitama, Japan|Research Site, Chiyoda-ku, Tokyo, Japan|Research Site, Hachioji-shi, Tokyo, Japan|Research Site, Itabashi-ku, Tokyo, Japan|Research Site, Shinagawa-ku, Tokyo, Japan|Research Site, Toshima-ku, Tokyo, Japan|Research Site, Amsterdam, Netherlands|Research Site, Hoorn, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Oslo, Norway|Research Site, Singapore, Singapore|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Midrand, Gauteng, South Africa|Research Site, Observatory, Western Cape, South Africa|Research Site, Parow, Western Cape, South Africa|Research Site, Cordoba, Andalucía, Spain|Research Site, Zaragoza, Aragón, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Reus, Cataluña, Spain|Research Site, Madrid, Spain|Research Site, Göteborg, Sweden|Research Site, Lund, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01439880
NCT01437930,Intervention With n-3 Polyunsaturated Fatty Acids (PUFA)-Supplemented Products in Moderate Hypertriglyceridemic Patients,,Completed,No Results Available,Hypertriglyceridemia,Dietary Supplement: n-3 PUFA,"blood lipids (total cholesterol, high density lipoprotein (HDL), low density lipoprotein (LDL), TAG)|blood pressure|high sensitive C-reactive protein|oxidised LDL|lipoprotein a|vascular cell adhesion molecule|intracellular adhesion molecule|fatty acid distribution in plasma lipids and erythrocyte membranes",University of Jena,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",H51_11,Sep-11,Feb-12,Apr-12,21-Sep-11,null,29-Jul-14,"Friedrich Schiller University, Institute of Nutrition, Jena, Germany",,https://ClinicalTrials.gov/show/NCT01437930
NCT01435382,A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 (RN316) in Subjects With Hypercholesterolemia,,Completed,Has Results,Hypercholesterolemia|Dyslipidemias|Hyperlipidemias|Lipid Metabolism Disorders|Metabolic Diseases,Biological: PF-04950615 (RN316),"Maximum Observed Plasma Concentration (Cmax) of PF‑04950615|Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04950615|Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast) of PF‑04950615|Area Under the Plasma Concentration-Time Curve From Time Zero To Infinity (AUCinf) of PF‑04950615|Apparent Clearance (CL/F) of PF-04950615 Subcutaneous Groups|Clearance (CL) of PF-04950615 Intravenous Group|Apparent Volume of Distribution (Vz/F) of PF-04950615 Subcutaneous Groups|Volume of Distribution at Steady State (Vss) of PF-04950615 Intravenous Group|Terminal Elimination Half-life (t1/2) of PF-04950615|Absolute Bioavailability of PF-04950615 Subcutaneous Groups|Absolute Value of Fasting Low-density Lipoprotein Cholesterol (LDL-C)|Percent Change From Baseline in Fasting Low-density Lipoprotein Cholesterol (LDL-C) at Day 2, 3, 4, 5, 6, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71 and 85|Duration of Fasting LDL-C Suppressed Below 70 mg/dL and 100 mg/dL",Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 1,49,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,B1481006,Oct-11,Feb-12,Apr-12,16-Sep-11,23-Jul-18,23-Jul-18,"Profil Institute for Clinical Research, Inc., Chula Vista, California, United States|Elite Research Institute, Miami, Florida, United States|Vince and Associates Clinical Research, Overland Park, Kansas, United States|PAREXEL International - Baltimore Early Phase Clinical Unit, Baltimore, Maryland, United States|Jasper Clinic, Inc., Kalamazoo, Michigan, United States|Prism Research, Saint Paul, Minnesota, United States|Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01435382
NCT01434745,SLOS: The Effect of Simvastatin in Patients Receiving Cholesterol Supplementation,,Unknown status,No Results Available,Smith-Lemli-Opitz Syndrome,Drug: Simvastatin|Dietary Supplement: Lactose,"Intellectual quotient (IQ)|Development Quotient (DQ)|Whole body cholesterol pool size, synthesis & absorption using stable isotope testing|Plasma and urine markers of sterol metabolism|Apparent diffusion coefficient (ADC) and fractional anisotopy FA and MRS lipids (brain MRI/MRS)|Log of response amplitude (electroretinogram)","Oregon Health and Science University|National Heart, Lung, and Blood Institute (NHLBI)",All,"1 Year to 89 Years   (Child, Adult, Older Adult)",Not Applicable,16,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,R01HL073980,Sep-11,Oct-14,Oct-14,15-Sep-11,null,23-Mar-12,"Oregon Health and Science University, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT01434745
NCT01431690,Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals,,Completed,No Results Available,Hypertriglyceridemia,Drug: warfarin|Drug: omefas|Drug: omega-3-acid ethyl esters,Pharmacokinetics of R- and S- warfarin|Pharmacodynamics of R- and S- warfarin|Total EPA+DHA,AstraZeneca,All,18 Years to 55 Years   (Adult),Phase 1,52,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OM-EPA-006,Aug-11,Oct-11,Oct-11,9-Sep-11,null,24-Apr-15,"Tempe, Arizona, United States",,https://ClinicalTrials.gov/show/NCT01431690
NCT01428791,Reducing Disparities in Late Life Depression and Metabolic Syndrome,BRIGHTEN-Heart,Unknown status,No Results Available,Depressive Symptoms|Metabolic Syndrome X|Overweight|Obesity|Hypertension|Hyperglycemia|Dyslipidemias,Behavioral: Generations older adult membership program|Behavioral: BRIGHTEN Heart Virtual Team intervention,"Clinical Depression Scores, as measured by PHQ-9|Cardiometabolic risk factors",Rush University Medical Center,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,250,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,1P50HL105189-01,Mar-11,Jan-15,Dec-15,5-Sep-11,null,13-May-15,"Cook County Health and Hospital System, Chicago, Illinois, United States|Mercy Hospital and Health System, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT01428791
NCT01427855,Dietary Protein Sources and Atherogenic Dyslipidemia,,Completed,No Results Available,Cardiovascular Disease|Dyslipidemia|Insulin Resistance|Inflammation,Other: High saturated fat red meat diet|Other: High saturated fat non-meat diet|Other: High saturated fat white meat diet|Other: Low saturated fat red meat diet|Other: Low saturated fat white meat diet|Other: Low saturated fat non meat diet,Change from baseline in LDL-Cholesterol|Change from baseline in ApoB|Change from baseline in Small + Medium Sized LDL|Change from baseline in Total Cholesterol/HDL Cholesterol ratio|Change from baseline in HDL-Cholesterol|Change from baseline in non-HDLC|Change from baseline in apoAI|Change from baseline in apoAII|Change from baseline in HDL2 Cholesterol|Change from baseline in HDL3 Cholesterol|Change from baseline in homeostasis model assessment-insulin resistance (HOMA-IR)|Change from baseline in C-Reactive Protein|Change from baseline in Tumor Necrosis Factor-alpha|Change from baseline in Interleukin-6|Change from baseline in Monocyte Chemotactic Protein-1 (MCP-1)|Change from baseline in RH-PAT index,"Children's Hospital & Research Center Oakland|National Institutes of Health (NIH)|National Heart, Lung, and Blood Institute (NHLBI)",All,"30 Years to 65 Years   (Adult, Older Adult)",Not Applicable,113,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",1R01HL106003-01A1,Jan-12,Nov-16,May-17,2-Sep-11,null,6-Nov-17,"Cholesterol Research Center, Children's Hospital Research Institute, Berkeley, California, United States",,https://ClinicalTrials.gov/show/NCT01427855
NCT01426412,A Study of LY3015014 in Healthy Participants With Elevated Low Density Lipoprotein Cholesterol,,Completed,Has Results,Hyperlipidemia,Drug: LY3015014 IV|Drug: Placebo IV|Drug: LY3015014 SC|Drug: Placebo SC,Number of Participants With Clinically Significant Effects|Pharmacokinetics (PK): Area Under the Concentration-Time Curve From Time 0 to the Last Time Point With a Measurable Concentration of LY3015014 [AUC(0-tlast)]|PK: Maximum Concentration (Cmax) of LY3015014|Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C)|Number of Participants With Detectable Levels of Anti-LY3015014 Antibodies,Eli Lilly and Company,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,69,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,13980|I5S-EW-EFJA,Sep-11,Jun-13,Jun-13,31-Aug-11,5-Apr-19,5-Apr-19,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glendale, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT01426412
NCT01423188,The Study of Quantitative Serial Trends in Lipids With ApolpoproteinA-I Stimulation,SUSTAIN,Completed,No Results Available,Coronary Artery Disease|Dyslipidemia,Drug: RVX000222|Drug: Placebo RVX000222,"The percent change in HDL-C from baseline to 24 weeks for RVX000222 200 mg daily compared to placebo|Within treatment group percent change in HDL-C from baseline to 24 weeks for RVX000222 and placebo groups.|The percent change in plasma apoA-I from baseline to 4 weeks, 12 weeks and 24 weeks for RVX000222 compared to placebo (within and between treatment groups).|The percent change in LDL-C, non-HDL-C, apoB, TG and HDL subclasses from baseline to 4 weeks, 12 weeks and 24 weeks for RVX000222 compared to placebo (within and between treatment groups)|Incidence of adverse events by treatment group|The percent change in HDL-C from baseline to 4 weeks and 12 weeks for RVX000222 compared to placebo (within and between treatment groups)|The percent change in hsCRP from baseline to 12 weeks and 24 weeks for RVX000222 compared to placebo (within and between treatment groups).",Resverlogix Corp|The Cleveland Clinic,All,"18 Years and older   (Adult, Older Adult)",Phase 2,176,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RVX222-CS-008,Aug-11,Jun-12,Aug-12,25-Aug-11,null,20-Sep-12,"East Burger Street, Bloemfontein, South Africa|Westdene, Bloemfontein, South Africa|Goodwood, Cape Town, South Africa|Kraaifontein, Cape Town, South Africa|Pinelands, Cape Town, South Africa|Chatsworth, Durban, South Africa|Congella, Durban, South Africa|Merebank, Durban, South Africa|Sydenham, Durban, South Africa|Tongaat, Durban, South Africa|Umhlanga, Durban, South Africa|Lenasia, Johannesburg, South Africa|Halfway House, Midrand, South Africa|Die Wilgers, Pretoria, South Africa|Eloffsdal, Pretoria, South Africa|Kuils River, Western Cape, South Africa|Parow, Western Cape, South Africa|Somerset West, Western Cape, South Africa|Stellenbosch, Western Cape, South Africa|Worcester, Western Cape, South Africa|Bloemfontein, South Africa|Cape Town, South Africa|Cape Town, South Africa|Johannesburg, South Africa|Western Cape, South Africa",,https://ClinicalTrials.gov/show/NCT01423188
NCT01422421,Intensive Blood Pressure and LDL Lowering in Diabetic Patients With Coronary Artery Disease,,Recruiting,No Results Available,Type 2 Diabetes|Coronary Artery Disease|Hypertension|Dyslipidemia,Other: intensive control|Other: standard control,composite endpoint|important secondary composite endpoint|all-cause mortality|myocardial infarction|stroke|Cardiovascular death|end stage renal disease|peripheral artery disease|new onset or deterioration of heart failure,"Takeshi Morimoto|University of the Ryukyus|Kyoto University, Graduate School of Medicine",All,"20 Years and older   (Adult, Older Adult)",Phase 4,1000,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention",H21-rinsho shiken ippan-017,Aug-11,Mar-22,Dec-29,24-Aug-11,null,28-Mar-19,"University Hospital, University of the Ryukyus, Nishihara, Okinawa, Japan|Saga University Hospital, Saga, Japan",,https://ClinicalTrials.gov/show/NCT01422421
NCT01420016,Prioritized Clinical Decision Support (CDS) to Reduce Cardiovascular Risk,,Completed,Has Results,Hypertension|Hyperlipidemia|Diabetes|Smoking|Cardiovascular Risk Factor|Cardiovascular Diseases,Other: Prioritized Clinical Decision Support,Predicted Annual Rate of Change in 10-year Risk of Fatal or Nonfatal Heart Attack or Stroke,"HealthPartners Institute|National Heart, Lung, and Blood Institute (NHLBI)",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,7914,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,09-096|R01HL102144-01,20-Aug-12,19-Aug-14,19-Aug-14,19-Aug-11,21-Sep-18,21-Sep-18,,,https://ClinicalTrials.gov/show/NCT01420016
NCT01420549,Efficacy and Safety of FDC in High Risk Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia,LANCE,Completed,No Results Available,Hypercholesterolemia|Dyslipidemia,"Drug: Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according with titration.|Drug: Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according with titration.","Changes in LDL-Cholesterol level|Changes in HDL, triglycerides and apolipoprotein B levels|Safety descriptive about occurence of adverse events, evaluation of results of general physical examination.",Ache Laboratorios Farmaceuticos S.A.,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,129,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ACH-TRZ-03(06/11),Mar-13,Nov-14,Nov-14,19-Aug-11,null,26-Oct-16,"Universidade Federal de São Paulo, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT01420549
NCT01418716,TRANSforming InTerprofessional Cardiovascular Prevention in Primary Care,TRANSIT,Completed,No Results Available,"Diabetes Mellitus, Type 2|Hypertension|Dyslipidemias|Cholesterol, LDL|Comorbitdity",Other: Facilitation|Other: Passive diffusion,Quality of the cardiovascular preventive care|Organisational outcomes|Blood pressure|c-LDL|Glycosylated hemoglobine (HgA1c)|Achieved therapeutic targets|Lifestyle habits|Use of public programs,Fonds de la Recherche en Santé du Québec|Université de Montréal,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,759,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,FRSQ-22424,Apr-11,Oct-13,Oct-16,17-Aug-11,null,17-Feb-17,"Centre de santé et de services sociaux de Laval, Laval, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01418716
NCT01414166,Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108),,Terminated,Has Results,Dyslipidemia,Drug: ERN/LRPT|Drug: placebo,Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) Averaged Across Week 12 and Week 16|Percent Change From Baseline in the Ratio of LDL-C to High-Desity Lipoprotein Cholesterol (HDL-C) at Week 16|Percent Change From Baseline in HDL-C at Week 16|Percent Change From Baseline in Triglycerides (TG) at Week 16|Percent Change From Baseline in Non-HDL-C at Week 16|Percent Change From Baseline in the Ratio of Total Cholesterol (TC) to HDL-C at Week 16|Percent Change From Baseline in Lipoprotein(a) (LP[a]) at Week 16|Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 16|Percent Change From Baseline in Apolipoprotein A-I (Apo A-I) at Week 16,Merck Sharp & Dohme Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 3,244,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",0524A-108|CTRI/2012/08/002873,Sep-11,Feb-13,Feb-13,11-Aug-11,14-Mar-14,13-May-15,,,https://ClinicalTrials.gov/show/NCT01414166
NCT01414647,The Health Effect of Diet Rich in Nordic Berries,Berry,Completed,No Results Available,Metabolic Syndrome|Impaired Glucose Tolerance|Low-grade Inflammation|Dyslipidemia,"Dietary Supplement: 300 g of strawberry, raspberry and cloudberry|Dietary Supplement: 400 g of bilberry|Other: Control diet",Glucose level|Cholesterol level|Inflammation markers|Markers of sterol metabolism|gene expression in PBMCs,"Marjukka Kolehmainen|VTT Technical Research Centre, Finland|University of Eastern Finland",All,"50 Years to 65 Years   (Adult, Older Adult)",Not Applicable,56,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,124//2005|40361/05,Jan-06,Dec-06,Mar-10,11-Aug-11,null,17-May-18,"University of Eastern Finland, Dpet of Public Health and Clinical Nutrition, Kuopio, Finland",,https://ClinicalTrials.gov/show/NCT01414647
NCT01414751,Influence of Intervention Methodologies on Patient Choice of Therapy,IMPACT,Unknown status,No Results Available,Communication|Hypercholesterolemia,Behavioral: Absolute risk reduction|Behavioral: Prolongation of life,Patient's satisfaction and confidence with the information given.|Influence of effectiveness format on patients' consent or refusal to a therapy offer,University of Southern Denmark|Danish Heart Foundation,All,"40 Years to 69 Years   (Adult, Older Adult)",Not Applicable,248,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant),CGH001,Nov-09,Jun-11,Aug-13,11-Aug-11,null,10-Jan-13,,,https://ClinicalTrials.gov/show/NCT01414751
NCT01414803,Tolerability and Efficacy of Rosuvastatin - Fenofibrate Combine Therapy in Korean Patients With Combined Hyperlipidemia,,Completed,No Results Available,Hyperlipidemia,Drug: Lipid modification,Incidence of elevation of CK>5x ULN or AST>3x ULN or ALT>3x ULN,Yonsei University,All,"20 Years to 70 Years   (Adult, Older Adult)",Phase 4,180,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4-2008-0390,Mar-09,Apr-11,Apr-11,11-Aug-11,null,11-Aug-11,"Severance Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01414803
NCT01412034,Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects,MODE,Completed,No Results Available,Homozygous Familial Hypercholesterolemia,Drug: CER-001,Percent change from baseline to follow-up in carotid mean vessel wall area|Change in carotid vessel wall volume,"Cerenis Therapeutics, SA",All,"12 Years and older   (Child, Adult, Older Adult)",Phase 2,23,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CER-001-CLIN-003,Nov-11,Oct-13,Aug-14,8-Aug-11,null,18-Aug-15,"Clinical Research Facility, Hartford, Connecticut, United States|Clinical Research Facility, N. Massapequa, New York, United States|Clinical Research Facility, Chicoutimi, Quebec, Canada|Clinical Research Facility, Quebec, Canada|Clinical Research Facility, Rome, Italy|Clinical Research Facility, Amsterdam, Netherlands|Clinical Research Facility, Maastricht, Netherlands|Clinical Research Facility, Nijmegen, Netherlands|Clinical Research Facility, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT01412034
NCT01410383,Efficacy and Safety Study of Eprotirome in HeFH Patients Who Are on Optimal Standard of Care,AKKA,Terminated,No Results Available,Heterozygous Familial Hypercholesterolaemia,Drug: Placebo|Drug: Eprotirome,Percent reduction in low-density lipoprotein cholesterol (LDL-C) from baseline,Karo Bio AB,All,"18 Years and older   (Adult, Older Adult)",Phase 3,236,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",KBT 009,Oct-11,Oct-13,Oct-14,5-Aug-11,null,3-Sep-12,,,https://ClinicalTrials.gov/show/NCT01410383
NCT01409434,Long Term Antihypertensive Exposure and Adverse Metabolic Effects: PEAR Follow-Up Study,,Completed,Has Results,Drug Induced Hyperglycemia|Secondary Hyperlipidemia,Drug: Oral Glucose Tolerance Test,Fasting Glucose (mg/dL)|Oral Glucose Tolerance Test (mg/dl h)|Triglycerides (mg/dL)|Low Density Lipoprotein (mg/dL)|High Density Lipoprotein (mg/dL),University of Florida,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,44,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,PEAR Follow-Up,Jun-10,Aug-13,Aug-13,4-Aug-11,16-Oct-14,16-Oct-14,"University of Florida College of Pharmacy, Gainesville, Florida, United States",,https://ClinicalTrials.gov/show/NCT01409434
NCT01408303,[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL,ESPRIT,Completed,Has Results,Hypertriglyceridemia|Cardiovascular Disease,"Drug: Olive oil, 4g|Drug: omega-3-carboxylic acids, 2g|Drug: omega-3-carboxylic acids, 4g",Serum Non-HDL Cholesterol,"AstraZeneca|Omthera Pharmaceuticals, Inc|Medpace, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,646,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",OM-EPA-004,Aug-11,Jun-12,Jun-12,3-Aug-11,5-Dec-14,5-Dec-14,"Muscle Shoals, Alabama, United States|Chandler, Arizona, United States|Phoenix, Arizona, United States|Little Rock, Arkansas, United States|Encinitas, California, United States|Lomita, California, United States|Los Angeles, California, United States|Sacramento, California, United States|San Diego, California, United States|Spring Valley, California, United States|Westlake Village, California, United States|Colorado Springs, Colorado, United States|Denver, Colorado, United States|Brandon, Florida, United States|Clearwater, Florida, United States|Coral Gables, Florida, United States|Hialeah, Florida, United States|Jacksonville, Florida, United States|Jacksonville, Florida, United States|Jupiter, Florida, United States|Melbourne, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|New Port Richey, Florida, United States|Ocala, Florida, United States|Orlando, Florida, United States|Oviedo, Florida, United States|Ponte Vedra, Florida, United States|St. Petersburg, Florida, United States|Addison, Illinois, United States|Chicago, Illinois, United States|Oakbrook Terrace, Illinois, United States|Indianapolis, Indiana, United States|Newton, Kansas, United States|Wichita, Kansas, United States|Wichita, Kansas, United States|Louisville, Kentucky, United States|Madisonville, Kentucky, United States|Auburn, Maine, United States|Oxon Hill, Maryland, United States|Troy, Michigan, United States|Edina, Minnesota, United States|Chesterfield, Missouri, United States|Kansas City, Missouri, United States|St. Louis, Missouri, United States|Butte, Montana, United States|Las Vegas, Nevada, United States|Berlin, New Jersey, United States|Endwell, New York, United States|New Windsor, New York, United States|Rochester, New York, United States|Cary, North Carolina, United States|Charlotte, North Carolina, United States|Hickory, North Carolina, United States|High Point, North Carolina, United States|Raleigh, North Carolina, United States|Raleigh, North Carolina, United States|Salisbury, North Carolina, United States|Statesville, North Carolina, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Lyndhurst, Ohio, United States|Marion, Ohio, United States|Oklahoma City, Oklahoma, United States|Tulsa, Oklahoma, United States|Eugene, Oregon, United States|Harleysville, Pennsylvania, United States|Jersey Shore, Pennsylvania, United States|Lansdale, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Mount Pleasant, South Carolina, United States|Mt Pleasant, South Carolina, United States|Rapid City, South Dakota, United States|Bristol, Tennessee, United States|Gray, Tennessee, United States|Kingsport, Tennessee, United States|Corpus Christi, Texas, United States|Houston, Texas, United States|Katy, Texas, United States|San Antonio, Texas, United States|Murray, Utah, United States|Salt Lake City, Utah, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Olympia, Washington, United States",,https://ClinicalTrials.gov/show/NCT01408303
NCT01408719,Effect of Beta-Glucan on Cholesterol Lowering,,Completed,Has Results,Hypercholesterolemia,Dietary Supplement: Control|Dietary Supplement: 3g LMW beta-glucan|Dietary Supplement: 5g LMW beta-glucan|Dietary Supplement: 3g HMW beta-glucan,Changs in Total Cholesterol|Changes in LDL Cholesterol|Cholesterol Absorption/Synthesis|Potential Gene-nutrient Interactions: CYP7A1 and APOE|Changes in Body Weight and Waist Circumference(WC),University of Manitoba|Agriculture and Agri-Food Canada,All,"18 Years to 78 Years   (Adult, Older Adult)",Not Applicable,45,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,B2010:216,Nov-10,Feb-12,Feb-12,3-Aug-11,11-Mar-14,5-Nov-15,"Richardson Centre for Functional Foods and Neutraceuticals, Winnipeg, Manitoba, Canada",,https://ClinicalTrials.gov/show/NCT01408719
NCT01406431,Pharmacokinetic Study of Livalo® Fixed Combination Drug in Healthy Subjects,,Completed,No Results Available,Hyperlipidemia|Hypertension,"Drug: Pitavastatin, Valsartan|Drug: Livalo® fixed combination drug","Cmax of study drugs after single oral administration|AUClast of study drugs after single oral administration|AUCinf, Tmax and t1/2β of study drugs after single oral administration",JW Pharmaceutical,Male,20 Years to 55 Years   (Adult),Phase 1,48,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),JW-PTV-102,Aug-11,Aug-11,Oct-12,1-Aug-11,null,3-Jan-13,"Asan Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01406431
NCT01406106,Effect of Plant Sterols on the Lipid Profile of Patients With Hypercholesterolaemia,,Unknown status,No Results Available,Hypercholesterolemia,Dietary Supplement: Plant stanol esters,"Change in lipid profile|Change in cardiovascular risk|Adherence to the dairy product (liquid yoghurt)|Adverse events|Adherence to the dietary recommendations|Frequency of food intake|Occurrence of cardiovascular events|Weight, height, body mass index (BMI)|Physical activity|Smoking habit|Systolic and diastolic blood pressure (two measurements):|Health problems|Lipid-lowering pharmacological treatment.|Socio-demographic data","Gerencia de Atención Primaria, Albacete|Fundación para la Investigación Sanitaria en Castilla-La Mancha (FISCAM)|Castilla-La Mancha Health Research Foundation.",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,182,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2009/001,Jan-10,Dec-11,Dec-12,29-Jul-11,null,29-Jul-11,,,https://ClinicalTrials.gov/show/NCT01406106
NCT01404897,"Effects of High Fruit, Vegetable, and Dairy Intake on Plasma Lipids and Blood Pressure in Healthy Individuals",,Completed,No Results Available,Cardiovascular Disease|Dyslipidemia|Blood Pressure,Other: Dietary Intervention,"Total:HDL-cholesterol ratio|HDL-cholesterol|Apolipoprotein B|Apolipoprotein AI|Small LDL particles|Large HDL particles|Blood Pressure|Triglycerides|Total Cholesterol|LDL-Cholesterol|Lipoprotein Subclasses (HDL, LDL, IDL, VLDL)|HOMA-IR",Children's Hospital & Research Center Oakland|Dairy Management Inc.,All,"22 Years and older   (Adult, Older Adult)",Not Applicable,36,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MM3274,Jul-11,Dec-13,Dec-13,28-Jul-11,null,26-Mar-15,"Cholesterol Research Center, Children's Hospital Oakland Research Institute, Berkeley, California, United States",,https://ClinicalTrials.gov/show/NCT01404897
NCT01402102,A Human Trial to Evaluate the Efficacy and Safety of Aged Garlic Powder on Improvement of Blood Lipids in Subjects With Hyperlipidemia,,Completed,Has Results,Hyperlipidemia,Dietary Supplement: Aged garlic powder|Dietary Supplement: Placebo powder,Changes in LDL-cholesterol(Low Density Lipoprotein - Cholesterol)|Changes in HDL-Cholesterol(High Density Lipoprotein - Cholesterol)|Changes in Triglycerides|Changes in Total Cholesterol|Changes in Apo-A1(Apolipoprotein A1)|Changes in Apo-B(Apolipoprotein B)|Changes in FFA(Free Fatty Acid),Chonbuk National University Hospital,All,"20 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care",Doul-BGarlic-001,Jul-10,Mar-11,Jul-11,26-Jul-11,4-Oct-12,12-Oct-12,"Clinical Trial Center for Functional Foods; Chonbuk National University Hospital, Jeonju, Jeollabuk-do, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01402102
NCT01402128,Efficacy and Safety of Fermented Barley on Decrement of Body Fat in Obese Subjects,,Completed,Has Results,Overweight; Hyperlipidemia,Dietary Supplement: Barley beta-glucan(3.0g)|Dietary Supplement: Placebo,Changes in Body Fat Mass(kg)|Changes in Percent Body Fat(%)|Changes in Visceral Adipose Tissue|Changes in LDL-C (LDL Low Density Lipoprotein-cholesterol)|Changes in HDL-C(High Density Lipoprotein-cholesterol)|Changes in Total Cholesterol|Changes in Triglyceride|Changes in FFA(Free Fatty Acid)|Changes in Apo-A1(Apolipoprotein A1)|Changes in Apo-B(Apolipoprotein B)|Changes in Subcutaneous Adipose Tissue,Chonbuk National University Hospital,All,"19 Years to 70 Years   (Adult, Older Adult)",Phase 2|Phase 3,80,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care",MTB-bG-001,Jun-10,Oct-10,May-11,26-Jul-11,25-Dec-12,25-Dec-12,"Clinical Trial Center for Functional Foods; Chonbuk National University Hospital, Jeonju, Jeollabuk-do, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01402128
NCT01402843,"Efficacy, Safety of Coadministered Pitavastatin and Valsartan in Patients With Hypertension and Dyslipidemia",COCTAIL,Completed,No Results Available,Hypertension|Dyslipidemia,"Drug: pitavastatin, valsartan, placebo","The experimental group should be compared with control group in the change of DBP and LDL-C on the basis of the baseline.|Change from Baseline in Systolic Blood Pressure at 6 months.|The changes and rate of lipid variables (TG, TC, HDL cholesterol and apolipoprotein B)",JW Pharmaceutical,All,"20 Years and older   (Adult, Older Adult)",Phase 3,150,Industry,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CWP-PTV-301,Jun-11,Jun-12,Jan-13,26-Jul-11,null,14-May-14,"Chungbuk National University Hospital, Chung Ju, Korea, Republic of|Konyang University Hospital, Daejeon, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Hallym University Medical Center, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Ajou University Medical Center, Suwon, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01402843
NCT01394380,Reduction of Sweetened Beverages and Intrahepatic Fat,REDUCS,Completed,No Results Available,Obesity|Dyslipidemia|Metabolic Syndrome,Other: artificially sweetened sodas,changes in intrahepatic fat concentration|changes in visceral fat volume|changes in day-long metabolic profile|changes in food intake from baseline,"University of Lausanne|Centre Hospitalier Universitaire Vaudois|University Hospital Inselspital, Berne",All,18 Years to 40 Years   (Adult),Not Applicable,29,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,171/11,Oct-11,Apr-14,Apr-14,14-Jul-11,null,4-Jun-14,"Clinical Research Center, CHUV, Lausanne, VD, Switzerland",,https://ClinicalTrials.gov/show/NCT01394380
NCT01391585,Expanding Comparative Effectiveness Research (CER) Capability Through Complex Patient Relationship Management,,Completed,No Results Available,Diabetes|Hyperlipidemia,Other: Text Message prompts,response rate to home monitoring prompts|response rate to prompt for lab text by text message|response to barrier questions for non-adherence,Denver Health and Hospital Authority|Agency for Healthcare Research and Quality (AHRQ),All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,135,Other|U.S. Fed,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,R24HS019453-01PRM|R24HS019453-01,Jun-11,Aug-12,Aug-12,12-Jul-11,null,11-Feb-14,"Denver Health, Denver, Colorado, United States",,https://ClinicalTrials.gov/show/NCT01391585
NCT01388816,"A Safety and Efficacy Study of DRL-17822, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Patients With Abnormal Cholesterol Levels",,Completed,Has Results,Type II Hyperlipidemia,Drug: DRL-17822 or placebo,Percent Change in HDL-C From Baseline|Safety and Tolerability of DRL-17822|Changes in Vital Signs Including Blood Pressure|To Evaluate Trough Levels of DRL-17822 in Plasma|Changes in CETP Inhibition in Plasma|Changes in Other Lipids and Apolipoproteins,Dr. Reddy's Laboratories Limited|PharmaNet,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,176,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DRL-17822/CD/004,Jul-11,May-12,Jun-12,7-Jul-11,22-Apr-14,22-Apr-14,"Genova, Italy|Milano, Italy|Modena, Italy|Palermo, Italy|Perugia, Italy|Gdynia, Poland|Gniewkowo, Poland|Katowice, Poland|Wroclaw, Poland|Chernivtsi, Ukraine|Kharkov, Ukraine|Kyiv, Ukraine",,https://ClinicalTrials.gov/show/NCT01388816
NCT01386853,Efficacy and Safety Study of Pitavastatin and Atorvastatin in High Risk Hypercholesterolemic Patients,,Unknown status,No Results Available,Hyperlipidemia,Drug: Pitavastatin|Drug: Atorvastatin,"The change of LDL-C|The proportion of patients achieving LDL-C < 100 mg/dL; the changes of HDL-C, TG, non-HDL-C, Apo A1 and Apo B, fasting plasma glucose, fasting insulin level, insulin resistance by the HOMA-IR, HbA1c, free fatty acid, and ADMA","Tai Tien Pharmaceuticals Co., Ltd.",All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 3,200,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TATPITA20101005,Jul-11,Mar-12,Jul-12,1-Jul-11,null,1-Jul-11,"Changhua Christian Hospital, Chang-hua, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|Chang Gung Memorial Hospital-LinKou, Taipei, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT01386853
NCT01384058,Effect of Ezetimibe or Simvastatin or Both on Low Densitiy Lipoprotein -Subfractions in Patients With Type 2 Diabetes,EZE,Completed,No Results Available,Diabetes Mellitus Type 2|Hypercholesterolemia,Drug: ezetimibe|Drug: simvastatin|Drug: Ezetimibe 10/Simvastatin 20,"Change of the concentration of apolipoprotein B (ApoB) in dense Low Densitiy Lipoprotein (dLDL) from baseline with ezetimibe, simvastatin or the combination of both drugs|Change of the concentrations of Total Cholesterol|Change of the concentrations of Low Densitiy Lipoprotein (LDL) -Cholesterol|Change of the concentrations of High Density Lipoprotein (HDL) -Cholesterol|Change of the concentrations of triglycerides",University Hospital Freiburg|Essex Pharma GmbH,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,41,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,442006|2006-005906-30,Nov-07,May-10,Jun-10,28-Jun-11,null,19-Jun-12,"Institut für Stoffwechselforschung, Frankfurt, Germany|Stephan Jacob, MD, Villingen-.Schwenningen, Germany",,https://ClinicalTrials.gov/show/NCT01384058
NCT01380730,LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy,LAPLACE,Completed,Has Results,Hyperlipidemia,Biological: Evolocumab|Other: Placebo to Evolocumab,Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12|Change From Baseline in LDL-C at Week 12|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12|Percent Change From Baseline in Apolipoprotein B at Week 12|Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 Ratio at Week 12,Amgen|TIMI Study Group,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,631,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",20101155,1-Jul-11,5-Apr-12,5-Apr-12,27-Jun-11,1-Oct-15,2-Nov-18,"Research Site, Birmingham, Alabama, United States|Research Site, Tucson, Arizona, United States|Research Site, Malvern, Arkansas, United States|Research Site, Anaheim, California, United States|Research Site, Carmichael, California, United States|Research Site, Newport Beach, California, United States|Research Site, Roseville, California, United States|Research Site, Westlake Village, California, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Littleton, Colorado, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Green Cove Springs, Florida, United States|Research Site, Melbourne, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Peoria, Illinois, United States|Research Site, Hammond, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Valparaiso, Indiana, United States|Research Site, Iowa City, Iowa, United States|Research Site, Lexington, Kentucky, United States|Research Site, Auburn, Maine, United States|Research Site, Bangor, Maine, United States|Research Site, Portland, Maine, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Marquette, Michigan, United States|Research Site, Ypsilanti, Michigan, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Great Falls, Montana, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Cortlandt Manor, New York, United States|Research Site, Williamsville, New York, United States|Research Site, Smithfield, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Mansfield, Ohio, United States|Research Site, Marion, Ohio, United States|Research Site, Sandusky, Ohio, United States|Research Site, Camp Hill, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, York, Pennsylvania, United States|Research Site, Florence, South Carolina, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Jackson, Tennessee, United States|Research Site, Jackson, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Tacoma, Washington, United States|Research Site, Madison, Wisconsin, United States|Research Site, Burnaby, British Columbia, Canada|Research Site, Kelowna, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Sarnia, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Woodstock, Ontario, Canada|Research Site, Gatineau, Quebec, Canada|Research Site, Lachine, Quebec, Canada|Research Site, Longueuil, Quebec, Canada|Research Site, Pointe-Claire, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Olomouc, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 4, Czechia|Research Site, Slany, Czechia|Research Site, Svitavy, Czechia|Research Site, Usti nad Orlici, Czechia|Research Site, Znojmo, Czechia|Research Site, Aalborg, Denmark|Research Site, Ballerup, Denmark|Research Site, Vejle, Denmark|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Dunaujvaros, Hungary|Research Site, Eger, Hungary|Research Site, Gyula, Hungary|Research Site, Kecskemet, Hungary|Research Site, Komarom, Hungary|Research Site, Mosonmagyarovar, Hungary|Research Site, Szolnok, Hungary|Research Site, Zalaegerszeg, Hungary",,https://ClinicalTrials.gov/show/NCT01380730
NCT01382277,Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume,REDUCT,Unknown status,No Results Available,Hyperlipidemia|Coronary Artery Disease,Drug: Rosuvastatin,Change from baseline in coronary atherosclerosis plaque volume using a 64 slice spiral CT at 76 weeks|Change from baseline in blood lipids at 26 weeks|Change from baseline in hsCRP at 26 weeks|Change from baseline in Carotid intima-media thickness at 76 weeks|Number of participants with adverse events and abnormal laboratory safety markers.|Change from baseline in blood lipids at 52 weeks|Change from baseline in blood lipids at 76 weeks|Change from baseline in hsCRP at 52 weeks|Change from baseline in hsCRP at 76 weeks,Peking University First Hospital,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,600,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,REDUCT,Mar-11,Apr-13,Apr-13,27-Jun-11,null,27-Jun-11,"Peking University First Hospital, Beijing, Beijing, China|Division of Cardiology, Peking University First Hospital, Beijing, China",,https://ClinicalTrials.gov/show/NCT01382277
NCT01377064,Home-based Exercise for Management of HIV-associated Cardiovascular Disease Risk,,Completed,No Results Available,Cardiovascular Diseases|Hyperlipidemia|Obesity,Behavioral: Physical Activity Group|Other: Standard Care Group,Amount of Physical Activity|Cardiorespiratory Fitness,University of South Carolina|National Institute of Nursing Research (NINR),All,"18 Years and older   (Adult, Older Adult)",Phase 1,60,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1R21NR011281,Mar-11,Jul-13,Jul-13,20-Jun-11,null,12-Dec-13,"The Citadel, Charleston, South Carolina, United States|University of South Carolina, Columbia, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT01377064
NCT01375075,A Study of LY2484595 in Japanese Subjects,,Completed,Has Results,Dyslipidemias,Drug: LY2484595|Drug: Placebo|Drug: Atorvastatin,Percent Change From Baseline to 12 Weeks in High Density Lipoprotein Cholesterol (HDL-C) and Low Density Lipoprotein Cholesterol (LDL-C) With LY2484595 and Placebo|Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) and Low Density Lipoprotein Cholesterol (LDL-C) With LY2484595 in Combination With Atorvastatin|Pharmacokinetics - Area Under the Curve (AUC) of LY2484595 and Atorvastatin|The Number and Severity of Episodes of Rashes at Any Time From Baseline Through Week 12|Change From Baseline to 12 Weeks in Blood Pressure|Change From Baseline to 12 Weeks in Aldosterone|Change From Baseline to 12 Weeks in Plasma Renin Activity|Change From Baseline to 12 Weeks in Serum Sodium|Change From Baseline to 12 Weeks in Serum Bicarbonate|Number of Myopathy and Liver Injury Events|Change From Baseline to 12 Week Endpoint in Highly-Sensitive C-Reactive Protein (hsCRP)|Percent Change From Baseline in Plasma Cholesteryl Ester Transfer Protein (CETP) Activity|Change From Baseline in Plasma CETP Mass,Eli Lilly and Company,All,"20 Years and older   (Adult, Older Adult)",Phase 2,165,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",13049|I1V-JE-EIAE,Jun-11,Mar-12,Mar-12,17-Jun-11,25-Oct-18,25-Oct-18,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyogo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kanagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kyoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT01375075
NCT01375751,Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study,RUTHERFORD,Completed,Has Results,"Hypercholesterolemia, Familial",Biological: Evolocumab|Biological: Placebo,Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12|Absolute Change From Baseline in LDL-C at Week 12|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (HDL-C) at Week 12|Percent Change From Baseline in Apolipoprotein B at Week 12|Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12|Percent Change From Baseline in Apolipoprotein B /Apolipoprotein A-1 Ratio at Week 12,Amgen,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,168,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",20090158,2-Aug-11,16-May-12,16-May-12,17-Jun-11,29-Sep-15,2-Nov-18,,,https://ClinicalTrials.gov/show/NCT01375751
NCT01375764,Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects,GAUSS,Completed,Has Results,Hyperlipidemia,Biological: Evolocumab|Drug: Ezetimibe|Other: Placebo to Evolocumab,Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12|Percent Change From Baseline in LDL-C at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe|Change From Baseline in LDL-C at Week 12|Change From Baseline in LDL-C at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe|Percent Change From Baseline in Non-HDL-C at Week 12|Percent Change From Baseline in Non-HDL-C at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe|Percent Change From Baseline in Apolipoprotein B at Week 12|Percent Change From Baseline in Apolipoprotein B at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe|Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12|Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe,Amgen,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,160,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",20090159,28-Jul-11,8-May-12,8-May-12,17-Jun-11,23-Dec-15,2-Nov-18,"Research Site, Anaheim, California, United States|Research Site, Mission Viejo, California, United States|Research Site, Westlake Village, California, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Savannah, Georgia, United States|Research Site, Auburn, Maine, United States|Research Site, Chevy Chase, Maryland, United States|Research Site, Butte, Montana, United States|Research Site, Henderson, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, New York, New York, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Akron, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Bristol, Tennessee, United States|Research Site, Camperdown, New South Wales, Australia|Research Site, Sydney, New South Wales, Australia|Research Site, Melbourne, Victoria, Australia|Research Site, Perth, Western Australia, Australia|Research Site, Bruxelles, Belgium|Research Site, Uccle, Belgium|Research Site, Saint Johnâ€™s, Newfoundland and Labrador, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Lachine, Quebec, Canada|Research Site, Ballerup, Denmark|Research Site, Vejle, Denmark|Research Site, Helsinki, Finland|Research Site, OYS, Finland|Research Site, Zaragoza, AragÃ³n, Spain|Research Site, Zaragoza, Aragón, Spain|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, L'Hospitalet de Llobregat, CataluÃ±a, Spain|Research Site, Reus, CataluÃ±a, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, L'Hospitalet de Llobregat, Cataluña, Spain|Research Site, Reus, Cataluña, Spain|Research Site, GÃ¶teborg, Sweden|Research Site, Göteborg, Sweden|Research Site, Lund, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT01375764
NCT01375777,Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels,MENDEL,Completed,Has Results,Hyperlipidemia,Biological: Evolocumab|Drug: Ezetimibe|Other: Placebo to Evolocumab,Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12|Change From Baseline in LDL-C at Week 12|Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12|Percent Change From Baseline in Apolipoprotein B at Week 12|Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 Ratio at Week 12,Amgen,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,411,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",20101154,6-Jul-11,2-Mar-12,2-Mar-12,17-Jun-11,5-Oct-15,28-Nov-18,"Research Site, Birmingham, Alabama, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Encinitas, California, United States|Research Site, Inglewood, California, United States|Research Site, San Diego, California, United States|Research Site, Tustin, California, United States|Research Site, DeLand, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Ponte Vedra, Florida, United States|Research Site, Sanford, Florida, United States|Research Site, Decatur, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Louisville, Kentucky, United States|Research Site, Bethesda, Maryland, United States|Research Site, Brockton, Massachusetts, United States|Research Site, Brooklyn Center, Minnesota, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Endwell, New York, United States|Research Site, New Windsor, New York, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Norman, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Mount Pleasant, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Arlington, Texas, United States|Research Site, Boerne, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Norfolk, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Renton, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Maroubra, New South Wales, Australia|Research Site, Carina Heights, Queensland, Australia|Research Site, AnthÃ©e, Belgium|Research Site, Dour, Belgium|Research Site, Gozee, Belgium|Research Site, Gribomont, Belgium|Research Site, Halen, Belgium|Research Site, Ham, Belgium|Research Site, Linkebeek, Belgium|Research Site, Retie, Belgium|Research Site, Bay Roberts, Newfoundland and Labrador, Canada|Research Site, Mount Pearl, Newfoundland and Labrador, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Granby, Quebec, Canada|Research Site, Aalborg, Denmark|Research Site, Ballerup, Denmark|Research Site, Vejle, Denmark",,https://ClinicalTrials.gov/show/NCT01375777
NCT01370590,A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1),,Completed,Has Results,Hypercholesterolemia,Drug: Atorvastatin|Drug: Ezetimibe|Drug: Ezetimibe/atorvastatin|Drug: Placebo to atorvastatin|Drug: Placebo to ezetimibe|Drug: Placebo to ezetimibe/atorvastatin,Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After 6 Weeks of Treatment|Percent Change From Baseline in Total Cholesterol (TC) After 6 Weeks of Treatment|Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) After 6 Weeks of Treatment|Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) After 6 Weeks of Treatment|Percent Change From Baseline in Apolipoprotein (Apo) B After 6 Weeks of Treatment|Percent Change From Baseline in Triglycerides (TG) After 6 Weeks of Treatment,Merck Sharp & Dohme Corp.,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 3,406,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0653C-185,Sep-11,Apr-12,Apr-12,10-Jun-11,5-Aug-13,2-Feb-15,,,https://ClinicalTrials.gov/show/NCT01370590
NCT01370603,A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1),,Completed,Has Results,Hypercholesterolemia,Drug: Atorvastatin|Drug: Ezetimibe|Drug: Ezetimibe/atorvastatin|Drug: Placebo to atorvastatin|Drug: Placebo to ezetimibe|Drug: Placebo to ezetimibe/atorvastatin,Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After 6 Weeks of Treatment|Percent Change From Baseline in Total Cholesterol (TC) After 6 Weeks of Treatment|Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) After 6 Weeks of Treatment|Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) After 6 Weeks of Treatment|Percent Change From Baseline in Apolipoprotein (Apo) B After 6 Weeks of Treatment|Percent Change From Baseline in Triglycerides (TG) After 6 Weeks of Treatment,Merck Sharp & Dohme Corp.,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 3,328,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0653C-190,Sep-11,May-12,May-12,10-Jun-11,10-Jul-13,2-Feb-15,,,https://ClinicalTrials.gov/show/NCT01370603
NCT01364961,Resveratrol and Serum Apo A-I,,Completed,No Results Available,Dyslipidemia,Dietary Supplement: Resveratrol capsules,ApoA-I level|Endothelial function and arterial stiffness|Endothelial function of the retinal microvasculature|Lipid and glucose metabolism during the fasting and postprandial phase|biomarkers for low-grade systemic inflammation and endothelial function,"Maastricht University Medical Center|DSM Nutritional Products, Inc.",All,"45 Years to 70 Years   (Adult, Older Adult)",Not Applicable,50,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",MEC 10-3-054,Jan-11,Dec-12,Aug-13,3-Jun-11,null,13-Nov-13,"Maastricht University Medical Center, Maastricht, Netherlands",,https://ClinicalTrials.gov/show/NCT01364961
NCT01365663,Multiple Ascending Dose Study of SPC4955 in Healthy Subjects,,Completed,No Results Available,Hypercholesterolemia,Drug: SPC4955|Drug: Saline 0.9%,Number of subjects experiencing adverse events|Peak Plasma Concentration (Cmax) of SPC4955|total Cholesterol|Area under the plasma concentration versus time curve (AUC) of SPC4955|LDL|HDL,Santaris Pharma A/S,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,18,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",SPC4955-901|EudraCT 2010-024363-40,May-11,Oct-11,Nov-11,3-Jun-11,null,31-Jan-12,"Nuvisan GmbH, Neu-Ulm, Germany",,https://ClinicalTrials.gov/show/NCT01365663
NCT01363141,Effect of a Low Advanced Glycation End Products (AGE) Diet in the Metabolic Syndrome,,Completed,No Results Available,Metabolic Syndrome,Other: Regular AGE Diet|Other: Low AGE Diet,Change in Blood Glucose and Insulin levels in 1 year as compared to baseline|Change in abdominal obesity in 1 year as compared to baseline|Change in markers of cardiovascular disease in 1 year as compared to baseline,Icahn School of Medicine at Mount Sinai|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"50 Years and older   (Adult, Older Adult)",Not Applicable,383,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GCO 03-0116-3|2R01DK091231-07A2,Dec-10,Dec-14,Dec-14,1-Jun-11,null,8-May-15,"Icahn School of Medicine at Mount Sinai, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01363141
NCT01360567,The Effect of Green Tea Extract on Type 2 Diabetes With Hyperlipidemia,,Completed,No Results Available,Type 2 Diabetes|Hyperlipidemia,Dietary Supplement: Green tea extract|Dietary Supplement: Placebo,Percent change of HOMA insulin resistance and TG|Percent change of HbA1C and Cholesterol,Taipei City Hospital|National Yang Ming University,All,20 Years to 60 Years   (Adult),Phase 3,102,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",100002-63-020|TCH-971103|TCHIRB-971103,May-11,Nov-12,Dec-12,25-May-11,null,30-Apr-13,"Chung-Hua Hsu, Taipei, Taiwan|Taipei City Hospital, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT01360567
NCT01356420,Sterol and Isoprenoid Disease Research Consortium: Smith-Lemli-Opitz Syndrome,STAIR-SLOS,Unknown status,No Results Available,Smith-Lemli-Opitz Syndrome,Dietary Supplement: Cholesterol supplementation,To define the rate of progression of clinical and biochemical measures in patients with Smith Lemli-Opitz syndrome receiving dietary cholesterol supplementation.|Correlate biochemical and clinical phenotypes|Identify clinical or biochemical markers for future therapeutic trials.|Identify a biochemical marker that can be used for diagnostic testing or screening.|Develop a registry and repository of biomaterials of SLOS patients,Oregon Health and Science University,All,"up to 85 Years   (Child, Adult, Older Adult)",Not Applicable,100,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STAIR 7001,Jan-11,Jan-16,null,19-May-11,null,20-Sep-12,"Pdgen, Nichd, Nih, Dhhs, Bethesda, Maryland, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Cincinnati Children'S Hospital Medical Center, Cincinnati, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Children'S Hospital of Pittsburgh of Upmc, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01356420
NCT01353820,Effects of Lactobacillus Delbruckii Lactis DN111244 Fermented Milk Consumption on Plasma Lipids Levels in Hypercholesterolaemic Adults,,Completed,No Results Available,Hypercholesterolemia,Dietary Supplement: 1- Low fat drinkable fermented by Lactobacillus Delbruckii lactis (DN111244) - >10E8 <5.10E9 cfu/mL|Dietary Supplement: 2- Low fat drinkable fermented by S. thermophilus and L. bulgaricus,,Danone Research,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,100,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",NU280,Sep-08,Dec-08,Mar-09,16-May-11,null,27-Oct-16,"AMED s.r.o (Poliklinika Budějovická), Praha, Czech Republic",,https://ClinicalTrials.gov/show/NCT01353820
NCT01354327,Effects of Limicol on LDL-cholesterol,,Completed,No Results Available,Hypercholesteremia,Dietary Supplement: Limicol|Dietary Supplement: Placebo,"Change from Baseline in blood LDL-cholesterol levels at 4 months|Change from Baseline in blood Vit. C, Vit. E, polyphenols and MDA levels at 4 months",Lescuyer Laboratory|CIC Hôpital de la Conception - Marseille|Aix Marseille Université,All,18 Years to 55 Years   (Adult),Not Applicable,47,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2008-A01169-46,Dec-08,May-11,May-11,16-May-11,null,16-May-11,"Morange, Marseille, France",,https://ClinicalTrials.gov/show/NCT01354327
NCT01354340,Dose Effect of Limicol on (LDL)-Cholesterol Levels,,Completed,No Results Available,Hypercholesterolaemia,Dietary Supplement: Limicol|Other: Placebo,"Change from Baseline in blood LDL-cholesterol levels after 4 weeks of supplementation (limicol double dose group versus placebo group)|Change from Baseline in blood LDL-cholesterol levels after 4 weeks of supplementation (limicol double dose group versus limicol simple dose group)|Change from Baseline in blood total cholesterol, HDL-cholesterol and TAG levels after 4 weeks of supplementation (limicol double dose group versus limicol simple dose group versus placebo group)|Change from Baseline in blood LDL-cholesterol, total cholesterol, HDL-cholesterol and TAG levels 4 weeks after end of supplementation (limicol double dose group versus limicol simple dose group versus placebo group)|Change from Baseline in CK, LDH and other safety biomarkers levels after 4 weeks of supplementation (limicol double dose group versus placebo group versus placebo group)",Lescuyer Laboratory|BioFortis,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,45,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2011-A00145-36,Apr-11,Dec-11,Jan-12,16-May-11,null,19-Apr-12,"Biofortis, Nantes, France",,https://ClinicalTrials.gov/show/NCT01354340
NCT01353404,Relative Bioavailability Study of Lipidil® Supra (Fenofibrate 160mg) Versus SYO-0805 (Fenofibrate 65mg),,Completed,No Results Available,Hyperlipidemia,Drug: Sequence 1|Drug: Sequence 2|Drug: Seqeunce 3|Drug: Sequence 4|Drug: Sequence 5|Drug: Sequence 6,Bioequivalence of Lipidil® Supra (fenofibrate 160mg) versus SYO-0805 (fenofibrate 65mg),Samyang Biopharmaceuticals Corporation,Male,20 Years to 50 Years   (Adult),Phase 1,24,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SYO0805,Jun-11,Aug-11,Aug-11,13-May-11,null,18-Dec-12,"Clinical Research Institute, Seoul National University Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01353404
NCT01351753,Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity,REVIVE,Suspended,No Results Available,Obesity|Metabolic Syndrome X,Drug: Metformin|Drug: Orlistat|Drug: Topiramate|Drug: Placebo,"Weight (change from baseline)|Brachial artery flow mediated dilatation (change from baseline)|Number of subjects with mild, moderate and serious adverse events.|Systolic and diastolic systemic arterial pressure (change from baseline)|Fasting lipids, glucose and other biomarkers of obesity risk (change from baseline)|Mood, anxiety, quality of life and cognitive function (change from baseline)|Body fat distribution (change from baseline)|Pulse wave velocity (PWV) and aortic augmentation pressure (change from baseline)|Peripheral arteriolar tonometry",University of Iowa,All,"40 Years to 75 Years   (Adult, Older Adult)",Phase 2,150,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",201012738,Mar-11,Oct-19,Oct-19,11-May-11,null,28-Aug-18,"University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States",,https://ClinicalTrials.gov/show/NCT01351753
NCT01350843,The Effects of Orange Juice on Plasma Lipids,,Completed,No Results Available,Insulin Resistance|Obesity|Dyslipidemia,Dietary Supplement: Orange Juice,Total Serum Cholesterol concentration|High Density Cholesterol (HDL)|Low density cholesterol|Gene expression in adipose tissue|leptin|IL-1|Blood Pressure|Ghrelin|GLP-1|insulin|IL-6|TNF alpha,University of Nottingham|Florida Department of Citrus,Male,40 Years to 60 Years   (Adult),Not Applicable,36,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,RIS 100058b,May-11,Dec-12,Feb-13,10-May-11,null,27-Mar-18,"David Greenfield Human Physiology Unit, University of Nottingham, Nottingham, Notts, United Kingdom",,https://ClinicalTrials.gov/show/NCT01350843
NCT01350960,Multiple Ascending Dose Study of SPC5001 in Treatment of Healthy Subjects and Subjects With FH,,Terminated,No Results Available,Hypercholesterolemia,Drug: SPC5001|Drug: Saline 0.9%,Safety and Tolerability|Peak Plasma Concentration (Cmax) of SPC5001|Lipid lowering effect|Area under the plasma concentration versus time curve (AUC) of SPC5001,Santaris Pharma A/S,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,24,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",SPC5001-901|EudraCT 2011-000489-36,May-11,Oct-11,Nov-11,10-May-11,null,22-Nov-11,"Centre for Huma Drug Research (CHDR), Leiden, Netherlands",,https://ClinicalTrials.gov/show/NCT01350960
NCT01350973,Efficacy of TAK-085 in Participants With Hypertriglyceridemia,,Completed,Has Results,Hypertriglyceridemia,Drug: Omega-3-acid ethyl esters 90 (TAK-085)|Drug: Eicosapentaenoic acid-ethyl (EPA-E),"Percent Change From Baseline in Triglyceride Level at the Final Visit|Percent Change From Baseline in Triglyceride Level Over Time|Percent Change From Baseline in Low-Density Lipoprotein - Cholesterol (LDL-C) Level Over Time|Percent Change From Baseline in Total Cholesterol Over Time|Percent Change From Baseline in High-Density Lipoprotein - Cholesterol (HDL-C) Level Over Time|Percent Change From Baseline in Non-High-Density Lipoprotein - Cholesterol Level Over Time|Number of Participants With Treatment Emergent Adverse Events (TEAEs)|Number of Participants With TEAEs Associated With Abnormal Changes in Vital Signs|Number of Participants With TEAEs Categorized Into Investigations System Organ Class (SOC) Related to Chemistry, Hematology or Urinalysis|Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings After Study Drug Administration",Takeda,All,"20 Years to 74 Years   (Adult, Older Adult)",Phase 3,611,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TAK-085/CCT-002|JapicCTI-090937|U1111-1120-7801|JapicCTI-R140452,Nov-09,Dec-10,Dec-10,10-May-11,20-Sep-16,20-Sep-16,,,https://ClinicalTrials.gov/show/NCT01350973
NCT01350999,Long-term Efficacy and Safety Study of TAK-085 in Participants With Hypertriglyceridemia,,Completed,Has Results,Hypertriglyceridemia,Drug: omega-3-acid ethyl esters 90 (TAK-085)|Drug: Eicosapentaenoic acid-ethyl (EPA),"Number of Participants With Treatment Emergent Adverse Events (TEAEs)|Number of Participants With TEAEs Associated With Abnormal Changes in Vital Signs|Number of Participants With TEAEs Associated With Abnormal Changes in Body Weight|Number of Participants With Clinically Significant Findings in Electrocardiogram After Study Drug Administration|Number of Participants With TEAEs Categorized Into Investigations System Organ Class (SOC) Related to Chemistry, Hematology or Urinalysis|Percent Change From Baseline in Triglyceride Level|Percent Change From Baseline in Low-Density Lipoprotein - Cholesterol (LDL-C)|Percent Change From Baseline in Total Cholesterol|Percent Change From Baseline in High-Density Lipoprotein - Cholesterol (HDL-C)|Percent Change From Baseline in Non-High-Density Lipoprotein - Cholesterol",Takeda,All,"20 Years to 74 Years   (Adult, Older Adult)",Phase 3,503,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TAK-085/OCT-001|JapicCTI-090936|U1111-1120-7892|JapicCTI-R140451,Nov-09,Jan-11,Jan-11,10-May-11,20-Sep-16,20-Sep-16,,,https://ClinicalTrials.gov/show/NCT01350999
NCT01350141,A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins,,Completed,Has Results,Hypercholesterolemia|Dyslipidemia,Other: Placebo|Drug: PF-04950615 (RN316),"Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Day 85|Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than 70 and Less Than 100 Milligram Per Deciliter (mg/dL)|Percentage of Participants Achieving at Least 30 Percent Decrease in Low-density Lipoprotein Cholesterol (LDL-C)|Change From Baseline in Lipid Parameters at Day 29, 57 and 85|Percent Change From Baseline in Lipid Parameters at Day 29, 57 and 85|Number of Participants With Treatment-Emergent Adverse Events (TEAEs)|Number of Treatment-Emergent Adverse Events (TEAEs) by Severity|Number of Participants With Clinically Significant Laboratory Abnormalities|Number of Participants With Clinically Significant Changes in Vital Signs and Electrocardiogram (ECG) Parameters|Number of Participants With Anti-drug (Anti-PF-04950615) Antibody (ADA)",Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 2,46,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",B1481012,Jun-11,Apr-12,Jun-12,9-May-11,8-Nov-17,8-Nov-17,"Achieve Clinical Research, LLC, Birmingham, Alabama, United States|Advance Outcome Management, Inc., Garden Grove, California, United States|Collaborative Neuroscience Network, Inc, Garden Grove, California, United States|Collaborative Neuroscience Network, Inc., Long Beach, California, United States|Elite Clinical Trials, Inc., Wildomar, California, United States|Innovative Research of West Florida, Inc., Clearwater, Florida, United States|Avail Clinical Research, LLC, DeLand, Florida, United States|Kendall South Medical Center, Inc., Miami, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Midwest Cardiology Associates, Overland Park, Kansas, United States|Stark Pharmacy, Overland Park, Kansas, United States|Vince and Associates Clinical Research, Overland Park, Kansas, United States|Saint Luke's Hospital, Kansas City, Missouri, United States|Saint Luke's Lipid and Diabetes Research Center, Kansas City, Missouri, United States|Advance Clinical Research, Saint Louis, Missouri, United States|Wake Internal Medicine Consultants, Inc., Raleigh, North Carolina, United States|Wake Research Associates, LLC, Raleigh, North Carolina, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Oklahoma Cardiovascular Research Group, Oklahoma City, Oklahoma, United States|Oklahoma Heart Hospital Physicians, Oklahoma City, Oklahoma, United States|Oklahoma Heart Hospital, Oklahoma City, Oklahoma, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|DeGarmo Institute of Medical Research, Greer, South Carolina, United States|Holston Medical Group, Kingsport, Tennessee, United States|Texas Center for Drug Development, Inc, Houston, Texas, United States|Martin Diagnostic Clinic, Tomball, Texas, United States|Aspen Clinical Research, LLC, Orem, Utah, United States|National Clinical Research - Richmond, Inc., Richmond, Virginia, United States|The Medical Arts Health Research Group, Kelowna, British Columbia, Canada|Q & T Research Chicoutimi, Chicoutimi, Quebec, Canada|Centre de Recherche Clinique de Laval, Laval, Quebec, Canada|Diex Research Montreal Inc., Montreal, Quebec, Canada|Diex Research Sherbrooke Inc., Sherbrooke, Quebec, Canada|Clinique des Maladies Lipidiques de Quebec Inc., Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01350141
NCT01349010,Efficacy and Safety of Imported Probucol to Treat Hyperlipidemia,,Completed,No Results Available,Hyperlipidemia,Drug: Probucol|Drug: Placebo,TC and LDL-C|oxLDL and MCP-1,Otsuka Beijing Research Institute,All,"20 Years and older   (Adult, Older Adult)",Phase 3,264,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",009-10-802-01,Apr-11,Jul-12,Feb-13,6-May-11,null,5-Jun-13,"The Sencond Xiangya Hospital of Central South University, Changsha, Hunan, China",,https://ClinicalTrials.gov/show/NCT01349010
NCT01342211,A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins,,Completed,Has Results,Hypercholesterolemia|Dyslipidemia,Biological: Placebo|Drug: Statin|Biological: PF-04950615 (RN316)|Drug: Satin,"Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Day 85|Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 70 and <100 Milligram Per Deciliter (mg/dL)|Percentage of Participants Achieving at Least 30 Percent Decrease in Low-density Lipoprotein Cholesterol (LDL-C)|Change From Baseline in Lipid Parameters at Day 29, 57 and 85|Percent Change From Baseline in Lipid Parameters at Day 29, 57 and 85|Number of Participants With Treatment-Emergent Adverse Events (TEAEs)|Number of Treatment-Emergent Adverse Events (TEAEs) by Severity|Number of Participants With Clinically Relevant Laboratory Abnormalities|Number of Participants With Clinically Significant Changes in Vital Signs and Electrocardiogram (ECG) Parameters|Number of Participants With Anti-drug Antibody (ADA)",Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 2,93,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",B1481005,Jul-11,Feb-12,Jun-12,27-Apr-11,11-Oct-17,11-Oct-17,"Orange County Research Center, Tustin, California, United States|Diablo Clinical Research, Inc., Walnut Creek, California, United States|Innovative Research of West Florida, Inc., Clearwater, Florida, United States|Avail Clinical Research, LLC, DeLand, Florida, United States|In Vivo Clinical Research, Inc., Doral, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Kendall South Medical Center, Miami, Florida, United States|North Georgia Clinical Research, Woodstock, Georgia, United States|North Georgia Internal Medicine, Woodstock, Georgia, United States|Vince and Associates Clinical Research, Overland Park, Kansas, United States|Heartland Research Associates, LLC, Wichita, Kansas, United States|L-MARC Research Center, Louisville, Kentucky, United States|Commonwealth Biomedical Research, LLC, Madisonville, Kentucky, United States|Maine Research Associates, Auburn, Maine, United States|Infinity Medical Research, North Dartmouth, Massachusetts, United States|Saint Luke's Hospital, Kansas City, Missouri, United States|Saint Luke's Lipid and Diabetes Research Center, Kansas City, Missouri, United States|The Center for Pharmaceutical Research, P.C., Kansas City, Missouri, United States|Medex Healthcare Research, Inc., Saint Louis, Missouri, United States|New Mexico Clinical Research & Osteoporosis Center, Incorporated, Albuquerque, New Mexico, United States|North Carolina Clinical Research, Raleigh, North Carolina, United States|PMG Research of Salisbury, Salisbury, North Carolina, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Oklahoma Cardiovascular Research Group (OCRG), Oklahoma City, Oklahoma, United States|Oklahoma Heart Hospital Physicians, Oklahoma City, Oklahoma, United States|Oklahoma Heart Hospital, Oklahoma City, Oklahoma, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States|Translational Research Center, Philadelphia, Pennsylvania, United States|Spartanburg Medical Research, Spartanburg, South Carolina, United States|New Orleans Center for Clinical Research, Knoxville, Tennessee, United States|Volunteer Research Group, Knoxville, Tennessee, United States|Texas Center for Drug Development, Inc., Houston, Texas, United States|Paragon Research Center, LLC, San Antonio, Texas, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|San Antonio Preventive & Diagnostic Medicine, PA, San Antonio, Texas, United States|National Clinical Research - Norfolk, Inc., Norfolk, Virginia, United States|National Clinical Research - Richmond, Inc., Richmond, Virginia, United States|The Medical Arts Health Research Group, Kelowna, British Columbia, Canada|Q & T Research Chicoutimi, Chicoutimi, Quebec, Canada|Centre de Recherche Clinique de Laval, Laval, Quebec, Canada|Diex Research Montreal Inc., Montreal, Quebec, Canada|Diex Research Sherbrooke Inc., Sherbrooke, Quebec, Canada|Clinique des Maladies Lipidiques de Quebec Inc., Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01342211
NCT01342666,Tomato Consumption and High Density Lipoprotein-cholesterol,,Completed,Has Results,Hypoalphalipoproteinemia,Dietary Supplement: Tomato consumption|Dietary Supplement: Cucumber consumption,High Density Lipoprotein Cholesterol (HDL-c),Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|Instituto Nacional de Cardiologia Ignacio Chavez,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,REF2039,Mar-09,Apr-11,Dec-11,27-Apr-11,12-Feb-13,28-Feb-13,"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, Tlalpan, Mexico",,https://ClinicalTrials.gov/show/NCT01342666
NCT01341613,Efficacy of Cardioviva™ Probiotic Supplement Capsule Formulation,,Completed,No Results Available,Hypercholesterolemia,Dietary Supplement: Cardioviva™ supplement capsule|Dietary Supplement: Placebo capsule,The primary outcome will be the percent difference in LDL-cholesterol from baseline to endpoint comparing subjects receiving treatment and placebo,Micropharma Limited,All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 2,131,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MP-0110,May-11,Oct-11,Oct-11,26-Apr-11,null,2-Nov-11,"APharma s.r.o., Prague, Czech Republic",,https://ClinicalTrials.gov/show/NCT01341613
NCT01340287,Effect of the Consumption of a Fermented Milk Enriched With Plant Sterols,,Completed,No Results Available,Hypercholesterolemia,"Dietary Supplement: 1- plain low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).|Dietary Supplement: 2- plain low-fat dairy fermented product (drinkable) without plant sterols-esters",,Danone Research,All,"21 Years to 75 Years   (Adult, Older Adult)",Not Applicable,168,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",NU281,Jul-08,May-09,Aug-09,22-Apr-11,null,27-Oct-16,"Renstar Medical Research, Ocala, Florida, United States",,https://ClinicalTrials.gov/show/NCT01340287
NCT01335997,Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143),,Terminated,Has Results,Primary Hypercholesterolemia|Mixed Dyslipidemia,Drug: ER niacin/laropiprant (ERN/LRPT)|Drug: ER niacin/laropiprant/simvastatin (ERN/LRPT/SIM)|Drug: Simvastatin (SIM)|Drug: Placebo Run-In|Drug: SIM-matching placebo,Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) Blood Levels|Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) Blood Levels,Merck Sharp & Dohme Corp.,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 3,1139,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",0524B-143|2011-001007-12,1-May-11,1-Jan-12,1-Jan-12,15-Apr-11,21-Jun-16,6-Feb-19,,,https://ClinicalTrials.gov/show/NCT01335997
NCT01333436,A Study to Evaluate Fasting/Postprandial Serum Apolipoprotein B-48 (ApoB-48) Levels in Diabetic Participants With Normal to Moderately High Low Density Lipoprotein-C (LDL-C) Levels (MK-0653A-259 AM1),,Completed,Has Results,Dyslipidemia|Hypercholesterolemia,Other: Test Meal,Postprandial Incremental Area Under the Curve From 0-6 Hours (iAUC)[0-6] of Apolipoprotein B-48 (ApoB-48)|Postprandial Mean ApoB-48 Peak Levels|Fasting ApoB-48 Levels,Merck Sharp & Dohme Corp.,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,93,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,0653A-259,20-Jul-11,12-May-12,12-May-12,12-Apr-11,9-Apr-13,5-May-17,"MSD Korea Ltd., Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01333436
NCT01332747,Clinical Study to Evaluate Antihyperlipidemic Effect of a Classical Unani Antiobesity Formulation,,Completed,No Results Available,Hyperlipidemia,Drug: safoof e muhazzil|Drug: compressed tablet of safoof e muhazzil|Drug: Atorvastatin,Total Cholesterol (TC)|Low density Lipoprotein (LDL)|Triglycerides (TG)|High Density Lipoprotein (HDL)|Very Low Density Lipoprotein (VLDL)|Waist to Hip ratio|Body Mass Index,Jamia Hamdard University,All,"20 Years to 70 Years   (Adult, Older Adult)",Phase 2,128,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MD/SM/2008-11,May-10,May-11,May-11,11-Apr-11,null,21-Oct-14,"Majeedia Hospital, New Delhi, Delhi, India",,https://ClinicalTrials.gov/show/NCT01332747
NCT01327014,Efficacy and Safety Study of Lipid-Lowering Effects of XueZhiKang (XZK) in Patients With Hyperlipidemia,,Completed,No Results Available,Hyperlipidemia,"Drug: XueZhiKang (XZK), a botanic product with multiple components|Drug: Placebo","Mean percentage change from baseline at week 12 (or the last assessment) on serum low-density lipoprotein cholesterol (LDL-C) level.|Mean percentage change from baseline at week 12 (or the last assessment on serum total cholesterol (TC) level.|Mean percentage change from baseline at week 12 (or the last assessment) on serum high-density lipoprotein cholesterol (HDL-C) level|Mean percentage change from baseline at week 12 (or the last assessment) on serum triglyceride (TG) level.|Mean percentage change from baseline at week 12 (or the last assessment) on serum non-HDL cholesterol level.|Mean percentage change from baseline at week 12 (or the last assessment) on serum apolipoprotein A-I (Apo A-I) and serum apolipoprotein-B (Apo-B) and the Apo-B/Apo A-I ratio.|Mean percentage change from baseline at week 12 (or the last assessment) on the serum TC/HDL-C ratio.|Percentage of patients who show a LDL-C level of <130 mg/dl or <100 mg/dl at end of the study.|Safety will be assessed by the incidence of adverse events (AEs), discontinuation due to the AEs, clinically relevant changes on laboratory test results, vital signs, physical examinations, and 12-lead electrocardiograms (ECG).","Beijing Peking University WBL Biotech Co., Ltd.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,116,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",WPU-201,Apr-11,Dec-12,Dec-12,1-Apr-11,null,23-Jul-14,"Robert Karns, MD A Medical Corporation, Beverly Hills, California, United States|Jellinger and Lerman, MD, Hollywood, Florida, United States|Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas, United States|Harold E Bays, MD, Louisville, Kentucky, United States|Eli M Roth, MD, Cincinnati, Ohio, United States|Cardiovascular Medical Associates, Philadelphia, Pennsylvania, United States|Osvaldo Brusco, MD, Corpus Christi, Texas, United States|Clinical Trial Network, Houston, Texas, United States|Chinese PLA General Hospital, Beijing, Beijing, China|Wuhan Union Hospital, Wuhan, Hubei, China|Second Xiangya Hospital of Central-South Univ, Changsha, Hunan, China|Shanghai Ruijin Hospital, Shanghai, Shanghai, China|Shanghai First People's Hospital, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT01327014
NCT01325818,The Effects of Pravastatin and Rosuvastatin on Coronary Plaques in Patients With Stable Angina Pectoris,,Unknown status,No Results Available,Coronary Disease|Hypercholesterolemia,"Drug: pravastatin, rosuvastatin","the percent change in fibrous cap thickness by optical coherence tomography|the percent change and the absolute change from baseline in coronary plaque volume and IB signal obtained by IB-IVUS|the absolute change from baseline in number of TCFA and plaque rupture, and in neointima thickness on stent struts by OCT|the percent change and the absolute change from baseline in total cholesterol and LDL cholesterol",Yokohama City University Medical Center,All,"20 Years and older   (Adult, Older Adult)",Phase 4,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,YCUMC20110324,Mar-11,Mar-11,Feb-16,30-Mar-11,null,1-Apr-11,"Yokohama City University Medical Center, Yokohama, Japan",,https://ClinicalTrials.gov/show/NCT01325818
NCT01326442,Vitamin D and Omega-3 Inhibit Metabolic Syndrome,,Completed,No Results Available,Type 2 Diabetes Mellitus|Hypertension|Hyperlipidemia|Obesity,Other: low glycemic diet|Dietary Supplement: vitamin D omega-3,body weight|Blood pressure|Blood lipids|Glucose homeostasis,University of Guelph,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2011MeckVitD,Apr-11,Dec-12,Dec-12,30-Mar-11,null,13-Jun-13,"University of Guelph, Guelph, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01326442
NCT01322711,"Atorvastatin, Aspirin, Oxidative Stress, Coagulation and Platelet Activation Indexes",,Unknown status,No Results Available,Type 2 Diabetes Mellitus|Hypercholesterolemia,Drug: Atorvastatin|Drug: Placebo,Evaluation of effect of Atorvastatin Therapy in Hypercholesterolemic Patients (n=30) and Diabetic Patients (n=30),University of Roma La Sapienza,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ATORVASA,Mar-11,Oct-15,Dec-15,25-Mar-11,null,28-May-15,"Stefania Basili, Rome, Italy",,https://ClinicalTrials.gov/show/NCT01322711
NCT01321034,Effect of Niacin in the Lipoprotein (a) Concentration,,Completed,No Results Available,Hypercholesterolemia,Drug: Niacin/Laropiprant,"absolute and relative Lp(a) lowering effect of 1g/20 mg and 2 g/40 mg day of Niacin/Laropiprant in subjects with normal Lp(a) (<30 mg/dL), high Lp(a) (30-60 mg/dL) and very high Lp(a) (>60 mg/dL g/40 mg day of Niacin/Laropiprant|absolute and relative Lp(a) lowering effect of 1g/20 mg and 2 g/40 mg day of Niacin/Laropiprant depending on the number of kringle IV-2 repeated copies on the apo(a) gene.",Instituto Aragones de Ciencias de la Salud|Hospital Miguel Servet,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,90,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EudraCT 2010-022258-17,Oct-11,Aug-12,Dec-12,23-Mar-11,null,10-Jan-13,"Hospital San Jorge, Huesca, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Hospital Royo Villanova, Zaragoza, Spain",,https://ClinicalTrials.gov/show/NCT01321034
NCT01317290,Supplementation of Alpha-linolenic Acid (ALA)-Rich Oil in Humans,ALA_KK,Completed,No Results Available,Overweight|Hypercholesterolemia,Dietary Supplement: n-3 PUFA free olive oil|Dietary Supplement: linseed oil,n-3 LC-PUFA in human lipids (EPA)|eicosanoid concentration in plasma,University of Jena|German Research Foundation,All,"20 Years to 70 Years   (Adult, Older Adult)",Early Phase 1,78,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",H50-11-KK,Feb-12,Sep-12,May-13,17-Mar-11,null,13-Nov-13,"Friedrich Schiller University of Jena, Jena, Thuringia, Germany",,https://ClinicalTrials.gov/show/NCT01317290
NCT01317524,The Effects of Homogenized and Unhomogenized Milk on Postprandial Metabolism in Healthy Overweight Men,,Completed,No Results Available,Hyperlipidemias|Inflammation|Atherosclerosis,Dietary Supplement: Homogenized milk|Dietary Supplement: Unhomogenized milk|Dietary Supplement: Skimmed Milk,Incremental Area Under the triacylglycerol Curve|Plasma inflammatory markers|Markers of endothelial activation,Maastricht University Medical Center|Dutch Dairy Association (NZO),Male,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,18,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention,MEC 10-3-089,Feb-11,Jun-11,Jun-11,17-Mar-11,null,1-Dec-11,"Maastricht University Medical Center, Maastricht, Limburg, Netherlands",,https://ClinicalTrials.gov/show/NCT01317524
NCT01313988,Efficacy Study on the Lipid-lowering Effect of Plant Sterols and Fish Oil,,Completed,No Results Available,Healthy|Mildly Elevated Cholesterol Levels,Dietary Supplement: Plant sterols and fish oil|Dietary Supplement: Plant sterols|Dietary Supplement: Placebo,Change in blood lipid profile|Change in EPA/DHA in red blood cells|Change in metabolomic parameters,Unilever R&D,All,"25 Years to 75 Years   (Adult, Older Adult)",Not Applicable,332,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",10018V,Jan-11,Jan-12,Jan-12,14-Mar-11,null,7-Feb-12,"KPL Good Food Practice AB, Uppsala, Sweden",,https://ClinicalTrials.gov/show/NCT01313988
NCT01314586,Flax Lignans and Heart Health,ISULignan,Completed,No Results Available,Hypercholesterolemia,Dietary Supplement: secoisolariciresinol diglucoside-containing extract of flaxseed,Change in serum total cholesterol from baseline to 12 weeks after intervention treatments|Change in serum glucose from baseline to 12 weeks after intervention treatments|Change in blood pressure from baseline to end of treatment|Changes in serum clinical chemistry from baseline to end of treatment,Iowa State University|Archer Daniels Midland Co.,All,"40 Years to 65 Years   (Adult, Older Adult)",Not Applicable,93,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",ADM Beneflax ISU-1,Dec-07,Jul-09,Nov-09,14-Mar-11,null,14-Mar-11,"Nutrition & Wellness Research Center, Ames, Iowa, United States",,https://ClinicalTrials.gov/show/NCT01314586
NCT01308203,Lipid Efficacy of the Extended Release Niacin/Laropiprant Combination in Patients With Cardiovascular Disease,,Terminated,No Results Available,Coronary Artery Disease|Dyslipidemias,Drug: Extended release niacin/laropiprant|Drug: placebo,"Nominal change from baseline in low density lipoprotein- cholesterol (LDL-C) at 12 weeks of treatment with the extended release niacin /laropiprant combination added to usual therapy.|Efficacy on other lipid variables: high density lipoprotein-cholesterol (HDL-C), triglycerides, total cholesterol (TC), TC/HDL-C ratio, apolipoprotein B (ApoB), apolipoprotein A1 (ApoA), ApoB/ApoA ratio and lipoprotein (a) [Lp(a)].",Daniel A. Siniawski|Merck Sharp & Dohme Corp.|Hospital Italiano de Buenos Aires,All,"21 Years to 75 Years   (Adult, Older Adult)",Phase 4,32,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",1608,Oct-11,Jan-13,Jan-13,4-Mar-11,null,19-Aug-15,"Hospital Italiano de Buenos Aires, Buenos Aires, Argentina",,https://ClinicalTrials.gov/show/NCT01308203
NCT01308710,The Effects of a Mediterranean Diet in Pediatric Hyperlipidemia,EARLYMedit,Completed,No Results Available,Hyperlipidemia,Dietary Supplement: Omega-3 fatty acid (Eicosapentaenoic acid),Endothelial function,"University of California, San Francisco|Vanderbilt University|Tufts University|University of Guelph|University of L'Aquila",All,8 Years to 17 Years   (Child),Phase 1,10,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",R56NR004909,Jan-10,Jul-11,Jul-11,4-Mar-11,null,27-Jan-14,"University of California, San Francisco, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT01308710
NCT01308866,Effectiveness of a Shared Decision Aid Tool for Cardiovascular Risk Prevention in Hypercholesterolemic Patients,PLEGATS,Completed,No Results Available,Hypercholesterolemia|Cardiovascular Risk,Behavioral: Share decision tool,Cardiovascular risk reduction|Life self-perceived quality|Anxiety and depression|Decision empowerment,Jordi Gol i Gurina Foundation|Preventive Services and Health Promotion Research Network,All,"14 Years to 75 Years   (Child, Adult, Older Adult)",Not Applicable,298,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,PLEGATS,Jul-07,Sep-10,Mar-11,4-Mar-11,null,4-Mar-11,"Capse-Gesclínic, Barcelona, Spain|Cap El Castell, Castelldefels, Spain",,https://ClinicalTrials.gov/show/NCT01308866
NCT01304992,Cholesterol-lowering Effects of Lupin Protein,,Completed,No Results Available,Hypercholesterolemia,Dietary Supplement: Protein drink - low dosage|Dietary Supplement: Protein drink - high dosage,Cholesterol metabolism|Protein metabolism|Body composition (body status)|High-sensitive CRP|Fasting glucose,University of Jena|German Federal Ministry of Education and Research,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,66,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",LSEP H48-11,Feb-11,Aug-11,Nov-11,28-Feb-11,null,27-Nov-12,"Friedrich Schiller University Jena, Department of Nutritional Physiology, Jena, Thuringia, Germany",,https://ClinicalTrials.gov/show/NCT01304992
NCT01301066,A 12-Week Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects,,Completed,Has Results,Dyslipidemia,Drug: Pitavastatin|Drug: Pravastatin,Change of Fasting Serum Low-density Lipoprotein Cholesterol (LDL-C) at 12 Weeks,"Kowa Research Institute, Inc.|Kowa Pharmaceuticals America, Inc.|Eli Lilly and Company",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,252,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NK-104-4.05US,Dec-10,Mar-13,Mar-13,23-Feb-11,29-Apr-14,29-Apr-14,"Phoenix, Arizona, United States|Beverly Hills, California, United States|Costa Mesa, California, United States|Long Beach, California, United States|Los Angeles, California, United States|Newport Beach, California, United States|San Francisco, California, United States|Washington, District of Columbia, United States|Coral Gables, Florida, United States|Fort Lauderdale, Florida, United States|Fort Pierce, Florida, United States|Miami Beach, Florida, United States|Miami, Florida, United States|Tampa, Florida, United States|Vero Beach, Florida, United States|Atlanta, Georgia, United States|Decatur, Georgia, United States|Springfield, Massachusetts, United States|Berkley, Michigan, United States|St. Louis, Missouri, United States|Hillsborough, New Jersey, United States|Randolph, New Jersey, United States|New York, New York, United States|Rochester, New York, United States|Huntersville, North Carolina, United States|Addison, Texas, United States|Austin, Texas, United States|Corpus Christi, Texas, United States|Fort Worth, Texas, United States|Harlingen, Texas, United States|Houston, Texas, United States|Longview, Texas, United States|Annandale, Virginia, United States|Seattle, Washington, United States|Spokane, Washington, United States",,https://ClinicalTrials.gov/show/NCT01301066
NCT01301794,Lovaza Mechanisms of Action,,Unknown status,No Results Available,Moderate Hypertriglyceridemia.,Dietary Supplement: Omega 3 fatty acid (Lovaza),Changes in lipoprotein metabolite content and their ability to activate PPAR-alpha in an established cell culture system.|Changes in plasma markers for atherosclerosis|Change in plasma markers of diabetes|Changes in plasma markers of liver function,Brigham and Women's Hospital|GlaxoSmithKline,All,"21 Years to 65 Years   (Adult, Older Adult)",Phase 4,40,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,BWHp001640,Aug-12,Aug-13,Aug-14,23-Feb-11,null,25-Feb-13,"Brigham and Women's Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01301794
NCT01294683,A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118),,Terminated,Has Results,Primary Hypercholesterolemia|Dyslipidemia,Drug: Simvastatin|Drug: Extended Release (ER) niacin/laropiprant/simvastatin (N/LRPT/SIM)|Drug: Extended Release (ER) niacin/laropiprant (N/LRPT)|Drug: Placebo,Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)|Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C)|Percentage of Participants With Consecutive Elevations in Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) of >=3 x Upper Limit of Normal (ULN)|Percentage of Participants With Elevations in ALT and/or AST of >=5 x ULN|Percentage of Participants With Elevations in ALT and/or AST of >=10 x ULN|Percentage of Participants With Creatine Kinase (CK) >=10 x ULN|Percentage of Participants With CK >=10 x ULN With Muscle Symptoms - Drug Related|Percentage of Participants Who Experienced at Least 1 Hepatitis-related Adverse Event (AE)|Percentage of Participants With New Onset of Diabetes|Percentage of Participants With a Confirmed Adjudicated Cardiovascular Event|Percentage of Participants Who Experienced at Least 1 AE|Percentage of Participants Who Were Discontinued From the Study Due to an AE,Merck Sharp & Dohme Corp.,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 3,977,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0524B-118|2010-023939-42,4-Feb-11,17-Jan-12,17-Jan-12,11-Feb-11,13-Dec-16,16-Aug-18,,,https://ClinicalTrials.gov/show/NCT01294683
NCT01291641,Investigate Effect on Mean IMT of Probucol And/or CilosTazol in Patients With Coronary Heart dIsease Taking HMGCoA Reductase Inhibitor Therapy,IMPACTonIMT,Completed,No Results Available,Hyperlipidemias,Drug: HMGCoA reductase inhibitor|Drug: HMGCoA reductase inhibitor + probucol|Drug: HMGCA reductase inhibitor + probucol + cilostazol,Difference of Carotid artery IMT (mean IMT) between screening and treatment completion(3 years after) or discontinuation|Time from enrollment date to the onset of composite cerebrovascular events|Number of composite cerebrovascular and cardiovascular events(including intervention)|The change of Biomarkers(1)|The change of Biomarkers(2)|The change of Biomarkers(3),"Seoul National University Hospital|Korea Otsuka Pharmaceutical Co., Ltd.",All,"20 Years and older   (Adult, Older Adult)",Phase 4,342,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,IMT-01,Mar-11,Dec-16,Mar-17,8-Feb-11,null,26-Apr-17,"Dong-A Medical Center, Seogu, Busan, Korea, Republic of|Samsung Medical Center, Seoul, Gangnam-Gu, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Boramae Medical Center, Dongjak-Gu, Seoul, Korea, Republic of|Seoul National University Hospital, Jongno-gu, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01291641
NCT01288443,Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy,,Completed,Has Results,Hypercholesterolemia,Drug: Alirocumab|Drug: Placebo (for alirocumab)|Drug: Atorvastatin,"Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis|Absolute Change From Baseline in Calculated LDL-C (mmol/L) at Week 12 - On-Treatment Analysis|Absolute Change From Baseline in Calculated LDL-C (mg/dL) at Week 12 - On-Treatment Analysis|Percentage of Participants Achieving Calculated LDL-C <100 mg/dL (2.59 mmol/L) and <70 mg/dL (1.81 mmol/L) at Week 12 - On-Treatment Analysis|Percent Change From Baseline in Total Cholesterol, High-density Lipoprotein Cholesterol (HDL-C), Non-HDL-C and Apolipoprotein B (Apo-B) at Week 12 - On-Treatment Analysis|Percent Change From Baseline in Fasting Triglycerides and Lipoprotein(a) at Week 12 - On-Treatment Analysis|Absolute Change in the Ratio Apolipoprotein B/Apolipoprotein A-1 (ApoB/ApoA-1) From Baseline to Week 12 - On-Treatment Analysis",Sanofi|Regeneron Pharmaceuticals,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,183,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DFI11565|U1111-1116-5252,Jan-11,Dec-11,Dec-11,2-Feb-11,24-Sep-15,24-Sep-15,"Investigational Site Number 840525, Tempe, Arizona, United States|Investigational Site Number 840516, Los Angeles, California, United States|Investigational Site Number 840528, Mission Viejo, California, United States|Investigational Site Number 840509, Newport Beach, California, United States|Investigational Site Number 840523, Palm Springs, California, United States|Investigational Site Number 840534, Westlake Village, California, United States|Investigational Site Number 840530, Colorado Springs, Colorado, United States|Investigational Site Number 840504, Aventura, Florida, United States|Investigational Site Number 840519, Aventura, Florida, United States|Investigational Site Number 840514, Jacksonville, Florida, United States|Investigational Site Number 840539, Jupiter, Florida, United States|Investigational Site Number 840502, Miami, Florida, United States|Investigational Site Number 840520, Pembroke Pines, Florida, United States|Investigational Site Number 840524, Ponte Vedra, Florida, United States|Investigational Site Number 840536, Port Orange, Florida, United States|Investigational Site Number 840507, St. Petersburg, Florida, United States|Investigational Site Number 840527, Chicago, Illinois, United States|Investigational Site Number 840506, Evansville, Indiana, United States|Investigational Site Number 840529, Indianapolis, Indiana, United States|Investigational Site Number 840515, Wichita, Kansas, United States|Investigational Site Number 840532, Madisonville, Kentucky, United States|Investigational Site Number 840535, Auburn, Maine, United States|Investigational Site Number 840503, Brockton, Massachusetts, United States|Investigational Site Number 840512, Las Vegas, Nevada, United States|Investigational Site Number 840505, Edison, New Jersey, United States|Investigational Site Number 840538, Rochester, New York, United States|Investigational Site Number 840508, Raleigh, North Carolina, United States|Investigational Site Number 840522, Statesville, North Carolina, United States|Investigational Site Number 840511, Cincinnati, Ohio, United States|Investigational Site Number 840526, Cincinnati, Ohio, United States|Investigational Site Number 840510, Lyndhurst, Ohio, United States|Investigational Site Number 840533, Tulsa, Oklahoma, United States|Investigational Site Number 840537, Eugene, Oregon, United States|Investigational Site Number 840521, Bristol, Tennessee, United States|Investigational Site Number 840531, Bountiful, Utah, United States|Investigational Site Number 840517, Norfolk, Virginia, United States|Investigational Site Number 840518, Richmond, Virginia, United States|Investigational Site Number 840513, Olympia, Washington, United States",,https://ClinicalTrials.gov/show/NCT01288443
NCT01288469,Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia,,Completed,Has Results,Hypercholesterolemia,Drug: Alirocumab|Drug: Placebo (for alirocumab)|Drug: Atorvastatin|Drug: Placebo (for atorvastatin),"Percent Change From Baseline in Calculated LDL-C at Week 8 - On-treatment Analysis|Absolute Change From Baseline in Calculated LDL-C (mmol/L) at Week 8 - On-treatment Analysis|Absolute Change From Baseline in Calculated LDL-C (mg/dL) at Week 8 - On-treatment Analysis|Percentage of Participants Achieving Calculated LDL-C <100 mg/dL (2.59 mmol/L) and < 70 mg/dL (1.81 mmol/L) at Week 8 - On-treatment Analysis|Percent Change From Baseline in Total Cholesterol, Fasting Triglycerides, Non-high-Density Lipoprotein Cholesterol (Non-HDL-C), Apolipoprotein B (Apo-B) and Lipoprotein(a) at Week 8 - On-treatment Analysis|Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Week 8 - On-treatment Analysis|Absolute Change in the Ratio Apolipoprotein B/Apolipoprotein A-1 (ApoB/ApoA-1) From Baseline to Week 8 - On-treatment Analysis",Sanofi|Regeneron Pharmaceuticals,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,92,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DFI11566|U1111-1117-9994,Jan-11,Sep-11,Sep-11,2-Feb-11,24-Sep-15,24-Sep-15,"Investigational Site Number 840616, Mesa, Arizona, United States|Investigational Site Number 840601, Tucson, Arizona, United States|Investigational Site Number 840610, Los Angeles, California, United States|Investigational Site Number 840608, Newport Beach, California, United States|Investigational Site Number 840603, Doral, Florida, United States|Investigational Site Number 840611, Jacksonville, Florida, United States|Investigational Site Number 840618, Jupiter, Florida, United States|Investigational Site Number 840612, Miami, Florida, United States|Investigational Site Number 840614, Miami, Florida, United States|Investigational Site Number 840607, St. Petersburg, Florida, United States|Investigational Site Number 840605, Chicago, Illinois, United States|Investigational Site Number 840619, Chicago, Illinois, United States|Investigational Site Number 840604, Edison, New Jersey, United States|Investigational Site Number 840606, Rochester, New York, United States|Investigational Site Number 840615, Cincinnati, Ohio, United States|Investigational Site Number 840617, Cincinnati, Ohio, United States|Investigational Site Number 840602, Eugene, Oregon, United States|Investigational Site Number 840621, Richmond, Virginia, United States|Investigational Site Number 840609, Olympia, Washington, United States|Investigational Site Number 840613, Oregon, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT01288469
NCT01286311,Tailored Communication to Reduce Cardiovascular Risk,,Completed,Has Results,Hypercholesterolemia|Coronary Artery Disease|Dyslipidemia|Hypertension,Behavioral: Direct-to-patient tailored cardiovascular risk message system,Comparative Outcomes: Intervention Group LDL Reduction Compared to Control Group LDL Reduction|Frequency of Clinical Encounters|Medication Prescriptions for Dyslipidemia|Percentage of Patients With Uncontrolled Hypertension Who Had an Increase in the Number of Antihypertensive Medication Drug Classes Prescribed|Presence of an Aspirin Prescription,Northwestern University|Agency for Healthcare Research and Quality (AHRQ),All,"40 Years to 79 Years   (Adult, Older Adult)",Not Applicable,464,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,Reducing CV Risk|K08HS015647,Jan-11,Jan-13,Jan-13,31-Jan-11,9-Feb-15,9-Feb-15,"Northwestern Medical Faculty Foundation General Internal Medicine Ambulatory Clinic, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT01286311
NCT01285544,The Efficacy and Tolerability of Two Formulations of Atorvastatin In Korean Adult With Hypercholesterolemia,,Completed,No Results Available,Dyslipidemia|Cardiovascular Disease|Hypercholesterolemia,Drug: Atorvastatin (Lipinon)|Drug: Atorvastatin (Lipitor),"the percent change of LDL-C level|the percent change in total cholesterol, triglyceride, high density lipoprotein cholesterol (HDL-C) level, apolipoprotein B/A1 ratio, LDL/HDL ratio, small dense LDL fraction, high-sensitive C reactive protein (hs-CRP)",Seoul National University Hospital|Dong-A Pharmaceutical,All,"20 Years to 79 Years   (Adult, Older Adult)",Phase 4,289,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Lipinon Study|H-0807-056-251,Sep-08,Jul-09,Jul-09,28-Jan-11,null,17-Dec-13,"Seoul National University Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01285544
NCT01282190,Effectiveness of Motivational Interview in Patients With Dyslipidemia,Dislip-EM,Completed,No Results Available,Patients With Dyslipidemia,Behavioral: Motivational interview,lipid levels|cardiovascular risk,Hospital Universitario Reina Sofia de Cordoba|Spanish Society of Family and Community Medicine,All,"40 Years to 75 Years   (Adult, Older Adult)",Not Applicable,207,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,PI-0100/2008,Jun-10,Mar-15,Mar-15,24-Jan-11,null,18-Aug-15,"Family Medicine Teaching Unit and Community, Córdoba, Spain",,https://ClinicalTrials.gov/show/NCT01282190
NCT01280604,Effect of Fenofibrate Conversion on Triglyceride Levels in Patients on Statin Therapy,,Completed,Has Results,Hyperlipidemias,Drug: Fenofibrate 54mg,"Triglyceride Levels|Low-density Lipoprotein (LDL)|High-density Lipoprotein,(HDL)|Alanine Aminotransferase(ALT)|Aspartate Aminotransferase (AST)|Serum Creatinine(SCr)",Kaiser Permanente,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,66,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KPGA-10KMani-01,Oct-10,Jan-13,Jan-13,21-Jan-11,8-Jun-15,8-Jun-15,"Kaiser Permanente of Georgia, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT01280604
NCT01278693,"Effect of Oral L-carnitine Supplement on Lipid Profile, Anemia, and Quality of Life of Patients",,Completed,No Results Available,Complication of Hemodialysis,Drug: L-carnitine|Drug: placebo,lipid profile|anemia|quality of life,Isfahan University of Medical Sciences,Female,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,54,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ASD-1213-11,Aug-09,Sep-10,Sep-10,19-Jan-11,null,19-Jan-11,"Noor university hospital, Isfahan, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT01278693
NCT01279590,Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM),,Completed,No Results Available,Myalgia|Hypercholesterolemia|Hyperlipidemia,Drug: PPD10558|Drug: Atorvastatin|Drug: Placebo,"Incidence of stopping treatment with double-blinded study drug due to statin-associated myalgia.|Change from Baseline in fasting lipid profile components (low density lipoprotein-cholesterol(LDL-C), high density lipoprotein-cholesterol(HDL-C), triglyceride(TG), total cholesterol(TC), Apolipoprotein B(ApoB), HDL-TG, LDL/HDL ratio and TC/HDL ratio)|Change from baseline in muscle strength measurements (Sit-to-stand(STS) performance and hand grip strength by Jamar Hydraulic Hand Dynamometer)|Frequency of pain rescue medication|Change from Baseline in inflammatory markers (Tumor necrosis factor α (TNF-α), C-reactive protein (CRP), and lipoprotein-associated phospholipase A2 (Lp-PLA2))|Change in patients' functional health and well-being as measured by the Short Form-36v2 Health Survey (SF-36)|Time to onset of statin -associated myalgia (SAM)|Time to stopping treatment with study drug due to SAM","Furiex Pharmaceuticals, Inc",All,"40 Years and older   (Adult, Older Adult)",Phase 2,282,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PPD10558-010,Mar-11,Nov-11,Nov-11,19-Jan-11,null,22-Dec-11,"Furiex research site, Anniston, Alabama, United States|Furiex research site, Phoenix, Arizona, United States|Furiex research site, Phoenix, Arizona, United States|Furiex research site, Huntington Park, California, United States|Furiex research site, Long Beach, California, United States|Furiex research site, Pismo Beach, California, United States|Furiex research site, San Diego, California, United States|Furiex research site, West Lake Village, California, United States|Furiex research site, Colorado Springs, Colorado, United States|Furiex research site, Golden, Colorado, United States|Furiex research site, Hartford, Connecticut, United States|Furiex research site, Boynton Beach, Florida, United States|Furiex research site, Coral Gables, Florida, United States|Furiex research site, Deerfield Beach, Florida, United States|Furiex research site, Fort Lauderdale, Florida, United States|Furiex research site, Gainesville, Florida, United States|Furiex research site, Opa Locka, Florida, United States|Furiex research site, Pembroke, Florida, United States|Furiex research site, Pembroke, Florida, United States|Furiex research site, Sanford, Florida, United States|Furiex research site, West Palm Beach, Florida, United States|Furiex research site, Honolulu, Hawaii, United States|Furiex Research site, Boise, Idaho, United States|Furiex research site, Nampa, Idaho, United States|Furiex research site, Chicago, Illinois, United States|Furiex research site, Mission, Kansas, United States|Furiex research site, Madisonville, Kentucky, United States|Furiex research site, Covington, Louisiana, United States|Furiex research site, Auburn, Maine, United States|Furiex research site, Oxon Hill, Maryland, United States|Furiex research site, Bay City, Michigan, United States|Furiex research site, St. Louis, Missouri, United States|Furiex research site, Billings, Montana, United States|Furiex research site, Butte, Montana, United States|Furiex research site, Missoula, Montana, United States|Furiex research site, Omaha, Nebraska, United States|Furiex research site, Great Neck, New York, United States|Furiex research site, Asheville, North Carolina, United States|Furiex research site, Cary, North Carolina, United States|Furiex research site, Charlotte, North Carolina, United States|Furiex research site, Harrisburg, North Carolina, United States|Furiex research site, Hickory, North Carolina, United States|Furiex research site, Hickory, North Carolina, United States|Furiex research site, High Point, North Carolina, United States|Furiex research site, Raleigh, North Carolina, United States|Furiex research site, Raleigh, North Carolina, United States|Furiex research site, Wilmington, North Carolina, United States|Furiex research site, Carlisle, Ohio, United States|Furiex research site, Cincinnati, Ohio, United States|Furiex research site, Columbus, Ohio, United States|Furiex research site, Kettering, Ohio, United States|Furiex research site, Springfield, Ohio, United States|Furiex research site, Altoona, Pennsylvania, United States|Furiex research site, Johnstown, Pennsylvania, United States|Furiex research site, Cumberland, Rhode Island, United States|Furiex research site, East Providence, Rhode Island, United States|Furiex research site, Anderson, South Carolina, United States|Furiex research site, Greenville, South Carolina, United States|Furiex research site, Greer, South Carolina, United States|Furiex research site, Mt. Pleasant, South Carolina, United States|Furiex research site, Pawley's Island, South Carolina, United States|Furiex research site, Bristol, Tennessee, United States|Furiex research site, Tomball, Texas, United States|Furiex research site, Salt Lake City, Utah, United States|Furiex research site, Norfolk, Virginia, United States|Furiex research site, Richmond, Virginia, United States|Furiex, Spokane, Washington, United States",,https://ClinicalTrials.gov/show/NCT01279590
NCT01274104,A Pilot Study on the Effect of Vitamin D Treatment in Patients With Statin-Associated Myalgia,,Withdrawn,No Results Available,Hyperlipidemia,Dietary Supplement: Vitamin D3|Other: Placebo,Brief Pain Inventory value,Avera McKennan Hospital & University Health Center,All,"18 Years to 88 Years   (Adult, Older Adult)",Phase 1,0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care",ARI-1350-Myalgia,Oct-10,Jul-11,Jul-11,11-Jan-11,null,22-Apr-15,"Avera Research Institute, Sioux Falls, South Dakota, United States",,https://ClinicalTrials.gov/show/NCT01274104
NCT01274559,Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133),,Terminated,Has Results,Primary Hypercholesterolemia|Mixed Dyslipidemia,Drug: Extended-release niacin/laropiprant (ERN/LRPT)|Drug: Placebo,Percent Change From Baseline at Week 12 in Low Density Lipoprotein-Cholesterol (LDL-C)|Percent Change From Baseline in LDL-C:High-density Lipoprotein Cholesterol (HDL-C) at Week 12|Percent Change From Baseline in HDL-C at Week 12|Percent Change From Baseline in Triglyceride (TG) at Week 12|Percent Change From Baseline in Non-HDL-C at Week 12|Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 12|Percent Change From Baseline in Apo B:Apolipoprotein A-I (Apo A-I) at Week 12|Percent Change From Baseline in Total Cholesterol (TC):HDL-C at Week 12|Percent Change From Baseline in Lipoprotein a [Lp(a)] at Week 12|Percent Change From Baseline in Apo A-I at Week 12|Percent Change From Baseline in TC at Week 12|Percent Change From Baseline in LDL-C at Week 4|Percent Change From Baseline in LDL-C:HDL-C at Week 4|Percent Change From Baseline in HDL-C at Week 4|Percent Change From Baseline in TG at Week 4|Percent Change From Baseline in Non-HDL-C at Week 4|Percent Change From Baseline in Apo B at Week 4|Percent Change From Baseline in Apo B:Apo A-I at Week 4|Percent Change From Baseline in TC:HDL-C at Week 4|Percent Change From Baseline in Lp(a) at Week 4|Percent Change From Baseline in Apo A-I at Week 4|Percent Change From Baseline in TC at Week 4|Number of Participants Who Achieve LDL-C Target Levels at Week 12 of Treatment,Merck Sharp & Dohme Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1173,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0524A-133|CTRI/2012/08/002857,1-Mar-11,26-Feb-13,26-Feb-13,11-Jan-11,14-Mar-14,16-Aug-18,,,https://ClinicalTrials.gov/show/NCT01274559
NCT01271751,Pilot Study With GFT505 (80mg) in Atherogenic Dyslipidaemic Patients With Abdominal Obesity,,Completed,No Results Available,Atherogenic Dyslipidaemia|Abdominal Obesity,Drug: GFT505 80mg|Drug: Placebo,Decrease in serum Triglycerides (TG) level|Increase in serum High Density Lipoprotein Cholesterol (HDL-C) level|Decrease in Low Density Lipoprotein Cholesterol (LDL-C) levels|Decrease in non-HDL-C (High Density Lipoprotein Cholesterol) levels,Genfit,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,96,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GFT505-208-3|2008-005779-86,Jan-09,Sep-09,Nov-09,7-Jan-11,null,7-Jan-11,"Site n°36, Aigrefeuille Sur Maine, France|Site n°78, Angers, France|Site n°79, Angers, France|Site n°80, Angers, France|Site n°82, Angers, France|Site n°21, Baune, France|Site n°16, Beaucouze, France|Site n°18, Briollay, France|Site n°14, Cholet, France|Site n°26, Cholet, France|Site n°42, Haute Goulaine, France|Site n°45, Heric, France|Site n°32, La Chapelle Sur Erdre, France|Site n°11, La Jubaudière, France|Site n°30, La Montagne, France|Site n°91, Laval, France|Site n°23, Le Mesnil en Vallée, France|Site n°35, le Temple de Bretagne, France|Site n°12, Les Ponts de Ce, France|Site n°17, Montreuil Juigne, France|Site n°74, Montrevault, France|Site n°10, Murs-Erigné, France|Site n°19, Murs-Erigné, France|Site n°40, Nantes, France|Site n°37, Nantes, France|Site n°31, Nantes, France|Site n°34, Nantes, France|Site n°41, Nort sur Erdre, France|Site n°33, Orvault, France|Site n°1, Paris, France|Site n°39, Sautron, France|Site n°13, Segre, France|Site n°38, St Etienne de Montluc, France|Site n°75, Tierce, France|Site n°77, Tierce, France|Site n°20, Vihiers, France|Site n°64, Brasov, Romania|Site n°61, Bucharest, Romania|Site n°60, Bucharest, Romania|Site n°63, Bucharest, Romania|Site n°62, Bucharest, Romania|Site n°65, Craiova, Romania|Site n°52, Bab Sâadoun Tunis, Tunisia|Site n°53, Bab Sâadoun Tunis, Tunisia|Site n°50, Tunis, Tunisia|Site n°51, Tunis, Tunisia|Site n°55, Tunis, Tunisia",,https://ClinicalTrials.gov/show/NCT01271751
NCT01267227,"Effect of Pterostilbene on Cholesterol, Blood Pressure and Oxidative Stress",,Completed,Has Results,Hyperlipidemia|Blood Pressure|Oxidative Stress,Drug: Pterostilbene 50 mg twice daily|Drug: Placebo|Drug: Grape Extract|Drug: Pterostilbene 125 mg twice daily,LDL|Blood Pressure|Subjective Adverse Effects,University of Mississippi Medical Center,All,"18 Years to 88 Years   (Adult, Older Adult)",Phase 2|Phase 3,80,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2010-0225,Dec-10,Feb-12,Feb-12,28-Dec-10,3-May-13,10-Jan-18,"University of Mississippi Medical Center, Jackson, Mississippi, United States",,https://ClinicalTrials.gov/show/NCT01267227
NCT01266876,Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH Hypercholesterolemia,,Completed,Has Results,Hypercholesterolemia,Drug: Alirocumab|Drug: Placebo,Percent Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis|Absolute Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis|Percentage of Participants Achieving Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 12 - On-treatment Analysis|Percentage of Participants Achieving LDL-C < 70 mg/dL (1.81 mmol/L) at Week 12 - On-treatment Analysis|Percent Change From Baseline in Total Cholesterol at Week 12 - On-treatment Analysis|Absolute Change From Baseline in Total Cholesterol at Week 12 - On-treatment Analysis|Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12 - On-treatment Analysis|Absolute Change From Baseline in HDL-C at Week 12 - On-treatment Analysis|Percent Change From Baseline in Triglycerides at Week 12 - On-treatment Analysis|Absolute Change From Baseline in Triglycerides at Week at 12 - On-treatment Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 - On-treatment Analysis|Absolute Change From Baseline in Non-HDL-C at Week 12 - On-treatment Analysis|Percent Change From Baseline in Apo Lipoprotein B (Apo-B) at Week 12 - On-treatment Analysis|Absolute Change From Baseline in Apo-B at Week 12 - On-treatment Analysis|Percent Change From Baseline in Apolipoprotein - A1 (Apo-A1) at Week 12 - On-treatment Analysis|Absolute Change From Baseline in Apo-A1 at Week 12 - On-treatment Analysis|Absolute Change in the Ratio ApoB/ApoA-1 From Baseline to Week 12 - On-treatment Analysis|Percent Change From Baseline in Lipoprotein(a) at Week 12 - On-treatment Analysis|Absolute Change From Baseline in Lipoprotein(a) at Week 12 - On-treatment Analysis,Regeneron Pharmaceuticals|Sanofi,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,77,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R727-CL-1003,Jan-11,Nov-11,Nov-11,24-Dec-10,22-Sep-15,22-Sep-15,"Huntsville, Alabama, United States|Mission Viejo, California, United States|Newport Beach, California, United States|Bridgeport, Connecticut, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Port Orange, Florida, United States|Chicago, Illinois, United States|Kansas City, Kansas, United States|Auburn, Maine, United States|Biddeford, Maine, United States|St. Louis, Missouri, United States|Concord, New Hampshire, United States|Durham, North Carolina, United States|Cincinnati, Ohio, United States|Nashville, Tennessee, United States|Houston, Texas, United States|Winnipeg, Manitoba, Canada|London, Ontario, Canada|Chicoutimi, Quebec, Canada|Montreal, Quebec, Canada|St. Foy, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01266876
NCT01262638,A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides,,Completed,No Results Available,Dyslipidemia,Drug: ETC-1002|Drug: Placebo,"To assess the LDL-C lowering efficacy of ETC-1002 versus placebo|To assess the efficacy of ETC-1002 to modulate TG and other lipid and cardio-metabolic biomarkers|To assess safety using adverse event reports, physical exams, vital signs, ECGs and clinical laboratory parameters",Esperion Therapeutics,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,177,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ETC-1002-003,Dec-10,Oct-11,Oct-11,17-Dec-10,null,29-Mar-19,"Chandler, Arizona, United States|Greenbrae, California, United States|Santa Rosa, California, United States|Jacksonville, Florida, United States|Chicago, Illinois, United States|Iowa City, Iowa, United States|Louisville, Kentucky, United States|Kalamazoo, Michigan, United States|Raleigh, North Carolina, United States|Houston, Texas, United States|Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01262638
NCT01258322,Pioglitazone Attenuates Dysmetabolism in Peritoneal Dialysis (PD) Patients,,Completed,No Results Available,Peritoneal Dialysis|Pioglitazone|Hypertriglyceridemia|Insulin Resistance|Inflammation,Drug: Pioglitazone,"change of serum TG level|the change of serum CHO, LDL. HDL level, HOMA-IR, adipocytokines level and CRP",Huashan Hospital|Baxter Healthcare Corporation,All,"Child, Adult, Older Adult",Not Applicable,70,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Neph-1000,Jan-08,Sep-08,Sep-08,10-Dec-10,null,10-Dec-10,,,https://ClinicalTrials.gov/show/NCT01258322
NCT01256476,Prevail-Us: A Study Of Pitavastatin 4 mg Vs. Pravastatin 40 mg In Patients With Primary Hyperlipidemia Or Mixed Dyslipidemia,PREVAIL-US,Completed,Has Results,Primary Dyslipidemia|Mixed Dyslipidemia,Drug: pitavastatin|Drug: pravastatin,Mean Percent Change in Low Density Lipoprotein Cholesterol(LDL-C) From Baseline to Week 12,"Kowa Research Institute, Inc.",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,328,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NK-104-4.04US,Oct-10,Jun-11,Jun-11,8-Dec-10,30-Apr-12,8-May-12,"Huntsville, Alabama, United States|Muscle Shoals, Alabama, United States|Chandler, Arizona, United States|Goodyear, Arizona, United States|Phoenix, Arizona, United States|Beverly Hills, California, United States|Los Angeles, California, United States|Newport Beach, California, United States|Colorado Springs, Colorado, United States|Clearwater, Florida, United States|Deland, Florida, United States|Fort Luaderdale, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Ovido, Florida, United States|Pembroke Pines, Florida, United States|Ponte Vedra, Florida, United States|Addison, Illinois, United States|Chicago, Illinois, United States|Evansville, Indiana, United States|Indianapolis, Indiana, United States|Kansas City, Kansas, United States|Erlanger, Kentucky, United States|Baltimore, Maryland, United States|Brockton, Massachusetts, United States|Edina, Minnesota, United States|Las Vegas, Nevada, United States|Berlin, New Jersey, United States|Rochester, New York, United States|Statesville, North Carolina, United States|Cincinnati, Ohio, United States|Lyndhurst, Ohio, United States|Willoughby Hills, Ohio, United States|Tulsa, Oklahoma, United States|Eugene, Oregon, United States|Greer, South Carolina, United States|Mt. Pleasant, South Carolina, United States|Corpus Christi, Texas, United States|Dallas, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Olympia, Washington, United States",,https://ClinicalTrials.gov/show/NCT01256476
NCT01251991,Cholesterol Lowering Treatment With Psyllium Husks and Isolated Soy Protein in Hypercholesterolemia,ProFi,Completed,No Results Available,Hypercholesterolemia,Drug: Psyllium husks|Dietary Supplement: Isolated soy protein|Dietary Supplement: Isolated whey protein|Other: Microcrystalline cellulose,"Change from baseline in LDL cholesterol at 6 weeks|Change from baseline in total cholesterol at 6 weeks|Change from baseline in HDL cholesterol at 6 weeks|Change from baseline in triglycerides at 6 weeks|Change from baseline in fasting plasma glucose at 6 weeks|Change from baseline in body weight at 6 weeks|Change from baseline in apolipoprotein B at 6 weeks|Change from baseline in small, dense LDL cholesterol at 6 weeks|Change from baseline in high sensitive CRP at 6 weeks",Aalborg University Hospital,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,41,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2010-022822-34,Jan-11,Jan-12,Jan-12,2-Dec-10,null,29-Jan-14,"The Lipid Clinic, Aalborg Hospital, Aalborg, RN, Denmark",,https://ClinicalTrials.gov/show/NCT01251991
NCT01250990,Effect of Niacin on Transport of HDL and Relationship to Atherogenic Lipoproteins and Lipolysis,ENTHRALL,Completed,Has Results,Dyslipidemias,Drug: Niacin|Other: Placebo,Rate of Appearance of 3H Cholesterol in the Total HDL Fraction Before and After 12 Weeks of Treatment With Niacin,"University of Pennsylvania|National Heart, Lung, and Blood Institute (NHLBI)",All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,22,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",811956|K23HL091130,Nov-10,May-11,May-11,1-Dec-10,24-Jun-16,28-Jul-16,"University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01250990
NCT01243151,Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia,,Completed,Has Results,Hypercholesterolemia|Dyslipidemia,Biological: PF-04950615 (RN316),"Number of Participants With Dose Limiting and Intolerable Treatment-Related Adverse Events (AEs)|Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Treatment-Related Adverse Events (AEs)|Number of Participants With Adverse Events (AEs) by Severity|Number of Participants With Laboratory Test Abnormalities|Number of Participants With Clinically Relevant Changes in Vital Signs|Number of Participants With Clinically Relevant Changes in Electrocardiogram (ECG) Parameters|Number of Participants With Anti-drug Antibodies (ADA)|Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-04950615|Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04950615|Maximum Observed Plasma Concentration (Cmax) of PF-04950615|Plasma Decay Half-Life (t1/2) of PF-04950615|Apparent Clearance (CL) of PF-04950615|Volume of Distribution at Steady State (Vss) of PF-04950615|Accumulation Ratio (Rac) of PF-04950615|Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Day 8, 15, 22, 29 and 78|Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Day 8, 15, 22, 29 and 78|Number of Participants Achieving LDL-C Less Than (<) 70 Milligram Per Deciliter (mg/dL)|Number of Participants Achieving LDL-C Less Than (<) 100 Milligram Per Deciliter (mg/dL)|Number of Participants With Greater Than or Equal to (>=) 50 Percent (%) Reduction in LDL-C From Baseline|Change From Baseline in Lipid Parameters: Apolipoprotein A1 (ApoA1) at Day 8, 15, 22, 29 and 78|Change From Baseline in Lipid Parameters: Apolipoprotein B (ApoB) at Day 8, 15, 22, 29 and 78|Change From Baseline in Lipid Parameters: Total Cholesterol at Day 8, 15, 22, 29 and 78|Change From Baseline in Lipid Parameters: High Density Lipoprotein Cholesterol (HDL-C) at Day 8, 15, 22, 29 and 78|Change From Baseline In Lipid Parameters: Non High Density Lipoprotein Cholesterol (Non HDL-C) at Day 8, 15, 22, 29 and 78|Change From Baseline In Lipid Parameters: Triglycerides (TG) at Day 8, 15, 22, 29 and 78|Percent Change From Baseline in Lipid Parameters: Apolipoprotein A1 (ApoA1) at Day 8, 15, 22, 29 and 78|Percent Change From Baseline In Lipid Parameters: Apolipoprotein B (ApoB) at Day 8, 15, 22, 29 and 78|Percent Change From Baseline In Lipid Parameters: Total Cholesterol at Day 8, 15, 22, 29 and 78|Percent Change From Baseline In Lipid Parameters: High Density Lipoprotein Cholesterol (HDL-C) at Day 8, 15, 22, 29 and 78|Percent Change From Baseline In Lipid Parameters: Non High Density Lipoprotein Cholesterol (Non HDL-C) at Day 8, 15, 22, 29 and 78|Percent Change From Baseline In Lipid Parameters: Triglycerides (TG) at Day 8, 15, 22, 29 and 78|Change From Baseline In Low Density Lipoprotein Cholesterol (LDL-C) Particle Size at Day 8, 15, 22, 36, 50, 64 and 78|Change From Baseline In Small Low Density Lipoprotein Cholesterol (LDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78|Change From Baseline In Medium Low Density Lipoprotein Cholesterol (LDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78|Change From Baseline In Large Low Density Lipoprotein Cholesterol (LDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78|Change From Baseline In Total Low Density Lipoprotein Cholesterol (LDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78|Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Levels at Baseline, Day 8, 15, 22, 36, 50, 64 and 78|C-Reactive Protein Levels at Day 8, 15, 21, 36, 57 and 78|Small High Density Lipoprotein-Cholesterol (HDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78|Medium High Density Lipoprotein-Cholesterol (HDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78|Large High Density Lipoprotein-Cholesterol (HDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78|Total High Density Lipoprotein-Cholesterol (HDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78|Small Very Low Density Lipoprotein-Cholesterol (VLDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78|Medium Very Low Density Lipoprotein-Cholesterol (VLDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78|Large Very Low Density Lipoprotein-Cholesterol (VLDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78|Total Very Low Density Lipoprotein-Cholesterol (VLDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78|High Density Lipoprotein-Cholesterol (HDL-C) Particle Size at Day 8, 15, 22, 36, 50, 64 and 78|Very Low Density Lipoprotein-Cholesterol (VLDL-C) Particle Size at Day 8, 15, 22, 36, 50, 64 and 78",Pfizer,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,68,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",B1481009,Feb-11,Oct-11,Oct-11,18-Nov-10,21-Jan-19,21-Jan-19,"California Clinical Trials Medical Group, Culver City, California, United States|Glendale Adventist Medical Center, Glendale, California, United States|SeaView Research, Inc., Miami, Florida, United States|SeaView Research, Inc., Miami, Florida, United States|Covance Clinical Research Unit, Inc., Honolulu, Hawaii, United States|Vince and Associates Clinical Research, Overland Park, Kansas, United States|Vince and Associates Clinical Research, Overland Park, Kansas, United States|Prism Research, Saint Paul, Minnesota, United States|Healthcare Discoveries, LLC dba ICON Development Solutions, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT01243151
NCT01242527,Epanova® for Lowering Very High Triglycerides,EVOLVE,Completed,Has Results,Severe Hypertriglyceridemia,Drug: placebo|Drug: omefas,Fasting Serum Triglycerides,AstraZeneca,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,399,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",OM-EPA-003,Jan-11,Mar-12,Apr-12,17-Nov-10,6-Sep-13,4-Aug-16,"National City, California, United States|Sacramento, California, United States|Manchester, Connecticut, United States|Coral Gables, Florida, United States|Hialeah, Florida, United States|Miami, Florida, United States|Ocala, Florida, United States|St Petersburg, Florida, United States|Summerfield, Florida, United States|Atlanta, Georgia, United States|Addison, Illinois, United States|Chicago, Illinois, United States|Louisville, Kentucky, United States|Auburn, Maine, United States|Olive Branch, Mississippi, United States|High Point, North Carolina, United States|Salisbury, North Carolina, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Oklahoma City, Oklahoma, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Bristol, Tennessee, United States|Johnson City, Tennessee, United States|Kingsport, Tennessee, United States|San Antonio, Texas, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Olympia, Washington, United States|Copenhagen, Denmark|Gentofte, Denmark|Herlev, Denmark|Viborg, Denmark|Baja, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Debrecen, Hungary|Satoraljaujhely, Hungary|Szekesfehervar, Hungary|Szikszo, Hungary|Karnal, Haryana, India|Bangalore, Karnataka, India|Bangalore, Karnataka, India|Bangalore, Karnataka, India|Banswada, Karnataka, India|Indore, Madhya Pradesh, India|Pune, Maharashtra, India|Jaipur City, Rajasthan, India|Chennai, Tamil nadu, India|Surat, India|Amsterdam, Netherlands|Groningen, Netherlands|Rotterdam, Netherlands|Rotterdam, Netherlands|Utrecht, Netherlands|Moscow, Russian Federation|Novosibirsk, Russian Federation|St Petersburg, Russian Federation|St Petersburg, Russian Federation|Kharkiv, Ukraine|Kharkiv, Ukraine|Kharkiv, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Zaporizhzhya, Ukraine",,https://ClinicalTrials.gov/show/NCT01242527
NCT01239992,Effect of Niacin/Laropiprant on Postprandial Lipoprotein Metabolism in Patients With Dyslipoproteinemia,,Terminated,Has Results,Hyperlipoproteinemia|Metabolic Syndrome,Drug: Niacin/ Laropiprant,Incremental Area Under the Plasma Triglyceride Curve Over 8 Hours Following a Standardized Oral Fat Tolerance Test|HDL Cholesterol|Fasting Triglycerides,Ludwig-Maximilians - University of Munich,All,"19 Years to 70 Years   (Adult, Older Adult)",Phase 4,12,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KP-Niacin-2010|2010-019954-42,Jun-11,Jan-13,Jul-13,15-Nov-10,10-Apr-14,10-Apr-14,"Medizinische Klinik II, Klinikum der Universitaet Muenchen, Grosshadern, Munich, Germany",,https://ClinicalTrials.gov/show/NCT01239992
NCT01239004,Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy,CERTAIN,Completed,No Results Available,Dyslipidemia|Hyperlipidemia|Hyperglycemia,Drug: Placebo|Drug: Colesevelam,Low-density lipoprotein cholesterol (LDL-C)|Fasting Plasma Glucose (FPG)|NMR Lipid subfractions and lipoprotein-IR score|Hemoglobin A1C (HbA1C)|Fructosamine|High sensitivity c-reactive protein (hs-CRP)|Niacin-related flushing|Homeostasis model assessment of insulin resistance (HOMA-IR) score|High-density lipoprotein cholesterol (HDL-C)|Non-high-density lipoprotein cholesterol (non-HDL-C)|Total Cholesterol (TC)|Triglycerides (TG)|Fasting Insulin,Radiant Research,All,"18 Years and older   (Adult, Older Adult)",Phase 4,140,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",Welchol-Niaspan 001,Nov-10,Aug-11,Aug-11,11-Nov-10,null,6-Jan-12,"Radiant Research, Chicago, Illinois, United States|Kansas City, Kansas, United States|Minneapolis, Minnesota, United States|St Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT01239004
NCT01237769,Effect of Vitamin D on Metabolic Parameters in Patients With the Metabolic Syndrome,,Unknown status,No Results Available,Metabolic Syndrome,Drug: Vitamin D3|Behavioral: Lifestyle advice,Change in metabolic syndrome incidence 3 months after starting treatment|Change in levels of fasting glucose|Change in levels of high-density lipoprotein cholesterol (HDL-C)|Change in levels of blood pressure|Changes in serum triglycerides|Changes in levels of low-density lipoprotein cholesterol (LDL-C)|Changes in levels of small dense low-density lipoprotein cholesterol (sdLDL-C),University of Ioannina,All,"16 Years to 75 Years   (Child, Adult, Older Adult)",Phase 4,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3,Oct-10,Mar-12,Mar-12,10-Nov-10,null,18-Aug-11,"Outpatient Lipid Clinic, University Hospital of Ioannina, Ioannina, Greece",,https://ClinicalTrials.gov/show/NCT01237769
NCT01235832,The Effect of Avocado on Cardiovascular Disease (CVD) Risk Factors,,Completed,No Results Available,Cardiovascular Disease|Hyperlipidemia,Other: Avocado Diet|Other: Lower-Fat Diet|Other: Moderate Fat Diet,Lipids and lipoproteins|Lipoprotein particle size|Oxidized-LDL|lipid hydroperoxide|Macrophage Cholesterol efflux|HDL anti-inflammatory function|Serum fatty acid profile|Inflammatory biomarkers,Penn State University|Hass Avocado Board,All,"21 Years to 70 Years   (Adult, Older Adult)",Not Applicable,54,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,PKE 106,Nov-10,Dec-12,Feb-13,8-Nov-10,null,28-Apr-15,"Penn State University, University Park, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01235832
NCT01236365,Statins in Children With Type 1 Diabetes and Hypercholesterolemia,,Completed,Has Results,"Diabetes Mellitus, Insulin-Dependent|Hypercholesterolemia",Drug: Atorvastatin|Drug: Atorvastatin Placebo,LDL-C Levels Assessed at Randomization and 6 Months|Hs-CRP Levels Assessed at Randomization and 6 Months|Relationship Between Glycemic Variability- Measured by the Mean Amplitude of Glycemic Excursion With Continuous Glucose Monitoring.|Gene Expression and Concentration of Key Molecules That Participate in the Inflammatory Process and Arterial Plaque Formation.|Subclinical Atherosclerosis and Vascular Stiffness With the Use of Abdominal Aortic MRI.,Nemours Children's Clinic|Pfizer|Medtronic|Quest Diagnostics,All,"10 Years to 20 Years   (Child, Adult)",Phase 3,42,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IRB# 185500,Oct-10,Oct-13,Nov-14,8-Nov-10,21-May-15,18-Jun-15,"Alfred I duPont Hospital, Wilmington, Delaware, United States|Nemours Children's Clinic, Jacksonville, Florida, United States|Nemours Children's Clinic, Orlando, Florida, United States|Nemours Children's Clinic, Pensacola, Florida, United States|Nemours Children's Clinic-Jefferson, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01236365
NCT01236430,A Study to Determine the Bioequivalence of SCH 900068 Compared to Marketed Products (Protocol No. P07551),,Completed,No Results Available,Hyperlipidemia,Drug: Ezetimibe|Drug: Ezetimibe/atorvastatin 10mg/10mg FDC|Drug: Atorvastatin 10mg|Drug: Atorvastatin 80mg|Drug: Ezetimibe/atorvastatin 10mg/80mg FDC,Area under the concentration-time-curve from time zero to infinity (AUC0-∞) of atorvastatin|Maximum plasma concentration (Cmax) of atorvastatin|Area under the concentration time-curves from time zero to the time of last measured concentration (AUC0-last) of unconjugated ezetimibe (EZ)|Maximum plasma concentration (Cmax) of unconjugated ezetimibe (EZ),Merck Sharp & Dohme Corp.,All,18 Years to 55 Years   (Adult),Phase 1,200,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P07551,Feb-11,Nov-11,Feb-12,8-Nov-10,null,31-Dec-14,,,https://ClinicalTrials.gov/show/NCT01236430
NCT01229566,Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia,,Unknown status,No Results Available,Severe Hypertriglyceridemia,Drug: AKR-963,Difference between AKR963 and Control [placebo or active control] treatment groups in triglyceride lowering effect [ Time Frame: 12 weeks ],"Trygg Pharma, Inc.",All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 3,240,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TRGG-963-002,Oct-10,Jul-12,Jul-12,27-Oct-10,null,24-Nov-11,"Illinois Recruiting, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT01229566
NCT01227330,Pilot Program to Improve Statin Adherence and Lower Cholesterol in Older Adults,,Completed,No Results Available,Hypercholesterolemia|Medication Adherence,Behavioral: Medication adherence intervention|Behavioral: Attention-control,Medication adherence|Serum cholesterol,University of Missouri-Columbia,All,"60 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,43,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MU HSIRB 1174637,Oct-10,Dec-13,Feb-14,25-Oct-10,null,24-Oct-16,"University of Missouri, Columbia, Missouri, United States",,https://ClinicalTrials.gov/show/NCT01227330
NCT01228032,The Health Outcomes Management and Evaluation (HOME) Study,HOME,Completed,No Results Available,Diabetes|Hyperlipidemia|Heart Disease|High Blood Pressure,Other: Care team,Quality of healthcare services received,Emory University|National Institute of Mental Health (NIMH),All,"18 Years and older   (Adult, Older Adult)",Phase 3,447,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,IRB00027782|2R01MH070437-06A1,Apr-10,Jul-15,Dec-15,25-Oct-10,null,26-Feb-16,"Cobb County Community Service Board, Marietta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT01228032
NCT01220336,Study of Medical Assistant Health Coaching in Primary Care for Patients With Chronic Conditions,HCPC,Completed,No Results Available,Diabetes|Hypertension|Hyperlipidemia,Behavioral: Health coaching by medical assistants in primary care,"Composite clinical outcome measure- improvement in either HgA1C, SBP, or LDL","University of California, San Francisco",All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,441,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor),UCSF CEPC,Apr-11,Jun-14,Jun-14,13-Oct-10,null,21-Oct-14,"Mission Neighborhood Health Center, San Francisco, California, United States|Southeast Health Center, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT01220336
NCT01218204,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin",,Completed,Has Results,Dyslipidaemias,Drug: 10mg atorvastatin|Drug: 80mg atorvastatin|Drug: GSK1292263 Placebo|Drug: 100mg GSK1292263|Drug: 300mg GSK1292263|Drug: 800mg GSK1292263|Drug: 10mg ezetimibe|Other: Washout,"Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)- Part A|Number of Participants With Any AEs and SAEs- Part B (Washout)|Number of Participants With Any AEs and SAEs- Part B (Run-in)|Number of Participants With Any AEs and SAEs- Part B (Pooled Treatment Arm)|Number of Participants With Abnormal- Clinically Significant Electrocardiogram (ECG) Findings- Part A|Number of Participants With Abnormal Clinically Significant ECG Findings- Part B (Washout)|Number of Participants With Abnormal Clinically Significant ECG Findings- Part B (Run-in)|Number of Participants With Abnormal Clinically Significant ECG Findings- Part B (Pooled Treatment Arm)|Number of Participants With Vital Signs of Potential Clinical Importance (PCI)- Part A|Number of Participants With Vital Signs of PCI- Part B (Washout)|Number of Participants With Vital Signs of Potential Clinical Importance- Part B (Run-in)|Number of Participants With Vital Signs of Potential Clinical Importance- Part B (Pooled Treatment Arm)|Number of Participants With Abnormal Hematology Value of PCI- Part A|Number of Participants With Abnormal Hematology Value of PCI- Part B (Washout)|Number of Participants With Abnormal Hematology Value of PCI- Part B (Run-in)|Number of Participants With Abnormal Hematology Value of PCI- Part B (Pooled Treatment Arm)|Number of Participants With Abnormal Clinical Chemistry Value of PCI- Part A|Number of Participants With Abnormal Clinical Chemistry Value of PCI- Part B (Washout)|Number of Participants With Abnormal Clinical Chemistry Value of PCI- Part B (run-in)|Number of Participants With Abnormal Clinical Chemistry Value of PCI- Part B (Pooled Treatment Arm)|Maximum Observed Concentration (Cmax) of GSK1292263- Part A|Cmax of GSK1292263- Part B (Pooled Treatment Arm)|Time of Occurrence of Cmax (Tmax) and Terminal Phase Half-life (t1/2) GSK1292263- Part A|Lag Time Before Observation of Drug Concentrations in Sampled Matrix (Tlag) of GSK1292263- Part A|Tmax and t1/2 of GSK1292263- Part B (Pooled Treatment Arm)|Tlag of GSK1292263- Part B (Pooled Treatment Arm)|Area Under the Concentration-time Curve From Time Zero (Pre-dose) to 24 Hours [AUC(0-24)] of GSK1292263- Part A|AUC(0-24) of GSK1292263- Part B (Pooled Treatment Arm)|Trough Concentration of GSK1292263|Cmax of Atorvastatin- Part A|Cmax of Atorvastatin- Part B (Pooled Treatment Arm)|Tmax of Atorvastatin- Part A|Tmax of Atorvastatin- Part B (Pooled Treatment Arm)|AUC (0-24) of Atorvastatin- Part A|AUC (0-24) of Atorvastatin- Part B (Pooled Treatment Arm)|Trough Concentration of Atorvastatin|Percent Change From Baseline for Lipid Metabolism: Apolipoprotein A1 and Apolipoprotein B100 at Day 14|Percent Change From Baseline in Lipid Metabolism: Apolipoprotein E at Day 14 (24 Hours)|Percent Change From Baseline in Lipid Metabolism: High Density Lipids Cholesterol (HDLc), Low Density Lipids Cholesterol (LDLc), Tryglycerides, Non-HDLc and Total Cholesterol at Day 14 (24 Hours)|Percent Change From Baseline in Lipid Metabolism: LDL/HDL Ratio at Day 14 (24 Hours)|Weighted Mean Area Under Concentration Curve From 0 to 24 Hours (AUC [0-24]) Change From Baseline for Triglycerides at Day 14|Cmax of Atorvastatin Metabolite (2-Hydroxyatorvastatin)- Part A|Cmax of Atorvastatin Metabolite (2-Hydroxyatorvastatin)- Part B (Pooled Treatment Arm)|Tmax of Atorvastatin Metabolite (2-Hydroxyatorvastatin)- Part A|Tmax of Atorvastatin Metabolite (2-Hydroxyatorvastatin)- Part B (Pooled Treatment Arm)|AUC (0-24) of Atorvastatin Metabolite (2-Hydroxyatorvastatin)- Part A|AUC (0-24) of Atorvastatin Metabolite (2-Hydroxyatorvastatin)- Part B (Pooled Treatment Arm)|Trough Concentration of Atorvastatin Metabolite (2-Hydroxyatorvastatin)",GlaxoSmithKline,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,287,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",113779,14-Sep-10,29-Jun-11,29-Jun-11,11-Oct-10,8-Nov-17,8-Nov-17,"GSK Investigational Site, Anniston, Alabama, United States|GSK Investigational Site, Chula Vista, California, United States|GSK Investigational Site, Stockton, California, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Port Orange, Florida, United States|GSK Investigational Site, Saint Petersburg, Florida, United States|GSK Investigational Site, Addison, Illinois, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Louisville, Kentucky, United States|GSK Investigational Site, Kalamazoo, Michigan, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Berlin, New Jersey, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Eugene, Oregon, United States|GSK Investigational Site, Spartanburg, South Carolina, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Renton, Washington, United States",,https://ClinicalTrials.gov/show/NCT01218204
NCT01217112,GWMD1092 - GWP42003 : GWP42004 Together Plus Alone in Type II Diabetes,,Completed,Has Results,"Dyslipidemias|Diabetes Mellitus, Type 2",Drug: GWP42003|Drug: GWP42004|Drug: Placebo,The Change From Baseline in Mean Serum High Density Lipoprotein Cholesterol Concentration After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean High Density Lipoprotein Cholesterol Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Serum Total Cholesterol Concentration After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Total Cholesterol Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Serum Low Density Lipoprotein Cholesterol Concentration After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Low Density Lipoprotein Cholesterol Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Serum High Density Lipoprotein : Low Density Lipoprotein Cholesterol Ratio After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean High Density Lipoprotein : Low Density Lipoprotein Cholesterol Ratio by Ultracentrifugation After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Very Low Density Lipoprotein Cholesterol Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Serum Triglyceride Concentration After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Triglyceride Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Serum Apolipoprotein A Concentration After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Serum Apolipoprotein B Concentration After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Serum Apolipoprotein B : Apolipoprotein A Ratio After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Serum Non-Esterified Fatty Acid Concentration After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Fasting Glucose Concentration After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Fructosamine Concentration After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Glycated Haemoglobin Concentration After 91 Days (13 Weeks) of Treatment|The Change From Baseline to the End of 91 Days (13 Weeks) of Treatment in the Mean Serum Glucose Concentration Two Hours Post Glucose Challenge (Oral Glucose Tolerance Test [OGTT])|The Change From Baseline to the End of 91 Days (13 Weeks) of Treatment in the Mean Serum Insulin Concentration Two Hours Post Glucose Challenge (Oral Glucose Tolerance Test)|The Change From Baseline in Mean Fasting Insulin Concentration After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean C-peptide Concentration After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Insulin Resistance Measured by Homeostasis Model Assessment 2 (HOMA2-IR) After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Insulin Sensitivity Measured by Homeostasis Model Assessment 2 (HOMA2) After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Insulin B Cell Function Measured by Homeostasis Model Assessment 2 (HOMA2) After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Body Mass Index After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Waist-to-hip Ratio After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Body Weight After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Waist Measurement After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Hip Measurement After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Visceral Abdominal Fat After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Subcutaneous Abdominal Fat After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Total Abdominal Fat After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Internal Non-Abdominal Fat After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Subcutaneous Non-Abdominal Fat After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Total Non-Abdominal Fat After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Total Internal Fat After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Total Subcutaneous Fat After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Total Fat After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Abdominal Adiposity After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean % Liver Fat After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Appetite 0-10 Numerical Rating Scale Score After 91 Days (13 Weeks) of Treatment|Adverse Events as a Measure of Patient Safety|The Change From Baseline in Mean Beck Depression Inventory-II (BDI-II) Score at the End of 91 Days (13 Weeks) of Treatment,GW Research Ltd,All,"18 Years and older   (Adult, Older Adult)",Phase 2,62,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GWMD1092|2010-020458-33,Oct-10,May-12,Sep-12,8-Oct-10,20-Jan-14,18-Sep-14,"Woolpit Health Centre, Bury St Edmonds, United Kingdom|Mount Farm Surgery, Bury St Edmonds, United Kingdom|University of Nottingham, Medical School at Derby, Royal Derby Hospital, Derby, United Kingdom|James Paget University Hospital, Gorleston-on-Sea, Norfolk, United Kingdom|MAC UK Neuroscience Ltd., Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT01217112
NCT01216956,Metabolic Effects of an 8 Week Niaspan Treatment in Patients With Abdominal Obesity and Mixed Dyslipidemia,,Completed,No Results Available,Insulin Sensitivity|Lipoproteins Metabolism|Non Esterified Fatty Acid Kinetics|Lipid Profile,Drug: Extended-release nicotinic acid versus placebo,Evolution of non-esterified fatty acid and triglycerides concentrations over time|Insulin sensitivity after treatment|Lipoproteins metabolism|Lipid profile,"Centre de Recherche en Nutrition Humaine Rhone-Alpe|Institut National de la Santé Et de la Recherche Médicale, France|GlaxoSmithKline",Male,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,24,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Basic Science,NIASPAN-C05-36,Sep-06,Jun-09,Mar-10,7-Oct-10,null,7-Oct-10,"Centre de Recherche en Nutrition Humaine, Nantes, France",,https://ClinicalTrials.gov/show/NCT01216956
NCT01212900,Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression,,Completed,Has Results,Atherosclerosis|Hypercholesterolemia,"Drug: Statins, HMG CoA",Change in Mean of Wall Volume of Internal Carotid Arteries,"National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)",All,"50 Years to 99 Years   (Adult, Older Adult)",Phase 4,230,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,100214|10-H-0214,30-Sep-10,30-Nov-16,22-Feb-17,1-Oct-10,31-Oct-18,30-Nov-18,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT01212900/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01212900
NCT01211847,Efficacy Study of Diazoxide Choline to Treat Hypertriglyceridemia,,Completed,No Results Available,Hypertriglyceridemia|Dyslipidemia,Drug: Diazoxide Choline Controlled-Release Tablet|Drug: Placebo,Triglyceride-lowering efficacy of DCCR|Improvement in other lipid profiles with DCCR,"Essentialis, Inc.|Medpace, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,44,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CT013,Oct-10,Sep-11,Dec-11,30-Sep-10,null,10-Jan-14,,,https://ClinicalTrials.gov/show/NCT01211847
NCT01212159,Telephone Based Management of Hyperlipidemia,,Completed,Has Results,Hyperlipidemia,Device: Self Monitoring Lipid Analyzer,LDL Level Change From Baseline|Medication Compliance|LDL Values at Two Week Interval,Temple University|Merck Sharp & Dohme Corp.,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,70,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12832,Nov-10,Jul-15,Aug-15,30-Sep-10,25-Sep-15,25-Sep-15,"Temple University Hospital, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01212159
NCT01212328,"A Multi-site, Individually Randomized, Controlled Translation Trial of Integrated and Comprehensive Care Strategies to Reduce Cardiovascular Disease (CVD) Risk Among 1,120 Type 2 Diabetes Mellitus(T2DM) Patients in South Asia",CARRS,Unknown status,No Results Available,Type 2 Diabetes Mellitus|Hypertension|Dyslipidaemia,Other: Care Coordinator + Decision Support Software|Other: Usual care,Multiple CVD risk factor control targets|Single risk factor control of at least one target either HbA1c or blood pressure or LDL-Cholesterol|The cost effectiveness analysis of the intervention compared to the usual care.|Quality of life|Prescriber and patient acceptability of the Digital Support software and care coordinator with management guidelines.,"Public Health Foundation of India|National Heart, Lung, and Blood Institute (NHLBI)|United Health Group, USA|All India Institute of Medical Sciences, New Delhi|Madras Diabetes Research Foundation, Chennai|Aga Khan University",All,"35 Years and older   (Adult, Older Adult)",Not Applicable,1120,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,UTRN 022342347-29072010248,Oct-10,Dec-13,Jun-14,30-Sep-10,null,5-Sep-11,"Bangalore Endocrinology and Diabetes Research Centre,, #35, 5th Cross,Malleswaram Circle,, Bangalore, Karnataka, India|St. John's Medical College & Hospital,, Sarjapur Road, Koramangala,, Bangalore, India|Diabetes Research Centre & MV Hospital for Diabetes,, No 4 West Madha Church Street, Royapuram, Chennai, India|Public Health Foundation of India, New Delhi, Delhi, India|Endocrine Division, Department of Medicine, Goa Medical College,, Bambolim, Goa, India|Department of Endocrinology, CARE Hospital,, Road No 1, Banjara Hills,, Hyderabad,, India|Osmania General Hospital,, 2nd Floor, Golden Jubilee Block, Afzalgunj,, Hyderabad, India|Amrita Institute of Medical Sciences, Kochi, Kerala, India|Topiwala National Medical College & BYL Nair Ch. Hospital,, Dr. A. L. Nair Road, Mumbai Central,, Mumbai, India|Department of CHS, The Aga Khan, University,, P.O. BOx. 3500 Stadium, Road,, Karachi, Pakistan",,https://ClinicalTrials.gov/show/NCT01212328
NCT01208961,"Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation",ECLIPSE,Completed,Has Results,Severe Hypertriglyceridemia,Drug: Epanova (4 g) and Lovaza (4 g)|Drug: Lovaza (4 g) and Epanova (4 g),AUC(0-t): Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (the Final Time With a Concentration ≥ LOQ)|AUC(Inf): Area Under the Plasma Concentration-time Curve From 0 to Infinity|C(Max): Maximum Plasma Concentration,AstraZeneca|Radiant Research,All,"18 Years and older   (Adult, Older Adult)",Phase 2,54,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OM-EPA-001,Sep-10,Nov-10,Nov-10,24-Sep-10,6-Jan-14,15-Jul-15,"Radiant Research, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT01208961
NCT01205750,Hepatic Insulin Sensitivity and Very Low Density Lipoprotein Triglyceride (VLDL-TG) Kinetics,,Completed,No Results Available,Obesity|Dyslipidemia,Other: Glucose clamp,VLDL-TG kinetics|Hepatic insulin sensitivity,University of Aarhus,Male,20 Years to 50 Years   (Adult),Not Applicable,24,Other,Interventional,Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,2009-0132,Mar-10,Sep-10,Sep-10,20-Sep-10,null,17-Jun-11,"Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark",,https://ClinicalTrials.gov/show/NCT01205750
NCT01190007,Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients,,Completed,Has Results,Hypertension|Hypercholesterolemia|Angina Pectoris,Drug: Caduet,Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change From Baseline in Trough Systolic Blood Pressure (SBP) at Each Visit in Participant Population With Both Hypertension and Hypercholesterolemia|Change From Baseline in Trough Systolic Blood Pressure (SBP) at Each Visit in Population With Both Angina Pectoris and Hypercholesterolemia|Change From Baseline in Trough Diastolic Blood Pressure (DBP) at Each Visit in Participant Population With Both Hypertension and Hypercholesterolemia|Change From Baseline in Trough Diastolic Blood Pressure (DBP) at Each Visit in Participant Population With Angina Pectoris and Hypercholesterolemia|Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Each Visit|Percent Change From Baseline in Total Cholesterol (TC) at Each Visit|Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Each Visit|Percent Change From Baseline in Triglyceride (TG) at Each Visit|Change From Baseline in Ratio of Low Density Lipoprotein Cholesterol (LDL-C) to High Density Lipoprotein Cholesterol (HDL-C) at Each Visit|Change From Baseline in Ratio of Total Cholesterol (TC) to High Density Lipoprotein Cholesterol (HDL-C) at Each Visit|Percent Change From Baseline in Apolipoprotein B at Each Visit,Pfizer,All,"20 Years and older   (Adult, Older Adult)",Phase 4,159,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A3841064,Aug-10,Feb-12,Feb-12,27-Aug-10,3-Dec-12,24-Dec-12,"Healthcare Corporation MEDOC Medical Dock&Clinic, Nagoya, Aichi, Japan|Beppu Medical Clinic, Dazaifu, Fukuoka, Japan|Morizono medical clinic, Kitakyushu, Fukuoka, Japan|Gakkentoshi Clinic, Nishi-ku, Fukuoka, Japan|Department of internal gastro-intestinal medicine Ohshima clinic, Sapporo, Hokkaido, Japan|Oofuji Clinic, Amagasaki, Hyogo, Japan|Mizutani Clinic, Kobe, Hyogo, Japan|Nada Clinic, Kobe, Hyogo, Japan|Idaimae-naika Clinic, Kawasaki, Kanagawa, Japan|Sakakibara Clinic, Wakaumekai Medical Corporation, Yokohama, Kanagawa, Japan|Masunaga Clinic, Fujimi, Saitama, Japan|Sugiura Clinic, Kawaguchi, Saitama, Japan|Masuda Clinic, Adachi-ku, Tokyo, Japan|Wakasugi Family Clinic, Arakawa-ku, Tokyo, Japan|Medical Care Law Person Corporation Kenseikai, Kobayashi Internal Medicine Clinic, Koto-ku, Tokyo, Japan|Banno Clinic, Ohta-ku, Tokyo, Japan|Hatano Medical Clinic, Setagaya-ku, Tokyo, Japan|Suzuki Circulatory Medical Clinic, Setagaya-ku, Tokyo, Japan|Yano Cardiovascular Clinic, Fukuoka, Japan|Nakaoka Clinic, Osaka, Japan",,https://ClinicalTrials.gov/show/NCT01190007
NCT01187056,The RISAP-study: a Complex Intervention in Risk Communication and Shared Decision-making in General Practice,RISAP,Completed,No Results Available,High Cholesterol|Cardiovascular Disease,Behavioral: Training programme,"The primary patient outcome is adherence to treatment choice.|satisfaction with decision.|self-rated health|anxiety|enablement|satisfaction with communication,|satisfaction and confidence in decision|number of contacts to health services","University of Aarhus|TrygFonden, Denmark",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,179,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,2007-41-1446,Nov-07,Jul-12,Jul-12,23-Aug-10,null,9-May-17,,,https://ClinicalTrials.gov/show/NCT01187056
NCT01185795,Efficacy of Cardioviva™ Probiotic Yogurt Formulation,,Completed,No Results Available,Hypercholesterolemia,Dietary Supplement: Cardioviva™ yogurt|Dietary Supplement: Placebo yogurt,The primary outcome variable will be the percent change from baseline in Low Density Lipoprotein Cholesterol (LDL-C),Micropharma Limited,All,"18 Years to 74 Years   (Adult, Older Adult)",Phase 2,150,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MP-001,Sep-08,Jan-09,Apr-09,20-Aug-10,null,2-Jul-12,,,https://ClinicalTrials.gov/show/NCT01185795
NCT01180764,Effects of Lovaza on High Density Lipoprotein (HDL) Composition and Function in Hypertriglyceridemia,,Withdrawn,No Results Available,Hypertriglyceridemia,Drug: Lovaza (Omega-3 acid ethyl esters)|Drug: Placebo,HDL Composition|HDL cholesterol composition by density subfraction|Safety,University of Utah|GlaxoSmithKline,All,"35 Years to 75 Years   (Adult, Older Adult)",Phase 4,0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",40562,Aug-10,Aug-12,Oct-12,12-Aug-10,null,8-Feb-16,"University of Utah, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT01180764
NCT01173939,Primary Prevention of Major Adverse Cardiac Events (MACE) With Standard and Intensive Statin Treatment in Patients With Diabetes: Survival and Cardiovascular Event Assessments,POSITIVE,Terminated,No Results Available,Hypercholesterolemia|Type 2 Diabetes|Hypertension,Drug: Pravastatin|Drug: Rosuvastatin,"MACE (time to event): MACE (time to event): myocardial infarction, unstable angina, cardiovascular death, revascularization, fatal/nonfatal cerebrovascular accident, peripheral arteriopathy, aortic event|Prevention of individual MACE|Prevention of MACE(combination of each category)|Prevention, frequency and distribution of type of the following non-MACE cardiac and cerebrovascular events during the study period: heart failure requiring hospitalization, transient ischemic attack (TIA), abnormal ankle-brachial index (abnormal ABI)|Frequency and distribution of type of MACE during the study period Including correlation with LDL-C, HDL-C and LDL-C/HDL-C ratio (hereafter referred to as ""L/H ratio"")|Frequency and distribution of type of deaths during the study period|Frequency and distribution of type of hospitalizations during the study period|Frequency of other events (malignancy, dementia, need of nursing care)|Frequency and type of adverse events",Positive Trial Group,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,10000,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,35,Jul-10,Jun-14,null,2-Aug-10,null,1-Jun-11,"Hiramitsu Heart Clinic, Nagoya city, Aichi pref., Japan|Medical Dock&Clinic, Nagoya city, Aichi pref., Japan|Matsuno Medical Clinic, Iyo gun, Ehime pref., Japan|Ishite Matsumoto Naika Junkanki Clinic, Matsuyama city, Ehime pref., Japan|Ehime Medical CO-OP Izumigawa Clinic, Niihama city, Ehime pref., Japan|Tsugawa Internal Medicine Clinic, Echizen city, Fukui pref., Japan|Fukui Chuo Clinic, Fukui city, Fukui pref., Japan|Koshino Clinic, Sakai city, Fukui pref., Japan|Fukuoka University Chikushi Hospital, Chikushino city, Fukuoka pref., Japan|Saiseikai Futsukaichi Hospital, Chikushino city, Fukuoka pref., Japan|Abies Clinic, Fukuoka city, Fukuoka pref., Japan|Hirano Medical Clinic, Fukuoka city, Fukuoka pref., Japan|Naitoh Clinic, Fukuoka city, Fukuoka pref., Japan|Saku Hospital, Fukuoka city, Fukuoka pref., Japan|Fukuoka Tokushukai Medical Center, Kasuga city, Fukuoka pref., Japan|Morizono Naika, Kitakyusyu city, Fukuoka pref., Japan|Kawai Naika Clinic, Gifu city, Gifu pref., Japan|Hiroshima General Hospital of West Japan Railway Company, Hiroshima city, Hiroshima pref., Japan|Hijirigaoka Hospital, Date city, Hokkaido pref., Japan|Kyoaikai Hospital, Hakodate city, Hokkaido pref., Japan|Miyazawa Cardiovascular And Internal Medicine Clinic, Kato-gun, Hokkaido pref., Japan|Jiyugaoka Yamada Clinic, Obihiro city, Hokkaido pref., Japan|Chikama Clinic, Sapporo city, Hokkaido pref., Japan|Hiro Clinic, Sapporo city, Hokkaido pref., Japan|Medical and Radiology Clinic Caress Sapporo Hokko Memorial Hospital, Sapporo city, Hokkaido pref., Japan|Seiwa Memorial Hospital, Sapporo city, Hokkaido pref., Japan|Medical Treatment Corporate Foundation Yubari Kibounomori Yubari City Clinic, Yubari city, Hokkaido pref., Japan|Ino Hospital, Himeji city, Hyogo pref., Japan|Katsuya Clinic, Amagasaki city, Hyogo pref, Japan|Kotani Diabetes Clinic, Kobe city, Hyogo pref, Japan|Shimizu Clinic, Kobe city, Hyogo pref, Japan|Dr. Kodama's Office of Internal Medicine, Nishinomiya city, Hyogo pref, Japan|Koga Hospital, Koga city, Ibaraki pref., Japan|Imura Internal Medicine Clinic, Hakusan city, Ishikawa pref., Japan|Yanagi Medical Clinic, Hakusan city, Ishikawa pref., Japan|Okyozuka Clinic, Ishikawa gun, Ishikawa pref., Japan|Koni Clinic, Kahoku gun, Ishikawa pref., Japan|Murata Clinic, Kahoku gun, Ishikawa pref., Japan|Arai Naika Clinic, Kanazawa city, Ishikawa pref., Japan|Dr. Hayakawa's Family Clinic, Kanazawa city, Ishikawa pref., Japan|Wakasa Medical Clinic, Kanazawa city, Ishikawa pref., Japan|Morita Hospital, Komatsu city, Ishikawa pref., Japan|Kawasaki Family Clinic, Ichinoseki, Iwate pref., Japan|Sugie Clinic, Iwate gun, Iwate pref., Japan|Katsura General Clinic, Morioka city, Iwate pref., Japan|Takamiya General Clinic, Shiwa gun, Iwate pref., Japan|Hayashi Clinic, Marugame city, Kagawa pref., Japan|Otsuka Internal Medicine Clinic, Marugame city, Kagawa pref., Japan|Center for Preventive Medical Treatment, NTT West Takamatsu Hospital, Takamatsu city, Kagawa pref., Japan|Hananomiya Clinic, Takamatsu city, Kagawa pref., Japan|Hasegawa Outpatients Clinic for Cardiovascular Disease, Takamatsu city, Kagawa pref., Japan|Kojima Clinic, Takamatsu city, Kagawa pref., Japan|Matsuoka Clinic, Takamatsu city, Kagawa pref., Japan|Osumi-Kanoya Hospital, Kanoya city, Kagoshima pref., Japan|Yakushima Tokushukai Hospital, Kumage gun, Kagoshima pref., Japan|Nemoto G.I.M. Clinic, Ashigara-kami gun, Kanagawa pref., Japan|Magokoro Internal Medicine and Orthopedic Clinic, Ashigarakami gun, Kanagawa pref., Japan|Kasuya Clinic, Atsugi City, Kanagawa pref., Japan|Kuboshima Clinic, Fujisawa city, Kanagawa pref., Japan|Takahashi Clinic, Fujisawa city, Kanagawa pref., Japan|Akizawa Clinic, Isehara city, Kanagawa pref., Japan|Medical Corp Takeda Clinic, Isehara city, Kanagawa pref., Japan|Hashimoto Clinic, Kamakura city, Kanagawa pref., Japan|Iroden Clinic, Kamakura city, Kanagawa pref., Japan|Kamakura Naika Shinryosyo, Kamakura city, Kanagawa pref., Japan|Shohei Clinic, Kamakura city, Kanagawa pref., Japan|Hatori Medical Clinic, Kawasaki city, Kanagawa pref., Japan|Hirayasu Iin, Kawasaki city, Kanagawa pref., Japan|Kamegaya Medical Clinic, Kawasaki city, Kanagawa pref., Japan|Kirimura Iin, Kawasaki city, Kanagawa pref., Japan|Kojima Clinic, Odawara city, Kanagawa pref., Japan|Hakuai Iin, Sagamihara city, Kanagawa pref., Japan|Sato Clinic, Sagamihara city, Kanagawa pref., Japan|Toshiba Rinkan Hospital, Sagamihara city, Kanagawa pref., Japan|Yamamoto Clinic, Sagamihara city, Kanagawa pref., Japan|Fukumura Clinic, Yokohama city, Kanagawa pref., Japan|Fukushi Clinic, Yokohama city, Kanagawa pref., Japan|International Goodwill Hospital, Yokohama city, Kanagawa pref., Japan|Kikuchi Clinic, Yokohama city, Kanagawa pref., Japan|Matsuo Naika Clinic, Yokohama city, Kanagawa pref., Japan|Miho-cho Cardiovascular Medical Clinic, Yokohama city, Kanagawa pref., Japan|Minamisawa Clinic, Yokohama city, Kanagawa pref., Japan|Miyoshi-Clinic, Yokohama city, Kanagawa pref., Japan|Paula's Clinic, Yokohama city, Kanagawa pref., Japan|Shimokurata Heart Clinic, Yokohama city, Kanagawa pref., Japan|Shinwakai Fukuda Iin, Yokohama city, Kanagawa pref., Japan|Shinyoshida Clinic, Yokohama city, Kanagawa pref., Japan|Suzuki Orthopedic Clinic, Yokohama city, Kanagawa pref., Japan|Yokohama City University Medical Center, Yokohama city, Kanagawa pref., Japan|Yokohama Sotetsu bldg. clinic of internal medicine, Yokohama city, Kanagawa pref., Japan|Hara Clinic, Yokosuka City, Kanagawa pref., Japan|Ueta Medical Clinic, Kochi city, Kochi pref., Japan|Nakayama Cardiovascular Clinic, Amakusa city, Kumamoto pref., Japan|Yamashita Clinic, Amakusa city, Kumamoto pref., Japan|National Health Insurance Central Hospital Aso, Aso city, Kumamoto pref., Japan|Sakanashi Heart Clinic, Aso city, Kumamoto pref., Japan|Koyasako iin, Kamimashiki gun, Kumamoto pref., Japan|Kawaguchi Hospital, Kikuchi city, Kumamoto pref., Japan|Miyamoto Internal Clinic, Kikuchi city, Kumamoto pref., Japan|Doi Cardiovascular Clinic, Kumamoto city, Kumamoto pref., Japan|Doi Naika-ichoka Clinic, Kumamoto city, Kumamoto pref., Japan|Haraguchi Circular&Internal Medical Clinic, Kumamoto city, Kumamoto pref., Japan|Jinnouchi Clinic Diabetes Care Center, Kumamoto city, Kumamoto pref., Japan|Kiyota Junkanki Naika Iin, Kumamoto city, Kumamoto pref., Japan|Maki Cardiovascular Clinic, Kumamoto city, Kumamoto pref., Japan|Nozuhara Clinic, Kumamoto city, Kumamoto pref., Japan|Ootsuka Hospital, Kumamoto city, Kumamoto pref., Japan|Shono Heart Clinic, Kumamoto city, Kumamoto pref., Japan|Suefuji Naika Junkankika, Kumamoto city, Kumamoto pref., Japan|Suizenji Tohya Hospital, Kumamoto city, Kumamoto pref., Japan|Terao Hospital, Kumamoto city, Kumamoto pref., Japan|Yi Medical Clinic, Kumamoto city, Kumamoto pref., Japan|Munakata Clinic, Shimomashiki gun, Kumamoto pref., Japan|Higashi Diabetes and Cardiovascular Clinic, Tamana city, Kumamoto pref., Japan|Yoshimura Jyunnkannkika Naika Iinn, Tamana city, Kumamoto pref., Japan|Universal Shipbuilding Co. Ariake Shipyard Ariake Infirmary, Tamana gun, Kumamoto pref., Japan|Miyagi Clinic Cardiovascular Medicine, Yatsushiro city, Kumamoto pref., Japan|Koide Iin, Kizugawa-city, Kyoto pref., Japan|Sawai medical Clinic, Kyotanabe city, Kyoto pref., Japan|Asamoto Clinic of Internal Medicine, Kyoto city, Kyoto pref., Japan|Gotoh Clinic, Kyoto city, Kyoto pref., Japan|Higashiyama Takeda Hospital, Kyoto city, Kyoto pref., Japan|Isoda Internal Medical Clinic, Kyoto city, Kyoto pref., Japan|Omoto Clinic, Kyoto city, Kyoto pref., Japan|Sakazaki Clinic, Kyoto city, Kyoto pref., Japan|Shinya Clinic, Kyoto city, Kyoto pref., Japan|Takagi Cardiology Clinic, Kyoto city, Kyoto pref., Japan|Takenaka Clinic, Kyoto city, Kyoto pref., Japan|Tegoshi Clinic, Kyoto city, Kyoto pref., Japan|Kimura Naika Clinic, Yosa gun, Kyoto pref., Japan|Shimizu Clinic, Ise city, Mie pref., Japan|Horii Clinic Kiodai, Nabari city, Mie pref., Japan|Yamoto-naika Clinic, Higashi matsushima city, Miyagi pref., Japan|Seisuikai Yoshioka QQ Clinic, Kurokawa gun, Miyagi pref., Japan|Ohtomo Clinic, Tome City, Miyagi pref., Japan|Shimoina Kosei Hospital, Shimoina gun, Nagano pref., Japan|Yokoyama Medical Clinic, Shiojiri city, Nagano pref., Japan|Sato Clinic, Suzaka city, Nagano pref., Japan|Hoshiko Clinic, Nagasaki city, Nagasaki pref., Japan|Shinagawa Clinic, Nagasaki city, Nagasaki pref., Japan|Iryohojin Yamamoto Naika, Nishisonogi gun, Nagasaki pref., Japan|Yamada Clinic, Gojo city, Nara pref., Japan|Uyama Naika Clinic, Ikoma city, Nara pref., Japan|Clinic Jinguumae, Kahihara city, Nara pref., Japan|Kasahara Clinic, Kahihara city, Nara pref., Japan|Sawada Clinic, Kashiba city, Nara pref., Japan|Doi Clinic, Kashihara city, Nara pref., Japan|Medical Corporation Kiriyama Clinic, Kashihara city, Nara pref., Japan|Miyamoto Clinic, Kashihara city, Nara pref., Japan|Oosumi Naika Iin, Kashihara city, Nara pref., Japan|Kondo Clinic Mamigaoka Purified Center, Kitakatsuragi gun, Nara pref., Japan|Matsuoka Clinic, Kitakatsuragi gun, Nara pref., Japan|Nakahori Iin, Kitakatsuragi gun, Nara pref., Japan|Seiwadai Clinic, Kitakatsuragi gun, Nara pref., Japan|Saiseikai Nara Hospital, Nara city, Nara pref., Japan|Takanohara Central Hospital, Nara city, Nara pref., Japan|Takanohara Suzuran-naika, Nara city, Nara pref., Japan|Ote Clinic of Internal Medicine, Sakurai city, Nara pref., Japan|Sakaguchi Clinic, Sakurai city, Nara pref., Japan|Kokuho Central Hospital, Shiki gun, Nara pref., Japan|Makiura Naika, Yamatokoriyama city, Nara pref., Japan|Matsuta Heart Clinic, Yamatokoriyama city, Nara pref., Japan|Nakatani Clinic, Yamatotakada city, Nara pref., Japan|Sano Clinic, Murakami city, Niigata pref., Japan|Kawaguchi Clinic, Nagaoka city, Niigata pref., Japan|Maeda Medical Clinic, Niigata city, Niigata pref., Japan|Watanabe NJ Clinic, Beppu city, Oiat pref., Japan|Hirata Clinic, Oita city, Oiat pref., Japan|Ninomiya Clinic, Oita city, Oiat pref., Japan|Sumi Cardiology Clinic, Oita city, Oiat pref., Japan|Tokumaru Digestive Internal Medicine Clinic, Oita city, Oiat pref., Japan|Tsuzaki Clinic, Oita city, Oiat pref., Japan|Ishida Medical Clinic, Usa city, Oiat pref., Japan|Hachiouji Naika Clinic, Kurashiki city, Okayama pref., Japan|Inada Clinic, Kurashiki city, Okayama pref., Japan|Hisamatsu Medical Clinic, Okayama city, Okayama pref., Japan|Yuhara Naika Clinic, Okayama city, Okayama pref., Japan|Hattori Clinic, Setouchi city, Okayama pref., Japan|Nishimura Clinic, Fujiidera city, Osaka pref., Japan|Ikeda Clinic, Higashiosaka city, Osaka pref., Japan|Ogawa Clinic, Higashiosaka city, Osaka pref., Japan|Taisei Clinic, Hirakata city, Osaka pref., Japan|Ishiga Clinic, Ibaraki city, Osaka pref., Japan|Masuda Clinic, Ibaraki city, Osaka pref., Japan|Kanazawa Clinic, Izumi city, Osaka pref., Japan|Misugi Clinic, Kaizuka city, Osaka pref., Japan|Yoshida Clinic, Kaizuka city, Osaka pref., Japan|Mori Iin, Kishiwada city, Osaka pref., Japan|Medical Corporation Joukokai Teranishi-geka naika, Moriguchi city, Osaka pref., Japan|Iryouhoujin Suisyoukai Murata Hospital, Osaka city, Osaka pref., Japan|Izuoka Clinic, Osaka city, Osaka pref., Japan|Keiju Hospital, Osaka city, Osaka pref., Japan|Kondo Clinic, Osaka city, Osaka pref., Japan|Kubota Clinic, Osaka city, Osaka pref., Japan|Matsushita Medical Clinic, Osaka city, Osaka pref., Japan|Nishizawa Clinic, Osaka city, Osaka pref., Japan|Osaka General Medical Center, Osaka city, Osaka pref., Japan|Senpuku Clinic, Osaka city, Osaka pref., Japan|Tai Internal Medicin Clinic, Osaka city, Osaka pref., Japan|Ueda Clinic, Osaka city, Osaka pref., Japan|Ohta Iin, Sakai city, Osaka pref., Japan|Ban Clinic, Suita city, Osaka pref., Japan|Iryohojin Nogi Naika Iin, Suita city, Osaka pref., Japan|Kobayashi Clinic, Suita city, Osaka pref., Japan|Ichida Internal Clinic, Takaishi city, Osaka pref., Japan|Yada Clinic, Takaishi city, Osaka pref., Japan|Ryo Clinic, Takatsuki city, Osaka pref., Japan|Matsuo Clinic, Yao city, Osaka pref., Japan|Enomoto Clinic, Ageo city, Saitama pref., Japan|Medimo Hanyu Clinic, Hanyu city, Saitama pref., Japan|Hirose Hospital, Kawagoe city, Saitama pref., Japan|Iryohojin Hogi Shinryojo, Kawaguchi city, Saitama pref., Japan|Tokutake Iin, Kawaguchi city, Saitama pref., Japan|Gamo Tenjinbashi Clinic, Koshigaya city, Saitama pref., Japan|Matsumoto Clinic, Koshigaya city, Saitama pref., Japan|Medical Corporation Shibuya Clinic, Kumagaya city, Saitama pref., Japan|Akimoto Clinic, Saitama city, Saitama pref., Japan|Iwatsuki-minami Hospital, Saitama city, Saitama pref., Japan|Suzuhiro Clinic, Saitama city, Saitama pref., Japan|Nashida naika clinic, Tokorozawa City, Saitama pref., Japan|Shizuoka Medical Alliance Shirahama Chuou Clinic, Shimoda city, Shizuoka pref., Japan|Akiyama Clinic, Shizuoka city, Shizuoka pref., Japan|Aoshima Clinic, Shizuoka city, Shizuoka pref., Japan|Eguchi Clinic, Shizuoka city, Shizuoka pref., Japan|Shizuoka Hospital, Shizuoka city, Shizuoka pref., Japan|Ueno Clinic, Yaizu city, Shizuoka pref., Japan|Takahashi Medical Clinic, Ohtawara city, Tochigi pref., Japan|Iryouhoujin Yuukoukai Morioka Naika Shonika, Oyama city, Tochigi pref., Japan|Takada Clinic, Tochigi city, Tochigi pref., Japan|Masuda Naika, Utsunomiya city, Tochigi pref., Japan|Murakami Clinic, Anan city, Tokushima pref., Japan|Fukushima Clinic, Itano gun, Tokushima pref., Japan|Yamamoto Naika Ityoka, Itano gun, Tokushima pref., Japan|Yuki National Health Insurance Hospital Of Minami Town, Kaifu gun, Tokushima pref., Japan|Sekishinkan Hospital, Komatsushima city, Tokushima pref., Japan|Ueta Clinic, Myozai gun, Tokushima pref., Japan|Kensei Uchimachi Clinic, Tokushima city, Tokushima pref., Japan|Kitagawa Naika Ityoka, Tokushima city, Tokushima pref., Japan|Kitasako Clinic, Tokushima city, Tokushima pref., Japan|Limbs Tokushima Clinic, Tokushima city, Tokushima pref., Japan|Matsumura Internal, Gastrointestial Medicine, Tokushima city, Tokushima pref., Japan|Okagawa Clinic, Tokushima city, Tokushima pref., Japan|Yokoi Internal Medicine, Tokushima city, Tokushima pref., Japan|Kimura Internal Medicine Clinic, Yoshinokawa city, Tokushima pref., Japan|Yata Clinic, Yoshinokawa city, Tokushima pref., Japan|Okubo Clinic, Akishima city, Tokyo, Japan|Juntendo University Hospital, Bunkyo ku, Tokyo, Japan|Choei Clinic, Edogawa ku, Tokyo, Japan|Shiraishi Iin, Edogawa ku, Tokyo, Japan|Hattori Clinic, Hachioji city, Tokyo, Japan|Toyoizumi Hospital, Hachioji city, Tokyo, Japan|Utsugidai Tajima Clinic, Hachioji City, Tokyo, Japan|Mochizuki Naika Clinic, Itabashi ku, Tokyo, Japan|Nishio Clinic, Itabashi ku, Tokyo, Japan|Ono Heart Clinic, Koto ku, Tokyo, Japan|Shiba Palace Clinic, Minato-ku, Tokyo, Japan|Kamada Clinic, Mitaka city, Tokyo, Japan|Tenjinmae Clinic, Mitaka city, Tokyo, Japan|Takayama Iin, Mitaka-shi, Tokyo, Japan|Sugawara Clinic, Nerima ku, Tokyo, Japan|Yamada Clinic, Ota-ku, Tokyo, Japan|Matsumura Gastroenterological Clinic, Setagaya ku, Tokyo, Japan|Magari Clinic, Shinjuku ku, Tokyo, Japan|Yotsuya Internal Medicine Clinic, Shinjuku ku, Tokyo, Japan|Yotsuya-Murakami Internal Medicine Clinic, Shinjuku ku, Tokyo, Japan|Obayashi Clinic, Sumida city, Tokyo, Japan|Sumidagawa Clinic, Sumida ku, Tokyo, Japan|ISHII Medical Clinic, Tachikawa-shi, Tokyo, Japan|Takahashi Ko Minako Clinic, Murayama city, Yamagata pref., Japan|Obanazawa City Clinic, Obanazawa city, Yamagata pref., Japan|Okuyama Clinic, Obanazawa city, Yamagata pref., Japan|Sakae Clinic, Obanazawa city, Yamagata pref., Japan|Honma Clinic, Sakata city, Yamagata pref., Japan|Isoda Clinic, Yamagata city, Yamagata pref., Japan|Nihei Clinic, Yamagata city, Yamagata pref., Japan|Shimasaki Clinic, Yamagata city, Yamagata pref., Japan|Yamagata Tokushukai Hospital, Yamagata city, Yamagata pref., Japan|Iwasaki Naika Iin, Iwakuni city, Yamaguchi pref., Japan|Kuwahara Clinic, Iwakuni city, Yamaguchi pref., Japan|Ayame Medical Clinic, Shimonoseki city, Yamaguchi pref., Japan|Johno Clinic, Shimonoseki city, Yamaguchi pref., Japan|Matsuda Medical Clinic, Shimonoseki city, Yamaguchi pref., Japan|Mizumachi Medical Clinic, Shimonoseki city, Yamaguchi pref., Japan|Noda Clinic, Shimonoseki city, Yamaguchi pref., Japan|Fujii Clinic, Ube City, Yamaguchi pref., Japan|Shakaiiryouhoujin Onaka Hospital, Ube City, Yamaguchi pref., Japan|Watada‐naika Hospital, Ube city, Yamaguchi pref., Japan|Ouchi Clinic, Yamaguchi city, Yamaguchi pref., Japan|Yoshizaki Clinic, Chuo city, Yamanashi pref., Japan|Takahashi Clinic, Nishi Yatsushiro gun, Yamanashi pref., Japan|Higashikatsura Medical Clinic, Tsuru city, Yamanashi pref., Japan|Fukushi Clinic, Aomori city, Japan|Kashiwagi Clinic, Ayase city, Japan|Hayashi Diabetes Clinic, Chigasaki city, Japan|Uchiyama Clinic, Joetsu city, Japan|Nitta Medical Clinic, Kamiinagun, Japan|Imai Clinic, Kawasaki city, Japan|Tani Clinic, Kitakyusyu City, Japan|Marumo Clinic, Koganei city, Japan|Ihara Clinic, Kyoto city, Japan|Goko-Hospital, Matsudo city, Japan|Satou Clinic, Moka city, Japan|Iino Clinic, Nirasaki city, Japan|Miura Clinic, Osaka City, Japan|Kuroda Iin, Otsuki City, Japan|Sasaki Clinic, Sendai city, Japan|Kamata Clinic of Internal Medicine, Shiki city, Japan|Nishikawa Clinic, Shimoda city, Japan|Satou Iin, Shimoinagun, Japan|Kumagai Clinic, Shinshiro city, Japan|Suzuki Clinic, Toyokawa city, Japan|Benibana Clinic, Yamagata city, Japan|Fujimi Clinic, Yokohama city, Japan|Hongo Clinic, Yokohama city, Japan|Jiyukai Yamada Naika, Yokohama city, Japan|Shonan Ochanomizu Clinic, Yokohama city, Japan|Tani Clinic Internal Medicine, Allergology & Rheumatology, Yokohama city, Japan",,https://ClinicalTrials.gov/show/NCT01173939
NCT01166633,Efficacy and Safety Study of Pitavastatin Versus Atorvastatin to Treat Hypercholesterolemia,PITCH,Completed,No Results Available,Hypercholesterolemia,Drug: pitavastatin|Drug: atorvastatin,"Proportion of the subjects whose ALT levels were over CTCAE grade II after treatment|1.Changes in ALT after treatment|2.Changes in AST after treatment|3.Changes in LDL-C, TC, TG and HDL-C after treatment|4.Changes in fat in liver after treatment",JW Pharmaceutical,All,"25 Years to 75 Years   (Adult, Older Adult)",Phase 4,200,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CWP-PTV-707,Jun-09,Nov-10,Feb-11,21-Jul-10,null,4-Apr-13,,,https://ClinicalTrials.gov/show/NCT01166633
NCT01165853,Effects of Consuming Sugar-Sweetened Beverages With Meals for 10 Weeks,IPOP,Completed,No Results Available,Metabolic Syndrome|Insulin Resistance|Dyslipidemia,Other: Glucose|Other: Fructose,24-hour triglyceride area under the curve|Insulin sensitivity index,"University of California, Davis|National Heart, Lung, and Blood Institute (NHLBI)",All,"40 Years to 72 Years   (Adult, Older Adult)",Not Applicable,32,Other|NIH,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",200412368|R01HL075675,Jul-05,Nov-07,Jul-12,20-Jul-10,null,30-May-17,"Clinical Research Center, Sacramento, California, United States",,https://ClinicalTrials.gov/show/NCT01165853
NCT01163838,Multiple-Dose Safety Study Of RN316 For TheTreatment Of Hypercholesterolemia,,Withdrawn,No Results Available,Hypercholesterolemia|Dyslipidemia,Biological: Placebo|Biological: 1 mg/kg every 2 weeks|Biological: 2 mg/kg every 4 weeks|Biological: 4 mg/kg every 4 weeks|Biological: 4 mg/kg every 8 weeks|Biological: 8 mg/kg every 8 weeks|Biological: 12 mg/kg every 8 weeks,"Incidence of dose limiting or intolerable treatment related adverse events (AEs).|Incidence, severity and causal relationship of treatment emergent AEs (TEAEs).|Incidence of abnormal and clinically relevant safety laboratories.|Abnormal and clinically relevant changes in vital signs, BP, and ECG parameters.|Incidence of anti-drug-antibodies.|PK parameter estimates including but not be limited to: AUC, Tmax, Cmax terminal elimination half life (t1/2), Clearance (CL), volume of distribution at steady state (Vss), and accumulation ratio (R) of RN316.|Absolute and percentage change in LDL C from baseline.|Proportion of subjects who achieve a target LDL C of <100 mg/mL.|Proportion of subjects who achieve a target LDL C of <70 mg/dL.|Proportion of subjects achieving 50% decrease in LDL C from baseline.",Pfizer,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",B1481002,Aug-10,Mar-11,Mar-11,16-Jul-10,null,23-Apr-15,,,https://ClinicalTrials.gov/show/NCT01163838
NCT01163851,Pharmacokinetic And Pharmacodynamic Study Of A Single-Dose Of PF-04950615 (RN316) In Combination With Atorvastatin,,Completed,Has Results,Hypercholesterolemia|Dyslipidemia,Biological: 4 mg/kg|Biological: 0.5 mg/kg,"Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-04950615|Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04950615|Maximum Observed Plasma Concentration (Cmax) of PF-04950615|Plasma Decay Half-Life (t1/2) of PF-04950615|Systemic Clearance (CL) of PF-04950615|Volume of Distribution at Steady State (Vss) of PF-04950615|Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC0-inf) of PF-04950615|Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Atorvastatin|Time to Reach Maximum Observed Plasma Concentration (Tmax) of Atorvastatin|Maximum Observed Plasma Concentration (Cmax) of Atorvastatin|Plasma Decay Half-Life (t1/2) of Atorvastatin|Apparent Oral Clearance (CL/F) of Atorvastatin|Apparent Volume of Distribution (Vz/F) of Atorvastatin|Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64|Change From Baseline in Fasting Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64|Change From Baseline in Fasting Non High-density Lipoprotein-Cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64|Change From Baseline in Fasting Triglycerides at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64|Change From Baseline in Fasting Apolipoprotein B (ApoB) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64|Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64|Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64|Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64|Percent Change From Baseline in Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64|Percent Change From Baseline in Fasting Non-High-density Lipoprotein-cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64|Percent Change From Baseline in Fasting Triglycerides Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64|Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64|Percent Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64|Percent Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64|Duration of Low Density Lipoprotein (LDL) Lowering Effects|Number of Participants With Toxicity or Intolerable Dose Criteria|Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Treatment-Emergent Adverse Events by Severity|Number of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Physical Examination|Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Vital Signs|Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Electrocardiogram (ECG) Parameters|Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Laboratory Parameters|Number of Participants With Positive Anti-drug Antibodies (ADA)",Pfizer,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,25,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,B1481003,Jul-10,Feb-11,Apr-11,16-Jul-10,7-May-15,1-Mar-18,"Premier Research Group, Limited, Peoria, Arizona, United States|Dedicated Phase 1, Inc., Phoenix, Arizona, United States|Premier Research Group Limited, Phoenix, Arizona, United States|Vince and Associates Clinical Research, Overland Park, Kansas, United States|Vince and Associates Clinical Research, Overland Park, Kansas, United States",,https://ClinicalTrials.gov/show/NCT01163851
NCT01161082,Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant Atorvastatin,,Completed,No Results Available,Hypercholesterolemia,Drug: REGN727(SAR236553),The primary endpoint in the study is to assess the incidence and severity of treatment-emergent adverse events in hyperlipidemic patients treated with REGN727 or placebo receiving stable doses of atorvastatin.|To assess the pharmacodynamic effect of REGN727 added to atorvastatin on lipids|To assess the pharmacodynamic effect of monotherapy REGN727 in hyperlipidemic patients|To assess the pharmacokinetics of REGN727 in hyperlipidemic patients with or without atorvastatin,Regeneron Pharmaceuticals|Sanofi,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,72,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",R727-CL-1001,Jun-10,May-11,May-11,13-Jul-10,null,27-Jan-15,"Site 1, Cincinnati, Ohio, United States|Site 2, Knoxville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT01161082
NCT01156597,Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes,,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: pioglitazone,Increased HDL-Cholesterol and Decreased Triglycerides|HDL Apolipoprotein Levels at Study End-point|Cholesterol Efflux Capacity of HDL,"University of Miami|Takeda Pharmaceuticals North America, Inc.",All,"35 Years to 70 Years   (Adult, Older Adult)",Phase 3,30,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,06-009A,Apr-08,Sep-10,Sep-10,5-Jul-10,11-Nov-14,21-Nov-14,"Diabetes Research Institute, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT01156597
NCT01154036,MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162),,Completed,Has Results,Hypercholesterolemia,Drug: ezetimibe 10 mg|Drug: atorvastatin|Drug: Comparator: rosuvastatin,Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) (Phase I)|Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) (Phase II).|Percentage of Participants That Reach Target LDL-C Level of < 100 mg/dL (Phase I)|Percentage of Participants That Reach Target LDL-C Level of < 100 mg/dL (Phase II)|Percentage of Participants That Reach Target LDL-C Level of < 70 mg/dL (Phase I)|Percentage of Participants That Reach Target LDL-C Level of < 70 mg/dL (Phase II)|Percent Change From Baseline in Total Cholesterol (TC) (Phase I)|Percent Change From Baseline in Total Cholesterol (TC) (Phase II)|Percent Change From Baseline in Triglycerides (TG) (Phase I)|Percent Change From Baseline in Triglycerides (TG) (Phase II)|Percent Change From Baseline in High-density Lipoprotein-Cholesterol (HDL-C) (Phase I)|Percent Change From Baseline in HDL-C (Phase II)|Percent Change From Baseline in Apolipoprotein B (Apo B) (Phase I)|Percent Change From Baseline in Apo B (Phase II)|Percent Change From Baseline in Apolipoprotein A-I (Apo A-I) (Phase I)|Percent Change From Baseline in Apo A-I (Phase II)|Percent Change From Baseline in Non-HDL-C (Phase I)|Percent Change From Baseline in Non-HDL-C (Phase II)|Percent Change From Baseline in TC/HDL-C Ratio (Phase I)|Percent Change From Baseline in TC/HDL-C Ratio (Phase II)|Percent Change From Baseline in LDL-C/HDL-C Ratio (Phase I)|Percent Change From Baseline in LDL-C/HDL-C Ratio (Phase II)|Percent Change From Baseline in Apo B/Apo A-I Ratio (Phase I)|Percent Change From Baseline in Apo B/Apo A-I Ratio (Phase II)|Percent Change From Baseline in Non-HDL-C/HDL-C Ratio (Phase I)|Percent Change From Baseline in Non-HDL-C/HDL-C Ratio (Phase II)|Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) (Phase I)|Percent Change From Baseline in Hs-CRP (Phase II),Merck Sharp & Dohme Corp.,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 3,1547,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0653C-162|2010_517,Jul-10,Sep-12,Oct-12,30-Jun-10,12-Feb-14,2-Nov-15,,,https://ClinicalTrials.gov/show/NCT01154036
NCT01152073,A Study Of Nutraceutical Drinks For Cholesterol (Evaluating Effectiveness and Tolerability),,Completed,No Results Available,Hyperlipidemia,Dietary Supplement: Placebo|Dietary Supplement: Second Formulation|Dietary Supplement: Third Formulation,LDL Reduction|HDL change from control formulation|CRP change from control formulation|Triglyceride reduction from control formulation,"Healthy Drink Discoveries, Inc.",All,"20 Years to 80 Years   (Adult, Older Adult)",Not Applicable,79,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",2009.35,Oct-09,Sep-10,Sep-10,29-Jun-10,null,16-Mar-12,"Mitchell Karl, M.D. -- Cardiology, Boca Raton, Florida, United States",,https://ClinicalTrials.gov/show/NCT01152073
NCT01150188,Effects of Amino Acids on Regional Lipid Metabolism,,Completed,No Results Available,Hypertriglyceridemia,Dietary Supplement: Amino acids|Dietary Supplement: Placebo,Very low density lipoprotein (VLDL) turnover|Fat oxidation|Lipolysis|Triglyceride uptake in muscle and adipose tissue,University of Arkansas|National Institute on Aging (NIA),All,"50 Years to 75 Years   (Adult, Older Adult)",Not Applicable,125,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",139210|1R01AG033761-01A1,Jun-10,Aug-16,Aug-16,24-Jun-10,null,27-Oct-16,"University of Arkansas for Medical Science, Reynolds Aging Institute, Little Rock, Arkansas, United States",,https://ClinicalTrials.gov/show/NCT01150188
NCT01148004,"The Influence of Ritonavir, Alone and in Combination With Lopinavir, on Fenofibric Acid Pharmacokinetics in Healthy Volunteers",,Completed,No Results Available,HIV|Fenofibrate|Protease Inhibitors|Hypertriglyceridemia|Glucuronosyltransferase,Drug: Fenofibrate|Drug: Ritonavir|Drug: Lopinavir/Ritonavir,Fenofibratae pharmacokinetic parameter values,National Institutes of Health Clinical Center (CC),All,18 Years to 60 Years   (Adult),Phase 1,25,NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,100124|10-CC-0124,13-May-10,29-Jul-13,29-Jul-13,22-Jun-10,null,15-May-19,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01148004
NCT01145742,Controlling Hypertension in Diabetes- Feasibility Study,COACH-D,Completed,No Results Available,Type 2 Diabetes|Hypertension|Hyperlipidemia,Behavioral: home health/primary care collaboration,Blood pressure|Hemoglobin A1c|LDL Cholesterol,Albert Einstein College of Medicine|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"30 Years and older   (Adult, Older Adult)",Not Applicable,56,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Primary Purpose: Health Services Research,2006-232,Nov-06,Sep-09,Sep-09,17-Jun-10,null,12-Dec-18,"Albert Einstein College of Medicine, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT01145742
NCT01146522,"Safety, Tolerability,Pharmacokinetics(PK)and Pharmacodynamics(PD)Assessment of LCQ908 in Patients With Severe Hypertriglyceridemia",,Completed,No Results Available,Hyperlipoproteinemia,Drug: LCQ908|Drug: Placebo,"Fasting and postprandial plasma triglycerides|Blood concentration to characterize LCQ908 kinetics|Different blood lipid biomarkers (such as phospholipids, apolipoproteins, and free fatty acids)",Novartis Pharmaceuticals|Novartis,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,8,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CLCQ908A2212,May-10,Oct-11,Oct-11,17-Jun-10,null,1-Jan-13,"Novartis Investigative Site, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01146522
NCT01142908,Cardiovascular Intervention Improvement Telemedicine Study,,Completed,Has Results,Cardiovascular Disease|Hypertension|Diabetes|Hyperlipidemia,Behavioral: Pharmacist CVD,Framingham Risk Percent (Estimate of 10 Year Risk of Cardiovascular Disease in Percent)|Mean Systolic Blood Pressure|Mean Diastolic Blood Pressure|Medication Non-adherence|Cholesterol LDL|Body Mass Index|HBA1C in Diabetic Patients,VA Office of Research and Development,All,"Child, Adult, Older Adult",Not Applicable,428,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IIR 08-297,Nov-11,Apr-15,May-15,11-Jun-10,9-May-16,9-May-16,"Durham VA Medical Center, Durham, NC, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01142908
NCT01138865,Effect of CPAP on Biomarkers in Patients With OSA,CPAP,Unknown status,No Results Available,Obstructive Sleep Apnea,Device: AutoSet Spirit--Wash--Modified-AutoSet Spirit|Device: Modified-AutoSet Spirit--Wash-AutoSet Spirit,Effect of CPAP therapy on blood pressure|Effect of CPAP therapy on insulin resistance|Effect of CPAP therapy on plasma hs-CRP|Effect of CPAP therapy on lipid profile|Effect of CPAP therapy on urinary albumin-creatinine ratio|Effect of CPAP on anthropometric parameters|Effect of CPAP on visceral fat and other imagings|Effect of CPAP on carotid intima medical thickness|Effect of CPAP on adipokines and oxidative stress markers|Effect of CPAP on inflammatory cytokine levels.,"All India Institute of Medical Sciences, New Delhi",All,"30 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",SKS/CPAP-OSAS/2009,Mar-12,Sep-14,Mar-15,8-Jun-10,null,24-Jun-13,"All India Institute of Medical Sciences, New Delhi, Delhi, India",,https://ClinicalTrials.gov/show/NCT01138865
NCT01139398,Effect of Limicol on (LDL)-Cholesterol Levels in Moderate Hypercholesterolaemia,,Completed,No Results Available,Delivery of Health Care,Dietary Supplement: Limicol (plant extract),"LDL-cholesterol levels|Total cholesterol, HDL-cholesterol, triglycerides levels",Lescuyer Laboratory|BioFortis,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,100,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",L2009-06,May-10,Nov-11,Jan-12,8-Jun-10,null,22-Feb-12,"Biofortis, Nantes, France",,https://ClinicalTrials.gov/show/NCT01139398
NCT01133522,"Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Evolocumab (AMG 145) in Adults With Hyperlipidemia on Stable Doses of a Statin",,Completed,Has Results,Hyperlipidemia,Biological: Evolocumab|Biological: Placebo,Number of Participants With Adverse Events|Number of Participants With Anti-Evolocumab Antibodies|Maximum Observed Plasma Concentration (Cmax) of Evolocumab|Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Evolocumab|Percent Change From Baseline to End of the Dosing Interval in LDL-C|Percent Change From Baseline to End of the Dosing Interval in PCSK9,Amgen,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,60,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",20080398,1-Jun-10,14-Sep-11,14-Sep-11,31-May-10,22-Oct-15,2-Nov-18,,,https://ClinicalTrials.gov/show/NCT01133522
NCT01133210,Effect of Maraviroc on Metabolic Function in Obese Subjects (Phase I),,Completed,No Results Available,Hypertriglyceridemia,Drug: Maraviroc|Other: placebo,effect of Maraviroc on plasma triglyceride concentration|Effect of Maraviroc on serum HDL concentration|effect of Maraviroc on serum LDL-cholesterol concentration|Effect of Maraviroc on plasma markers of cardiometabolic risk and inflammation,Washington University School of Medicine|Pfizer,All,18 Years to 64 Years   (Adult),Phase 1,27,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,10-0533,Jan-11,Aug-12,Nov-12,28-May-10,null,10-Dec-13,"Washington University School of Medicine, St. Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT01133210
NCT01131832,Genetic Basis for Heterogeneity in Response of Plasma Lipids to Plant Sterols,,Completed,No Results Available,Hyperlipidemia,Dietary Supplement: Plant sterol|Dietary Supplement: Placebo,Serum Lipids|Serum non-cholesterol sterols|Genotype via single nucleotide polymorphism analysis|Cholesterol synthesis measurement by deuterium incorporation|Change in cholesterol absorption due to plant sterol consumption,University of Manitoba,All,"30 Years to 75 Years   (Adult, Older Adult)",Phase 4,71,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,B2007:073,Sep-10,Feb-12,Feb-12,27-May-10,null,9-May-17,"USDA-ARS, Beltsville Human Nutrition Research Center, Beltsville, Maryland, United States|Richardson Centre for Functional Foods and Nutraceuticals, University of Manitoba, Winnipeg, Manitoba, Canada",,https://ClinicalTrials.gov/show/NCT01131832
NCT01129050,Effects of Omega-3 Fatty Acids on Markers of Inflammation,,Completed,No Results Available,Obesity|Hypertriglyceridemia|Insulin Resistance|Hypertension,Dietary Supplement: Fish Oil|Dietary Supplement: Flaxseed Oil|Dietary Supplement: Placebo,"Change from baseline in inflammatory markers (MCP-1, IL-6, and sICAM-1) at 8 weeks.|Change from baseline in red blood cells (RBC) Fatty Acids at 8 weeks.|Change from baseline in low-density lipoprotein (LDL) cholesterol at 8 weeks.|Change from baseline in high-density lipoprotein (HDL) cholesterol at 8 weeks.|Change from baseline in triglycerides at 8 weeks.",Stanford University|National Center for Complementary and Integrative Health (NCCIH),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,102,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",SU-05042010-5842|R21AT003465-01,Apr-07,Dec-08,Dec-08,24-May-10,null,1-Jun-17,"Stanford University School of Medicine, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT01129050
NCT01126684,Effects of Atorvastatin on Blood Pressure and Urinary Albumin Excretion,,Completed,No Results Available,Hypertension|Hypercholesterolemia,Drug: Atorvastatin|Drug: Placebo,Ambulatory blood pressure|Urinary Albumin Excretion|Insulin Sensitivity|Arterial Stiffness|Urinary levels of nephrin|Urinary levels of podocalyxin|Urinary levels of Endothelin-1|Urinary levels of Asymmetric Dimethylarginine|Urinary levels of indices of oxidative stress,Aristotle University Of Thessaloniki,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",STAY,Jun-08,Dec-09,null,20-May-10,null,20-May-10,"AHEPA University Hospital of Thessaloniki, Thessaloniki, Greece",,https://ClinicalTrials.gov/show/NCT01126684
NCT01122355,Comparison of Fenofibrate and Niacin in Patients With Hypertriglyceridemia and Low High-Density Lipoprotein (HDL)-Cholesterol,,Completed,No Results Available,Hypertriglyceridemia With Low HDL-cholesterol,Drug: lipid modification,percent change of apoB/A1,Yonsei University,All,"20 Years to 79 Years   (Adult, Older Adult)",Phase 4,240,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4-2008-0530,Feb-09,Jan-10,Jan-10,13-May-10,null,31-May-10,,,https://ClinicalTrials.gov/show/NCT01122355
NCT01122394,Reducing Risk of Recurrence,RRR,Completed,Has Results,Stroke|TIA|Hypertension|Hyperlipidemia,Behavioral: TI|Behavioral: AP,Systolic Blood Pressure|Dietary Sodium|Total Cholesterol/High Density Lipoprotein Ratio|Exercise Adherence|Antihypertensive/ Lipid-lowering Medication Adherence,VA Office of Research and Development,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,140,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,CDP 09-414,Jan-10,Jun-15,Jun-15,13-May-10,20-Oct-16,20-Oct-16,"Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01122394
NCT01122667,Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038),,Completed,No Results Available,Dyslipidemia,Drug: anacetrapib,"Area Under the Curve (AUC(0 to infinity)) of anacetrapib|Safety and tolerability of a single dose administration of 100mg anacetrapib, measured by the number of clinical and laboratory adverse events",Merck Sharp & Dohme Corp.,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,24,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0859-038|MK0859-038,Jun-10,Jun-11,Jun-11,13-May-10,null,14-Aug-15,,,https://ClinicalTrials.gov/show/NCT01122667
NCT01120873,The Effect of Metamin 3D on the Lipid and Glucose in Subjects With Metabolic Syndrome,,Completed,No Results Available,Metabolic Syndrome,Drug: Metamin 3D,Total cholesterol|Triglycerides|Low-density lipoprotein cholesterol|The plasma insulin by meal tolerant test|Glycosylated hemoglobin|Fasting plasma glucose|Systolic and diastolic blood pressure|The plasma glucose by meal tolerant test|Aspartate aminotransferase|Alanine aminotransferase|Creatinine,Taichung Veterans General Hospital,All,"30 Years to 75 Years   (Adult, Older Adult)",Phase 3,110,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",S06203,Mar-07,Jun-09,Jun-09,11-May-10,null,11-May-10,"Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taichang, Taiwan",,https://ClinicalTrials.gov/show/NCT01120873
NCT01114490,Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039),,Completed,No Results Available,Dyslipidemia,Drug: anacetrapib,"Area Under the Curve (AUC(0 to infinity)) of anacetrapib|Tolerability of a single dose administration of 100mg anacetrapib, measured by the number of clinical and laboratory adverse events",Merck Sharp & Dohme Corp.,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,24,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0859-039|2010_530,May-10,Jul-10,Jul-10,3-May-10,null,14-Oct-15,,,https://ClinicalTrials.gov/show/NCT01114490
NCT01113099,Improving Adherence to Prescribing Guidelines for Cholesterol Lowering in Hospitalized Diabetic Patients,,Completed,No Results Available,Diabetes|Dyslipidemia,Other: Academic detailing,Statin prescription at hospital discharge,"Washington University School of Medicine|National Heart, Lung, and Blood Institute (NHLBI)",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,247,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,02-1072|R01HL070790,Jun-06,Jun-07,Jun-07,29-Apr-10,null,29-Apr-10,"Barnes Jewish Hospital, St. Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT01113099
NCT01112423,Safety Study of BMS-823778 in Subjects With Hypercholesterolemia,,Completed,No Results Available,Dyslipidemia,Drug: BMS-823778|Drug: Placebo,"Lowering of LDL-C|Pharmacokinetics (measuring trough concentrations)|Pharmacodynamic effects of BMS-823778 on Total cholesterol, HDL-C, Triglycerides, non-HDL-C, free fatty acids, Apolipoprotein fractions, HPA axis marker and free testosterone and sex hormone binding globulin (SHBG)",Bristol-Myers Squibb,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,60,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",MB121-003,Jun-10,Dec-10,Dec-10,28-Apr-10,null,12-Oct-15,"Osborne Research Center, Little Rock, Arkansas, United States|Pra International, Lenexa, Kansas, United States|Sterling Research Grp, Ltd., Cincinnati, Ohio, United States|Cetero Research - San Antonio, San Antonio, Texas, United States|National Clinical Research - Norfolk, Inc., Norfolk, Virginia, United States|National Clinical Research - Richmond, Inc., Richmond, Virginia, United States|Local Institution, Brisbane, Queensland, Australia|Local Institution, Winnipeg, Manitoba, Canada|Local Institution, Mount Pearl, Newfoundland and Labrador, Canada|Local Institution, London, Ontario, Canada|Local Institution, Drummondville, Quebec, Canada|Local Institution, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01112423
NCT01110642,Novel Treatment for Syndromic Ichthyoses,,Withdrawn,No Results Available,Syndromic Ichthyoses|CHILD Syndrome|Smith Lemli Opitz Syndrome|Conradi Syndrome,Drug: Lovastatin,Physician global assessment of severity (PGAS)|Total body surface area (TBSA),Northwestern University,All,"1 Year and older   (Child, Adult, Older Adult)",Phase 2,0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4/15/2010,Jul-11,null,null,26-Apr-10,null,19-May-15,,,https://ClinicalTrials.gov/show/NCT01110642
NCT01109498,"Safety and Efficacy in LPL-Deficient Subjects of AMT-011, an Adeno-Associated Viral Vector Expressing Human Lipoprotein Lipase [S447X]",,Unknown status,No Results Available,Familial Lipoprotein Lipase Deficiency,"Genetic: Alipogene Tiparvovec (AMT-011), Human LPL [S447X]|Drug: Mycophenolate mofetil|Drug: cyclosporine",Reduction of fasting triglyceride (TG) concentrations|safety profile of AMT-011|Reduction of TG concentrations|Biological activity and expression of the transgene product.|Evaluation immune respons|To assess the shedding of the viral vector,Amsterdam Molecular Therapeutics|International Antiviral Therapy Evaluation Center,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,14,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CT-AMT-011-01,Aug-07,Jun-13,Jun-13,23-Apr-10,null,30-Sep-11,"Ecogene-21 Clinical Trial Center/ Centre de santé et de services sociaux de Chicoutimi, Chicoutimi, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01109498
NCT01108978,Evaluating the Efficacy and Safety of Dehypotin® in the Patients With Type 2 Diabetes Mellitus or Cardiovascular Disease,,Terminated,No Results Available,Type 2 Diabetes Mellitus|Cardiovascular Disease|Hypercholesterolemia,Drug: Placebo|Drug: Dehypotin,"Evaluation absolute and percentage reductions in low-density lipoprotein cholesterol (LDL-C) by fasting biochemistry examination|Evaluation of total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), triglycerides by fasting biochemistry examination","Nang Kuang Pharmaceutical Co., Ltd.|National Taiwan University Hospital",All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 4,60,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",200911064M,May-10,May-11,May-11,22-Apr-10,null,9-Jun-11,"Nang Kuang Pharmaceutical Co., LTD, Tainan, Xinhua Township, Taiwan",,https://ClinicalTrials.gov/show/NCT01108978
NCT01105975,A Study of LY2484595 in Patients With High LDL-C or Low HDL-C,,Completed,Has Results,Dyslipidemia,Drug: LY2484595|Drug: Atorvastatin|Drug: Simvastatin|Drug: Rosuvastatin|Drug: Placebo for LY2484595|Drug: Placebo for Statins,Percent Change From Baseline to 12 Weeks Endpoint in High Density Lipoprotein Cholesterol (HDL-C) With LY2484595 in Combination With Atorvastatin and Atorvastatin Monotherapy|Percent Change From Baseline to 12 Weeks Endpoint in Low Density Lipoprotein Cholesterol (LDL-C) With LY2484595 in Combination With Atorvastatin and Atorvastatin Monotherapy|Percent Change From Baseline to 12 Weeks Endpoint in High Density Lipoprotein Cholesterol (HDL-C) With LY2484595 and Placebo|Percent Change From Baseline to 12 Weeks Endpoint in Low Density Lipoprotein Cholesterol (LDL-C) With LY2484595 and Placebo|Percent Change From Baseline to 12 Weeks Endpoint in High Density Lipoprotein Cholesterol (HDL-C) With LY2484595 in Combination With Simvastatin or Rosuvastatin and Simvastatin/Rosuvastatin Monotherapy|Percent Change From Baseline to 12 Weeks Endpoint in Low Density Lipoprotein Cholesterol (LDL-C) With LY2484595 in Combination With Simvastatin or Rosuvastatin and Simvastatin/Rosuvastatin Monotherapy|Pharmacokinetics - LY2484595 Area Under the Concentration-Time Curve (AUC) at Steady-State|Percent Change From Baseline to 12 Weeks Endpoint in Plasma Cholesteryl Ester Transfer Protein (CETP) Activity|Percent Change From Baseline to 12 Weeks Endpoint in Plasma Cholesteryl Ester Transfer Protein (CETP) Mass|The Number of Episodes of Rashes at Any Time From Baseline Through Week 12|Change From Baseline to 12 Weeks Endpoint in Blood Pressure (BP)|Change From Baseline to 12 Weeks Endpoint in Serum Aldosterone|Change From Baseline to 12 Weeks Endpoint in Plasma Renin Activity|Change From Baseline to 12 Weeks Endpoint in Serum Potassium|Change From Baseline to 12 Weeks Endpoint in Serum Sodium|Change From Baseline to 12 Weeks Endpoint in Serum Bicarbonate|Change From Baseline to 18 Weeks Endpoint in EuroQoL Questionnaire - 5 Dimensions (EQ-5D) Score,Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 2,398,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",12468|I1V-MC-EIAF,Apr-10,Jun-11,Jun-11,19-Apr-10,22-Mar-18,22-Mar-18,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fayetteville, Arkansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Diego, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Spring Valley, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vista, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Golden, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brandon, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jacksonville, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Longwood, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ponte Vedra, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Waterloo, Iowa, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wichita, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lexington, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Auburn, Maine, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baltimore, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Picayune, Mississippi, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Edison, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Endwell, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cary, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charlotte, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greensboro, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hickory, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Raleigh, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salisbury, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wilmington, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Winston-Salem, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Red Lion, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yardley, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greer, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mount Pleasant, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Simpsonville, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bristol, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kingsport, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tacoma, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oregon, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ballerup, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vejle, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bochum, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leipzig, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amsterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Breda, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Eindhoven, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Geleen, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Groningen, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leiderdorp, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rotterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zoetermeer, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gdynia, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warsaw, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wroclaw, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Reading, Berkshire, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chorley, Lancashire, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liverpool, Merseyside, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glasgow, Scotland, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Birmingham, United Kingdom",,https://ClinicalTrials.gov/show/NCT01105975
NCT01105598,A Multiple Ascending Dose Study of ETC-1002 in Subjects With Mild Dyslipidemia,,Completed,No Results Available,Mild Dyslipidemia,Drug: ETC-1002 or placebo,"Assessment of safety and tolerability using adverse event reports, physical exams, vitals signs, ECGs, and clinical lab values|Characterization of pharmacokinetic parameters and percent change from baseline in pharmacodynamic endpoints",Esperion Therapeutics,All,18 Years to 55 Years   (Adult),Phase 1,53,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ETC-1002-002,20-Apr-10,2-Oct-10,2-Oct-10,16-Apr-10,null,28-Mar-19,"Jasper Clinic, Inc., Kalamazoo, Michigan, United States",,https://ClinicalTrials.gov/show/NCT01105598
NCT01103648,Effect of Simvastatin and Ezetimibe on Lipid and Inflammation,,Completed,No Results Available,Prediabetes|Hypercholesterolemia|Inflammation|Cardiovascular Risk,Drug: Simvastatin|Drug: Ezetimibe|Drug: Combination Simvastatin plus Ezetimibe,C reactive protein|Interleukin-6|Tumor necrosis factor alpha|Tumor Necrosis Factor Alpha,Federal University of São Paulo,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FUSaoPaulo,Jun-05,May-06,Nov-07,15-Apr-10,null,15-Apr-10,"Hospital do Rim e Hipertensao da UNIFESP, Sao Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT01103648
NCT01103921,The Metabolic Effects of Consuming Sugar-Sweetened Beverages for Two Weeks,DRS,Completed,No Results Available,Metabolic Syndrome|Insulin Resistance|Dyslipidemia,Other: Glucose|Other: Fructose|Other: High-Fructose Corn Syrup|Other: No sugar (Aspartame),24-hour triglyceride area under the curve|Insulin sensitivity index,"University of California, Davis|National Heart, Lung, and Blood Institute (NHLBI)",All,18 Years to 40 Years   (Adult),Not Applicable,214,Other|NIH,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Basic Science",200715772|R01HL091333|R01HL107256,Oct-08,Jan-14,Jan-14,15-Apr-10,null,30-May-17,"Clinical Research Center, Sacramento, California, United States",,https://ClinicalTrials.gov/show/NCT01103921
NCT01104519,A Study of Niaspan on Endothelium-Dependent and Endothelium-Independent Vascular Reactivity (0000-093),,Completed,No Results Available,Dyslipidemia,Drug: Niaspan|Drug: Comparator: Placebo,flow-mediated dilation (FMD) of brachial artery|Nitroglycerin (GTN) induced dilation of brachial artery,Merck Sharp & Dohme Corp.,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,12,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0000-093|093|2010_524,Mar-08,Jul-08,Jul-08,15-Apr-10,null,30-Jul-15,,,https://ClinicalTrials.gov/show/NCT01104519
NCT01101204,The Effects of Hypolipemic and Antidiabetic Treatment on Cytokines,MSF,Unknown status,No Results Available,Diabetes|Dyslipidemia|Inflammation|Cytokines,"Drug: Metformin 1000mg, simvastatin 10mg and fenofibrate 100mg",Antiinflammatory effects of combined antidiabetic and hypolipemic treatment|Insulin sensitivity|Coagulation parameters,Medical University of Silesia,All,35 Years to 64 Years   (Adult),Not Applicable,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,MSF,Jul-12,Oct-12,Dec-12,9-Apr-10,null,9-Jul-12,"Department of Clinical Pharmacology, Katowice, Poland",,https://ClinicalTrials.gov/show/NCT01101204
NCT01099176,Effects of Hypolipemic Treatment on Adipokines,,Completed,No Results Available,Hyperlipidemia|Impaired Fasting Glycemia,Drug: To compare monotherapies and combined therapy with each other,Adipokines|Proinflammatory cytokines,"Medical University of Silesia|Ministry of Scientific Research and Information Technology, Poland",All,35 Years to 64 Years   (Adult),Not Applicable,78,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Basic Science",Ministry of Science,May-08,May-09,Sep-09,6-Apr-10,null,9-Apr-10,"Department of Pharmacology, Katowice, Śląskie, Poland",,https://ClinicalTrials.gov/show/NCT01099176
NCT01096446,Intravenous Fat Emulsions and Premature Infants,,Terminated,Has Results,Hypertriglyceridemia|Hyperglycemia,Drug: Intravenous Fat Emulsions,Number of Infants Serum Triglyceride Level Higher Than 200 mg/dl|Regain Birthweight|Infants Will Achieve 90 Calories/Kilogram/Day|Maintain Appropriate for Gestational Age Status at Discharge|Initiation of Glucose,OSF Healthcare System,All,up to 2 Days   (Child),Not Applicable,19,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OSF-118,Apr-08,May-10,Jul-10,31-Mar-10,20-Nov-14,20-Nov-14,"Children's Hospital of Illinois at OSF Saint Francis Medical Center, Peoria, Illinois, United States",,https://ClinicalTrials.gov/show/NCT01096446
NCT01089231,Effects of Omega-3 Fatty Acids on the Human Gene Expression,,Completed,Has Results,Hyperlipidemia|Healthy,Dietary Supplement: Fish oil|Dietary Supplement: Placebo (corn oil),Gene Expression Changes|Fatty Acid Composition of Erythrocyte Membranes (Omega-3 Index)|Blood Lipids,Gottfried Wilhelm Leibniz Universität Hannover,Male,20 Years to 51 Years   (Adult),Phase 4,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",GWLUH-001|GWLUH2010,Mar-10,Jul-10,Jul-11,18-Mar-10,2-Dec-11,19-Dec-11,"Gottfried Wilhelm Leibniz University of Hanover, Hanover, Lower Saxony, Germany",,https://ClinicalTrials.gov/show/NCT01089231
NCT01088776,Omega-3 Fatty Acid Supplementation in Children,,Completed,No Results Available,Chronic Kidney Disease|Hypertriglyceridemia,Dietary Supplement: n-3 Fatty Acid supplement|Dietary Supplement: Placebo,Fasting Blood Lipid Profiles(TG levels)|Platelet aggregation|CBC|Cholesterol Levels (LDL and HDL)|Tolerability of n-3 fatty acid supplements by our participants,The Hospital for Sick Children,All,"2 Years to 18 Years   (Child, Adult)",Phase 2,4,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",1000012569,Mar-10,Feb-12,Mar-16,17-Mar-10,null,21-Oct-16,"The Hospital for Sick Children, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01088776
NCT01087086,Reduction of the Metabolic Syndrome in Navarra-Spain,RESMENA-S,Completed,No Results Available,Metabolic Syndrome|Obesity|Diabetes|Cardiovascular Disease,Behavioral: Crononutrition|Behavioral: American Heart Association,Body fat|Lipid profile|Glucose Profile|Inflammation state|Oxidative stress|Psychological tests|Peripheral neurotransmitters|Epigenetics|Fatty Liver biomarkers / Non invasive liver scoring system.,"Clinica Universidad de Navarra, Universidad de Navarra|Hospital of Navarra",All,"35 Years to 70 Years   (Adult, Older Adult)",Not Applicable,109,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RESMENA-S,Jan-10,Dec-10,Nov-11,15-Mar-10,null,12-May-16,"University of Navarra, Pamplona, Navarra, Spain",,https://ClinicalTrials.gov/show/NCT01087086
NCT01085149,The Effect Of Simvastatin On Bone Remodeling In Socket Of Mandibular Teeth,,Unknown status,No Results Available,Hypercholesterolemia,Drug: Simvastatin,bone height and density in former socket|bone mineralization,Hadassah Medical Organization,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),h123-HMO-CTIL,May-10,Oct-10,null,11-Mar-10,null,11-Mar-10,"Oral and Maxillofacial Clinic, Hadassah, Jerusalem, Israel",,https://ClinicalTrials.gov/show/NCT01085149
NCT01082562,Safety Study of BMS-844421 for Treatment of Hypercholesterolemia,,Terminated,No Results Available,Atherosclerosis|Hypercholesterolemia,Drug: BMS-844421|Drug: 0.9% sodium chloride injection solution,"To asses safety, tolerability, pharmacodynamic effects of BMS-844421 on PCSK9 concentrations|Assess single and multiple dose pharmacokinetics of BMS-844421|Assess the absolute bioavailability of single BMS-844421 SC doses|Assess the effects of multiple doses of BMS-844421on lipid components",Bristol-Myers Squibb,All,18 Years to 45 Years   (Adult),Phase 1,40,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CV198-002|2009-012032-32,Apr-10,Jul-10,Jul-10,8-Mar-10,null,26-Jan-11,"Local Institution, Berlin, Germany",,https://ClinicalTrials.gov/show/NCT01082562
NCT01081548,A Clinical Trial Study to Evaluate Efficacy and Safety of Atorvastatin in Korean Patients With Hypercholesterolemia,,Completed,No Results Available,Hypercholesterolemia,Drug: atorvastatin,,Yonsei University,All,"Child, Adult, Older Adult",Phase 4,17,Other,Interventional,Intervention Model: Parallel Assignment|Masking: None (Open Label),4-2008-0288,Aug-08,Jul-09,Jul-09,5-Mar-10,null,5-Mar-10,"Severance Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01081548
NCT01078675,An Study to Evaluate Rosuvastatin in Children and Adolescents With Familial Hypercholesterolaemia,,Completed,Has Results,Familial Hypercholesterolaemia,Drug: rosuvastatin calcium,"Percent Change From Baseline in LDL-C|Sexual Maturation by Tanner Staging at Baseline|Single Dose PK - Cmax|Percent Change From Baseline in Height|Sexual Maturation by Tanner Staging at Month 12|Sexual Maturation by Tanner Staging at Month 24|Single Dose PK - Tmax|Single Dose PK - AUC(0-24)|Percent Change From Baseline in HDL-C, TC, TG, Non-HDL-C, LDL-C/HDL-C, TC/HDL-C, Non HDL C/HDL-C, ApoB, ApoA-1, and ApoB/ApoA-1|Change From Baseline in Max and Mean Carotid Intima and Media Wall Thickness (cIMT)|Adverse Events|Total Duration of Exposure|Overal Treatment Adherence",AstraZeneca,All,6 Years to 17 Years   (Child),Phase 3,315,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D3561C00002,Feb-10,Feb-13,Feb-13,2-Mar-10,2-Feb-15,7-Apr-15,"Research Site, Cincinnati, Ohio, United States|Research Site, Leuven, Belgium|Research Site, Vancouver, British Columbia, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Amsterdam, Netherlands|Research Site, Groningen, Netherlands|Research Site, Hoorn, Netherlands|Research Site, Leiderdorp, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Waalwijk, Netherlands|Research Site, Oslo, Norway",,https://ClinicalTrials.gov/show/NCT01078675
NCT01077479,Metformin in Preventing Androgen Deprivation Therapy Induced Insulin Resistance and Metabolic Syndrome,MVENT,Completed,No Results Available,Metabolic Syndrome|Hypercholesterolemia,Drug: Metformin,The percentage change in insulin resistance measured by homeostasis model assessment (HOMAIR) from baseline to 12 and 24 weeks|To assess the efficacy of metformin in abrogating ADT-induced insulin resistance as measured by whole-body insulin sensitivity index(ISI) at 3 and 6 months|To assess the efficacy of metformin in reducing the incidence of ADT-induced metabolic syndrome at 3 and 6 months|To assess the efficacy of metformin in reducing ADT-induced percentage body fat mass gain 6 months|To assess the efficacy of metformin in reducing ADT-induced hypercholesterolemia at 3 and 6 months|To validate measurement of insulin resistance by HOMAIR with euglycemic hyperinsulinemic clamp in a subgroup group of participants,Western Sydney Local Health District,Male,"18 Years and older   (Adult, Older Adult)",Phase 2,28,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,HGWH009,Feb-10,Jun-13,Jun-13,1-Mar-10,null,15-May-14,"Westmead Hospital, Sydney, New South Wales, Australia",,https://ClinicalTrials.gov/show/NCT01077479
NCT01071291,Effects of Niaspan™ on High-density Lipoprotein (HDL) in Healthy Male Subjects (0000-069),,Completed,No Results Available,Dyslipidemia,Drug: Niaspan|Drug: Comparator: Placebo,Change from baseline in cholesterol efflux|Change from the baseline in High-Density Lipoprotein Cholesterol (HDL-C),Merck Sharp & Dohme Corp.,Male,18 Years to 55 Years   (Adult),Phase 1,37,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0000-069|069|2010_510,Feb-10,Aug-10,Sep-10,19-Feb-10,null,12-Oct-15,,,https://ClinicalTrials.gov/show/NCT01071291
NCT01071525,"The Effect of Niacin Administration on Oxidative Stress in Patients With Hypercholesterolmia, as Measured by the Use of a Novel Biomarker",,Unknown status,No Results Available,Hypercholesterolemia,Drug: Niacin\Laropiprant,Effect on oxidative stress,Rambam Health Care Campus,All,"18 Years and older   (Adult, Older Adult)",Phase 3,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Niacin-OS,Apr-10,Aug-10,Oct-10,19-Feb-10,null,1-Mar-10,"Rambam Health Care Campus, Haifa, Israel",,https://ClinicalTrials.gov/show/NCT01071525
NCT01071967,Effect of a Community-based Nursing Intervention on Mortality in Chronically Ill Older Adults,,Unknown status,No Results Available,Heart Failure|Coronary Disease|Diabetes Mellitus|Asthma|Hypertension|Hypercholesterolemia,Other: Community-based nurse care management,All-cause mortality|Blood pressure control|Total cholesterol control|Low density cholesterol control|Triglycerides control|Weight control,Health Quality Partners|Centers for Medicare and Medicaid Services,All,65 Years and older   (Older Adult),Not Applicable,2000,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,95-C-91360/3-01,Apr-02,Dec-14,Dec-16,19-Feb-10,null,10-Sep-13,"Health Quality Partners, Doylestown, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01071967
NCT01069783,Study of A3309 in Patients With Dyslipidemia,,Completed,No Results Available,Dyslipidemia,Drug: A3309|Drug: Placebo,Change from baseline in low-density lipoprotein (LDL) cholesterol,Albireo,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,36,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",A3309-005,Feb-10,Sep-10,Sep-10,17-Feb-10,null,13-Oct-16,"BCRC, Linköping, Sweden",,https://ClinicalTrials.gov/show/NCT01069783
NCT01064934,Randomized Controlled Trial of Lipid Apheresis in Patients With Elevated Lipoprotein(a),ELAILa,Withdrawn,No Results Available,Hyperlipoproteinemia(a)|Progressive Cardiovascular Disease,Procedure: Lipid apheresis|Other: Standard care,"Composite endpoint, defined as first occurrence of one of the following: myocardial infarction, interventional therapeutic procedure, CABG, cerebrovascular accident, hospitalization due to ACS, periph. art. revasc., death from cardiovascular cause|Components of the primary endpoint considered individually|Death from any cause","Charite University, Berlin, Germany",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ELAILa-01,Sep-10,Aug-15,Aug-15,9-Feb-10,null,4-Jun-15,"Lipidambulanz, Interdisziplinäres Stoffwechsel-Centrum, CVK, Charite, Berlin, Germany",,https://ClinicalTrials.gov/show/NCT01064934
NCT01058083,Safety Study of BMS-770767 in Subjects With Hypercholesterolemia,,Completed,No Results Available,Dyslipidemia,Drug: BMS-770767|Drug: Placebo,"Lowering of LDL-C|Pharmacokinetics (Blood Level) of BMS-770767|Pharmacodynamic effects of BMS-770767 on Total cholesterol, HDL-C, Triglycerides, non-HDL-C, non-esterified free fatty acids, Apolipoprotein fractions, HPA axis marker and free testosterone and sex hormone binding globulin (SHBG)",Bristol-Myers Squibb,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,81,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MB117-004|2009-014306-33,May-10,Mar-11,Mar-11,28-Jan-10,null,19-Apr-12,"Harrell, Robert, Little Rock, Arkansas, United States|Cetero Research - San Antonio, San Antonio, Texas, United States|Local Institution, Blacktown, New South Wales, Australia|Local Institution, Hornsby, New South Wales, Australia|Local Institution, Caboolture, Queensland, Australia|Local Institution, South Brisbane, Queensland, Australia|Local Institution, Daw Park, South Australia, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Bathurst, New Brunswick, Canada|Local Institution, Brampton, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Charlottetown, Prince Edward Island, Canada|Local Institution, Mirabel, Quebec, Canada|Local Institution, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01058083
NCT01056549,Exenatide (Byetta ®) Regulation of Intestinal and Hepatic Lipoprotein Particle Production in Humans,,Completed,No Results Available,Hyperlipidemia,Drug: exenatide,"The objective is to examine the change in apoB48 production rate after one subcutaneous injection of exenatide, under conditions of a pancreatic clamp and a steady state fed state.|The secondary objective is to examine the change in apoB100 production rate in the same conditions, and the secondary measure is the difference between exenatide and placebo in the mean production of TRL-apoB100","University Health Network, Toronto|Eli Lilly and Company",All,18 Years to 60 Years   (Adult),Not Applicable,15,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,REB 09-0428-B,Jan-10,Sep-11,Sep-11,26-Jan-10,null,22-Jun-12,"Toronto General Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01056549
NCT01054508,Effect of Tredaptive on Serum Lipoproteins and Inflammatory Markers,,Completed,No Results Available,Hypercholesterolemia,Drug: nicotinic acid/laropiprant,"The investigators expect the majority (90% or more) of patients to achieve a 15% increase in HDL level.|Changes in paraoxonase activity, changes in oxidised LDL, changes in glycated LDL, changes in HDL inflammatory index.",Manchester University NHS Foundation Trust,All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 4,38,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",TRED012010,Jun-10,Jan-12,Jan-12,22-Jan-10,null,12-Oct-12,"Manchester Royal Infirmary, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT01054508
NCT01052311,The Impact of Tredaptive on Flow-Mediated Dilation in Cardiac Patients,,Terminated,No Results Available,Coronary Artery Disease|Dyslipidemia,Drug: Tredaptive (1 g extended release niacin+ 20 mg laropiprant)|Drug: Placebo|Drug: Tredaptive,"To evaluate the impact of 3 months' administration of ERN/LRPT compared to placebo added to statins on endothelial function, assessed by brachial artery vasoreactivity in stable CAD patients.|To evaluate the impact of 3 months' administration of ERN/LRPT compared to placebo added to statins on platelet function in stable CAD patients.",Sheba Medical Center,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,8,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",SHEBA-09-7418-MS-CTIL,Jul-10,Jan-13,Jan-13,20-Jan-10,null,19-Oct-16,"Leviev Heart Center, Sheba Medical Center, Tel Hashomer, Israel",,https://ClinicalTrials.gov/show/NCT01052311
NCT01050465,MedlinePlus Health Prescriptions: Developing a Pragmatic Approach for Clinic Use,,Completed,No Results Available,Acne Vulgaris|Allergic Rhinitis|Anxiety|Asthma|Back Pain|Prostatic Hyperplasia|Bursitis|Chronic Obstructive Pulmonary Disease|Cough|Coronary Artery Disease|Depression|Diabetes Mellitus|Diarrhea|Gastroesophageal Reflux|Fibromyalgia|Headache|HIV Infections|Hypothyroidism|Hyperlipidemia|Hypertension|Influenza|Sleep Initiation and Maintenance Disorders|Irritable Bowel Syndrome|Migraine Disorders|Obesity|Obstructive Sleep Apnea|Osteoarthritis|Senile Osteoporosis|Shoulder Pain|Sinusitis|Smoking Cessation|Tobacco Use Cessation|Menopause|Urinary Incontinence|Urinary Tract Infection|Vaginitis|Vertigo,Other: health information prescription,seeking information using MedlinePlus,University of Missouri-Columbia|National Library of Medicine (NLM),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,907,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),HHSN276200800445P,May-09,Oct-10,Dec-10,15-Jan-10,null,30-Sep-16,,,https://ClinicalTrials.gov/show/NCT01050465
NCT01047501,Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL),ANCHOR,Completed,No Results Available,Hypertriglyceridemia,Drug: AMR101 (ethyl icosapentate)|Drug: Placebo,Difference between AMR101 (ethyl icosapentate) and placebo treatment groups in triglyceride lowering effect|Difference between AMR101 (ethyl icosapentate) and placebo treatment groups in other lipid and biomarker levels,Amarin Pharma Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 3,702,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",AMR-01-01-0017|The ANCHOR Study,Dec-09,Feb-11,null,13-Jan-10,null,27-Nov-13,"Amarin Investigational Site, Muscle Shoals, Alabama, United States|Amarin Investigational Site, Scottsboro, Alabama, United States|Amarin Investigational Site, Phoenix, Arizona, United States|Amarin Investigational Site, Tucson, Arizona, United States|Amarin Investigational Site, Anaheim, California, United States|Amarin Investigational Site, Burbank, California, United States|Amarin Investigational Site, Chino, California, United States|Amarin Investigational Site, Encinitas, California, United States|Amarin Investigational Site, Irvine, California, United States|Amarin Investigational Site, Los Angeles, California, United States|Amarin Investigational Site, Los Angeles, California, United States|Amarin Investigational Site, Spring Valley, California, United States|Amarin Investigational Site, Westlake Village, California, United States|Amarin Investigational Site, Golden, Colorado, United States|Amarin Investigational Site, Wheat Ridge, Colorado, United States|Amarin Investigational Site, Aventura, Florida, United States|Amarin Investigational Site, Clearwater, Florida, United States|Amarin Investigational Site, Coral Gables, Florida, United States|Amarin Investigational Site, Hialeah, Florida, United States|Amarin Investigational Site, Jacksonville, Florida, United States|Amarin Investigational Site, Jacksonville, Florida, United States|Amarin Investigational Site, Miami, Florida, United States|Amarin Investigational Site, New Port Richey, Florida, United States|Amarin Investigational Site, New Port Richey, Florida, United States|Amarin Investigational Site, Orlando, Florida, United States|Amarin Investigational Site, Port Orange, Florida, United States|Amarin Investigational Site, West Palm Beach, Florida, United States|Amarin Investigational Site, Augusta, Georgia, United States|Amarin Investigational Site, Augusta, Georgia, United States|Amarin Investigational Site, Addison, Illinois, United States|Amarin Investigational Site, Morton, Illinois, United States|Amarin Investigational Site, Indianapolis, Indiana, United States|Amarin Investigational Site, Kansas City, Kansas, United States|Amarin Investigational Site, Newton, Kansas, United States|Amarin Investigational Site, Wichita, Kansas, United States|Amarin Investigational Site, Louisville, Kentucky, United States|Amarin Investigational Site, Munfordville, Kentucky, United States|Amarin Investigational Site, Auburn, Maine, United States|Amarin Investigational Site, Baltimore, Maryland, United States|Amarin Investigational Site, Elkridge, Maryland, United States|Amarin Investigational Site, Troy, Michigan, United States|Amarin Investigational Site, Olive Branch, Mississippi, United States|Amarin Investigational Site, St. Louis, Missouri, United States|Amarin Investigational Site, Butte, Montana, United States|Amarin Investigational Site, Concord, New Hampshire, United States|Amarin Investigational Site, Endwell, New York, United States|Amarin Investigational Site, New Windsor, New York, United States|Amarin Investigational Site, Syracuse, New York, United States|Amarin Investigational Site, Charlotte, North Carolina, United States|Amarin Investigational Site, Durham, North Carolina, United States|Amarin Investigational Site, Hickory, North Carolina, United States|Amarin Investigational Site, Raleigh, North Carolina, United States|Amarin Investigational Site, Statesville, North Carolina, United States|Amarin Investigational Site, Wilmington, North Carolina, United States|Amarin Investigational Site, Winston-Salem, North Carolina, United States|Amarin Investigational Site, Cincinnati, Ohio, United States|Amarin Investigational Site, Cincinnati, Ohio, United States|Amarin Investigational Site, Cleveland, Ohio, United States|Amarin Investigational Site, Kettering, Ohio, United States|Amarin Investigational Site, Norman, Oklahoma, United States|Amarin Investigational Site, Tulsa, Oklahoma, United States|Amarin Investigational Site, Beaver, Pennsylvania, United States|Amarin Investigational Site, Harleysville, Pennsylvania, United States|Amarin Investigational Site, Jersey Shore, Pennsylvania, United States|Amarin Investigational Site, Lansdale, Pennsylvania, United States|Amarin Investigational Site, Philadelphia, Pennsylvania, United States|Amarin Investigational Site, Mt. Pleasant, South Carolina, United States|Amarin Investigational Site, Rapid City, South Dakota, United States|Amarin Investigational Site, Dallas, Texas, United States|Amarin Investigational Site, Houston, Texas, United States|Amarin Investigational Site, Houston, Texas, United States|Amarin Investigational Site, Lake Jackson, Texas, United States|Amarin Investigational Site, San Antonio, Texas, United States|Amarin Investigational Site, San Antonio, Texas, United States|Amarin Investigational Site, Temple, Texas, United States|Amarin Investigational Site, Ettrick, Virginia, United States|Amarin Investigational Site, Norfolk, Virginia, United States|Amarin Investigational Site, Richmond, Virginia, United States|Amarin Investigational Site, Richmond, Virginia, United States|Amarin Investigational Site, Wauwatosa, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT01047501
NCT01047683,Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL,MARINE,Completed,No Results Available,Hypertriglyceridemia,Drug: AMR101 (ethyl icosapentate)|Drug: Placebo,Difference between AMR101 (ethyl icosapentate) and placebo treatment groups in triglyceride lowering effect|Difference between AMR101 (ethyl icosapentate) and placebo treatment groups in other lipid and biomarker levels,Amarin Pharma Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 3,229,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AMR-01-01-0016,Dec-09,Oct-10,Jul-11,13-Jan-10,null,17-Jan-14,"Amarin Investigational Site, Sacramento, California, United States|Amarin Investigational Site, Golden, Colorado, United States|Amarin Investigational Site, Miami, Florida, United States|Amarin Investigational Site, Miami, Florida, United States|Amarin Investigational Site, Ocala, Florida, United States|Amarin Investigational Site, Addison, Illinois, United States|Amarin Investigational Site, Chicago, Illinois, United States|Amarin Investigational Site, Louisville, Kentucky, United States|Amarin Investigational Site, Butte, Montana, United States|Amarin Investigational Site, Raleigh, North Carolina, United States|Amarin Investigational Site, Winston-Salem, North Carolina, United States|Amarin Investigational Site, Cincinnati, Ohio, United States|Amarin Investigational Site, Cincinnati, Ohio, United States|Amarin Investigational Site, Lynhurst, Ohio, United States|Amarin Investigational Site, Tulsa, Oklahoma, United States|Amarin Investigational Site, Corpus Christi, Texas, United States|Amarin Investigational Site, Houston, Texas, United States|Amarin Investigational Site, Richmond, Virginia, United States|Amarin Investigational Site, Aalborg, Denmark|Amarin Investigational Site, Herlev, Denmark|Amarin Investigational Site, Oulu, Finland|Amarin Investigational Site, Dresden, Germany|Amarin Investigational Site, Giessen, Germany|Amarin Investigational Site, Magdeburg, Germany|Amarin Investigational Site, Muenchen, Germany|Amarin Investigational Site, Muenchen, Germany|Amarin Investigational Site, Nuernberg, Germany|Amarin Investigational Site, Ahmedabad, India|Amarin Investigational Site, Bangalore, India|Amarin Investigational Site, Bangalore, India|Amarin Investigational Site, Bangalore, India|Amarin Investigational Site, Gopalapuram, India|Amarin Investigational Site, Indore, India|Amarin Investigational Site, Mysore, India|Amarin Investigational Site, Genova, Italy|Amarin Investigational Site, Palermo, Italy|Amarin Investigational Site, Guadalajara, Jalisco, Mexico|Amarin Investigational Site, Mexico City, Mexico|Amarin Investigational Site, Mexico City, Mexico|Amarin Investigational Site, Monterrey Nuevo Leon, Mexico|Amarin Investigational Site, Amsterdam, Netherlands|Amarin Investigational Site, Groningen, Netherlands|Amarin Investigational Site, Rotterdam, Netherlands|Amarin Investigational Site, Rotterdam, Netherlands|Amarin Investigational Site, Utrecht, Netherlands|Amarin Investigational Site, Moscow, Russian Federation|Amarin Investigational Site, Moscow, Russian Federation|Amarin Investigational Site, St Petersburg, Russian Federation|Amarin Investigational Site, St. Petersburg, Russian Federation|Amarin Investigational Site, St. Petersburg, Russian Federation|Amarin Investigational Site, Bloemfontein, South Africa|Amarin Investigational Site, Cape Town, South Africa|Amarin Investigational Site, Johannesburg, South Africa|Amarin Investigational Site, Parktown, South Africa|Amarin Investigational Site, Pretoria, South Africa|Amarin Investigational Site, Somerset West, South Africa|Amarin Investigational Site, Ivano-Frankivsk, Ukraine|Amarin Investigational Site, Kiev, Ukraine|Amarin Investigational Site, Kyiv, Ukraine|Amarin Investigational Site, Odessa, Ukraine",,https://ClinicalTrials.gov/show/NCT01047683
NCT01046968,Lepticore in Metabolic Syndrome and Weight Loss,,Completed,No Results Available,Obesity|Hyperlipidemia|Hyperglycemia,Dietary Supplement: Lepticore,Improvement of symptoms of metabolic syndrome|Change in weight,University of Yaounde 1|Cameroon Nutritional Science Society,All,19 Years to 52 Years   (Adult),Phase 1|Phase 2,92,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Basic Science",LNNB232,Aug-09,Nov-09,Nov-09,12-Jan-10,null,12-Jan-10,"Laboratory of Nutrition and Nutritional Biochemistry, Yaounde, Centre, Cameroon",,https://ClinicalTrials.gov/show/NCT01046968
NCT01047280,Use of Conjugated Linoleic Acid as a Nutraceutical for Weight Loss in Humans,CLA,Completed,No Results Available,Body Weight|Body Composition|Hyperlipidemia|Inflammation|Oxidative Stress,"Dietary Supplement: Clarinol G-80 ® treatment|Dietary Supplement: Safflower oil|Dietary Supplement: G-c9, t11","Changes in body weight, body fat mass, and lean body mass|Changes in inflammation and oxidation markers",University of Manitoba,Male,18 Years to 60 Years   (Adult),Phase 1,36,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",B2005:183,Nov-06,Mar-08,May-09,12-Jan-10,null,12-Jan-10,,,https://ClinicalTrials.gov/show/NCT01047280
NCT01043354,TACTICS (Targeting Adherence to Cholesterol-lowering Therapy to Improve Control Study),TACTICS,Completed,No Results Available,Hypercholesterolemia,Behavioral: stage-matched intervention|Behavioral: framing effects intervention|Behavioral: attention placebo intervention,LDL control|medication adherence|diet adherence|exercise adherence,Narrows Institute for Biomedical Research,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,247,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,ADA 7-08-CR-68,Sep-08,Jun-12,Jun-12,6-Jan-10,null,2-Apr-14,"VA New York Harbor Healthcare System, NY and BK Campuses, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01043354
NCT01043380,Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound,PRECISE-IVUS,Completed,No Results Available,Hypercholesterolemia|Coronary Artery Disease,Drug: Combination therapy with Lipitor [Atorvastatin] and Zetia [Ezetimibe]|Drug: Lipitor (Atorvastatin) monotherapy,"Absolute change from baseline to follow-up in percent atheroma volume (PAV) in the target lesion|Percentage change from baseline (before randomization) to follow-up (9-12 months after randomization) in the atheroma volume|Change and percentage change from baseline to follow-up in the minimum lumen diameter (MLD) and percent diameter stenosis (%DS)|Percentage changes from baseline to follow-up in serum lipids|Correlation between regression of coronary plaque and serum lipids profiles|Changes in hs-CRP from baseline to follow-up|Correlation between regression of coronary plaque and inflammatory markers (white blood cell count and hs-CRP)|Change and percentage change from baseline to follow-up in the PV of the PCI target lesion|Change and percentage change from baseline to follow-up in the MLD and %DS of the PCI target lesion|MACE (cardiac death, non-fatal Q wave and/or non-Q wave myocardial infarction, target vessel revascularization [percutaneous coronary intervention or coronary artery bypass grafting])|All-cause death|Safety (Adverse events, subjective symptoms/objective findings, physical tests), blood tests [hematology, clinical chemistry, glucose metabolism test], urinalysis)",Kumamoto University,All,"30 Years to 85 Years   (Adult, Older Adult)",Phase 4,245,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UMIN000002959,Jan-10,Mar-14,Sep-14,6-Jan-10,null,1-Apr-15,"Kumamoto University, Kumamoto, Japan",,https://ClinicalTrials.gov/show/NCT01043380
NCT01041521,The Impact of Omega Three Fatty Acids on Vascular Function in HIV,HOST,Completed,No Results Available,High Triglyceride Level|HIV Infection,Drug: Lovaza,triglyceride level|vascular function,"Christine A. Wanke|National Heart, Lung, and Blood Institute (NHLBI)|Tufts University",All,"18 Years and older   (Adult, Older Adult)",Phase 4,129,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",LVZ112667|1R01HL096585-01A1,Jan-10,Aug-14,Aug-15,31-Dec-09,null,15-Dec-16,"Tufts University School of Medicine, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01041521
NCT01035086,Intervention With Lupin Kernel Fibre in Hypercholesterolemic Subjects,,Completed,No Results Available,Hypercholesterolemia,Dietary Supplement: fabricated food,"cholesterol metabolism (blood lipids)|general excretion parameters, neutral sterols, bile acids, short-chain fatty acids, fibre excretion, cytotoxicity, genotoxicity",University of Jena|German Federal Ministry of Education and Research,All,"20 Years to 75 Years   (Adult, Older Adult)",Not Applicable,54,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",LSEP H36-08,Jun-08,Dec-08,Dec-08,18-Dec-09,null,5-Dec-12,"Friedrich Schiller University Jena, Institute of Nutrition, Department of Nutrional Physiology, Jena, Thuringia, Germany",,https://ClinicalTrials.gov/show/NCT01035086
NCT01034540,Effects of Prescription Omega-3 Acids on Glucose and Lipoprotein Lipids in Subjects With Hypertriglyceridemia,,Completed,Has Results,Hypertriglyceridemia,Drug: POM3|Drug: Placebo,Difference Between Treatments in Liquid Meal Tolerance Test (LMTT) Matsuda Insulin Sensitivity Index (MISI).|Difference Between Treatments in LMTT Insulin Secretion Index and Disposition Index.,Provident Clinical Research|GlaxoSmithKline,All,"18 Years to 79 Years   (Adult, Older Adult)",Not Applicable,23,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",PRV-09009,Mar-10,Dec-10,Feb-11,17-Dec-09,22-Oct-13,22-Oct-13,"Provident Clinical Research (now Biofortis), Addison, Illinois, United States",,https://ClinicalTrials.gov/show/NCT01034540
NCT01029522,Dyslipidemia in Cardiovascular Disease,KoLipilou,Completed,No Results Available,Dyslipidemia,Drug: Atorvastatin (Lipilou)|Drug: Atorvastatin (Lipitor),LDL-C,Chong Kun Dang Pharmaceutical,All,"20 Years to 85 Years   (Adult, Older Adult)",Phase 4,244,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",224CHL08F,Aug-08,Oct-08,Nov-09,10-Dec-09,null,9-Aug-12,,,https://ClinicalTrials.gov/show/NCT01029522
NCT01027325,Resistant Starch Insulin Sensitivity Trial,RESIST,Completed,No Results Available,Healthy|Cardiovascular Disease|Atherogenic Dyslipidemia|Insulin Resistance,Other: Dietary Intervention,"Triglycerides|LDL subfractions|Total cholesterol|HDL-cholesterol|apolipoproteins B, AI",Children's Hospital & Research Center Oakland|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"20 Years and older   (Adult, Older Adult)",Not Applicable,52,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,1RC1DK086472-01,Jun-10,Aug-11,Nov-12,7-Dec-09,null,14-Jan-13,"Cholesterol Research Center, Berkeley, California, United States|Children's Hospital Oakland Research Institute, Oakland, California, United States",,https://ClinicalTrials.gov/show/NCT01027325
NCT01026103,Tri Staple Technology Stapler Used in Gastric Bypass,,Completed,Has Results,Sleep Apnea|Hypertension|Hyperlipidemia|Coronary Artery Disease|Gastroesophageal Reflux Disease|Osteoarthritis|Diabetes,Device: Tri Staple Technology stapler,Proportion of Patients With an Uneventful Creation of a Functional Staple Line|Incidence of Intra-operative Bleeding Requiring Intervention|Length of Hospital Stay|Incidence of Serosal Tearing,Medtronic - MITG,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,28,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AS09004,Jan-10,Mar-11,Mar-11,4-Dec-09,14-Mar-14,14-Mar-14,"Clarian Bariatric Center/Indiana University, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT01026103
NCT01025492,Study of Trilipix Effects on Lipids and Arteries,,Terminated,Has Results,Dyslipidemia,Drug: Trilipix|Drug: placebo,Apolipoprotein A-I Serum Concentration,University of Utah|Abbott,All,"30 Years to 75 Years   (Adult, Older Adult)",Phase 4,24,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",30151,Nov-09,Mar-11,Mar-11,3-Dec-09,1-Sep-16,1-Sep-16,"University of Utah, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT01025492
NCT01023607,Evaluation of Statin-induced Lipid-rich Plaque Progression by Optical Coherence Tomography (OCT) Combined With Intravascular Ultrasound (IVUS),,Completed,No Results Available,Coronary Artery Disease|Hyperlipidemia,Drug: Atorvastatin|Drug: Rosuvastatin,"To compare the effects of atorvastatin 20mg and atorvastatin 60mg on the changes of FCT assessed by OCT and plaque burden by IVUS.|To investigate the changes of FCT assessed by OCT and plaque burden by IVUS in comparisons of atorvastatin 60 mg vs rosuvastatin 10 mg, and atorvastatin 20 mg vs rosuvastatin 10 mg.|To investigate the changes of remodeling index assessed by IVUS in comparisons of atorvastatin 60 mg vs atorvastatin 20 mg,atorvastatin 60 mg vs rosuvastatin 10 mg, and atorvastatin 20 mg vs rosuvastatin 10 mg|To investigate the changes of macrophage infiltration semi-quantitatively by OCT in comparisons of atorvastatin 60 mg vs atorvastatin 20 mg,atorvastatin 60 mg vs rosuvastatin 10 mg, and atorvastatin 20 mg vs rosuvastatin 10 mg",Harbin Medical University,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,120,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,HMUOCT-STATIN,Dec-09,Aug-13,Aug-13,2-Dec-09,null,11-Sep-13,"The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China",,https://ClinicalTrials.gov/show/NCT01023607
NCT01013662,Lipid Profile in Patients With Severe Sepsis or Septic Shock Under Strict or Liberal Glycemic Control,,Completed,No Results Available,Septic Shock|Sepsis,Procedure: glycemic control,establish a relationship between lipid metabolism alterations and glycemic control,University of Sao Paulo,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,69,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,scap1501,Jan-05,Jul-07,Jul-07,16-Nov-09,null,4-Aug-11,,,https://ClinicalTrials.gov/show/NCT01013662
NCT01011699,Nicotinamide Versus Sevelamer Hydrochloride on Phosphatemia Control on Chronic Hemodialysed Patients,NICOREN,Terminated,No Results Available,Chronic Renal Failure|Hemodialysis,Drug: nicotinamide|Drug: sevelamer|Drug: cinacalcet,"The comparison between nicotinamide and Sevelamer was primarily to demonstrate the noninferiority of nicotinamide in terms of control of the phosphatemia observed during the 4th, 5th and 6th months before to introduce Cinacalcet ®.|To demonstrate noninferiority of nicotinamide in terms of effect on dyslipidemia (evaluated by the ratio LDL / HDL cholesterol), the risk of hypercalcemia (PCa> 2.37 mmol / l) and increase of phospho-calcic product (> 3 , 79 mmol/l).|To evaluate the difference between nicotinamide and sevelamer on vascular calcification|To evaluate the difference between nicotinamide and sevelamer on bone mass loss and fracture risk|Evaluate the percentage of population requiring use of cinacalcet® to control PTH (75-300 pg/ml). Evaluate his benefit on phosphatemia and calcemia control. Prevent the need for surgical PTX, and evaluate the additional cost of treatment by cinacalcet|Evaluate roles of metabolites of nicotinamide (efficacy and side effects) through another study|Compare the cost-effectiveness ratio of these two treatments","Centre Hospitalier Universitaire, Amiens",All,"18 Years and older   (Adult, Older Adult)",Phase 3,176,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PHRCIR08-PR-FOURNIER|Eudract N°2008-004673-17,Jan-10,Jun-13,Jun-13,11-Nov-09,null,16-May-16,"Centre Hospitalier Général, Soissons, Aisne, France|Centre Hospitalier, Lisieux, Calvados, France|ALURAD, Limoges, Limousin, France|Centre Hospitalier Universitaire, Reims, Marne, France|Association Régionale Promotion Dialyse à domicile (ARPDD), Reims, Marne, France|Association pour le Développement de l'Hémodialyse, Hénin-Beaumont, Nord-Pas de Calais, France|Polyclinique de la Louvière, Lille, Nord, France|CHRU, Lille, Nord, France|Hôpital Victor Provo, Roubaix, Nord, France|Centre Hospitalier Général, Valenciennes, Nord, France|Centre Hospitalier Général, Beauvais, Oise, France|Clinique Saint Côme, Compiegne, Oise, France|Centre Hospitalier Général, Creil, Oise, France|Clinique du Bois Bernard, Bois Bernard, Pas de calais, France|Centre Hospitalier, Boulogne sur mer, Pas de calais, France|Centre Hospital-Universitaire d'Amiens, Amiens, Picardie, France|Clinique de l'Europe, Rouen, Seine maritime, France|Centre Hospitalier, Cambrai, France",,https://ClinicalTrials.gov/show/NCT01011699
NCT01012219,A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED),,Completed,Has Results,Primary Hypercholesterolemia|Mixed Hyperlipidemia,Drug: niacin (+) laropiprant|Drug: Comparator: aspirin|Drug: Comparator: clopidogrel|Drug: Comparator: laropiprant|Drug: Comparator: placebo,Cutaneous Bleeding Time (BT),Merck Sharp & Dohme Corp.,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,36,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0524A-114|2009_689,Nov-09,Mar-10,Apr-10,11-Nov-09,18-Apr-11,2-Nov-15,,,https://ClinicalTrials.gov/show/NCT01012219
NCT01010399,"Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects",BuLLET,Completed,Has Results,Hypertriglyceridemia|HIV Infection,Dietary Supplement: Lovaza|Drug: fosamprenavir/ritonavir,Proportion of Subjects With Triglycerides <200 mg/dL|Proportion of Subjects With HIV-1 RNA <50 Copies/mL,"Felizarta, Franco, M.D.|GlaxoSmithKline",All,"18 Years and older   (Adult, Older Adult)",Phase 4,36,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,COL112948,Sep-09,Nov-10,Nov-10,10-Nov-09,18-Apr-12,18-Apr-12,"Franco Felizarta, MD, Bakersfield, California, United States",,https://ClinicalTrials.gov/show/NCT01010399
NCT01010516,Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia,,Unknown status,No Results Available,Dyslipidemia,Drug: High-dose rosuvastatin|Drug: Statin plus fenofibrate|Drug: Statin plus niacin ER/laropiprant,Changes in non-HDL-C levels,University of Ioannina,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2,Oct-09,Dec-11,null,10-Nov-09,null,10-Aug-11,"University of Ioannina Medical School, Ioannina, Greece",,https://ClinicalTrials.gov/show/NCT01010516
NCT01010841,Trial of Two Dietary Programs on Cardiometabolic Risk Factors in Subjects With Metabolic Syndrome,HMS4,Completed,No Results Available,Metabolic Syndrome|Overweight|Obesity|Hypercholesterolemia,Dietary Supplement: UltraMealPlus 360 (Medical food)|Other: Low-glycemic-load diet,"TG-to-HDL ratio|Components of metabolic syndrome (TG, HDL, resolution of MetS)|Glucose intolerance (fasting glucose/insulin, leptin, HbA1c, HOMA score)|CVD risk factors (cholesterol, LDL, chol/HDL, apoAI, apoB, apoAII, apoCII, apoCIII, apoE, homocysteine, RBC fatty acids, Framingham risk score)|Inflammatory cytokines (TNF-alpha, IL-6, sICAM, sVCAM, MCP1)|Body composition (weight, BMI, % body fat, % lean mass, waist-to-hip ratio, DEXA scanning)|Subjective assessment (MOS-MCS/PCS questionnaires, VAS-satiety/craving questionnaires)","MetaProteomics LLC|University of Florida|University of Connecticut|University of California, Irvine",Female,"20 Years to 75 Years   (Adult, Older Adult)",Not Applicable,89,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HMS4-MUL-CT,Aug-08,Mar-10,Apr-10,10-Nov-09,null,12-Jan-12,"Mark McIntosh MD, Jacksonville, Florida, United States",,https://ClinicalTrials.gov/show/NCT01010841
NCT01007344,Flaxseed Compared With Placebo in Patients With Hypercholesterolemia,,Completed,No Results Available,Familial or Severe Hypercholesterolemia,Dietary Supplement: flaxseed|Dietary Supplement: whole wheat flour,"fasting serum total cholesterol, triglycerides, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) and C-reactive protein|LH (luteinizing hormone, FSH (follicle-stimulating hormone), DHEA-S (Dihydroepiandrosterone sulfate), free testosterone, androstenedione|complete blood count",The Hospital for Sick Children,All,"8 Years to 18 Years   (Child, Adult)",Phase 3,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",1000008297,Oct-09,Dec-10,Dec-10,4-Nov-09,null,27-Aug-13,"The Hospital for Sick Children, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01007344
NCT01003847,Differential Metabolic Effects of Fenofibrate and Fatty Acid,,Completed,No Results Available,Hypertriglyceridemia,"Drug: fenofibrate, fatty acid, placebo",flow-mediated dilation|insulin resistance,Gachon University Gil Medical Center,All,"25 Years to 75 Years   (Adult, Older Adult)",Phase 4,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,GMC-200911,Nov-09,Sep-10,Sep-10,29-Oct-09,null,10-May-11,"Gil Medical Center, Incheon, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01003847
NCT01004237,Additive Effects of Pravastatin and Valsartan,,Completed,No Results Available,Hypertension|High Cholesterol,"Drug: pravastatin, valsartan, pravastatin+valsartan",flow-mediated dilation|insulin resistance,Gachon University Gil Medical Center,All,"25 Years to 75 Years   (Adult, Older Adult)",Phase 4,52,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,GMC-200912,Nov-09,Apr-12,Apr-12,29-Oct-09,null,9-Aug-12,"Gil Medical Center, Incheon, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01004237
NCT00999453,The Effects of Lowering Low-density Lipoprotein Cholesterol Levels to New Targets on Cardiovascular Complications in Peritoneal Dialysis Patients,,Completed,No Results Available,Hypercholesterolemia,Other: LDL-cholesterol,"Cardiovascular complication including acute coronary syndrome, cerebrovascular infarction and cardiovascular death","Clinical Research Center for End Stage Renal Disease, Korea|Ministry of Health & Welfare, Korea",All,"20 Years to 70 Years   (Adult, Older Adult)",Not Applicable,43,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A-02,Oct-09,Nov-15,Nov-15,21-Oct-09,null,17-Mar-17,"Kyungpook National University Hospital, Daegu, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT00999453
NCT00990808,The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3),,Completed,No Results Available,Dyslipidemia,Drug: anacetrapib|Drug: Comparator: atorvastatin|Drug: Comparator: placebo to MK0859|Drug: Comparator: placebo to atorvastatin,Difference in Production Rate (PR) and Fractional Catabolic Rate (FCR) of Low Density Lipoprotein (LDL) apoB100 following treatment with MK0859 and atorvastatin versus atorvastatin alone|Difference in FCR of LDL apoB100 following treatment with MK0859 versus placebo,Merck Sharp & Dohme Corp.,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,46,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0859-026,Nov-09,Jun-11,Jul-11,7-Oct-09,null,4-Jun-15,,,https://ClinicalTrials.gov/show/NCT00990808
NCT00986986,Study of Niacin on Endothelial Function in HIV-infected Subjects With Low High Density Lipoprotein Cholesterol Levels,,Completed,Has Results,HIV Infections|Dyslipidemia|Endothelial Dysfunction,Drug: extended release niacin,Change in Flow-mediated Vasodilation (FMD) From Baseline to Study Week 12|Flow Mediated Vasodilation|High-density Lipoprotein Cholesterol (HDL) Change From Baseline to Study Week 12|HDL,University of Hawaii|United States Department of Defense,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ENDO|Department of Defense,Nov-07,Apr-10,Apr-10,30-Sep-09,18-Dec-12,18-Dec-12,"University of Hawaii - Hawaii Center for AIDS, Honolulu, Hawaii, United States",,https://ClinicalTrials.gov/show/NCT00986986
NCT00981981,Effect of the Molecular Weight of Oat β-glucan on Its Ability to Lower Serum Cholesterol,Bluebird,Completed,No Results Available,Hypercholesterolemia,Dietary Supplement: Wheat bran|Dietary Supplement: 3g high MW|Dietary Supplement: 4g medium MW|Dietary Supplement: 3g medium MW|Dietary Supplement: 4g low MW,Serum LDL-cholesterol lowering effect of 3g high MW beta-glucan|Correlation between serum LDL-cholesterol lowering and log(MW*C)|Total cholesterol|Serum triglycerides|Serum HDL cholesterol|Fasting serum glucose|Serum aspartate transaminase|serum c-reactive protein|Serum urea|Serum creatinine|Time course of changes in blood lipids|Blood pressure|Macronutrient composition of diet|Symptoms questionnaire|apolipoprotein B|Serum markers of cholesterol absorption and synthesis,"Glycemic Index Laboratories, Inc|CreaNutrition, AG|University of Guelph|University of Sydney|Laval University|Reading Scientific Services Ltd.|University of Toronto|Agriculture and Agri-Food Canada",All,"35 Years to 70 Years   (Adult, Older Adult)",Phase 2,367,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GIL8034,Nov-08,Jul-09,Aug-09,22-Sep-09,null,21-Jun-11,"SUGiRS Human Nutrition Unit, School of Molecular & Microbial Biosciences, Unviersity of Sydney, Sydney, New South Wales, Australia|Human Nutraceutical Research Unit, Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, Ontario, Canada|Glycemic Index Laboratories, Inc., Toronto, Ontario, Canada|Nutraceuticals and Functional Foods Institute, Faculte des science de l'agriculture et de l'alimentation, Universite Laval, Laval, Quebec, Canada|Reading Scientific Services, Ltd (RSSL), Reading, Berkshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT00981981
NCT00979368,Safety Study of BMS-816336 in Healthy Male Subjects,,Completed,No Results Available,"Diabetes Mellitus, Non-Insulin-Dependent|Dyslipidemia",Drug: BMS-816336|Drug: Placebo,Exposure to the investigational drug will be measured to assess safety and tolerability|To assess the single dose Pharmacokinetics of BMS-816336,Bristol-Myers Squibb,Male,18 Years to 55 Years   (Adult),Phase 1,40,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)",MB124-001,Nov-09,Feb-10,Feb-10,18-Sep-09,null,23-Feb-11,"Local Institution, Melbourne, Victoria, Australia",,https://ClinicalTrials.gov/show/NCT00979368
NCT00977288,A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029),,Completed,No Results Available,Dyslipidemia,Drug: anacetrapib|Drug: Comparator: atorvastatin|Drug: Comparator: Placebo,"The percent change from baseline in Low Density Lipoprotein -Cholesterol at week 8|The percent change from baseline in High Density Lipoprotein-Cholesterol and safety (hepatitis related AEs, myalgia, rhabdomyolysis, blood pressure, laboratory tests: ALT, AST, CK, Na, Cl, bicarbonate, and K), at week 8",Merck Sharp & Dohme Corp.,All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 2,408,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0859-029|2009_662,Sep-09,Mar-10,Apr-14,15-Sep-09,null,6-May-15,,,https://ClinicalTrials.gov/show/NCT00977288
NCT00974272,Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation,,Completed,No Results Available,Type 2 Diabetes Mellitus|Impaired Glucose Tolerance,Drug: Exenatide|Other: Normal Saline,"Triglyceride concentration in serum|serum or plasma lipoproteins, apolipoproteins and inflammatory markers; endothelial function",Carl T. Hayden VA Medical Center,All,"35 Years to 70 Years   (Adult, Older Adult)",Phase 4,39,U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PR-015,Aug-06,Nov-08,Nov-08,10-Sep-09,null,10-Sep-09,"Phoenix VA Medical Center, Phoenix, Arizona, United States",,https://ClinicalTrials.gov/show/NCT00974272
NCT00972829,Tolerability and Lipid Lowering Effect of Weekly/Biweekly Crestor in Statin Intolerant Patients Treated With Zetia,,Unknown status,No Results Available,Hypercholesterolemia,Drug: Rosuvastatin|Drug: Ezetimibe,Low-density lipoprotein (LDL) cholesterol|The ability to remain on Crestor for the study period,Bronx VA Medical Center,All,"18 Years and older   (Adult, Older Adult)",Phase 4,30,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment,BAR-09-07,Sep-09,Dec-10,Mar-11,9-Sep-09,null,10-Sep-09,"Bronx VA Medical Center, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT00972829
NCT00973115,Efficacy and Safety of Morning Versus Evening Intake of Simvast Controlled Release (CR) Tablet in Patients With Hyperlipidemia,,Completed,No Results Available,Hyperlipidemia,Drug: Simvastatin CR,"the percent change from baseline in LDL cholesterol|the change and the percent change from baseline for total cholesterol, HDL cholesterol, Triglyceride, apolipoprotein A-I, apolipoprotein B, and lipoprotein(a)",Hanmi Pharmaceutical Company Limited,All,"19 Years to 75 Years   (Adult, Older Adult)",Phase 3,132,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HM-SIM-302,Nov-07,Aug-09,Aug-09,9-Sep-09,null,12-Oct-16,"8 Sites, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT00973115
NCT00973271,Diazoxide Choline Controlled-Release Tablet (DCCR) for Very High Triglycerides,,Withdrawn,No Results Available,Hypertriglyceridemia,Drug: 290 mg DCCR|Drug: 435 mg DCCR|Drug: 135 mg fenofibric acid|Drug: Placebo|Drug: atorvastatin,The effect of DCCR on triglycerides in subjects without diabetes mellitus who have very high triglycerides over a period of 84 days|The effects of DCCR on Apo B and non-HDL in subjects without diabetes mellitus who have very high triglycerides over a period of 84 days,"Essentialis, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PV011,Mar-11,Nov-11,Dec-11,9-Sep-09,null,1-Sep-16,,,https://ClinicalTrials.gov/show/NCT00973271
NCT00966225,LIP-01 in Hypercholesterolemia,,Completed,No Results Available,Hypercholesterolemia,Dietary Supplement: LIP-01,To determine a safe and tolerable dose of LIP-01,Afexa Life Sciences Inc,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,40,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LIP-01-2009-1,Sep-09,Jan-12,Jan-12,26-Aug-09,null,31-Jan-12,"Medicus Research, LLC, Northridge, California, United States|The Northern Alberta Clinical Trials and Research Centre, Edmonton, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT00966225
NCT00965055,Ezetimibe in Patients Hypo-responsive to Statins,,Terminated,No Results Available,High Cholesterol|Coronary Artery Disease,Drug: Ezetimibe|Drug: Atorvastatin,"LDL-C reduction|LDL-C reduction as well as changes in TG, HDL, and non-HDL Cholesterol.","University of California, San Diego|Merck Sharp & Dohme Corp.",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,2,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",90948,Sep-09,Sep-11,Sep-12,25-Aug-09,null,28-Jan-13,"UCSD Medical Center in Hillcrest Clinical Trials Facility, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT00965055
NCT00961636,A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant [MK0524A]) in Patients With Dyslipidemia (0524A-102),,Completed,Has Results,Dyslipidemia,Drug: ER niacin (+) laropiprant (ERN/LRPT)|Drug: Extended-release niacin (ERN)|Drug: Placebo to ERN/LRPT,Number Participants With Days Per Week With Global Flushing Severity Score (GFSS) ≥4 Partitioned Into 6 Categories During the Postwithdrawal Period|Number of Participants With Maximum GFSS ≥4 During the Post-withdrawal Period,Merck Sharp & Dohme Corp.,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,1152,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0524A-102|2009_634,Oct-09,Jan-11,Jan-11,19-Aug-09,17-Feb-12,16-Feb-15,,,https://ClinicalTrials.gov/show/NCT00961636
NCT00959842,Effects of Lovaza on Lipoprotein Composition and Function in Mild Hypertriglyceridemia,ELLF,Completed,No Results Available,Hypertriglyceridemia,Drug: Lovaza,"The primary endpoint will be the effect of treatment on lipoprotein binding to target cells.|Performance of VLDL as a substrate for lipolysis.|Plasma LpL mass and activity.|VLDL, LDL, HDL oxylipin and fatty acid content",Sanford Research|GlaxoSmithKline,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 1|Phase 2,15,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LVZ 112860|GSK - LVZ 112860,Sep-09,Feb-10,Feb-10,17-Aug-09,null,18-Nov-14,"Sanford Research/USD, Sioux Falls, South Dakota, United States",,https://ClinicalTrials.gov/show/NCT00959842
NCT00955227,Can Cholesterol Lowering Drugs Influence Circulating Omega-3 Fatty Acid Levels,,Completed,No Results Available,Hypercholesterolemia|Hyperlipidemia,Dietary Supplement: Flax seed oil (ALA)|Drug: Ezetimibe,"Levels of circulating omega-3 fatty acid (ALA)|The n6:n3 fatty acid ratio will be calculated Total cholesterol, LDL, HDL, and triglyceride levels will also be measured",University of Manitoba|Canadian Institutes of Health Research (CIHR),All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),B2009:054,Jul-09,May-11,Dec-15,10-Aug-09,null,12-May-16,"St. Boniface General Hospital, Winnipeg, Manitoba, Canada|St. Boniface General Hospital Research Centre, Winnipeg, Manitoba, Canada",,https://ClinicalTrials.gov/show/NCT00955227
NCT00955903,"Calorie Restriction and Changes in Body Composition, Disease, Function, and Quality of Life in Older Adults",CROSSROADS,Completed,Has Results,Obesity|Diabetes|Hypertension|Hyperlipidemia,Behavioral: Exercise|Behavioral: Reduced Calorie Diet|Behavioral: Weight Maintenance Diet,Change in Abdominal Fat Mass|Cardiometabolic Risk Factors|Weight Change/Maintenance,University of Alabama at Birmingham,All,65 Years and older   (Older Adult),Phase 3,167,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,F090430012,Jun-10,Aug-14,Aug-14,10-Aug-09,28-Jun-17,5-Sep-17,"University of Alabama at Birmingham, Birmingham, Alabama, United States",,https://ClinicalTrials.gov/show/NCT00955903
NCT00947635,Cholesterol and Fatty Acid Synthesis in Islet and Liver Transplant Patients and Effect of Dietary Intervention,,Completed,No Results Available,"Immunosuppression|Hyperlipidemias|Diabetes Mellitus, Type 1",Dietary Supplement: Dietary intervention - supplements,Cholesterol and fatty acid synthesis|Blood lipid levels,University of Alberta|Canadian Institutes of Health Research (CIHR),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,46,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Islet-Liver-MTC,Nov-05,Jun-09,Jun-09,28-Jul-09,null,28-Jul-09,"University of Alberta, Edmonton, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT00947635
NCT00945737,A Study on the Effects of Soy Protein on Blood Lipids in Men and Women With Mild to Moderate Hypercholesterolemia,PRV-08009,Completed,No Results Available,Hypercholesterolemia,Dietary Supplement: Soy protein; 25 grams/day|Dietary Supplement: Control protein,The difference between treatment groups in the percent change from baseline to the end of treatment in LDL-C|Changes in other lipid levels and other related biomarkers,"Solae, LLC",All,"18 Years to 79 Years   (Adult, Older Adult)",Not Applicable,60,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",PRV-08009,Apr-09,Aug-09,Aug-09,24-Jul-09,null,7-Jun-12,"Provident Clinical Research, Addison, Illinois, United States|Provident Clinical Research, Bloomington, Indiana, United States",,https://ClinicalTrials.gov/show/NCT00945737
NCT00944645,MK0524A Bioequivalence Study (0524A-059),,Completed,Has Results,Dyslipidemia,Drug: niacin (+) laropiprant (Source 1)|Drug: Comparator: niacin (+) laropiprant (Source 2),Maximum Plasma Concentration (Cmax) of Nicotinuric Acid|Total Amount of Urinary Excretion of Niacin and Its Metabolites|Area Under Curve (AUC 0-infinity) of Laropiprant|Maximum Concentration (Cmax) of Laropiprant,Merck Sharp & Dohme Corp.,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,188,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0524A-059|MK0524A-059|2009_613,Oct-06,Jan-07,Jan-07,23-Jul-09,25-Nov-09,19-Jun-15,,,https://ClinicalTrials.gov/show/NCT00944645
NCT00944827,Combination Treatment With Green Tea Extract and Statins in Patients With Hypercholesterolemia,GTE-Stat,Completed,No Results Available,Hypercholesterolemia,Dietary Supplement: Green Tea Extract - Catechins|Dietary Supplement: Placebo,"Reduction in Total CHO and LDH|lipids profile, body composition, visceral adiposity, Redox status, glucose disposal, Insulin sensitivity index, liver fat infiltration, quality of life parameters","University of Thessaly|Greek Ministry of Development|General Hospital of Trikala, Dept of Internal Medicine|University General Hospital of Larissa, Dept of Medicine",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care",3-22/846/06-2007|22/08-06-2007|no3/10-01-2007|846/22/15-06-2007,Sep-07,Oct-09,Oct-09,23-Jul-09,null,3-Dec-10,"General Hospital of Trikala, Trikala, Thessaly, Greece",,https://ClinicalTrials.gov/show/NCT00944827
NCT00943124,MK0524B Bioequivalence Study (0524B-070),,Completed,Has Results,Dyslipidemia,Drug: MK0524B (ER niacin (+) laropiprant (+) simvastatin)|Drug: MK0524A (ER niacin + laropiprant)|Drug: Simvastatin,Plasma Area Under the Curve (AUC(0 to 48hr)) for Simvastatin Acid|Peak Plasma Concentration (Cmax) of Simvastatin Acid|Plasma Area Under the Curve (AUC(0 to 48 Hour)) for Simvastatin|Peak Plasma Concentration (Cmax) of Simvastatin|Plasma Area Under the Curve (AUC(0 to Infinity)) for Laropiprant|Peak Plasma Concentration (Cmax) of Laropiprant|Peak Plasma Concentration (Cmax) of Nicotinuric Acid|Total Urinary Excretion of Niacin and Its Metabolites,Merck Sharp & Dohme Corp.,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,220,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0524B-070|MK0524B-070|2009_612,Jul-07,Aug-07,Aug-07,22-Jul-09,6-Jan-10,19-Jun-15,,,https://ClinicalTrials.gov/show/NCT00943124
NCT00943306,"Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial Hypercholesterolemia",,Completed,Has Results,Familial Hypercholesterolemia,Drug: lomitapide,Percent Change in Low Density Lipoprotein Cholesterol (LDL-C)|Percent Change in Total Cholesterol|Percent Change in Apolipoprotein B (Apo B)|Percent Change in Triglycerides|Percent Change in Non High Density Lipoprotein Cholesterol (Non-HDL-C)|Percent Change in Very Low Density Lipoprotein Cholesterol (VLDL-C)|Percent Change in Lp(a)|Percent Change in High Density Lipoprotein Cholesterol (HDL-C)|Percent Change in Apolipoprotein AI (Apo AI),"Aegerion Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,19,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AEGR-733-012,29-Oct-09,17-Sep-12,1-Dec-14,22-Jul-09,10-May-18,13-Jun-18,"Cedars-Sinai Medical Center, Los Angeles, California, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Robarts Research Institute, London, Ontario, Canada|Lipid Clinic and University of Montreal Community Genomic Medicine Center, Chicoutimi, Quebec, Canada|Medicina Interna Universitaria, Ferrara, Sicily, Italy|Dipartimento di Medicina Clinica e Delle Patologie Emergenti, Palermo, Sicily, Italy|Centro Universitario Dislipidemie, Milano, Italy|DAI Ematologia, Oncologia, Anatomia Patologica e Medicina, Roma, Italy|Cardiology Research, Bloemfontein, South Africa|University of Capetown, Cape town, South Africa",,https://ClinicalTrials.gov/show/NCT00943306
NCT00940966,A Pilot Study to Determine the Efficacy of a Low Carbohydrate Diet in Treatment of Adolescents With Metabolic Syndrome,,Completed,No Results Available,Elevated Triglycerides|Systolic Hypertension|Insulin Resistance|Abdominal Obesity,Dietary Supplement: standard ADA diet|Dietary Supplement: energy restricted very-low carbohydrate diet|Dietary Supplement: low glycemic diet,weight loss,CAMC Health System,All,"12 Years to 18 Years   (Child, Adult)",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,06-02-1776,Jul-06,May-12,May-12,17-Jul-09,null,3-Feb-15,"Wvu Department of Pediatrics, Charleston, West Virginia, United States",,https://ClinicalTrials.gov/show/NCT00940966
NCT00941603,Phase 2 Dose-Ranging Efficacy and Safety Trial of SCH 900271 in Participants With Primary Hypercholesterolemia or Mixed Hyperlipidemia (P05675),,Completed,Has Results,Primary Hypercholesterolemia|Mixed Hyperlipidemia,Drug: SCH 900271 15mg|Drug: SCH 900271|Drug: Placebo,Change From Baseline in Direct LDL-C at Week 8|Change From Baseline in Direct Non-HDL-C at Week 8,Merck Sharp & Dohme Corp.,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,619,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",P05675|MK-8271-004,29-Jun-09,22-Feb-10,22-Feb-10,17-Jul-09,12-Apr-16,25-Sep-18,,,https://ClinicalTrials.gov/show/NCT00941603
NCT00937898,Beef in an Optimal Lean Diet (BOLD) Effects on Cardiovascular Disease (CVD) Risk,BOLD,Completed,No Results Available,Hypercholesterolemia|Hypertriglyceridemia,Dietary Supplement: BOLD+ Diet|Dietary Supplement: BOLD diet,"Lipids (Total cholesterol, LDL-C, HDL-C, TG)|Apolipoprotein levels|Vascular function|Oxidative Stress",Penn State University|National Cattlemen's Beef Association,All,"21 Years to 65 Years   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,PKE101,Aug-07,Aug-11,Mar-12,13-Jul-09,null,15-May-13,,,https://ClinicalTrials.gov/show/NCT00937898
NCT00938249,Effects of Monascus Garlic Fermented Extract on Serum Triglyceride Level,,Completed,No Results Available,Hypertriglyceridemias,Dietary Supplement: Monascus Garlic Fermented Extract|Dietary Supplement: Placebo,Fasting triglyceride level|Abdominal circumference|Visceral fat area by CT scan|Serum total cholesterol and LDL cholesterol levels|Serum adiponectin level,"Hiroshima University|Wakunaga Pharmaceutical Co., Ltd.",All,"20 Years to 70 Years   (Adult, Older Adult)",Not Applicable,55,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention",eki-146,Jul-09,Feb-10,Feb-10,13-Jul-09,null,26-Apr-10,"Hiroshima University, Hiroshima, Japan",,https://ClinicalTrials.gov/show/NCT00938249
NCT00938405,Efficacy of Colesevelam in Subjects With Type 1 Diabetes Mellitus,,Completed,No Results Available,"Diabetes Mellitus, Type 1|Hyperlipidemias",Drug: Colesevelam HCl|Drug: Placebo,"To demonstrate a 10% LDL reduction in type 1 diabetic subjects with initial LDL > 100 after twelve weeks in the colesevelam group.|To evaluate colesevelam use for glucose control as measured by A1c using a 0.4% confidence interval at baseline and after one, two, and three months of therapy.|To evaluate colesevelam use for non-inferiority of percent of target range glucose values and time spent in hyper- and hypoglycemic ranges as determined by CGM readings at baseline and after one, two, and three months of therapy.|In addition change in insulin dose at one, two and three months from baseline will be evaluated.","University of Colorado Denver School of Medicine Barbara Davis Center|Daiichi Sankyo, Inc.",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,45,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",DSI-WCH-100,Jul-09,Dec-09,Dec-09,13-Jul-09,null,20-May-14,"Barbara Davis Center for Diabetes, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT00938405
NCT00934219,Triglyceride Lowering Study,TGLL,Unknown status,No Results Available,Hypertriglyceridemia,Drug: Omega-3-Acid Ethyl Esters,triglycerides level,"Jewish Hospital, Cincinnati, Ohio|GlaxoSmithKline",All,"18 Years and older   (Adult, Older Adult)",Phase 4,25,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TgLL8506,Jul-09,Jul-12,Dec-12,8-Jul-09,null,8-Jul-09,"Jewish Hospital Cholesterol Center, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00934219
NCT00934908,Prevention of Weight Gain and Dyslipidemia by Green Tea in Patients Initiating Therapy With Olanzapine,,Withdrawn,No Results Available,Bipolar Disorder|Schizophrenia,Dietary Supplement: Green Tea|Other: Placebo,Attenuation of weight and fat gain in patients initiating therapy with Zyprexa®|Attenuation of negative changes in the plasma lipid profile in patients initiating therapy with Zyprexa®.,Medical University of South Carolina|Eli Lilly and Company,All,18 Years to 55 Years   (Adult),Not Applicable,0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",Green Tea and Olanzapine,Mar-09,Mar-09,Mar-09,8-Jul-09,null,18-Jul-18,"Medical University of South Carolina, Charleston, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT00934908
NCT00935259,Lipid Biomarker Study in Men With Dyslipidemia After Simvastatin Treatment (Study MK-0000-140)(COMPLETED),,Completed,Has Results,"Hypercholesterolemia, Dyslipidemia",Drug: Simvastatin|Drug: Placebo,Arachidonic Acid Level After 2 Weeks of Treatment|Fasting Blood Lipidomic Levels After 2 Weeks of Treatment|Serum Proprotein Convertase Subtilisin-like/Kexin Type 9 (PCSK9) Level|Blood Linoleic Acid Levels|Change in Fasting Delta 5 Desaturase Enzyme Activity Compared to Placebo,Merck Sharp & Dohme Corp.,Male,"30 Years to 70 Years   (Adult, Older Adult)",Phase 1,31,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0000-140|2009_609,Jul-09,Oct-09,Oct-09,8-Jul-09,20-Feb-12,8-Oct-15,,,https://ClinicalTrials.gov/show/NCT00935259
NCT00933647,Cardioprotective Effects of Green Tea Versus Maté Intake,,Unknown status,No Results Available,Dyslipidemia|Inflammation|Obesity,Dietary Supplement: Yerba Mate Tea|Dietary Supplement: Green tea|Dietary Supplement: Apple tea,"Improvement of lipid (total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides and total cholesterol / HDL-cholesterol ratio) and inflammatory profiles (C- reactive protein and fibrinogen).|Decreases in body weight, body mass index, body fat ratio, abdominal and waist circumferences and waist to hip ratio. Changes in glucose and insulin will also be evaluated.",Instituto de Cardiologia do Rio Grande do Sul,All,35 Years to 60 Years   (Adult),Phase 3,195,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Projeto Chimarrão,Nov-07,Sep-09,Dec-09,7-Jul-09,null,13-Jul-09,"Instituto de Cardiologia / Fundação Universitária de Cardiologia, Porto Alegre, RS, Brazil",,https://ClinicalTrials.gov/show/NCT00933647
NCT00932620,Comparison of Simvastatin Versus Simvastatin/Ezetimibe on Small Dense Low -Density Lipoprotein (LDL),,Completed,Has Results,Hypercholesterolemia,Drug: SIMVASTATIN 40 mg|Drug: SIMVASTATIN/EZETIMIBE 10/10 mg,Changes in Small Dense Low-density Lipoprotein Cholesterol (sdLDL-C) Levels|Changes in Low-density Lipoprotein Cholesterol (LDL-C),University of Ioannina,All,"Child, Adult, Older Adult",Phase 4,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1,Jun-09,Apr-10,Apr-10,3-Jul-09,12-Aug-11,19-Aug-11,"University Hospital of Ioannina, Ioannina, Greece",,https://ClinicalTrials.gov/show/NCT00932620
NCT00931879,Lovaza® and Microvascular Function in Type 2 Diabetes,,Completed,Has Results,Hypertriglyceridemia|Diabetic Neuropathy,Drug: omega-3-ethyl esters|Drug: Placebo,"Efficacy Measures Are Nerve Conduction Studies, Specifically Changes in Conduction Amplitude.|Measurements of Indices of Large and Small Fiber Nerve Function Including Heart Rate Variation Measures.|Measurements of Indices of Large and Small Fiber Nerve Function Using Vibration and Thermal Thresholds.|Percent Change in Measurements of Indices of Large and Small Fiber Nerve Function Including Vibration Thresholds|Measurements of Indices of Large and Small Fiber Nerve Function Including Markers of Inflammation and Oxidative Stress.|Efficacy Measures Are Nerve Conduction Studies; Specifically, Increases in Conduction Velocity.|Efficacy Measures Are Nerve Conduction Studies, Specifically Changes in Latency.|Efficacy Measures Are Nerve Conduction Studies, Specifically Changes in F-wave Conduction|Efficacy Measures Examining Increased Vascular Response to Ischemic Block and to Local Warming at the Dorsum of the Foot.",Eastern Virginia Medical School|GlaxoSmithKline,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,44,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",LVZ111903,Oct-09,Jul-12,Jul-12,2-Jul-09,9-May-17,9-May-17,"Strelitz Diabetes Center, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00931879
NCT00928616,Differential Effects of a Diet Supplementation With Plant Sterol Esters on Human Monocytes,PSE-MO,Unknown status,No Results Available,Hyperlipidemia,Dietary Supplement: margarine + plant sterol esters|Dietary Supplement: margarine (placebo),"monocyte subpopulations|serum parameters (lipids, plant sterol concentrations, inflammation parameters)","University Hospital, Saarland",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,16,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",108/07,Apr-09,Jun-09,Jun-09,26-Jun-09,null,26-Jun-09,"Universitätsklinikum des Saarlandes, Klinik für Innere Medizin III, Homburg, Saarland, Germany",,https://ClinicalTrials.gov/show/NCT00928616
NCT00928694,Fenofibrate Bioequivalence Study (0767-031),,Completed,Has Results,Dyslipidemia,Drug: fenofibrate (U.S. formulation)|Drug: fenofibrate (UK formulation),Area Under the Curve (AUC(0 to Infinity)) of Fenofibric Acid|Maximum Plasma Concentration (Cmax) of Fenofibric Acid,Merck Sharp & Dohme Corp.,All,18 Years to 45 Years   (Adult),Phase 1,14,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0767-031|MK0767-031|2009_606,Feb-03,Apr-03,Apr-04,26-Jun-09,11-Dec-09,19-Aug-15,,,https://ClinicalTrials.gov/show/NCT00928694
NCT00928889,"Effects of Nateglinide vs Acarbose on Postprandial Glucose Fluctuation, Dyslipidemia, and Inflammatory Factors",ENERGY,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Nateglinide 120 mg|Drug: Acarbose 50 mg,Change From Baseline in Postprandial Glucose Excursion (PPGE) at the End of the Study (Week 4)|Change From Baseline in Peak Postprandial Glucose at the End of the Study (Week 4)|Change From Baseline in Postprandial Glucose Area Under the Curve at the End of the Study (Week 4)|Change From Baseline in Total Cholesterol at the End of the Study (Week 4)|Change From Baseline in Triglycerides at the End of the Study (Week 4)|Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at the End of the Study (Week 4)|Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at the End of the Study (Week 4)|Change From Baseline in Free Fatty Acids (FFA) at the End of the Study (Week 4)|Change From Baseline in High-sensitivity C-reactive Protein (hsCRP) at the End of the Study (Week 4)|Change From Baseline in Glycosylated Serum Albumin (GSA) at the End of the Study (Week 4),Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 4,160,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CDJN608ACN06,Jul-09,Jun-10,Jun-10,26-Jun-09,7-Jul-11,10-May-12,"People's Liberation Army. The Military General Hospital of BeiJing, BeiJing, China|Peiking University First Hospital, BeiJing, China|Chinese PLA General Hospital, Beijing, China|The First Affiliated Hospital, Zhongshan (Sun Yat-sen) University, Guangzhou, China|The Second Affiliated Hospital, Zhongshan (Sun Yat-sen) University, Guangzhou, China|Nanfang Hospital, the Affiliated South Hospital of the Southern Medical University, Guangzhou, China",,https://ClinicalTrials.gov/show/NCT00928889
NCT00927459,"Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High Cholesterol",,Terminated,No Results Available,Hypercholesterolemia,Drug: PRO-040201|Drug: Placebo,Safety and tolerability of PRO-040201|Pharmacokinetics of PRO-040201 in Humans|Pharmacodynamics of PRO-040201 in Humans,Arbutus Biopharma Corporation,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,23,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,TKM-ApoB-001,Jun-09,Dec-09,Jan-10,25-Jun-09,null,22-Jan-10,"Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00927459
NCT00926744,Nutrition and Exercise Intervention Study,NEXIS,Unknown status,No Results Available,Hypertension|Dyslipidemia|Diabetes|Low Back Pain,Behavioral: physical activity,"Objectively measured amount of physical activity|Surrogate measurement of lifestyle-related diseases (blood pressure, FPG, cho, etc)|Incidence of lifestyle-related diseases (hypertension, dyslipidemia, diabetes)|Incidence of musculoskeletal and joint pain",National Institute of Health and Nutrition,All,30 Years to 64 Years   (Adult),Not Applicable,1085,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",qde402mm|21170901,Apr-06,Apr-14,Mar-18,24-Jun-09,null,29-Mar-17,"National Institute of Health and Nutrition, Shinjuku, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT00926744
NCT00927199,Efficacy of High-oleic Canola and Flaxseed Oils for Hypercholesterolemia and Cardiovascular Disease Risk Factors,,Completed,No Results Available,Cardiovascular Disease,Dietary Supplement: High-Oleic Canola Oil|Dietary Supplement: High-Oleic Canola/Flaxseed Oil Blend|Dietary Supplement: Western Dietary Control,"Serum Lipids|Inflammatory Biomarkers: C-Reactive Protein, Interleukin-6, sE-Selectin, sVCAM-1, sICAM-1|Intima-Medial Thickness by Carotid Ultrasound|Energy Expenditure by Indirect Calorimetry|Body Composition by Dual Emission X-Ray Absorptiometry (DEXA)|Oxidation and Conversion of U-13C-Alpha Linolenic Acid|Plasma Fatty Acid Concentrations|Arterial Stiffness Index by Pulse Wave Analysis",University of Manitoba|Canola Council of Canada|Flax Canada 2015 Inc.|Agri-Food Research and Development Initiative,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,36,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,B2007:071,Sep-07,Jun-08,Jun-08,24-Jun-09,null,1-Feb-13,"Richardson Centre for Functional Foods and Nutraceuticals, University of Manitoba, Winnipeg, Manitoba, Canada",,https://ClinicalTrials.gov/show/NCT00927199
NCT00923403,"Efficacy of Sterol-Fortified Low Fat Soy Beverage on Cholesterol Metabolism, Inflammation and Oxidative Status in Humans - Study II",,Completed,No Results Available,Hypercholesterolemia,Dietary Supplement: plant sterol enriched soymilk|Dietary Supplement: control dairy milk,plasma cholesterol,"University of Manitoba|WhiteWave Foods, Inc.",All,20 Years to 60 Years   (Adult),Phase 1|Phase 2,33,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,555-210,Aug-08,Dec-08,Jan-09,18-Jun-09,null,18-Jun-09,"Richardson Centre for Functional Foods and Nutraceuticals, Winnipeg, Manitoba, Canada",,https://ClinicalTrials.gov/show/NCT00923403
NCT00923676,Treatment of Hyperlipidemia and Sexual Dysfunction,,Unknown status,No Results Available,Sexual Dysfunction|Hyperlipidemia,Drug: fenofibrate|Drug: Rosuvastatin|Drug: fenofibrate + rosuvastatin,"International index of erectile dysfunction (IIEF) in men and Female sexual function index (FSFI) in women|Blood lipids, inflammatory markers","University of Campania ""Luigi Vanvitelli""",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,300,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,DGMM/03/2007,Apr-08,Oct-15,Apr-16,18-Jun-09,null,18-Nov-15,"Department of Geriatrics and Metabolic Diseases, Naples, Italy",,https://ClinicalTrials.gov/show/NCT00923676
NCT00924274,Effect of Rapeseed Oil and Sunflower Oil,,Unknown status,No Results Available,Familial Hypercholesterolemia,Dietary Supplement: rapeseed oil|Dietary Supplement: sunflower oil,"Blood analysis including fasting serum lipoproteins (TC, LDLc; HDLc; TG, Lp(a), Apolipoprotein A-1, Apolipoprotein B, BB, hs-CRP, GOT, GPT, GGT, acid composition of plasma lipids.|Motivation, compliance, increase of quality of life.|Acceptance and approach to the disease.|Improvement of knowledge and understanding about the disease by the patients.",Medical University of Vienna,All,"6 Years to 18 Years   (Child, Adult)",Not Applicable,24,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",EROSO,Mar-08,Jul-10,Dec-10,18-Jun-09,null,18-Jun-09,"Division of Nutrition and Metabolism, Department of Pediatrics, Medical University of Vienna, Vienna, Austria",,https://ClinicalTrials.gov/show/NCT00924274
NCT00924339,Soy Food Intervention Trial,SOYFIT,Unknown status,No Results Available,Familial Hypercholesterolemia,Dietary Supplement: soy protein diet|Dietary Supplement: rapeseed oil,"Blood analysis include: TC, LDLc, HDLc, TG, Lp(a), ApoA1, Apo B, Electrolytes, Albumin, Creatinin and CRP|uric acid and the isoflavones: daidzein, glycetein, genistein and equol",Medical University of Vienna,All,"4 Years to 18 Years   (Child, Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SOYFIT,Sep-09,Mar-11,Sep-11,18-Jun-09,null,18-Jun-09,"Division of Nutrition and Metabolism, Department of Pediatrics, Medical University of Vienna, Vienna, Austria",,https://ClinicalTrials.gov/show/NCT00924339
NCT00921960,St. Vincent's Screening To Prevent Heart Failure Study,STOP-HF,Completed,No Results Available,Left Ventricular Dysfunction|Myocardial Infarction|Hypertension|Diabetes|Obesity,Other: Intervention Care,Prevalence and severity of LVD,"St Vincent's University Hospital, Ireland|University College Dublin|Crofton Cardiac Centre, Dublin|The Heartbeat Trust",All,"40 Years and older   (Adult, Older Adult)",Not Applicable,1378,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,SVUH - HFU - 020,Jan-05,Dec-17,Dec-17,17-Jun-09,null,27-Jul-18,"St Vincent's University Hospital, Dublin, Ireland",,https://ClinicalTrials.gov/show/NCT00921960
NCT00917579,Bioequivalence Study Comparing A New 10 Mg Atorvastatin Tablet To A 10 Mg Atorvastatin Commercial Tablet,,Completed,Has Results,Hypercholesterolemia,Drug: Atorvastatin,Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC Infinity)|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)|Maximum Observed Plasma Concentration (Cmax)|Time to Reach Maximum Plasma Concentration (Tmax)|Plasma Elimination Half-life (t1/2),Pfizer,All,18 Years to 55 Years   (Adult),Phase 4,76,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),A2581166,Jul-08,Sep-08,Sep-08,10-Jun-09,14-Oct-09,20-Oct-09,"Pfizer Investigational Site, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT00917579
NCT00917644,Bioequivalence Study Comparing A New 80 Mg Atorvastatin Tablet To A 80 Mg Atorvastatin Commercial Tablet,,Completed,Has Results,Hypercholesterolemia,Drug: Atorvastatin|Genetic: Atorvastatin,Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC Infinity)|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)|Maximum Observed Plasma Concentration (Cmax)|Time to Reach Maximum Plasma Concentration (Tmax)|Plasma Elimination Half-life (t1/2),Pfizer,All,18 Years to 55 Years   (Adult),Phase 4,76,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),A2581167,Jul-08,Sep-08,Sep-08,10-Jun-09,15-Oct-09,20-Oct-09,"Pfizer Investigational Site, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT00917644
NCT00917878,Postprandial Effects of Milk and Milk Constituents,,Completed,No Results Available,Hyperlipidemia|Inflammation,Dietary Supplement: Milk|Dietary Supplement: Protein|Dietary Supplement: Calcium|Dietary Supplement: Control,Plasma inflammatory markers|Serum lipids,Maastricht University Medical Center|Nederlandse Zuivel Organisatie,Male,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,16,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,MEC 08-3-096,Mar-09,Jul-09,Jul-09,10-Jun-09,null,27-Apr-18,"Maastricht University Medical Center, Maastricht, Netherlands",,https://ClinicalTrials.gov/show/NCT00917878
NCT00915902,Fish Oil Study for High Triglyceride Levels in Children,,Completed,Has Results,Hypertriglyceridemia,Drug: Omega-3-acid ethyl esters|Drug: Placebo,Change in Triglyceride Level,Samuel Gidding|GlaxoSmithKline|Johns Hopkins University|Thomas Jefferson University|Nemours Children's Clinic,All,10 Years to 17 Years   (Child),Phase 2|Phase 3,42,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",GIDDING,Jul-09,Sep-12,Sep-12,8-Jun-09,7-May-14,8-Dec-15,"A. I. duPont Hospital for Children, Wilmington, Delaware, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Thomas Jefferon University, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00915902
NCT00910988,Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone,,Completed,Has Results,Hyperglycemia|Hyperlipidemia,Drug: Olanzapine|Drug: Ziprasidone,Whole Body Insulin Sensitivity|Hepatic Insulin Sensitivity|Peripheral Insulin Sensitivity|Adipose Tissue Insulin Sensitivity,Washington University School of Medicine|Pfizer,Male,18 Years to 45 Years   (Adult),Not Applicable,46,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,08-0540,Feb-09,Jun-12,Jun-12,1-Jun-09,15-Jan-14,18-Jul-18,"Washington University School of Medicine, Saint Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT00910988
NCT00908011,Addition of Ezetimibe (Ezetrol®) to Ongoing Therapy With Rosuvastatin (Crestor®) in HIV Positive Patients Not Reaching Cholesterol Targets,,Completed,Has Results,Hypercholesterolemia|HIV Infections,Drug: Ezetimibe|Drug: Rosuvastatin (standard care),"The Primary Endpoint is the Difference in Final Value of Serum Apolipoprotein B Between Participants Treated With Rosuvastatin Versus Participants Treated With Both Rosuvastatin and Ezetimibe.|Percent Change in Apolipoprotein B, Percent and Absolute Change Total Cholesterol, LDL, HDL, Triglycerides, Apolipoprotein A1, apolipoproteinB/apoliporoteinA1 Ratio and C-reactive Protein|Assessment of Safety Parameters, Specifically Incidence of Complications as Measured by an Increase in AST &/or ALT ≥3-fold ULN & a CK ≥10-fold ULN","University of British Columbia|Merck Frosst-Schering Pharma, G.P.",All,"19 Years and older   (Adult, Older Adult)",Not Applicable,43,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H08-00287,Jun-09,Dec-14,Jan-15,25-May-09,1-Jan-16,1-Jan-16,"St. Paul's Hospital HIV Immunodeficiency/Metabolic Clinic, Vancouver, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT00908011
NCT00903409,"Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects",,Completed,Has Results,Hypertriglyceridemia,Drug: Simvastatin + Lovaza® (omega-3-acid ethyl esters),"Median Percent Change of Non-HDL-C (High Density Lipoprotein-Cholesterol) in Switchers vs. Non-Switchers Subjects From LOV111858 End-of-Treatment (Week 8) to Month 4 of Extension Study (LOV111818)|Median Percent Change of Lipid Measurements From LOV111858 End-of-Treatment Week 8 to Months 4, 12, and 24 of the Open-Label Extension Study (LOV111818) in ""Switchers"" vs. Non-switchers|Median Percent Change of Lipid Measurements From LOV111858 End-of-Treatment Week 8 to LOV111818 Months 4, 12, and 24 of the Open-Label Extension Trial",GlaxoSmithKline,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 3,188,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Primary Purpose: Treatment,111818|LOV111858,15-Nov-05,27-Jun-08,27-Jun-08,18-May-09,4-Aug-09,9-Oct-17,"GSK Investigational Site, Mobile, Alabama, United States|GSK Investigational Site, Encinitas, California, United States|GSK Investigational Site, Fresno, California, United States|GSK Investigational Site, Greenbrae, California, United States|GSK Investigational Site, Sacramento, California, United States|GSK Investigational Site, Thousand Oaks, California, United States|GSK Investigational Site, Hollywood, Florida, United States|GSK Investigational Site, Pinellas Park, Florida, United States|GSK Investigational Site, Tampa, Florida, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Dunwoody, Georgia, United States|GSK Investigational Site, Suwanee, Georgia, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Bloomington, Indiana, United States|GSK Investigational Site, Evansville, Indiana, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Louisville, Kentucky, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Edina, Minnesota, United States|GSK Investigational Site, Wentzville, Minnesota, United States|GSK Investigational Site, Kansas City, Missouri, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Charlotte, North Carolina, United States|GSK Investigational Site, Hickory, North Carolina, United States|GSK Investigational Site, Salisbury, North Carolina, United States|GSK Investigational Site, Statesville, North Carolina, United States|GSK Investigational Site, Wilmington, North Carolina, United States|GSK Investigational Site, Winston-Salem, North Carolina, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Warwick, Rhode Island, United States|GSK Investigational Site, Bristol, Tennessee, United States|GSK Investigational Site, Plano, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Norfolk, Virginia, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Lakewood, Washington, United States|GSK Investigational Site, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00903409
NCT00903617,Study to Test GSK256073 in Patients With Dyslipidemia,,Completed,Has Results,Dyslipidaemias,Drug: GSK256073|Drug: Placebo|Drug: Niaspan,"The GSK256073 Area Under Concentration-time Curve (AUC) and High Density Lipoprotein Cholesterol (HDLc) Data to Evolve the Exposure-response Pharmacokinetic/Pharmacodynamic (PK/PD) Relationship for Changes in HDLc Levels|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Electrocardiography (ECG) Findings|Change From Baseline in Vital Signs-Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)|Change From Baseline in Vital Signs-Heart Rate|Number of Participants With Abnormal Hematology Values|Number of Participants With Abnormal Clinical Chemistry Values|Number of Participants With Abnormal Urinalysis Results|Average Global Flushing Score|Number of Participants With Self Reported Assessment of Flushing|Average Number of Flushing Episodes|Average Time to Onset of Flushing|Participant's Average Duration of Flushing|Number of Participants Who Withdrew Due to Flushing|Mean Episode of Flushing as Measured by Visual Analogue Scale (VAS)|Percent Change From Baseline in Fasting Plasma HDLc and Apolipoprotein A-I (ApoA1) Concentrations Over Eight Weeks of Administration With GSK256073 or Placebo|Percent Change From Baseline in Fasting Levels of Total Cholesterol (TC), Triglyceride (TG), Glucose, Low Density Lipoprotein Cholesterol (LDLc), Apolipoprotein A2 (ApoAII), Apolipoprotein B (ApoB) Over 8 Weeks of Administration With GSK256073 or Placebo|Percent Change From Baseline in Insulin Over Eight Weeks of Administration With GSK256073 or Placebo|Percent Change From Baseline in Lipoprotein (a) (Lp[a]) Over Eight Weeks of Administration With GSK256073 or Placebo|Percent Change From Baseline in Non-esterified Fatty Acids (NEFA) Over Eight Weeks of Administration With GSK256073 or Placebo|Plasma PK- Maximum Observed Concentration (Cmax)|Plasma PK- Time of Occurrence of Cmax (Tmax)|Plasma PK- AUC(0-t)",GlaxoSmithKline,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,80,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",112795,15-Jun-09,16-Feb-10,16-Feb-10,18-May-09,21-Sep-17,21-Sep-17,"GSK Investigational Site, Pembroke Pines, Florida, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Louisville, Kentucky, United States|GSK Investigational Site, Auburn, Maine, United States|GSK Investigational Site, Brooklyn Center, Minnesota, United States|GSK Investigational Site, Statesville, North Carolina, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Olympia, Washington, United States|GSK Investigational Site, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00903617
NCT00901823,"Open-Label, Single- and Multiple-Dose Pharmacokinetic Study of Diazoxide Choline",,Withdrawn,No Results Available,Hypertriglyceridemia,Drug: Diazoxide choline|Drug: Diazoxide choline high dose,"Compare the single-dose and steady-state, fed and fasting PK profiles of two dose levels of diazoxide administered as DCCR|Assess the impact of dosing in the absence of food on the steady-state pharmacokinetic profiles of two dose levels of diazoxide administered orally as DCCR under fed conditions","Essentialis, Inc.",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PK010,Mar-11,Mar-11,Mar-11,14-May-09,null,1-Sep-16,,,https://ClinicalTrials.gov/show/NCT00901823
NCT00897975,Red Yeast Rice and Phytosterols In Statin Intolerance,,Completed,No Results Available,Hyperlipidemia,Dietary Supplement: red yeast rice|Drug: phytosterol|Behavioral: therapeutic lifestyle program|Drug: placebo,LDL cholesterol levels|myalgia compared to prior statin usage|other lipoprotein levels|weight loss in TLC program vs. baseline,Chestnut Hill Health System,All,"21 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,200,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FWA00005390 Chestnut HillHC,Jul-09,Nov-10,Jul-11,12-May-09,null,18-Jul-11,"Abington Memorial Hospital, Abington, Pennsylvania, United States|Chestnut Hill Hospital, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00897975
NCT00895141,Effect of Saturated Fat on Large Low-density Lipoprotein (LDL) and High-density Lipoprotein (HDL),,Completed,No Results Available,Dyslipidemia,Dietary Supplement: Saturated Fat Diet,"Large LDL (LDL I + 2a) (mg/dl)|Large HDL (HDL2b) (mg/dl)|LDL peak particle size|Triglycerides (mg/dl)|Total Cholesterol (mg/dl)|LDL cholesterol (mg/dl)|HDL cholesterol (mg/dl)|Apolipoprotein AI (mg/dl)|Apolipoprotein B (mg/dl)|Medium LDL (LDL2b) (mg/dl)|Small LDL (LDL3a) (mg/dl)|Hepatic Lipase Activity|Lipoprotein Lipase Activity|Cholesteryl Ester Transfer Protein Activity|Very Small LDL (LDL3b, 4a, 4b) (mg/dl)",Children's Hospital & Research Center Oakland|Dairy Management Inc.,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,53,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Basic Science,MM3355,Apr-09,Sep-10,Apr-11,8-May-09,null,14-Jan-13,"Cholesterol Research Center, Berkeley, California, United States",,https://ClinicalTrials.gov/show/NCT00895141
NCT00895193,Alternative Options to Minimize Niacin-Induced Flushing,,Completed,Has Results,Hypercholesterolemia|Flushing,Other: Apple pectin|Drug: Aspirin 325 mg|Other: Placebo,Incidence of Flushing|Time to Flushing|Duration of Flushing|Maximum Flushing Severity Score,"Patrick Moriarty, MD, FACP, FACC|University of Kansas Medical Center",All,"21 Years to 70 Years   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care",11627,Jan-09,Dec-10,Dec-10,8-May-09,17-Mar-14,5-Jun-14,"University of Kansas Medical Center, Kansas City, Kansas, United States",,https://ClinicalTrials.gov/show/NCT00895193
NCT00891293,"A Second Open-Label Extension of a Double-Blind, Parallel, Phase IV Study to Assess the Efficacy and Safety of Adjunctive Lovaza® (Formerly Known as Omacor®) Therapy in Hypertriglyceridemic Subjects Treated With Antara™",,Completed,Has Results,Hypertriglyceridemia,Drug: Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters),Percent Change in Serum Triglycerides From LOV111859/OM5 (Double-blind [DB] Study) Baseline to Week 8 of LOV111860/OM5X (1st Open-label [OL] Extension Study) and From LOV111859/OM5 (DB) Baseline to Month 24 of LOV111821/OM5XX (2nd OL Extension).|Percent Change in Total Cholesterol From LOV111859/OM5 (Double-blind [DB] Study) Baseline to Week 8 of LOV111860/OM5X (1st Open-label [OL] Extension Study) and From LOV111859/OM5 (DB Study) Baseline to Month 24 of LOV111821/OM5XX (2nd OL Extension Study).|Percent Change in VLDL-C From LOV111859/OM5 (Double-blind [DB] Study) Baseline to Week 8 of LOV111860/OM5X (1st Open-label [OL] Extension Study) and From LOV111859/OM5 (DB Study) Baseline to Month 24 of LOV111821/OM5XX (2nd OL Extension Study)|Percent Change in LDL-C From LOV111859/OM5 (Double-blind [DB] Study) Baseline to Week 8 of LOV111860/OM5X (1st Open-label [OL] Extension Study) and From LOV111859/OM5 (DB Study) Baseline to Month 24 of LOV111821/OM5XX (2nd OL Extension Study)|Percent Change in HDL-C From LOV111859/OM5 (Double-blind [DB] Study) Baseline to Week 8 of LOV111860/OM5X (1st Open-label [OL] Extension Study) and From LOV111859/OM5 (DB Study) Baseline to Month 24 of LOV111821/OM5XX (2nd OL Extension Study)|Percent Change in Ratio of Total-C:HDL-C From LOV111859/OM5 (Double-blind [DB] Study) Baseline to Week 8 of LOV111860/OM5X (1st Open-label [OL] Extension Study) and From LOV111859/OM5 (DB Study) Baseline to Month 24 of LOV111821/OM5XX (2nd OL Ext. Study)|Percent Change in Apo A-1 From LOV111859/OM5 (Double-blind [DB] Study) Baseline to Week 8 of LOV111860/OM5X (1st Open-label [OL] Extension Study) and From LOV111859/OM5 (DB Study) Baseline to Month 24 of LOV111821/OM5XX (2nd OL Extension Study|Percent Change in Apo B From LOV111859/OM5 (Double-blind [DB[ Study) Baseline to Week 8 of LOV111860/OM5X (1st Open-label [OL] Extension Study) From LOV111859/OM5 (DB Study) Baseline to Month 24 of LOV111821/OM5XX (2nd OL Extension Study)|Percent Change in Non-HDL-C From LOV111859/OM5 (Double-blind [DB] Study) Baseline to Week 8 of LOV111860/OM5X (1st Open-label [OL] Extension Study) and From LOV111859/OM5 (DB Study) Baseline to Month 24 of LOV111821/OM5XX (2nd OL Extension Study),GlaxoSmithKline,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 4,93,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,111821,Mar-06,May-08,May-08,1-May-09,28-Jul-09,25-Jan-11,"GSK Investigational Site, Spring Valley, California, United States|GSK Investigational Site, Washington, District of Columbia, United States|GSK Investigational Site, Coral Gables, Florida, United States|GSK Investigational Site, Hollywood, Florida, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Longwood, Florida, United States|GSK Investigational Site, Pinellas Park, Florida, United States|GSK Investigational Site, Duhwoody, Georgia, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Bloomington, Indiana, United States|GSK Investigational Site, Louisville, Kentucky, United States|GSK Investigational Site, Auburn, Maine, United States|GSK Investigational Site, Scarborough, Maine, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Wentzville, Minnesota, United States|GSK Investigational Site, Kansas City, Missouri, United States|GSK Investigational Site, St. Louis, Missouri, United States|GSK Investigational Site, Hickory, North Carolina, United States|GSK Investigational Site, Salisbury, North Carolina, United States|GSK Investigational Site, Statesville, North Carolina, United States|GSK Investigational Site, Winston-Salem, North Carolina, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Cumberland, Rhode Island, United States|GSK Investigational Site, Mount Pleasant, South Carolina, United States|GSK Investigational Site, Bristol, Tennessee, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Norfolk, Virginia, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Winchester, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00891293
NCT00891306,Efficacy and Safety of Human Lipoprotein Lipase (LPL)[S447X] Expressed by an Adeno-Associated Viral Vector in LPL-deficient Subjects,,Completed,No Results Available,Familial Lipoprotein Lipase Deficiency,"Genetic: Alipogene Tiparvovec (AMT-011), Human LPL [S447X]|Drug: mycophenolate mofetil|Drug: cyclosporine|Drug: methylprednisolone",Reduction of triglyceride (TG) concentrations|Reduction of chylomicrons and/or chylomicron-TG ratio|To determine the biological activity and expression of the lipoprotein lipase [LPLS447X] transgene product|To assess the safety profile|To assess shedding of viral vector,Amsterdam Molecular Therapeutics|The Clinical Trial Company,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,5,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CT-AMT-011-02,Feb-09,Aug-10,Apr-11,1-May-09,null,29-Sep-11,"ECOGENE-21 Clinical Trial Center / Centre de santé et de services sociaux de Chicoutimi, Chicoutimi, Quebec, Canada|Centre des Maladies Lipidiques de Québec, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00891306
NCT00889226,Efficacy and Safety Study of Pitavastatin Compared to atoRvastatin in Type 2 dIabeTes Mellitus With Hypercholesterolemia,ESPRIT,Completed,No Results Available,Hypercholesterolemia With Type2DM,Drug: Pitavastatin|Drug: Atorvastatin,"Proportion of patients achieving LDL- C＜100mg/dL|The change of LDL-C, TC, TG, HDL-C, Apo A1, Apo B|The change of hs-CRP 3|The change of fasting insulin|The change of adiponectin|The change of brachial ankle PWV|Adverse events|Any abnormal change of physical examination and Lab result",JW Pharmaceutical,All,"25 Years to 75 Years   (Adult, Older Adult)",Phase 4,161,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CWP_PTV4_704,Apr-08,May-09,Jan-10,28-Apr-09,null,4-Apr-13,,,https://ClinicalTrials.gov/show/NCT00889226
NCT00887653,Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy,,Completed,Has Results,HIV|Hyperlipidemia|Hypertriglyceridemia|HIV Infections,Drug: raltegravir,Change From Baseline Triglycerides|Proportion of Patients With Plasma Viral Load Below the Limit of Detection,The Miriam Hospital|Tufts Medical Center|Merck Sharp & Dohme Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 3,20,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2007-09,May-09,Jun-12,Apr-14,24-Apr-09,10-Oct-14,10-Oct-14,"Tufts University, Boston, Massachusetts, United States|Miriam Hospital Immunology Clinic, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT00887653
NCT00885495,Darunavir/Ritonavir and Rosuvastatin Pharmacokinetic Study,,Unknown status,No Results Available,HIV Infections,"Drug: darunavir, ritonavir, rosuvastatin|Drug: rosuvastatin, darunavir, ritonavir","To investigate the effect of darunavir/ritonavir on the pharmacokinetics of rosuvastatin.|To investigate the effect of rosuvastatin on the steady state pharmacokinetics of darunavir/ritonavir.|To compare the change in low-density lipoprotein (LDL) cholesterol with rosuvastatin therapy alone, darunavir/ritonavir therapy alone and with the co-administration of rosuvastatin and darunavir/ritonavir.",University of Cincinnati,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,12,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IDC 40,Jan-09,Jun-09,Aug-09,22-Apr-09,null,22-Apr-09,"University of Cincinnati AIDS Clinical Trials Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00885495
NCT00885872,Rosuvastatin Evaluation of Atherosclerotic Chinese Patients (REACH),REACH,Unknown status,No Results Available,Hyperlipidemia|Atherosclerosis,Drug: Rosuvastatin (Crestor),Change in the percentage of volume of lipid rich necrotic core (LRNC)using high-resolution MRI|change in volume of wall and normalized wall index (NWI),Chinese PLA General Hospital|AstraZeneca,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,60,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,REACH|D3560L00091,Mar-09,Mar-12,Mar-12,22-Apr-09,null,27-May-10,"Chinese PLA General Hospital, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT00885872
NCT00881478,Family Intervention for Obese Children Using Portion Control Strategy for Weight Control,FOCUS,Completed,No Results Available,Obesity,Other: Nutrition counseling + portion control tool|Other: Nutrition counseling,Change in age and gender adjusted BMI z-score|Change in age and gender adjusted waist circumference percentile|Change in age and gender adjusted blood pressure percentile|Change in fasting lipid profile|Change in fasting insulin and fasting glucose|Change in plasma visfatin level|Change in plasma adiponectin level|Proportion of children achieving a BMI below the 85th percentile for age and gender,University of Calgary,All,8 Years to 16 Years   (Child),Not Applicable,102,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,E22161,Aug-09,Aug-14,Aug-14,15-Apr-09,null,3-Sep-14,"Alberta Children's Hospital, Calgary, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT00881478
NCT00879710,Effect of Diabetes Mellitus on Cholesterol Metabolism,,Completed,Has Results,Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus|Hypercholesterolemia,Drug: simvastatin or ezetimibe,Changes in LDL Cholesterol|Changes in Cholesterol Absorption or Synthesis Rates From the Baseline,Medical College of Wisconsin,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,57,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PRO00002485,Aug-08,Jul-13,Jul-13,10-Apr-09,18-Apr-16,18-Apr-16,"Medical College of Wisconsin /Froedtert Hospital, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00879710
NCT00879112,Study of MB07811 in Subjects With Hypercholesterolemia,,Withdrawn,No Results Available,Hypercholesterolemia,Drug: MB07811|Drug: Placebo,Evaluate the effects of MB07811 compared to placebo on LDL-C|Evaluate the effects of MB07811 on other lipid markers compared to placebo|Assess the safety and tolerability of MB07811,Ligand Pharmaceuticals,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,80,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MB07811-201,Apr-09,Dec-09,Dec-09,9-Apr-09,null,12-Aug-11,"Scripps Clinic, Clinical Research, San Diego, California, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|University Clinical Research, Pembroke Pines, Florida, United States|Radiant Research, Chicago, Illinois, United States|Midwest Institute for Clinical Research, Indianapolis, Indiana, United States|Commonwealth Biomedical Research, Madisonville, Kentucky, United States|Troy Internal Medicine, Troy, Michigan, United States|Coastal Carolina Research Center, Inc., Goose Creek, South Carolina, United States|Research Across America, Dallas, Texas, United States|National Clinical Research - Norfolk, Norfolk, Virginia, United States|National Clinical Research, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00879112
NCT00876330,Improving Antihypertensive and Lipid-Lowering Therapy,CERT2,Unknown status,No Results Available,Hyperlipidemia|Hypertension,Other: Clinical Decision Support for Hypertension|Other: Automated Telephone Outreach for Antihypertensive Therapy|Other: Clinical Decision Support for Lipid-lowering Therapy|Other: Automated Telephone Outreach for Lipid-lowering Therapy,The main outcome measure will be the proportion of patients at treatment goal.,VA Boston Healthcare System|Agency for Healthcare Research and Quality (AHRQ),All,"18 Years to 89 Years   (Adult, Older Adult)",Not Applicable,6000,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1U18HS016970-01,May-09,Dec-12,Mar-13,6-Apr-09,null,20-Sep-12,,,https://ClinicalTrials.gov/show/NCT00876330
NCT00871351,Evaluation of Ezetimibe and Atorvastatin Coadministration Versus Atorvastatin or Rosuvastatin Monotherapy in Japanese Patients With Hypercholesterolemia (Study P06027)(COMPLETED),,Completed,Has Results,Primary Hypercholesterolemia,Drug: Ezetimibe|Drug: Atorvastatin|Drug: Rosuvastatin,Percent Change in Low-Density Lipoprotein - Cholesterol (LDL-C) Values|Percent Change in LDL-C|Number of Participants Whose LDL-C Levels Reached the Lipid Management Target Values|Percent Change in Total Lipids and High Sensitivity C-reactive Protein (Hs-CRP)|Percent Change in Total Lipids and Hs-CRP,Merck Sharp & Dohme Corp.,All,"20 Years and older   (Adult, Older Adult)",Phase 4,125,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P06027,1-Feb-09,1-May-10,1-May-10,30-Mar-09,23-Aug-11,10-May-17,,,https://ClinicalTrials.gov/show/NCT00871351
NCT00868127,Safety of Lapaquistat Acetate in Subjects With Hypercholesterolemia,,Completed,No Results Available,Hypercholesterolemia,Drug: Lapaquistat acetate|Drug: Lapaquistat acetate and additional lipid-lowering therapy,Adverse Events|Vital Signs|Clinical Laboratory Blood Sample for Lipid Panel|Clinical Laboratory Serum Chemistries|Clinical Laboratory Hematology|Clinical Laboratory Serum Human Chorionic Gonadotropin|Clinical Laboratory Urinalysis|Physical Examination|12-lead Electrocardiogram|Best Corrected Visual Acuity|Percent change from Baseline in calculated Low Density Lipoprotein Cholesterol|Percent change from Baseline in calculated Non-High Density Lipoprotein Cholesterol|Percent change from Baseline in calculated Total Cholesterol|Percent change from Baseline in calculated Triglycerides|Percent change from Baseline in calculated High Density Lipoprotein Cholesterol|Percent change from Baseline in Derived ratios Total Cholesterol / High Density Lipoprotein Cholesterol and Low Density Lipoprotein Cholesterol / High Density Lipoprotein Cholesterol,Takeda,All,"18 Years and older   (Adult, Older Adult)",Phase 3,574,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,01-04-TL-475-010|U1111-1122-8368,Dec-05,Jul-07,Jul-07,24-Mar-09,null,24-May-12,,,https://ClinicalTrials.gov/show/NCT00868127
NCT00867165,Pediatric Study to Evaluate the Efficacy and Safety of Ezetimibe Monotherapy in Children With Primary Hypercholesterolemia (P05522),,Completed,Has Results,Primary Hypercholesterolemia,Drug: ezetimibe|Drug: Placebo,Percentage Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12|Percentage Change From Baseline in Total Cholesterol (TC) at Week 12|Percentage Change From Baseline in Apolipoprotein B (Apo B) at Week 12|Percentage Change From Baseline High-density Lipoprotein Cholesterol (HDL-C) at Week 12|Percentage Change From Baseline in Non-HDL-C at Week 12|Percentage Change From Baseline in Triglycerides (TG) at Week 12|Percent Change From Baseline in LDL-C at Week 2|Percent Change From Baseline in LDL-C at Week 4|Percent Change From Baseline in LDL-C at Week 8|Percentage Change From Baseline in TC at Week 2|Percentage Change From Baseline in TC at Week 4|Percentage Change From Baseline in TC at Week 8|Percentage Change From Baseline HDL-C at Week 2|Percentage Change From Baseline HDL-C at Week 4|Percentage Change From Baseline HDL-C at Week 8|Percentage Change From Baseline in Non-HDL-C at Week 2|Percentage Change From Baseline in Non-HDL-C at Week 4|Percentage Change From Baseline in Non-HDL-C at Week 8|Percentage Change From Baseline in TG at Week 2|Percentage Change From Baseline in TG at Week 4|Percentage Change From Baseline in TG at Week 8|Percentage Change From Baseline in Apolipoprotein A-I (Apo A-I) at Week 12|Percentage Change From Baseline in TC:HDL-C Ratio at Week 2|Percentage Change From Baseline in TC:HDL-C Ratio at Week 4|Percentage Change From Baseline in TC:HDL-C Ratio at Week 8|Percentage Change From Baseline in TC:HDL-C Ratio at Week 12|Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 2|Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 4|Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 8|Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 12|Percentage Change From Baseline in Apo B:Apo A-I Ratio at Week 12|Percentage Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 4|Percentage Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 12|Percent Change From Baseline in Sitosterol at Week 2|Percentage Change From Baseline in Sitosterol at Week 4|Percentage Change From Baseline in Sitosterol at Week 8|Percentage Change From Baseline in Sitosterol at Week 12|Percentage Change From Baseline in Campesterol at Week 2|Percentage Change From Baseline in Campesterol at Week 4|Percentage Change From Baseline in Campesterol at Week 8|Percentage Change From Baseline in Campesterol at Week 12|Percentage Change From Baseline in Cholestanol at Week 2|Percentage Change From Baseline in Cholestanol at Week 4|Percentage Change From Baseline in Cholestanol at Week 8|Percentage Change From Baseline in Cholestanol at Week 12|Percentage Change From Baseline in Lathosterol at Week 2|Percentage Change From Baseline in Lathosterol at Week 4|Percentage Change From Baseline in Lathosterol at Week 8|Percentage Change From Baseline in Lathosterol at Week 12,Merck Sharp & Dohme Corp.,All,6 Years to 10 Years   (Child),Phase 3,138,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",P05522|2008-006271-70|MK-0653-170,21-May-09,13-Apr-12,13-Apr-12,23-Mar-09,30-May-13,10-May-17,,,https://ClinicalTrials.gov/show/NCT00867165
NCT00864643,Efficacy and Safety of Lapaquistat Acetate Coadministered With Atorvastatin in Subjects With Hypercholesterolemia,,Completed,No Results Available,Hypercholesterolemia,Drug: Lapaquistat acetate and atorvastatin|Drug: Atorvastatin,Percent change from Baseline in Low Density Lipoprotein Cholesterol|Percent change from Baseline in Total Cholesterol|Percent change from Baseline in High-Density Lipoprotein Cholesterol|Percent change from Baseline in Triglycerides|Percent change from Baseline in Apolipoprotein B|Percent change from Baseline in Apolipoprotein A1|Percent change from Baseline in Very-Low Density Lipoprotein Cholesterol,Takeda,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 2,172,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",01-04-TL-475-011|U1111-1122-7848,Sep-04,Feb-05,Feb-05,19-Mar-09,null,24-May-12,,,https://ClinicalTrials.gov/show/NCT00864643
NCT00865228,Efficacy of Lapaquistat Acetate in Subjects With Hypercholesterolemia,,Terminated,No Results Available,Hypercholesterolemia,Drug: Lapaquistat acetate|Drug: Placebo,Percent change from Baseline in the Fasting Plasma Low-Density Lipoprotein Cholesterol concentration|Change from Baseline in Total Cholesterol|Percent change from Baseline in apolipoprotein B|Percent change from Baseline in apolipoprotein A1|Change from Baseline in Triglycerides|Percent change from Baseline in High-Density Lipoprotein Cholesterol|Percent change from Baseline in Very Low-Density Lipoprotein Cholesterol|Percent change from Baseline in non- High-Density Lipoprotein Cholesterol|Percent change from Baseline in derived ratio of Low-Density Lipoprotein Cholesterol / High-Density Lipoprotein Cholesterol|Percent change from Baseline in derived ratio of Total Cholesterol / High-Density Lipoprotein Cholesterol|Percent change from Baseline in derived ratio of apolipoprotein B / apolipoprotein A1|Change from Baseline in high sensitivity C-Reactive Protein.,Takeda,All,"18 Years and older   (Adult, Older Adult)",Phase 2,224,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TAK-475_201|U1111-1122-8404,Jul-07,Nov-07,Nov-07,19-Mar-09,null,24-May-12,"Long Beach, California, United States|Sacramento, California, United States|San Diego, California, United States|Hollywood, Florida, United States|Jacksonville, Florida, United States|New Port Richey, Florida, United States|Chicago, Illinois, United States|Wichita, Kansas, United States|Louisville, Kentucky, United States|Margate, New Jersey, United States|Charlotte, North Carolina, United States|Raleigh, North Carolina, United States|Statesville, North Carolina, United States|Wilmington, North Carolina, United States|Winston-Salem, North Carolina, United States|Medford, Oregon, United States|Perkasie, Pennsylvania, United States|Sellerville, Pennsylvania, United States|Bristol, Tennessee, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00865228
NCT00863564,"Acute Effects of Dietary Proteins on Postprandial Lipemia, Incretin Responses and Subclinical Inflammation in Obese Subjects",,Completed,No Results Available,Obesity|Postprandial Lipemia|Atherosclerosis|Inflammation|Postprandial Incretins,Dietary Supplement: Caseine|Dietary Supplement: Cod|Dietary Supplement: Gluten|Dietary Supplement: Whey Isolate,Triglyceride|Incretins|Inflammatory markers,Aarhus University Hospital|The Danish Obesity Research Centre|Nordic Centre of Excellence,All,"40 Years to 75 Years   (Adult, Older Adult)",Not Applicable,12,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,CERN-PPL-JHJ-5a,Mar-09,Oct-09,Oct-09,18-Mar-09,null,10-Nov-09,"Department of Clinical Nutrion, Aarhus, Denmark",,https://ClinicalTrials.gov/show/NCT00863564
NCT00863265,"Phytosterols, Ezetimibe, and Cholesterol Metabolism",Phyteaux-III,Completed,Has Results,Hypercholesterolemia|Coronary Heart Disease,Drug: Ezetimibe|Other: Phytosterols + ezetimibe|Other: Placebo,Cholesterol Excretion|Percent Cholesterol Absorption|LDL Cholesterol,"Washington University School of Medicine|Utah State University|National Heart, Lung, and Blood Institute (NHLBI)",All,"18 Years to 80 Years   (Adult, Older Adult)",Early Phase 1,22,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",CANUSU-phyto3|R01HL050420,Jun-09,Oct-09,Feb-10,17-Mar-09,1-Jun-18,1-Jun-18,"Center for Advance Nutrition at Utah State University, Logan, Utah, United States",,https://ClinicalTrials.gov/show/NCT00863265
NCT00861861,Comparison of Pitavastatin With Atorvastatin in Increasing High Density Lipoprotein - Cholesterol (HDL-C) and Adiponectin in Patients With Dyslipidemia and Coronary Artery Disease (CAD),COMPACT-CAD,Completed,No Results Available,Hypercholesterolemia|Coronary Artery Disease,Drug: Pitavastatin|Drug: Atorvastatin,HDL-cholesterol (HDL-C); Adiponectin; High-Molecular- Weight Adiponectin(HMW Adiponectin)|TC; LDL-C; HDL-C; HDL2-C; HDL3-C; TG; smalldenseLDL; MDA-LDL; FPG; HbA1c; Cr; RLP-C; apoA-I; apoB; apoC-Ⅱ; apoC-Ⅲ,Kumamoto University,All,"20 Years to 85 Years   (Adult, Older Adult)",Phase 4,129,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Kumamoto-746,Sep-08,Oct-13,Oct-13,16-Mar-09,null,14-Oct-13,"Kumamoto University Graduate School of Medical Sciences Department of Cardiocascular Medicine, Kumamoto, Japan",,https://ClinicalTrials.gov/show/NCT00861861
NCT00861731,Ezetimibe/Simvastatin Combination in Proteinuric Nephropathy,VICTORY,Unknown status,No Results Available,Hypercholesterolemia|Chronic Nephropathy,Drug: simvastatin|Drug: EZE/simvastatin,To assess whether EZE-statin combined therapy is more effective than statin alone to achieve the optimum lipid control (LDL-cholesterol < 70 mg/dl) in chronic proteinuric nephropathy.|To assess the effect of EZE-statin combined therapy vs statin monotherapy on other outcome variables including: - renal parameters - inflammatory status - markers of endothelial dysfunction,Azienda Ospedaliero Universitaria di Sassari,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AOUSS-Nefologia-001,Nov-08,Jul-09,Jul-09,13-Mar-09,null,28-Apr-09,"Istituto di Patologia Medica - Azienda Ospedaliero Universitaria, Sassari, Italy",,https://ClinicalTrials.gov/show/NCT00861731
NCT00860509,Comparison of Low and High Phytosterol Diets With Respect to Cholesterol Metabolism,Phyteaux-II,Completed,No Results Available,Hypercholesterolemia|Coronary Heart Disease,Other: Low Phytosterol and High Phytosterol Diets,Fecal cholesterol excretion|Intestinal cholesterol absorption,Washington University School of Medicine|Pennington Biomedical Research Center,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",PBRC26030,Nov-06,Mar-07,Mar-07,12-Mar-09,null,3-May-12,"Pennington Biomedical Research Center-Louisana State University System, Baton Rouge, Louisiana, United States",,https://ClinicalTrials.gov/show/NCT00860509
NCT00860054,Addition of Phytosterols to a Low Phytosterol Diet,phyteaux-I,Completed,No Results Available,Hypercholesterolemia|Coronary Heart Disease,Dietary Supplement: Different amount of phytosterols are added into diets,Fecal cholesterol excretion|intestinal cholesterol absorption,Washington University School of Medicine|Pennington Biomedical Research Center,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,18,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",PBRC25025|R01HL050420,Mar-06,Sep-06,Oct-08,11-Mar-09,null,19-Apr-12,"Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States",,https://ClinicalTrials.gov/show/NCT00860054
NCT00858637,Efficacy and Safety Study of MCI-196 Versus Simvastatin for Dyslipidaemia in Chronic Kidney Disease (CKD) Subjects on Dialysis,,Completed,Has Results,Chronic Kidney Disease,Drug: MCI-196|Drug: Placebo of Simvastatin|Drug: Simvastatin|Drug: Placebo of MCI-196,"Percent Change in Serum LDL-cholesterol Levels From Week 16 to Week 20 (LOCF) (ITT2)|Percent Change in Serum LDL-cholesterol Levels From Baseline to Week 16 (LOCF) (ITT1)|Change in Phosphorus(P), Calcium(Ca), Calcium-phosphorus Ion Product(PxCa) and Parathyroid Hormone (PTH)|Vital Signs, Adverse Events, and Laboratory Values",Mitsubishi Tanabe Pharma Corporation,All,"18 Years and older   (Adult, Older Adult)",Phase 3,260,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MCI-196-E11,Mar-09,Mar-10,Mar-10,10-Mar-09,17-Oct-14,30-Dec-14,"Brest, Belarus|Gomel, Belarus|Grodno, Belarus|Minsk, Belarus|Vitebsk, Belarus|Gabrovo, Bulgaria|Plovdiv, Bulgaria|Sofia, Bulgaria|Karlovac, Croatia|Osijek, Croatia|Esbjerg, Denmark|Roskilde, Denmark|Jakarta, Indonesia|Malang, Indonesia|Medan, Indonesia|Palembang, Indonesia|Tamanlarea Makassar, Indonesia|Ashkelon, Israel|Nahariya, Israel|Bellano, Italy|Catania, Italy|Lecco, Italy|Merate, Italy|Milano, Italy|Oggiono, Italy|Riga, Latvia|Valmiera, Latvia|Kaunas, Lithuania|Kedauniai, Lithuania|Vilnius, Lithuania|Johor, Malaysia|Kelantan, Malaysia|Penang, Malaysia|Perak, Malaysia|Bucharest, Romania|Timisoara, Romania|Singapore, Singapore|Bangkok, Thailand|Phitsanulok, Thailand",,https://ClinicalTrials.gov/show/NCT00858637
NCT00854503,Metabolic and Vascular Effects of Statins in Untreated Dyslipidemic Diabetic Patients,,Completed,No Results Available,Type 2 Diabetes|Diabetic Dyslipidemia,Drug: Simvastatin|Drug: Rosuvastatin,Glucose tolerance assessed by HbA1c and fasting glucose|insulin-resistance assessed by clamp. Endothelial function assessed by FMD %. Inflammatory status assessed by biochemical markers.,University of Rome Tor Vergata,All,"50 Years to 75 Years   (Adult, Older Adult)",Phase 3,30,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,131/08,Sep-08,Mar-10,Dec-10,3-Mar-09,null,12-May-11,"University of Rome Tor Vergata, Rome, Italy",,https://ClinicalTrials.gov/show/NCT00854503
NCT00852267,Lipoprotein Effects of Substituting Beef Protein for Carbohydrate,,Completed,No Results Available,Healthy|Cardiovascular Disease|Atherogenic Dyslipidemia,"Other: High Carbohydrate, High Saturated Fat Diet|Other: Low Carbohydrate, High Saturated Fat Diet|Other: Low Carbohydrate, Low Saturated Fat Diet",Total Cholesterol|Non-HDL Cholesterol|Apolipoprotein B|LDL-Cholesterol/HDL-Cholesterol|Apolipoprotein B/Apolipoprotein AI|LDL peak diameter|LDL subclass 3 (LDL3)|HDL subclass 2 (HDL2),Children's Hospital & Research Center Oakland|National Cattlemen's Beef Association,Male,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,2007-068,Jan-08,Aug-09,Dec-09,26-Feb-09,null,5-Oct-11,"Cholesterol Research Center, Berkeley, California, United States",,https://ClinicalTrials.gov/show/NCT00852267
NCT00847197,A Study to Evaluate MK1903 in Patients With Dyslipidemia (MK1903-004),,Completed,Has Results,Dyslipidemia,Drug: MK1903|Drug: Comparator: Placebo,Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) (mg/dL)|Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) (mg/dL)|Percent Change From Baseline in Triglycerides (mg/dL),Merck Sharp & Dohme Corp.,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,191,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",1903-004|2009_542,Jun-08,Sep-09,Sep-09,19-Feb-09,22-Sep-10,21-Dec-15,,,https://ClinicalTrials.gov/show/NCT00847197
NCT00845637,Effect of Eggplant Extract on Lipid Profile During Fasting and Postprandial Period,,Completed,No Results Available,Dyslipidemia,Drug: Eggplant extract|Drug: Placebo,Lipid profile|Anthropometric measures,Hospital de Clinicas de Porto Alegre,All,"Child, Adult, Older Adult",Phase 1,59,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",4004,Mar-04,Mar-07,Mar-08,18-Feb-09,null,24-Feb-09,"Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil",,https://ClinicalTrials.gov/show/NCT00845637
NCT00846300,A Brief Intervention to Improve Medication Knowledge and Adherence Among Family Medicine Patients in South Texas,,Completed,No Results Available,"Diabetes Mellitus, Type 2|Hyperlipidemia|Hypertension",Behavioral: Physician counseling for health behavior change,Change in self-reported medication knowledge|Change in self-reported medication compliance|Change in HbA1c for patients with Diabetes|Change in Lipids|Change in blood pressure,The University of Texas Health Science Center at San Antonio,All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,150,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment,HP000016-01,Aug-01,May-03,May-03,18-Feb-09,null,8-Oct-15,"Christus Memorial Hospital, Corpus Christi, Texas, United States|Valley Baptist Family Medicine Residency Program, Harlingen, Texas, United States|Laredo Medical Group, Laredo, Texas, United States|McAllen Family Medicine Residency Program, McAllen, Texas, United States|Family Medicine Residency Program, Christus Santa Rosa Hospital, San Antonio, Texas, United States|Dept Family & Community Medicine, UTHSCSA, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00846300
NCT00844376,Bioavailability Study for New Atorvastatin Formulation,,Completed,Has Results,Hypercholesterolemia,Drug: Atorvastatin suspension|Drug: Lipitor,Area Under the Curve From Predose (Time Zero) to 48 Hours Post-dose (AUC48)|Area Under the Curve From Predose (Time Zero) to Extrapolated Infinite Time (AUC Infinity)|Maximum Observed Plasma Concentration (Cmax)|Area Under the Curve From Predose (Time Zero) to Last Quantifiable Concentration (AUClast)|Terminal Phase Rate Constant (Kel)|Time to Reach Maximum Plasma Concentration (Tmax)|Plasma Elimination Half-life (t1/2),Pfizer,All,18 Years to 55 Years   (Adult),Phase 4,12,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),A2581164,Feb-08,Mar-08,Mar-08,16-Feb-09,21-Oct-09,28-Oct-09,"Pfizer Investigational Site, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00844376
NCT00844402,Safety and Efficacy of Long-Term Treatment With Atorvastatin in Patients With Primary Biliary Cirrhosis,,Completed,No Results Available,Primary Biliary Cirrhosis|Hypercholesterolemia,Drug: Atorvastatin,"Low-density lipoprotein cholesterol (LDL-C)|Intima-media thickness of the common carotid artery (IMT), vascular wall stiffness (stiffness index SI), flow-mediated dilation of the brachial artery (FMD)|Total cholesterol, triglycerides, VLDL-C, HDL-C, lipid profile, hs-CRP, AP, GGT, bilirubin, bile acids, immunoglobins|AST, ALT, CK, PZ, AT, albumin, creatinine, blood cell count",Medical University of Graz,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MT_PBC-2,Jan-06,Nov-07,Nov-07,16-Feb-09,null,16-Feb-09,"Department of Internal Medicine, Medical University of Graz, Graz, Austria",,https://ClinicalTrials.gov/show/NCT00844402
NCT00843661,Coadministration of Ezetimibe With Fenofibrate Versus Pravastatin Monotherapy for the Treatment of Hyperlipidaemia in HIV-infected Patients,,Unknown status,No Results Available,HIV|Hyperlipidemia|HIV Infections,Drug: ezetimibe|Drug: fenofibrate|Drug: pravastatin,"per cent changes of LDL cholesterol, comparison between the 2 treatment regimens",Ospedale di Circolo - Fondazione Macchi|Merck Sharp & Dohme Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 4,60,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EFP01,Mar-09,Dec-11,Jul-12,13-Feb-09,null,2-Aug-11,"Ospedale di Circolo and Fondazione Macchi, Varese, Italy",,https://ClinicalTrials.gov/show/NCT00843661
NCT00833976,Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia,,Completed,Has Results,High Triglycerides|Hypercholesterolemia|Schizophrenia|Schizoaffective Disorder|Bipolar Disorder,Drug: Lovaza,Change in Triglycerides From Baseline to 16 Weeks|Change in Total Cholesterol From Baseline to 16 Weeks|Tolerability of Omega-3 Fatty Acid Capsules (Lovaza),Massachusetts General Hospital|GlaxoSmithKline,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,65,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2008-P-002219,Jul-09,Mar-13,Mar-13,2-Feb-09,4-Apr-16,2-Jul-17,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00833976
NCT00829348,Short Message Service (SMS) Impact on Patient Compliance Receiving Long Term Lipid Lowering Therapy With Statins,,Completed,No Results Available,Dyslipidemia,Other: No intervention|Behavioral: Short Message Service (SMS),"Number of patients who achieve target goals|Total cholesterol, LDL, HDL, TG",Hillel Yaffe Medical Center,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Health Services Research,61-2005-CTIL,Aug-06,Jul-09,Jul-09,27-Jan-09,null,30-Dec-09,"Hillel Yaffe medical center, Hadera, Israel",,https://ClinicalTrials.gov/show/NCT00829348
NCT00827606,Atorvastatin Three Year Pediatric Study,,Completed,Has Results,Familial Hypercholesterolemia,Drug: atorvastatin,Low Density Lipoprotein Cholesterol (LDL-C; Millimoles Per Liter [mMol/L]) During the Study|Percent Change From Baseline in LDL-C|High-Density Lipoprotein Cholesterol (HDL-C; mMol/L) During the Study|Percent Change From Baseline in HDL-C|Total Cholesterol (mMol/L) During the Study|Percent Change From Baseline in Total Cholesterol|Trigylcerides (mMol/L) During the Study|Percent Change From Baseline in Trigylcerides|Very Low-Density Lipoprotein (VLDL; mMol/L) During the Study|Percent Change From Baseline in VLDL|Apoliprotein A-1 (Apo A-1; Grams Per Liter [g/L]) During the Study|Percent Change From Baseline in Apo A-1|Apoliprotein B (Apo B; g/L) During the Study|Percent Change From Baseline in Apo B|Number of Participants With Shift From Baseline in Tanner_Stage by Timepoint and Baseline Tanner_Stage|Height (Centimeters [cm]) During the Study: Males|Percent Change From Baseline in Height: Males|Height (cm) During the Study: Females|Percent Change From Baseline in Height: Females|Weight (Kilograms [kg]) During the Study: Males|Percent Change From Baseline in Weight: Males|Weight (kg) During the Study: Females|Percent Change From Baseline in Weight: Females|Body Mass Index (BMI in kg Per Square Meter [kg/m^2]) During the Study: Males|Percent Change From Baseline in BMI: Males|BMI (kg/m^2) During the Study: Females|Percent Change From Baseline in BMI: Females|Age (Years) During the Study: Males|Percent Change From Baseline in Age: Males|Age (Years) During the Study: Females|Percent Change From Baseline in Age: Females|Flow-Mediated Dilatation (FMD) During the Study|Percent Change From Baseline in FMD|Percentage of Participants With Overall Expected Maturation and Development Consistent With Expectations as Assessed by the Investigator|Percentage of Participants by Study Drug Compliance Category,Pfizer,All,6 Years to 15 Years   (Child),Phase 3,272,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A2581173|2008-006130-95,Mar-09,Oct-13,Oct-13,23-Jan-09,2-Jun-15,22-Sep-16,"Phoenix Children's Hospital, Phoenix, Arizona, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Florida, Gainesville, Florida, United States|Johns Hopkins University, Balitmore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Johns Hopkins, Baltimore, Maryland, United States|MEDPACE Clinical Pharmacology Unit, Cincinnati, Ohio, United States|The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Cliniques Universitaires Saint-Luc / Pediatrie generale, Bruxelles, Belgium|Universitaire Ziekenhuizen Leuven / Center for Metabolic Diseases, Leuven, Belgium|Clinique des maladies lipidiques de Quebec Inc, Sainte-Foy,, Quebec, Canada|Clinique des Maladies Lipidiques de Quebec, Quebec, Canada|Charite Campus Virchow-Klinikum, Berlin, Germany|Augenaerztliche Gemeinschaftspraxis, Freiburg, Germany|1st Pediatrics Clinic , University of Athens, Agia Sofia Hospital, Athens, Greece|Semmelweis Medical University, Budapest, Hungary|Fejer Megyei Szent Gyorgy Korhaz, Szekesfehervar, Hungary|Dipartimento di Medicina Clinica e delle Patologie Emergenti-University Hospital of Palermo, Palermo, Italy|Dipartimento di Clinica e Terapia Medica, Università degli Studi di Roma La Sapienza, Roma, Italy|Rikshospitalet Lipidklinikken, Oslo, Norway|Poradnia Chorob Metabolicznych, Bydgoszcz, Poland|Klinika Chorob Metabolicznych, Warszawa, Poland|Hospital de la Concepcion, San German, Puerto Rico|Moscow State Healthcare Institution 'Morozovskaya Children's City Clinical Hospital', Moscow, Russian Federation|Saint-Petersburg State Pediatric Medical Academy, Saint-Petersburg, Russian Federation|Saint-Petersburg State Healthcare Institution ""Children's Polyclinic #35"", Saint-Petersburg, Russian Federation|Autonomous Non-Profit Organization Medical Center 21 Century, St Petersburg, Russian Federation|Metabolicka ambulancia, 2. Detská klinika Lekárskej fakulty Univerzity Komenského, Bratislava, Slovakia|Detska fakultna nemocnica Kosice-old, Kosice, Slovakia|Detska fakultna nemocnica Kosice, Kosice, Slovakia|Lipmet, s.r.o., Poprad, Slovakia|Fakultna nemocnica Trencin, Trencin, Slovakia|Hospital General Universitario de Elche, Elche, Alicante, Spain|Hospital de Merida, Merida, Badajoz, Spain|Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain|Hospital Santa Creu I Sant Pau, Barcelona, Spain|Hospital Sant Joan de Deu, Esplugues de Llobregat, Spain|Dr. med. Jean-Marc Nuoffer, CH-3010 Bern, Switzerland|Hacettepe University Medical Faculty. Department of Pediatrics. Nutrition and Metabolism Unit, Ankara, Turkey|Gazi University, Medical Faculty, Ankara, Turkey|Ege University Medical Faculty, Izmir, Turkey",,https://ClinicalTrials.gov/show/NCT00827606
NCT00826774,Improving the Management of Obesity in Primary Care Practice (The Power-UP Trial),Power-UP,Completed,No Results Available,Obesity|Hypercholesterolemia|Metabolic Syndrome|Hypertension|Diabetes,Behavioral: Usual Care|Behavioral: Brief Lifestyle Counseling|Behavioral: Enhanced Brief Lifestyle Counseling,Weight|Prevalence of the metabolic syndrome|Blood Pressure|Lipid levels|Sexual function|Mood|Homeostasis model assessment of insulin resistance (HOMA-IR),"University of Pennsylvania|National Heart, Lung, and Blood Institute (NHLBI)",All,"21 Years and older   (Adult, Older Adult)",Phase 3,390,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,805684|U01HL087072,Jan-08,Feb-11,Jun-11,22-Jan-09,null,15-May-12,,,https://ClinicalTrials.gov/show/NCT00826774
NCT00821574,Reducing the Overall Risk Level in Patients Suffering From Metabolic Syndrome,LesScore,Completed,No Results Available,"Hypertension, Dyslypidaemia",Drug: Fluvastatin|Drug: Valsartan|Drug: Hydrochlorothiazide,"Change in global risk from baseline to 3 and 9 months, as evaluated by the SCORE algorithm|Change from baseline after 3 and 9 months in the individual risk factors (e.g. blood pressure, lipid variables)|Proportion of patients with controlled glycemia|Percentage of patients no longer classifiable as having metabolic syndrome",Novartis,All,"40 Years to 65 Years   (Adult, Older Adult)",Phase 4,144,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CXUO320BIT02,Jul-05,Mar-07,Mar-07,13-Jan-09,null,1-Mar-17,,,https://ClinicalTrials.gov/show/NCT00821574
NCT00819910,Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL),RAFAEL,Terminated,Has Results,Hypertriglyceridemia in Type 4 Hyperlipidemia|Non Diabetic Subjects With Normoglycemia,Drug: Rosiglitazone|Drug: Placebo (Rosiglitazone)|Drug: Placebo (Fenofibrate)|Drug: Fenofibrate,"Percent Change in Triglyceride (TG) Levels Post Treatment|Post-treatment Percent Change in High-Density Lipoprotein (HDL) Levels|Post-treatment Percent Change in Low-Density Lipoprotein (LDL) Levels|Post-treatment Percent Change in Apolipoprotein A-I (Apo AI), Apolipoprotein A-II (Apo AII) and Apolipoprotein C-III (Apo CIII) Levels|Mean Levels of Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) at Initial Visit and Final Visit",Ahmad Slim|GlaxoSmithKline|Brooke Army Medical Center,All,"18 Years and older   (Adult, Older Adult)",Phase 4,41,U.S. Fed|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",C.2007.122,Sep-08,May-10,May-10,9-Jan-09,26-Feb-14,24-Apr-14,"Brooke Army Medical Center, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00819910
NCT00816829,Effect of Fenofibrate on Sleep Apnea Syndrome,,Terminated,Has Results,Dyslipidemia|Sleep Apnea Syndrome|Overweight|Obesity,Drug: Placebo|Drug: Fenofibrate,Obstructive Apneas|Desaturations|Sleep Time With Oxygen Saturation Below 90%|Apneas|Hypopneas|Index Apnea/Hypopnea|Mixed Apneas|Central Apneas|Index of Apneas|Index of Hypopneas,Solvay Pharmaceuticals,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,34,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",C LF178P 05 01|2005-000548-98,Sep-05,Jan-08,Jan-08,5-Jan-09,7-Jul-09,22-Jul-09,"Site 1, Paris, France",,https://ClinicalTrials.gov/show/NCT00816829
NCT00814723,Fluvastatin 80 mg Ret. vs Combination With Ezetimibe 10 mg in Patients With High Cardiovascular Risk,,Completed,No Results Available,Hypercholesterolemia,Drug: fluvastatin|Drug: Fluvastatin plus ezetimibe,"Reduction in Low density lipoprotein cholesterol (LDL-C)|Total cholesterol, triglycerides, HDL-C, lipoprotein subfractions, hs-CRP|adverse events, CK elevation, liver enzyme elevation",Medical University of Graz,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,90,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2004-002535-12,Sep-05,Sep-07,Sep-07,25-Dec-08,null,25-Dec-08,"Depart. of Internal Medicine, Medical University of Graz, Graz, Austria",,https://ClinicalTrials.gov/show/NCT00814723
NCT00813527,Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol Levels,,Completed,No Results Available,Hyperlipidemias,Drug: Lapaquistat acetate and fenofibrate|Drug: Fenofibrate,"Percent change from Baseline in direct fasting plasma low-density lipoprotein cholesterol.|Change from baseline in calculated low-density lipoprotein cholesterol.|Change from baseline in non- high-density lipoprotein cholesterol.|Change from baseline in total cholesterol.|Change from baseline in apolipoprotein B.|Change from baseline in triglycerides.|Change from baseline in high-density lipoprotein cholesterol.|Change from baseline in apolipoprotein A1.|Change from baseline in very-low-density lipoprotein cholesterol.|Change from baseline in derived ratios including total cholesterol/high-density lipoprotein cholesterol, low-density lipoprotein cholesterol/high-density lipoprotein cholesterol, and apolipoprotein B/ apolipoprotein Al.|Change from baseline in high-sensitivity C-reactive protein.|Percentage of Subjects Achieving Target Direct low-density lipoprotein cholesterol Levels.",Takeda,All,"18 Years and older   (Adult, Older Adult)",Phase 2,213,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",01-05-TL-475-031|U1111-1122-8178,Feb-06,Jan-07,Jan-07,23-Dec-08,null,24-May-12,"Huntsville, Alabama, United States|Sierra Vista, Arizona, United States|Beverly Hills, California, United States|Long Beach, California, United States|Spring Valley, California, United States|Colorado Springs, Colorado, United States|Golden, Colorado, United States|Waterbury, Connecticut, United States|Jacksonville, Florida, United States|Kissimmee, Florida, United States|Miami, Florida, United States|Ocala, Florida, United States|Pembroke Pines, Florida, United States|Pinellas Park, Florida, United States|West Palm Beach, Florida, United States|Warner Robins, Georgia, United States|Chicago, Illinois, United States|Peoria, Illinois, United States|Indianapolis, Indiana, United States|Wichita, Kansas, United States|Edina, Minnesota, United States|St. Louis, Missouri, United States|Raleigh, North Carolina, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Hillsboro, Oregon, United States|Beaver, Pennsylvania, United States|Goose Creek, South Carolina, United States|Nashville, Tennessee, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Coquitlam, British Columbia, Canada|Victoria, British Columbia, Canada|London, Ontario, Canada|Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00813527
NCT00812955,"Safety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol (""Bad Cholesterol"") and Triglycerides",,Completed,Has Results,"Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia",Drug: ABT-143|Drug: simvastatin,"Mean Percent Change From Baseline to the Final Visit in Low-density Lipoprotein Cholesterol (LDL-C) (Full Analysis Set)|Mean Percent Change From Baseline to the Final Visit in Low-density Lipoprotein Cholesterol (LDL-C), With ABT-143 Capsules 10/135 Milligrams Versus Simvastatin Capsules 40 Milligrams (Full Analysis Set)|Mean Percent Change From Baseline to the Final Visit in Low-density Lipoprotein Cholesterol (LDL-C), With ABT-143 Capsules 5/135 Milligrams Versus Simvastatin Capsules 40 Milligrams (Full Analysis Set)",AstraZeneca,All,"18 Years and older   (Adult, Older Adult)",Phase 3,474,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",M10-667,Nov-08,Jun-09,Jun-09,22-Dec-08,1-Aug-12,3-Oct-12,"Site Reference ID/Investigator# 12654, Birmingham, Alabama, United States|Site Reference ID/Investigator# 12634, Columbiana, Alabama, United States|Site Reference ID/Investigator# 12559, Huntsville, Alabama, United States|Site Reference ID/Investigator# 12499, Ozark, Alabama, United States|Site Reference ID/Investigator# 12673, Chandler, Arizona, United States|Site Reference ID/Investigator# 17282, Scottsdale, Arizona, United States|Site Reference ID/Investigator# 12657, Little Rock, Arkansas, United States|Site Reference ID/Investigator# 12489, Anaheim, California, United States|Site Reference ID/Investigator# 12495, Carmichael, California, United States|Site Reference ID/Investigator# 12467, Chula Vista, California, United States|Site Reference ID/Investigator# 12498, Long Beach, California, United States|Site Reference ID/Investigator# 12602, Los Angeles, California, United States|Site Reference ID/Investigator# 12510, Norwalk, California, United States|Site Reference ID/Investigator# 12550, Palm Desert, California, United States|Site Reference ID/Investigator# 16503, Roseville, California, United States|Site Reference ID/Investigator# 12678, Sacramento, California, United States|Site Reference ID/Investigator# 14241, Sacramento, California, United States|Site Reference ID/Investigator# 12473, San Diego, California, United States|Site Reference ID/Investigator# 12497, Walnut Creek, California, United States|Site Reference ID/Investigator# 12680, West Hills, California, United States|Site Reference ID/Investigator# 12461, Colorado Springs, Colorado, United States|Site Reference ID/Investigator# 12600, Colorado Springs, Colorado, United States|Site Reference ID/Investigator# 12679, Waterbury, Connecticut, United States|Site Reference ID/Investigator# 12598, Clearwater, Florida, United States|Site Reference ID/Investigator# 15542, Coral Gables, Florida, United States|Site Reference ID/Investigator# 12477, Daytona Beach, Florida, United States|Site Reference ID/Investigator# 12668, Delray Beach, Florida, United States|Site Reference ID/Investigator# 15483, Fort Lauderdale, Florida, United States|Site Reference ID/Investigator# 12645, Fort Myers, Florida, United States|Site Reference ID/Investigator# 12672, Hollywood, Florida, United States|Site Reference ID/Investigator# 17504, Jacksonville, Florida, United States|Site Reference ID/Investigator# 12781, Jacksonville, Florida, United States|Site Reference ID/Investigator# 12665, Jupiter, Florida, United States|Site Reference ID/Investigator# 12682, Longwood, Florida, United States|Site Reference ID/Investigator# 15486, Melbourne, Florida, United States|Site Reference ID/Investigator# 12502, New Port Richey, Florida, United States|Site Reference ID/Investigator# 12647, Ocala, Florida, United States|Site Reference ID/Investigator# 12520, Orlando, Florida, United States|Site Reference ID/Investigator# 12687, Ormond Beach, Florida, United States|Site Reference ID/Investigator# 12583, Sarasota, Florida, United States|Site Reference ID/Investigator# 12652, Tampa, Florida, United States|Site Reference ID/Investigator# 12557, West Palm Beach, Florida, United States|Site Reference ID/Investigator# 12621, Winter Haven, Florida, United States|Site Reference ID/Investigator# 16505, Winter Park, Florida, United States|Site Reference ID/Investigator# 12675, Augusta, Georgia, United States|Site Reference ID/Investigator# 12620, Dunwoody, Georgia, United States|Site Reference ID/Investigator# 12653, Roswell, Georgia, United States|Site Reference ID/Investigator# 12555, Suwanee, Georgia, United States|Site Reference ID/Investigator# 12787, Woodstock, Georgia, United States|Site Reference ID/Investigator# 12514, Chicago, Illinois, United States|Site Reference ID/Investigator# 12487, Peoria, Illinois, United States|Site Reference ID/Investigator# 12627, Peoria, Illinois, United States|Site Reference ID/Investigator# 12529, Evansville, Indiana, United States|Site Reference ID/Investigator# 12688, Indianapolis, Indiana, United States|Site Reference ID/Investigator# 15485, South Bend, Indiana, United States|Site Reference ID/Investigator# 12676, Arkansas City, Kansas, United States|Site Reference ID/Investigator# 12597, Wichita, Kansas, United States|Site Reference ID/Investigator# 12472, Louisville, Kentucky, United States|Site Reference ID/Investigator# 12658, Mount Sterling, Kentucky, United States|Site Reference ID/Investigator# 12586, Baltimore, Maryland, United States|Site Reference ID/Investigator# 12480, Bethesda, Maryland, United States|Site Reference ID/Investigator# 12638, Oxon Hill, Maryland, United States|Site Reference ID/Investigator# 12513, Springfield, Massachusetts, United States|Site Reference ID/Investigator# 12663, Kalamazoo, Michigan, United States|Site Reference ID/Investigator# 12609, Brooklyn Center, Minnesota, United States|Site Reference ID/Investigator# 16622, Edina, Minnesota, United States|Site Reference ID/Investigator# 12625, Jackson, Mississippi, United States|Site Reference ID/Investigator# 12560, Olive Branch, Mississippi, United States|Site Reference ID/Investigator# 12677, St. Louis, Missouri, United States|Site Reference ID/Investigator# 12534, St. Peters, Missouri, United States|Site Reference ID/Investigator# 12592, Billings, Montana, United States|Site Reference ID/Investigator# 12655, Omaha, Nebraska, United States|Site Reference ID/Investigator# 12587, Las Vegas, Nevada, United States|Site Reference ID/Investigator# 12554, Berlin, New Jersey, United States|Site Reference ID/Investigator# 12637, Elizabeth, New Jersey, United States|Site Reference ID/Investigator# 12463, Hillsborough, New Jersey, United States|Site Reference ID/Investigator# 12660, Trenton, New Jersey, United States|Site Reference ID/Investigator# 12506, Albuquerque, New Mexico, United States|Site Reference ID/Investigator# 12539, Johnson City, New York, United States|Site Reference ID/Investigator# 12631, Syracuse, New York, United States|Site Reference ID/Investigator# 17503, Cary, North Carolina, United States|Site Reference ID/Investigator# 12650, Charlotte, North Carolina, United States|Site Reference ID/Investigator# 12504, Charlotte, North Carolina, United States|Site Reference ID/Investigator# 12558, Charlotte, North Carolina, United States|Site Reference ID/Investigator# 12671, Charlotte, North Carolina, United States|Site Reference ID/Investigator# 12527, Hickory, North Carolina, United States|Site Reference ID/Investigator# 12608, Morehead City, North Carolina, United States|Site Reference ID/Investigator# 12535, Salisbury, North Carolina, United States|Site Reference ID/Investigator# 12656, Statesville, North Carolina, United States|Site Reference ID/Investigator# 17641, Wilmington, North Carolina, United States|Site Reference ID/Investigator# 12606, Winston-Salem, North Carolina, United States|Site Reference ID/Investigator# 12614, Akron, Ohio, United States|Site Reference ID/Investigator# 12662, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 12545, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 12640, Kettering, Ohio, United States|Site Reference ID/Investigator# 12786, Mason, Ohio, United States|Site Reference ID/Investigator# 12630, Warren, Ohio, United States|Site Reference ID/Investigator# 12551, Oklahoma City, Oklahoma, United States|Site Reference ID/Investigator# 12611, Tulsa, Oklahoma, United States|Site Reference ID/Investigator# 12585, Medford, Oregon, United States|Site Reference ID/Investigator# 12610, Beaver, Pennsylvania, United States|Site Reference ID/Investigator# 12589, Duncansville, Pennsylvania, United States|Site Reference ID/Investigator# 12607, Harleysville, Pennsylvania, United States|Site Reference ID/Investigator# 12641, Jersey Shore, Pennsylvania, United States|Site Reference ID/Investigator# 12507, Melrose Park, Pennsylvania, United States|Site Reference ID/Investigator# 12624, Perkasie, Pennsylvania, United States|Site Reference ID/Investigator# 12669, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 12788, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 12525, Pittsburgh, Pennsylvania, United States|Site Reference ID/Investigator# 12601, Tipton, Pennsylvania, United States|Site Reference ID/Investigator# 12686, Warminster, Pennsylvania, United States|Site Reference ID/Investigator# 12623, Mount Pleasant, South Carolina, United States|Site Reference ID/Investigator# 12681, Mount Pleasant, South Carolina, United States|Site Reference ID/Investigator# 12485, Simpsonville, South Carolina, United States|Site Reference ID/Investigator# 12639, Summerville, South Carolina, United States|Site Reference ID/Investigator# 15642, Germantown, Tennessee, United States|Site Reference ID/Investigator# 12643, Jackson, Tennessee, United States|Site Reference ID/Investigator# 12470, Dallas, Texas, United States|Site Reference ID/Investigator# 16081, Dallas, Texas, United States|Site Reference ID/Investigator# 12492, Dallas, Texas, United States|Site Reference ID/Investigator# 12464, Fort Worth, Texas, United States|Site Reference ID/Investigator# 12646, San Antonio, Texas, United States|Site Reference ID/Investigator# 16601, San Antonio, Texas, United States|Site Reference ID/Investigator# 12540, San Antonio, Texas, United States|Site Reference ID/Investigator# 12466, San Antonio, Texas, United States|Site Reference ID/Investigator# 12622, San Antonio, Texas, United States|Site Reference ID/Investigator# 12538, Norfolk, Virginia, United States|Site Reference ID/Investigator# 12616, Richmond, Virginia, United States|Site Reference ID/Investigator# 12476, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00812955
NCT00810979,Comparison of SLx-4090 Combined With Statin Therapy Versus Statin Alone in Reducing LDL-C in Patients With Hyperlipidemia,,Completed,No Results Available,Hyperlipidemia,Drug: SLx-4090|Other: Placebo|Drug: Statin,Reduction in LDL-C|Adverse events,"Kadmon Corporation, LLC",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,133,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",SLx-4090-08-06,Jan-09,Sep-09,Sep-09,18-Dec-08,null,28-Jan-15,"Birmingham, Alabama, United States|Tempe, Arizona, United States|Tuscon, Arizona, United States|Jacksonville, Florida, United States|Atlanta, Georgia, United States|Addison, Illinois, United States|Chicago, Illinois, United States|Chicago, Illinois, United States|Indianapolis, Indiana, United States|Louisville, Kentucky, United States|Edina, Minnesota, United States|St. Louis, Missouri, United States|Rochester, New York, United States|Raleigh, North Carolina, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Mt. Pleasant, South Carolina, United States|Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00810979
NCT00809874,Effects of Dietary Proteins on Postprandial Lipaemia and Incretin Responses in Obese Subjects,,Completed,No Results Available,Postprandial Lipaemia|Postprandial Incretins|Postprandial Inflammation,Dietary Supplement: Casein|Dietary Supplement: Whey Isolate|Dietary Supplement: Whey Hydrolysate|Dietary Supplement: Alphalact-Albumin,Triglyceride|Incretins,Aarhus University Hospital|The Danish Obesity Research Centre|Nordic Centre of Excellence|Arla Foods,All,"40 Years to 75 Years   (Adult, Older Adult)",Not Applicable,11,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,CERN-PPL-JHJ,Feb-08,Dec-08,Dec-08,17-Dec-08,null,10-Nov-09,"Department of Clinical Nutrion, Aarhus, Denmark",,https://ClinicalTrials.gov/show/NCT00809874
NCT00808093,Repeat Dose Food Effect Study of GSK256073F in Healthy Adult Subjects,,Completed,No Results Available,Dyslipidaemias,Drug: GSK256073,"1. AUC0-inf, Cmax, and Ctrough (Ct) under fasting conditions|2. AUC0-inf, Cmax, and Ctrough (Ct) under fed conditions|1. Safety and tolerability will be assessed by vital signs, ECGs, clinical laboratory data, spontaneous AE reporting, nursing/physician observation and assessment of flushing via a visual analog scale|2. Tmax, t½ (if data permits), Ae (amount excreted in the urine), CLr (renal clearance), Cmax, ss, and Cτ following repeat dose|3. Pharmacodynamic endpoints may include TC, NEFA, HDL, LDL, TG, ApoA1, ApoA2, ApoB, Lp(a), CETP, adiponectin, liposcience (particle sizing) or other markers of dyslipidemia on Days 1, 14, 21, and 28, as data permit.",GlaxoSmithKline,All,18 Years to 55 Years   (Adult),Phase 1,30,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,106777,12-May-08,27-Aug-08,27-Aug-08,15-Dec-08,null,5-Jun-17,"GSK Investigational Site, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00808093
NCT00804427,Effect of Fish Oil on Plasma Triglycerides in Adults,,Completed,No Results Available,Hypertriglyceridemia,Dietary Supplement: Fish oil (90% triglycerides)|Dietary Supplement: Fish oil (60% triglycerides)|Dietary Supplement: Fish oil (ethyl esters)|Dietary Supplement: Soy oil,"Change from baseline in Triglycerides at 3 months|Change from baseline in LDL particle concentration (LDL1, LDL2, LDL3, LDL4) at 3 months|Change from baseline in LDL phenotype pattern (A, B, or A/B) at 3 months",Stanford University|Nordic Naturals,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",SU-12042008-1358,Dec-08,Feb-10,Apr-10,8-Dec-08,null,30-May-17,"Stanford University School of Medicine, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT00804427
NCT00802516,Long Term Effects of Plant Sterol and Stanol Esters,LTS,Completed,No Results Available,Hypercholesterolemia,Dietary Supplement: stanol ester|Dietary Supplement: sterol ester|Dietary Supplement: No intervention,the endothelial function of the vessel wall in statin-treated patients.,Maastricht University Medical Center|ZonMw: The Netherlands Organisation for Health Research and Development,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",MEC03-046.3,Jun-03,Jan-05,Jun-05,5-Dec-08,null,12-Oct-17,"Maastricht University, Maastricht, Netherlands",,https://ClinicalTrials.gov/show/NCT00802516
NCT00797186,Less Invasive Detection and Treatment of Very Early Coronary Artery Disease in Patients With Diabetes Mellitus,,Unknown status,No Results Available,Type 2 Diabetes|Microvascular Dysfunction,Other: Intensive risk factor management,LDL density|HDL|change in microvascular perfusion,University of Virginia|National Institutes of Health (NIH)|Pfizer|Astellas Pharma Inc,All,"21 Years to 85 Years   (Adult, Older Adult)",Not Applicable,150,Other|NIH|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,13761|1K23HL093118-01,Nov-08,Dec-11,Dec-11,25-Nov-08,null,30-May-11,"University of Virginia, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00797186
NCT00797407,Effectiveness of Creatine in Preventing Muscle Aching From Cholesterol-Lowering Statin Drugs,,Completed,No Results Available,Hypercholesterolemia|Aches|Cramps|Weakness,Dietary Supplement: Creatine,"Combined visual analog pain scales (0-10) for aching, cramping and weakness",The Cleveland Clinic,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,12,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,06-297,Aug-06,Dec-06,Dec-06,25-Nov-08,null,25-Nov-08,"Wooster Family Health Center, Cleveland Clinic, Wooster, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00797407
NCT00794664,Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who Are Not on Apheresis,,Completed,Has Results,Hypercholesterolemia|Coronary Heart Disease,Drug: Mipomersen|Drug: Placebo,Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Primary Efficacy Time Point|LDL-C at Baseline and the Primary Efficacy Time Point (PET)|Percent Change From Baseline in Apolipoprotein B (Apo-B) at Primary Efficacy Time Point|Apo-B at Baseline and the Primary Efficacy Time Point (PET)|Percentage Change From Baseline in Total Cholesterol at Primary Efficacy Time Point (PET)|Total Cholesterol at Baseline and the Primary Efficacy Time Point (PET)|Percentage Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Primary Efficacy Time Point (PET)|Non-HDL-C at Baseline and the Primary Efficacy Time Point (PET),"Kastle Therapeutics, LLC|Ionis Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,58,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MIPO3500108|2008-006020-53,Jan-09,May-10,Oct-10,20-Nov-08,21-Mar-13,9-Sep-16,"Jupiter, Florida, United States|Winter Park, Florida, United States|Atlanta, Georgia, United States|Kansas City, Kansas, United States|Boston, Massachusetts, United States|St Louis, Missouri, United States|Concord, New Hampshire, United States|Cincinnati, Ohio, United States|Aiken, South Carolina, United States|Winnipeg, Manitoba, Canada|Chicoutimi, Quebec, Canada|Montreal, Quebec, Canada|Hardec Kralove, Czech Republic|Pilsen, Czech Republic|Praha, Czech Republic|Uherske Hradiste, Czech Republic|Berlin, Germany|Freiburg, Germany|Heidelberg, Germany|Koln (Lindenthal), Germany|Cape Town, South Africa|Cape Town, South Africa|Gauteng, South Africa|Pretoria, South Africa|Guildford, Surrey, United Kingdom|London, United Kingdom|Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT00794664
NCT00794677,Effects of Ezetimibe on the Absorption of Oxidized Cholesterol,,Completed,Has Results,Hypercholesterolemia,Drug: ezetimibe,Log[Area-under-the-plasma-concentration-curve(AUC) 0-8 Hours 7-ketocholesterol] After an Oral Bolus|Log(Maximal Plasma Concentration (Cmax) of 7-ketocholesterol) After an Oral Bolus,Children's Hospital & Research Center Oakland|Merck Schering-Plough,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,26,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science",MM6997,Jun-06,Feb-08,Sep-08,20-Nov-08,4-Sep-09,4-Sep-09,"Cholesterol Research Center, Berkeley, California, United States",,https://ClinicalTrials.gov/show/NCT00794677
NCT00793364,Effect of Plant Stanol Ester-Containing Spread on Estimated Cardiovascular Risk in Comparison to Mediterranean Diet,,Completed,No Results Available,Hypercholesterolemia,Dietary Supplement: Stanol ester spread|Dietary Supplement: Placebo spread|Dietary Supplement: Mediterranean Diet,"Primary endpoint: Change from baseline in cardiovascular (CVD) risk as assessed by the PROCAM and Framingham risk engines.|Change from baseline in major CVD risk factors [TC, LDL-C, HDL-C, TG, apoB], in an inflammatory marker [C-reactive protein], in hemostatic parameters (PAI-I, fibrinogen), liver function tests at the end of the study vs baseline.",Hellenic Atherosclerosis Society|Minerva SA,All,"45 Years to 80 Years   (Adult, Older Adult)",Phase 4,150,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",MINERVA 01|171108,Nov-08,Mar-09,Apr-09,19-Nov-08,null,28-May-09,"Aristotelian University, Hippocration Hospital, Thessaloniki, Greece",,https://ClinicalTrials.gov/show/NCT00793364
NCT00789295,Mediterranean Diet and Postprandial Lipemia,,Completed,No Results Available,Postprandial Lipemia|Type 2 Diabetes,Other: Mediterranean diet and Low-Carbohydrates diet,Postprandial response triglyceride of chylomicrons and large VLDL|Blood glucose and insulin response to test meal|Lipolytic activities,Federico II University,All,"40 Years to 65 Years   (Adult, Older Adult)",Not Applicable,null,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",29102008,Mar-04,null,null,11-Nov-08,null,11-Nov-08,"Department of Clinical and Experimental Medicine, Federico II University Hospital,, Naples, Italy",,https://ClinicalTrials.gov/show/NCT00789295
NCT00787306,Cardiovascular Health And Risk Modification in Family Health Teams,Multi-CHARM,Completed,No Results Available,Cardiovascular Risk Factors|Hypertension|Hyperlipidemia|Diabetes,Behavioral: Active risk factor surveillance,mean systolic blood pressure|Proportion of adults with 3 cardiovascular risk factors under optimal control,University of Toronto,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 3,229,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,MOH-1048,Oct-08,Jun-09,Jun-09,7-Nov-08,null,3-Apr-18,"Granovsky Gluskin Family Medicine Cwntre, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00787306
NCT00782184,Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED),,Completed,Has Results,Hypercholesterolemia,Drug: ezetimibe/simvastatin 10/40|Drug: atorvastatin 40 mg|Drug: atorvastatin 20 mg,Percent Change From Baseline in Low Density Lipoprotein (LDL)-C|Number of Participants Reaching LDL-C Target Goals of <70 mg/dL|Number of Participants Reaching LDL-C Target Goal <77 mg/dL|Number of Participants Reaching LDL-C Target Goal <100 mg/dL|Percent Change From Baseline in Total Cholesterol|Percent Change From Baseline in Triglycerides|Percent Change From Baseline in High-Density Lipoprotein (HDL) Cholesterol|Percent Change From Baseline in Non-HDL Cholesterol|Percent Change From Baseline in LDL-Cholesterol/HDL-Cholesterol Ratio|Percent Change From Baseline in Total Cholesterol/HDL-Cholesterol Ratio|Percent Change From Baseline in Non-HDL Cholesterol/HDL-Cholesterol Ratio|Percent Change From Baseline in Apolipoprotein B|Percent Change From Baseline in Apolipoprotein A-1|Percent Change From Baseline in Apolipoprotein B/A-1 Ratio|Percent Change From Baseline in High-sensitivity C-Reactive Protein (Hs-CRP),Merck Sharp & Dohme Corp.,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 3,250,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0653A-134|2008_576,Nov-08,Sep-10,Sep-10,31-Oct-08,31-Oct-11,14-Apr-17,,,https://ClinicalTrials.gov/show/NCT00782184
NCT00783263,A Study of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients With Hypercholesterolemia (MK0653-139),,Completed,Has Results,Hypercholesterolemia,Drug: Comparator: rosuvastatin 5 mg + ezetimibe 10 mg|Drug: Comparator: rosuvastatin 10 mg|Drug: Comparator: rosuvastatin 10 mg + ezetimibe 10 mg|Drug: Comparator: rosuvastatin 20 mg,"Percent Change From Baseline in LDL-Cholesterol (mg/dL) After 6 Weeks of Treatment|Percent Change From Baseline in LDL-Cholesterol (mg/dL) After 6 Weeks of Treatment in Each Stratum|Number of Participants Who Reached Their Target LDL-C Level|Number of Participants in Each Stratum Who Reached Their Target LDL-C Level|Number of Participants Who Reached the LDL-C Level of <70 mg/dl|Number of Participants in Each Stratum Who Reached the LDL-C Level of <70 mg/dl|Percent Change From Baseline in Other Lipid, Lipoprotein, Apolipoprotein and High-sensitivity C-reactive Protein (Hs-CRP)Levels",Merck Sharp & Dohme Corp.,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 3,440,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0653-139|2008_567,Nov-08,May-10,May-10,31-Oct-08,14-Sep-11,6-Apr-17,,,https://ClinicalTrials.gov/show/NCT00783263
NCT00783549,"A Study in Healthy Volunteers of Single Doses of Orally Administered Investigational Product to Investigate Safety, Tolerability, and Pharmacokinecs.",,Completed,No Results Available,Dyslipidaemias,Drug: an undetermined dose of GSK1292263|Drug: ascending dose of GSK1292263,"Safety and tolerability parameters including adverse events, clinical laboratory, electrocardiogram, and vital signs assessments.|Pharmacokinetic parameters, maximum observed plasma drug concentration, time to maximum observe.|Pharmacodynamic endpoints|• Pharmacokinetic parameters following a dose, with and without food, and bioavailability|Relationships betwen drug exposures and pharmacodynamic parameters, safety, and tolerability, as appropriate.",GlaxoSmithKline,All,18 Years to 55 Years   (Adult),Phase 1,76,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,111596,4-Sep-08,31-Mar-09,31-Mar-09,31-Oct-08,null,7-Jul-17,"GSK Investigational Site, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00783549
NCT00782015,Effects of Almonds on Vascular Reactivity in Patients With Coronary Artery Disease,,Completed,No Results Available,Vascular Disease|Endothelial Dysfunction|Heart Disease|Cardiovascular Diseases|Hypertension,Dietary Supplement: Almonds|Dietary Supplement: Placebo Comparator:,"Endothelial Function as determined by flow mediated dilation and and biochemical markers of endothelial function.|Biochemical markers of inflammation, such as cytokines|Biochemical markers of dyslipidemia, such as lipid profiles|Biomarkers of oxidative stress, such as isoprostanes and 8OHdG",Tufts University|Boston University,All,"20 Years to 80 Years   (Adult, Older Adult)",Not Applicable,45,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TuftsIRB8723,Oct-08,Jan-11,Jan-11,29-Oct-08,null,28-Apr-17,"Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University (HNRCA), Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00782015
NCT00778804,Preventing Heart Disease in Underserved Patients,,Completed,No Results Available,Hypertension|Diabetes Mellitus|Hyperlipidemia,Behavioral: telemedicine,"Framingham 10-year risk index|Blood pressure, cholesterol, 6 minute walk test, glucose and A1c, CVD knowledge and risk perception",Temple University|Geisinger Clinic|Insight Telehealth Systems|Pennsylvania Department of Health,All,"22 Years to 85 Years   (Adult, Older Adult)",Not Applicable,465,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,4159,Jul-04,Feb-07,Feb-07,23-Oct-08,null,23-Oct-08,"Geisinger Medical Center, Danville, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Temple University Hosptial, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00778804
NCT00777517,Bioequivalence Study On Pediatric Appropriate Formulation,,Completed,No Results Available,Hypercholesterolemia,Drug: Lipitor|Drug: Atorvastatin pediatric formulation,"Primary study endpoints will be AUClast, AUCinf (if data permit) and Cmax from plasma atorvastatin concentration data.|Secondary endpoints will include Tmax and t1/2 (if data permit) of atorvastatin ; AUClast, AUCinf, Cmax, Tmax, and t1/2 (if data permit) of o-hydroxyatorvastatin and p-hydroxyatorvastatin.",Pfizer,All,18 Years to 55 Years   (Adult),Phase 1,76,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),A2581174,Nov-08,Feb-09,Feb-09,22-Oct-08,null,27-Aug-09,"Pfizer Investigational Site, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT00777517
NCT00776321,"Eprotirome for the Treatment of Dyslipidemia, Efficacy and Safety 12-Week, Phase ii Study to Assess the Safety and Efficacy of KB2115 in Patients With Primary Hypercholesterolemia",,Completed,No Results Available,Primary Hypercholesterolemia,Drug: Eprotirome|Drug: Placebo,"LDL cholesterol|Lipid variables, Thyroid hormone levels, Bone markers,DEXA, ECG, Echocardiography, liver enzymes",Karo Bio AB,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,142,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention,EudraCT No: 2006-003191-35,Sep-06,Oct-07,Oct-07,21-Oct-08,null,21-Oct-08,"Jens Kristensen, Huddinge, Sweden",,https://ClinicalTrials.gov/show/NCT00776321
NCT00772174,Efficacy and Safety Study of Pioglitazone Combined With Metformin on Metabolic Syndrome in Subjects With Type 2 Diabetes,PRISMA,Completed,No Results Available,Diabetes Mellitus,Drug: Pioglitazone and Metformin|Drug: Metformin,"Increase in High-Density Lipoprotein cholesterol levels.|The change from Baseline in Metabolic Syndrome, as defined by the International Diabetes Federation (aggregate waist circumference, fasting plasma glucose, triglycerides and high-density lipoprotein cholesterol).|The change from Baseline in Metabolic Syndrome, as defined by the International Diabetes Federation (blood pressure).|The change from Baseline in Individual Metabolic Parameters (insulin sensitivity and beta-cell function, inflammatory cytokines, adipokines, endothelial functionality).|Adverse Events.|The change from Baseline in Laboratory Parameters (hematology, chemistry and urinalysis).",Takeda,All,"35 Years to 75 Years   (Adult, Older Adult)",Phase 3,418,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IT-PIO-108|2006-000725-54|PIOc/LAN07/TIF|U1111-1115-9278,Jan-07,Feb-08,Feb-08,15-Oct-08,null,5-Jul-10,,,https://ClinicalTrials.gov/show/NCT00772174
NCT00770445,Efficacy of Pioglitazone and Metformin on Cardiovascular Risk in Subjects With Insulin-Treated Type 2 Diabetes Mellitus.,PIOcomb,Completed,No Results Available,Diabetes Mellitus,Drug: Pioglitazone and insulin|Drug: Pioglitazone and metformin and insulin|Drug: Metformin and insulin,Change from Baseline in Matrix Metallo Proteinase 9.|Change from Baseline in 24-hour Blood Pressure Profile.|Change from Baseline in Intima Media Thickness.|Change from Baseline in 24-hour Urinary Sample.|Change from Baseline in N-terminal Pro-hormone Brain Natriuretic Peptide.|Change from Baseline in 8-iso Prostaglandin F2 alpha.|Change from Baseline in Albumin.|Change from Baseline in Creatinine.|Change from Baseline in C/A-quotient.|Change from Baseline in Homeostasis Model Assessment - Insulin Sensitivity.|Change from Baseline in Total Cholesterol.|Change from Baseline in Low-Density Lipoprotein.|Change from Baseline in High-Density Lipoprotein.|Change from Baseline in Triglycerides.|Change from Baseline in Glycosylated Hemoglobin.|Change from Baseline in Glucose.|Change from Baseline in Insulin.|Change from Baseline in Intact Proinsulin.|Change from Baseline in C-peptide.|Change from Baseline in Adiponectin.|Change from Baseline in High Molecular Weight Adiponectin.|Change from Baseline in High-Sensitivity C-Reactive Protein.|Change from Baseline in Fibrinogen.|Change from Baseline in E-selectin|Change from Baseline in Nuclear Factor-kappa B.|Change from Baseline in Plasminogen Activator Inhibitor-1.|Change from Baseline in Nitrotyrosine.|Change from baseline in Insulin Consumption.|Change from Baseline in Endothelial Function measured by Laser-Doppler-flowmetry.|Change from Baseline in Body Weight.|Change from Baseline in Electrocardiograms|Change from Baseline in Alanine Aminotransferase Laboratory Safety Variable.|Change from Baseline in Aspartate Aminotransferase Laboratory Safety Variable.|Change from Baseline in Gamma-glutamyl transferase Laboratory Safety Variable.|Change from Baseline in Glomerular Filtration Rate Laboratory Safety Variable.|Change from Baseline in Alkaline Phosphatase Laboratory Safety Variable.|Change from Baseline in Leucocytes Laboratory Safety Variable.|Change from Baseline in Hemoglobin Laboratory Safety Variable.|Change from Baseline in Thrombocytes Laboratory Safety Variable.|Change from Baseline in Creatinine Kinase Laboratory Safety Variable.|Change from Baseline in Creatinine Laboratory Safety Variable.|Change from Baseline in Capillary Blood Glucose Laboratory Safety Variable.|Change from Baseline in Potassium Laboratory Safety Variable.|Change from Baseline in Circadian (7 point) Blood Glucose Profile (Week 24).|Change from Baseline in Circadian (7 point) Blood Glucose Profile (Week 12).,Takeda,All,"30 Years to 75 Years   (Adult, Older Adult)",Phase 4,121,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ATS K028|2007-006706-14|DE-PIO-028|U1111-1113-1888,May-08,Jul-10,Jul-10,10-Oct-08,null,18-Aug-10,"Lichtenfels, Bavaria, Germany|Frankfurt, Hessen, Germany|Kassel, Hessen, Germany|Wiesbaden, Hessen, Germany|Bad Oeynhausen, North Rhine-Westphalia, Germany|Dinslaken, North Rhine-Westphalia, Germany|Duisburg, North Rhine-Westphalia, Germany|Essen, North Rhine-Westphalia, Germany|Münster, North Rhine-Westphalia, Germany|Wuppertal, North Rhine-Westphalia, Germany|Mainz, Rheinland-Pfalz, Germany|Diez, Rhineland-Palatinate, Germany|Landau, Rhineland-Palatinate, Germany|Dresden, Saxony, Germany|Leipzig, Saxony, Germany|Jena, Thüringen, Germany|Berlin, Germany|Hamburg, Germany",,https://ClinicalTrials.gov/show/NCT00770445
NCT00770640,Efficacy of Pioglitazone and Insulin in Treating Subjects With Type 2 Diabetes Mellitus and Renal Failure.,PIOren,Completed,No Results Available,Diabetes Mellitus,Drug: Pioglitazone and insulin|Drug: Insulin,Change of total daily Insulin Dose.|Individual insulin doses to assess the number of patients with insulin reduction of greater than or equal to 30%.|Change from Baseline in Glycosylated Hemoglobin.|Change from Baseline in Glucose.|Change from Baseline in Insulin.|Change from Baseline in C-peptide.|Change from Baseline in Intact Proinsulin.|Change from Baseline in Adiponectin.|Change from Baseline in Angiotensin.|Change from Baseline in Relaxin.|Change from Baseline in fetuin A.|Change from Baseline in Carbonyl Protein.|Change from Baseline in Myeloperoxidase.|Change from Baseline in Matrix-Gla Protein.|Change from Baseline in High Sensitivity C-reactive Protein.|Change from Baseline in Cholesterol.|Change from Baseline in High-Density Lipoprotein.|Change from Baseline in Low-Density Lipoprotein.|Change from Baseline in Oxidized Low-Density Lipoprotein.|Change from Baseline in Triglycerides.|Change from Baseline in Matrix Metalloproteinase -9.|Change from Baseline in Monocyte Chemoattractant Protein -1.|Change from Baseline in E-selectin.|Pioglitazone in serum.|Change from Baseline in intact Parathyroid Hormone.,Takeda,All,"30 Years to 80 Years   (Adult, Older Adult)",Phase 2,40,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ATS K029|2007-006744-21|DE-PIO-029|U1111-1114-1645,Aug-08,Jun-10,Jun-10,10-Oct-08,null,1-Sep-10,"Schwetzingen, Baden-Württemberg, Germany|Wiesbaden, Hessen, Germany|Bottrop, Nordrhein-Westfalen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Lüdenscheid, Nordrhein-Westfalen, Germany|Solingen, Nordrhein-Westfalen, Germany|Alzey, Rheinland-Pfalz, Germany|Ingelheim, Rheinland-Pfalz, Germany|Mainz, Rheinland-Pfalz, Germany",,https://ClinicalTrials.gov/show/NCT00770640
NCT00770653,Efficacy of Pioglitazone/Metformin Combination Therapy in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia.,,Completed,Has Results,Diabetes Mellitus|Dyslipidemias,Drug: Pioglitazone and Metformin|Drug: Glimepiride and Metformin,The Mean Increase From Baseline in High-Density Lipoprotein Cholesterol.|Change From Baseline in High-Density Lipoprotein Cholesterol.|Change From Baseline in High-Density Lipoprotein/Low-Density Lipoprotein Ratio.|Change From Baseline in Triglycerides.|Change From Baseline in Low-Density Lipoprotein Subfractions.|Change From Baseline in Low-Density Lipoprotein Cholesterol.|Change From Baseline in Glycosylated Hemoglobin.|Change From Baseline in Fasting Intact Proinsulin.|Change From Baseline in Fasting Glucose.|Change From Baseline in Adiponectin.|Change From Baseline in High Sensitivity C-reactive Protein (Original).|Change From Baseline in High Sensitivity C-reactive Protein (≤ 10 mg/L).|Change From Baseline in Systolic Blood Pressure.|Change From Baseline in Diastolic Blood Pressure.|Intake of Study Medication Greater Than 80% and Less Than 120%.|Change From Baseline in Nitrotyrosine.|Change From Baseline in Soluble CD40 Ligand.|Change From Baseline in Matrix Metallo Proteinase-9.|Change From Baseline in Soluble Intracellular Adhesion Molecule.|Change From Baseline in Soluble Vascular Cell Adhesion Molecule.|Change From Baseline in Thromboxane B2.|Change From Baseline in Platelet Function.|Change From Baseline in E-Selectin.|Change From Baseline in Von-Willebrand Factor.|Change From Baseline in Erythrocyte Deformability (0.30%).|Change From Baseline in Erythrocyte Deformability (0.60%)|Change From Baseline in Erythrocyte Deformability (1.20).|Change From Baseline in Erythrocyte Deformability (3.00).|Change From Baseline in Erythrocyte Deformability (6.00).|Change From Baseline in Erythrocyte Deformability (12.00).|Change From Baseline in Erythrocyte Deformability (30.00).|Change From Baseline in Erythrocyte Deformability (60.00).,Takeda,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,305,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ATS K024|2006-004455-37|D-PIO-114|U1111-1114-1678,Apr-07,May-09,May-09,10-Oct-08,6-Oct-10,6-Oct-10,"Bretten, Baden-Württemberg, Germany|Deggingen, Baden-Württemberg, Germany|Dettenheim, Baden-Württemberg, Germany|Künzelsau, Baden-Württemberg, Germany|Rottweil, Baden-Württemberg, Germany|Spaichingen, Baden-Württemberg, Germany|Stockach, Baden-Württemberg, Germany|Wangen, Baden-Württemberg, Germany|Augsburg, Bayern, Germany|Feldafing, Bayern, Germany|Furth im Wald, Bayern, Germany|Immenstadt, Bayern, Germany|Lichtenfels, Bayern, Germany|München, Bayern, Germany|Schweinfurt, Bayern, Germany|Waldkraiburg, Bayern, Germany|Wallerfing, Bayern, Germany|Weilersbach, Bayern, Germany|Würzburg, Bayern, Germany|Ketzin, Brandenburg, Germany|Rüdersdorf, Brandenburg, Germany|Bermerhaven, Bremen, Germany|Bensheim, Hessen, Germany|Ehrenberg, Hessen, Germany|Gersfeld, Hessen, Germany|Kassel, Hessen, Germany|Kelkheim, Hessen, Germany|Offenbach, Hessen, Germany|Schwerin, Mecklenburg-Vorpommern, Germany|Celle, Niedersachsen, Germany|Einbeck, Niedersachsen, Germany|Hannover, Niedersachsen, Germany|Hildesheim, Niedersachsen, Germany|Bad Berleburg, Nordrhein-Westfalen, Germany|Bad Laasphe, Nordrhein-Westfalen, Germany|Bad Oeynhausen, Nordrhein-Westfalen, Germany|Bocholt, Nordrhein-Westfalen, Germany|Dinslaken, Nordrhein-Westfalen, Germany|Dorsten, Nordrhein-Westfalen, Germany|Duisburg, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Frechen, Nordrhein-Westfalen, Germany|Isselburg, Nordrhein-Westfalen, Germany|Kamen, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Marl, Nordrhein-Westfalen, Germany|Menden, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Siegen, Nordrhein-Westfalen, Germany|Diez, Rheinland-Pfalz, Germany|Mainz, Rheinland-Pfalz, Germany|Neuwied, Rheinland-Pfalz, Germany|Rodenbach, Rheinland-Pfalz, Germany|Simmern, Rheinland-Pfalz, Germany|Magdeburg, Sachsen-Anhalt, Germany|Borna, Sachsen, Germany|Dresden, Sachsen, Germany|Meißen, Sachsen, Germany|Mittweida, Sachsen, Germany|Reinfeld, Schleswig-Holstein, Germany|Altenburg, Thüringen, Germany|Blankenhain, Thüringen, Germany|Berlin, Germany|Hamburg, Germany",,https://ClinicalTrials.gov/show/NCT00770653
NCT00770835,Efficacy and Safety of Pioglitazone in Treating Subjects With Vascular Complications Associated With Type 2 Diabetes Mellitus.,SPLENDOR,Completed,No Results Available,Diabetes Mellitus,Drug: Pioglitazone and Metformin|Drug: Glibenclamide and Metformin,"Increase from Baseline in the number of Endothelial Progenitor Cells (CD34+KDR+).|Change from Baseline in Circulating Progenitor Cells Integrated Markers of cardiovascular risk (CD34+).|Change from Baseline in Flow Mediated Dilation Integrated Markers of cardiovascular risk.|Modulation of Endothelial Progenitor Cell recruitment (vascular endothelial growth factor, erythropoietin and stromal cell-derived factor-1).|Measure of Glucose Control (glycosylated hemoglobin and fasting plasma glucose).|Measure of Lipid Parameters (total lipids, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein B and apolipoprotein A1).|Change from Baseline in lipid parameters (free fatty acids and oxidized low-density lipoprotein).|Change from Baseline in insulin sensitivity (insulin indexes by 2 hour oral glucose tolerance test with glucose, insulin and C-peptide estimation).|Change from Baseline in Inflammation Markers (high-sensitivity C-reactive protein, IL-6, vascular adhesion molecules (E-selectin, vascular cell adhesion molecule-1), monocyte chemotactic protein-1 and tumor necrosis factor-alpha).|Change from Baseline in Adipokines (adiponectin).|Change from Baseline in Oxidative Stress (maleic dialdehyde, ferric reducing antioxidant power and lipid hydroperoxide.|Urinary albumin excretion.",Takeda,All,"40 Years to 70 Years   (Adult, Older Adult)",Phase 4,39,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IT-PIO-109|2007-003077-44|U1111-1114-3045,Mar-09,May-11,May-11,10-Oct-08,null,12-Jul-11,"Padova, Italy|Pisa, Italy",,https://ClinicalTrials.gov/show/NCT00770835
NCT00770952,Efficacy of Pioglitazone and Glimepiride Combination Therapy in Treating Subjects With Type 2 Diabetes Mellitus.,,Completed,No Results Available,Diabetes Mellitus,Drug: Pioglitazone and Glimepiride|Drug: Glimepiride,Change from Baseline in Homeostatic Model Assessment - Beta cell.|Change from Baseline in Glycosylated Hemoglobin.|Change from Baseline in oral glucose tolerance testing.|Change from Baseline in Insulin.|Change from Baseline in Proinsulin.|Change from Baseline in C-peptide.|Change from Baseline in High sensitivity C-Reactive Protein.|Change from Baseline in Adiponectin.|Change from Baseline in Homeostatic Model Assessment - Sensitivity.|Change from Baseline in Triglycerides|Change from Baseline in Low Density Lipoprotein-Cholesterol|Change from Baseline in High Density Lipoprotein-Cholesterol|Change from Baseline in Total Cholesterol,Takeda,All,"30 Years to 75 Years   (Adult, Older Adult)",Phase 3,91,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ATS K020|2006-002271-41|D-PIO-112|U1111-1114-3221,Dec-06,Dec-08,Dec-08,10-Oct-08,null,5-Jul-10,"Villingen-Schwenningen, Baden-Württemberg, Germany|Aschaffenburg, Bayern, Germany|Ingolstadt, Bayern, Germany|Frankfurt, Hessen, Germany|Frielendorf, Hessen, Germany|Rotenburg, Hessen, Germany|Hannover, Niedersachsen, Germany|Dortmund, Nordrhein-Westfalen, Germany|Siegen, Nordrhein-Westfalen, Germany|Kallstadt, Rheinland-Pfalz, Germany|Mainz, Rheinland-Pfalz, Germany|Mayen, Rheinland-Pfalz, Germany|Neuwied, Rheinland-Pfalz, Germany|Rhaunen, Rheinland-Pfalz, Germany|Friedrichsthal, Saarland, Germany|Meißen, Sachsen, Germany|Berlin, Germany",,https://ClinicalTrials.gov/show/NCT00770952
NCT00770146,Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk Hypercholesterolemic Patients,,Completed,Has Results,Hypercholesterolemia|Coronary Heart Disease,Drug: Mipomersen sodium|Drug: Placebo,Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at the Primary Efficacy Time Point|Low-density Lipoprotein Cholesterol (LDL-C) at Baseline and at the Primary Efficacy Time Point|Percent Change From Baseline in Apolipoprotein B at the Primary Efficacy Time Point|Apolipoprotein B at Baseline and at the Primary Efficacy Time Point|Percent Change From Baseline in Total Cholesterol at the Primary Efficacy Time Point|Total Cholesterol at Baseline and at the Primary Efficacy Time Point|Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol at the Primary Efficacy Time Point|Non-High-Density Lipoprotein Cholesterol at Baseline and at the Primary Efficacy Time Point,"Kastle Therapeutics, LLC|Ionis Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,158,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",301012-CS12,Nov-08,May-10,Oct-10,9-Oct-08,20-Mar-13,9-Sep-16,"Birmingham, Alabama, United States|Birmingham, Alabama, United States|Huntsville, Alabama, United States|Muscle Shoals, Alabama, United States|Litchfield Park, Arizona, United States|Beverly Hills, California, United States|Escondido, California, United States|Los Angeles, California, United States|Mission Viejo, California, United States|Newport Beach, California, United States|San Diego, California, United States|Santa Rosa, California, United States|Thousand Oaks, California, United States|Westlake Village, California, United States|Aventura, Florida, United States|Inverness, Florida, United States|Jacksonville, Florida, United States|Longwood, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|New Port Richey, Florida, United States|Pembroke Pines, Florida, United States|Pensacola, Florida, United States|Ponte Verda, Florida, United States|Port Orange, Florida, United States|Sandy Springs, Georgia, United States|Chicago, Illinois, United States|Chicago, Illinois, United States|Chicago, Illinois, United States|Bloomingtom, Indiana, United States|Evansville, Indiana, United States|Indianapolis, Indiana, United States|Indianapolis, Indiana, United States|Louisville, Kentucky, United States|Baltimore, Maryland, United States|Brockton, Massachusetts, United States|New Bedford, Massachusetts, United States|Edina, Minnesota, United States|Kansas City, Missouri, United States|Berlin, New Jersey, United States|Johnson City, New York, United States|Charlotte, North Carolina, United States|Greenville, North Carolina, United States|Wilson, North Carolina, United States|Cincinnati, Ohio, United States|Mentor, Ohio, United States|Norman, Oklahoma, United States|Tulsa, Oklahoma, United States|Portland, Oregon, United States|Lansdale, Pennsylvania, United States|Murrells Inlet, South Carolina, United States|Simpsonville, South Carolina, United States|Spartanburg, South Carolina, United States|Rapid City, South Dakota, United States|Dallas, Texas, United States|Dallas, Texas, United States|Grapevine, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Olympia, Washington, United States",,https://ClinicalTrials.gov/show/NCT00770146
NCT00768274,"Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol",,Completed,No Results Available,Dyslipidemia|Atherosclerosis|Acute Coronary Syndrome|Cardiovascular Disease,Drug: RVX000222|Drug: Placebo,"Safety, pharmacokinetics and changes in lipid parameters from baseline and placebo.",Resverlogix Corp,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,72,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RVX222-CS-003,Sep-08,Aug-09,null,8-Oct-08,null,25-Jul-16,"Covance Clinical Research Unit, Inc., Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT00768274
NCT00769132,"A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED)",,Completed,Has Results,Hypercholesterolemia,Drug: Comparator: niacin + laropiprant|Drug: Comparator: niacin|Drug: Comparator: laropiprant|Drug: Comparator: placebo,Urinary 11-dehydrothromboxane B2 (11-dTxB2)|Prostaglandin I Metabolite (PGI-M),Merck Sharp & Dohme Corp.,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,26,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0524A-075|2008_561,Aug-07,Oct-07,Nov-07,8-Oct-08,27-Nov-08,18-Sep-15,,,https://ClinicalTrials.gov/show/NCT00769132
NCT00766688,Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing High Doses of Statins in Patients With Primary Severe Hypercholesterolemia,,Terminated,No Results Available,Hypercholesterolemia,Drug: AVE5530|Drug: Placebo,Percent change from baseline in calculated LDL-C|Percent change from baseline in Total-Cholesterol and Apo-B,Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,643,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",EFC10841|EudraCT 2008-002849-23,Oct-08,Apr-09,Jun-09,6-Oct-08,null,16-May-16,"Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|sanofi-aventis Australia & New Zealand administrative office, Macquarie Park, New South Wales, Australia|Sanofi-Aventis Administrative Office, Diegem, Belgium|Sanofi-Aventis Administrative Office, Sofia, Bulgaria|Sanofi-Aventis Administrative Office, Laval, Canada|Sanofi-Aventis Administrative Office, Praha, Czech Republic|Sanofi-Aventis Administrative Office, Paris, France|Sanofi-Aventis Administrative Office, Natanya, Israel|Sanofi-Aventis Administrative Office, Gouda, Netherlands|Sanofi-Aventis Administrative Office, Moscow, Russian Federation|Sanofi-Aventis Administrative Office, Brastislava, Slovakia|Sanofi-Aventis Administrative Office, Midrand, South Africa|Sanofi-Aventis Administrative Office, Kiev, Ukraine",,https://ClinicalTrials.gov/show/NCT00766688
NCT00761904,The Effect of Providing Free Samples of Generic Cardiovascular Medications to Physicians,SAMPLES,Unknown status,No Results Available,Hypertension|Hyperlipidemia,"Behavioral: Free Generic Samples (hydrochlorothiazide, simvastatin)",Percentage of prescriptions filled for generic medications|Patient adherence - Amount of prescriptions actually filled (Proportion of Days Covered) within each class in the first year of use of an anti-hypertensive or lipid-lowering medication|The sum of medication costs for all prescriptions used to treat either hypertension or hypercholesterolemia.|Guideline adherence - Proportion of patients who received first-line anti-hypertensive medications suggested by JNC-VII when medications are initiated.,Brigham and Women's Hospital,All,"Child, Adult, Older Adult",Not Applicable,660,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research,08-001010|1K23HL090505-01,Dec-10,Apr-11,Apr-11,30-Sep-08,null,5-May-10,"Brigham and Women's Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00761904
NCT00762112,Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus,,Terminated,No Results Available,Diabetes Mellitus,Drug: TAK-559,Change from baseline in clinical laboratory hematology tests.|Change from baseline in clinical laboratory chemistry tests.|Blood pressure measurements.|Pulse measurements.|Body weight.|Physical examinations.|12-lead electrocardiogram.|Adverse event occurrence.|Change from baseline in glycosylated hemoglobin.|Change from baseline in fasting plasma glucose.|Change from baseline in fasting insulin.|Change from baseline in fasting C-peptide.|Change from baseline in triglycerides.|Change from baseline in total cholesterol.|Change from baseline in high-density lipoprotein.|Change from baseline in low-density lipoprotein.|Change from baseline in very-low-density lipoprotein.|Change from baseline in low-density lipoprotein fractionation.|Change from baseline in intermediate-density lipoprotein size.|Change from baseline in large low-density lipoprotein size.|Change from baseline in small low-density lipoprotein size.|Change from baseline in medium-small low-density lipoprotein size.|Change from baseline in very-small low-density lipoprotein size.|Change from baseline in mean low-density lipoprotein size.|Change from baseline in apolipoproteins A1 and B.|Change from baseline in atherosclerosis marker plasminogen activator inhibitor 1.|Change from baseline in atherosclerosis marker fibrinogen.|Change from baseline in inflammation marker Interleukin-6.|Change from baseline in inflammation marker C-reactive protein.,Takeda,All,"25 Years to 80 Years   (Adult, Older Adult)",Phase 3,316,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,01-03-TL-559-017|U1111-1128-4850,Nov-03,Dec-04,Dec-04,30-Sep-08,null,12-Nov-12,,,https://ClinicalTrials.gov/show/NCT00762112
NCT00762164,Comparison of the Effect of Vytorin 10/80 Tablet Split Into 4 and Simvastatin 20 Milligrams on Low-density Lipoprotein (LDL) Cholesterol,,Completed,Has Results,Hypercholesterolemia,Drug: Vytorin|Drug: Simvastatin,LDL Cholesterol|Total Cholesterol,Bronx VA Medical Center,All,"18 Years and older   (Adult, Older Adult)",Phase 4,34,U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",VA---19-07-01,Mar-07,Apr-09,May-09,30-Sep-08,3-Jul-13,3-Jul-13,"Bronx VA Medical Center, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT00762164
NCT00762190,Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus,,Terminated,No Results Available,Diabetes Mellitus,Drug: TAK-559 and insulin|Drug: Insulin,"Incidence of Adverse events.|Clinical safety lab tests.|12-lead electrocardiogram.|Urinalysis.|Change from Baseline in Blood pressure and pulse.|Change from Baseline in Body weight.|Left ventricular mass index by body surface area measured by echocardiogram.|Change from Baseline in total daily dose of insulin.|Change from Baseline in triglycerides.|Change from Baseline in cholesterol.|Change from Baseline in total, high-density lipoproteins.|Change from Baseline in low-density lipoproteins.|Change from Baseline in low-density lipoprotein fractionation.|Change from Baseline in very low-density lipoprotein.|Change from Baseline in free fatty acids.|Change from Baseline in apolipoproteins (AI, B).",Takeda,All,"25 Years to 65 Years   (Adult, Older Adult)",Phase 3,348,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",01-03-TL-559-016|U1111-1128-1034,Nov-03,Dec-04,Dec-04,30-Sep-08,null,12-Nov-12,,,https://ClinicalTrials.gov/show/NCT00762190
NCT00762229,Evaluation of LDL Cholesterol in Patients Switched From 10 to 5 Milligrams of Zetia (Ezetimibe),,Completed,Has Results,Hypercholesterolemia,Drug: Ezetimibe 10 mg|Drug: Ezetimibe 5 mg,LDL Cholesterol|Total Cholesterol,Bronx VA Medical Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,39,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,VA---19-07-051,Jul-07,Sep-08,Sep-08,30-Sep-08,14-Jun-13,14-Jun-13,"Bronx VA Medical Center, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT00762229
NCT00762684,Efficacy and Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus,,Terminated,No Results Available,Diabetes Mellitus,Drug: TAK-559|Drug: Placebo,Change from baseline in glycosylated hemoglobin.|Change from baseline in fasting plasma glucose.|Change from baseline in serum insulin.|Change from baseline in C-peptide.|Change from baseline in triglycerides.|Change from baseline in total cholesterol.|Change from baseline in high-density lipoprotein.|Change from baseline in low-density lipoprotein.|Change from baseline in very-low-density lipoprotein.|Change from base line in apolipoproteins A1 and B 100.|Change from baseline in free fatty acids.|Change from baseline in thrombosis marker (plasminogen activator inhibitor-1)|Change from baseline in thrombosis marker (fibrinogen)|Change from baseline in inflammation marker (Interleukin-6).|Change from baseline in inflammation marker (C-reactive protein).|Change from baseline in urinary albumin to creatinine ratio.,Takeda,All,"25 Years to 75 Years   (Adult, Older Adult)",Phase 3,8,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",01-04-TL-559-028|U1111-1127-7965,Nov-04,Dec-04,Dec-04,30-Sep-08,null,12-Nov-12,,,https://ClinicalTrials.gov/show/NCT00762684
NCT00762736,Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Type 2 Diabetes Mellitus,,Completed,No Results Available,Diabetes Mellitus,Drug: Pioglitazone and azilsartan|Drug: Pioglitazone,Change from Baseline in glycosylated hemoglobin.|Change from Baseline in fasting plasma glucose.|Change from Baseline in total cholesterol.|Change from Baseline in high-density lipoprotein.|Change from Baseline in low-density lipoprotein.|Change from Baseline in triglycerides.|Change from Baseline in body weight.|Change from Baseline in systolic and diastolic blood pressure.|Change from Baseline in incidence of edema (peripheral).|Change from Baseline in microalbuminuria excretion.|Change from Baseline in high-sensitivity C-reactive protein.|Change from Baseline in matrix metalloproteinase-9.,Takeda,All,"18 Years and older   (Adult, Older Adult)",Phase 2,704,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",01-04-TL-OPI-525|U1111-1115-8992,Jul-04,Oct-05,Oct-05,30-Sep-08,null,28-Feb-12,"Birmingham,, Alabama, United States|Huntsville, Alabama, United States|Sierra Vista, Arizona, United States|Sun City, Arizona, United States|Tucson, Arizona, United States|Burbank, California, United States|Escondido, California, United States|Irvine, California, United States|La Jolla, California, United States|National City, California, United States|Riverside, California, United States|Sacramento, California, United States|San Diego, California, United States|Spring Valley, California, United States|Coral Gables, Florida, United States|Deland, Florida, United States|Hollywood, Florida, United States|Miami, Florida, United States|New Port Richey, Florida, United States|Opalocka, Florida, United States|Pembroke Pines, Florida, United States|Sarasota, Florida, United States|Vero Beach, Florida, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Warner Robins, Georgia, United States|Honolulu, Hawaii, United States|Lihue, Hawaii, United States|Chicago, Illinois, United States|Dyersburg, Indiana, United States|Overland Park, Kansas, United States|Wichita, Kansas, United States|New Orleans, Louisiana, United States|Shreveport, Louisiana, United States|Salisbury, Massachusetts, United States|Cadillac, Michigan, United States|Detroit, Michigan, United States|Livonia, Michigan, United States|Kansas City, Missouri, United States|St. Louis, Missouri, United States|Las Vegas, Nevada, United States|North Las Vegas, Nevada, United States|Berlin, New Jersey, United States|Blackwood, New Jersey, United States|Trenton, New Jersey, United States|Albany, New York, United States|Kingston, New York, United States|Charlotte, North Carolina, United States|Marion, Ohio, United States|Clinton, Oklahoma, United States|Oklahoma City, Oklahoma, United States|Allentown, Pennsylvania, United States|Altoona, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Scotland,, Pennsylvania, United States|Woonsocket, Rhode Island, United States|Greer, South Carolina, United States|Arlington, Texas, United States|Dallas, Texas, United States|Fort Worth, Texas, United States|Midland,, Texas, United States|North Richard Hills, Texas, United States|San Antonio, Texas, United States|Renton, Washington, United States|Buenos Aires, Argentina|Cordoba, Argentina|Rosario-Santa Fe, Argentina|Santa Fe, Argentina|Ushuaia - Tierre del Fuego, Argentina|Santiago, Chile|Aguascalientes, Mexico|Cuernavaca, Mexico|Durango, Mexico|Guadalajara, Mexico|Mexico City, Mexico|Pueblo, Mexico|Ica, Peru|Lima, Peru",,https://ClinicalTrials.gov/show/NCT00762736
NCT00762957,Safety and Efficacy of TAK-559 in Combination With Metformin in Patients With Type 2 Diabetes Mellitus.,,Terminated,No Results Available,Diabetes Mellitus,Drug: TAK-559 and metformin|Drug: Metformin,Change from baseline in glycosylated hemoglobin.|Change from baseline in fasting plasma glucose.|Change from baseline in serum insulin.|Change from baseline in C-peptide.|Change from baseline in triglycerides.|Change from baseline in total cholesterol.|Change from baseline in high-density lipoprotein.|Change from baseline in low-density lipoprotein.|Change from baseline in very-low-density lipoprotein.|Change from baseline in apolipoproteins A1 and B 100.|Change from baseline in free fatty acids.|Change from baseline in thrombosis marker plasminogen activator inhibitor-1|Change from baseline in thrombosis marker fibrinogen.|Change from baseline in inflammation marker Interleukin-6.|Change from baseline in inflammation marker C-reactive protein.|Change from baseline in urinary albumin to creatinine ratio.,Takeda,All,"25 Years to 75 Years   (Adult, Older Adult)",Phase 3,15,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",01-04-TL-559-029|U1111-1128-4945,Nov-04,Dec-04,Dec-04,30-Sep-08,null,28-Feb-12,,,https://ClinicalTrials.gov/show/NCT00762957
NCT00763022,Efficacy of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus,,Completed,No Results Available,Diabetes Mellitus,Drug: TAK-559|Drug: Placebo,"Change in Baseline in Glycosylated hemoglobin.|Change in Baseline in Fasting Plasma Glucose.|Change in Baseline in Serum insulin.|Change in Baseline in C-peptide.|Change in Baseline in Lipids (triglycerides, total cholesterol, high-density lipoprotein, low-density lipoprotein, very-low-density lipoprotein).|Change in Baseline in Lipids (low-density lipoprotein fractionation).|Change in Baseline in Apolipoproteins Al and B100.|Change in Baseline in Free fatty acids.|Markers of thrombosis (plasminogen activator inhibitor-i).|Markers of thrombosis (fibrinogen).|Markers of inflammation (interleukin-6).|Markers of inflammation (C-reactive protein).|Urinary albumin/creatinine ratio.",Takeda,All,"25 Years to 75 Years   (Adult, Older Adult)",Phase 3,302,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",01-02-TL-559-014|U1111-1127-8487,Nov-03,Dec-04,Dec-04,30-Sep-08,null,12-Nov-12,,,https://ClinicalTrials.gov/show/NCT00763022
NCT00763347,Efficacy and Safety Study of SYR-619 in Treating Subjects With Type 2 Diabetes Mellitus,,Terminated,No Results Available,Diabetes Mellitus,Drug: SYR-619|Drug: Placebo|Drug: Alogliptin,"Change from baseline in glycosylated hemoglobin.|Change from baseline in fasting plasma glucose.|Change from baseline in 1,5 anhydroglucitol.|Change from baseline in proinsulin.|Change from baseline in insulin.|Change from baseline in proinsulin/insulin ratio.|Change from baseline in C-peptide.|Homeostasis model assessment insulin resistance.|Homeostasis model assessment beta-cell function.|Incidence of marked hyperglycemia (fasting plasma glucose ≥200 mg/dL [≥11.10 mmol/L]).|Incidence of rescue.|Clinical response endpoint incidence of glycosylated hemoglobin ≤6.5%.|Clinical response endpoint incidence of glycosylated hemoglobin ≤7.0%.|Clinical response endpoint incidence of glycosylated hemoglobin improvement ≥1.0%.|Clinical response endpoint incidence of glycosylated hemoglobin improvement ≥1.5%.|Clinical response endpoint incidence of glycosylated hemoglobin improvement ≥2.0%.|Fasting lipids (triglycerides, total cholesterol, high-density lipoprotein and low-density lipoprotein cholesterol).|Postprandial area under the concentration-time curve and peak 2-hour values of plasma glucose, insulin and C-peptide during a 3-hour mixed-meal tolerance test in a subset of subjects.|Plasma concentration of SYR-619.|Physical examination findings (including a clinical examination of skin and digits).|Vital sign measurements.|Body temperature measurements.|12-lead electrocardiogram tracings.|Incidence of adverse events.|Incidence of hypoglycemia (blood glucose <60 mg/dL [<3.33 mmol/L]) in the presence of symptoms or blood glucose <50 mg/dL [<2.78 mmol/L]) regardless of symptoms).|Clinical laboratory evaluations (hematology and serum chemistry).|Clinical laboratory evaluation (urinalysis).",Takeda,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,82,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",01-06-TL-SYR-619-003|U1111-1124-2377,Nov-06,Feb-07,Feb-07,30-Sep-08,null,21-May-12,,,https://ClinicalTrials.gov/show/NCT00763347
NCT00760344,Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus,,Completed,No Results Available,Diabetes Mellitus,Drug: SYR-472|Drug: Placebo|Drug: Sitagliptin,"Change from baseline in glycosylated hemoglobin|Change from baseline in fasting plasma glucose|Change from baseline in 1,5-Anhydroglucitol|Change from baseline in Proinsulin|Change from baseline in Insulin|Change from baseline in Proinsulin/insulin ratio|Change from baseline in C-peptide|Change from baseline in Homeostasis model assessment of insulin resistance.|Change from baseline in Homeostasis model assessment of beta-cell function.|Incidence of marked hyperglycemia (fasting plasma glucose greater than or equal to 200 mg/dL [11.10 mmol/L]).|Incidence of rescue.|Clinical response endpoint incidence of glycosylated hemoglobin less than or equal to 6.5%.|Clinical response endpoint incidence of glycosylated hemoglobin less than or equal to 7.0%.|Change from baseline in Fasting lipids (triglycerides, total cholesterol, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol).|Body weight.",Takeda,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,386,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",01-06-TL-SYR-472-006|U1111-1129-7916,Mar-07,Mar-08,Mar-08,26-Sep-08,null,22-Jun-16,"Birmingham, Alabama, United States|Mobile, Alabama, United States|Montgomery, Alabama, United States|Phoenix, Arizona, United States|Tempe, Arizona, United States|Tucson, Arizona, United States|Anderson, Arkansas, United States|Little Rock, Arkansas, United States|Pine Bluff, Arkansas, United States|Carmichael, California, United States|Chino, California, United States|Long Beach, California, United States|Los Angeles, California, United States|Los Gatos, California, United States|Orange, California, United States|Pico Rivera, California, United States|Rolling Hills Estates, California, United States|Roseville, California, United States|Rowland Heights, California, United States|Sacramento, California, United States|Santa Ana, California, United States|Stockton, California, United States|Torrance, California, United States|Arvada, Colorado, United States|Colorado Springs, Colorado, United States|Highlands Ranch, Colorado, United States|Avon, Connecticut, United States|Rocky Hill, Connecticut, United States|Newark, Delaware, United States|Aventura, Florida, United States|Edgewater, Florida, United States|Hollywood, Florida, United States|Jacksonville, Florida, United States|Kissimmee, Florida, United States|Merritt Island, Florida, United States|Miami, Florida, United States|New Port Richey, Florida, United States|Ocala, Florida, United States|Pembroke Pines, Florida, United States|Tampa, Florida, United States|Zanesville, Florida, United States|Atlanta, Georgia, United States|Roswell, Georgia, United States|Waycross, Georgia, United States|Idaho Falls, Idaho, United States|Chicago, Illinois, United States|Avon, Indiana, United States|Fort Wayne, Indiana, United States|Des Moines, Iowa, United States|Waterloo, Iowa, United States|Topeka, Kansas, United States|Wichita, Kansas, United States|Crestview, Kentucky, United States|Oxon Hill, Maryland, United States|Detroit, Michigan, United States|Troy, Michigan, United States|Olive Branch, Mississippi, United States|Kansas City, Missouri, United States|St. Louis, Missouri, United States|Omaha, Nebraska, United States|Las Vegas, Nevada, United States|West Caldwell, New Jersey, United States|Wildwood Crest, New Jersey, United States|Albuquerque, New Mexico, United States|East Islip, New York, United States|Lewiston, New York, United States|New York, New York, United States|North Massapequa, New York, United States|Wantagh, New York, United States|Hickory, North Carolina, United States|Statesville, North Carolina, United States|Tabor City, North Carolina, United States|Bismarck, North Dakota, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Mason, Ohio, United States|Wadsworth, Ohio, United States|Norman, Oklahoma, United States|Oklahoma City, Oklahoma, United States|Tulsa, Oklahoma, United States|Eugene, Oregon, United States|Medford, Oregon, United States|Bensalem, Pennsylvania, United States|Connellsville, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Shippensburg, Pennsylvania, United States|Charleston, South Carolina, United States|Greer, South Carolina, United States|North Myrtle Beach, South Carolina, United States|Chattanooga, Tennessee, United States|Memphis, Tennessee, United States|New Tazewell, Tennessee, United States|Carrolton, Texas, United States|Dallas, Texas, United States|Georgetown, Texas, United States|Houston, Texas, United States|Killeen, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Spanish Fork, Utah, United States|Richmond, Virginia, United States|Suffolk, Virginia, United States|Virginia Beach, Virginia, United States|Spokane, Washington, United States|Zapopan, Jalisco, Mexico|Monterrey, Nuevo Leon, Mexico|Mexico DF, Mexico|Monterrey, Mexico|Nezahualcoyotl, Mexico|Puebla, Mexico|Veracruz, Mexico",,https://ClinicalTrials.gov/show/NCT00760344
NCT00758303,A Study to Evaluate the Lipid Regulating Effects of TRIA-662,,Completed,No Results Available,Hyperlipidemia,Drug: Low Dose TRIA-662|Drug: High Dose TRIA-662|Drug: Placebo for TRIA-662,"The primary efficacy parameter is the percent change in total serum Triglycerides from baseline to end of study|The secondary efficacy parameters include the percent change in total cholesterol (TC), its major lipoprotein sub-fractions and the effects on inflammatory markers",Cortria Corporation,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,211,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Cortria-001,Sep-07,Dec-08,Dec-08,25-Sep-08,null,13-Sep-13,,,https://ClinicalTrials.gov/show/NCT00758303
NCT00758927,The Effects of Omega-3 Fatty Acid (OMACOR) on the Low-density Lipoprotein (LDL) Sub-fraction in Type 2 Diabetic Patients,,Unknown status,No Results Available,"Diabetes Mellitus, Type 2|Hypercholesterolemia|Hypertriglyceridemia",Drug: Omega-3 acid 4 grams per day|Drug: Placebo control,Percentage change of plasma small dense LDL measured by ultracentrifuge-non denaturing polyacrylamide gel electrophoresis|The percentage change of plasma HDL sub-fraction measured by ultracentrifuge-non denaturing polyacrylamide gel electrophoresis,"Inje University|Kuhnil Pharmaceutical Co., Ltd.",All,"40 Years to 70 Years   (Adult, Older Adult)",Phase 4,70,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,08-OM-9408,Jul-09,Apr-10,Jul-10,25-Sep-08,null,6-Aug-09,"Dong-A University Medical Center, Busan, Korea, Republic of|Paik Diabetes Center, Busan, Korea, Republic of|Endocrinology and Metabolism, Maryknoll General Hospital, Busan, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT00758927
NCT00759720,Efficacy and Safety of TAK-559 Combined With Glyburide in Treating Subjects With Type 2 Diabetes Mellitus.,ORIGAMI,Terminated,No Results Available,Diabetes Mellitus,Drug: TAK-559 and glyburide|Drug: Glyburide,"Change from Baseline in Glycosylated hemoglobin level.|Change from baseline in Glycosylated hemoglobin level.|Change from baseline in Fasting plasma glucose.|Change from Baseline in Serum insulin.|Change from Baseline in C-peptide.|Change from Baseline in Lipids (triglyceride, total cholesterol, high-density lipoprotein, low-density lipoprotein and very low-density lipoproteins)|Change from Baseline in Apolipoproteins [A1 and B]).|Change from Baseline in Free fatty acids.|Markers of thrombosis (plasminogen activator inhibitor-1 and fibrinogen).|Markers of inflammation (interleukin-6 and C-reactive protein).|Urinary albumin/creatinine ratio.|Low-density lipoprotein fractionation [L-DL particles (total), intermediate-density lipoprotein, large L-DL, small L-DL (total), medium-small L-DL, very-small L-DL, mean L-DL size].",Takeda,All,"25 Years to 75 Years   (Adult, Older Adult)",Phase 3,447,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",01-02-TL-559-013|U1111-1127-8392,Nov-03,Dec-04,Dec-04,25-Sep-08,null,2-Feb-12,,,https://ClinicalTrials.gov/show/NCT00759720
NCT00758004,Bioequivalence Study Of Pediatric Appropriate Formulation,,Completed,No Results Available,Hypercholesterolemia,Drug: Atorvastatin|Drug: Atorvastatin pediatric appropriate formulation,"Primary study endpoints will be AUClast, AUCinf (if data permit) and Cmax from plasma atorvastatin concentration data.|Secondary endpoints will include Tmax and t1/2 (if data permit) of atorvastatin ; AUClast, AUCinf, Cmax, Tmax, and t1/2 (if data permit) of o-hydroxyatorvastatin and p-hydroxyatorvastatin.",Pfizer,All,18 Years to 55 Years   (Adult),Phase 1,76,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),A2581175,Oct-08,Mar-09,Mar-09,23-Sep-08,null,18-Nov-09,"Pfizer Investigational Site, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00758004
NCT00756405,Effects of Dietary Antioxidants on Cardiovascular Risk Factors,,Completed,No Results Available,Obesity|Hyperlipidemia|Hypertension,Behavioral: Antioxidant diet|Dietary Supplement: Antioxidant supplement|Dietary Supplement: Placebo,"Change from baseline in inflammatory Markers [monocyte chemotactic protein-1 (MCP-1), interleukin-6 (IL-6), and soluble intercellular adhesion molecule-1 (sICAM-1)] at 8 weeks|Blood concentrations of antioxidants at baseline and 8 weeks|Dietary antioxidants",Christopher Gardner|National Center for Complementary and Integrative Health (NCCIH)|Stanford University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,88,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",SU-08202008-1284|1R21AT003245-01,Mar-07,Dec-08,Dec-08,22-Sep-08,null,30-May-17,"Stanford University School of Medicine, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT00756405
NCT00755404,Effect of an L-Carnitine-Containing Peritoneal Dialysis (PD) Solution on Insulin Sensitivity in Diabetic Patients on Continuous Ambulatory Peritoneal Dialysis (CAPD),,Unknown status,No Results Available,End Stage Renal Disease|Diabetes,Drug: PD Solution|Drug: PD solution containing L-carnitine,To assess the efficacy of L-Carnitine containing PD solution on insulin sensitivity evaluated by measuring insulin requirement|To assess the efficacy of L-Carnitine containing PD solution on plasma lipids and lipoprotein profile|To assess the efficacy of L-Carnitine containing PD solution on hematological parameters (hemoglobin and EPO requirements),Iperboreal Pharma Srl,All,"18 Years and older   (Adult, Older Adult)",Phase 2,20,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IP-003-05,Jun-07,Oct-13,Dec-13,19-Sep-08,null,26-Mar-13,"Renal, Dialysis and Transplant Unit, University of Bari, Bari, Italy|Nephology and Dialysis Unit, ""Salvini"" Hospital, Bollate, Italy|Division of Nephrology, University of ""G. d'Annunzio"", Chieti, Italy|Nephrology and Dialysis Unit, Desio Hospital, Desio, Italy|Nephrology and Dialysis Unit, ""Maria SS dello Splendore"" Hospital, Giulianova, Italy|Division of Nephrology and Dialysis, Ospedale Policlinico Maggiore, Milano, Italy|Nephrology and Dialysis Unit, ""G. Bernabeo"" Hospital, Ortona, Italy|Renal Unit, Policlinico MultiMedica, Sesto San Giovanni, Italy|Division of Nephrology and Dialysis, ""Mazzini"" Hospital, Teramo, Italy",,https://ClinicalTrials.gov/show/NCT00755404
NCT00755456,Effect of an L-carnitine-containing Peritoneal Dialysis (PD) Solution on Insulin Sensitivity in Patients on Continuous Ambulatory Peritoneal Dialysis (CAPD),,Unknown status,No Results Available,End Stage Renal Disease|Insulin Resistance,Drug: PD solution|Drug: PD solution containing L-carnitine,To assess the efficacy of L-Carnitine containing PD solution on insulin sensitivity evaluated by euglycemic hyperinsulinemic clamp|To assess the efficacy of L-Carnitine containing PD solution on plasma lipids and lipoprotein profile|To assess the efficacy of L-Carnitine containing PD solution on hematological parameters (hemoglobin and EPO requirements),Iperboreal Pharma Srl,All,"18 Years and older   (Adult, Older Adult)",Phase 2,80,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IP-002-05,Jan-08,Oct-13,Dec-13,19-Sep-08,null,26-Mar-13,"Renal and Dialysis, Bari Policlinic Hospital, Bari, Italy|Renal, Dialysis and Transplant Unit, University of Bari, Bari, Italy|Nephology and Dialysis Unit, ""Salvini"" Hospital, Bollate, Italy|Division of Nephrology, University of ""G. d'Annunzio"", Chieti, Italy|Nephrologyand Dialysis Unit, Desio Hospital, Desio, Italy|Nephrology and Dialysis Unit, ""Maria SS dello Splendore"" Hospital, Giulianova, Italy|Nephrology and Dialysis Unit, ""Renzetti"" Hospital, Lanciano, Italy|Division of Nephrology and Dialysis, Ospedale Policlinico Maggiore, Milano, Italy|Nephrology and Dialysis Unit, ""G. Bernabeo"" Hospital, Ortona, Italy|Renal Unit, Policlinico MultiMedica, Sesto San Giovanni, Italy|Nephrology and Dialysis Unit, ""SS Annunziata"" Hospital, Sulmona, Italy|Division of Nephrology and Dialysis, ""Mazzini"" Hospital, Teramo, Italy|Nephrology and Dialysis Unit, ""San Pio da Pietrelcina"" Hospital, Vasto, Italy",,https://ClinicalTrials.gov/show/NCT00755456
NCT00754403,Efficacy of Pioglitazone and Fortamet Combination Therapy in Subjects With Type 2 Diabetes,,Completed,No Results Available,Diabetes Mellitus,Drug: Pioglitazone and metformin|Drug: Metformin,Change from randomization in Glycosylated Hemoglobin|Change from randomization in Fasting Plasma Glucose|Change from randomization in Insulin|Change from randomization in Pro-Insulin|Change from randomization in Homeostasis Model Assessment|Change from randomization in Triglycerides|Change from randomization in Total Cholesterol|Change from randomization in Low-Density Lipoprotein Cholesterol|Change from randomization in high-density Lipoprotein Cholesterol|Change from randomization in Lipid Fractionation|Change from randomization in High Sensitivity C-Reactive Protein|Change from randomization in Creatine Phosphokinase,Takeda,All,"18 Years and older   (Adult, Older Adult)",Phase 4,312,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",01-05-TL-OPIXT-010|U1111-1114-2423,Jul-05,Oct-06,Oct-06,18-Sep-08,null,5-Jul-10,,,https://ClinicalTrials.gov/show/NCT00754403
NCT00754507,A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Atorvastatin for at Least 4 Weeks.,,Completed,No Results Available,Hypercholesterolemia,"Drug: colesevelam HCl tablets, and atorvastatin tablets|Drug: colesevelam HCl placebo tablets and atorvastatin tablets",The primary efficacy parameter is the percent change in LDL-C from baseline to endpoint.|The absolute change in LDL-C from baseline to endpoint|The absolute change and % change in total cholesterol|The absolute change and % change in triglycerides|The absolute change and % change in HDL-C|The absolute change and % change in C-reactive protein,"Daiichi Sankyo, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 4,65,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WEL-406,Nov-02,Jun-03,Apr-05,18-Sep-08,null,3-Apr-15,"Los Angeles, California, United States|Castle Rock, Colorado, United States|Jacksonville, Florida, United States|Pembroke Pines, Florida, United States|St. Petersburg, Florida, United States|Indianapolis, Indiana, United States|Rochester, New York, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Bartlett, Tennessee, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00754507
NCT00755352,A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Pravastatin for at Least 4 Weeks.,,Completed,No Results Available,Hypercholesterolemia,Drug: pravastatin tablets and Welchol tablets|Drug: pravastatin tablets and Welchol placebo tablets,The primary efficacy parameter was the percent change in LDL-C from baseline to endpoint.|The absolute change in LDL-C from baseline to endpoint.|The absolute change and % change of total cholesterol from baseline to endpoint|The absolute change and % change of triglycerides from baseline to endpoint|The absolute change and % change of HDL-C from baseline to endpoint|The absolute change and % change of c-reactive protein from baseline to endpoint,"Daiichi Sankyo, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 4,67,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WEL-407,Nov-02,Jun-03,Apr-05,18-Sep-08,null,3-Apr-15,"Los Angeles, California, United States|Castle Rock, Colorado, United States|Jacksonville, Florida, United States|Pembroke Pines, Florida, United States|St. Petersburg, Florida, United States|Chicago, Illinois, United States|Indianapolis, Indiana, United States|Louisville, Kentucky, United States|Rochester, New York, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Bartlett, Tennessee, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00755352
NCT00753779,A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Simvastatin for at Least 4 Weeks.,,Completed,No Results Available,Hypercholesterolemia,"Drug: colesevelam HCl tablets, and simvastatin tablets|Drug: simvastatin tablets and colesevelam HCl placebo",The percent change in LDL-C from baseline to endpoint|The absolute change in LDL-C from baseline to endpoint|The absolute and % change of total cholesterol|The absolute and % change in triglycerides|The absolute and % change in HDL-C,"Daiichi Sankyo, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 4,72,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WEL-405,Nov-02,Jun-03,Apr-05,17-Sep-08,null,3-Apr-15,"Los Angeles, California, United States|Castle Rock, Colorado, United States|Jacksonville, Florida, United States|Pembroke Pines, Florida, United States|St. Petersburg, Florida, United States|Chicago, Illinois, United States|Indianapolis, Indiana, United States|Rochester, New York, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Bartlett, Tennessee, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00753779
NCT00753883,Ezetrol Post-Marketing Study,,Completed,No Results Available,Hyperlipidemia,Drug: simvastatin|Drug: Ezetimibe,The change in lipid profiles after study drug treatment.,Merck Sharp & Dohme Corp.,All,"20 Years to 80 Years   (Adult, Older Adult)",Phase 4,40,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2008_024|MK0653-154,Jul-06,May-08,null,17-Sep-08,null,17-Sep-08,,,https://ClinicalTrials.gov/show/NCT00753883
NCT00754039,Study to Compare Welchol and TriCor to TriCor Alone in Patients With High Cholesterol,,Completed,No Results Available,"Hypercholesterolemia|Hyperlipidemia, Familial Combined",Drug: colesevelam HCl tablets and fenofibrate tablets|Drug: fenofibrate tablets and Welchol placebo tablets,% change in LDL-C from baseline|The absolute change in LDL-C from baseline|The absolute change and % change in LDL-C from week -8 (untreated)|The percentage of patients who achieved target LDL-C,"Daiichi Sankyo, Inc.",All,"30 Years to 70 Years   (Adult, Older Adult)",Phase 4,129,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",WEL-403,Feb-03,Sep-03,Mar-04,17-Sep-08,null,3-Apr-15,"Longwood, Florida, United States|Ocala, Florida, United States|Winterpark, Florida, United States|Chicago, Illinois, United States|Lombard, Illinois, United States|Overland Park, Kansas, United States|Stateville, North Carolina, United States|Cincinnati, Ohio, United States|San Antonio, Texas, United States|Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00754039
NCT00751608,Effect of APL180 on Endothelial Function in Familial Hypercholesterolemia Patients,,Withdrawn,No Results Available,Familial Hypercholesterolemia,Drug: APL180|Drug: Placebo,Change in forearm blood flow during each treatment,Novartis Pharmaceuticals|Novartis,All,18 Years to 50 Years   (Adult),Phase 2,0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",CAPL180A2207,Sep-06,Feb-09,Feb-09,12-Sep-08,null,23-Sep-16,,,https://ClinicalTrials.gov/show/NCT00751608
NCT00748852,Safety Study of JTT-302 in Subjects With Low HDL-C Levels,,Completed,No Results Available,Dyslipidemia,Drug: JTT-302,"Evaluate the safety profile of JTT-302 when administered for 8 weeks or 12 weeks|Percent change and change from baseline after four, eight or 12 weeks exposure to JTT-302 in Lipid Parameters",Akros Pharma Inc.,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,103,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AT302-U-06-004,Jan-07,Mar-08,Mar-08,9-Sep-08,null,4-Feb-13,"Santa Ana, California, United States",,https://ClinicalTrials.gov/show/NCT00748852
NCT00749788,Efficacy and Safety Study of JTT-302 in Subjects With Low HDL-C Levels,,Completed,No Results Available,Dyslipidemia,Drug: JTT-302|Drug: Placebo,Percent change from baseline in HDL-C at Week 4|Percent change and change from baseline at week 4 in lipid parameters|Evaluate the safety profile of JTT-302 when administered for 4 weeks,Akros Pharma Inc.,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,150,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",AT302-U-06-003,Dec-06,Feb-08,Feb-08,9-Sep-08,null,4-Feb-13,"Santa Ana, California, United States",,https://ClinicalTrials.gov/show/NCT00749788
NCT00749801,Efficacy and Safety of Geneferm Nattokinase,,Completed,No Results Available,Hyperlipidemia,Drug: Nattokinase,"Fibrinogen, FDP (fibrin degradation product), D-dimer, Total cholesterol, LDL-C (Low-density lipoprotein cholesterol), HDL-C (High-density lipoprotein cholesterol), Triglyceride (TG), and Uric acid|Vital signs and self-evaluated questionnaire","Chi Mei Medical Hospital|GeneFerm Biotechnology Co., Ltd.",All,"40 Years and older   (Adult, Older Adult)",Not Applicable,47,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",Geneferm-N01,May-07,Mar-08,Apr-08,9-Sep-08,null,9-Sep-08,"Chi Mei Medical Hospital, Tainan, Taiwan",,https://ClinicalTrials.gov/show/NCT00749801
NCT00746460,The Healthy Options Feasibility Study,,Completed,No Results Available,Obesity|Sedentary Lifestyle|Dyslipidemia|Hypertension|Cigarette Smoking|Diabetes,Behavioral: CVD risk profile,Feasibility of using health care providers other than physicians within a GMF to conduct a CV risk assessment and intervention on primary prevention patients|Patient's CV risk factors and overall CV risk|Subject's adherence with lifestyle changes and prescribed medications|Satisfaction of the nurse|Satisfaction of the patient,McGill University|Pfizer,All,"30 Years to 79 Years   (Adult, Older Adult)",Not Applicable,50,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,CLIN-08001,Jun-08,Apr-09,Oct-09,4-Sep-08,null,14-Jan-14,"McGill Cardiovascular Health Improvement Program, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00746460
NCT00746811,Trial to Assess the Effects of P-OM3 on LDL-C in Subjects With Primary Hypercholesterolemia,,Unknown status,No Results Available,Primary Hypercholesterolemia,Drug: P-OM3|Drug: Placebo,The primary outcome variable will be the percent change from baseline in LDL-C during each treatment.|Changes in other lipid and biomarker levels,Provident Clinical Research|GlaxoSmithKline,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 4,32,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",PRV-08007,Jan-10,Jul-10,Oct-10,4-Sep-08,null,28-Jan-10,"Provident Clinical Research, Addison, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00746811
NCT00745407,Effects of Fenofibrate on Adipocytokine Levels In Hypertriglyceridemic Patients,,Completed,No Results Available,Hypertriglyceridemia,Drug: fenofibrate,,Gachon University Gil Medical Center,All,"25 Years to 80 Years   (Adult, Older Adult)",Phase 4,null,Other,Interventional,Intervention Model: Crossover Assignment|Primary Purpose: Treatment,GMC 200511,Jan-05,null,Aug-08,3-Sep-08,null,3-Sep-08,"Gil Medical Center, Incheon, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT00745407
NCT00745836,Effects of Atorvastatin on Adiponectin Levels and Insulin Sensitivity In Hypercholesterolemic Patients,,Completed,No Results Available,Hypercholesterolemia,Drug: statin,,Gachon University Gil Medical Center,All,"25 Years to 80 Years   (Adult, Older Adult)",Phase 4,null,Other,Interventional,Intervention Model: Parallel Assignment|Primary Purpose: Treatment,GMC-200508,Jan-05,null,Aug-08,3-Sep-08,null,3-Sep-08,"Gil Medical Center, Incheon, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT00745836
NCT00741715,Evaluation of Efficacy and Safety of AVE5530 Co-administered With Atorvastatin in Primary Hypercholesterolemia,,Terminated,No Results Available,Hypercholesterolemia,Drug: AVE5530|Drug: atorvastatin|Drug: placebo,"Percent change from baseline in calculated LDL-C|Percent change from baseline in total cholesterol, HDL-C, TG, Apo-A1, Apo-B and CRP",Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1736,Industry,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",EFC6911,Aug-08,May-09,Jun-09,26-Aug-08,null,16-May-16,"Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Puerto Rico, Puerto Rico",,https://ClinicalTrials.gov/show/NCT00741715
NCT00739999,8-Week PK/PD Atorvastatin Study In Children And Adolescents With Heterozygous Familial Hypercholesterolemia,,Completed,Has Results,Pediatric Heterozygous Hypercholesterolemia,Drug: Atorvastatin,Parent-metabolite Population Pharmacokinetic (PK) Model for Atorvastatin and Its Metabolites: Atorvastatin Apparent Clearance (CL/F)|Parent-metabolite Population Pharmacokinetic (PK) Model for Atorvastatin and Its Metabolites: Apparent Volume of Distribution of the Central Compartment (Vc/F)|Absolute Change From Baseline in Pharmacodynamic Responses of Low-density Lipoprotein Cholesterol (LDL-C)|Percent Change From Baseline in Pharmacodynamic Responses of Low-density Lipoprotein Cholesterol (LDL-C)|Absolute Change From Baseline in Total Cholesterol (TC)|Percent Change From Baseline in Total Cholesterol (TC)|Absolute Change From Baseline in Triglycerides (TG)|Percent Change From Baseline in Triglycerides (TG)|Absolute Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C)|Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C)|Absolute Change From Baseline in Apolipoprotein A-1 (Apo A-1)|Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1)|Absolute Change From Baseline in Apolipoprotein B (Apo B)|Percent Change From Baseline in Apolipoprotein B (Apo B)|Absolute Change From Baseline in Very Low-density Lipoprotein-cholesterol (VLDL-C)|Percent Change From Baseline in Very Low-density Lipoprotein-cholesterol (VLDL-C)|Absolute Change From Baseline in Flow-Mediated Dilatation at Week 8|Percent Change From Baseline in Flow-Mediated Dilatation at Week 8,Pfizer,All,6 Years to 17 Years   (Child),Phase 1,39,Industry,Interventional,Intervention Model: Parallel Assignment|Masking: None (Open Label),A2581172,Dec-08,May-09,May-09,22-Aug-08,20-Aug-10,20-Aug-10,"Pfizer Investigational Site, Quebec, Canada|Pfizer Investigational Site, Athens, Greece|Pfizer Investigational Site, Oslo, Norway",,https://ClinicalTrials.gov/show/NCT00739999
NCT00738933,Dietary Phytosterols and Human Aortic Valve,,Unknown status,No Results Available,Hypercholesterolemia|Atherosclerosis,Dietary Supplement: Dietary plant stanols|Dietary Supplement: Dietary plant sterols|Dietary Supplement: placebo,Composition of serum and aortic valve sterols at the time of aortic valve operation,Helsinki University|University of Eastern Finland,All,"40 Years to 80 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",231857,Apr-08,Dec-11,Dec-11,21-Aug-08,null,14-Feb-11,"Department of Medicine, Div. of Internal Medicine, Helsinki Univ. Central Hospital (HUCH), Helsinki, Finland",,https://ClinicalTrials.gov/show/NCT00738933
NCT00738985,Efficacy of Ezetimibe/Simvastatin 10/20 mg and MK0524A (1-2 g/Day) in Mixed Hyperlipidemia and Two or More Risk Factors,,Withdrawn,No Results Available,Cardiovascular Diseases|Hyperlipidemia,Drug: ezetimibe/simvastatin 10/20 mg + placebo|Drug: ezetimibe/simvastatin 10/20 mg + MK0524A,Lipid parameters efficacy comparing ezetimibe/simvastatin alone vs. ezetimibe/simvastatin plus MK0524A (CORDAPTIVE),Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|Merck Sharp & Dohme Corp.,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2008_019,Nov-09,Sep-10,Sep-10,21-Aug-08,null,24-Mar-15,,,https://ClinicalTrials.gov/show/NCT00738985
NCT00734032,A Phase II Clinical Study of SB-480848 in Dyslipidemic Patients,,Completed,Has Results,Atherosclerosis,Drug: SB480848 40mg EC Tablet|Drug: SB480848 80mg EC Tablet|Drug: SB480848 160mg EC Tablet|Drug: SB480848 Placebo Tablet,"Change From Baseline to Week 4 in Plasma Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Activity|Percent Inhibition of Lp-PLA2 Activity in Plasma Over Time|Change From Baseline in Lp-PLA2 Activity at Week 1, 2 and Follow-up",GlaxoSmithKline,All,"20 Years to 80 Years   (Adult, Older Adult)",Phase 2,107,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",LPL110118,26-Aug-08,16-Jan-09,16-Jan-09,13-Aug-08,12-Jan-18,12-Jan-18,"GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT00734032
NCT00730236,A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH),,Completed,Has Results,Homozygous Familial Hypercholesterolemia,Drug: AEGR-733,Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)|Percent Change From Baseline in Total Cholesterol (TC)|Percent Change From Baseline for Apolipoprotein B (Apo B)|Percent Change From Baseline in Triglycerides|Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C)|Percent Change From Baseline in Non-HDL-C|Percent Change From Baseline in Apolipoprotein AI (Apo AI)|Absolute Change From Baseline in Hepatic Fat Percent|Absolute Change From Baseline in Alanine Aminotransferase (ALT)|Absolute Change From Baseline in Aspartate Aminotransferase (AST)|Absolute Change From Baseline in Total Bilirubin|Absolute Change From Baseline in Weight,"Aegerion Pharmaceuticals, Inc.|FDA Office of Orphan Products Development",All,"18 Years and older   (Adult, Older Adult)",Phase 3,29,Industry|U.S. Fed,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AEGR-733-005 / UP1002,Dec-07,Sep-10,Oct-11,8-Aug-08,22-Feb-13,20-Mar-18,"Cedars-Sinai Medical Center, Los Angeles, California, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Robarts Research Institute, London, Ontario, Canada|Lipid Clinic and University of Montreal Community Genomic Medicine Center, Chicoutimi, Quebec, Canada|Dipartimento di Medicina Clinica e Della Patalogie Emergenti, Palermo, Sicily, Italy|Medicina Interna Universitaria, Ferrara, Italy|Centro Universitario Dislipidemie, Milano, Italy|Dipartimento di Clinica e Terapia Medica, Roma, Italy|Cardiology Research, Bloemfontein, South Africa|University of Capetown, Cape town, South Africa",,https://ClinicalTrials.gov/show/NCT00730236
NCT00728910,Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study,CENTAUR,Completed,Has Results,Dyslipidemia,Drug: Atorvastatin|Drug: ABT335|Drug: ER Niacin,The Apolipoprotein A-I Fractional Catabolic Rate (FCR)|Apo-A1 Production Rate|Post-prandial Triglyceride Incremental Area Under the Curve (iAUC),University of Pennsylvania|Abbott,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,25,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,807965 CNTR|CTRC #1123,Jun-08,Aug-09,Aug-09,6-Aug-08,29-Feb-16,29-Feb-16,"CTRC (Clinical Translational Research Center), Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00728910
NCT00729027,Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing Statins in Patients With Primary Hypercholesterolemia,,Terminated,No Results Available,Hypercholesterolemia,Drug: 25 mg/day AVE5530|Drug: 50 mg/day AVE5530|Drug: placebo,Percent change from baseline in calculated LDL-C|Percent change from baseline in Total-Cholesterol and Apo-B,Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1015,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",EFC6910|EudraCT: 2008-001550,Jul-08,Jun-09,Jun-09,6-Aug-08,null,16-May-16,"Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|sanofi-aventis Australia & New Zealand administrative office, Macquarie Park, New South Wales, Australia|Sanofi-Aventis Administrative Office, Diegem, Belgium|Sanofi-Aventis Administrative Office, Laval, Canada|Sanofi-Aventis Administrative Office, Praha, Czech Republic|Sanofi-Aventis Administrative Office, Horsholm, Denmark|Sanofi-Aventis Administrative Office, Paris, France|Sanofi-Aventis Administrative Office, Berlin, Germany|Sanofi-Aventis Administrative Office, Budapest, Hungary|Sanofi-Aventis Administrative Office, Natanya, Israel|Sanofi-Aventis Administrative Office, Gouda, Netherlands|Sanofi-Aventis Administrative Office, Lysaker, Norway|Sanofi-Aventis Administrative Office, Warszawa, Poland|Sanofi-Aventis Administrative Office, Moscow, Russian Federation|Sanofi-Aventis Administrative Office, Barcelona, Spain|Sanofi-Aventis Administrative Office, Bromma, Sweden",,https://ClinicalTrials.gov/show/NCT00729027
NCT00728338,Docosahexenoic Acid (DHA) Supplementation and Cardiovascular Disease in Men With High Triglycerides,,Completed,No Results Available,Hypertriglyceridemia,Dietary Supplement: Docosahexenoic acid (DHA)|Dietary Supplement: Olive oil,Plasma biomarkers of inflammation|Granulocyte maturation|fasting and post-prandial serum lipids and lipoproteins|blood pressure and blood clotting|plasma biomarkers for diabetes,"USDA, Western Human Nutrition Research Center|VA Northern California Health Care System|DSM Nutritional Products, Inc.",Male,"39 Years to 66 Years   (Adult, Older Adult)",Not Applicable,40,U.S. Fed|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",WHNRC002,Jun-03,Nov-05,Nov-05,5-Aug-08,null,8-Aug-08,"Usda, Ars, Whnrc, Davis, California, United States",,https://ClinicalTrials.gov/show/NCT00728338
NCT00727857,Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.,,Completed,Has Results,Diabetes Mellitus,Drug: Pioglitazone and metformin|Drug: Pioglitazone|Drug: Metformin,Percent Change From Baseline in Glycosylated Hemoglobin|Change From Baseline in Fasting Plasma Glucose|Change From Baseline in Fasting Insulin|Change From Baseline in Homeostasis Model Assessment - Insulin Resistance|Median Percent Change From Baseline in High Sensitivity C-reactive Protein|Change From Baseline in Adiponectin|Change From Baseline in Total Cholesterol|Change From Baseline in Low-Density Lipoprotein Cholesterol|Change From Baseline in High-Density Lipoprotein Cholesterol|Change From Baseline in Triglycerides|Change From Baseline in Mean Low Density Lipoprotein Particle Concentration|Change From Baseline in Mean Low Density Lipoprotein Particle Size|Change From Baseline in Large Low Density Lipoprotein (L3) Concentration|Change From Baseline in Intermediate-Density Low Density Lipoprotein Concentration|Change From Baseline in Medium-Small Low Density Lipoprotein Concentration|Change From Baseline in Small Low Density Lipoprotein Concentration|Change From Baseline in Very Small Low Density Lipoprotein Concentration|Change From Baseline in Mean High Density Lipoprotein Particle Concentration|Change From Baseline in Mean High Density Lipoprotein Particle Size|Change From Baseline in Large High Density Lipoprotein (H4+H5) Concentration|Change From Baseline in Intermediate-Medium High Density Lipoprotein (H3) Concentration|Change From Baseline in Small High Density Lipoprotein (H1+H2) Concentration|Change From Baseline in Mean Very Low Density Lipoprotein Particle Concentration|Change From Baseline in Mean Very Low Density Lipoprotein Particle Size|Change From Baseline in Large-Chylomicrons Very Low Density Lipoprotein Concentration|Change From Baseline in Medium-Intermediate Very Low Density Lipoprotein (V3+V4) Concentration|Change From Baseline in Small Very Low Density Lipoprotein (V1+V2) Concentration,Takeda,All,"18 Years and older   (Adult, Older Adult)",Phase 3,600,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",01-06-TL-OPIMET-008|U1111-1114-0371,Jun-07,Aug-08,Aug-08,4-Aug-08,9-Mar-10,29-Jul-11,"Birmingham, Alabama, United States|Haleyville, Alabama, United States|Montgomery, Alabama, United States|Pell City, Alabama, United States|Phoenix, Arizona, United States|Tucson, Arizona, United States|Anaheim, California, United States|Artesia, California, United States|Dinuba, California, United States|Long Beach, California, United States|Los Angeles,, California, United States|Norwalk, California, United States|Orange, California, United States|Santa Ana, California, United States|Santa Monica, California, United States|Pueblo, Colorado, United States|Altamonte Springs, Florida, United States|Coral Gables, Florida, United States|Hialeah, Florida, United States|Miami,, Florida, United States|Panama City, Florida, United States|Plantation, Florida, United States|St Petersburg, Florida, United States|St. Cloud, Florida, United States|Tampa, Florida, United States|Columbus, Georgia, United States|Boise, Idaho, United States|Coeur d' Alene,, Idaho, United States|Chicago, Illinois, United States|Flossmoor, Illinois, United States|Peoria, Illinois, United States|Elkhart, Indiana, United States|Shawnee,, Kansas, United States|Southfield, Michigan, United States|Chesterfield, Missouri, United States|Billings, Montana, United States|Elizabeth, New Jersey, United States|Fayetteville, New York, United States|New York, New York, United States|Durham, North Carolina, United States|Pinehurst, North Carolina, United States|Cincinnati, Ohio, United States|Perrysburg, Ohio, United States|Zanesville, Ohio, United States|Oklahoma City, Oklahoma, United States|Eugene, Oregon, United States|Fleetwood, Pennsylvania, United States|Norristown, Pennsylvania, United States|Cranston, Rhode Island, United States|Simpsonville,, South Carolina, United States|Varnville, South Carolina, United States|Fayetteville, Tennessee, United States|Corpus Christi, Texas, United States|Dallas, Texas, United States|El Paso, Texas, United States|Houston, Texas, United States|McAllen, Texas, United States|Mission, Texas, United States|New Braunfels, Texas, United States|North Richland Hills, Texas, United States|San Antonio,, Texas, United States|Bountiful, Utah, United States|Salt Lake City, Utah, United States|Petersburg, Virginia, United States|Port Orchard, Washington, United States|Spokane, Washington, United States|Providencia-Santiago, Chile|Temuco, Chile|Zapopan, Jalisco, Mexico|Monterrey, Nuevo Leon, Mexico|Aibonito, Puerto Rico|Caguas, Puerto Rico|Ciales, Puerto Rico|Coto Laurel, Puerto Rico|Guayma, Puerto Rico|Guaynabo, Puerto Rico|Rio Piedras, Puerto Rico",,https://ClinicalTrials.gov/show/NCT00727857
NCT00724217,Standard Process 21 Day Purification Program Project,SPPP,Unknown status,No Results Available,Hyperlipidemia,Other: Standard Process 21 Day Purification Program (SPPP),"Serum lipids|Total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, homocysteine, C-reactive protein, blood pressure, heart rate variability, body mass index",Logan College of Chiropractic,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RD0530080135,Jul-08,Mar-09,Mar-09,29-Jul-08,null,29-Jul-08,"Logan College of Chiropractic, Chesterfield, Missouri, United States",,https://ClinicalTrials.gov/show/NCT00724217
NCT00722917,Efficacy and Safety of TAK-379 in Adult Subjects With Type 2 Diabetes Mellitus,,Terminated,No Results Available,Diabetes Mellitus,Drug: TAK-379|Drug: Pioglitazone|Drug: Placebo,Change from Baseline in Glycosylated Hemoglobin|Change from baseline in glycosylated hemoglobin.|Change from baseline in fasting plasma glucose.|Change from baseline in body weight.|Number of patients with elevation of alanine aminotransferase greater than three times the Upper Limit of Normal during treatment.|Plasma concentrations of TAK-379 and its metabolite M-I via a sparse sampling population approach.,Takeda,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,323,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TAK-379_201|U1111-1125-0948,Jul-08,Apr-09,Apr-09,28-Jul-08,null,22-Jun-16,"Artesia, California, United States|Norwalk, California, United States|Santa Ana, California, United States|Santa Monica, California, United States|Panama City, Florida, United States|Cranston, Rhode Island, United States|Dallas, Texas, United States|Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00722917
NCT00723385,Effects of Vitamin D on Lipids,,Completed,No Results Available,Hypercholesterolemia|Vitamin D Deficiency,Dietary Supplement: Vitamin D (1000 or 2000 IU/day)|Other: Placebo,LDL-cholesterol|Vitamin D and metabolite concentrations with supplementation and time course of repletion in deficient or insufficient subjects|Measures of inflammatory markers,"University of California, San Francisco|National Institute on Aging (NIA)",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,130,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",AG0104|5R01AG015982,Jul-08,Jul-12,Jul-12,28-Jul-08,null,8-Apr-15,"Jewish Home, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT00723385
NCT00718965,Evaluation of Efficacy and Safety of AVE5530 in Patients With Primary Hypercholesterolemia,,Terminated,No Results Available,Hypercholesterolemia,Drug: AVE5530|Drug: Placebo,percent change from baseline in calculated LDL-C|percent change from baseline in total cholesterol and Apo-B,Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,826,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",EFC6909,Jul-08,Nov-08,Jun-09,21-Jul-08,null,16-May-16,"Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Puerto Rico, Puerto Rico",,https://ClinicalTrials.gov/show/NCT00718965
NCT00713167,The Efficacy of Red Grape Seed Extract on Lipid Profile and Oxidized Low-Density Lipoprotein (OX-LDL),GSE,Completed,No Results Available,Hyperlipidemia,Drug: Grape Seed Extract (Vitagrape)|Drug: Placebo of Grape Seed Extract,OX-LDL|LDL|HDL|Blood Pressure|Triglyceride|Total Cholesterol|Body Mass Index|LDL/HDL,Shahid Beheshti University of Medical Sciences|Tabriz University,All,21 Years to 64 Years   (Adult),Phase 2|Phase 3,55,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SBMU 87-01-106-5694,Jul-08,Dec-08,Feb-09,11-Jul-08,null,21-May-09,"Ghorbanihaghjo, Tabriz, East Azarbayejan, Iran, Islamic Republic of|Maryam, Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT00713167
NCT00711919,Pitavastatin on Carotid Intima-media Thickness,PEACE,Unknown status,No Results Available,Hyperlipidemia|Carotid Artery Diseases,Drug: Pitavastatin,"absolute changes in carotid intima-media thickness from baseline to final visit|relative change in carotid intima-media thickness|change in LDL-C, HDL-C, TG and RLP-C|change in hs-CRP and IL-6|new onset or recurrence of ischemic heart disease, heart failure, stroke and atherosclerosis obliterans|sudden death|side effects",Kyoto Prefectural University of Medicine,All,"20 Years to 80 Years   (Adult, Older Adult)",Not Applicable,300,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,C-255|UMIN000001229,Jul-07,Dec-09,null,9-Jul-08,null,10-Sep-09,"Ayabe City Hospital, Ayabe, Kyoto, Japan|Fukuchiyama City Hospital, Fukuchiyama, Kyoto, Japan|Tanabe Central Hospital, Kyotanabe, Kyoto, Japan|Kumihama Hospital, Kyotango, Kyoto, Japan|Maizuru Medical Center, Maizuru, Kyoto, Japan|Maizuru Kyosai Hospital, Maizuru, Kyoto, Japan|Saiseikai Kyoto Hospital, Nagaokakyo, Kyoto, Japan|Nantan General Hospital, Nantan, Kyoto, Japan|Meiji University of Integrative Medicine Hospital, Nantan, Kyoto, Japan|Gakken Toshi Hospital, Seika, Kyoto, Japan|Uji Hospital, Uji, Kyoto, Japan|Kyoto Prefectural Yosanoumi Hospital, Yosano, Kyoto, Japan|Shiga Hospital, Higashioumi, Shiga, Japan|Omihachiman Community Medical Center, Omihachiman, Shiga, Japan|Saiseikai Shigaken Hospital, Rittou, Shiga, Japan|Takeda Hospital, Kyoto, Japan|Kyoto Prefectural University of Medicine, Kyoto, Japan|Kyoto First Red Cross Hospital, Kyoto, Japan",,https://ClinicalTrials.gov/show/NCT00711919
NCT00712049,Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT),NASCIT,Unknown status,No Results Available,Dyslipidemia|Atherosclerosis,Drug: simvastatin|Drug: Nicotinic Acid,"change of carotid and femoral IMT from baseline to 6 and 12 months follow up and occurrence of major adverse cardiovascular events (MACE)|changes of grey scale median (GSM) score from baseline to follow-up, and changes of serum levels of total cholesterol, low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), triglycerides and lipoprotein (a).",Medical University of Vienna,All,"18 Years and older   (Adult, Older Adult)",Phase 4,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Version 1.0-2007,Jun-08,null,null,9-Jul-08,null,22-Jul-11,"Medical University Vienna, Vienna, Austria",,https://ClinicalTrials.gov/show/NCT00712049
NCT00707993,Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics,,Completed,Has Results,Diabetes Mellitus,Drug: Alogliptin|Drug: Glipizide,Change From Baseline in Glycosylated Hemoglobin at Week 52.|Change From Baseline in Glycosylated Hemoglobin|Incidence of Hypoglycemia|Incidence of Marked Hyperglycemia (Fasting Plasma Glucose ≥200 mg Per dL).|Incidence of Hyperglycemic Rescue|Change From Baseline in Fasting Plasma Glucose|Change From Baseline in 2-hour Postprandial Glucose|Change From Baseline in Fasting Proinsulin|Change From Baseline in Insulin|Change From Baseline in Proinsulin/Insulin Ratio|Homeostasis Model Assessment of Beta Cell Function|Change From Baseline in Body Weight|Change From Baseline in Serum Lipids (Total Cholesterol)|Change From Baseline in Serum Lipids (High-Density Lipoprotein Cholesterol)|Change From Baseline in Serum Lipids (Low-Density Lipoprotein Cholesterol)|Change From Baseline in Serum Lipids (Triglycerides)|Change From Baseline in High Sensitivity C-reactive Protein|Incidence of Subjects Achieving Glycosylated Hemoglobin <=7%|Incidence of Glycosylated Hemoglobin Decrease From Baseline.,Takeda,All,65 Years to 90 Years   (Older Adult),Phase 3,441,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SYR-322_303|2008-000959-10|U1111-1112-7905,Jun-08,Aug-10,Aug-10,2-Jul-08,24-May-13,24-May-13,"Alexander City, Alabama, United States|Foothill Ranch, California, United States|Huntington Park, California, United States|Long Beach, California, United States|Los Angeles, California, United States|Redlands, California, United States|Prospect, Connecticut, United States|Bradenton, Florida, United States|Fort Myers, Florida, United States|Miami, Florida, United States|Ormond Beach, Florida, United States|Winter Park, Florida, United States|Roswell, Georgia, United States|Aurora, Illinois, United States|LaPorte, Indiana, United States|South Bend, Indiana, United States|Salisbury, Maryland, United States|Clarkston, Michigan, United States|Omaha, Nebraska, United States|Hamilton, New Jersey, United States|Albuquerque, New Mexico, United States|Beachwood, Ohio, United States|Westlake, Ohio, United States|Zanesville, Ohio, United States|Bensalem, Pennsylvania, United States|Aiken, South Carolina, United States|Greenville, South Carolina, United States|Greer, South Carolina, United States|Taylors, South Carolina, United States|Corpus Christi, Texas, United States|Dallas, Texas, United States|Pasadena, Texas, United States|San Antonio, Texas, United States|Tomball, Texas, United States|Ogden, Utah, United States|Salt Lake City, Utah, United States|Budapest, Hungary|Miskoic, Hungary|Nyiregyhaza, Hungary|Karnal, Haryana, India|Bangalore, Karnataka, India|Belgaum, Karnataka, India|Mumbai, Maharashrta, India|Ashkelon, Israel|Haifa, Israel|Holon, Israel|Nahariya, Israel|Rishon Le-Zion, Israel|Zefat, Israel|Saltillo, Coahuila, Mexico|Pachuca, Hidalgo, Mexico|Morelia, Michoacan, Mexico|Monterrey, Nuevo Leon, Mexico|Aguascalientes, Mexico|Durango, Mexico|Guadalajara, Mexico|Mexico DF, Mexico|Nezahualcoyotl, Mexico|Arequipa, Peru|Lima, Peru|Piura, Peru|Gdansk, Poland|Krakow, Poland|Warszawa, Poland|Baia Mare, Romania|Brasov, Romania|Bucharest, Romania|Galati, Romania|Satu Mare, Romania|Arkhangelsk, Russian Federation|Irkutsk, Russian Federation|Smolensk, Russian Federation|Cape Town, South Africa|Centurion, South Africa|Durban, South Africa|Johannesburg, South Africa|Port Elizabeth, South Africa|Pretoria, South Africa|Donetsk, Ukraine|Kharkiv, Ukraine",,https://ClinicalTrials.gov/show/NCT00707993
NCT00708370,A Study to Evaluate the Efficacy of a Counselling and Advisory Care for Health (COACH) Program in Dyslipidemic Patients.,DISSEMINATE,Completed,No Results Available,Dyslipidemia,Other: COACH|Other: No intervention for placebo,"Percentage (%) change from baseline to week 24 in serum LDL-C levels.|Subjects' lifestyle modification as assessed by the incidence and frequency of smoking, consumption of foods high in salt, sugar and/or fat content, alcohol consumption, and exercise habits at baseline and weeks 24 and 36.|Percentage (%) change from baseline in serum LDL-C (week 36), TC (week 24 and 36), HDL-C (week 24 and 36), TG (week 24 and 36) and TC/HDL-C ratio (week 24 and 36).|Subjects' satisfaction with the Health Booklet and the COACH program after 24 weeks.|Absolute change in SBP and DBP from baseline to weeks 24 and 36.|Percentage (%) change in Framingham CHD risk score from baseline to weeks 24 and 36.",Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 4,297,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),A2581162,Aug-08,May-10,Jun-10,2-Jul-08,null,14-Apr-11,"Pfizer Investigational Site, Jitra, Kubang Pasu, Kedah, Malaysia|Pfizer Investigational Site, Kulim, Kedah, Malaysia|Pfizer Investigational Site, Sik, Kedah, Malaysia|Pfizer Investigational Site, Kubang Kerian, Kelantan, Malaysia|Pfizer Investigational Site, Cheras, Kuala Lumpur, Malaysia|Pfizer Investigational Site, Cheras, Kuala Lumpur, Malaysia|Pfizer Investigational Site, Nilai, Negeri Sembilan, Malaysia|Pfizer Investigational Site, Tampin, Negeri Sembilan, Malaysia|Pfizer Investigational Site, Bagan Serai, Perak, Malaysia|Pfizer Investigational Site, Lenggong, Perak, Malaysia|Pfizer Investigational Site, Slim River, Perak, Malaysia|Pfizer Investigational Site, Kapar, Selangor, Malaysia|Pfizer Investigational Site, Petaling Jaya, Selangor, Malaysia|Pfizer Investigational Site, Puchong, Selangor, Malaysia|Pfizer Investigational Site, Sungai Buloh, Selangor, Malaysia|Pfizer Investigational Site, Kemaman, Terengganu, Malaysia|Pfizer Investigational Site, Kerteh, Kemaman, Terengganu, Malaysia|Pfizer Investigational Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Pfizer Investigational Site, Kuala Lumpur, Malaysia|Pfizer Investigational Site, Kuala Lumpur, Malaysia|Pfizer Investigational Site, Melaka, Malaysia|Pfizer Investigational Site, Shah Alam, Malaysia",,https://ClinicalTrials.gov/show/NCT00708370
NCT00707746,Safety and Efficacy Study of ISIS 301012 (Mipomersen) Administration in High Risk Statin Intolerant Subjects,ASSIST,Completed,Has Results,Metabolic Diseases|Hyperlipidemias|Metabolic Disorder|Hypercholesterolemia|Dyslipidemias|Lipid Metabolism Disorders,Drug: mipomersen|Drug: placebo,Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at the Primary Efficacy Time Point|Low-density Lipoprotein Cholesterol at Baseline and the Primary Efficacy Time Point|Summary of Participants With Adverse Events|Percent Change From Baseline in Apolipoprotein B at the Primary Efficacy Time Point|Apolipoprotein B at Baseline and at the Primary Efficacy Time Point|Percent Change From Baseline in Total Cholesterol at the Primary Efficacy Time Point|Total Cholesterol at Baseline and at the Primary Efficacy Time Point|Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol at the Primary Efficacy Time Point|Non-High-Density Lipoprotein Cholesterol at Baseline and at the Primary Efficacy Time Point,"Kastle Therapeutics, LLC|Ionis Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,34,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",301012-CS19|2007-005140-24,Oct-08,Aug-10,Jan-11,1-Jul-08,5-Apr-13,9-Sep-16,"Amsterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT00707746
NCT00706849,Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease,RADICHOL II,Completed,Has Results,Heterozygous Familial Hypercholesterolemia|Coronary Artery Disease,Drug: mipomersen sodium|Drug: placebo,Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at the Primary Efficacy Time Point|LDL Cholesterol at Baseline and at the Primary Efficacy Time Point|Percent Change From Baseline in Apolipoprotein B at the Primary Efficacy Time Point|Apolipoprotein B at Baseline and at the Primary Efficacy Time Point|Percent Change From Baseline in Total Cholesterol at the Primary Efficacy Time Point|Total Cholesterol at Baseline and at the Primary Efficacy Time Point|Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol at the Primary Efficacy Time Point|Non-High-Density Lipoprotein Cholesterol at Baseline and at the Primary Efficacy Time Point,"Kastle Therapeutics, LLC|Ionis Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,124,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",301012-CS7,Jul-08,Dec-09,May-10,30-Jun-08,21-Mar-13,9-Sep-16,"La Jolla, California, United States|Los Angeles, California, United States|Mission Viejo, California, United States|Newport Beach, California, United States|Santa Ana, California, United States|Thousand Oaks, California, United States|Bridgeport, Connecticut, United States|Melbourne, Florida, United States|Pensacola, Florida, United States|Chicago, Illinois, United States|Naperville, Illinois, United States|Kansas City, Kansas, United States|Biddeford, Maine, United States|Scarborough, Maine, United States|Boston, Massachusetts, United States|Ann Arbor, Michigan, United States|St. Louis, Missouri, United States|Las Vegas, Nevada, United States|Concord, New Hampshire, United States|New York, New York, United States|The Rogosin Institute Comprehensive Lipid Control Center, New York, New York, United States|Charlotte, North Carolina, United States|Charlotte, North Carolina, United States|Durham, North Carolina, United States|Cincinnati, Ohio, United States|ResEvo, LLC, Cuyahoga Falls, Ohio, United States|Franklin, Ohio, United States|Oklahoma City, Oklahoma, United States|Portland, Oregon, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Dallas, Texas, United States|Grapevine, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Seattle, Washington, United States|Calgary, Alberta, Canada|Vancouver, British Columbia, Canada|Winnipeg, Manitoba, Canada|London, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Chicoutimi, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Sherbrooke, Quebec, Canada|St. Foy, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00706849
NCT00704314,Does Simvastatin Affect Insulin Sensitivity in Dyslipidemic Type 2 Diabetic Patients?,,Completed,No Results Available,Hypercholesterolemia|Diabetes|Cardiovascular Disease,Drug: Simvastatin|Drug: Placebo,insulin sensitivity|ectopic lipid deposition in liver and muscle,Medical University of Vienna|Austrian Science Fund (FWF)|European Foundation for the Study of Diabetes|EU grant|Merck Sharp & Dohme Corp.,All,"21 Years to 70 Years   (Adult, Older Adult)",Not Applicable,20,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",EK: 258/2002,Oct-02,Jul-05,Jul-05,24-Jun-08,null,24-Jun-08,"Medical University of Vienna, Vienna, Austria",,https://ClinicalTrials.gov/show/NCT00704314
NCT00703690,MK0767 in Metabolic Syndrome-Dyslipidemia (0767-016),,Terminated,No Results Available,Metabolic X Syndrome Dyslipidemia,Drug: MK0767|Drug: Comparator: fenofibrate|Drug: Comparator: Placebo (unspecified),a dose-response will be seen across the doses of MK0767 and placebo in lowering fasting triglyceride.|MK0767 will be safe and well tolerated,Merck Sharp & Dohme Corp.,All,"21 Years to 65 Years   (Adult, Older Adult)",Phase 2,436,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0767-016|MK0767-016|2007_641,Jan-02,Dec-03,Dec-03,23-Jun-08,null,12-Jun-15,,,https://ClinicalTrials.gov/show/NCT00703690
NCT00701727,Ezetimibe Reverse Cholesterol Transport (RCT) Pilot Study,,Completed,Has Results,Hypercholesterolemia,Drug: ezetimibe|Drug: Placebo,"Fecal Excretion of Plasma-derived Cholesterol|Change From Baseline in Total Cholesterol, From Fasting Plasma Samples|de Novo Cholesterol Synthesis (DNC)|Cholesterol Efflux Rate (Ra Cholesterol)|Triglycerides (TG)|Low-density Lipoprotein (LDL);|High-density Lipoprotein (HDL)",Radiant Research,All,"21 Years to 75 Years   (Adult, Older Adult)",Phase 4,31,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Ezetimibe RCT-001,Jun-08,Mar-09,Mar-09,19-Jun-08,18-Apr-11,18-Apr-11,"Radiant Research, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00701727
NCT00701883,Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol,MBX-8025,Completed,No Results Available,Hyperlipidemia,Drug: Placebo|Drug: MBX-8025|Drug: Atorvastatin,Lipid levels will be measured in patients with hyperlipidemia to assess the benefits of the investigational drug,"CymaBay Therapeutics, Inc.",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,183,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","70,961|M8025-20711",Aug-07,Aug-08,Aug-08,19-Jun-08,null,12-Jun-15,"Radiant Research, Birmingham, Alabama, United States|Anasazi Internal Medicine Research, Phoenix, Arizona, United States|Diabetes/Lipid Management and Research Center, Huntington Beach, California, United States|Radiant Research, Santa Rosa, California, United States|Clinical Research Consulting LLC, Milford, Connecticut, United States|Genesis Research International, Indianapolis, Indiana, United States|Midwest Institute for Clinical Research Inc., Indianapolis, Indiana, United States|L-Marc Research Center, Louisville, Kentucky, United States|Maine Research Associates, Auburn, Maine, United States|Health Trends Research LLC, Baltimore, Maryland, United States|Troy Internal Medicine Research, Troy, Michigan, United States|Bridgewater Medical Group, Bridgewater, New Jersey, United States|Clifton-Wallington Medical Group, Clifton, New Jersey, United States|Rochester Clinical Research, Albuquerque, New Mexico, United States|United Medical Associates P.C., Binghamton, New York, United States|Rochester Clinical Research, Rochester, New York, United States|Southgate Medical Group, West Seneca, New York, United States|Great Lakes Medical Research, Westfield, New York, United States|PharmQuest, Greensboro, North Carolina, United States|Crescent Medical Research, Salisbury, North Carolina, United States|Piedmont Medical Research Associates, Winston-Salem, North Carolina, United States|PHA-Adult Medicine, Philadelphia, Pennsylvania, United States|Radiant Research, Greer, South Carolina, United States|Tricities Medical Research, Bristol, Tennessee, United States|Holston Medical Group Clinical Research, Kingsport, Tennessee, United States|Dallas Diabetes and Endocrine Center, Dallas, Texas, United States|Diabetes and Glandular Disease Research, San Antonio, Texas, United States|Walla Walla Clinic, Walla Walla, Washington, United States",,https://ClinicalTrials.gov/show/NCT00701883
NCT00700037,Change in Plaque Characteristics With Atorvastatin,EASY-FIT,Completed,No Results Available,Acute Coronary Syndrome|Atherosclerosis|Dyslipidemia,Drug: high-dose atorvastatin|Drug: low-dose atorvastatin,Fibrous cap thickness by OCT|macrophage number,Wakayama Medical University,All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 4,70,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,wakayamamu08-001,Aug-09,Feb-12,Feb-12,18-Jun-08,null,29-Oct-14,"Wakayama Medical University, Wakayama, Japan",,https://ClinicalTrials.gov/show/NCT00700037
NCT00698256,"Effect of High Stanol Ester Dose on Serum Lipids, Carotenoids and Fat-soluble Vitamins",maxsta,Completed,No Results Available,Hypercholesterolemia,Dietary Supplement: vegetable oil-based spread and oat-based drink (no brand name available),"Serum lipids, Serum fat soluble vitamins and carotenoids, squalene and non-cholesterol sterols",Marjukka Kolehmainen|Raisio Plc|University of Eastern Finland,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,50,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care",132\\2007,Feb-08,May-08,Dec-08,17-Jun-08,null,17-Apr-12,"University of kuopio, Kuopio, Finland",,https://ClinicalTrials.gov/show/NCT00698256
NCT00699023,Ezetimibe and Statins on Postprandial Lipemia in Type 2 Diabetes,EZE,Completed,No Results Available,Postprandial Lipemia|Type 2 Diabetes,Drug: ezetimibe tablets|Drug: simvastatin tablets|Drug: placebo,Incremental AUC after a fat-rich meal of cholesterol concentration in chylomicron and VLDL fractions|Incremental AUC after a fat rich-meal of apo B48 concentration- marker of the number of intestinally derived lipoproteins- in chylomicron and VLDL|Fasting LDL concentration|Cholesterol/triglyceride ratio in postprandial chylomicrons and VLDL fractions.|Postprandial LDL size|Concentration and Composition of different lipoprotein subclasses in the fasting condition.,Federico II University,All,"40 Years to 65 Years   (Adult, Older Adult)",Phase 4,13,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",239/07,Jun-08,Oct-09,Oct-09,17-Jun-08,null,4-Nov-09,"Department of Clinical and Experimental Medicine, Federico II University Hospital,, Naples, Italy",,https://ClinicalTrials.gov/show/NCT00699023
NCT00697203,A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C),,Completed,No Results Available,Dyslipidemia,Drug: Placebo|Drug: Pravastatin|Drug: dalceptrapib,"Percentage and absolute change from baseline in HDL-C level\n|Change from baseline in: TC, TG, HDL-C, LDL-C, HDL-2, HDL-3, ApoAI, ApoAII, ApoB, ApoE, LpAI, oxidized LDL, and ratios of these lipid parameters\n|Fasting glucose and insulin levels|AEs, lab parameters, vital signs, ECG",Hoffmann-La Roche,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,292,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NC18589,Jul-05,May-06,May-06,13-Jun-08,null,2-Nov-16,"Mobile, Alabama, United States|Scottsdale, Arizona, United States|Newark, Delaware, United States|Miami, Florida, United States|Chicago, Illinois, United States|Evansville, Indiana, United States|Indianapolis, Indiana, United States|Iowa City, Iowa, United States|Overland Park, Kansas, United States|Wichita, Kansas, United States|Louisville, Kentucky, United States|Chalmette, Louisiana, United States|Slidell, Louisiana, United States|Auburn, Maine, United States|Scarborough, Maine, United States|Baltimore, Maryland, United States|Bethesda, Maryland, United States|Townson, Maryland, United States|St Louis, Missouri, United States|Concord, New Hampshire, United States|Charlotte, North Carolina, United States|Statesville, North Carolina, United States|Winston-salem, North Carolina, United States|Cincinnati, Ohio, United States|Springdale, Ohio, United States|Oklahoma City, Oklahoma, United States|Philidelphia, Pennsylvania, United States|Warminster, Pennsylvania, United States|Fort Worth, Texas, United States|Houston, Texas, United States|Richmond, Virginia, United States|Seattle, Washington, United States|Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00697203
NCT00696475,Diazoxide Choline in Hypertriglyceridemia,,Completed,No Results Available,Hypertriglyceridemia,Drug: Diazoxide choline|Drug: Placebo,"To assess the effect on triglycerides of repeated doses of Diazoxide Choline Controlled-Release Tablet over a period of 56 days in hypertriglyceridemic subjects|To assess the effect on other lipid parameters (LDL, HDL, VLDL, and non-HDL cholesterol), insulin, glucose and weight of repeated doses of Diazoxide Choline Controlled-Release Tablet over a period of 56 days in hypertriglyceridemic subjects|To assess the safety and tolerability of repeated doses of Diazoxide Choline Controlled-Release Tablet over a period of 56 days in hypertriglyceridemic subjects","Essentialis, Inc.|Medpace, Inc.",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,80,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PC007,Jun-08,Jan-09,Mar-09,12-Jun-08,null,8-Nov-10,"National Research Institute, Los Angeles, California, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Allied Research International/Cetero Research, Miami Gardens, Florida, United States|Meridien Research, Tampa, Florida, United States|Midwest Institute for Clinical Research, Indianapolis, Indiana, United States|L-MARC Research Center, Louisville, Kentucky, United States|St. Luke's Lipid and Diabetes Research Center, Kansas City, Missouri, United States|Piedmont Medical Research Associates, Winston Salem, North Carolina, United States|Metabolic and Atherosclerosis Research Center (MARC), Cincinnati, Ohio, United States|Sterling Research Group, Ltd, Cincinnati, Ohio, United States|Frederick C. Smith Clinic, Marion, Ohio, United States|TriCities Medical Research, Bristol, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT00696475
NCT00694109,An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia,,Completed,Has Results,"Lipid Metabolism, Inborn Errors|Hypercholesterolemia, Autosomal Dominant|Hyperlipidemias|Metabolic Diseases|Hyperlipoproteinemia Type II|Metabolism, Inborn Errors|Genetic Diseases, Inborn|Infant, Newborn, Diseases|Metabolic Disorder|Congenital Abnormalities|Hypercholesterolemia|Hyperlipoproteinemias|Dyslipidemias|Lipid Metabolism Disorders",Drug: Mipomersen Sodium,Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C)|Percent Change From Baseline in Apolipoprotein B (Apo B)|Percent Change From Baseline in Total Cholesterol|Percent Change From Baseline in Non High Density Lipoprotein Cholesterol (Non-HDL-C)|Percent Change From Baseline in Triglycerides|Percent Change From Baseline in Lipoprotein (a)|Percent Change From Baseline in LDL Particles' Size (Total)|Percent Change From Baseline in LDL Particles' Size (Large)|Percent Change From Baseline in LDL Particles' Size (Medium)|Percent Change From Baseline in LDL Particles' Size (Small)|Percent Change From Baseline in LDL Particles' Size (Very Small)|Percent Change From Baseline in HDL Particles' Size (Large)|Percent Change From Baseline in HDL Particles' Size (Medium)|Percent Change From Baseline in HDL Particles' Size (Small)|Percent Change From Baseline in Intermediate Density Lipoprotein Particles' Size|Percent Change From Baseline in Very Low Density Lipoprotein (VLDL) Particles' Size (Large) and Chylomicron Particles' Size|Percent Change From Baseline in VLDL Particles' Size (Medium)|Percent Change From Baseline in VLDL Particles' Size (Small)|Percent Change From Baseline in Total VLDL Particles' Size and Chylomicron Particles' Size|Change From Baseline in C-Reactive Protein|Percent Change From Baseline in Apolipoprotein A-1,"Kastle Therapeutics, LLC|Ionis Pharmaceuticals, Inc.",All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,144,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,301012-CS6|2005-003450-10,Apr-08,Sep-14,Sep-14,10-Jun-08,21-Dec-15,9-Sep-16,"Mission Viejo, California, United States|Newport Beach, California, United States|Bridgeport, Connecticut, United States|Melbourne, Florida, United States|Winter Park, Florida, United States|Chicago, Illinois, United States|Kansas City, Kansas, United States|Biddeford, Maine, United States|Boston, Massachusetts, United States|St Louis, Missouri, United States|Concord, New Hampshire, United States|New York, New York, United States|Charlotte, North Carolina, United States|Durham, North Carolina, United States|Cincinnati, Ohio, United States|Franklin, Ohio, United States|Portland, Oregon, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Seattle, Washington, United States|Sao Paulo, Brazil|Winnipeg, Manitoba, Canada|London, Ontario, Canada|Chicoutimi, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Sherbrooke, Quebec, Canada|Quebec, Canada|Singapore, Singapore|Observatory, South Africa|Parktown, South Africa|Taipei, Taiwan|London, United Kingdom",,https://ClinicalTrials.gov/show/NCT00694109
NCT00694239,Risk Assessment and Treat Compliance in Hypertension Education Trial,RATCHET,Completed,No Results Available,Hypertension|Dyslipidemia,Behavioral: Knowledge of Cardiovascular Risk Assessment,Medication Compliance|Patient perception of cardiovascular risk|Pilot Feasibility Study|Blood Pressure|Cholesterol Level|Framingham Risk Score (stroke and coronary artery disease),"Lawson Health Research Institute|University of Western Ontario, Canada|The Physicians' Services Incorporated Foundation",All,"30 Years to 84 Years   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R-07-053|13014E,May-07,Mar-11,Mar-11,10-Jun-08,null,30-Jun-11,"University of Western Ontario, London, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00694239
NCT00694616,Prevalence of Metabolic Syndrome in Obstructive Sleep Apnea (OSA) and Effect of Treatment With Continuous Positive Airway Pressure (Auto-CPAP) on Metabolic Syndrome,,Completed,No Results Available,Obstructive Sleep Apnea|Metabolic Syndrome,Device: AutoSet Spirit|Device: Modified-AutoSet Spirit,"Proportion of subjects satisfying the National Cholesterol Education Program-Adult Treatment Panel (NCEP-ATP III) criteria for the diagnosis of metabolic syndrome|Individual components of the NCEP-ATP III criteria (FBS, BP, LDL cholesterol, HDL cholesterol, triglycerides) and insulin resistance (assessed by HOMA-IR)","All India Institute of Medical Sciences, New Delhi",All,"30 Years to 65 Years   (Adult, Older Adult)",Not Applicable,90,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SKS/OSA/CPAP/2008,Jul-08,May-10,Dec-10,10-Jun-08,null,25-Jun-13,"All India Institute of Medical Sciences, New Delhi, India",,https://ClinicalTrials.gov/show/NCT00694616
NCT00690937,"A Multicenter, Active and Placebo-controlled Study of Enteric Coated Sevelamer in Patients With Mild to Moderate Hypercholesteremia",Sevelamer ECS,Completed,No Results Available,Hypercholesterolemia,Drug: Enteric coated sevelamer|Drug: Colesevelam Cholestagel|Drug: Placebo,"The primary safety endpoints are: The type and number of AEs and proportion of patients with AEs.|Assessment of clinical laboratory parameters including blood chemistry, liver function tests, and renal function tests and hematology (CBC).|The primary efficacy endpoint is: The percent change in LDL cholesterol from baseline.|The secondary efficacy endpoints are: the absolute change in LDL cholesterol from baseline.|The percent change in total cholesterol, HDL cholesterol and triglycerides from baseline.","Genzyme, a Sanofi Company|Manipal Acunova Ltd.|Sanofi",All,"18 Years and older   (Adult, Older Adult)",Phase 2,120,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,ECS00107|ELLS,Feb-08,Dec-08,Dec-08,5-Jun-08,null,19-Mar-14,"Diacon Hospital and Research Center, Bangalore, India|M S Ramaiah Medical College and Memorial Hospital, Bangalore, India|Appollo first Med Hospital, Chennai, India|Associates in Clinical Endocronolgy Education & Research (ACEER), Chennai, India|Care Hospital, Hyderabad, India|Diabetes Endocrine Nutrition Management and Research Center, Mumbai, India|P D Hinduja National Hospital and Medical Research Centre, Mumbai, India|Indraprastha Apollo Hospitals, New Delhi, India",,https://ClinicalTrials.gov/show/NCT00690937
NCT00691288,Effect of Omega-3 Fatty Acid Supplementation on Hypertriglyceridemia in HIV-infected Children,,Terminated,No Results Available,Hypertriglyceridemia,Drug: Omega Pure followed by placebo|Drug: Placebo followed by Omega Pure,"Percentage change in triglyceride levels|Changes in cholesterol profiles (LDL, HDL, and total:HDL ratio), amylase, platelet function, AST, and ALT|Reporting of side effects, compliance, and discontinuation|Effect on control of HIV (vial load, CD4)",The Hospital for Sick Children|Canadian Foundation for AIDS Research (CANFAR)|The Physicians' Services Incorporated Foundation|Ocean Nutrition,All,"5 Years to 18 Years   (Child, Adult)",Phase 2,13,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",1000011295,Jun-08,Oct-11,Dec-12,5-Jun-08,null,12-Jun-14,"The Hospital for Sick Children, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00691288
NCT00690443,Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in Hypercholesterolemia,,Completed,Has Results,Hypercholesterolemia,Drug: Atorvastatin|Drug: AEGR-733,"Percent Change in LDL-C After 8 Weeks of Therapy|Percent Changes in LDL-C at Week 4 + Baseline Serum Lipoproteins (TC, Non-HDL, VLDL, TGs, HDL-C, Apolopoproteins A1 and B), High Sensitivity C-reactive Protein and Change in Body Weight.","Aegerion Pharmaceuticals, Inc.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,44,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",AEGR-733-006,May-08,Sep-08,Sep-08,4-Jun-08,25-Feb-13,23-Feb-18,"Linda Murray, DO - Radiant Research, Pinellas Park, Florida, United States|Sheila Rodstein, MD, Edina, Minnesota, United States|Dennis McCluskey, MD - Radiant Research, Mogadore, Ohio, United States|Michele Reynolds, MD, Dallas, Texas, United States|William Jennings, MD - Radiant Research, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00690443
NCT00688558,Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels,,Completed,No Results Available,Dyslipidemia,Drug: JTT-705 600 mg and simvastatin 40 mg|Drug: Placebo and simvastatin 40 mg,% change from baseline in HDL-C; inhibition of CETP activity|% change from baseline in LDL-C and TC/HDL-C|Plasma concentration of JTT-705,Akros Pharma Inc.,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,92,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AT705-X-03-003,Feb-04,Dec-04,Mar-06,3-Jun-08,null,3-Jun-08,"Amsterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT00688558
NCT00688857,Open-label Pharmacokinetic Study of Diazoxide Choline Coated vs. Uncoated Formulations,,Completed,No Results Available,Hypertriglyceridemia,Drug: Diazoxide choline,Compare the pharmacokinetic (PK) profiles of diazoxide choline controlled-release coated tablets versus uncoated tablets in healthy volunteers under fed conditions.|Assess diazoxide choline pharmacokinetic (PK) parameters under fasted conditions|Assess the safety and tolerability of diazoxide choline controlled-release coated tablets versus uncoated tablets in healthy volunteers.,"Essentialis, Inc.|Cetero Research, San Antonio",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,12,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PK008,May-08,Jun-08,Jul-08,3-Jun-08,null,8-Nov-10,"PRACS Institute, Ltd. - Cetero Research, Fargo, North Dakota, United States",,https://ClinicalTrials.gov/show/NCT00688857
NCT00688896,Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia,,Completed,No Results Available,Type II Hyperlipidemia,Drug: JTT-705 600 mg and pravastatin 40 mg|Drug: JTT-705 300 mg and pravastatin 40 mg|Drug: Placebo and pravastatin 40 mg,% change from baseline in HDL-C; inhibition of CETP activity|% change from baseline in LDL-C and TC/HDL-C|Plasma concentration of JTT-705,Akros Pharma Inc.,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,155,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AT705-X-02-001,Jun-02,Apr-03,Mar-04,3-Jun-08,null,3-Jun-08,"Amsterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT00688896
NCT00689442,Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels,,Completed,No Results Available,Dyslipidemia,Drug: JTT-705 600 mg and atorvastatin 20 mg|Drug: Placebo and atorvastatin 20 mg,% change from baseline in HDL-C; inhibition of CETP activity|% change from baseline in LDL-C and TC/HDL-C|Plasma concentration of JTT-705,Akros Pharma Inc.,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,105,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AT705-X-03-002,Jan-04,Nov-04,Mar-06,3-Jun-08,null,3-Jun-08,"Amsterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT00689442
NCT00687271,A Study of MK-6213 Co-Administered With Atorvastatin in Participants With Hypercholesterolemia (MK-6213-006),,Completed,Has Results,Hypercholesterolemia,Drug: MK-6213|Drug: Atorvastatin calcium|Drug: Placebo for MK-6312 160 mg|Drug: Placebo for Atorvastatin 20 mg,Percentage Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)|Percentage of Participants Who Experience at Least 1 Adverse Event (AE)|Percentage of Participants That Had Study Drug Discontinued Due to an AE|Percentage Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)|Percentage Change From Baseline in Apolipoprotein B (ApoB)|Percentage Change From Baseline in Total Cholesterol (TC)|Percentage Change From Baseline in HDL-C|Percentage Change From Baseline in TG,Merck Sharp & Dohme Corp.,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,334,Industry,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",6213-006|2007_514|2007-003684-41|MK-6314-006,14-Jun-08,8-Jan-09,8-Jan-09,30-May-08,1-Nov-18,14-Jan-19,,,https://ClinicalTrials.gov/show/NCT00687271
NCT00686010,"Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia",,Completed,No Results Available,Type II Hyperlipidaemia,Drug: Placebo|Drug: JTT-705 300mg|Drug: JTT-705 600mg|Drug: JTT-705 900mg,"%change from baseline in HDL-C, Inhibition of CETP activity|%change from baseline in LDL-C and TC/HDL ratio",Japan Tobacco Inc.,All,"22 Years to 65 Years   (Adult, Older Adult)",Phase 2,198,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CAY2-1,May-00,Jan-01,Jun-01,29-May-08,null,29-May-08,"Amsterdam, Utrecht, Rotterdam, Nijmegen, Arnhem, Groningen, Dordrecht, Hoorn, Groningen, Amsterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT00686010
NCT00685737,Safety of a Hypolipidemic Agent in Healthy Normal Volunteers,PNAI-002,Completed,No Results Available,Hyperlipidemia,Drug: 1-MNA|Drug: Placebo,The single dose pharmacokinetics and safety of 1-MNA and an assessment of any gender-based differences in plasma pharmacokinetics|The effect of 1-MNA on triglycerides and lipase activity and lipid profiles after single oral dosages,Pharmena North America,All,18 Years to 50 Years   (Adult),Phase 1,20,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",PNAI-002,Dec-07,Jun-08,Jun-08,28-May-08,null,27-Jun-08,"Buffalo Clinical Research Center, Buffalo, New York, United States",,https://ClinicalTrials.gov/show/NCT00685737
NCT00683618,Compare the Efficacy of Rosuvastatin to Atorvastatin in High Risk Patients With Hypercholesterolemia,,Completed,Has Results,Hypercholesterolemia,Drug: Rosuvastatin|Drug: Atorvastatin,Percentage Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) Concentration After 6 Weeks of Treatment Comparing Rosuvastatin 5mg With Atorvastatin 10mg|Percentage Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) Concentration After 6 Weeks of Treatment Comparing Rosuvastatin 10mg With Atorvastatin 10mg|Percentage Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) at Week 6|Percentage Change From Baseline in Total Cholesterol (TC ) at Week 6|Percentage Change From Baseline in Triglycerides (TG) at Week 6|Percentage Change From Baseline in Non High Density Lipoprotein-Cholesterol (nonHDL-C) at Week 6|Percentage Change From Baseline in Apolipoprotein B (ApoB) at Week 6|Percentage Change From Baseline in Apolipoprotein A-I (ApoA-I) at Week 6|Percentage Change From Baseline in Total Cholesterol/High Density Lipoprotein-Cholesterol (TC/HDL-C) at Week 6|Percentage Change From Baseline in Low Density Lipoprotein Cholesterol/High Density Lipoprotein Cholesterol (LDL-C/HDL-C) at Week 6|Percentage Change From Baseline in Non High Density Lipoprotein Cholesterol/High Density Lipoprotein Cholesterol (nonHDL-C/HDL-C) at Week 6|Percentage Change From Baseline in Apolipoprotein B/Apolipoprotein A I (ApoB/ApoA-I) at Week 6|Percentage of Patients Achieved ATP III Guideline (2001) Low Density Lipoprotein Cholesterol (LDL-C) Goal at Week 6|6 weeksPercentage of Patients Achieved ATP III Guideline (2001) Non High Density Lipoprotein-Cholesterol (nonHDL-C) Goal at Week 6|Percentage of Patients Achieved National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) III Guideline (2001) Low Density Lipoprotein-Cholesterol (LDL-C) Goal After Titration,AstraZeneca,All,"18 Years and older   (Adult, Older Adult)",Phase 3,934,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D356FC00007,May-08,Jul-09,Jul-09,23-May-08,12-Mar-12,21-Mar-12,"Research Site, Wuhan, Hubei, China|Research Site, Changsha, Hunan, China|Research Site, Shenyang, Liaoning, China|Research Site, Beijing, China|Research Site, Shanghai, China|Research Site, Tianjin, China",,https://ClinicalTrials.gov/show/NCT00683618
NCT00680017,30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease,,Completed,Has Results,Dyslipidemia|Kidney Disease,Drug: ABT-335 plus rosuvastatin|Drug: Rosuvastatin,Median Percent Change in Triglycerides From Baseline to Week 8.|Mean Percent Change in High-Density Lipoprotein Cholesterol From Baseline to Week 8.,AstraZeneca,All,"18 Years and older   (Adult, Older Adult)",Phase 3,280,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",M10-313,Jun-08,Apr-11,Apr-11,19-May-08,16-Jul-12,3-Oct-12,"Site Reference ID/Investigator# 22521, Birmingham, Alabama, United States|Site Reference ID/Investigator# 22478, Huntsville, Alabama, United States|Site Reference ID/Investigator# 8365, Madison, Alabama, United States|Site Reference ID/Investigator# 8416, Montgomery, Alabama, United States|Site Reference ID/Investigator# 7869, Chula Vista, California, United States|Site Reference ID/Investigator# 8435, Fountain Valley, California, United States|Site Reference ID/Investigator# 22487, Lincoln, California, United States|Site Reference ID/Investigator# 22426, Long Beach, California, United States|Site Reference ID/Investigator# 8096, Los Angeles, California, United States|Site Reference ID/Investigator# 22962, Norwalk, California, United States|Site Reference ID/Investigator# 8311, Riverside, California, United States|Site Reference ID/Investigator# 22816, Sacramento, California, United States|Site Reference ID/Investigator# 8510, Simi Valley, California, United States|Site Reference ID/Investigator# 22821, West Hills, California, United States|Site Reference ID/Investigator# 7958, Arvada, Colorado, United States|Site Reference ID/Investigator# 15881, Denver, Colorado, United States|Site Reference ID/Investigator# 8399, Westminster, Colorado, United States|Site Reference ID/Investigator# 23224, Boynton Beach, Florida, United States|Site Reference ID/Investigator# 22474, Clearwater, Florida, United States|Site Reference ID/Investigator# 21803, Coral Springs, Florida, United States|Site Reference ID/Investigator# 22811, Daytona Beach, Florida, United States|Site Reference ID/Investigator# 27103, Hollywood, Florida, United States|Site Reference ID/Investigator# 8398, Hudson, Florida, United States|Site Reference ID/Investigator# 26723, Kissimmee, Florida, United States|Site Reference ID/Investigator# 37676, Kissimmee, Florida, United States|Site Reference ID/Investigator# 8231, Lauderdale Lakes, Florida, United States|Site Reference ID/Investigator# 22486, Longwood, Florida, United States|Site Reference ID/Investigator# 22520, New Port Richey, Florida, United States|Site Reference ID/Investigator# 8226, Orlando, Florida, United States|Site Reference ID/Investigator# 22477, Ormond Beach, Florida, United States|Site Reference ID/Investigator# 8386, Pembroke Pines, Florida, United States|Site Reference ID/Investigator# 22518, Plant City, Florida, United States|Site Reference ID/Investigator# 12882, Port Charlotte, Florida, United States|Site Reference ID/Investigator# 37675, St. Cloud, Florida, United States|Site Reference ID/Investigator# 8410, West Palm Beach, Florida, United States|Site Reference ID/Investigator# 21802, Winter Haven, Florida, United States|Site Reference ID/Investigator# 8136, Atlanta, Georgia, United States|Site Reference ID/Investigator# 23503, Dunwoody, Georgia, United States|Site Reference ID/Investigator# 7948, Macon, Georgia, United States|Site Reference ID/Investigator# 22819, Roswell, Georgia, United States|Site Reference ID/Investigator# 22813, Suwanee, Georgia, United States|Site Reference ID/Investigator# 27682, Chicago, Illinois, United States|Site Reference ID/Investigator# 8227, Peoria, Illinois, United States|Site Reference ID/Investigator# 13922, Mishawaka, Indiana, United States|Site Reference ID/Investigator# 8094, Council Bluffs, Iowa, United States|Site Reference ID/Investigator# 22430, Iowa City, Iowa, United States|Site Reference ID/Investigator# 8093, Paducah, Kentucky, United States|Site Reference ID/Investigator# 38405, Baton Rouge, Louisiana, United States|Site Reference ID/Investigator# 8903, Shreveport, Louisiana, United States|Site Reference ID/Investigator# 21805, Auburn, Maine, United States|Site Reference ID/Investigator# 8092, Rockville, Maryland, United States|Site Reference ID/Investigator# 8225, Fall River, Massachusetts, United States|Site Reference ID/Investigator# 8407, Springfield, Massachusetts, United States|Site Reference ID/Investigator# 8415, Royal Oak, Michigan, United States|Site Reference ID/Investigator# 22222, Brooklyn Center, Minnesota, United States|Site Reference ID/Investigator# 8408, Olive Branch, Mississippi, United States|Site Reference ID/Investigator# 22703, Berlin, New Jersey, United States|Site Reference ID/Investigator# 22707, Elizabeth, New Jersey, United States|Site Reference ID/Investigator# 22702, Hillsborough, New Jersey, United States|Site Reference ID/Investigator# 8387, Flushing, New York, United States|Site Reference ID/Investigator# 8177, Great Neck, New York, United States|Site Reference ID/Investigator# 8146, Lake Success, New York, United States|Site Reference ID/Investigator# 22427, Williamsville, New York, United States|Site Reference ID/Investigator# 22481, Charlotte, North Carolina, United States|Site Reference ID/Investigator# 22708, Charlotte, North Carolina, United States|Site Reference ID/Investigator# 8434, Morehead City, North Carolina, United States|Site Reference ID/Investigator# 8417, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 8147, Columbus, Ohio, United States|Site Reference ID/Investigator# 22488, Mason, Ohio, United States|Site Reference ID/Investigator# 22479, Oklahoma City, Oklahoma, United States|Site Reference ID/Investigator# 23225, Oklahoma City, Oklahoma, United States|Site Reference ID/Investigator# 22482, Tulsa, Oklahoma, United States|Site Reference ID/Investigator# 8345, Bend, Oregon, United States|Site Reference ID/Investigator# 22704, Medford, Oregon, United States|Site Reference ID/Investigator# 8400, Portland, Oregon, United States|Site Reference ID/Investigator# 8411, Bethlehem, Pennsylvania, United States|Site Reference ID/Investigator# 8405, Carlisle, Pennsylvania, United States|Site Reference ID/Investigator# 22387, Duncansville, Pennsylvania, United States|Site Reference ID/Investigator# 22815, Jersey Shore, Pennsylvania, United States|Site Reference ID/Investigator# 12881, Johnstown, Pennsylvania, United States|Site Reference ID/Investigator# 22706, Perkasie, Pennsylvania, United States|Site Reference ID/Investigator# 8095, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 22705, Tipton, Pennsylvania, United States|Site Reference ID/Investigator# 22817, Warminster, Pennsylvania, United States|Site Reference ID/Investigator# 8098, Providence, Rhode Island, United States|Site Reference ID/Investigator# 22823, Charleston, South Carolina, United States|Site Reference ID/Investigator# 8364, Columbia, South Carolina, United States|Site Reference ID/Investigator# 22429, Greenville, South Carolina, United States|Site Reference ID/Investigator# 22428, Mount Pleasant, South Carolina, United States|Site Reference ID/Investigator# 25302, Summerville, South Carolina, United States|Site Reference ID/Investigator# 22812, Dallas, Texas, United States|Site Reference ID/Investigator# 8536, Edinburg, Texas, United States|Site Reference ID/Investigator# 22810, Fort Worth, Texas, United States|Site Reference ID/Investigator# 24742, Houston, Texas, United States|Site Reference ID/Investigator# 26722, Houston, Texas, United States|Site Reference ID/Investigator# 8406, Houston, Texas, United States|Site Reference ID/Investigator# 8232, Lubbock, Texas, United States|Site Reference ID/Investigator# 22480, San Antonio, Texas, United States|Site Reference ID/Investigator# 8397, San Antonio, Texas, United States|Site Reference ID/Investigator# 21804, Ogden, Utah, United States|Site Reference ID/Investigator# 22423, Salt Lake City, Utah, United States|Site Reference ID/Investigator# 8413, Gig Harbor, Washington, United States|Site Reference ID/Investigator# 24402, Carolina, Puerto Rico|Site Reference ID/Investigator# 22545, Humacao, Puerto Rico|Site Reference ID/Investigator# 8301, Manati, Puerto Rico|Site Reference ID/Investigator# 8299, Ponce, Puerto Rico|Site Reference ID/Investigator# 8418, Ponce, Puerto Rico|Site Reference ID/Investigator# 8419, Ponce, Puerto Rico|Site Reference ID/Investigator# 8421, San Juan, Puerto Rico|Site Reference ID/Investigator# 8300, San Juan, Puerto Rico|Site Reference ID/Investigator# 8422, San Juan, Puerto Rico|Site Reference ID/Investigator# 8423, San Juan, Puerto Rico|Site Reference ID/Investigator# 8420, Toa Baja, Puerto Rico|Site Reference ID/Investigator# 8298, Yabucoa, Puerto Rico",,https://ClinicalTrials.gov/show/NCT00680017
NCT00678743,An Open-Label Extension to Assess the Continued Efficacy of Omacor Plus Simvastatin,,Unknown status,No Results Available,Mixed Dyslipidemia,Drug: Omacor + simvastatin,"The primary efficacy endpoint will be the percent change in non-HDL-C from baseline (average of weeks -2, -1, and 0) of the PRV-06009 double-blind study to Week 6 of PRV-06009X|The percent change in non-HDL-C from baseline (average of weeks -2, -1, and 0) of the PRV-06009 double-blind study to week 52 of PRV-06009X open-label treatment|The percent change in non-HDL-C from baseline (average of weeks -2, -1, and 0) of the PRV-06009 double-blind study to week 104 of PRV-06009X open-label treatment",Provident Clinical Research|Reliant Pharmaceuticals,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 4,13,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PRV-06009X,Aug-07,Aug-09,Sep-09,16-May-08,null,16-May-08,,,https://ClinicalTrials.gov/show/NCT00678743
NCT00678067,Effects of Docosahexaenoic and Eicosapentaenoic Acids in Hypercholesterolemic Children Plus Diet on Docosahexaenoic Acid (DHA) Status,DHA-RICHOIL,Completed,No Results Available,Hypercholesterolemia,Dietary Supplement: Docosahexaenoic acid|Dietary Supplement: Docosahexaenoic acid (DHA)+ Eicosapentaenoic acid (EPA)|Dietary Supplement: Germ oil|Other: National Cholesterol Education Program (NCEP) Step I Diet,Plasma Docosahexaenoic Acid (DHA) levels in DHA group and DHA+EPA group versus placebo after intervention|Blood lipid profile variation in DHA Group and DHA+EPA Group versus placebo group after intervention,University of Milan,All,3 Years to 13 Years   (Child),Not Applicable,36,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DHA-RICH1,Jun-05,Nov-06,Nov-06,15-May-08,null,19-May-08,,,https://ClinicalTrials.gov/show/NCT00678067
NCT00677248,LDL-Cholesterol Lowering Effect of KB2115 as Add on to Ezetimibe,,Completed,No Results Available,Hypercholesterolemia,Drug: Ezetimibe and placebo|Drug: Eprotirome and ezetimibe,LDL cholesterol|Triglycerides,Karo Bio AB,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,120,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2007-007831-24,Apr-08,Sep-08,Oct-08,14-May-08,null,1-Dec-08,"Karo Bio AB, HUddinge, Sweden",,https://ClinicalTrials.gov/show/NCT00677248
NCT00677313,An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy,,Completed,No Results Available,Lipodystrophy,Drug: metreleptin,"To provide metreleptin, an investigational medication, under a treatment protocol to subjects with lipodystrophy that is associated with diabetes mellitus and/or hypertriglyceridemia|To monitor the safety and tolerability of metreleptin in subjects with lipodystrophy that is associated with diabetes mellitus and/or hypertriglyceridemia|Information on the efficacy of metreleptin as assessed by its effects on fasting triglyceride concentrations, HbA1c, and fasting glucose concentrations in subjects with lipodystrophy that is associated with diabetes mellitus and/or hypertriglyceridemia",Bristol-Myers Squibb,All,"5 Years and older   (Child, Adult, Older Adult)",Not Applicable,41,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MB002-002|FHA101,Mar-09,Jan-15,Jan-15,14-May-08,null,30-Apr-15,"Research Site, Santa Barbara, California, United States|Research Site, Chicago, Illinois, United States|Research Site, Ann Arbor, Michigan, United States|Local Institution, Reno, Nevada, United States|Research Site, Greenville, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00677313
NCT00676260,Efficacy of Pioglitazone on Microcirculation in Type 2 Diabetes Patients Treated With Insulin,,Completed,No Results Available,Diabetes Mellitus,Drug: Pioglitazone|Drug: Placebo,Capillary filtration capacity.|Isovolumetric venous pressure.|Capillary pressure.|Postural vasoconstriction.|Maximum blood flow.|Capillary recruitment.|24-hour ambulatory blood pressure.|Interleukin-6|C-Reactive Protein.|Vascular Endothelium Growth Factor.,Takeda,All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 2,29,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AD4833/EC412|U1111-1114-1082,Dec-02,Aug-04,Aug-04,13-May-08,null,28-Feb-12,"Exeter, United Kingdom",,https://ClinicalTrials.gov/show/NCT00676260
NCT00673881,ABT-335 (Choline Fenofibrate) Reverse Cholesterol Transport (RCT) Study,,Completed,Has Results,Dyslipidemia,Drug: choline fenofibrate,Mean Change in Calculated Low Density Lipoprotein Cholesterol|Mean Change in Plasma Triglycerides|Mean Change in High Density Lipoprotein Cholesterol|Total Cholesterol|Plasma Cholesterol Efflux|Change in Plasma Cholesterol Ester Fractional Catabolic Rate (FCR)|Percent Change in de Novo Cholesterol Synthesis|Change in Neutral Sterol Excretion|Change in Bile Acid Excretion|Neutral Sterol Endogenous Excretion|Endogenous Bile Acid Excretion,Radiant Research,All,"21 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,25,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ABT-335-001,Mar-08,May-09,May-09,7-May-08,20-Apr-11,20-Apr-11,"Radiant Research, 515 N State St, #2700, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00673881
NCT00672633,Trial of Lovaza in Adolescents With Mild to Moderately Elevated Triglycerides,,Terminated,Has Results,Hypertriglyceridemia,Drug: Lovaza|Drug: Placebo,Fasting Triglycerides|LDL Cholesterol|HDL Cholesterol,Boston Children’s Hospital|GlaxoSmithKline,All,"10 Years to 19 Years   (Child, Adult)",Phase 2,25,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",8010028,Apr-08,Dec-11,Mar-12,6-May-08,29-May-13,29-May-13,"Children's Hospital Boston, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00672633
NCT00672919,Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone.,COMPLEMENT,Completed,No Results Available,Diabetes Mellitus,Drug: Pioglitazone,Change from Baseline in Triglyceride Levels|Change from Baseline in Total Cholesterol|Change from Baseline in direct Low Density Lipoprotein cholesterol|Change from Baseline in High Density Lipoprotein cholesterol|Change from Baseline in apolipoprotein B (apoB)|Change from Baseline in apolipoprotein A1 (apoA1)|Change from Baseline in Free Fatty Acids|Change from Baseline in Lipid Fractionation|Change from Baseline in C-reactive Protein,Takeda,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,305,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,01-03-TL-OPI-523|U1111-1115-8914,Nov-03,Aug-04,Aug-04,6-May-08,null,28-Feb-12,"Birmingham,, Alabama, United States|Tucson, Arizona, United States|Bellflower, California, United States|Burlingame, California, United States|Fresno,, California, United States|La Jolla, California, United States|Long Beach, California, United States|Pasadena, California, United States|Arvada, Colorado, United States|Norwalk, Connecticut, United States|Waterbury, Connecticut, United States|Aventura, Florida, United States|Hollywood, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|N. Miami Beach, Florida, United States|Tallahassee, Florida, United States|West Palm Beach, Florida, United States|Columbus,, Georgia, United States|Idaho Falls, Idaho, United States|Chicago Heights, Illinois, United States|Evansville,, Indiana, United States|Des Moines, Iowa, United States|Lafayette, Louisiana, United States|Fall River, Massachusetts, United States|Waltham, Massachusetts, United States|Tupelo, Mississippi, United States|Chesterfield, Missouri, United States|Omaha, Nebraska, United States|Staten Island, New York, United States|Raleigh, North Carolina, United States|Winston-Salem, North Carolina, United States|Centerville, Ohio, United States|Dayton, Ohio, United States|Medford, Oregon, United States|Meadville, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Warwick, Rhode Island, United States|Chattanooga, Tennessee, United States|Morristown, Tennessee, United States|Murfreesboro, Tennessee, United States|Nashville, Tennessee, United States|Arlington, Texas, United States|Houston, Texas, United States|Midland, Texas, United States|San Antonio, Texas, United States|Ogden, Utah, United States|Orange, Virginia, United States|Virginia Beach,, Virginia, United States|Man, West Virginia, United States|Wausau, Wisconsin, United States|Carolina, Puerto Rico|PoncE, Puerto Rico",,https://ClinicalTrials.gov/show/NCT00672919
NCT00669500,Body Worlds 3 Nutrition Display,,Completed,No Results Available,Obesity|Hyperlipidemia,Behavioral: Lifestyle intervention,"Determine the willingness of the public to participate in an intervention trial - NutritionQuest's Alive!TM - available in a public forum.|To determine among individuals enrolled in the Alive!TM intervention, changes in measurements of body composition from pre- to post-intervention.",Oregon Health and Science University,All,"Child, Adult, Older Adult",Not Applicable,3188,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,OHSU eIRB3694,Jul-07,Mar-08,Mar-08,30-Apr-08,null,28-Sep-11,"Oregon Health & Science University, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT00669500
NCT00668109,"Assessment of Efficacy of Vardenafil in Subjects With Erectile Dysfunction and Diabetes, Hypertension or Hyperlipidemia",LUTECIA,Completed,No Results Available,Erectile Dysfunction,"Drug: Levitra (Vardenafil, BAY38-9456)|Drug: Tadalafil",Sexual encounter profile question 3 observed within 15 minutes to 4 hours for vardenafil and 22 to 26 hours for the tadalafil group|Sexual encounter profile question 2|Hardness of erection|Other diary based variables|Safety and tolerability,Bayer,Male,"18 Years and older   (Adult, Older Adult)",Phase 3,614,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,10893,Dec-03,Jun-04,Jun-04,28-Apr-08,null,23-Dec-14,"Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Edegem, Belgium|Roeselare, Belgium|Barranquilla, Colombia|Bogotá, Colombia|Medellín, Colombia|Santa Fé de Bogotá, Colombia|Santafe de Bogotá, Colombia|Helsinki, Finland|Helsinki, Finland|Oulu, Finland|Freiburg, Baden-Württemberg, Germany|Stuttgart, Baden-Württemberg, Germany|Königsbrunn, Bayern, Germany|München, Bayern, Germany|München, Bayern, Germany|Weiden, Bayern, Germany|Marburg, Hessen, Germany|Hannover, Niedersachsen, Germany|Osnabrück, Niedersachsen, Germany|Westerstede, Niedersachsen, Germany|Mönchengladbach, Nordrhein-Westfalen, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Hamburg, Germany|Haifa, Israel|Jerusalem, Israel|Tel Aviv, Israel|Tel Hashomer, Israel|Catania, Italy|Milano, Italy|Milano, Italy|Milano, Italy|Padova, Italy|Pavia, Italy|Perugia, Italy|Pisa, Italy|Iguala, Guerrero, Mexico|Monterrey, Nuevo León, Mexico|Durango, Mexico|México, D. F., Mexico|México, D.F., Mexico|México, D.F., Mexico|Nijverdal, Netherlands|Utrecht, Netherlands|Moelv, Norway|Oslo, Norway|Sarpsborg, Norway|Trondheim, Norway|Callao, Peru|Lima, Peru|Lima, Peru|George, Eastern Cape, South Africa|Johannesburg, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Pietermaritzburg, Kwa Zulu Natal, South Africa|Newcastle, Kwa Zulu-Natal, South Africa|Durban, KwaZulu Natal, South Africa|Durban, KwaZulu- Natal, South Africa|Durban, KwaZulu-Natal, South Africa|Cape Town, Western Cape, South Africa|Cape Town, Western Cape, South Africa|San Juan de Alicante, Alicante, Spain|L'Hospitalet de Llobregat, Barcelona, Spain|Vigo, Pontevedra, Spain|A Coruña, Spain|Castellón de la Plana, Spain|Málaga, Spain|Palma de Mallorca, Spain|Zaragoza, Spain|Borås, Sweden|Skövde, Sweden|Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT00668109
NCT00665834,Comparison of Rosuvastatin and Atorvastatin in Patients With Acute Coronary Syndrome,,Completed,No Results Available,Dyslipidemia|Acute Coronary Syndromes,Drug: rosuvastatin|Drug: placebo|Drug: atorvastatin,Compare efficacy of rosuvastatin 20 mg versus atorvastatin 80 mg in measuring ApoB/ApoA ratio at 3 months in acute coronary syndrome patients receiving the study treatment after percutaneous coronary intervention (PCI).|Efficacy of rosuvastatin 20 mg versus atorvastatin 80 mg in reducing LDL-C 1 month and 3 months post PCI.|Efficacy of early-started rosuvastatin 20 mg versus placebo on hs-CRP from admission to start of study treatment post PCI.|Efficacy of rosuvastatin 20 mg versus atorvastatin 80 mg in reducing ApoB/ApoA-1 ratio at 1 month.,Queen's University|AstraZeneca,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,18,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DMED 938-06,Apr-06,Sep-07,Sep-07,24-Apr-08,null,29-Mar-16,"Kingston General Hospital, Kingston, Ontario, Canada|Vascular Disease Prevention and Research Centre, Hotel Dieu Hospital, Kingston, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00665834
NCT00666172,"Effects of Worksite Wellness Interventions on Vascular Function, Insulin Sensitivity and High-Density Lipoprotein in Overweight or Obese Women",,Completed,No Results Available,Atherosclerosis|Diabetes Mellitus|Obesity|Dyslipidemia|Hypertension,Behavioral: Exercise|Behavioral: Weight Loss,"Measure endothelial function determined by brachial artery reactivity to stress, at baseline/following 6m program participation comparison of change between subj randomized to exercise with weight-loss intervention vs. those randomized to exerci...","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)",Female,"18 Years and older   (Adult, Older Adult)",Phase 2,270,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,080108|08-H-0108,8-Apr-08,1-Nov-12,1-Nov-12,24-Apr-08,null,16-May-19,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00666172
NCT00666250,Effects of Xoçai Antioxidant Supplements on Atherosclerosis Risk Factors,,Completed,No Results Available,Hypertension|Dyslipidemia|Hyperglycemia,Dietary Supplement: Xocai Activ drink,Blood pressure|Plasma Lipids|Arterial Compliance|Fasting and post-challenge glucose and insulin|urine microalbumin/creatinine ratio,University of Utah,All,"18 Years to 95 Years   (Adult, Older Adult)",Not Applicable,10,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention,Xocai01,Jan-06,Apr-08,Apr-08,24-Apr-08,null,8-Feb-16,"Cardiovascular Genetics, University of Utah, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT00666250
NCT00664469,INdians Followed for INtensive Lipid Lowering Treatment and Its safetY,INFINITY,Terminated,No Results Available,Hypercholesterolemia,"Drug: ezetimibe|Drug: Comparator: Simvastatin 20, 40 and 80 mg|Drug: Comparator: Atorvastatin|Drug: Comparator: Rosuvastatin",The primary measure of efficacy will be the percentage of patients in each treatment arm achieving a target LDL-C > 2.0 mmol/L at week 6 assessment. This will be calculated as the percentage of patients achieving this end point at 6 weeks of treatment us,Sunnybrook Health Sciences Centre|Merck Frosst Canada Ltd.|Schering-Plough,All,"18 Years and older   (Adult, Older Adult)",Phase 3,64,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2008_006|MK0653-153,Aug-07,Mar-10,Nov-10,23-Apr-08,null,28-Jul-11,"Merck Frosst Canada Ltd., Kirkland, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00664469
NCT00664742,The Effect of Fluvastatin XL® Treatment in Patients With Metabolic Syndrome,,Completed,Has Results,Metabolic Syndrome,Drug: Fluvastatin XL®,"Change in Total Cholesterol (TC), High Density Lipoprotein-Cholesterol (HDL-C), Low Density Lipoprotein-Cholesterol (LDL-C) and Triglycerides (TG) Levels From Baseline to Week-6|Percentage of Participants Achieving Total Cholesterol (TC), Low Density Lipoprotein-Cholesterol (LDL-C), High Density Lipoprotein-Cholesterol (HDL-C) and Triglycerides (TG) Predefined Target Lipid Levels",Novartis,All,"20 Years to 90 Years   (Adult, Older Adult)",Phase 4,614,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CXUO320BTR03,Sep-06,Oct-07,Oct-07,23-Apr-08,17-May-11,17-May-11,"Götzepe Education and Research Hospital, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT00664742
NCT00664859,"12-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia",,Completed,No Results Available,Dyslipidemia,Drug: LCP-AtorFen,"The primary endpoints are the mean percent changes in non-HDL cholesterol, HDL cholesterol, TG levels from the double-blind baseline (Week 0) to end-of-treatment (Week 52), and from the open-label baseline (Visit 1) to Week 52 (Visit 8).|Number (percentage) of subjects at end-of-treatment (Visit 8; Week 52) who achieve the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) goal of non-HDL cholesterol of 30 mg/dL higher than the LDL cholesterol.",Veloxis Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,220,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LCP-AtorFen-2001-1X,Oct-07,Feb-09,Feb-09,23-Apr-08,null,19-Dec-14,"Radiant Research, 515 N State St, Suite 2700, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00664859
NCT00663234,IMPAACT P1063: Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia,,Terminated,Has Results,HIV Infections|Hyperlipidemia,Drug: Atorvastatin,Percentage of Participants Experiencing at Least One Treatment-related Adverse Event (AE)|Percentage of Participants Experiencing at Least One Adverse Event (AE)|Percentage of Participants Who Met the LDL Cholesterol (LDL-C) Efficacy Criteria (Intention to Treat)|Percentage of Participants Who Met the LDL Cholesterol (LDL-C) Efficacy Criteria (Data Available)|Percentage of Participants Who Met the LDL Cholesterol (LDL-C) Efficacy Criteria (Per Protocol)|Percentage of Participants Who Met the LDL Cholesterol (LDL-C) Efficacy Criteria and Did Not Experience a Primary Safety Endpoint Attributable to Study Drug|Percentage of Participants Who Met the LDL Cholesterol (LDL-C) Efficacy Criteria by Age Group|Percentage of Participants Who Met the LDL Cholesterol (LDL-C) Efficacy Criteria by NNRTI Treatment|Percent Change in LDL Cholesterol (LDL-C) From Study Entry|Percentage of Participants Experiencing at Least One Treatment-related Adverse Event (AE) by Age Group|Percentage of Participants Experiencing at Least One Adverse Event (AE) by Age Group|Percent Change in Fasting Total Cholesterol (TC) From Study Entry|Percent Change in Triglycerides (TG) From Study Entry|Percent Change in HDL-cholesterol (HDL-C) From Study Entry|Percent Change in Apolipoprotein A1 (Apo A-1) From Study Entry|Percent Change in Apolipoprotein B (Apo B) From Study Entry|Percent Change in High-sensitivity CRP (Hs-CRP) From Study Entry|Percent Change in Interleukin 6 (IL-6) From Study Entry|Percentage of Participants With Undetectable Plasma HIV-1 RNA,International Maternal Pediatric Adolescent AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),All,"10 Years to 23 Years   (Child, Adult)",Phase 1|Phase 2,28,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IMPAACT P1063|U01AI068632|10167,Aug-09,Dec-14,Dec-14,22-Apr-08,6-Apr-16,6-Apr-16,"Univ. of Colorado Denver NICHD CRS (5052), Aurora, Colorado, United States|Univ. of Miami Ped. Perinatal HIV/AIDS CRS (4201), Miami, Florida, United States|University of South Florida Tampa (5018), Tampa, Florida, United States|Chicago Children's CRS (4001), Chicago, Illinois, United States|Tulane University (5095), New Orleans, Louisiana, United States|Boston Medical Center Ped. HIV Program NICHD CRS (5011), Boston, Massachusetts, United States|Bronx-Lebanon Hospital IMPAACT CRS (6901), Bronx, New York, United States|New York University NY (5012), New York, New York, United States|Metropolitan Hospital (5003), New York, New York, United States|St. Jude/UTHSC CRS (6501), Memphis, Tennessee, United States|Texas Children's Hosp. CRS (3801), Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00663234
NCT00663845,Assessing Efficacy and Safety of Flexible Dosing With Vardenafil in Subjects With Erectile Dysfunction and Hyperlipidemia,,Completed,No Results Available,Erectile Dysfunction,"Drug: Levitra (Vardenafil, BAY38-9456)|Drug: Placebo",Sexual Encounter Profile Question 2 and 3 and International Index of Erectile Function - Erectile Function domain|Duration of erection leading to positive Sexual Encounter Profile Question 3|Safety and tolerability|Other patient diary based variables,Bayer|GlaxoSmithKline,Male,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,395,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",12165,May-06,null,Apr-07,22-Apr-08,null,11-Oct-13,,,https://ClinicalTrials.gov/show/NCT00663845
NCT00664287,Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082),,Withdrawn,No Results Available,Dyslipidemia,Drug: niacin (+) laropiprant|Drug: placebo (unspecified),"Lipid modification results of MK0524A (niacin (+) laropiprant) compared to placebo on LDL-C throughout the study and at 17 weeks.|Lipid modification results of MK0524A (niacin (+) laropiprant) on blood lipids such as LDL-C, HDL-C, triglycerides, etc., throughout the study and at 17 weeks.",Merck Sharp & Dohme Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 3,0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0524A-082|2008_504,Sep-08,Nov-09,null,22-Apr-08,null,9-Apr-15,,,https://ClinicalTrials.gov/show/NCT00664287
NCT00660075,Effects of Sitagliptin on Postprandial Lipemia in Men With Type 2 Diabetes,,Completed,Has Results,Diabetes Mellitus|Postprandial Lipemia,Drug: Sitagliptin|Drug: Placebo,"Measurement of the Area Under the Curve of Plasma Triglycerides (TG) Levels During Postprandial Period (Time 0,2,4,6,8 Hours)",Laval University|Merck Sharp & Dohme Corp.,Male,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,36,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SITA001,Feb-08,Jan-09,Apr-09,17-Apr-08,11-Dec-12,11-Dec-12,"Laval University Medical Center, Quebec City, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00660075
NCT00659321,Efficacy of Nicotine Acid on Dyslipidaemia in Patients With Metabolic Syndrome,,Completed,No Results Available,Metabolic Syndrome|Dyslipidaemia,Drug: nicotine acid|Drug: placebo,Placebo controlled evaluation of effectiveness of nicotine acid in treatment of postprandial dyslipidemia in patients with metabolic syndrome,GWT-TUD GmbH|Technische Universität Dresden|University of Regensburg,All,"30 Years to 75 Years   (Adult, Older Adult)",Phase 3,68,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",NIASPAN-DD-2005,Jan-07,Sep-08,Dec-08,16-Apr-08,null,11-Jan-12,"GWT-TUD GmbH, Centre for Clinical Studies, Dresden, Germany",,https://ClinicalTrials.gov/show/NCT00659321
NCT00656851,Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome,WU197,Completed,Has Results,HIV Infections|Cardiovascular Disease|Insulin Resistance|HIV Lipodystrophy|The Metabolic Syndrome,Drug: Pioglitazone|Behavioral: Exercise Training,Myocardial Glucose Utilization Rate|Myocardial Glucose Utilization Rate Per Unit Insulin|Myocardial Fatty Acid Utilization Rate|Myocardial Fatty Acid Oxidation Rate|Myocardial Fatty Acid Esterification|Myocardial Contractile Function During Diastole|Myocardial Contractile Function During Systole|Fasting Lipids and Lipoproteins|Fasting Glucose Insulin and HOMA,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,28 Years to 50 Years   (Adult),Not Applicable,24,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,DK59531 (completed)|HRPO 05-0976,Sep-05,Aug-09,Aug-10,11-Apr-08,20-Aug-13,28-Aug-13,"Washington University School of Medicine, St. Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT00656851
NCT00655863,Efficacy of Alogliptin and With Pioglitazone in Patients With Type 2 Diabetes.,,Completed,Has Results,Diabetes Mellitus,Drug: Alogliptin and Pioglitazone|Drug: Alogliptin|Drug: Placebo,Change From Baseline in Postprandial Incremental Area Under the Curve for Total Triglycerides at Week 16.|Change From Baseline in Postprandial Incremental Area Under the Curve for Total Triglycerides at Week 4.|Change From Baseline in Postprandial Incremental Area Under the Curve Changes for Lipid Parameters.|Change From Baseline in Postprandial Incremental Area Under the Curve for Lipoprotein Parameters.|Postprandial Changes Over Time From Baseline for Glucagon-like Peptide-1 (GLP-1)|Postprandial Changes Over Time From Baseline for Glucose|Postprandial Changes Over Time From Baseline for Insulin|Postprandial Changes Over Time From Baseline for Glucagon|Change From Baseline in Glycosylated Hemoglobin|Change From Baseline in Fasting Plasma Glucose|Change From Baseline in Postprandial C-Peptide|Change From Baseline in Postprandial Proinsulin|Change From Baseline in High-sensitive C-reactive Protein (Hs-CRP)|Change From Baseline in Adiponectin|Change From Baseline in Anti-Vascular Cell Adhesion Molecule (VCAM)|Change From Baseline in Anti-Intercellular Adhesion Molecule (ICAM)|Change From Baseline in e-Selectin|Change From Baseline in Endothelial Function Through Pulse Wave Tonometry,Takeda,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,71,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SYR-322_301|2007-000486-38|U1111-1113-2081|NL22649.029.08,Jul-07,Dec-09,Dec-09,10-Apr-08,27-May-13,27-May-13,"Amsterdam, Netherlands|Gothenburg, Sweden",,https://ClinicalTrials.gov/show/NCT00655863
NCT00655265,A Study of the Safety and Efficacy of Patients With Familial Hypercholesterolaemia Taking Colesevelam as add-on Therapy to Their Existing Medication,,Completed,No Results Available,Familial Hypercholesterolemia,Drug: Colesevelam hydrochloride film-coated tablets|Drug: Placebo,"Relative reduction in LDL cholesterol|Relative reduction in HDL, total cholesterol, ApoA1,ApoB,ApoB/ApoA1ratio, triglycerides","Genzyme, a Sanofi Company|Sanofi",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,86,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CHOL00107|EudraCT 2007-000582-37,Aug-07,Dec-08,Oct-09,9-Apr-08,null,11-Feb-14,"Service d'Endocrinologie, Metabolisme Prevention des Maladies Cardio-Vasculaires, Paris Cedex, France|Kardiologie, Marburg, Germany|Academic Medical Centre, Amsterdam, Netherlands|University Medical Centre, Nijmegen, Netherlands|University Medical Centre, Utrecht, Netherlands|TweeSteden Ziekenhius, Waalwijk, Netherlands|Centre for Metabolism and Endocrinology, Huddinge, Sweden|Department of Medicine, University of Manchester, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT00655265
NCT00654394,Progression of Carotid Artery Atheroma in Moderately Hypercholesterolemic Subjects,,Completed,No Results Available,Carotid Artery Stenosis|Hypercholesterolemia,Drug: Rosuvastatin,Changes in carotid wall volume as measured by MRI scan|Safety: adverse events & abnormal laboratory markers|Other changes in the structure and composition of the carotid arterial wall as defined in the protocol.,AstraZeneca,All,"18 Years and older   (Adult, Older Adult)",Phase 3,200,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,4522IL/0044|D3560C00044,Jan-00,null,Aug-04,8-Apr-08,null,16-Mar-09,,,https://ClinicalTrials.gov/show/NCT00654394
NCT00654407,Mercury II - Compare the Efficacy and Safety of Lipid Lowering Agents Atorvastatin and Simvastatin With Rosuvastatin in High Risk Subjects With Type IIa and IIb Hypercholesterolemia,,Completed,No Results Available,Hypercholesterolemia,Drug: Rosuvastatin|Drug: Atorvastatin|Drug: Simvastatin,Low density Lipoprotein cholesterol level - reaching internationally recognised LDL cholesterol goal levels.|Percentage change in other cholesterol & triglyceride measures|Safety evaluation|To compare the efficacy of rosuvastatin with atorvastatin and simvastatin,AstraZeneca,All,"18 Years and older   (Adult, Older Adult)",Phase 3,4875,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4522IL/0068|D3560C00068,Nov-01,null,Sep-04,8-Apr-08,null,16-Mar-09,,,https://ClinicalTrials.gov/show/NCT00654407
NCT00654446,IIIb 6 Week Open Label Multicentre Rosuvastatin & Simvastatin,,Completed,No Results Available,Fredrickson Type IIa & Type IIb Dyslipidaemia,Drug: Rosuvastatin|Drug: Simvastatin,Development of Proteinuria|Renal effects of rosuvastatin and simvastatin|Low density lipoproteins cholesterol levels|Safety: adverse events & abnormal laboratory markers,AstraZeneca,All,"18 Years and older   (Adult, Older Adult)",Phase 3,442,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4522IL/0099,Sep-02,null,Apr-04,8-Apr-08,null,16-Mar-09,,,https://ClinicalTrials.gov/show/NCT00654446
NCT00654537,"STELLAR-Rosuvastatin vs. Atorvastatin, Pravastatin, Simvastatin Across Dose Ranges",STELLAR,Completed,No Results Available,Hypercholesterolemia,Drug: Rosuvastatin|Drug: Atorvastatin|Drug: Pravastatin|Drug: Simvastatin,Percentage change in low density lipoprotein cholesterol.|Percentage change in other lipid parameters as defined by the protocol|Safety evaluation,AstraZeneca,All,"18 Years and older   (Adult, Older Adult)",Phase 3,5625,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4522IL/0065|D3560C00065,Apr-01,null,Oct-04,8-Apr-08,null,16-Mar-09,,,https://ClinicalTrials.gov/show/NCT00654537
NCT00654602,48-wk Open Label Phase IIIb to Evaluate Efficacy and Safety,,Completed,No Results Available,Dyslipidaemia,Drug: Rosuvastatin|Behavioral: Maintenance of specific diet,Reduction in low density lipoprotein cholesterol levels|Safety: adverse events & abnormal laboratory markers|Maintenance of lowered low density lipoprotein cholesterol level,AstraZeneca,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1500,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4522IL/0091|D3560C00091,Feb-02,null,Nov-04,8-Apr-08,null,28-May-09,,,https://ClinicalTrials.gov/show/NCT00654602
NCT00654628,Begin With The Right Patients With Dual-Inhibition Action Therapy Through Vytorin for Newly Diagnosed Dyslipidemia Patients (0653A-172)(COMPLETED),BRAVO,Completed,Has Results,Hypercholesterolemia,Drug: ezetimibe (+) simvastatin,The Percentage of Participants Achieving Low Density Lipoprotein-C (LDL-C) Treatment Goal After 6-week Treatment.|The Percentage of Participants Achieving Low Density Lipoprotein-C (LDL-C) Treatment Goal After 12-week Treatment.|Mean Percent Change From Baseline of Low Density Lipoprotein-Cholesterol (LDL-C) at Week 6|Mean Percent Change From Baseline of Total-Cholesterol (TC) at Week 6|Mean Percent Change From Baseline of High Density Lipoprotein-C (HDL-C) at Week 6|Mean Percent Change of Triglycerides From Baseline at Week 6|Mean Percent Change From Baseline of Low Density Lipoprotein-Cholesterol (LDL-C) at Week 12|Mean Percent Change From Baseline of Total-Cholesterol (TC) at Week 12|Mean Percent Change From Baseline of High Density Lipoprotein-C (HDL-C) at Week 12|Mean Percent Change of Triglycerides From Baseline at Week 12,Merck Sharp & Dohme Corp.,All,"20 Years to 79 Years   (Adult, Older Adult)",Phase 4,173,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0653A-172|2008_010,1-Aug-07,1-Jul-09,1-Jul-09,8-Apr-08,26-Aug-10,5-May-17,,,https://ClinicalTrials.gov/show/NCT00654628
NCT00653445,Compare the Safety & Efficacy of Rosuvastatin 40mg in Combination With Ezetimibe 10mg,EXPLORER,Completed,No Results Available,Hypercholesterolemia|Coronary Heart Disease|Atherosclerosis,Drug: Rosuvastatin|Drug: Ezetimibe,To compare the efficacy of rosuvastatin alone with rosuvastatin combined with ezetimibe by measuring fasting low-density lipoprotein cholesterol (LDL-C) levels at baseline and Week 6|To compare the efficacy of rosuvastatin alone with rosuvastatin combined with ezetimibe by measuring fasting blood lipid levels levels at baseline and Week 6|Safety: by measuring adverse events & abnormal laboratory markers to compare safety & tolerability of rosuvastatin alone with rosuvastatin combined with ezetimibe,AstraZeneca,All,"18 Years and older   (Adult, Older Adult)",Phase 3,null,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D3569C00006,Jun-04,null,Jun-05,7-Apr-08,null,26-Mar-09,,,https://ClinicalTrials.gov/show/NCT00653445
NCT00653523,Coadministration of Ezetimibe and Simvastatin in Patients With Primary Hypercholesterolemia (P05457),,Completed,Has Results,Hypercholesterolemia,Drug: Ezetimibe|Drug: Simvastatin,Number of Participants With Adverse Events and Adverse Reactions,Merck Sharp & Dohme Corp.,All,"20 Years and older   (Adult, Older Adult)",Phase 3,151,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P05457,1-Dec-07,1-Jun-09,1-Jun-09,7-Apr-08,30-Jun-10,10-May-17,,,https://ClinicalTrials.gov/show/NCT00653523
NCT00653588,Polaris - Crestor 40 mg vs Atorvastatin 80 mg for 26 Weeks,POLARIS,Completed,No Results Available,Hypercholesterolemia|Coronary Heart Disease,Drug: Rosuvastatin|Drug: Atorvastatin,To compare the efficacy of rosuvastatin with atorvastatin by assessing the percentage change from baseline to week 8 in LDL-C concentrations in subjects with hypercholesterolaemia and CHD or CHD risk equivalents.|To compare the efficacy of rosuvastatin with atorvastatin in modifying other lipids and lipoproteins at week 8,AstraZeneca,All,"45 Years to 75 Years   (Adult, Older Adult)",Phase 3,null,Industry,Interventional,Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,4522IL/0106|D3569C00005,Apr-03,null,Sep-04,7-Apr-08,null,16-Mar-09,,,https://ClinicalTrials.gov/show/NCT00653588
NCT00653744,Rosuvastatin Versus Atorvastatin in the Treatment of Hypercholesterolaemia in African American Subjects(ARIES),ARIES,Completed,No Results Available,Hypercholesterolemia|Dyslipidaemia,Drug: Rosuvastatin|Drug: Atorvastatin,Low density lipoproteins cholesterol levels|Other blood lipid level changes|Safety: adverse events & abnormal laboratory markers,AstraZeneca,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1700,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4522US/0002|D3560L00022,Mar-02,null,Mar-04,7-Apr-08,null,16-Mar-09,,,https://ClinicalTrials.gov/show/NCT00653744
NCT00653796,Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With High Cholesterol (P03434),,Completed,No Results Available,Hypercholesterolemia|Atherosclerosis,Drug: Ezetimibe + Atorvastatin|Drug: Atorvastatin,"Percent change in LDL-C from baseline to endpoint.|Percent change from baseline to endpoint in total cholesterol, HDL-C and triglycerides.|Safety: adverse events, laboratory test results, vital signs.",Merck Sharp & Dohme Corp.,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,148,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",P03434,1-Sep-03,1-Aug-04,1-Aug-04,7-Apr-08,null,11-May-17,,,https://ClinicalTrials.gov/show/NCT00653796
NCT00653835,Ezetimibe Plus Simvastatin Versus Simvastatin in Untreated Subjects With High Cholesterol (P03435),,Completed,No Results Available,Hypercholesterolaemia|Atherosclerosis,Drug: Ezetimibe + Simvastatin|Drug: Simvastatin,"Percent change in LDL-C from baseline to endpoint.|Percent of subjects who achieve LDL-C ESC goal (ie, <3 mmol/L [115 mg/dL]) at endpoint.|Percent change from baseline to endpoint in total cholesterol, HDL-C and triglycerides.|Safety: adverse events, laboratory test results, vital signs.",Merck Sharp & Dohme Corp.,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,153,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",P03435,1-Sep-03,1-Aug-04,1-Aug-04,7-Apr-08,null,11-May-17,,,https://ClinicalTrials.gov/show/NCT00653835
NCT00653913,Evaluation of Potential for Drug Interaction Between SCH 58235 (Ezetimibe) and Pitavastatin (Study P03962)(COMPLETED),,Completed,No Results Available,Hypercholesterolemia,Drug: SCH 58235|Drug: pitavastatin,"Compare plasma concentrations of SCH 58235 (ezetimibe) and pitavastatin after administration of each drug alone and in combination, using Cmax and AUC(0-24h).|Compare plasma concentrations of SCH 58235 (ezetimibe) and pitavastatin administration of each drug alone and in coadministration, using Tmax, plasma concentration 24 h after last dose, and AUC(I).|Adverse events, laboratory tests results, and vital signs.",Merck Sharp & Dohme Corp.,Male,"20 Years to 65 Years   (Adult, Older Adult)",Phase 1,18,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P03962,Mar-04,Sep-04,Sep-04,7-Apr-08,null,8-Apr-15,,,https://ClinicalTrials.gov/show/NCT00653913
NCT00653965,Treatment of Hypercholesterolaemia in Hispanic Subjects (STARSHIP),STARSHIP,Completed,No Results Available,Hypercholesterolemia|Dyslipidaemia,Drug: Rosuvastatin|Drug: Atorvastatin,Low density lipoproteins cholesterol levels|Other blood lipid level changes|Safety: adverse events & abnormal laboratory markers,AstraZeneca,All,"18 Years and older   (Adult, Older Adult)",Phase 3,3000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4522US/0007|D3560L00027,May-03,null,Feb-05,7-Apr-08,null,16-Mar-09,,,https://ClinicalTrials.gov/show/NCT00653965
NCT00654095,Coadministration of Ezetimibe and Atorvastatin in Patients With Primary Hypercholesterolemia (P05456),,Completed,Has Results,Hypercholesterolemia,Drug: Ezetimibe|Drug: atorvastatin,Number of Participants With Adverse Events and Adverse Reactions,Merck Sharp & Dohme Corp.,All,"20 Years and older   (Adult, Older Adult)",Phase 3,146,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P05456,1-Dec-07,1-Jun-09,1-Jun-09,7-Apr-08,5-Oct-10,9-May-17,,,https://ClinicalTrials.gov/show/NCT00654095
NCT00654173,Comparing the Efficacy and Safety of Rosuvastatin With Atorvastatin and Simvastatin (SOLAR),SOLAR,Completed,No Results Available,Hypercholesterolemia,Drug: Rosuvastatin|Drug: Simvastatin|Drug: Atorvastatin,"Percentage of subjects who achieve low density lipoprotein cholesterol goals while receiving treatment with rosuvastatin, compared to subjects receiving treatment with simvastatin or atorvastatin.|Percentage changes in other blood lipid levels while receiving treatment with rosuvastatin, compared to subjects receiving treatment with simvastatin or atorvastatin|Safety: adverse events & abnormal laboratory markers",AstraZeneca,All,"18 Years and older   (Adult, Older Adult)",Phase 3,4444,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4522US/0003|D3560L00023,Jun-02,null,Sep-04,7-Apr-08,null,16-Mar-09,,,https://ClinicalTrials.gov/show/NCT00654173
NCT00654225,Treatment of Hypercholesterolaemia in South Asian Subjects (IRIS),IRIS,Completed,No Results Available,Hypercholesterolemia|Dyslipidaemia,Drug: Rosuvastatin|Drug: Atorvastatin,Low density lipoproteins cholesterol levels|Safety: adverse events & abnormal laboratory markers,AstraZeneca,All,"18 Years and older   (Adult, Older Adult)",Phase 3,2340,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4522US/0006|D3560L00026,Oct-02,null,Mar-05,7-Apr-08,null,16-Mar-09,,,https://ClinicalTrials.gov/show/NCT00654225
NCT00652847,Randomized Parallel Group Trial Of The Efficacy And Safety Of Ezetimibe With A Statin Versus Statin Dose Doubling In Patients With Persistent Primary Hypercholesterolemia (0653-152)(COMPLETED),,Completed,No Results Available,Hypercholesterolemia,Drug: ezetimibe|Drug: statins,The primary measure of efficacy will be the percent change in plasma LDL-cholesterol between baseline and the final study assessment after six weeks of treatment.,Merck Sharp & Dohme Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 4,1140,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0653-152|MK0653-152|2008_005,May-05,May-07,May-07,4-Apr-08,null,13-Mar-17,,,https://ClinicalTrials.gov/show/NCT00652847
NCT00653185,Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus,,Completed,No Results Available,Diabetes Mellitus,Drug: SYR-472|Drug: Placebo,"Change from baseline in glycosylated hemoglobin|Change from baseline in fasting plasma glucose|1,5-Anhydroglucitol|Change in Proinsulin|Change in Proinsulin/insulin ratio|Change in baseline C-peptide|Change from baseline in insulin|Change in Homeostasis model assessment of beta cell function|Change in Homeostasis model assessment of insulin resistance|Incidence of rescue|Clinical response endpoint incidence of glycosylated hemoglobin less than or equal to 6.5%|Clinical response endpoint incidence of glycosylated hemoglobin less than or equal to 7.0%|Change from baseline in Fasting lipids (triglycerides, total cholesterol, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol)|Body weight",Takeda,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,369,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",01-06-TL-SYR-472-007|U1111-1183-0302,May-07,Mar-08,Mar-08,4-Apr-08,null,22-Jun-16,"Birmingham, Alabama, United States|Mobile, Alabama, United States|Montgomery, Alabama, United States|Pell City, Alabama, United States|Tallassee, Alabama, United States|Sierra Vista, Arizona, United States|Fountain Valley, California, United States|Los Angeles, California, United States|National City, California, United States|Pismo Beach, California, United States|Clearwater, Florida, United States|North Miami Beach, Florida, United States|Ocoee, Florida, United States|Orlando, Florida, United States|Plantation, Florida, United States|Dawsonville, Georgia, United States|Gainesville, Georgia, United States|Naperville, Illinois, United States|Elkhart, Indiana, United States|Indianapolis, Indiana, United States|Slidell, Louisiana, United States|Taunton, Massachusetts, United States|Ann Arbor, Michigan, United States|Great Falls, Montana, United States|Scottsbluff, Nebraska, United States|Las Vegas, Nevada, United States|Brooklyn, New York, United States|Charlotte, North Carolina, United States|Shelby, North Carolina, United States|Sparta, North Carolina, United States|Fargo, North Dakota, United States|Bensalem, Ohio, United States|Dayton, Ohio, United States|Kettering, Ohio, United States|Central Point, Oregon, United States|Altoona, Pennsylvania, United States|Providence, Rhode Island, United States|Clemson, South Carolina, United States|Columbia, South Carolina, United States|Greer, South Carolina, United States|Rapid City, South Dakota, United States|Cleveland, Tennessee, United States|Kingsport, Tennessee, United States|Arlington, Texas, United States|Fort Worth, Texas, United States|North Richland Hills, Texas, United States|San Antonio, Texas, United States|Spring, Texas, United States|Sugarland, Texas, United States|Hampton, Virginia, United States|Richmond, Virginia, United States|Santiago, Chile|Temuco, Chile|Ostrava, Czech Republic|Prague, Czech Republic|Guatemala, Guatemala|Quetzaltenango, Guatemala|Eger, Hungary|Szentes, Hungary|Riga, Latvia|Sigulda, Latvia|Valmiera, Latvia|Kaunas, Lithuania|Kedainiai, Lithuania|Klaipeda, Lithuania|Vilnius, Lithuania|Ponce, Puerto Rico|Alba Iulia, Romania|Baia Mare, Romania|Bihor, Romania|Brasov, Romania|Bucharest, Romania|Constanta, Romania|Ploiesti, Romania|Satu Mare, Romania|Targoviste, Romania|Kemerovo, Russian Federation|Moscow, Russian Federation|St. Petersburg, Russian Federation|Ufa, Russian Federation|Volgograd, Russian Federation|Yaroslavl, Russian Federation|Banska Bystrica, Slovakia|Bratislava, Slovakia|Presov, Slovakia|Kharkiv, Ukraine|Vinnytsya, Ukraine",,https://ClinicalTrials.gov/show/NCT00653185
NCT00651560,Vytorin As Strategy To Reduce Dislipidemia In Adults (0653A-148),,Completed,No Results Available,Hyperlipidemia,Drug: ezetimibe (+) simvastatin,Evaluate the hypolipidemic effect of Vytorin after 4 weeks treatment in adult patients with mix dislipidemia to reduce the cardiovascular risk and achieve the ATP-III goals.|To determine the capability of Vytorin to allow adults patients with dislipidemia and previously treated with atorvastatin to get further reduction of the cardiovascular risk and to achieve the ATP-III goals.,Merck Sharp & Dohme Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 3,167,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0653A-148|MK0653A-148|2008_008,1-Nov-05,23-Dec-05,23-Dec-05,3-Apr-08,null,29-Mar-17,,,https://ClinicalTrials.gov/show/NCT00651560
NCT00651963,Open Label Study Evaluating The Use Of Combination Therapy Of Ezetimibe And Statins In Patients With Dyslipidemia In Colombia (0653-141)(COMPLETED),,Completed,No Results Available,Lipid Metabolism Disorder,Drug: ezetimibe,Lipid profile,Merck Sharp & Dohme Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 4,80,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0653-141|MK0653-141|2008_007,Sep-04,Mar-05,Mar-05,3-Apr-08,null,13-Mar-17,,,https://ClinicalTrials.gov/show/NCT00651963
NCT00652327,Comparison of Ezetimibe Added to Ongoing Statin Therapy Versus Doubling the Dose of Statin in the Treatment of Hypercholesterolemia (P04355),,Completed,Has Results,Hypercholesterolemia,"Drug: Ezetimibe + Statin (simvastatin, atorvastatin, or pravastatin)|Drug: Double Statin (simvastatin, atorvastatin, or pravastatin)","Percentage Change in Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline at Study Endpoint, After 8 Weeks of Treatment",Merck Sharp & Dohme Corp.,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,83,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P04355,Dec-05,Jul-07,Jul-07,3-Apr-08,10-Jun-10,16-Jul-15,,,https://ClinicalTrials.gov/show/NCT00652327
NCT00652431,Assessment of Interaction Between Vytorin and Niaspan in Healthy Subjects (P04955AM2),,Completed,No Results Available,Hypercholesterolemia|Hyperlipidemia,Drug: Vytorin + Niaspan|Drug: Vytorin|Drug: Niaspan,"Evaluate the potential for a PK interaction between NIASPAN and components of VYTORIN, using Tmax, Cmax, and AUC.|Evaluate safety and tolerability: laboratory test results, ECGs, adverse events, vital signs.",Merck Sharp & Dohme Corp.,All,18 Years to 55 Years   (Adult),Phase 1,18,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P04955|Doc ID: 3498819,May-07,Jul-07,Jul-07,3-Apr-08,null,15-Nov-16,,,https://ClinicalTrials.gov/show/NCT00652431
NCT00652444,"Effect Of Ezetimibe Coadministration With Simvastatin In A Middle Eastern Population: A Prospective, Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial (0653-151)",,Completed,No Results Available,Hypercholesterolemia,Drug: ezetimibe|Drug: simvastatin|Drug: Placebo (Unspecified),Percentage reduction of LDL-C after 6 weeks of treatment.,Merck Sharp & Dohme Corp.,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,120,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0653-151|2008_004,Sep-03,Aug-04,Aug-04,3-Apr-08,null,22-Jan-16,,,https://ClinicalTrials.gov/show/NCT00652444
NCT00650663,Ezetimibe Plus Simvastatin Versus Simvastatin Alone in African-American Subjects With Primary Hypercholesterolemia (P03377),,Completed,No Results Available,Hypercholesterolemia|Atherosclerosis,Drug: Ezetimibe + Simvastatin|Drug: Simvastatin,"Percent change in LDL-C from baseline to endpoint.|Percent change from baseline to endpoint in TC, TG, HDL-C, non-HDL-C, and ApoB.",Merck Sharp & Dohme Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 4,247,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",P03377,1-Oct-03,1-Sep-04,1-Sep-04,2-Apr-08,null,11-May-17,,,https://ClinicalTrials.gov/show/NCT00650663
NCT00650689,Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With Primary Hypercholesterolemia and Coronary Heart Disease (P03396),,Completed,No Results Available,Hypercholesterolemia|Atherosclerosis|Coronary Artery Disease,Drug: Ezetimibe + Atorvastatin|Drug: Atorvastatin,"Change from baseline to endpoint in LDL-C.|Change from baseline to endpoint in total cholesterol, HDL-C, and triglycerides.|Safety/tolerability: adverse events, laboratory test results, vital signs",Merck Sharp & Dohme Corp.,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,122,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",P03396,May-03,Dec-04,Dec-04,2-Apr-08,null,7-Jul-15,,,https://ClinicalTrials.gov/show/NCT00650689
NCT00650819,Comparison of Ezetimibe Plus Simvastatin Versus Ezetimibe or Simvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03757)(COMPLETED),,Completed,No Results Available,Hypercholesterolemia,Drug: Ezetimibe + Simvastatin|Drug: Simvastatin|Drug: Ezetimibe,"Percent change from baseline in LDL-C concentration.|Percent change from baseline in total cholesterol, triglycerides, and HDL-C.",Merck Sharp & Dohme Corp.,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,240,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",P03757,1-Jun-04,1-Feb-05,1-Feb-05,2-Apr-08,null,11-May-17,,,https://ClinicalTrials.gov/show/NCT00650819
NCT00651014,Ezetimibe Plus Simvastatin Versus Simvastatin in Patients With Hypercholesterolemia and Coronary Risk Factors (P03405),,Terminated,No Results Available,Hypercholesterolemia|Atherosclerosis,Drug: Ezetimibe|Drug: Placebo,"Percentage of patients reaching LDL-C goal of < 2.5 mmol/L (97 mg/dL) at endpoint.|Percent change from baseline to endpoint in LDL-C.|Percent change from baseline to endpoint in total cholesterol (TC) triglycerides, HDL-C, non-HDL-C, LDL-C/HDL-C ratio, TC/HDL-C ratio, and apolipoprotein B.|Safety/tolerability: adverse events, laboratory test results, vital signs.",Merck Sharp & Dohme Corp.|Merck Frosst Canada Ltd.,All,"18 Years and older   (Adult, Older Adult)",Phase 4,82,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",P03405,Jan-04,Jun-06,Jun-06,2-Apr-08,null,16-Apr-15,,,https://ClinicalTrials.gov/show/NCT00651014
NCT00651144,Assessment of Potential Interaction Between Ezetimibe and Rosuvastatin in Healthy Subjects With High Cholesterol (P03317),,Completed,No Results Available,Hypercholesterolemia|Atherosclerosis,Drug: Ezetimibe + Rosuvastatin|Drug: Rosuvastatin|Drug: Placebo|Drug: Ezetimibe,"Percent change from baseline in total cholesterol, LDL-C, HDL-C, and triglycerides.|Safety: adverse events, laboratory test results, physical examination, vital signs.|Evaluate potential for PK interaction between ezetimibe and rosuvastatin as indicated by Cmax and AUC.",Merck Sharp & Dohme Corp.,All,18 Years to 55 Years   (Adult),Phase 1,40,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,P03317,Mar-03,May-03,May-03,2-Apr-08,null,16-Apr-15,,,https://ClinicalTrials.gov/show/NCT00651144
NCT00651274,Comparison of Co-administration of Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Primary Hypercholesterolemia (P03476),,Completed,No Results Available,Atherosclerosis|Hypercholesterolemia|Coronary Heart Disease,Drug: Ezetimibe|Drug: Placebo,"Percent change from baseline in LDL-cholesterol with ezetimibe added to simvastatin versus continued simvastatin alone.|Percentage of subjects who achieve target LDL-C as defined by the ESC or NCEP guidelines with ezetimibe added to simvastatin versus continued simvastatin alone|Percent change from baseline in total cholesterol, HDL-C and triglycerides with ezetimibe added to simvastatin versus continued simvastatin alone.",Merck Sharp & Dohme Corp.,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,144,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",P03476,1-Apr-03,1-Aug-04,1-Aug-04,2-Apr-08,null,11-May-17,,,https://ClinicalTrials.gov/show/NCT00651274
NCT00651378,Switching to Rosuvastatin Versus Adding Ezetimibe to Atorvastatin Versus Doubling the Dose of Atorvastatin in Patients With Hypercholesterolemia and Risk Factors (P03708),,Terminated,No Results Available,Hypercholesterolemia|Atherosclerosis|Coronary Artery Disease,Drug: Rosuvastatin|Drug: Ezetimibe + Atorvastatin|Drug: Double Atorvastatin,"Percent change in LDL-C level from baseline to the study endpoint.|Percent changes from baseline to the end of treatment in the concentrations of total cholesterol (TC), non-HDL-C, apo B, triglycerides (TG), HDL-C, LDL-C/HDL-C ratio, and TC/HDL-C ratio.|Adverse events, laboratory test results, vital signs.",Merck Sharp & Dohme Corp.,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,87,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P03708,1-Sep-04,1-Jun-05,1-Jun-05,2-Apr-08,null,11-May-17,,,https://ClinicalTrials.gov/show/NCT00651378
NCT00651391,Effect of Ezetimibe Plus Simvastatin on Flow-Mediated Brachial Artery Vasoactivity in Subjects With Primary Hypercholesterolemia (Study P03336),,Terminated,No Results Available,Hypercholesterolemia|Atherosclerosis,Drug: Ezetimibe + Simvastatin|Drug: Simvastatin|Drug: Placebo,"Change from baseline to endpoint in flow-mediated vasodilation: percent change in the mean diameter between 1-minute, post-cuff release diameter and image obtained prior to cuff application.|Change from baseline to endpoint in NTG-induced vasodilation: percent change in the diameter between the post-NTG and pre-NTG diameters.|Changes from baseline to endpoint in LDL-C, HDL-C, TG, TC, and CRP.",Merck Sharp & Dohme Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 3,28,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",P03336,1-Oct-03,1-Sep-04,1-Sep-04,2-Apr-08,null,11-May-17,,,https://ClinicalTrials.gov/show/NCT00651391
NCT00651404,Ezetimibe Plus Atorvastatin Versus Atorvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03406),,Completed,No Results Available,Hypercholesterolemia|Atherosclerosis,Drug: Ezetimibe|Drug: Placebo,"Percent change from baseline to end of treatment in LDL-C.|Percent of subjects who achieve the target LDL-C goal as defined by the ESC/NCEP guidelines.|Percent change from baseline to end of treatment in total cholesterol, HDL-C and triglycerides.|Safety/tolerability: adverse events, laboratory test results, vital signs, physical examinations.",Merck Sharp & Dohme Corp.,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,137,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",P03406,Jan-04,Dec-04,Dec-04,2-Apr-08,null,8-Apr-15,,,https://ClinicalTrials.gov/show/NCT00651404
NCT00647543,Atorvastatin Study For The Treatment Of High Cholesterol In Patients From Thailand,,Completed,No Results Available,Dyslipidemias,Drug: Atorvastatin,Percentage of patients who achieved low-density lipoprotein cholesterol (LDL-C) target|Adverse events and laboratory test changes|Percentage of patients who achieved LDL-C target|Change and percent change from baseline in LDL-C|Change and percent change from baseline in high-density lipoprotein cholesterol (HDL-C)|Change and percent change from baseline in LDL/HDL ratio|Change and percent change from baseline in total cholesterol|Change and percent change from baseline in triglycerides,Pfizer,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,242,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A2581111,Aug-03,null,Apr-04,31-Mar-08,null,5-May-08,"Pfizer Investigational Site, Bangkok, Thailand|Pfizer Investigational Site, Bangkok, Thailand|Pfizer Investigational Site, Chiang Mai, Thailand|Pfizer Investigational Site",,https://ClinicalTrials.gov/show/NCT00647543
NCT00645775,Effect of Irvingia Gabonensis (Bush Mango)on Parameters Associated With Metabolic Syndrome,,Completed,No Results Available,Metabolic Syndrome|Obesity|Dyslipidemia,Dietary Supplement: IGOB131,Weight change|Change in blood lipids and hormone levels,Gateway Health Alliance|University of Yaounde,All,19 Years to 50 Years   (Adult),Not Applicable,102,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GHAIGOB131CT,Nov-06,Mar-07,Apr-07,28-Mar-08,null,28-Mar-08,"Laboratory of Nutrition & Nutritional Biochemistry, Yaounde, Centre, Cameroon",,https://ClinicalTrials.gov/show/NCT00645775
NCT00644670,A Study Of The Efficacy Of Atorvastatin For Lowering Cholesterol In High-Risk Patients With High Cholesterol,,Completed,No Results Available,Dyslipidemias,Drug: Atorvastatin,"Percentage of subjects in entire group who achieved low-density lipoprotein cholesterol (LDL-C) target of <115 mg/dL|Mean percent change from baseline in LDL-C, high-density lipoprotein cholesterol (HDL-C), non-HDL-C (triglycerides of >200 mg/dL), total cholesterol, triglycerides, and apolipoprotein B for statin-naive patients|Proportion of subjects across different LDL-C strata who achieved LDL-C target|Proportion of diabetic subjects in entire group who achieved LDL-C target|Proportion of subject on statin therapy at baseline who achieved LDL-C target and total cholesterol target (<190 mg/dL)|Change from baseline in hemoglobin A1c levels|Adverse events and laboratory test changes|Proportion of subjects in entire group who achieved LDL-C target",Pfizer,All,"30 Years to 80 Years   (Adult, Older Adult)",Phase 4,232,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A2581099,Jun-03,null,Mar-04,27-Mar-08,null,28-Mar-08,"Pfizer Investigational Site, Antwerpen, Belgium|Pfizer Investigational Site, Brasschaat, Belgium|Pfizer Investigational Site, Brussels, Belgium|Pfizer Investigational Site, Edegem, Belgium|Pfizer Investigational Site, Genk, Belgium|Pfizer Investigational Site, Gent, Belgium|Pfizer Investigational Site, Gilly (charleroi), Belgium|Pfizer Investigational Site, La Louvière, Belgium|Pfizer Investigational Site, Liège, Belgium|Pfizer Investigational Site, Mechelen, Belgium|Pfizer Investigational Site, Menen, Belgium|Pfizer Investigational Site, Merksem, Belgium|Pfizer Investigational Site, Mortsel, Belgium|Pfizer Investigational Site, Roeselare, Belgium|Pfizer Investigational Site, Seraing, Belgium|Pfizer Investigational Site, Wilrijk, Belgium|Pfizer Investigational Site, Wingene, Belgium",,https://ClinicalTrials.gov/show/NCT00644670
NCT00644709,A Study Of Atorvastatin For The Treatment Of High Cholesterol In Patients At High Risk Of Coronary Heart Disease (CHD),,Completed,No Results Available,Dyslipidemias,Drug: Atorvastatin,"Achievement of low-density lipoprotein cholesterol (LDL-C) target of <115 mg/dL|Achievement of LDL-C target and total cholesterol target (<190 mg/dL) concomitantly|LDL-C, high-density lipoprotein cholesterol (HDL-C), total cholesterol, and triglyceride levels|Percent change from baseline of base study in LDL-C, HDL-C, non-HDL-C (triglycerides of >200 mg/dL), total cholesterol, and triglycerides in patients who were statin-naive at baseline of base study|Achievement of LDL-C target grouped according to whether patients had achieved target at the start of this extension study|Adverse events and laboratory test changes|Achievement of LDL-C target|Achievement of LDL-C target by diabetic patients",Pfizer,All,"30 Years to 80 Years   (Adult, Older Adult)",Phase 4,196,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A2581112,Sep-03,null,Mar-05,27-Mar-08,null,28-Mar-08,"Pfizer Investigational Site, Antwerpen, Belgium|Pfizer Investigational Site, Brasschaat, Belgium|Pfizer Investigational Site, Brussels, Belgium|Pfizer Investigational Site, Genk, Belgium|Pfizer Investigational Site, Gent, Belgium|Pfizer Investigational Site, Gilly (charleroi), Belgium|Pfizer Investigational Site, La Louvière, Belgium|Pfizer Investigational Site, Mechelen, Belgium|Pfizer Investigational Site, Menen, Belgium|Pfizer Investigational Site, Merksem, Belgium|Pfizer Investigational Site, Mortsel, Belgium|Pfizer Investigational Site, Roeselare, Belgium|Pfizer Investigational Site, Seraing, Belgium|Pfizer Investigational Site, Wilrijk, Belgium|Pfizer Investigational Site, Wingene, Belgium",,https://ClinicalTrials.gov/show/NCT00644709
NCT00645151,A Study Of The Efficacy Of Atorvastatin In Lowering Cholesterol In Latin American Patients With High Cholesterol,LA ATGOAL,Completed,No Results Available,Dyslipidemias,Drug: Atorvastatin,Responder rate in patients who achieved low-density lipoprotein cholesterol (LDL-C) level|Percentage of patients achieving LDL goal at 2 and 4 weeks|Lipid changes at week 4 & 8,Pfizer,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,512,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A2581104,Apr-04,null,Feb-05,27-Mar-08,null,10-Apr-08,"Pfizer Investigational Site, Belo Horizonte, MG, Brazil|Pfizer Investigational Site, Curitiba, PR, Brazil|Pfizer Investigational Site, Porto Alegre, RS, Brazil|Pfizer Investigational Site, Porto Alegre, RS, Brazil|Pfizer Investigational Site, São José, SC, Brazil|Pfizer Investigational Site, São Paulo, SP/Brazil, Brazil|Pfizer Investigational Site, Campinas, SP, Brazil|Pfizer Investigational Site, Campinas, SP, Brazil|Pfizer Investigational Site, Sao Paulo, SP, Brazil|Pfizer Investigational Site, Sao Paulo, SP, Brazil|Pfizer Investigational Site, São José do Rio Preto, SP, Brazil|Pfizer Investigational Site, São Paulo, SP, Brazil|Pfizer Investigational Site, Rio de Janeiro, Brazil|Pfizer Investigational Site, Santiago, Región Metropolitana, Chile|Pfizer Investigational Site, Bogota, Cundinamarca, Colombia|Pfizer Investigational Site, Bogotá, Cundinamarca, Colombia|Pfizer Investigational Site, Barranquilla, Colombia|Pfizer Investigational Site, Bogotá, C/marca, Colombia|Pfizer Investigational Site, Cali, Valle, Colombia|Pfizer Investigational Site, Quito, Pichincha / Ecuador, Ecuador|Pfizer Investigational Site, Guatemala, Guatemala|Pfizer Investigational Site, Guadalajara, Jalisco, Mexico|Pfizer Investigational Site, Zapopan, Jalisco, Mexico|Pfizer Investigational Site, Monterrey, Nuevo Leon, Mexico|Pfizer Investigational Site, Monterrey, Nuevo Leon, Mexico|Pfizer Investigational Site, Chihuahua, Mexico|Pfizer Investigational Site, Durango, Mexico|Pfizer Investigational Site, Panama, Panama|Pfizer Investigational Site, Dtto. Federal, Caracas, Venezuela|Pfizer Investigational Site, Caracas, Dtto Federal, Venezuela|Pfizer Investigational Site, Caracas, Dtto Federal, Venezuela|Pfizer Investigational Site, Caracas, Edo. Miranda, Venezuela|Pfizer Investigational Site, Caracas, Venezuela",,https://ClinicalTrials.gov/show/NCT00645151
NCT00645424,A Study To Evaluate The Safety And Efficacy Of Atorvastatin In Patients With Diabetes And High Cholesterol,,Completed,No Results Available,Hyperlipidemias,Drug: atorvastatin,"Percentage change in LDL-C levels from baseline to Week 12|Percentage of subjects with low-density lipoprotein cholesterol (LDL-C) levels of <100 mg/dL (LDL-C responders) at Week 12|Percentage change from baseline in TC, high-density lipoprotein cholesterol, triglycerides, and high sensitivity C-reactive protein at Weeks 4, 8, and 12|Adverse events at Weeks 4, 8, and 12|Clinical laboratory changes at Weeks 4, 8, and 12|Vital signs at Weeks 4, 8, and 12|Percentage change in LDL-C levels from baseline at Weeks 4 and 8|Percentage of LDL-C responders at Weeks 4 and 8|Percentage of subjects with total cholesterol (TC) levels of <160 mg/dL (TC responders) at Weeks 4, 8, and 12",Pfizer,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,155,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A2581123,Dec-03,null,Oct-04,27-Mar-08,null,5-May-08,"Pfizer Investigational Site, Kaohsiung Hsien, Taiwan|Pfizer Investigational Site, Kaohsiung, Taiwan|Pfizer Investigational Site, Taichung, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Taoyuan Hsien, Taiwan",,https://ClinicalTrials.gov/show/NCT00645424
NCT00640276,Safety and Efficacy Study of Pitavastatin in Patient With a Metabolic Syndrome,ProPit,Completed,No Results Available,Hypercholesterolemia|Metabolic Syndrome,Drug: pitavastatin|Behavioral: Lifestyle Modification,"A change of metabolic syndrome risk component|Changes of cardiometabolic profiles : lipid profiles, hs-CRP, adiponectin, HMW adiponectin|Changes of abdominal visceral fat|Changes of insulin resistance : OGTT(75g), HOMA",JW Pharmaceutical,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,187,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CWP_PTV_706,Apr-08,Feb-11,Jun-11,21-Mar-08,null,30-Mar-12,"Seoul National University Bundang Hospital, Bundang-gu, Gyeonggi-do, Korea, Republic of|Hanyang Univ. Guri Hospital, Guri-si, Gyeonggi-do, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT00640276
NCT00640549,Atorvastatin and LDL Profile in Non-Insulin Dependent Diabetes Mellitus,ALPIN,Terminated,No Results Available,"Hyperlipidemia|Diabetes Mellitus, Type 2|Non-Insulin Dependent Diabetes Mellitus",Drug: Atorvastatin|Drug: Placebo,"Changes in concentration of HDL subfractions 2a and 2b compared with screening (visit 1)|Changes in concentration of LDL subfractions LDL-5 and LDL-6 compared with screening (visit 1)|Changes in concentration of apolipoprotein B in VLDL, IDL, LDL-1 through LDL-6 and apolipoprotein A I in HDL subfractions 2a, 2b, and HDL-3 compared with screening (visit 1)|Changes in Cholesterol ester transfer protein (CETP), lipoprotein and hepatic lipase activity compared with screening (visit 1)|Changes in concentration of triglycerides, LDL, and HDL compared with screening (visit 1)|Changes in size of LDL subfractions compared with screening (visit 1)",Pfizer,All,"35 Years to 75 Years   (Adult, Older Adult)",Phase 4,41,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",A2581040,Mar-03,null,Oct-04,21-Mar-08,null,1-Apr-08,"Pfizer Investigational Site, Bad Muenster Am Stein, Germany|Pfizer Investigational Site, Bosenheim, Germany|Pfizer Investigational Site, Bretten, Germany|Pfizer Investigational Site, Dresden, Germany|Pfizer Investigational Site, Duisburg, Germany|Pfizer Investigational Site, Essen, Germany|Pfizer Investigational Site, Goch, Germany|Pfizer Investigational Site, Heidelberg, Germany|Pfizer Investigational Site, Kuenzing, Germany|Pfizer Investigational Site, Offenbach, Germany|Pfizer Investigational Site, Offenbach, Germany|Pfizer Investigational Site, Offenbach, Germany|Pfizer Investigational Site, Rain, Germany|Pfizer Investigational Site, Schwabenheim, Germany",,https://ClinicalTrials.gov/show/NCT00640549
NCT00639158,Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood,,Completed,Has Results,Dyslipidemias|Coronary Heart Disease|Combined (Atherogenic) Dyslipidemia|Mixed Dyslipidemia,Drug: ABT-335|Drug: placebo|Drug: atorvastatin|Drug: ezetimibe,Median Percent Change in Triglycerides From Baseline to Final Visit|Mean Percent Change in High-Density Lipoprotein Cholesterol (HDL-C) From Baseline to Final Visit|Mean Percent Change in Apolipoprotein AI (apoAI) From Baseline to Final Visit|Mean Percent Change in Very Low-Density Lipoprotein Cholesterol (VLDL-C) From Baseline to Final Visit|Mean Percent Change in Apolipoprotein CIII (apoCIII) From Baseline to Final Visit|Mean Percent Change in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Final Visit|Mean Percent Change in Apolipoprotein B (apoB) From Baseline to Final Visit|Median Percent Change in High-Sensitivity C-Reactive Protein (hsCRP) From Baseline to Final Visit,Abbott,All,"18 Years and older   (Adult, Older Adult)",Phase 3,543,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",M10-275,Feb-08,Oct-08,null,20-Mar-08,5-Nov-09,13-Jun-11,"Birmingham, Alabama, United States|Columbiana, Alabama, United States|Hueytown, Alabama, United States|Ozark, Alabama, United States|Tuscaloosa, Alabama, United States|Sierra Vista, Arizona, United States|Hot Springs, Arkansas, United States|Carmichael, California, United States|Concord, California, United States|Long Beach, California, United States|Long Beach, California, United States|Los Angeles, California, United States|Norwalk, California, United States|Roseville, California, United States|Sacramento, California, United States|Santa Ana, California, United States|Tustin, California, United States|West Hills, California, United States|Colorado Springs, Colorado, United States|Denver, Colorado, United States|Clearwater, Florida, United States|Delray Beach, Florida, United States|Fort Myers, Florida, United States|Holly Hill, Florida, United States|Jacksonville, Florida, United States|Jacksonville, Florida, United States|Kissimmee, Florida, United States|Longwood, Florida, United States|Miami, Florida, United States|New Port Richey, Florida, United States|New Smyrna Beach, Florida, United States|Ocala, Florida, United States|Ormond Beach, Florida, United States|Pembroke Pines, Florida, United States|Sarasota, Florida, United States|Tampa, Florida, United States|Winter Haven, Florida, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Roswell, Georgia, United States|Suwanee, Georgia, United States|Woodstock, Georgia, United States|Boise, Idaho, United States|Chicago, Illinois, United States|Chicago, Illinois, United States|Peoria, Illinois, United States|Evansville, Indiana, United States|Evansville, Indiana, United States|Indianapolis, Indiana, United States|Iowa City, Iowa, United States|Arkansas City, Kansas, United States|Overland Park, Kansas, United States|Wichita, Kansas, United States|Louisville, Kentucky, United States|Mt. Sterling, Kentucky, United States|Slidell, Louisiana, United States|Baltimore, Maryland, United States|Oxon Hill, Maryland, United States|Brockton, Massachusetts, United States|Edina, Minnesota, United States|Olive Branch, Mississippi, United States|St Louis, Missouri, United States|St Louis, Missouri, United States|St. Louis, Missouri, United States|St. Peters, Missouri, United States|Billings, Montana, United States|Las Vegas, Nevada, United States|Berlin, New Jersey, United States|Elizabeth, New Jersey, United States|Hillsborough, New Jersey, United States|Trenton, New Jersey, United States|Johnson City, New York, United States|Charlotte, North Carolina, United States|Hickory, North Carolina, United States|Morehead City, North Carolina, United States|Raleigh, North Carolina, United States|Salisbury, North Carolina, United States|Statesville, North Carolina, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Mason, Ohio, United States|Mogadore, Ohio, United States|Warren, Ohio, United States|Tulsa, Oklahoma, United States|Hillsboro, Oregon, United States|Duncansville, Pennsylvania, United States|Harleysville, Pennsylvania, United States|Jersey Shore, Pennsylvania, United States|Lansdale, Pennsylvania, United States|Melrose Park, Pennsylvania, United States|Newtown, Pennsylvania, United States|Perkasie, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Sellersville, Pennsylvania, United States|Tipton, Pennsylvania, United States|Warminster, Pennsylvania, United States|Cumberland, Rhode Island, United States|Anderson, South Carolina, United States|Greenville, South Carolina, United States|Greer, South Carolina, United States|Simpsonville, South Carolina, United States|Summerville, South Carolina, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Fort Worth, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Salt Lake City, Utah, United States|Salt Lake City, Utah, United States|West Jordan, Utah, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Roanoke, Virginia, United States|Virginia Beach, Virginia, United States|Spokane, Washington, United States|Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00639158
NCT00639223,Safety of Red Yeast Rice for High Cholesterol in Individuals With Statin Intolerance,,Completed,Has Results,Hypercholesterolemia|Statin-Associated Myopathy,Dietary Supplement: Red Yeast Rice|Drug: Pravastatin|Behavioral: Lifestyle modification program,Withdrawal of Therapy Due to Muscle Symptoms That Are Either Intolerable and/or Associated With a Creatine Kinase(CK) >500|Change in LDL-Cholesterol Measured at the Beginning and End of the Study,University of Pennsylvania|Chestnut Hill Health System,All,"21 Years to 80 Years   (Adult, Older Adult)",Phase 2,43,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",806827,Jan-08,Jul-08,Oct-08,20-Mar-08,18-Jan-10,18-Jan-10,"Chestnut Hill Hospital, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00639223
NCT00639041,Changes in Blood Lipids After Long-term Consumption of n-3 LC-PUFA-Enriched Dairy Products,,Completed,No Results Available,Hypertriglyceridemia,Dietary Supplement: n-3 LC-PUFA|Dietary Supplement: Placebo,"blood lipids (total cholesterol, high density cholesterol (HDL), low density cholesterol (LDL), TAG)|blood pressure|fibrinogen|homocysteine",University of Jena,All,"43 Years to 69 Years   (Adult, Older Adult)",Not Applicable,51,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",LSEP H26_06|Gerhard.Jahreis@uni-jena.de,Apr-06,May-07,May-07,19-Mar-08,null,22-Sep-11,"Facility: University of Jena, Institute of Nutrition, Department of Nutritional Physiology, Jena, Thuringia, Germany",,https://ClinicalTrials.gov/show/NCT00639041
NCT00637078,STITCH2 (Simplified Therapeutic Intervention to Control Hypertension and Hypercholesterolemia),STITCH2,Completed,No Results Available,Hypertension|Hypercholesterolemia,"Other: Treatment algorithm:caduet, Amlodipine, ACEI-ARB combo dose, a-blocker, b-blocker or spironolactone, dyslipidemic therapy with ezetamide",Proportion of subjects whose systolic BP [SBP] <140 mmHg and diastolic BP [DBP] <90 mmHg)or proportion whose cholesterol levels are at or below threshold based on their global artherosclerotic risk profile compared at the practice level.|Secondary measures include the change at 6 months in SBP and DBP and cholesterol levels. These outcomes will be compared at the practice level,"University of Western Ontario, Canada|Pfizer",All,"18 Years and older   (Adult, Older Adult)",Phase 4,1000,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RPO702,Feb-08,Jun-10,Dec-10,17-Mar-08,null,14-Jun-12,"Robarts Research Insititute, London, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00637078
NCT00634608,Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow,,Completed,No Results Available,Allergic Rhinitis|Asthma|Back Pain|Benign Prostatic Hypertrophy|Bursitis|Depression|Anxiety|Diabetes Mellitus|Esophageal Reflux|HIV Infections|Hyperlipidemia|Hypertension|Insomnia|Irritable Bowel Syndrome|Obesity|Osteoporosis (Senile)|Shoulder Pain|Sinusitis|Symptomatic Menopause|Urinary Incontinence|Urinary Tract Infection|Vaginitis,Other: Health Information Prescription,health information experiences of the patient|clinician feedback on the health information prescription process,University of Missouri-Columbia|National Library of Medicine (NLM),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,224,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),HHSN276200700263P,Feb-08,Mar-09,Sep-09,13-Mar-08,null,30-Sep-16,"University of Missouri, Department of Internal Medicine, Columbia, Missouri, United States",,https://ClinicalTrials.gov/show/NCT00634608
NCT00634673,Postprandial Fatty Acids and FABP2 in Type 2 Diabetes Mellitus (DM),,Completed,No Results Available,Dyslipidemia|Type 2 Diabetes Mellitus,Other: sandwich,postprandial serum fatty acids|serum endothelin serum fibrinogen,Hospital de Clinicas de Porto Alegre,All,"40 Weeks to 75 Years   (Child, Adult, Older Adult)",Not Applicable,26,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),HCPA05060,Jun-06,Oct-07,Oct-07,13-Mar-08,null,13-Mar-08,"Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil",,https://ClinicalTrials.gov/show/NCT00634673
NCT00635544,Cross-Over Multicentre Study in Adolescents,HELENA-COMS,Completed,No Results Available,Overweight|Hyperlipidemia,Other: dietary treatment,blood glucose and lipids|blood hormones and inflammatory status parameters,Federico II University,Female,13 Years to 16 Years   (Child),Not Applicable,80,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,H3|Contract number: 007034,Jan-07,Jan-08,Apr-08,13-Mar-08,null,28-Jan-09,"Department of Nutrition and Dietetics, Harokopio University, Athens, Greece|Pécsi Tudományegyetem Anyagcseregondozó, Pecs, Hungary|Dipartimento di Pediatria Università di Napoli ""Federico II"", Napoli, Italy|Instituto del Frio. Departamento de Metabolismo y Nutrición, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT00635544
NCT00632840,Pharmacological Regulation of Fat Transport in Metabolic Syndrome,,Completed,No Results Available,Obesity|Lipid Disorders|Hypertriglyceridemia|Cardiovascular Disease,Drug: Atorvastatin and fenofibrate,VLDL-apoC-III transport rate,"The University of Western Australia|National Heart Foundation, Australia",Male,"25 Years to 70 Years   (Adult, Older Adult)",Phase 4,11,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",UWA_DC012008,Jun-01,Dec-02,Dec-07,11-Mar-08,null,11-Mar-08,,,https://ClinicalTrials.gov/show/NCT00632840
NCT00630734,Genetic Predictors of Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and Pravastatin,,Completed,Has Results,HIV Infections|Hyperlipidemia,Drug: Pravastatin|Drug: Darunavir|Drug: Ritonavir|Other: Washout,Relative Change in Pravastatin Area Under the Plasma Concentration-time Curve (AUC) Over the Dosing Interval|Relative Change in Pravastatin Maximum Plasma Concentration (Cmax)|Pravastatin Alone: Pravastatin Area Under the Plasma Concentration-time Curve (AUC) Over the Dosing Interval|Pravastatin Alone: Pravastatin Maximum Plasma Concentration (Cmax)|Pravastatin + Darunavir/Ritonavir: Pravastatin Area Under the Plasma Concentration-time Curve (AUC) Over the Dosing Interval|Pravastatin + Darunavir/Ritonavir: Pravastatin Maximum Plasma Concentration (Cmax),"University of Colorado, Denver|Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA",All,18 Years to 60 Years   (Adult),Phase 4,32,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,07-0272|TMC114HIV4003,Feb-08,Oct-09,Sep-10,7-Mar-08,15-Nov-12,22-May-14,"University of Colorado Denver, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT00630734
NCT00630877,Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin,,Completed,Has Results,Dyslipidemia,Drug: Niacin extended-release (NER)|Drug: Niacin extended-release (NER) placebo|Drug: Aspirin (ASA)|Drug: Aspirin (ASA) placebo,Flushing ASsessment Tool (FAST) Test-retest Reliability--mean Flushing Severity Score|FAST Test-retest Reliability--maximum Flushing Severity Score|FAST Cross-sectional Construct Validity--mean Flushing Severity Score|FAST Cross-sectional Construct Validity--maximum Flushing Severity Score|FAST Longitudinal Construct Validity--mean Flushing Severity Score|FAST Longitudinal Construct Validity--maximum Flushing Severity Score|FAST Responsiveness--mean Flushing Severity Score|FAST Responsiveness--maximum Flushing Severity Score|Maximum Severity of Flushing Events Overall During the Study,Abbott,All,"18 Years and older   (Adult, Older Adult)",Phase 3,276,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",M10-229,Feb-08,Jun-08,Jun-08,7-Mar-08,9-Oct-09,9-Oct-09,"Birmingham, Alabama, United States|Anaheim, California, United States|Walnut Creek, California, United States|Denver, Colorado, United States|Brooksville, Florida, United States|Daytona Beach, Florida, United States|Hollywood, Florida, United States|Jacksonville, Florida, United States|Largo, Florida, United States|Miami, Florida, United States|Pembroke Pines, Florida, United States|Boise, Idaho, United States|Chicago, Illinois, United States|Arkansas City, Kansas, United States|Topeka, Kansas, United States|Wichita, Kansas, United States|Wichita, Kansas, United States|St Louis, Missouri, United States|St. Louis, Missouri, United States|Las Vegas, Nevada, United States|Durham, North Carolina, United States|High Point, North Carolina, United States|Salisbury, North Carolina, United States|Statesville, North Carolina, United States|Cincinnati, Ohio, United States|Portland, Oregon, United States|Duncansville, Pennsylvania, United States|Harleysville, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Greer, South Carolina, United States|Austin, Texas, United States|Carrollton, Texas, United States|Dallas, Texas, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|Magna, Utah, United States|Murray, Utah, United States|Sandy, Utah, United States|Gig Harbor, Washington, United States|Menomonee Falls, Wisconsin, United States|Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00630877
NCT00631189,Evaluation of the Efficacy and Safety of Rosuvastatin 5 mg Versus Pravastatin 40 mg and Atorvastatin 10 mg in Type IIa and IIb Hypercholesterolaemic Patients,CAP-Chol,Completed,Has Results,Type IIa and IIb Hypercholesterolaemia,Drug: Rosuvastatin|Drug: Pravastatin|Drug: Atorvastatin,"Change in Low Density Lipoprotein Cholesterol (LDL-C) Level After 8 Weeks|To Compare the Percentage of Patients Reaching the Overall LDL-C Goal According to the French Agency for the Safety of Health Products (AFSSAPS) 2005 Guidelines for the Management of Dyslipidaemic Patients|To Compare the Percentage of Patients Reaching the LDL-C Goal, in Relation to the Number of Risk Factors, According to the French Agency for the Safety of Health Products (AFSSAPS) 2005 Guidelines for the Management of Dyslipidaemic Patients|Compare the Percentage of Total Cholesterol Variation From Baseline and After 8 Weeks of Treatment|Compare the Percentage of HDL-C (High Density Lipoprotein Cholesterol) Variation From Baseline and After 8 Weeks of Treatment|Compare the Percentage of Variation From Baseline Triglycerides Values and After 8 Weeks|Compare the Percentage of Variation From Baseline Apolipoprotein B/Apolipoprotein A1 Ratio and After 8 Weeks of Treatment|Compare the Percentage of Variation of C-reactive Protein (CRP)|Compare the Percentage of Variation of Phospholipase A2 (PLA2)|Compare the Numbers of Patients Achieving the LDL-C Goal According to the National Cholesterol Education Program Adult Treatment Panel III (NCEP) ATP III) Guidelines for the Management of Dyslipidaemic Patients|Compare the Numbers of Patients Achieving the LDL-C Goal According to the European Atherosclerosis Society (EAS) Guidelines for the Management of Dyslipidaemic Patients|To Evaluate Clinical and Laboratory Safety",AstraZeneca,All,"18 Years and older   (Adult, Older Adult)",Phase 4,668,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D3560L00068|EudraCT No 2006-006697-15,Oct-07,Oct-08,Oct-08,7-Mar-08,17-Sep-10,26-Nov-13,"Research Site, Aix En Provence, France|Research Site, Allaire, France|Research Site, Amiens, France|Research Site, Ancerville, France|Research Site, Angers, France|Research Site, Annecy, France|Research Site, Anzin, France|Research Site, Arles, France|Research Site, Arthez de Bearn, France|Research Site, Aspach Le Bas, France|Research Site, Aubagne, France|Research Site, Auchel, France|Research Site, Bailleul, France|Research Site, Balma, France|Research Site, Beaucaire, France|Research Site, Belfort, France|Research Site, Bersee, France|Research Site, Bezenet, France|Research Site, Beziers, France|Research Site, Biarritz, France|Research Site, Blois, France|Research Site, Boersch, France|Research Site, Bondues, France|Research Site, Bondy, France|Research Site, Bordeaux, France|Research Site, Brignoud, France|Research Site, Bruay La Buissiere, France|Research Site, Bruges, France|Research Site, Cabanac Et Villagrains, France|Research Site, Cadaujac, France|Research Site, Caen, France|Research Site, Cannes La Bocca, France|Research Site, Carnon, France|Research Site, Caylus, France|Research Site, Cernay, France|Research Site, Cestas, France|Research Site, Champcueil, France|Research Site, Chanceaux Sur Choisille, France|Research Site, Chilly-mazarin, France|Research Site, Clary, France|Research Site, Collioure, France|Research Site, Colombier Fontaine, France|Research Site, Colomiers, France|Research Site, Coulonieix Chamiers, France|Research Site, Crecy La Chapelle, France|Research Site, Crotenay, France|Research Site, Cuise La Motte, France|Research Site, Derval, France|Research Site, Dijon, France|Research Site, Eckbolsheim, France|Research Site, Eckwersheim, France|Research Site, Epernay, France|Research Site, Epinal, France|Research Site, Etang Sur Arroux, France|Research Site, Evreux, France|Research Site, Fargues St Hilaire, France|Research Site, Folembray, France|Research Site, Fos Sur Mer, France|Research Site, Franconville La Garenne, France|Research Site, Gamarde Les Bains, France|Research Site, Gambsheim, France|Research Site, Gradignan, France|Research Site, Grand Couronne, France|Research Site, Grendelbruch, France|Research Site, Guise, France|Research Site, Harnes, France|Research Site, Horbourg Wihr, France|Research Site, Is Sur Tille, France|Research Site, Ivry Sur Seine, France|Research Site, Jarville La Malgrange, France|Research Site, Jeumont, France|Research Site, La Ciotat, France|Research Site, La Courneuve, France|Research Site, La Creche, France|Research Site, La Francheville, France|Research Site, Lacrouzette, France|Research Site, Lamagistere, France|Research Site, Laval, France|Research Site, Le Bouscat, France|Research Site, Le Cannet, France|Research Site, Le Passage, France|Research Site, Leognan, France|Research Site, Les Issambres, France|Research Site, Lille, France|Research Site, Lucheux, France|Research Site, Marcq En Baroeul, France|Research Site, Marseille, France|Research Site, Maslacq, France|Research Site, Mauguio, France|Research Site, Meaux-beauval, France|Research Site, Mennecy, France|Research Site, Mensignac, France|Research Site, Merlimont, France|Research Site, Metz, France|Research Site, Miramont de Guyenne, France|Research Site, Mittersheim, France|Research Site, Monfort En Chalosse, France|Research Site, Monguilhem, France|Research Site, Mont de Marsan, France|Research Site, Montauroux, France|Research Site, Montbeliard, France|Research Site, Monteux, France|Research Site, Montfrin, France|Research Site, Montigny Les Metz, France|Research Site, Montpellier, France|Research Site, Moreuil, France|Research Site, Muespach, France|Research Site, Nancy, France|Research Site, Nogent Sur Marne, France|Research Site, Noyon, France|Research Site, Oberhausbergen, France|Research Site, Orchamps, France|Research Site, Palau Del Vidre, France|Research Site, Paris, France|Research Site, Pauillac, France|Research Site, PAU, France|Research Site, Perigueux, France|Research Site, Pfulgriesheim, France|Research Site, Phalempin, France|Research Site, Pont A Mousson, France|Research Site, Pouilly En Auxois, France|Research Site, Poussan, France|Research Site, Pradines, France|Research Site, Puteaux, France|Research Site, Quimperle, France|Research Site, Rognac, France|Research Site, Rohrwiller, France|Research Site, Roncq, France|Research Site, Roquevaire, France|Research Site, Roubaix, France|Research Site, Saint Etienne, France|Research Site, Saint Martin D'oney, France|Research Site, Saint Medard En Jalles, France|Research Site, Saint Remy, France|Research Site, Salles, France|Research Site, Sarlat La Caneda, France|Research Site, Semur En Auxois, France|Research Site, Serres Castet, France|Research Site, Soissons, France|Research Site, Sorcy Saint Martin, France|Research Site, St Etienne de Montluc, France|Research Site, St Etienne, France|Research Site, St Girons, France|Research Site, St Jean de Braye, France|Research Site, St Leu La Foret, France|Research Site, St Morillon, France|Research Site, St Remy de Provence, France|Research Site, St. Emilion, France|Research Site, Strasbourg, France|Research Site, Tarare, France|Research Site, Targon, France|Research Site, Tartas, France|Research Site, Tassin La Demi-lune, France|Research Site, Thones, France|Research Site, Thun St Amand, France|Research Site, Toulon, France|Research Site, Toulouse, France|Research Site, Trie Sur Baise, France|Research Site, Varces Allieres Et Risset, France|Research Site, Vatan, France|Research Site, Velizy Villacoublay, France|Research Site, Vence, France|Research Site, Vieux Boucau, France|Research Site, Villard Bonnot, France|Research Site, Villette D'anthon, France|Research Site, Viry Chatillon, France|Research Site, Wasselonne, France|Research Site, Wattignies, France|Research Site, Wattrelos, France|Research Site, Yerres, France|Research Site, Yffiniac, France",,https://ClinicalTrials.gov/show/NCT00631189
NCT00627380,Yoga for the Management of HIV-Metabolic Syndromes,,Completed,No Results Available,HIV Infections|HIV Metabolic Cardiovascular Syndrome|HIV Lipodystrophy|HIV Metabolic Syndromes|Hypertension,Behavioral: Yoga lifestyle intervention|Other: Standard of care,"The primary efficacy outcome is a metabolic parameter: insulin integrated area under the curve (AUC) during the oral glucose tolerance test.|Fasting lipid/lipoprotein levels.|Body composition: visceral and subcutaneous adipose tissue areas (VAT, SAT), trunk/limb adipose ratio.|Cardiovascular disease risk: Framingham 10-yr CVD risk calculation|Quality of life: SF36 MOS|Safety: CD4 count and plasma HIV RNA",Washington University School of Medicine|National Center for Complementary and Integrative Health (NCCIH),All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,60,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R21AT003083|WU187,Nov-05,Jun-09,Jun-09,3-Mar-08,null,26-Jul-10,"Washington University School of Medicine, St. Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT00627380
NCT00626041,U-CHAMP: Urban Cardiovascular Health Assessment and Management Program,U-CHAMP,Unknown status,No Results Available,Cardiovascular Diseases|Hypertension|Hyperlipidemia|Hyperglycemia,Other: participant referral to primary care network physician,"Change in systolic blood pressure between baseline (average of visits one and two) and program end (final visit).|Proportion of screened participants identified as being above blood pressure, cholesterol and blood glucose targets at visit two|Proportion of participants that achieve published blood pressure (lipid and diabetes when appropriate) targets by program end|Proportion of individuals that obtain both a baseline and end of program full lipid panel|Change in Framingham Global Cardiovascular Risk score (in those participants that do not have known vascular disease or diabetes and have a recorded baseline and end-of-study full lipid panel).|Proportion of individuals that have changes in drug therapy (new medication and/or dosage increase).",University of Calgary|University of Alberta,All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,110,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,03 71550000144,Feb-08,Dec-10,Jun-11,29-Feb-08,null,27-Jan-10,"Calgary Safeway Pharmacy - Crowfoot Location, Calgary, Alberta, Canada|Coop Pharmacy - Crowfoot Location, Calgary, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT00626041
NCT00626392,Study to Evaluate the EFFECTS of Acetylsalicylic Acid (ASA) on Niaspan®-Induced Flushing in Subjects With Dyslipidemia,ASA EFFECTS,Completed,Has Results,Dyslipidemia,Drug: niacin extended-release (NER)|Drug: aspirin (ASA)|Drug: aspirin placebo (ASA Pbo),Maximum Severity of Flushing Events During Week 1 of Niacin Extended-release (NER) Treatment|Maximum Severity of Flushing Events Overall During 4 Weeks of Niacin Extended-release (NER) Treatment|Mean of Maximum Severity of Flushing Events Overall During 4 Weeks of Niacin Extended-release (NER) Treatment|Mean Number of Moderate or Greater Flushing Events Per Subject Per Week Overall During 4 Weeks of Niacin Extended-release (NER) Treatment,Abbott,All,"18 Years and older   (Adult, Older Adult)",Phase 3,277,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",M10-241,Feb-08,Apr-08,Apr-08,29-Feb-08,25-Aug-09,2-Sep-09,"Huntsville, Alabama, United States|Scottsdale, Arizona, United States|Tucson, Arizona, United States|Tucson, Arizona, United States|Anaheim, California, United States|Los Angeles, California, United States|Newport Beach, California, United States|Stockton, California, United States|Vista, California, United States|Westlake Village, California, United States|Coral Gables, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Pembroke Pines, Florida, United States|West Palm Beach, Florida, United States|N. Dartmouth, Massachusetts, United States|Rochester, New York, United States|Charlotte, North Carolina, United States|Winston-Salem, North Carolina, United States|Penndel, Pennsylvania, United States|Johnston, Rhode Island, United States|Mt. Pleasant, South Carolina, United States|Simpsonville, South Carolina, United States|Colleyville, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00626392
NCT00627159,ICA-CHAMP: Indo-Central Asian Cardiovascular Health Assessment and Management Program,ICA-CHAMP,Unknown status,No Results Available,Cardiovascular Diseases|Hypertension|Hyperlipidemia,Other: High risk assessment|Other: Low to moderate risk,"Baseline and one year change in blood pressure and total cholesterol, HDL cholesterol and TC/HDL ratio (High and low to moderate risk program participants)|Cardiovascular risk profile and risk scores (Joint British Societies Cardiovascular Disease Risk Prediction Chart) of all participants at baseline and upon completion of the High Risk Assessment and Calgary Health Region Multicultural education programs.|Baseline profiles of attendees versus no-shows at both High Risk Assessment clinics and Calgary Health Region Multicultural education programs|""No-show"" rates at High Risk Assessment clinics and Calgary Health Region Multicultural education program vs. historical rates.|Proportion of High Risk Assessment Clinic attendees identified as having occult Coronary Artery Disease and requiring angioplasty and/or Coronary Artery Bypass Graft.|Post Hoc variation of the Joint British Societies Cardiovascular Disease Risk Prediction Chart versus ETHRISK|Participant and community leader/volunteer satisfaction with the program|Participant opinion regarding usefulness of the culturally-sensitive educational information provided at the screening session.",University of Calgary|Pfizer,All,"45 Years and older   (Adult, Older Adult)",Not Applicable,375,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,NRA3840015,May-07,Apr-08,Jun-08,29-Feb-08,null,29-Feb-08,"Hindu Society of Calgary, Calgary, Alberta, Canada|Dashmesh Cultural Centre, Calgary, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT00627159
NCT00625014,Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Haloperidol in Healthy Humans,,Completed,No Results Available,Insulin Resistance|Dyslipidemia,Drug: Haloperidol,"To determine the effect of subchronic haloperidol treatment on HGO, whole body peripheral glucose disposal, fatty acid flux and fuel oxidation.",Leiden University Medical Center|Dutch Diabetes Research Foundation,Male,20 Years to 40 Years   (Adult),Not Applicable,8,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),P05.009,Mar-05,Jul-05,Jul-05,28-Feb-08,null,28-Feb-08,"Leiden University Medical Center, Leiden, Netherlands",,https://ClinicalTrials.gov/show/NCT00625014
NCT00625170,Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Antipsychotic Drugs in Healthy Humans,,Completed,No Results Available,Insulin Resistance|Dyslipidemia,Drug: olanzapine|Drug: Haloperidol,"To determine the effect of subchronic olanzapine and haloperidol treatment on HGO, whole body peripheral glucose disposal, fatty acid flux and fuel oxidation.",Leiden University Medical Center|Dutch Diabetes Research Foundation,Male,20 Years to 40 Years   (Adult),Not Applicable,11,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant),P03.136,May-04,Dec-04,Dec-04,28-Feb-08,null,28-Feb-08,"Leiden University Medical Center, Leiden, Netherlands",,https://ClinicalTrials.gov/show/NCT00625170
NCT00621101,Pharmacokinetic Drug Interaction Between Ezetimibe and Sirolimus After Single Dose Administration in Healthy Subjects,,Completed,No Results Available,Pharmacokinetics|Drug Interactions|Hypercholesterolemia|Immunosuppression,"Drug: 1 tablet Ezetrol(R) (ezetimibe), MSD Sharp & Dohme GmbH, Germany|Drug: 1 tablet Rapamune(R) (sirolimus), Wyeth Pharma, Germany|Drug: 1 tablet Ezetrol(R) + 1 tablet Rapamune(R)","Primary characteristics: for ezetimibe: AUC0-∞, Cmax; for sirolimus: AUC0-∞, Cmax|Second. characteristics: for ezetimibe: CLR, Ae (urine), Ae (feces); for ezetimibe glucuronide: AUC0-∞, Cmax, Ae (urine), Ae (feces); for ezetimibe, ezetimibe glucuronide and sirolimus: AUC0-t, t½, tmax",University Medicine Greifswald,All,18 Years to 45 Years   (Adult),Phase 1,24,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,Eze-Siro|EudraCT-No. 2006-006597-18,Apr-07,Jun-07,Jun-07,22-Feb-08,null,22-Feb-08,"Department of Clinical Pharmacology, Greifswald, Germany",,https://ClinicalTrials.gov/show/NCT00621101
NCT00621699,Pharmacokinetic Drug Interaction Between Ezetimibe and Tacrolimus After Single Dose Administration in Healthy Subjects,,Completed,No Results Available,Pharmacokinetics|Drug Interactions|Hypercholesterolemia|Immunosuppression,"Drug: 1 tablet Ezetrol(R) (ezetimibe), MSD Sharp & Dohme GmbH, Germany|Drug: 1 capsule Prograf(R) (tacrolimus), Astellas Pharma GmbH, Germany|Drug: 1 tablet Ezetrol(R) + 1 capsules Prograf(R)","Primary characteristics: for ezetimibe: AUC0-∞, Cmax; for tacrolimus: AUC0-∞, Cmax|Second. characteristics: for ezetimibe: CLR, Ae (urine), Ae (feces); for ezetimibe glucuronide: AUC0-∞, Cmax, Ae (urine), Ae (feces); for ezetimibe, ezetimibe glucuronide and tacrolimus: AUC0-t, t½, tmax",University Medicine Greifswald,All,18 Years to 45 Years   (Adult),Phase 1,24,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,Eze-Tacro|2006-006549-14,Sep-07,Nov-07,Nov-07,22-Feb-08,null,22-Feb-08,"Department of Clinical Pharmacology, Greifswald, Germany",,https://ClinicalTrials.gov/show/NCT00621699
NCT00616772,"Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood",FIRST,Completed,Has Results,Coronary Artery Disease|Coronary Heart Disease|Dyslipidemia,Drug: ABT-335|Drug: Placebo|Other: Atorvastatin,Rate of Change in Mean Posterior-wall Carotid Intima-media Thickness (cIMT)|Rate of Change in Mean of Maximal Posterior-wall Carotid Intima-media Thickness (cIMT)|Rate of Change in Composite of Mean of the Mean Posterior-wall Intima-media Thickness (IMT)|Rate of Change in Composite of Mean of Maximal Posterior-wall Intima-media Thickness (IMT)|Rate of Change in Composite of Mean of Maximal Posterior-wall and Anterior-wall Intima-media Thickness (IMT),"AbbVie (prior sponsor, Abbott)|AbbVie",All,"45 Years and older   (Adult, Older Adult)",Phase 3,682,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",M10-158,Feb-08,Sep-12,Sep-12,15-Feb-08,20-Jan-14,2-Jul-18,"Site Reference ID/Investigator# 6747, Chandler, Arizona, United States|Site Reference ID/Investigator# 7089, Gilbert, Arizona, United States|Site Reference ID/Investigator# 7097, Mesa, Arizona, United States|Site Reference ID/Investigator# 26394, Phoenix, Arizona, United States|Site Reference ID/Investigator# 6848, Scottsdale, Arizona, United States|Site Reference ID/Investigator# 7059, Tempe, Arizona, United States|Site Reference ID/Investigator# 7094, Tempe, Arizona, United States|Site Reference ID/Investigator# 7098, Tempe, Arizona, United States|Site Reference ID/Investigator# 25082, Anaheim, California, United States|Site Reference ID/Investigator# 21347, Corona, California, United States|Site Reference ID/Investigator# 21483, Garden Grove, California, United States|Site Reference ID/Investigator# 21351, Huntington Beach, California, United States|Site Reference ID/Investigator# 21346, Laguna Hills, California, United States|Site Reference ID/Investigator# 21341, Long Beach, California, United States|Site Reference ID/Investigator# 21342, Norwalk, California, United States|Site Reference ID/Investigator# 21321, Santa Ana, California, United States|Site Reference ID/Investigator# 26242, Tustin, California, United States|Site Reference ID/Investigator# 15283, Arvada, Colorado, United States|Site Reference ID/Investigator# 7085, Aurora, Colorado, United States|Site Reference ID/Investigator# 6749, Denver, Colorado, United States|Site Reference ID/Investigator# 7077, Denver, Colorado, United States|Site Reference ID/Investigator# 7092, Golden, Colorado, United States|Site Reference ID/Investigator# 7722, Littleton, Colorado, United States|Site Reference ID/Investigator# 7721, Littleton, Colorado, United States|Site Reference ID/Investigator# 11925, Aventura, Florida, United States|Site Reference ID/Investigator# 15861, Boynton Beach, Florida, United States|Site Reference ID/Investigator# 14422, Deerfield Beach, Florida, United States|Site Reference ID/Investigator# 19281, Delray Beach, Florida, United States|Site Reference ID/Investigator# 20881, Hollywood, Florida, United States|Site Reference ID/Investigator# 20882, Kissimmee, Florida, United States|Site Reference ID/Investigator# 19321, Melbourne, Florida, United States|Site Reference ID/Investigator# 21353, Melbourne, Florida, United States|Site Reference ID/Investigator# 18503, Melbourne, Florida, United States|Site Reference ID/Investigator# 18841, Vero Beach, Florida, United States|Site Reference ID/Investigator# 19961, Vero Beach, Florida, United States|Site Reference ID/Investigator# 7166, West Palm Beach, Florida, United States|Site Reference ID/Investigator# 6744, West Palm Beach, Florida, United States|Site Reference ID/Investigator# 19301, Atlanta, Georgia, United States|Site Reference ID/Investigator# 7051, Atlanta, Georgia, United States|Site Reference ID/Investigator# 7109, Atlanta, Georgia, United States|Site Reference ID/Investigator# 7326, Dawsonville, Georgia, United States|Site Reference ID/Investigator# 7325, Decatur, Georgia, United States|Site Reference ID/Investigator# 7057, Dunwoody, Georgia, United States|Site Reference ID/Investigator# 7101, Dunwoody, Georgia, United States|Site Reference ID/Investigator# 11324, Roswell, Georgia, United States|Site Reference ID/Investigator# 6741, Roswell, Georgia, United States|Site Reference ID/Investigator# 7103, Suwanee, Georgia, United States|Site Reference ID/Investigator# 10761, Addison, Illinois, United States|Site Reference ID/Investigator# 6748, Aurora, Illinois, United States|Site Reference ID/Investigator# 6742, Aurora, Illinois, United States|Site Reference ID/Investigator# 7128, Belleville, Illinois, United States|Site Reference ID/Investigator# 7069, Chicago, Illinois, United States|Site Reference ID/Investigator# 6849, Chicago, Illinois, United States|Site Reference ID/Investigator# 6867, Chicago, Illinois, United States|Site Reference ID/Investigator# 6751, Chicago, Illinois, United States|Site Reference ID/Investigator# 6847, Chicago, Illinois, United States|Site Reference ID/Investigator# 7049, Chicago, Illinois, United States|Site Reference ID/Investigator# 7093, Gurnee, Illinois, United States|Site Reference ID/Investigator# 6746, Hazel Crest, Illinois, United States|Site Reference ID/Investigator# 6743, Melrose Park, Illinois, United States|Site Reference ID/Investigator# 7090, Naperville, Illinois, United States|Site Reference ID/Investigator# 6750, Oak Brook, Illinois, United States|Site Reference ID/Investigator# 6788, Oak Park, Illinois, United States|Site Reference ID/Investigator# 6927, Vernon Hills, Illinois, United States|Site Reference ID/Investigator# 7076, Erlanger, Kentucky, United States|Site Reference ID/Investigator# 8103, Bloomington, Minnesota, United States|Site Reference ID/Investigator# 15121, Brooklyn Center, Minnesota, United States|Site Reference ID/Investigator# 7050, Edina, Minnesota, United States|Site Reference ID/Investigator# 7084, Edina, Minnesota, United States|Site Reference ID/Investigator# 6860, Saint Louis, Missouri, United States|Site Reference ID/Investigator# 13182, Saint Louis, Missouri, United States|Site Reference ID/Investigator# 14423, Saint Louis, Missouri, United States|Site Reference ID/Investigator# 14541, Saint Louis, Missouri, United States|Site Reference ID/Investigator# 6740, Saint Louis, Missouri, United States|Site Reference ID/Investigator# 7053, Saint Louis, Missouri, United States|Site Reference ID/Investigator# 6784, Saint Peters, Missouri, United States|Site Reference ID/Investigator# 7063, Henderson, Nevada, United States|Site Reference ID/Investigator# 7070, Henderson, Nevada, United States|Site Reference ID/Investigator# 7106, Las Vegas, Nevada, United States|Site Reference ID/Investigator# 7518, Las Vegas, Nevada, United States|Site Reference ID/Investigator# 7119, Las Vegas, Nevada, United States|Site Reference ID/Investigator# 7129, Las Vegas, Nevada, United States|Site Reference ID/Investigator# 7071, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 7100, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 14321, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 21355, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 7074, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 7065, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 7075, Dayton, Ohio, United States|Site Reference ID/Investigator# 24802, Kettering, Ohio, United States|Site Reference ID/Investigator# 7068, Mason, Ohio, United States|Site Reference ID/Investigator# 7104, Bellaire, Texas, United States|Site Reference ID/Investigator# 7060, Carrollton, Texas, United States|Site Reference ID/Investigator# 15282, Dallas, Texas, United States|Site Reference ID/Investigator# 6745, Dallas, Texas, United States|Site Reference ID/Investigator# 7083, Dallas, Texas, United States|Site Reference ID/Investigator# 7127, Dallas, Texas, United States|Site Reference ID/Investigator# 7110, Dallas, Texas, United States|Site Reference ID/Investigator# 21356, Deer Park, Texas, United States|Site Reference ID/Investigator# 11923, Fort Worth, Texas, United States|Site Reference ID/Investigator# 7321, Houston, Texas, United States|Site Reference ID/Investigator# 21354, Houston, Texas, United States|Site Reference ID/Investigator# 21358, Houston, Texas, United States|Site Reference ID/Investigator# 26482, Houston, Texas, United States|Site Reference ID/Investigator# 7079, Houston, Texas, United States|Site Reference ID/Investigator# 7096, Houston, Texas, United States|Site Reference ID/Investigator# 7126, Houston, Texas, United States|Site Reference ID/Investigator# 8186, Houston, Texas, United States|Site Reference ID/Investigator# 11323, Houston, Texas, United States|Site Reference ID/Investigator# 7130, Houston, Texas, United States|Site Reference ID/Investigator# 11924, Irving, Texas, United States|Site Reference ID/Investigator# 13863, Irving, Texas, United States|Site Reference ID/Investigator# 7099, McKinney, Texas, United States|Site Reference ID/Investigator# 19121, New Braunfels, Texas, United States|Site Reference ID/Investigator# 26244, Pearland, Texas, United States|Site Reference ID/Investigator# 7105, Plano, Texas, United States|Site Reference ID/Investigator# 7061, San Antonio, Texas, United States|Site Reference ID/Investigator# 7320, San Antonio, Texas, United States|Site Reference ID/Investigator# 7914, San Antonio, Texas, United States|Site Reference ID/Investigator# 7058, San Antonio, Texas, United States|Site Reference ID/Investigator# 18402, San Antonio, Texas, United States|Site Reference ID/Investigator# 7052, San Antonio, Texas, United States|Site Reference ID/Investigator# 7062, San Antonio, Texas, United States|Site Reference ID/Investigator# 22947, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00616772
NCT00613613,Fenofibrate and Pharmacogenetic Impact in Dyslipidemia,FPI,Completed,No Results Available,Dyslipidemia,Drug: fenofibrate,Triglyceride lowering response|Pharmacokinetic parameters based on genotype,University of Minnesota - Clinical and Translational Science Institute|Laval University,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,56,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,0708M15441|AHA Grant #0755839Z,Jan-08,Oct-13,Dec-13,13-Feb-08,null,3-Dec-14,"University of Minnesota, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00613613
NCT00608699,A Study To See If GSK256073A Can Block Niacin-Induced Flushing In Healthy Volunteers,,Completed,No Results Available,Healthy Subjects|Dyslipidaemias,Drug: GSK256073A tablets + IR niacin tablets,Intensity of reported flushing - visual analogue scale; self reported assessment of flushing|Safety and tolerability of GSK256073A and immediate release niacin|Standard and Secondary pharmacokinetic endpoints of interest|Pharmacodynamic response,GlaxoSmithKline,Male,18 Years to 55 Years   (Adult),Phase 1,24,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic,HMA111316,Dec-07,Apr-08,Apr-08,6-Feb-08,null,30-Apr-12,"GSK Investigational Site, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00608699
NCT00607347,Atenolol Exposure as Risk for Adverse Metabolic Responses to Beta Blockers,,Completed,No Results Available,Hypertension,Other: Glucose,"Correlation of area under curve (AUC) up to 24 hour time point of atenolol plasma drug concentrations and glucose/insulin values obtained from OGTT and triglycerides|HDL-cholesterol, fatty acids, total cholesterol",University of Florida,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,24,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,UF IRB 591-2007|U01GM074492|GCRC grant RR00082,Feb-08,Jun-09,Jun-09,5-Feb-08,null,20-Sep-11,"University of Florida, Gainesville, Florida, United States",,https://ClinicalTrials.gov/show/NCT00607347
NCT00607373,Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia,RADICHOL 1,Completed,Has Results,"Lipid Metabolism, Inborn Errors|Hypercholesterolemia, Autosomal Dominant|Hyperlipidemias|Metabolic Diseases|Hyperlipoproteinemia Type II|Metabolism, Inborn Errors|Genetic Diseases, Inborn|Infant, Newborn, Diseases|Metabolic Disorder|Congenital Abnormalities|Hypercholesterolemia|Hyperlipoproteinemias|Dyslipidemias|Lipid Metabolism Disorders",Drug: mipomersen|Drug: Placebo,Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Primary Efficacy Time Point|LDL-C at Baseline and the Primary Efficacy Time Point (PET)|Percent Change From Baseline in Apolipoprotein B (Apo-B) at Primary Efficacy Time Point|Apo-B at Baseline and the Primary Efficacy Time Point (PET)|Percentage Change From Baseline in Total Cholesterol at Primary Efficacy Time Point (PET)|Total Cholesterol at Baseline and the Primary Efficacy Time Point (PET)|Percentage Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Primary Efficacy Time Point (PET)|Non-HDL-C at Baseline and the Primary Efficacy Time Point (PET),"Kastle Therapeutics, LLC|Ionis Pharmaceuticals, Inc.",All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,51,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",301012CS5|2005-003449-15,Jul-07,Mar-09,Mar-09,5-Feb-08,21-Mar-13,9-Sep-16,"Charlotte, North Carolina, United States|Cincinnati, Ohio, United States|Sao Paulo, SP, Brazil|Chicoutimi, Quebec, Canada|Ste Foy, Quebec, Canada|Mistri Wing, Singapore|Observatory, South Africa|Parktown, South Africa|Taipei, Taiwan|London, United Kingdom",,https://ClinicalTrials.gov/show/NCT00607373
NCT00605787,TTA in Treatment of Diabetes and Dyslipidemia,TODDY,Completed,No Results Available,Type 2 Diabetes Mellitus|Dyslipidemia,Drug: Tetradecylthioacetic acid (TTA),Plasma lipids|Plasma glucose|Safety blood parameters,Haukeland University Hospital|University of Bergen,Male,30 Years to 60 Years   (Adult),Phase 2,16,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NSD18032|REKIII021.01|SLV01-1232,Jan-02,Jun-03,Dec-07,31-Jan-08,null,31-Jan-08,"Haukeland University Hospital, Bergen, Norway",,https://ClinicalTrials.gov/show/NCT00605787
NCT00603291,BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus,,Completed,Has Results,Obesity,Drug: Lorcaserin 10 mg QD|Drug: Lorcaserin 10 mg BID|Drug: Matching Placebo,Co-primary Endpoint- Proportion (%) of Patients Achieving > or = 5% Weight Loss From Baseline to Week 52|Percent Change in Body Weight From Baseline to Week 52,Arena Pharmaceuticals,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,604,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",APD356-010,Dec-07,Jun-10,Oct-10,29-Jan-08,7-Feb-13,7-Feb-13,"Arena Pharmaceuticals, Inc., San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT00603291
NCT00603590,Phase II Study of Heart Polypill Safety and Efficacy in Primary Prevention of Cardiovascular Disease,Polypill,Completed,Has Results,Cardiovascular Disease|Hypertension|Hyperlipidemia|Heart Disease,Drug: Polypill|Drug: Placebo drug,Systolic Blood Pressure|Diastolic Blood Pressure|LDL Cholesterol,Tehran University of Medical Sciences|University of Birmingham,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 2,475,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",301/148|CCT-NAPN 15388,Nov-06,Jun-08,Jul-08,29-Jan-08,23-Jun-09,2-Oct-09,"Kalaleh Heart Study Center, Kalaleh, Golestan, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT00603590
NCT00603876,Efficacy of Almonds Added to Chronic Statin Therapy,,Completed,No Results Available,Hyperlipidemia,Dietary Supplement: Almonds,"Measure of lipid panel including subfractions and Lp(a) and almond adherence|Measurement of height, weight, waist circumference, blood pressure and physical activity",University of Kansas|Almond Board of California|University of Kansas Medical Center,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KU FY08 GRF|10998,Jul-08,Dec-12,Dec-12,29-Jan-08,null,22-May-13,"University of Kansas Medical Center, Kansas City, Kansas, United States|KU MedWest, Shawnee, Kansas, United States",,https://ClinicalTrials.gov/show/NCT00603876
NCT00603902,BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management,,Completed,Has Results,Obesity,Drug: Lorcaserin 10 mg QD|Drug: Lorcaserin 10 mg BID|Drug: Matching Placebo,Co-primary Endpoint- Proportion (%) of Patients Achieving > or = 5% Weight Loss From Baseline to Week 52|Percent Change in Body Weight From Baseline to Week 52,Arena Pharmaceuticals,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,4008,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",APD356-011,Jan-08,Jul-09,Aug-09,29-Jan-08,7-Feb-13,7-Feb-13,"Arena Pharmaceuticals, Inc., San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT00603902
NCT00598910,Effect of Omacor on Triglycerides in HIV Infected Subjects,,Terminated,No Results Available,Hyper-Triglyceridemia,Drug: Omacor|Drug: Placebo,Percent change in serum triglycerides from baseline to treatment endpoint versus placebo|Absolute change in serum triglycerides|Absolute and percent change in cholesterol and cholesterol subfractions|Absolute and percent change in apolipoprotein A and B,Solvay Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 4,51,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",S185.4.001|2007-001921-86,Aug-07,Sep-08,Mar-09,23-Jan-08,null,30-Mar-09,"Site 2, Bochum, Germany|Site 1, Hannover, Germany|Site 3, London, United Kingdom|Site 4, London, United Kingdom|Site 5, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT00598910
NCT00593424,Effect of Changing Diet on Fasting and Post Fat Load Lipoproteins,,Completed,No Results Available,Hypertriglyceridemia|Diabetes Mellitus,Other: Low Fat/High Carbohydrate|Other: High Monounsaturated Fat/Low Carbohydrate,Paired t-test or Wilcoxon signed rank test will be used to evaluate the change in fasting triglycerides with the diets.|Post-prandial lipids will be evaluated by t-test or Wilcoxon signed rank test for AUC of triglyceride and remnant lipoprotein measured by immunoseparation.,University of Arkansas,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,15,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care",7407,Aug-02,Nov-05,Nov-05,15-Jan-08,null,2-Sep-11,"Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, United States",,https://ClinicalTrials.gov/show/NCT00593424
NCT00593632,A Controlled Trial of High Dietary Fiber Intake on Serum Lipids,,Completed,No Results Available,Hyperlipidemia,Dietary Supplement: Uncle Sam Cereal,"To test whether 30-40g of daily dietary fiber increases HDL, lowers total cholesterol and LDL levels in patients at 12 weeks|To test whether Lipoprotein (a), triglyceride level, LDL: HDL ratio, fibrinogen, CRP, Urine f1 2 isoprostane and body weight will be lowered in patients after 12weeks.",The Cleveland Clinic|Attune Foods,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,07-852,Jan-08,Jul-11,Jul-13,15-Jan-08,null,9-Mar-17,"Cleveland Clinic, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00593632
NCT00593047,LDL-Cholesterol Lowering Effect of KB2115 as Add on to Statin,,Completed,No Results Available,Dyslipidemia,Drug: KB2115,LDL cholesterol|Triglyceride,Karo Bio AB,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,180,Industry,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",KBT004|2007-004413-33,Nov-07,Jul-08,Sep-08,14-Jan-08,null,1-Dec-08,"Carl-Peter Anderberg, Gothemburg, Sweden",,https://ClinicalTrials.gov/show/NCT00593047
NCT00585143,Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered Concomitantly,,Completed,No Results Available,"Dyslipidemia, Renal Insufficiency",Drug: ABT-335|Drug: Rosuvastatin,Blood concentrations of the active ingredients and metabolites of ABT-335 and rosuvastatin|Safety and tolerability of the study drugs,AstraZeneca,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,37,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,M10-070,Jan-08,Oct-08,Oct-08,3-Jan-08,null,28-Sep-12,"Site Reference ID/Investigator# 6610, Gainesville, Florida, United States|Site Reference ID/Investigator# 6738, Miami, Florida, United States|Site Reference ID/Investigator# 7723, Minneapolis, Minnesota, United States|Site Reference ID/Investigator# 7319, Knoxville, Tennessee, United States|Site Reference ID/Investigator# 6928, San Antonio, Texas, United States|Site Reference ID/Investigator# 8280, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00585143
NCT00574808,Improved Delivery of Cardiovascular Care Through Outreach Facilitation,IDOCC,Completed,No Results Available,Hypertension|Dyslipidemia|Diabetes|Chronic Kidney Disease|Cardiovascular Disease|Stroke|Transient Ischemic Attacks,Other: Outreach Facilitation implementing elements of the Chronic Care Model,Quality of care process index = ∑ of recommended services received by patient/ ∑ of the recommended services for which the patient was eligible|Quality of care outcome index = ∑ of recommended targets reached / ∑ of the number of targets for which the patient is eligible based on the number of conditions suffered by the patient,"C. T. Lamont Primary Care Research Centre|Dept of Family Medicine, Faculty of Medicine, Hebrew University, Jerusalem, Israel|Institute of Population Health, University of Ottawa|Ottawa Heart Institute Research Corporation|Ottawa Cardiovascular Centre|Ottawa Regional Stroke Program|Bruyere Research Institute|Champlain Primary Care Practices",All,"40 Years and older   (Adult, Older Adult)",Phase 1,194,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research,IDOCC|937200801,Apr-07,Feb-13,Feb-13,17-Dec-07,null,6-Oct-14,"Elisabeth Bruyere Health Centre, Ottawa, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00574808
NCT00572429,Effects of Mixed Exercise Regime and L-Carnitine Supplementation in HIV Patients on HAART,HIV,Withdrawn,No Results Available,HIV Infections|Hyperlipidemia|Exercise,Dietary Supplement: l-carnitine,"Exercise and L-carnitine supplementation will reduce blood lactate levels, increase the VO2sub-max and the VLDL to leucine enrichment ratio in HIV/HAART patients, suggesting an overall improvement of muscle and hepatic mitochondrial function.","University of California, Davis",All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,0,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",200715081,Jul-08,Dec-10,Dec-10,13-Dec-07,null,19-Dec-12,"CARES, Sacramento, California, United States",,https://ClinicalTrials.gov/show/NCT00572429
NCT00570739,"Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.",,Completed,Has Results,Type 2 Diabetes Mellitus|Hypercholesterolemia|Pre-diabetes,Drug: Metformin HCl and Colesevelam Placebo|Drug: Metformin HCl tablets and Colesevelam tablets|Drug: Colesevelam placebo|Drug: Colesevelam,"Percent Change of Hemoglobin A1C (HbA1C) From Baseline to 16 Weeks When Given as Initial Therapy to Drug-naïve, Diabetic Subjects.|Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) in Pre-Diabetic Subjects From Baseline to 16 Weeks|Percent Change in Hemoglobin A1C (HbA1C) When Given to Drug-naïve, Diabetic Subjects From Baseline to 4, 8, 12 and 16 Weeks.|Fasting Plasma Glucose When Given to Drug-naïve, Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks|Fasting Insulin When Given to Drug-naïve, Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks|Fasting C-Peptide Levels When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks|30 Minute Post-Meal Glucose Levels When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks|1 Hour Post-Meal Glucose Levels When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks|2 Hour Post-Meal Glucose Levels to in Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks|2 Hour Post-Meal Insulin Levels When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks|2 Hour Post-Meal C-Peptide Levels When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks|The Percent Change of Low Density Lipoprotein Cholesterol (LDL-C) When Given to Drug-naïve, Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change of Non-High Density Lipoprotein (Non-HDL) Levels When Given to Drug-naïve, Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change of High Density Lipoprotein Cholesterol(HDL-C) When Given to Drug-naïve, Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change of Total Cholesterol (TC) When Given to Drug-naïve, Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change of Triglycerides (TG)When Given to Drug-naïve, Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change of Apolipoprotein A-1 (Apo A-1) When Given to Drug-naïve, Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change of Apolipoprotein B (Apo B)When Given to Drug-naïve, Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change of Apolipoprotein C3 (Apo C3)When Given to Drug-naïve, Diabetic Subjects From Baseline to 8, and 16 Weeks|Change in the Levels of Various Lipoprotein Particles When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks|Change in the Size of Various Lipoprotein Particles When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks|Change in the Calculated Total Triglycerides When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks|Change in the Calculated Very Low Density Lipoprotein Triglycerides When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks|Change in the Calculated High Density Lipoprotein Cholesterol When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks|Percent of Subjects Achieving HbA1c Goal of <7.0% at Weeks 4, 8, 12, and 16 if Baseline HbA1c Was > or = to 7.0% When Given to Drug-naïve, Diabetics|Percent of Subject Achieving HbA1c Goal of <6.5% at Weeks 4, 8, 12, and 16 When Given to Drug-naïve, Diabetic Subjects|Percent of Subjects Achieving Low Density Lipoprotein-Cholesterol of <100 mg/dL at Weeks 8, 16 When Given to Drug-naïve, Diabetic Subjects|Percent of Subjects Achieving Low Density Lipoprotein-Cholesterol Goal of <70 mg/dL at Weeks 8, 16 When Given as to Drug-naïve, Diabetics|Change in Body Weight When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks|Change in Waist-to-Hip Ratio When Given to Drug-Naive Diabetic Subjects From Baseline to 16 Weeks|Change in Plasma Glucose Area Under the Curve (0 to 120 Minutes) From the Baseline Glucose Tolerance Test (GTT) to the 16 Week GTT|Percent Change of Various Calculated Lipid Parameters When Given as Initial Therapy to Drug-naïve, Diabetic From Baseline to 16 Weeks Subjects|Percent of Subjects Achieving 2-Hr. Post Meal Glucose Goal of <180 mg/dL When Given to Drug-naïve, Diabetic Subjects From Baseline to Week 16|Percent of Subjects Achieving Hs-C-Reactive Protein Goal of <2.0 mg/L When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks|Percent Change in Low Density Lipoprotein-Cholesterol in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change in Non-High Density Lipoprotein-Cholesterol in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change in High Density Lipoprotein-Cholesterol in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change in Total Cholesterol in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change in Apolipoprotein A-1 in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change in Apolipoprotein B in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change in Apolipoprotein CIII in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change in Triglycerides in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change in Hs-C-Reactive Protein in Pre-Diabetic Subjects From Baseline to 16 Weeks|Level of Various Lipoprotein Particles in Pre-Diabetic Subjects From Baseline to 16 Weeks|Particle Size of Various Lipoprotein Particles in Pre-Diabetic Subjects From Baseline to 16 Weeks|Change of Various Calculated Lipid Parameters in Pre-Diabetic Subjects From Baseline to 16 Weeks|Percent Change of HbA1c in Pre-Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks|Percent Change of Fasting Plasma Glucose in Pre-Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks|Percent Change of Fasting Insulin in Pre-Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks|Change of Fasting C-peptide Levels in Pre-Diabetic Subjects From Baseline to 16 Weeks|Change of Glucose Levels 30 Minutes Post Oral Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks|Change of Glucose Levels 1 Hour Post Oral Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks|Change of Glucose Levels 2 Hours Post Oral Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks|Change of Insulin Levels 2 Hours Post Oral Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks|Change of C-Peptide Levels 2 Hours Post Oral Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks|Percent of Subjects Achieving Low Density Lipoprotein-Cholesterol of <100 mg/dL at Weeks 8, 16 in Pre-Diabetic Subjects|Percent of Subjects Achieving Low Density Lipoprotein-Cholesterol of <70 mg/dL at Weeks 8, 16 in Pre-Diabetic Subjects|Change in Body Weight in Pre-Diabetic Subjects From Baseline to 16 Weeks|Change in Waist-to-Hip Ratio in Pre-Diabetic Subjects From Baseline to 16 Weeks|Area Under the Curve for Plasma Glucose From 0 to 120 Minutes During the Oral Glucose Tolerance Tests in Pre-Diabetic Subjects From Baseline to 16 Weeks|Percent Achievement of <140 mg/dL Plasma Glucose 2 Hours Post the Oral Glucose Tolerance Test in Pre-Diabetic Subjects Whose Corresponding Baseline Value Was >or= to 140 mg/dL From Baseline to 16 Weeks|Percent Achievement of <110 mg/dL Fasting Plasma Glucose in Pre-Diabetic Subjects Whose Corresponding Baseline Value Was > or = to 110 mg/dL From Baseline to 4, 8, 12, and 16 Weeks|Percent Achievement of <100 mg/dL Fasting Plasma Glucose in Pre-Diabetic Subjects Whose Corresponding Baseline Value Was > or = to 100 mg/dL From Baseline to 4, 8, 12 and 16 Weeks|Percent Achievement of <140 mg/dL Plasma Glucose Post 2 Hour Glucose Tolerance Test and Fasting Plasma Glucose <110 mg/dL in Pre-Diabetic Subjects From Baseline to 16 Weeks|Percent Achievement of Hs-C-Reactive Protein <2.0 mg/L in Pre-Diabetic Subjects Whose Corresponding Baseline Value Was > or = to 2.0 mg/L From Baseline to 16 Weeks|Percent of Subjects Meeting Type 2 Diabetes Criteria (Fasting Plasma Glucose >or= to 126 mg/dL or Plasma Glucose >or= to 200 mg/dL Post 2 Hr Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks","Daiichi Sankyo, Inc.",All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 3,502,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","WEL-411|IND 68,466",Nov-07,Apr-09,May-09,11-Dec-07,13-Jul-10,27-Jul-10,"Birmingham, Alabama, United States|Los Gatos, California, United States|Tarzana, California, United States|Ocala, Florida, United States|Pocatello, Idaho, United States|Gary, Indiana, United States|New Orleans, Louisiana, United States|Olive Branch, Mississippi, United States|Dundee, New York, United States|West Seneca, New York, United States|Statesville, North Carolina, United States|Kent, Ohio, United States|Marion, Ohio, United States|Portland, Oregon, United States|Corpus Christi, Texas, United States|Dallas, Texas, United States|San Antonio, Texas, United States|Barranquilla, Atlántico, Colombia|Bogota, Cundinamarca, Colombia|Bucaramanga, Santander, Colombia|Mumbai, Dadar, India|Durgapura, Jaipur, India|Bangalore, Karnataka, India|Cochin, Kerala, India|Nasik, Mahārāshtra, India|Las Palmas, Chihuahua, Mexico|Delegacion, Cuauhtemoc, Mexico|Guadalajara, Jalisco, Mexico|Monterrey, Nuevo Leon, Mexico|Hermosillo, Sonora, Mexico|Merida, Yucatan, Mexico",,https://ClinicalTrials.gov/show/NCT00570739
NCT00569959,Assessment of Non-Fasting vs. Fasting Lipid Measures in Diabetes Patients,,Completed,No Results Available,Diabetes Mellitus|Normal Glucose Metabolism|Hyperlipidemia,Other: fasting 12+ hours|Other: Non-fasting,LDL-Cholesterol|Other lipid parameters,HealthPartners Institute,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,03363-05-A,Nov-06,null,Jun-07,10-Dec-07,null,26-Nov-15,"Park Nicollet Internal and Family Medicine Clinics, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00569959
NCT00566267,"A Randomized, Double-Blinded Study of Simvastatin 20 mg/Day Versus Vytorin 10/20 in Subjects With Lipid Profiles Not Meeting Current NCEP Guidelines, Following a Low-Carbohydrate Diet",LOCUST,Completed,No Results Available,Hyperlipidemia,Drug: simvastatin 20 mg/ezetimibe,LDL cholesterol|Other lipid measures|Safety and tolerability,Merck Sharp & Dohme Corp.|Corporal Michael J. Crescenz VA Medical Center,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2|Phase 3,58,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",00887|MIRB Number: 00887|PROM # 0025,Apr-06,null,Nov-07,3-Dec-07,null,3-Dec-07,,,https://ClinicalTrials.gov/show/NCT00566267
NCT00565292,A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia (MK-0859-011)(COMPLETED),,Completed,No Results Available,Hypercholesterolemia|Hyperlipidemia,Drug: MK0859,,Merck Sharp & Dohme Corp.,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,50,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,0859-011|2007_655,Jul-06,Aug-06,Aug-06,29-Nov-07,null,25-Feb-15,,,https://ClinicalTrials.gov/show/NCT00565292
NCT00562575,Evaluation of Safety and Effects of SLx-4090 After Dosing for 14 Days in Subjects With High Triglycerides,,Completed,No Results Available,Hypertriglyceridemia,Drug: SLx-4090|Drug: Placebo,Serum triglycerides|Adverse events and vital signs,"Kadmon Corporation, LLC",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,24,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",SLx-4090-07-03,May-07,Feb-08,Feb-08,22-Nov-07,null,2-Feb-15,"FOCUS Clinical Drug Development GmbH, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT00562575
NCT00559962,Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS,,Completed,Has Results,Hyperlipidemia,Drug: AEGR-733|Drug: placebo|Drug: AEGR-733 and atorvastatin|Drug: AEGR-733 and fenofibrate|Drug: AEGR-733 and ezetimibe,Absolute Change From Baseline in Percent Hepatic Fat,"Aegerion Pharmaceuticals, Inc.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,260,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",AEGR-733-004,Oct-07,Oct-08,Nov-08,19-Nov-07,22-Feb-13,23-Feb-18,"Scripps Clinic, San Diego, California, United States|Radiant Research, Santa Rosa, California, United States|MedStar Research Institute, Washington, District of Columbia, United States|Radiant Research, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|LMARC, Louisville, Kentucky, United States|Maine Research Associates, Auburn, Maine, United States|Health Trends Research, Baltimore, Maryland, United States|Johns Hopkins, Baltimore, Maryland, United States|Washington Univ. School of Medicine, Saint Louis, Missouri, United States|Sterling Research Group, Cincinnati, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Baylor College of Medicine, Houston, Texas, United States|Clinical Trial Network, Houston, Texas, United States|dgd Research, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00559962
NCT00560430,Regulation of Inflammatory Parameters by Telmisartan in Hypertensive Patients,METATEL,Completed,No Results Available,Hypertension|Metabolic Syndrome|Hypertriglyceridemia,Drug: telmisartan|Drug: placebo,change in IL-6|change in fasting lipids;|change in postprandial lipid metabolism|change in inflammatory parameters|change in glucose metabolism,Ludwig-Maximilians - University of Munich|Bayer,All,19 Years to 60 Years   (Adult),Phase 3,56,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",KPUK0106|EudraCT 2006-003567-31,Nov-07,Sep-09,Oct-09,19-Nov-07,null,15-Jul-10,"Center for Cardiovascular Research, University Berlin, Berlin, Germany|Med. Dept. 2, University Munich, Munich, Germany",,https://ClinicalTrials.gov/show/NCT00560430
NCT00552747,Effect of Fenofibrate on Endothelial Function and High-density Lipoproteins (HDL)in Patients With Coronary Heart Disease,,Completed,No Results Available,Coronary Heart Disease|Hyperlipidemia,Drug: fenofibrate|Drug: placebo,endothelial function|HDL particle distribution|HDL associated antioxidant capacity,"National Heart Institute, Mexico",Male,18 Years to 60 Years   (Adult),Phase 4,76,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",fenofibrate,Oct-07,Mar-10,Jan-11,2-Nov-07,null,10-Mar-11,"Endocrinology Department National Institute of Cardiology Ignacio Chavez, Mexico City, Mexico",,https://ClinicalTrials.gov/show/NCT00552747
NCT00552097,Effect of Ezetimibe Plus Simvastatin Versus Simvastatin Alone on Atherosclerosis in the Carotid Artery (ENHANCE)(P02578),ENHANCE,Completed,No Results Available,Atherosclerosis|Hypercholesterolemia|Hyperlipoproteinemia Type II,Drug: ezetimibe (plus simvastatin)|Drug: placebo (plus simvastatin),Change in ultrasound-determined average carotid artery intima-media thickness (IMT) on a per subject basis between baseline and endpoint.|Proportion of subjects with a reduction in ultrasound-determined average carotid artery IMT between baseline and endpoint.|Change in ultrasound-determined maximum carotid artery IMT on a per subject basis between baseline and endpoint.|Proportion of subjects developing new carotid artery plaques between baseline and endpoint.|Change in ultrasound-determined average carotid artery plus average common femoral artery IMT on a per subject basis between baseline and endpoint.,Merck Sharp & Dohme Corp.,All,"30 Years to 75 Years   (Adult, Older Adult)",Phase 3,720,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",P02578,1-Jun-02,25-Apr-06,25-Apr-06,1-Nov-07,null,11-May-17,,,https://ClinicalTrials.gov/show/NCT00552097
NCT00551694,A Second Study to Determine the Effect of GSK256073A on HVTs,,Completed,No Results Available,Healthy Subjects|Dyslipidaemias,Drug: GSK256073A tablets,"AEs, 12-Lead ECG, vital signs, nursing/physician observation, safety lab tests, flushing throughout the study.|AUC and Cmax|Measures of accumulation ratios throughout the study (Ro, Rp, and Rs)[Period 2]|Tmax, t½, Ae, and CLr , Cmax, ss, Ct, t½, Ae, CLr, and accumulation ratios throughout the study|PD response: NEFA and TG (6 and 24 hours post- dose), LDL, HDL, ApoA1, ApoA2, Apo B and Lp(a) on Days 1, 14, and 15.",GlaxoSmithKline,All,18 Years to 55 Years   (Adult),Phase 1,4,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,HMA110541,Oct-07,Dec-07,Dec-07,31-Oct-07,null,4-Jun-12,"GSK Investigational Site, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00551694
NCT00549926,"Yokohama Assessment of Fluvastatin, Pravastatin, Pitavastatin and Atorvastatin in Acute Coronary Syndrome (Yokohama-ACS)",Yokohama-ACS,Completed,No Results Available,Coronary Disease|Hypercholesterolemia,Drug: Fluvastatin|Drug: Pravastatin|Drug: Pitavastatin|Drug: Atorvastatin,the percent change in coronary plaque volume the percent change in integrated backscatter signal obtained by integrated backscatter IVUS|absolute change from baseline in coronary plaque volume|absolute and percent changes in minimal lumen diameter(MLD) and percent(%) stenosis|absolute and percent changes in total cholesterol(TC);low-density lipoprotein(LDL)-cholesterol(LDL-C),Yokohama City University Medical Center,All,"20 Years and older   (Adult, Older Adult)",Phase 4,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Yokohama-ACS,Oct-07,null,Feb-10,26-Oct-07,null,17-Feb-10,"Yokohama City University Medical Center, Yokohama, Japan",,https://ClinicalTrials.gov/show/NCT00549926
NCT00548145,The Clinical Study of Pitavastatin Treatment for Group of Mild to Moderate Alzheimer's Disease,PIT-ROAD,Terminated,Has Results,Alzheimer Disease|Hypercholesterolemia,"Drug: Pitavastatin|Drug: cholesterol-lowering medicine other than statin(e.g.,Ezetimibe,Colestimide)","Alzheimer's Disease Assessment Scale-cognitive Component-Japanese Version(ADAS-Jcog)|MMSE, Neuropsychiatric Inventory, GDS-15, Zarit Burden Scale, Physical Self-Maintenance Scale, IADL, Everyday Memory Checklist, TC, HDL-C, Non HDL-C*, Apo A1, Apo B, Apo E *: Non HDL-C = (TC) - (HDL-C)","Osaka University|Kowa Company, Ltd.",All,"20 Years to 85 Years   (Adult, Older Adult)",Not Applicable,38,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OSK-07098,Nov-07,Oct-11,Mar-12,23-Oct-07,14-Jun-12,14-Jun-12,"Osaka University Hospital, Suita, Osaka, Japan",,https://ClinicalTrials.gov/show/NCT00548145
NCT00547274,Dyslipidemia in Type 2 Diabetes (0767-034),,Terminated,No Results Available,"Diabetes Mellitus, Type II|Dyslipidemia",Drug: MK0767,,Merck Sharp & Dohme Corp.,All,"21 Years and older   (Adult, Older Adult)",Phase 3,111,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0767-034|2007_635|MK-0767-034,Jul-03,Nov-03,Nov-03,22-Oct-07,null,12-Jun-15,,,https://ClinicalTrials.gov/show/NCT00547274
NCT00542386,A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia,,Completed,Has Results,Chronic Kidney Disease|Dialysis|Hyperphosphatemia|Dyslipidemia,Drug: MCI-196|Drug: Placebo,The Change in Serum Phosphorus|The Change in LDL-cholesterol|The Change in Total-cholesterol|The Change in HDL-cholesterol|The Change in Triglycerides|The Change in PTH|The Change in Ca|The Change in Ca x P Ion Product|The Incidence of Adverse Events,Mitsubishi Tanabe Pharma Corporation,All,"18 Years and older   (Adult, Older Adult)",Phase 3,642,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MCI-196-E08,Dec-07,Nov-09,Nov-09,11-Oct-07,6-Oct-14,6-Oct-14,"Ajka, Hungary|Baja, Hungary|Budapest, Hungary|Esztergom, Hungary|Gyor, Hungary|Hatvan, Hungary|Kisvarda, Hungary|Lecco, Italy|Modena, Italy|Pavia, Italy|Roma, Italy|Skopje, Macedonia, The Former Yugoslav Republic of|Alor Star, Malaysia|Ipoh, Malaysia|Kajang, Malaysia|Klang, Malaysia|Kota Kinabalu, Malaysia|Kuala Terengganu, Malaysia|Kuantan, Malaysia|Kuching, Malaysia|Melaka, Malaysia|Seremban, Malaysia|Taiping, Malaysia|Lodz, Poland|Plock, Poland|Poznan, Poland|Rybnik, Poland|Warszawa, Poland|Wroclaw, Poland|Zielona Gora, Poland|Arkhangelsk, Russian Federation|Armavir, Russian Federation|Chelyabinsk, Russian Federation|Chita, Russian Federation|Ekaterinburg, Russian Federation|Irkutsk, Russian Federation|Ivanovo, Russian Federation|Kaluga, Russian Federation|Kemerovo, Russian Federation|Khabarovsk, Russian Federation|Krasnodar, Russian Federation|Krasnoyarsk, Russian Federation|Moscow, Russian Federation|Nizhniy Novgorod, Russian Federation|Novokuznetsk, Russian Federation|Novorossiysk, Russian Federation|Novosibirsk, Russian Federation|Omsk, Russian Federation|Petrozavodsk, Russian Federation|Rostov-on Don, Russian Federation|Smolensk, Russian Federation|St. Petersburg, Russian Federation|Tomsk, Russian Federation|Tumen, Russian Federation|Tver, Russian Federation|Vladimir, Russian Federation|Vladivostok, Russian Federation|Volzhskiy, Russian Federation|Yaroslavl, Russian Federation|Belgrade, Serbia|Kragujevac, Serbia|NIS, Serbia|Novi Sad, Serbia|Chernivtsi, Ukraine|Dnepropetrovsk, Ukraine|Ivano-Frankivsk, Ukraine|Kharkiv, Ukraine|Kiev, Ukraine|Mykolaiv, Ukraine|Ternopil, Ukraine|Uzhgorod, Ukraine|Zaporizhya, Ukraine|Zhytomyr, Ukraine",,https://ClinicalTrials.gov/show/NCT00542386
NCT00541554,"Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia",,Unknown status,No Results Available,Hyperprolactinemia|Weight Gain|Dyslipidemia,Drug: Abilify (aripiprazole),,"Genovate Biotechnology Co., Ltd.,",All,"12 Years to 65 Years   (Child, Adult, Older Adult)",Phase 4,null,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,31-06-P05,Oct-07,null,Feb-09,10-Oct-07,null,10-Oct-07,,,https://ClinicalTrials.gov/show/NCT00541554
NCT00540293,Lipitor Korean Atorvastatin Goal Achievement Across Risk Levels Study,AT GOAL,Completed,Has Results,Dyslipidemias,Drug: Atorvastatin,Percent of Subjects in the Total and Each Cardiovascular Risk Group Achieving Low Density Lipoprotein-cholesterol (LDL-C) Target After 8 Weeks of Treatment.|Percent of Subjects in the Total Group and Each Cardiovascular Risk Group Achieving LDL-C Target After 4 Weeks of Treatment.|Changes in Lipid Parameters in Subjects in the Total Group and Each Cardiovascular Risk Group After 4 and 8 Weeks of Treatment|Percent Changes From Baseline in Lipid Parameters in Subjects in the Total Group and Each Cardiovascular Risk Group After 4 and 8 Weeks of Treatment|Subjects Who Achieved LDL-C Target With no Titration of Atorvastatin and After One Step Titration of Atorvastatin.|Percent of Subjects Who Achieved LDL-C Target With no Titration of Atorvastatin and After One Step Titration of Atorvastatin.|Change From Baseline in High Sensitive Circulating C-reactive Protein (Hs-CRP) After 4 and 8 Weeks of Treatment|Percent Change From Baseline in High Sensitive Circulating C-reactive Protein (Hs-CRP) After 4 and 8 Weeks of Treatment|Changes From Baseline in Selected Inflammatory Markers After 8 Weeks of Treatment.|Percent Changes From Baseline in Selected Inflammatory Markers After 8 Weeks of Treatment.,Pfizer,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,425,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A2581157,Oct-07,May-08,May-08,8-Oct-07,26-Jun-09,25-Aug-09,"Pfizer Investigational Site, Daegu, Korea, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Korea, Republic of|Pfizer Investigational Site, Busan, Korea, Republic of|Pfizer Investigational Site, Busan, Korea, Republic of|Pfizer Investigational Site, Daegu, Korea, Republic of|Pfizer Investigational Site, Daejeon, Korea, Republic of|Pfizer Investigational Site, Gwangju, Korea, Republic of|Pfizer Investigational Site, Gwangju, Korea, Republic of|Pfizer Investigational Site, Gyeonggi-do, Korea, Republic of|Pfizer Investigational Site, Gyeonggi-do, Korea, Republic of|Pfizer Investigational Site, Incheon, Korea, Republic of|Pfizer Investigational Site, Kyunggi-do, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT00540293
NCT00540111,Effect of Soluble Fiber on Hypertriglyceridemia and Immune Profile in HIV-positive Individuals.,,Completed,No Results Available,Hypertriglyceridemia|HIV Infections,Dietary Supplement: soluble fiber® (partially hydrolyzed guar gum),"Serum TG and TG/HDL-c ratio reduction was observed at all time points, but statistical significance was found just at M0 and M2. Regarding serum cytokines, TNFα- and IL-6 significantly decreased between M0 and M2, and only IL-6 reduced between M1 and M2.",UPECLIN HC FM Botucatu Unesp|Fundação de Amparo à Pesquisa do Estado de São Paulo,All,18 Years to 60 Years   (Adult),Not Applicable,19,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,upeclin/HC/FMB-Unesp-01,Mar-05,Jul-07,Oct-07,5-Oct-07,null,10-Feb-10,,,https://ClinicalTrials.gov/show/NCT00540111
NCT00536211,Physical Inactivity and Insulin Resistance in Skeletal Muscle.,,Withdrawn,No Results Available,Metabolic Syndrome X|Insulin Resistance|Hypertension|Hypercholesterolemia|Obesity,Behavioral: Exercise|Drug: Metformin,"Insulin sensitivity; following 12 weeks of exercise training and 1 and 3 days of detraining and + or - Metformin.|PGC-1 alpha transcription and mitochondrial fatty acid oxidation and enzyme activity in skeletal muscle; following 12 weeks of exercise training and 1, 2, and 3 days of detraining and + or - Metformin.",University of Kansas|US Department of Veterans Affairs|University of Kansas Medical Center,All,20 Years to 55 Years   (Adult),Not Applicable,0,Other|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1095378,Jun-09,Oct-11,Dec-11,27-Sep-07,null,11-Aug-15,"Harry S. Truman Memorial Veterans' Hospital, Columbia, Missouri, United States",,https://ClinicalTrials.gov/show/NCT00536211
NCT00536510,Effect of MK0524A on Cholesterol Levels (0524A-048),,Completed,Has Results,Hypercholesterolemia|Hyperlipidemia,Drug: laropiprant/niacin (MK0524A)|Drug: Comparator: placebo,Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) After 12 Weeks|Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) After 12 Weeks,Merck Sharp & Dohme Corp.,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,646,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0524A-048|2007_621,Apr-07,Mar-08,Mar-08,27-Sep-07,13-May-09,2-Sep-15,,,https://ClinicalTrials.gov/show/NCT00536510
NCT00535405,A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128),,Completed,Has Results,Hypercholesterolemia,Drug: Atorvastatin 10 mg|Drug: Ezetimibe 10 mg/simvastatin 20 mg|Drug: Atorvastatin 20 mg|Drug: Ezetimibe 10 mg/simvastatin 40 mg|Drug: Atorvastatin 40 mg,Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 12|Percentage of Patients Who Achieved LDL-C <70 mg/dL at Week 12|Percentage of Patients Without Atherosclerosis Vascular Disease (AVD) Who Achieved LDL-C <100 mg/dL or Patients With AVD Who Achieved LDL-C <70 mg/dL at Week 12|Percentage of Patients Who Achieved LDL-C <100 mg/dL at Week 12|Percentage of Patients With High Risk for CHD Who Achieved LDL-C <70 mg/dL at Week 12|Percentage of Patients With AVD Who Achieved LDL-C <70 mg/dL at Week 12,Merck Sharp & Dohme Corp.|Merck Shering-Plough JV Study,All,65 Years and older   (Older Adult),Phase 3,1289,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0653A-128|2007_588,Nov-07,Mar-09,Mar-09,26-Sep-07,25-May-10,14-Apr-17,,,https://ClinicalTrials.gov/show/NCT00535405
NCT00535535,Fructose-Induced Palmitate Synthesis in Overweight Subjects,,Completed,No Results Available,Elevated Triglycerides|Diabetes|Cardiovascular Disease,Dietary Supplement: Fructose|Dietary Supplement: Fructose and Glucose,"A comparison of the iAUC in VLDL TG palmitate 4 hours after F:G1:1, 1g/kg, vs. 1) fructose 0.5g/kg, and 2) F:G:1:1, 2g/kg.|Linear regression analysis of the relationship between the iAUC in VLDL TG palmitate after oral fructose and markers of carbohydrate and lipid flux",Rockefeller University|The Rogosin Institute,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,15,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single|Primary Purpose: Prevention,LHU-0616,Aug-07,Dec-11,Dec-11,26-Sep-07,null,23-Sep-13,"Rockefeller University, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00535535
NCT00535886,The Effects of Natural Versus Man-Made Trans Fatty Acids on Lipoprotein Profiles: A Pilot Study,,Completed,No Results Available,Cardiovascular Disease|Diabetes|Dyslipidemia,Dietary Supplement: Man-made Trans FA|Dietary Supplement: Natural Trans FA|Dietary Supplement: Oleic Acid,"The primary outcome measure will be the ratio of total to high density lipoprotein (HDL) cholesterol. Blood draws will take place at screening, three weeks, and five weeks.|Related secondary outcome measures include concentrations of low density lipoprotein (LDL) cholesterol, HDL cholesterol, triglyceride (TG) and Lp(a) measured at screening, three weeks, and five weeks.",Children's Hospital & Research Center Oakland|National Cattlemen's Beef Association,Male,"18 Years and older   (Adult, Older Adult)",Not Applicable,15,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,MM6222|IRB# 2005-45,Nov-05,null,Apr-06,26-Sep-07,null,7-May-08,"Children's Hospital Oakland Research Institute, Oakland, California, United States",,https://ClinicalTrials.gov/show/NCT00535886
NCT00533312,MK0524A Clinical Efficacy Study (0524A-026)(COMPLETED),,Completed,No Results Available,Hypercholesterolemia,"Drug: Comparator : placebo (unspecified) / Duraton of Treatment: 4 Weeks|Drug: MK0524A, niacin (+) laropiprant / Duration of Treatment : 4 Weeks|Drug: Comparator : niacin / Duraton of Treatment: 4 Weeks",To assess the HDL-C raising efficacy of MK-0524A when compared with niacin extended release (NIASPAN) and placebo.|To asses the triglyceride-lowering effects of MK-0524A when compared with niacin extended release (NIASPAN) and placebo.,Merck Sharp & Dohme Corp.,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,407,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,0524A-026|2007_619,Apr-05,Jul-05,Jan-07,21-Sep-07,null,7-Apr-17,,,https://ClinicalTrials.gov/show/NCT00533312
NCT00532311,Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With Hypercholesterolemia,,Terminated,No Results Available,Hypercholesterolemia,Drug: Lapaquistat acetate and stable statin therapy|Drug: Stable statin therapy,Change from Baseline in fasting plasma Low Density Lipoprotein cholesterol|Change from Baseline in Triglycerides|Change from Baseline in Total Cholesterol|Change from Baseline in High Density Lipoprotein cholesterol|Change from Baseline in Very Low Density Lipoprotein cholesterol|Change from Baseline in apolipoprotein A1|Change from Baseline in apolipoprotein B|Change from Baseline in non- High Density Lipoprotein cholesterol|Change from Baseline in the ratio of Low Density Lipoprotein cholesterol/High Density Lipoprotein cholesterol|Change from Baseline in the ratio of Total Cholesterol/High Density Lipoprotein cholesterol|Change from Baseline in the ratio of apolipoprotein A1/apolipoprotein B|Change from Baseline in high-sensitivity C-reactive protein|Percentage of subjects who achieve Low Density Lipoprotein cholesterol concentrations less than 1.81 mmol/L (70 mg/dL)|Percentage of subjects who achieve Low Density Lipoprotein cholesterol concentrations less than 2.59 mmol/L (100 mg/dL)|Percentage of subjects who achieve Low Density Lipoprotein cholesterol concentrations less than 3.37 mmol/L (130 mg/dL),Takeda,All,"18 Years and older   (Adult, Older Adult)",Phase 3,411,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TAK-475_307|U1111-1122-8479,Jul-07,Apr-08,Apr-08,20-Sep-07,null,22-Jun-16,"Birmingham, Alabama, United States|Huntsville, Alabama, United States|Mobile, Alabama, United States|Tuscaloosa, Alabama, United States|Chandler, Arizona, United States|Gilbert, Arizona, United States|Glendale, Arizona, United States|Tucson, Arizona, United States|Artesia, California, United States|Long Beach, California, United States|Santa Ana, California, United States|Santa Rosa, California, United States|Tustin, California, United States|Walnut Creek, California, United States|Colorado Springs, Colorado, United States|Golden, Colorado, United States|Washington, District of Columbia, United States|Coral Gables, Florida, United States|Ft. Meyers, Florida, United States|Hollywood, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|New Port Richey, Florida, United States|Pembroke Pines, Florida, United States|Pensacola, Florida, United States|Pinellas Park, Florida, United States|Sarasota, Florida, United States|St. Petersburg, Florida, United States|West Palm Beach, Florida, United States|Dunwoody, Georgia, United States|Idaho Falls, Idaho, United States|Aurora, Illinois, United States|Chicago, Illinois, United States|Evansville, Indiana, United States|Indianapolis, Indiana, United States|Iowa City, Iowa, United States|Overland Park, Kansas, United States|Wichita, Kansas, United States|Louisville, Kentucky, United States|CantonAuburn, Maine, United States|Scarborough, Maine, United States|Baltimore, Maryland, United States|Haverhill, Massachusetts, United States|Ann Arbor, Michigan, United States|Brooklyn Center, Minnesota, United States|Edina, Minnesota, United States|Olive Branch, Mississippi, United States|St. Louis, Missouri, United States|Billings, Montana, United States|Margate, New Jersey, United States|Wilwood, New Jersey, United States|Asheville, North Carolina, United States|Charlotte, North Carolina, United States|Durham, North Carolina, United States|Hickory, North Carolina, United States|Raleigh, North Carolina, United States|Salisbury, North Carolina, United States|Statesville, North Carolina, United States|Wilmington, North Carolina, United States|Winston Salem, North Carolina, United States|Cincinnati, Ohio, United States|Kettering, Ohio, United States|Mentor, Ohio, United States|Zanesville, Ohio, United States|Oklahoma City, Oklahoma, United States|Portland, Oregon, United States|Altoona, Pennsylvania, United States|Dowington, Pennsylvania, United States|Sellerville, Pennsylvania, United States|Warwick, Rhode Island, United States|Goose Creek, South Carolina, United States|Greer, South Carolina, United States|Mt Pleasant, South Carolina, United States|Mt. Pleasant, South Carolina, United States|Simpsonville, South Carolina, United States|Bristol, Tennessee, United States|Austin, Texas, United States|Corpus Christi, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|Irving, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Burke, Virginia, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Wauwatosa, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00532311
NCT00532558,Efficacy of Lapaquistat Acetate on Blood Cholesterol Levels in Treating Subjects With Hypercholesterolemia,,Terminated,No Results Available,Hypercholesterolemia,Drug: Lapaquistat acetate|Drug: Placebo,Change from Baseline in fasting plasma Low Density Lipoprotein cholesterol|Change from Baseline in Total Cholesterol|Change from Baseline in High Density Lipoprotein cholesterol|Change from Baseline in Very Low Density Lipoprotein cholesterol|Change from Baseline in apolipoprotein A1 Timeframe: Week 12 or Final Visit|Change from Baseline in apolipoprotein B|Change from Baseline in non- High Density Lipoprotein cholesterol|Change from Baseline in the ratio of Low Density Lipoprotein cholesterol/High Density Lipoprotein cholesterol|Change from Baseline in the ratio of Total Cholesterol/High Density Lipoprotein cholesterol|Change from Baseline in the ratio of apolipoprotein A1/apolipoprotein B|Change from Baseline in Triglycerides,Takeda,All,"18 Years and older   (Adult, Older Adult)",Phase 3,657,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TAK-475_306|U1111-1122-8417,Oct-07,May-08,May-08,20-Sep-07,null,24-May-12,"Tallinn, Estonia|Tartu, Estonia|Balatonfured, Hungary|Budapest, Hungary|Debrecen, Hungary|Pecs, Hungary|Szekszárd, Hungary|Érd, Hungary|Beer Sheva, Israel|Hadera, Israel|Haifa, Israel|Jerusalem, Israel|Kfar-Saba, Israel|Nahariya, Israel|Safed, Israel|Tel Aviv, Israel|Daugavpils, Latvia|Kuldiga, Latvia|Riga, Latvia|Amsterdam, Netherlands|Breda, Netherlands|GA Nijmegen, Netherlands|Groningen, Netherlands|Hoorn, Netherlands|Rotterdam, Netherlands|Utrecht, Netherlands|Zoetermeer, Netherlands|Elverum, Norway|Hamar, Norway|Kongsberg, Norway|Oslo, Norway|Ålesund, Norway|Moscow, Russian Federation|Saratov, Russian Federation|St. Petersburg, Russian Federation|Tyumen, Russian Federation|Volgograd, Russian Federation|Bratislava, Slovakia|Dolný Kubín, Slovakia|Kosice, Slovakia|Nitra, Slovakia|Nové Mesto Nad Váhom, Slovakia|Trebišov, Slovakia|Cordoba, Spain|Madrid, Spain|Pontevedra, Spain|REUS (Tarragona), Spain|Valencia, Spain|Dnepropetrovsk, Ukraine|Kharkiv, Ukraine|Kharkov, Ukraine|Kiev, Ukraine|Kyiv, Ukraine|Lutsk, Ukraine|Lviv, Ukraine|Belfast, United Kingdom|Bolton, United Kingdom|Glasgow, Scotland, United Kingdom|Oldham, United Kingdom|Paignton, Devon, United Kingdom|Sheffield, United Kingdom",,https://ClinicalTrials.gov/show/NCT00532558
NCT00530946,A Randomized Study To Evaluate Efficacy And Safety Of A Fixed Combination Therapy Of Amlodipine And Atorvastatin,,Completed,Has Results,Hypertension|Hypercholesterolemia,Drug: Amlodipine 2.5mg/Atorvastatin 5mg|Drug: Amlodipine 2.5mg/Atorvastatin 10mg|Drug: Amlodipine 5mg/Atorvastatin 5mg|Drug: Amlodipine 5mg/Atorvastatin 10mg,Change in Systolic Blood Pressure|Percent Change in Low Density Lipoprotein-Cholesterol|Change in Systolic Blood Pressure From Baseline to Each Observation Point|Change in Diastolic Blood Pressure From Baseline to Each Observation Point|Percent Change in Low Density Lipoprotein-Cholesterol From Baseline to Each Observation Point|Percent Change in Total Cholesterol From Baseline to Each Observation Point|Percent Change in High Density Lipoprotein-Cholesterol From Baseline to Each Observation Point|Percent Change in Triglycerides From Baseline to Each Observation Point|Change in Low Density Lipoprotein-Cholesterol/ High Density Lipoprotein-Cholesterol Ratio (LDL-C/HDL-C) From Baseline to Each Observation Point|Change in Total Cholesterol/ High Density Lipoprotein-Cholesterol Ratio (TC/HDL-C) From Baseline to Each Observation Point|Change in Apolipoprotein B From Baseline to Each Observation Point,Pfizer,All,"20 Years to 79 Years   (Adult, Older Adult)",Phase 3,165,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A3841058,Sep-07,Apr-08,Apr-08,18-Sep-07,13-Apr-09,27-Nov-18,"Pfizer Investigational Site, Fukuoka-shi, Fukuoka-ken, Japan|Pfizer Investigational Site, Kitakyushu-shi, Fukuoka-ken, Japan|Pfizer Investigational Site, Kurume-shi, Fukuoka-ken, Japan|Pfizer Investigational Site, Maebaru-shi, Fukuoka-ken, Japan|Pfizer Investigational Site, Annaka, Gunma, Japan|Pfizer Investigational Site, Sapporo-shi, Hokkaido, Japan|Pfizer Investigational Site, Teine, Hokkaido, Japan|Pfizer Investigational Site, Yokohama-shi, Kanagawa-ken, Japan|Pfizer Investigational Site, Yamashita-cho, Naka-ku, Kanagawa-ken, Japan|Pfizer Investigational Site, Kita-ku, Osaka-fu, Japan|Pfizer Investigational Site, Koshigaya-shi, Saitama-ken, Japan|Pfizer Investigational Site, Chofu, Tokyo, Japan|Pfizer Investigational Site, Kiyose, Tokyo, Japan|Pfizer Investigational Site, Setagaya-ku, Tokyo, Japan|Pfizer Investigational Site, Shinagawa-Ku, Tokyo, Japan|Pfizer Investigational Site, Shinagawa, Tokyo, Japan|Pfizer Investigational Site, Osaka, Japan",,https://ClinicalTrials.gov/show/NCT00530946
NCT00529178,Pravastatin Efficacy and Safety Trial in Hypercholesterolemic Patients With Chronic Liver Disease,,Completed,No Results Available,Hypercholesterolemia,Drug: Pravastatin,"serum LDL-C|ALT value|change in HDL-C, TC and TG|clinical symptoms related to acute hepatic injury",Bristol-Myers Squibb,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,232,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CV123-246,Dec-02,Mar-05,Mar-05,14-Sep-07,null,25-Apr-11,,,https://ClinicalTrials.gov/show/NCT00529178
NCT00526682,The Use of Irvingia Gabonensis (Bush Mango)and Cissus Quadrangularis to Reduce Weight and Blood Lipids,,Completed,No Results Available,Obesity|Overweight|Dyslipidemia,Dietary Supplement: Irvingia/cissus combo,Weight change|Blood lipids Body fat Fasting blood glucose,Gateway Health Alliance,All,19 Years to 55 Years   (Adult),Not Applicable,72,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",GHACT010,Jan-07,null,Apr-07,10-Sep-07,null,10-Sep-07,,,https://ClinicalTrials.gov/show/NCT00526682
NCT00525824,"12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe",GRAVITY,Completed,Has Results,Hypercholesterolemia|Coronary Heart Disease|Atherosclerosis,Drug: Rosuvastatin (Crestor)|Drug: Ezetimibe|Drug: Simvastatin,Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After 6 Weeks Combination Treatment|Percent Change in High-density Lipoprotein Cholesterol (HDL-C) After 6 Weeks Combination Treatment|Percent Change in Total Cholesterol (TC) After 6 Weeks Combination Treatment|Percent Change in Triglycerides (TG) After 6 Weeks Combination Treatment|Percent Change in Non-high-density Lipoprotein Cholesterol (nonHDL-C) After 6 Weeks Combination Treatment|Percent Change in Apolipoprotein B (ApoB) After 6 Weeks Combination Treatment|Percent Change in Apolipoprotein A1 (ApoA-1) After 6 Weeks Combination Treatment|Percent Change in TC/HDL-C After 6 Weeks Combination Treatment|Percent Change in LDL-C/HDL-C After 6 Weeks Combination Treatment|Percent Change in Non-HDL-C/HDL-C After 6 Weeks Combination Treatment|Percent Change in ApoB/ApoA-1 After 6 Weeks Combination Treatment|Percent Change in High-sensitivity C-reactive Protein (Hs-CRP) After 6 Weeks Combination Treatment|Percent Change in LDL-C After 6 Weeks Monotherapy,AstraZeneca,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1743,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D356FC00003,Aug-07,Sep-08,Sep-08,6-Sep-07,7-Oct-09,13-May-11,"Research Site, Brentwood, Tennessee, United States|Research Site, Buenos Aires, Argentina|Research Site, Sao Paulo, SP, Brazil|Research Site, Santiago, Chile|Research Site, Brentwood, Colombia|Research Site, Brentwood, Lithuania|Research Site, Zwinderen, Netherlands|Research Site, Lima, San Isidro Lima, Peru|Research Site, Brentwood, Venezuela",,https://ClinicalTrials.gov/show/NCT00525824
NCT00526058,(H.E.L.P.)Apheresis Therapy to Compare the Reduction of LDL (Low Density Lipoprotein) Cholesterol,FUTURA,Completed,Has Results,Hypercholesterolemia,Device: Secura then Futura|Device: Futura then Secura,Percent Change in Pre- and Post-treatment Reductions of Low-density Lipoprotein Cholesterol (LDL-C) Levels Between the Approved H.E.L.P. System and the Modified H.E.L.P. System.|Percent Change of the Pre and Post Treatment Value|Clinical Lab Profiles (Pre- and Post-Treatment)|Device Parameters,B. Braun Medical Inc.,All,"25 Years to 70 Years   (Adult, Older Adult)",Not Applicable,18,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,LDLc-A-US2-0406,Aug-07,Oct-08,Dec-08,6-Sep-07,30-Jul-10,14-Sep-18,"Hartford Hospital, Hartford, Connecticut, United States|University of Kansas Medical Center, Kansas City, Kansas, United States",,https://ClinicalTrials.gov/show/NCT00526058
NCT00521742,Efficacy of Pioglitazone Compared to Glyburide in Treating Subjects With Type 2 Diabetes Mellitus and Mild Cardiac Disease,,Completed,No Results Available,Diabetes Mellitus,Drug: Pioglitazone|Drug: Glyburide,Change in the walking distance during a standardized 6-minute walk test.|Morbidity and Mortality Due to Cardiovascular Events.|Change in Cardiovascular Treatment Program.|Change from Baseline in 12-lead Electrocardiogram Parameter (Ventricular Heart Rate)|Change from Baseline in Electrocardiogram Parameter (Left Ventricular Mass)|Change from Baseline in Electrocardiogram Parameter (Left Ventricular Ejection Fraction)|Change from Baseline in Electrocardiogram Parameter (Cardiac Index)|Change from Baseline in Electrocardiogram Parameter (Fractional Shortening)|Change in Blood Pressure|Change in Heart Rate|Change in Body Weight,"Takeda|Takeda Pharmaceuticals North America, Inc.",All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 3,300,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",01-00-TL-OPI-520|U1111-1114-1616,Mar-01,Jan-03,Jan-03,28-Aug-07,null,28-Feb-12,,,https://ClinicalTrials.gov/show/NCT00521742
NCT00521820,Safety Comparison of Pioglitazone and Glyburide in Type 2 Diabetes Subjects With Mild to Moderate Congestive Heart Failure,,Terminated,No Results Available,Diabetes Mellitus,Drug: Pioglitazone|Drug: Glyburide,"Progression of Congestive Heart Failure.|Change from baseline in Glycosylated Hemoglobin.|Change from baseline in Fasting Plasma Glucose.|Change from baseline in Triglycerides.|Change from baseline in cholesterol (total cholesterol, high-density lipoprotein and low-density lipoprotein).|Change from baseline in 6 Minute Walking test distance|Physician & Subject Congestive Heart Failure Global Assessment Score|Change in New York Heart Association classification|Minnesota Living with Heart Failure Questionnaire total score.|Changes in blood pressure and heart rate.|All cause mortality.",Takeda,All,"18 Years and older   (Adult, Older Adult)",Phase 3,518,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",01-00-TL-OPI-504|U1111-1114-1029,Jun-00,Oct-03,Oct-03,28-Aug-07,null,28-Feb-12,,,https://ClinicalTrials.gov/show/NCT00521820
NCT00519714,A Study to Evaluate the Lipid Regulating Effects of 1-Methylnicotinamide (1-MNA),,Completed,No Results Available,Hypertriglyceridemia,Dietary Supplement: 1-Methylnicotinamide (1-MNA)|Dietary Supplement: Placebo,"The percent change in total serum Triglycerides from baseline to end of study|The percent change in total cholesterol, low-density lipoprotein cholesterol, very low-density lipoprotein cholesterol, high-density lipoprotein cholesterol , total apolipoprotein B , apolipoprotein A1 and TG/HDL-C ratio from baseline to end of study.","Montreal Heart Institute|Commonwealth Medical Clinic|Institut de Recherches Cliniques de Montreal|Clinique des maladies lipidiques de Québec|Centre de médecine genique communautaire|Omnispec clinical research Inc|Manna Research|St. Jerome Medical Research Inc.|Royal Victoria Hospital, Canada|Hotel Dieu Hospital|St Michael's Hospital Health Center|Cambridge Cardiac Care Centre|Maritime Research Center|Rhodin Recherche Clinique|Queen Elizabeth II Health Sciences Centre|First Line Medical Ltd|Diabetes Research, Vancouver General Hosp|The Allin Clinic|St Paul's Hospital Healthy Heart Clinical Trial|The Clinical Trials Centre|Recherche Invascor Inc|MSHJ Research Associates|Dr.Kim W Tan",All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,195,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",PNAI-MNA-001,Sep-07,Oct-08,Nov-08,23-Aug-07,null,22-Jun-10,"Institut de Cardiologie de Montreal, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00519714
NCT00518960,The Effects of ProAlgaZyme on HDL Cholesterol in Individuals With Metabolic Syndrome,,Unknown status,No Results Available,Metabolic Syndrome|Hyperlipidemia,Drug: ProAlgaZyme,"HDL Cholesterol|Lipid Panel (Total Chol., LDL-Chol., Triglycerides, Total Chol./HDL-Chol. ratio)|C-Reactive Protein|Blood Pressure","Health Enhancement Products, Inc.|MAPS Applied Research Center",All,"40 Years to 70 Years   (Adult, Older Adult)",Not Applicable,28,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",H-0003-02|MARC007-003,Apr-07,null,Sep-07,21-Aug-07,null,21-Aug-07,"MAPS Applied Research Center (MARC), Edina, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00518960
NCT00515307,Bone Marrow Stem Cells as a Source of Allogenic Hepatocyte Transplantation in Homozygous Familial Hypercholesterolemia,,Completed,No Results Available,"Hypercholesterolemia, Familial",Procedure: Cellular transplantation,Serum cholesterol and LDL levels|Tracking the infused cells,University of Tehran,Female,"Child, Adult, Older Adult",Phase 1,1,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DDRC 85-15,Jun-07,May-08,Jun-08,13-Aug-07,null,29-Aug-08,"Digestive Disease Research Center, Shariati Hospital, North Kargar Ave., Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT00515307
NCT00510809,Effect of Policosanol as Monotherapy and Adjunctive to Statin Therapy,,Completed,Has Results,High Cholesterol,Drug: Policosanol|Other: Placebo|Drug: Policosanol Plus Already In Use Statin Therapy,Lipid Profile|Adverse Events Reported,"James Backes, PharmD|Marcor Development Corporation|University of Kansas Medical Center",All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,54,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",QB840230|10494,Jul-07,Mar-10,May-10,2-Aug-07,20-Jul-12,8-Oct-15,"University of Kansas Medical Center, Kansas City, Kansas, United States",,https://ClinicalTrials.gov/show/NCT00510809
NCT00508937,Dietary Protein and Insulin Sensitivity Study,,Completed,No Results Available,Insulin Resistance|Type 2 Diabetes|Metabolic Syndrome|Cardiovascular Disease|Dyslipidemia,Other: Diet,Insulin Sensitivity by Frequently Sampled Intravenous Glucose Tolerance test|Total Cholesterol|LDL Cholesterol|HDL Cholesterol|Triglycerides|LDL peak particle size|LDL subclasses|Apolipoprotein B|Apolipoprotein A1,Children's Hospital & Research Center Oakland|Dairy Management Inc.,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,250,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention,MM3717,Feb-07,Nov-09,Dec-09,30-Jul-07,null,5-Oct-11,"Cholesterol Research Center, Berkeley, California, United States|San Francisco General Hospital, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT00508937
NCT00506961,Evaluate the Efficacy and Safety of Rosuvastatin Versus Simvastatin in Type 2 Diabetic Patients With Dyslipidemia,,Completed,No Results Available,Diabetes Mellitus|Dyslipidemia,Drug: Rosuvastatin|Drug: Simvastatin,The percentage of patients achieving the combined treatment goal of LDL-C < 100mg/dl and non-HDL-C < 130 mg/dl at week 12 with rosuvastatin treatment compared with simvastatin treatment|Achieving the combined treatment goal of LDL-C (<100 mg/dL) and non-HDL-C (130 mg/dL) at week 4;|Percentage of patients achieving the LDL-C goal of <100 mg/dL at week 4 and week 12;|Percentage of patients achieving the LDL-C goal of ＜70 mg/dL at Week;The mean percent change from baseline in lipid profile at week 4 and week 12;,"Taipei Veterans General Hospital, Taiwan",All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 4,90,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,AZ-RSV-RT-01,Jun-06,Jul-07,Jul-07,25-Jul-07,null,6-Dec-11,"Taichung Veterans General Hospital, Taichung, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT00506961
NCT00504309,Vascular and Lipid Effects of Omega-3 Fatty Acids in People With Moderately Elevated Triglycerides,OMEGA,Completed,Has Results,Hypertriglyceridemia,"Drug: 4/day of 4g P-OM3 capsules|Drug: 4/day of 1g P-OM3 capsules|Drug: Corn Oil Placebo, 4 capsules/day for 8 weeks",Lipid Profile|Flow-mediated Dilation (FMD)|Blood Pressure|Heart Rate|Erythrocyte Fatty Acids|Cytokine Inflammatory Markers|Fasting Glucose|Psychosocial Profile Questionnaires|C-reactive Protein (CRP)|Fasting Insulin|Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) and Quantitative Insulin Sensitivity Check Index (QUICKI),Penn State University|Reliant Pharmaceuticals,All,"21 Years to 65 Years   (Adult, Older Adult)",Not Applicable,28,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",G214,Jul-07,Jan-09,Jan-09,20-Jul-07,13-Mar-18,13-Mar-18,"Penn State University General Clinical Research Center, University Park, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00504309
NCT00504829,Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia,,Completed,No Results Available,Dyslipidemia,Drug: LCP-AtorFen|Drug: atorvastatin|Drug: fenofibrate,The primary objectives of the study are to assess the non-HDL cholesterol and triglyceride lowering efficacy as well as the HDL cholesterol increasing efficacy of LCP AtorFen versus atorvastatin.|The secondary objectives of the study are to assess the non-HDL and LDL cholesterol lowering efficacy as well as the HDL cholesterol increasing efficacy of LCP-AtorFen versus fenofibrate.,Veloxis Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 2,220,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,LCP-AtorFen-2001,Jul-07,Feb-08,Feb-08,20-Jul-07,null,15-Apr-08,"Radiant Research, 515 N State Street, Suite 2700, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00504829
NCT00502047,Effect of the Plantago Ovata Husk on the Lipid Profile of Patients With Hypercholesterolemia,,Completed,No Results Available,Hypercholesterolemia|Cardiovascular Disease,Drug: Plantago ovata husk,"To determine the capacity to reduce by 5% the concentrations of plasma LDL-c by treatment with soluble fibre-Plantago ovata husk- added to a low saturated fat diet in patients with moderate hypercholesterolemia.|To study the combined cholesterol lowering effect of treatment with Plantago ovata husk and statins to achieve the therapeutic objective|To analyse the effect of Plantago ovata husk fibre on blood pressure|To evaluate whether the response on plasma lipids is modulated by the polymorphisms of apolipoprotein E, cholesterol ester transfer protein (CETP), apolipoprotein A-V and Fatty acid binding protein 2 (FABP2)",Rottapharm Spain,All,"20 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,255,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,PLAN-EC-HIPERL-02|EudraCT number: 2004-002184-24,Sep-05,null,Jul-07,17-Jul-07,null,17-Jul-07,"Hosp. Universitario San Joan de Reus, (Spain), Reus, Tarragona, Spain",,https://ClinicalTrials.gov/show/NCT00502047
NCT00496730,"A Multicenter, Randomized, Open Label Study to Evaluate the Lipid Lowering Efficacy and Safety of Vytorin® 10/20 vs. Atorvastatin 10mg in Hypercholesterolemia Patients With Metabolic Syndrome in Korea (0653A-129)(COMPLETED)",,Completed,Has Results,Hypercholesterolemia,Drug: simvastatin (+) ezetimibe|Drug: Comparator: atorvastatin,Mean Percent Change of Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline After 8 Weeks.|Number of Patients Attaining LDL-C Goal After 8 Weeks Treatment.,Merck Sharp & Dohme Corp.,All,"20 Years to 79 Years   (Adult, Older Adult)",Phase 3,256,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0653A-129|MK0653A-129|2007_017,Jul-07,Aug-08,Aug-08,4-Jul-07,17-Nov-09,14-Apr-17,,,https://ClinicalTrials.gov/show/NCT00496730
NCT00494312,Safety Study of Pioglitazone Compared To Glyburide on Liver Function,,Completed,No Results Available,Diabetes Mellitus|Liver,Drug: Pioglitazone|Drug: Glyburide,"Incidence of liver inflammation or injury greater than 3 times the upper limit of normal, as monitored by serum alanine aminotransaminase elevation.|Incidence of alanine aminotransferase greater than 8 times the upper limit of normal.|Incidence of alanine aminotransferase greater than 3 times the upper limit of normal but less than or equal to 8 times the upper limit of normal on 4 consecutive measurements within a 3-month period.|Incidence of alanine aminotransferase greater than 3 times the upper limit of normal and total bilirubin greater than 2 times the upper limit of normal.|Change from Baseline or greater than 1.5 times the upper limit of normal (whichever is greater) in the level of alanine aminotransferase, aspartate aminotransferase, total or direct bilirubin, alkaline phosphatase or gamma-glutamyl transpeptidase.",Takeda,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,2120,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",01-00-TL-OPI-506|U1111-1114-1564,Oct-00,Jun-05,Jun-05,29-Jun-07,null,28-Feb-12,,,https://ClinicalTrials.gov/show/NCT00494312
NCT00493337,A Community Pharmacist-led Intervention to Improve Adherence to Lipid-lowering Treatment,,Completed,No Results Available,Hypercholesterolemia,Behavioral: advanced adherence counseling+reminder|Device: Compliance Card,"The primary outcome will be mean differences in adherence over 365 days after randomization by comparing the two intervention groups with the control group.|Mean differences in adherence over 180 days after randomization by comparing the two intervention groups with the control group.|Mean differences in adherence over 270 days after randomization by comparing the two intervention groups with the control group.|If the pre-specified effect on mean adherence is measured, change in LDL-C will also be assessed.|Complete discontinuation defined as more than 182 consecutive days of the one year observation period uncovered (<50%).","Utrecht Institute for Pharmaceutical Sciences|Service Apotheek BV|Harvard University|Department of Clinical Pharmacy, University Medical Centre St Radboud, The Netherlands.|Scientific Institute for Dutch Pharmacists, The Netherlands|Federation of Patients and Consumer Organisations in the Netherlands",All,65 Years to 90 Years   (Older Adult),Not Applicable,373,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),NL18496.041.07,May-08,Mar-10,Mar-10,28-Jun-07,null,28-Jun-10,"Service Apotheek BV, Enter, Netherlands",,https://ClinicalTrials.gov/show/NCT00493337
NCT00493506,ProAlgaZyme Novel Algae Infusion: Applications in Immunodeficiency,,Completed,No Results Available,HIV Infections|Hepatitis B|Dyslipidemia,Drug: ProAlgaZyme,"CD4+ T-lymphocytes|HIV Viral Load|hsCRP (C-reactive protein)|Total cholesterol|Liver enzymes (ALT, ALP, GGT)|MDA (malonaldehyde) and thiol proteins|RBC and WBC counts","Health Enhancement Products, Inc.|University of Yaounde",All,19 Years to 45 Years   (Adult),Not Applicable,59,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,H-0002-01|087/2006,May-06,null,Sep-06,28-Jun-07,null,28-Jun-07,"Laboratory of Nutrition and Nutritional Biochemistry (LNNB), Department of Biochemistry, University of Yaounde I, Yaounde, Cameroon",,https://ClinicalTrials.gov/show/NCT00493506
NCT00491400,Effect of a Fibrate and a Statin on Endothelial Dysfunction,,Terminated,Has Results,Diabetes Mellitus|Metabolic Syndrome,Drug: Fenofibrate|Drug: Atorvastatin,Brachial Artery Flow-mediated Dilation|Serum Lipids,Boston University,All,"30 Years and older   (Adult, Older Adult)",Not Applicable,28,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",H-23185,Sep-05,Dec-08,Dec-08,26-Jun-07,24-Oct-12,24-Oct-12,"Boston Medical Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00491400
NCT00491530,"A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia",,Completed,Has Results,Mixed Dyslipidemia,Drug: ABT-335|Drug: rosuvastatin calcium|Drug: simvastatin|Drug: atorvastatin calcium,Percentage of Subjects Reporting Adverse Events During Combination Therapy in the Preceding Double-Blind Studies or in the Preceding Open-Label Year 1 Study or in This Open-Label Year 2 Study|Median Percent Change in Triglycerides From Baseline to Week 104 of This Open-Label Year 2 Study|Mean Percent Change in High-Density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 104 of This Open-Label Year 2 Study|Mean Percent Change in Direct Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 104 of This Open-Label Year 2 Study|Mean Percent Change in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Week 104 of This Open-Label Year 2 Study|Mean Percent Change in Very Low-Density Lipoprotein Cholesterol (VLDL-C) From Baseline to Week 104 of This Open-Label Year 2 Study|Mean Percent Change in Total Cholesterol (Total-C) From Baseline to Week 104 of This Open-Label Year 2 Study,Abbott,All,"18 Years and older   (Adult, Older Adult)",Phase 3,310,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,M06-884,Jun-07,Nov-08,Nov-08,26-Jun-07,7-Dec-09,20-Jan-12,"Medical Information Specialist, Abbott Park, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00491530
NCT00490672,Community Based Multiple Risk Factors Intervention Strategy,CORFIS,Completed,No Results Available,Hypertension|Diabetes Mellitus|Hyperlipidemia,Behavioral: No Active Intervention.|Behavioral: Community Based Multiple Risk Factor Intervention Strategies,Proportion of patients able to reach treatment goals.|The safety of the drug product used in the study will be assessed using the procedure for adverse drug reactions reporting for marketed medicinal products regulated by the Malaysian regulatory authority.,"Ministry of Health, Malaysia",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,770,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CT07-02|NMRR ID Number: 447,Aug-07,Dec-08,Jan-09,25-Jun-07,null,7-Apr-15,"Horeb Sdn Bhd, Kuala Lumpur, Federal Territory, Malaysia|Klinik Tan & Mano Sdn Bhd, Kuala Lumpur, Federal Territory, Malaysia|Klinik Kaulsay, Kuala Lumpur, Federal Territory, Malaysia|Klinik Unimed Plaza Damansara, Kuala Lumpur, Federal Territory, Malaysia|Poliklinik Kumpulan City (Plaza Damansara), Kuala Lumpur, Federal Territory, Malaysia|Klinik Shafi, Kuala Lumpur, Federal Territory, Malaysia|Poliklinik Kepong Baru, Kuala Lumpur, Federal Territory, Malaysia|Klinik Chew, Kuala Lumpur, Federal Territory, Malaysia|Klinik Reddy Setapak, Kuala Lumpur, Federal Territory, Malaysia|Klinik Medik (Dr Amir & Rakan-Rakan), Kuala Lumpur, Federal Territory, Malaysia|Klinik Keluarga, Kuala Lumpur, Federal Territory, Malaysia|Klinik Vicky, Kuala Lumpur, Federal Territory, Malaysia|Klinik Care Poliklinik & Surgeri, Kuala Lumpur, Federal Territory, Malaysia|Klinik Tenaga Baru, Kuala Lumpur, Federal Territory, Malaysia|Kumpulan Medi-Systems Sdn Bhd, Kuala Lumpur, Federal Territory, Malaysia|Poliklinik Salak Selatan, Kuala Lumpur, Federal Territory, Malaysia|Klinik Sharon, Kuala Lumpur, Federal Territory, Malaysia|Klinik Medi Pesona, Kuala Lumpur, Federal Territory, Malaysia|Klinik Sharani, Kuala Lumpur, Federal Territory, Malaysia|Klinik Prime Care, Kuala Lumpur, Federal Territory, Malaysia|PoliKlinik Bangsar, Kuala Lumpur, Federal Territory, Malaysia|Poliklinik Medics, Kuala Lumpur, Federal Territory, Malaysia|Klinik Famili TTDI, Kuala Lumpur, Federal Territory, Malaysia|Klinik Dr Khalil, Kuala Lumpur, Federal Territoy, Malaysia|Klinik Ehsan, Mentakab, Pahang, Malaysia|Klinik Dan Surgeri Putra, Ampang, Selangor, Malaysia|Klinik Idzham Sdn Bhd, Ampang, Selangor, Malaysia|Klinik Mediviron, Ampang, Selangor, Malaysia|Klinik Putera (Poliklinik Bistari), Ampang, Selangor, Malaysia|Klinik Tan & Mano, Ampang, Selangor, Malaysia|Poliklinik Gomez 24 Jam, Ampang, Selangor, Malaysia|Poliklinik Penawar, Ampang, Selangor, Malaysia|Klinik Hayati (Poliklinik & Surgeri), Batu Caves, Selangor, Malaysia|Klinik Nathan Dan Rakan-Rakan, Batu Caves, Selangor, Malaysia|Poliklinik Idaman, Batu Caves, Selangor, Malaysia|Poliklinik Kumpulan City, Batu Caves, Selangor, Malaysia|Klinik Keluarga Azian & Elina, Klang, Selangor, Malaysia|Klinik Keluarga Siva Lim, Klang, Selangor, Malaysia|Lok Dispensary, Klang, Selangor, Malaysia|Klinik Bandaran, Klang, Selangor, Malaysia|Klinik Kelang, Klang, Selangor, Malaysia|Klinik Lim, Klang, Selangor, Malaysia|Klinik Yuen, Klang, Selangor, Malaysia|Klinik Stella Maris Sdn Bhd, Klang, Selangor, Malaysia|Klinik Utama, Klang, Selangor, Malaysia|Klinik Wan Elina, Klang, Selangor, Malaysia|Poliklinik Hari, Klang, Selangor, Malaysia|Klinik Ng & Lim, Klang, Selangor, Malaysia|Klinik Khaty Am, Petaling Jaya, Selangor, Malaysia|Poliklinik Shaik (Sunway) Sdn Bhd, Petaling Jaya, Selangor, Malaysia|Klinik Primecare, Petaling Jaya, Selangor, Malaysia|Klinik Petaling Jaya, Petaling Jaya, Selangor, Malaysia|Klinik Alam Medic, Petaling Jaya, Selangor, Malaysia|Klinik Rakan Medik, Petaling Jaya, Selangor, Malaysia|Poliklinik Rakyat, Petaling Jaya, Selangor, Malaysia|Klinik Kelana Puteri, Petaling Jaya, Selangor, Malaysia|Klinik Ready Care, Petaling Jaya, Selangor, Malaysia|Poliklinik Hidayah, Petaling Jaya, Selangor, Malaysia|Klinik Dr Shamsuddin, Petaling Jaya, Selangor, Malaysia|Klinik Hafiz, Puchong, Selangor, Malaysia|Klinik Leong, Puchong, Selangor, Malaysia|Klinik Raya, Puchong, Selangor, Malaysia|Klinik Reddy, Puchong, Selangor, Malaysia|Klinik Ng Singh & Rakan-Rakan, Rawang, Selangor, Malaysia|Klinik Sarrimadh, Seri Kembangan, Selangor, Malaysia|Klinik Bandaran Sdn Bhd, Shah Alam, Selangor, Malaysia|Klinik Kelang, Shah Alam, Selangor, Malaysia|Poliklinik Sri Muda, Shah Alam, Selangor, Malaysia|Klinik Dan Surgeri Alpha Medic, Shah Alam, Selangor, Malaysia|Klinik Medic Bestari, Subang Jaya, Selangor, Malaysia|Klinik Medifom, Subang Jaya, Selangor, Malaysia|Victor Medical Practice, Subang Jaya, Selangor, Malaysia|Klinik Medijaya, Subang Jaya, Selangor, Malaysia|Klinik Dr Nur Ainita, Subang Jaya, Selangor, Malaysia|Klinik Taipan, Subang Jaya, Selangor, Malaysia|Poliklinik Roshan, Subang Jaya, Selangor, Malaysia|Klinik Kok dan Wendy, Subang Jaya, Selangor, Malaysia|MAS Medical Centre, Subang, Selangor, Malaysia",,https://ClinicalTrials.gov/show/NCT00490672
NCT00490178,Acceptability Study of a New Fixed Combination of Fenofibrate 80 mg BID and Metformin 1000 mg BID in Type 2 Diabetes and Dyslipidemia,,Completed,No Results Available,"Diabetes Mellitus, Type 2|Dyslipidemia",Drug: Fenofibrate 80 mg and metformin 1000 mg (fixed combination),,Solvay Pharmaceuticals,All,"20 Years to 80 Years   (Adult, Older Adult)",Phase 3,29,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C LF23-0121 06 02|2006-002848-28,Mar-07,null,null,22-Jun-07,null,3-Sep-07,"Site 3, Marseille, France|Site 1, Nantes, France|Site 2, Tours, France",,https://ClinicalTrials.gov/show/NCT00490178
NCT00488449,Study Of Pharmacokinetics and Pharmacodynamics Effects Of GSK256073A On Healthy Volunteers,,Completed,No Results Available,Healthy Subjects|Dyslipidaemias,Drug: GSK256073A tablets,"AEs, 12-Lead ECG, vital signs, nursing/physician observation, safety lab tests, flushing|AUC and Cmax|Measures of accumulation ratios|Tmax, t½, Ae, and CLr (Parts A & B) Cmax, ss, Ct, t½, Ae, CLr, and accumulation ratios (Part B)|PD response: NEFA and TG (6 and 24 hours post- dose)|LDL, HDL, ApoA1, ApoA2, Apo B and Lp(a)|Levels of GSK256073 to derive pharmacokinetic parameters following repeat dose administration.|Lipid levels",GlaxoSmithKline,All,18 Years to 55 Years   (Adult),Phase 1,56,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Diagnostic,HMA110015,Jun-07,Nov-07,Nov-07,20-Jun-07,null,4-Jun-12,"GSK Investigational Site, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00488449
NCT00487994,Safety and Efficacy of Lapaquistat Acetate Taken Alone and With Atorvastatin in Subjects With Primary Dyslipidemia,,Completed,No Results Available,Dyslipidemia,Drug: Lapaquistat acetate|Drug: Lapaquistat acetate and atorvastatin|Drug: Atorvastatin,Lens Opacity Classification System findings|Best corrected visual acuity|Adverse Events|Clinical Laboratory Tests|Vital signs (blood pressure and pulse rate) and weight|12-lead Electrocardiogram|Physical Examination|Change from Baseline in Low Density Lipoprotein cholesterol|Change from Baseline in High Density Lipoprotein cholesterol|Change from Baseline in Total Cholesterol|Change from Baseline in Triglycerides|Change from Baseline in Very Low Density Lipoprotein cholesterol|Change from Baseline in Apolipoprotein A1|Change from Baseline in Apolipoprotein B,Takeda,All,"18 Years and older   (Adult, Older Adult)",Phase 3,2130,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",01-04-TL-475-002|2004-000775-34|U1111-1122-7619,Nov-04,May-07,May-07,19-Jun-07,null,24-May-12,"Birmingham, Alabama, United States|Mobile, Alabama, United States|Northport, Alabama, United States|Chandler, Arizona, United States|Phoenix, Arizona, United States|Sierra Vista, Arizona, United States|Jonesboro, Arkansas, United States|Little Rock, Arkansas, United States|Anaheim, California, United States|Rancho Cucamonga, California, United States|Santa Rosa, California, United States|Golden, Colorado, United States|Coral Gables, Florida, United States|Fort Myers, Florida, United States|Jacksonville, Florida, United States|Sarasota, Florida, United States|West Palm Beach, Florida, United States|Dunwoody, Georgia, United States|Boise, Idaho, United States|Idaho Falls, Idaho, United States|Arlington Heights, Illinois, United States|Chicago, Illinois, United States|Elk Grove Village, Illinois, United States|Evansville, Indiana, United States|Indianapolis, Indiana, United States|Waterloo, Iowa, United States|Kansas City, Kansas, United States|Overland Park, Kansas, United States|Louisville, Kentucky, United States|New Orleans, Louisiana, United States|Flint, Michigan, United States|Edina, Minnesota, United States|St. Louis, Missouri, United States|Omaha, Nebraska, United States|Ship Bottom, New Jersey, United States|Rochester, New York, United States|Syracuse, New York, United States|Charlotte, North Carolina, United States|Statesville, North Carolina, United States|Wilmington, North Carolina, United States|Winston-Salem, North Carolina, United States|Cincinatti, Ohio, United States|Tulsa, Oklahoma, United States|Philadelphia, Pennsylvania, United States|Tipton, Pennsylvania, United States|Anderson, South Carolina, United States|Mt. Pleasant, South Carolina, United States|Simpsonville, South Carolina, United States|Cordova, Tennessee, United States|Morristown, Tennessee, United States|Corpus Christi, Texas, United States|Dallas, Texas, United States|Fort Worth, Texas, United States|Houston, Texas, United States|Plano, Texas, United States|San Antonio, Texas, United States|Temple, Texas, United States|Texarkana, Texas, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Lakewood, Washington, United States|Buenos Aires, Argentina|Ciudad Autonoma de Buenos Aires, Argentina|Cordoba, Argentina|La Plata, Argentina|Moron, Argentina|Pilar, Argentina|Rosario, Argentina|Salta, Argentina|Santa Fe, Argentina|Santiago de Chile, Chile|Brno, Czech Republic|Olomouc, Czech Republic|Praha, Czech Republic|Tartu, Estonia|Berlin, Germany|Freiburg, Germany|Görlitz, Germany|Hamburg, Germany|Mannheim, Germany|Munich, Germany|Mönchengladbach, Germany|Schwerin, Germany|Budapest, Hungary|Debrecen, Hungary|Esztergom, Hungary|Gyula, Hungary|Győr, Hungary|Kecskemét, Hungary|Warszawa, Hungary|Riga, Latvia|Kaunas, Lithuania|Vilnius-21, Lithuania|Vilnius, Lithuania|Distrito Federal, Mexico|Guadalajara, Mexico|Jalisco, Mexico|Mexico City, Mexico|San Luis Potosi, Mexico|Zapopan, Mexico|Es Velp, Netherlands|Groningen, Netherlands|Leiden, Netherlands|Rotterdam, Netherlands|Zoetermeer, Netherlands|Lima, Peru|Bialystok, Poland|Bydgoszcz, Poland|Gdansk, Poland|Gorzow Wielkopolski, Poland|Grudziadz, Poland|Plonsk, Poland|Torun, Poland|Wloclawek, Poland|Wroclaw, Poland|Moscow, Russian Federation|Saint-Petersburg, Russian Federation|Saratov, Russian Federation|Komárno, Slovakia|Kosice, Slovakia|Levice, Slovakia|Cape Town, South Africa|Johannesburg, South Africa|Parow, South Africa|Western Cape, South Africa|Truro, Cornwall, United Kingdom|Blackpool, Lancashire, United Kingdom|Bolton, Lancashire, United Kingdom|Guildford, Surrey, United Kingdom",,https://ClinicalTrials.gov/show/NCT00487994
NCT00486941,Lifestyle Intervention in Primary Health Care - the Björknäs Study,,Completed,No Results Available,Hypertension|Type 2 Diabetes|Obesity|Dyslipidemia,Behavioral: Exercise and diet - based on DPS and DPP,"Changes in anthropometry (BMI, waist and hip cf)|Maximal oxygen uptake (VO2max)|Health-related quality of life (EQ 5D, SF-36)|Self-reported physical activity|Blood pressure|Total cholesterol, HDL and triglycerides|Glucose tolerance (OGTT)","Umeå University|County Council of Norrbotten, Sweden",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,151,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,EPN-Umea 02-512,Feb-03,null,Mar-06,15-Jun-07,null,20-Jul-07,"Björknäs Health Centre, Boden, Sweden",,https://ClinicalTrials.gov/show/NCT00486941
NCT00485095,The Effect of Plant Sterol Supplement on Blood Cholesterol,,Completed,No Results Available,High Blood Cholesterol Level,Behavioral: Intake of plant sterols,,Oslo University Hospital|Mills DA,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,41,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",2.2006.3407,Jan-07,Jul-07,Jul-07,12-Jun-07,null,1-Jul-11,"Lipidklinikken, Rikshospitalet Radiumhospitalet HF, Oslo, Norway|Rikshospitalet Radiumhospitalet HF, Oslo, Norway, Oslo, Norway",,https://ClinicalTrials.gov/show/NCT00485095
NCT00484419,"Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin",,Completed,Has Results,Type 2 Diabetes|Hyperlipidemia,Drug: Colesevelam HCl|Drug: rosiglitazone maleate|Drug: sitagliptin phosphate,Mean Percentage of Change in HbA1c From Week 0(Baseline) to Week 16 Endpoint|Mean Percentage of Change in Glycosylated Hemoglobin (HbA1c) From Week 0(Baseline) to Week 16 Endpoint Least Squares Mean|Mean Percentage of Change in HbA1c From Week 0(Baseline) to Week 8|Change in Fasting Plasma Glucose (FPG) From Week 0(Baseline) to Week 8 Least Squares Mean|Change in FPG From Week 0(Baseline) to Week 16 Least Squares Mean|Mean Change in FPG From Week 0(Baseline) to Week 8|Mean Change in FPG From Week 0(Baseline) to Week 16|Change in Fasting Insulin From Week 0(Baseline) to Week 8 Least Squares Mean|Change in Fasting Insulin From Week 0(Baseline) to Week 16 Least Squares Mean|Mean Change in Fasting Insulin From Week 0(Baseline) to Week 8|Mean Change in Fasting Insulin From Week 0(Baseline) to Week 16|Change in Post-prandial Glucose From Week 0(Baseline) to Week 16 Least Squares Mean|Mean Change in Post-prandial Glucose From Week 0(Baseline) to Week 16|Mean Change in Post-prandial Insulin From Week 0(Baseline) to Week 16|Change in Low-Density Lipoprotein-C(LDL-C) From Week 0(Baseline) to Week 16 Least Squares Mean|Mean Change in LDL-C From Week 0(Baseline) to Week 16|Mean Percentage of Change in LDL-C Levels From Week 0(Baseline) to Week 16|Mean Percentage of Change in LDL-C Levels From Week 0(Baseline) to Week 16 (Least Squares Mean),"Daiichi Sankyo, Inc.",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,169,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Wel-409,May-07,Apr-08,Apr-08,8-Jun-07,17-Jun-09,4-Oct-16,"La Mesa, California, United States|Los Angeles, California, United States|Los Gatos, California, United States|San Antonio, California, United States|Chiefland, Florida, United States|Gary, Indiana, United States|Baltimore, Maryland, United States|Dearborn, Michigan, United States|W. Bloomfield, Michigan, United States|Las Vegas, Nevada, United States|Yonkers, New York, United States|Lexington, North Carolina, United States|Winston-Salem, North Carolina, United States|Munroe Falls, Ohio, United States|Zaneville, Ohio, United States|Portland, Oregon, United States|Jersey Shore, Pennsylvania, United States|Clemson, South Carolina, United States|Harriman, Tennessee, United States|Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT00484419
NCT00482404,Effects of Romantic Affection on Blood Chemistry and Immune Parameters,,Completed,No Results Available,Stress|Hypercholesterolemia,Behavioral: Romantic kissing,,Arizona State University|National Institute of Mental Health (NIMH),All,"18 Years to 80 Years   (Adult, Older Adult)",Early Phase 1,null,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment,1001 R03 MH075757-01A1,Feb-07,null,May-07,5-Jun-07,null,5-Jun-07,,,https://ClinicalTrials.gov/show/NCT00482404
NCT00481364,Atorvastatin Treatment to Attenuate the Progression of Cardiovascular Disease in Hemodialysis Patients,,Completed,No Results Available,Vascular Calcification|Atherosclerosis|Dyslipidemia|Inflammation,Drug: atorvastatin|Drug: placebo,progression of coronary artery calcification score|progression of carotid artery intima-media thickness|changes in the level of hsCRP|changes in the endothelial function,Ercan OK|Pfizer|Ege University,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,446,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,06-4.1/2,Nov-06,Dec-08,Dec-08,1-Jun-07,null,9-Sep-13,"Ege University School of Medicine, Division of Nephrology, Bornova, Izmir, Turkey",,https://ClinicalTrials.gov/show/NCT00481364
NCT00479973,The Anti-Diabetic and Cholesterol-Lowering Effects of Cinnamon and Cassia Bark,,Unknown status,No Results Available,Type 2 Diabetes|Hypercholesterolemia,Dietary Supplement: Cinnamonforce|Dietary Supplement: Placebo,"The primary objective measures will consist of fasting blood glucose, insulin and HA1C.|Total-C, TG, HDL, LDL, BP, weight, BMI, waist/hip ratio, self-monitoring blood glucose, HOMA-IR, AST, ALT, total protein, albumin, alk phos, total/direct bilirubin, creatinine, BUN, PT, PTT, fibrinogen, adverse effects, Diabetes-39, SF-36","University Health Network, Toronto|The Canadian College of Naturopathic Medicine",All,"30 Years to 75 Years   (Adult, Older Adult)",Phase 2,70,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",dug2006-1,Sep-07,null,May-08,30-May-07,null,20-Nov-07,"Canadian College of Naturopathic Medicine, Toronto, Ontario, Canada|UHN - Toronto Western Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00479973
NCT00479388,Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067),,Completed,Has Results,Primary Hypercholesterolemia|Mixed Dyslipidemia,Drug: Comparator: simvastatin|Drug: niacin (+) laropiprant|Drug: Comparator: atorvastatin calcium,Percent Change From Baseline in Low Density Lipoprotein Cholesterol at Week 12|Percent Change From Baseline in High Density Lipoprotein Cholesterol at Week 12|Percent Change From Baseline in Triglycerides at Week 12,Merck Sharp & Dohme Corp.,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,1216,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0524A-067|2007_521,Jul-07,Jul-08,Oct-08,28-May-07,31-Jul-09,10-Mar-15,,,https://ClinicalTrials.gov/show/NCT00479388
NCT00479713,A Study to Assess the Cholesterol Lowering Effect of an Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Patients With High Cholesterol and With High Cardiovascular Risk (0653A-809)(COMPLETED),,Completed,Has Results,Hypercholesterolemia,Drug: ezetimibe (+) simvastatin|Drug: Comparator : rosuvastatin calcium|Drug: Comparator: Placebo (unspecified),Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) at Study Endpoint After Six Weeks of Treatment|The Percentage of Participants Achieving Designated Low Density Lipoprotein-Cholesterol (LDL-C) Levels After 6 Weeks of Treatment,Merck Sharp & Dohme Corp.,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 3,618,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0653A-809|2007_552,1-Feb-07,1-Mar-08,1-Mar-08,28-May-07,10-Jun-09,5-May-17,,,https://ClinicalTrials.gov/show/NCT00479713
NCT00479882,MK-0524B Lipid Study (MK-0524B-063),,Completed,Has Results,Primary Hypercholesterolemia|Mixed Dyslipidemia,Drug: Comparator: simvastatin|Drug: MK-0524A|Drug: Placebo|Drug: MK-0524B,Percentage Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)|Percentage Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C)|Percentage of Participants With Consecutive Elevations in Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) of >=3 x Upper Limit of Normal (ULN)|Percentage of Participants With Creatine Kinase (CK) >=10 x ULN|Percentage of Participants With CK >=10 x ULN With Muscle Symptoms|Percentage of Participants With CK >=10 x ULN With Muscle Symptoms - Drug Related|Percentage of Participants With New Diagnosis of Impaired Fasting Blood Glucose|Percentage of Participants With New Diagnosis of Diabetes|Percentage of Participants With Worsening of the Pre-existing Conditions of Diabetes in Participants With Diabetes at Baseline|Percentage of Participants With a Confirmed Adjudicated Cardiovascular Event|Percentage of Participants Who Experience at Least 1 Clinical Adverse Event (AE)|Percentage of Participants Who Experience at Least 1 Laboratory AE|Percentage of Participants Who Were Discontinued From the Study Due to a Clinical AE|Percentage of Participants Who Were Discontinued From the Study Due to a Laboratory AE|Percentage of Participants Who Experience at Least 1 Hepatitis-related Non-serious Clinical AE|Percentage Change From Baseline in LDL-C at Week 4|Percentage Change From Baseline in HDL-C at Week 4,Merck Sharp & Dohme Corp.,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 3,2414,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0524B-063|MK-0524B-063|2007_504,15-Jun-07,16-Jun-08,16-Jun-08,28-May-07,1-Apr-16,6-Feb-19,,,https://ClinicalTrials.gov/show/NCT00479882
NCT00477594,Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia,,Completed,Has Results,"Lipid Metabolism, Inborn Errors|Hypercholesterolemia, Autosomal Dominant|Hyperlipidemias|Metabolic Diseases|Hyperlipoproteinemia Type II|Metabolism, Inborn Errors|Genetic Diseases, Inborn|Infant, Newborn, Diseases|Metabolic Disorder|Congenital Abnormalities|Hypercholesterolemia|Hyperlipoproteinemias|Dyslipidemias|Lipid Metabolism Disorders",Drug: mipomersen sodium,Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)|Low-density Lipoprotein Cholesterol (LDL-C) Over Time|Percent Change From Baseline in Apolipoprotein B|Apolipoprotein B Over Time|Percent Change From Baseline in Total Cholesterol|Total Cholesterol Over Time|Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol|Non-High-Density Lipoprotein Cholesterol Over Time|Number of Participants With Treatment-Emergent Adverse Events (AEs)|Percent Change From Baseline in Clinical Chemistry Parameters|Percent Change From Baseline in Hematology Parameters|Percent Change From Baseline in Blood Pressure|Percent Change From Baseline in Pulse Rate|Percent Change From Baseline in Respiratory Rate,"Kastle Therapeutics, LLC|Ionis Pharmaceuticals, Inc.",All,"12 Years and older   (Child, Adult, Older Adult)",Phase 2,21,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,301012-CS17|2007-001024-12,May-07,Mar-11,Jul-11,24-May-07,5-Apr-13,9-Sep-16,"Chicago, Illinois, United States|Auburn, Maine, United States|Biddeford, Maine, United States|Scarborough, Maine, United States|Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00477594
NCT00477477,Nutritional Treatment of Overweight Adolescents With Cardiovascular Risk Factors (PowerUp),,Terminated,No Results Available,Childhood Obesity|Dyslipidemia|Insulin Resistance|Hypertension,Other: Diet,Insulin resistance|Inflammation|dyslipidemia|blood pressure|coagulopathy|vascular function|liver function testing|Metabolomic profile,"Boston Children’s Hospital|National Heart, Lung, and Blood Institute (NHLBI)",All,8 Years to 17 Years   (Child),Not Applicable,27,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,07-01-0020|K23HL085308,May-07,May-12,Sep-12,23-May-07,null,27-Oct-14,"Children's Hospital Boston, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00477477
NCT00477191,Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis,,Terminated,Has Results,Psoriasis|Metabolic Syndrome|Hyperlipidemia|Obesity|Hypertension,Drug: Etanercept,Change in CRP Levels From Baseline to 6 Months of Treatment in Subjects With Psoriasis and Metabolic Syndrome|Change in Plasma Glucose in Subjects With Psoriasis and Metabolic Syndrome|Change of Endothelial Function by Measurement of Flow-mediated Vasodilation Using the Reactive Hyperemia Index (RHI) in 6 Months|Change in the Safety and Tolerability of Etanercept in Patients With Psoriasis and Metabolic Syndrome Over a 6-month Period.,Massachusetts General Hospital|Amgen,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,18,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,2007-P-000494,May-07,Dec-13,Dec-13,22-May-07,16-May-16,16-May-16,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00477191
NCT00477204,Clinical Trial of Zocor (Simvastatin) and Vytorin (Ezetimibe/Simvastatin) in Adolescents With Type 1 Diabetes,,Completed,Has Results,Type 1 Diabetes Mellitus|Dyslipidemia,Drug: Simvastatin|Drug: Ezetimibe/Simvastatin,Change in LDL-c From Baseline to 6 Months in Subjects With Type 1 Diabetes Taking Vytorin or Zocor.|No Secondary Outcomes,"University of Colorado, Denver|Merck Sharp & Dohme Corp.|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",All,"12 Years to 18 Years   (Child, Adult)",Phase 2,9,Other|Industry|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",06-1036|K23DK075360,May-07,Aug-10,Aug-10,22-May-07,21-Jun-13,28-Aug-13,"Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT00477204
NCT00475826,Evaluation of Chylomicrons Metabolism in Sub-Clinical Atherosclerosis in Patients Whit Heterozigous Familial Hypercholesterolemia (FH) Treated With Statin Plus Ezetimibe,,Unknown status,No Results Available,Heterozigous Familial Hypercholesterolemia,Drug: Statins and Ezetimibe,Evaluate if there is any correlation among the reduction of the plasma clearance of chylomicrons by the artificial chylomicrons technique and the presence of sub-clinical atherosclerosis|Evaluate if ezetimibe/simvastatin enhances the effects of simvastatin alone in the removal of chylomicrons in patients with HF.,University of Sao Paulo|Merck Sharp & Dohme Corp.,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,null,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single,1067/06,Apr-07,null,null,21-May-07,null,21-Mar-08,"Heart Institute, Sao Paulo, SP, Brazil",,https://ClinicalTrials.gov/show/NCT00475826
NCT00474864,Study To Evaluate The Effects Of GW856553 On Endothelial Function/Vascular Compliance In Subjects With Dyslipidaemia.,,Completed,No Results Available,Healthy Subjects|Dyslipidaemias|Dyslipidaemia,Drug: GW856553,"Forearm blood flow ratio measured at baseline and day 28.|Forearm blood flow ratio at (baseline and day28). Augmentation Index(baseline and day28). Pulse wave velocity (baseline and day28). pHSP-27 levels (baseline and day28).|Safety and tolerability parameters (weekly)|Measurement of total and phosphorylated heat shock protein-27 (pHSP-27) levels in sorbitol induced whole blood cells of patients with dyslipidaemia|Safety and tolerability parameters, including physical examination, blood pressure, heart rate, 12-lead electrocardiograms (ECGs), clinical laboratory tests, and adverse events reporting",GlaxoSmithKline,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,66,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,PM1108357,Jul-07,Apr-08,Apr-08,17-May-07,null,6-Jun-12,"GSK Investigational Site, Cambridge, United Kingdom|GSK Investigational Site, Cardiff, United Kingdom|GSK Investigational Site, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT00474864
NCT00474240,AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia,,Completed,Has Results,Hypercholesterolemia,Drug: Atorvastatin 20 mg|Drug: AEGR-733 5 mg|Drug: AEGR-733 10 mg|Drug: Placebo|Drug: AEGR-733 5 mg + atorvastatin 20 mg|Drug: AEGR-733 10 mg + atorvastatin 20 mg,Percent Change From Baseline in LDL-C at 8 Weeks|Percent Change From Baseline of Other Lipids,"Aegerion Pharmaceuticals, Inc.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,157,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",AEGR-733-003,Apr-07,Oct-08,Oct-08,16-May-07,21-Feb-13,20-Mar-18,"Medical Affiliated Research Center, Huntsville, Alabama, United States|Jacksonville Center for Clinical research, Jacksonville, Florida, United States|Jacksonville Center For Clinical Research, Jacksonville, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|North Georgia Clinical Research, Woodstock, Georgia, United States|Radiant Research, Chicago, Illinois, United States|Medsphere Medical Research Center, Evansville, Indiana, United States|Midwest Institute for Clinical Research, Indianapolis, Indiana, United States|Maine Research Associates, Auburn, Maine, United States|Health Trends Research, Baltimore, Maryland, United States|Piedmont Medical Research Associates, Winston-Salem, North Carolina, United States|Sterling Research Group, Cincinnati, Ohio, United States|Coastal Carolina Research Center, Goose Creek, South Carolina, United States|Dallas Diabetes and Endocrine Center, Dallas, Texas, United States|Diabetes and Glandular Disease Research, Dallas, Texas, United States|Hampton Roads Center for Clinical Research, Norfolk, Virginia, United States|National Clinical Research, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00474240
NCT00473655,Effect of Rosuvastatin on Triglyceride Levels in Mexican Hypertriglyceridemic Patients,,Completed,Has Results,Hypertriglyceridemia|Hyperlipoproteinemia Type IV|Hyperlipoproteinemia Type V|Hyperlipoproteinemia Type IIb|Hyperlipidemia,Drug: rosuvastatin,Change (Reduction) in Triglycerides Levels From Baseline to End of Treatment (Week 8)|Non-HDL-C Reduction|LDL-C Reduction|Total Cholesterol Reduction|HDL-C Increase|ApoA1 Levels|hsCRP Reduction|Adverse Events Reported|ApoB Levels,AstraZeneca,All,"18 Years and older   (Adult, Older Adult)",Phase 4,334,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,DM-CRESTOR-0002,Jan-07,Feb-09,Feb-09,15-May-07,8-Jun-10,16-Dec-10,"Research Site, Mexico City, DF, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Monterrey, Nuevo Leon, Mexico",,https://ClinicalTrials.gov/show/NCT00473655
NCT00469365,Pharmacy Interventions to Improve Chronic Disease Medication Refill,,Completed,No Results Available,Diabetes|Hypertension|Hyperlipidemia|Heart Diseases|Depression|Psychoses,Behavioral: pharmacist contact with the patient via telephone|Behavioral: Pharmacist contact with the patient's physician via fax|Behavioral: Usual care,"The primary outcome was the number of days from the index date until the next date on which the patient filled a prescription for any qualified medication, or until the end of the study follow-up period.|Secondary outcomes included indicators for whether the patient filled any medication within 30 days for their chronic disease, and whether the patient filled any medication within 30 days.",Medical University of South Carolina|Agency for Healthcare Research and Quality (AHRQ),All,"Child, Adult, Older Adult",Phase 3,3048,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,P01HS010871,Jan-06,null,Aug-06,4-May-07,null,26-Nov-08,"Medical University of South Carolina, Charleston, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT00469365
NCT00466154,The Effect of Serum LDL Lowering on Aspirin Resistance,,Completed,No Results Available,Aspirin Resistance|Hypercholesterolemia,Drug: Aspirin,Spearsman's correlation coefficients will be calculated to determine the relation between changes in lipid parameters and changes in LDL tendency to oxidation and platelet aggregation.,Ziv Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HP 5-173 S,Jul-05,null,Jan-07,27-Apr-07,null,20-Feb-13,"Internal Medicine Department A ,Ziv Goverment Hospital, Safed, Israel",,https://ClinicalTrials.gov/show/NCT00466154
NCT00466401,Effect of Ezetimibe on Platelet Aggregation and LDL Tendency to Peroxidation,,Completed,No Results Available,Hypercholesterolemia,Drug: Simvastatin|Drug: Ezetimibe,,Ziv Hospital|Merck Sharp & Dohme Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 4,20,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HP-5-155-S,Feb-05,null,Aug-07,27-Apr-07,null,20-Feb-13,"Internal Medicine Department A ,Ziv Goverment Hospital, Safed, Israel",,https://ClinicalTrials.gov/show/NCT00466401
NCT00466869,"A Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effect of Betahistine on Plasma Lipids in Patients Treated With Simvastatin",,Terminated,No Results Available,Hypercholesterolemia,Drug: Betahistine,"The primary efficacy parameter is change in LDL-C from baseline (randomization) to Week 4 and the percentage of patients that reduce their LDL-C by 10% or more.|Change in Total Cholesterol from baseline (randomization) to Week 4.|Change in Triglycerides l from baseline (randomization) to Week 4.|Change in High density lipoprotein (HDL-C) from baseline (randomization) to Week 4.|Change in Total cholesterol to HDL-C ratio from baseline (randomization) to Week 4.|Change in ApoB from baseline (randomization) to Week 4.|Change in hemoglobin A1c [HbA1c], and fasting plasma glucose [FPG] from baseline (randomization) to Week 4.|Change in Caloric intake and macronutrients intake from baseline (randomization) to Week 4.|Change in body weight from baseline (randomization) to Week 4.|Change in waist circumference from baseline (randomization) to Week 4.",OBEcure Ltd.,All,"30 Years to 75 Years   (Adult, Older Adult)",Phase 2,30,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,BET203,May-07,null,Sep-07,27-Apr-07,null,26-Sep-07,"Internal Medicine Department A-Wolfson Medical Center, Holon, Israel|Internal Medicine Department A-Meir Medical Center, Kfar Saba, Israel",,https://ClinicalTrials.gov/show/NCT00466869
NCT00465751,Effects of FXR Activation on Hepatic Lipid and Glucose Metabolism,,Completed,No Results Available,Metabolic Syndrome|Familial Hypertriglyceridemia|Familial Combined Hyperlipidemia,Drug: chenodeoxycholic acid|Drug: placebo capsules,plasma triglyceride concentrations|hepatic insulin sensitivity|heptic triglyceride content,"University Hospital, Basel, Switzerland",All,"18 Years to 65 Years   (Adult, Older Adult)",Early Phase 1,30,Other,Interventional,"Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EKBB 211/04 SB,Oct-04,null,null,25-Apr-07,null,9-Mar-12,"University Hospital Basel, Basel, Switzerland",,https://ClinicalTrials.gov/show/NCT00465751
NCT00465088,An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME),SUPREME,Completed,Has Results,Hyperlipidemia|Mixed Dyslipidemia,Drug: Niacin ER/Simvastatin Tablets|Drug: atorvastatin,"Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 12|Percent Change in HDL-C From Baseline to Week 8|Percent Change in Non-HDL-C From Baseline to Week 8|Percent Change in Non-HDL-C From Baseline to Week 12|Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 12|Percent Change in Triglycerides From Baseline to Week 12|Percent Change in LDL-C:HDL-C Ratio|Percent Change in Total Cholesterol From Baseline to Week 12|Percent Change in Total Cholesterol:HDL-C Ratio|Percent Change in Lipoprotein A From Baseline to Week 12|Percentage of Subjects Meeting With HDL-C >/= 40 mg/dL at Week 12|Percentage of Subjects Meeting National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) III Goal for LDL-C at Week 12|Percentage of Subjects With Triglycerides < 150 mg/dL at Week 12|Percentage of Subjects With HDL-C >/= 40 mg/dL, LDL-C Meeting NCEP ATP III Goal, and Triglycerides < 150 mg/dL at Week 12",Abbott,All,"21 Years and older   (Adult, Older Adult)",Phase 3,199,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,019-05-06-CR|M10-013,Apr-07,Feb-08,null,24-Apr-07,13-May-09,13-Jun-11,"Anaheim, California, United States|Huntington Park, California, United States|Long Beach, California, United States|Sacramento, California, United States|Walnut Creek, California, United States|Brooksville, Florida, United States|Daytona Beach, Florida, United States|Gainesville, Florida, United States|Largo, Florida, United States|Merritt Island, Florida, United States|Miami, Florida, United States|Pembroke Pines, Florida, United States|Calhoun, Georgia, United States|Decatur, Georgia, United States|Dunwoody, Georgia, United States|Boise, Idaho, United States|Chicago, Illinois, United States|Arkansas City, Kansas, United States|Newton, Kansas, United States|Shawnee Mission, Kansas, United States|Topeka, Kansas, United States|Wichita, Kansas, United States|Auburn, Maine, United States|Baltimore, Maryland, United States|Missoula, Montana, United States|Charlotte, North Carolina, United States|High Point, North Carolina, United States|Canfield, Ohio, United States|Cincinnati, Ohio, United States|Dayton, Ohio, United States|Protland, Oregon, United States|Chicora, Pennsylvania, United States|Duncansville, Pennsylvania, United States|Harleysville, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Austin, Texas, United States|Carrollton, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Magna, Utah, United States|Salt Lake City, Utah, United States|Richmond, Virginia, United States|Gig Harbor, Washington, United States|Menomonee Falls, Wisconsin, United States|Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00465088
NCT00463606,A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia,,Completed,Has Results,Hypercholesterolemia|Dyslipidemia,Drug: ABT-335 and rosuvastatin calcium|Drug: ABT-335|Drug: rosuvastatin calcium,"Mean Percent Change From Baseline to the Final Visit in High-density Lipoprotein Cholesterol (HDL-C) (Full Analysis Set)|Mean Percent Change From Baseline to the Final Visit in Triglycerides (Full Analysis Set)|Mean Percent Change From Baseline to the Final Visit in Low-density Lipoprotein Cholesterol (LDL-C) (Full Analysis Set)|Mean Percent Change From Baseline to the Final Visit in Non-high-density Lipoprotein Cholesterol (Non-HDL-C), With ABT-335 135 mg in Combination With Rosuvastatin 5 mg Versus ABT-335 135 mg Monotherapy (Full Analysis Set)|Mean Percent Change From Baseline to the Final Visit in Non-high-density Lipoprotein Cholesterol (Non-HDL-C), With ABT-335 135 mg in Combination With Rosuvastatin 5 mg Versus Rosuvastatin 5 mg Monotherapy (Full Analysis Set)|Mean Percent Change From Baseline to the Final Visit in Very-low-density Lipoprotein Cholesterol (VLDL-C) (Full Analysis Set)|Mean Percent Change From Baseline to the Final Visit in Apolipoprotein B (ApoB) (Full Analysis Set)|Median Percent Change From Baseline to the Final Visit in High Sensitivity C-reactive Protein (hsCRP) (Full Analysis Set)|Mean Percent Change From Baseline to the Final Visit in Total Cholesterol (Full Analysis Set)",AstraZeneca,All,"18 Years and older   (Adult, Older Adult)",Phase 3,760,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",M06-844,Apr-07,Feb-08,Feb-08,20-Apr-07,1-Aug-12,3-Oct-12,"Site Reference ID/Investigator# 5469, Birmingham, Alabama, United States|Site Reference ID/Investigator# 4428, Birmingham, Alabama, United States|Site Reference ID/Investigator# 4985, Birmingham, Alabama, United States|Site Reference ID/Investigator# 4493, Huntsville, Alabama, United States|Site Reference ID/Investigator# 4510, Huntsville, Alabama, United States|Site Reference ID/Investigator# 4431, Ozark, Alabama, United States|Site Reference ID/Investigator# 4519, Tuscaloosa, Alabama, United States|Site Reference ID/Investigator# 4395, Chandler, Arizona, United States|Site Reference ID/Investigator# 4483, Gilbert, Arizona, United States|Site Reference ID/Investigator# 4411, Scottsdale, Arizona, United States|Site Reference ID/Investigator# 4417, Little Rock, Arkansas, United States|Site Reference ID/Investigator# 4702, Anaheim, California, United States|Site Reference ID/Investigator# 5593, Chula Vista, California, United States|Site Reference ID/Investigator# 4503, Concord, California, United States|Site Reference ID/Investigator# 4530, Encinitas, California, United States|Site Reference ID/Investigator# 4458, Fair Oaks, California, United States|Site Reference ID/Investigator# 4542, Fresno, California, United States|Site Reference ID/Investigator# 4574, Fresno, California, United States|Site Reference ID/Investigator# 4441, Lincoln, California, United States|Site Reference ID/Investigator# 4432, Long Beach, California, United States|Site Reference ID/Investigator# 5579, Los Angeles, California, United States|Site Reference ID/Investigator# 4980, Norwalk, California, United States|Site Reference ID/Investigator# 4392, Sacramento, California, United States|Site Reference ID/Investigator# 4896, Sacramento, California, United States|Site Reference ID/Investigator# 5582, San Diego, California, United States|Site Reference ID/Investigator# 6236, West Hills, California, United States|Site Reference ID/Investigator# 4442, Aurora, Colorado, United States|Site Reference ID/Investigator# 4419, Colorado Springs, Colorado, United States|Site Reference ID/Investigator# 4391, Waterbury, Connecticut, United States|Site Reference ID/Investigator# 4401, Coral Gables, Florida, United States|Site Reference ID/Investigator# 4453, Fort Lauderdale, Florida, United States|Site Reference ID/Investigator# 4490, Holly Hill, Florida, United States|Site Reference ID/Investigator# 4420, Hollywood, Florida, United States|Site Reference ID/Investigator# 5011, Jacksonville, Florida, United States|Site Reference ID/Investigator# 4444, Jacksonville, Florida, United States|Site Reference ID/Investigator# 4399, Jupiter, Florida, United States|Site Reference ID/Investigator# 4433, Kissimmee, Florida, United States|Site Reference ID/Investigator# 4469, Largo, Florida, United States|Site Reference ID/Investigator# 4525, Melbourne, Florida, United States|Site Reference ID/Investigator# 4477, Miami, Florida, United States|Site Reference ID/Investigator# 4430, New Port Richey, Florida, United States|Site Reference ID/Investigator# 4409, New Smyrna Beach, Florida, United States|Site Reference ID/Investigator# 4416, Ocala, Florida, United States|Site Reference ID/Investigator# 4528, Ocala, Florida, United States|Site Reference ID/Investigator# 5103, Orlando, Florida, United States|Site Reference ID/Investigator# 4446, Ormond Beach, Florida, United States|Site Reference ID/Investigator# 4524, Pensacola, Florida, United States|Site Reference ID/Investigator# 4505, Sarasota, Florida, United States|Site Reference ID/Investigator# 5580, Sarasota, Florida, United States|Site Reference ID/Investigator# 4494, West Palm Beach, Florida, United States|Site Reference ID/Investigator# 4407, West Palm Beach, Florida, United States|Site Reference ID/Investigator# 4512, Winter Haven, Florida, United States|Site Reference ID/Investigator# 5478, Blue Ridge, Georgia, United States|Site Reference ID/Investigator# 4388, Decatur, Georgia, United States|Site Reference ID/Investigator# 4511, Dunwoody, Georgia, United States|Site Reference ID/Investigator# 4981, Roswell, Georgia, United States|Site Reference ID/Investigator# 4448, Roswell, Georgia, United States|Site Reference ID/Investigator# 4497, Suwanee, Georgia, United States|Site Reference ID/Investigator# 4439, Woodstock, Georgia, United States|Site Reference ID/Investigator# 4472, Arlington Heights, Illinois, United States|Site Reference ID/Investigator# 5585, Chicago, Illinois, United States|Site Reference ID/Investigator# 4520, Peoria, Illinois, United States|Site Reference ID/Investigator# 4527, Avon, Indiana, United States|Site Reference ID/Investigator# 4485, Evansville, Indiana, United States|Site Reference ID/Investigator# 4445, Indianapolis, Indiana, United States|Site Reference ID/Investigator# 4438, Lafayette, Indiana, United States|Site Reference ID/Investigator# 5010, Newburgh, Indiana, United States|Site Reference ID/Investigator# 4403, Iowa City, Iowa, United States|Site Reference ID/Investigator# 4393, Arkansas City, Kansas, United States|Site Reference ID/Investigator# 4526, Overland Park, Kansas, United States|Site Reference ID/Investigator# 4423, Wichita, Kansas, United States|Site Reference ID/Investigator# 4424, Wichita, Kansas, United States|Site Reference ID/Investigator# 5027, Lexington, Kentucky, United States|Site Reference ID/Investigator# 4471, Louisville, Kentucky, United States|Site Reference ID/Investigator# 4406, New Orleans, Louisiana, United States|Site Reference ID/Investigator# 4509, Slidell, Louisiana, United States|Site Reference ID/Investigator# 5635, Auburn, Maine, United States|Site Reference ID/Investigator# 4502, Scarborough, Maine, United States|Site Reference ID/Investigator# 5070, Baltimore, Maryland, United States|Site Reference ID/Investigator# 4412, Haverhill, Massachusetts, United States|Site Reference ID/Investigator# 4487, Springfield, Massachusetts, United States|Site Reference ID/Investigator# 5533, Ann Arbor, Michigan, United States|Site Reference ID/Investigator# 6237, Ann Arbor, Michigan, United States|Site Reference ID/Investigator# 5583, Portage, Michigan, United States|Site Reference ID/Investigator# 4480, Brooklyn Center, Minnesota, United States|Site Reference ID/Investigator# 4515, Jackson, Mississippi, United States|Site Reference ID/Investigator# 4492, Olive Branch, Mississippi, United States|Site Reference ID/Investigator# 5636, Tupelo, Mississippi, United States|Site Reference ID/Investigator# 4500, Kansas City, Missouri, United States|Site Reference ID/Investigator# 4499, St. Peters, Missouri, United States|Site Reference ID/Investigator# 4979, Billings, Montana, United States|Site Reference ID/Investigator# 4481, Missoula, Montana, United States|Site Reference ID/Investigator# 4460, Las Vegas, Nevada, United States|Site Reference ID/Investigator# 4466, Las Vegas, Nevada, United States|Site Reference ID/Investigator# 5484, Las Vegas, Nevada, United States|Site Reference ID/Investigator# 5444, Concord, New Hampshire, United States|Site Reference ID/Investigator# 4908, Elizabeth, New Jersey, United States|Site Reference ID/Investigator# 4504, South Bound Brook, New Jersey, United States|Site Reference ID/Investigator# 4394, Toms River, New Jersey, United States|Site Reference ID/Investigator# 4402, Trenton, New Jersey, United States|Site Reference ID/Investigator# 4427, Albuquerque, New Mexico, United States|Site Reference ID/Investigator# 4463, Bronxville, New York, United States|Site Reference ID/Investigator# 4415, New York, New York, United States|Site Reference ID/Investigator# 4440, Rochester, New York, United States|Site Reference ID/Investigator# 4464, Syracuse, New York, United States|Site Reference ID/Investigator# 4425, Williamsville, New York, United States|Site Reference ID/Investigator# 4473, Asheville, North Carolina, United States|Site Reference ID/Investigator# 4531, Charlotte, North Carolina, United States|Site Reference ID/Investigator# 4396, Charlotte, North Carolina, United States|Site Reference ID/Investigator# 5494, Hickory, North Carolina, United States|Site Reference ID/Investigator# 4479, Morehead City, North Carolina, United States|Site Reference ID/Investigator# 4461, Raleigh, North Carolina, United States|Site Reference ID/Investigator# 4498, Salisbury, North Carolina, United States|Site Reference ID/Investigator# 4405, Statesville, North Carolina, United States|Site Reference ID/Investigator# 4476, Winston-Salem, North Carolina, United States|Site Reference ID/Investigator# 4390, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 4400, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 4501, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 4517, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 5584, Columbus, Ohio, United States|Site Reference ID/Investigator# 4410, Mogadore, Ohio, United States|Site Reference ID/Investigator# 4443, Sandusky, Ohio, United States|Site Reference ID/Investigator# 4523, Warren, Ohio, United States|Site Reference ID/Investigator# 4488, Oklahoma City, Oklahoma, United States|Site Reference ID/Investigator# 4451, Oklahoma City, Oklahoma, United States|Site Reference ID/Investigator# 4422, Tulsa, Oklahoma, United States|Site Reference ID/Investigator# 4482, Tulsa, Oklahoma, United States|Site Reference ID/Investigator# 4467, Medford, Oregon, United States|Site Reference ID/Investigator# 4470, Carlisle, Pennsylvania, United States|Site Reference ID/Investigator# 5581, Downingtown, Pennsylvania, United States|Site Reference ID/Investigator# 4434, Feasterville, Pennsylvania, United States|Site Reference ID/Investigator# 4478, Harleysville, Pennsylvania, United States|Site Reference ID/Investigator# 4436, Jersey Shore, Pennsylvania, United States|Site Reference ID/Investigator# 4397, Lansdale, Pennsylvania, United States|Site Reference ID/Investigator# 4426, Melrose Park, Pennsylvania, United States|Site Reference ID/Investigator# 4894, Newtown, Pennsylvania, United States|Site Reference ID/Investigator# 4496, Penndel, Pennsylvania, United States|Site Reference ID/Investigator# 4404, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 4437, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 4387, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 4447, Warminster, Pennsylvania, United States|Site Reference ID/Investigator# 4506, Charleston, South Carolina, United States|Site Reference ID/Investigator# 5443, Greenville, South Carolina, United States|Site Reference ID/Investigator# 4484, Greer, South Carolina, United States|Site Reference ID/Investigator# 4455, Moncks Corner, South Carolina, United States|Site Reference ID/Investigator# 4513, Mount Pleasant, South Carolina, United States|Site Reference ID/Investigator# 4521, Simpsonville, South Carolina, United States|Site Reference ID/Investigator# 4982, Summerville, South Carolina, United States|Site Reference ID/Investigator# 5586, Sioux Falls, South Dakota, United States|Site Reference ID/Investigator# 4435, Jackson, Tennessee, United States|Site Reference ID/Investigator# 4454, Johnson City, Tennessee, United States|Site Reference ID/Investigator# 4529, Nashville, Tennessee, United States|Site Reference ID/Investigator# 5454, Arlington, Texas, United States|Site Reference ID/Investigator# 5578, Houston, Texas, United States|Site Reference ID/Investigator# 5669, Houston, Texas, United States|Site Reference ID/Investigator# 4893, San Antonio, Texas, United States|Site Reference ID/Investigator# 4429, San Antonio, Texas, United States|Site Reference ID/Investigator# 4457, San Antonio, Texas, United States|Site Reference ID/Investigator# 4465, San Antonio, Texas, United States|Site Reference ID/Investigator# 4508, San Antonio, Texas, United States|Site Reference ID/Investigator# 4892, San Antonio, Texas, United States|Site Reference ID/Investigator# 5948, San Antonio, Texas, United States|Site Reference ID/Investigator# 4413, Temple, Texas, United States|Site Reference ID/Investigator# 4456, Falls Church, Virginia, United States|Site Reference ID/Investigator# 4459, Richmond, Virginia, United States|Site Reference ID/Investigator# 4408, Richmond, Virginia, United States|Site Reference ID/Investigator# 4421, Lakewood, Washington, United States|Site Reference ID/Investigator# 4468, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00463606
NCT00462748,A Study to Determine the Number of Patients Who Reach Optimal Cholesterol Levels on Each of Three Different Treatments (0653A-121),,Completed,Has Results,Hypercholesterolemia,Drug: ezetimibe (+) simvastatin|Drug: Comparator: atorvastatin|Drug: Comparator: rosuvastatin,Percentage of Patients Achieving a Target of Fasting LDL-C of <2mmol/l at Study End,Merck Sharp & Dohme Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 3,786,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0653A-121|MK0653A-121|2007_013,Mar-07,Jun-08,Jun-08,19-Apr-07,17-Aug-09,14-Apr-17,,,https://ClinicalTrials.gov/show/NCT00462748
NCT00462046,Efficacy and Safety of Berberine in the Treatment of Diabetes With Dyslipidemia,,Completed,No Results Available,"Diabetes Mellitus, Type 2|Metabolic Syndrome",Drug: Berberine,Fasting glucose levels|OGTT 2h glucose levels|HbA1c|Serum Triglycerides|Serum Total Cholesterol|HDL-c|LDL-c|Glucose Disposal Rate|BMI|Blood pressure,Shanghai Jiao Tong University School of Medicine,All,"25 Years to 70 Years   (Adult, Older Adult)",Phase 3,120,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double|Primary Purpose: Treatment,CCEMD001,Apr-05,null,Sep-06,18-Apr-07,null,18-Apr-07,,,https://ClinicalTrials.gov/show/NCT00462046
NCT00459745,"A Study to Evaluate Daily Pravastatin, Fenofibrate or Pravafen in the Treatment of Combined Hyperlipidemia",,Completed,No Results Available,Combined Hyperlipidemia,Drug: Pravafen|Drug: Pravastatin|Drug: Fenofibrate,"Primary endpoints will assess differences in change from baseline in non-HDL-C, for the patients receiving Pravafen versus the patients receiving Pravastatin or Fenofibrate at the end of the 12-week portion of the study.|Secondary endpoints will assess differences in change from baseline in TC, TG, LDL-C, HDL-C and TC/HDL-C for the pts receiving the combo therapy vs the pts receiving Pravastatin or Fenofibrate|Differences in change from baseline in ALT, AST and CK as well as overall safety for the pts receiving the combo therapy vs the pts receiving Pravastatin or Fenofibrate at the end of the 12-week of the study",Shionogi|Integrium|Shionogi Inc.,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,481,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Sc-PRAVA-06-02,Apr-07,Apr-08,Jul-09,12-Apr-07,null,24-Apr-18,"Anasazi Internal Medicine, Phoenix, Arizona, United States|Cochise Clinical Research, Sierra Vista, Arizona, United States|Memorial Research Medical Clinic, Long Beach, California, United States|Clinical Trials Research, Roseville, California, United States|Orange County Research Center, Tustin, California, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Drug Study Institute, Jupiter, Florida, United States|Mima Century Research Associates, Melbourne, Florida, United States|Cardiology Research Associates, Ormond Beach, Florida, United States|Atlanta Vascular Research Foundation, Atlanta, Georgia, United States|East-West Medical Research Institute, Honolulu, Hawaii, United States|Welborn Clinic Research Center, Evansville, Indiana, United States|MediSphere Medical Research Center LLC, Evansville, Indiana, United States|Research Institute of Middle America, Jeffersonville, Indiana, United States|Welborn Clinic Gateway, Newburgh, Indiana, United States|Lemarc Research Center, Louisville, Kentucky, United States|Bluegrass Clinical Research, Inc., Louisville, Kentucky, United States|Androscoggin Cardiology Associates, Auburn, Maine, United States|MODEL Clinical Research, Baltimore, Maryland, United States|Health Trends Research, LLC, Baltimore, Maryland, United States|MD Medical Research, Oxon Hill, Maryland, United States|Clinical Research Center of Cape Cod, Inc, West Yarmouth, Massachusetts, United States|Clinical Study Site, Florissant, Missouri, United States|Mercy Medical Group, Manchester, Missouri, United States|Comprehensive Clinical Research, Berlin, New Jersey, United States|Bronx Nephrology Hypertension, P.C., Bronx, New York, United States|Capital Cardiology Associates, Troy, New York, United States|Metrolina Medical Research, Charlotte, North Carolina, United States|Sensenbrenner Primary Care LLC, Charlotte, North Carolina, United States|Triangle Medical Research Associates, Raleigh, North Carolina, United States|Wake Research Associates, Raleigh, North Carolina, United States|Crescent Medical Research Associates, Salisbury, North Carolina, United States|Piedmont Medical Research Associates, Winston-Salem, North Carolina, United States|Sterling Research Group, Cincinnati, Ohio, United States|The Lindner Clinical Trial Center, Cincinnati, Ohio, United States|Ohio Clinical Research, Hudson, Ohio, United States|Wells Institute for Health Awareness, Kettering, Ohio, United States|Ohio Clinical Research, LLC, Lyndhurst, Ohio, United States|Bluestem Cardiology, Bartlesville, Oklahoma, United States|Lynn Institute of Norman, Norman, Oklahoma, United States|Willamette Valley Clinical Studies, Eugene, Oregon, United States|Fleetwood Clinical Research, Fleetwood, Pennsylvania, United States|Philadelphia Clinical Research, LLC, Philadelphia, Pennsylvania, United States|Southern Berks Family Medicine, Reading, Pennsylvania, United States|Tipton Medical Center, Tipton, Pennsylvania, United States|Palmetto Medical Research Associates, Mount Pleasant, South Carolina, United States|Upstate Pharmaceutical Research, Simpsonville, South Carolina, United States|TriCities Medical Research Associates, Bristol, Tennessee, United States|Holston Medical Group, Kingsport, Tennessee, United States|Clinical Trials Research, Austin, Texas, United States|Texas Medical Research LLC, San Antonio, Texas, United States|Hampton Roads Center for Clinical Research, Norfolk, Virginia, United States|Clinical Research Associates of Tidewater, Norfolk, Virginia, United States|National Clinical Research, Richmond, Virginia, United States|Rainier Clinical Research Center Inc., Renton, Washington, United States|Cedar Research LLC, Tacoma, Washington, United States",,https://ClinicalTrials.gov/show/NCT00459745
NCT00457938,Novel Therapies for Metabolic Complications of Lipodystrophies,,Completed,No Results Available,Insulin Resistance|Hypertriglyceridemia|Diabetes|Hepatic Steatosis,Other: low-fat diet ( Still recruiting )|Other: Diet,"Project specific: improvement in serum triglycerides, insulin resistance, liver triglyceride content, liver volume, Hgb A1c,","University of Texas Southwestern Medical Center|National Institutes of Health (NIH)|Takeda|Amylin Pharmaceuticals, LLC.",All,"14 Years to 70 Years   (Child, Adult, Older Adult)",Not Applicable,4,Other|NIH|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,RO1-074959|DK074959,Apr-06,Nov-14,Nov-14,9-Apr-07,null,16-Oct-18,"UT Southwestern Medical Center, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT00457938
NCT00458055,High-Density Lipoprotein (HDL) Treatment Study,,Completed,No Results Available,"Coronary Arteriosclerosis|Hypoalphalipoproteinemias|Genetic Diseases, Inborn",Drug: Atorvastatin; Fenofibrate; Niacin,HDL cholesterol|apo AI,McGill University Health Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,19,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MUHC-RI 0906,Nov-06,Sep-07,Sep-07,9-Apr-07,null,4-Jun-08,"MUHC-Royal Victoria Hospital, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00458055
NCT00458081,Evaluation of the Rimonabant Impact on the Regression of Asymptomatic Damage Caused by Cardiovascular Risk Factors,RIALTO,Terminated,No Results Available,"Obesity|Microalbuminuria|Diabetes Mellitus, Type 2|Dyslipidemia",Drug: Rimonabant|Drug: Placebo,"Relative change in the microalbuminuria level.|Percentage of patients whose albuminuria levels decrease, stabilise, are progressing towards macroalbuminuria, are unaltered.|Relative change and absolute change of Weight, Waist circumference, Body mass index (weight and height), Specific lipid parameters, Glycaemia control parameters, Proinflammatory markers, Adipocytokines, Glomerular filtration rate, Blood pressure|Evaluation of the Quality of Life (questionnaire IWQOL).|Safety (including neuropsychiatric events) and Laboratory assessments.",Sanofi,All,"30 Years to 75 Years   (Adult, Older Adult)",Phase 3,174,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RIMON_L_01031|EudraCT # : 2006-002951-33,Mar-07,Jan-09,Jan-09,9-Apr-07,null,10-Dec-10,"Sanofi-Aventis Administrative Office, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT00458081
NCT00457262,Effects of Soy Protein on Serum paraoxonase1 Activity and Lipoproteins in Postmenopausal Women,,Completed,No Results Available,Postmenopausal|Hyperlipidemia,Procedure: soy consumption,"decrease of LDL,increase of HDL,increase of paraoxonase 1",Iran University of Medical Sciences,Female,51 Years to 57 Years   (Adult),Not Applicable,42,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention,1344,Jan-06,null,Aug-06,6-Apr-07,null,6-Apr-07,,,https://ClinicalTrials.gov/show/NCT00457262
NCT00457275,Observational Study to Evaluate LDL-C Lowering Effect of Ezetimibe (0653-070),,Completed,No Results Available,Hypercholesterolemia,"Drug: MK0653, ezetimibe / Duration of Treatment: 4 Weeks",Approval,Merck Sharp & Dohme Corp.,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,440,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0653-070|2007_012,Apr-05,Nov-05,Nov-05,6-Apr-07,null,10-Mar-17,,,https://ClinicalTrials.gov/show/NCT00457275
NCT00457756,The Effect of BiosLife on Serum Lipids,,Completed,No Results Available,Hypercholesterolemia,Dietary Supplement: BiosLife Complete|Dietary Supplement: Placebo,LDL cholesterol|HDL cholesterol|triglycerides|LDL particle number|LDL particle size distribution|HDL particle number|HDL particle size distribution|VLDL particle number,University of Utah|Unicity International,All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BiosLife 2005-4,Jan-07,Jul-07,Jul-07,6-Apr-07,null,8-May-08,"Cardiovascular Genetics, University of Utah, 420 Chipeta Way, Room 1160, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT00457756
NCT00455325,Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS),ARCH-MS,"Active, not recruiting",No Results Available,Metabolic Syndrome X|Overweight|Hypertension|Dyslipidemias|Prediabetic State,Drug: Placebo Comparator Limb 1|Drug: Chloroquine,Insulin sensitivity,"Washington University School of Medicine|National Heart, Lung, and Blood Institute (NHLBI)",All,18 Years to 60 Years   (Adult),Phase 2,35,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,395|P50HL083762,Mar-07,Jan-20,Dec-20,3-Apr-07,null,17-Apr-19,"Washington University in St. Louis, Saint Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT00455325
NCT00455403,Atheroma Reduction With Chloroquine in Patients With the Metabolic Syndrome (ARCH-MS),ARCH-MS,"Active, not recruiting",No Results Available,Metabolic Syndrome X|Overweight|Hypertension|Dyslipidemias|Prediabetic State,Drug: Chloroquine|Drug: Placebo Comparator,Carotid intima-media thickness,"Washington University School of Medicine|National Heart, Lung, and Blood Institute (NHLBI)|Singulex",All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,150,Other|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",201110238(3)|P50HL083762,Apr-06,Jan-20,Jun-20,3-Apr-07,null,17-Apr-19,"Washington University School of Medicine, Saint Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT00455403
NCT00454831,Efficacy and Safety of HEP-40 Chitosan for Mild to Moderately Elevated Cholesterol,HEP-40,Completed,No Results Available,Hypercholesterolemia,Device: HEP-40 chitosan,"Percent change in serum LDL-C between the baseline and 4-week visit compared to placebo.|Percent change in serum LDL-C from baseline to 8- and 12-weeks of treatment compared to placebo|Percent change in serum total cholesterol from baseline to 12 weeks of treatment compared to placebo|Percent change in serum HDL-C from baseline to 12 weeks of treatment compared to placebo|Percent change in serum triglycerides from baseline to 12 weeks of treatment compared to placebo|Safety and tolerability over the 12-week active treatment period, as determined by treatment-emergent adverse events.",DNP Canada|JSS Medical Research Inc.,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,207,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",153-PTL-001,Feb-06,null,Sep-07,2-Apr-07,null,16-Nov-07,"JSS Medical Research Inc., Westmount, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00454831
NCT00451828,Cholesterol and Pharmacogenetic Study,CAP,Completed,No Results Available,Hyperlipidemia|Hypercholesterolemia|Coronary Heart Disease|Cardiovascular Disease,Drug: Simvastatin,Total Cholesterol|LDL Cholesterol|HDL Cholesterol|Triglycerides|C-reactive protein|Total Cholesterol/HDL Cholesterol|Apolipoprotein B|Apolipoprotein AI|Apolipoprotein CIII|LDL Peak Particle size|LDL Subfractions,"Children's Hospital & Research Center Oakland|National Heart, Lung, and Blood Institute (NHLBI)|San Francisco General Hospital|University of California, Los Angeles|Cedars-Sinai Medical Center|University of Washington|Duke University",All,"30 Years and older   (Adult, Older Adult)",Phase 4,1000,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,MM2277,Mar-02,Oct-04,null,26-Mar-07,null,5-Oct-11,"San Francisco General Hospital, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT00451828
NCT00447070,Effect of Atazanavir on Endothelial Function in HIV-Infected Patients,ENDOPACT,Completed,No Results Available,HIV Infections|Dyslipidemia,Drug: ATAZANAVIR,Change of flow-mediated dilation in the forearm after 6 months using the protease inhibitor atazanavir in a potent antiviral therapy combination compared with a combination including current proteinase inhibitor.|Changes in plasma lipid profiles and further clinical chemistry parameters after 6 months of treatment compared to baseline.,"Foundation for Cardiovascular Research, Zurich|Bristol-Myers Squibb",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,50,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment,ICN 99034,Aug-04,null,May-06,14-Mar-07,null,27-May-09,"University Hospital Zurich, Infectiology, Zurich, ZH, Switzerland",,https://ClinicalTrials.gov/show/NCT00447070
NCT00443755,Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance,,Completed,Has Results,Type 2 Diabetes|Insulin Resistance|Metabolic Syndrome,Drug: metformin|Drug: pioglitazone|Drug: Placebo,Change From Baseline in Insulin Sensitivity as Measured by Glucose Infusion Rate (GIR)|Change From Baseline in Fasting Blood Glucose Level|Change From Baseline in Glycosylated Hemoglobin (HbA1c)|Change From Baseline in Insulin Levels|Change From Baseline in Lipid Profile|Change From Baseline in the Thrombotic Biomarker Fibrinogen|Change From Baseline in the Thrombotic Biomarker Plasminogen Activator Inhibitor-1 (PAI-1)|Change From Baseline in the Inflammatory Biomarker Interleukin 6 (IL-6)|Change From Baseline in the Inflammatory Biomarker C-Reactive Protein (CRP)|Change From Baseline in Inflammatory Biomarker Tumor Necrosis Factor-alpha (TNF-α)|Change From Baseline in the Inflammatory Biomarker Adiponectin,"Mayo Clinic|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Takeda Pharmaceuticals North America, Inc.|National Center for Research Resources (NCRR)",All,"20 Years and older   (Adult, Older Adult)",Phase 2,28,Other|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",05-004002|R01DK041973|KL2RR024151|UL1RR024150,Aug-05,Aug-10,Aug-10,6-Mar-07,6-Jun-13,31-Oct-13,"Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00443755
NCT00442897,Vytorin (10/20 Or 10/40) Compared to Atorvastatin (10 mg or 20 mg) in Patients With Coronary Artery Disease (0653A-126)(COMPLETED),,Completed,Has Results,Hypercholesterolemia,Drug: simvastatin (+) ezetimibe|Drug: Comparator: atorvastatin,Number of Participants Reaching the LDL-C (Low Density Lipoprotein-Cholesterol) Goal (< 100 mg/dl) After 6 Weeks of Treatment|Number of Participants Reaching the LDL-C Goal (< 100 mg/dl) After 12 Weeks of Treatment,Merck Sharp & Dohme Corp.,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,229,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0653A-126|MK0653A-126|2007_006,Sep-06,Oct-08,Oct-08,5-Mar-07,9-Nov-09,14-Apr-17,,,https://ClinicalTrials.gov/show/NCT00442897
NCT00442845,Establish The Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST),ACTFAST,Completed,No Results Available,"Coronary Arteriosclerosis|Diabetes Mellitus, Type 2|Cerebrovascular Accident|Dyslipidemia|Peripheral Vascular Disease",Drug: Atorvastatin (Lipitor),"Proportion of subjects achieving a LDL-C target of < 100 mg/dL (2.6 mmol/L) after 12 weeks.|Percentage of subjects achieving:|LDL-C target <100 mg/dL (<2.6 mmol/L) after 6 weeks of treatment.|Total cholesterol (TC)/HDL-C ratio target (<4.0) after 6 and 12 weeks of treatment.|Either the LDL-C <100mg/dL (<2.6 mmol/L) or TC/HDL-C ratio (<4.0) targets after 6 and 12 weeks of treatment.|Both the LDL-C <100mg/dL (<2.6 mmol/L) and TC/HDL-C ratio (<4.0) targets after 6 and 12 weeks of treatment.|LDL-C <100mg/dL (<2.6 mmol/L) or TC/HDL-C ratio (<4.0) targets after 6 and 12 weeks of treatment by LDL-C strata.|LDL-C target (<100 mg/dL) by primary inclusion diagnosis (CHD, CHD-equivalent, diabetes or 10-year CHD risk-equivalent >20%).|The mean percent change in LDL-C, high density lipoprotein cholesterol (HDL-C),TC/HDL-C ratio, non HDL-C (in subjects with triglycerides [TG] ≥200 mg/dL or 2.3 mmol/L), TC and TG from baseline to 6 and 12 weeks of treatment.|Change from baseline in apolipoprotein-B (Apo-B) and change from baseline in glycosylated hemoglobin (HbA1c) was assessed at 12 weeks.",Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 4,2080,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A2581087,Jan-03,Feb-04,Feb-04,2-Mar-07,null,22-Apr-15,"Pfizer Investigational Site, Mississauga, Ontario, Cameroon|Pfizer Investigational Site, Calgary, Alberta, Canada|Pfizer Investigational Site, Edmonton, Alberta, Canada|Pfizer Investigational Site, Medicine Hat, Alberta, Canada|Pfizer Investigational Site, Red Deer, Alberta, Canada|Pfizer Investigational Site, Campbell River, British Columbia, Canada|Pfizer Investigational Site, Maple Ridge, British Columbia, Canada|Pfizer Investigational Site, Nanaimo, British Columbia, Canada|Pfizer Investigational Site, New Westminster, British Columbia, Canada|Pfizer Investigational Site, Richmond, British Columbia, Canada|Pfizer Investigational Site, Surrey, British Columbia, Canada|Pfizer Investigational Site, Vancouver, British Columbia, Canada|Pfizer Investigational Site, Vernon, British Columbia, Canada|Pfizer Investigational Site, Victoria, British Columbia, Canada|Pfizer Investigational Site, Brandon, Manitoba, Canada|Pfizer Investigational Site, Winnipeg, Manitoba, Canada|Pfizer Investigational Site, Ajax, Ontario, Canada|Pfizer Investigational Site, Brampton, Ontario, Canada|Pfizer Investigational Site, Burlington, Ontario, Canada|Pfizer Investigational Site, Cambridge, Ontario, Canada|Pfizer Investigational Site, Cornwall, Ontario, Canada|Pfizer Investigational Site, Etobicoke, Ontario, Canada|Pfizer Investigational Site, Mississauga, Ontario, Canada|Pfizer Investigational Site, Niagara Falls, Ontario, Canada|Pfizer Investigational Site, North York, Ontario, Canada|Pfizer Investigational Site, Orillia, Ontario, Canada|Pfizer Investigational Site, Oshawa, Ontario, Canada|Pfizer Investigational Site, Rexdale, Ontario, Canada|Pfizer Investigational Site, Sarnia, Ontario, Canada|Pfizer Investigational Site, Scarborough, Ontario, Canada|Pfizer Investigational Site, Simcoe, Ontario, Canada|Pfizer Investigational Site, Thunder Bay, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Weston, Ontario, Canada|Pfizer Investigational Site, Whitby, Ontario, Canada|Pfizer Investigational Site, Willowdale, Ontario, Canada|Pfizer Investigational Site, Chicoutimi, Quebec, Canada|Pfizer Investigational Site, Cowansville, Quebec, Canada|Pfizer Investigational Site, Drummondville, Quebec, Canada|Pfizer Investigational Site, Joliette, Quebec, Canada|Pfizer Investigational Site, Laval, Quebec, Canada|Pfizer Investigational Site, Levis, Quebec, Canada|Pfizer Investigational Site, Maria, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Newport, Quebec, Canada|Pfizer Investigational Site, Pointe Claire, Quebec, Canada|Pfizer Investigational Site, Repentigny, Quebec, Canada|Pfizer Investigational Site, Saint Hyacinthe, Quebec, Canada|Pfizer Investigational Site, Sainte Foy, Quebec, Canada|Pfizer Investigational Site, Sherbrooke, Quebec, Canada|Pfizer Investigational Site, St-georges (beauce), Quebec, Canada|Pfizer Investigational Site, St. Lambert, Quebec, Canada|Pfizer Investigational Site, Thetford Mines, Quebec, Canada|Pfizer Investigational Site, Vaudreuil, Quebec, Canada|Pfizer Investigational Site, Saskatoon, Saskatchewan, Canada|Pfizer Investigational Site, Quebec, Canada|Pfizer Investigational Site, Tricase, (le), Italy|Pfizer Investigational Site, Vimercate, (mi), Italy|Pfizer Investigational Site, Somma Lombardo, (va), Italy|Pfizer Investigational Site, Asti, Italy|Pfizer Investigational Site, Bari, Italy|Pfizer Investigational Site, Belluno, Italy|Pfizer Investigational Site, Bologna, Italy|Pfizer Investigational Site, Bolzano, Italy|Pfizer Investigational Site, Catania, Italy|Pfizer Investigational Site, Chieti, Italy|Pfizer Investigational Site, Ferrara, Italy|Pfizer Investigational Site, Firenze, Italy|Pfizer Investigational Site, Foggia, Italy|Pfizer Investigational Site, Grosseto, Italy|Pfizer Investigational Site, Napoli, Italy|Pfizer Investigational Site, Novara, Italy|Pfizer Investigational Site, Palermo, Italy|Pfizer Investigational Site, Perugia, Italy|Pfizer Investigational Site, Potenza, Italy|Pfizer Investigational Site, Prato, Italy|Pfizer Investigational Site, Roma, Italy|Pfizer Investigational Site, Salerno, Italy|Pfizer Investigational Site, San Donato Milanese, Italy|Pfizer Investigational Site, Sassari, Italy|Pfizer Investigational Site, Savona, Italy|Pfizer Investigational Site, Siena, Italy|Pfizer Investigational Site, Torino, Italy|Pfizer Investigational Site, Venezia, Italy|Pfizer Investigational Site, Hospitalet de Llobregat, Barcelona, Spain|Pfizer Investigational Site, Girona, Cataluna, Spain|Pfizer Investigational Site, Galdakao, Vizcaya, Spain|Pfizer Investigational Site, Avila, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Granada, Spain|Pfizer Investigational Site, Huelva, Spain|Pfizer Investigational Site, Jerez de La Frontera, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Marbella, Spain|Pfizer Investigational Site, Sevilla, Spain|Pfizer Investigational Site, Tarragona, Spain|Pfizer Investigational Site, Valencia, Spain|Pfizer Investigational Site, Newtonabbey, Belfast, United Kingdom|Pfizer Investigational Site, Aylesbury, Buckinghamshire, United Kingdom|Pfizer Investigational Site, ELY, Cambs, United Kingdom|Pfizer Investigational Site, Peterborough, Cambs, United Kingdom|Pfizer Investigational Site, Newtonabbey, Co Antrim, United Kingdom|Pfizer Investigational Site, Hastings, East Sussex, United Kingdom|Pfizer Investigational Site, High Valleyfield, Fife, United Kingdom|Pfizer Investigational Site, Rutherglen, Glasgow, United Kingdom|Pfizer Investigational Site, Leslie, Fife, Glenrotheshire, United Kingdom|Pfizer Investigational Site, Sunbury on Thames, Middlesex, United Kingdom|Pfizer Investigational Site, Frome, Somerset, United Kingdom|Pfizer Investigational Site, Barry, South Glamorgan, United Kingdom|Pfizer Investigational Site, Doncaster, South Yorkshire, United Kingdom|Pfizer Investigational Site, Stairfoot, Barnsley, South Yorkshire, United Kingdom|Pfizer Investigational Site, Addlestone, Surrey, United Kingdom|Pfizer Investigational Site, East Horsley, Surrey, United Kingdom|Pfizer Investigational Site, Atherstone, Warks, United Kingdom|Pfizer Investigational Site, Balsall Common, West Midlands, United Kingdom|Pfizer Investigational Site, Pound Hill, Crawley, West Sussex, United Kingdom|Pfizer Investigational Site, Trowbridge, Wiltshire, United Kingdom|Pfizer Investigational Site, Chippenham, Wilts, United Kingdom|Pfizer Investigational Site, Sheffield, Yorkshire, United Kingdom|Pfizer Investigational Site, Bath, United Kingdom|Pfizer Investigational Site",,https://ClinicalTrials.gov/show/NCT00442845
NCT00441480,Effect of Plant Sterols Esterified to Fish Oil Fatty Acids on Plasma Lipid Levels,,Completed,Has Results,Dyslipidemia,Dietary Supplement: Plant sterols esters|Dietary Supplement: placebo,LDL Cholesterol|LDL-C|Triglycerides|Total Cholesterol|HDL Cholesterol|HDL-cholestrol|CRP|Apolipoprotein B100|Apolipoprotein A,Enzymotec,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,91,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CardiaBeat_003,Mar-07,Jun-08,Jun-08,1-Mar-07,14-Aug-09,13-Jan-12,"Sheba medical center, Tel-HaShomer, Israel",,https://ClinicalTrials.gov/show/NCT00441480
NCT00441857,Effect of Plant Stanols on Cholesterol Absorption,DOSE,Completed,No Results Available,Hypercholesterolemia,Behavioral: plant stanol consumption,cholesterol absorption efficiency|changes in blood lipids,Oy Foodfiles Ltd,All,"25 Years to 68 Years   (Adult, Older Adult)",Phase 4,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,DOSE,Mar-07,null,May-07,1-Mar-07,null,6-Jul-07,"Oy Foodfiles Ltd, Kuopio, Finland",,https://ClinicalTrials.gov/show/NCT00441857
NCT00442325,Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets,ACTFAST 2,Completed,No Results Available,"Coronary Arteriosclerosis|Diabetes Mellitus, Type 2|Cerebrovascular Accident|Dyslipidemia|Peripheral Vascular Disease",Drug: Atorvastatin (Lipitor),"Proportion of subjects achieving a LDL-C target of < 100 mg/dL (2.6 mmol/L) after 12 weeks.|Percentage of subjects achieving:|LDL-C target <100 mg/dL (<2.6 mmol/L) after 6 weeks of treatment.|Total cholesterol (TC)/HDL-C ratio target (<4.0) after 6 and 12 weeks of treatment.|Either the LDL-C <100mg/dL (<2.6 mmol/L) or TC/HDL-C ratio (<4.0) targets after 6 and 12 weeks of treatment.|Both the LDL-C <100mg/dL (<2.6 mmol/L) and TC/HDL-C ratio (<4.0) targets after 6 and 12 weeks of treatment.|LDL-C <100mg/dL (<2.6 mmol/L) or TC/HDL-C ratio (<4.0) targets after 6 and 12 weeks of treatment by LDL-C strata.|LDL-C target (<100 mg/dL) by primary inclusion diagnosis (CHD, CHD-equivalent, diabetes or 10-year CHD risk-equivalent >20%).|The mean percent change in LDL-C, high density lipoprotein cholesterol (HDL-C),TC/HDL-C ratio, non HDL-C (in subjects with triglycerides [TG] ≥200 mg/dL or 2.3 mmol/L), TC and TG from baseline to 6 and 12 weeks of treatment. Change from baseline in apol",Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 4,595,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A2581095,Jan-03,null,Feb-04,1-Mar-07,null,25-Oct-07,"Pfizer Investigational Site, Ioannina, Greece|Pfizer Investigational Site, Kallithea, Athens, Greece|Pfizer Investigational Site, Pireaus, Greece|Pfizer Investigational Site, Thessaloniki, Greece|Pfizer Investigational Site, Budapest, Hungary|Pfizer Investigational Site, Gyula, Hungary|Pfizer Investigational Site, Kecskemet, Hungary|Pfizer Investigational Site, Nyíregyháza, Hungary|Pfizer Investigational Site, Szekszárd, Hungary|Pfizer Investigational Site, Tullamore, Co. Offlay, Ireland|Pfizer Investigational Site, Tallaght, Dublin, Ireland|Pfizer Investigational Site, Gorey, Wexford, Ireland|Pfizer Investigational Site, Cork, Ireland|Pfizer Investigational Site, Dublin 8, Ireland|Pfizer Investigational Site, Dublin, Ireland|Pfizer Investigational Site, Galway, Ireland|Pfizer Investigational Site, Czestochowa, Poland|Pfizer Investigational Site, Poznan, Poland|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, Wroclaw, Poland|Pfizer Investigational Site, Zabrze, Poland|Pfizer Investigational Site, Aveiro, Portugal|Pfizer Investigational Site, Lisboa, Portugal|Pfizer Investigational Site, Porto, Portugal|Pfizer Investigational Site, Vila Franca de Xira, Portugal|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Bratislava, Slovakia|Pfizer Investigational Site, Kosice, Slovakia|Pfizer Investigational Site, Bern, Switzerland|Pfizer Investigational Site, Genève, Switzerland|Pfizer Investigational Site, Mendrisio, Switzerland|Pfizer Investigational Site, Zürich, Switzerland|Pfizer Investigational Site",,https://ClinicalTrials.gov/show/NCT00442325
NCT00440154,A Study Evaluating the Safety and Efficacy of AVE5530 (4 Weeks) in Patients With Mild to Moderate Hypercholesterolemia,,Completed,No Results Available,Hypercholesterolemia,Drug: AVE5530|Drug: placebo|Drug: ezetimibe,Percent change in LDL-C from baseline|Absolute change from in LDL-C levels|Percent change in other lipids and lipoprotein fractions from baseline,Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 2,206,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",DRI6589|EudraCT: 2006-005469-20,Feb-07,Oct-07,Oct-07,26-Feb-07,null,16-Dec-08,"Sanofi-Aventis Administrative Office, Santiago, Chile|Sanofi-Aventis Administrative Office, Budapest, Hungary|Sanofi-Aventis Administrative Office, Seoul, Korea, Republic of|Sanofi-Aventis Administrative Office, Mexico, Mexico|Sanofi-Aventis Administrative Office, Moscow, Russian Federation|Sanofi-Aventis Administrative Office, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT00440154
NCT00438425,Portfolio 5 - Multicentre Dietary Advice on Serum Lipids in Hyperlipidemia,,Completed,No Results Available,Hyperlipidemia|Cardiovascular Disease,Dietary Supplement: Dietary Portfolio - Intensive|Dietary Supplement: Dietary Portfolio - Routine|Dietary Supplement: Control (low saturated fat therapeutic diet),Primary Outcome Measures Described Below|Secondary Outcome Measures Described Below,"University of Toronto|Canadian Institutes of Health Research (CIHR)|Loblaw Companies Limited|Solae, LLC|Unilever R&D",All,"21 Years to 100 Years   (Adult, Older Adult)",Not Applicable,351,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,REB 04-056c|CIHR RCT#: 68767,25-Jun-07,30-Sep-09,31-Mar-10,22-Feb-07,null,15-Oct-18,"Healthy Heart Program, St. Paul's Hospital, Vancouver, British Columbia, Canada|Richardson Centre for Functional Foods and Nutraceuticals, University of Manitoba, Winnipeg, Manitoba, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Institute on Nutraceuticals and Functional Foods and the Lipid Research Center, Laval University Hospital Research Center, Quebec City, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00438425
NCT00438893,Effects of a Long Term Dietary Portfolio and of Sequential Removal of Food Components From the Diet,,Completed,No Results Available,Hyperlipidemia|Cardiovascular Diseases|Hypercholesterolemia,Dietary Supplement: Dietary portfolio of cholesterol-lowering foods,Total cholesterol|LDL cholesterol|C-reactive protein|Blood pressure|Body Weight|Apolipoprotein A1 and B|Lp(a)|Routine Biochemistry and hematology measurements|Compliance to dietary portfolio components|24 hour urinary markers and electrolytes (optional)|Oxidative stress markers,"University of Toronto|Canada Research Chairs Endowment of the Federal Government of Canada|Natural Sciences and Engineering Research Council, Canada|Loblaw Companies Limited|Almond Board of California|Unilever R&D",All,"21 Years and older   (Adult, Older Adult)",Not Applicable,66,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,REB 03-043|HC-CT#100934,1-Sep-03,May-09,May-09,22-Feb-07,null,15-Oct-18,"Clinical Nutrition & Risk Factor Modification Centre, St. Michael's Hospital Health Centre, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00438893
NCT00437892,Statins to Reduce D-dimer Levels in Patients With Venous Thrombosis,,Terminated,No Results Available,Venous Thromboembolism|Hypercholesterolemia,Drug: atorvastatin|Behavioral: diet,proportion of patients with elevated D-dimer at day 90|proportion of patients with elevated D-dimer levels at Day 30;|proportion of patients with elevated D-dimer levels at Day 0 and subsequent normalization of D-dimer levels at Day 30 and Day 90;|proportion of patients with recurrent VTE,Università degli Studi dell'Insubria,All,"18 Years and older   (Adult, Older Adult)",Phase 2,10,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,7948,May-07,May-11,May-11,21-Feb-07,null,19-Aug-11,"University of Bologna, Bologna, Italy|Ospedale di Piacenza, Piacenza, Italy|University Of Insubria, Varese, Italy",,https://ClinicalTrials.gov/show/NCT00437892
NCT00435045,"Evaluation of Efficacy and Safety of Omacor, Co-Administered With Atorvastatin, in Subjects With Hypertriglyceridemia",,Completed,Has Results,Hypertriglyceridemia,Drug: Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor] plus atorvastatin|Drug: atorvastatin,Percent Change in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Week 8 During 10 mg Atorvastatin Treatment Period|Percent Change in Total Cholesterol (TC) From Baseline to Week 8 During 10 mg Atorvastatin Treatment Period|Percent Change in High Density Lipoprotein (HDL)Cholesterol From Baseline to Week 8 During 10 mg Atorvastatin Treatment Period|Percent Change in Low Density Lipoprotein (LDL) Cholesterol (Beta-quantification) From Baseline to Week 8 During 10 mg Atorvastatin Treatment Period|Percent Change in Triglycerides From Baseline to Week 8 During 10 mg Atorvastatin Treatment Period|Percent Change in Very Low Density Lipoproteins (VLDL) Cholesterol From Baseline to Week 8 During 10 mg Atorvastatin Treatment Period|Percent Change in Apolipoprotein-A-1 From Baseline to Week 8 During 10 mg Atorvastatin Treatment Period|Percent Change in Apolipoprotein C-III From Baseline to Week 8 During 10 mg Atorvastatin Treatment Period|Percent Change in Total Cholesterol/High Density Lipoprotein Cholesterol Ratio From Baseline to Week 8 During 10 mg Atorvastatin Treatment Period|Percent Change in Triglycerides/High Density Lipoprotein Cholesterol Ratio From Baseline to Week 8 During 10 mg Atorvastatin Treatment Period|Percent Change in Docosahexaenoic Acid (DHA) From Baseline to Week 8 During 10 mg Atorvastatin Treatment Period|Percent Change in Eicosapentaenoic Acid (EPA) From Baseline to Week 8 During 10 mg Atorvastatin Treatment Period|Percent Change in Low Density Lipoprotein Particle Concentration Total From Baseline to Week 8 During 10 mg Atorvastatin Treatment Period|Percent Change in Low Density Lipoprotein Particle Size From Baseline to Week 8 During 10 mg Atorvastatin Treatment Period|Percent Change in Lipoprotein-Phosphoslipase A2 From Baseline to Week 8 During 10 mg Atorvastatin Treatment Period|Percent Change in High Density Lipoprotein (HDL) Particle Concentration Total From Baseline to Week 8 During 10 mg Atorvastatin Treatment Period|Percent Change in High Density Lipoprotein (HDL) Particle Size From Baseline to Week 8 During 10 mg Atorvastatin Treatment Period|Percent Change in Very Low Density Lipoproteins and Chylomicron Particle Concentration Total From Baseline to Week 8 During 10 mg Atorvastatin Treatment Period|Percent Change in Very Low Density Lipoproteins Size From Baseline to Week 8 During 10 mg Atorvastatin Treatment Period|Percent Change in Intermediate Density Lipoprotein Particle Concentration From Baseline to Week 8 During 10 mg Atorvastatin Treatment Period|Percent Change in Remnant-like Particle Cholesterol From Baseline to Week 8 During 10 mg Atorvastatin Treatment Period|Percent Change in Total Adiponectin From Baseline to Week 8 During 10 mg Atorvastatin Treatment Period|Percent Change in Non-High Density Lipoprotein Cholesterol From Baseline to Week 12 During 20 mg Atorvastatin Treatment Period|Percent Change in Non-High Density Lipoprotein Cholesterol From Baseline to Week 16 During 40 mg Atorvastatin Treatment Period,GlaxoSmithKline,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 3,245,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",OM9L,Feb-07,Oct-07,Oct-07,14-Feb-07,12-May-09,2-Feb-17,,,https://ClinicalTrials.gov/show/NCT00435045
NCT00433823,A Study Evaluating the Effects of Lipid Lowering Treatment on Steroid Synthesis,,Unknown status,No Results Available,Coronary Heart Disease|Diabetes Mellitus|Non-Coronary Atherosclerotic Disease|Hypercholesterolemia,"Drug: Atorvastatin, Ezetimibe",,Abant Izzet Baysal University,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,null,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),MK-19,Jan-07,null,Jan-08,12-Feb-07,null,12-Feb-07,"Bolu Izzet Baysal School of Medicine, Bolu, Turkey",,https://ClinicalTrials.gov/show/NCT00433823
NCT00434096,Japanese Study of Rimonabant in Obese Patients With Dyslipidemia (VENUS),,Terminated,No Results Available,Obesity,Drug: rimonabant (SR141716)|Drug: placebo,body weight: relative change from baseline|triglycerides: relative change from baseline|HDL-cholesterol ;visceral fat area|Safety: Adverse events,Sanofi,All,"20 Years and older   (Adult, Older Adult)",Phase 3,915,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",EFC5749,Feb-07,Nov-08,Feb-09,12-Feb-07,null,20-Jul-09,"Sanofi-Aventis Administrative Office, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT00434096
NCT00432276,Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus,,Completed,Has Results,Diabetes Mellitus,Drug: Alogliptin|Drug: Pioglitazone|Drug: Metformin|Drug: Placebo,Change From Baseline in Glycosylated Hemoglobin (HbA1c)|Change From Baseline in HbA1c Over Time|Percentage of Participants With Glycosylated Hemoglobin ≤ 6.5%|Percentage of Participants With Glycosylated Hemoglobin ≤ 7.0%|Percentage of Participants With Glycosylated Hemoglobin ≤ 7.5%|Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 0.5%|Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 1.0%|Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 1.5%|Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 2.0%|Change From Baseline in Fasting Plasma Glucose|Percentage of Participants With Marked Hyperglycemia|Percentage of Participants Meeting Hyperglycemic Rescue Criteria|Change From Baseline in Fasting Proinsulin|Change From Baseline in Fasting Insulin|Change From Baseline in Proinsulin/Insulin Ratio|Change From Baseline in C-peptide|Change From Baseline in Calculated HOMA Insulin Resistance|Change From Baseline in Calculated HOMA Beta-cell Function|Change From Baseline in Body Weight|Change From Baseline in Total Cholesterol|Change From Baseline in High-Density Lipoprotein Cholesterol|Change From Baseline in Low-Density Lipoprotein Cholesterol|Change From Baseline in Triglycerides|Change From Baseline in Free Fatty Acids|Change From Baseline in Apolipoprotein A1|Change From Baseline in Apolipoprotein A2|Change From Baseline in Apolipoprotein B|Change From Baseline in Apolipoprotein C-III|Change From Baseline in Plasminogen Activator Inhibitor-1|Change From Baseline in High-sensitivity C-Reactive Protein|Change From Baseline in Adiponectin|Change From Baseline in Nuclear Magnetic Resonance Lipid Fractionation Total Triglycerides|Change From Baseline in Very Low Density Lipoprotein (VLDL) / Chylomicron Particles|Change From Baseline in VLDL / Chylomicron Triglycerides|Change From Baseline in VLDL Particles|Change From Baseline in Mean VLDL Particle Size|Change From Baseline in Intermediate Density Lipoprotein (IDL) Particles|Change From Baseline in Low Density Lipoprotein (LDL) Particles|Change From Baseline in Mean LDL Particle Size|Change From Baseline in High Density Lipoprotein (HDL) Particles|Change From Baseline in Mean HDL Particle Size,Takeda,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,803,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",01-06-TL-322OPI-004|2006-006025-73|U1111-1112-3363,Jan-07,May-09,Jun-09,7-Feb-07,4-Apr-13,4-Apr-13,"Birmingham, Alabama, United States|Huntsville, Alabama, United States|Lake Havasu City, Arizona, United States|Little Rock, Arkansas, United States|Foothill Ranch, California, United States|Los Alamitos, California, United States|Los Angeles, California, United States|Pismo Beach, California, United States|San Diego, California, United States|Golden, Colorado, United States|Clearwater, Florida, United States|Hialeah, Florida, United States|Lakeland, Florida, United States|Marianna, Florida, United States|Miami, Florida, United States|North Miami Beach, Florida, United States|Pembroke Pines, Florida, United States|Sebastian, Florida, United States|South Miami, Florida, United States|Tampa, Florida, United States|Winter Park, Florida, United States|Blue Ridge, Georgia, United States|Conyers, Georgia, United States|Decatur, Georgia, United States|Duluth, Georgia, United States|Dunwoody, Georgia, United States|Warner Robins, Georgia, United States|Boise, Idaho, United States|Coeur D'Alene, Idaho, United States|Burr Ridge, Illinois, United States|Chicago, Illinois, United States|Melrose Park, Illinois, United States|Naperville, Illinois, United States|O'Fallon, Illinois, United States|Bloomington, Indiana, United States|Mishawaka, Indiana, United States|Overland Park, Kansas, United States|Marrero, Louisiana, United States|Elkton, Maryland, United States|Rockville, Maryland, United States|Towson, Maryland, United States|Marlborough, Massachusetts, United States|Bay City, Michigan, United States|St. Clair Shores, Michigan, United States|McCook, Nebraska, United States|Las Vegas, Nevada, United States|Blackwood, New Jersey, United States|Trenton, New Jersey, United States|West Caldwell, New Jersey, United States|Asheboro, North Carolina, United States|Charlotte, North Carolina, United States|Mooresville, North Carolina, United States|Shelby, North Carolina, United States|Sparta, North Carolina, United States|Bismarck, North Dakota, United States|Orrville, Ohio, United States|Norman, Oklahoma, United States|Ashland, Oregon, United States|Aliquippa, Pennsylvania, United States|Altoona, Pennsylvania, United States|Dawningtown, Pennsylvania, United States|Fleetwood, Pennsylvania, United States|Kingston, Pennsylvania, United States|Norristown, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Tipton, Pennsylvania, United States|Florence, South Carolina, United States|Taylors, South Carolina, United States|Williamston, South Carolina, United States|Watertown, South Dakota, United States|Kingsport, Tennessee, United States|Milan, Tennessee, United States|Nashville, Tennessee, United States|Arlington, Texas, United States|Austin, Texas, United States|Colleyville, Texas, United States|El Paso, Texas, United States|Garland, Texas, United States|Houston, Texas, United States|Hurst, Texas, United States|San Antonio, Texas, United States|Seguin, Texas, United States|Hampton, Virginia, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Virginia Beach, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00432276
NCT00432029,Correlation of Flicker Induced and Flow Mediated Vasodilatation in Patients With Endothelial Dysfunction and Healthy Volunteers.,,Completed,No Results Available,"Diabetes Mellitus, Type 1|Hypertension|Hypercholesterolemia|Regional Blood Flow","Procedure: Forearm blood flow measurement, Flow mediated dilation (FMD)|Device: Zeiss Retinal Vessel Analyzer (RVA), Stimulation with Flicker-light",Retinal vessel diameters (Retinal vessel analyzer)|Forearm Blood Flow,Medical University of Vienna,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,80,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,OPHT-180506,Dec-06,Dec-07,Jan-08,6-Feb-07,null,4-Jul-08,"Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria",,https://ClinicalTrials.gov/show/NCT00432029
NCT00430755,Improving the Quality of Patient Care by Using a Clinical Expert System.,CLEOS,Completed,Has Results,Hypertension|Diabetes|Hypercholesterolemia|Vasculitis|Coronary Heart Diseases,Device: Computer-assisted history|Procedure: physician taken history|Other: Computer-assisted history taking,"Detection of Medical Problems (by Number of Problems Reported by Computer Assisted History, That Were Not Reported by Physician Taken History)",Robert Bosch Gesellschaft für Medizinische Forschung mbH,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,98,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,RBK080,Aug-05,Dec-08,Dec-08,2-Feb-07,18-Dec-15,18-Dec-15,"Robert-Bosch-Hospital, Stuttgart, Germany",,https://ClinicalTrials.gov/show/NCT00430755
NCT00429845,Effect of Nutritional Intervention on the Lipid Profile of HIV-Positive Patients Who Start HAART: a Randomized Trial,,Completed,No Results Available,HIV Infections,Behavioral: Nutritional,"Total cholesterol and of triglycerides levels|HDL-cholesterol, LDL-cholesterol, weight, waist to hip ratio",Hospital de Clinicas de Porto Alegre,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,80,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,HCPA2004-012,Mar-04,null,Feb-07,1-Feb-07,null,1-Feb-07,"Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil",,https://ClinicalTrials.gov/show/NCT00429845
NCT00430430,Lipoprotein Turnover on Low- and High-MUFA Portfolio Diets,,Completed,No Results Available,Hyperlipidemia|Cardiovascular Diseases|Diet Therapy,Procedure: High MUFA dietary portfolio|Procedure: Low MUFA dietary portfolio,"HDL-C and VLDL-TG, synthesis and fractional catabolic rates of their respective apolipoproteins, apo AI and B100|LDL-C, LDL particle size, total and VLDL triglyceride, C-reactive protein, intravascular enzymes, HDL subfractions, blood glucose and insulin (HOMA models S and B), and relation of listed outcomes to kinetic parameters",University of Toronto|Canadian Institutes of Health Research (CIHR),All,"21 Years to 70 Years   (Adult, Older Adult)",Phase 2,24,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,REB 05-120,Apr-07,Apr-09,Apr-09,1-Feb-07,null,27-Oct-16,"Risk Factor Modification Centre, St. Michael's Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00430430
NCT00427960,Study of Asian Patients With Hypercholesterolaemia in the UK - Rosuvastatin 5mg Versus Atorvastatin 10mg,,Terminated,Has Results,Hypercholesterolaemia,Behavioral: Dietary advice|Drug: rosuvastatin|Drug: atorvastatin,"Percentage Change in Low Density Lipoprotein - Cholesterol (LDL-C)|The Percentage of Participants Reaching the General Medical Services (GMS) Contract Target of Total Cholesterol (TC) <5 mmol/L|The Percentage of Participants Reaching the Joint British Societies' Guideline (JBS 2) Targets of TC <4 mmol/L and LDL-C <2 mmol/L|The Percentage of Participants Reaching the European (EAS) Targets of LDL-C<2.5 or 3.00 mmol/L, Depending on Risk Category, and the Combined LDL-C and TC Target of LDL-C<2.5 or 3.0 mmol/L and TC<4.5 or 5.0 mmol/L, Both Depending on Risk Category.|The Percentage Change From Baseline(week6) in TC|The Percentage Change From Baseline (Week 6) in High-density Lipoprotein Cholesterol (HDL-C)|The Percentage of Participants Reaching the Joint British Societies Guideline (JBS 2) Target of TC <4 mmol/L|The Percentage Change From Baseline (Week 6)in Non-HDL-C|The Percentage Change From Baseline (Week 6) in Apolipoprotein-B (ApoB)|The Percentage Change From Baseline (Week 6) in Apolipoprotein-A1 (ApoA1)|The Percentage Change From Baseline (Week 6)in LDL-C/HDL-C Ratio|The Percentage Change From Baseline (Week 6) in TC/HDL-C Ratio|The Percentage Change From Baseline(Week 6) in Non-HDL-C/HDL-C Ratio|The Percentage Change From Baseline (Week 6) in ApoB/ApoA1 Ratio|The Percentage of Participants Reaching the European (EAS) Targets of LDL-C<2.5 or 3.00 mmol/L, Depending on Risk Category.",AstraZeneca,All,"18 Years and older   (Adult, Older Adult)",Phase 4,55,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,D3560L00060|SHUKRA,Dec-06,Feb-08,Feb-08,29-Jan-07,22-Mar-10,16-Dec-10,"Research Site, Allerton, United Kingdom|Research Site, Birmingham, United Kingdom|Research Site, Blackburn, United Kingdom|Research Site, Bolton, United Kingdom|Research Site, Crawley, United Kingdom|Research SIte, Glasgow, United Kingdom|Research Site, Newcastle, United Kingdom|Research SIte, Sheffield, United Kingdom|Research SIte, Slough, United Kingdom",,https://ClinicalTrials.gov/show/NCT00427960
NCT00423488,"Ezetimibe and Simvastatin in Primary Hypercholesterolemia, Diabetes Mellitus Type 2, and Coronary Heart Disease (COMPLETED)",,Completed,Has Results,"Hypercholesterolemia|Diabetes Mellitus, Type 2|Coronary Disease",Drug: Ezetimibe 10 mg|Drug: Simvastatin 20 mg|Drug: Ezetimibe Placebo|Drug: Simvastatin Placebo,"Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Endpoint, After 6 Weeks of Treatment",Merck Sharp & Dohme Corp.|Schering-Plough,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,93,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",P04037,12-Jul-05,16-Feb-07,16-Feb-07,18-Jan-07,9-Mar-10,29-Jun-18,,,https://ClinicalTrials.gov/show/NCT00423488
NCT00423579,The Effects of Ezetimibe/Simvastatin 10/20 mg Versus Simvastatin 40 mg in High Cholesterol and Coronary Heart Disease Study (P04039AM2)(COMPLETED),,Completed,Has Results,Hypercholesterolemia|Coronary Disease,Drug: Ezetimibe/Simvastatin 10/20 mg|Drug: simvastatin 40 mg,Change in Low-density-lipoprotein Cholesterol (LDL-C) at 6 Weeks,Merck Sharp & Dohme Corp.|Schering-Plough,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,120,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",P04039,1-Jul-06,1-Mar-08,1-Mar-08,18-Jan-07,25-Aug-09,9-May-17,,,https://ClinicalTrials.gov/show/NCT00423579
NCT00422396,"Effects of Micronized Fenofibrate on Fasting and Postprandial Lipoproteins, Inflammatory Mediators and Thrombosis",,Completed,No Results Available,Hypertriglyceridemia With the Metabolic Syndrome,Drug: Fenofibrate (drug),1. lipids and lipoproteins,University of Michigan|Abbott,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,877-017,Jan-01,Apr-02,Apr-02,17-Jan-07,null,10-Feb-17,"Northwestern University preventive Cardiology Center, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00422396
NCT00422006,Study of the Role of PCSK9 and FXR in the Physiopathology of the Joint Dyslipidemia Associated to the Human Immunoresistance,,Completed,No Results Available,Obesity,"Procedure: biopsy of muscle, of liver, and of adipose tissue|Procedure: clamp euglycemic - hyperglycemic|Behavioral: diet|Other: biopsies for biological and genetic analyses","To evaluate the relationship between the expression levels of PCSK9 and FXR in the liver, adipose tissue and muscle and the different components of the insulin resistance syndrome obese patients submitted to bariatric surgery|Relationship between the levels of hepatic expression of PCSK9 and FXR and the degree of NASH in these patients. - Search for mutations and polymorphisms in the gene PCSK9 and FXR and their promoter regions",Nantes University Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,111,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,BRD 06/8-I|ID RCB 2006-A00196-45|DGS2006-0090,Feb-08,Nov-13,Nov-13,15-Jan-07,null,3-Apr-14,"CHU de Nantes, Nantes, France",,https://ClinicalTrials.gov/show/NCT00422006
NCT00422266,Effect of Omega -3 Fatty Acids Supplements and Plant Sterol Enriched Food in Dyslipidemic Adults,,Completed,No Results Available,Dyslipidemia,Drug: Omega 3 fatty acids and plant sterol enriched drink|Dietary Supplement: Omega 3 fatty acids and plant sterols,"Changes in TC, LDL-C, HDL-C, Triglycerides, and Fasting blood glucose.|Changes in LDL particle size, apo B, CRP and fibrinogen.","Centre for Chronic Disease Control, India",Male,35 Years to 55 Years   (Adult),Phase 3,178,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",CCDC-6980,Dec-06,null,Mar-07,15-Jan-07,null,26-Sep-07,"National Thermal Power Corporation, Delhi, Badarpur, India",,https://ClinicalTrials.gov/show/NCT00422266
NCT00421005,Fluvastatin After Heart Transplantation,,Unknown status,No Results Available,Heart Transplantation|Hypercholesterolemia,Drug: fluvastatin,,University of Bologna,All,"18 Years and older   (Adult, Older Adult)",Phase 4,56,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,126/2004/U/Sper,Nov-04,Nov-08,Nov-08,11-Jan-07,null,29-Apr-09,"Policlinico S.Orsola-Malpighi, Bologna, Italy",,https://ClinicalTrials.gov/show/NCT00421005
NCT00418834,Ezetimibe and Atorvastatin vs. Atorvastatin in Patients Age 65 and Older at High Risk for Coronary Heart Disease (CHD)(0653-112),,Completed,Has Results,Hypercholesterolemia,Drug: ezetimibe and atorvastatin|Drug: atorvastatin|Drug: Placebo (unspecified),Percent Change From Baseline in LDL-C at Week 6|Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12|Number of Patients Who Achieved Low Density Lipoprotein Cholesterol (LDL-C) <70 mg/dL at Week 6|Number of Patients Who Achieved Low Density Lipoprotein Cholesterol (LDL-C) <70 mg/dL at Week 12|Number of Patients Who Achieved LDL-C <100 mg/dL for Patients Without Atherosclerotic Vascular Disease (AVD) and LDL-C <70 mg/dL for Patients With Atherosclerotic Vascular Disease (AVD) at Week 6|Number of Patients Who Achieved LDL-C<100 mg/dL for Patients Without AVD and LDL-C<70 mg/dL for Patients With AVD at Week 12,Merck Sharp & Dohme Corp.,All,65 Years and older   (Older Adult),Phase 3,1053,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0653-112|MK0653-112|2006_549,Jan-07,Oct-08,Oct-08,5-Jan-07,6-Oct-09,6-Apr-17,,,https://ClinicalTrials.gov/show/NCT00418834
NCT00414986,Using Learning Teams for Reflective Adaptation for Diabetes and Depression,ULTRA-DM/MDD,Completed,No Results Available,Type 2 Diabetes|Hyperlipidemia|Hypertension|Depression,Behavioral: Standard CQI intervention|Behavioral: Chronic Care Improvement (CCI) Intervention|Behavioral: Self-directed practice comparison,"Surveillance of Hemoglobin A1c, blood pressure, lipids, depression process of care|HEDIS-like measures of acute phase management of depression|Patient report (by survey) of their primary care experience","University of Colorado, Denver|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institute of Mental Health (NIMH)",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1565,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,05-0457|R18DK067083|MH069806,Sep-05,Feb-12,Feb-12,22-Dec-06,null,22-Nov-12,"University of Colorado Health Sciences Center, Denver, Colorado, United States",,https://ClinicalTrials.gov/show/NCT00414986
NCT00413972,Effects of Vytorin Versus Placebo in Subjects With Primary Hypercholesterolemia (Study P04420),,Completed,Has Results,Hypercholesterolemia,Drug: ezetimibe with simvastatin|Drug: Ezetimibe with Simvastatin|Drug: Placebo,Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Endpoint After 8 Weeks of Treatment,Merck Sharp & Dohme Corp.|Schering-Plough,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,392,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",P04420|SCH 465981,Apr-06,Nov-06,Nov-06,20-Dec-06,25-May-10,14-Jul-15,,,https://ClinicalTrials.gov/show/NCT00413972
NCT00412698,European Trial About Effect of RimoNabant on Abdominal Obese Patients With dysLipidemia,ETERNAL,Terminated,No Results Available,Obesity|Dyslipidemias,Drug: rimonabant|Drug: Placebo,"Change in HDL-C and triglyceride levels|Waist circumference and body weight|Glycemic parameters : FPG, fasting insulinemia, HbA1c,|Lipid parameters : Total Cholesterol, HDL-C, LDL-C, triglyceride levels|Inflammatory parameter : Hs-CRP|Quality of life : IWQOL questionnaire completed|Incidence of adverse events in each group, including neuro-psychiatric adverse events|Standard laboratory assessments|In selected sites, a sub study will be conducted in which additional Lipid parameters will be measured: HDL subfractions, Apo A1, Apo A2, Apo B and Apo C3, Lp A1, LpA1/A2, Lp(a), Oxidized-LDL and LDL size|In selected sites, a sub study will be conducted in which additional Inflammatory parameters will be measured: Adiponectin-High Molecular Weight, Intracellular adhesion molecule 1(ICAM-I) and TNFalpha.",Sanofi,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,645,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RIMON_R_00962|EUDRACT # : 2006-001715-30,Dec-06,Jan-09,Jan-09,18-Dec-06,null,10-Dec-10,"Sanofi-Aventis Administrative Office, Prague, Czech Republic|Sanofi-Aventis Administrative Office, Helsinki, Finland|Sanofi-Aventis Administrative Office, Berlin, Germany|Sanofi-Aventis Administrative Office, Athens, Greece|Sanofi-Aventis Administrative Office, Budapest, Hungary|Sanofi-Aventis Administrative Office, Dublin, Ireland|Sanofi-Aventis Administrative Office, Milan, Italy|Sanofi-Aventis Administrative Office, Gouda, Netherlands|Sanofi-Aventis Administrative Office, Lysaker, Norway|Sanofi-Aventis Administrative Office, Porto-Salvo, Portugal|Sanofi-Aventis Administrative Office, Bratislava, Slovakia|Sanofi-Aventis Administrative Office, Stockholm, Sweden|Sanofi-Aventis Administrative Office, Meyrin, Switzerland|Sanofi-Aventis Administrative Office, Istanbul, Turkey|Sanofi-Aventis Administrative Office, Guildford, United Kingdom",,https://ClinicalTrials.gov/show/NCT00412698
NCT00412113,A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk,TOGETHER,Completed,Has Results,Dyslipidemia|Hypertension,Drug: Amlodipine besylate|Drug: Amlodipine besylate/atorvastatin calcium single pill combination,Subjects With Blood Pressure (BP) <140/90 Millimeters of Mercury (mmHg) and Low Density Lipoprotein Cholesterol (LDL-C) <100 Milligrams Per Deciliter(mg/dL) at Week 6|Change From Baseline to Week 6 in Framingham Predicted Absolute 10-year Risk|Subjects With Blood Pressure of <140/90 mmHg and LDL-C <100 mg/dL at Week 4|Subjects With BP <140/90 mmHg and LDL-C <130 mg/dL at Week 4.|Subjects With BP <140/90 mmHg and LDL-C <130 mg/dL at Week 6.|Subjects With LDL-C < 100 mg/dL at Week 4|Subjects With LDL-C < 100 mg/dL at Week 6|Subjects With BP < 140/90 mmHg at Week 4|Subjects With BP < 140/90 mmHg at Week 6|Change From Baseline to Week 4 in Systolic Blood Pressure (SBP).|Change From Baseline to Week 4 in Diastolic Blood Pressure (DBP)|Change From Baseline to Week 4 in Pulse Rate|Change From Baseline to Week 6 in Systolic Blood Pressure (SBP)|Change From Baseline to Week 6 in Diastolic Blood Pressue (DBP)|Change From Baseline to Week 6 in Pulse Rate|Change From Baseline in LDL at Week 4.|Change From Baseline in High Density Lipoprotein (HDL) at Week 4.|Change in Total Cholesterol (TC) From Baseline to Week 4.|Change From Baseline in Triglycerides (TG) to Week 4.|Change From Baseline in LDL at Week 6.|Change From Baseline in HDL at Week 6.|Change From Baseline in Total Cholesterol (TC) to Week 6.|Change From Baseline in Triglycerides (TG) at Week 6.|Change From Baseline to Week 4 in Framingham Predicted Absolute 10-year Risk.,Pfizer,All,"21 Years and older   (Adult, Older Adult)",Phase 4,245,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",A3841045,Jan-07,Apr-08,Apr-08,15-Dec-06,6-Nov-09,20-Nov-09,"Pfizer Investigational Site, Birmingham, Alabama, United States|Pfizer Investigational Site, Birmingham, Alabama, United States|Pfizer Investigational Site, Birmingham, Alabama, United States|Pfizer Investigational Site, Mesa, Arizona, United States|Pfizer Investigational Site, Garden Grove, California, United States|Pfizer Investigational Site, Mission Viejo, California, United States|Pfizer Investigational Site, Rancho Santa Margarita, California, United States|Pfizer Investigational Site, Torrance, California, United States|Pfizer Investigational Site, Gainesville, Florida, United States|Pfizer Investigational Site, Kissimmee, Florida, United States|Pfizer Investigational Site, Melbourne, Florida, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, Safety Harbor, Florida, United States|Pfizer Investigational Site, St. Petersburg, Florida, United States|Pfizer Investigational Site, Augusta, Georgia, United States|Pfizer Investigational Site, Tucker, Georgia, United States|Pfizer Investigational Site, South Bend, Indiana, United States|Pfizer Investigational Site, Erlanger, Kentucky, United States|Pfizer Investigational Site, Auburn, Maine, United States|Pfizer Investigational Site, Warren, Michigan, United States|Pfizer Investigational Site, Minneapolis, Minnesota, United States|Pfizer Investigational Site, Chesterfield, Missouri, United States|Pfizer Investigational Site, Florissant, Missouri, United States|Pfizer Investigational Site, Omaha, Nebraska, United States|Pfizer Investigational Site, Henderson, Nevada, United States|Pfizer Investigational Site, Henderson, Nevada, United States|Pfizer Investigational Site, Belvidere, New Jersey, United States|Pfizer Investigational Site, Bridgewater, New Jersey, United States|Pfizer Investigational Site, Clifton, New Jersey, United States|Pfizer Investigational Site, Elizabeth, New Jersey, United States|Pfizer Investigational Site, Hillsborough, New Jersey, United States|Pfizer Investigational Site, Trenton, New Jersey, United States|Pfizer Investigational Site, Brooklyn, New York, United States|Pfizer Investigational Site, Buffalo, New York, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Oklahoma City, Oklahoma, United States|Pfizer Investigational Site, Tulsa, Oklahoma, United States|Pfizer Investigational Site, Bensalem, Pennsylvania, United States|Pfizer Investigational Site, Lansdale, Pennsylvania, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Providence, Rhode Island, United States|Pfizer Investigational Site, Goose Creek, South Carolina, United States|Pfizer Investigational Site, Mount Pleasant, South Carolina, United States|Pfizer Investigational Site, Bristol, Tennessee, United States|Pfizer Investigational Site, Kingsport, Tennessee, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, Plano, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, Chesapeake, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00412113
NCT00409773,Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED),,Completed,Has Results,Hypercholesterolemia|Metabolic Syndrome,Drug: ezetimibe (+) simvastatin|Drug: Comparator: atorvastatin calcium|Drug: Comparator: Placebo (unspecified),Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 6|Percent Change From Baseline in Total Cholesterol(mg/dL) at Week 6|Percent Change From Baseline in Triglyceride (TG) (mg/dL) at Week 6|Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 6|Percent Change From Baseline in Non- High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 6|Percent Change From Baseline in Very Low Density Lipoprotein Cholesterol (VLDL-C) at Week 6|Percent Change From Baseline in Apolipoprotein- B (Apo-B) at Week 6|Percent Change From Baseline in Apolipoprotein-A1 (Apo-A1) at Week 6|Percent Change From Baseline in Total-Cholesterol: High Density Lipoprotein-Cholesterol (Total-C:HDL- C) at Week 6|Percent Change From Baseline in Low Density Lipoprotein Cholesterol: High Density Lipoprotein Cholesterol (LDL-C: HDL-C) at Week 6|Percent Change From Baseline in Apolipoprotein-B: Apolipoprotein-A1 (Apo-B:Apo-A1) at Week 6|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol: High Density Lipoprotein Cholesterol (Non-HDL-C:HDL-C) at Week 6|Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 6 in Patients With Atherosclerotic Vascular Disease (AVD)|Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 6 in Patients Without Atherosclerotic Vascular Disease (AVD)|Percent Change From Baseline in High-Sensitivity C-reactive (Hs-CRP) (mg/dL) at Week 6,Merck Sharp & Dohme Corp.,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 3,1143,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0653A-107|2006_527,Jan-07,Jul-08,Jul-08,11-Dec-06,4-Aug-09,14-Apr-17,,,https://ClinicalTrials.gov/show/NCT00409773
NCT00409240,Multi-Targeted Cardiac Risk Intervention in Type 2 Diabetes,,Completed,Has Results,Diabetes|Hypertension|Dyslipidemia,Other: MEDIC,"Percent of Patients Achieving Hemoglobin A1C Goal, LDL Cholesterol Goal, and Systolic Blood Pressure Goal From the Enrollment Until the End of the Study",Providence VA Medical Center|Sandra A. Daugherty Foundation,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 3,103,U.S. Fed|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1127912,Oct-06,Jun-08,Jun-08,8-Dec-06,11-Apr-14,11-Apr-14,"Providence VAMC, PRovidence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT00409240
NCT00407537,Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors,CRUCIAL,Completed,Has Results,Hypertension|Hypercholesterolemia,Drug: Amlodipine besylate/atorvastatin calcium single pill combination,Framingham 10-year Risk of Total Coronary Heart Disease (CHD) at Month 12|Framingham 10-year Risk of Total CHD at Month 4|European Systematic COronary Risk Evaluation (SCORE) 10-year Risk of Fatal Cardiovascular Disease (CVD) at Month 12|European SCORE 10-year Risk of Fatal CVD at Month 4|Framingham 10-year Risk of Stroke at Month 12|Framingham 10-year Risk of Stroke at Month 4|Change From Baseline in Framingham 10-year Risk of Developing Total CHD|Change From Baseline European SCORE 10-year Risk of Developing Fatal CVD|Mean Systolic and Diastolic Blood Pressure at Month 4|Mean Systolic and Diastolic Blood Pressure at Month 12|Change From Baseline in Systolic Blood Pressure (SBP) at Month 4|Change From Baseline in Diastolic Blood Pressure (DBP) at Month 4|Change From Baseline in SBP at Month 12|Change From Baseline in DBP at Month 12|Mean Lipid Parameters at Month 4|Mean Lipid Parameters at Month 12|Change From Baseline in Lipid Parameters at Month 4|Change From Baseline in Lipid Parameters at Month 12|Percentage of Participants at Conventional Treatment Goals According to Global and Local Guidelines for Blood Pressure at 4 and 12 Months|Percentage of Participants at Conventional Treatment Goals According to Global and Local Guidelines for LDL at 4 and 12 Months|Number of Participants With Lipid and Antihypertensive Treatments Used at 4 and 12 Months|Number of Participants With Increase of Treatment Dosages After 4 Months.,Pfizer,All,"35 Years to 79 Years   (Adult, Older Adult)",Phase 4,1531,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A3841047,Mar-07,Oct-09,Oct-09,5-Dec-06,11-Nov-11,23-Jul-15,"Pfizer Investigational Site, Desamparados, San Jose, Costa Rica|Pfizer Investigational Site, Heredia, Costa Rica|Pfizer Investigational Site, San Jose, Costa Rica|Pfizer Investigational Site, Breznicki Hum, Croatia|Pfizer Investigational Site, Cakovec, Croatia|Pfizer Investigational Site, Crikvenica, Croatia|Pfizer Investigational Site, Karlovac, Croatia|Pfizer Investigational Site, Rijeka, Croatia|Pfizer Investigational Site, Spisic Bukovica, Croatia|Pfizer Investigational Site, Split, Croatia|Pfizer Investigational Site, Sv. Kriz Zacretje, Croatia|Pfizer Investigational Site, Varazdin, Croatia|Pfizer Investigational Site, Zagreb, Croatia|Pfizer Investigational Site, Brno, Czech Republic|Pfizer Investigational Site, Klatovy, Czech Republic|Pfizer Investigational Site, Kralupy nad Vltavou, Czech Republic|Pfizer Investigational Site, Lanskroun, Czech Republic|Pfizer Investigational Site, Olomouc, Czech Republic|Pfizer Investigational Site, Pelhrimov, Czech Republic|Pfizer Investigational Site, Praha 4, Czech Republic|Pfizer Investigational Site, Praha 8, Czech Republic|Pfizer Investigational Site, Pruhonice, Czech Republic|Pfizer Investigational Site, Usti nad Labem, Czech Republic|Pfizer Investigational Site, Vratimov, Czech Republic|Pfizer Investigational Site, Zlin 4, Czech Republic|Pfizer Investigational Site, San Cristobal, Dominican Republic|Pfizer Investigational Site, Santo Domingo, Dominican Republic|Pfizer Investigational Site, Santo Domingo, Dominican Republic|Pfizer Investigational Site, Cilandak, Jakarta Selatan, Indonesia|Pfizer Investigational Site, Bandung, Indonesia|Pfizer Investigational Site, Jakarta, Indonesia|Pfizer Investigational Site, Jakarta, Indonesia|Pfizer Investigational Site, Semarang, Indonesia|Pfizer Investigational Site, Surabaya, Indonesia|Pfizer Investigational Site, Tangerang, Indonesia|Pfizer Investigational Site, Tanggerang, Indonesia|Pfizer Investigational Site, Amman, Jordan|Pfizer Investigational Site, Amman, Jordan|Pfizer Investigational Site, Irbid, Jordan|Pfizer Investigational Site, Wonju-si, Gangwon-Do, Korea, Republic of|Pfizer Investigational Site, Seongnam-si, Gyeonggi-do, Korea, Republic of|Pfizer Investigational Site, Busan, Korea, Republic of|Pfizer Investigational Site, Busan, Korea, Republic of|Pfizer Investigational Site, Daegu, Korea, Republic of|Pfizer Investigational Site, Daegu, Korea, Republic of|Pfizer Investigational Site, Daejeon, Korea, Republic of|Pfizer Investigational Site, Gwangju, Korea, Republic of|Pfizer Investigational Site, Incheon, Korea, Republic of|Pfizer Investigational Site, Seoul,, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Suwon, Korea, Republic of|Pfizer Investigational Site, Kuwait, Kuwait|Pfizer Investigational Site, Sasat, Kuwait|Pfizer Investigational Site, Beirut, Lebanon|Pfizer Investigational Site, Jbeil, Lebanon|Pfizer Investigational Site, Kuala Pilah, Negeri Sembilan, Malaysia|Pfizer Investigational Site, Seremban, Negeri Sembilan, Malaysia|Pfizer Investigational Site, Batu Caves, Selangor, Malaysia|Pfizer Investigational Site, Petaling Jaya, Selangor, Malaysia|Pfizer Investigational Site, Butterworth, Malaysia|Pfizer Investigational Site, Kuala Lumpur, Malaysia|Pfizer Investigational Site, Kuala Lumpur, Malaysia|Pfizer Investigational Site, Mexico, DF, Mexico|Pfizer Investigational Site, Mexico, DF, Mexico|Pfizer Investigational Site, Mexico, DF, Mexico|Pfizer Investigational Site, Mexico, DF, Mexico|Pfizer Investigational Site, Toluca, Estado de Mexico, Mexico|Pfizer Investigational Site, Guadalajara, Jalisco, Mexico|Pfizer Investigational Site, Guadalajara, Jalisco, Mexico|Pfizer Investigational Site, Durango, Mexico|Pfizer Investigational Site, San Luis Potosi, Mexico|Pfizer Investigational Site, Panama City, Panama|Pfizer Investigational Site, Panama, Panama|Pfizer Investigational Site, San Juan, Metro Manila, Philippines|Pfizer Investigational Site, Makati City, Philippines|Pfizer Investigational Site, Manila, Philippines|Pfizer Investigational Site, Marikina City, Philippines|Pfizer Investigational Site, Quezon City, Philippines|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Saint Petersburg, Russian Federation|Pfizer Investigational Site, Saint-Petersburg, Russian Federation|Pfizer Investigational Site, Saint-Petersburg, Russian Federation|Pfizer Investigational Site, Smolensk, Russian Federation|Pfizer Investigational Site, St. Petersburg, Russian Federation|Pfizer Investigational Site, St. Petersburg, Russian Federation|Pfizer Investigational Site, St. Petersburg, Russian Federation|Pfizer Investigational Site, Volgograd, Russian Federation|Pfizer Investigational Site, Voronezh, Russian Federation|Pfizer Investigational Site, Riyadh 11426, Saudi Arabia|Pfizer Investigational Site, Kaohsiung, Taiwan|Pfizer Investigational Site, Kaohsiung, Taiwan|Pfizer Investigational Site, Taichung, Taiwan|Pfizer Investigational Site, Taichung, Taiwan|Pfizer Investigational Site, Tainan, Taiwan|Pfizer Investigational Site, Tainan, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Rajthevee, Bangkok, Thailand|Pfizer Investigational Site, Saimai, Bangkok, Thailand|Pfizer Investigational Site, Bangkok, Thailand|Pfizer Investigational Site, Ankara, Turkey|Pfizer Investigational Site, Ankara, Turkey|Pfizer Investigational Site, Istanbul, Turkey|Pfizer Investigational Site, Istanbul, Turkey|Pfizer Investigational Site, Istanbul, Turkey|Pfizer Investigational Site, Istanbul, Turkey|Pfizer Investigational Site, Izmir, Turkey|Pfizer Investigational Site, Izmir, Turkey|Pfizer Investigational Site, Abu Dhabi, United Arab Emirates|Pfizer Investigational Site, Al Ain, United Arab Emirates|Pfizer Investigational Site, Dubai, United Arab Emirates|Pfizer Investigational Site, Naguanagua/Valencia, Carabobo, Venezuela|Pfizer Investigational Site, Caracas, Dtto Capital/Municipio Libertador, Venezuela|Pfizer Investigational Site, Caracas, Dtto Capital/Municipio Libertador, Venezuela|Pfizer Investigational Site, Valencia, Estado Carabobo, Venezuela",,https://ClinicalTrials.gov/show/NCT00407537
NCT00405769,Lipid Lowering in Patients With Statin Intolerance,,Completed,No Results Available,Hyperlipidemia|Coronary Artery Disease,Drug: red yeast rice|Drug: placebo,"LDL-cholesterol levels at baseline, 12 weeks and 6 months in 2 groups in a lifestyle intervention program|HDL, TG, Total cholesterol, cardiac CRP,",Chestnut Hill Health System,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,64,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",FWA00005390,Jan-07,null,Oct-07,30-Nov-06,null,31-Oct-07,"Chestnut Hill Hospital, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00405769
NCT00405067,The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate Hypercholesterolemia,,Completed,Has Results,Hypercholesterolemia,Drug: BMS-201038 (AEGR-733)|Drug: Ezetimibe,Percent Change in LDL-C at 12 Weeks Therapy Compared to Baseline Between Treatments|Percent of Change at 12 Weeks Therapy Compared to Baseline Between Treatments for the Following Parameters: Total Cholesterol (TC)|Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at 12 Weeks as Compared to Baseline.|Percent Change in Tryglycerides (TGs) at 12 Weeks Compared to Baseline|Percent Change in HDL-C at 12 Weeks Compared to Baseline|Percent Change in Lipoprotein(a)[Lp(a)]at 12 Weeks as Compared to Baseline|Percent Change in Apolipoprotein A1 (Apo A1) at 12 Weeks as Compared to Baseline|Percent Change in Apolipoprotein B (Apo B) at 12 Weeks as Compared to Baseline|Percent Change in High-sensitivity C-reactive Protein (Hs-CRP) at 12 Weeks as Compared to Baseline|Percent Change in Body Weight at 12 Weeks as Compared to Baseline,"Aegerion Pharmaceuticals, Inc.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,60,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,AEGR-733-001,May-06,Jan-07,Jan-07,29-Nov-06,4-Mar-14,4-Mar-14,"Pharmanet, Inc, Princeton, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT00405067
NCT00405171,Efavirenz to Nevirapine Switch and Low-Density Lipoprotein (LDL)-Dyslipidemia,,Completed,No Results Available,HIV Infections|Hypercholesterolemia|Antiretroviral Therapy,Drug: Nevirapine,Decrease in LDL cholesterol between baseline and week 52,"University Hospital, Caen|Boehringer Ingelheim",All,"18 Years and older   (Adult, Older Adult)",Phase 4,40,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,SIROCCO,Jun-03,null,Feb-06,29-Nov-06,null,28-Oct-10,"Côte de Nacre University hospital, Caen, France",,https://ClinicalTrials.gov/show/NCT00405171
NCT00405197,MARIS Study; Mediterranean Approach to Reduce Insulin-Resistance Study,,Completed,No Results Available,Insulin Resistance|Metabolic Syndrome X|Dyslipidemia|Hypertension|Overweight,Behavioral: Isocaloric diet high in MUFA or Mediterranean diet,Fasting Insulin|Systolic/ diastolic blood pressure|plasma glucose|serum HDL-cholesterol|serum triglycerides|waist-hip circumference|serum total cholesterol|serum LDL-cholesterol|Blood sample will be stored for measuring markers of inflammation.|Additionally in half of the subjects insulin sensitivity will be measured by the euglycemic hyperinsulinemic clamp.|Molecular markers in fat and muscle biopsies,Wageningen University|Netherlands Heart Foundation|Unilever R&D,All,"40 Years to 65 Years   (Adult, Older Adult)",Not Applicable,60,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Prevention,NHS 2003B068,Nov-06,null,Apr-07,29-Nov-06,null,12-Dec-07,"Hospital Gelderse Vallei, Ede, Netherlands|Wageningen University, Division of Human Nutrition, Wageningen, Netherlands",,https://ClinicalTrials.gov/show/NCT00405197
NCT00404001,Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia,,Completed,No Results Available,Hypercholesterolemia,Drug: MD-0727,Low density lipoprotein cholesterol (LDL-C)|Total cholesterol,"Ironwood Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,150,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MCP-104-201,Nov-06,null,Jul-07,27-Nov-06,null,1-Oct-07,"Microbia Investigational Site, Birmingham, Alabama, United States|Microbia Investigational Site, Los Angeles, California, United States|Microbia Investigational Site, Walnut Creek, California, United States|Microbia Investigational Site, New Port Richey, Florida, United States|Microbia Investigational Site, Chicago, Illinois, United States|Microbia Investigational Site, Indianapolis, Indiana, United States|Microbia Investigational Site, Overland, Kansas, United States|Microbia Investigational Site, Louisville, Kentucky, United States|Microbia Investigational Site, Edina, Minnesota, United States|Microbia Investigational Site, Kansas City, Missouri, United States|Microbia Investigational Site, Statesville, North Carolina, United States|Microbia Investigational Site, Winston-Salem, North Carolina, United States|Microbia Investigational Site, Cincinnati, Ohio, United States|Microbia Investigational Site, Marion, Ohio, United States|Microbia Investigational Site, Charleston, South Carolina, United States|Microbia Investigational Site, Bristol, Tennessee, United States|Microbia Investigational Site, San Antonio, Texas, United States|Microbia Investigational Site, Richmond, Virginia, United States|Microbia Investigational Site, Lakewood, Washington, United States|Microbia Investigational Site, Olympia, Washington, United States",,https://ClinicalTrials.gov/show/NCT00404001
NCT00400231,The Fenofibrate and Metformin for Atherogenic Dyslipidemia (FAMA) Study,,Completed,No Results Available,Metabolic Syndrome x,Drug: Study drugs: Metformin and fenofibrate|Drug: Study Drug: Metformin|Drug: Study Drug: fenofibrate|Drug: Metformin and Fenofibrate placebo,"triglyceride levels|HDL-C, Resistin, insulin resistance",University of Pennsylvania|Abbott,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,124,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic",800860,Aug-05,Dec-07,Mar-08,16-Nov-06,null,20-Mar-17,"University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00400231
NCT00397826,Evaluation of the Effects of Simvastatin 40mg,,Completed,No Results Available,Hypercholesterolemia,Drug: MK0733,"Total cholesterol, ldl-c, hdl-c, and triglycerides|Pulse wave velocity|Baroreflex sensitivity|Serum nitrite, nitrate and urine c-gmp levels after 12 weeks treatment",Cardinal Tien Hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 4,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0733-265,Jan-05,Jan-06,Dec-15,10-Nov-06,null,7-Jan-16,,,https://ClinicalTrials.gov/show/NCT00397826
NCT00398294,To Evaluate the Lipid-Lowering Efficacy and Safety of Simvastatin 40 Mg Tablet In Patients With Hypercholesterolemia (0733-264),,Completed,No Results Available,Hypercholesterolemia,"Drug: MK0733, simvastatin / Duration of Treatment: 12 Weeks","Total cholesterol, ldl-c, hdl-c, and triglycerides after 12 weeks",Merck Sharp & Dohme Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 4,30,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0733-264|2006_044,1-May-05,4-Apr-06,4-Apr-06,10-Nov-06,null,11-Apr-17,"Merck Sharp & Dohme (I.A.) Corp., Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT00398294
NCT00397358,Effect of Extraneal (Icodextrin)on Triglyceride Levels in PD Patients,,Withdrawn,No Results Available,Peritoneal Dialysis|Hypertriglyceridemia,Drug: Extraneal (7.5% icodextrin) Peritoneal Dialysis Solution,Change from baseline in fasting triglyceride levels.,Baxter Healthcare Corporation,All,"18 Years and older   (Adult, Older Adult)",Phase 4,0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,31656,Nov-06,Jun-07,Jun-07,9-Nov-06,null,8-May-17,"Kaiser Santa Clara - Homestead, Santa Clara, California, United States|Nephrology Specialists, Michigan City, Indiana, United States|Dialysis Center of Lincoln, Lincoln, Nebraska, United States",,https://ClinicalTrials.gov/show/NCT00397358
NCT00396240,ORBITAL: Open-Label Primary Care Study: Rosuvastatin Based Compliance Initiatives Linked To Achievement Of LDL Goals,,Withdrawn,No Results Available,Primary Hypercholesterolaemia,Drug: Rosuvastatin|Procedure: Initiatives to improve compliance,"Comparison of the rosuvastatin therapy (10mg daily, titrated to 20mg at 12 weeks if necessary), alone or in combination with enhanced compliance initiatives, at 6 months, in bringing subjects with prim. hypercholesterolaemia to the EAS LDL-C target goals|To investigate the effect of rosuvastatin, both with and without compliance initiatives on number and percentage of subjects within the EAS or local LDL-C and TC target goals after 12 week therapy,|Safety of treatment.",AstraZeneca,All,"18 Years and older   (Adult, Older Adult)",Phase 4,1294,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D3560L00008|ORBITAL,Feb-02,null,null,6-Nov-06,null,26-Mar-09,,,https://ClinicalTrials.gov/show/NCT00396240
NCT00395473,Ezetimibe Added to Statin Therapy (EASY) Study (0653-087)(COMPLETED),,Completed,No Results Available,Hypercholesterolemia,"Drug: MK0653, ezetimibe / Duration of Treatment: 6 Weeks",Percent (%) reduction in plasma low-density lipoprotein cholesterol (ldl-c) concentration after 6 weeks of treatment,Merck Sharp & Dohme Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 3,141,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0653-087|2006_041,Mar-05,Nov-05,Nov-05,3-Nov-06,null,8-Mar-17,,,https://ClinicalTrials.gov/show/NCT00395473
NCT00395512,Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes Mellitus,,Completed,Has Results,Diabetes Mellitus,Drug: Alogliptin|Drug: Pioglitazone|Drug: Placebo,Change From Baseline to Week 26 in Glycosylated Hemoglobin (HbA1c)|Change From Baseline in HbA1c Over Time|Change From Baseline in Fasting Plasma Glucose Over Time|Percentage of Participants With Marked Hyperglycemia|Percentage of Participants Meeting Rescue Criteria|Percentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 6.5%|Percentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 7.0%|Percentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 7.5%|Percentage of Participants With a Decrease in Glycosylated Hemoglobin Greater Than or Equal to 0.5%|Percentage of Participants With a Decrease in Glycosylated Hemoglobin Greater Than or Equal to 1.0%|Percentage of Participants With a Decrease in Glycosylated Hemoglobin Greater Than or Equal to 1.5%.|Percentage of Participants With a Decrease in Glycosylated Hemoglobin Greater Than or Equal to 2.0%|Change From Baseline in Fasting Proinsulin|Change From Baseline in Insulin|Change From Baseline in Proinsulin/Insulin Ratio|Change From Baseline in C-peptide Levels|Change From Baseline in Calculated Homeostatic Model Assessment Insulin Resistance|Change From Baseline in Homeostatic Model Assessment Beta Cell Function|Change From Baseline in Body Weight|Change From Baseline in Total Cholesterol Level|Change From Baseline in Low-Density Lipoprotein Cholesterol|Change From Baseline in High-Density Lipoprotein Cholesterol|Change From Baseline in Triglyceride Levels|Change From Baseline in Free Fatty Acids|Change From Baseline in Plasminogen Activator Inhibitor-1|Change From Baseline in High-sensitivity C-Reactive Protein|Change From Baseline in Adiponectin|Change From Baseline in Apolipoprotein A1|Change From Baseline in Apolipoprotein A2|Change From Baseline in Apolipoprotein B|Change From Baseline in Apolipoprotein C-III|Change From Baseline in Nuclear Magnetic Resonance Lipid Fractionation Total Triglycerides|Change From Baseline in Very Low Density Lipoprotein (VLDL) / Chylomicron Particles|Change From Baseline in VLDL / Chylomicron Triglycerides|Change From Baseline in VLDL Particles|Change From Baseline in Mean VLDL Particle Size|Change From Baseline in Intermediate Density Lipoprotein (IDL) Particles|Change From Baseline in Low Density Lipoprotein (LDL) Particles|Change From Baseline in Mean LDL Particle Size|Change From Baseline in High Density Lipoprotein (HDL) Particles|Change From Baseline in Mean HDL Particle Size,Takeda,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,655,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",01-06-TL-322OPI-002|2006-005492-17|U1111-1113-8616,Nov-06,Feb-08,Feb-08,3-Nov-06,27-Mar-13,27-Mar-13,"Columbiana, Alabama, United States|Hueytown, Alabama, United States|Huntsville, Alabama, United States|Northport, Alabama, United States|Tucson, Arizona, United States|Jonesboro, Arkansas, United States|Little Rock, Arkansas, United States|Searcy, Arkansas, United States|Foothill Ranch, California, United States|Irvine, California, United States|Northridge, California, United States|San Diego, California, United States|San Mateo, California, United States|Santa Monica, California, United States|Jacksonville, Florida, United States|Melbourne, Florida, United States|Miami, Florida, United States|Port Charlotte, Florida, United States|Sebastian, Florida, United States|South Miami, Florida, United States|Winter Haven, Florida, United States|Augusta, Georgia, United States|Barnesville, Georgia, United States|Columbus, Georgia, United States|Savannah, Georgia, United States|Chicago, Illinois, United States|Libertyville, Illinois, United States|South Bend, Indiana, United States|Bossier City, Louisiana, United States|Elkton, Maryland, United States|Prince Frederick, Maryland, United States|Towson, Maryland, United States|North Dartmouth, Massachusetts, United States|Bay City, Michigan, United States|Benzonia, Michigan, United States|Portage, Michigan, United States|St Clair Shores, Michigan, United States|Picayune, Mississippi, United States|St Louis, Missouri, United States|Billings, Montana, United States|Las Vegas, Nevada, United States|Elizabeth, New Jersey, United States|Hamilton, New Jersey, United States|Cicero, New York, United States|Charlotte, North Carolina, United States|Mooresville, North Carolina, United States|Northeast, North Dakota, United States|Franklin, Ohio, United States|Ashland, Oregon, United States|Altoona, Pennsylvania, United States|Fleetwood, Pennsylvania, United States|Harleysville, Pennsylvania, United States|Havertown, Pennsylvania, United States|Norristown, Pennsylvania, United States|Northern Cambria, Pennsylvania, United States|Penndel, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Charleston, South Carolina, United States|Florence, South Carolina, United States|Orangeburg, South Carolina, United States|Taylors, South Carolina, United States|Williamston, South Carolina, United States|Morristown, Tennessee, United States|Arlington, Texas, United States|Colleyville, Texas, United States|Conroe, Texas, United States|Corpus Christi, Texas, United States|Dallas, Texas, United States|Euless, Texas, United States|Fort Worth, Texas, United States|Garland, Texas, United States|Houston, Texas, United States|Katy, Texas, United States|San Antonio, Texas, United States|Seguin, Texas, United States|Sugarland, Texas, United States|Tomball, Texas, United States|Ogden, Utah, United States|Arlington, Virginia, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Lewisburg, West Virginia, United States|Milwaukee, Wisconsin, United States|Cap. Fed., Buenos Aires, Argentina|Chacabuco, Buenos Aires, Argentina|La Plata, Buenos Aires, Argentina|Mar del Plata, Buenos Aires, Argentina|Morón, Buenos Aires, Argentina|Córdoba, Argentina|Kingswood, New South Wales, Australia|Fitzroy, Victoria, Australia|Frankston, Victoria, Australia|Fortaleza, CE, Brazil|Goiás, GO, Brazil|Belém, PA, Brazil|Curitiba, PR, Brazil|Maringá, RP, Brazil|Marília, SP, Brazil|Mogi das Cruzes, SP, Brazil|Pleven, Bulgaria|Santiago, Chile|Slavonski Brod, Croatia|Pärnu, Estonia|Guatemala, Guatemala|Budapest, Hungary|Eger, Hungary|Gyula, Hungary|Mako, Hungary|Nyiregyhaza, Hungary|Pecs, Hungary|Hyderabad, Andhra Pradesh, India|Bangalore, Karnataka, India|Aurangabad, Maharashtra, India|Mumbai, Maharashtra, India|Nagpur, Maharashtra, India|Chennai, Tamil Nadu, India|Hadera, Israel|Haifa, Israel|Holon, Israel|Jaffa Tel Aviv, Israel|Jerusalem, Israel|Nahariya, Israel|Riga, Latvia|Kaunas, Lithuania|Kedainiai, Lithuania|Aguascalientes, Mexico|Mexico City, Mexico|Monterrey, Mexico|Christchurch, New Zealand|Hamilton, New Zealand|Bialystok, Poland|Bytom, Poland|Gdansk, Poland|Gniewkowo, Poland|Kamieniec Zabkowicki, Poland|Krakow, Poland|Leczyca, Poland|Brasov, Romania|Bucharest, Romania|Galati, Romania|Ekaterinburg, Russian Federation|Kazan, Russian Federation|Moscow, Russian Federation|Belgrade, Serbia|Kragujevac, Serbia|Nis, Serbia|Interna klinika II, Nitra, Slovakia|Banska Bysterica, Slovakia|Lucenec, Slovakia|Riverside, Slovakia|Sahy, Slovakia|Port Elizabeth, Eastern Cape, South Africa|Johannesburg, Gauteng, South Africa|Durban, Kwa-Zulu Natal, South Africa|East Lynne, Pretoria, South Africa|Bellville, Western Province, South Africa|Cape Town, Western Province, South Africa|Dnipropetrovsk, Ukraine|Kharkiv, Ukraine|Lviv, Ukraine|Odesa, Ukraine",,https://ClinicalTrials.gov/show/NCT00395512
NCT00395135,BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management,,Completed,Has Results,Obesity,Drug: Lorcaserin 10 mg BID|Drug: Matching Placebo BID,Year 1: Co-Primary Endpoint- Proportion (%) of Patients Achieving > or = 5% Weight Loss From Baseline to Week 52|Year 2: Proportion (%) of Patients Maintaining > or = 5% Weight Loss at Week 104|Year 1: Percent Change in Body Weight From Baseline to Week 52|Year 2: Percent Change in Body Weight From Week 52 to Week 104,Arena Pharmaceuticals,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,3182,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",APD356-009,Nov-06,Feb-09,Feb-09,2-Nov-06,7-Feb-13,7-Feb-13,"Arena Pharmaceuticals, Inc., San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT00395135
NCT00393419,Federal Study of Adherence to Medications in the Elderly (FAME),,Completed,No Results Available,Medication Adherence|Hypertension|Hyperlipidemia,Behavioral: Comprehensive pharmacy care program,Change in proportion of pills taken compared to baseline (0-2months) at 8months|Between-group comparison of medication persistence at 14months|Change in blood pressure and low-density lipoprotein cholesterol at 8months,Walter Reed Army Medical Center|American Society of Health-System Pharmacists,All,65 Years and older   (Older Adult),Not Applicable,200,U.S. Fed|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Educational/Counseling/Training,04-36002,Jun-04,null,Aug-06,27-Oct-06,null,27-Oct-06,"Walter Reed Army Medical Center, Washington, District of Columbia, United States",,https://ClinicalTrials.gov/show/NCT00393419
NCT00389896,A Crossover Study to Evaluate the Efficacy of Simvastatin in Elevating HDL-C Levels in Patients With Type 2 Diabetes (0733-216)(COMPLETED),,Completed,No Results Available,HDL Cholesterol,Drug: MK0733 / Duration of Treatment: 18 Weeks|Drug: Comparator: placebo (unspecified) / Duration of Treatment: 18 Weeks,HDL-C raising effects after 6 weeks|Effect on other lipids and lipoproteins at 6 weeks,Merck Sharp & Dohme Corp.,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,150,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,0733-216|2006_536,26-Jul-01,4-Oct-02,4-Oct-02,19-Oct-06,null,10-Apr-17,,,https://ClinicalTrials.gov/show/NCT00389896
NCT00386971,Effects of L-Carnitine on Postprandial Clearance of Triglyceride-rich Lipoproteins in HIV Patients on HAART,,Completed,No Results Available,Hyperlipidemia|HIV Infections,Dietary Supplement: L-carnitine|Other: placebo,L-carnitine supplementation will improve fasting TGRL levels and the postprandial response|L-carnitine will impact upon the relationship between insulin and NEFA or adipokines in the postprandial state,"University of California, Davis",All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,13,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",200614280|GCRC protocol 109,Oct-06,Dec-09,Dec-09,12-Oct-06,null,30-May-17,"GCRC UC Davis, Sacramento, California, United States",,https://ClinicalTrials.gov/show/NCT00386971
NCT00385658,Efficacy of Fluvastatin and Fenofibrate in Comparison to Simvastatin and Ezetimibe in Patients With Metabolic Syndrome,,Completed,No Results Available,Dyslipidemia,"Drug: Fluvastatin extended release, fenofibrate|Drug: Fixed combination simvastatin/ezetimibe",High density lipoprotein cholesterol (HDL-C) measured at the end of each study period.|Compared at the end of each treatment period:|patients reaching target levels of low density lipoprotein cholesterol (LDL-C) <100mg/dl|patients reaching target levels of non-HDL-C <130mg/|LDL-C/HDL-C|Triglycerides|LDL subfractions in a subgroup of patients,Novartis,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,75,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CXUO320BDE35,Aug-06,Mar-07,Mar-07,11-Oct-06,null,24-Feb-17,"Investigative Centers, Germany|Novartis Pharma AG, Basel, Switzerland",,https://ClinicalTrials.gov/show/NCT00385658
NCT00385931,Efficacy and Safety of Valsartan and the Combination of Valsartan and Simvastatin,,Completed,No Results Available,Hypertension|Hypercholesterolemia|Dyslipidemia,Drug: Valsartan and simvastatin,"Change from baseline in ambulatory systolic blood pressure at 12 weeks|Change from baseline at 12 weeks for ambulatory diastolic blood pressure, systolic and diastolic blood pressure (std cuff), day and nighttime blood pressures, biochemical markers of endothelial function & lipid levels|Safety and tolerability",Novartis,All,"50 Years and older   (Adult, Older Adult)",Phase 3,412,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CVAS489A2301,Jan-02,Apr-03,Apr-03,11-Oct-06,null,8-Nov-11,"Novartis Pharmaceuticals, East Hanover, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT00385931
NCT00384293,Carotid IMT (Intima Media Thickening) Study (0524A-041)(TERMINATED),ACHIEVE,Terminated,Has Results,"Hypercholesterolemia, Familial",Drug: Comparator: niacin (+) laropiprant (MK0524A)|Drug: Comparator: placebo,Change in Mean Carotid Intima Media Thickness|Change in Lipid Profile,Merck Sharp & Dohme Corp.,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,937,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0524A-041|2006_506,Sep-06,Aug-08,Aug-08,6-Oct-06,2-Sep-09,30-Sep-15,,,https://ClinicalTrials.gov/show/NCT00384293
NCT00379756,A Study Evaluating Vardenafil Compared to Placebo in Subjects With Erectile Dysfunction (ED) and Dyslipidemia,,Completed,No Results Available,Erectile Dysfunction,Drug: LEVITRA (vardenafil)|Drug: placebo,Erectile function (EF) domain score of the International Index of Erectile Function (IIEF)|Mean success rate of insertion based on attempts|Mean success rates of maintenance based on attempts|Mean duration of erection leading to completion of successful intercourse as measured by Sexual Encounter Profile Question 3 [SEP-3]|Change from Baseline in scores for questions on the IIEF questionnaire and scores of the other non-EF domains of the IIEF|Number of participants with normal erectile function having EF domain scores of 26 and above|Change from Baseline in participant's diary results|Mean duration of erection regardless of SEP-3 Response|Change from Baseline in duration of erection leading to completion of successful intercourse.|Number of participants with response 'Yes' for Global Assessment Question|Mean score for Keep It Simple (KIS) scale,GlaxoSmithKline,Male,18 Years to 64 Years   (Adult),Phase 4,395,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",106718,22-May-06,17-May-07,17-May-07,22-Sep-06,null,16-Aug-17,"GSK Investigational Site, Fairhope, Alabama, United States|GSK Investigational Site, Homewood, Alabama, United States|GSK Investigational Site, Huntsville, Alabama, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Concord, California, United States|GSK Investigational Site, Huntington Park, California, United States|GSK Investigational Site, Long Beach, California, United States|GSK Investigational Site, Modesto, California, United States|GSK Investigational Site, Newport Beach, California, United States|GSK Investigational Site, Orangevale, California, United States|GSK Investigational Site, Santa Ana, California, United States|GSK Investigational Site, Walnut Creek, California, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Wheat Ridge, Colorado, United States|GSK Investigational Site, New Britain, Connecticut, United States|GSK Investigational Site, Aventura, Florida, United States|GSK Investigational Site, Clearwater, Florida, United States|GSK Investigational Site, Coral Gables, Florida, United States|GSK Investigational Site, Fort Myers, Florida, United States|GSK Investigational Site, North Miami, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Pembroke Pines, Florida, United States|GSK Investigational Site, Pinecrest, Florida, United States|GSK Investigational Site, Saint Petersburg, Florida, United States|GSK Investigational Site, Sarasota, Florida, United States|GSK Investigational Site, South Miami, Florida, United States|GSK Investigational Site, Tampa, Florida, United States|GSK Investigational Site, West Palm Beach, Florida, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Columbus, Georgia, United States|GSK Investigational Site, Dawsonville, Georgia, United States|GSK Investigational Site, Roswell, Georgia, United States|GSK Investigational Site, Woodstock, Georgia, United States|GSK Investigational Site, Avon, Indiana, United States|GSK Investigational Site, Evansville, Indiana, United States|GSK Investigational Site, Fort Wayne, Indiana, United States|GSK Investigational Site, Jeffersonville, Indiana, United States|GSK Investigational Site, Wichita, Kansas, United States|GSK Investigational Site, Lexington, Kentucky, United States|GSK Investigational Site, Madisonville, Kentucky, United States|GSK Investigational Site, Shreveport, Louisiana, United States|GSK Investigational Site, Swansea, Maine, United States|GSK Investigational Site, Taunton, Massachusetts, United States|GSK Investigational Site, Kalamazoo, Michigan, United States|GSK Investigational Site, Saint Louis Park, Minnesota, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Lawrenceville, New Jersey, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Rochester, New York, United States|GSK Investigational Site, West Seneca, New York, United States|GSK Investigational Site, Charlotte, North Carolina, United States|GSK Investigational Site, Fayetteville, North Carolina, United States|GSK Investigational Site, Winston-Salem, North Carolina, United States|GSK Investigational Site, Shippensburg, Pennsylvania, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Amarillo, Texas, United States|GSK Investigational Site, Salt Lake City, Utah, United States|GSK Investigational Site, Norfolk, Virginia, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Seattle, Washington, United States|GSK Investigational Site, Menomonee Falls, Wisconsin, United States|GSK Investigational Site, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00379756
NCT00378833,Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054),,Completed,No Results Available,Hypercholesterolemia|Hyperlipidemia,Drug: niacin (+) laropiprant|Drug: niacin,Global Flushing Severity Score (GFSS) over 16 weeks|Safety/tolerability,Merck Sharp & Dohme Corp.,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,1300,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0524A-054|2006_529,Jul-06,Mar-07,Mar-07,21-Sep-06,null,16-Feb-17,,,https://ClinicalTrials.gov/show/NCT00378833
NCT00379249,Rosuvastatin ORBITAL Germany,,Completed,No Results Available,Hypercholesterolemia,Drug: Rosuvastatin,"Cumulative direct/indirect disease-related costs were compared applying a societal perspective|Costs include resource utilization for ambulatory, hospital, rehabilitative and nursing care, medication, physiotherapy, transportation, and productivity loss)|Achievement of the 1998 European LDL-C goal of <115 mg/dL (3.0 mmol/L)|Changes in the lipid profile and compliance with therapy.",AstraZeneca,All,"18 Years and older   (Adult, Older Adult)",Phase 3,8000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D3560L00001|ORBITAL,Feb-02,null,Feb-04,21-Sep-06,null,26-Mar-09,,,https://ClinicalTrials.gov/show/NCT00379249
NCT00376584,Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED),,Completed,No Results Available,Hypercholesteremia|Hyperlipidemia,Drug: MK-0524A|Drug: ER Niacin|Drug: Placebo,Global Flushing Severity Score (GFSS) during 7 days of treatment|Percentage of Participants Who Experience at Least 1 Adverse Event|Percentage of Participants Who Were Discontinued from the Study Due to an Adverse Event,Merck Sharp & Dohme Corp.,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,825,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0524A-023|MK0524A-023|2006_504,Jul-06,Jan-07,Jan-07,15-Sep-06,null,16-Feb-17,,,https://ClinicalTrials.gov/show/NCT00376584
NCT00365742,Statin Therapy Vs. Therapeutic Lifestyle Changes and Supplements,,Completed,No Results Available,Hyperlipidemia,Drug: simvastatin|Drug: red yeast rice|Drug: pharmaceutical grade fish oil|Behavioral: therapeutic lifestyle changes,LDL-c cholesterol|total cholesterol|HDL|Triglycerides|cardiac CRP,Chestnut Hill Health System,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,FWA00005390-Chestnut Hill Hosp,Apr-06,null,Jun-06,17-Aug-06,null,17-Aug-06,,,https://ClinicalTrials.gov/show/NCT00365742
NCT00362908,"Effects of Low and Moderate Fat Diets on Lipids, Inflammation and Vascular Reactivity in the Metabolic Syndrome",,Completed,No Results Available,Metabolic Syndrome X|Dyslipidemias,Behavioral: Moderate Fat and Moderate Carbohydrate Diet|Behavioral: Low Fat and High Carbohydrate Diet,Non-HDL cholesterol|C-reactive protein|Brachial artery reactivity,"University of Washington|National Heart, Lung, and Blood Institute (NHLBI)",All,"30 Years to 75 Years   (Adult, Older Adult)",Not Applicable,71,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",29854-B|R01HL083117|422,Sep-06,Sep-09,Jun-10,15-Aug-06,null,28-Oct-10,"Northwest Lipid Research Clinic, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00362908
NCT00362934,Comparison of the Combination of Fenofibrate and Simvastatin Versus Atorvastatin,,Completed,No Results Available,Hyperlipidemia,Drug: fenofibrate / simvastatin|Drug: Atorvastatin,Percent change from baseline to 12 weeks of treatment in Triglycerides|Percent change from baseline to 12 weeks of treatment in HDL-C|Percent change from baseline to 12 weeks of treatment in LDL-C,Solvay Pharmaceuticals,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,516,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",C LF0242780-01 05 03|2006-000519-21,Oct-06,Aug-08,Aug-08,15-Aug-06,null,8-Jul-09,"Site 501, Haskovo, Bulgaria|Site 505, Pleven, Bulgaria|Site 503, Plovdiv, Bulgaria|Site 506, Plovdiv, Bulgaria|Site 500, Sofia, Bulgaria|Site 502, Sofia, Bulgaria|Site 504, Sofia, Bulgaria|Site 507, Sofia, Bulgaria|Site 509, Sofia, Bulgaria|Site 511, Sofia, Bulgaria|Site 508, Varna, Bulgaria|Site 510, Varna, Bulgaria|Site 109, Chrudim, Czech Republic|Site 117, Havirov, Czech Republic|Site 101, Olomouc, Czech Republic|Site 114, Olomouc, Czech Republic|Site 116, Ostrava, Czech Republic|Site 107, Pardubice, Czech Republic|Site 111, Pardubice, Czech Republic|Site 113, Plzen, Czech Republic|Site 108, Praha 1, Czech Republic|Site 100, Praha 2, Czech Republic|Site 104, Praha 5, Czech Republic|Site 110, Praha 6, Czech Republic|Site 115, Praha, Czech Republic|Site 103, Teplice, Czech Republic|Site 106, Trutnov, Czech Republic|Site 118, Unicov, Czech Republic|Site 102, Usti nad Orlici, Czech Republic|Site 203, Berlin, Germany|Site 204, Bochum, Germany|Site 205, Dresden, Germany|Site 206, Gorlitz, Germany|Site 202, Hamburg, Germany|Site 208, Karlsruhe, Germany|Site 207, Leipzig, Germany|Site 201, Magdeburg, Germany|Site 209, Nuernberg, Germany|Site 200, Unterschneidheim, Germany|Site 301, Banska Bystrica, Slovakia|Site 307, Bratislava, Slovakia|Site 310, Bratislava, Slovakia|Site 311, Bratislava, Slovakia|Site 312, Bratislava, Slovakia|Site 309, Dolny kubin, Slovakia|Site 302, Kosice, Slovakia|Site 305, Lucenec, Slovakia|Site 306, Nitra, Slovakia|Site 304, Nove Zamky, Slovakia|Site 308, Presov, Slovakia|Site 303, Vrable, Slovakia|Site 300, Zilina, Slovakia|Site 416, Donetsk, Ukraine|Site 401, Kharkov, Ukraine|Site 412, Kiev, Ukraine|Site 402, Kyiv, Ukraine|Site 404, Kyiv, Ukraine|Site 408, Kyiv, Ukraine|Site 410, Kyiv, Ukraine|Site 414, Lutsk, Ukraine|Site 406, Lviv, Ukraine|Site 407, Odessa, Ukraine|Site 409, Odessa, Ukraine|Site 411, Odessa, Ukraine|Site 405, Simferopol, Ukraine|Site 413, Uzhorod, Ukraine|Site 400, Vinnitsa, Ukraine|Site 415, Zaporozhye, Ukraine",,https://ClinicalTrials.gov/show/NCT00362934
NCT00363233,The Potential Effects and Mechanisms of Flax Lignans on Type 2 Diabetes Mellitus,,Completed,No Results Available,Type 2 Diabetes|Hypercholesterolemia,Drug: flax lignans,Total cholesterol at 3 months|LDL and triglycerides at 3 months; Blood glucose and HbA1C at 3 months,Chinese Academy of Sciences,All,"50 Years to 79 Years   (Adult, Older Adult)",Phase 2|Phase 3,80,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,04DZ14007,Mar-06,null,Dec-06,15-Aug-06,null,9-Jan-07,"Institute for Nutritional Sciences, Chinese Academy of Sciences; Huadong Hospital, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT00363233
NCT00362323,Fenofibrate and Metformin Fixed Combination vs Metformin - FAME METFO,,Completed,No Results Available,Dyslipidemia/Glucose Metabolism Disorder,Drug: fenofibrate (F) + metformin (M) hydrochloride fixed combination|Drug: Metformin,TG / HDL-C ratio|Lipid and glycemic parameters,Solvay Pharmaceuticals,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,482,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",C LF23-0121 06 01|2006-000924-15,Oct-06,Aug-08,Mar-09,10-Aug-06,null,16-Apr-10,"C LF23-0121 06 01 Site107, Brno, Czech Republic|C LF23-0121 06 01 Site108, Holesov, Czech Republic|C LF23-0121 06 01 Site101, Karlovy Vary, Czech Republic|C LF23-0121 06 01 Site106, Olomouc, Czech Republic|C LF23-0121 06 01 Site109, Olomouc, Czech Republic|C LF23-0121 06 01 Site103, Pardubice, Czech Republic|C LF23-0121 06 01 Site102, Praha, Czech Republic|C LF23-0121 06 01 Site104, Praha, Czech Republic|C LF23-0121 06 01 Site105, Praha, Czech Republic|C LF23-0121 06 01 Site 204, Bailleul, France|C LF23-0121 06 01 Site 200, Bondy, France|C LF23-0121 06 01 Site 207, Cholet, France|C LF23-0121 06 01 Site 208, Evreux, France|C LF23-0121 06 01 Site 201, Pantin, France|C LF23-0121 06 01 Site 202, Tours, France|C LF23-0121 06 01 Site 205, Wattrelos, France|C LF23-0121 06 01 Site 406, Balatonfüred, Hungary|C LF23-0121 06 01 Site 400, Budapest, Hungary|C LF23-0121 06 01 Site 401, Budapest, Hungary|C LF23-0121 06 01 Site 402, Budapest, Hungary|C LF23-0121 06 01 Site 403, Budapest, Hungary|C LF23-0121 06 01 Site 405, Budapest, Hungary|C LF23-0121 06 01 Site 407, Budapest, Hungary|C LF23-0121 06 01 Site 408, Budapest, Hungary|C LF23-0121 06 01 Site 404, Debrecen, Hungary|C LF23-0121 06 01 Site 501, Bangalore, India|C LF23-0121 06 01 Site 504, Bangalore, India|C LF23-0121 06 01 Site 516, Bangalore, India|C LF23-0121 06 01 Site 519, Bangalore, India|C LF23-0121 06 01 Site 508, Chennai, India|C LF23-0121 06 01 Site 510, Chennai, India|C LF23-0121 06 01 Site 505, Hyderabad, India|C LF23-0121 06 01 Site 509, Hyderabad, India|C LF23-0121 06 01 Site 517, Hyderabad, India|C LF23-0121 06 01 Site 511, Karnataka, India|C LF23-0121 06 01 Site 512, Maharashtra, India|C LF23-0121 06 01 Site 502, Mumbai, India|C LF23-0121 06 01 Site 503, Mumbai, India|C LF23-0121 06 01 Site 518, Nasik, India|C LF23-0121 06 01 Site 506, Pune, India|C LF23-0121 06 01 Site 514, Tiruvanathapuram-Kerala, India|C LF23-0121 06 01 Site 800, Vilnius, Lithuania|C LF23-0121 06 01 Site 801, Vilnius, Lithuania|C LF23-0121 06 01 Site 802, Vilnius, Lithuania|C LF23-0121 06 01 Site 600, Bialystok, Poland|C LF23-0121 06 01 Site 613, Bydgoszcz, Poland|C LF23-0121 06 01 Site 618, Grudziadz, Poland|C LF23-0121 06 01 Site 603, Katowice, Poland|C LF23-0121 06 01 Site 601, Kraków, Poland|C LF23-0121 06 01 Site 607, Kraków, Poland|C LF23-0121 06 01 Site 610, Kraków, Poland|C LF23-0121 06 01 Site 615, Kutno, Poland|C LF23-0121 06 01 Site 605, Olsztyn, Poland|C LF23-0121 06 01 Site 604, Opole, Poland|C LF23-0121 06 01 Site 606, Poznan, Poland|C LF23-0121 06 01 Site 609, Poznan, Poland|C LF23-0121 06 01 Site 621, Sliwinska, Poland|C LF23-0121 06 01 Site 617, Starogard Gdanski, Poland|C LF23-0121 06 01 Site 616, Szczecin, Poland|C LF23-0121 06 01 Site 602, Warszawa, Poland|C LF23-0121 06 01 Site 608, Warszawa, Poland|C LF23-0121 06 01 Site 619, Warszawa, Poland|C LF23-0121 06 01 Site 620, Warszawa, Poland|C LF23-0121 06 01 Site 611, Wroclaw, Poland|C LF23-0121 06 01 Site 612, Wroclaw, Poland|C LF23-0121 06 01 Site 614, Zgierz, Poland|C LF23-0121 06 01 Site 700, Bratislava, Slovakia|C LF23-0121 06 01 Site 703, Kosice, Slovakia|C LF23-0121 06 01 Site 702, Lucenec, Slovakia|C LF23-0121 06 01 Site 701, Skalica, Slovakia",,https://ClinicalTrials.gov/show/NCT00362323
NCT00362765,Fenofibrate and Metformin Insulin Sensitivity in Type 2 Diabetics Study,,Terminated,No Results Available,Type 2 Diabetes|Dyslipidemia,Drug: Fenofibrate|Drug: Metformin|Drug: Placebo,"Endogenous Glucose Production (EGP) and Glucose Disposal Rate (GDR) by two-step hyperinsulinemic euglycemic clamp (HEC)|Gluconeogenesis, Glycogenolysis, Skeletal muscle and liver fat content, Abdominal fat content, Body energy expenditure and respiratory quotient, Lipids and glycemic parameters",Solvay Pharmaceuticals,All,"40 Years to 75 Years   (Adult, Older Adult)",Phase 2|Phase 3,8,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",C LF23-0121 05 03|2005-003347-31,Oct-06,null,Jul-07,10-Aug-06,null,13-Aug-08,"Site 2, Turku, Finland|Site 3, Dublin, Ireland|Site 1, Pisa, Italy",,https://ClinicalTrials.gov/show/NCT00362765
NCT00361868,Fenofibrate and Metformin Fixed Combination vs Rosiglitazone - FAME ROSI,,Terminated,No Results Available,Dyslipidemia|Glucose Metabolism Disorder,Drug: fenofibrate (F) + metformin (M) hydrochloride fixed combination|Drug: Rosiglitazone,HbA1c/TG|Lipid and glycemic parameters.,Solvay Pharmaceuticals,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,88,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",C LF23-0121 05 01|2005-006060-63,Jun-06,Dec-07,Dec-07,9-Aug-06,null,27-Jun-08,"Site105, Pula, Croatia|Site102, Rijeka, Croatia|Site103, Split, Croatia|Site104, Varazdin, Croatia|Site100, Zagreb, Croatia|Site101, Zagreb, Croatia|Site 205, Jyväskylä, Finland|Site 206, Kokkola, Finland|Site 208, Laukaa, Finland|Site 207, Oulu, Finland|Site 303, Bassens, France|Site 307, Bordeaux, France|Site 305, Murs Erigne, France|Site 302, Seysses, France|Site 304, Strasbourg, France|Site 301, Thouars, France|Site 306, Vihiers, France|Site 405, Berlin, Germany|Site 410, Borna, Germany|Site 403, Bretten, Germany|Site 402, Dresden, Germany|Site 404, Frankfurt, Germany|Site 400, Freiburg, Germany|Site 401, Hannover, Germany|Site 409, Ilvesheim, Germany|Site 411, Ilvesheim, Germany|Site 407, Leipzig, Germany|Site 406, Rodgau, Germany|Site 413, Rotenburg, Germany|Site 408, Schwerin, Germany|Site 412, Villingen-Schwenningen, Germany|Site 509, Almere, Netherlands|Site 502, Breda, Netherlands|Site 503, Eindhoven, Netherlands|Site 504, Groningen, Netherlands|Site 505, Leiden, Netherlands|Site 506, Nijmegen, Netherlands|Site 500, Rotterdam, Netherlands|Site 507, Velp, Netherlands|Site 508, Zoetermeer, Netherlands|Site 610, Bialystok, Poland|Site 606, Elblag, Poland|Site 608, Gdansk, Poland|Site 600, Lodz, Poland|Site 605, Otolinska, Poland|Site 604, Radom, Poland|Site 613, Starogard Gdanski, Poland|Site 601, Warszawa, Poland|Site 607, Warszawa, Poland|Site 612, Warszawa, Poland|Site 602, Wroclaw, Poland|Site 603, Wroclaw, Poland|Site 704, Brasov, Romania|Site 701, Bucharest, Romania|Site 703, Bucharest, Romania|Site 700, Cluj-Napoca, Romania|Site 702, Iasi, Romania|Site 705, Targu-Mures, Romania|Site 807, Kharkiv, Ukraine|Site 811, Kharkiv, Ukraine|Site 812, Kharkiv, Ukraine|Site 800, Kiev, Ukraine|Site 803, Kiev, Ukraine|Site 808, Kiev, Ukraine|Site 809, Kiev, Ukraine|Site 810, Kiev, Ukraine|Site 813, Kiev, Ukraine|Site 805, Lviv, Ukraine|Site 804, Odessa, Ukraine|Site 802, Vinnitsa, Ukraine",,https://ClinicalTrials.gov/show/NCT00361868
NCT00362180,Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration,,Completed,Has Results,"Lipid Metabolism, Inborn Errors|Hyperlipidemias|Metabolic Diseases|Hypolipoproteinemia|Hypolipoproteinemias|Hypobetalipoproteinemias|Metabolism, Inborn Errors|Genetic Diseases, Inborn|Infant, Newborn, Diseases|Congenital Abnormalities|Metabolic Disorder|Hypercholesterolemia|Dyslipidemias|Lipid Metabolism Disorders",Drug: mipomersen|Drug: Placebo,Change From Baseline in Liver Triglyceride (TG) Content As Measured by Magnetic Resonance Spectroscopy (MRS)|Baseline Apolipoprotein B|Percent Change in Apolipoprotein B From Baseline to Day 99|Baseline Low-Density Lipoprotein Cholesterol|Percent Change in Low-Density Lipoprotein Cholesterol From Baseline to Day 99|Baseline Total Cholesterol|Percent Change in Total Cholesterol From Baseline to Day 99,"Kastle Therapeutics, LLC|Ionis Pharmaceuticals, Inc.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,38,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",301012-CS10|2005-005783-90,Jul-06,Mar-10,Sep-10,9-Aug-06,24-Jun-15,21-Oct-16,"Amsterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT00362180
NCT00362206,Comparison of the Combination of Fenofibrate and Simvastatin Versus Pravastatin,,Completed,No Results Available,Hyperlipidemia,Drug: Fenofibrate/Simvastatin|Drug: Pravastatin,Percent change from baseline to 12 weeks of treatment in Triglycerides|Percent change from baseline to 12 weeks of treatment in HDL-C|Percent change from baseline to 12 weeks of treatment in LDL-C,Solvay Pharmaceuticals,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,423,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",C LF0242780-01 05 04|2006-000515-15,Sep-06,Sep-08,Sep-08,9-Aug-06,null,8-Jul-09,"Site 40, Athens, Greece|Site 39, Ioannina, Greece|Site 41, Thessaloniki, Greece|Site 37, Beer Yaakov, Israel|Site 19, Haifa, Israel|Site 22, Holon, Israel|Site 18, Jerusalem, Israel|Site 38, Kfar Saba, Israel|Site 17, Ramat Gan, Israel|Site 21, Ramat Gan, Israel|Site 20, Rechovot, Israel|Site 24, Safed, Israel|Site 23, Tel-Aviv, Israel|Site 5, Arad, Romania|Site 7, Bacau, Romania|Site 1, Bucuresti, Romania|Site 6, Cluj-Napoca, Romania|Site 4, Oradea, Romania|Site 3, Ploiesti, Romania|Site 2, Targu Mures, Romania|Site 27, Barnaul, Russian Federation|Site 31, Kemerovo, Russian Federation|Site 32, Krasnoyarsk, Russian Federation|Site 25, Moscow, Russian Federation|Site 28, Novosibirsk, Russian Federation|Site 26, Smolensk, Russian Federation|Site 29, St. Petersburg, Russian Federation|Site 30, Voronezh, Russian Federation|Site 10, Alberton, South Africa|Site 9, Bloemfontein, South Africa|Site 14, Cape Town, South Africa|Site 35, Durban, South Africa|Site 33, Hillcrest, South Africa|Site 34, Kempton Park, South Africa|Site 16, Komatipoort, South Africa|Site 13, Krugersdorp, South Africa|Site 11, Parow, South Africa|Site 12, Port Elizabeth, South Africa|Site 8, Pretoria, South Africa|Site 36, Umkomaas, South Africa|Site 15, Worcester, South Africa",,https://ClinicalTrials.gov/show/NCT00362206
NCT00361530,Carotid Intima-media Thickness in Japan Statin Treatment Against Recurrent Stroke(J-STARS Echo),,Completed,No Results Available,Ischemic Stroke,Drug: Statin,"Intima-media complex thickness (IMT) of the common carotid artery (CCA)|Plaque score, number of plaque, recurrent cerebrovascular events","Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan|Ministry of Health, Labour and Welfare, Japan|Hiroshima University|National Cerebral and Cardiovascular Center",All,"45 Years to 80 Years   (Adult, Older Adult)",Phase 3,854,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,J-STARS echo|C000000212,Mar-04,Jul-14,null,8-Aug-06,null,25-Apr-16,"National Cardiovascular Center (NCVC), Suita-shi, Osaka, Japan|Hiroshima University Hospital, Hiroshima, Japan",,https://ClinicalTrials.gov/show/NCT00361530
NCT00361699,hsCRP in Japan Statin Treatment Against Recurrent Stroke (J-STARS hsCRP),,Completed,No Results Available,Ischemic Stroke,Drug: Statin,serum level of high sensitive CRP|recurrent stroke,"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan|Ministry of Health, Labour and Welfare, Japan|Hiroshima University|Osaka University",All,"45 Years to 80 Years   (Adult, Older Adult)",Phase 3,1095,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,J-STARS hsCRP|C000000211,Mar-04,Jul-14,null,8-Aug-06,null,25-Apr-16,"Hiroshima University Hospital, Hiroashima, Hiroshima, Japan|Osaka University, Suita-shi, Osaka, Japan",,https://ClinicalTrials.gov/show/NCT00361699
NCT00360217,The Triglyceride Lowering Effect of an Omega-3 Fat (DHA) in Addition to Statin Therapy for Patients With CAD or Diabetes,,Completed,No Results Available,Hypertriglyceridemia (TG>200<500)|Hyperlipidemia|Coronary Artery Disease|Coronary Risk Equivalent|Diabetes,Drug: docosahexanoic acid (DHA),Lowering of triglyceride level|Alteration of LDL particle size,Maine Center for Lipids and Cardiovascular Health,All,"21 Years to 80 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,1,Jan-06,null,May-07,4-Aug-06,null,18-Nov-11,"Maine Center for Lipids and Cardiovascular Health, Scarborough, Maine, United States",,https://ClinicalTrials.gov/show/NCT00360217
NCT00360074,Phase 4 Study in Secondary Hypothyroidism: Body Weight Adapted Thyroxin Treatment and Triiodothyronine Supplementation,,Completed,No Results Available,Secondary Hypothyroidism|Hypopituitarism|Hyperlipidemias,"Drug: Thyroxin, Triiodothyronine",well-being|cognitive function|lipid metabolism|muscle function / ankle reflex time,University Hospital Freiburg,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,25,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,FH 326/03,Feb-04,null,Apr-07,3-Aug-06,null,9-Jun-08,"University Hospital Freiburg, Department of Medicine, Freiburg, Baden-Württemberg, Germany",,https://ClinicalTrials.gov/show/NCT00360074
NCT00357955,Combined Behavioral and Pharmacological Intervention for Cardiovascular Risk Reduction in Diabetic Patients,,Completed,Has Results,Diabetes|Hypertension|Dyslipidemia|Coronary Arteriosclerosis,Behavioral: Behavioral counseling and peer support|Behavioral: Interactive Education|Behavioral: Role modeling|Procedure: Pharmacologic case management,"Percentage of Participans With A1c<7%, LDL Cholesterol <100mg/dL, Systolic Blood Pressure <130mm Hg and Diastolic Blood Pressure <80 mm Hg",Providence VA Medical Center|Rhode Island Foundation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,118,U.S. Fed|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12733,Aug-04,May-08,May-08,28-Jul-06,13-May-14,13-May-14,"Providence VAMC, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT00357955
NCT00358033,Strategies to Maintain Cardiac Risk Control After Discharge From Cardiovascular Risk Reduction Clinic,,Completed,No Results Available,Diabetes|Dyslipidemia|Hypertension|Coronary Atherosclerosis,Behavioral: Counseling|Behavioral: Interactive Education|Behavioral: Group Support|Procedure: Pharmacologic case management,"The number of patients who had non-compliance to ADA target goals in smoking, LDL cholesterol, blood pressure or Hb A1c.",Providence VA Medical Center|Merck Sharp & Dohme Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 3,200,U.S. Fed|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12712,Jul-03,May-08,May-08,28-Jul-06,null,16-Apr-14,"Providence VAMC, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT00358033
NCT00355615,PLUTO: Pediatric Lipid-redUction Trial of rOsuvastatin,,Completed,Has Results,Familial Hypercholesterolemia,Drug: Rosuvastatin|Drug: Placebo,"Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline (Day 0) to the End of the 12-week Double-blind Treatment Phase|Percent Change in LDL-C and Other Lipid Parameters From Baseline to Week 6, and at End of Double-blind Dose Treatment Phase (Week 12)|Percent Control Rate Based on Achievement of LDL-C Target of <110 mg/dL During Double-blind Dose Treatment|Percent Change in HDL-C|Percent Change in Non-HDL-C at 12 Weeks|Percent Change in Triglycerides (TG)|Percent Change in Total Cholesterol (TC)|Percent Change in Apolipoprotein A-1 (ApoA-1)|Percent Change in Apolipoprotein B (ApoB)|Percent Change in ApoB/ApoA-1|Percent Change in LDL-C/HDL-C|Percent Change in TC/HDL-C|Percent Change in Non-HDL-C/HDL-C",AstraZeneca,All,10 Years to 17 Years   (Child),Phase 3,173,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D3561C00087|PLUTO,Jul-06,Jul-08,Jul-08,24-Jul-06,20-Jul-09,31-Aug-11,"Research Site, Los Angeles, California, United States|Research Site, Hyde Park, New York, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Wexford, Pennsylvania, United States|Research Site, Hamilton, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Laval, Quebec, Canada|Research Site, Sherbrook, Quebec, Canada|Research SIte, Amsterdam, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Groningen, Netherlands|Research Site, Hoorn, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Utrecht, Netherlands|Research SIte, Waalwijk, Netherlands|Research Site, Oslo, Norway|Research Site, Cordoba, Spain|Research Site, Madrid, Spain|Research Site, Reus, Spain",,https://ClinicalTrials.gov/show/NCT00355615
NCT00352183,Comparison of the Combination of Fenofibrate and 40 mg Simvastatin Versus 40 mg Simvastatin Monotherapy,,Completed,No Results Available,Cardiovascular Diseases,Drug: Fenofibrate/Simvastatin|Drug: Simvastatin,Triglycerides|Percent change from baseline to 12 weeks of treatment in HDL-C|Percent change from baseline to 12 weeks of treatment in LDL-C|Percent change from baseline to 24 weeks of treatment in Triglycerides|Percent change from baseline to 24 weeks of treatment in HDL-C|Percent change from baseline to 24 weeks of treatment in LDL-C,Solvay Pharmaceuticals,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",C LF0242780-01 05 02|ACTRN012605000777695,Jan-06,Aug-08,Aug-08,14-Jul-06,null,8-Jul-09,"Site 204, Adelaide, Australia|Site 214, Adelaide, Australia|Site 203, Bendigo, Australia|Site 207, Brisbane, Australia|Site 208, Brisbane, Australia|Site 221, Brisbane, Australia|Site 202, Burnie, Australia|Site 201, Camperdown, Australia|Site 220, Coffs Harbour, Australia|Site 218, Daw Park, Australia|Site 212, Elizabeth Vale, Australia|Site 217, Fitzroy, Australia|Site 222, Fremantle, Australia|Site 216, Geelong, Australia|Site 225, Ingleburn, Australia|Site 213, Kippa-ring, Australia|Site 209, Launceston, Australia|Site 219, Liverpool, Australia|Site 223, Malvern, Australia|Site 211, Meadowbrook, Australia|Site 224, Miranda, Australia|Site 210, Nambour, Australia|Site 205, Parkville, Australia|Site 206, Sale, Australia|Site 215, Sydney, Australia|Site 301, Tallinn, Estonia|Site 302, Tallinn, Estonia|Site 303, Tallinn, Estonia|Site 305, Tallinn, Estonia|Site 306, Tallinn, Estonia|Site 304, Tartu, Estonia|Site 307, Tartu, Estonia|Site 603, Balatonfured, Hungary|Site 605, Budapest, Hungary|Site 608, Budapest, Hungary|Site 604, Gyongyos, Hungary|Site 602, Gyor, Hungary|Site 610, Hodmezovasarhely, Hungary|Site 609, Kecskemet, Hungary|Site 601, Miskolc, Hungary|Site 607, Sopron, Hungary|Site 606, Szekesfehervar, Hungary|Site 403, Daugavpils, Latvia|Site 406, Jekabpils, Latvia|Site 401, Ogre, Latvia|Site 402, Riga, Latvia|Site 405, Riga, Latvia|Site 404, Tukums, Latvia|Site 502, Alytus, Lithuania|Site 503, Kaunas, Lithuania|Site 506, Kaunas, Lithuania|Site 505, Klaipeda, Lithuania|Site 507, Klaipeda, Lithuania|Site 508, Palanga, Lithuania|Site 504, Siauliai, Lithuania|Site 501, Vilnius, Lithuania|Site 102, Auckland, New Zealand|Site 103, Auckland, New Zealand|Site 107, Blenheim, New Zealand|Site 101, Christchurch, New Zealand|Site 108, Dunedin, New Zealand|Site 104, Hamilton, New Zealand|Site 111, Hastings, New Zealand|Site 106, Nelson, New Zealand|Site 110, Newtown, Wellington, New Zealand|Site 109, Takapuna, Auckland, New Zealand|Site 105, Tauranga, New Zealand",,https://ClinicalTrials.gov/show/NCT00352183
NCT00349765,Effects of Various Higher Fat and Lower Fat Snacks on Cardiovascular Risk Factors in Men and Women.,,Completed,No Results Available,Hypercholesterolemia,"Behavioral: higher fat, high polyunsaturated fat diet|Behavioral: higher fat, high saturated and trans fat diet|Behavioral: lower fat diet",total cholesterol|low-density lipoprotein cholesterol|high-density lipoprotein cholesterol|triglycerides|C-reactive protein|lipoprotein a|very low-density lipoprotein cholesterol|LDL pattern A or B|blood pressure|body fat|waist circumference|intramyocellular lipid,"University of Alabama at Birmingham|SmartFoods, Inc.",All,"19 Years to 65 Years   (Adult, Older Adult)",Phase 2,42,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,X041217008,Mar-05,null,Feb-06,10-Jul-06,null,14-Sep-07,,,https://ClinicalTrials.gov/show/NCT00349765
NCT00350038,"Irbesartan, Ciprofibrate and Their Combination Onto the Endothelial Functions",,Completed,No Results Available,Hypertension|Dyslipidemia,Drug: Irbesartan|Drug: Ciprofibrate,Microvascular reactivity|Reach of target blood pressure|Measurements of safety laboratory parameters,Sanofi|Bristol-Myers Squibb,All,"45 Years to 70 Years   (Adult, Older Adult)",Phase 4,60,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,L_8759,Feb-05,null,Aug-07,10-Jul-06,null,23-Jan-08,"Sanofi-aventis, Budapest, Hungary",,https://ClinicalTrials.gov/show/NCT00350038
NCT00349375,Comparison of the Combination of Fenofibrate and 20 mg Simvastatin Versus 40 mg Simvastatin Monotherapy,,Completed,No Results Available,Hyperlipidemia,Drug: Fenofibrate/Simvastatin|Drug: Simvastatin,Percent change from baseline to 24 weeks of treatment in Triglycerides|Percent change from baseline to 24 weeks of treatment in HDL-C|Percent change from baseline to 24 weeks of treatment in LDL-C,Solvay Pharmaceuticals,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,1040,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",C LF0242780-01 05 01|2005-003270-14,Nov-05,Sep-08,Sep-08,7-Jul-06,null,8-Jul-09,"Site 008, Brno, Czech Republic|Site 009, Brno, Czech Republic|Site 010, Brno, Czech Republic|Site 015, Hradisk, Czech Republic|Site 019, Karlovy Vary, Czech Republic|Site 014, Kladno, Czech Republic|Site 005, Nymburk, Czech Republic|Site 012, Olomouc, Czech Republic|Site 013, Olomouc, Czech Republic|Site 007, Plzen, Czech Republic|Site 018, Plzeň, Czech Republic|Site 001, Prague, Czech Republic|Site 002, Prague, Czech Republic|Site 003, Prague, Czech Republic|Site 004, Prague, Czech Republic|Site 016, Pribram, Czech Republic|Site 017, Pribram, Czech Republic|Site 011, Slany, Czech Republic|Site 006, Tabor, Czech Republic|Site 201, Copenhagen, Denmark|Site 205, Copenhagen, Denmark|Site 203, Hvidovre, Denmark|Site 302, Bouliac, France|Site 314, Briollay, France|Site 318, Corsept, France|Site 301, Dijon, France|Site 317, La Montagne, France|Site 321, Le mesnil en Valee, France|Site 316, Loudon, France|Site 308, Mont de Marsan, France|Site 312, Murs-Erigne, France|Site 310, Nantes, France|Site 304, Niort, France|Site 319, Orvault, France|Site 306, Paris, France|Site 305, Pouilly en Auxois, France|Site 307, Rouen, France|Site 311, Rouen, France|Site 303, Saint Justin, France|Site 315, Thouars, France|Site 309, Vieux Conde, France|Site 313, Vihiers, France|Site 320, Vue, France|Site 109, Deidesheim, Germany|Site 108, Frankfurt, Germany|Site 101, Freiburg, Germany|Site 111, Hamburg, Germany|Site 103, Hannover, Germany|Site 104, Ilvesheim, Germany|Site 110, Kassel, Germany|Site 106, Mannheim, Germany|Site 114, Munchen, Germany|Site 113, Neu-Anspach, Germany|Site 105, Offenbach, Germany|Site 107, Offenbach, Germany|Site 115, Paderborn Kernstadt, Germany|Site 102, Rodgau, Germany|Site 112, Wermsdorf, Germany|Site 406, Bekescsaba, Hungary|Site 401, Budapest, Hungary|Site 411, Budapest, Hungary|Site 412, Budapest, Hungary|Site 405, Debrecen, Hungary|Site 402, Gyongyos, Hungary|Site 409, Gyula, Hungary|Site 410, Kecskemet, Hungary|Site 404, Miskolc, Hungary|Site 413, Mosonmagyarovar, Hungary|Site 407, Oroshaza, Hungary|Site 408, Szeged, Hungary|Site 403, Szolnok, Hungary|Site 508, Breda, Netherlands|Site 509, De Bilt, Netherlands|Site 511, Den Bosch, Netherlands|Site 502, Eindhoven, Netherlands|Site 514, Eindhoven, Netherlands|Site 503, Groningen, Netherlands|Site 512, Hengelo, Netherlands|Site 506, Leiden, Netherlands|Site 507, Nijmegen, Netherlands|Site 501, Rotterdam, Netherlands|Site 513, Tiel, Netherlands|Site 510, Utrecht, Netherlands|Site 505, Velp, Netherlands|Site 504, Zoetermeer, Netherlands|Site 606, Chrzanow, Poland|Site 601, Gdansk, Poland|Site 603, Katowice, Poland|Site 609, Sopot, Poland|Site 602, Warsaw, Poland|Site 607, Warsaw, Poland|Site 608, Warsaw, Poland|Site 605, Wroclaw, Poland|Site 610, Wroclaw, Poland|Site 604, Zabrze, Poland|Site 701, Dnipropetrovsk, Ukraine|Site 702, Dnipropetrovsk, Ukraine|Site 709, Dnipropetrovsk, Ukraine|Site 712, Donetsk, Ukraine|Site 703, Kharkiv, Ukraine|Site 705, Kharkiv, Ukraine|Site 711, Kharkov, Ukraine|Site 704, Kyiv, Ukraine|Site 706, Kyiv, Ukraine|Site 707, Kyiv, Ukraine|Site 708, Kyiv, Ukraine|Site 715, Kyiv, Ukraine|Site 713, Lugansk, Ukraine|Site 714, Odessa, Ukraine|Site 710, Zaporizhya, Ukraine",,https://ClinicalTrials.gov/show/NCT00349375
NCT00348725,Acceptability of a Fixed Combination of Fenofibrate and Metformin,,Completed,No Results Available,Dyslipidemia/Glucose Metabolism Disorder,Drug: fenofibrate and metformin fixed combination (drug),Quotation by Visual Numeric Rating Scale before and after 4-week treatment|Assessment of safety by reporting of Adverse Events,Solvay Pharmaceuticals,All,"20 Years to 80 Years   (Adult, Older Adult)",Phase 3,69,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C LF23-0121 04 02,Apr-05,null,null,6-Jul-06,null,3-Sep-07,"Site 24, Anzin, France|Site 23, Bachant, France|Site 21, Baune, France|Site 32, Bersee, France|Site 34, Briollay, France|Site 27, Denain, France|Site 28, Denain, France|Site 5, Le Temple de Bretagne, France|Site 29, Nantes, France|Site 2, Nantes, France|Site 8, Nantes, France|Site 9, Nantes, France|Site 1, Nort sur Erdre, France|Site 13, Parcay les Pins, France|Site 26, Quarouble, France|Site 7, Saint Aignan le Grand, France|Site 4, Saint Herblain, France|Site 30, Saint-Amand, France|Site 11, Sautron, France|Site 17, Segre, France|Site 10, St Etienne de Montluc, France|Site 33, Thiant, France|Site 12, Thouars, France|Site 25, Vieux Conde, France|Site 20, Vihiers, France",,https://ClinicalTrials.gov/show/NCT00348725
NCT00348751,CholGate - The Effect of Alerting Versus on Demand Computer Based Decision Support on Treatment of Dyslipidaemia by General Practitioners,,Completed,No Results Available,"Decision Support Systems, Clinical",Device: CholGate,The percentage of correctly screened patients using anonymous patient record data.|The percentage of correctly treated patients using anonymous patient record data.,Erasmus Medical Center|Dutch Heart Foundation,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,null,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),2000B161,Jun-04,null,Nov-05,6-Jul-06,null,8-May-08,"Department of Medical informatics, ErasmusMC, Rotterdam, South Holland, Netherlands",,https://ClinicalTrials.gov/show/NCT00348751
NCT00349128,Fenofibrate in Dyslipidemia and Metformin-Controlled Diabetes,,Completed,No Results Available,Dyslipidemia/Glucose Metabolism Disorder,Drug: fenofibrate and metformin combination (drug),Change in fasting triglycerides.|Assessment of lipid and glucose metabolisms.,Solvay Pharmaceuticals,All,"20 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,382,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,C LF23-0121 03 01,Jan-04,null,null,6-Jul-06,null,3-Sep-07,"Site 201, Katowice, Poland|Site 203, Katowice, Poland|Site 202, Warszawa, Poland|Site 204, Zabrze, Poland|Site 111, Dnipropetrovsk, Ukraine|Site 113, Dnipropetrovsk, Ukraine|Site 108, Kharkiv, Ukraine|Site 109, Kharkiv, Ukraine|Site 101, Kyiv, Ukraine|Site 102, Kyiv, Ukraine|Site 103, Kyiv, Ukraine|Site 104, Kyiv, Ukraine|Site 105, Kyiv, Ukraine|Site 106, Kyiv, Ukraine|Site 107, Kyiv, Ukraine|Site 112, Zaporizhya, Ukraine|Site 35, Acomb, United Kingdom|Site 21, Atherstone, United Kingdom|Site 14, Balsall Common, United Kingdom|Site 32, Bangor, United Kingdom|Site 23, Barry, United Kingdom|Site 36, Basingstoke, United Kingdom|Site 8, Bexhill-on-Sea, United Kingdom|Site 20, Camberley, United Kingdom|Site 22, Chesterfield, United Kingdom|Site 10, Chippenham, United Kingdom|Site 13, Coventry, United Kingdom|Site 31, Doncaster, United Kingdom|Site 15, Downpatrick, United Kingdom|Site 17, Ely, United Kingdom|Site 4, Ely, United Kingdom|Site 11, Fife, United Kingdom|Site 1, Frome, United Kingdom|Site 16, Harrow, United Kingdom|Site 5, Hastings, United Kingdom|Site 26, Haverfordwest, United Kingdom|Site 19, Keresley end, United Kingdom|Site 9, Kingswood, United Kingdom|Site 25, Newtownabbey, United Kingdom|Site 33, Northampton, United Kingdom|Site 28, Odiham, United Kingdom|Site 3, Paignton, United Kingdom|Site 12, Petersborough, United Kingdom|Site 7, Randalstown, United Kingdom|Site 27, Slough, United Kingdom|Site 6, Soham, United Kingdom|Site 2, South Glamorgan, United Kingdom|Site 34, Stratford on Avon, United Kingdom|Site 29, Swindon, United Kingdom|Site 30, Trowbridge, United Kingdom|Site 18, Yaxley, United Kingdom",,https://ClinicalTrials.gov/show/NCT00349128
NCT00349284,A Controlled-Study of Fenofibrate 145 mg and Ezetimibe 10 mg in Type IIb Dyslipidemic Patients With Features of the Metabolic Syndrome,,Completed,No Results Available,Hyperlipidemia Combined,Drug: Combination of 145 mg fenofibrate and 10 mg ezetimibe,TG and HDL-C levels.,Solvay Pharmaceuticals,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,181,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,C LF 178P 04 01|2004-002408-13,Jan-05,null,null,6-Jul-06,null,3-Sep-07,"Site 113, Charleroi, Belgium|Site 112, Couillet, Belgium|Site 115, Dessel, Belgium|Site 114, Dour, Belgium|Site 106, Genk, Belgium|Site 102, Genly, Belgium|Site 111, Komen, Belgium|Site 109, Kortessem, Belgium|Site 104, Kortrijk, Belgium|Site 108, Luik, Belgium|Site 107, Menen, Belgium|Site 105, Moen, Belgium|Site 101, Oosteeklo, Belgium|Site 110, Oostham, Belgium|Site 116, Seraing, Belgium|Site 103, Turnhout, Belgium|Site 213, Bondy, France|Site 211, Le Beausset, France|Site 209, Nantes, France|Site 202, Orvault, France|Site 212, Paris Cedex, France|Site 206, Paris, France|Site 208, Paris, France|Site 203, Saint Cyr, France|Site 210, Six Fours les Plages, France|Site 201, St Sébastian sur Loire, France|Site 205, St Sébastian sur Loire, France|Site 207, St Sébastian sur Loire, France|Site 204, Toulon, France|Site 313, Borna, Germany|Site 307, Bretten, Germany|Site 306, Dresden, Germany|Site 305, Erbach, Germany|Site 304, Frankfurt, Germany|Site 308, Frankfurt, Germany|Site 311, Frankfurt, Germany|Site 301, Ilvesheim, Germany|Site 302, Leipzig, Germany|Site 303, Leipzig, Germany|Site 314, Mannheim, Germany|Site 309, Offenbach, Germany|Site 312, Offenbach, Germany|Site 310, Rodgau, Germany",,https://ClinicalTrials.gov/show/NCT00349284
NCT00346697,Omega-3 Fatty Acids for High Triglycerides in HIV-infected Patients,,Completed,Has Results,HIV Infections|AIDS|Dyslipidemia|Hypertriglyceridemia,Drug: Omega-3 fatty acid administration|Drug: Placebo,Change in Triglyceride Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group.|Change in Total Cholesterol Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group|Change in Non-HDL Cholesterol Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group|Change in HDL Cholesterol Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group|Change in HOMA-IR From Baseline in the LOVAZA Group Compared to the Placebo Group|Change in CD4+ T-cell Counts From Baseline in the LOVAZA Group Compared to the Placebo Group|Change in hsCRP Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group.|Change in IL-6 Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group.|Change in TNF-a Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group.|Change in sTNFR1 Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group.|Change in sTNFR2 Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group.|Change in CTX Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group.|Change in P1NP Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group.|Change in Collagen ADP From Baseline in the LOVAZA Group Compared to the Placebo Group.|Change in Collagen Epinephrine From Baseline in the LOVAZA Group Compared to the Placebo Group.,"Brown, Todd, M.D., Ph.D.|National Center for Complementary and Integrative Health (NCCIH)|GlaxoSmithKline",All,"18 Years and older   (Adult, Older Adult)",Phase 4,48,Other|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",K23AT002862-01,Oct-06,Apr-10,Apr-10,30-Jun-06,5-Nov-14,5-Nov-14,"Veterans Administration of Greater Los Angeles Health System, Los Angeles, California, United States|Georgetown University, Washington, District of Columbia, United States|Johns Hopkins University, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00346697
NCT00345410,Dose-Ranging Study Evaluating AVE1625 in Abdominally Obese Patients With Atherogenic Dyslipidemia,,Completed,No Results Available,Obesity|Dyslipidemia,Drug: AVE1625 B,"Absolute change from baseline in body weight at 24 weeks|- relative change from baseline to 24 weeks in plasma HDL-cholesterol and triglycerides levels ; - change from baseline to 24 weeks in waist circumference ; Other criteria: glycemic control parameters.|Safety: physical examination, vital signs, adverse events, ECG, laboratory tests.|Pharmacokinetics: plasma AVE1625 concentrations",Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 2,345,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",DRI6412,Jun-06,Jun-07,Jun-07,28-Jun-06,null,19-Dec-08,"Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT00345410
NCT00345657,Efficacy Study of Extended-Release Niacin/Lovastatin Versus Usual Care,,Completed,No Results Available,Hyperlipidemia|Mixed Hyperlipidemia|Dyslipidemia,Drug: Niacin Extended Release/Lovastatin,Lipid parameter change at 3 and 6 months|Percent of patients achieving ATP III LDL goals at 3 and 6 months,In His Image|Kos Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 4,100,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IHI-A001,Jul-03,null,May-04,28-Jun-06,null,28-Jun-06,"Family Medical Care of Tulsa, Tulsa, Oklahoma, United States",,https://ClinicalTrials.gov/show/NCT00345657
NCT00345722,The Effect of Strawberries in a Cholesterol-Lowering Dietary Portfolio,,Completed,No Results Available,Hyperlipidemia|Cardiovascular Diseases|Hypercholesterolemia,Procedure: strawberry dietary intervention,"Total cholesterol measured at weeks 0, 2, and 4 of each phase|LDL cholesterol measured at weeks 0, 2, and 4 of each phase|C-reactive protein measured at weeks 0, 2 and 4 of each phase|Blood pressure measured at weeks 0, 2 and 4 of each phase|Apolipoprotein A1 and B measured at weeks 0, 2, and 4 of each phase|Lp(a) measured at weeks 0, 2, and 4 of each phase|Oxidative stress measured at weeks 0, 2, and 4 of each phase|Strawberry intake measured at weeks 0, 2, and 4 of each phase|Compliance to portfolio diet components measured at weeks 0, 2 and 4 of each phase|24 hour urinary potassium measured at weeks 0 and 4 of each phase|24 hour urinary calcium measured at weeks 0 and 4 of each phase","University of Toronto|California Strawberry Commission|Almond Board of California|Unilever R&D|Natural Sciences and Engineering Research Council, Canada",All,"21 Years and older   (Adult, Older Adult)",Phase 2,50,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,REB 03-043C|HC-CT#100934,Jun-06,null,Feb-07,28-Jun-06,null,8-May-07,"Clinical Nutrition & Risk Factor Modification Centre, St. Michael's Hospital Health Centre, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00345722
NCT00344175,Follow-on Protocol of Pitavastatin Versus Simvastatin in Patients With Hypercholesterolemia or Dyslipidemia and Coronary Heart Disease Risk Factors,,Completed,Has Results,Hypercholesterolemia|Dyslipidemia|Coronary Heart Disease,Drug: pitavastatin|Drug: simvastatin,Number of Patients Attaining NCEP LDL-C Target at Week 16|Number of Patients Attaining NCEP LDL-C Target at Week 44|Percent Change From Baseline in LDL-C,Kowa Research Europe,All,"18 Years and older   (Adult, Older Adult)",Phase 3,178,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NK-104-309,Jun-06,Aug-07,Aug-07,26-Jun-06,18-Jan-10,2-Feb-10,"Y Forskning, Bispebjerg Hospital, Copenhagen Nv, Denmark|Frederiks Hospital, Kardiologisk, Frederiksberg, Denmark|Kolesterollaboratoriet, Hellerup, Denmark|CCBR A/S, Vejle, Denmark|Middellaan 5, Breda, Netherlands|Bomanshof 8, Eindhoven, Netherlands|Damsterdiep 9, Groningen, Netherlands|Doezastraat 1, Leiden, Netherlands|Kamerlingh Onnesstraat 16-18, Nijmegen, Netherlands|Mathenesserlaan 247, Rotterdam, Netherlands|Reigerstraat 30, Velp, Netherlands|Parkdreef 142, Zoetermeer, Netherlands|Hospital Clinico S. Juan de Alicante, San Juan, Alicante, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital Ramon y Cajal, Madrid, Spain|Fundacion Jimenez Diaz, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain|Angelholms Sjukhus, Medicinkliniken, Angelhom, Sweden|Sahlgrenska University Hospital, Intermedicin, Gothenburg, Sweden|Hjartmottagningen, Helsingborg, Sweden|Lakarcentrum Nyponet, Karineholm, Sweden|Medicinkliniken, Ludvika, Sweden|Huslakaren i Sandviken, Sandviken, Sweden|Narsjukhuset Sandviken, Kardiologlab, Medicin, Sandviken, Sweden|Hjart & Karlcenter, Sodertalje, Sweden|Karolinska Universitetssjukhuset, Stockholm, Sweden|Hjarthuset AB, Varberg, Sweden",,https://ClinicalTrials.gov/show/NCT00344175
NCT00344370,Follow-On Study of Pitavastatin Versus Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia,,Completed,Has Results,Type II Diabetes Mellitus|Dyslipidemia,Drug: Pitavastatin|Drug: Atorvastatin,NCEP LDL-C Target Attainment|Percent Change From Baseline in LDL-C,Kowa Research Europe,All,"Child, Adult, Older Adult",Phase 3,214,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NK-104-310,Aug-06,Apr-08,Apr-08,26-Jun-06,18-Jan-10,2-Feb-10,"CCBR Aalborg, Aalborg, Denmark|CCBR A/S, Vejle, Denmark|CCBR Vejle, Vejle, Denmark|Gemeinschaftspraxis am Bahnhof, Berlin-Spandau, Germany|Pharmakologisches Studienzentum Chemnitz, Chemnitz, Germany|Internistische Diabetische Schwerpunktpraxis Dr., Frankfurt Am Main, Germany|Internistische Gemeinschaftspraxis, Mainz, Germany|Gemeinschaftspraxis Dr. Senftleber, Dr. Kohler, Messkirch, Germany|Bhagwan Mahaveer Jain Heart Centre, Bangalore, India|Sri Ramachandra Medical College Hospital, Chennai, India|Apollo Hospitals, Hyderabaad, India|CARE Group of Hospitals, Hyderabaad, India|PD Hinduja Hospital, Mumbai, India|Andromed Breda, Breda, Netherlands|Andromed Eindhoven, Eindhoven, Netherlands|Andromed Noord, Groningen, Netherlands|Andromed Leiden, Leiden, Netherlands|Andromed Nijmegen, Nijmegen, Netherlands|Andromed Rotterdam, Rotterdam, Netherlands|Andromed Oost, Velp, Netherlands|Andromed Zoetermeer, Zoetermeer, Netherlands|Podlaski Osrodek Kardiologii, Bialystok, Poland|NZOZ GCP Dobra Praktyka Lekaska, Gruziadz, Poland|NZOZ Terapia Optima, Katowice, Poland|NZOZ Esculap, Przychodnia Lekary Rodzinnych, Losice, Poland|NZOZ Centrum, Poradnia Kardiologiczna, Siedlce, Poland|Spec. Gab. Lek. Internistyczno-Kardiologicznly, Tarnow, Poland|Woj.Szp.Spec.Nr 1 im. Prof. J. Gasinskiego, Tychy, Poland|Instytut Zywnosci i Zywienia, Warszawa, Poland|Lecznica PROSEN SMO, Warszawa, Poland|Szpital Wolski,im. Dr A. Gostynskiej, Warszawa, Poland|Synexus Reading Clinical Research Centre, Berkshire, United Kingdom|Synexus Lancashire Clinical Research Centre, Lancashire, United Kingdom|Synexus Merseyside Clinical Research Centre, Liverpool, United Kingdom|Synexus Manchester Clinical Research Centre, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT00344370
NCT00337415,MK0354 Clinical Efficacy and Tolerability Study (0354-004),,Terminated,No Results Available,Dyslipidemia,Drug: MK0354,proprietary information - exploratory (non-confirmatory) trial,Merck Sharp & Dohme Corp.,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,65,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,0354-004,May-06,Aug-06,Aug-06,16-Jun-06,null,18-May-15,,,https://ClinicalTrials.gov/show/NCT00337415
NCT00335699,Korean Rosuvastatin Effectiveness Study in Nondiabetic Metabolic Syndrome,,Completed,No Results Available,Hypercholesterolemia,Drug: Rosuvastatin,"The primary objective of this study is to compare the effect of rosuvastatin 10mg with atorvastatin 10mg in the percentage reduction of LDL-C in Subjects with metabolic syndrome after 6 weeks of treatment.|The secondary objectives of this study are to compare the effects of rosuvastatin 10mg with atorvastatin 10mg in subjects with metabolic syndrome, after 6weeks of treatment, on:|Bringing subjects to their established NCEP ATP III target goals for LDL-C|Bringing subjects to their non-HDL target goal(based on NCEP-ATP III criteria)|Modifying other lipids and lipid ratios|Modifying inflammatory markers|Glucose and insulin resistance|Safety",AstraZeneca,All,"18 Years and older   (Adult, Older Adult)",Phase 4,370,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D3560L00053|KREST,Aug-05,null,Jan-07,12-Jun-06,null,17-Dec-07,"Research Site, DaeGu, Korea, Republic of|Research Site, IkSan, Korea, Republic of|Research Site, JeonJu, Korea, Republic of|Research Site, JinJu, Korea, Republic of|Research Site, KwangJu, Korea, Republic of|Research Site, Pusan, Korea, Republic of|Research Site, Ulsan, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT00335699
NCT00332761,Caduet in an Untreated Subject Population,CUSP,Completed,No Results Available,Hypertension|Dyslipidemia,Drug: Caduet,"The percentage of subjects achieving both blood pressure goal (<140/90 mmHg) and LDL-C goal (<100 mg/dL) at Week 4.|The percentage of subjects achieving both blood pressure goal (<140/90 mmHg) and LDL-C goal (<100 mg/dL) at Week 8.|Change from Baseline to Week 4 in SBP, DBP, and Framingham 10-year CHD risk score.|Percent change from Baseline to Week 4 in LDL-C, HDL, TC, and TG.|The percentage of study subjects achieving each of the following goals at Week 4: SBP, DBP, and LDL-C.|Change from Baseline to Week 8 in SBP, DBP, and Framingham 10-year CHD risk score.|Percent change from Baseline to Week 8 in LDL-C, HDL, TC, and TG.|The percentage of study subjects achieving each of SBP, DBP, and LDL-C goals at Week 8.",Pfizer,All,"21 Years and older   (Adult, Older Adult)",Phase 4,220,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,A3841046,Jun-06,null,Sep-07,2-Jun-06,null,20-Aug-08,"Pfizer Investigational Site, Jonesboro, Arkansas, United States|Pfizer Investigational Site, Little Rock, Arkansas, United States|Pfizer Investigational Site, Garden Grove, California, United States|Pfizer Investigational Site, Long Beach, California, United States|Pfizer Investigational Site, Tustin, California, United States|Pfizer Investigational Site, Aventura, Florida, United States|Pfizer Investigational Site, Ft. Lauderdale, Florida, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, Pembroke Pines, Florida, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Decatur, Georgia, United States|Pfizer Investigational Site, Bossier City, Louisiana, United States|Pfizer Investigational Site, Fair Haven, Michigan, United States|Pfizer Investigational Site, Livonia, Michigan, United States|Pfizer Investigational Site, Jackson, Mississippi, United States|Pfizer Investigational Site, Jackson, Mississippi, United States|Pfizer Investigational Site, Excelsior Springs, Missouri, United States|Pfizer Investigational Site, Berlin, New Jersey, United States|Pfizer Investigational Site, Elizabeth, New Jersey, United States|Pfizer Investigational Site, Princeton, New Jersey, United States|Pfizer Investigational Site, South Bound Brook, New Jersey, United States|Pfizer Investigational Site, Binghamton, New York, United States|Pfizer Investigational Site, Monroe, North Carolina, United States|Pfizer Investigational Site, Winston-Salem, North Carolina, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Dayton, Ohio, United States|Pfizer Investigational Site, Eugene, Oregon, United States|Pfizer Investigational Site, Bensalem, Pennsylvania, United States|Pfizer Investigational Site, Kingsport, Tennessee, United States|Pfizer Investigational Site, Beaumont, Texas, United States|Pfizer Investigational Site, Colleyville, Texas, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, Temple, Texas, United States|Pfizer Investigational Site, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00332761
NCT00331487,Study to Compare Pioglitazone and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia,,Completed,No Results Available,Diabetes Mellitus,Drug: Pioglitazone|Drug: Rosiglitazone,Change in fasting triglyceride level|Change in fasting low-density lipoprotein cholesterol.|Change in fasting high-density lipoprotein cholesterol.|Change in fasting total cholesterol.|Change in fasting free fatty acids.|Change in plasminogen activator inhibitor 1|Change in high-sensitivity C-reactive protein|Change in fasting C-peptide.|Homeostasis model assessment-insulin resistance mode.|Change in fasting insulin.|Homeostasis model assessment-beta cell function.|Change in glycosylated hemoglobin.|Change in fasting plasma glucose.|Low-density lipoprotein particle concentration.|Low-density lipoprotein particle size.|High-density lipoprotein particle size.|Very low-density lipoprotein particle size.|Apolipoprotein A-I.|Apolipoprotein B|Lipoprotein a|Apolipoprotein C-III.,Takeda|Eli Lilly and Company,All,"35 Years and older   (Adult, Older Adult)",Phase 3,719,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",H6E-US-GLAI|U1111-1115-9039,Sep-00,Mar-04,Mar-04,31-May-06,null,28-Feb-12,"Anniston, Alabama, United States|Birmingham, Alabama, United States|Tucson, Arizona, United States|Concord, California, United States|Fremont, California, United States|Los Angeles, California, United States|Palos Verdes Estates, California, United States|San Diego, California, United States|Santa Barbara, California, United States|Santa Rosa, California, United States|Aurora, Colorado, United States|Englewood, Colorado, United States|Avon, Connecticut, United States|Hamden, Connecticut, United States|Longwood, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Atlanta, Georgia, United States|Fayetteville, Georgia, United States|Honolulu, Hawaii, United States|Idaho Falls, Idaho, United States|Chicago, Illinois, United States|Indianapolis, Indiana, United States|South Bend, Indiana, United States|New Orleans, Louisiana, United States|Baltimore, Maryland, United States|Frederick, Maryland, United States|Salisbury, Massachusetts, United States|South Yarmouth, Massachusetts, United States|Waltham, Massachusetts, United States|Minneapolis, Minnesota, United States|Chesterfield, Missouri, United States|Omaha, Nebraska, United States|East Setauket, New York, United States|Endwell, New York, United States|New York, New York, United States|Rochester, New York, United States|Staten Island, New York, United States|Charlotte, North Carolina, United States|Durham, North Carolina, United States|Greenville, North Carolina, United States|Morehead City, North Carolina, United States|Wilmington, North Carolina, United States|Columbus, Ohio, United States|Franklin, Ohio, United States|Tulsa, Oklahoma, United States|Portland, Oregon, United States|Salem, Oregon, United States|Philadelphia, Pennsylvania, United States|Pottstown, Pennsylvania, United States|Providence, Rhode Island, United States|Mount Pleasant, South Carolina, United States|Knoxville, Tennessee, United States|Memphis, Tennessee, United States|Beaumont, Texas, United States|Conroe, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|Lake Jackson, Texas, United States|San Antonio, Texas, United States|Ogden, Utah, United States|Mechanicsville, Virginia, United States|Newport News, Virginia, United States|Virginia Beach, Virginia, United States|Federal Way, Washington, United States|Wenatchee, Washington, United States|Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00331487
NCT00330785,Open Label Study Assessing Effectiveness Of Amlodipine/Atorvastatin In Subjects With Hypertension and Dyslipidaemia,JEWEL I,Completed,No Results Available,Hypertension|Dyslipidemia,Drug: Amlodipine/Atorvastatin,"To evaluate the number of patients who reach target blood pressure (BP) and|LDL-C targets as defined by their governing guidelines.|To assess changes from baseline to end of treatment for the following efficacy|parameters: LDL-C, total cholesterol (TC), triglycerides, high-density lipoprotein|cholesterol (HDL-C), HDL-C/LDL-C ratio, TC/HDL-C ratio. Systolic Blood Pressure|(SBP) and Diastolic Blood Pressue (DBP).",Pfizer,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,1250,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A3841018,Oct-04,null,Sep-05,29-May-06,null,8-Jan-10,"Pfizer Investigational Site, Calgary, Alberta, Canada|Pfizer Investigational Site, Calgary, Alberta, Canada|Pfizer Investigational Site, Calgary, Alberta, Canada|Pfizer Investigational Site, Calgary, Alberta, Canada|Pfizer Investigational Site, Calgary, Alberta, Canada|Pfizer Investigational Site, Red Deer, Alberta, Canada|Pfizer Investigational Site, Campbell River, British Columbia, Canada|Pfizer Investigational Site, Chilliwack, British Columbia, Canada|Pfizer Investigational Site, New Westminster, British Columbia, Canada|Pfizer Investigational Site, North Vancouver, British Columbia, Canada|Pfizer Investigational Site, Quesnel, British Columbia, Canada|Pfizer Investigational Site, Vancouver, British Columbia, Canada|Pfizer Investigational Site, Vancouver, British Columbia, Canada|Pfizer Investigational Site, Vancouver, British Columbia, Canada|Pfizer Investigational Site, Vancouver, British Columbia, Canada|Pfizer Investigational Site, Vancouver, British Columbia, Canada|Pfizer Investigational Site, Winnipeg, Manitoba, Canada|Pfizer Investigational Site, Winnipeg, Manitoba, Canada|Pfizer Investigational Site, Antigonish, Nova Scotia, Canada|Pfizer Investigational Site, Digby, Nova Scotia, Canada|Pfizer Investigational Site, Halifax, Nova Scotia, Canada|Pfizer Investigational Site, Halifax, Nova Scotia, Canada|Pfizer Investigational Site, Truro, Nova Scotia, Canada|Pfizer Investigational Site, Wolfville, Nova Scotia, Canada|Pfizer Investigational Site, Alymer, Ontario, Canada|Pfizer Investigational Site, Corunna, Ontario, Canada|Pfizer Investigational Site, Exeter, Ontario, Canada|Pfizer Investigational Site, Hamilton, Ontario, Canada|Pfizer Investigational Site, Kingston, Ontario, Canada|Pfizer Investigational Site, London, Ontario, Canada|Pfizer Investigational Site, London, Ontario, Canada|Pfizer Investigational Site, London, Ontario, Canada|Pfizer Investigational Site, London, Ontario, Canada|Pfizer Investigational Site, London, Ontario, Canada|Pfizer Investigational Site, London, Ontario, Canada|Pfizer Investigational Site, London, Ontario, Canada|Pfizer Investigational Site, North York, Ontario, Canada|Pfizer Investigational Site, North York, Ontario, Canada|Pfizer Investigational Site, Oshawa, Ontario, Canada|Pfizer Investigational Site, Oshawa, Ontario, Canada|Pfizer Investigational Site, Peterborough, Ontario, Canada|Pfizer Investigational Site, Sarnia, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Waterloo, Ontario, Canada|Pfizer Investigational Site, Weston, Ontario, Canada|Pfizer Investigational Site, Whitby, Ontario, Canada|Pfizer Investigational Site, Charlottetown, Prince Edward Island, Canada|Pfizer Investigational Site, Bonaventure, Quebec, Canada|Pfizer Investigational Site, Chomedy, Quebec, Canada|Pfizer Investigational Site, Gatineau, Quebec, Canada|Pfizer Investigational Site, Granby, Quebec, Canada|Pfizer Investigational Site, Longueuil, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Pointe-Claire, Quebec, Canada|Pfizer Investigational Site, Sherbrooke, Quebec, Canada|Pfizer Investigational Site, St Jerome, Quebec, Canada|Pfizer Investigational Site, St-Georges Ouest, Quebec, Canada|Pfizer Investigational Site, St-Marc Des Carrieres, Quebec, Canada|Pfizer Investigational Site, St. Lambert, Quebec, Canada|Pfizer Investigational Site, Ste-foy, Quebec, Canada|Pfizer Investigational Site, Regina, Saskatchewan, Canada|Pfizer Investigational Site, Quebec, Canada|Pfizer Investigational Site, Quebec, Canada|Pfizer Investigational Site, Quebec, Canada|Pfizer Investigational Site, Rimouski, Canada|Pfizer Investigational Site, St-Gedeon Beauce, Canada|Pfizer Investigational Site, St. John's, Canada|Pfizer Investigational Site, St. John's, Canada|Pfizer Investigational Site, St. John's, Canada|Pfizer Investigational Site, Ayr, Ayrshire, United Kingdom|Pfizer Investigational Site, Sandy, Bedfordshire, United Kingdom|Pfizer Investigational Site, Peterborough, Cambs, United Kingdom|Pfizer Investigational Site, Thornhill, Cardiff, United Kingdom|Pfizer Investigational Site, Fowey, Cornwall, United Kingdom|Pfizer Investigational Site, Darlington, County Durham, United Kingdom|Pfizer Investigational Site, Darlington, County Durham, United Kingdom|Pfizer Investigational Site, Paignton, Devon, United Kingdom|Pfizer Investigational Site, Plymouth, Devon, United Kingdom|Pfizer Investigational Site, Bournemouth, Dorset, United Kingdom|Pfizer Investigational Site, Angus, Dundee, United Kingdom|Pfizer Investigational Site, Central Milton Keyne, England, United Kingdom|Pfizer Investigational Site, Lancaster, England, United Kingdom|Pfizer Investigational Site, Surrey, England, United Kingdom|Pfizer Investigational Site, Wishaw, Lanarkshire, England, United Kingdom|Pfizer Investigational Site, Leigh-on-sea, Essex, United Kingdom|Pfizer Investigational Site, nEWPORT, gWENT, United Kingdom|Pfizer Investigational Site, Letchworth, Hertfordshire, United Kingdom|Pfizer Investigational Site, Canterbury, Kent, United Kingdom|Pfizer Investigational Site, Whitstable, Kent, United Kingdom|Pfizer Investigational Site, Blackpool, Lancashire, United Kingdom|Pfizer Investigational Site, Spalding, Lincolnshire, United Kingdom|Pfizer Investigational Site, Bangor, Belfast, Northern Ireland, United Kingdom|Pfizer Investigational Site, Coatbridge, Scotland, United Kingdom|Pfizer Investigational Site, Glasgow, Scotland, United Kingdom|Pfizer Investigational Site, Frome, Somerset, United Kingdom|Pfizer Investigational Site, Stairfoot, Barnsley, South Yorkshire, United Kingdom|Pfizer Investigational Site, Weybridge, Surrey, United Kingdom|Pfizer Investigational Site, Leeds, West Yorkshire, United Kingdom|Pfizer Investigational Site, Sheffield, Yorkshire, United Kingdom|Pfizer Investigational Site, Aberdeen, United Kingdom|Pfizer Investigational Site, Berkshire, United Kingdom|Pfizer Investigational Site, Cambridge, United Kingdom|Pfizer Investigational Site, Canterbury, United Kingdom|Pfizer Investigational Site, Coventry, United Kingdom|Pfizer Investigational Site, Coventry, United Kingdom|Pfizer Investigational Site, Dorking, United Kingdom|Pfizer Investigational Site, Dundee, United Kingdom|Pfizer Investigational Site, Glasgow, United Kingdom|Pfizer Investigational Site, Glasgow, United Kingdom|Pfizer Investigational Site, Glasgow, United Kingdom|Pfizer Investigational Site, Hertfordshire, United Kingdom|Pfizer Investigational Site, Kent, United Kingdom|Pfizer Investigational Site, Leeds, United Kingdom|Pfizer Investigational Site, Newcastle-upon-Tyne, United Kingdom|Pfizer Investigational Site, Newcastle-upon-Tyne, United Kingdom|Pfizer Investigational Site, Nottingham, United Kingdom|Pfizer Investigational Site, Rochdale, United Kingdom|Pfizer Investigational Site, Shrewsbury, United Kingdom|Pfizer Investigational Site, Stourbridge, United Kingdom|Pfizer Investigational Site, Swanley, United Kingdom|Pfizer Investigational Site, Swindon, United Kingdom|Pfizer Investigational Site",,https://ClinicalTrials.gov/show/NCT00330785
NCT00330876,Study of Pitavastatin in Elderly Patients With Primary Hypercholesterolemia or Combined Dyslipidemia,,Completed,Has Results,Hypercholesterolemia|Dyslipidemias,Drug: Pitavastatin,Change From Baseline in LDL-C|Change From Baseline in Total Cholesterol,Kowa Research Europe,All,65 Years and older   (Older Adult),Phase 3,545,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NK-104-308EU,Jun-06,Dec-07,Dec-07,29-May-06,18-Jan-10,16-Mar-10,"Copenhagen University Hospital, Copenhagen, Denmark|Medical Center, Copenhagen, Denmark|CCBR A/S, Vejle, Denmark|Kardiologische Gemeinschaftspraxis Prof. Reifart, Bad Soden/Taunus, Germany|Praxis Dr. Boenninghoff, Beckum, Germany|Klinische Forschung Berlin Mitte, Berlin, Germany|GWT-TUK GmbH, Zentrum fur Klinische Studien, Dresden, Germany|Gemeinschaftspraxis Dr. Krause, Th. Menke, Goch, Germany|Klinische Forschung Hamburg, Hamburg, Germany|Innere Medizin I/Medizinische Klinik, Heidelberg, Germany|Gemeinschaftspraxis H. Holz Dr. Med, K. W. Klingl, Lampertheim, Germany|ZET-Studien GmbH Leipzig, Leipzig, Germany|Internistische Gemeinschaftspraxis, Mainz, Germany|Praxis Dr. Wachter, Mannheim, Germany|Gemeinschaftspraxis Melcherstaette, Melcherstaette, Germany|Gemeinschaftspraxis Dr. Senftleber, Dr. Kohler, Messkirch, Germany|Praxisgemeinschaft im Kleinen Biergrund, Offenbach/M, Germany|Gemeinschaftspraxis Drs. Mockesch, Weinheim, Germany|Intermed Institud Fur Klinische Forschung und Arzn, Wiesbaden, Germany|Gemeinschaftspraxis Dr. Emden, Frank Drewes, Worpswede, Germany|Department of Internal Medicine, Soroka Medical Center, Beersheva, Israel|Department of Internal Medicine A, Rambal Medical Center, Haifa, Israel|Department of Internal Medicine, Wolfson Medical Center, Holon, Israel|Center for Research, Hadassah University Hospital, Jerusalem Ein Kerem, Israel|Meir Hospital, Kfar Saba, Israel|Department of Medicine, Hadassah Medical Center, Mount Scopus Jerusalem, Israel|Department of Internal Medicine, Rivka Sieff Medical Center, Safed, Israel|Institute of Metabolic Diseases, Tel Aviv, Israel|Institute of Lipid & Atherosclerosis Research, Tel Hashomer, Israel|Andromed Breda, Breda, Netherlands|Andromed Noord, Groningen, Netherlands|Vasculair Onderzoek Centrum Hoorn, Hoorn, Netherlands|Andromed Leiden, Leiden, Netherlands|Andromed Nijmegen, Nijmegen, Netherlands|Andromed Rotterdam, Rotterdam, Netherlands|Albert Schweitzer Ziekenhuis, Sliedrecht, Netherlands|Rivierenland Tiel, Tiel, Netherlands|Andromed Oost, Velp, Netherlands|Andromed Zoetermeer, Zoetermeer, Netherlands|Oldfield Surgery, Bath, United Kingdom|St James's Surgery, Bath, United Kingdom|The Pulteney Practice, Bath, United Kingdom|Birmingham Clinical Research Centre, Birmingham, United Kingdom|Stonehill Medical Center, Bolton, United Kingdom|Chorley Clinical Research Centre, Chorley, United Kingdom|Saltash Health Center, Cornwall, United Kingdom|Gomersal Lane Surgery, Dronfield, United Kingdom|Townhead Research, Irvine, United Kingdom|Crosby Clinical Research Centre, Liverpool, United Kingdom|The Symons Medical Center, Maidenhead, United Kingdom|Manchester Clinical Research Centre, Manchester, United Kingdom|Greenwood Medical Center, Nottingham, United Kingdom|Reading Clinical Research Centre, Reading, United Kingdom|Elm Lane Surgery, Sheffield, United Kingdom|Brook Lane Surgery, Southampton, United Kingdom|Bradford Road Medical Center, Wiltshire, United Kingdom|Rowden Medical Partnership, Wiltshire, United Kingdom|The Porch Surgery, Wiltshire, United Kingdom|The Burns Medical Practice, Yorkshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT00330876
NCT00330980,"Effects of Statin Medications on Mental Processes, Behavior, and Serotonin Levels",,Completed,No Results Available,Dyslipidemias,Drug: 40 mg Pravastatin (Pravachol)|Drug: 20 mg Simvastatin|Drug: Placebo,"Effects of statins on cognition, serotonin biochemistry, and aggression|Effect of statins on mood, and other cognitive, behavioral, and biochemical measures","University of California, San Diego|National Heart, Lung, and Blood Institute (NHLBI)",All,"20 Years and older   (Adult, Older Adult)",Phase 4,1000,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",394|R01HL063055,Apr-00,Mar-04,Mar-04,29-May-06,null,20-Mar-14,"University of California, San Diego, La Jolla, California, United States",,https://ClinicalTrials.gov/show/NCT00330980
NCT00329862,Laparoscopic Adjustable Gastric Banding With Truncal Vagotomy,,Terminated,No Results Available,Morbid Obesity|Obstructive Sleep Apnea|Hypertension|Urinary Incontinence|Hypertriglyceridemia|Diabetes|Hypercholesterolemia,Procedure: Laparoscopic Truncal Vagotomy,"Excess body weight loss measured @ 6, 12, 18, 24, 30, 36, 42, 48, 54, 60 weeks|BMI reduction measured @ 6, 12, 18, 24, 30, 36, 42, 48, 54, 60 weeks|Reduction and or elimination of co-morbidities @ 6, 12, 18, 24, 30, 36, 42, 48, 54, 60 weeks","Central Carolina Surgery, PA|EndoVx, Inc.",All,18 Years to 60 Years   (Adult),Not Applicable,25,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LAGBTV,May-06,May-06,May-06,25-May-06,null,15-Nov-11,,,https://ClinicalTrials.gov/show/NCT00329862
NCT00329069,The Role of Atorvastatin on Monocyte Function in Patients With Coronary Artery Disease and Hypercholesterolemia,,Completed,No Results Available,Coronary Artery Disease|Hypercholesterolemia|Monocyte Function,Drug: atorvastatin (drug),VEGF-A induced monocyte chemotaxis after 1-month treatment with atorvastatin 40 mg or a placebo once a day|PlGF-1 induced monocyte chemotaxis after 1-month treatment with atorvastatin 40 mg or a placebo once a day|HGF-induced monocyte chemotaxis after 1-month treatment with atorvastatin 40 mg or a placebo once a day|MCP-1-induced monocyte chemotaxis after 1-month treatment with atorvastatin 40 mg or a placebo once a day|VEGF-A+MCP-1-induced monocyte chemotaxis after 1-month treatment with atorvastatin 40 mg or a placebo once a day|HGF+MCP-1-induced monocyte chemotaxis after 1-month treatment with atorvastatin 40 mg or a placebo once a day,University of Ulm|Pfizer,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Diagnostic,ATV-D-01-007 G,May-02,null,Mar-06,24-May-06,null,24-May-06,"University Hospital Ulm, Ulm, Germany",,https://ClinicalTrials.gov/show/NCT00329069
NCT00329160,Rosuvastatin in the Long-term Treatment of Hypercholesterolaemic Subjects With Coronary Heart Disease,,Completed,Has Results,Hypercholesteremia,Drug: Rosuvastatin|Drug: HMG CoA inhibitor,Percent Change From Baseline (Before the Start of Rosuvastatin Treatment) to Week 76 in the Plaque Volume (PV)|Change From Baseline to Week 76 in Plaque Volume (PV) in the Target Lesion|Percent Change From Baseline to Specified Measurement Time Points in Low-density Lipoprotein （LDL-C）|Percent Change in High-sensitivity C-reactive Protein (HS-CRP) From Baseline to Specified Measurement Time Points,AstraZeneca|Shionogi,All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 4,214,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D3565L00002|0407E1841,Oct-05,Oct-08,Oct-08,24-May-06,15-Jul-11,31-Aug-11,"Research Site, Gifu, Japan|Research Site, Hamada, Japan|Research Site, Hiroshima, Japan|Research Site, Ichinomiya, Japan|Research Site, Inba-mura, Japan|Research Site, Izumisano, Japan|Research Site, Izumi, Japan|Research Site, Izumo, Japan|Research Site, Kagoshima, Japan|Research Site, Kanazawa, Japan|Research Site, Kasuga, Japan|Research Site, Kobe, Japan|Research Site, Komaki, Japan|Research Site, Konan-cho, Japan|Research Site, Kumamoto, Japan|Research Site, Kurume, Japan|Research Site, Kyoto, Japan|Research Site, Omiya, Japan|Research Site, Osaka, Japan|Research Site, Sapporo, Japan|Research Site, Shinjo, Japan|Research Site, Shunan, Japan|Research Site, Suita, Japan|Research Site, Tokyo, Japan|Research Site, Ube, Japan|Research Site, Yamaguchi, Japan|Research Site, Yokohama, Japan",,https://ClinicalTrials.gov/show/NCT00329160
NCT00329173,PULSAR - A Prospective Study to Evaluate the Utility of Low Doses of the Statins Atorvastatin and Rosuvastatin.,,Completed,No Results Available,Hypercholesterolaemia,Drug: Rosuvastatin|Drug: Atorvastatin,Reduction in LDL-c after 6 weeks|Changes in other lipids and lipoproteins|Achievement of NCEP -ATP III target goal LDL-Cholesterol and non HDL-C|Achievement of EAS LDL-c and non HDL-C target goals after 6 weeks treatment.|Comparison of cost effectiveness and also safety,AstraZeneca,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4522IL/0102|PULSAR|D3569C00001,Nov-03,null,Aug-04,24-May-06,null,16-Mar-09,,,https://ClinicalTrials.gov/show/NCT00329173
NCT00328523,TWICE (Ezetimibe Together With Any Statin Cholesterol Enhancement)(0653-060),,Completed,No Results Available,Hypercholesterolaemia|Hyperlipidaemia,"Drug: MK-0653, ezetimibe|Drug: Duration of Treatment: 3 months",Percent of patients attaining the ldl cholesterol target goal based on the lipids result at the end of the study (3 months).|Treatment with ezetimibe 10 mg/day will be well tolerated and no difference in tolerance will be shown between the 3 treatment groups.,Merck Sharp & Dohme Corp.,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,1496,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0653-060|2006_024,Jun-04,Jan-06,Jan-06,22-May-06,null,10-Mar-17,,,https://ClinicalTrials.gov/show/NCT00328523
NCT00327054,Effectiveness of Nigella Sativa (Kalonji) Seed in Dyslipidemia,,Completed,No Results Available,Hypercholesterolemia|Hypertension|Diabetes Mellitus|Metabolic Syndrome X,Drug: Nigella sativa seed,The primary end point for the trial is serum low-density lipoprotein (LDL) cholesterol concentration measured at six weeks after intervention.|Serum total cholesterol concentrations measured at six weeks after intervention|Serum concentrations of high-density lipoprotein (HDL) cholesterol measured at six weeks after intervention|Serum triglyceride concentrations measured at six weeks after intervention|Serum blood sugar concentrations measured at six weeks after intervention|Blood pressure measured at six weeks after intervention|Changes in serum creatinine after six weeks intervention,Aga Khan University,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,05201MED(Grant Fund#1VJ),Feb-06,null,Mar-07,17-May-06,null,1-Jul-15,"Aga Khan University, Karachi, Sindh, Pakistan",,https://ClinicalTrials.gov/show/NCT00327054
NCT00326326,"Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.",,Completed,No Results Available,Dyslipidemia,"Drug: CP-778,875",HDL-C Safety and Efficacy,Pfizer,All,"30 Years to 70 Years   (Adult, Older Adult)",Phase 2,84,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,A5561005,Jul-06,null,Jun-07,16-May-06,null,7-May-09,"Pfizer Investigational Site, Anniston, Alabama, United States|Pfizer Investigational Site, Huntsville, Alabama, United States|Pfizer Investigational Site, Greenbrae, California, United States|Pfizer Investigational Site, Los Angeles, California, United States|Pfizer Investigational Site, Walnut Creek, California, United States|Pfizer Investigational Site, DeFuniak Springs, Florida, United States|Pfizer Investigational Site, Destin, Florida, United States|Pfizer Investigational Site, Jupiter, Florida, United States|Pfizer Investigational Site, Melbourne, Florida, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Conyers, Georgia, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, Iowa City, Iowa, United States|Pfizer Investigational Site, Lexington, Kentucky, United States|Pfizer Investigational Site, Baltimore, Maryland, United States|Pfizer Investigational Site, Springfield, Missouri, United States|Pfizer Investigational Site, Omaha, Nebraska, United States|Pfizer Investigational Site, Las Vegas, Nevada, United States|Pfizer Investigational Site, Mount Vernon, New York, United States|Pfizer Investigational Site, Oklahoma City, Oklahoma, United States|Pfizer Investigational Site, Tulsa, Oklahoma, United States|Pfizer Investigational Site, Kingsport, Tennessee, United States|Pfizer Investigational Site, Bryan, Texas, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, Newport News, Virginia, United States|Pfizer Investigational Site, Richmond, Virginia, United States|Pfizer Investigational Site, Richmond, Virginia, United States|Pfizer Investigational Site, Richmond, Virginia, United States|Pfizer Investigational Site, Yakima, Washington, United States|Pfizer Investigational Site, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00326326
NCT00325780,Long-Term Extension Study of Pitavastatin in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia,,Completed,Has Results,Hypercholesterolemia|Dyslipidemia,Drug: Pitavastatin,Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)|Change From Baseline in Total Cholesterol,Kowa Research Europe,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,1355,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NK-104-307|2005-001112-41,Jul-06,Nov-07,Nov-07,15-May-06,18-Jan-10,2-Feb-10,"Y Forskning, Bispebjerg Hospital, Copenhagen Nv, Denmark|Copenhagen University Hospital, Copenhagen, Denmark|Medical Center, Copenhagen, Denmark|Frederiks Hospital, Kardiologisk, Frederiksberg, Denmark|Kolesterollaboratoriet, Hellerup, Denmark|CCBR A/S, Vejle, Denmark|Geri-Med Oy, Helsinki, Finland|Kaisaniemen Laakariasema, Helsinki, Finland|Keravan Laakarikeskus, Helsinki, Finland|SOK-Tyoterveyshuolto, Tampere, Finland|TYKS University Hospital, Turku, Finland|Kardiologische Gemeinschaftspraxis Prof. Reifart, Bad Soden/Taunus, Germany|Praxis Dr. Boenninghoff, Beckum, Germany|Gemeinschaftspraxis am Bahnhof, Berlin-Spandau, Germany|Klinische Forschung Berlin Mitte, Berlin, Germany|Pharmakologisches Studienzentum Chemnitz, Chemnitz, Germany|GWT-TUK mbH, Zentrum fur Klinische Studien, Dresden, Germany|Internistische Diabetische Schwerpunktpraxis Dr., Frankfurt Am Main, Germany|Gemeinschaftspraxis Dr. Krause, Th. Menke, Goch, Germany|Klinische Forschung Hamburg, Hamburg, Germany|Innere Medizin I/Medizinische Klinik, Heidelberg, Germany|Gemeinschaftspraxis H. Holz Dr. Med, K. W. Klingl, Lampertheim, Germany|ZET-Studien GmbH Leipzig, Leipzig, Germany|Internistische Gemeinschaftspraxis, Mainz, Germany|Praxis Dr. Wachter, Mannheim, Germany|Gemeinschaftspraxis Melcherstaette, Melcherstaette, Germany|Gemeinschaftspraxis Dr. Senftleber, Dr. Kohler, Messkirch, Germany|Praxisgemeinschaft im Kleinen Biergrund, Offenbach/M, Germany|Gemeinschaftspraxis Drs. Mockesch, Weinheim, Germany|Intermed Institud fur Klinische Forschung und Arzn, Wiesbaden, Germany|Gemeinschaftspraxis Dr. Emden, Frank Drewes, Worpswede, Germany|Care Hospital, Andhra Pradesh, India|School of Diabetology, Nizam Institute of Medical Sciences, Andhra Pradesh, India|Bhagwan Mahaveer Jain Heart Centre, Bangalore, India|Sri Ramachandra Medical College Hospital, Chennai, India|Heart Care Clinic, Gujarat, India|Apollo Hospitals, Hyderabad, India|CARE Group of Hospitals, Hyderabad, India|St. John's Medical College Hospital, Karnataka, India|Bathia Hospital, Maharashtra, India|LTMMC & General Hospital, Maharashtra, India|Sir J. J. Group of Hospitals, Maharashtra, India|King Edward Medical College & Hospital, Maharashtra, India|Ruby Hall Clinic, Maharashtra, India|Lokmanya Hospital, Maharashtra, India|PD Hinduja Hospital, Mumbai, India|Sir Gagaram Hospital, New Delhi, India|Apollo Hospital, Tamil Nadu, India|Department of Cardiology, Tamil Nadu, India|Department of Internal Medicine, Soroka Medical Center, Beersheva, Israel|Department of Internal Medicine A, Rambal Medical Center, Haifa, Israel|Department of Internal Medicine, Wolfson Medical Center, Holon, Israel|Center for Research, Hadassah University Hospital, Jerusalem Ein Kerem, Israel|Meir Hospital, Kfar Saba, Israel|Department of Medicine, Hadassah Medical Center, Mount Scopus Jerusalem, Israel|Department of Internal Medicine, Rivka Sieff Medical Center, Safed, Israel|Institute of Metabolic Diseases, Tel Aviv, Israel|Institute of Lipid & Atherosclerosis Research, Tel Hashomer, Israel|Dipartimento di Medicina Clinica e Biotecnologia Applicata, Bologna, Italy|Centro di Ricerca Clinica, Chieti, Italy|Gerontologia e Geriatria - Universita degli Studi, Ferrara, Italy|Dipartimento di Medicina Interna DIMI, Genova, Italy|Universita di Modena e Reggio Emilia, Policlinico, Modena, Italy|Dipartimento di Medicina Clinica e Sperimentale, Napoli, Italy|Medicina Clinica e delle Patologie Emergenti, Palermo, Italy|Dipartimento di Medicina Interna e Scienze Biomediche, Parma, Italy|U.O. Malattie Metaboliche e Diabetologia, Treviglio, Italy|Azienda Ospedaliero-Universitaria, Trieste, Italy|Andromed Breda, Breda, Netherlands|Middellaan 5, Breda, Netherlands|Andromed Eindhoven, Eindhoven, Netherlands|Bomanshof 8, Eindhoven, Netherlands|Andromed Noord, Groningen, Netherlands|Damsterdiep 9, Groningen, Netherlands|Vasculair Onderzoek Centrum Hoorn, Hoorn, Netherlands|Andromed Leiden, Leiden, Netherlands|Doezastraat 1, Leiden, Netherlands|Andromed Nijmegen, Nijmegen, Netherlands|Kamerlingh Onnesstraat 16-18, Nijmegen, Netherlands|Andromed Rotterdam, Rotterdam, Netherlands|Mathenesserlaan 247, Rotterdam, Netherlands|Albert Schweitzer Ziekenhuis, Sliedrecht, Netherlands|Andromed Oost, Velp, Netherlands|Reigerstraat 30, Velp, Netherlands|Rivierenland Tiel, Wp Tiel, Netherlands|Andromed Zoetermeer, Zoetermeer, Netherlands|Parkdreef 142, Zoetermeer, Netherlands|Nyomen Legekontor, Kongsberg, Norway|Radhuset Spesialistsenter, Oslo, Norway|Rikshospitalet - University Hospital, Oslo, Norway|Skedsmo Medisinske Senter A.S., Skedsmokorset, Norway|Podlaski Osrodek Kardiologii, Bialystok, Poland|NZOZ GCP Dobra Praktyka Lekaska, Gruziadz, Poland|NZOZ Terapia Optima, Katowice, Poland|NZOZ Esculap, Przychodnia Lekary Rodzinnych, Losice, Poland|NZOZ Centrum, Poradnia Kardiologiczna, Siedlce, Poland|Spec. Gab. Lek. Internistyczno-Kardiologicznly, Tarnow, Poland|Woj.Szp.Spec.Nr 1 im. Prof. J. Gasinskiego, Tychy, Poland|Instytut Zywnosci i Zywienia, Warszawa, Poland|Lecznica PROSEN SMO, Warszawa, Poland|Szpital Wolski,im. Dr A. Gostynskiej, Warszawa, Poland|Kemerovo Cardiology Dispensary, Kemerovo, Russian Federation|Central Clinical Hospital 1 of RZD, Moscow, Russian Federation|City Clinical Hospital 23, Moscow, Russian Federation|City Clinical Hospital 64, Moscow, Russian Federation|Federal State Institution Out-Patient Clinic ï€£3 of Russian Federation of Presidentâ€™s Management, Moscow, Russian Federation|Moscow City Clinical Hospital 68, Moscow, Russian Federation|Moscow Regional Research Clinic Institute n.a.M.F.Vladimirov, Department of Therapy, Moscow, Russian Federation|State Educational Institution of Higher Professional Education â€œMoscow State University of Medicine and Dentistry of Federal Agency of Health Care and Social Developmentâ€�, Department of Internal Diseases and Rheumatology based at City Clinica, Moscow, Russian Federation|State Educational Institution of Higher Professional Education â€œMoscow State University of Medicine and Dentistry of Federal Agency of Health Care and Social Developmentâ€�, Hospital Therapy Department # 1 based at City Clinical Hospital # 40, Moscow, Russian Federation|State Educational Institution of Higher Professional Education â€œMoscow State University of Medicine and Dentistry of Federal Agency of Health Care and Social Developmentâ€�, Hospital Therapy Department #1 based at City Clinical Hospital # 52, Moscow, Russian Federation|State Educational Institution of Higher Professional Education â€œRussian State Medical University Federal Agency of Health Care and Social Developmentâ€�, Department of Polyclinic Therapy based at Diagnostic Center # 1, Moscow, Russian Federation|State Educational Institution of Higher Professional Education â€œRussian State Medical University Federal Agency of Health Care and Social Developmentâ€�, Department of Therapy based at City Hospital # 4, Moscow, Russian Federation|State Educational Institution of Higher Professional Education â€œRussian State Medical University of Federal Agency of Health Care and Social Developmentâ€�, Department of Hospital Therapy #1 based at City Clinical Hospital #15, Cardiology Depar, Moscow, Russian Federation|State Institution â€œResearch Institute of Physical and Chemical Medicineâ€� of Federal Agency of Health Care and Social Development, Laboratory of Clinical Cardiology based at Bauman City Hospital # 29, Moscow, Russian Federation|State Institution â€œRussian Cardiology Research Complexâ€� of Federal Agency of Health Care and Social Development, Myasnikov Clinical Cardiology Institute, Department of Hemodialysis and Plasmapheresis, Moscow, Russian Federation|State Research Center for Preventive Medicine, Moscow, Russian Federation|Novosibirsk Reg. Clinical Cardiology Dispensary, Novosibirsk, Russian Federation|Central Medical Unit 122, St. Pb, Saint Petersburg, Russian Federation|Clinical Hospital of Russian Academy of Sciences, Saint Petersburg, Russian Federation|Consulting and Diagnostic Center 85, Saint Petersburg, Russian Federation|Krestovsky Island Medical Institute, Saint Petersburg, Russian Federation|Pokrovskaya City Hospital, Saint Petersburg, Russian Federation|St. Petersburg State Medical Institution â€œOut-patient Clinic # 109â€�, Saint Petersburg, Russian Federation|St.Petersburg State Medical Institution â€œPokrovskaya City Hospitalâ€�, Cardiology Department #2, Saint Petersburg, Russian Federation|State Educational Institution of Higher Professional Education, â€œSaint-Petersburg State Medical University n.a.Academician I.P.Pavlov of Federal Agency of Health Care and Social Developmentâ€�, Chair and Department of Faculty Therapy, Saint Petersburg, Russian Federation|State Educational Institution of Higher Professional Education, â€œSaint-Petersburg State Medical University n.a.Academician I.P.Pavlov of Federal Agency of Health Care and Social Developmentâ€�, Institute of Cardiovascular Diseases, Saint Petersburg, Russian Federation|Hospital Clinico S. Juan de Alicante, San Juan, Alicante, Spain|Hospital Clinic i Provincial, Villaroel, Barcelona, Spain|Hospital de San Vicente, Alicante, Spain|Hospital Santa Creu I Sant Pau, Barcelona, Spain|Hospital Universitario de Bellvitge, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital Ramon y Cajal, Madrid, Spain|Centro de Especialidades Pedro Gonzalez Bueno, Madrid, Spain|Fundacion Jimenez Diaz, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Centro de Salud de Ventanielles, Oviedo, Spain|Hospital Marques de Valdecilla, Santander, Spain|Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain|Hospital Virgen del Roci-o, Sevilla, Spain|Hospital Dr. Peset, Valencia, Spain|Hospital de Sagunto, Valencia, Spain|Hospital Clinico Lozano Blesa, Zaragoza, Spain|Hospital Miguel Servet, Zaragoza, Spain|Angelholms Sjukhus, Medicinkliniken, Angelhom, Sweden|Sahlgrenska University Hospital, Intermedicin, Gothenburg, Sweden|Hjartmottagningen, Helsingborg, Sweden|Lakarcentrum Nyponet, Karineholm, Sweden|Medicinkliniken, Ludvika, Sweden|Huslakaren i Sandviken, Sandviken, Sweden|Narsjukhuset Sandviken, Kardiologlab, Medicin, Sandviken, Sweden|Hjart & Karlcenter, Sodertalje, Sweden|Karolinska Universitetssjukhuset, Stockholm, Sweden|Hjarthuset AB, Varberg, Sweden|Oldfield Surgery, Bath, United Kingdom|St James's Surgery, Bath, United Kingdom|St Michael's Partnership, Bath, United Kingdom|The Pulteney Practice, Bath, United Kingdom|Birmingham Clinical Research Centre, Birmingham, United Kingdom|Stonehill Medical Center, Bolton, United Kingdom|Avondale Surgery, Chesterfield, United Kingdom|Chorley Clinical Research Centre, Chorley, United Kingdom|Saltash Health Center, Cornwall, United Kingdom|Gomersal Lane Surgery, Dronfield, United Kingdom|Townhead Research, Irvine, United Kingdom|Crosby Clinical Research Centre, Liverpool, United Kingdom|The Symons Medical Center, Maidenhead, United Kingdom|Manchester Clinical Research Centre, Manchester, United Kingdom|Greenwood Medical Center, Nottingham, United Kingdom|Knowle House Surgery, Plymouth, United Kingdom|Reading Clinical Research Centre, Reading, United Kingdom|Elm Lane Surgery, Sheffield, United Kingdom|The Burngreave Surgery, Sheffield, United Kingdom|Brook Lane Surgery, Southampton, United Kingdom|St Helier Hospital, Surrey, United Kingdom|Box Surgery, Wiltshire, United Kingdom|Bradford Road Medical Center, Wiltshire, United Kingdom|Eastleigh Surgery, Wiltshire, United Kingdom|Lovemead Group Practice, Wiltshire, United Kingdom|Rowden Medical Partnership, Wiltshire, United Kingdom|St Chad's Surgery, Wiltshire, United Kingdom|The Health Centre, Wiltshire, United Kingdom|The Porch Surgery, Wiltshire, United Kingdom|The Burns Medical Practice, Yorkshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT00325780
NCT00325455,MK0859 Dose-Ranging Study (0859-003),,Terminated,No Results Available,Hypercholesterolemia|Mixed Hyperlipemia,Drug: MK0859,To assess the cholesterol changing effects of MK0859|Acceptable safety profile,Merck Sharp & Dohme Corp.,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,500,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0859-003|2006_006,Jun-06,Feb-07,Mar-07,12-May-06,null,2-Mar-15,,,https://ClinicalTrials.gov/show/NCT00325455
NCT00324350,Intensive Glycemic Control and Skeletal Health Study,ACCORD-BONE,Completed,Has Results,Atherosclerosis|Cardiovascular Diseases|Hypercholesterolemia|Hypertension|Diabetes Mellitus|Coronary Disease,"Drug: hypoglycemic agents, hydroxymethylglutaryl-CoA Reductase inhibitors, hypertensive agents",Number of Participants With at Least One Non-vertebral Fracture|Number of Participants With at Least One Fall|Number of Participants With > 2 cm of Height Loss,"University of California, San Francisco|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",All,"40 Years to 79 Years   (Adult, Older Adult)",Phase 3,7287,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention,R01DK069514,Oct-03,Jun-09,Jun-09,11-May-06,5-Oct-12,5-Oct-12,"Berman Center for Outcomes & Clinical Research, Minneapolis, Minnesota, United States|Wake Forest University, Winston-Salem, North Carolina, United States|Case Western Reserve University, Cleveland, Ohio, United States|Veterans Affairs, Memphis, Tennessee, United States|Population Health Research Institute, Hamilton, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00324350
NCT00321789,A Patient-Spouse Intervention for Self-Managing High Cholesterol,CouPLES,Completed,Has Results,Hypercholesterolemia,Behavioral: spouse-assisted intervention,Low-density Lipoprotein Cholesterol|Caloric Intake|Saturated Fat (Grams/Day)|Total Fat (Grams/Day)|Cholesterol Intake|Fiber Intake|Frequency of Moderate Intensity Physical Activity|Duration of Moderate Intensity Physical Activity|Total Fat (%)|Saturated Fat (%)|Number of Participants With Goal LDL-C|Number of Participants Prescribed Cholesterol Medication,US Department of Veterans Affairs|VA Office of Research and Development,All,"Child, Adult, Older Adult",Not Applicable,255,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor),IIR 05-273,Sep-07,Jul-10,Aug-10,4-May-06,26-Sep-14,24-Apr-15,"Durham VA Medical Center, Durham, NC, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00321789
NCT00318864,Biological CVD Risk Factors in Older Depressed Patients,,Completed,No Results Available,Depression|Hypertension|Hypercholesterolemia,Behavioral: Cognitive behavioral therapy,Change in depression|Change in typical and atypical risk factors,Stanford University,All,"55 Years and older   (Adult, Older Adult)",Not Applicable,70,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,CBarrTaylor|5P01AG018784-02,Jun-02,null,Jul-05,27-Apr-06,null,27-Apr-06,"Stanford Medical Center, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT00318864
NCT00319449,Adding Ezetimibe Tablet to Ongoing Treatment With Atorvastatin in Subjects With High Cholesterol and Multiple Coronary Heart Disease Risk Factors (Study P04060)(COMPLETED),,Completed,Has Results,Hypercholesterolemia|Coronary Arteriosclerosis,Drug: Ezetimibe|Drug: Placebo|Drug: Atorvastatin 10 mg,"Low Density Lipoprotein-cholesterol (LDL-C) at Baseline and After 6 Weeks of Treatment With Ezetimibe 10 mg Added to Atorvastatin 10 mg Versus Placebo Added to Atorvastatin 10 mg|Number of Participants Who Achieve the Target LDL-C Concentration of < 3.3 mmol/L (130 mg/dL)|High Density Lipoprotein-cholesterol (HDL-C), Total Cholesterol and Triglycerides at Baseline and After 6 Weeks of Treatment With Ezetimibe 10 mg Added to Atorvastatin 10 mg Versus Placebo Added to Atorvastatin 10 mg",Merck Sharp & Dohme Corp.|PT. Schering-Plough. Tbk Indonesia,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,22,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",P04060,Sep-05,Oct-06,Oct-06,27-Apr-06,10-May-11,12-Oct-15,,,https://ClinicalTrials.gov/show/NCT00319449
NCT00316095,Combination of Telmisartan and Simvastatin in the Treatment of Hypertension and Hypercholesterolemia,,Completed,No Results Available,Hypertension|Dyslipidemias,Drug: telmisartan|Drug: simvastatin,"Change in 24-hour ambulatory blood pressure measurement (ABPM) measured mean diastolic blood pressure (DBP)|Change in 24-hour ambulatory blood pressure measurement (ABPM) measured mean low density lipoprotein (LDL)|Change in the 24-hour ABPM (Ambulatory Blood Pressure Monitoring) measured mean SBP|Changes in Trough-to-peak ratios of SBP and DBP, taken from ABPM|Changes in Seated morning DBP and SBP|Response rate to blood pressure treatment|Response rate to lipid lowering treatment|Change in Total cholesterol|Change in HDL-cholesterol|Change in triglycerides|Change in Apolipoprotein B|Change in free fatty acids|Change in Adiponectin|Change in HOMA-index|Change in haemoglobin A1C|Changes in high sensitive c-reactive protein|Changes in microalbuminuria|Adverse events|Changes in clinical laboratory parameter|Assessment of pulse rate",Boehringer Ingelheim,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1695,Industry,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double|Primary Purpose: Treatment,1228.1|EudraCT No.: 2005-002851-41,Apr-06,Aug-07,Aug-07,20-Apr-06,null,1-Nov-13,"Boehringer Ingelheim Investigational Site, Benatky nad Jizerou, Czech Republic|Boehringer Ingelheim Investigational Site, Brno, Czech Republic|Boehringer Ingelheim Investigational Site, Mlada Boleslav, Czech Republic|Boehringer Ingelheim Investigational Site, Plzen, Czech Republic|Boehringer Ingelheim Investigational Site, Praha 5, Czech Republic|Boehringer Ingelheim Investigational Site, Pribram, Czech Republic|Boehringer Ingelheim Investigational Site, Unicov, Czech Republic|Boehringer Ingelheim Investigational Site, Usti nad Orlici, Czech Republic|ALTI, Angers, France|Boehringer Ingelheim Investigational Site, Angers, France|Boehringer Ingelheim Investigational Site, Sidi Daoud Tunis, France|Boehringer Ingelheim Investigational Site, Tunis, France|Boehringer Ingelheim Investigational Site, Haag, Germany|Boehringer Ingelheim Investigational Site, Mainz, Germany|Boehringer Ingelheim Investigational Site, Neuburg a. d. Donau, Germany|Boehringer Ingelheim Investigational Site, Nurnberg, Germany|Boehringer Ingelheim Investigational Site, Rednitzhembach, Germany|Boehringer Ingelheim Investigational Site, Unterschneidheim, Germany|Boehringer Ingelheim Investigational Site, Westerkappeln, Germany|Boehringer Ingelheim Investigational Site, Wiesbaden, Germany|Boehringer Ingelheim Investigational Site, Wurzburg, Germany|Boehringer Ingelheim Investigational Site, Hong Kong, Hong Kong|Chonnam National University Hospital, Kwangju, Korea, Republic of|Hallym University Sacred Heart Hospital, Kyunggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Korea University Medical Center, Seoul, Korea, Republic of|St. Mary Hospital, Seoul, Korea, Republic of|Boehringer Ingelheim Investigational Site, Almere, Netherlands|Boehringer Ingelheim Investigational Site, Beek en Donk, Netherlands|Andromed Breda, Breda, Netherlands|Gemini Ziekenhuis, Den Helder, Netherlands|Andromed Eindhoven, Eindhoven, Netherlands|Boehringer Ingelheim Investigational Site, Ewijk, Netherlands|Andromed Noord, Groningen, Netherlands|Andromed Leiden, Leiden, Netherlands|Andromed Nijmegen, Nijmegen, Netherlands|Boehringer Ingelheim Investigational Site, Oude Pekela, Netherlands|Andromed Rotterdam, Rotterdam, Netherlands|Julius Center for Patient oriented Research, Utrecht, Netherlands|Andromed Oost, Velp, Netherlands|Boehringer Ingelheim Investigational Site, Wildervank, Netherlands|Andromed Zoetermeer, Zoetermeer, Netherlands|Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation|Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation|Boehringer Ingelheim Investigational Site, Bratislava, Slovakia|Boehringer Ingelheim Investigational Site, Kosice, Slovakia|Boehringer Ingelheim Investigational Site, Kralovsky Chmlec, Slovakia|Boehringer Ingelheim Investigational Site, Liptovsky Hradok, Slovakia|Boehringer Ingelheim Investigational Site, Nitra, Slovakia|Boehringer Ingelheim Investigational Site, Povazska Bystrica, Slovakia|Boehringer Ingelheim Investigational Site, Presov, Slovakia|Boehringer Ingelheim Investigational Site, Trencin, Slovakia|Boehringer Ingelheim Investigational Site, Vrable, Slovakia|Boehringer Ingelheim Investigational Site, Boksburg, South Africa|Boehringer Ingelheim Investigational Site, Cape Town, South Africa|Boehringer Ingelheim Investigational Site, Cape Town, South Africa|Boehringer Ingelheim Investigational Site, Durban, South Africa|Boehringer Ingelheim Investigational Site, Johannesburg, South Africa|Boehringer Ingelheim Investigational Site, Krugersdorp, South Africa|Boehringer Ingelheim Investigational Site, Midrand, South Africa|Medicinkliniken, Goteborg, Sweden|Medicinkliniken, Lule?, Sweden|Boehringer Ingelheim Investigational Site, Lule?, Sweden|Endokrinologkliniken, Malmo, Sweden|Boehringer Ingelheim Investigational Site, Rattvik, Sweden|Medicinkliniken, Stockholm, Sweden|Boehringer Ingelheim Investigational Site, Uppsala, Sweden|National Cheng Kung University Hospital, Tainan, Taiwan|Mackay Memorial Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital, Taoyuan, Taiwan|Boehringer Ingelheim Investigational Site, Dnepropetrovsk, Ukraine|Boehringer Ingelheim Investigational Site, Dnepropetrovsk, Ukraine|Boehringer Ingelheim Investigational Site, Ivano-Frankovsk, Ukraine|Boehringer Ingelheim Investigational Site, Kharkov, Ukraine|Boehringer Ingelheim Investigational Site, Kharkov, Ukraine|Boehringer Ingelheim Investigational Site, Kiev, Ukraine|Boehringer Ingelheim Investigational Site, Kiev, Ukraine|Boehringer Ingelheim Investigational Site, Kiev, Ukraine|Boehringer Ingelheim Investigational Site, Kiev, Ukraine|Boehringer Ingelheim Investigational Site, Lutsk, Ukraine|Boehringer Ingelheim Investigational Site, Lvov, Ukraine|Boehringer Ingelheim Investigational Site, Lvov, Ukraine|Boehringer Ingelheim Investigational Site, Zaporozhye, Ukraine",,https://ClinicalTrials.gov/show/NCT00316095
NCT00312923,Preliminary Study of Safety and Efficacy of Policosanol,,Completed,Has Results,Dyslipidemia|HIV Infections,Drug: Policosanol|Dietary Supplement: Placebo,LDL Cholesterol|Triglycerides,Rush University Medical Center|National Center for Complementary and Integrative Health (NCCIH),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,54,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",R21AT003077-01,Sep-05,Jul-09,Sep-09,11-Apr-06,15-Jul-13,26-Jul-13,"Rush University Medical Center, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00312923
NCT00311987,"Study of 3,5-Diiodothyropropionic Acid (DITPA) in Hypercholesterolemic Patients",,Terminated,No Results Available,Hypercholesterolemia,"Drug: 3,5-Diiodothyropropionic acid (DITPA) therapy","To evaluate DITPA as a lipid modifying agent in combination with standard therapy in patients with LDL cholesterol (LDL-C) levels greater than the NCEP ATP III goals, as determined by patient's risk category, in order to achieve NCEP III LDL-C goals|To evaluate the effect of DITPA on other lipid targets: triglyceride|total cholesterol|ratio of total cholesterol to high-density lipoprotein (HDL)|ratio of LDL to HDL|HDL cholesterol|lipoprotein a [Lp (a)]|apolipoprotein A-I|apolipoprotein B100|and LDL subfractions|To evaluate the effect of DITPA on weight and waist circumference|To evaluate the effect of DITPA on high sensitivity C-reactive protein (hs CRP)|To evaluate the safety of DITPA in this patient population",Johns Hopkins University,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,NA_00001376,Apr-06,null,Apr-07,7-Apr-06,null,2-Apr-13,"Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00311987
NCT00309712,Diabetes and Combined Lipid Therapy Regimen (DIACOR) Study,,Completed,No Results Available,Type II Diabetes Mellitus|Mixed Dyslipidemia,Drug: fenofibrate 160 mg and placebo|Drug: simvastatin 20 mg and placebo|Drug: fenofibrate 160 mg and simvastatin 20 mg,"percent of patients achieving study goal oftriglycerides <200 mg/dL|Percent of patients achieving all study goals: LDL-C < 100 mg/dL, HDL-C:40 mg/dL, Triglycerides <200 mg/dL and the Percent of patients achieving non-HDL cholesterol <130 mg/dL","Intermountain Health Care, Inc.|Abbott|Merck Sharp & Dohme Corp.",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,300,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,128-009,Aug-02,null,Sep-06,3-Apr-06,null,21-Aug-08,"McKay Dee Hospital, Ogden, Utah, United States|LDS Hospital, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT00309712
NCT00309738,Study to Compare the Efficacy and Safety of Pitavastatin and Simvastatin,,Completed,Has Results,Hypercholesterolemia|Dyslipidemia,Drug: pitavastatin|Drug: simvastatin,Percent Change From Baseline in LDL-C|Number of Patients Attaining NCEP LDL-C Target (< 160 mg/dL),Kowa Research Europe,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,355,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NK-104-304,Sep-05,Oct-06,Oct-06,3-Apr-06,18-Jan-10,16-Mar-10,"CCBR A/S, Aalborg, Denmark|CCBR A/S, Ballerup, Denmark|Y Forskning, Bispebjerg Hospital, Copenhagen NV, Denmark|Frederiks Hospital, Kardiologisk, Frederiksberg, Denmark|Kolesterollaboratoriet, Hellerup, Denmark|CCBR A/S, Vejle, Denmark|Middellaan 5, Breda, Netherlands|Bomanshof 8, Eindhoven, Netherlands|Damsterdiep 9, Groningen, Netherlands|Doezastraat 1, Leiden, Netherlands|Kamerlingh Onnesstraat 16-18, Nijmegen, Netherlands|Mathenesserlaan 247, Rotterdam, Netherlands|Reigerstraat 30, Velp, Netherlands|Parkdreef 142, Zoetermeer, Netherlands|Hospital Clinico S. Juan de Alicante, San Juan, Alicante, Spain|Hospital Clinic i Provincial, Villaroel, Barcelona, Spain|Hospital Universitario de Bellvitge, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Fundacion Jimenez Diaz, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Ramon y Cajal, Madrid, Spain|Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain|Hospital de Sagunto, Valencia, Spain|Angelholms Sjukhus, Medicinkliniken, Angelhom, Sweden|Sahlgrenska University Hospital, Intermedicin, Gothenburg, Sweden|Hjartmottagningen, Helsingborg, Sweden|Lakarcentrum Nyponet, Karineholm, Sweden|Medicinkliniken, Ludvika, Sweden|Hjartmottagningen, Malmo, Sweden|Huslakaren i Sandviken, Sandviken, Sweden|Narsjukhuset Sandviken, Kardiologlab, Medicin, Sandviken, Sweden|Hjart & Karlcenter, Sodertalje, Sweden|Karolinska Universitetssjukhuset, Stockholm, Sweden|Hjarthuset AB, Varberg, Sweden",,https://ClinicalTrials.gov/show/NCT00309738
NCT00309751,Study Comparing Pitavastatin and Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia,,Completed,Has Results,Type II Diabetes Mellitus|Dyslipidemia,Drug: Pitavastatin|Drug: Atorvastatin,Percent Change From Baseline Low Density Lipoprotein Cholesterol (LDL-C)|Number of Patients Attaining National Cholesterol Education Program (NCEP) LDL-C Target,Kowa Research Europe,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,418,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NK-104-305,Dec-05,Jun-07,Jun-07,3-Apr-06,18-Jan-10,23-Feb-10,"CCBR Aalborg, Aalborg, Denmark|CCBR A/S, Ballerup, Denmark|CCBR Vejle, Vejle, Denmark|Gemeinschaftspraxis am Bahnhof, Berlin-Spandau, Germany|Pharmakologisches Studienzentum Chemnitz, Chemnitz, Germany|Internistische Diabetische Schwerpunktpraxis Dr., Frankfurt Am Main, Germany|Internistische Gemeinschaftspraxis, Mainz, Germany|Gemeinschaftspraxis Dr. Senftleber, Dr. Kohler, Messkirch, Germany|Bhagwan Mahaveer Jain Heart Centre, Bangalore, India|Sri Ramachandra Medical College Hospital, Chennai, India|Apollo Hospitals, Hyderabaad, India|CARE Group of Hospitals, Hyderabaad, India|PD Hinduja Hospital, Mumbai, India|Andromed Breda, Breda, Netherlands|Andromed Eindhoven, Eindhoven, Netherlands|Andromed Noord, Groningen, Netherlands|Andromed Leiden, Leiden, Netherlands|Andromed Nijmegen, Nijmegen, Netherlands|Andromed Rotterdam, Rotterdam, Netherlands|Andromed Oost, Velp, Netherlands|Andromed Zoetermeer, Zoetermeer, Netherlands|Podlaski Osrodek Kardiologii, Bialystok, Poland|NZOZ GCP Dobra Praktyka Lekaska, Gruziadz, Poland|NZOZ Terapia Optima, Katowice, Poland|NZOZ Esculap, Przychodnia Lekary Rodzinnych, Losice, Poland|NZOZ Centrum, Poradnia Kardiologiczna, Siedlce, Poland|Spec. Gab. Lek. Internistyczno-Kardiologicznly, Tarnow, Poland|Woj.Szp.Spec.Nr 1 im. Prof. J. Gasinskiego, Tychy, Poland|Instytut Zywnosci i Zywienia, Warszawa, Poland|Lecznica PROSEN SMO, Warszawa, Poland|Szpital Wolski,im. Dr A. Gostynskiej, Warszawa, Poland|Synexus Reading Clinical Research Centre, Berkshire, United Kingdom|Synexus Lancashire Clinical Research Centre, Lancashire, United Kingdom|Synexus Merseyside Clinical Research Centre, Liverpool, United Kingdom|Synexus Manchester Clinical Research Centre, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT00309751
NCT00309777,Study to Compare the Efficacy and Safety of Pitavastatin and Simvastatin,,Completed,Has Results,Hypercholesterolemia|Dyslipidemia,Drug: Pitavastatin|Drug: Simvastatin,Percent Change From Baseline in Low Density Lipoprotein-cholesterol (LDL-C) at 12 Weeks|National Cholesterol Education Program (NCEP) LDL-C Target Attainment,Kowa Research Europe,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,857,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NK-104-302|EudraCT number 2005-001033-15,Sep-05,Oct-06,Oct-06,3-Apr-06,16-Dec-09,12-Jan-10,"Geri-Med Oy, Helsinki, Finland|Kaisaniemen Laakariasema, Helsinki, Finland|Keravan Laakarikeskus, Helsinki, Finland|SOK-tyoterveyshuolto, Tampere, Finland|TYKS University Hospital, Turku, Finland|Dipartimento Di Medicina Clinica e Biotecnologia Applicata, Bologna, Italy|Centro di Ricerca Clinica, Chieti, Italy|Gerontologia e Geriatria - Universita degli Studi, Ferrara, Italy|Dipartimento di Medicina Interna DIMI, Genova, Italy|Universita di Modena e Reggio Emilia, Policlinico, Modena, Italy|Dipartimento di Medicina Clinica e Sperimentale, Napoli, Italy|Medicina Clinica e delle Patologie Emergenti, Palermo, Italy|Dipartimento di Medicina Interna e Scienze Biomediche, Parma, Italy|U.O Malattie Metaboliche e Diabetologia, Treviglio, Italy|Azienda Ospedaliero-Universitaria, Trieste, Italy|Volvat Medisinske Senter, Fredrikstad, Norway|Nyomen Legekontor, Kongsberg, Norway|Radhuset Spesialistsenter, Oslo, Norway|Rikshospitalet - University Hospital, Oslo, Norway|Skedsmo Medisinske Senter A.S., Skedsmokorset, Norway|Kemerovo Cardiology Dispensary, Kemerovo, Russian Federation|Central Clinical Hospital 1 of RZD, Moscow, Russian Federation|City Clinical Hospital 23, Moscow, Russian Federation|City Clinical Hospital 64, Moscow, Russian Federation|Moscow City Clinical Hospital 68, Moscow, Russian Federation|State Research Center for Preventive Medicine, Moscow, Russian Federation|Novosibirsk Reg. Clinical Cardiology Dispensary, Novosibirsk, Russian Federation|Central Medical Unit 122, St. Pb, Saint Petersburg, Russian Federation|Clinical Hospital of Russian Academy of Sciences, Saint Petersburg, Russian Federation|Consulting and Diagnostic Center 85, Saint Petersburg, Russian Federation|Krestovsky Island Medical Institute, Saint Petersburg, Russian Federation|Pokrovskaya City Hospital, Saint Petersburg, Russian Federation|St Michael's Partnership, Bath, United Kingdom|Avondale Surgery, Chesterfield, United Kingdom|Knowle House Surgery, Plymouth, United Kingdom|The Burngreave Surgery, Sheffield, United Kingdom|St Helier Hospital, Surrey, United Kingdom|Box Surgery, Wiltshire, United Kingdom|Eastleigh Surgery, Wiltshire, United Kingdom|Lovemead Group Practice, Wiltshire, United Kingdom|St Chad's Surgery, Wiltshire, United Kingdom|The Health Centre, Wiltshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT00309777
NCT00308386,DYNAMIC Study: (Diabetes Nurse Case Management And Motivational Interviewing for Change),,Completed,No Results Available,Diabetes Mellitus|Hypertension|Hyperlipidemia,Behavioral: Nurse Case Management intervention,"% of patients reaching goal HbA1C (<7)|% of patients with BP goal (<130/80)|% of patients with LDL at goal (<100)|% of patients at goal for all three parameters (HbA1C <7, BP <130/80, LDL <100)|% of patients with yearly ophthalmologic exam|% of patients with yearly foot exam|% of patients with assessment for nephropathy|% of patients with nephropathy on ACE inhibitor or ARB|% of patients on aspirin|% of patients at or above CES-D depression score 16 for severe depression|Change in weight|Emotional distress (PAID survey)|Diabetes specific quality of life (ADD QOL)|Diabetes self care activities survey|Patient satisfaction survey (DTSQ)|Costs and cost-effectiveness|Physician satisfaction - survey filled out by physician",Milton S. Hershey Medical Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"18 Years and older   (Adult, Older Adult)",Phase 3,550,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R18 67495 (completed)|R18DK067495,10-Aug-06,27-Jul-11,27-Jul-11,29-Mar-06,null,20-Feb-19,"Penn State College of Medicine, Hershey, Pennsylvania, United States|Reading Hospital, Reading, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00308386
NCT00306384,Long-term Safety of Alogliptin in Patients With Type 2 Diabetes Mellitus,,Completed,Has Results,Diabetes Mellitus,Drug: Alogliptin,Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)|Change From Baseline Over Time in Glycosylated Hemoglobin|Change From Baseline in Fasting Plasma Glucose|Percentage of Participants With Marked Hyperglycemia|Change From Baseline in Proinsulin Level|Change From Baseline in Insulin Level|Change From Baseline in C-peptide Level|Change From Baseline in Body Weight|Percentage of Participants With a Clinical Response,Takeda,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,3323,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SYR-322-OLE-012|2005-004672-20|U1111-1113-8455,Mar-06,Nov-11,Nov-11,23-Mar-06,22-Mar-13,22-Mar-13,"Birmingham, Alabama, United States|Peoria, Arizona, United States|Phoenix, Arizona, United States|Anaheim, California, United States|Artesia, California, United States|Fresno, California, United States|Los Angeles, California, United States|Mission Viejo, California, United States|Northridge, California, United States|Orange, California, United States|San Diego, California, United States|Tustin, California, United States|Walnut Creek, California, United States|Colorado Springs, Colorado, United States|Denver, Colorado, United States|Norwalk, Connecticut, United States|Washington, District of Columbia, United States|Clearwater, Florida, United States|Hollywood, Florida, United States|Kissimmee, Florida, United States|Longwood, Florida, United States|New Port Richie, Florida, United States|Ocala, Florida, United States|Ocoee, Florida, United States|St. Cloud, Florida, United States|Lawrenceville, Georgia, United States|Honolulu, Hawaii, United States|Idaho Falls, Idaho, United States|Chicago, Illinois, United States|Avon, Indiana, United States|Elkhart, Indiana, United States|Evansville, Indiana, United States|Lafayette, Indiana, United States|Erlanger, Kentucky, United States|Baltimore, Maryland, United States|Sudbury, Massachusetts, United States|Chesterfield, Missouri, United States|St. Louis, Missouri, United States|Omaha, Nebraska, United States|Berlin, New Jersey, United States|Burlington, North Carolina, United States|Charlotte, North Carolina, United States|Morehead City, North Carolina, United States|Pinehurst, North Carolina, United States|Winston-Salem, North Carolina, United States|Cincinnatti, Ohio, United States|Dayton, Ohio, United States|Tulsa, Oklahoma, United States|Medford, Oregon, United States|Lansdale, Pennsylvania, United States|West Grove, Pennsylvania, United States|Charleston, South Carolina, United States|Columbia, South Carolina, United States|Simpsonville, South Carolina, United States|Bristol, Tennessee, United States|Cookeville, Tennessee, United States|Milan, Tennessee, United States|Dallas, Texas, United States|San Antonio, Texas, United States|Temple, Texas, United States|Texarkana, Texas, United States|Burlington, Vermont, United States|Buenos Aires, La Plata, Argentina|Buenos Aires, Moron, Argentina|Rosario, Sante Fe, Argentina|Buenos Aires, Argentina|Ciudadd Autonoma de Buenos Aires, Argentina|Cordoba, Argentina|Mar del Plata, Argentina|Fortaleza, Ceara, Brazil|Curitiba, Parana, Brazil|Porto Alegre, Rio Grande do Sul, Brazil|Mogi das Cruzes, Sao Paulo, Brazil|Santos, Sao Paulo, Brazil|Sao Paulo, Brazil|Santiago, Chile|Ostrava, Czech Republic|Prague, Czech Republic|Praha, Czech Republic|Sternberk, Czech Republic|Zlin, Czech Republic|Santo Domingo Oeste, Dominican Republic|Aschaffenburg, Germany|Berlin, Germany|Frankfurt, Germany|Hamburg, Germany|Hannover, Germany|Munich, Germany|Nuremberg, Germany|Schwerin, Germany|Wiesbaden, Germany|Witten, Germany|Guatemala, Guatemala|Almere, Netherlands|De Bilt, Netherlands|Geleen, Netherlands|Oud-Beijerland, Netherlands|Rotterdam, Netherlands|Zwijndrecht, Netherlands|Bellavista, Lima, Peru|San Isidro, Lima, Peru|Ica, Peru|Lima, Peru|Bytom, Poland|Kamieniec Zabkowicki, Poland|Krakow, Poland|Leczyca, Poland|Lodz, Poland|Radom, Poland|Pretoria, Gauteng, South Africa|Cape Town, Western Cape, South Africa|Somerset West, Western Cape, South Africa|Durban, South Africa|Johannesburg, South Africa|Parow, South Africa",,https://ClinicalTrials.gov/show/NCT00306384
NCT00304993,Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia,,Completed,No Results Available,Metabolic Syndrome X|Insulin Resistance,Drug: fenofibrate|Drug: niacin|Drug: rosiglitazone,"The effect of treatment on Peak LDL particle size|The effect of treatment on:|traditional lipid parameters (LDL-C, HDL-C, triglycerides)|% of lipids in regions IIIa+IIIb of a gradient gel electrophoresis|LDL phenotype|fasting glucose|Hemoglobin A1c","Foundation Research, Florida|GlaxoSmithKline|Kos Pharmaceuticals|Abbott",All,"18 Years and older   (Adult, Older Adult)",Phase 4,30,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SNARED,Jan-01,null,Feb-05,21-Mar-06,null,21-Mar-06,"Foundation Research, St. Petersburg, Florida, United States",,https://ClinicalTrials.gov/show/NCT00304993
NCT00300430,"Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.",,Completed,Has Results,Dyslipidemia|Coronary Heart Disease|Mixed Dyslipidemia,Drug: ABT-335 and rosuvastatin calcium|Drug: ABT-335 and atorvastatin calcium|Drug: ABT-335 and simvastatin,"Percentage of Subjects Reporting Adverse Events During Combination Therapy, Either in the Preceding Double-Blind Studies or in This Open-Label Study|Median Percent Change in Triglycerides From Baseline to Week 52 of the Open-Label Study|Mean Percent Change in High-Density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 52 of the Open-Label Study|Mean Percent Change in Direct Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 52 of the Open-Label Study|Mean Percent Change in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Week 52 in This Open-Label Study|Mean Percent Change in Very Low-Density Lipoprotein Cholesterol (VLDL-C) From Baseline to Week 52 of the Open-Label Study|Mean Percent Change in Total Cholesterol From Baseline to Week 52 of the Open-Label Study|Mean Percent Change in Apolipoprotein B (Apo B) From Baseline to Week 52 of the Open-Label Study|Median Percent Change in High-Sensitivity C-Reactive Protein (hsCRP) From Baseline to Week 52 of the Open-Label Study",Abbott,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1911,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,M05-758,Sep-06,Mar-08,null,9-Mar-06,23-Jul-09,23-Jul-09,"Global Medical Information, North Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00300430
NCT00300456,Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood,,Completed,Has Results,Dyslipidemia|Coronary Heart Disease|Mixed Dyslipidemia,Drug: ABT-335|Drug: Simvastatin|Drug: Placebo,Mean Percent Change in Triglycerides From Baseline to Final Visit|Mean Percent Change in High-Density Lipoprotein Cholesterol (HDL-C) From Baseline to Final Visit|Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Final Visit|Mean Percent Change in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Final Visit|Mean Percent Change in Very Low-Density Lipoprotein Cholesterol (VLDL-C)From Baseline to Final Visit|Mean Percent Change in Total Cholesterol From Baseline to Final Visit|Mean Percent Change in Lipoprotein Apo B (Apo B) From Baseline to Final Visit|Median Percent Change in High-Sensitivity C-Reactive Protein (hsCRP) From Baseline to Final Visit,Abbott,All,"18 Years and older   (Adult, Older Adult)",Phase 3,657,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",M05-749,Mar-06,Mar-07,null,9-Mar-06,25-Mar-09,3-Jun-09,"Global Medical Information, North Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00300456
NCT00300469,Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood,,Completed,Has Results,Mixed Dyslipidemia|Coronary Heart Disease|Dyslipidemia,Drug: ABT-335|Drug: Atorvastatin|Drug: Placebo,Mean Percent Change in Triglycerides From Baseline to Final Visit|Mean Percent Change in High-Density Lipoprotein Cholesterol (HDL-C) From Baseline to Final Visit|Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Final Visit|Mean Percent Change in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Final Visit|Mean Percent Change in Very Low-Density Lipoprotein Cholesterol (VLDL-C) From Baseline to Final Visit|Mean Percent Change in Total Cholesterol From Baseline to Final Visit|Mean Percent Change in Lipoprotein Apo B (Apo B) From Baseline to Final Visit|Median Percent Change in High-Sensitivity C-Reactive Protein (hsCRP) From Baseline to Final Visit,Abbott,All,"18 Years and older   (Adult, Older Adult)",Phase 3,613,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",M05-750,Mar-06,Feb-07,null,9-Mar-06,25-Mar-09,3-Jun-09,"Global Medical Information, North Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00300469
NCT00300482,Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood,,Completed,Has Results,Dyslipidemia|Coronary Heart Disease|Mixed Dyslipidemia,Drug: ABT-335|Drug: Rosuvastatin Calcium|Drug: Placebo,Mean Percent Change in Triglycerides From Baseline to Final Visit|Mean Percent Change in High-Density Lipoprotein Cholesterol (HDL-C) From Baseline to Final Visit|Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Final Visit|Mean Percent Change in Non-Low-Density Lipoprotein Cholesterol (Non-HDL-C)From Baseline to Final Visit|Mean Percent Change in Very Low-Density Lipoprotein Cholesterol (VLDL-C) From Baseline to Final Visit|Mean Percent Change in Total Cholesterol From Baseline to Final Visit|Mean Percent Change in Lipoprotein Apo B (Apo B) From Baseline to Final Visit|Median Percent Change in High-Sensitivity C-Reactive Protein (hsCRP) From Baseline to Final Visit,Abbott,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1445,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",M05-748,Mar-06,Dec-06,null,9-Mar-06,25-Mar-09,10-Jun-09,"Global Medical Information, North Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00300482
NCT00299169,Randomized Trial Comparing N of 1 Trials to Standard Practice to Improve Adherence to Statins in Patients With Diabetes,,Terminated,No Results Available,Diabetes|Cardiovascular Disease|Hyperlipidemia,Behavioral: N of 1 Trials,mean LDL levels|the proportions of participants taking statins at the end of the trial,Lawson Health Research Institute,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,6,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R-06-135|IRF-061-05,Sep-06,null,Nov-07,6-Mar-06,null,8-Jan-08,"St. Joseph's Health Care London, London, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00299169
NCT00298909,Exercise Versus Niacin in Patients With Coronary Artery Disease (CAD) and Low High-Density Lipoproteins (HDL),,Completed,No Results Available,Coronary Disease|Hypolipoproteinemia,Behavioral: physical exercise|Drug: niaspan (extended-release niacin)|Drug: niacin|Other: control,relative effect on flow-mediated dilatation of radial artery|lipid profile|biochemical markers of atherosclerosis|expression of monocyte surface markers|oxidative stress|thrombogenicity,University of Leipzig,All,"35 Years to 75 Years   (Adult, Older Adult)",Phase 4,48,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Leipzig-02,Mar-06,Jun-09,Jun-09,3-Mar-06,null,31-Jul-12,"University of Leipzig Heart Center, Leipzig, Germany",,https://ClinicalTrials.gov/show/NCT00298909
NCT00296400,Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease,PLANET II,Completed,Has Results,Hyperlipidemia,Drug: Rosuvastatin|Drug: Atorvastatin,Urinary Protein/Creatinine Ratio at Week 52 [LOCF]|Urinary Protein/Creatinine Ratio at Week 26.|Urinary Albumin/Creatinine Ratio at Week 26|Urinary Albumin/Creatinine Ratio at Week 52 [LOCF]|Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26|Change From Baseline in eGFR at Week 52 [LOCF]|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Total Cholesterol [TC] at Week 26.|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Total Cholesterol [TC] at Week 52.|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 26|Correlation of Changes From Baseline inUrinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in High Density Lipoprotein Cholesterol [HDL-C] at Week 26|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 52|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Non-high Density Lipoprotein Cholesterol [nonHDL-C] at Week 26|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 52|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Triglyceride [TG] at Week 26|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TG at Week 52|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 26|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 52|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Apolipoprotein A-1 [ApoA-1] at Week 26|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 52|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Apolipoprotein B [ApoB] at Week 26|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 52|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC at Week 26|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC at Week 52|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C at Week 26|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C at Week 52|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 26|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 52|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 26|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 52|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TG at Week 26|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TG at Week 52|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 26|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 52|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 26|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 52|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 26|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 52|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52|Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in TC at Week 26|Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in TC at Week 52|Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in LDL-C at Week 26|Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in LDL-C at Week 52|Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in HDL-C at Week 26|Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in HDL-C at Week 52|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C at Week 26|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C at Week 52|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TG at Week 26|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TG|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TC/HDL-C Ratio at Week 26|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TC/HDL-C Ratio at Week 52|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoA1 at Week 26|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoA1 at Week 52|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB at Week 26|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB at Week 52|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52,AstraZeneca,All,"18 Years and older   (Adult, Older Adult)",Phase 2,237,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D3569C00011|PLANET II,Feb-06,Jun-09,Jun-09,27-Feb-06,30-Dec-10,16-Jun-11,"Research Site, Avondale, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Pasadena, California, United States|Research Site, Riverside, California, United States|Research Site, Clearwater, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Augusta, Georgia, United States|Research Site, Topeka, Kansas, United States|Research Site, Columbia, Maryland, United States|Research Site, Springfield, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Columbia, Missouri, United States|Research Site, Orchard Park, New York, United States|Research Site, Winston Salem, North Carolina, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Columbia, South Carolina, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Richmond, Virginia, United States|Research Site, Gig Harbor, Washington, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Curitiba, PR, Brazil|Research Site, Sao Paulo, SP, Brazil|Research Site, Blagoevgrad, Bulgaria|Research Site, Burgas, Bulgaria|Research Site, Gabrovo, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Veliko Turnovo, Bulgaria|Research Site, Vancouver, British Columbia, Canada|Research Site, St John's, Newfoundland and Labrador, Canada|Research Site, Courtice, Ontario, Canada|Research Site, East York, Ontario, Canada|Research Site, Oakville, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Richmond Hill, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Thunder Bay, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Fredericia, Denmark|Research Site, Herlev, Denmark|Research Site, Holbaek, Denmark|Research Site, Kobenhavn, Denmark|Research Site, Roskilde, Denmark|Research Site, Viborg, Denmark|Research Site, Berlin, Germany|Research Site, Cloppenburg, Germany|Research Site, Demmin, Germany|Research Site, Dusseldorf, Germany|Research Site, Elsenfeld, Germany|Research Site, Gottingen, Germany|Research Site, Hannover, Germany|Research Site, Wurzburg, Germany|Research Site, Ajka, Hungary|Research Site, Baja, Hungary|Research Site, Balatonfured, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Eger, Hungary|Research Site, Gyula, Hungary|Research Site, Gy�r, Hungary|Research Site, Keszthely, Hungary|Research Site, Miskolc, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Szolnok, Hungary|Research Site, Szombathely, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Bergamo, BG, Italy|Research Site, Bologna, BO, Italy|Research Site, Brescia, BS, Italy|Research Site, Acireale, CT, Italy|Research Site, Foggia, FG, Italy|Research Site, Firenze, FI, Italy|Research Site, Parma, PR, Italy|Research Site, Reggio Calabria, RC, Italy|Research Site, Sassari, SS, Italy|Research Site, Teramo, TE, Italy|Research Site, Torino, TO, Italy|Research Site, Castelfranco Veneto, TV, Italy|Research Site, Treviso, TV, Italy|Research Site, Mestre, VE, Italy|Research Site, Mexico, DF, Mexico|Research Site, Zapopan, Jalisco, Mexico|Research Site, Cuernavaca, Morelos, Mexico|Research Site, Aguascalientes, Mexico|Research Site, D.F, Mexico|Research Site, Durango, Mexico|Research Site, San Luis Potos�, Mexico|Research Site, Cluj Napoca, Cluj, Romania|Research Site, Timisoara, Timis, Romania|Research Site, Brasov, Romania|Research Site, Bucuresti, Romania|Research Site, Constanta, Romania|Research Site, Craiova, Romania|Research Site, Iasi, Romania|Research Site, Suceava, Romania|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Parow, W Cape, South Africa|Research Site, Cape Town, South Africa|Research Site, Durban, South Africa|Research Site, Pretoria, South Africa",,https://ClinicalTrials.gov/show/NCT00296400
NCT00295373,Exercise And Rosuvastatin Treatment: Is There an Anti-Inflammatory Synergy?,,Unknown status,No Results Available,Nonfamilial Hypercholesterolemia|Physical Inactivity,Drug: Rosuvastatin|Behavioral: Exercise Training,"The following measures will be made at 0, 10 and 20 weeks:|Monocyte cell-surface expression of TLR4, CD14, and CD16|LPS-stimulated whole blood production of IL-6 and TNF-α|Serum levels of hsCRP and TNF-α|Serum levels of Endotoxin LDL, OxLDL, HDL, sCD14, and|Lipopolysaccharide Binding Protein.|Creatine kinase & ALT (0, 5, 10 weeks; rosuvastatin group)|Creatine kinase & ALT (48hrs after 1st and 5th exercise|bout; rosuvastatin + exercise group)",Purdue University,All,"40 Years to 65 Years   (Adult, Older Adult)",Phase 4,48,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0HQ01|IRB Protocol Ref.#: 0504001888,Feb-06,null,Aug-07,23-Feb-06,null,20-Apr-07,"Purdue University, West Lafayette, Indiana, United States",,https://ClinicalTrials.gov/show/NCT00295373
NCT00293878,Study on the Safety and Effects on Lipids of FM-VP4 in Subjects With Primary Hypercholesterolemia,,Completed,No Results Available,Hypercholesterolemia,Drug: Disodium Ascorbyl Phytostanol Phosphate (FM-VP4),"Percent change from baseline in LDL-C at 12 weeks|Percent change from baseline in TC, HDL-C, TG, HDL:LDL ratio and CRP at 12 weeks|Percent change from baseline in serum lipids at 2, 4 and 8 weeks|Safety",Forbes Medi-Tech,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,150,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CL2005-001,Nov-05,null,null,20-Feb-06,null,26-Feb-07,"Coastal Clinical Research, Mobile, Alabama, United States|Radiant Research, San Diego, California, United States|Radiant Research, Daytona Beach, Florida, United States|Radiant Research, Gainesville, Florida, United States|Radiant Research, Boise, Idaho, United States|Radiant Research, Chicago, Illinois, United States|Midwest Institute for Clinical Research, Indianapolis, Indiana, United States|PRA International Pharmacology Center, Lenexa, Kansas, United States|The Center for Pharmaceutical Research, Kansas City, Missouri, United States|Radiant Research, Portland, Oregon, United States|Coastal Carolina Research Center, Mount Pleasant, South Carolina, United States|Radiant Research, Austin, Texas, United States|Research Across America, Dallas, Texas, United States|Radiant Research, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT00293878
NCT00291824,Cardiovascular Lifestyle Study: Effects and Expense of a Cardiovascular Risk Reduction Clinic in Primary Care,,Unknown status,No Results Available,Hypertension|Hyperlipidemia|Hyperglycemia|Cardiovascular Disease|Smoking,Behavioral: Cardiovascular risk factors and willingness to change,"Current Interview or Chart|International classification of diseases|Characteristics/demographics (dob, gender, marital status, living arrangement, employment, culture, language, spiritual beliefs, concurrent diseases - number/type).|Cognition: 10 item short portable mental status questionnaire (SPMSQ)(Pfeiffer, 1975)|Number of MD visits for cardiovascular risk factor|Percentage change in cardiovascular risk scores over time.|Percentage of targeted weight and exercise goals achieved (blood pressure control, smoking cessation, weight control, cholesterol control, sugar control, exercise levels). (Grundy, et al, 1999)|Self efficacy scale (Lorig et al, 1996)|Social support - personal resource questionnaire 85 (Weinert & Brandt 1987).|Depression (MADRS)(Montgomery & Asberg 1979) (Montgomery et al 1985) (Browne, Steiner Roberts et al 2002).|Coping (Moos and Billings 1984)|Expenditures of health and social services (Browne et al 2001)|Calculate the number of Framingham points for each risk factor|Blood samples|Counselling|Education|Motivational Interviewing|Behavior Change",Caroline Medical Group|Health Canada,All,"Child, Adult, Older Adult",Phase 1,670,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double|Primary Purpose: Prevention,PHCTF G03-02656,Aug-04,null,Feb-06,15-Feb-06,null,15-Feb-06,"Caroline Medical Group, Burlington, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00291824
NCT00289900,Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024),,Completed,Has Results,Mixed Hyperlipidemia,Drug: MK-0524A|Drug: Atorvastatin|Drug: Simvastatin,Percentage Change From Baseline in the LDL-C/HDL-C Ratio|Percentage Change From Baseline in HDL-C|Percentage Change From Baseline in Triglycerides (TG)|Percentage Change From Baseline in Non-HDL-C|Percentage Change From Baseline in LDL-C|Percentage Change From Baseline in Apolipoprotein (Apo) B|Percentage Change From Baseline in Apo A-I|Percentage Change From Baseline in Total Cholesterol (TC)|Percentage Change From Baseline in Lipoprotein (a) (Lp[a])|Percentage Change From Baseline in C-reactive Protein (CRP)|Percentage Change From Baseline in TC/HDL-C Ratio|Percentage of Participants With Consecutive Elevations in Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) of >=3 x Upper Limit of Normal (ULN)|Percentage of Participants With Elevations in ALT and/or AST of >=5 x ULN|Percentage of Participants With Elevations in ALT and/or AST of >=10 x ULN|Percentage of Participants With Creatine Kinase (CK) >=10 x ULN|Percentage of Participants With CK >=10 x ULN With Muscle Symptoms|Percentage of Participants With CK >=10 x ULN With Muscle Symptoms - Drug Related|Percentage of Participants With New Diagnosis of Impaired Fasting Blood Glucose|Percentage of Participants With New Diagnosis of Diabetes|Percentage of Participants With a Confirmed Adjudicated Cardiovascular Event|Percentage of Participants Who Experience at Least 1 Clinical Adverse Event (AE)|Percentage of Participants Who Experience at Least 1 Laboratory Adverse Event (AE)|Percentage of Participants Who Were Discontinued From the Study Due to a Clinical AE|Percentage of Participants Who Were Discontinued From the Study Due to a Laboratory AE|Percentage of Participants Who Experience at Least 1 Hepatitis-related Clinical AE,Merck Sharp & Dohme Corp.,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,2340,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0524B-024|MK-0524B-024|2005_103,24-Jan-06,6-Aug-10,6-Aug-10,10-Feb-06,26-Jan-16,31-Aug-18,,,https://ClinicalTrials.gov/show/NCT00289900
NCT00288483,Cholesterol-Lowering Effects of Policosanol,,Terminated,No Results Available,Hypercholesterolemia|Combined Hyperlipidemia,Drug: Policosanol,Decrease in LDL cholesterol|Changes in other lipoproteins,Drug Commission of the German Medical Association|Madaus AG,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,null,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,PC53W0.01,Sep-00,null,Jul-01,8-Feb-06,null,21-Jul-06,,,https://ClinicalTrials.gov/show/NCT00288483
NCT00286234,"Niacin, N-3 Fatty Acids and Insulin Resistance",,Completed,No Results Available,Metabolic Syndrome|Hypertriglyceridemia,Drug: omega-3 acid ethyl esters|Drug: extended release niacin|Drug: placebo|Drug: combined treatment,"Serum TG and HDL-C|Insulin sensitivity, postprandial triglyceridemia, peripheral arterial tonometry",National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"40 Years to 69 Years   (Adult, Older Adult)",Phase 4,10,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DK61486 (completed),Oct-07,Aug-08,Dec-08,3-Feb-06,null,1-May-13,"Sanford Clinic Clinical Research Services, Sioux Falls, South Dakota, United States",,https://ClinicalTrials.gov/show/NCT00286234
NCT00286429,Efficacy and Safety Study of Alogliptin and Insulin in the Treatment of Type 2 Diabetes.,,Completed,Has Results,Diabetes Mellitus,Drug: Alogliptin and insulin|Drug: Insulin,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26.|Change From Baseline in Glycosylated Hemoglobin (Week 4).|Change From Baseline in Glycosylated Hemoglobin (Week 8).|Change From Baseline in Glycosylated Hemoglobin (Week 12).|Change From Baseline in Glycosylated Hemoglobin (Week 16).|Change From Baseline in Glycosylated Hemoglobin (Week 20).|Change From Baseline in Fasting Plasma Glucose (Week 1).|Change From Baseline in Fasting Plasma Glucose (Week 2).|Change From Baseline in Fasting Plasma Glucose (Week 4).|Change From Baseline in Fasting Plasma Glucose (Week 8).|Change From Baseline in Fasting Plasma Glucose (Week 12).|Change From Baseline in Fasting Plasma Glucose (Week 16).|Change From Baseline in Fasting Plasma Glucose (Week 20).|Change From Baseline in Fasting Plasma Glucose (Week 26).|Number of Participants With Marked Hyperglycemia (Fasting Plasma Glucose ≥ 200 mg Per dL).|Number of Participants Requiring Rescue.|Change From Baseline in C-peptide (Week 4).|Change From Baseline in C-peptide (Week 8).|Change From Baseline in C-peptide (Week 12).|Change From Baseline in C-peptide (Week 16).|Change From Baseline in C-peptide (Week 20).|Change From Baseline in C-peptide (Week 26).|Number of Participants With Glycosylated Hemoglobin ≤ 6.5%.|Number of Participants With Glycosylated Hemoglobin ≤ 7.0%.|Number of Participants With Glycosylated Hemoglobin ≤ 7.5%.|Number of Participants With Glycosylated Hemoglobin Decrease From Baseline ≥ 0.5%.|Number of Participants With Glycosylated Hemoglobin Decrease From Baseline ≥ 1.0%.|Number of Participants With Glycosylated Hemoglobin Decrease From Baseline ≥ 1.5%.|Number of Participants With Glycosylated Hemoglobin Decrease From Baseline ≥ 2.0%.|Change From Baseline in Body Weight (Week 8).|Change From Baseline in Body Weight (Week 12).|Change From Baseline in Body Weight (Week 20).|Change From Baseline in Body Weight (Week 26).,Takeda,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,390,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SYR-322-INS-011|2005-004671-38|U1111-1113-8369,Feb-06,May-07,May-07,3-Feb-06,12-Aug-11,3-Feb-12,"Phoenix, Arizona, United States|Anaheim, California, United States|Artesia, California, United States|Fresno, California, United States|Mission Viejo, California, United States|Northridge, California, United States|Orange, California, United States|San Diego, California, United States|Tustin, California, United States|Walnut Creek, California, United States|Denver, Colorado, United States|Cocoa Beach, Florida, United States|Longwood, Florida, United States|New Port Richey, Florida, United States|Ocala, Florida, United States|St. Cloud, Florida, United States|Tampa, Florida, United States|Lawrenceville, Georgia, United States|Honolulu, Hawaii, United States|Avon, Indiana, United States|Evansville, Indiana, United States|Lafayette, Indiana, United States|St. Louis, Missouri, United States|Omaha, Nebraska, United States|Berlin, New Jersey, United States|Burlington, North Carolina, United States|Charlotte, North Carolina, United States|Hickory, North Carolina, United States|Morehead City, North Carolina, United States|Pinehurst, North Carolina, United States|Winston Salem, North Carolina, United States|Cincinnati, Ohio, United States|Tulsa, Oklahoma, United States|Medford, Oregon, United States|Lansdale, Pennsylvania, United States|Charleston, South Carolina, United States|Columbia, South Carolina, United States|Simpsonville, South Carolina, United States|Cookeville, Tennessee, United States|Corpus Christi, Texas, United States|Dallas, Texas, United States|San Antonio, Texas, United States|Temple, Texas, United States|Texarkana, Texas, United States|Burlington, Vermont, United States|Multiple Cities, Argentina|Multiple Cities, Australia|Multiple Cities, Brazil|Multiple Cities, Chile|Multiple Cities, Czech Republic|Multiple Cities, Germany|Multiple Cities, Guatemala|Multiple Cities, Hungary|Multiple Cities, India|Multiple Cities, Mexico|Multiple Cities, Netherlands|Multiple Cities, New Zealand|Multiple Cities, Peru|Multiple Cities, Poland|Multiple Cities, South Africa",,https://ClinicalTrials.gov/show/NCT00286429
NCT00286442,Efficacy and Safety of Alogliptin Combined With Metformin in Participants With Type 2 Diabetes Mellitus,,Completed,Has Results,Diabetes Mellitus,Drug: Alogliptin and metformin|Drug: Metformin,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26.|Change From Baseline in Glycosylated Hemoglobin (Week 4).|Change From Baseline in Glycosylated Hemoglobin (Week 8).|Change From Baseline in Glycosylated Hemoglobin (Week 12).|Change From Baseline in Glycosylated Hemoglobin (Week 16).|Change From Baseline in Glycosylated Hemoglobin (Week 20).|Change From Baseline in Fasting Plasma Glucose (Week 1).|Change From Baseline in Fasting Plasma Glucose (Week 2).|Change From Baseline in Fasting Plasma Glucose (Week 4).|Change From Baseline in Fasting Plasma Glucose (Week 8).|Change From Baseline in Fasting Plasma Glucose (Week 12).|Change From Baseline in Fasting Plasma Glucose (Week 16).|Change From Baseline in Fasting Plasma Glucose (Week 20).|Change From Baseline in Fasting Plasma Glucose (Week 26).|Number of Participants With Marked Hyperglycemia (Fasting Plasma Glucose ≥ 200 mg Per dL).|Number of Participants Requiring Rescue.|Change From Baseline in Fasting Proinsulin (Week 4).|Change From Baseline in Fasting Proinsulin (Week 8).|Change From Baseline in Fasting Proinsulin (Week 12).|Change From Baseline in Fasting Proinsulin (Week 16).|Change From Baseline in Fasting Proinsulin (Week 20).|Change From Baseline in Fasting Proinsulin (Week 26).|Change From Baseline in Insulin (Week 4).|Change From Baseline in Insulin (Week 8).|Change From Baseline in Insulin (Week 12).|Change From Baseline in Insulin (Week 16).|Change From Baseline in Insulin (Week 20).|Change From Baseline in Insulin (Week 26).|Change From Baseline in Proinsulin/Insulin Ratio (Week 4).|Change From Baseline in Proinsulin/Insulin Ratio (Week 8).|Change From Baseline in Proinsulin/Insulin Ratio (Week 12).|Change From Baseline in Proinsulin/Insulin Ratio (Week 16).|Change From Baseline in Proinsulin/Insulin Ratio (Week 20).|Change From Baseline in Proinsulin/Insulin Ratio (Week 26).|Change From Baseline in C-peptide (Week 4).|Change From Baseline in C-peptide (Week 8).|Change From Baseline in C-peptide (Week 12).|Change From Baseline in C-peptide (Week 16).|Change From Baseline in C-peptide (Week 20).|Change From Baseline in C-peptide (Week 26).|Number of Participants With Glycosylated Hemoglobin ≤ 6.5%.|Number of Participants With Glycosylated Hemoglobin ≤ 7.0%.|Number of Participants With Glycosylated Hemoglobin ≤ 7.5%.|Number of Participants With Glycosylated Hemoglobin Decrease From Baseline ≥ 0.5%.|Number of Participants With Glycosylated Hemoglobin Decrease From Baseline ≥ 1.0%.|Number of Participants With Glycosylated Hemoglobin Decrease From Baseline ≥ 1.5%.|Number of Participants With Glycosylated Hemoglobin Decrease From Baseline ≥ 2.0%.|Change From Baseline in Body Weight (Week 8).|Change From Baseline in Body Weight (Week 12).|Change From Baseline in Body Weight (Week 20).|Change From Baseline in Body Weight (Week 26).,Takeda,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,527,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SYR-322-MET-008|2005-004668-22|U1111-1113-8393,Mar-06,Jun-07,Jun-07,3-Feb-06,25-Aug-11,3-Feb-12,"Phoenix, Arizona, United States|Anaheim, California, United States|Artesia, California, United States|Fresno, California, United States|Los Angeles, California, United States|Mission Viejo, California, United States|Northridge, California, United States|Orange, California, United States|San Diego, California, United States|Walnut Creek, California, United States|Denver, Colorado, United States|Washington, District of Columbia, United States|Cocoa Beach, Florida, United States|Longwood, Florida, United States|Ocala, Florida, United States|Ocoee, Florida, United States|St. Cloud, Florida, United States|Honolulu, Hawaii, United States|Avon, Indiana, United States|Elkhart, Indiana, United States|Evansville, Indiana, United States|St. Louis, Missouri, United States|Omaha, Nebraska, United States|Berlin, New Jersey, United States|Burlington, North Carolina, United States|Hickory, North Carolina, United States|Morehead City, North Carolina, United States|Pinehurst, North Carolina, United States|Winston Salem, North Carolina, United States|Cincinnati, Ohio, United States|Medford, Oregon, United States|Lansdale, Pennsylvania, United States|Charleston, South Carolina, United States|Columbia, South Carolina, United States|Simpsonville, South Carolina, United States|Corpus Christi, Texas, United States|Dallas, Texas, United States|San Antonio, Texas, United States|Texarkana, Texas, United States|Burlington, Vermont, United States|Multiple Cities, Argentina|Multiple Cities, Australia|Multiple Cities, Brazil|Multiple Cities, Chile|Multiple Cities, Czech Republic|Multiple Cities, Germany|Multiple Cities, Guatemala|Multiple Cities, Hungary|Multiple Cities, India|Multiple Cities, Mexico|Multiple Cities, Netherlands|Multiple Cities, New Zealand|Multiple Cities, Peru|Multiple Cities, Poland|Multiple Cities, South Africa|Multiple Cities, United Kingdom",,https://ClinicalTrials.gov/show/NCT00286442
NCT00286455,Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes,,Completed,Has Results,Diabetes Mellitus,Drug: Alogliptin|Drug: Placebo,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26.|Change From Baseline in Glycosylated Hemoglobin (Week 4).|Change From Baseline in Glycosylated Hemoglobin (Week 8).|Change From Baseline in Glycosylated Hemoglobin (Week 12).|Change From Baseline in Glycosylated Hemoglobin (Week 16).|Change From Baseline in Glycosylated Hemoglobin (Week 20).|Change From Baseline in Fasting Plasma Glucose (Week 1).|Change From Baseline in Fasting Plasma Glucose (Week 2).|Change From Baseline in Fasting Plasma Glucose (Week 4).|Change From Baseline in Fasting Plasma Glucose (Week 8).|Change From Baseline in Fasting Plasma Glucose (Week 12).|Change From Baseline in Fasting Plasma Glucose (Week 16).|Change From Baseline in Fasting Plasma Glucose (Week 20).|Change From Baseline in Fasting Plasma Glucose (Week 26).|Number of Participants With Marked Hyperglycemia (Fasting Plasma Glucose ≥ 200 mg Per dL).|Number of Participants Requiring Rescue.|Change From Baseline in Fasting Proinsulin (Week 4).|Change From Baseline in Fasting Proinsulin (Week 8).|Change From Baseline in Fasting Proinsulin (Week 12).|Change From Baseline in Fasting Proinsulin (Week 16).|Change From Baseline in Fasting Proinsulin (Week 20).|Change From Baseline in Fasting Proinsulin (Week 26).|Change From Baseline in Insulin (Week 4).|Change From Baseline in Insulin (Week 8).|Change From Baseline in Insulin (Week 12).|Change From Baseline in Insulin (Week 16).|Change From Baseline in Insulin (Week 20).|Change From Baseline in Insulin (Week 26).|Change From Baseline in Proinsulin/Insulin Ratio (Week 4).|Change From Baseline in Proinsulin/Insulin Ratio (Week 8).|Change From Baseline in Proinsulin/Insulin Ratio (Week 12).|Change From Baseline in Proinsulin/Insulin Ratio (Week 16).|Change From Baseline in Proinsulin/Insulin Ratio (Week 20).|Change From Baseline in Proinsulin/Insulin Ratio (Week 26).|Change From Baseline in C-peptide (Week 4).|Change From Baseline in C-peptide (Week 8).|Change From Baseline in C-peptide (Week 12).|Change From Baseline in C-peptide (Week 16).|Change From Baseline in C-peptide (Week 20).|Change From Baseline in C-peptide (Week 26).|Number of Participants With Glycosylated Hemoglobin ≤ 6.5%.|Number of Participants With Glycosylated Hemoglobin ≤ 7.0%.|Number of Participants With Glycosylated Hemoglobin ≤ 7.5%.|Number of Participants With Glycosylated Hemoglobin Decrease From Baseline ≥ 0.5%.|Number of Participants With Glycosylated Hemoglobin Decrease From Baseline ≥ 1.0%.|Number of Participants With Glycosylated Hemoglobin Decrease From Baseline ≥ 1.5%.|Number of Participants With Glycosylated Hemoglobin Decrease From Baseline ≥ 2.0%.|Change From Baseline in Body Weight (Week 8).|Change From Baseline in Body Weight (Week 12).|Change From Baseline in Body Weight (Week 20).|Change From Baseline in Body Weight (Week 26).|Change From Baseline in Glucagon (Week 4).|Change From Baseline in Glucagon (Week 8).|Change From Baseline in Glucagon (Week 12).|Change From Baseline in Glucagon (Week 16).|Change From Baseline in Glucagon (Week 20).|Change From Baseline in Glucagon (Week 26).,Takeda,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,329,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SYR-322-PLC-010|2005-004670-24|U1111-1113-8462,Feb-06,Jul-07,Jul-07,3-Feb-06,29-Aug-11,3-Feb-12,"Birmingham, Alabama, United States|Peoria, Arizona, United States|Phoenix, Arizona, United States|Anaheim, California, United States|Artesia, California, United States|Fresno, California, United States|Lafayette, California, United States|Northridge, California, United States|Orange, California, United States|San Diego, California, United States|Walnut Creek, California, United States|Colorado Springs, Colorado, United States|Denver, Colorado, United States|Washington, District of Columbia, United States|Cocoa Beach, Florida, United States|Kissimmee, Florida, United States|Longwood, Florida, United States|Ocala, Florida, United States|Ocoee, Florida, United States|St. Cloud, Florida, United States|Honolulu, Hawaii, United States|Idaho Falls, Idaho, United States|Avon, Indiana, United States|Elkhart, Indiana, United States|Evansville, Indiana, United States|Baltimore, Maryland, United States|Sudbury, Massachusetts, United States|St. Louis, Missouri, United States|Omaha, Nebraska, United States|Berlin, New Jersey, United States|Burlington, North Carolina, United States|Morehead City, North Carolina, United States|Pinehurst, North Carolina, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Tulsa, Oklahoma, United States|Lansdale, Pennsylvania, United States|West Grove, Pennsylvania, United States|Charleston, South Carolina, United States|Columbia, South Carolina, United States|Simpsonville, South Carolina, United States|Bristol, Tennessee, United States|Cookeville, Tennessee, United States|Milan, Tennessee, United States|Corpus Christi, Texas, United States|Dallas, Texas, United States|San Antonio, Texas, United States|Temple, Texas, United States|Texarkana, Texas, United States|Burlington, Vermont, United States|Multiple Cities, Argentina|Multiple Cities, Australia|Multiple Cities, Brazil|Multiple Cities, Chile|Multiple Cities, Czech Republic|Multiple Cities, Dominican Republic|Multiple Cities, Germany|Multiple Cities, Guatemala|Multiple Cities, Hungary|Multiple Cities, India|Multiple Cities, Mexico|Multiple Cities, Netherlands|Multiple Cities, New Zealand|Multiple Cities, Peru|Multiple Cities, Poland|Multiple Cities, South Africa|Multiple Cities, United Kingdom",,https://ClinicalTrials.gov/show/NCT00286455
NCT00286468,Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus.,,Completed,Has Results,Diabetes Mellitus,Drug: Alogliptin and glyburide|Drug: Glyburide,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26.|Change From Baseline in Glycosylated Hemoglobin (Week 4).|Change From Baseline in Glycosylated Hemoglobin (Week 8).|Change From Baseline in Glycosylated Hemoglobin (Week 12).|Change From Baseline in Glycosylated Hemoglobin (Week 16).|Change From Baseline in Glycosylated Hemoglobin (Week 20).|Change From Baseline in Fasting Plasma Glucose (Week 1).|Change From Baseline in Fasting Plasma Glucose (Week 2).|Change From Baseline in Fasting Plasma Glucose (Week 4).|Change From Baseline in Fasting Plasma Glucose (Week 8).|Change From Baseline in Fasting Plasma Glucose (Week 12).|Change From Baseline in Fasting Plasma Glucose (Week 16).|Change From Baseline in Fasting Plasma Glucose (Week 20).|Change From Baseline in Fasting Plasma Glucose (Week 26).|Number of Participants With Marked Hyperglycemia (Fasting Plasma Glucose ≥ 200 mg Per dL).|Number of Participants Requiring Rescue.|Change From Baseline in Fasting Proinsulin (Week 4).|Change From Baseline in Fasting Proinsulin (Week 8).|Change From Baseline in Fasting Proinsulin (Week 12).|Change From Baseline in Fasting Proinsulin (Week 16).|Change From Baseline in Fasting Proinsulin (Week 20).|Change From Baseline in Fasting Proinsulin (Week 26).|Change From Baseline in Insulin (Week 4).|Change From Baseline in Insulin (Week 8).|Change From Baseline in Insulin (Week 12).|Change From Baseline in Insulin (Week 16).|Change From Baseline in Insulin (Week 20).|Change From Baseline in Insulin (Week 26).|Change From Baseline in Proinsulin/Insulin Ratio (Week 4).|Change From Baseline in Proinsulin/Insulin Ratio (Week 8).|Change From Baseline in Proinsulin/Insulin Ratio (Week 12).|Change From Baseline in Proinsulin/Insulin Ratio (Week 16).|Change From Baseline in Proinsulin/Insulin Ratio (Week 20).|Change From Baseline in Proinsulin/Insulin Ratio (Week 26).|Change From Baseline in C-peptide (Week 4).|Change From Baseline in C-peptide (Week 8).|Change From Baseline in C-peptide (Week 12).|Change From Baseline in C-peptide (Week 16).|Change From Baseline in C-peptide (Week 20).|Change From Baseline in C-peptide (Week 26).|Number of Participants With Glycosylated Hemoglobin ≤ 6.5%.|Number of Participants With Glycosylated Hemoglobin ≤ 7.0%.|Number of Participants With Glycosylated Hemoglobin ≤ 7.5%.|Number of Participants With Glycosylated Hemoglobin Decrease From Baseline ≥ 0.5%.|Number of Participants With Glycosylated Hemoglobin Decrease From Baseline ≥ 1.0%.|Number of Participants With Glycosylated Hemoglobin Decrease From Baseline ≥ 1.5%.|Number of Participants With Glycosylated Hemoglobin Decrease From Baseline ≥ 2.0%.|Change From Baseline in Body Weight (Week 8).|Change From Baseline in Body Weight (Week 12).|Change From Baseline in Body Weight (Week 20).|Change From Baseline in Body Weight (Week 26).,Takeda,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,500,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SYR-322-SULF-007|2005-004667-36|U1111-1113-8506,Apr-06,Jun-07,Jun-07,3-Feb-06,25-Aug-11,3-Feb-12,"Birmingham, Alabama, United States|Peoria, Arizona, United States|Phoenix, Arizona, United States|Anaheim, California, United States|Artesia, California, United States|Fresno, California, United States|Los Angeles, California, United States|Mission Viejo, California, United States|Northridge, California, United States|Orange, California, United States|San Diego, California, United States|Tustin, California, United States|Walnut Creek, California, United States|Denver, Colorado, United States|Washington, District of Columbia, United States|Cocoa Beach, Florida, United States|Kissimmee, Florida, United States|Longwood, Florida, United States|New Port Richey, Florida, United States|Ocala, Florida, United States|Ocoee, Florida, United States|St. Cloud, Florida, United States|Tampa, Florida, United States|Lawrenceville, Georgia, United States|Honolulu, Hawaii, United States|Idaho Falls, Idaho, United States|Avon, Indiana, United States|Evansville, Indiana, United States|Lafayette, Indiana, United States|Erlanger, Kentucky, United States|Baltimore, Maryland, United States|St. Louis, Missouri, United States|Omaha, Nebraska, United States|Berlin, New Jersey, United States|Burlington, North Carolina, United States|Morehead City, North Carolina, United States|Pinehurst, North Carolina, United States|Winston Salem, North Carolina, United States|Cincinnati, Ohio, United States|Dayton, Ohio, United States|Tulsa, Oklahoma, United States|Lansdale, Pennsylvania, United States|West Grove, Pennsylvania, United States|Charleston, South Carolina, United States|Columbia, South Carolina, United States|Simpsonville, South Carolina, United States|Cookville, Tennessee, United States|Milan, Tennessee, United States|Corpus Christi, Texas, United States|Dallas, Texas, United States|San Antonio, Texas, United States|Temple, Texas, United States|Texarkana, Texas, United States|Burlington, Vermont, United States|Multiple Cities, Argentina|Multiple Cities, Australia|Multiple Cities, Brazil|Multiple Cities, Chile|Multiple Cities, Dominican Republic|Multiple Cities, Guatemala|Multiple Cities, India|Multiple Cities, Mexico|Multiple Cities, Netherlands|Multiple Cities, New Zealand|Multiple Cities, Peru|Multiple Cities, Poland|Multiple Cities, South Africa|Multiple Cities, United Kingdom",,https://ClinicalTrials.gov/show/NCT00286468
NCT00286481,Efficacy of Lapaquistat Acetate Alone or Combined With Simvastatin in Subjects With Hypercholesterolemia,,Completed,No Results Available,Hypercholesterolemia,Drug: Lapaquistat acetate and simvastatin|Drug: Simvastatin,Change from Baseline in Low Density Lipoprotein cholesterol|Adverse Events|Physical Examination|Safety Laboratory Tests|12- lead Electrocardiogram assessments|Best Corrected Visual Acuity results|Vital Signs|Change from Baseline in Triglycerides|Change from Baseline in Total Cholesterol|Change from Baseline in High Density Lipoprotein cholesterol|Change from Baseline in Very Low Density Lipoprotein cholesterol|Change from Baseline in apolipoprotein A1|Change from Baseline in apolipoprotein B|Change from Baseline in non- High Density Lipoprotein cholesterol|Change from Baseline in the ratio of Low Density Lipoprotein cholesterol/High Density|Change from Baseline in the ratio of Total Cholesterol/High Density Lipoprotein cholesterol|Change from Baseline in the ratio of apolipoprotein A1/apolipoprotein B|Change from Baseline in high-sensitivity C-reactive protein|Percentage of subjects who achieve Low Density Lipoprotein cholesterol concentrations less than 2.59 mmol/L (100 mg/dL)|Percentage of subjects who achieve Low Density Lipoprotein cholesterol concentrations less than 3.37 mmol/L (130 mg/dL)|Percentage of subjects who achieve Low Density Lipoprotein cholesterol concentrations less than 4.14 mmol/L (160 mg/dL),Takeda,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1362,Industry,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",01-05-TL-475-020|U1111-1122-7978,Mar-06,May-07,May-07,3-Feb-06,null,24-May-12,"Huntsville, Alabama, United States|Chandler, Arizona, United States|Scottsdale, Arizona, United States|Sierra Vista, Arizona, United States|Tucson, Arizona, United States|Beverly Hills, California, United States|Long Beach, California, United States|Sacramento, California, United States|Spring Valley, California, United States|Colorado Springs, Colorado, United States|Hialeah, Florida, United States|Hollywood, Florida, United States|Jacksonville, Florida, United States|Jupiter, Florida, United States|Kissimmee, Florida, United States|Miami, Florida, United States|Ocala, Florida, United States|Pembroke Pines, Florida, United States|Pinellas Park, Florida, United States|Stuart, Florida, United States|West Palm Beach, Florida, United States|Arlington Heights, Illinois, United States|Chicago, Illinois, United States|Peoria, Illinois, United States|Indianapolis, Indiana, United States|Overland Park, Kansas, United States|Wichita, Kansas, United States|Louisville, Kentucky, United States|Edina, Minnesota, United States|St. Louis, Missouri, United States|Las Vegas, Nevada, United States|Margate City, New Jersey, United States|Raleigh, North Carolina, United States|Statesville, North Carolina, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Kettering, Ohio, United States|Bartlesville, Oklahoma, United States|Portland, Oregon, United States|Beaver, Pennsylvania, United States|Downingtown, Pennsylvania, United States|Tipton, Pennsylvania, United States|Goose Creek, South Carolina, United States|Jackson, Tennessee, United States|Nashville, Tennessee, United States|San Antonio, Texas, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Lakewood, Washington, United States|Abbotsford, British Columbia, Canada|Coquitlam, British Columbia, Canada|Victoria, British Columbia, Canada|Winnipeg, Manitoba, Canada|Mount Pearl, Newfoundland and Labrador, Canada|St. John's, Newfoundland and Labrador, Canada|Cornwall, Ontario, Canada|London, Ontario, Canada|Oakville, Ontario, Canada|Oshawa, Ontario, Canada|Thornhill, Ontario, Canada|Toronto, Ontario, Canada|Cornwall, Prince Edward Island, Canada|Mirabel, Quebec, Canada|Sherbrooke, Quebec, Canada|St. Lambert, Quebec, Canada|Ste-Foy, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00286481
NCT00286494,Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus,,Completed,Has Results,Diabetes Mellitus,Drug: Alogliptin and pioglitazone|Drug: Pioglitazone,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26.|Change From Baseline in Glycosylated Hemoglobin (Week 4).|Change From Baseline in Glycosylated Hemoglobin (Week 8).|Change From Baseline in Glycosylated Hemoglobin (Week 12).|Change From Baseline in Glycosylated Hemoglobin (Week 16).|Change From Baseline in Glycosylated Hemoglobin (Week 20).|Change From Baseline in Fasting Plasma Glucose (Week 1).|Change From Baseline in Fasting Plasma Glucose (Week 2).|Change From Baseline in Fasting Plasma Glucose (Week 4).|Change From Baseline in Fasting Plasma Glucose (Week 8).|Change From Baseline in Fasting Plasma Glucose (Week 12).|Change From Baseline in Fasting Plasma Glucose (Week 16).|Change From Baseline in Fasting Plasma Glucose (Week 20).|Change From Baseline in Fasting Plasma Glucose (Week 26).|Number of Participants With Marked Hyperglycemia (Fasting Plasma Glucose ≥ 200 mg Per dL).|Number of Participants Requiring Rescue.|Change From Baseline in Fasting Proinsulin (Week 4).|Change From Baseline in Fasting Proinsulin (Week 8).|Change From Baseline in Fasting Proinsulin (Week 12).|Change From Baseline in Fasting Proinsulin (Week 16).|Change From Baseline in Fasting Proinsulin (Week 20).|Change From Baseline in Fasting Proinsulin (Week 26).|Change From Baseline in Insulin (Week 4).|Change From Baseline in Insulin (Week 8).|Change From Baseline in Insulin (Week 12).|Change From Baseline in Insulin (Week 16).|Change From Baseline in Insulin (Week 20).|Change From Baseline in Insulin (Week 26).|Change From Baseline in Proinsulin/Insulin Ratio (Week 4).|Change From Baseline in Proinsulin/Insulin Ratio (Week 8).|Change From Baseline in Proinsulin/Insulin Ratio (Week 12).|Change From Baseline in Proinsulin/Insulin Ratio (Week 16).|Change From Baseline in Proinsulin/Insulin Ratio (Week 20).|Change From Baseline in Proinsulin/Insulin Ratio (Week 26).|Change From Baseline in C-peptide (Week 4).|Change From Baseline in C-peptide (Week 8).|Change From Baseline in C-peptide (Week 12).|Change From Baseline in C-peptide (Week 16).|Change From Baseline in C-peptide (Week 20).|Change From Baseline in C-peptide (Week 26).|Number of Participants With Glycosylated Hemoglobin ≤ 6.5%.|Number of Participants With Glycosylated Hemoglobin ≤ 7.0%.|Number of Participants With Glycosylated Hemoglobin ≤ 7.5%.|Number of Participants With Glycosylated Hemoglobin Decrease From Baseline ≥ 0.5%.|Number of Participants With Glycosylated Hemoglobin Decrease From Baseline ≥ 1.0%.|Number of Participants With Glycosylated Hemoglobin Decrease From Baseline ≥ 1.5%.|Number of Participants With Glycosylated Hemoglobin Decrease From Baseline ≥ 2.0%.|Change From Baseline in Body Weight (Week 8).|Change From Baseline in Body Weight (Week 12).|Change From Baseline in Body Weight (Week 20).|Change From Baseline in Body Weight (Week 26).,Takeda,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,493,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SYR-322-TZD-009|2005-004669-40|U1111-1113-8552,Feb-06,Aug-07,Aug-07,3-Feb-06,27-Sep-11,3-Feb-12,"Birmingham, Alabama, United States|Phoenix, Arizona, United States|Anaheim, California, United States|Artesia, California, United States|Fresno, California, United States|Mission Viejo, California, United States|Northridge, California, United States|Orange, California, United States|San Diego, California, United States|Walnut Creek, California, United States|Colorado Springs, Colorado, United States|Denver, Colorado, United States|Norwalk, Connecticut, United States|Washington, District of Columbia, United States|Clearwater, Florida, United States|Cocoa Beach, Florida, United States|Hollywood, Florida, United States|Kissimmee, Florida, United States|Longwood, Florida, United States|New Port Richey, Florida, United States|Ocala, Florida, United States|Ocoee, Florida, United States|St. Cloud, Florida, United States|Tampa, Florida, United States|Lawrenceville, Georgia, United States|Honolulu, Hawaii, United States|Idaho Falls, Idaho, United States|Chicago, Illinois, United States|Avon, Indiana, United States|Elkhart, Indiana, United States|Evansville, Indiana, United States|Lafayette, Indiana, United States|Erlanger, Kentucky, United States|Baltimore, Maryland, United States|Sudbury, Massachusetts, United States|Chesterfield, Missouri, United States|St. Louis, Missouri, United States|Omaha, Nebraska, United States|Berlin, New Jersey, United States|Burlington, North Carolina, United States|Charlotte, North Carolina, United States|Hickory, North Carolina, United States|Morehead City, North Carolina, United States|Pinehurst, North Carolina, United States|Wilmington, North Carolina, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Dayton, Ohio, United States|Tulsa, Oklahoma, United States|Medford, Oregon, United States|Lansdale, Pennsylvania, United States|West Grove, Pennsylvania, United States|Charleston, South Carolina, United States|Columbia, South Carolina, United States|Simpsonville, South Carolina, United States|Bristol, Tennessee, United States|Cookeville, Tennessee, United States|Milan, Tennessee, United States|Corpus Christi, Texas, United States|Dallas, Texas, United States|San Antonio, Texas, United States|Temple, Texas, United States|Texarkana, Texas, United States|Burlington, Vermont, United States|Multiple Cities, Argentina|Multiple Cities, Australia|Multiple Cities, Brazil|Multiple Cities, Czech Republic|Multiple Cities, Germany|Multiple Cities, Guatemala|Multiple Cities, Hungary|Multiple Cities, India|Multiple Cities, Mexico|Multiple Cities, Netherlands|Multiple Cities, New Zealand|Multiple Cities, Peru|Multiple Cities, South Africa",,https://ClinicalTrials.gov/show/NCT00286494
NCT00282659,"The Use of Magnesium to Improve Blood Pressure, Cholesterol, and Glucose Control",,Unknown status,No Results Available,Coronary Artery Disease|Hypertension|Dyslipidemia|Diabetes,Drug: magnesium L-lactate,"Blood pressure, cardiac output, systemic vascular resistance, thoracic fluid content, total cholesterol, low density lipoprotein, high density lipoprotein, triglycerides, and blood glucose",Hartford Hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 4,240,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,WHIT001799HI,Jan-06,null,Jun-08,27-Jan-06,null,5-Nov-07,"Hartford Hospital, Hartford, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00282659
NCT00280995,Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy,,Completed,No Results Available,"Hypercholesterolemia, Familial",Drug: ISIS 301012,Percent reduction in LDL-cholesterol from baseline,"Kastle Therapeutics, LLC|Ionis Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,12,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,301012CS8|EudraCT No.: 2005-004796-38,Jan-06,Apr-07,Aug-07,24-Jan-06,null,3-Aug-16,"Chicago, Illinois, United States|New York City, New York, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Houston, Texas, United States|Amsterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT00280995
NCT00281008,Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy,,Completed,No Results Available,"Hypercholesterolemia, Familial",Drug: ISIS 301012 or Placebo,Percent reduction in LDL-cholesterol from baseline,"Kastle Therapeutics, LLC|Ionis Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,44,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",301012CS9|2005-004797-24,Feb-06,Jul-07,Dec-07,24-Jan-06,null,3-Aug-16,"Chicago, Illinois, United States|Auburn, Maine, United States|Scarborough, Maine, United States|New York City, New York, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Houston, Texas, United States|Amsterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT00281008
NCT00278928,Fat Tolerance From Lipid Emulsion Infusion Packaged in Glass or Plastic,,Terminated,No Results Available,Hypertriglyceridemia,Drug: Liposyn III 20% (lipid infusion)|Drug: Intralipid 20% (lipid infusion),Serum triglyceride level|Total lipid infusion dose at 7 days of life (gms/kg/day),Beth Israel Deaconess Medical Center,All,up to 10 Days   (Child),Not Applicable,82,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single|Primary Purpose: Prevention,2005P000275,Jan-06,null,Apr-07,19-Jan-06,null,14-Mar-17,"Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00278928
NCT00276458,To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 20 mg (0653-079)(COMPLETED),,Completed,Has Results,Hypercholesterolemia,Drug: Comparator: atorvastatin|Drug: Comparator: Placebo|Drug: Comparator: ezetimibe|Drug: Comparator: Placebo.,Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Week 6|Percent Change in High Density Lipoprotein -Cholesterol (HDL-C)at Week 6|Percent Change in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 6|Percent Change From Baseline in Total-Cholesterol at Week 6|Percent Change From Baseline in Triglycerides (TG) at Week 6|Percent Change From Baseline in Apolipoprotein B at Week 6|Percent Change From Baseline in Total-Cholesterol:High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6|Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6|Percent Change From Baseline in Apolipoprotein B: Apolipoprotein A-I Ratio at Week 6|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (HDL-C):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6|Percent Change From Baseline in C-Reactive Protein (CRP) at Week 6|Number of Participants Who Attained Target LDL-C <100 mg/dL at Week 6,Merck Sharp & Dohme Corp.,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 3,196,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0653-079|2005_104,Feb-06,Jan-08,Jan-08,13-Jan-06,8-Jul-09,4-Apr-17,,,https://ClinicalTrials.gov/show/NCT00276458
NCT00276484,To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 40 mg (0653-090),,Completed,Has Results,Hypercholesterolemia,Drug: atorvastatin|Drug: ezetimibe,Percent Change From Baseline to Week 6 in Low-Density Lipoprotein (LDL)-C|Percent Change From Baseline to Week 6 in High-Density Lipoprotein Cholesterol (HDL-C)|Percent Change From Baseline to Week 6 in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C)|Percent Change From Baseline to Week 6 in Total-Cholesterol|Percent Change From Baseline to Week 6 in Triglycerides (TG)|Percent Change From Baseline to Week 6 in Apolipoprotein B (Apo B)|Percent Change From Baseline to Week 6 in Apolipoprotein A-I (Apo A-I)|Percent Change From Baseline to Week 6 in Total-Cholesterol (TC):High-Density Lipoprotein Cholesterol (HDL-C) Ratio|Percent Change From Baseline to Week 6 in Low-Density Lipoprotein-Cholesterol:High-Density Lipoprotein-Cholesterol (LDL-C:HDL-C) Ratio|Percent Change From Baseline to Week 6 in Apolipoprotein B:Apolipoprotein A-I (Apo B:Apo A-I) Ratio|Percent Change From Baseline to Week 6 in Non-High-Density Lipoprotein-Cholesterol:High-Density Lipoprotein-Cholesterol (Non-HDL-C:HDL-C) Ratio|Percent Change From Baseline to Week 6 in C Reactive Protein (CRP)|Number of Patients Who Attained Target Low-Density Lipoprotein Cholesterol (LDL-C) <70 mg/dL at Week 6,Merck Sharp & Dohme Corp.,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 3,579,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0653-090|2005_105,Feb-06,Feb-08,Mar-08,13-Jan-06,13-Apr-09,5-Apr-17,,,https://ClinicalTrials.gov/show/NCT00276484
NCT00275145,Effects of Resistance and Aerobic Exercise on Cardiovascular Health,STRRIDE2,Completed,No Results Available,Cardiovascular Diseases|Heart Diseases|Obesity|Hyperlipidemia|Insulin Resistance|Metabolic Syndrome X,Behavioral: Resistance Training|Behavioral: Aerobic Exercise|Behavioral: Combo|Behavioral: Continued Sedentary lifestyle,"Major Cardiometabolic Risk Factors: lipoproteins; Ectopic Fat (Visceral Fat, Liver fat); body composition (fat mass, lean body mass; and Insulin Sensitivity|Metabolic Syndrome (ATP III defined); Maximal Oxygen consumption; muscle biopsy measures (oxidative enzymes, capillary density, myofiber diameter)","Duke University|National Heart, Lung, and Blood Institute (NHLBI)",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,261,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,Pro00014514|R01HL057354|0438,May-04,Dec-08,Dec-08,11-Jan-06,null,24-May-13,"Duke University, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00275145
NCT00272402,Reducing Clinical Inertia in Diabetes Care,,Completed,No Results Available,Diabetes Mellitus|Hypertension|Hyperlipidemia,Behavioral: Cognitive Behavioral Intervention|Behavioral: Office System Redesign Intervention,Clinical inertia|Direct Medical Costs,HealthPartners Institute|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,61,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,0308300|R01DK068314,Feb-06,Jun-08,Dec-09,6-Jan-06,null,5-Sep-12,"HealthPartners Research Foundation, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00272402
NCT00271817,To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED),,Completed,Has Results,Hypercholesterolemia,Drug: Comparator: ezetimibe/simvastatin + niacin (ER)|Drug: Comparator: Placebo to ezetimibe/simvastatin|Drug: Comparator: niacin (ER) tablet|Drug: Comparator: ezetimibe (+) simvastatin|Drug: Comparator: Placebo to Niacin (ER)|Drug: Comparator: ezetimibe/simvastatin and niacin (ER)|Drug: Comparator: ezetimibe and simvastatin|Drug: Comparator: Placebo to niacin (ER),Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)|Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)|Percent Change From Baseline in High-Density Lipoprotein-Cholesterol (HDL-C)|Percent Change From Baseline in Triglycerides (TG),Merck Sharp & Dohme Corp.,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 3,1220,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0653A-091|2005_091,Dec-05,Feb-08,Feb-08,4-Jan-06,3-Aug-09,11-Apr-17,,,https://ClinicalTrials.gov/show/NCT00271817
NCT00270439,Omentectomy for the Treatment of Diabetes Mellitus Type 2,,Completed,No Results Available,Diabetes Mellitus Type 2|Dyslipidemia|Hypercholesterolemia|Obesity,Procedure: removal of omentum,Insulin sensitivity as measured by the minimal model and HOMA score|Improvement in dyslipidemia|Decreased use of oral hypoglycemics,Vanderbilt University|United States Surgical Corporation,All,18 Years to 55 Years   (Adult),Phase 1,10,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,50967,Jan-06,Jan-07,Mar-07,26-Dec-05,null,14-Sep-09,"Vanderbilt University, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT00270439
NCT00269204,Lipid Efficacy/Tolerability Study (0524A-020),,Completed,No Results Available,Primary Hypercholesterolaemia|Mixed Hyperlipidaemia,Drug: niacin (+) laropiprant|Drug: ER-niacin,Reductions of LDL-C concentrations at 24 weeks and better tolerability|Elevations in HDL-C concentrations at 24 weeks,Merck Sharp & Dohme Corp.,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 3,1620,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0524A-020|MK0524A-020|2005_095,Dec-05,Dec-06,Dec-06,23-Dec-05,null,27-Jul-15,,,https://ClinicalTrials.gov/show/NCT00269204
NCT00269217,Lipid Efficacy Study (0524B-022)(COMPLETED),,Completed,No Results Available,Primary Hypercholesterolemia|Mixed Hyperlipidemia,Drug: niacin (+) laropiprant (+) simvastatin|Drug: Comparator: niacin (+) laropiprant|Drug: Comparator: simvastatin,"Coadministered MK0524B will be more efficacious in reducing LDL-C concentrations compared to MK0524A.|Coadministered MK0524B will have a greater effect on HDL-C, TG, LDL-C, LDL-C:HDL-C, non-HDL-C, Apo B, and Apo A-I than simvastatin.|Coadministered MK0524B will have a greater effect on HDL-C, TG, LDL-C:HDL-C, non-HDL-C, Apo B, and Apo A-I than MK0524A.",Merck Sharp & Dohme Corp.,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 3,1400,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0524B-022|MK0524B-022|2005_098,Jan-06,Jan-07,Jan-07,23-Dec-05,null,7-Apr-17,,,https://ClinicalTrials.gov/show/NCT00269217
NCT00268697,Efficacy of Lapaquistat Acetate Alone and With Ezetimibe in Subjects With Primary Dyslipidemia.,,Completed,No Results Available,Hypercholesterolemia,Drug: Lapaquistat acetate|Drug: Lapaquistat acetate and ezetimibe|Drug: Ezetimibe,Change from Baseline in fasting plasma Low Density Lipoprotein cholesterol|Change from Baseline in Triglycerides|Change from Baseline in Total Cholesterol|Change from Baseline in High Density Lipoprotein cholesterol|Change from Baseline in Very Low Density Lipoprotein cholesterol|Change from Baseline in apolipoprotein A1|Change from Baseline in apolipoprotein B|Change from Baseline in non- High Density Lipoprotein cholesterol|Change from Baseline in the ratio of Low Density Lipoprotein cholesterol/High Density Lipoprotein cholesterol|Change from Baseline in the ratio of Total Cholesterol/High Density Lipoprotein cholesterol|Change from Baseline in the ratio of apolipoprotein A1/apolipoprotein B|Change from Baseline in high-sensitivity C-reactive protein|Percentage of subjects who achieve Low Density Lipoprotein cholesterol concentrations less than 2.59 mmol/L (100 mg/dL)|Percentage of subjects who achieve Low Density Lipoprotein cholesterol concentrations less than 3.37 mmol/L (130 mg/dL)|Best corrected visual acuity|Adverse Events|Clinical Laboratory Tests|Vital Signs|12-lead Electrocardiogram|Physical Examination,Takeda,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1267,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TAK-475/EC303|2005-002315-25|U1111-1122-8322,Oct-05,Jan-07,Jan-07,22-Dec-05,null,24-May-12,"Tallinn, Estonia|Tartu, Estonia|Riga, Latvia|Moscow, Russian Federation|Saratov, Russian Federation|Smolensk, Russian Federation|St. Petersburg, Russian Federation|Tyumen, Russian Federation|Kragujevac, Serbia",,https://ClinicalTrials.gov/show/NCT00268697
NCT00267254,A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol.,,Completed,No Results Available,Hyperlipidemia|Dyslipidemia|Hypercholesterolemia,Drug: torcetrapib/atorvastatin|Drug: simvastatin,"Percent change in LDL-C and HDL-C from baseline, after six weeks of treatment.|Changes in other lipid parameters and other biomarkers.",Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,640,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A5091030,Jan-06,null,Aug-06,20-Dec-05,null,21-Nov-07,"Pfizer Investigational Site, Birmingham, Alabama, United States|Pfizer Investigational Site, Mobile, Alabama, United States|Pfizer Investigational Site, Mesa, Arizona, United States|Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Tempe, Arizona, United States|Pfizer Investigational Site, Little Rock, Arkansas, United States|Pfizer Investigational Site, Los Angeles, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, Santa Rosa, California, United States|Pfizer Investigational Site, Boynton Beach, Florida, United States|Pfizer Investigational Site, Melbourne, Florida, United States|Pfizer Investigational Site, Merritt Island, Florida, United States|Pfizer Investigational Site, Palm Bay, Florida, United States|Pfizer Investigational Site, Safety Harbor, Florida, United States|Pfizer Investigational Site, Tampa, Florida, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, Newton, Kansas, United States|Pfizer Investigational Site, Topeka, Kansas, United States|Pfizer Investigational Site, Wichita, Kansas, United States|Pfizer Investigational Site, Madisonville, Kentucky, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Ann Arbor, Michigan, United States|Pfizer Investigational Site, Canton, Michigan, United States|Pfizer Investigational Site, Portage, Michigan, United States|Pfizer Investigational Site, Troy, Michigan, United States|Pfizer Investigational Site, Minneapolis, Minnesota, United States|Pfizer Investigational Site, Kansas City, Missouri, United States|Pfizer Investigational Site, St. Louis, Missouri, United States|Pfizer Investigational Site, Butte, Montana, United States|Pfizer Investigational Site, Lincoln, Nebraska, United States|Pfizer Investigational Site, Las Vegas, Nevada, United States|Pfizer Investigational Site, Concord, New Hampshire, United States|Pfizer Investigational Site, Trenton, New Jersey, United States|Pfizer Investigational Site, Cooperstown, New York, United States|Pfizer Investigational Site, East Syracuse, New York, United States|Pfizer Investigational Site, Rochester, New York, United States|Pfizer Investigational Site, Charlotte, North Carolina, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Clinton, South Carolina, United States|Pfizer Investigational Site, Cordova, Tennessee, United States|Pfizer Investigational Site, Memphis, Tennessee, United States|Pfizer Investigational Site, Milan, Tennessee, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Fort Worth, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, Payson, Utah, United States|Pfizer Investigational Site, Salt Lake City, Utah, United States|Pfizer Investigational Site, Norfolk, Virginia, United States|Pfizer Investigational Site, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00267254
NCT00267267,A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.,,Terminated,No Results Available,Hyperlipidemia|Dyslipidemia,Drug: torcetrapib/atorvastatin|Drug: ezetimibe/simvastatin,"Percent change in LDL-C and HDL-C from baseline, after six weeks of treatment.|Changes in other lipid parameters and other biomarkers.",Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1784,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,A5091035,Jan-06,null,Jan-07,20-Dec-05,null,10-Dec-07,"Pfizer Investigational Site, Birmingham, Alabama, United States|Pfizer Investigational Site, Birmingham, Alabama, United States|Pfizer Investigational Site, Chandler, Arizona, United States|Pfizer Investigational Site, Mesa, Arizona, United States|Pfizer Investigational Site, Jonesboro, Arkansas, United States|Pfizer Investigational Site, Anaheim, California, United States|Pfizer Investigational Site, Escondido, California, United States|Pfizer Investigational Site, Fresno, California, United States|Pfizer Investigational Site, Los Altos, California, United States|Pfizer Investigational Site, Los Angeles, California, United States|Pfizer Investigational Site, Palm Springs, California, United States|Pfizer Investigational Site, Paramount, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, Santa Rose, California, United States|Pfizer Investigational Site, Walnut Creek, California, United States|Pfizer Investigational Site, Westlake Village, California, United States|Pfizer Investigational Site, Golden, Colorado, United States|Pfizer Investigational Site, New Haven, Connecticut, United States|Pfizer Investigational Site, Newark, Delaware, United States|Pfizer Investigational Site, Washington, District of Columbia, United States|Pfizer Investigational Site, Atlantis, Florida, United States|Pfizer Investigational Site, Boca Raton, Florida, United States|Pfizer Investigational Site, Daytona Beach, Florida, United States|Pfizer Investigational Site, DeFuniak Springs, Florida, United States|Pfizer Investigational Site, Destin, Florida, United States|Pfizer Investigational Site, Lakeland, Florida, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, Orlando, Florida, United States|Pfizer Investigational Site, Pensacola, Florida, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Honolulu, Hawaii, United States|Pfizer Investigational Site, Aurora, Illinois, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, Rockford, Illinois, United States|Pfizer Investigational Site, Springfield, Illinois, United States|Pfizer Investigational Site, Evansville, Indiana, United States|Pfizer Investigational Site, Evansville, Indiana, United States|Pfizer Investigational Site, Evansville, Indiana, United States|Pfizer Investigational Site, Des Moines, Iowa, United States|Pfizer Investigational Site, Newton, Kansas, United States|Pfizer Investigational Site, Overland Park, Kansas, United States|Pfizer Investigational Site, Pratt, Kansas, United States|Pfizer Investigational Site, Topeka, Kansas, United States|Pfizer Investigational Site, Edgewood, Kentucky, United States|Pfizer Investigational Site, Erlanger, Kentucky, United States|Pfizer Investigational Site, Louisville, Kentucky, United States|Pfizer Investigational Site, Columbia, Maryland, United States|Pfizer Investigational Site, Ayer, Massachusetts, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Milford, Massachusetts, United States|Pfizer Investigational Site, Bloomfield Hills, Michigan, United States|Pfizer Investigational Site, Grand Rapids, Michigan, United States|Pfizer Investigational Site, Troy, Michigan, United States|Pfizer Investigational Site, Brooklyn Center, Minnesota, United States|Pfizer Investigational Site, Edina, Minnesota, United States|Pfizer Investigational Site, St. Cloud, Minnesota, United States|Pfizer Investigational Site, Columbia, Missouri, United States|Pfizer Investigational Site, Jefferson City, Missouri, United States|Pfizer Investigational Site, Manchester, Missouri, United States|Pfizer Investigational Site, Springfield, Missouri, United States|Pfizer Investigational Site, Springfield, Missouri, United States|Pfizer Investigational Site, Omaha, Nebraska, United States|Pfizer Investigational Site, Omaha, Nebraska, United States|Pfizer Investigational Site, Omaha, Nebraska, United States|Pfizer Investigational Site, Las Vegas, Nevada, United States|Pfizer Investigational Site, Las Vegas, Nevada, United States|Pfizer Investigational Site, Cooperstown, New York, United States|Pfizer Investigational Site, Endwell, New York, United States|Pfizer Investigational Site, Lewiston, New York, United States|Pfizer Investigational Site, Manlius, New York, United States|Pfizer Investigational Site, Rochester, New York, United States|Pfizer Investigational Site, Rochester, New York, United States|Pfizer Investigational Site, Syracuse, New York, United States|Pfizer Investigational Site, West Seneca, New York, United States|Pfizer Investigational Site, Cary, North Carolina, United States|Pfizer Investigational Site, Charlotte, North Carolina, United States|Pfizer Investigational Site, Huntersville, North Carolina, United States|Pfizer Investigational Site, Monroe, North Carolina, United States|Pfizer Investigational Site, Raleigh, North Carolina, United States|Pfizer Investigational Site, Wilmington, North Carolina, United States|Pfizer Investigational Site, Winston-Salem, North Carolina, United States|Pfizer Investigational Site, Winston-Salem, North Carolina, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Cleveland, Ohio, United States|Pfizer Investigational Site, Fairview Park, Ohio, United States|Pfizer Investigational Site, Beaver, Pennsylvania, United States|Pfizer Investigational Site, Bensalem, Pennsylvania, United States|Pfizer Investigational Site, Doylestown, Pennsylvania, United States|Pfizer Investigational Site, Harleysville, Pennsylvania, United States|Pfizer Investigational Site, Lancaster, Pennsylvania, United States|Pfizer Investigational Site, Pittsburgh, Pennsylvania, United States|Pfizer Investigational Site, Pittsburgh, Pennsylvania, United States|Pfizer Investigational Site, Sayre, Pennsylvania, United States|Pfizer Investigational Site, Lincoln, Rhode Island, United States|Pfizer Investigational Site, Providence, Rhode Island, United States|Pfizer Investigational Site, Anderson, South Carolina, United States|Pfizer Investigational Site, Mount Pleasant, South Carolina, United States|Pfizer Investigational Site, Simpsonville, South Carolina, United States|Pfizer Investigational Site, Bristol, Tennessee, United States|Pfizer Investigational Site, Chattanooga, Tennessee, United States|Pfizer Investigational Site, Germantown, Tennessee, United States|Pfizer Investigational Site, Johnson City, Tennessee, United States|Pfizer Investigational Site, Memphis, Tennessee, United States|Pfizer Investigational Site, Memphis, Tennessee, United States|Pfizer Investigational Site, Memphis, Tennessee, United States|Pfizer Investigational Site, Memphis, Tennessee, United States|Pfizer Investigational Site, Selmer, Tennessee, United States|Pfizer Investigational Site, Arlington, Texas, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, Bountiful, Utah, United States|Pfizer Investigational Site, Salt Lake City, Utah, United States|Pfizer Investigational Site, Newport News, Virginia, United States|Pfizer Investigational Site, Norfolk, Virginia, United States|Pfizer Investigational Site, Renton, Washington, United States|Pfizer Investigational Site, Spokane, Washington, United States",,https://ClinicalTrials.gov/show/NCT00267267
NCT00267280,A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031).,,Terminated,No Results Available,Hyperlipidemia|Dyslipidemia|Hypercholesterolemia,Drug: torcetrapib/atorvastatin|Drug: simvastatin,"Percent change in LDL-C and HDL-C from baseline, after six weeks of treatment.|Changes in other lipid parameters and other biomarkers.",Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,640,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A5091031,Jan-06,Dec-06,Dec-06,20-Dec-05,null,17-Feb-12,"Pfizer Investigational Site, Birmingham, Alabama, United States|Pfizer Investigational Site, Mesa, Arizona, United States|Pfizer Investigational Site, Alhambra, California, United States|Pfizer Investigational Site, Inglewood, California, United States|Pfizer Investigational Site, Los Angeles, California, United States|Pfizer Investigational Site, Santa Ana, California, United States|Pfizer Investigational Site, Wilmington, Delaware, United States|Pfizer Investigational Site, Fort Lauderdale, Florida, United States|Pfizer Investigational Site, Hollywood, Florida, United States|Pfizer Investigational Site, Jacksonville, Florida, United States|Pfizer Investigational Site, Merritt Island, Florida, United States|Pfizer Investigational Site, Pensacola, Florida, United States|Pfizer Investigational Site, Vero Beach, Florida, United States|Pfizer Investigational Site, Winter Park, Florida, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Conyers, Georgia, United States|Pfizer Investigational Site, Woodstock, Georgia, United States|Pfizer Investigational Site, Hinsdale, Illinois, United States|Pfizer Investigational Site, La Grange, Illinois, United States|Pfizer Investigational Site, Park Ridge, Illinois, United States|Pfizer Investigational Site, Springfield, Illinois, United States|Pfizer Investigational Site, Kansas City, Kansas, United States|Pfizer Investigational Site, Lexington, Kentucky, United States|Pfizer Investigational Site, Baltimore, Maryland, United States|Pfizer Investigational Site, Bethesda, Maryland, United States|Pfizer Investigational Site, Elkton, Maryland, United States|Pfizer Investigational Site, Flint, Michigan, United States|Pfizer Investigational Site, Springfield, Missouri, United States|Pfizer Investigational Site, Lawrenceville, New Jersey, United States|Pfizer Investigational Site, Albany, New York, United States|Pfizer Investigational Site, Seaford, New York, United States|Pfizer Investigational Site, Charlotte, North Carolina, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Mansfield, Ohio, United States|Pfizer Investigational Site, Hillsboro, Oregon, United States|Pfizer Investigational Site, Beaver, Pennsylvania, United States|Pfizer Investigational Site, Flourtown, Pennsylvania, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Yardley, Pennsylvania, United States|Pfizer Investigational Site, Greenville, South Carolina, United States|Pfizer Investigational Site, Collierville, Tennessee, United States|Pfizer Investigational Site, Kingsport, Tennessee, United States|Pfizer Investigational Site, Knoxville, Tennessee, United States|Pfizer Investigational Site, North Richland Hills, Texas, United States|Pfizer Investigational Site, Spring, Texas, United States|Pfizer Investigational Site, Salt Lake City, Utah, United States|Pfizer Investigational Site, West Jordan, Utah, United States|Pfizer Investigational Site, Richmond, Virginia, United States|Pfizer Investigational Site, Bellevue, Washington, United States|Pfizer Investigational Site, Puyallup, Washington, United States|Pfizer Investigational Site, Tacoma, Washington, United States",,https://ClinicalTrials.gov/show/NCT00267280
NCT00264667,Study In Patients With Dyslipidaemia,,Completed,No Results Available,Metabolic Syndrome X,Drug: GW677954,"Percentage change from baseline in non-HDL-C based on log-transformed data at week 24.|Percentage change from baseline in lipids, in Homeostasis Model Assessment-insulin sensitivity (HOMA-S), C-Reactive Protein (CRP), Fasting Plasma Glucose (FPG), body weight and waist circumference.",GlaxoSmithKline,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,290,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,ADG103440,Dec-05,null,Jun-07,13-Dec-05,null,28-Oct-16,"GSK Investigational Site, Cordoba, Córdova, Argentina|GSK Investigational Site, Córdoba, Córdova, Argentina|GSK Investigational Site, Buenos Aires, Argentina|GSK Investigational Site, Buenos Aires, Argentina|GSK Investigational Site, Cordoba, Argentina|GSK Investigational Site, San Juan, Argentina|GSK Investigational Site, Kippa Ring, Queensland, Australia|GSK Investigational Site, Meadowbrook, Queensland, Australia|GSK Investigational Site, Elizabeth Vale, South Australia, Australia|GSK Investigational Site, Keswick, South Australia, Australia|GSK Investigational Site, Camperdown, Victoria, Australia|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, San Jose, Costa Rica|GSK Investigational Site, Ahmedabad, India|GSK Investigational Site, Bangalore, India|GSK Investigational Site, Bangalore, India|GSK Investigational Site, Chennai, India|GSK Investigational Site, Mumbai, India|GSK Investigational Site, Riga, Latvia|GSK Investigational Site, Riga, Latvia|GSK Investigational Site, Riga, Latvia|GSK Investigational Site, Riga, Latvia|GSK Investigational Site, Pachuca, Hidalgo, Mexico|GSK Investigational Site, Guadalajara, Jalisco, Mexico|GSK Investigational Site, Durango, Mexico|GSK Investigational Site, Mexico, D.F., Mexico|GSK Investigational Site, Auckland, New Zealand|GSK Investigational Site, Christchurch, New Zealand|GSK Investigational Site, Rotorua, New Zealand|GSK Investigational Site, Karachi, Pakistan|GSK Investigational Site, Lahore, Pakistan|GSK Investigational Site, Brasov, Romania|GSK Investigational Site, Bucharest, Romania|GSK Investigational Site, Deva, Romania|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, S.-Petresburg, Russian Federation|GSK Investigational Site, Kosice, Slovakia|GSK Investigational Site, Kosice, Slovakia|GSK Investigational Site, Alicante, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Granada, Spain|GSK Investigational Site, Granada, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Móstoles/Madrid, Spain|GSK Investigational Site, Santiago de Compostela, Spain|GSK Investigational Site, Tarrasa, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT00264667
NCT00264394,Cardiovascular Risk Factor Management in HIV Infection,,Completed,No Results Available,"Coronary Heart Disease|Dyslipidemia|Diabetes Mellitus, Non-Insulin-Dependent|HIV Infection",Behavioral: Updated CHD risk profiles|Behavioral: Guidelines,"Reduction in total cholesterol in the entire SHCS population|The reduction in total cholesterol, systolic and diastolic blood pressure, and Framingham 10-year CHD risk score in individuals with a greater than or equal to 10% 10 year risk of CHD (according to the Framingham risk profile)","University Hospital, Basel, Switzerland|Swiss National Science Foundation|Bristol-Myers Squibb",All,"18 Years and older   (Adult, Older Adult)",Phase 4,4097,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,SNF 3345-062041 SHCS 480|480,Jul-06,Oct-08,Feb-10,12-Dec-05,null,28-May-15,"Departement Innere Medizin Kantonsspital St. Gallen, St. Gallen, Canton St. Gall, Switzerland|Ospedale Civico Lugano, Lugano, Canton Ticino, Switzerland|Abteilung für Infektionskrankheiten & Spitalhygiene, Universitätsspital Zürich, Zurich, Canton Zurich, Switzerland|University Hospital Basel, Basel, Kanton Basel Stadt, Switzerland|Division Maladies Infectieuses, Hopital Universitaire Vaudois (CHUV), Lausanne, Vaud, Switzerland|Klinik und Poliklinik für Infektiologie, Inselspital, Berne, Switzerland|Division des Maladies Infectieuses, Hopital Universitaire Geneve, Geneva, Switzerland",,https://ClinicalTrials.gov/show/NCT00264394
NCT00263081,Efficacy of Lapaquistat Acetate Co-Administered With Current Lipid-Lowering Treatment on Blood Cholesterol Levels in Subjects With Homozygous Familial Hypercholesterolemia,,Terminated,No Results Available,Hypercholesterolemia,Drug: Lapaquistat acetate and current lipid-lowering treatment|Drug: Current lipid-lowering treatment,Change from Baseline in Low Density Lipoprotein cholesterol|Change from Baseline in calculated Low Density Lipoprotein cholesterol|Change from Baseline in non- High Density Lipoprotein cholesterol|Change from Baseline in Triglycerides|Change from Baseline in Total Cholesterol|Change from Baseline in High Density Lipoprotein cholesterol|Change from Baseline in Very Low Density Lipoprotein cholesterol|Change from Baseline in apolipoprotein A1|Change from Baseline in apolipoprotein B|Lipoprotein cholesterol/High Density Lipoprotein cholesterol|Change from Baseline in the ratio of Total Cholesterol/High Density Lipoprotein cholesterol|Change from Baseline in the ratio of apolipoprotein A1/apolipoprotein B|Change from Baseline in high-sensitivity C-reactive protein,Takeda,All,"8 Years and older   (Child, Adult, Older Adult)",Phase 3,44,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",01-05-TL-475-016|2005-003626-26|U1111-1122-7919,Nov-05,Mar-07,Mar-07,7-Dec-05,null,24-May-12,"Cincinnati, Ohio, United States|Columbus, Ohio, United States|Québec, Canada|Paris, France|Strasbourg, France|Jerusalem, Israel|Bialystok, Poland|Warszawa, Poland|Zabrze, Poland|Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT00263081
NCT00257686,Study to Compare the Efficacy and Safety of Pitavastatin and Pravastatin in Elderly Patients,,Completed,Has Results,Hypercholesterolemia or Combined Dyslipidemia,Drug: Pitavastatin|Drug: Pravastatin,Percent Change From Baseline in LDL-C|Percent Change From Baseline in TC,Kowa Research Europe,All,65 Years and older   (Older Adult),Phase 3,962,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NK-104-306,Sep-05,May-06,May-06,23-Nov-05,18-Jan-10,16-Mar-10,"CCBR A/S, Aalborg, Denmark|Copenhagen University Hospital, Copenhagen, Denmark|Medical Center, Copenhagen, Denmark|CCBR A/S, Vejle, Denmark|Kardiologische Gemeinschaftspraxis Prof. Reifart, Bad Soden / Taunus, Germany|Praxis Dr. Boenninghoff, Beckum, Germany|Klinische Forschung Berlin Mitte, Berlin, Germany|GWT-TUK mbH, Zentrum fur Klinische Studien, Dresden, Germany|Gemeinschaftspraxis Dr. Krause, Th. Menke, Goch, Germany|Klinische Forschung Hamburg, Hamburg, Germany|Innere Medizin I / Medizinische Klinik, Heidelberg, Germany|Gemeinschaftspraxis H. Holz Dr. med, K. W. Klingl, Lampertheim, Germany|ZET-Studien GmbH Leipzing, Leipzig, Germany|Internistische Gemeinschaftspraxis, Mainz, Germany|Praxis Dr. Wachter, Mannheim, Germany|Gemeinschaftspraxis Melcherstaette, Melcherstaette, Germany|Gemeinschaftspraxis Dr. Senftleber, Dr. Kohler, Messkirch, Germany|Praxisgemeinschaft im Kleinen Biergrund, Offenbach/M, Germany|Gemeinschaftspraxis Melcherstaette, Stuhr-Brinkum, Germany|Gemeinschaftspraxis Drs. Mockesch, Weinheim, Germany|Intermed Institud Fur Klinische Forschung und Arzn, Wiesbaden, Germany|Gemeinschaftspraxis Dr. Emden, Frank Drewes, Worpswede, Germany|Department of Internal Medicine, Soroka Medical Center, Beersheva, Israel|Department of Internal Medicine A, Rambal Medical Center, Haifa, Israel|Department of Internal Medicine, Wolfson Medical Center, Holon, Israel|Center for Research, Hadassah University Hospital, Jerusalem Ein Kerem, Israel|Meir Hospital, Kfar Saba, Israel|Department of Medicine, Hadassah Medical Center, Mount Scopus Jerusalem, Israel|Department of Internal Medicine, Rivka Sieff Medical Center, Safed, Israel|Institute of Metabolic Diseases, Tel Aviv, Israel|Institue of Lipid & Atherosclerosis Research, Tel Hashomer, Israel|Andromed Oost, ES Velp, Netherlands|Andromed Noord, Groningen, Netherlands|Vasculair Onderzoek Centrum Hoorn, Hoorn, Netherlands|Andromed Leiden, Leiden, Netherlands|Andromed Nijmegen, Rotterdam, Netherlands|Andromed Rotterdam, Rotterdam, Netherlands|Albert Schweitzer ziekenhuis, Sliedrecht, Netherlands|Andromed Breda, VL Breda, Netherlands|Rivierenland Tiel, WP Tiel, Netherlands|Andromed Zoetermeer, Zoetermeer, Netherlands|Albert Schweitzer ziekenhuis, Zwijndrecht, Netherlands|Oldfield Surgery, Bath, United Kingdom|St James's Surgery, Bath, United Kingdom|The Pulteney Practice, Bath, United Kingdom|Birmingham Clinical Research Centre, Birmingham, United Kingdom|Stonehill Medical Center, Bolton, United Kingdom|Chorley Clinical Research Centre, Chorley, United Kingdom|Saltash Health Center, Cornwall, United Kingdom|Gomersal Lane Surgery, Dronfield, United Kingdom|Townhead Research, Irvine, United Kingdom|Crosby Clinical Research Centre, Liverpool, United Kingdom|The Symons Medical Center, Maidenhead, United Kingdom|Manchester Clinical Research Centre, Manchester, United Kingdom|Greenwood Medical Center, Nottingham, United Kingdom|Reading Clinical Research Centre, Reading, United Kingdom|Elm Lane Surgery, Sheffield, United Kingdom|Brook Lane Surgery, Southampton, United Kingdom|Bradford Road Medical Center, Wiltshire, United Kingdom|Rowden Medical Partnership, Wiltshire, United Kingdom|The Porch Surgery, Wiltshire, United Kingdom|The Burns Medical Practice, Yorkshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT00257686
NCT00256178,Efficacy of Lapaquistat Acetate and Simvastatin in Subjects With Primary Dyslipidemia.,,Completed,No Results Available,Hypercholesterolemia,Drug: Lapaquistat acetate and simvastatin|Drug: Simvastatin,Change from Baseline in fasting plasma Low Density Lipoprotein cholesterol|Change from Baseline in Triglycerides|Change from Baseline in Total Cholesterol|Change from Baseline in High Density Lipoprotein cholesterol|Change from Baseline in Very Low Density Lipoprotein cholesterol|Change from Baseline in apolipoprotein A1|Change from Baseline in apolipoprotein B|Change from Baseline in non- High Density Lipoprotein cholesterol|Change from Baseline in the ratio of Low Density Lipoprotein cholesterol/High Density Lipoprotein cholesterol|Change from Baseline in the ratio of Total Cholesterol/High Density Lipoprotein cholesterol|Change from Baseline in the ratio of apolipoprotein A1/apolipoprotein B|Change from Baseline in high-sensitivity C-reactive protein|Percentage of subjects who achieve Low Density Lipoprotein cholesterol concentrations less than 1.81 mmol/L (70 mg/dL)|Percentage of subjects who achieve Low Density Lipoprotein cholesterol concentrations less than 2.59 mmol/L (100 mg/dL)|Percentage of subjects who achieve Low Density Lipoprotein cholesterol concentrations less than 3.37 mmol/L (130 mg/dL)|Best corrected visual acuity|Adverse Events|Clinical Laboratory Tests|Vital Signs|12-lead Electrocardiogram|Physical Examination,Takeda,All,"18 Years and older   (Adult, Older Adult)",Phase 3,411,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TAK-475/EC302|2005-002313-21|U1111-1122-8212,Oct-05,Mar-07,Mar-07,21-Nov-05,null,24-May-12,"Benešov, Czech Republic|Holice v Čechách, Czech Republic|Kladno, Czech Republic|Mladá Boleslav, Czech Republic|Olomouc, Czech Republic|Praha, Czech Republic|Trutnov, Czech Republic|Zlín, Czech Republic|Ústí nad Orlicí, Czech Republic|Pärnu, Estonia|Tallinn, Estonia|Tartu, Estonia|Aura, Finland|Helsinki, Finland|Hyvinkää, Finland|Oulu, Finland|Tampere, Finland|Turku, Finland|Berlin, Germany|Bochum, Germany|Chemnitz, Germany|Dresden, Germany|Frankfurt, Germany|Goerlitz, Germany|Leipzig, Germany|Nurnberg, Germany|Krakow, Poland|Lublin, Poland|Niemodlin, Poland|Skierniewice, Poland|Sroda Wlkp., Poland|Starachowice, Poland|Swietokrzyski, Poland|Warszawa, Poland|Zakopane, Poland|Bloemfontein, South Africa|Cape Town, South Africa|Johannesburg, South Africa|Pretoria, South Africa|Randburg, South Africa|Tongaat, South Africa|Bath, United Kingdom|Birmingham, United Kingdom|Blackpool, United Kingdom|Blantyre, United Kingdom|Chippenham, United Kingdom|Eastwood, United Kingdom|Glasgow, United Kingdom|Harrow, United Kingdom|Hinckley, United Kingdom|Newport Isle of Wight, United Kingdom|Nottingham, United Kingdom|Woolpit, United Kingdom",,https://ClinicalTrials.gov/show/NCT00256178
NCT00256516,"Low Carbohydrate Portfolio or ""Eco-Atkins"" Diet",,Completed,No Results Available,Hypercholesterolemia|Cardiovascular Diseases,Other: Eco-Atkins diet (high vegetable protein and vegetable fat)|Other: NCEP diet,"total and low-density lipoprotein (LDL) cholesterol|LDL:HDL cholesterol ratio|weight reduction|blood pressure|high-density lipoprotein (HDL) cholesterol|HDL2 and HDL3, triglyceride, apolipoprotein A1 and B, Lp(a) and LDL particle size|glucose, insulin and measurements of oxidative stress",University of Toronto,All,"21 Years to 70 Years   (Adult, Older Adult)",Phase 2,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment,REB 05-025,Apr-05,null,Dec-06,21-Nov-05,null,20-May-13,"Risk Factor Modification Centre, St. Michael's Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00256516
NCT00255216,Policosanol for the Treatment of Hypercholesterolemia,,Completed,No Results Available,Hyperlipidemia,Drug: Policosanol supplement (oral capsule) vs. placebo,"Primary Outcome Variables:|Percent change in LDL-C between baseline and 8 weeks in the policosanol and placebo arms.|Secondary Outcome Variables:|Percent change between baseline and 8 weeks in both study arms for the following parameters:|• total cholesterol, HDL-C, and triglycerides|• hs-CRP|• LDL Particle concentration|• ALT|• Adverse effects profile",Atrium Health,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,Poli-01,Jan-05,null,Aug-05,18-Nov-05,null,18-Nov-05,"Center for Cardiovascular Health, Charlotte, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00255216
NCT00254475,A Study to Evaluate the Efficacy of Valsartan/Simvastatin Combinations in Patients With Both Essential Hypertension and Hypercholesterolemia,,Completed,No Results Available,Essential Hypertension|Hypercholesterolemia,Drug: simvastatin|Drug: valsartan,"Low density lipoproteins after 6 weeks|Lipid profile at 6, 12 wks|BP < 140/90 mmHg in non diabetics, or < 130/80 mmHg in diabetics, and LDL-C < 2.6, 3.4 or 4.1 mmol/l based on risk group at 6, 12 wks|SBP < 140 mmHg in non diabetics, < 130 mmHg in diabetics, or 20 mmHg decrease in SBP from baseline and DBP < 90 mmHg in non diabetics, DBP < 80 mmHg in diabetics, or 10 mmHg decrease in DBP from baseline at 6, 12 wks|Systolic and diastolic bp at 6, 12 wks|Serious/adverse events, labs, physical exams, vitals up to 12 wks",Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 3,871,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,CVAS489A2403,Nov-05,Sep-06,Sep-06,16-Nov-05,null,19-Aug-14,"Investigative Centers, Germany|Novartis Pharmaceuticals, Basel, Switzerland",,https://ClinicalTrials.gov/show/NCT00254475
NCT00252018,The Effect of Broccoli Sprouts as a Nutritional Supplement in the Prevention of Cardiovascular Disease,,Completed,No Results Available,Diabetes Mellitus|Hypertension|Hypercholesterolemia|Cardiovascular Disease,Behavioral: Daily intake of broccoli sprouts,Improvement of endothelial function as measured by FMD,Bispebjerg Hospital,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,160,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention,KF 01-257/04,Jan-06,Mar-07,Mar-07,11-Nov-05,null,14-May-08,"Bispebjerg Hospital, Copenhagen, Denmark",,https://ClinicalTrials.gov/show/NCT00252018
NCT00249249,Study to Compare the Efficacy of Pitavastatin With That of Atorvastatin in Lowering Cholesterol Levels,,Completed,Has Results,Primary Hypercholesterolemia|Dyslipidemia,Drug: Pitavastatin|Drug: Atorvastatin,Percent Change From Baseline Low Density Lipoprotein-cholesterol (LDL-C) at Week 12|Percent Change From Baseline in Total Cholesterol (TC)|Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C)|TC:HDL-C Ratio|Triglycerides (TG)|Non-HDL:HDL Ratio|Apolipoprotein B (Apo B)|Apolipoprotein-A1 (Apo-A1)|Apo-B:Apo-A1 Ratio|High Sensitivity C-reactive Protein (Hs-CRP) at 12 Weeks|Oxidized LDL at 12 Weeks|National Cholesterol Education Program [NCEP]LDL-C Target Attainment,Kowa Research Europe,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,830,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,NK-104-301|EudraCT number 2005-001000-39,Oct-05,null,Nov-06,7-Nov-05,16-Dec-09,12-Jan-10,"Y Forskning, Bispebjerg Hospital, Copenhagen Nv, Denmark|Copenhagen University Hospital, Copenhagen, Denmark|Medical Center, Copenhagen, Denmark|Frederiks Hospital, Kardiologisk, Frederiksberg, Denmark|Kolesterollaboratoriet, Hellerup, Denmark|CCBR A/S, Vejle, Denmark|Geri-Med Oy, Helsinki, Finland|Kaisaniemen Laakariasema, Helsinki, Finland|keravan Laakarikeskus, Helsinki, Finland|SOK-tyoterveyshuolto, Tampere, Finland|TYKS University Hospital, Turku, Finland|Kardiologische Gemeinschaftspraxis Prof. Reifart, Bad Soden/Taunus, Germany|Praxis Dr. Boenninghoff, Beckum, Germany|Gemeinschaftspraxis am Bahnhof, Berlin-Spandau, Germany|Klinische Forschung Berlin Mitte, Berlin, Germany|Pharmakologisches Studienzentum Chemnitz, Chemnitz, Germany|GWT-TUK mbH, Zentrum fur Klinische Studien, Dresden, Germany|Internistische Diabetische Schwerpunktpraxis Dr., Frankfurt Am Main, Germany|Gemeinschaftspraxis Dr. Krause, Th. Menke, Goch, Germany|Klinische Forschung Hamburg, Hamburg, Germany|Innere Medizin I/Medizinische Klinik, Heidelberg, Germany|Gemeinschaftspraxis H. Holz Dr. Med, K. W. Klingl, Lampertheim, Germany|ZET-Studien GmbH Leipzig, Leipzig, Germany|Internistische Gemeinschaftspraxis, Mainz, Germany|Praxis Dr. Wachter, Mannheim, Germany|Gemeinschaftspraxis Melcherstaette, Melcherstaette, Germany|Gemeinschaftspraxis Dr. Senftleber, Dr. Kohler, Messkirch, Germany|Praxisgemeinschaft im Kleinen Biergrund, Offenbach/M, Germany|Gemeinschaftspraxis Drs. Mockesch, Weinheim, Germany|Intermed Institud Fur Klinische Forschung und Arzn, Wiesbaden, Germany|Gemeinschaftspraxis Dr. Emden, Frank Drewes, Worpswede, Germany|Apollo Hospital, Andhra Pradesh, India|Care Hospital, Andhra Pradesh, India|School of Diabetology, Nizam Institute of Medical Sciences, Andhra Pradesh, India|Bhagwan Mahaveer Jain Heart Centre, Bangalore, India|Sri Ramachandra Medical College Hospital, Chennai, India|Heart Care Clinic, Gujarat, India|Apollo Hospitals, Hyderabaad, India|CARE Group of Hospitals, Hyderabaad, India|St. John's Medical College Hospital,, Karnataka, India|St. John's Medical College Hospital, Karnataka, India|Bathia Hospital, Maharashtra, India|LTMMC & General Hospital, Maharashtra, India|Sir J. J. Group of Hospitals, Maharashtra, India|King Edward Medical College & Hospital, Maharashtra, India|Ruby Hall Clinic, Maharashtra, India|Lokmanya Hospital, Maharashtra, India|PD Hinduja Hospital, Mumbai, India|Apollo Hospital, New Delhi, India|Sir Gagaram Hospital, New Delhi, India|Apollo Hospital, Tamil Nadu, India|Department of Cardiology, Tamil Nadu, India|Department of Internal Medicine, Soroka Medical Center, Beersheva, Israel|Department of Internal Medicine A, Rambam Medical Center, Haifa, Israel|Department of Internal Medicine, Wolfson Medical Center, Holon, Israel|Center for Research, Hadassah University Hospital, Jerusalem Ein Kerem, Israel|Meir Hospital, Kfar Saba, Israel|Department of Medicine, Hadassah Medical Center, Mount Scopus Jerusalem, Israel|Department of Internal Medicine, Rivka Sieff Medical Center, Safed, Israel|Institute of Metabolic Diseases, Tel Aviv, Israel|Institute of Lipid & Atherosclerosis Research, Tel Hashomer, Israel|Dipartimento di Medicina Clinica e Biotecnologia Applicata, Bologna, Italy|Centro di Ricerca Clinica, Chieti, Italy|Gerontologia e Geriatria - Universita degli Studi, Ferrara, Italy|Dipartimento di Medicina Interna DIMI, Genova, Italy|Universita di Modena e Reggio Emilia, Policlinico, Modena, Italy|Dipartimento di Medicina Clinica e Sperimentale, Napoli, Italy|Medicina Clinica e delle Patologie Emergenti, Palermo, Italy|Dipartimento di Medicina Interna e Scienze Biomediche, Parma, Italy|U.O Malattie Metaboliche e Diabetologia, Treviglio, Italy|Azienda Ospedaliero-Universitaria, Trieste, Italy|Andromed Breda, Breda, Netherlands|Middellaan 5, Breda, Netherlands|Andromed Eindhoven, Eindhoven, Netherlands|Bomanshof 8, Eindhoven, Netherlands|Andromed Noord, Groningen, Netherlands|Damsterdiep 9, Groningen, Netherlands|Vasculair Onderzoek Centrum Hoorn, Hoorn, Netherlands|Andromed Leiden, Leiden, Netherlands|Doezastraat 1, Leiden, Netherlands|Andromed Nijmegen, Nijmegen, Netherlands|Kamerlingh Onnesstraat 16-18, Nijmegen, Netherlands|Andromed Rotterdam, Rotterdam, Netherlands|Mathenesserlaan 247, Rotterdam, Netherlands|Albert Schweitzer Ziekenhuis, Sliedrecht, Netherlands|Andromed Oost, Velp, Netherlands|Reigerstraat 30, Velp, Netherlands|Rivierenland Tiel, Wp Tiel, Netherlands|Andromed Zoetermeer, Zoetermeer, Netherlands|Parkdreef 142, Zoetermeer, Netherlands|Volvat Medisinske Senter, Fredrikstad, Norway|Nyomen Legekontor, Kongsberg, Norway|Radhuset Spesialistsenter, Oslo, Norway|Rikshospitalet - University Hospital, Oslo, Norway|Skedsmo Medisinske Senter A.S., Skedsmokorset, Norway|Podlaski Osrodek Kardiologii, Bialystok, Poland|NZOZ GCP Dobra Praktyka Lekaska, Gruziadz, Poland|NZOZ Terapia Optima, Katowice, Poland|NZOZ Esculap, Przychodnia Lekary Rodzinnych, Losice, Poland|NZOZ Centrum, Poradnia Kardiologiczna, Siedlce, Poland|Spec. Gab. Lek. Internistyczno-Kardiologicznly, Tarnow, Poland|Woj.Szp.Spec.Nr 1 im. Prof. J. Gasinskiego, Tychy, Poland|Instytut Zywnosci i Zywienia, Warszawa, Poland|Lecznica PROSEN SMO, Warszawa, Poland|Szpital Wolski im. Dr A. Gostynskiej, Warszawa, Poland|Kemerovo Cardiology Dispensary, Kemerovo, Russian Federation|Central Clinical Hospital 1 of RZD, Moscow, Russian Federation|City Clinical Hospital 23, Moscow, Russian Federation|City Clinical Hospital 64, Moscow, Russian Federation|Federal State Institution Out-Patient Clinic ï€£3 of Russian Federation of Presidentâ€™s Management, Moscow, Russian Federation|Federal State Institution Outpatient Clinic ï€£3 of Russian Federation of Presidentâ€™s Management, Moscow, Russian Federation|Moscow City Clinical Hospital 68, Moscow, Russian Federation|Moscow Regional Research Clinic Institute n.a.M.F.Vladimirov, Department of Therapy, Moscow, Russian Federation|State Educational Institution of Higher Professional Education â€œMoscow State University of Medicine and Dentistry of Federal Agency of Health Care and Social Developmentâ€�, Department of Internal Diseases and Rheumatology based at City Clinica, Moscow, Russian Federation|State Educational Institution of Higher Professional Education â€œMoscow State University of Medicine and Dentistry of Federal Agency of Health Care and Social Developmentâ€�, Hospital Therapy Department # 1 based at City Clinical Hospital # 40, Moscow, Russian Federation|State Educational Institution of Higher Professional Education â€œMoscow State University of Medicine and Dentistry of Federal Agency of Health Care and Social Developmentâ€�, Hospital Therapy Department #1 based at City Clinical Hospital # 52, Moscow, Russian Federation|State Educational Institution of Higher Professional Education â€œRussian State Medical University Federal Agency of Health Care and Social Developmentâ€�, Department of Polyclinic Therapy based at Diagnostic Center # 1, Moscow, Russian Federation|State Educational Institution of Higher Professional Education â€œRussian State Medical University Federal Agency of Health Care and Social Developmentâ€�, Department of Therapy based at City Hospital # 4, Moscow, Russian Federation|State Educational Institution of Higher Professional Education â€œRussian State Medical University of Federal Agency of Health Care and Social Developmentâ€�, Department of Hospital Therapy #1 based at City Clinical Hospital #15, Cardiology Dept, Moscow, Russian Federation|State Institution â€œResearch Institute of Physical and Chemical Medicineâ€� of Federal Agency of Health Care and Social Development, Laboratory of Clinical Cardiology based at Bauman City Hospital # 29, Moscow, Russian Federation|State Institution â€œRussian Cardiology Research Complexâ€� of Federal Agency of Health Care and Social Development, Myasnikov Clinical Cardiology Institute, Department of Hemodialysis and Plasmapheresis, Moscow, Russian Federation|State Research Center for Preventive Medicine, Moscow, Russian Federation|Novosibirsk Reg. Clinical Cardiology Dispensary, Novosibirsk, Russian Federation|Central Medical Unit 122, St. Pb, Saint Petersburg, Russian Federation|Clinical Hospital of Russian Academy of Sciences, Saint Petersburg, Russian Federation|Consulting and Diagnostic Center 85, Saint Petersburg, Russian Federation|Krestovsky Island Medical Institute, Saint Petersburg, Russian Federation|Pokrovskaya City Hospital, Saint Petersburg, Russian Federation|St. Petersburg State Medical Institution â€œOut-patient Clinic # 109â€�, Saint Petersburg, Russian Federation|St. Petersburg State Medical Institution â€œOutpatient Clinic # 109â€�, Saint Petersburg, Russian Federation|St. Petersburg State Medical Institution â€œPokrovskaya City Hospitalâ€�, Cardiology Department #2, Saint Petersburg, Russian Federation|State Educational Institution of Higher Professional Education, â€œSaint-Petersburg State Medical University n.a.Academician I.P.Pavlov of Federal Agency of Health Care and Social Developmentâ€�, Chair and Department of Faculty Therapy, Saint Petersburg, Russian Federation|State Educational Institution of Higher Professional Education, â€œSaint-Petersburg State Medical University n.a.Academician I.P.Pavlov of Federal Agency of Health Care and Social Developmentâ€�, Institute of Cardiovascular Diseases, Saint Petersburg, Russian Federation|Hospital Clinico S. Juan de Alicante, San Juan, Alicante, Spain|Hospital Clinic i Provincial, Villaroel, Barcelona, Spain|Hospital de San Vicente, Alicante, Spain|Hospital Santa Creu I Sant Pau,, Barcelona, Spain|Hospital Santa Creu I Sant Pau, Barcelona, Spain|Hospital Universitario de Bellvitge, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital Ramon y Cajal, Madrid, Spain|Centro de Especialidades Pedro Gonzalez Bueno, Madrid, Spain|Fundacion Jimenez Diaz, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Centro de Salud de Ventanielles, Oviedo, Spain|Hospital Marques de Valdecilla, Santander, Spain|Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain|Hospital Virgen del Roci-o, Sevilla, Spain|Hospital Dr. Peset, Valencia, Spain|Hospital Clinico Lozano Blesa, Zaragoza, Spain|Hospital Miguel Servet, Zaragoza, Spain|Angelholms Sjukhus, Medicinkliniken, Angelhom, Sweden|Sahlgrenska University Hospital, Intermedicin, Gothenburg, Sweden|Hjartmottagningen, Helsingborg, Sweden|Lakarcentrum Nyponet, Karineholm, Sweden|Medicinkliniken, Ludvika, Sweden|Huslakaren i Sandviken, Sandviken, Sweden|Narsjukhuset Sandviken, Kardiologlab, Medicin, Sandviken, Sweden|Hjart & Karlcenter, Sodertalje, Sweden|Karolinska Universitetssjukhuset, Stockholm, Sweden|Hjarthuset AB, Varberg, Sweden|Oldfield Surgery, Bath, United Kingdom|St James's Surgery, Bath, United Kingdom|St Michael's Partnership, Bath, United Kingdom|The Pulteney Practice, Bath, United Kingdom|Birmingham Clinical Research Centre, Birmingham, United Kingdom|Stonehill Medical Center, Bolton, United Kingdom|Avondale Surgery, Chesterfield, United Kingdom|Chorley Clinical Research Centre, Chorley, United Kingdom|Saltash Health Center, Cornwall, United Kingdom|Gomersal Lane Surgery, Dronfield, United Kingdom|Townhead Research, Irvine, United Kingdom|Crosby Clinical Research Centre, Liverpool, United Kingdom|The Symons Medical Center, Maidenhead, United Kingdom|Manchester Clinical Research Centre, Manchester, United Kingdom|Greenwood Medical Center, Nottingham, United Kingdom|Knowle House Surgery, Plymouth, United Kingdom|Reading Clinical Research Centre, Reading, United Kingdom|Elm Lane Surgery, Sheffield, United Kingdom|The Burngreave Surgery, Sheffield, United Kingdom|Brook Lane Surgery, Southampton, United Kingdom|St Helier Hospital, Surrey, United Kingdom|Box Surgery, Wiltshire, United Kingdom|Bradford Road Medical Center, Wiltshire, United Kingdom|Eastleigh Surgery, Wiltshire, United Kingdom|Lovemead Group Practice, Wiltshire, United Kingdom|Rowden Medical Partnership, Wiltshire, United Kingdom|St Chad's Surgery, Wiltshire, United Kingdom|The Health Centre, Wiltshire, United Kingdom|The Porch Surgery, Wiltshire, United Kingdom|The Burns Medical Practice, Yorkshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT00249249
NCT00249899,Efficacy of Lapaquistat Acetate Alone or Combined With High-Dose Statin Therapy in Subjects With Hypercholesterolemia,,Terminated,No Results Available,Hypercholesterolemia,Drug: Lapaquistat acetate and stable statin therapy|Drug: Stable statin therapy,Change from Baseline in Low Density Lipoprotein cholesterol|Adverse Events|Physical Examination|Safety Laboratory Tests|12- lead Electrocardiogram assessments|Best Corrected Visual Acuity results|Vital Signs|Change from Baseline in Triglycerides|Change from Baseline in Total Cholesterol|Change from Baseline in High Density Lipoprotein cholesterol|Change from Baseline in Very Low Density Lipoprotein cholesterol|Change from Baseline in apolipoprotein A1|Change from Baseline in apolipoprotein B|Change from Baseline in non- High Density Lipoprotein cholesterol|Change from Baseline in the ratio of Low Density Lipoprotein cholesterol/High Density|Change from Baseline in the ratio of Total Cholesterol/High Density Lipoprotein cholesterol|Change from Baseline in the ratio of apolipoprotein A1/apolipoprotein B|Change from Baseline in high-sensitivity C-reactive protein|Percentage of subjects who achieve Low Density Lipoprotein cholesterol concentrations less than 1.81 mmol/L (70 mg/dL)|Percentage of subjects who achieve Low Density Lipoprotein cholesterol concentrations less than 2.59 mmol/L (100 mg/dL)|Percentage of subjects who achieve Low Density Lipoprotein cholesterol concentrations less than 3.37 mmol/L (130 mg/dL),Takeda,All,"18 Years and older   (Adult, Older Adult)",Phase 3,649,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",01-05-TL-475-021|2005-004876-19|U1111-1122-8008,Nov-05,Mar-07,Mar-07,7-Nov-05,null,24-May-12,"Santa Ana, California, United States|Chicago, Illinois, United States|Iowa City, Iowa, United States|Kansas City, Kansas, United States|Auburn, Maine, United States|Scarborough, Maine, United States|Baltimore, Maryland, United States|Saint Louis, Missouri, United States|Concord, New Hampshire, United States|Cincinnati, Ohio, United States|Houston, Texas, United States|Salt Lake City, Utah, United States|Seattle, Washington, United States|Calgary, Alberta, Canada|Vancouver, British Columbia, Canada|Chicoutimi, Quebec, Canada|Laval, Quebec, Canada|Montreal, Quebec, Canada|Ste-Foy, Quebec, Canada|Bellville, South Africa|Johannesburg, South Africa|Parow, South Africa|Pretoria, South Africa",,https://ClinicalTrials.gov/show/NCT00249899
NCT00249912,Efficacy of Lapaquistat Acetate Alone or Combined With Rosuvastatin in Subjects With Hypercholesterolemia,,Completed,No Results Available,Hypercholesterolemia,Drug: Lapaquistat acetate and rosuvastatin|Drug: Rosuvastatin,Change from Baseline in Low Density Lipoprotein cholesterol|Adverse Events|Physical Examination|Safety Laboratory Tests|12- lead Electrocardiogram assessments|Best Corrected Visual Acuity results|Vital Signs|Change from Baseline in Triglycerides|Change from Baseline in Total Cholesterol|Change from Baseline in High Density Lipoprotein cholesterol|Change from Baseline in Very Low Density Lipoprotein cholesterol|Change from Baseline in apolipoprotein A1|Change from Baseline in apolipoprotein B|Change from Baseline in non- High Density Lipoprotein cholesterol|Change from Baseline in the ratio of Low Density Lipoprotein cholesterol/High Density|Change from Baseline in the ratio of Total Cholesterol/High Density Lipoprotein cholesterol|Change from Baseline in the ratio of apolipoprotein A1/apolipoprotein B|Change from Baseline in high-sensitivity C-reactive protein|Percentage of subjects who achieve Low Density Lipoprotein cholesterol concentrations less than 1.81 mmol/L (70 mg/dL)|Percentage of subjects who achieve Low Density Lipoprotein cholesterol concentrations less than 2.59 mmol/L (100 mg/dL)|Percentage of subjects who achieve Low Density Lipoprotein cholesterol concentrations less than 3.37 mmol/L (130 mg/dL),Takeda,All,"18 Years and older   (Adult, Older Adult)",Phase 3,415,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",01-05-TL-475-022|U1111-1122-8106,Oct-05,Apr-07,Apr-07,7-Nov-05,null,24-May-12,"Birmingham, Alabama, United States|Haleyville, Alabama, United States|Mobile, Alabama, United States|Scottsdale, Arizona, United States|Long Beach, California, United States|Mission Viejo, California, United States|Orange, California, United States|Redondo Beach, California, United States|Rolling Hills Estates, California, United States|San Diego, California, United States|Torrance, California, United States|Tustin, California, United States|Avon, Connecticut, United States|Bristol, Connecticut, United States|De Land, Florida, United States|Ft. Lauderdale, Florida, United States|Hialeah, Florida, United States|Jacksonville, Florida, United States|Jupiter, Florida, United States|Melbourne, Florida, United States|Miami, Florida, United States|Naples, Florida, United States|Ocala, Florida, United States|Pembroke Pines, Florida, United States|Plantation, Florida, United States|Hayden Lake, Idaho, United States|Meridian, Idaho, United States|Arlington Heights, Illinois, United States|Aurora, Illinois, United States|Chicago, Illinois, United States|Peoria, Illinois, United States|Indianapolis, Indiana, United States|Iowa City, Iowa, United States|Kansas City, Kansas, United States|Witchita, Kansas, United States|Louisville, Kentucky, United States|Thibodaux, Louisiana, United States|Auburn, Maine, United States|Haverhill, Massachusetts, United States|Benzonia, Michigan, United States|Detroit, Michigan, United States|Kansas City, Missouri, United States|St. Louis, Missouri, United States|Missoula, Montana, United States|Concord, New Hampshire, United States|West Seneca, New York, United States|Raleigh, North Carolina, United States|Statesville, North Carolina, United States|Winstom-Salem, North Carolina, United States|Grand Forks, North Dakota, United States|Akron, Ohio, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Kettering, Ohio, United States|Tulsa, Oklahoma, United States|Eugene, Oregon, United States|Portland, Oregon, United States|Lansdale, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Scotland, Pennsylvania, United States|Cranston, Rhode Island, United States|Anderson, South Carolina, United States|Bristol, Tennessee, United States|Cordova, Tennessee, United States|Kingsport, Tennessee, United States|Austin, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|McKinney, Texas, United States|Midland, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Burke, Virginia, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Weber City, Virginia, United States|Bellevue, Washington, United States|Burien, Washington, United States|Edmonds, Washington, United States|Seattle, Washington, United States|Spokane, Washington, United States|Calgary, Alberta, Canada|Portage La Prairie, Manitoba, Canada|London, Ontario, Canada|Oakville, Ontario, Canada|Oshawa, Ontario, Canada|Thornhill, Ontario, Canada|Toronto, Ontario, Canada|Chicoutimi, Quebec, Canada|St. Jerome, Quebec, Canada|Ste-Foy, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00249912
NCT00249938,Evaluation of Combination Cholesterol Treatments in Patients With High Cholesterol.,,Completed,No Results Available,Hyperlipidemia|Dyslipidemia,Drug: Minute Maid Heart Wise orange juice|Drug: Welchol,"LDL cholesterol|Triglycerides, HDL cholesterol, total cholesterol, C-reactive protein, Apolipoprotein B","University of Colorado, Denver|Daiichi Sankyo, Inc.",All,"18 Years to 89 Years   (Adult, Older Adult)",Phase 4,60,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,04-0823,Mar-05,null,Aug-06,7-Nov-05,null,28-Mar-17,"University of Colorado at Denver and Health Sciences Center, Denver, Colorado, United States",,https://ClinicalTrials.gov/show/NCT00249938
NCT00246376,"Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia",HeartPositive,Completed,Has Results,Cardiovascular Diseases|Heart Diseases|HIV Infections|Hyperlipidemia|Hypertriglyceridemia|Insulin Resistance|Atherosclerosis,Behavioral: Diet|Behavioral: Exercise|Drug: Niacin|Drug: Fenofibrate|Other: Placebos,Triglycerides|Non-HDL-C|HDL-C|Total Cholesterol|Total Cholesterol : HDL-C Ratio|Insulin Sensitivity|Body Composition,"Baylor College of Medicine|National Heart, Lung, and Blood Institute (NHLBI)|Legacy Community Health Center",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,221,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",H-14105|R01HL073696,Jan-04,Sep-09,Feb-12,31-Oct-05,21-Mar-16,21-Mar-16,"Baylor College of Medicine, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00246376
NCT00246402,Acipimox to Improve Hyperlipidemia and Insulin Sensitivity Associated With HIV,,Completed,No Results Available,Insulin Resistance|Cardiovascular Diseases|Heart Diseases|HIV Infections|Hypertriglyceridemia|Hyperlipidemia,Drug: Acipimox,"Fasting Triglyceride Concentration (Initial, after 3 months)|Insulin Sensitivity (Initial, after 3 months)","National Heart, Lung, and Blood Institute (NHLBI)",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,30,NIH,Interventional,Allocation: Randomized|Masking: Double|Primary Purpose: Prevention,337|R21HL073675,Sep-02,null,Aug-06,31-Oct-05,null,15-May-14,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00246402
NCT00246636,Evaluation of Efficacy and Safety of Omacor (Omega-3-acid Ethyl Esters) as Add-on Therapy in Hypertriglyceridemic Subjects Treated With Antara (Fenofibrate) Followed by an 8-week Extension,,Completed,No Results Available,Hypertriglyceridemia,Drug: Antara (fenofibrate) + Lovaza|Drug: Antara (fenofibrate),OM5X/LOV111860 - Difference between double-blind Lovaza (omega-3-acid ethyl esters) + fenofibrate (Group 1) and placebo + fenofibrate (Group 2) treatment groups in percent change in fasting serum TG level from baseline of OM5 to end of OM5X|OM5/LOV111859 - Difference between Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor]+ fenofibrate and placebo + fenofibrate treatment groups in percent change in TG level from baseline|OM5X/LOV111860 - Difference between double-blind Lovaza (omega-3-acid ethyl esters) + fenofibrate (Group 1) and placebo + fenofibrate (Group 2) treatment groups in percent change for other lipid and biomarkers from baseline of OM5 to end of OM5X|OM5/LOV111859 - Difference between Lovaza (omega-3-acid ethyl esters) + fenofibrate and placebo + fenofibrate treatment groups in percent change for other lipid and biomarkers from baseline,GlaxoSmithKline,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 4,167,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",OM5 program (Reliant)|OM5/LOV111859 (original study)|OM5X/LOV111860 (1st extension),Oct-05,Feb-07,Mar-07,31-Oct-05,null,14-Dec-09,,,https://ClinicalTrials.gov/show/NCT00246636
NCT00246701,Evaluation of Efficacy and Safety of Combined Omacor (Omega-3-acid Ethyl Esters) and Simvastatin Therapy in Hypertriglyceridemic Subjects,COMBOS,Completed,No Results Available,Hypertriglyceridemia,Drug: Simvastatin|Drug: Simvastatin + Lovaza,Difference between simvastatin + Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor] and simvastatin + placebo treatment groups in the percent change from baseline to end-of-treatment in non-high-density lipoprotein cholesterol|OM6/LOV111858 - Difference between simvastatin + Lovaza (omega-3-acid ethyl esters) and simvastatin + placebo treatment groups in the percent change from baseline to end-of-treatment in other lipid and biomarker levels,GlaxoSmithKline,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 3,256,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",OM6 program (Reliant)|LOV111818,1-Nov-05,1-Jun-06,1-Jun-06,31-Oct-05,null,28-Mar-17,,,https://ClinicalTrials.gov/show/NCT00246701
NCT00245388,Efficacy and Safety of BMS-298585 Alone or in Combination With Pravastatin in Subjects With Mixed Dyslipidemia,,Completed,No Results Available,Dyslipidemia,Drug: Muraglitazar,"To compare at a .05 level of significance, after 6 weeks of oral administration of double-blind treatment the percent change from baseline to average triglycerides (TG), week 5-6 between 5, 10 and 20 mg|Percent changes from baseline to average at week 5-6 of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), non-HDL-C, apolipoprotein A1 (ApoA1), and free fatty acid (FFA) levels",Bristol-Myers Squibb,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2|Phase 3,330,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CV168-008,Apr-02,null,Jul-02,28-Oct-05,null,23-Apr-12,"Local Institution, Phoenix, Arizona, United States|Local Institution, Little Rock, Arkansas, United States|Local Institution, Irvine, California, United States|Local Institution, Long Beach, California, United States|Local Institution, Raleigh, California, United States|Local Institution, Roseville, California, United States|Local Institution, Sacramento, California, United States|Local Institution, San Diego, California, United States|Local Institution, Santa Ana, California, United States|Local Institution, Longmont, Colorado, United States|Local Institution, Clearwater, Florida, United States|Local Institution, Cooper City, Florida, United States|Local Institution, Deland, Florida, United States|Local Institution, Inverness, Florida, United States|Local Institution, Longwood, Florida, United States|Local Institution, Pembroke Pines, Florida, United States|Local Institution, Sarasota, Florida, United States|Local Institution, Stuart, Florida, United States|Local Institution, Dunwoody, Georgia, United States|Local Institution, Melbourne, Georgia, United States|Local Institution, Peoria, Illinois, United States|Local Institution, Indianapolis, Indiana, United States|Local Institution, Iowa City, Iowa, United States|Local Institution, Overland Park, Kansas, United States|Local Institution, Wichita, Kansas, United States|Local Institution, Louisville, Kentucky, United States|Local Institution, Marrero, Louisiana, United States|Local Institution, Baltimore, Maryland, United States|Local Institution, Bethesda, Maryland, United States|Local Institution, Edina, Minnesota, United States|Local Institution, Minneapolis, Minnesota, United States|Local Institution, Kansas City, Missouri, United States|Local Institution, Saint Louis, Missouri, United States|Local Institution, Toms River, New Jersey, United States|Local Institution, Manlius, New York, United States|Local Institution, Hickory, North Carolina, United States|Local Institution, Winston-Salem, North Carolina, United States|Local Institution, Columbus, Ohio, United States|Local Institution, Bend, Oregon, United States|Local Institution, Hillsboro, Oregon, United States|Local Institution, Portland, Oregon, United States|Local Institution, Philadelphia, Pennsylvania, United States|Local Institution, Sellersville, Pennsylvania, United States|Local Institution, Warminster, Pennsylvania, United States|Local Institution, Greer, South Carolina, United States|Local Institution, Mount Pleasant, South Carolina, United States|Local Institution, Austin, Texas, United States|Local Institution, Dallas, Texas, United States|Local Institution, San Angelo, Texas, United States|Local Institution, San Antonio, Texas, United States|Local Institution, Olympia, Washington, United States|Local Institution, Seattle, Washington, United States|Local Institution, Yakima, Washington, United States|Local Institution, Ottawa, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00245388
NCT00244231,Efficacy and Safety Study of Nidadd in the Management of Hyperlipidemia,,Completed,No Results Available,Hyperlipidemia,Drug: Nidadd,"Change from baseline in HDL-c levels|Changes from baseline in serum total cholesterol , LDL-c, and triglycerides","Genovate Biotechnology Co., Ltd.,",All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 3,70,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,GBL03-NSR,Oct-03,null,Aug-05,26-Oct-05,null,1-Mar-07,,,https://ClinicalTrials.gov/show/NCT00244231
NCT00242944,Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome (JAPAN-ACS),,Completed,No Results Available,Coronary Disease|Hypercholesterolemia,Drug: Pitavastatin|Drug: Atorvastatin,"plaque volume|total cholesterol (TC)|low-density lipoprotein (LDL)-cholesterol (LDL-C)|high-density lipoprotein (HDL)-cholesterol (HDL-C)|HDL2-C|HDL3-C|remnant like particles-cholesterol (RLP-C)|small dense LDL-C|non-HDL-C|LDL-C/HDL-C|apolipoprotein AI (apoA-I)|apoB|apoE|apoB/apoA-I|malondialdehyde-modified LDL (MDA-LDL)|phospholipids|lipoprotein(a) [Lp(a)]|high-sensitivity C-reactive protein (hs-CRP)|pentraxin 3|leukocytes|coronary plaque area at culprit region|minimal lumen diameter (MLD) and percent (%) stenosis|major adverse cardiac events (cardiac death, Q or non-Q myocardial infarction and target vessel revascularization)|number of deaths from any cause|frequency of adverse drug reactions",Kyoto University|Yamaguchi University Hospital|Juntendo University School of Medicine,All,"20 Years and older   (Adult, Older Adult)",Phase 4,307,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,H17-49,Nov-05,Oct-07,Mar-08,21-Oct-05,null,17-Dec-09,"Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan|Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan|Kyoto University Graduate School of Medicine, Kyoto, Japan",,https://ClinicalTrials.gov/show/NCT00242944
NCT00241488,DISCOVERY Asia - Crestor in Type IIa and IIb Hypercholesteremia,,Completed,No Results Available,Hypercholesterolemia,Drug: Rosuvastatin,"The primary objective of the study is to compare the efficacy of rosuvastatin 10 mg with atorvastatin 10 mg by assessment of the percentage of subjects who reach EAS LDL-C target goals after 12 weeks of therapy|Secondary objectives of the study are:|1. To compare the efficacy of rosuvastatin 10 mg with atorvastatin 10mg by assessment of the percentage of subjects who reach EAS TC treatment goals after 12 weeks of therapy.|2. Percentage change in LDL-C, TC, HDL-C and TG from pre-dose (week 0) and 12 weeks which will be performed separately for the switched and the naïve patients.|3. To compare rosuvastatin 10 mg with atorvastatin 10 mg after 12 weeks of treatment with respect to the incidence and severity of adverse events and abnormal laboratory values.",AstraZeneca,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1362,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D3560L00009|DISCOVERY-Asia,Jun-03,Dec-05,Feb-07,19-Oct-05,null,7-Feb-08,"Beijing, China|Ching Qing, China|Guang Zhou, China|Harbin, China|Ji Nan, China|Nanjing, China|Shanghai, China|Shenyang, China|Wu Han, China|New Territories, Hong Kong|Busan, Korea, Republic of|Cheonan-si, Korea, Republic of|Daegu, Korea, Republic of|Ilsan, Korea, Republic of|Incheon-Si, Korea, Republic of|Kwangju, Korea, Republic of|Pusan, Korea, Republic of|Pyungchon Kyonggi, Korea, Republic of|Seoul, Korea, Republic of|Suwon, Korea, Republic of|Wonju, Korea, Republic of|Kuching, Sarawak, Malaysia|Bandar Sunway, Selangor, Malaysia|Shah Alam, Selangor, Malaysia|Kuala Lumpur, Malaysia|Penang, Malaysia|Petaling Jaya, Malaysia|Seberang Perai Utara, Malaysia|Chunghua City, Taiwan|Kaohsiung, Taiwan|Taichung City, Taiwan|Taipei, Taiwan|Tao-Yuan, Taiwan|Bangkok, Thailand",,https://ClinicalTrials.gov/show/NCT00241488
NCT00240266,Study of High Density Lipoprotein Cholesterol (HDL-C)-Raising Mechanism of Rosuvastatin (CRESTOR™) by Quantifying the Key Steps of Reverse Cholesterol Transport (RCT),,Completed,No Results Available,Metabolic Syndrome|Dyslipidemia,Drug: Rosuvastatin,"Determine the effect of treatment with rosuvastatin on the capacity of plasma to promote cholesterol efflux, which is the first and likely rate limiting step in reverse cholesterol transport.|Determine the effect of treatment with rosuvastatin on:|- cholesterol esterification by measuring plasma lecithin:cholesterol acyl transferase concentration and capacity to esterify cholesterol, one of the stops in RCT.|- plasma concentration of cholesterol ester transfer protein and capacity to transfer cholesterol from HDL-C to apoB-containing lipoproteins, one of the steps in RCT.|- plasma concentration of preβ1-HDL.|- plasma concentration of LDL cholesterol, HDL-C and apoA-1.",AstraZeneca,Male,"45 Years to 65 Years   (Adult, Older Adult)",Phase 3,15,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,4522AS/0003,Aug-03,Nov-04,Dec-04,18-Oct-05,null,19-Nov-10,"Research Site, Melbourne, Victoria, Australia",,https://ClinicalTrials.gov/show/NCT00240266
NCT00240279,The Effect of Rosuvastatin on Aortic Stiffness in Hemodialysis Patients in the AURORA Study,,Completed,No Results Available,Hypercholesterolemia,Drug: Rosuvastatin|Procedure: aortic pulse wave velocity measurements,"To investigate the effect of rosuvastatin compared to placebo on the aortic stiffness in hemodialysis patients as measured by pulse wave velocity (at 3, 6 and 12 months)|To investigate the effect of rosuvastatin compared to placebo on the aortic pressure wave in hemodialysis patients (at 3 months/ 6 months and 12 months).",AstraZeneca,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 3,10,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,4522IL/0096 Dutch SubStudy|D3562C00096,Jan-03,Oct-08,Oct-08,18-Oct-05,null,19-Nov-10,"Research Site, Nieuwegein, Netherlands",,https://ClinicalTrials.gov/show/NCT00240279
NCT00240305,A Study to Investigate the Effect of Rosuvastatin (CRESTOR®) on High Density Lipoprotein Kinetics in Patients With the Metabolic Syndrome,,Completed,No Results Available,Metabolic Syndrome|Dyslipidemia,Drug: Rosuvastatin,"Determine the dose-related effect of treatment with rosuvastatin on production & fractional catabolism of apolipoprotein A-I (apoA-I) and apolipoprotein A-II (apoA-II), & on the plasma apoA-I, apoA-II & high-density lipoprotein cholesterol (HDL-C) c|Determine the dose-related effect of treatment with rosuvastatin on cellular cholesterol efflux,total cholesterol, low-density lipoprotein cholesterol (LDL-C), non-LDL-C, triglyceride & pre1-HDL concentrations,HDL2,HDL3 cholesterol ratio|Cholesteryl ester transfer protein (CETP) and lecithin:cholesterol acyl transferase (LCAT) activity|Lathosterol and campesterol, total apolipoprotein B (apoB), nonesterified fatty acids (NEFA) and apolipoprotein C-III (apoC-III) plasma concentrations.",AstraZeneca,Male,"30 Years to 70 Years   (Adult, Older Adult)",Phase 3,15,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,4522AS/0004,Apr-04,null,May-06,18-Oct-05,null,16-Mar-09,"Research Site, Perth, Western Australia, Australia",,https://ClinicalTrials.gov/show/NCT00240305
NCT00240357,Effect of an Internet Based Compliance Enhancement Tool in Subjects With Hypercholesterolemia,,Withdrawn,No Results Available,Hypercholesterolemia,Procedure: Lifestyle Regulation,"The primary endpoint is the number and percentage of subjects from each group (rosuvastatin or rosuvastatin + a compliance enhancement tool) who reached the DSAM LDL-C target goal (LDL-C < 3.0 mmol/L) after 6 months therapy (24 weeks).|Number and percentage of subjects within the DSAM LDL-C target goal after 3 months therapy|Compliance with study drug assessed by tablet count data|Number and percentage of subjects increasing rosuvastatin dosage from 10 mg to 20 mg at week 12|Percentage change in TC, HDL-C, LDL-C, TG from week 0 to week 24|Change in weight after 6 months therapy|Change in waistline after 6 months therapy",AstraZeneca,All,"18 Years and older   (Adult, Older Adult)",Phase 4,1175,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D3560L00002|Orbital,Feb-03,null,null,18-Oct-05,null,26-Mar-09,"Research Site, Aabenraa, Denmark|Research Site, Aalbaek, Denmark|Research Site, Aalborg, Denmark|Research Site, Aarhus C, Denmark|Research Site, Aerup, Denmark|Research Site, Albertslund, Denmark|Research Site, Ans by, Denmark|Research Site, Bagsvaerd, Denmark|Research Site, Billund, Denmark|Research Site, Birkeroed, Denmark|Research Site, Broby, Denmark|Research Site, Broendby Strand, Denmark|Research Site, Broenshoej, Denmark|Research Site, Copenhagen V, Denmark|Research Site, Elsingore, Denmark|Research Site, Farum, Denmark|Research Site, Fredericia, Denmark|Research Site, Frederiksberg C, Denmark|Research Site, Frederikshavn, Denmark|Research Site, Frederikssund, Denmark|Research Site, Gentofte, Denmark|Research Site, Glesborg, Denmark|Research Site, Glostrup, Denmark|Research Site, Goerlev Sjaelland, Denmark|Research Site, Grenå, Denmark|Research Site, Greve, Denmark|Research Site, Grindsted, Denmark|Research Site, Haarlev, Denmark|Research Site, Hadsund, Denmark|Research Site, Haslev, Denmark|Research Site, Hedehusene, Denmark|Research Site, Hellerup, Denmark|Research Site, Helsinge, Denmark|Research Site, Herning, Denmark|Research Site, Hilleroed, Denmark|Research Site, Hoeng, Denmark|Research Site, Hoersholm, Denmark|Research Site, Holbaek, Denmark|Research Site, Hornbaek, Denmark|Research Site, Horsens, Denmark|Research Site, Humlebaek, Denmark|Research Site, Hvidovre, Denmark|Research Site, Ikast, Denmark|Research Site, Jaegerspris, Denmark|Research Site, Kalundborg, Denmark|Research Site, Karlslunde, Denmark|Research Site, Kastrup, Denmark|Research Site, Kgs. Lyngby, Denmark|Research Site, Kjellerup, Denmark|Research Site, Kokkedal, Denmark|Research Site, Kolding, Denmark|Research Site, Kvaerndrup, Denmark|Research Site, Langeskov, Fyn, Denmark|Research Site, Lyngby, Denmark|Research Site, Lystrup, Denmark|Research Site, Maeloev, Denmark|Research Site, Middelfart, Denmark|Research Site, Morud, Denmark|Research Site, Naerum, Denmark|Research Site, Naestved, Denmark|Research Site, Noerre Alslev, Denmark|Research Site, Noerresundby, Denmark|Research Site, Nyborg, Denmark|Research Site, Nykoebing F, Denmark|Research Site, Odense C, Denmark|Research Site, Odense NV, Denmark|Research Site, Oelstykke, Denmark|Research Site, Oksboel, Denmark|Research Site, Randers, Denmark|Research Site, Risskov, Denmark|Research Site, Roedovre, Denmark|Research Site, Roskilde, Denmark|Research Site, Roslev, Denmark|Research Site, Rudkoebing, Denmark|Research Site, Rungsted Kyst, Denmark|Research Site, Saeby, Denmark|Research Site, Sakskoebing, Denmark|Research Site, Saltum, Denmark|Research Site, Skals, Denmark|Research Site, Skive, Denmark|Research Site, Skovlunde, Denmark|Research Site, Slagelse, Denmark|Research Site, Snekkersten, Denmark|Research Site, Soenderborg, Denmark|Research Site, Soendersoe, Denmark|Research Site, Solroed Strand, Denmark|Research Site, Soroe, Denmark|Research Site, Stege, Denmark|Research Site, Stenlille, Denmark|Research Site, Struer, Denmark|Research Site, Svendborg, Denmark|Research Site, Svendstrup, Denmark|Research Site, Taastrup, Denmark|Research Site, Thorsoe, Denmark|Research Site, Toelloese, Denmark|Research Site, Toender, Denmark|Research Site, Ullerslev, Denmark|Research Site, Vaerloese, Denmark|Research Site, Vanloese, Denmark|Research Site, Varde, Denmark|Research Site, Vedbaek, Denmark|Research Site, Vejle, Denmark|Research Site, Viborg, Denmark|Research Site, Viby J, Denmark|Research Site, Vinderup, Denmark|Research Site, Virum, Denmark|Research Site, Viuf, Denmark|Research Site, Vojens, Denmark|Research Site, Ålestrup, Denmark",,https://ClinicalTrials.gov/show/NCT00240357
NCT00239330,Direct Statin Comparison of LDL-C Values: an Evaluation of Rosuvastatin Therapy,,Completed,No Results Available,Hypercholesteremia,Drug: Rosuvastatin|Drug: Atorvastatin,"The primary objective of the study is to compare the efficacy of rosuvastatin 10 mg with atorvastatin 10 mg by assessment of the percentage of subjects who reach EAS LDL-C target goals after 12 weeks of therapy.|To compare the efficacy of rosuvastatin 10 mg with atorvastatin 10 mg by assessment of the percentage of subjects who reach EAS TC treatment goal after 12 weeks of therapy.|To compare the percentage change in LDL-C, TC, HDL-C and TG from pre-dose rosuvastatin 10 mg / atorvastatin 10 mg (week 0) and at 12 weeks. This will be performed separately for the switched and the naïve subjects.|To compare the efficacy of rosuvastatin 10 mg with atorvastatin 10 mg in modifying lipids (Non-HDL-C, TC/HDL-C, LDL-C/ HDL-C, non-HDL-C/HDL-C) at week 12. This will be performed separately for the switched and the naïve subjects.|To compare rosuvastatin 10 mg with atorvastatin 10 mg after 12 & 24 weeks of treatment with respect to the incidence & severity of adverse events & abnormal laboratory values.",AstraZeneca,All,"18 Years and older   (Adult, Older Adult)",Phase 3,824,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D3560L00011|DISCOVERY,Jun-03,Feb-05,Feb-05,17-Oct-05,null,19-Nov-10,"Research Site, Antwerpen, Belgium|Research Site, Arlon, Belgium|Research Site, Assebroek, Belgium|Research Site, Ath, Belgium|Research Site, Aye, Belgium|Research Site, Bastogne, Belgium|Research Site, Baudour, Belgium|Research Site, Borgerhout, Belgium|Research Site, Bornem, Belgium|Research Site, Bouge, Belgium|Research Site, Brugge, Belgium|Research Site, Brussels, Belgium|Research Site, Charleroi, Belgium|Research Site, Dendermonde, Belgium|Research Site, Frameries, Belgium|Research Site, Gent, Belgium|Research Site, Hasselt, Belgium|Research Site, Havré, Belgium|Research Site, Kortenberg, Belgium|Research Site, Leuven, Belgium|Research Site, Mol, Belgium|Research Site, Namur, Belgium|Research Site, Oostende, Belgium|Research Site, Roeselare, Belgium|Research Site, Schoten, Belgium|Research Site, Sint-Agatha-Berchem, Belgium",,https://ClinicalTrials.gov/show/NCT00239330
NCT00239967,An International Study of Rimonabant in Dyslipidemia With AtheroGenic Risk In Abdominally Obese Patients,ADAGIO-lipids,Completed,No Results Available,Dyslipidemia|Obesity,Drug: Rimonabant (SR141716)|Drug: Placebo,"HDL cholesterol and TG plasma levels over a period of one year.|Cholesterol content of HDL2 and HDL3 subfractions,HDL particle size,ApoB,ApoA1,ApoCIII, FFA, indeces of LDL size,hs-CRP,adipokines, fasting glycemia and insulinemia, HbA1c),waist and weight measurements,visceral fat measured by CT scan",Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,803,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",EFC5823,May-05,Feb-07,Feb-07,17-Oct-05,null,7-Apr-09,"Sanofi-aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-aventis Administrative Office, Macquarie Park, Australia|Sanofi-aventis Administrative Office, Sao Paulo, Brazil|Sanofi-aventis Administrative Office, Laval, Canada|Sanofi-aventis Administrative Office, Horsholm, Denmark|Sanofi-aventis Administrative Office, Causeway Bay, Hong Kong|Sanofi-aventis Administrative Office, Milano, Italy|Sanofi-aventis Administrative Office, Seoul, Korea, Republic of|Sanofi-aventis Administrative Office, Kuala Lumpur, Malaysia|Sanofi-aventis Administrative Office, Mexico, Mexico|Sanofi-aventis Administrative Office, Singapore, Singapore|Sanofi-aventis Administrative Office, Midrand, South Africa|Sanofi-aventis Administrative Office, Bromma, Sweden|Sanofi-aventis Administrative Office, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT00239967
NCT00236210,A Randomized Controlled Trial of a Novel Community-based Primary and Secondary Cardiovascular Prevention Program,,Completed,No Results Available,Vascular Disease|Diabetes|Hypertension|Hyperlipidemia|Obesity,Behavioral: Action Score|Behavioral: VIP program,"The percentage of patients who attained a significant reduction in their global cardiovascular risk at 6 and 12 months. This was determined a priori by the investigators to be an increase in the ACTION Score of 5 or more.|Secondary outcomes were change in the average ACTION Score, change in individual risk domains as measured by the ACTION Score, patient satisfaction, and quality of life, all after 6 months and 12 months, comparing intervention versus control.",Group Health Centre|Ontario Ministry of Health and Long Term Care|McMaster University|Coalition for the Acquisition of Sound Habits|Ministry of Northern Development and Mines Youth Internship Program|Pfizer,All,"30 Years and older   (Adult, Older Adult)",Not Applicable,422,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,Go3-03031,Aug-04,Jul-06,Jul-06,12-Oct-05,null,4-Aug-09,"Group Health Centre, Sault Ste. Marie, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00236210
NCT00231569,Dose-escalating Safety Study in Subjects on Stable Statin Therapy,,Completed,No Results Available,Hypercholesterolemia,Drug: ISIS 301012 or Placebo,"Percent reduction in LDL-cholesterol from baseline|Percent reduction in apoB-100|Percent change in HDL-cholesterol, triglycerides, total cholesterol, non-HDL cholesterol, VLDL plus LDL-cholesterol and LDL-cholesterol particle size and concentration|Percent change from baseline in LDL/HDL and apoB-100/apo-A1 ratios|AEs, SAEs, physical examination data, vital signs, and laboratory analyzes","Kastle Therapeutics, LLC|Ionis Pharmaceuticals, Inc.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,74,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",301012CS4|EudraCT No.: 2005-002119-26,Sep-05,Jun-07,Dec-07,4-Oct-05,null,3-Aug-16,"Auburn, Maine, United States|Amsterdam, Netherlands|Leiden, Netherlands|Rotterdam, Netherlands|Utrecht, Netherlands",,https://ClinicalTrials.gov/show/NCT00231569
NCT00231621,A Study on Efficacy and Safety of Topiramate in Treatment of Obese Subjects With Dyslipidemia,,Terminated,No Results Available,Obesity|Hyperlipidemia|Hypertriglyceridemia,Drug: topiramate,"Percent change in body weight and the percent change in fasting serum triglycerides from baseline (Week 0) to Week 60.|Absolute change in body weight, body mass index, triglycerides, and absolute and percentage changes in cholesterol measures from baseline to Week 60. Safety evaluations throughout study.","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,179,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CR003730,May-01,null,Jun-02,4-Oct-05,null,8-Jun-11,,,https://ClinicalTrials.gov/show/NCT00231621
NCT00227500,Pravastatin for Hyperlipidaemia in HIV.,,Completed,No Results Available,HIV Infections|Lipid Metabolism|Glucose Metabolism|Metabolic Abnormality|Lipodystrophy|Cardiovascular Disease,Drug: Pravastatin,Between-group difference in time weighted change from baseline in fasting serum total cholesterol|Includes: between-group difference in time weighted change: from wk 4 in fasting serum total cholesterol as well as from baseline in HDL-cholesterol and triglycerides; in total and regional body fat; in endothelial function,"Kirby Institute|The University of New South Wales|National Heart, Lung, and Blood Institute (NHLBI)|Garvan Institute of Medical Research|St Vincent's Hospital, Sydney",All,"18 Years and older   (Adult, Older Adult)",Phase 4,40,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,PRAVA|PRAVA / RO1 HL65953-01,Jul-01,null,Oct-04,28-Sep-05,null,9-Jun-06,"St. Vincents Hospital, Sydney, New South Wales, Australia",,https://ClinicalTrials.gov/show/NCT00227500
NCT00225589,A Study Measuring Effects on Intima Media Thickness: An Evaluation of Rosuvastatin 40 mg (METEOR),,Completed,No Results Available,Hypercholesteremia,Drug: Rosuvastatin calcium,"Assess the effects of rosuvastatin treatment on the change in the mean maximum intima media thickness (IMT) of the 12 vessel segments: the near & far walls of the CCA, the carotid bulb & the ICA|Assess the effects of rosuvastatin treatment on the following variables, with the same analyses being applied to the IMT variables:|Change in the mean maximum IMT of the near & far walls of the right & left CCA, carotid bulb, ICA|Change in the mean IMT of the near & far walls of the right & left CCA|Change in LDL-C, TC, HDL-C, TG, nonHDL-C, ApoB, ApoA-I, nonHDL-C/HDL-C, & ApoB/ApoA-I|Change in inflammatory marker: C-reactive protein (CRP)|Safety & tolerability, by evaluating the incidence & severity of adverse events & abnormal laboratory values",AstraZeneca,All,"45 Years to 70 Years   (Adult, Older Adult)",Phase 3,840,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double,4522IL/0088|METEOR|D3562C00088,Aug-02,May-06,May-06,26-Sep-05,null,19-Nov-10,"Research Site, Alhambra, California, United States|Research Site, La Jolla, California, United States|Research Site, Los Angeles, California, United States|Research Site, San Diego, California, United States|Research Site, Santa Ana, California, United States|Research Site, Chicago, Illinois, United States|Research Site, Boston, Massachusetts, United States|Research Site, Brooklyn Center, Minnesota, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Salisbury, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Glen Mills, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Houston, Texas, United States|Research Site, Kirkland, Washington, United States|Research Site, Renton, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Madison, Wisconsin, United States|Research Site, Brussels (Anderlecht), Belgium|Research Site, Brussels, Belgium|Research Site, Leuven, Belgium|Research Site, Praha 2, Czech Republic|Research Site, Slaný, Czech Republic|Research Site, Kuopio, Finland|Research Site, Auboue, France|Research Site, Bagnolet, France|Research Site, Boulogne Billancourt, France|Research Site, Briey, France|Research Site, Delme, France|Research Site, Drancy, France|Research Site, Fresnes En Woevre, France|Research Site, Ivry Sur Seine, France|Research Site, Jarny, France|Research Site, Les Lilas, France|Research Site, Marange Silvange, France|Research Site, Mars La Tour, France|Research Site, Metz, France|Research Site, Meudon, France|Research Site, Montigny Les Metz, France|Research Site, Moutiers, France|Research Site, Paris cedex 14, France|Research Site, Paris, France|Research Site, St Germain En Laye, France|Research Site, Thionville, France|Research Site, Yerres, France|Research Site, Yutz, France|Research Site, München, Bayern, Germany|Research Site, Essen, Nordrhein-Westfalen, Germany|Research Site, Essen, Germany|Research Site, München, Germany|Research Site, Amsterdam, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Bekkestua, Norway|Research Site, Oslo, Norway|Research Site, Skedsmokorset, Norway",,https://ClinicalTrials.gov/show/NCT00225589
NCT00225628,Improving Quality With Outpatient Decision Support,,Completed,No Results Available,Diabetes Mellitus|Coronary Artery Disease|Osteoporosis|Hypertension|Hyperlipidemia,Behavioral: Computerized Reminders Medications Monitoring|Behavioral: Computerized Test Results Management Application|Behavioral: Computerized Reminders Hypertension Management|Behavioral: Computerized Reminders Osteoporosis Screening and Mgt,"1) Compliance to guidelines regarding the outpatient laboratory monitoring of prescription medication regiments|2) Compliance to guidelines regarding the follow-up of abnormal test results, including critically abnormal test results, abnormal cholesterol, abnormal HbA1c, abnormal pap smears and abnormal mammogram|3) Compliance to guidelines regarding the management of hypertension in the general ambulatory population and amongst ethnic minority groups|4) Compliance to guidelines regarding the screening and management of osteoporosis|1) Patient satisfaction regarding communication with physicians|2) Physician satisfaction regarding follow-up of abnormal test results",Agency for Healthcare Research and Quality (AHRQ),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,3000,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,5U18HS011046,Sep-00,null,Dec-06,26-Sep-05,null,26-Sep-05,"Brigham and Women's Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00225628
NCT00225849,Japanese Primary Prevention Project With Aspirin,,Unknown status,No Results Available,Hypertension|Hyperlipidemia|Diabetes Mellitus,Drug: Aspirin,"Composite event of cerebro/cardiovascular (CV) death, nonfatal cerebral stroke (of any cause) and nonfatal myocardial infarction (MI)|CV death|Non CV death|Nonfatal cerebral stroke|Nonfatal MI|Angina pectoris|Transient ischemic attack|Arteriosclerotic disease requiring surgery or intervention|Extracranial bleeding requiring transfusion or admission|Severe side-effects that lead to interruption of the study medication.","Ministry of Health, Labour and Welfare, Japan|Japan Heart Foundation|Bayer",All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 4,10000,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,JPPP-05-07|MHLW2004-CV(Adult disease)-010,Mar-05,null,Sep-10,26-Sep-05,null,26-Sep-05,"Keio University School of Medicine, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT00225849
NCT00224848,Guideline Adherence for Heart Health,GLAD Heart,Completed,No Results Available,Cardiovascular Diseases|Hypercholesterolemia|Hypertension,Behavioral: Palm-Pilot Intervention,Proportion of patients treated appropriately with respect to lipid-lowering therapy within four months after lipid testing|Rate of appropriate treatment among patients with high blood pressure,"National Heart, Lung, and Blood Institute (NHLBI)",All,"21 Years to 84 Years   (Adult, Older Adult)",Phase 2,61,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,314|R01HL070742,Jul-02,Sep-07,Aug-08,23-Sep-05,null,7-Nov-16,,,https://ClinicalTrials.gov/show/NCT00224848
NCT00225017,Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study,SABAR,Completed,Has Results,HIV Infection|Hyperlipidemia,Drug: Atazanavir|Drug: current antiretroviral regimen,Percentage Change in Brachial Artery Flow Mediated (FMD) Vasodilation Between Arms From Baseline to Week 24|Change in Total Cholesterol Levels From Baseline to Week 24|Changes in LDL Particle Number From Baseline to Week 24,Northwestern University|Bristol-Myers Squibb,All,"18 Years and older   (Adult, Older Adult)",Phase 3,50,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SABAR,Jun-05,Jun-08,Jun-08,23-Sep-05,2-Aug-12,2-Aug-12,"University of California, San Diego, California, United States|Northwestern Universtiy, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|University of Cincinnati, Cincinnati, Ohio, United States|University of Wisconsin, Madison, Wisconsin, United States|ACLIRES - Argentina S.R.L., Buenos Aires, Argentina|Universita degli studi di Modena e Reggio Emilia, Modena, Italy",,https://ClinicalTrials.gov/show/NCT00225017
NCT00225264,Efficacy Study of Pioglitazone and Glimepiride on the Rate of Progression of Atherosclerotic Disease.,CHICAGO,Completed,No Results Available,Diabetes Mellitus,Drug: Pioglitazone|Drug: Glimepiride,"Absolute change from Baseline in carotid intima-media thickness.|Change from Baseline in carotid intima-media thickness.|Change from Baseline in coronary artery calcium-volume score.|Change from Baseline in abdominal adipose tissue content and distribution.|Incidence of cardiovascular events as a composite of cardiovascular mortality, nonfatal myocardial infarction and nonfatal stroke|Incidence of cardiovascular events as a composite of cardiovascular mortality, nonfatal MI, nonfatal stroke, coronary revascularization, carotid endarterectomy/stenting, hospitalization for unstable angina and hospitalization for CHF",Takeda,All,"45 Years to 85 Years   (Adult, Older Adult)",Phase 3,458,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",01-02-TL-OPI-518|U1111-1114-2799,Oct-03,May-06,May-06,23-Sep-05,null,28-Feb-12,"Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00225264
NCT00225277,Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus,PERISCOPE,Completed,Has Results,Diabetes Mellitus,Drug: Pioglitazone|Drug: Glimepiride,Nominal Change From Baseline in Percent Atheroma Volume|Nominal Change From Baseline in Normalized Total Atheroma Volume|Number of Subjects Experiencing Any of the Composite Endpoint A Cardiovascular Events|Number of Subjects Experiencing Any of the Composite Endpoint B Cardiovascular Events|Number of Subjects Experiencing Any of the Composite Endpoint C Cardiovascular Events,Takeda,All,"35 Years to 85 Years   (Adult, Older Adult)",Phase 3,547,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",01-01-TL-OPI-516|U1111-1114-0400,Jul-03,Oct-07,Oct-07,23-Sep-05,10-Jun-09,28-Feb-12,"Birmingham, Alabama, United States|Phoenix, Arizona, United States|Huntington Beach, California, United States|Los Angeles, California, United States|Sacramento, California, United States|San Diego, California, United States|Torrance, California, United States|Bridgeport, Connecticut, United States|Farmington, Connecticut, United States|Washington, District of Columbia, United States|Bay Pines, Florida, United States|Jacksonville, Florida, United States|Decatur, Georgia, United States|Boise, Idaho, United States|Chicago, Illinois, United States|Edgewood, Kentucky, United States|Lexington, Kentucky, United States|Louisville, Kentucky, United States|New Orleans, Louisiana, United States|Bangor, Maine, United States|Baltimore, Maryland, United States|Detroit, Michigan, United States|Flint, Michigan, United States|Kalamazoo, Michigan, United States|Petoskey, Michigan, United States|Pontiac, Michigan, United States|Royal Oak, Michigan, United States|Ypsilanti, Michigan, United States|Duluth, Minnesota, United States|Minneapolis, Minnesota, United States|St. Cloud, Minnesota, United States|Columbia, Missouri, United States|Camden, New Jersey, United States|Albany, New York, United States|Bronx, New York, United States|Mineola, New York, United States|New York, New York, United States|Rochester, New York, United States|Troy, New York, United States|West Islip, New York, United States|Williamsville, New York, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Westlake, Ohio, United States|Oklahoma City, Oklahoma, United States|Tulsa, Oklahoma, United States|Abington, Pennsylvania, United States|Bryn Mawr, Pennsylvania, United States|Hershey, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Providence, Rhode Island, United States|Greenville, South Carolina, United States|Memphis, Tennessee, United States|Oak Ridge, Tennessee, United States|Amarillo, Texas, United States|Houston, Texas, United States|Lubbock, Texas, United States|San Antonio, Texas, United States|Charlottesville, Virginia, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Everett, Washington, United States|Green Bay, Wisconsin, United States|Ciudad de Buenos Aires, Argentina|Cordoba, Argentina|Quilmes, Argentina|Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|Victoria, British Columbia, Canada|Winnepeg, Manitoba, Canada|Saint John, New Brunswick, Canada|London, Ontario, Canada|Ottawa, Ontario, Canada|Montreal, Quebec, Canada|Sainte Foy, Quebec, Canada|Saskatoon, Saskatchewan, Canada|Santiago, Chile",,https://ClinicalTrials.gov/show/NCT00225277
NCT00214604,Type III Dysbetalipoproteinemia,,Completed,No Results Available,Hyperlipoproteinemia Type III,Drug: Rosuvastatin|Drug: rosuvastatin|Drug: pravastatin,"Percent change from baseline in non-HDL-C after 6 weeks of treatment at a given dose during the 18-week randomized crossover period.|Efficacy of once daily treatment with rosuvastatin 10mg, rosuvastatin 20mg and provastatin 40mg in subjects with dysbetalipoproteinemia after 6 weeks of treatment at any given dose during the 18-week randomized crossover period.",AstraZeneca,All,"18 Years and older   (Adult, Older Adult)",Phase 3,30,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,D3560C00071,Feb-05,Feb-07,Feb-07,22-Sep-05,null,19-Nov-10,"Research Site, Oslo, Norway|Research Site, Cape Town, South Africa",,https://ClinicalTrials.gov/show/NCT00214604
NCT00214617,Effect of Crestor on Lipoprotein Metabolism in Humans,,Completed,No Results Available,Hypercholesterolemia,Drug: Rosuvastatin at 5 mg/day and 40 mg/day,Rate of production of VLDL apoB|Rate of clearance of VLDL apoB|Rate of production of LDL apoB|Rate of clearance of LDL apoB|Rate of production of HDL apoA-I|Rate of clearance of HDL apoA-I|Activity of cholesteryl ester transfer protein,Atlanta Research and Education Foundation|AstraZeneca,All,"50 Years to 75 Years   (Adult, Older Adult)",Phase 4,8,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AREF_Le_IRUSROSU 0021|IRUSROSU 0021,Jan-05,null,Feb-06,22-Sep-05,null,20-Jun-17,"Atlanta Research and Education Foundation, Decatur, Georgia, United States",,https://ClinicalTrials.gov/show/NCT00214617
NCT00216463,Safety and Tolerability of Varying Load and Dose of ISIS 301012 in People With Elevated LDL-cholesterol Levels,,Completed,No Results Available,Hypercholesterolemia,Drug: ISIS 301012 or Placebo,"Percent reduction in LDL-cholesterol from baseline|Percent reduction in apoB-100 from baseline|Percent change from baseline in HDL-cholesterol, triglycerides, total cholesterol, non-HDL cholesterol, VLDL and LP(a)|Percent change from baseline in LDL/HDL and apoB-100/apo-A1 ratios","Kastle Therapeutics, LLC|Ionis Pharmaceuticals, Inc.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,50,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",301012CS3|EudraCT No.: 2004-003934-32,Aug-05,Mar-07,Aug-07,22-Sep-05,null,3-Aug-16,"Berlin, Germany",,https://ClinicalTrials.gov/show/NCT00216463
NCT00217061,Effect of a Decision Aid About Statin Use in Patients With Type 2 Diabetes Mellitus,,Completed,No Results Available,Diabetes Mellitus|Dyslipidemia|Hypercholesterolemia|Cardiovascular Disease,Device: Decision Aid Statin Choice,Adherence to the decision to use or not to use statins|Decisional conflict|Knowledge and understanding of risk|Quality of life (generic and disease specific)|Anxiety state|Trust in clinician,Mayo Clinic,All,"18 Years and older   (Adult, Older Adult)",Phase 3,98,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single,38-05,Apr-05,Oct-05,Oct-05,22-Sep-05,null,23-May-11,"Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00217061
NCT00218998,Effective Endurance Training in Metabolic Syndrome,,Completed,No Results Available,Impaired Glucose Tolerance|Overweight|Hypertension|Dyslipidemia,Behavioral: exercise training,To reduce risk factors related to metabolic syndrome|Improve endothelial functions in patient with metabolic syndrome,Norwegian University of Science and Technology,All,"20 Years and older   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Prevention,Training in metabolic syndrome,Jan-04,null,null,22-Sep-05,null,31-Mar-17,"The medical faculty at norwegian university of science and technology, Trondheim, Norway",,https://ClinicalTrials.gov/show/NCT00218998
NCT00220974,Study to Assess if Internet-Based Tailored Advice Could Modify Behaviour to Improve Health,,Completed,No Results Available,Hypercholesterolemia,Behavioral: Internet-based tailored advice on cardiovascular risk,"To determine the effectiveness of a consumer-mediated, Internet-based strategy for identification and intervention in hypercholesterolemia.|To determine the effectiveness of a consumer-mediated, Internet-based strategy in the adoption of healhier behaviour and lifestyle","The George Institute|Lipid and Cardiovascular Risk Assessment Service, ICPMR, Westmead Hospital|Royal Prince Alfred Hospital, Sydney, Australia|Pfizer|Medical benefit Fund (MBF)",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,3708,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double,I-CAT,Oct-04,Dec-06,Dec-06,22-Sep-05,null,13-Feb-09,"The George Institute for International Health, Camperdown, New South Wales, Australia",,https://ClinicalTrials.gov/show/NCT00220974
NCT00221754,Pravastatin and Protease Inhibitors in HIV-Infected Patients,,Completed,No Results Available,HIV Infection|Hypercholesterolemia,Drug: Pravastatin (drug),HIV RNA|Lipid biological markers|Plasma level of protease inhibitors|CD4 count at 12 weeks|Safety,"University Hospital, Bordeaux|Ministry of Health, France",All,"18 Years and older   (Adult, Older Adult)",Phase 2,21,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,9268-02|2001-026,Mar-03,null,Mar-04,22-Sep-05,null,13-Jun-07,"Hôpital Saint André, Service de médecine interne et maladies infectieuses, Bordeaux, France",,https://ClinicalTrials.gov/show/NCT00221754
NCT00222833,The Effect of Switching to Aripiprazole on Heart Health in Overweight and Obese Patients With Schizophrenia,,Completed,No Results Available,Overweight|Hyperlipidemia|Cardiovascular Diseases,Drug: Aripiprazole,"To examine heart health factors: serum lipids, serum leptin, fasting blood glucose, body weight, and blood pressure|Changes in clinical state|Pre-existing or emergent side effects|Cognition and insight|Attitude towards medication|Social functioning|Quality of life",University of Pittsburgh|Bristol-Myers Squibb,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,30,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0312010|PITT#02 90599,Oct-04,Dec-05,Dec-05,22-Sep-05,null,15-Jan-08,"Western Psychiatric Institute and Clinic of UPMC, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00222833
NCT00195793,A 16 Week Comparative Study of Fenofibrate Versus Ezetimibe as Add-on Therapy to Atorvastatin,,Completed,No Results Available,Hyperlipidemia,Drug: fenofibrate|Drug: ezetimibe|Drug: atorvastatin,Percent change from Combination Baseline to 12 weeks post-Combination Baseline in direct measured HDL-C and TG.|Advanced lipid and inflammatory parameters,Abbott,All,"18 Years and older   (Adult, Older Adult)",Phase 3,174,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,M03-661,Aug-04,null,null,20-Sep-05,null,4-Oct-07,,,https://ClinicalTrials.gov/show/NCT00195793
NCT00202878,IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103),,Completed,Has Results,Hypercholesterolemia|Myocardial Infarction,Drug: ezetimibe/simvastatin|Drug: simvastatin|Drug: Placebo for simvastatin 40 mg|Drug: Placebo for ezetimibe 10 mg/simvastatin 40 mg combination,"Time to First Occurrence of Cardiovascular Death, Major Coronary Event, or Non-fatal Stroke (Kaplan-Meier Estimate of Percentage of Participants Experiencing a Qualifying Event)|Time to First Occurrence of Death From Any Cause, Major Coronary Event, or Non-fatal Stroke (Kaplan-Meier Estimate of Percentage of Participants Experiencing a Qualifying Event)|Time to First Occurrence of Coronary Heart Disease (CHD) Death, Non-fatal MI, or Urgent Coronary Revascularization With PCI or CABG ≥ 30 Days After Randomization (Kaplan-Meier Estimate of Percentage of Participants Experiencing a Qualifying Event)|Time to First Occurrence of CV Death, Nonfatal MI, UA With Hospitalization, All Revascularization Occurring ≥30 Days After Randomization, and Non-fatal Stroke (Kaplan-Meier Estimate of Percentage of Participants Experiencing a Qualifying Event)",Merck Sharp & Dohme Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 3,18144,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",P04103|MK-0653A-080,17-Oct-05,18-Sep-14,18-Sep-14,20-Sep-05,30-Sep-15,21-Sep-18,,,https://ClinicalTrials.gov/show/NCT00202878
NCT00202904,Effectiveness and Safety of Ezetimibe Added to Atorvastatin in Patients With High Cholesterol and Coronary Heart Disease (Study P03740),,Completed,No Results Available,Hypercholesterolemia|Coronary Heart Disease,Drug: ezetimibe|Drug: placebo,"To compare the efficacy of ezetimibe 10 mg added daily to ongoing treatment with atorvastatin 10 mg versus placebo added daily to ongoing treatment with atorvastatin 10 mg in reducing the concentration of LDL-C at endpoint|To compare the percentage of subjects who achieve target LDL-C goal (as defined by the ESC or NCEP guidelines at the time of database lock) with ezetimibe 10 mg added to atorvastatin 10 mg daily versus placebo added to atorvastatin 10 mg daily|To compare the change in concentrations of total cholesterol, HDL-C and triglycerides with ezetimibe 10 mg added to atorvastatin 10 mg daily versus placebo added to atorvastatin 10 mg daily|To compare the safety and tolerability of ezetimibe 10 mg added to atorvastatin 10 mg daily versus placebo added to atorvastatin 10 mg daily",Merck Sharp & Dohme Corp.,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,81,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",P03740,May-05,Oct-06,Oct-06,20-Sep-05,null,29-Apr-15,,,https://ClinicalTrials.gov/show/NCT00202904
NCT00203476,"A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction",,Completed,Has Results,Hyperlipidemia|Hypercholesterolemia,Drug: Niacin|Drug: Colestipol|Drug: Ezetimibe,LDL Goal Attainment|LFT Elevation|Incidents of Rhabdomyolysis|Change in HDL From Baseline to 12 Weeks.,Tuscaloosa Research & Education Advancement Corporation|American Society of Health-System Pharmacists Research and Education Foundation,All,"50 Years and older   (Adult, Older Adult)",Phase 4,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TREAC Cholesterol Study,May-05,Jan-08,Jan-08,20-Sep-05,12-Aug-14,12-Aug-14,"Tuscaloosa Research & Education Advancement Corporation, Tuscaloosa, Alabama, United States",,https://ClinicalTrials.gov/show/NCT00203476
NCT00205660,"Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole",BMS,Completed,Has Results,Schizophrenia|Type 2 Diabetes Mellitus,Other: Stayers|Other: Switchers,Change in Total Body Fat (kg).|Change in Whole Body Sensitivity (mg/kg/Min),Washington University School of Medicine|Bristol-Myers Squibb,All,18 Years to 60 Years   (Adult),Phase 4,51,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BMS #942370,Feb-05,Aug-09,Aug-09,20-Sep-05,15-Jan-19,15-Jan-19,"Washington University School of Medicine, Saint Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT00205660
NCT00192621,Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects,,Completed,No Results Available,HIV Infections|Dyslipidemias|Glucose Metabolism Disorders|Metabolic Diseases|Lipodystrophy|Cardiovascular Disease,Drug: Combivir (zidovudine [AZT] / lamivudine [3TC])|Drug: Kaletra (lopinavir [LPVr]),"To determine effect of 6 wks ART with LPVr and CBV, alone and in combination, in HIV negative healthy subjects with respect to changes from baseline in genes related to mitochondrial and lipid metabolism in adipocytes|includes: To determine the effect of 6 wks of ART with LPVr and CBV in HIV negative subjects with respect to: changes from baseline in genes related to mitochondrial and lipid and glucose metabolism in monocytes.","Kirby Institute|St Vincent's Hospital, Sydney|National Heart, Lung, and Blood Institute (NHLBI)|Garvan Institute of Medical Research|Prince of Wales Hospital, Sydney",All,"18 Years and older   (Adult, Older Adult)",Phase 4,50,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,SAMA 002 Version 5|ACTR012605000661673,Nov-04,Dec-06,Dec-06,19-Sep-05,null,12-Apr-12,"St Vincents Hospital, Sydney, New South Wales, Australia",,https://ClinicalTrials.gov/show/NCT00192621
NCT00194402,SLIM: Combined Effects of Slo-Niacin and Atorvastatin on Lipoproteins and Inflammatory Markers in Hyperlipidemia,,Completed,No Results Available,Dyslipidemia,"Drug: Slo-Niacin, atorvastatin","LDL-C change for atorvastatin 10 mg, Slo-Niacin 1500 mg, and the two together.|Change in HDL-C, HDL2-C, HDL3-C, LDL-C:HDL-C, triglyceride, remnant lipoprotein, apoproteins A-I and B, LDL buoyancy, hsCRP, glucose, insulin, and SGOT.",University of Washington|Upsher-Smith Laboratories,All,"21 Years to 75 Years   (Adult, Older Adult)",Phase 4,64,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,03-6262-A,Aug-03,Jan-06,Jan-06,19-Sep-05,null,21-Aug-08,"Northwest Lipid Research Clinic, University of Washington, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00194402
NCT00194428,"Weight and Metabolic Effects of an Almond Enriched Hypocaloric, Low Fat Diet on Overweight and Obese Persons",,Completed,No Results Available,Obesity|Metabolic Syndrome X|Hyperlipidemia|Hypertension,Behavioral: Almond enriched diet|Behavioral: Low fat caloric diet,"To evaluate the effects of an almond-enriched (2 oz/day) hypocaloric, low-fat diet on body weight and body composition in overweight and obese persons|To evaluate the effects of the almond enriched diet on established and emerging surrogate markers of coronoary artery disease (CAD) risk",Temple University|Almond Board of California,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,123,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,802132,Feb-05,Oct-07,Oct-09,19-Sep-05,null,28-Mar-13,"Temple University, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00194428
NCT00184951,Pharmacokinetic Study of Rosuvastatin and Lopinavir/Ritonavir in HIV Patients,,Completed,No Results Available,HIV Infections|Hyperlipidemia,Drug: Rosuvastatin,"pharmacokinetics on week 0,4,8 and 12|evaluation of lipid lowering activity on week 0,4,8,12|endothelial function will be measured at week 0 & 12 (optional for patients from Leiden and Nijmegen)",Radboud University|Abbott|AstraZeneca,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,30,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UMCN-AKF 03.01,Apr-04,Jul-05,Jul-05,16-Sep-05,null,22-Oct-08,"University of Bonn, Bonn, Germany|University of Cologne, Cologne, Germany|University of Amsterdam, Amsterdam, Netherlands|University of Leiden, Leiden, Netherlands|University of Nijmegen, Nijmegen, Netherlands",,https://ClinicalTrials.gov/show/NCT00184951
NCT00185107,Effect of Combination Therapy With Two Drugs (Colesevelam and Ezetimibe) in Patients With High Cholesterol,,Completed,No Results Available,Hypercholesterolemia,Drug: Colesevelam Hydrochloride|Drug: Ezetimibe|Drug: Simvastatin,"The percent change in LDL-C from the start of the study|- The absolute change in LDL-C from baseline|- The percent change in LDL-C from baseline|- The absolute changes and percent changes in TG, non-HDL-|C, HDL-C, total cholesterol and other lipid measures|- The percentages of patients who achieve target levels of LDL-C at the end of the study","Daiichi Sankyo, Inc.",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,45,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,WEL-408,Mar-05,null,Oct-05,16-Sep-05,null,11-Sep-07,"Scripps Clinic, San Diego, California, United States|Renstar Medical Research, Ocala, Florida, United States|Radiant Research, Overland Park, Kansas, United States|L-MARC Research Center, Louisville, Kentucky, United States|Radiant Research, Edina, Minnesota, United States|Medical Office, Statesville, North Carolina, United States|Linder Clinical Trial Center, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00185107
NCT00185705,"Treatment of Insulin Resistance in Hypertensive, Obese Adolescents",,Unknown status,No Results Available,Hypertension|Insulin Resistance|Dyslipidemia,Drug: Telmisartan,"This pilot study will provide data essential for designing a larger trial to test the hypothesis that telmisartan treatment of obese children with insulin resistance and hypertension will result in improved insulin levels and systolic blood pressure.|Secondary outcome measures will include the effects of telmisartan on total cholesterol, triglyceride, HDL and LDL levels, body mass index (BMI), and body fat distribution.",Stanford University,All,"10 Years to 18 Years   (Child, Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,Telmisartan adolescents,Oct-06,null,Jun-07,16-Sep-05,null,14-Feb-07,"Stanford Medical Center, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT00185705
NCT00186537,"Comparing Tricor, Avandia, or Weight Loss to Lower Cardiovascular Risk Factors in People With High Triglycerides.",,Completed,Has Results,Insulin Resistance|Hypertriglyceridemia,Drug: Rosiglitazone|Drug: Fenofibrate|Behavioral: Weight Loss,Pre- and Post-Intervention Triglyceride Levels|Pre- and Post-Intervention LDL Cholesterol Levels|Pre- and Post-Intervention HDL Cholesterol Levels,Stanford University|Abbott,All,"30 Years to 65 Years   (Adult, Older Adult)",Not Applicable,47,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,79301|SPO 28829,Sep-03,Sep-08,Sep-08,16-Sep-05,5-May-16,12-Jan-17,"Stanford University Medical Center, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT00186537
NCT00189085,Effects of Ezetimibe on Postprandial Hyperlipidemia and Endothelial Function,,Completed,No Results Available,Metabolic Syndrome,Drug: simvastatin and ezetimibe,Postprandial lipemia|Postprandial endothelial function,UMC Utrecht,Male,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,20,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,EZET,Dec-04,null,Jul-05,16-Sep-05,null,10-Jun-10,"Department of Vascular Medicine UMC Utrecht, Utrecht, Netherlands",,https://ClinicalTrials.gov/show/NCT00189085
NCT00169559,"Dyslipidemia Study Investigating The Increase In ""Good Cholesterol""",,Completed,No Results Available,Dyslipidaemias,Drug: GW590735|Drug: fenofibrate,"change from baseline in fasting plasma HDLc concentration at the end of eight weeks of double blind treatment|changes from baseline in: fasting plasma total cholesterol, TG, LDLc, ApoA1, ApoA2, Lipoprotein containing ApoA1 and not ApoA2, Lipoprotein containing both ApoA1 and ApoA2, Apo B100, Apo CIII, Free Fatty Acid, insulin, fibrinogen, and C-reactive protein",GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 2,250,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",PAA20001,Nov-03,Apr-05,Apr-05,15-Sep-05,null,22-Oct-12,"GSK Investigational Site, Birmingham, Alabama, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Beverly Hills, California, United States|GSK Investigational Site, Healdsburg, California, United States|GSK Investigational Site, Orange, California, United States|GSK Investigational Site, Spring Valley, California, United States|GSK Investigational Site, Walnut Creek, California, United States|GSK Investigational Site, Deland, Florida, United States|GSK Investigational Site, Fort Lauderdale, Florida, United States|GSK Investigational Site, Fort Lauderdale, Florida, United States|GSK Investigational Site, Ft Lauderale, Florida, United States|GSK Investigational Site, Hollywood, Florida, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Pembroke Pines, Florida, United States|GSK Investigational Site, Orland Park, Illinois, United States|GSK Investigational Site, Evansville, Indiana, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Iowa City, Iowa, United States|GSK Investigational Site, Louisville, Kentucky, United States|GSK Investigational Site, Auburn, Maine, United States|GSK Investigational Site, Brooklyn Center, Minnesota, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Endwell, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Rochester, New York, United States|GSK Investigational Site, Williamsville, New York, United States|GSK Investigational Site, Statesville, North Carolina, United States|GSK Investigational Site, Wilmington, North Carolina, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Medford, Oregon, United States|GSK Investigational Site, Allentown, Pennsylvania, United States|GSK Investigational Site, Erie, Pennsylvania, United States|GSK Investigational Site, Sioux Falls, South Dakota, United States|GSK Investigational Site, Bristol, Tennessee, United States|GSK Investigational Site, Kingsport, Tennessee, United States|GSK Investigational Site, Bryan, Texas, United States|GSK Investigational Site, Conroe, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Norfolk, Virginia, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Calgary, Alberta, Canada|GSK Investigational Site, Winnipeg, Manitoba, Canada|GSK Investigational Site, Laval, Quebec, Canada|GSK Investigational Site, Québec, Quebec, Canada|GSK Investigational Site, Sainte-Foy, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00169559
NCT00171093,A 10-12 Week Study to Evaluate the Safety and Efficacy of 320 mg Valsartan and 80 mg Simvastatin in Combination and as Monotherapies in Treating Hypertension and Hypercholesterolemia,,Completed,No Results Available,HYPERTENSION|HYPERCHOLESTEROLEMIA,Drug: valsartan + simvastatin,"Change in average ambulatory systolic blood pressure over 24 hours|Change in serum low density lipoprotein cholesterol (LDL-C )|Adverse events and serious adverse events at each study visit for 42 days|Change in average ambulatory systolic blood pressure over 24 hours between two different treatment therapies|Change in 24 hour ambulatory blood pressure in the daytime compared to nighttime|Change in 24 hour ambulatory blood pressure 21-24 hours after last dose of study medication|Change in total cholesterol, triglycerides, and high densitiy lipoprotein cholesterol (HDL-C) from baseline after 42 days",Novartis,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,369,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CVAS489A2316,Sep-04,Jan-06,null,15-Sep-05,null,23-Feb-17,"Novartis Pharmaceuticals, E. Hanover, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT00171093
NCT00171236,Efficacy and Safety of Fluvastatin in Children With Heterozygous Familial Hypercholesterolemia,,Completed,No Results Available,Heterozygous Familial Hypercholesterolemia|Mixed Dyslipidemia,Drug: Fluvastatin,,Novartis,All,10 Years to 16 Years   (Child),Phase 3,84,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CXUO320B2301,Oct-01,Mar-05,Mar-05,15-Sep-05,null,8-Nov-11,"Novartis, Basel, Switzerland",,https://ClinicalTrials.gov/show/NCT00171236
NCT00171262,Trial to Evaluate the Efficacy of Fluvastatin on Certain Markers,,Completed,No Results Available,Dyslipidemia,Drug: Fluvastatin,Change from baseline in serum inflammatory markers after 52 weeks|Change from baseline in fibrosis parameters and endothelial function after 52 weeks|Adverse events and serious adverse events after 52 weeks|Change from baseline in laboratory tests of kidney function after 12 weeks,Novartis,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,120,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CXUO320BES02,Aug-04,Jun-07,Jun-07,15-Sep-05,null,23-Feb-17,"Novartis, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT00171262
NCT00171288,Efficacy and Safety Study of Fluvastatin and Ezetimibe Combined Versus Fluvastatin Alone,,Completed,No Results Available,Dyslipidemia,"Drug: fluvastatin, ezetimibe","Change from baseline in low density lipoprotein cholesterol after 12 weeks|Change from baseline in total triglyceride, high density lipoprotein cholesterol, and composition of low density lipoprotein cholesterol after 12 weeks|Change from baseline in circulating marker of inflammation after 12 weeks",Novartis,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,83,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CXUO320BES03,Aug-03,Aug-05,Aug-05,15-Sep-05,null,8-Nov-11,"Novartis, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT00171288
NCT00171327,Efficacy and Safety of Fluvastatin or Valsartan and Their Combination in Dyslipidemic Patients With Hypertension and Endothelial Dysfunction,,Completed,No Results Available,Hypertension|Dyslipidemia,"Drug: valsartan, fluvastatin","Percent change from baseline in brachial artery flow-mediated vasodilation after 8 weeks|Percent change from baseline in brachial artery flow-mediated vasodilation after 16 weeks compared to 8 weeks|Percent change from baseline in low density lipoprotein cholesterol, total cholesterol, and triglycerides|Evaluating blood pressure effect on endothelial function|Evaluating total cholesterol effect on endothelial function",Novartis,All,"30 Years to 65 Years   (Adult, Older Adult)",Phase 4,213,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CXUO320BRU01,Jul-04,Sep-05,Sep-05,15-Sep-05,null,8-Nov-11,"Novartis, Moscow, Russian Federation",,https://ClinicalTrials.gov/show/NCT00171327
NCT00172419,The Effects of Atorvastatin on Vulnerable Plaques in Untreated Dyslipidemic Patients.,,Completed,No Results Available,Hyperlipidemia,Drug: Atorvastatin,"Plaque location and activity at baseline, and compare with the follow-up scans site by site.|Lipid profile|Biomarkers","National Taiwan University Hospital|National Science Council, Taiwan|Pfizer",All,"30 Years to 80 Years   (Adult, Older Adult)",Not Applicable,43,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,931204,Mar-07,Dec-08,Dec-08,15-Sep-05,null,5-Jan-09,"National Taiwan University Hospital, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT00172419
NCT00174304,Open Label Study To Assess The Effectiveness Of Amlodipine-Atorvastatin Combination In Hypertension And Dyslipidemia.,JEWEL II,Completed,No Results Available,Hypertension|Hyperlipidemia,Drug: Amlodipine/atorvastatin single pill,"To evaluate the effectiveness of amlodipine/atorvastatin therapy by assessing percentage of subjects who reach target BP and LDL-C targets as defined by their governing guidelines.|To asses changes since baseline of lab parameters, BP, safety of titration of amlodipine.atorvastatin to reach targets, to validate Expectations and Satisfaction with Treatment questionnaires.",Pfizer,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,1120,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A3841029,Oct-04,null,Sep-06,15-Sep-05,null,8-Jan-10,"Pfizer Investigational Site, Salzburg, Austria|Pfizer Investigational Site, St. Poelten, Austria|Pfizer Investigational Site, Vienna, Austria|Pfizer Investigational Site, Wels, Austria|Pfizer Investigational Site, Bierbeek, Belgium|Pfizer Investigational Site, Braine-L'Alleud, Belgium|Pfizer Investigational Site, Brugge, Belgium|Pfizer Investigational Site, De Pinte, Belgium|Pfizer Investigational Site, GozÃ©e, Belgium|Pfizer Investigational Site, Seraing, Belgium|Pfizer Investigational Site, Wemmel, Belgium|Pfizer Investigational Site, Wilrijk, Belgium|Pfizer Investigational Site, Zedelgem, Belgium|Pfizer Investigational Site, Helsinki, Finland|Pfizer Investigational Site, Kuopio, Finland|Pfizer Investigational Site, Kuopio, Finland|Pfizer Investigational Site, Oulu, Finland|Pfizer Investigational Site, Oulu, Finland|Pfizer Investigational Site, Tampere, Finland|Pfizer Investigational Site, Turku, Finland|Pfizer Investigational Site, Turku, Finland|Pfizer Investigational Site, Vantaa, Finland|Pfizer Investigational Site, Heraklion, Crete, Greece|Pfizer Investigational Site, Athens, Greece|Pfizer Investigational Site, Ioannina, Greece|Pfizer Investigational Site, Larissa, Greece|Pfizer Investigational Site, Melissia, Greece|Pfizer Investigational Site, Pireaus, Greece|Pfizer Investigational Site, Rio, Patra, Greece|Pfizer Investigational Site, Thessaloniki, Greece|Pfizer Investigational Site, Thessaloniki, Greece|Pfizer Investigational Site, Budapest, Hungary|Pfizer Investigational Site, Budapest, Hungary|Pfizer Investigational Site, Budapest, Hungary|Pfizer Investigational Site, Debrecen, Hungary|Pfizer Investigational Site, KecskemÃ©t, Hungary|Pfizer Investigational Site, Miskolc, Hungary|Pfizer Investigational Site, MosonmagyarÃ³vÃ¡r, Hungary|Pfizer Investigational Site, PÃ©cs, Hungary|Pfizer Investigational Site, SzekszÃ¡rd, Hungary|Pfizer Investigational Site, Gorey, Wexford, Ireland|Pfizer Investigational Site, New Ross, Wexford, Ireland|Pfizer Investigational Site, Vimercate, (mi), Italy|Pfizer Investigational Site, Somma Lombardo, (va), Italy|Pfizer Investigational Site, San Sisto, PG, Italy|Pfizer Investigational Site, Mestre, VE, Italy|Pfizer Investigational Site, Asti, Italy|Pfizer Investigational Site, Bologna, Italy|Pfizer Investigational Site, Bologna, Italy|Pfizer Investigational Site, Bologna, Italy|Pfizer Investigational Site, Bolzano, Italy|Pfizer Investigational Site, Brescia, Italy|Pfizer Investigational Site, Catania, Italy|Pfizer Investigational Site, Catania, Italy|Pfizer Investigational Site, Chieti, Italy|Pfizer Investigational Site, Ferrara, Italy|Pfizer Investigational Site, Firenze, Italy|Pfizer Investigational Site, Foggia, Italy|Pfizer Investigational Site, Genova, Italy|Pfizer Investigational Site, Grosseto, Italy|Pfizer Investigational Site, Napoli, Italy|Pfizer Investigational Site, Novara, Italy|Pfizer Investigational Site, Palermo, Italy|Pfizer Investigational Site, Palermo, Italy|Pfizer Investigational Site, Perugia, Italy|Pfizer Investigational Site, Potenza, Italy|Pfizer Investigational Site, Prato, Italy|Pfizer Investigational Site, Roma, Italy|Pfizer Investigational Site, Salerno, Italy|Pfizer Investigational Site, Sassari, Italy|Pfizer Investigational Site, Siena, Italy|Pfizer Investigational Site, Torino, Italy|Pfizer Investigational Site, Venezia, Italy|Pfizer Investigational Site, Guilhufe - Pnf, Penafiel, Portugal|Pfizer Investigational Site, Matosinhos, Sra. da Hora, Portugal|Pfizer Investigational Site, Coimbra, Portugal|Pfizer Investigational Site, Faro, Portugal|Pfizer Investigational Site, Leiria, Portugal|Pfizer Investigational Site, Lisboa, Portugal|Pfizer Investigational Site, Lisboa, Portugal|Pfizer Investigational Site, Lisbon, Portugal|Pfizer Investigational Site, Porto, Portugal|Pfizer Investigational Site, Porto, Portugal|Pfizer Investigational Site, S. Martinho Do Bispo, Portugal|Pfizer Investigational Site, Viana Do Castelo, Portugal|Pfizer Investigational Site, Izola, Slovenia|Pfizer Investigational Site, Ljubljana, Slovenia|Pfizer Investigational Site, Maribor, Slovenia|Pfizer Investigational Site, San Sebastian, Guipuzcoa, Spain|Pfizer Investigational Site, Reus, Tarragona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Baden, AG, Switzerland|Pfizer Investigational Site, Bern, BE, Switzerland|Pfizer Investigational Site, Basel, BS, Switzerland|Pfizer Investigational Site, St. Gallen, SG, Switzerland|Pfizer Investigational Site, MÃ¼nsterlingen, TG, Switzerland|Pfizer Investigational Site, Lugano, TI, Switzerland|Pfizer Investigational Site, Lausanne, VD, Switzerland|Pfizer Investigational Site",,https://ClinicalTrials.gov/show/NCT00174304
NCT00174330,Comparing Amlodipine/Atorvastatin Co-Administration To Amlodipine Alone In Patients With Hypertension And Dyslipidemia,,Completed,No Results Available,Hypertension|Hyperlipidemia,Drug: atorvastatin|Drug: amlodipine,To evaluate efficacy of the dual therapy of atorvastatin 10mg or 20mg + amlodipine 5mg or 10mg vs. amlodipine 5mg or 10mg alone|To provide comparative evaluation of the safety profile of the dual therapy with atorvastatin + amlodipine versus amlodipine alone.,Pfizer,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,330,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A3841026,May-05,null,Feb-06,15-Sep-05,null,21-Feb-07,"Pfizer Investigational Site, Beijing, Beijing, China|Pfizer Investigational Site, Guangzhou, Guangdong, China|Pfizer Investigational Site, Guangzhou, Guangdong, China|Pfizer Investigational Site, Guangzhou, Guangdong, China|Pfizer Investigational Site, Nanjing, Jiangsu, China|Pfizer Investigational Site, Shen Yang, Liaoning, China|Pfizer Investigational Site, Shanghai, Shanghai, China|Pfizer Investigational Site, Hangzhou, Zhejiang, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Shanghai, China|Pfizer Investigational Site, Shanghai, China|Pfizer Investigational Site, Shanghai, China|Pfizer Investigational Site, Tianjin, China",,https://ClinicalTrials.gov/show/NCT00174330
NCT00174993,Efficacy of Pioglitazone on Macrovascular Outcome in Patients With Type 2 Diabetes,PROactive,Completed,No Results Available,Diabetes Mellitus,Drug: Pioglitazone|Drug: Placebo,"Time to the Composite of All Cause Mortality, Non-Fatal Myocardial Infarction, Stroke, Acute Coronary Syndrome, Major Leg Amputation, Cardiac Intervention, Bypass Surgery or Leg Revascularization.|Time to All Cause Mortality.|Time to Non-Fatal Myocardial Infarction.|Time to Acute Coronary Syndrome.|Time to Cardiac Intervention (including coronary artery bypass graft or percutaneous coronary intervention).|Time to Stroke.|Time to Major Leg Amputation (above the ankle).|Time to Bypass Surgery|Time to Revascularization of the Leg.|Time to Cardiovascular Mortality.",Takeda|Eli Lilly and Company,All,"35 Years to 75 Years   (Adult, Older Adult)",Phase 3,4373,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AD4833/EC444|U1111-1114-2854,May-01,Jan-05,Jan-05,15-Sep-05,null,28-Feb-12,"Multiple Cities, Austria|Multiple Cities, Belgium|Multiple Cities, Czech Republic|Multiple Cities, Denmark|Multiple Cities, Estonia|Multiple Cities, Finland|Multiple Cities, France|Multiple Cities, Germany|Multiple Cities, Hungary|Multiple Cities, Italy|Multiple Cities, Latvia|Multiple Cities, Lithuania|Multiple Cities, Netherlands|Multiple Cities, Norway|Multiple Cities, Poland|Multiple Cities, Slovakia|Multiple Cities, Sweden|Multiple Cities, Switzerland|Multiple Cities, United Kingdom",,https://ClinicalTrials.gov/show/NCT00174993
NCT00175071,Effect of Vegetable Oils for Use by the Snack Food Industry on Plasma Lipid Levels and Inflammatory Markers,,Completed,No Results Available,Hyperlipidemias|Metabolic Syndrome X|Cardiovascular Diseases,Behavioral: Comparison of cooking oils,"Serum lipid, lipoprotein and apolipoprotein concentrations, measures of inflammation, cholesteryl ester transfer protein (CETP) and lecithin-cholesterol acetyltransferase (LCAT) activities, endogenous lipid synthesis rates, expression of genes associated",Tufts University,Female,"50 Years to 85 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",HL54727-1537,Mar-04,Apr-07,Jul-12,15-Sep-05,null,13-Jul-18,"Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00175071
NCT00175084,"Effect of Dietary Amino Acid Profile on Lipoprotein Metabolism, Vascular Reactivity and Inflammatory Markers",,Completed,No Results Available,Hyperlipidemias|Metabolic Syndrome X|Cardiovascular Diseases,Behavioral: Comparison of dietary protein amino acid profile,"Serum lipid and lipoprotein concentrations, endothelial function, blood pressure, indicators of nitrous oxide end products, homocysteine, inflammation and oxidation markers.",Tufts University,All,"50 Years to 85 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention,HL58008-1188,Oct-04,Jun-07,Dec-12,15-Sep-05,null,23-May-14,"Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00175084
NCT00175097,Soybean Based Diets and CVD Risk Factors,,Completed,No Results Available,Hypercholesterolemia,Other: Diet: soybeans and products made thereof|Other: Diet: soybean flour and products made thereof|Other: Diet: soybean milk|Other: Diet: Animal protein based diet,"Fasting and non-fasting plasma lipids, apolipoproteins; end of each dietary phase|Vascular endothelial function; end of each dietary phase|Susceptibility of LDL to oxidation; end of each dietary phase|C-reactive protein; end of each dietary phase|Endogenous cholesterol synthesis; end of each dietary phase|Endogenous triglyceride synthesis; end of each dietary phase|Plasma and Urinary Isoflavone levels; end of each dietary phase|Genotyping of candidate genes involved in the variability observed in response to dietary modification",Tufts University,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",HL 58008-1785|R01HL058008,Jun-01,May-05,May-05,15-Sep-05,null,2-Dec-14,"Division of Cardiology, Tufts-New England Medical Center Hospitals, Tufts University School of Medicine, Boston, Massachusetts, United States|Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00175097
NCT00166036,Effect of Statins on Oxidative Stress and Endothelial Progenitor Cells,STOPCAP,Completed,Has Results,Diabetes Mellitus|Metabolic Syndrome X|Hypercholesterolemia,Drug: Atorvastatin|Drug: Pravastatin,Change in Plasma Thiobarbituric Acid Reactive Substance (TBARS) Levels|Change in Flow-mediated Dilatation (FMD),Emory University,All,"21 Years to 80 Years   (Adult, Older Adult)",Phase 2,36,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1038-2004,Sep-04,Mar-08,Apr-09,14-Sep-05,8-Sep-14,8-Sep-14,"Emory University Hospital, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT00166036
NCT00166166,Endothelial Hyperpolarization in Humans,,Terminated,Has Results,Hyperlipidemia,Drug: Tetraethylammonium (TEA)|Drug: L-NG-monomethyl Arginine (L-NMMA)|Drug: Bradykinin|Drug: Sodium nitroprusside|Drug: Acetylcholine|Drug: Saline|Drug: Fluconazole,"Percent Change in Forearm Blood Flow (FBF) After Tetraethylammonium (TEA) Administration|Percent Change in Forearm Blood Flow (FBF) After Administration of L-NG-monomethyl Arginine (L-NMMA)|Percent Change in Forearm Blood Flow (FBF) After Administration of L-NG-monomethyl Arginine (L-NMMA) and Tetraethylammonium (TEA)|Percent Change in Forearm Blood Flow (FBF) After Fluconazole Administration|Percent Change in Forearm Blood Flow (FBF) After L-NG-monomethyl Arginine (L-NMMA) and Fluconazole Administration|Percent Change in Forearm Blood Flow (FBF) After Fluconazole and Tetraethylammonium (TEA) Administration|Forearm Blood Flow (FBF) After Sodium Nitroprusside Administration|Change in Tissue Plasminogen Activator (t-PA) Release|Change in Tissue Plasminogen Activator (t-PA) Release After Tetraethylammonium (TEA) and Bradykinin Administration|Change in Tissue Plasminogen Activator (t-PA) Release After Fluconazole and Bradykinin Administration|Change in Tissue Plasminogen Activator (t-PA) Release After Fluconazole, Tetraethylammonium (TEA), and Bradykinin Administration","Emory University|National Heart, Lung, and Blood Institute (NHLBI)",All,"21 Years to 65 Years   (Adult, Older Adult)",Phase 2,174,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,IRB00021886|1R01HL079115-01|0605-2002,Jul-02,Jan-13,Jan-13,14-Sep-05,13-May-15,15-Aug-18,"Emory University School of Medicine, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT00166166
NCT00166504,Ezetimibe Plus (+) Simvastatin Versus Atorvastatin Comparative Study (0653A-092)(COMPLETED),,Completed,Has Results,Hypercholesterolemia,Drug: ezetimibe (+) simvastatin|Drug: atorvastatin,LDL-C Lowering Efficacy,Merck Sharp & Dohme Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 4,203,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0653A-092|MK0653A-092|2005_070,Oct-05,Oct-07,Oct-07,14-Sep-05,5-Nov-08,11-Apr-17,,,https://ClinicalTrials.gov/show/NCT00166504
NCT00163150,Vasomotor Reactivity In Cerebral Small Vessel Disease And New Approach To Treat Lacunar Stroke,LA BICHAT,Completed,No Results Available,Cerebrovascular Accident|Hypercholesterolemia,Drug: Atorvastatin,"Evaluate the efficacy of atorvastatin treatment during 3 months (80mg/day) on cerebral vasoreactivity (CVR) in lacunar patients. CVR, humeral and carotid vasoreactivity will be measured in all patients at M0 and M3.|Evaluate the efficacy of atorvastatin treatment during 3 months (80mg/day) on endothelium dependant and independent vasomotoricity of humeral and / or common carotid artery (according to validation study) in lacunar patients.",Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 4,128,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,A2581063,Jun-03,null,Feb-06,13-Sep-05,null,14-Mar-08,"Pfizer Investigational Site, Paris, Cedex 18, France",,https://ClinicalTrials.gov/show/NCT00163150
NCT00163163,Carotid Atorvastatin Study in Hyperlipidemic Post-Menopausal Women,,Completed,No Results Available,Hypercholesterolaemia,Procedure: Echographic measurements|Procedure: Blood samples,Mean change in carotid IMT from baseline to month 12.|Mean change from baseline to month 12 of carotid internal diameter (ID)|wall cross sectional area (WCSA); carotid arterial mass (AM)|pulse pressure (PP); cross sectional distensibility and compliance (DC and CC)|pulse wave velocity (PWV); Lipid profile,Pfizer,Female,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,400,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,A2581051,Jan-03,null,Jul-06,13-Sep-05,null,18-Mar-08,"Pfizer Investigational Site, Afsnee Gent, Belgium|Pfizer Investigational Site, Assenede, Belgium|Pfizer Investigational Site, Brussels, Belgium|Pfizer Investigational Site, Bruxelles, Belgium|Pfizer Investigational Site, Bruxelles, Belgium|Pfizer Investigational Site, Bruxelles, Belgium|Pfizer Investigational Site, Bruxelles, Belgium|Pfizer Investigational Site, Bruxelles, Belgium|Pfizer Investigational Site, Ertvelde, Belgium|Pfizer Investigational Site, Gent, Belgium|Pfizer Investigational Site, Linkebeek, Belgium|Pfizer Investigational Site, Sint-niklaas, Belgium|Pfizer Investigational Site, Tielt, Belgium|Pfizer Investigational Site, Wetteren, Belgium|Pfizer Investigational Site, Wondelgem, Belgium|Pfizer Investigational Site, Achenheim, France|Pfizer Investigational Site, Ancerville, France|Pfizer Investigational Site, Augny, France|Pfizer Investigational Site, Bar Le Duc, France|Pfizer Investigational Site, Boersch, France|Pfizer Investigational Site, Bois-Colombes, France|Pfizer Investigational Site, Boissy Saint Leger, France|Pfizer Investigational Site, Bouzonville, France|Pfizer Investigational Site, Colombey-Les-Belles, France|Pfizer Investigational Site, Dammarie Les Lys, France|Pfizer Investigational Site, Docelles, France|Pfizer Investigational Site, Dourdan, France|Pfizer Investigational Site, Eckbolsheim, France|Pfizer Investigational Site, Epinay S/orge, France|Pfizer Investigational Site, Etampes, France|Pfizer Investigational Site, Frouard, France|Pfizer Investigational Site, Gambsheim, France|Pfizer Investigational Site, Haguenau, France|Pfizer Investigational Site, Kilstett, France|Pfizer Investigational Site, Laxou, France|Pfizer Investigational Site, le Grand Quevilly, France|Pfizer Investigational Site, Le Mesnil Esnard, France|Pfizer Investigational Site, Leuville Sur Orge, France|Pfizer Investigational Site, Lingolsheim, France|Pfizer Investigational Site, Longpont Sur Orge, France|Pfizer Investigational Site, Mars LA Tour, France|Pfizer Investigational Site, Metz, France|Pfizer Investigational Site, Moutiers, France|Pfizer Investigational Site, Nancy, France|Pfizer Investigational Site, Nancy, France|Pfizer Investigational Site, Nancy, France|Pfizer Investigational Site, Paris, France|Pfizer Investigational Site, Paris, France|Pfizer Investigational Site, Paris, France|Pfizer Investigational Site, Paris, France|Pfizer Investigational Site, Paris, France|Pfizer Investigational Site, Pont a Mousson, France|Pfizer Investigational Site, Pont-a-mousson, France|Pfizer Investigational Site, Pulnoy, France|Pfizer Investigational Site, Rouen, France|Pfizer Investigational Site, Sainte Genevieve Des Bois, France|Pfizer Investigational Site, Sauvigny, France|Pfizer Investigational Site, Savigny Sur Orge, France|Pfizer Investigational Site, Sotteville Les Rouen Cedex, France|Pfizer Investigational Site, Souffelweyersheim, France|Pfizer Investigational Site, St Max, France|Pfizer Investigational Site, Strasbourg, France|Pfizer Investigational Site, Strasbourg, France|Pfizer Investigational Site, Terville, France|Pfizer Investigational Site, Toul, France|Pfizer Investigational Site, Vandoeuvre Les Nancy, France|Pfizer Investigational Site, Vandoeuvre, France|Pfizer Investigational Site, Verdun, France|Pfizer Investigational Site, Vincennes, France|Pfizer Investigational Site, Ed Voerendaal, Netherlands|Pfizer Investigational Site, En Vaals, Netherlands|Pfizer Investigational Site, Ve Maastricht, Netherlands",,https://ClinicalTrials.gov/show/NCT00163163
NCT00163202,Comparative Atorvastatin Pleiotropic Effects,CAP,Completed,No Results Available,Coronary Arteriosclerosis|Hypercholesterolemia,Procedure: Blood samples|Drug: Atorvastatin,"Percentages changes of the hs-CRP between baseline (means between week-2 to -1 and week 0 (V2) values) and week 26 (V5).|1/ the percentage change at visit 3 (5-week treatment), visit 4 (13-week-treatment) and visit 5 (26-week treatment) from baseline value in triglycerides, total cholesterol; HDL-cholesterol, LDL-cholesterol, apolipoprotein B 2/ the percentage change at",Pfizer|MDS Pharma Services|Bio-Inova Life Sciences International,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,330,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,A2581065,Jun-02,null,Aug-05,13-Sep-05,null,18-Mar-08,"Pfizer Investigational Site, Calgary, Alberta, Canada|Pfizer Investigational Site, Edmonton, Alberta, Canada|Pfizer Investigational Site, Vancouver, British Columbia, Canada|Pfizer Investigational Site, Winnipeg, Manitoba, Canada|Pfizer Investigational Site, Halifax, Nova Scotia, Canada|Pfizer Investigational Site, London, Ontario, Canada|Pfizer Investigational Site, Oshawa, Ontario, Canada|Pfizer Investigational Site, Sarnia, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Weston, Ontario, Canada|Pfizer Investigational Site, Chicoutimi, Quebec, Canada|Pfizer Investigational Site, Laval, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Sherbrooke, Quebec, Canada|Pfizer Investigational Site, Ste-foy, Quebec, Canada|Pfizer Investigational Site, Saskatoon, Saskatchewan, Canada|Pfizer Investigational Site, Brno-Bohunice, Czech Republic|Pfizer Investigational Site, Jindrichuv Hradec, Czech Republic|Pfizer Investigational Site, Prague 2, Czech Republic|Pfizer Investigational Site, Prague 2, Czech Republic|Pfizer Investigational Site, Prague 5, Czech Republic|Pfizer Investigational Site, Clermont-ferrand, Cedex, France|Pfizer Investigational Site, Langres, Cedex, France|Pfizer Investigational Site, Besancon, France|Pfizer Investigational Site, Brest, France|Pfizer Investigational Site, Chambery, France|Pfizer Investigational Site, Clamart, France|Pfizer Investigational Site, Clermont-ferrand, France|Pfizer Investigational Site, Creil, France|Pfizer Investigational Site, Dijon, France|Pfizer Investigational Site, Evecquemont, France|Pfizer Investigational Site, GAP, France|Pfizer Investigational Site, Henin-beaumont, France|Pfizer Investigational Site, Le Kremlin Bicetre Cedex, France|Pfizer Investigational Site, Lille, France|Pfizer Investigational Site, Marseille Cedex 05, France|Pfizer Investigational Site, Metz Cedex 01, France|Pfizer Investigational Site, Monaco, France|Pfizer Investigational Site, Montpellier, France|Pfizer Investigational Site, Mulhouse, France|Pfizer Investigational Site, Nancy, France|Pfizer Investigational Site, Nantes Saint Herblain, France|Pfizer Investigational Site, Paris Cedex 05, France|Pfizer Investigational Site, Paris Cedex 15, France|Pfizer Investigational Site, Paris Cedex 18, France|Pfizer Investigational Site, Paris, France|Pfizer Investigational Site, Paris, France|Pfizer Investigational Site, Pessac, France|Pfizer Investigational Site, Poissy, France|Pfizer Investigational Site, Pontoise, France|Pfizer Investigational Site, Roubaix, France|Pfizer Investigational Site, Saint Michel, France|Pfizer Investigational Site, Thionville, France|Pfizer Investigational Site, Toulouse, France|Pfizer Investigational Site, Tourcoing, France|Pfizer Investigational Site, Vandoeuvre Les Nancy, France|Pfizer Investigational Site, Vandoeuvre, France|Pfizer Investigational Site, Belchatow, Poland|Pfizer Investigational Site, Gdynia, Poland|Pfizer Investigational Site, Rawa Mazowiecka, Poland|Pfizer Investigational Site, Torun, Poland|Pfizer Investigational Site, Wroclaw, Poland|Pfizer Investigational Site, Zamosc, Poland|Pfizer Investigational Site, Bucharest, Sector 2, Romania|Pfizer Investigational Site, Bucharest, Sector 2, Romania|Pfizer Investigational Site, Bucharest, Sector 5, Romania|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Volgograd, Russian Federation|Pfizer Investigational Site, Bratislava, Slovakia|Pfizer Investigational Site, Bratislava, Slovakia",,https://ClinicalTrials.gov/show/NCT00163202
NCT00153738,Phytosterol Supplementation and Cardiovascular Risk,,Completed,No Results Available,Hypercholesteremia,Drug: phytosterol,Ingestion of the supplement will result in reduced LDL cholesterol.,The Cooper Institute|Cargill,All,"20 Years to 70 Years   (Adult, Older Adult)",Not Applicable,72,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single|Primary Purpose: Prevention,CI0129,Mar-04,null,Aug-05,12-Sep-05,null,13-Mar-14,"The Cooper Institute, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT00153738
NCT00157482,Ezetimibe and Simvastatin in Dyslipidemia of Diabetes,,Completed,No Results Available,Type 2 Diabetes,Drug: Ezetimibe|Drug: Simvastatin,"LDL-cholesterol, at 16 weeks of treatment. LDL-cholesterol is measured at -4, 0, 8, 12 and 16 weeks.|Total cholesterol, apolipoprotein A1 and B, lipoprotein and triglycerides, at -4, 0, 8, 12 and 16 weeks|Explorative|Urinary albumin excretion, at -4, 0, 8 and 16 weeks",Mario Negri Institute for Pharmacological Research,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,108,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Diagnostic,ESD,Jan-05,null,Dec-06,12-Sep-05,null,13-Feb-07,"ASl of Ponte San Pietro - Diabetologic Unit, Ponte San Pietro, Bergamo, Italy|Clinical Research Center for Rare Diseases, Ranica, Bergamo, Italy|Hospital ""Treviglio Caravaggio "" - Diabetologic Unit, Treviglio, Bergamo, Italy|Hospital ""Ospedali Riuniti di Bergamo"" - Diabetologic Unit, Bergamo, Italy",,https://ClinicalTrials.gov/show/NCT00157482
NCT00157638,Integrating Family Medicine and Pharmacy to Advance Primary Care Therapeutics,,Completed,No Results Available,Diabetes|Hypertension|Hyperlipidemia|Constipation|Pain,Behavioral: integration of pharmacist into primary care|Drug: optimizing therapeutic treatments|Behavioral: optimizing processes of care,"Number and types of patients referred and assessed|Characterization and quantification of pharmacist activities|Numbers and types of drug-related problems identified and resolved|Medication changes made|Number of recommendations implemented|Process indicators (measurement of blood pressure, Cholesterol, hemoglobin A1C)|Surrogate clinical outcomes (values of blood pressure, Cholesterol, hemoglobin A1C)|Symptom improvement (constipation, pain)|Health resource utilization|Satisfaction with service|Uptake of pharmacist recommendations|Extent of knowledge translation|Extent of collaboration|Satisfaction with integrated pharmacist program|Set up costs|Pharmacist and physician time costs|Travel cost|Space requirements|Medication costs|Health services utilization",Hamilton Health Sciences Corporation|McMaster University,All,65 Years and older   (Older Adult),Phase 4,1400,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Educational/Counseling/Training,G03-02671,Feb-04,null,Jul-06,12-Sep-05,null,11-Sep-06,"McMaster University, Hamilton, Ontario, Canada|University of Ottawa, Ottawa, Ontario, Canada|University of Toronto, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00157638
NCT00157911,A Study to Evaluate Ezetimibe in Korean Patients With Primary Hypercholesterolemia (0653-042),,Completed,No Results Available,Hypercholerolemia,Drug: MK0653; ezetimibe / Duration of Treatment: 12 weeks|Drug: Comparator: simvastatin / Duration of Treatment: 12 weeks,"LDL-C|TC, TG, HDL-C, Apolipoprotein A1, Apolipoprotein B, lipoprotein (a), LDL-C:HDL-C ratio, TC:HDL-C ratio",Merck Sharp & Dohme Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 3,136,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0653-042|MK0653-042|2005_065,Dec-02,Oct-03,Dec-03,12-Sep-05,null,10-Mar-17,,,https://ClinicalTrials.gov/show/NCT00157911
NCT00157924,Ezetimibe (+) Simvastatin vs. Atorvastatin Comparative Study in DM or Metabolic Syndrome Patients (0653A-093),,Completed,No Results Available,Hypercholesterolemia,Drug: simvastatin (+) ezetimibe|Drug: atorvastatin,LDL-C lowering efficacy|Safety,Merck Sharp & Dohme Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 4,190,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0653A-093|MK0653A-093|2005_064,Nov-05,Sep-07,Sep-07,12-Sep-05,null,15-Mar-17,,,https://ClinicalTrials.gov/show/NCT00157924
NCT00158899,GW501516 In Subjects Who Have Low Level Of High-Density Lipoprotein Cholesterol,,Completed,No Results Available,Dyslipidaemias|Dyslipidaemia,Drug: GW501516 oral tablets,The change from baseline in fasting plasma HDLc concentration at the end of 12 weeks of double-blind treatment.|Changes from baseline at the end of 12 weeks of double-blind treatment of total cholesterol and other lipid parameters. Population pharmacokinetic parameters including oral clearance and apparent volume of distribution of GW501516.,GlaxoSmithKline,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,424,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,PAD20001,Aug-04,Jun-06,Jun-06,12-Sep-05,null,30-May-17,"GSK Investigational Site, Bruxelles, Belgium|GSK Investigational Site, Liège, Belgium|GSK Investigational Site, Hellerup, Denmark|GSK Investigational Site, Tallinn, Estonia|GSK Investigational Site, Tallinn, Estonia|GSK Investigational Site, Tallinn, Estonia|GSK Investigational Site, Kuopio, Finland|GSK Investigational Site, Tampere, Finland|GSK Investigational Site, Caen cedex 4, France|GSK Investigational Site, Créteil, France|GSK Investigational Site, Gières, France|GSK Investigational Site, Lagord, France|GSK Investigational Site, Poitiers, France|GSK Investigational Site, Toulouse, France|GSK Investigational Site, Haag, Bayern, Germany|GSK Investigational Site, Hoehenkirchen-Siegertsbrunn, Bayern, Germany|GSK Investigational Site, Gelnhausen, Hessen, Germany|GSK Investigational Site, Koenigslutter, Niedersachsen, Germany|GSK Investigational Site, Winsen/Lohe, Niedersachsen, Germany|GSK Investigational Site, Beckum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Goch, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, Viersen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Mainz, Rheinland-Pfalz, Germany|GSK Investigational Site, Magdeburg, Sachsen-Anhalt, Germany|GSK Investigational Site, Wolmirstedt, Sachsen-Anhalt, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Schmiedeberg, Sachsen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Kaunas, Lithuania|GSK Investigational Site, Vilnius, Lithuania|GSK Investigational Site, Vilnius, Lithuania|GSK Investigational Site, Almere, Netherlands|GSK Investigational Site, Den Haag, Netherlands|GSK Investigational Site, Deurne, Netherlands|GSK Investigational Site, Etten-leur, Netherlands|GSK Investigational Site, Nijverdal, Netherlands|GSK Investigational Site, Rijswijk, Netherlands|GSK Investigational Site, Roelofarendsveen, Netherlands|GSK Investigational Site, Rotterdam, Netherlands|GSK Investigational Site, Soerendonk, Netherlands|GSK Investigational Site, Bekkestua, Norway|GSK Investigational Site, Fredrikstad, Norway|GSK Investigational Site, Hamar, Norway|GSK Investigational Site, Oslo, Norway|GSK Investigational Site, Oslo, Norway|GSK Investigational Site, Oslo, Norway|GSK Investigational Site, Paradis, Norway|GSK Investigational Site, Soerumsand, Norway|GSK Investigational Site, Stavanger, Norway|GSK Investigational Site, Coimbra, Portugal|GSK Investigational Site, Malmö, Sweden",,https://ClinicalTrials.gov/show/NCT00158899
NCT00160329,Atazanavir or Boosted Atazanavir Substitution for Ritonavir Boosted PI in Patients With Hyperlipidemia,,Completed,No Results Available,Hyperlipidemia|HIV Infections,Drug: Atazanavir,"Compare the three arms (ATV, ATV/r and continued ritonavir boosted-PI) in the following primary endpoint: % subjects who have normal serum lipid profile off lipid lowering agents and maintain CD4 counts > 75% of baseline line values.|% subjects with serum lipids within normal limits at week 48 off of any lipid lowering agent.|% subjects who maintain CD4 counts > 75% of baseline values at week 48.|Compare the change in CD4 count and CD4 % at 24 and 48 weeks between the three study arms.1.2.4Compare HIV plasma viral load profile over 24 and 48 weeks as DAVG between the three study arms.|Compare lipid profile over 48 weeks, change in total cholesterol, TC/HDL ratio and triglycerides.|Compare the evolution of genotypic and phenotypic drug resistance over 12 and 48 weeks between the three arms.|Compare the evolution of viral fitness as measured by replication capacity assay at 12 and 48 weeks between the three arms.|Explore determinates of viral fitness and the relationship of viral fitness with the 'CD4/VL disconnect' state.",Stanford University|Bristol-Myers Squibb,All,"18 Years and older   (Adult, Older Adult)",Phase 3,60,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,De-Escalate Trial|IRB # 79603|Spo# 29750,Jan-04,Apr-07,Mar-09,12-Sep-05,null,21-Jul-11,"Stanford University School of Medicine, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT00160329
NCT00151788,Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Carotid Artery Disease. This Study is Also Known as CAPTIVATE.,,Terminated,No Results Available,Atherosclerosis|Heterozygous Familial Hypercholesterolemia,Drug: Pactimibe sulfate,"To demonstrate the effect of pactimibe versus placebo, when added to usual medical care, on the intima-media thickness (IMT) of the carotid arteries in subjects with heterozygous familial hypercholesterolemia (HeFH) and carotid atherosclerosis.|To assess the effects of pactimibe versus placebo, when added to usual medical care:|- on the incidence and the time to first occurrence of|cardiovascular events,|- on inflammatory and oxidative markers, such as serum|high-sensitivity C-reactive protein (hsCRP), plasma|interleukin 6 (IL-6), plasma myeloperoxidase (MPO) and|serum nitrotyrosine.|To compare the safety of pactimibe versus placebo, when added to usual medical care, particularly with respect to the incidence of clincal and laboratory adverse events.","Daiichi Sankyo, Inc.",All,"40 Years to 75 Years   (Adult, Older Adult)",Phase 2|Phase 3,796,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,505-205,Feb-04,Mar-06,Mar-06,9-Sep-05,null,18-Jan-12,"Santa Ana, California, United States|Chicago, Illinois, United States|Baltimore, Maryland, United States|St. Louis, Missouri, United States|Cincinnati, Ohio, United States|Houston, Texas, United States|Salt Lake City, Utah, United States|Seattle, Washington, United States|Vancouver, British Columbia, Canada|Toronto, Ontario, Canada|Chicoutimi, Quebec, Canada|Chomedey Laval, Quebec, Canada|Montreal, Quebec, Canada|Ste-Foy, Quebec, Canada|Jerusalem, Israel|Amsterdam, Zuidoost, Netherlands|Capelle a/d Ijssel, Netherlands|Dordrecht, Netherlands|Etten-Leur, Netherlands|Goes, Netherlands|Gorinchem, Netherlands|Gouda, Netherlands|Groningen, Netherlands|Hoorn, Netherlands|Leiden, Netherlands|Rotterdam, Netherlands|Tilburg, Netherlands|Oslo, Norway|Bellville, South Africa|Midrand, South Africa|Pretoria, South Africa|Barcelona, Spain|Cordoba, Spain|Linkoping, Sweden|Stockholm, Sweden|London, United Kingdom|Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT00151788
NCT00152698,Effect of Irbesartan on Endothelial Function of the Retinal Vasculature in Patients With Hypercholesterolemia,,Completed,No Results Available,Hypercholesterolemia,Drug: Irbesartan,Comparison of retinal endothelial function between hypercholesterolemic patients and healthy control subjects|Effect of AT1-receptor blockade on retinal endothelial function in hypercholesterolemic patients,University of Erlangen-Nürnberg Medical School|Bristol-Myers Squibb,Male,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,80,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Retina-Irbesartan,Nov-09,Dec-09,Dec-09,9-Sep-05,null,21-Jan-13,"CRC, Medizinsiche Klinik 4, Nephrology and Hypertension, University of Erlangen-Nürnberg, Erlangen, Bavaria, Germany",,https://ClinicalTrials.gov/show/NCT00152698
NCT00150371,Canadians Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration,CANACTFAST,Completed,No Results Available,Hypercholesterolemia,Drug: atorvastatin,"Proportion (%) of subjects achieving their LDL-C target after 12 weeks of treatment according to their 10-year CHD risk category (based on the new canadian guidelines on the management and treatment of dyslipidemia).|The global proportion (%) of patients reaching targets when risk categories are combined The proportion (%) of subjects achieving BOTH their LDL-C and TC/HDL-C ratio targets after 6 and 12 weeks of treatment, globally and according to their 10-year",Pfizer,All,"30 Years to 79 Years   (Adult, Older Adult)",Phase 3,1100,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A2581091,Jun-04,null,May-05,8-Sep-05,null,3-Jul-09,"Pfizer Investigational Site, Calgary, Alberta, Canada|Pfizer Investigational Site, Calgary, Alberta, Canada|Pfizer Investigational Site, Calgary, Alberta, Canada|Pfizer Investigational Site, Edmonton, Alberta, Canada|Pfizer Investigational Site, Edmonton, Alberta, Canada|Pfizer Investigational Site, Edmonton, Alberta, Canada|Pfizer Investigational Site, Coquitlam, British Columbia, Canada|Pfizer Investigational Site, Coquitlam, British Columbia, Canada|Pfizer Investigational Site, Kelowna, British Columbia, Canada|Pfizer Investigational Site, Langley, British Columbia, Canada|Pfizer Investigational Site, Surrey, British Columbia, Canada|Pfizer Investigational Site, Vancouver, British Columbia, Canada|Pfizer Investigational Site, Victoria, British Columbia, Canada|Pfizer Investigational Site, Winnipeg, Manitoba, Canada|Pfizer Investigational Site, Winnipeg, Manitoba, Canada|Pfizer Investigational Site, Moncton, New Brunswick, Canada|Pfizer Investigational Site, Rothesay, New Brunswick, Canada|Pfizer Investigational Site, Saint John, New Brunswick, Canada|Pfizer Investigational Site, Halifax, B3K 5R3, Nova Scotia, Canada|Pfizer Investigational Site, Halifax, Nova Scotia, Canada|Pfizer Investigational Site, Halifax, Nova Scotia, Canada|Pfizer Investigational Site, Halifax, Nova Scotia, Canada|Pfizer Investigational Site, Brampton, Ontario, Canada|Pfizer Investigational Site, Burlington, Ontario, Canada|Pfizer Investigational Site, Courtice, Ontario, Canada|Pfizer Investigational Site, Downsview, Ontario, Canada|Pfizer Investigational Site, Fort Erie, Ontario, Canada|Pfizer Investigational Site, Hamilton, Ontario, Canada|Pfizer Investigational Site, Hawkesbury, Ontario, Canada|Pfizer Investigational Site, Kitchener, Ontario, Canada|Pfizer Investigational Site, Lindsay, Ontario, Canada|Pfizer Investigational Site, Markham, Ontario, Canada|Pfizer Investigational Site, Midland, Ontario, Canada|Pfizer Investigational Site, Napanee, Ontario, Canada|Pfizer Investigational Site, Newmarket, Ontario, Canada|Pfizer Investigational Site, Niagara Falls, Ontario, Canada|Pfizer Investigational Site, North Bay, Ontario, Canada|Pfizer Investigational Site, North York, Ontario, Canada|Pfizer Investigational Site, Oshawa, Ontario, Canada|Pfizer Investigational Site, Oshawa, Ontario, Canada|Pfizer Investigational Site, Ottawa, Ontario, Canada|Pfizer Investigational Site, Saint Catherines, Ontario, Canada|Pfizer Investigational Site, Sarnia, Ontario, Canada|Pfizer Investigational Site, St. Catherines, Ontario, Canada|Pfizer Investigational Site, Thornhill, Ontario, Canada|Pfizer Investigational Site, Thunder Bay, Ontario, Canada|Pfizer Investigational Site, Thunder Bay, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Windsor, Ontario, Canada|Pfizer Investigational Site, Charlottetown, Prince Edward Island, Canada|Pfizer Investigational Site, Montague, Prince Edward Island, Canada|Pfizer Investigational Site, Amos, Quebec, Canada|Pfizer Investigational Site, Chicoutimi, Quebec, Canada|Pfizer Investigational Site, Cowansville, Quebec, Canada|Pfizer Investigational Site, Greenfield Park, Quebec, Canada|Pfizer Investigational Site, Greenfield Park, Quebec, Canada|Pfizer Investigational Site, Greenfield Park, Quebec, Canada|Pfizer Investigational Site, Laval, Quebec, Canada|Pfizer Investigational Site, Laval, Quebec, Canada|Pfizer Investigational Site, Laval, Quebec, Canada|Pfizer Investigational Site, Le Gardeur, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Plessisville, Quebec, Canada|Pfizer Investigational Site, Saint-Eustache, Quebec, Canada|Pfizer Investigational Site, Salaberry du Valleyfield, Quebec, Canada|Pfizer Investigational Site, Sherbrooke, Quebec, Canada|Pfizer Investigational Site, St. Leonard, Quebec, Canada|Pfizer Investigational Site, Ste. Foy, Quebec, Canada|Pfizer Investigational Site, Vaudreuil, Quebec, Canada|Pfizer Investigational Site, Regina, Saskatchewan, Canada|Pfizer Investigational Site, Saskatoon, Saskatchewan, Canada|Pfizer Investigational Site, Saskatoon, Saskatchewan, Canada|Pfizer Investigational Site, Saskatoon, Saskatchewan, Canada|Pfizer Investigational Site, Saskatoon, Saskatchewan, Canada|Pfizer Investigational Site, Saskatoon, Saskatchewan, Canada|Pfizer Investigational Site, Quebec, Canada|Pfizer Investigational Site, St. John's, Canada|Pfizer Investigational Site, St. John's, Canada",,https://ClinicalTrials.gov/show/NCT00150371
NCT00150384,Clinical Utility of Caduet in Achieving Blood Pressure and Lipid Endpoints in a Specific Patient Population,CAPABLE,Completed,No Results Available,Hypertension|Dyslipidemia,Drug: Amlodipine/Atorvastatin,"To evaluate the efficacy of Caduet therapy by assessing the percentage of intent-to-treat subjects achieving both BP and lipid treatment goals (JNC VII and NCEP ATP III)|To assess the percentage of subjects achieving treatment goals(JNC VII and NCEP) stratified by the final BP and lipid therapy doses, respectively, the change from baseline in lipid profile, SBP and DBP",Pfizer,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,500,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A3841025,Jul-04,null,Aug-05,8-Sep-05,null,22-Apr-15,"Pfizer Investigational Site, Birmingham, Alabama, United States|Pfizer Investigational Site, Birmingham, Alabama, United States|Pfizer Investigational Site, Huntsville, Alabama, United States|Pfizer Investigational Site, Little Rock, Arkansas, United States|Pfizer Investigational Site, Los Angeles, California, United States|Pfizer Investigational Site, Oakland, California, United States|Pfizer Investigational Site, Pico Rivera, California, United States|Pfizer Investigational Site, Bridgeport, Connecticut, United States|Pfizer Investigational Site, Washington, District of Columbia, United States|Pfizer Investigational Site, Washington, District of Columbia, United States|Pfizer Investigational Site, Aventura, Florida, United States|Pfizer Investigational Site, Gainesville, Florida, United States|Pfizer Investigational Site, Jacksonville, Florida, United States|Pfizer Investigational Site, Orlando, Florida, United States|Pfizer Investigational Site, Pensacola, Florida, United States|Pfizer Investigational Site, Vero Beach, Florida, United States|Pfizer Investigational Site, Athens, Georgia, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Augusta, Georgia, United States|Pfizer Investigational Site, Columbus, Georgia, United States|Pfizer Investigational Site, Columbus, Georgia, United States|Pfizer Investigational Site, Decatur, Georgia, United States|Pfizer Investigational Site, Lincolnton, Georgia, United States|Pfizer Investigational Site, Savannah, Georgia, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, Maywood, Illinois, United States|Pfizer Investigational Site, Merrillville, Indiana, United States|Pfizer Investigational Site, Overland Park, Kansas, United States|Pfizer Investigational Site, Bossier City, Louisiana, United States|Pfizer Investigational Site, New Orleans, Louisiana, United States|Pfizer Investigational Site, New Orleans, Louisiana, United States|Pfizer Investigational Site, Shreveport, Louisiana, United States|Pfizer Investigational Site, Shreveport, Louisiana, United States|Pfizer Investigational Site, Baltimore, Maryland, United States|Pfizer Investigational Site, Baltimore, Maryland, United States|Pfizer Investigational Site, Columbia, Maryland, United States|Pfizer Investigational Site, Randallstown, Maryland, United States|Pfizer Investigational Site, Rockville, Maryland, United States|Pfizer Investigational Site, Westminster, Maryland, United States|Pfizer Investigational Site, Brockton, Massachusetts, United States|Pfizer Investigational Site, Wellesley Hills, Massachusetts, United States|Pfizer Investigational Site, Detroit, Michigan, United States|Pfizer Investigational Site, Detroit, Michigan, United States|Pfizer Investigational Site, Lansing, Michigan, United States|Pfizer Investigational Site, Livonia, Michigan, United States|Pfizer Investigational Site, Jackson, Mississippi, United States|Pfizer Investigational Site, Jackson, Mississippi, United States|Pfizer Investigational Site, Kansas City, Missouri, United States|Pfizer Investigational Site, Kansas City, Missouri, United States|Pfizer Investigational Site, St. Louis, Missouri, United States|Pfizer Investigational Site, St. Louis, Missouri, United States|Pfizer Investigational Site, St. Louis, Missouri, United States|Pfizer Investigational Site, Cherry Hill, New Jersey, United States|Pfizer Investigational Site, East Orange, New Jersey, United States|Pfizer Investigational Site, Elizabeth, New Jersey, United States|Pfizer Investigational Site, Hammonton, New Jersey, United States|Pfizer Investigational Site, South Bound Brook, New Jersey, United States|Pfizer Investigational Site, Voorhees, New Jersey, United States|Pfizer Investigational Site, Woodbury, New Jersey, United States|Pfizer Investigational Site, Brooklyn, New York, United States|Pfizer Investigational Site, Brooklyn, New York, United States|Pfizer Investigational Site, Buffalo, New York, United States|Pfizer Investigational Site, Mineola, New York, United States|Pfizer Investigational Site, Charlotte, North Carolina, United States|Pfizer Investigational Site, Greenville, North Carolina, United States|Pfizer Investigational Site, Monroe, North Carolina, United States|Pfizer Investigational Site, Monroe, North Carolina, United States|Pfizer Investigational Site, Winston-Salem, North Carolina, United States|Pfizer Investigational Site, Winston-Salem, North Carolina, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Dayton, Ohio, United States|Pfizer Investigational Site, Dayton, Ohio, United States|Pfizer Investigational Site, Maumee, Ohio, United States|Pfizer Investigational Site, Perrysburg, Ohio, United States|Pfizer Investigational Site, Bensalem, Pennsylvania, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Bamberg, South Carolina, United States|Pfizer Investigational Site, Charleston, South Carolina, United States|Pfizer Investigational Site, Clinton, South Carolina, United States|Pfizer Investigational Site, Mt. Pleasant, South Carolina, United States|Pfizer Investigational Site, Simpsonville, South Carolina, United States|Pfizer Investigational Site, Bartlett, Tennessee, United States|Pfizer Investigational Site, Jackson, Tennessee, United States|Pfizer Investigational Site, Beaumont, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, Emporia, Virginia, United States|Pfizer Investigational Site, Norfolk, Virginia, United States|Pfizer Investigational Site, Norfolk, Virginia, United States|Pfizer Investigational Site, Richmond, Virginia, United States|Pfizer Investigational Site, Richmond, Virginia, United States|Pfizer Investigational Site, Viginia Beach, Virginia, United States|Pfizer Investigational Site, Virginia Beach, Virginia, United States|Pfizer Investigational Site, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00150384
NCT00147251,Stop Atherosclerosis in Native Diabetics Study,,Completed,No Results Available,Cardiovascular Disease|Hypertension|Hyperlipidemia|Diabetes|Carotid Atherosclerosis,Drug: FDA approved drugs to treat blood pressure and cholesterol,"combined carotid artery intimal medial thickness measured at 3 years and clinical CVD events tracked throughout the 3 years|left ventricular (LV) function and geometry|level of stenosis of the carotid artery|number of plaques in the carotid artery|various safety measures, such as liver enzyme levels, clinical myositis, postural hypotension, glomerular filtration rate, urine albumin/creatinine ratio",Medstar Health Research Institute,All,"40 Years and older   (Adult, Older Adult)",Phase 4,548,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,2000-285|Grant # 1 U01 HL67031,May-03,null,May-07,7-Sep-05,null,1-Nov-06,"Chinle Comprehensive Health Care, Chinle, Arizona, United States|Phoenix Indian Medical Center, Phoenix, Arizona, United States|USPHS Indian Hospital, Lawton, Oklahoma, United States|Black Hills Center for American Indian Health, Rapid City, South Dakota, United States",,https://ClinicalTrials.gov/show/NCT00147251
NCT00144937,Multifactorial Intervention on Cardiovascular Risk Factors in Subjects With Peripheral Arterial Disease,,Unknown status,No Results Available,Peripheral Arterial Disease|Hypercholesterolemia|Hypertension|Diabetes Mellitus|Smoking,"Drug: Stepwise therapy for dyslipidemia, hypertension and diabetes|Behavioral: Dietary recommendations|Behavioral: Increase in physical activity|Behavioral: Smoking cessation",Lowering of LDL cholesterol concentrations and blood pressure levels (at 12 months). Increase in use of antiplatelet agents (at 12 months)|Decrease in basal glycaemia and HbA1c(only subjects with diabetes)|Lowering of serum triglycerides and total cholesterol.|Increase in serum HDL cholesterol|Improvement in cardiovascular risk (Framingham Score and UKPDS engine)|Weight reduction|Increase in physical activity|Changes in dietary intake|Smoking cessation|Improvement in health-related quality of life (SF-36)|Improvement of intermittent claudication|Improvement of arm-ankle index|Effect of control of cardiovascular risk factors on metabolic and inflammatory markers associated with cardiovascular disease|Changes in serum concentrations of hepatic enzymes|Changes in use of statins and fibrates|Changes in use of antihypertensive drugs and hypoglycemic agents|Cardiovascular events|All the above-mentioned primary and secondary outcomes will be evaluated at 12 months,Hospital de Sabadell|Bristol-Myers Squibb,All,"45 Years to 80 Years   (Adult, Older Adult)",Phase 4,120,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Educational/Counseling/Training,2003020,Mar-03,null,Aug-05,5-Sep-05,null,5-Sep-05,"Hospital de Sabadell, Sabadell, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT00144937
NCT00145431,Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder.,,Terminated,No Results Available,Hyperlipoproteinemia Type III,Drug: torcetrapib/atorvastatin|Drug: atorvastatin|Drug: fenofibrate,Change in LDL-C and non-HDL-C levels.|Changes in other lipid and biomarker variable levels.,Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,41,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,A5091024,Mar-05,Dec-06,Dec-06,5-Sep-05,null,17-Feb-12,"Pfizer Investigational Site, Anaheim, California, United States|Pfizer Investigational Site, Huntington Beach, California, United States|Pfizer Investigational Site, Orange, California, United States|Pfizer Investigational Site, Pacific Palisades, California, United States|Pfizer Investigational Site, Studio City, California, United States|Pfizer Investigational Site, Tustin, California, United States|Pfizer Investigational Site, Hollywood, Florida, United States|Pfizer Investigational Site, Longwood, Florida, United States|Pfizer Investigational Site, Tripler Army Medical Center, Hawaii, United States|Pfizer Investigational Site, Scarborough, Maine, United States|Pfizer Investigational Site, Portage, Michigan, United States|Pfizer Investigational Site, Portage, Michigan, United States|Pfizer Investigational Site, Olive Branch, Mississippi, United States|Pfizer Investigational Site, Rochester, New York, United States|Pfizer Investigational Site, Syracuse, New York, United States|Pfizer Investigational Site, West Seneca, New York, United States|Pfizer Investigational Site, Sellersville, Pennsylvania, United States|Pfizer Investigational Site, Greer, South Carolina, United States|Pfizer Investigational Site, Memphis, Tennessee, United States|Pfizer Investigational Site, Salt Lake City, Utah, United States|Pfizer Investigational Site, Seattle, Washington, United States|Pfizer Investigational Site, Madison, Wisconsin, United States|Pfizer Investigational Site, London, Ontario, Canada|Pfizer Investigational Site, Chicoutimi, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00145431
NCT00145574,Efficacy and Safety of Colesevelam in Pediatric Patients With Genetic High Cholesterol,,Completed,Has Results,Hypercholesterolemia,Drug: colesevelam HCl|Drug: placebo,Percent Change in Plasma Low Density Lipoprotein-cholesterol (LDL-C) From Day 1 (Study Baseline) to Week 8.|Percent Change in Plasma Total Cholesterol (TC) From Day 1 (Study Baseline) to Week 8.|Percent Change in Plasma Triglycerides (TG) From Day 1 (Study Baseline) to Week 8.|Percent Change in Plasma High-density Lipoprotein-cholesterol (HDL-C) From Day 1 (Study Baseline) to Week 8.|Percent Change in Plasma Non-high Density Lipoprotein-cholesterol (Non-HDL-C) From Day 1 (Study Baseline) to Week 8.|Percent Change in Plasma Apolipoprotien A-I (Apo A-1) From Day 1 (Study Baseline) to Week 8.|Percent Change in Plasma Apolipoprotein B (Apo B) From Day 1 (Study Baseline) to Week 8.|Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Study Baseline (Day 1) to Week 26.|Percent Change in Total Cholesterol From Study Baseline (Day 1) to Week 26.|Percent Change in Triglycerides From Study Baseline (Day 1) to Week 26.|Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Study Baseline (Day 1) to Week 26.|Percent Change in Non-high-density Lipoprotein Cholesterol From Study Baseline (Day 1) to Week 26.|Percent Change in Apolipoprotein A-I From Study Baseline (Day 1) to Week 26.|Percent Change in Apolipoprotein B From Study Baseline (Day 1) to Week 26.,"Daiichi Sankyo, Inc.",All,10 Years to 17 Years   (Child),Phase 4,194,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WEL-410,Nov-05,Dec-07,Dec-07,5-Sep-05,26-Jan-10,15-Apr-10,"Washington, District of Columbia, United States|St. Louis, Missouri, United States|Bronx, New York, United States|New Hyde Park, New York, United States|New York, New York, United States|Cincinnati, Ohio, United States|Wexford, Pennsylvania, United States|Salt Lake City, Utah, United States|Camperdown NSW, Australia|Vienna, Austria|Vancouver, British Columbia, Canada|Toronto, Ontario, Canada|Chicoutimi, Quebec, Canada|Laval, Quebec, Canada|Stefoy, Quebec, Canada|Holon, Israel|Jerusalem, Israel|Kefer Saba, Israel|Tel-Hashomer, Israel|Amsterdam, Netherlands|Rotterdam, Netherlands|Oslo, Norway|Observatory, South Africa|Pretoria, South Africa|Tygerberg, South Africa",,https://ClinicalTrials.gov/show/NCT00145574
NCT00145717,China Plant Sterol Trial,,Completed,No Results Available,Hypercholesterolemia|Cardiovascular Diseases,Drug: Plant sterol enriched milk tea,Low density lipoprotein cholesterol levels|Total cholesterol levels;|High density lipoprotein cholesterol levels;|Triglycerides levels;|Liking and adherence,The George Institute|Peking University,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,300,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention,CPST,Apr-05,null,Jul-05,5-Sep-05,null,5-Sep-05,"Peking University Health Science Centre, Beijing, China",,https://ClinicalTrials.gov/show/NCT00145717
NCT00143234,Amlodipine/Atorvastatin Combination to Reduce the Health Risk of High Blood Pressure and High Cholesterol Levels,GEMINI-AALA,Completed,No Results Available,Hypertension|Hyperlipidemia,Drug: Amlodipine/atorvastatin single pill,"To evaluate the efficacy of amlodipine/atorvastatin therapy by assessing the percentage of intent-to-treat subjects achieving both BP and lipid treatment goals (JNC VII and NCEP ATP III)|To assess changes from baseline in lipid profile and systolic and diastolic BP after 14 weeks treatment; and in this secondary and the primary objectives stratified by prior BP and lipid therapy, and in diabetic subjects; safety",Pfizer,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,1825,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A3841024,May-04,null,Jul-05,2-Sep-05,null,22-Apr-15,"Pfizer Investigational Site, Buenos Aires, Argentina|Pfizer Investigational Site, Buenos Aires, Argentina|Pfizer Investigational Site, Buenos Aires, Argentina|Pfizer Investigational Site, Buenos Aires, Argentina|Pfizer Investigational Site, Buenos Aires, Argentina|Pfizer Investigational Site, St. Leonards, New South Wales, Australia|Pfizer Investigational Site, Southport, Queensland, Australia|Pfizer Investigational Site, Woolloongabba, Queensland, Australia|Pfizer Investigational Site, Heidelberg, Victoria, Australia|Pfizer Investigational Site, Melbourne, Victoria, Australia|Pfizer Investigational Site, Prahran, Victoria, Australia|Pfizer Investigational Site, Fremantle, Western Australia, Australia|Pfizer Investigational Site, Belo Horizonte, MG, Brazil|Pfizer Investigational Site, Belo Horizonte, MG, Brazil|Pfizer Investigational Site, Belo Horizonte, MG, Brazil|Pfizer Investigational Site, Recife, PE, Brazil|Pfizer Investigational Site, Botucatu, SP, Brazil|Pfizer Investigational Site, Campinas, SP, Brazil|Pfizer Investigational Site, Ribeirao Preto, SP, Brazil|Pfizer Investigational Site, Sao Paulo, SP, Brazil|Pfizer Investigational Site, SÃ£o Paulo, SP, Brazil|Pfizer Investigational Site, Santiago, RegiÃ³n Metropolitana, Chile|Pfizer Investigational Site, Santiago, RM, Chile|Pfizer Investigational Site, Guatemala, Guatemala|Pfizer Investigational Site, Pokfulam Road, Hong Kong|Pfizer Investigational Site, Sai ying Pun, Hong Kong|Pfizer Investigational Site, Hyderabad, Andhra Pradesh, India|Pfizer Investigational Site, Hyderabad, Andhra Pradesh, India|Pfizer Investigational Site, Bangalore, Karnataka, India|Pfizer Investigational Site, Mumbai, Maharashtra, India|Pfizer Investigational Site, Pune, Maharashtra, India|Pfizer Investigational Site, Mumbai, Nagpada Junction, India|Pfizer Investigational Site, New Delhi, India|Pfizer Investigational Site, New Delhi, India|Pfizer Investigational Site, New Delhi, India|Pfizer Investigational Site, Jakarta, Indonesia|Pfizer Investigational Site, Jakarta, Indonesia|Pfizer Investigational Site, Surabaya, Indonesia|Pfizer Investigational Site, Jerusalem, Israel|Pfizer Investigational Site, Jerusalem, Israel|Pfizer Investigational Site, Rehovot, Israel|Pfizer Investigational Site, Tel Aviv, Israel|Pfizer Investigational Site, Tel Hashomer, Israel|Pfizer Investigational Site, Amman, Jordan|Pfizer Investigational Site, Amman, Jordan|Pfizer Investigational Site, Seo-gu, Busan, Korea, Republic of|Pfizer Investigational Site, Jung-gu, Daegu, Korea, Republic of|Pfizer Investigational Site, Dong-gu, Kwangji, Korea, Republic of|Pfizer Investigational Site, Anyang-city, Kyungki-do, Korea, Republic of|Pfizer Investigational Site, Guri-City, Kyungki-do, Korea, Republic of|Pfizer Investigational Site, Gangnam-gu, Seoul, Korea, Republic of|Pfizer Investigational Site, Yongdeungpo-gu, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Sasat, Kuwait|Pfizer Investigational Site, Beirut, Lebanon|Pfizer Investigational Site, Kubang Kerian, Kelantan, Malaysia|Pfizer Investigational Site, Seremban, Negeri Sembilan, Malaysia|Pfizer Investigational Site, Kuching, Sarawak, Malaysia|Pfizer Investigational Site, Kuala Lumpur, Malaysia|Pfizer Investigational Site, Kuala Lumpur, Malaysia|Pfizer Investigational Site, Mexico, D.F, Mexico|Pfizer Investigational Site, Aguascalientes, Mexico|Pfizer Investigational Site, Metepec, Mexico|Pfizer Investigational Site, Mexico, Mexico|Pfizer Investigational Site, Puebla, Mexico|Pfizer Investigational Site, San Luis Potosi, Mexico|Pfizer Investigational Site, Casablanca, Morocco|Pfizer Investigational Site, Peshawar, N.w.f.p., Pakistan|Pfizer Investigational Site, Faisalabad, Punjab, Pakistan|Pfizer Investigational Site, Islamabad, Punjab, Pakistan|Pfizer Investigational Site, Lahore, Punjab, Pakistan|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, San Juan, Metro Manila, Philippines|Pfizer Investigational Site, Phippine General Hospital, Taft Avenue, Manila City, Philippines|Pfizer Investigational Site, Filinvest, Alabang, Philippines|Pfizer Investigational Site, Manila, Philippines|Pfizer Investigational Site, Quezon City, Philippines|Pfizer Investigational Site, Quezon City, Philippines|Pfizer Investigational Site, Al-Khobar, Saudi Arabia|Pfizer Investigational Site, Riyadh, Saudi Arabia|Pfizer Investigational Site, Riyadh, Saudi Arabia|Pfizer Investigational Site, Singapore, Singapore|Pfizer Investigational Site, Singapore, Singapore|Pfizer Investigational Site, Worcester, Cape Province, South Africa|Pfizer Investigational Site, Arcadia, Pretoria, Gauteng, South Africa|Pfizer Investigational Site, Midrand, Johannesburg, Gauteng, South Africa|Pfizer Investigational Site, Sunnyside, Pretoria, Gauteng, South Africa|Pfizer Investigational Site, Chatsworth, Natal, South Africa|Pfizer Investigational Site, Cape Town, South Africa|Pfizer Investigational Site, Cape Town, South Africa|Pfizer Investigational Site, Cape Town, South Africa|Pfizer Investigational Site, Gauteng, South Africa|Pfizer Investigational Site, Kwa-Zulu Natal, South Africa|Pfizer Investigational Site, Niao-Sung Hsiang, Kaohsiung, Taiwan|Pfizer Investigational Site, Guei-Shan Shiang, Tau-Yuan Shian, Taiwan|Pfizer Investigational Site, Changhua City, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Khet Rajathevee, Bangkok, Thailand|Pfizer Investigational Site, Bangkok, Thailand|Pfizer Investigational Site, Chiang Mai, Thailand|Pfizer Investigational Site, Tunis, Tunisia|Pfizer Investigational Site, Cebeci, Ankara, Turkey|Pfizer Investigational Site, Sihhiye, Ankara, Turkey|Pfizer Investigational Site, Haydarpasa, Istanbul, Turkey|Pfizer Investigational Site, Alsancak, Izmir, Turkey|Pfizer Investigational Site, Talas, Kayseri, Turkey|Pfizer Investigational Site, Adana, Turkey|Pfizer Investigational Site, Antalya, Turkey|Pfizer Investigational Site, Diyarbakir, Turkey|Pfizer Investigational Site, Istanbul, Turkey|Pfizer Investigational Site, Abu Dhabi, United Arab Emirates|Pfizer Investigational Site, Dubai, United Arab Emirates|Pfizer Investigational Site, Sharjah, United Arab Emirates|Pfizer Investigational Site",,https://ClinicalTrials.gov/show/NCT00143234
NCT00143663,Effect of Lapaquistat Acetate on Blood Cholesterol Levels in Subjects With Elevated Cholesterol,,Completed,No Results Available,Dyslipidemia,Drug: Lapaquistat Acetate|Drug: Placebo,Change from Baseline in Low-Density Lipoprotein cholesterol|Change from Baseline in Calculated Low-Density Lipoprotein cholesterol|Change from Baseline in High-Density Lipoprotein cholesterol|Change from Baseline in the ratio of Low-Density Lipoprotein cholesterol/ High-Density Lipoprotein cholesterol|Change from Baseline in Very Low-Density Lipoprotein cholesterol|Change from Baseline in non- High-Density Lipoprotein cholesterol|Change from Baseline in Triglycerides|Change from Baseline in Total Cholesterol|Change from Baseline in the ratio of Total Cholesterol/High-Density Lipoprotein cholesterol|Change from Baseline in apolipoprotein A1|Change from Baseline in apolipoprotein B|Change from Baseline in the ratio of apolipoprotein B/ apolipoprotein A1|Change from Baseline in High-Sensitivity C-reactive Protein,Takeda,All,"18 Years and older   (Adult, Older Adult)",Phase 3,361,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",01-04-TL-475-008|U1111-1122-7722,Sep-05,Apr-06,Apr-06,2-Sep-05,null,24-May-12,"Northport, Alabama, United States|Mesa, Arizona, United States|Chula Vista, California, United States|Encinitas, California, United States|Long Beach, California, United States|Pismo Beach, California, United States|Sacramento, California, United States|San Diego, California, United States|Golden, Colorado, United States|Aventura, Florida, United States|Clearwater, Florida, United States|Daytona Beach, Florida, United States|Hollywood, Florida, United States|Jacksonville, Florida, United States|Jupiter, Florida, United States|New Port Richy, Florida, United States|Pembroke Pines, Florida, United States|Elk Grove Village, Illinois, United States|Peoria, Illinois, United States|Evansville, Indiana, United States|Indianapolis, Indiana, United States|Arkansas City, Kansas, United States|Wichita, Kansas, United States|Louisville, Kentucky, United States|Livonia, Michigan, United States|Las Vegas, Nevada, United States|Margate, New Jersey, United States|New Hyde Park, New York, United States|Charlotte, North Carolina, United States|Raleigh, North Carolina, United States|Statesville, North Carolina, United States|Wilmington, North Carolina, United States|Winston-Salem, North Carolina, United States|Medford, Oregon, United States|Downingtown, Pennsylvania, United States|Sellersville, Pennsylvania, United States|Tipton, Pennsylvania, United States|Warwick, Rhode Island, United States|Charleston, South Carolina, United States|Mt. Pleasant, South Carolina, United States|Bristol, Tennessee, United States|Dallas, Texas, United States|San Antonio, Texas, United States|Ogden, Utah, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00143663
NCT00143676,Efficacy of Lapaquistat Acetate and Atorvastatin on Blood Cholesterol Levels in Subjects With Primary Hypercholesterolemia,,Completed,No Results Available,Hypercholesterolemia,Drug: Lapaquistat acetate and atorvastatin|Drug: Atorvastatin,Change from Baseline in Low Density Lipoprotein cholesterol|Adverse Events|Physical Examination|Safety Laboratory Tests|Electrocardiogram assessments|Best Corrected Visual Acuity results|Vital Signs|Change from Baseline in Triglycerides|Change from Baseline in Total Cholesterol|Change from Baseline in High Density Lipoprotein cholesterol|Change from Baseline in Very Low Density Lipoprotein cholesterol|Change from Baseline in apolipoprotein A1|Change from Baseline in apolipoprotein B|Change from Baseline in non- High Density Lipoprotein cholesterol|Change from Baseline in the ratio of Low Density Lipoprotein cholesterol/High Density Lipoprotein cholesterol|Change from Baseline in the ratio of Total Cholesterol/High Density Lipoprotein cholesterol|Change from Baseline in the ratio of apolipoprotein A1/apolipoprotein B|Change from Baseline in high-sensitivity C-reactive protein|Percentage of subjects who achieve Low Density Lipoprotein cholesterol concentrations less than 1.813 mmol/L (70 mg/dL)|Percentage of subjects who achieve Low Density Lipoprotein cholesterol concentrations less than 2.590 mmol/L (100 mg/dL)|Percentage of subjects who achieve Low Density Lipoprotein cholesterol concentrations less than 3.367 mmol/L (130 mg/dL),Takeda,All,"18 Years and older   (Adult, Older Adult)",Phase 3,448,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",01-04-TL-475-009|U1111-1122-7783,Aug-05,Aug-06,Aug-06,2-Sep-05,null,24-May-12,"Birmingham, Alabama, United States|Northport, Alabama, United States|Sierra Vista, Arizona, United States|Tucson, Arizona, United States|Jonesboro, Arkansas, United States|Searcy, Arkansas, United States|Anaheim, California, United States|Carmichael, California, United States|Chula Vista, California, United States|Escondido, California, United States|Pismo Beach, California, United States|Santa Rosa, California, United States|Golden, Colorado, United States|Waterbury, Connecticut, United States|Clearwater, Florida, United States|Daytona Beach, Florida, United States|Hollywood, Florida, United States|Jacksonville, Florida, United States|Jupiter, Florida, United States|Kissimmee, Florida, United States|Miami, Florida, United States|New Port Richey, Florida, United States|Ocala, Florida, United States|Pembroke Pines, Florida, United States|West Palm Beach, Florida, United States|Honolulu, Hawaii, United States|Arlington Heights, Illinois, United States|Chicago, Illinois, United States|Peoria, Illinois, United States|Bloomington, Indiana, United States|Evansville, Indiana, United States|Indianapolis, Indiana, United States|Waterloo, Iowa, United States|Arkansas City, Kansas, United States|Kansas City, Kansas, United States|Overland Park, Kansas, United States|Wichita, Kansas, United States|Louisville, Kentucky, United States|Auburn, Maine, United States|Livonia, Michigan, United States|Edina, Minnesota, United States|Omaha, Nebraska, United States|Las Vegas, Nevada, United States|Edison, New Jersey, United States|Margate, New Jersey, United States|New Hyde Park, New York, United States|Rochester, New York, United States|Syracuse, New York, United States|Hickory, North Carolina, United States|Raleigh, North Carolina, United States|Statesville, North Carolina, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Tulsa, Oklahoma, United States|Medford, Oregon, United States|Portland, Oregon, United States|Allentown, Pennsylvania, United States|Altoona, Pennsylvania, United States|Downingtown, Pennsylvania, United States|Sellerville, Pennsylvania, United States|Tipton, Pennsylvania, United States|Warwick, Rhode Island, United States|Charleston, South Carolina, United States|Mt. Pleasant, South Carolina, United States|Simpsonville, South Carolina, United States|Chattanooga, Tennessee, United States|Morristown, Tennessee, United States|Corpus Christi, Texas, United States|Dallas, Texas, United States|Euless, Texas, United States|San Antonio, Texas, United States|The Colony, Texas, United States|Ogden, Utah, United States|Salt Lake City, Utah, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Renton, Washington, United States|Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00143676
NCT00141141,Efficacy And Safety Study Of Atorvastatin Versus Simvastatin In Type 2 Diabetic Subjects With Hypercholesterolemia,,Completed,No Results Available,Hypercholesterolemia,Drug: Atorvastatin|Drug: Simvastatin,To evaluate the decrease of LDL-C after 24 weeks of treatment.|To evaluate the changes from baseline of targeted blood markers.|To evaluate safety of Atorvastatin vs Simvastatin,Pfizer,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,383,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A2581053,Jan-04,null,Apr-07,1-Sep-05,null,31-Oct-08,"Pfizer Investigational Site, S. Benedetto Del Tronto, Ascoli Piceno, Italy|Pfizer Investigational Site, S.Pietro Vernotico, Brindisi, Italy|Pfizer Investigational Site, Casarano, Lecce, Italy|Pfizer Investigational Site, Pavia, PV, Italy|Pfizer Investigational Site, Orbassano, Torino, Italy|Pfizer Investigational Site, Mestre, VE, Italy|Pfizer Investigational Site, Ancona, Italy|Pfizer Investigational Site, Asti, Italy|Pfizer Investigational Site, Bari, Italy|Pfizer Investigational Site, Cagliari, Italy|Pfizer Investigational Site, Campobasso, Italy|Pfizer Investigational Site, Catania, Italy|Pfizer Investigational Site, Catania, Italy|Pfizer Investigational Site, Catanzaro, Italy|Pfizer Investigational Site, Ferrara, Italy|Pfizer Investigational Site, Genova, Italy|Pfizer Investigational Site, Messina, Italy|Pfizer Investigational Site, Milano, Italy|Pfizer Investigational Site, Milano, Italy|Pfizer Investigational Site, Milano, Italy|Pfizer Investigational Site, Napoli, Italy|Pfizer Investigational Site, Napoli, Italy|Pfizer Investigational Site, Palermo, Italy|Pfizer Investigational Site, Parma, Italy|Pfizer Investigational Site, Perugia, Italy|Pfizer Investigational Site, Pisa, Italy|Pfizer Investigational Site, Potenza, Italy|Pfizer Investigational Site, Rimini, Italy|Pfizer Investigational Site, Roma, Italy|Pfizer Investigational Site, Roma, Italy|Pfizer Investigational Site, Roma, Italy|Pfizer Investigational Site, Roma, Italy|Pfizer Investigational Site, S. Benedetto del Tronto (AP), Italy|Pfizer Investigational Site, Torino, Italy|Pfizer Investigational Site, Udine, Italy",,https://ClinicalTrials.gov/show/NCT00141141
NCT00139178,Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir.,,Completed,No Results Available,HIV Associated Lipodystrophy Syndrome.|HIV|Hypercholesterolemia|Lipoatrophy,Drug: Different HAART regimens,"Changes in peripheral fat mass, determined by DEXA-Changes Change from baseline in fasting lipids and subsets hereof. Development of impaired glucose tolerance and insulin resistance.|Changes in body composition from baseline, determined by patient and physician in a standardized questionnaire and by standardized clinical examination.|Proportion of patients with HIV-RNA < 20 copies after 24, 48, 72 and 96 weeks.|Change in CD4 cell count from baseline after 24, 48, 72 and 96 weeks.|Incidence of adverse events.|Incidence of clinical disease progression.|Proportion of patients who have virological, immunological or clinical failure or treatment-limiting adverse events at week 24,48 and 96.|Change in plasma lactate from baseline.|Time to discontinuation of the allocated therapy and reasons for this.|Incidence of genotypical and virological resistance. Development of osteopenia, judged by DEXA-scan. Compliance – proportion of patients who report to take 90%, respectively 95% of their medications at week 4, 48 and 96.","Danish HIV Research Group|Odense University Hospital|Rigshospitalet, Denmark|Hvidovre University Hospital|Aarhus University Hospital",All,"18 Years and older   (Adult, Older Adult)",Phase 4,100,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,26122450,Mar-04,null,Apr-07,31-Aug-05,null,5-Sep-05,"Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark|Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark|Department of Infectious Diseases, Hvidovre University Hospital, Hvidovre, Denmark|Department of Infectious diseases, Odense University Hospital, Odense, Denmark",,https://ClinicalTrials.gov/show/NCT00139178
NCT00138762,A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol,,Completed,No Results Available,Hyperlipidemia,Drug: torcetrapib/atorvastatin|Drug: atorvastatin|Drug: placebo,LDL and HDL levels|other lipid parameters,Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,3800,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,A5091018,Jul-04,Aug-06,Aug-06,30-Aug-05,null,17-Feb-12,"Pfizer Investigational Site, Mobile, Alabama, United States|Pfizer Investigational Site, Mesa, Arizona, United States|Pfizer Investigational Site, Oro Valley, Arizona, United States|Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Sun City, Arizona, United States|Pfizer Investigational Site, Little Rock, Arkansas, United States|Pfizer Investigational Site, Anaheim, California, United States|Pfizer Investigational Site, Carmichael, California, United States|Pfizer Investigational Site, Concord, California, United States|Pfizer Investigational Site, Greenbrae, California, United States|Pfizer Investigational Site, Los Angeles, California, United States|Pfizer Investigational Site, Mission Viejo, California, United States|Pfizer Investigational Site, Sacramento, California, United States|Pfizer Investigational Site, Santa Ana, California, United States|Pfizer Investigational Site, Stockton, California, United States|Pfizer Investigational Site, Thouasand Oaks, California, United States|Pfizer Investigational Site, Tustin, California, United States|Pfizer Investigational Site, Upland, California, United States|Pfizer Investigational Site, Walnut Creek, California, United States|Pfizer Investigational Site, Westlake Village, California, United States|Pfizer Investigational Site, Boulder, Colorado, United States|Pfizer Investigational Site, Waterbury, Connecticut, United States|Pfizer Investigational Site, Newark, Delaware, United States|Pfizer Investigational Site, Coral Gables, Florida, United States|Pfizer Investigational Site, Ft. Pierce, Florida, United States|Pfizer Investigational Site, Jacksonville, Florida, United States|Pfizer Investigational Site, Jupiter, Florida, United States|Pfizer Investigational Site, Lake Worth, Florida, United States|Pfizer Investigational Site, Melbourne, Florida, United States|Pfizer Investigational Site, Palm Bay, Florida, United States|Pfizer Investigational Site, Sebastian, Florida, United States|Pfizer Investigational Site, Stuart, Florida, United States|Pfizer Investigational Site, Vero Beach, Florida, United States|Pfizer Investigational Site, Wellington, Florida, United States|Pfizer Investigational Site, West Palm Beach, Florida, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, Creve Coevr, Illinois, United States|Pfizer Investigational Site, Peoria, Illinois, United States|Pfizer Investigational Site, Rockford, Illinois, United States|Pfizer Investigational Site, Iowa City, Iowa, United States|Pfizer Investigational Site, Kansas City, Kansas, United States|Pfizer Investigational Site, Overland Park, Kansas, United States|Pfizer Investigational Site, Wichita, Kansas, United States|Pfizer Investigational Site, Erlanger, Kentucky, United States|Pfizer Investigational Site, Louisville, Kentucky, United States|Pfizer Investigational Site, Covington, Louisiana, United States|Pfizer Investigational Site, Slidell, Louisiana, United States|Pfizer Investigational Site, Scarborough, Maine, United States|Pfizer Investigational Site, Baltimore, Maryland, United States|Pfizer Investigational Site, Bethesda, Maryland, United States|Pfizer Investigational Site, Elkton, Maryland, United States|Pfizer Investigational Site, Jackson, Mississippi, United States|Pfizer Investigational Site, Jefferson City, Missouri, United States|Pfizer Investigational Site, Kansas City, Missouri, United States|Pfizer Investigational Site, Billings, Montana, United States|Pfizer Investigational Site, Lincoln, Nebraska, United States|Pfizer Investigational Site, Omaha, Nebraska, United States|Pfizer Investigational Site, Las Vegas, Nevada, United States|Pfizer Investigational Site, Endwell, New York, United States|Pfizer Investigational Site, Lake Success, New York, United States|Pfizer Investigational Site, Rochester, New York, United States|Pfizer Investigational Site, Williamsville, New York, United States|Pfizer Investigational Site, Charlotte, North Carolina, United States|Pfizer Investigational Site, Concord, North Carolina, United States|Pfizer Investigational Site, Fayetteville, North Carolina, United States|Pfizer Investigational Site, Monroe, North Carolina, United States|Pfizer Investigational Site, Raleigh, North Carolina, United States|Pfizer Investigational Site, Winston-Salem, North Carolina, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Elyria, Ohio, United States|Pfizer Investigational Site, Olmsted Township, Ohio, United States|Pfizer Investigational Site, Westlake, Ohio, United States|Pfizer Investigational Site, Tulsa, Oklahoma, United States|Pfizer Investigational Site, Beaverton, Oregon, United States|Pfizer Investigational Site, Hillsboro, Oregon, United States|Pfizer Investigational Site, Portland, Oregon, United States|Pfizer Investigational Site, Warwick, Rhode Island, United States|Pfizer Investigational Site, Greer, South Carolina, United States|Pfizer Investigational Site, Spartanburg, South Carolina, United States|Pfizer Investigational Site, Kingsport, Tennessee, United States|Pfizer Investigational Site, Nashville, Tennessee, United States|Pfizer Investigational Site, Austin, Texas, United States|Pfizer Investigational Site, Beaumont, Texas, United States|Pfizer Investigational Site, Bryan, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, The Colony, Texas, United States|Pfizer Investigational Site, Salt Lake City, Utah, United States|Pfizer Investigational Site, Newport News, Virginia, United States|Pfizer Investigational Site, Norfolk, Virginia, United States|Pfizer Investigational Site, Richmond, Virginia, United States|Pfizer Investigational Site, Renton, Washington, United States|Pfizer Investigational Site, Yakima, Washington, United States|Pfizer Investigational Site, Milwaukee, Wisconsin, United States|Pfizer Investigational Site, Oregon, Wisconsin, United States|Pfizer Investigational Site, Bruxelles, Belgium|Pfizer Investigational Site, Dottignies, Belgium|Pfizer Investigational Site, Ham, Belgium|Pfizer Investigational Site, Hasselt, Belgium|Pfizer Investigational Site, Hoeilaart, Belgium|Pfizer Investigational Site, La Louviere, Belgium|Pfizer Investigational Site, Leuven, Belgium|Pfizer Investigational Site, Wilsele, Belgium|Pfizer Investigational Site, Beckum, Germany|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Bochum, Germany|Pfizer Investigational Site, Erlangen, Germany|Pfizer Investigational Site, Essen, Germany|Pfizer Investigational Site, Feldafing, Germany|Pfizer Investigational Site, Hamburg, Germany|Pfizer Investigational Site, Heidelberg, Germany|Pfizer Investigational Site, Homburg/Saar, Germany|Pfizer Investigational Site, Karlsruhe, Germany|Pfizer Investigational Site, Kuenzing, Germany|Pfizer Investigational Site, Nuernberg, Germany|Pfizer Investigational Site, Offenbach, Germany|Pfizer Investigational Site, Rodgau, Germany|Pfizer Investigational Site, Schwerin, Germany|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Suwon, Korea, Republic of|Pfizer Investigational Site, Mexico, D.f., Mexico|Pfizer Investigational Site, Tlalpan, D.f., Mexico|Pfizer Investigational Site, Mexico, DF, Mexico|Pfizer Investigational Site, Monterrey, Nuevo Leon, Mexico|Pfizer Investigational Site, Puebla, Mexico|Pfizer Investigational Site, Bekkestua, Norway|Pfizer Investigational Site, Elverum, Norway|Pfizer Investigational Site, Honefoss, Norway|Pfizer Investigational Site, Jessheim, Norway|Pfizer Investigational Site, Kongsberg, Norway|Pfizer Investigational Site, Lena, Norway|Pfizer Investigational Site, Lierskogen, Norway|Pfizer Investigational Site, Molde, Norway|Pfizer Investigational Site, Moss, Norway|Pfizer Investigational Site, Oslo, Norway|Pfizer Investigational Site, Roverud, Norway|Pfizer Investigational Site, Skedsmokorset, Norway|Pfizer Investigational Site, Tromso, Norway|Pfizer Investigational Site, Goteborg, Sweden|Pfizer Investigational Site, Jarfalla, Sweden|Pfizer Investigational Site, Linkoping, Sweden|Pfizer Investigational Site, Orebro, Sweden|Pfizer Investigational Site, Strangnas, Sweden|Pfizer Investigational Site, Umea, Sweden|Pfizer Investigational Site, Penzance, Cornwall, United Kingdom|Pfizer Investigational Site, Woolwell, Plymouth, Devon, United Kingdom|Pfizer Investigational Site, Middlesex, Harrow, United Kingdom|Pfizer Investigational Site, Garston, Hertfordshire, United Kingdom|Pfizer Investigational Site, Blackpool, Lancashire, United Kingdom|Pfizer Investigational Site, Blackpool, Lancs. Fy3 7dq, United Kingdom|Pfizer Investigational Site, Addlestone, Surrey, United Kingdom|Pfizer Investigational Site, East Horsley, Leatherhead, Surrey, United Kingdom|Pfizer Investigational Site, Warminster, Wiltshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT00138762
NCT00139061,Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate,,Completed,No Results Available,Hyperlipidemia,Drug: Torcetrapib/Atorvastatin|Drug: Fenofibrate,To assess HDL-C increase and non-HDL lowering effect of torcetrapib/atorvastatin vs. fenofibrate.|Changes in levels of lipid parameters and other biomarkers,Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,128,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,A5091034,Mar-05,null,May-06,30-Aug-05,null,31-Oct-07,"Pfizer Investigational Site, Angers, France|Pfizer Investigational Site, Angers, France|Pfizer Investigational Site, Bordeaux Cauderan, France|Pfizer Investigational Site, Briollay, France|Pfizer Investigational Site, Dijon, France|Pfizer Investigational Site, Hagondange, France|Pfizer Investigational Site, Haut Mauco, France|Pfizer Investigational Site, Jarny, France|Pfizer Investigational Site, Lille, France|Pfizer Investigational Site, Mars LA Tour, France|Pfizer Investigational Site, Metz, France|Pfizer Investigational Site, Monguilhem, France|Pfizer Investigational Site, Mont de Marsan CEDEX, France|Pfizer Investigational Site, Mont de Marsan, France|Pfizer Investigational Site, Mont de Marsan, France|Pfizer Investigational Site, Mont de Marsan, France|Pfizer Investigational Site, Moutiers, France|Pfizer Investigational Site, Murs Erigne, France|Pfizer Investigational Site, Nantes, France|Pfizer Investigational Site, Pouilly en Auxois, France|Pfizer Investigational Site, Saint Justin, France|Pfizer Investigational Site, Saint Martin D'Oney, France|Pfizer Investigational Site, Seysses, France|Pfizer Investigational Site, Strasbourg, France|Pfizer Investigational Site, Thouars, France|Pfizer Investigational Site, Tierce, France",,https://ClinicalTrials.gov/show/NCT00139061
NCT00136799,Efficacy and Safety of Fluvastatin in Different Doses in Adults With Mixed Dyslipidemia or Primary Hypercholesterolemia,,Completed,No Results Available,Mixed Dyslipidemia|Hypercholesterolemia,Drug: Fluvastatin,Percent change from baseline in low density lipoprotein cholesterol after 12 weeks|Percent change from baseline in total cholesterol after 12 weeks|Percent change from baseline in high density lipoprotein cholesterol after 12 weeks|Percent change from baseline in total triglycerides after 12 weeks,Novartis,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,325,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CXUO320B2302,Jun-05,Apr-06,Apr-06,29-Aug-05,null,23-Feb-17,"Novartis, Shangai, China",,https://ClinicalTrials.gov/show/NCT00136799
NCT00136942,A Swiss Study With Atorvastatin in Hyperlipidemic Patients Measuring LDL-Cholesterol,ACTFAST SWISS,Completed,No Results Available,Hyperlipidemia,Drug: Atorvastatin,"The proportion of patients achieving LDL-C target as defined by local swiss AGLArecommendations across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.|The proportion of patients across different AGLA-categories (primary and secondary prevention) achieving LDL-C target as defined by AGLA-recommendations across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.",Pfizer,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,370,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A2581089,Apr-05,null,null,29-Aug-05,null,3-Mar-08,"Pfizer Investigational Site, Langenthal, BE, Switzerland|Pfizer Investigational Site, Thun, BE, Switzerland|Pfizer Investigational Site, Binningen, BL, Switzerland|Pfizer Investigational Site, Liestal, BL, Switzerland|Pfizer Investigational Site, Basel, BS, Switzerland|Pfizer Investigational Site, Duedingen, FR, Switzerland|Pfizer Investigational Site, Geneve, GE, Switzerland|Pfizer Investigational Site, Onex, GE, Switzerland|Pfizer Investigational Site, Pfaeffikon, SZ, Switzerland|Pfizer Investigational Site, Siebnen, SZ, Switzerland|Pfizer Investigational Site, Lugano, TI, Switzerland|Pfizer Investigational Site, Malvaglia, TI, Switzerland|Pfizer Investigational Site, Melide, TI, Switzerland|Pfizer Investigational Site, Vezia, TI, Switzerland|Pfizer Investigational Site, Ecublens, VD, Switzerland|Pfizer Investigational Site, Lausanne, VD, Switzerland|Pfizer Investigational Site, Prilly, VD, Switzerland|Pfizer Investigational Site, Unteraegeri, ZG, Switzerland|Pfizer Investigational Site, Zug, ZG, Switzerland|Pfizer Investigational Site, Zuerich, ZH, Switzerland",,https://ClinicalTrials.gov/show/NCT00136942
NCT00136981,Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone.,RADIANCE 1,Completed,No Results Available,"Hypercholesterolemia, Familial|Hyperlipidemia",Drug: torcetrapib/atorvastatin|Drug: atorvastatin,Change in intima media thickness as measures by carotid ultrasound|Changes in levels of lipids and other biomarkers.,Pfizer,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,800,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,A5091003,Dec-03,null,Nov-06,29-Aug-05,null,22-Apr-15,"Pfizer Investigational Site, Hartford, Connecticut, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Minneapolis, Minnesota, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, Salt Lake City, Utah, United States|Pfizer Investigational Site, Seattle, Washington, United States|Pfizer Investigational Site, Vancouver, British Columbia, Canada|Pfizer Investigational Site, Winnipeg, Manitoba, Canada|Pfizer Investigational Site, Chicoutimi, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Quebec, Canada|Pfizer Investigational Site, Prague 4, Czech Republic|Pfizer Investigational Site, Prague, Czech Republic|Pfizer Investigational Site, Kuopio, Finland|Pfizer Investigational Site, OYS, Finland|Pfizer Investigational Site, PARIS Cedex, France|Pfizer Investigational Site, Toul Cedex, France|Pfizer Investigational Site, Brescia, Italy|Pfizer Investigational Site, Pavia, Italy|Pfizer Investigational Site, Alkmaar, Netherlands|Pfizer Investigational Site, Amsterdam, Netherlands|Pfizer Investigational Site, Delft, Netherlands|Pfizer Investigational Site, Goes, Netherlands|Pfizer Investigational Site, Groningen, Netherlands|Pfizer Investigational Site, Hoorn, Netherlands|Pfizer Investigational Site, Leiden, Netherlands|Pfizer Investigational Site, Nijmegen, Netherlands|Pfizer Investigational Site, Rotterdam, Netherlands|Pfizer Investigational Site, Sliedrecht, Netherlands|Pfizer Investigational Site, Utrecht, Netherlands|Pfizer Investigational Site, Waalwijk, Netherlands|Pfizer Investigational Site, Parow, Cape Town, South Africa|Pfizer Investigational Site, Parktown, Johannesburg, South Africa|Pfizer Investigational Site, Cape Town, South Africa",,https://ClinicalTrials.gov/show/NCT00136981
NCT00137462,Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.,,Completed,No Results Available,Hyperlipidemia,Drug: torcetrapib/atorvastatin|Drug: atorvastatin,"Change in lipid parameters (HDL, LDL) at various timepoints over 12 months.|Changes in levels of lipids and other biomarkers.",Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,900,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,A5091019,Nov-04,null,Sep-06,29-Aug-05,null,16-Nov-07,"Pfizer Investigational Site, Huntsville, Alabama, United States|Pfizer Investigational Site, Union Grove, Alabama, United States|Pfizer Investigational Site, Fresno, California, United States|Pfizer Investigational Site, Los Angeles, California, United States|Pfizer Investigational Site, Orange, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, Denver, Colorado, United States|Pfizer Investigational Site, Denver, Colorado, United States|Pfizer Investigational Site, Golden, Colorado, United States|Pfizer Investigational Site, Bridgeport, Connecticut, United States|Pfizer Investigational Site, Fairfield, Connecticut, United States|Pfizer Investigational Site, Trumbull, Connecticut, United States|Pfizer Investigational Site, Waterbury, Connecticut, United States|Pfizer Investigational Site, Washington, District of Columbia, United States|Pfizer Investigational Site, Boynton Beach, Florida, United States|Pfizer Investigational Site, Fort Lauderdale, Florida, United States|Pfizer Investigational Site, Gainesville, Florida, United States|Pfizer Investigational Site, Gainesville, Florida, United States|Pfizer Investigational Site, Gainsville, Florida, United States|Pfizer Investigational Site, Sebastian, Florida, United States|Pfizer Investigational Site, Vero Beach, Florida, United States|Pfizer Investigational Site, Rockford, Illinois, United States|Pfizer Investigational Site, Springfield, Illinois, United States|Pfizer Investigational Site, Olathe, Kansas, United States|Pfizer Investigational Site, Overland Park, Kansas, United States|Pfizer Investigational Site, Madisonville, Kentucky, United States|Pfizer Investigational Site, Burlington, Massachusetts, United States|Pfizer Investigational Site, Grand Rapids, Michigan, United States|Pfizer Investigational Site, Troy, Michigan, United States|Pfizer Investigational Site, Albuquerque, New Mexico, United States|Pfizer Investigational Site, Albuquerque, New Mexico, United States|Pfizer Investigational Site, Orchard Park, New York, United States|Pfizer Investigational Site, Syracuse, New York, United States|Pfizer Investigational Site, Syracuse, New York, United States|Pfizer Investigational Site, Williamsville, New York, United States|Pfizer Investigational Site, Charlotte, North Carolina, United States|Pfizer Investigational Site, Cleveland, Ohio, United States|Pfizer Investigational Site, Columbus, Ohio, United States|Pfizer Investigational Site, Keizer, Oregon, United States|Pfizer Investigational Site, Salem, Oregon, United States|Pfizer Investigational Site, Doylestown, Pennsylvania, United States|Pfizer Investigational Site, Charleston, South Carolina, United States|Pfizer Investigational Site, Mt. Pleasant, South Carolina, United States|Pfizer Investigational Site, Mt. Pleasant, South Carolina, United States|Pfizer Investigational Site, Kingsport, Tennessee, United States|Pfizer Investigational Site, Morristown, Tennessee, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, McKinney, Texas, United States|Pfizer Investigational Site, Edmonton, Alberta, Canada|Pfizer Investigational Site, Coquitlam, British Columbia, Canada|Pfizer Investigational Site, London, Ontario, Canada|Pfizer Investigational Site, London, Ontario, Canada|Pfizer Investigational Site, Ottawa, Ontario, Canada|Pfizer Investigational Site, Sarnia, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Charlottetown, Prince Edward Island, Canada|Pfizer Investigational Site, Mirabel, Quebec, Canada|Pfizer Investigational Site, Pointe-Claire, Quebec, Canada|Pfizer Investigational Site, St. Georges de Beauce, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00137462
NCT00134173,A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease,ILLUSTRATE,Completed,No Results Available,Coronary Disease|Coronary Arteriosclerosis|Hyperlipidemia,Drug: torcetrapib/atorvastatin|Drug: atorvastatin,Change coronary artery atheroma volume as measured by intravascular ultrasound.|Changes in levels of lipids and other biomarkers.,Pfizer,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,1100,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,A5091005,Oct-03,null,Sep-06,24-Aug-05,null,10-Dec-07,"Pfizer Investigational Site, Birmingham, Alabama, United States|Pfizer Investigational Site, Mobile, Alabama, United States|Pfizer Investigational Site, Little Rock, Arkansas, United States|Pfizer Investigational Site, Fresno, California, United States|Pfizer Investigational Site, Los Altos, California, United States|Pfizer Investigational Site, Los Angeles, California, United States|Pfizer Investigational Site, Mountain View, California, United States|Pfizer Investigational Site, Sacramento, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, San Francisco, California, United States|Pfizer Investigational Site, Santa Rosa, California, United States|Pfizer Investigational Site, Stockton, California, United States|Pfizer Investigational Site, Boulder, Colorado, United States|Pfizer Investigational Site, Denver, Colorado, United States|Pfizer Investigational Site, Brandford, Connecticut, United States|Pfizer Investigational Site, Farmington, Connecticut, United States|Pfizer Investigational Site, Guilford, Connecticut, United States|Pfizer Investigational Site, New Haven, Connecticut, United States|Pfizer Investigational Site, Atlantis, Florida, United States|Pfizer Investigational Site, Clearwater, Florida, United States|Pfizer Investigational Site, Dunedin, Florida, United States|Pfizer Investigational Site, Fort Lauderdale, Florida, United States|Pfizer Investigational Site, Jacksonville, Florida, United States|Pfizer Investigational Site, Largo, Florida, United States|Pfizer Investigational Site, Melbourne, Florida, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, Orlando, Florida, United States|Pfizer Investigational Site, Pensacola, Florida, United States|Pfizer Investigational Site, Safety Harbor, Florida, United States|Pfizer Investigational Site, Sarasota, Florida, United States|Pfizer Investigational Site, Tampa, Florida, United States|Pfizer Investigational Site, Blue Island, Illinois, United States|Pfizer Investigational Site, Merrionette Park, Illinois, United States|Pfizer Investigational Site, Rockford, Illinois, United States|Pfizer Investigational Site, Elkhart, Indiana, United States|Pfizer Investigational Site, Goshen, Indiana, United States|Pfizer Investigational Site, Hobart, Indiana, United States|Pfizer Investigational Site, Merrillville, Indiana, United States|Pfizer Investigational Site, Davenport, Iowa, United States|Pfizer Investigational Site, Des Moines, Iowa, United States|Pfizer Investigational Site, West Des Moines, Iowa, United States|Pfizer Investigational Site, Shawnee Mission, Kansas, United States|Pfizer Investigational Site, Louisville, Kentucky, United States|Pfizer Investigational Site, Bogalusa, Louisiana, United States|Pfizer Investigational Site, Covington, Louisiana, United States|Pfizer Investigational Site, New Orleans, Louisiana, United States|Pfizer Investigational Site, Auburn, Maine, United States|Pfizer Investigational Site, Lewiston, Maine, United States|Pfizer Investigational Site, Portland, Maine, United States|Pfizer Investigational Site, Scarborough, Maine, United States|Pfizer Investigational Site, Baltimore, Maryland, United States|Pfizer Investigational Site, Columbia, Maryland, United States|Pfizer Investigational Site, Salisbury, Maryland, United States|Pfizer Investigational Site, Takoma Park, Maryland, United States|Pfizer Investigational Site, Ann Arbor, Michigan, United States|Pfizer Investigational Site, Flint, Michigan, United States|Pfizer Investigational Site, Kalamazoo, Michigan, United States|Pfizer Investigational Site, Lapeer, Michigan, United States|Pfizer Investigational Site, Petoskey, Michigan, United States|Pfizer Investigational Site, Royal Oak, Michigan, United States|Pfizer Investigational Site, Saginaw, Michigan, United States|Pfizer Investigational Site, Ypsilanti, Michigan, United States|Pfizer Investigational Site, Duluth, Minnesota, United States|Pfizer Investigational Site, Maplewood, Minnesota, United States|Pfizer Investigational Site, Minneapolis, Minnesota, United States|Pfizer Investigational Site, St. Cloud, Minnesota, United States|Pfizer Investigational Site, St. Paul, Minnesota, United States|Pfizer Investigational Site, Southaven, Mississippi, United States|Pfizer Investigational Site, Kansas City, Missouri, United States|Pfizer Investigational Site, Omaha, Nebraska, United States|Pfizer Investigational Site, Ridgewood, New Jersey, United States|Pfizer Investigational Site, Albuquerque, New Mexico, United States|Pfizer Investigational Site, Carlsbad, New Mexico, United States|Pfizer Investigational Site, Albany, New York, United States|Pfizer Investigational Site, Bay Shore, New York, United States|Pfizer Investigational Site, Buffalo, New York, United States|Pfizer Investigational Site, Flushing, New York, United States|Pfizer Investigational Site, Johnson City, New York, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, Oneonta, New York, United States|Pfizer Investigational Site, Poughkeepsie, New York, United States|Pfizer Investigational Site, Rochester, New York, United States|Pfizer Investigational Site, Troy, New York, United States|Pfizer Investigational Site, Williamsville, New York, United States|Pfizer Investigational Site, Eden, North Carolina, United States|Pfizer Investigational Site, Greensboro, North Carolina, United States|Pfizer Investigational Site, Greenville, North Carolina, United States|Pfizer Investigational Site, Raleigh, North Carolina, United States|Pfizer Investigational Site, Reidsville, North Carolina, United States|Pfizer Investigational Site, Winston-Salem, North Carolina, United States|Pfizer Investigational Site, Bellevue, Ohio, United States|Pfizer Investigational Site, Cleveland, Ohio, United States|Pfizer Investigational Site, Clyde, Ohio, United States|Pfizer Investigational Site, Defiance, Ohio, United States|Pfizer Investigational Site, Fostoria, Ohio, United States|Pfizer Investigational Site, Middleburg Heights, Ohio, United States|Pfizer Investigational Site, Orange Village, Ohio, United States|Pfizer Investigational Site, Toledo, Ohio, United States|Pfizer Investigational Site, Wauseon, Ohio, United States|Pfizer Investigational Site, Westlake, Ohio, United States|Pfizer Investigational Site, Oklahoma City, Oklahoma, United States|Pfizer Investigational Site, Tulsa, Oklahoma, United States|Pfizer Investigational Site, Eugene, Oregon, United States|Pfizer Investigational Site, Florence, Oregon, United States|Pfizer Investigational Site, Hillsboro, Oregon, United States|Pfizer Investigational Site, Doylestown, Pennsylvania, United States|Pfizer Investigational Site, Harrisburg, Pennsylvania, United States|Pfizer Investigational Site, Hershey, Pennsylvania, United States|Pfizer Investigational Site, Lancaster, Pennsylvania, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Pittsburgh, Pennsylvania, United States|Pfizer Investigational Site, Wormleysburg, Pennsylvania, United States|Pfizer Investigational Site, Greenville, South Carolina, United States|Pfizer Investigational Site, Chattanooga, Tennessee, United States|Pfizer Investigational Site, Knoxville, Tennessee, United States|Pfizer Investigational Site, Memphis, Tennessee, United States|Pfizer Investigational Site, Oak Ridge, Tennessee, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, Annandale, Virginia, United States|Pfizer Investigational Site, Charlottesville, Virginia, United States|Pfizer Investigational Site, Falls Church, Virginia, United States|Pfizer Investigational Site, Norfolk, Virginia, United States|Pfizer Investigational Site, Richmond, Virginia, United States|Pfizer Investigational Site, Bellevue, Washington, United States|Pfizer Investigational Site, Seattle, Washington, United States|Pfizer Investigational Site, Huntington, West Virginia, United States|Pfizer Investigational Site, Milwaukee, Wisconsin, United States|Pfizer Investigational Site, Aalst, Belgium|Pfizer Investigational Site, Bruxelles, Belgium|Pfizer Investigational Site, Genk, Belgium|Pfizer Investigational Site, Calgary, Alberta, Canada|Pfizer Investigational Site, Victoria, British Columbia, Canada|Pfizer Investigational Site, Halifax, Nova Scotia, Canada|Pfizer Investigational Site, Ottawa, Ontario, Canada|Pfizer Investigational Site, Torono, Ontario, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Montréal, Quebec, Canada|Pfizer Investigational Site, Nijmegen, Netherlands|Pfizer Investigational Site, Rotterdam, Netherlands|Pfizer Investigational Site, Katowice, Poland|Pfizer Investigational Site, Krakow, Poland|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, Oviedo, Asturias, Spain|Pfizer Investigational Site, L´Hospitalet del Llobregat, Barcelona, Spain|Pfizer Investigational Site, Vigo, Pontevedra, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT00134173
NCT00134238,Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin.,RADIANCE 2,Terminated,No Results Available,Mixed Hyperlipidemia,Drug: torcetrapib/atorvastatin|Drug: atorvastatin,Change in intima media thickness as measured by carotid ultrasound|Changes in levels of lipids and other biomarkers.,Pfizer,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,755,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,A5091004,Nov-03,Dec-06,Dec-06,24-Aug-05,null,17-Feb-12,"Pfizer Investigational Site, Gilbert, Arizona, United States|Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Scottsdale, Arizona, United States|Pfizer Investigational Site, Alhambra, California, United States|Pfizer Investigational Site, Encinitas, California, United States|Pfizer Investigational Site, La Jolla, California, United States|Pfizer Investigational Site, Los Angeles, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, Hartford, Connecticut, United States|Pfizer Investigational Site, Melbourne, Florida, United States|Pfizer Investigational Site, Palm Bay, Florida, United States|Pfizer Investigational Site, Sebastian, Florida, United States|Pfizer Investigational Site, Stuart, Florida, United States|Pfizer Investigational Site, Vero Beach, Florida, United States|Pfizer Investigational Site, Overland Park, Kansas, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Cambridge, Massachusetts, United States|Pfizer Investigational Site, Edina, Minnesota, United States|Pfizer Investigational Site, Minneapolis, Minnesota, United States|Pfizer Investigational Site, Kansas City, Missouri, United States|Pfizer Investigational Site, Concord, New Hampshire, United States|Pfizer Investigational Site, Bronxville, New York, United States|Pfizer Investigational Site, Buffalo, New York, United States|Pfizer Investigational Site, Mount Vernon, New York, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, Williamsville, New York, United States|Pfizer Investigational Site, Durham, North Carolina, United States|Pfizer Investigational Site, Raleigh, North Carolina, United States|Pfizer Investigational Site, Winston-Salem, North Carolina, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, Salt Lake City, Utah, United States|Pfizer Investigational Site, Newport News, Virginia, United States|Pfizer Investigational Site, Norfolk, Virginia, United States|Pfizer Investigational Site, Richmond, Virginia, United States|Pfizer Investigational Site, Bothell, Washington, United States|Pfizer Investigational Site, Kirkland, Washington, United States|Pfizer Investigational Site, Renton, Washington, United States|Pfizer Investigational Site, Seattle, Washington, United States|Pfizer Investigational Site, Vancouver, British Columbia, Canada|Pfizer Investigational Site, Winnipeg, Manitoba, Canada|Pfizer Investigational Site, Chicoutimi, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Quebec, Canada|Pfizer Investigational Site, Prague 4, Czech Republic|Pfizer Investigational Site, Kuopio, Finland|Pfizer Investigational Site, Paris Cedex, France|Pfizer Investigational Site, Nijmegen, Netherlands|Pfizer Investigational Site, Rotterdam, Netherlands|Pfizer Investigational Site, Utrecht, Netherlands",,https://ClinicalTrials.gov/show/NCT00134238
NCT00134485,Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia,,Completed,No Results Available,"Hypercholesterolemia, Familial|Hyperlipidemia",Drug: torcetrapib/atorvastatin|Drug: atorvastatin,Change in HDL-C and LDL-C|Changes in other lipid parameters,Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,400,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,A5091026,Mar-05,null,Mar-06,24-Aug-05,null,30-Oct-07,"Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, Washington, District of Columbia, United States|Pfizer Investigational Site, Lutz, Florida, United States|Pfizer Investigational Site, Tampa, Florida, United States|Pfizer Investigational Site, Tripler AMC, Hawaii, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, Indianapolis, Indiana, United States|Pfizer Investigational Site, Iowa City, Iowa, United States|Pfizer Investigational Site, Auburn, Maine, United States|Pfizer Investigational Site, Scarborough, Maine, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Charlotte, North Carolina, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, Madison, Wisconsin, United States|Pfizer Investigational Site, Camperdown, New South Wales, Australia|Pfizer Investigational Site, Woolloongabba, Queensland, Australia|Pfizer Investigational Site, North Adelaide, South Australia, Australia|Pfizer Investigational Site, Clayton, Victoria, Australia|Pfizer Investigational Site, Perth, Western Australia, Australia|Pfizer Investigational Site, Darlinghurst, Australia|Pfizer Investigational Site, Chicoutimi, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Ste-Foy, Quebec, Canada|Pfizer Investigational Site, Aalborg, Denmark|Pfizer Investigational Site, Arhus C, Denmark|Pfizer Investigational Site, Dijon, France|Pfizer Investigational Site, Nantes cedex 01, France|Pfizer Investigational Site, Paris, France|Pfizer Investigational Site, Kopavogur, Iceland|Pfizer Investigational Site, Oslo, Norway|Pfizer Investigational Site, Oslo, Norway|Pfizer Investigational Site, Parow, Cape Town, South Africa|Pfizer Investigational Site, Bellville, Western Cape, South Africa|Pfizer Investigational Site, Bloemfontein, South Africa|Pfizer Investigational Site, Cape Town, South Africa|Pfizer Investigational Site, Goteborg, Sweden|Pfizer Investigational Site, Linkoping, Sweden|Pfizer Investigational Site, Malmo, Sweden|Pfizer Investigational Site, Stockholm, Sweden|Pfizer Investigational Site",,https://ClinicalTrials.gov/show/NCT00134485
NCT00134498,A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides,,Completed,No Results Available,Hypertriglyceridemia|Hyperlipoproteinemia Type IV,Drug: torcetrapib/atorvastatin|Drug: atorvastatin,Change in HDL-C and non-HDL-C levels|Changes in levels of other lipid and biomarkers.,Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,160,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,A5091025,Feb-05,null,Nov-06,24-Aug-05,null,16-Nov-07,"Pfizer Investigational Site, Anaheim, California, United States|Pfizer Investigational Site, Huntington Beach, California, United States|Pfizer Investigational Site, Los Angeles, California, United States|Pfizer Investigational Site, Orangevale, California, United States|Pfizer Investigational Site, Orange, California, United States|Pfizer Investigational Site, Pacific Palisades, California, United States|Pfizer Investigational Site, Studio City, California, United States|Pfizer Investigational Site, Tustin, California, United States|Pfizer Investigational Site, Walnut Creek, California, United States|Pfizer Investigational Site, Farmington, Connecticut, United States|Pfizer Investigational Site, Washington, District of Columbia, United States|Pfizer Investigational Site, Hollywood, Florida, United States|Pfizer Investigational Site, Longwood, Florida, United States|Pfizer Investigational Site, West Palm Beach, Florida, United States|Pfizer Investigational Site, Tripler AMC, Hawaii, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, Indianapolis, Indiana, United States|Pfizer Investigational Site, Overland Park, Kansas, United States|Pfizer Investigational Site, Baton Rouge, Louisiana, United States|Pfizer Investigational Site, Scarborough, Maine, United States|Pfizer Investigational Site, Bethesda, Maryland, United States|Pfizer Investigational Site, Ann Arbor, Michigan, United States|Pfizer Investigational Site, Canton, Michigan, United States|Pfizer Investigational Site, Portage, Michigan, United States|Pfizer Investigational Site, Richland, Michigan, United States|Pfizer Investigational Site, St. Cloud, Minnesota, United States|Pfizer Investigational Site, Olive Branch, Mississippi, United States|Pfizer Investigational Site, Jefferson City, Missouri, United States|Pfizer Investigational Site, St. Louis, Missouri, United States|Pfizer Investigational Site, Las Vegas, Nevada, United States|Pfizer Investigational Site, Rochester, New York, United States|Pfizer Investigational Site, Syracuse, New York, United States|Pfizer Investigational Site, West Seneca, New York, United States|Pfizer Investigational Site, Statesville, North Carolina, United States|Pfizer Investigational Site, Sellersville, Pennsylvania, United States|Pfizer Investigational Site, Warwick, Rhode Island, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, Richmond, Virginia, United States|Pfizer Investigational Site, Madison, Wisconsin, United States|Pfizer Investigational Site, Halifax, Nova Scotia, Canada|Pfizer Investigational Site, London, Ontario, Canada|Pfizer Investigational Site, Chicoutimi, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Ste-Foy, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00134498
NCT00134511,Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder,,Completed,No Results Available,"Hypercholesterolemia, Familial",Drug: Torcetrapib/atorvastatin,Change in LDL-C and HDL-C|Other lipid variables,Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,30,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A5091027,Mar-05,null,Nov-05,24-Aug-05,null,7-Nov-07,"Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Chicoutimi, Quebec, Canada|Pfizer Investigational Site, Ste-Foy, Quebec, Canada|Pfizer Investigational Site, Parktown, Johannesburg, South Africa|Pfizer Investigational Site, Bloemfontein, South Africa|Pfizer Investigational Site, Cape Town, South Africa",,https://ClinicalTrials.gov/show/NCT00134511
NCT00133380,A Study in People With High Cholesterol,,Completed,No Results Available,Hypercholesterolemia,Drug: PPAR alpha|Drug: atorvastatin|Drug: placebo,"Effects on ""bad"" cholesterol, LDL-C, after 12 weeks|Evaluate safety after 12 weeks|Effects on other lipids and biomarkers associated with atherosclerosis after 12 weeks|Evaluate interaction of the 2 different study medications",Eli Lilly and Company,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,300,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,9591|H8D-MC-EMBF,Jul-05,null,Sep-06,23-Aug-05,null,6-Apr-07,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fayetteville, Arkansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Stockton, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Highlands Ranch, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brandon, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kissimmee, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Longwood, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oviedo, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chicago, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kansas City, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wichita, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lexington, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Auburn, Maine, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rockville, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Benzonia, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cadillac, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Interlochen, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Excelsior Springs, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charlotte, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greensboro, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Raleigh, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wilmington, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Winston-Salem, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mansfield, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Portland, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Stoneboro, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bristol, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kingsport, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT00133380
NCT00132717,A 12 Week Study of MK0653A in Patients Who Have Been Hospitalized for a Possible Heart Problem (0653A-808),,Completed,No Results Available,Hypercholesterolemia,Drug: MK0653A (ezetimibe [+] simvastatin)|Drug: Comparator: atorvastatin|Drug: Comparator: fluvastatin|Drug: Comparator: lovastatin|Drug: Comparator: pravastatin|Drug: Comparator: rosuvastatin|Drug: Comparator: simvastatin,Evaluate the effectiveness of MK0653A compared to doubling the statin dose as shown by the low-density lipoprotein cholesterol (LDL-C) values achieved after 12 weeks of treatment|To determine the effect of MK0653A compared to doubling the statin dose on total cholesterol (TC) after 12 weeks,Merck Sharp & Dohme Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0653A-808|2004_046,1-Jan-05,1-Jun-07,1-Jun-07,22-Aug-05,null,7-Apr-17,,,https://ClinicalTrials.gov/show/NCT00132717
NCT00133094,Systematic Management of High Cholesterol Utilizing Computer Monitoring,,Completed,No Results Available,Hypercholesterolemia,Drug: Simvastin|Procedure: Computer-based decision support technology,Total cholesterol and LDL-C cholesterol lowering|Verification that the decision support program provides equivalent recommendations for management of elevated cholesterol as would an expert in the management of hypercholesterolemia,US Department of Veterans Affairs|University of Pittsburgh|VA Office of Research and Development,All,"45 Years to 70 Years   (Adult, Older Adult)",Not Applicable,220,U.S. Fed|Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,XVA 72-029|00262,Jun-06,null,Dec-07,22-Aug-05,null,7-Apr-15,"VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00133094
NCT00129402,Effects of Ezetimibe With Simvastatin in the Therapy of Adolescents With HeFH (Study P02579),,Completed,Has Results,Hypercholesterolemia,Drug: ezetimibe with simvastatin|Drug: simvastatin,Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)|Percent Change From Baseline in Total Cholesterol (TC)|Percent Change From Baseline in Non High-density Lipoprotein Cholesterol (Non HDL-C)|Percent Change From Baseline in Triglycerides (TG)|Percent Change From Baseline in Apolipoprotein B (Apo B)|Percent Change From Baseline in HDL-C,Merck Sharp & Dohme Corp.,All,10 Years to 17 Years   (Child),Phase 3,248,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",P02579|EUDRACT NUMBER:2004-002627-40;|SCH 58235;|DOC ID 2526810,Aug-05,Jun-07,Jun-07,11-Aug-05,11-Feb-10,21-Sep-15,,,https://ClinicalTrials.gov/show/NCT00129402
NCT00127751,Heart Disease on the Mend,,Completed,No Results Available,Coronary Heart Disease|Stroke|Hyperlipidemia|Hypertension,Behavioral: Enhance health lifestyle changes and medication compliance,Cardiovascular disease risk score|Low-density lipoprotein (LDL)-cholesterol|Systolic blood pressure|Body mass index (BMI)|Physical activity score|Nutrition score,Stanford University|The Health Trust of Santa Clara County,All,"35 Years and older   (Adult, Older Adult)",Phase 2,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,373765,May-00,null,May-03,8-Aug-05,null,25-Aug-05,"Stanford University School of Medicine, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT00127751
NCT00125125,Fluvastatin in Adults With Dislipidemia With History of Muscle Problems,,Completed,No Results Available,Dyslipidemia,Drug: Fluvastatin,"Change from baseline in low density lipoprotein cholesterol after 12 weeks|Tolerability as assessed by muscle-related adverse events, and muscle-related adverse events leading to discontinuation|Change from baseline in total cholesterol, triglycerides, high density lipoprotein cholesterol, and lipoprotein subtypes after 12 weeks|Number of patients who reach target LDL after 12 weeks|Change from baseline in marker of inflammation after 12 weeks",Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 4,218,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CXUO320B2406,May-05,Dec-05,Dec-05,29-Jul-05,null,17-May-17,"Novartis, East Hanover, New Jersey, United States|Investigative Centers, Germany",,https://ClinicalTrials.gov/show/NCT00125125
NCT00123435,Veterans Walk for Health Study,VWH,Completed,No Results Available,Cardiovascular Diseases|Diabetes Mellitus|Hyperlipidemia|Hypertension|Obesity,Behavioral: Nutritional counseling|Behavioral: Walking program|Device: Simple pedometer|Device: Enhanced pedometer,Weight loss|Average daily activity level|Quality of life and participant satisfaction,US Department of Veterans Affairs|VA Office of Research and Development,Male,"18 Years and older   (Adult, Older Adult)",Not Applicable,254,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,D3358-R,Jul-05,Nov-07,Jun-09,22-Jul-05,null,21-Aug-15,"VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT00123435
NCT00120718,The Effect of Fasudil on Vascular Function in Humans,,Completed,No Results Available,Atherosclerosis|Hypercholesterolemia,Drug: fasudil,Vascular reactivity|Rho kinase expression|Rho kinase activity|eNOS expression|eNOS activity|inflammatory markers,Brigham and Women's Hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,2002-P-000890,Jun-02,Jan-07,Jan-07,19-Jul-05,null,30-Sep-08,"Brigham and Women's Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00120718
NCT00117494,Rosuvastatin Versus Pravastatin in HIV Patients Treated With Boosted Protease Inhibitors (PI) (ANRS126),,Completed,No Results Available,Hyperlipidemia|HIV Infections,Drug: Pravastatin|Drug: Rosuvastatin,"Compare the change in LDL cholesterol between D0 and D45, in patients receiving rosuvastatin (10 mg/day) or pravastatin (40 mg/day) and treated by antiretroviral agents including a boosted protease inhibitor on D45.|Changes in triglycerides and HDL cholesterol on D45|Percentage of patients with a normal value of LDL cholesterol, HDL cholesterol and triglycerides on D45 Clinical and biological safety parameters of rosuvastatin and pravastatin|Distribution profile of the diameter of LDL cholesterol particles|Cmin of rosuvastatin and pravastatin on D15|Cmin of protease inhibitors on D15.",French National Agency for Research on AIDS and Viral Hepatitis,All,"18 Years and older   (Adult, Older Adult)",Phase 4,86,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2005-001451-38|ANRS 126,Oct-05,Mar-07,Jun-07,7-Jul-05,null,22-Dec-11,"service de Médecine Interne Hopital Hotel Dieu, Paris, France",,https://ClinicalTrials.gov/show/NCT00117494
NCT00116519,A Study in People With Abnormal Fat Levels in the Blood,,Completed,No Results Available,Dyslipidemia,Drug: PPAR alpha|Drug: placebo,Effects on HDL-C and Triglycerides after 12 weeks|Safety after 12 weeks|Effects on LDL-C after 12 weeks|Effects on biomarkers of atherosclerosis after 12 weeks|Effects on factors of metabolic syndrome after 12 weeks,Eli Lilly and Company,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,300,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,5750|H8D-MC-EMBB,Jul-05,null,Oct-06,30-Jun-05,null,26-Jan-07,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Hoover, Alabama, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Fayetteville, Arkansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, San Diego, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Vista, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Golden, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Highlands Ranch, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Littleton, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Brandon, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Jupiter, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Kissimmee, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Longwood, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Oviedo, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Chicago, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Jeffersonville, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, West Des Moines, Iowa, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Kansas City, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Wichita, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Lexington, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Auburn, Maine, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Baltimore, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Rockville, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Benzonia, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Cadillac, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Flint, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Interlochen, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Ypsilanti, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Tupelo, Mississippi, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Excelsior Springs, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Las Vegas, Nevada, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, West Seneca, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Westfield, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Charlotte, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Greensboro, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, High Point, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Raleigh, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Wilmington, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Winston-Salem, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Grand Forks, North Dakota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Cleveland, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, East Cleveland, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Bend, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Portland, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Danville, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Red Lion, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Stoneboro, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Columbia, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Greer, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Simpsonville, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Bristol, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Kingsport, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Houston, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Spokane, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Wenatchee, Washington, United States",,https://ClinicalTrials.gov/show/NCT00116519
NCT00114855,The Effect of Hypocol® on Lipids in Subjects With Mild Hypercholesterolemia and Mildly Elevated Blood Glucose,,Completed,No Results Available,Hyperlipidemia|Glucose Metabolism Disorders,Drug: HYPOCOL®,"The effect of HypoCol on lipids in subjects with mild hypercholesterolemia.|The effect of HypoCol on fasting glucose, glycosylated hemoglobin (HbA1c) and high sensitive CRP.","Oslo University Hospital|Pharmalogica|Wearnes Biotech @ Medicals|Beijing Peking University WBL Biotech Co., Ltd.",All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,40,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,HYPOCOL protocol 15.12.2004|S-04329 (REK Sør)|11850 (NSD)|05/896 TSP (ShDir)|200303963-3 (SLV),Mar-05,Dec-05,Jun-06,20-Jun-05,null,6-Jul-11,"Lipidklinikken, Rikshospitalet, Oslo, Norway",,https://ClinicalTrials.gov/show/NCT00114855
NCT00114634,Short-term Behavioral Effects of Cholesterol Therapy in Smith-Lemli-Opitz Syndrome,,Completed,Has Results,Smith-Lemli-Opitz Syndrome,"Dietary Supplement: Egg yolk preparation with cholesterol|Dietary Supplement: Egg substitute, without cholesterol",Hyperactivity Sub-scale of the Aberrant Behavior Checklist-Community (ABC-C).|ABC Irritability Sub-scale|ABC Lethargy Sub-scale|ABC Stereotypy Sub-scale|ABC Inappropriate Behavior Sub-scale|ABC Total Score,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC),All,4 Years to 17 Years   (Child),Phase 2,13,NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",050168|05-CH-0168,Jun-05,Feb-09,Feb-09,16-Jun-05,9-Apr-14,29-Jan-16,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00114634
NCT00111891,An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032),,Completed,No Results Available,Dyslipidemia,Drug: niacin (+) laropiprant|Drug: Comparator: placebo (unspecified),Acute cutaneous symptoms induced by niacin for 7 days.|Tolerability,Merck Sharp & Dohme Corp.,All,"25 Years to 75 Years   (Adult, Older Adult)",Phase 2,575,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0524-032|MK0524A-032|2005_032,Jun-05,Aug-05,Aug-05,27-May-05,null,17-Feb-17,,,https://ClinicalTrials.gov/show/NCT00111891
NCT00110435,A Multicenter Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Products in Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia (MK-0653A-077),,Completed,No Results Available,Type 2 Diabetes Mellitus|Hypercholesterolemia,"Drug: MK0653A, ezetimibe (+) simvastatin|Drug: Duration of Treatment: 4 wk placebo run in then 6 wk active|Drug: Comparator: atorvastatin",Percent reduction in LDL-C from baseline after 6 weeks of treatment|Percent of patients attaining LDL-C <70 mg/dl after 6 weeks of treatment,Merck Sharp & Dohme Corp.,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 3,1229,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0653A-077|MK0653A-077|2005_022,May-05,Dec-05,Dec-05,10-May-05,null,14-Mar-17,,,https://ClinicalTrials.gov/show/NCT00110435
NCT00109603,Effect of Tenofovir Disoproxil Fumarate on Lipid Levels in HIV Infected Adults on Stable Anti-HIV Drug Therapy,,Completed,No Results Available,HIV Infections|Dyslipidemia|Hyperlipidemia|Hypercholesterolemia|Hypertriglyceridemia,Drug: Tenofovir disoproxil fumarate,"Fasting non-HDL cholesterol at baseline and Weeks 12, 16, and 28|Fasting HDL, total cholesterol, and triglycerides|direct LDL by ultracentrifugation|viral load, CD4 count, and other clinical and laboratory measures",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,17,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,ACTG A5206,May-05,Jul-07,Nov-07,2-May-05,null,30-Oct-12,"University of Southern California, Los Angeles, California, United States|University of California, San Diego Antiviral Research Center, San Diego, California, United States|University of Colorado Health Sciences Center, Denver, Denver, Colorado, United States|University of Miami, Miami, Florida, United States|Indiana University Hospital, Indianapolis, Indiana, United States|Methodist Hospital of Indiana, Indianapolis, Indiana, United States|Wishard Hospital, Indianapolis, Indiana, United States|University of Maryland, Institute of Human Virology, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Washington University (St. Louis), St. Louis, Missouri, United States|Beth Israel Medical Center, New York, New York, United States|NYU/Bellevue, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|University of Pennsylvania, Philadelphia, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Texas, Galveston, Galveston, Texas, United States|University of Puerto Rico, San Juan, Puerto Rico",,https://ClinicalTrials.gov/show/NCT00109603
NCT00108459,Low Carbohydrate Diet Compared to Calorie and Fat Restricted Diet in Patients With Obesity and Type II Diabetes,,Completed,No Results Available,Obesity|Type 2 Diabetes|Hyperlipidemia,Behavioral: Low Carbohydrate Diet,,US Department of Veterans Affairs|VA Office of Research and Development,All,"18 Years and older   (Adult, Older Adult)",Phase 3,156,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ENDA-002-03F,Sep-04,null,Dec-07,18-Apr-05,null,21-Jan-09,"VA Medical Center, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00108459
NCT00108485,Study of the Use of Niaspan for Treatment of Dyslipidemia in Diabetic Nephropathy,,Terminated,Has Results,"Diabetes Mellitus, Type 2|Kidney Failure, Chronic|Hyperlipidemia",Drug: Extended release niacin|Other: Placebo,Change in Proteinuria,University of Miami,All,"18 Years and older   (Adult, Older Adult)",Phase 3,9,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20043224,Apr-05,Dec-12,Dec-12,18-Apr-05,12-May-16,22-Jun-16,"Univesity of Miami/Diabetes Research Institute, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT00108485
NCT00108511,Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides,,Completed,No Results Available,Hypertriglyceridemia,Drug: Gemfibrozil,,US Department of Veterans Affairs|VA Office of Research and Development,All,"19 Years to 74 Years   (Adult, Older Adult)",Phase 1,null,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double|Primary Purpose: Treatment,CLNB-009-04S,Oct-04,null,Sep-07,18-Apr-05,null,21-Jan-09,"Roudebush VA Medical Center, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT00108511
NCT00108212,Effect of Diet on Men and Women With Genetic Alterations Associated With Abnormal Blood Tests,,Completed,No Results Available,Dyslipidemia,Behavioral: Diet,,US Department of Veterans Affairs|VA Office of Research and Development,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,null,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CARD-005-03S,Jan-05,null,Dec-07,15-Apr-05,null,21-Jan-09,"VA Maryland Health Care System, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00108212
NCT00107744,Clinical Trial of Protein and Blood Pressure,ProBP,Completed,Has Results,Hypertension|Hypercholesterolemia,Dietary Supplement: Soy protein-milk protein-carbohydrate|Dietary Supplement: Milk protein-carbohydrate-soy protein|Dietary Supplement: Carbohydrate-soy protein-milk protein,Change From Baseline in Average Systolic Blood Pressure at 8 Weeks|Change From Baseline in Serum LDL-cholesterol at 8 Weeks|Body Weight at 8 Weeks,"Tulane University|National Heart, Lung, and Blood Institute (NHLBI)",All,"22 Years and older   (Adult, Older Adult)",Not Applicable,352,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",H0330|R01HL068057,Sep-03,Apr-08,Apr-08,8-Apr-05,4-Jul-18,4-Jul-18,,,https://ClinicalTrials.gov/show/NCT00107744
NCT00106236,Efficacy of Exercise at a Fitness Club for Cardiovascular Risk Reduction,,Completed,No Results Available,Diabetes Mellitus|Hypertension|Hyperlipidemia,Behavioral: exercise,Systolic blood pressure|low-density lipoprotein cholesterol|hemoglobin A1c|Body weight|waist circumference|diastolic blood pressure|HDL-cholesterol|triglyceride|casual blood glucose|high-sensitivity C-reactive protein|white blood cell count|estimated VO2max|bicycle time|leg muscle strength|health-related QOL (Quality of Life),Sapporo Health Promotion Foundation,All,"45 Years to 89 Years   (Adult, Older Adult)",Phase 1|Phase 2,561,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),SHPCR-2003-1,Apr-03,null,Apr-04,22-Mar-05,null,14-Jul-09,"Sapporo Health Promotion Center, Sapporo, Hokkaido, Japan",,https://ClinicalTrials.gov/show/NCT00106236
NCT00105066,The Effects of Metformin on Blood Vessel Structure and Function,,Completed,Has Results,Obesity|Hypertension|Hypercholesterolemia|Hyperglycemia,Drug: Metformin|Drug: Placebo,Change in Arterial Stiffness Compared to Baseline|Change in Flow Mediated Dilation (FMD),National Institute on Aging (NIA)|National Institutes of Health Clinical Center (CC),All,"21 Years to 80 Years   (Adult, Older Adult)",Phase 2,77,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AG0017,Jan-04,May-08,May-08,4-Mar-05,18-Jan-17,18-Jan-17,"National Institute on Aging (NIA), Harbor Hospital, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00105066
NCT00101439,A Study to Evaluate the Effects of Ezetimibe (MK-0653) on the Postprandial (Following a Meal) Lipoprotein Response in Participants With Primary Hypercholesterolemia (High Cholesterol) (MK-0653-072)(COMPLETED),,Completed,Has Results,Hypercholesterolemia,Drug: ezetimibe|Drug: Comparator: placebo,Total Cholesterol Concentration of Chylomicron (Sf≥400) Fractions After a Cholesterol-Rich Test Meal|Total Cholesterol Concentration of Chylomicron-remnant (Sf 60-400) Subfractions After a Cholesterol-Rich Test Meal,Merck Sharp & Dohme Corp.,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,58,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0653-072|MK-0653-072|2005_001,10-Nov-05,24-Oct-06,8-Nov-06,11-Jan-05,10-Jun-16,7-Feb-19,,,https://ClinicalTrials.gov/show/NCT00101439
NCT00093899,A Study to Evaluate an Investigational Drug in Patients With Mixed Hyperlipidemia (0653A-071)(COMPLETED),,Completed,No Results Available,Hyperlipidemia|Hypercholesterolemia|Hypertriglyceridemia,Drug: ezetimibe (+) simvastatin,"Plasma LDL-C.|Plasma HDL-C, non-HDL-C, and TG. Tolerability",Merck Sharp & Dohme Corp.,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 3,611,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0653A-071|2004_044,Nov-04,Sep-05,Sep-05,8-Oct-04,null,14-Mar-17,,,https://ClinicalTrials.gov/show/NCT00093899
NCT00092560,Two Investigational Drugs in Patients With Mixed Hyperlipidemia (0653-036),,Completed,No Results Available,Hypercholesterolemia|Hypertriglyceridemia,"Drug: MK0653, ezetimibe|Drug: Comparator: fenofibrate monotherapy",Plasma LDL-C vs. fenofibrate for 12 weeks.|All plasma lipid parameters vs. ezetimibe; all non-LDL lipid parameters vs. fenofibrate; safety and tolerability.,Merck Sharp & Dohme Corp.,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,587,Industry,Interventional,Primary Purpose: Treatment,0653-036|2004_035,Dec-02,Dec-03,Dec-03,28-Sep-04,null,28-Feb-17,,,https://ClinicalTrials.gov/show/NCT00092560
NCT00092573,Study of Ezetimibe and Fenofibrate in Patients With Mixed Hyperlipidemia (0653-036)(COMPLETED),,Completed,No Results Available,Hypercholesterolemia|Hypertriglyceridemia,"Drug: MK0653, ezetimibe|Drug: Comparator: fenofibrate monotherapy","Tolerability|Plasma LDL-C, HDL-C and triglycerides after 12 weeks.",Merck Sharp & Dohme Corp.,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,576,Industry,Interventional,Primary Purpose: Treatment,0653-036 Extension|2004_036,Apr-03,Nov-04,Nov-04,28-Sep-04,null,28-Feb-17,,,https://ClinicalTrials.gov/show/NCT00092573
NCT00092586,Study of an Approved Drug With a Statin (a Medication That Lowers Cholesterol Levels) as Compared to Statin Therapy Alone in Patients With High Cholesterol (0653-040),,Completed,No Results Available,Hypercholesterolemia,"Drug: MK0653, ezetimibe|Drug: Comparator: statins",Percent change in LDL-C|Percentage of patients reaching NCEP ATP III target LDL-C levels,Merck Sharp & Dohme Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 3,2904,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0653-040|2004_037,Sep-02,Oct-03,Oct-03,28-Sep-04,null,28-Feb-17,,,https://ClinicalTrials.gov/show/NCT00092586
NCT00092651,A Study of MK0653A (Ezetimibe (+) Simvastatin) in Patients With Hypercholesterolemia (0653A-038),,Completed,No Results Available,Hypercholesterolemia,"Drug: MK0653A, ezetimibe (+) simvastatin|Drug: Comparators: simvastatin and ezetimibe","Plasma LDL-C|Plasma LDL-C, TG and HDL-C. The proportion of patients achieving LDL-C targets. Tolerability.",Merck Sharp & Dohme Corp.,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,1398,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0653A-038|2004_048,Sep-02,Jun-03,Jun-03,28-Sep-04,null,13-Mar-17,,,https://ClinicalTrials.gov/show/NCT00092651
NCT00092664,An Extension Study of An Investigational Drug in Patients With Hypercholesterolemia (0653A-038)(COMPLETED),,Completed,No Results Available,Hypercholesterolemia,"Drug: MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 14 weeks",Plasma LDL-C.|Plasma TG and HDL-C; proportion of patients achieving LDL-C targets; tolerability.,Merck Sharp & Dohme Corp.,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,1104,Industry,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0653A-038 Extension|2004_043,Jan-03,Sep-03,Sep-03,28-Sep-04,null,13-Mar-17,,,https://ClinicalTrials.gov/show/NCT00092664
NCT00092690,MK0653A (Ezetimibe (+) Simvastatin) Compared to an Approved Drug (Atorvastatin) for the Treatment of High Cholesterol (0653A-051)(COMPLETED),,Completed,No Results Available,Hypercholesterolemia,"Drug: MK0653A, ezetimibe (+) simvastatin|Drug: Comparator: atorvastatin",Plasma LDL-C averaged across all doses after 6 weeks|Plasma LDL-C for each dose; plasma HDL-C averaged across all doses,Merck Sharp & Dohme Corp.,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 3,1902,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0653A-051|2004_051,Jun-03,Mar-04,Mar-04,28-Sep-04,null,13-Mar-17,,,https://ClinicalTrials.gov/show/NCT00092690
NCT00092716,Comparing an Investigational Medication Versus an Approved Medication in Reducing Cholesterol Levels (0653-025),,Completed,No Results Available,Hypercholesterolemia,"Drug: MK0653, ezetimibe / Duration of Treatment: 28 weeks|Drug: Comparator: atorvastatin / Duration of Treatment: 28 weeks",To evaluate the effect on the reduction in low density lipoprotein cholesterol (LDL-C) after the initial 6-week treatment period.|Assess safety/tolerability and evaluate effect on HDL-C & on reduction of LDL-C|Evaluate % of pts who attain their NCEP-ATP III goal for LDL-C @ each dose level,Merck Sharp & Dohme Corp.,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 3,655,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,0653-025|2004_047,May-02,Apr-03,Apr-03,28-Sep-04,null,1-Mar-17,,,https://ClinicalTrials.gov/show/NCT00092716
NCT00092833,Investigational Drug in Patients With Hypercholesterolemia or in Patients With Sitosterolemia (0653-026)(COMPLETED),,Terminated,No Results Available,"Hypercholesterolemia, Familial|Lipid Metabolism, Inborn Errors",Drug: Comparator: ezetimibe,Incidence of clinical and laboratory adverse experiences in in patients with homozygous FH or homozygous sitosterolemia taking ezetimibe 10 mg/day,Merck Sharp & Dohme Corp.,All,"8 Years and older   (Child, Adult, Older Adult)",Phase 3,49,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0653-026|2004_034,Jul-02,May-05,May-05,28-Sep-04,null,28-Feb-17,,,https://ClinicalTrials.gov/show/NCT00092833
NCT00092846,A 6-Month Consumer Behavior Study of a Self-Management System (0803-084)(COMPLETED),,Completed,No Results Available,Hypercholesterolemia,"Drug: MK0803, lovastatin|Behavioral: Self-Management System",Percentage of patients who make appropriate decision for self-management.|Percentage of patients who make appropriate decision to discontinue therapy or consult with a physician; the incidence of adverse experiences.,Merck Sharp & Dohme Corp.,All,"45 Years and older   (Adult, Older Adult)",Phase 3,1000,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,0803-084|2004_061,4-Dec-02,1-Sep-03,null,28-Sep-04,null,2-Oct-17,,,https://ClinicalTrials.gov/show/NCT00092846
NCT00092599,Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-801),,Completed,No Results Available,Hypercholesterolemia|Coronary Disease,"Drug: MK0653, ezetimibe|Drug: Comparator: ezetimibe, placebo",Percentage of patients reaching LDL goal of <2.60 mmol/L after 6 weeks of treatment|Safety and tolerability.,Merck Sharp & Dohme Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 3,410,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0653-801|2004_039,Feb-03,Jun-04,Jul-04,27-Sep-04,null,13-Mar-17,,,https://ClinicalTrials.gov/show/NCT00092599
NCT00092612,Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-802)(COMPLETED),,Completed,No Results Available,Hypercholesterolemia|Coronary Disease,"Drug: MK0653, ezetimibe|Drug: Comparator: ezetimibe, placebo","Percentage of patients reaching their target LDL-C goal of </= 2.60 mmol/L, after 6 weeks of treatment|Safety and tolerability.",Merck Sharp & Dohme Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 3,372,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0653-802|2004_040,May-03,Jun-04,Jun-04,27-Sep-04,null,13-Mar-17,,,https://ClinicalTrials.gov/show/NCT00092612
NCT00092625,Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-803),,Completed,No Results Available,Hypercholesterolemia|Coronary Disease,"Drug: MK0653, ezetimibe|Drug: Comparator: ezetimibe, placebo","Percentage of patients reaching their target LDL-C goal of </= 2.60 mmol/L, after 6 weeks of treatment.|Safety and tolerability.",Merck Sharp & Dohme Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 3,442,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0653-803|2004_041,Mar-03,Jul-04,Aug-04,27-Sep-04,null,13-Mar-17,,,https://ClinicalTrials.gov/show/NCT00092625
NCT00092638,An Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-804)(COMPLETED),,Completed,No Results Available,Hypercholesterolemia|Coronary Disease,"Drug: MK0653, ezetimibe|Drug: Comparator: ezetimibe, placebo","Percentage of patients reaching their target LDL-C goal of </= 2.60 mmol/L, after 6 weeks of treatment.|Safety and tolerability.",Merck Sharp & Dohme Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,0653-804|2004_042,May-03,Jul-04,Aug-04,27-Sep-04,null,13-Mar-17,,,https://ClinicalTrials.gov/show/NCT00092638
NCT00092157,Effectiveness of Two Approved Drugs in Lowering High Cholesterol (0733-224),,Completed,No Results Available,Hypercholesterolemia,"Drug: MK0733, simvastatin|Drug: Comparator: simvastatin","Fasting triglyceride levels at 12 weeks.|Total Cholesterol, LDL-C, HDL-C, VLDL-C, VLDL-TG, Apo A-I, and Apo B, CRP, PAI-1, fibrinogen, fasting plasma glucose, and fasting insulin",Merck Sharp & Dohme Corp.,All,"21 Years to 65 Years   (Adult, Older Adult)",Phase 3,571,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0733-224|2004_060,1-May-02,3-Mar-03,4-Mar-03,24-Sep-04,null,12-Apr-17,,,https://ClinicalTrials.gov/show/NCT00092157
NCT00090298,Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Drugs in Patients With Elevated Cholesterol Levels (0653A-058),,Completed,No Results Available,Hypercholesterolemia,"Drug: MK0653A, ezetimibe (+) simvastatin|Drug: Comparator: Rosuvastatin","LDL-C lowering efficacy after 6 weeks.|Safety;changes in TC, non-HDL-C, TG, HDL-C, Apo B, LDL-C/HCL-C ratio.",Merck Sharp & Dohme Corp.,All,"18 Years to 69 Years   (Adult, Older Adult)",Phase 3,2815,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0653A-058|2004_001,Apr-04,Dec-04,Dec-04,30-Aug-04,null,13-Mar-17,,,https://ClinicalTrials.gov/show/NCT00090298
NCT00090168,Cholesterol Lowering Level of MK0653A+Simvastatin in Patients With Hypercholesterolemia and Atherosclerotic or Coronary Vascular Disease (0653A-806)(COMPLETED),,Completed,No Results Available,Hypercholesterolemia|Atherosclerotic Disease|Coronary Disease,"Drug: MK0653A , ezetimibe (+) simvastatin|Drug: Comparator: atorvastatin|Drug: Duration of Treatment: 6 weeks",LDL-C lowering|Total cholesterol (TC) lowering,Merck Sharp & Dohme Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 3,435,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0653A-806|2004_002,27-Jan-04,20-Oct-04,10-Nov-04,27-Aug-04,null,7-Apr-17,,,https://ClinicalTrials.gov/show/NCT00090168
NCT00090402,Fish Oil and Alpha Lipoic Acid in Treating Alzheimer's Disease,,Completed,Has Results,Alzheimer's Disease|Oxidative Stress|Dementia|Hyperlipidemia|Inflammation,Dietary Supplement: Fish Oil|Dietary Supplement: Lipoic Acid|Other: Fish Oil Placebo|Other: Lipoic Acid Placebo,F2-isoprostane Level Urine F2-Isoprostanes|Change in Mini-Mental State Exam (MMSE) Score From Baseline to 12 Months|Change in Activities of Daily Living/Instrumental Activities of Daily Living (ADL/IADL) Scores From Baseline to 12 Months,Oregon Health and Science University|National Institute on Aging (NIA)|National Center for Research Resources (NCRR),All,"55 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,39,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",IA0062|1R21AG023805-01|5R21AG023805-02|AG08017|M01RR000334,Apr-04,3-Jan-06,Aug-07,26-Aug-04,26-Feb-10,21-Jul-17,"Oregon Health and Science University, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT00090402
NCT00080275,Evaluation of the Safety & Efficacy of a Combination of Niacin ER & Simvastatin in Patients With Dyslipidemia (OCEANS),,Completed,No Results Available,Hypercholesterolemia,Drug: Niacin Extended-Release and simvastatin Tablets,,Kos Pharmaceuticals,All,"21 Years and older   (Adult, Older Adult)",Phase 3,600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,019-02-03-CR|OCEANS,Mar-04,null,null,29-Mar-04,null,1-Nov-06,,,https://ClinicalTrials.gov/show/NCT00080275
NCT00080132,"Implitapide in Patients With Hypertriglyceridemia (HTG) on Maximal, Concurrent Triglyceride-Lowering Therapy",,Terminated,No Results Available,Hypertriglyceridemia,Drug: implitapide,,Medical Research Laboratories International,All,"8 Years to 70 Years   (Child, Adult, Older Adult)",Phase 2,50,Industry,Interventional,Masking: None (Open Label)|Primary Purpose: Treatment,MRL 2002-003,Oct-04,null,Apr-05,25-Mar-04,null,24-Jun-05,"Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio, United States|The Methodist Hospital, Houston, Texas, United States|Academic Medical Center Amsterdam, Amsterdam, Netherlands|Andromed Noord, Groningen, Netherlands|Andromed Leiden, Leiden, Netherlands|Andromed Rotterdam, Rotterdam, Netherlands|Andromed Oost, Velp, Netherlands|Andromed Zoetermeer, Zoetermeer, Netherlands|Lipidklinikken - Rikshospitalet, Oslo, Norway",,https://ClinicalTrials.gov/show/NCT00080132
NCT00079846,Implitapide in Patients With Homozygous Familial Hypercholesterolemia (HoFH) on Maximal Concurrent Lipid-Lowering Therapy,,Terminated,No Results Available,Familial Hypercholesterolemia,Drug: Implitapide,,Medical Research Laboratories International,All,"8 Years to 70 Years   (Child, Adult, Older Adult)",Phase 2,60,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,MRL 2002-001,Sep-03,null,Apr-05,18-Mar-04,null,24-Jun-05,"Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio, United States|Lipid Clinic and Community Genomic Center, Complexe Hospitalier de la Sagamie, Chicoutimi, Quebec, Canada|Lipid Research Center, CHUL du CHUQ, Sainte-Foy, Quebec, Canada|Hadassah University Hospital, Jerusalem, Israel|Academic Medical Center Amsterdam, Amsterdam, Netherlands|Lipidklinikken - Rikshospitalet, Oslo, Norway",,https://ClinicalTrials.gov/show/NCT00079846
NCT00079859,Implitapide in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) on Maximal Concurrent Lipid-Lowering Therapy,,Terminated,No Results Available,Familial Hypercholesterolemia,Drug: Implitapide,,Medical Research Laboratories International,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,120,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,MRL 2002-002,Oct-03,null,Apr-05,18-Mar-04,null,24-Jun-05,"Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio, United States|Andromed Leiden, Leiden, Netherlands|Andromed Rotterdam, Rotterdam, Netherlands|Andromed Oost, Velp, Netherlands|Andromed Zoetermeer, Zoetermeer, Netherlands|Lipidklinikken - Rikshospitalet, Oslo, Norway",,https://ClinicalTrials.gov/show/NCT00079859
NCT00079638,Comparative Efficacy Evaluation of Lipids When Treated With Niaspan & Statin or Other Lipid-Modifying Therapies-COMPELL,,Completed,No Results Available,Dyslipidemia|Coronary Heart Disease|Atherosclerosis|Stroke|Diabetes,Drug: Niacin|Drug: Atorvastatin|Drug: Simvastatin|Drug: Ezetimibe|Drug: Rosuvastatin,Mean percent change in LDL-C from Baseline to Week 12,Kos Pharmaceuticals,All,"21 Years and older   (Adult, Older Adult)",Phase 4,300,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,001-09-03-CR|COMPELL,Apr-04,null,May-05,12-Mar-04,null,1-Nov-06,,,https://ClinicalTrials.gov/show/NCT00079638
NCT00074633,"Evaluating ""Health at Every Size""(HAES) as an Alternative Obesity Treatment Model",,Completed,No Results Available,"Hypercholesterolemia|Hypertension|Depression|Diabetes Mellitus, Type 2","Behavioral: Health at Every Size (HAES)|Behavioral: Diet (Traditional, moderate energy restriction)",,"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of California, Davis|United States Department of Agriculture (USDA)",Female,30 Years to 45 Years   (Adult),Not Applicable,79,NIH|Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OBFRETTO (completed),Jan-00,null,null,19-Dec-03,null,13-Jan-10,"Nutrition Department, University of California, Davis, Davis, California, United States|Western Human Nutrition Research Center, Davis, California, United States",,https://ClinicalTrials.gov/show/NCT00074633
NCT00069524,Antihyperlipidemic Effects of Oyster Mushrooms,,Completed,No Results Available,HIV Infections|Hyperlipidemia,Drug: oyster mushroom,,National Center for Complementary and Integrative Health (NCCIH)|Office of Dietary Supplements (ODS),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,20,NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R21AT001782-01,Jun-04,null,May-06,1-Oct-03,null,26-Sep-07,"General Clinical Research Center, San Francisco General Hospital, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT00069524
NCT00065624,Antioxidant Functions of Lipoic Acid,,Completed,No Results Available,Hypercholesterolemia,Drug: lipoic acid,,National Center for Complementary and Integrative Health (NCCIH),All,"50 Years to 75 Years   (Adult, Older Adult)",Phase 2,16,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,R21AT001062-01A2,Nov-03,null,Jul-07,31-Jul-03,null,2-Oct-07,"Vanderbilt University Medical Center, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT00065624
NCT00064792,Simvastatin Therapy in Smith-Lemli-Opitz Syndrome,,Completed,Has Results,Smith-Lemli-Opitz Syndrome,Drug: Simvastatin Susp.|Drug: OraPlus,Serum Cholesterol to Total Sterol Ratio|Cerebral Spinal Fluid Dehydrocholesterol to Total Sterol Ratio,"Forbes Porter, M.D.|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)",All,"4 Years to 18 Years   (Child, Adult)",Phase 2,23,NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",030225|03-CH-0225,Jul-03,Dec-10,Dec-10,14-Jul-03,6-Jun-14,6-Jun-14,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00064792
NCT00059254,Differential Metabolism of Dietary Fatty Acids,,Completed,No Results Available,Obesity|Diabetes|Hyperlipidemia,Dietary Supplement: Oleic acid (OA)|Dietary Supplement: Palmitic Acid (PA),Oxygen consumption|Carbon dioxide production|Respiratory quotient|excess Post exercise oxygen consumption (EPOC),"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|The University of Texas Medical Branch, Galveston",All,18 Years to 35 Years   (Adult),Not Applicable,19,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",DMDFA (COMPLETED)|R01DK055384,Sep-00,Apr-05,Apr-05,23-Apr-03,null,12-Oct-17,"Utmb Gcrc, Galveston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00059254
NCT00056511,Comparing Effects of 3 Sources of Garlic on Cholesterol Levels,,Completed,No Results Available,Hypercholesterolemia,Drug: Fresh garlic or garlic supplements,"LDL-cholesterol; measured at baseline, once a month, and post-intervention|HDL-cholesterol; measured at baseline, once a month, and post-intervention|Triacylglycerols; measured at baseline, once a month, and post-intervention|Blood pressure; measured at baseline, once a month, and post-intervention|Platelet aggregation; measured at baseline, once a month, and post-intervention",National Center for Complementary and Integrative Health (NCCIH)|Office of Dietary Supplements (ODS),All,"30 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,220,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,R01AT001108-01,May-02,null,Apr-05,18-Mar-03,null,18-Aug-06,"Stanford Center for Research in Disease Prevention, Palo Alto, California, United States",,https://ClinicalTrials.gov/show/NCT00056511
NCT00051415,Safety and Effectiveness of Flaxseed for Reducing High Cholesterol,,Completed,No Results Available,Hypercholesterolemia,Behavioral: Flaxseed-supplemented diet,,National Center for Complementary and Integrative Health (NCCIH),All,"45 Years to 75 Years   (Adult, Older Adult)",Phase 2|Phase 3,60,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,R21AT001291-01,Jan-03,null,Jan-05,15-Jan-03,null,18-Aug-06,"University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00051415
NCT00029835,Obese Patients With Untreated Dyslipidemias,RIO-Lipids,Completed,No Results Available,Obesity|Dyslipidemia,Drug: Rimonabant (SR141716),Change from baseline in body weight at 1 year.|Metabolic parameters,Sanofi,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,1033,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",EFC4735,Sep-01,Nov-03,Nov-03,24-Jan-02,null,20-Apr-09,"Clinic of Physicians and Surgeons, LTD, Mesa, Arizona, United States|Arizona Clinical Research Center, Inc., Tucson, Arizona, United States|Irvine Center for Clinical Research (ICCR), Irvine, California, United States|Los Angeles Clinical Trials, Los Angeles, California, United States|Apexute, Santa Ana, California, United States|Clinical Research of South Florida, Coral Gables, Florida, United States|Radiant Research, Stuart, Florida, United States|nTouch Research, Peoria, Illinois, United States|nTouch Research, South Bend, Indiana, United States|Bluegrass Clinical Research, Inc., Louisville, Kentucky, United States|Johns Hopkins Women's Research Core, Lutherville, Maryland, United States|Baystate Medical Center, Springfield, Massachusetts, United States|Twin Cities Clinical Research, Arden Hills, Minnesota, United States|Radiant Research, Edina, Minnesota, United States|Women's Clinic of Lincoln, PC, Lincoln, Nebraska, United States|New Mexico Clinical Research & Osteoporosis Center, Inc., Albuquerque, New Mexico, United States|Clinical Research Services, Bismarck, North Dakota, United States|University of Cincinnati College of Medicine, Cincinnati, Ohio, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Clinical Research Division, Newtown, Pennsylvania, United States|Clinical Research Center of Reading, LLC, West Reading, Pennsylvania, United States|Medical University of South Carolina, Division of Clinical Pharmacology, Charleston, South Carolina, United States|Nashville Medical Research Institute, Nashville, Tennessee, United States|Radiant Research, Salt Lake City, Utah, United States|Clinical Research Center of Northern Virginia, Falls Church, Virginia, United States|Hunter Holmes McGuire Medical Center Research Service (151), Richmond, Virginia, United States|Vancouver Medical Weight Loss Clinic, Vancouver, Washington, United States|Addiction & Psychiatric Medicine Research, Morgantown, West Virginia, United States|Sanofi-aventis Administrative Office, Macquarie Park, Australia|Sanofi-aventis Administrative Office, Laval, Canada|Sanofi-aventis Administrative Office, Helsinki, Finland|Sanofi-aventis Administrative Office, Milano, Italy|Sanofi-aventis Administrative Office, Barcelona, Spain|Sanofi-aventis Administrative Office, Bromma, Sweden|Sanofi-aventis Administrative Office, Geneva, Switzerland",,https://ClinicalTrials.gov/show/NCT00029835
NCT00029250,Garlic in Hyperlipidemia Caused by HAART,,Withdrawn,No Results Available,HIV Infections|Hypercholesterolemia|Hypertriglyceridemia|Hyperglycemia,Drug: Garlic powder standardized to allicin,,National Center for Complementary and Integrative Health (NCCIH),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,0,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,R21AT000328-01,Nov-01,May-03,May-03,10-Jan-02,null,22-Mar-13,"Bastyr University Center for Natural Health, Seattle, Washington, United States|University of Washington Harborview Medical Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00029250
NCT00017953,Look AHEAD: Action for Health in Diabetes,LookAHEAD,"Active, not recruiting",No Results Available,Diabetes|Myocardial Infarction|Stroke|Kidney Diseases|Bone Diseases|Dyslipidemia,Behavioral: Lifestyle Intervention|Behavioral: Diabetes Support and Education,The primary outcome is the aggregate occurrence of severe cardiovascular events.|Change in lifespan|Change in health care costs|change in frailty|change in diabetic microvascular complications|change in quality of life,"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Heart, Lung, and Blood Institute (NHLBI)|National Institute of Nursing Research (NINR)|National Institute on Minority Health and Health Disparities (NIMHD)|Office of Research on Women's Health (ORWH)|Centers for Disease Control and Prevention",All,"55 Years to 76 Years   (Adult, Older Adult)",Not Applicable,5145,NIH|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SHOW|U01DK057136|U01DK057149|U01DK056990|U01DK057177|U01DK057171|U01DK057151|U01DK057182|U01DK057131|U01DK057002|U01DK057078|U01DK057154|U01DK057178|U01DK057219|U01DK057008|U01DK057135|U01DK056992,Jun-01,Sep-12,Jan-20,21-Jun-01,null,8-Mar-18,"The University of Alabama at Birmingham, Birmingham, Alabama, United States|Southwestern American Indian Center, Phoenix, Arizona, United States|University of Southern California, Los Angeles, California, United States|University of Colorado Health Sciences Center, Aurora, Colorado, United States|Louisiana State University, Baton Rouge, Louisiana, United States|Johns Hopkins Pro-Health, Baltimore, Maryland, United States|Diabetes Center, Boston, Massachusetts, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Northern Navajo Medical Center, Shiprock, New Mexico, United States|Columbia University, New York, New York, United States|University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|The Miriam Hospital, Providence, Rhode Island, United States|The University of Tennessee, Memphis, Memphis, Tennessee, United States|Baylor College of Medicine, Houston, Texas, United States|University of Texas Health Sciences Center, San Antonio, Texas, United States|University of Washington, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00017953
NCT00005905,Leptin to Treat Lipodystrophy,,Completed,No Results Available,Lipodystrophy,Drug: hu Leptin (A-100),,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC),All,"Child, Adult, Older Adult",Phase 2,20,NIH,Interventional,Primary Purpose: Treatment,000146|00-DK-0146,Jun-00,null,Apr-03,12-Jun-00,null,4-Mar-08,"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00005905
NCT00005669,Metformin to Treat Obesity in Children With Insulin Resistance,,Completed,Has Results,Hyperinsulinemia|Obesity,Drug: Metformin HCL|Drug: Placebo,Changes in Body Weight as Determined by Body Mass Index-standard Deviation Score (BMI-SDS).|Change in Body Weight as Determined by BMI|Change in Body Weight|Change in Body Fat by DEXA|Change in Body Fat by Bod Pod,"Jack Yanovski, M.D.|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)",All,6 Years to 12 Years   (Child),Phase 2,100,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",000134|00-CH-0134,May-00,Aug-09,May-11,22-May-00,7-Apr-11,8-May-15,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00005669
